<SEC-DOCUMENT>0001698530-21-000105.txt : 20211119
<SEC-HEADER>0001698530-21-000105.hdr.sgml : 20211119
<ACCEPTANCE-DATETIME>20211119073602
ACCESSION NUMBER:		0001698530-21-000105
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		89
CONFORMED PERIOD OF REPORT:	20210930
FILED AS OF DATE:		20211119
DATE AS OF CHANGE:		20211119

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXICURE, INC.
		CENTRAL INDEX KEY:			0001698530
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				815333008
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39011
		FILM NUMBER:		211426384

	BUSINESS ADDRESS:	
		STREET 1:		2430 N. HALSTED ST.
		CITY:			CHICAGO
		STATE:			IL
		ZIP:			60614
		BUSINESS PHONE:		847-673-1700

	MAIL ADDRESS:	
		STREET 1:		2430 N. HALSTED ST.
		CITY:			CHICAGO
		STATE:			IL
		ZIP:			60614

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Max-1 Acquisition Corp
		DATE OF NAME CHANGE:	20170221
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>xcur-20210930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:ec2cf3ab-02c5-4899-a9f4-a2b651188a5f,g:ebea5fae-f5ab-4d4a-8517-3fed58ff79ef,d:30c50c718dda42d28fbdd6dcd4fa2365--><html xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xcur="http://www.exicuretx.com/20210930" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>xcur-20210930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80L2ZyYWc6YmE0MTA1MzBkZTU1NGZjOTk5OWY3NDdlNzM1MmY4NTUvdGFibGU6Mjk2OTc4OTIwNjRhNGJlMTg0YjM3NWNlMmNkZmM4MGUvdGFibGVyYW5nZToyOTY5Nzg5MjA2NGE0YmUxODRiMzc1Y2UyY2RmYzgwZV8zLTEtMS0xLTA_82d314e4-3f14-487b-b2bf-e07f60d91f41">0001698530</ix:nonNumeric><ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" format="ixt:date-month-day" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80L2ZyYWc6YmE0MTA1MzBkZTU1NGZjOTk5OWY3NDdlNzM1MmY4NTUvdGFibGU6Mjk2OTc4OTIwNjRhNGJlMTg0YjM3NWNlMmNkZmM4MGUvdGFibGVyYW5nZToyOTY5Nzg5MjA2NGE0YmUxODRiMzc1Y2UyY2RmYzgwZV80LTEtMS0xLTA_622dc1ce-fe28-4afc-aff7-c408efa6114b">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80L2ZyYWc6YmE0MTA1MzBkZTU1NGZjOTk5OWY3NDdlNzM1MmY4NTUvdGFibGU6Mjk2OTc4OTIwNjRhNGJlMTg0YjM3NWNlMmNkZmM4MGUvdGFibGVyYW5nZToyOTY5Nzg5MjA2NGE0YmUxODRiMzc1Y2UyY2RmYzgwZV81LTEtMS0xLTA_dc226eb0-015a-427f-93b0-7266a8c9b006">2021</ix:nonNumeric><ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80L2ZyYWc6YmE0MTA1MzBkZTU1NGZjOTk5OWY3NDdlNzM1MmY4NTUvdGFibGU6Mjk2OTc4OTIwNjRhNGJlMTg0YjM3NWNlMmNkZmM4MGUvdGFibGVyYW5nZToyOTY5Nzg5MjA2NGE0YmUxODRiMzc1Y2UyY2RmYzgwZV82LTEtMS0xLTA_24bab51d-75b6-425a-8cbc-99836ca768d6">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80L2ZyYWc6YmE0MTA1MzBkZTU1NGZjOTk5OWY3NDdlNzM1MmY4NTUvdGFibGU6Mjk2OTc4OTIwNjRhNGJlMTg0YjM3NWNlMmNkZmM4MGUvdGFibGVyYW5nZToyOTY5Nzg5MjA2NGE0YmUxODRiMzc1Y2UyY2RmYzgwZV83LTEtMS0xLTA_5c0f7dee-a865-4e3c-a629-1114fbdb99ea">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="xcur-20210930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i04b6fc849e294cd184b4de031b935e57_I20211112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-11-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0041572b03444403ad89282293144d76_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7508d7c37391421a854292655f2865a7_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1a551c230f14800abc2fa41ca7ad2a3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i889966d2ad0d48b1a39ab264208b8278_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77adf0b70cbf4775bddca74d6b334c92_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i501a27e325104650a73ad03cfcd4faa7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae971ef694a140e68a703e4451c6c2e3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i846826e778c54bd7b5bc352eb593aee3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dea9cf71d074399a074543cd69ce8c7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6201937a06d74f6d89fca534176e3345_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71bb35af2d12464b9a9e8594554ebb5f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f6c6875545040a48cde06a5f5b74823_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d560c291f0e4806b54ba5e47f9e4337_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib50af716c597410c87b2e6c906cd80f9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a52bc4a3c0d4c7cbfa5ea8a045321fa_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie38be6e4d7ba4275b47ca89d4c64b7f9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d4ca9f881df45978d9417d0ab7dc94e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac6b52ac45d04a2588c506176895e21f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc50c37ab44c4df39214039f0d7b1151_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ec0151a0c3948b38923be5743f1344a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62ce8e911e4846bd9009ddd7272195ab_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96f79fc5e863496fa7949c405ecc957f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id04667370fcb4287af7d78737a293eb4_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id42a638fb6864f9d9e37c2babc3b3899_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i992a828696e04df48d18d2f8bc76598e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd96764703204097bea35e7a9db99a49_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9dcdb6a39c9748148c55ed098113f458_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17d0ab6befad44789b59d2b647f01e28_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8045808dcb149df893c7a2d3e216476_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b100964d44d428faaab570e10ff8900_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i978591bf15364b7ea2e8132edee5fb1c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b8227feae1749778133a28312e507ba_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i290713ee60b04dd08da1a92f4da5adfd_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf9e5d3ecf814b9ab2f88960463e4dd8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbd40097533240cc82bcab253f741f47_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i719acf51485c46e1b4361db7fe272812_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d9766a167f349bb92052a2b44a794db_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifca2e3b16c794fc4a70ed80eb0c74b8d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c58992375514840acc525804de3b5bf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia27678044cb14d4281421247fb96281d_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab3dbd6a7f674d7083db2fa3c9db78a2_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i507ff9b7892843ad987a51c1c29c0a35_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3e5273956124a8099431ab285dc59c1_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6257175c451430abb2778376da96411_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6575d7f8daec4ae4abac4b2ef1bb98b4_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i602a59ce297c424b93795664859a8674_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8b0e758c6064f6291d39bb97bb331c8_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a09fd187a41481abc00b2e5f81774d2_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71026660fee448b3b596180fe34cbeca_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff8d18ca423a4767b541788b25f1e8bf_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0372b5960b948f488c30f66137194f2_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b2c76fc1f31458f93f96af1cff6f08f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47fe6eddfdbe4eed90628172bad98597_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cb024c41379417ebfea69a16d594eb0_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2055279aba744bfa86fba3a79756df14_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38e64861bfb143a6a581ccee7a5ad430_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6db610d7a4604665833e6884c7e4d50c_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9ef743ad4504fe6a4762417ee298525_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f68996929254ee4bbba614e977012de_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d81767196a447c99e736999c49bbd94_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if22d9a712dc144118a697b351d62e799_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42d47dd822a748b791c92e60630a2428_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66eacee5840b45e29eab0ce41b30f033_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e35705736534c78843742303282feb9_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i447f37e612cc480fb09d01d85dfe8a92_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe0cf5fbf4e1438fb46d794ecd6487cc_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if042bb6dd7e349bab540c21e2b62d94c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ead1c261b0940cab128efb701608748_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ic4e83e9c6d3f41cba0167701375d65af_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">xcur:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="agreement"><xbrli:measure>xcur:agreement</xbrli:measure></xbrli:unit><xbrli:context id="i7c9b511297334f1596139d6ed967838a_D20210730-20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:IpsenCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i101b7a1d41f042c7be4608f1ec08064c_D20210730-20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:IpsenCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="xcur:ExercisePeriodAxis">xcur:ExercisePeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3771528d3f494af69c08d167b87d572b_D20210730-20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:IpsenCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="xcur:ExercisePeriodAxis">xcur:ExercisePeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20b3f5cd0c964a8e9b2b710ca2d7aec4_I20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:IpsenCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd51ee58a09548a296ac27e125b6aaf5_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:IpsenCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="xcur:CollaborationAgreementPerformanceObligationAxis">xcur:IpsenHDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i577ec678c36d41cb95beb6bb59053c95_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:IpsenCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="xcur:CollaborationAgreementPerformanceObligationAxis">xcur:IpsenASMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia146a37ad8c04dd3a46243658527ace5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:IpsenCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e7d092153af4ab295e43b76a46e94f7_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:IpsenCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0eb88576f2154b229cc5f904054ddcaf_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:IpsenCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7d7e4233d934ae2905015e902539333_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:IpsenCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cc70e8bc70d42888c31d1910622f129_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:IpsenCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25a109363b9444d0b161c5f239e1f5d2_D20191113-20191113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-13</xbrli:startDate><xbrli:endDate>2019-11-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62ddab29023047f19bcd9cdd54f54b72_D20191113-20191113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">xcur:DevelopmentandCommercializationLicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-13</xbrli:startDate><xbrli:endDate>2019-11-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadf638d109364478ada9ed12098f78a3_D20191113-20191113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-13</xbrli:startDate><xbrli:endDate>2019-11-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6c60cafc25843e7aa83623d15b8db40_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i202fe08011f74b3bb586c3b5936aade6_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i334dc3567c6c404c81c2439542a6c976_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib58e437af4b84283a34ce171354bebca_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f46863e9a324f25a2a99c8d4fc202db_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib068c60a143742cab222adf4b1fc4d6e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0f5e47c15a04e01ae8607547bdbb25b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe437bd3033d4b10b7ec04a3e962b1fa_D20190217-20190217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:DermelixLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-17</xbrli:startDate><xbrli:endDate>2019-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b1064f27e214d639fb5a6444e15afc9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:DermelixLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7111ceb9bee457d80c964d377cc8997_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:DermelixLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a7767cbe5314379a5bbad2a39574623_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:DermelixLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1972cd63fd53468ca6ea728506874004_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:DermelixLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6df20868c6bf4088a7c126fd9b4c448f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:DermelixLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8868537d91414e59b86b641af9be949f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:IpsenCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i603ebaab9dc547c9b12a83e9eed30a32_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:IpsenCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2eeecde261e4327b21ed0de06f04e52_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:IpsenCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a37c9da460c48809897a601836d2643_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb811529c5b84fc488584f1160906a17_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbfce07014ab4a519300435d21964c4d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47cd4e78b2384bf799057776f855682a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0018e41fbb07474dba5b83bb48cc8e03_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib82780d8d54341299de5c10d925f31a6_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3ceab8c75694c4993355dcd2ae5c9fe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40174dd466594c3ab62a59e071f6cefd_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xcur:ComputersandSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d6ec4e189a747bd803d814ff65b5f44_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xcur:ComputersandSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9c2eeac1b3a491ba5d5b4821b396ce8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8817be1e21d4636989a972eaf99d676_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac3a1146a0b04454a629ec3468190f98_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00fa9951d7744973a1c8d2aa533d73dc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0053a355b9114313a12f8f7a031d65fc_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f345e6eb7f04fe4b6eab2801122fe23_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9282a032bc9d437cbb449818fa2c4843_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23975282c1f34d05bda28777e4086e31_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia247df9dcde04691921f7589b38fdf6a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2705fb27647c4404a185735a84cd5bae_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7567e0c7c5914bf5bde30bc572efc791_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6bd93e3d37e4fcb8e2b2027637863ed_I20200925"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7978f6f7e1b748cbabd1e2488f7447b7_D20200925-20200925"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementTranche1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-25</xbrli:startDate><xbrli:endDate>2020-09-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34a25167a0434d11aa0d2091e882e0a7_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementTranche2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8b146e3b6574d4ca6373ba4278baaa4_D20200925-20200925"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-25</xbrli:startDate><xbrli:endDate>2020-09-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="installmentpayment"><xbrli:measure>xcur:installmentPayment</xbrli:measure></xbrli:unit><xbrli:context id="i6c070a76443f46c79d54256b1cbf28fa_I20221001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89a02e4e5ce34167a93a3c5c5bff753f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d913806ddcd4fe38da350a6c3ed1feb_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9b3e45e1e944cbfa8d1c6fa857fb39c_D20200925-20200925"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-25</xbrli:startDate><xbrli:endDate>2020-09-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic85ffe60044641adbba3cef493f35219_I20200925"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementTranche1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77889ae6ab624d1295d8b058f98f0543_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6126506f80104557ba998535d441061c_I20200925"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementTranche2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice5e4b94c8ca4a1c808b55cb400e24e7_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementTranche2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f010890f93049f2ae4c474fd0f3290c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementTranche2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5116d3a6dd234ef8a2099862dd24c82b_D20200302-20200302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">xcur:HerculesTechnologyGrowthCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-02</xbrli:startDate><xbrli:endDate>2020-03-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i9576e645ea7c457ca92b31b2bdd21d44_D20200701-20200701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">xcur:ChicagoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i271a8511a8d74205a164612b6225fd65_I20200701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">xcur:ChicagoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="extensionperiod"><xbrli:measure>xcur:extensionPeriod</xbrli:measure></xbrli:unit><xbrli:unit id="votepershare"><xbrli:measure>xcur:votePerShare</xbrli:measure></xbrli:unit><xbrli:context id="i27fa1ea6e2df45148c9b25b975903963_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd76f03fda964ae290754abfcc474c0f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8169de03b9ae4915bce1475ec011bdcd_I20210327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c3f90d09e82457cb147316b3d91afa0_I20210428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2dfcf33b3dd445fac1ae79f628e0c43_I20210503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b1d431f25394a5c823a69f4d9ab4c33_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic64e0711d9f74fb89ed048800885e19f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53500ad38bdf4e52898d5f52b87b27ef_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecc89148ecae49e08ec084733d34a7aa_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c4c5418937146598e8abc57dcc888bc_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0deb149ab1ef4764ab8d4cdbf04c52b6_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ed6144e7375437b82d12e674ba92210_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73a5c9b5040b4db1b63fd576e252a033_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4e62853255f45b2b31cd2904be103fe_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57be8b97989949c89b339f60ea0c9c10_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i078e9e8c3ffe4962a86e337d4adc40ed_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i284324b6f8f04a0a9d2178e2163abdef_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff67e94dbcb44135b28d7b8a3cc93f58_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88948d106e48468baa525705927f987b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0c01f0c5533412a95c4f674b3fca01f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xcur:ExicureInc.2017EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cf18d06bb4048079daf994c18213de9_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xcur:ExicureInc.2017EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab7fc37403bc4ae2845774e5e03fe94c_D20210101-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xcur:ExicureInc.2017EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id55f75e995434a9dbf67ef6793958099_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie212c3441c564ae7beb10ac73b3f5f39_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c783d5073c74f03a909d7ebe8913ac0_I20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4333b7976f584c9cb7edb39e5c5abebd_D20170901-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8d6615560b5454ea9d90fe9e4254cc7_D20210514-20210514"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-14</xbrli:startDate><xbrli:endDate>2021-05-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c0e7a1b94874bc79ecebefc5fac4988_D20210101-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i982ad11b02e442eabda7ce00ba0f8e6f_D20200101-20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7a30565b6414f62b985b9824a0b50b0_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if808fd669ed14a3eb6ab7ba40be06723_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7dd8d8dbeff24010a0f6b35ba5d055da_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3196c46080b4a98afd913b13a6d4a34_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i320897d327b3429885b686fa2ddd6d58_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc041bea74db41bc8b34b9c2abac7ec1_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i999eb37ba3c84d41978cdddb2073c9c0_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id73356acb7214cc990e0f0fdb073fe06_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3853bdccdca84ad7b18ecb46c72865db_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6aeb1a850cfb47d0a5ac9c85fe47090e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b82c3458cdf484196d37803505070a6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia356a586489a48ba88f9458d0242cdf9_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i773b254eadab4295b1ffc8c03ceb00b8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic894455288284da09cf40a767a1e085c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if589413bdfb14e7bbc638c0c928b54e3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02e0beb6fe6341f7a29be934913d195d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ddff9f5fe814e669c4e7af58af7e785_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab9b918edd71485aaa8ea0f447186603_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic679721ac45b4f7fb6a4951133fb72b5_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5da161d8e266400a93c4f383d423b29f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if76f066c63564146bf012992a98ddce9_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i597ea376c91548b4a05158f306bea587_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5719399e939a44d98b39d249c039d68d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e30264806374843a74cbde5714a8879_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d14cf3685554550979e56c0584d59a2_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23729b7c757546618ffd14bfc2bf93dd_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7f4cd3d9bdd4d918c745f1ede290f0d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78855d9d0c4747009459828fe157b733_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3521ed35239b4892871886f1c9a86593_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2c85780c2fe44a5a264af346e3d74fe_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8414c9548ccf4c85ba53fb4883723dac_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic82a774e2c8d4a41b3170db670ad8155_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf7c24c0d5bd4c578f72a33ccc3c05bf_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i020262a33e8049ff9ab935e2b201f6fb_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i439032d25541463e8e6c4621ef8fd111_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a58bfb15835492ab090e8b81401af85_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ddced473eff483780d1373964171762_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5731c03b9fc44849a8c3fb5ed3c6949a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56aca844fa034db2b2e2a7b18d0023e7_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9718465693743c3b538b21283198504_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i313d98866f5747ea9ad78d453628370d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibda75316052d4dbe9d661f043c9b1956_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib677e14bc757464bb5589291a71b4e61_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d8d9676d98849f883d2748566593b17_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0974ff1702c42d395bd413417d4a0d9_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c8552c18039495daa749078cb358e04_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64760482c2c9480ea6bc6748d1d90ce7_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icea87c7e3d6a4dfba48ae4131cda39e8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86c21c42f5cd42dfa1f7346b010764d4_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62ff7db7da784f799e2dfe0c311b9e0f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i965562b1554547d1a09c7766cedd87ae_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9531f369bf98470ba15fba85df910ef3_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia886151578c443df8e7d2e02ad3a907b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied37c8b6308741fda6f2b2dcb570461d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc5f1ed1d0574ff59b0f1eed86e46da0_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b19f1632fda44cfb2cbf056cb55773e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie60c424895d44cb6a873a2f566d9ba85_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id804d84aba2942da9b78003f9fa2d272_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cb225e6af3547baa416759169909bcb_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cba3845e261446285d53d1b68bd1b2b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i086920543bec4d90bb757a3cefcb83ef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic202372402d84018b4b88f88701033d0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83369fca8bab4aab90e8db725e903baf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2996ac3939c042e3ab6d42a6553a235a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8883903151f24f5fa017edecc72b8b35_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i719acee816814d07916c8dfd5ca71de9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ca413f9b9054d00bbda5b1373b22305_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34fe6e6e209446768a2cf34d62dad6aa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62f9200c696c41d78a853e83862f647b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d5744490b0d4c738db4cd2bb4e0aa81_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfc85e952cc2497fbeee275f739aa825_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ed86c954d924fc8a28507f2891286eb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifaf0a15420cb4a7294217b68929d7235_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1e7126375264b1c93061499c8d47b5e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71bd3df32bb94d4fae58db8bff589a4e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic259c1b511b64ac2978a410b11be349b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a439123584f4408a9d60d89e70d2703_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0667ee8e62af460ca0b2e1c8843b72c2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64cfed00d63048338a59cf563ea272b8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1126e3e21a654b5fb23bb497bc28aa43_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c44bd27d0ac448590035ac735a75a7b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b2c5cfdc76544d29619b3bd1e9955a8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa0ce1eb50024db289d3b452e949a956_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f8b49f540eb4a5f880bed694d3fd14d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03125214387d41b9a8017ffe8a649dac_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9361796fa9024b2182ac08a2f7e2bf59_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8264fbfff9464a9baa8088b432d019fd_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">xcur:ConsultingServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18f420eacb594066840b698845eaa3a4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001698530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">xcur:ConsultingServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i30c50c718dda42d28fbdd6dcd4fa2365_1"></div><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:17.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.912%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">______________________________________</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGV4dHJlZ2lvbjo2MWFiMTkzYzUyMTk0ZjJmYWY1NWI3MGJiZDc4ODA0Ml8yMzk2_d83ce2ee-1088-4770-9276-fa58e55cafc8">10-Q</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">______________________________________</span></div><div style="margin-bottom:6pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" format="ixt:fixed-true" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGV4dHJlZ2lvbjo2MWFiMTkzYzUyMTk0ZjJmYWY1NWI3MGJiZDc4ODA0Ml8yNDA1_0091e9b1-b920-461a-bacd-fbfb433d9dce">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGV4dHJlZ2lvbjo2MWFiMTkzYzUyMTk0ZjJmYWY1NWI3MGJiZDc4ODA0Ml8zMjk4NTM0ODg1NzUz_ae8d7262-ada4-4894-a218-6137d5ac32d5">September 30, 2021</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">or</span></div><div style="margin-bottom:9pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" format="ixt:fixed-false" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGV4dHJlZ2lvbjo2MWFiMTkzYzUyMTk0ZjJmYWY1NWI3MGJiZDc4ODA0Ml8yMzk4_73344343-0d46-4df3-9954-f520f56ecb28">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGV4dHJlZ2lvbjo2MWFiMTkzYzUyMTk0ZjJmYWY1NWI3MGJiZDc4ODA0Ml8yMzky_2bfbcab9-080e-4ea4-bc89-ce14c621bec0">001-39011</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">______________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGV4dHJlZ2lvbjo2MWFiMTkzYzUyMTk0ZjJmYWY1NWI3MGJiZDc4ODA0Ml8yNDAz_1a35f61b-50e4-48d7-b79d-c50504cf7bff">EXICURE, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_____________________________________</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.929%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGFibGU6YWUzOGVhMzVkMjkyNDUyZjg3MWVhNDViYTc2ODYyODIvdGFibGVyYW5nZTphZTM4ZWEzNWQyOTI0NTJmODcxZWE0NWJhNzY4NjI4Ml8wLTAtMS0xLTA_9936fe16-26ef-40a5-bf0f-7b6294dfe381">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGFibGU6YWUzOGVhMzVkMjkyNDUyZjg3MWVhNDViYTc2ODYyODIvdGFibGVyYW5nZTphZTM4ZWEzNWQyOTI0NTJmODcxZWE0NWJhNzY4NjI4Ml8wLTItMS0xLTA_94d58e1b-aec5-4f3c-98b4-b887cabb33be">81-5333008</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGV4dHJlZ2lvbjo2MWFiMTkzYzUyMTk0ZjJmYWY1NWI3MGJiZDc4ODA0Ml8yMzkz_265c7caa-6dc2-4deb-acca-e728b17ceaf7">2430 N. Halsted St.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGV4dHJlZ2lvbjo2MWFiMTkzYzUyMTk0ZjJmYWY1NWI3MGJiZDc4ODA0Ml8yNDA2_36c16d1d-0799-49a9-add1-0bcb5b43a11c">Chicago</ix:nonNumeric>, <ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGV4dHJlZ2lvbjo2MWFiMTkzYzUyMTk0ZjJmYWY1NWI3MGJiZDc4ODA0Ml8yNDA3_07af11cb-1cb6-48a8-8ff7-ed0add1899cf">IL</ix:nonNumeric> <ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGV4dHJlZ2lvbjo2MWFiMTkzYzUyMTk0ZjJmYWY1NWI3MGJiZDc4ODA0Ml8yMzk5_7c08a4a1-ccb0-4b2c-8b81-2f3994fb71f5">60614</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code <ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGV4dHJlZ2lvbjo2MWFiMTkzYzUyMTk0ZjJmYWY1NWI3MGJiZDc4ODA0Ml8yNDAx_ab375b35-660e-49bd-8ec7-74e70b2d8c0c">(847)</ix:nonNumeric> <ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGV4dHJlZ2lvbjo2MWFiMTkzYzUyMTk0ZjJmYWY1NWI3MGJiZDc4ODA0Ml8yNDAy_55713e8f-8ba6-4157-a9a4-552a38f9493c">673-1700</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.944%"><tr><td style="width:1.0%"></td><td style="width:36.006%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.881%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGFibGU6ZmY3Y2E3M2VlZjY4NDA3YzkxYjgyZTE0OTZlYmMwNmIvdGFibGVyYW5nZTpmZjdjYTczZWVmNjg0MDdjOTFiODJlMTQ5NmViYzA2Yl8xLTAtMS0xLTA_eb0c7624-c229-45c0-add5-cb36e1140695">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGFibGU6ZmY3Y2E3M2VlZjY4NDA3YzkxYjgyZTE0OTZlYmMwNmIvdGFibGVyYW5nZTpmZjdjYTczZWVmNjg0MDdjOTFiODJlMTQ5NmViYzA2Yl8xLTItMS0xLTA_3f06ac78-f2f2-45dd-9f3e-649b5ae2e4aa">XCUR</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGFibGU6ZmY3Y2E3M2VlZjY4NDA3YzkxYjgyZTE0OTZlYmMwNmIvdGFibGVyYW5nZTpmZjdjYTczZWVmNjg0MDdjOTFiODJlMTQ5NmViYzA2Yl8xLTQtMS0xLTA_9fd95f69-1aff-4d56-8bef-9cc3389cb4b7">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGV4dHJlZ2lvbjo2MWFiMTkzYzUyMTk0ZjJmYWY1NWI3MGJiZDc4ODA0Ml8yMzk0_f7112e49-3f40-42fa-9a7e-9713f85fbb5a">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#9744;</span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGV4dHJlZ2lvbjo2MWFiMTkzYzUyMTk0ZjJmYWY1NWI3MGJiZDc4ODA0Ml8yNDA4_24419e3d-5a3e-4e67-a5ab-71ac66e8ce84">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.716%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large&#160;accelerated&#160;filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGFibGU6YzllOTNiNDJkMGQ0NGU5YmFmZjZiZTgwMDcyZDJkMzUvdGFibGVyYW5nZTpjOWU5M2I0MmQwZDQ0ZTliYWZmNmJlODAwNzJkMmQzNV8xLTAtMS0xLTA_40b5cbb4-322d-4ab2-ab41-bf6af1e3b0a4">Non-accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" format="ixt:fixed-true" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGFibGU6YzllOTNiNDJkMGQ0NGU5YmFmZjZiZTgwMDcyZDJkMzUvdGFibGVyYW5nZTpjOWU5M2I0MmQwZDQ0ZTliYWZmNmJlODAwNzJkMmQzNV8xLTQtMS0xLTA_410e2118-de13-4c5d-843e-dff989a6e75a">&#9746;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" format="ixt:fixed-true" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGFibGU6YzllOTNiNDJkMGQ0NGU5YmFmZjZiZTgwMDcyZDJkMzUvdGFibGVyYW5nZTpjOWU5M2I0MmQwZDQ0ZTliYWZmNmJlODAwNzJkMmQzNV8yLTQtMS0xLTA_1bce75d0-057c-43ad-b5ab-6d0d998ed680">&#9746;</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.<ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGV4dHJlZ2lvbjo2MWFiMTkzYzUyMTk0ZjJmYWY1NWI3MGJiZDc4ODA0Ml8yMzk1_50cacafe-6741-4590-9655-f2e0b3808168">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGV4dHJlZ2lvbjo2MWFiMTkzYzUyMTk0ZjJmYWY1NWI3MGJiZDc4ODA0Ml8yNDA5_9ec6d1eb-de5e-44f6-a07c-2c2253089953">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of November 12, 2021, there were <ix:nonFraction unitRef="shares" contextRef="i04b6fc849e294cd184b4de031b935e57_I20211112" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGV4dHJlZ2lvbjo2MWFiMTkzYzUyMTk0ZjJmYWY1NWI3MGJiZDc4ODA0Ml8yMzA3_f22406d8-c548-4a98-83e3-8634edfe170d">88,120,951</ix:nonFraction> shares of the registrant&#8217;s common stock, par value $0.0001 per share, outstanding.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:17.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.912%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div></div><div id="i30c50c718dda42d28fbdd6dcd4fa2365_7"></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUARTERLY REPORT ON FORM 10-Q</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.314%"><tr><td style="width:1.0%"></td><td style="width:86.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.631%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.050%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_13">PART I - FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_19">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_16">Item 1. Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_19">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_19">Unaudited Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_19">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_22">Unaudited Condensed Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_22">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_25">Unaudited Condensed Consolidated Statements of Comprehensive (Loss) Income</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_25">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_28">Unaudited Condensed Consolidated Statements of Changes in Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_28">10</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_31">Unaudited Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_31">12</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_34">Notes to Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_37">14</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_82">Item 2. Management's Discussion and Analysis and Results of Operations</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_82">41</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_112">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_112">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_115">Item 4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_115">56</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_118">PART II - OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_121">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_121">Item 1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_121">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_124">Item 1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_124">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_127">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_127">98</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_130">Item 3. Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_130">98</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_133">Item 4. Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_133">98</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_136">Item 5. Other Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_136">98</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_139">Item 6. Exhibits</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_139">99</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_142">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_142">101</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i30c50c718dda42d28fbdd6dcd4fa2365_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q, including the sections titled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; contains express or implied &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical fact contained in this Quarterly Report on Form 10-Q are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221;, &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;predict,&#8221; &#8220;seek,&#8221; &#8220;contemplate,&#8221; &#8220;project,&#8221; &#8220;continue,&#8221; &#8220;potential,&#8221; &#8220;ongoing&#8221; or the negative of these terms or other comparable terminology. Forward-looking statements also include the assumptions underlying or relating to such statements. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe that the expectations reflected in the forward-looking statements contained herein are reasonable, such expectations or any of the forward-looking statements may prove to be incorrect and actual results could differ materially from those projected or assumed in the forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to inherent risks and uncertainties, including, but not limited to, the risk factors described in the &#8220;Risk Factor Summary&#8221; below and set forth in Part II, Item 1A &#8220;Risk Factors&#8221; below and for the reasons described elsewhere in this Quarterly Report on Form 10-Q. All forward-looking statements and reasons why results may differ included in this report are made as of the date hereof and we do not intend to update any forward-looking statements except as required by law or applicable regulations. These forward-looking statements include, but are not limited to, statements concerning the following:</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">our ability to raise substantial additional capital to fund our planned operations in the near term and to continue as a going concern;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.25pt">our expectations regarding the impact of the ongoing COVID-19 pandemic including the expected duration of disruption and immediate and long-term delays, interruptions or other adverse effects to clinical trials, patient enrollment and clinical activation, delays in regulatory review, preclinical research and development, or R&amp;D, collaboration and partnership programs, manufacturing and supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy overall, and the overall impact of the COVID-19 pandemic on our business, financial condition and results of operations;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates of expenses, use of cash, timing of future cash needs, ongoing losses, future revenue, including our estimates used to determine revenue recognition in connection with our collaboration agreements, and capital requirements, including our expectations relating to our needs for additional financing; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, timing, progress and results of our current and future preclinical studies, clinical trials, collaboration and partnership programs, including our ongoing clinical trials and any planned clinical trials for XCUR-FXN, cavrotolimod (AST-008) or any of our other product candidates, and the R&amp;D programs we are pursuing or may pursue;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to advance our product candidates into, and successfully complete, clinical trials;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and likelihood of regulatory filings for our current and future product candidates including any Investigational New Drug, or IND, application, Investigational Medicinal Product Dossier, or IMPD, Clinical Trial Application, or CTA, New Drug Application, or NDA, or other regulatory submissions;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain regulatory approval of our product candidates in the indications for which we plan to develop them, and any related restrictions, limitations or warnings in the label of an approved drug or therapy;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size and growth potential of the markets for our product candidates, if approved, and the rate and degree of market acceptance of our product candidates, including reimbursement that may be received from payors;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the diversion of healthcare resources away from the conduct of clinical trials as a result of the ongoing COVID-19 pandemic, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel, quarantines or social distancing protocols imposed or recommended by federal or state governments, employers and others or voluntarily adopted in connection with the ongoing COVID-19 pandemic;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our dependence on current and future collaborators for advancement of therapeutic candidates pursuant to the terms of such collaborations, including ability to obtain and maintain regulatory approval and commercialization, if approved; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the status of clinical trials, development timelines and discussions with regulatory authorities related to product candidates under development by us and our collaborators;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our receipt and timing of any milestone payments or royalties under any current or future research collaboration and license agreements or arrangements; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify and develop therapeutic candidates for treatment of additional disease indications; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance of any approved therapeutic candidates; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the commercialization of any approved therapeutic candidates; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the implementation of our business model and strategic plans for our business, technologies and therapeutic candidates; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain additional funds for our operations; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain intellectual property protection for our technologies and therapeutic candidates and our ability to operate our business without infringing the intellectual property rights of others; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reliance on third parties to conduct our preclinical studies and clinical trials; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reliance on third party supply and manufacturing partners to supply the materials and components for, and manufacture, our R&amp;D, preclinical and clinical trial supplies; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding our ability to attract and retain qualified key management and technical personnel; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act of 2012;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of government laws and regulations as well as developments relating to our competitors or our industry; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other factors that may impact our financial and clinical results.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">among other things, those listed in Part II, Item 1A of this Quarterly Report on Form 10-Q under the section titled &#8220;Risk Factors&#8221; and elsewhere in this Quarterly Report on Form 10-Q. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any forward-looking statement in this Quarterly Report on Form 10-Q reflects our current view with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our business, results of operations, industry and future growth. Given these uncertainties, you should not place undue reliance on these forward-looking statements. No forward-looking statement is a guarantee of future performance. You should read this Quarterly Report on Form 10-Q and the documents that we reference herein and have filed with the SEC as exhibits thereto completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements. Except as required by law, we assume no, and specifically decline any, obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q also contains or may contain estimates, projections and other information concerning our industry, our business and the markets for certain therapeutics, including data regarding the estimated size of those markets, their projected growth rates and the incidence of certain medical conditions. Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained these industry, business, market and other data from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources. In some cases, we do not expressly refer to the sources from which these data are derived.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except where the context otherwise requires, in this Quarterly Report on Form 10-Q, the &#8220;Company,&#8221; &#8220;Exicure,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refers to Exicure, Inc., a Delaware corporation, and, where appropriate, its subsidiary. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">SUMMARY RISK FACTORS</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing in common stock involves numerous risks, including the risks described in &#8220;Item 1A. Risk Factors&#8221; of this Quarterly Report on Form 10-Q. Below are some of these risks, any one of which could materially adversely affect our business, financial condition, results of operations and prospects. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our consolidated financial statements have been prepared assuming that we will continue as a going concern.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are a clinical-stage biotechnology company with a history of losses. We expect to continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability, which could result in a decline in the market value of our common stock.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our approach to the discovery and development of innovative therapeutic treatments based on our technology is unproven and may not result in marketable products.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our therapeutic candidates are in early stages of development and may fail in development or suffer delays that materially and adversely affect their commercial viability.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product development involves a lengthy and expensive process with an uncertain outcome, and results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will need substantial additional funds to advance the development of our therapeutic candidates, and we cannot guarantee that we will have sufficient funds available in the future to develop and commercialize our current or future therapeutic candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business could be adversely affected by the effects of health epidemics, including the global COVID&#8209;19 pandemic, in regions where we or third parties on which we rely have business operations and at our clinical trial sites, as well as the business or operations of our contract research organizations, or CROs, or other third parties with whom we conduct business.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we continue to experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be further delayed or prevented.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not successfully engage in strategic transactions, including any additional collaborations we seek, which could adversely affect our ability to develop and commercialize product candidates, impact our cash position, increase our expense and present significant distractions to our management.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If third parties on which we depend to conduct our preclinical studies and clinical trials do not perform as contractually required, fail to satisfy regulatory or legal requirements, or miss expected deadlines, our development program could be delayed with materially adverse effects on our business, financial condition, results of operations and prospects.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Because we rely on third-party manufacturing and supply partners, our supply of research and development, preclinical studies and clinical trial materials may become limited or interrupted or may not be of satisfactory quantity or quality.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face competition from entities that have developed or may develop therapeutic candidates for our target disease indications, including companies developing novel treatments and technology platforms based on modalities and technology similar to ours. If these companies develop technologies, including delivery technologies, or therapeutic candidates more rapidly than we do or their technologies are more effective, our ability to develop and successfully commercialize therapeutic candidates may be adversely affected.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The market may not be receptive to our therapeutic candidates based on a novel therapeutic modality, and we may not generate any future revenue from the sale or licensing of therapeutic candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any inability to attract and retain qualified key management and technical personnel would impair our ability to implement our business plan.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We currently license patent rights from Northwestern University and may in the future license patent rights from third-party owners or licensees. If Northwestern University or such other owners or licensees do not properly or successfully obtain, maintain or enforce the patents underlying such licenses, or if they retain or license to others any competing rights, our competitive position and business prospects may be adversely affected. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i30c50c718dda42d28fbdd6dcd4fa2365_13"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I - FINANCIAL INFORMATION</span></div><div id="i30c50c718dda42d28fbdd6dcd4fa2365_16"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements.</span></div><div id="i30c50c718dda42d28fbdd6dcd4fa2365_19"></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS </span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfNC0xLTEtMS0w_c473202f-01c0-44f6-bd94-c8f16d27e930">51,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfNC0zLTEtMS0w_ef5ead5f-667f-4826-a42c-2278447cfc67">33,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfNS0xLTEtMS0w_33e360f1-0ee8-411e-abe9-bddc30cdb0b4">8,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfNS0zLTEtMS0w_68e49fe8-8909-4d53-a210-69f76f90b029">48,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfNi0xLTEtMS0w_f54d07fc-0706-4bdc-a2bc-694313de286a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfNi0zLTEtMS0w_2a0e150c-c809-4ade-8154-aacc6f504d24">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfOC0xLTEtMS0w_505ed6bf-2c7e-4900-8f87-80ff6f173313">3,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfOC0zLTEtMS0w_b93c3cb3-6cc2-4425-b918-715477ff8c2c">4,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfOS0xLTEtMS0w_6d495a78-59ff-4c29-bebb-5b374aaf2798">64,147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfOS0zLTEtMS0w_9d328223-4ce3-4f11-ba55-80f2af93ba1d">86,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMTAtMS0xLTEtMA_06288101-94ab-4fae-8427-824ee9ef7911">4,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMTAtMy0xLTEtMA_bf3f3747-ca4e-41c3-ade0-96a1af2e656f">4,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMTEtMS0xLTEtMA_b332521b-58b4-4643-8466-89f82cf7c4c2">8,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMTEtMy0xLTEtMA_b5f6b81c-a610-492e-89ac-dc8a594f193c">8,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMTItMS0xLTEtMA_227b0497-6f68-43d5-872f-e2a0a1fd244d">1,465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMTItMy0xLTEtMA_ef1a4f53-24bd-48d0-a2cb-2251093e66f2">1,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 73pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMTMtMS0xLTEtMA_8e6bfb47-ca2b-49e8-9083-bd18b9d7d0b7">77,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMTMtMy0xLTEtMA_ffdbd6f6-3b35-4f1d-b9cb-9446b06c3b23">100,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMTctMS0xLTEtMA_87c430ff-8be9-4450-94bb-c658332e196e">2,485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMTctMy0xLTEtMA_32171fba-16be-4d41-b8a2-62b9e2137500">1,866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMTgtMS0xLTEtMA_278e7b4c-4bcb-4f7d-9791-0e3d077a186f">5,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMTgtMy0xLTEtMA_9b7ebf16-08dd-41b7-8834-3740adca3124">3,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMTktMS0xLTEtMA_c9b2cb2a-5d18-42cf-a2d3-cd28c35a6634">14,015</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMTktMy0xLTEtMA_5a47a0c9-d8ba-4bd1-a8a4-cdd43220616f">8,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMjAtMS0xLTEtMA_01f1033f-0ff0-47d3-be6a-bdfa7994e193">21,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMjAtMy0xLTEtMA_8708f8c8-a677-4ba9-881b-deaca33fcb89">13,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMjEtMS0xLTEtMA_669d13a8-f91d-4d56-8ea1-a3b8cd4bb112">16,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMjEtMy0xLTEtMA_ec74842d-dd21-4ae7-9f41-a9b1652e2f8f">16,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, noncurrent</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMjMtMS0xLTEtMA_bd5f3981-2a0a-43c6-affa-4e233e30d57d">16,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMjMtMy0xLTEtMA_452609a0-e915-4e29-8c77-969f1841c35b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability, noncurrent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMjQtMS0xLTEtMA_5f314675-8210-46dd-86b0-56e388adcf86">7,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMjQtMy0xLTEtMA_0aed3e66-ee80-4b53-b13e-97ae41021bbf">7,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMjUtMS0xLTEtMA_a4684aa1-0aee-44aa-afc4-fb31b4c05fbf">656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMjUtMy0xLTEtMA_d2ab32a5-7e92-497d-8c24-9811a66233b3">656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMjctMS0xLTEtMA_dddd4a9e-57cc-4143-be55-d3a65fe65f21">63,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMjctMy0xLTEtMA_90c10f08-d666-437f-aff4-f692aff294b7">38,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjkxZTE0YTFkMzEwOTRhOTU5YjJlNzgyM2Y0N2JjZjVlXzIx_41c967ae-c3ed-4c2a-a7d1-683156fea705"><ix:nonFraction unitRef="usdPerShare" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjkxZTE0YTFkMzEwOTRhOTU5YjJlNzgyM2Y0N2JjZjVlXzIx_516665e8-23a0-4f5f-a7e5-eeb3e9242b5a">0.0001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjkxZTE0YTFkMzEwOTRhOTU5YjJlNzgyM2Y0N2JjZjVlXzQ1_56cfb601-18c5-452d-90c9-013faed00344"><ix:nonFraction unitRef="shares" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjkxZTE0YTFkMzEwOTRhOTU5YjJlNzgyM2Y0N2JjZjVlXzQ1_ec13fe0c-97c8-4241-8724-b7c9436ecdfb">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjkxZTE0YTFkMzEwOTRhOTU5YjJlNzgyM2Y0N2JjZjVlXzY3_0d29349d-87d9-4d38-bdfa-b42fe4bfacad"><ix:nonFraction unitRef="shares" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjkxZTE0YTFkMzEwOTRhOTU5YjJlNzgyM2Y0N2JjZjVlXzY3_7a7e57ad-9538-4603-9c09-8143eed4ce88"><ix:nonFraction unitRef="shares" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjkxZTE0YTFkMzEwOTRhOTU5YjJlNzgyM2Y0N2JjZjVlXzY3_9d5a51be-1b8a-4582-8943-71dd2986f785"><ix:nonFraction unitRef="shares" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjkxZTE0YTFkMzEwOTRhOTU5YjJlNzgyM2Y0N2JjZjVlXzY3_bab0e058-655f-4fbe-bba3-e7f804520daf">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding, September&#160;30, 2021 and December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzAtMS0xLTEtMA_f3bd872b-a801-448a-a315-a4e9c82794a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzAtMy0xLTEtMA_d8463d02-8c62-47a8-9e11-0e1f54b2ff83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjEwYmRjOTQwMzM1NzQyODBiZmFiMzYyN2Q0Zjk3OWRkXzE5_67e18e89-9a42-422e-a147-c07cac871486"><ix:nonFraction unitRef="usdPerShare" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjEwYmRjOTQwMzM1NzQyODBiZmFiMzYyN2Q0Zjk3OWRkXzE5_ba995eb9-690b-4c02-8cba-483aeb9dd470">0.0001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjEwYmRjOTQwMzM1NzQyODBiZmFiMzYyN2Q0Zjk3OWRkXzQz_96e23a82-ecd4-4254-8c0e-31184f4de851"><ix:nonFraction unitRef="shares" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjEwYmRjOTQwMzM1NzQyODBiZmFiMzYyN2Q0Zjk3OWRkXzQz_bbf9e719-b434-46a1-a880-45b6bdfa7fd3">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjEwYmRjOTQwMzM1NzQyODBiZmFiMzYyN2Q0Zjk3OWRkXzY1_9a52432a-4ae1-4b89-adc2-d69ad8f11631"><ix:nonFraction unitRef="shares" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjEwYmRjOTQwMzM1NzQyODBiZmFiMzYyN2Q0Zjk3OWRkXzY1_ce5c4972-d716-479b-a3e0-4bc6e5a54622">88,108,543</ix:nonFraction></ix:nonFraction> issued and outstanding, September&#160;30, 2021; <ix:nonFraction unitRef="shares" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjEwYmRjOTQwMzM1NzQyODBiZmFiMzYyN2Q0Zjk3OWRkXzk2_2650a44d-ddd4-4fb1-b1d1-2dd243401f55"><ix:nonFraction unitRef="shares" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjEwYmRjOTQwMzM1NzQyODBiZmFiMzYyN2Q0Zjk3OWRkXzk2_53e61338-21bb-48c8-9ed4-1950ceae7af3">87,651,352</ix:nonFraction></ix:nonFraction> issued and outstanding, December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzEtMS0xLTEtMA_dc207781-e2b5-4c9c-b36c-baaa82cd2d5a">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzEtMy0xLTEtMA_4b698081-b2d1-47df-bff8-95d190ca484c">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzItMS0xLTEtMA_028c1e53-eb46-4b0c-a693-0d59db4bf4ad">170,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzItMy0xLTEtMA_e0fbd84b-a331-426a-a4d7-e1771f64b37d">167,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzMtMS0xLTEtMA_9a71d086-94c0-41ae-8673-2a3f51a34b69">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzMtMy0xLTEtMA_f665e1cd-cf85-49f1-88df-dd04e0708e95">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzQtMS0xLTEtMA_06ae3b34-5aef-4191-8c9c-45d19035d870">156,242</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzQtMy0xLTEtMA_22c620c9-e35d-49c9-9a86-876301d8488d">105,965</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzUtMS0xLTEtMA_dc67d9a3-3afa-45fc-b906-11f9b1ed5cf8">13,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzUtMy0xLTEtMA_ddd686a3-bc8e-4ccb-bfca-1521435a1ac1">61,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzYtMS0xLTEtMA_593d0963-5f61-4a77-b66d-32d5ae4899d8">77,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzYtMy0xLTEtMA_935f8ccd-5003-4d7f-95a2-614b329c2099">100,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the unaudited condensed consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i30c50c718dda42d28fbdd6dcd4fa2365_22"></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.873%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.491%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.518%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.491%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.826%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.491%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.831%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Collaboration revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="xcur:RevenueFromContractWithCustomerNetOfCumulativeCatchUpAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMy0xLTEtMS0w_249d54e0-92d8-44d1-b544-2ae77ef046f1">3,677</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="xcur:RevenueFromContractWithCustomerNetOfCumulativeCatchUpAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMy0zLTEtMS0w_b3a7faaa-6336-40c1-8814-bfdab5f2b272">2,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="xcur:RevenueFromContractWithCustomerNetOfCumulativeCatchUpAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMy01LTEtMS0w_2290b48d-a8fd-4ea8-8867-4b6e81a94299">2,601</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="xcur:RevenueFromContractWithCustomerNetOfCumulativeCatchUpAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMy03LTEtMS0w_f48c6a98-5ce1-41cd-a408-972d80f8834d">16,473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfNC0xLTEtMS0w_2382fdca-2fd6-48d1-975e-40c3a8fe356a">3,677</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfNC0zLTEtMS0w_b4f53199-cfe1-4951-87e7-e81af2c1907f">2,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfNC01LTEtMS0w_e7fad401-ddd3-4b32-a033-b18e26591c1b">2,601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfNC03LTEtMS0w_c3bb0339-3e60-4577-a320-9cbab109c22b">16,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Research and development expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfNi0xLTEtMS0w_ec5b7421-0f66-4188-b38f-1d42bfa8565b">16,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfNi0zLTEtMS0w_17330122-71cb-4727-a90d-1e5e73f410ad">9,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfNi01LTEtMS0w_d43b9c21-87fe-42f6-aa3d-3ddf998013fa">37,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfNi03LTEtMS0w_a52b8461-8492-454b-8214-b8b8a02c78db">22,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;General and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfNy0xLTEtMS0w_648a153a-b32e-4e25-bf5b-b0f804346b8d">2,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfNy0zLTEtMS0w_552e89f5-0c2f-4175-9a98-ce731c771bce">2,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfNy01LTEtMS0w_6522fdb5-41bd-483a-a492-6b6d9a92bf6c">8,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfNy03LTEtMS0w_1237860d-f9a2-415c-b561-063eda495507">7,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfOC0xLTEtMS0w_c1a9a44e-8d79-4a24-bddb-d98ba37e2433">19,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfOC0zLTEtMS0w_a38e041e-fa58-4e4a-b9ce-5e3cd559bf46">11,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfOC01LTEtMS0w_4254547d-97ed-49db-aec1-c2ec74daea68">46,499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfOC03LTEtMS0w_22ff2b9f-196f-40aa-9779-0a162eef7c97">29,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfOS0xLTEtMS0w_95c0a346-9302-46e8-a0b1-f718505e4927">23,081</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfOS0zLTEtMS0w_ac9447eb-eee6-44c4-9901-c1953f9f8515">9,120</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfOS01LTEtMS0w_414de35a-d686-4285-bdba-dbf1b65d07b7">49,100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfOS03LTEtMS0w_f4069a75-9705-4da0-8156-523b38b59096">12,976</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Dividend income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930" decimals="-3" name="us-gaap:InvestmentIncomeDividend" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTEtMS0xLTEtMA_da43a2c7-01bf-4c57-b5b8-9e351db6ce32">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="-3" name="us-gaap:InvestmentIncomeDividend" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTEtMy0xLTEtMA_23c108d9-8218-4ecc-ae23-5e616bcd77ad">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" name="us-gaap:InvestmentIncomeDividend" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTEtNS0xLTEtMA_c4da4e9b-8079-441f-8695-276c5154859f">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" name="us-gaap:InvestmentIncomeDividend" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTEtNy0xLTEtMA_d88e87ab-2ce8-4f24-8ed0-18ee8e523597">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTItMS0xLTEtMA_ad366147-93c6-428c-a995-61e5e09cd3f6">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTItMy0xLTEtMA_e9b41c78-a7a3-4a8a-be2f-89beeaa905a6">205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTItNS0xLTEtMA_06fa4fe4-a8b4-499d-98e5-c2084412398e">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTItNy0xLTEtMA_1b0da67c-7601-40f2-96f0-3551b257d828">832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTMtMS0xLTEtMA_3704e49d-98fb-4c7a-b0a4-5968f7bc88bb">455</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTMtMy0xLTEtMA_a3ede132-aa87-447d-bf4a-b023efb8baae">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTMtNS0xLTEtMA_7b5a58bd-32bf-4f5f-a31d-de7a10e67f47">1,314</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTMtNy0xLTEtMA_97a64e2a-53d1-44c7-a250-99c0b7a0049c">155</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other (expense) income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTQtMS0xLTEtMA_74d04947-dae6-4185-ad9b-cb05b8fa7645">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTQtMy0xLTEtMA_58c1d99a-9bee-4cc5-a173-98a79e38d992">118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTQtNS0xLTEtMA_a437fb42-bcf0-4d64-966b-bb8d6d180abd">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTQtNy0xLTEtMA_eaf84def-6d0c-41e8-b78f-982f09af5529">271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total other (expense) income, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTUtMS0xLTEtMA_5a89ec35-4a40-4d4b-8017-aea94e572f9a">450</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTUtMy0xLTEtMA_ae485cae-797c-4584-87c9-1869a09bbc5a">298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTUtNS0xLTEtMA_a9b98f11-4bd2-4c5f-8d89-1648b7740e52">1,177</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTUtNy0xLTEtMA_08eeec07-73f1-42f6-96e1-e5e66fe19558">993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTYtMS0xLTEtMA_ec30eacc-dea9-4517-9cb4-a3ad427b5c78">23,531</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTYtMy0xLTEtMA_c77a60e8-315b-425f-9a26-5535c4773177">8,822</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTYtNS0xLTEtMA_b336d545-9d78-4222-bb80-d91f8aff8e35">50,277</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTYtNy0xLTEtMA_cf247959-7699-45ba-89c7-b66a82233314">11,983</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTctMS0xLTEtMA_c2fb6856-0835-4288-be30-b9830bd2ee93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTctMy0xLTEtMA_72deaf70-7398-4fcc-8fff-4deb10e26942">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTctNS0xLTEtMA_2ea88444-c1f9-4581-a19e-2ecaaff8ac8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTctNy0xLTEtMA_3ed3c6d8-612f-40e5-b61b-6336a1761e43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTgtMS0xLTEtMA_94a29fdd-367b-4ea9-a730-bc9f21efb427">23,531</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTgtMy0xLTEtMA_37af539d-ed77-4a03-8288-fe40d50e4262">8,822</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTgtNS0xLTEtMA_474119c7-0fe9-456e-b2a9-2df09cea4e08">50,277</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTgtNy0xLTEtMA_f8b22b3b-deab-466d-a1fe-5d331c8966e0">11,983</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per common share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMjAtMS0xLTEtMA_5c818a51-eb86-4593-b214-a61baa199eb3"><ix:nonFraction unitRef="usdPerShare" contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMjAtMS0xLTEtMA_91b6fe31-b04e-486c-bbff-79c8a83a8179">0.27</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMjAtMy0xLTEtMA_239a3a28-39ee-42e8-bb43-23385b60e1e7"><ix:nonFraction unitRef="usdPerShare" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMjAtMy0xLTEtMA_a8e25838-1079-476d-8596-bf4dc308c33c">0.10</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMjAtNS0xLTEtMA_e3fb8312-8b42-4c2c-8911-acabed80a520"><ix:nonFraction unitRef="usdPerShare" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMjAtNS0xLTEtMA_e5b1bdfd-fd4a-4684-85a5-cdd7e3ef1478">0.57</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMjAtNy0xLTEtMA_6d61adac-7543-44d5-a864-31eae859827c"><ix:nonFraction unitRef="usdPerShare" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMjAtNy0xLTEtMA_8bcb45f0-2ff0-4491-90b0-440aa1d98e6d">0.14</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic and diluted common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMjMtMS0xLTEtMA_6a32eb69-b3c4-4883-a9f8-24ec73d714b0"><ix:nonFraction unitRef="shares" contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMjMtMS0xLTEtMA_b5bb72be-5235-4905-baaf-f1cd4e6dd852">88,105,066</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMjMtMy0xLTEtMA_6e96028f-c740-4f7e-ab2d-52cb737a5ea2"><ix:nonFraction unitRef="shares" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMjMtMy0xLTEtMA_b2d241c0-355b-4bc1-ab64-e2b01f0b5db7">87,227,136</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMjMtNS0xLTEtMA_d576c33f-a239-41d6-8a68-aa53b3c83431"><ix:nonFraction unitRef="shares" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMjMtNS0xLTEtMA_d86f9092-0ac2-4430-9651-343836b66c77">88,001,222</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMjMtNy0xLTEtMA_0119c157-1c20-41cd-a5c8-65f9a7909137"><ix:nonFraction unitRef="shares" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMjMtNy0xLTEtMA_12b8bb9f-804d-424d-a048-7cd3d17797b5">87,160,520</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the unaudited condensed consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i30c50c718dda42d28fbdd6dcd4fa2365_25"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.849%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.565%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yNS9mcmFnOjk3MWQxY2Y0NDlhMzRlYzJhYWYyMTY0NTk0ZGFmMDJmL3RhYmxlOjU0YWRlZWQwMDlmMzRjODlhYzAzMjBmZWMxNDcwM2U0L3RhYmxlcmFuZ2U6NTRhZGVlZDAwOWYzNGM4OWFjMDMyMGZlYzE0NzAzZTRfMi0xLTEtMS0w_b0ca7db5-9d0a-4a85-a48d-b33f7f460f70">23,531</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yNS9mcmFnOjk3MWQxY2Y0NDlhMzRlYzJhYWYyMTY0NTk0ZGFmMDJmL3RhYmxlOjU0YWRlZWQwMDlmMzRjODlhYzAzMjBmZWMxNDcwM2U0L3RhYmxlcmFuZ2U6NTRhZGVlZDAwOWYzNGM4OWFjMDMyMGZlYzE0NzAzZTRfMi0zLTEtMS0w_9a1a8380-ed4f-4631-814c-babfc2d8a322">8,822</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yNS9mcmFnOjk3MWQxY2Y0NDlhMzRlYzJhYWYyMTY0NTk0ZGFmMDJmL3RhYmxlOjU0YWRlZWQwMDlmMzRjODlhYzAzMjBmZWMxNDcwM2U0L3RhYmxlcmFuZ2U6NTRhZGVlZDAwOWYzNGM4OWFjMDMyMGZlYzE0NzAzZTRfMi01LTEtMS0w_700df0c4-edfe-43fc-a7b0-876281da6e8d">50,277</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yNS9mcmFnOjk3MWQxY2Y0NDlhMzRlYzJhYWYyMTY0NTk0ZGFmMDJmL3RhYmxlOjU0YWRlZWQwMDlmMzRjODlhYzAzMjBmZWMxNDcwM2U0L3RhYmxlcmFuZ2U6NTRhZGVlZDAwOWYzNGM4OWFjMDMyMGZlYzE0NzAzZTRfMi03LTEtMS0w_95aa02fc-1db0-48ae-9d3a-c8954ad86c41">11,983</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Unrealized (losses) gains on available for sale securities, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yNS9mcmFnOjk3MWQxY2Y0NDlhMzRlYzJhYWYyMTY0NTk0ZGFmMDJmL3RhYmxlOjU0YWRlZWQwMDlmMzRjODlhYzAzMjBmZWMxNDcwM2U0L3RhYmxlcmFuZ2U6NTRhZGVlZDAwOWYzNGM4OWFjMDMyMGZlYzE0NzAzZTRfNC0xLTEtMS0w_e72866d5-505e-467d-97ec-1147132eb1a2">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yNS9mcmFnOjk3MWQxY2Y0NDlhMzRlYzJhYWYyMTY0NTk0ZGFmMDJmL3RhYmxlOjU0YWRlZWQwMDlmMzRjODlhYzAzMjBmZWMxNDcwM2U0L3RhYmxlcmFuZ2U6NTRhZGVlZDAwOWYzNGM4OWFjMDMyMGZlYzE0NzAzZTRfNC0zLTEtMS0w_41f3f9fe-0767-440c-aacd-48b792b88ae5">138</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yNS9mcmFnOjk3MWQxY2Y0NDlhMzRlYzJhYWYyMTY0NTk0ZGFmMDJmL3RhYmxlOjU0YWRlZWQwMDlmMzRjODlhYzAzMjBmZWMxNDcwM2U0L3RhYmxlcmFuZ2U6NTRhZGVlZDAwOWYzNGM4OWFjMDMyMGZlYzE0NzAzZTRfNC01LTEtMS0w_85f70d23-5585-46d6-91bd-c4706faddc29">84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yNS9mcmFnOjk3MWQxY2Y0NDlhMzRlYzJhYWYyMTY0NTk0ZGFmMDJmL3RhYmxlOjU0YWRlZWQwMDlmMzRjODlhYzAzMjBmZWMxNDcwM2U0L3RhYmxlcmFuZ2U6NTRhZGVlZDAwOWYzNGM4OWFjMDMyMGZlYzE0NzAzZTRfNC03LTEtMS0w_d22b2542-272d-468c-b265-91bbaf961bd6">227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yNS9mcmFnOjk3MWQxY2Y0NDlhMzRlYzJhYWYyMTY0NTk0ZGFmMDJmL3RhYmxlOjU0YWRlZWQwMDlmMzRjODlhYzAzMjBmZWMxNDcwM2U0L3RhYmxlcmFuZ2U6NTRhZGVlZDAwOWYzNGM4OWFjMDMyMGZlYzE0NzAzZTRfNS0xLTEtMS0w_e520c06a-8c7e-40ce-8487-bd7a4ffc9793">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yNS9mcmFnOjk3MWQxY2Y0NDlhMzRlYzJhYWYyMTY0NTk0ZGFmMDJmL3RhYmxlOjU0YWRlZWQwMDlmMzRjODlhYzAzMjBmZWMxNDcwM2U0L3RhYmxlcmFuZ2U6NTRhZGVlZDAwOWYzNGM4OWFjMDMyMGZlYzE0NzAzZTRfNS0zLTEtMS0w_7304b25b-8cdd-4a93-afe2-33f438bd080d">138</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yNS9mcmFnOjk3MWQxY2Y0NDlhMzRlYzJhYWYyMTY0NTk0ZGFmMDJmL3RhYmxlOjU0YWRlZWQwMDlmMzRjODlhYzAzMjBmZWMxNDcwM2U0L3RhYmxlcmFuZ2U6NTRhZGVlZDAwOWYzNGM4OWFjMDMyMGZlYzE0NzAzZTRfNS01LTEtMS0w_df281670-f09e-4190-9b8f-b2c0ed898828">84</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yNS9mcmFnOjk3MWQxY2Y0NDlhMzRlYzJhYWYyMTY0NTk0ZGFmMDJmL3RhYmxlOjU0YWRlZWQwMDlmMzRjODlhYzAzMjBmZWMxNDcwM2U0L3RhYmxlcmFuZ2U6NTRhZGVlZDAwOWYzNGM4OWFjMDMyMGZlYzE0NzAzZTRfNS03LTEtMS0w_b9037294-b57d-4c83-82df-451a283c2170">227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yNS9mcmFnOjk3MWQxY2Y0NDlhMzRlYzJhYWYyMTY0NTk0ZGFmMDJmL3RhYmxlOjU0YWRlZWQwMDlmMzRjODlhYzAzMjBmZWMxNDcwM2U0L3RhYmxlcmFuZ2U6NTRhZGVlZDAwOWYzNGM4OWFjMDMyMGZlYzE0NzAzZTRfNi0xLTEtMS0w_07720176-df55-42e9-a4e7-a8a5686033a1">23,537</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yNS9mcmFnOjk3MWQxY2Y0NDlhMzRlYzJhYWYyMTY0NTk0ZGFmMDJmL3RhYmxlOjU0YWRlZWQwMDlmMzRjODlhYzAzMjBmZWMxNDcwM2U0L3RhYmxlcmFuZ2U6NTRhZGVlZDAwOWYzNGM4OWFjMDMyMGZlYzE0NzAzZTRfNi0zLTEtMS0w_ccb5853a-4a77-4cb3-9b84-b08501e3b48a">8,960</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yNS9mcmFnOjk3MWQxY2Y0NDlhMzRlYzJhYWYyMTY0NTk0ZGFmMDJmL3RhYmxlOjU0YWRlZWQwMDlmMzRjODlhYzAzMjBmZWMxNDcwM2U0L3RhYmxlcmFuZ2U6NTRhZGVlZDAwOWYzNGM4OWFjMDMyMGZlYzE0NzAzZTRfNi01LTEtMS0w_6c0f4fe9-864d-477b-b14c-5883c0056581">50,361</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yNS9mcmFnOjk3MWQxY2Y0NDlhMzRlYzJhYWYyMTY0NTk0ZGFmMDJmL3RhYmxlOjU0YWRlZWQwMDlmMzRjODlhYzAzMjBmZWMxNDcwM2U0L3RhYmxlcmFuZ2U6NTRhZGVlZDAwOWYzNGM4OWFjMDMyMGZlYzE0NzAzZTRfNi03LTEtMS0w_dc48a6e3-d4ee-456e-afcb-5e09734bd9e8">11,756</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;See accompanying notes to the unaudited condensed consolidated financial statements.</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:49.5pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i30c50c718dda42d28fbdd6dcd4fa2365_28"></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except shares)</span></div></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.064%"><tr><td style="width:1.0%"></td><td style="width:35.887%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.936%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.080%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.984%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.791%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.643%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional Paid-in- Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Stockholders' Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1a551c230f14800abc2fa41ca7ad2a3_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMi0xLTEtMS0w_60bdbeaf-7563-4f3a-a280-e47f820b1a2b">87,651,352</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1a551c230f14800abc2fa41ca7ad2a3_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMi0zLTEtMS0w_f632e6cd-4546-4b45-8cbc-9da760050008">9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i889966d2ad0d48b1a39ab264208b8278_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMi01LTEtMS0w_dec40d7f-3b15-4fa4-a127-4527fb37ddb2">167,379</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77adf0b70cbf4775bddca74d6b334c92_I20201231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMi03LTEtMS0w_a6625123-8ee4-42d1-ae49-fc7e17d913da">105,965</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i501a27e325104650a73ad03cfcd4faa7_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMi05LTEtMS0w_60a12930-25a9-42fd-9fef-8fa9969dc0fa">83</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMi0xMS0xLTEtMA_b26ded8f-9fc0-4289-b984-06d2b3c16d42">61,506</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iae971ef694a140e68a703e4451c6c2e3_D20210101-20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMy0xLTEtMS0w_131ae5fe-538d-45ed-b06b-36763e73ef3e">342,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i846826e778c54bd7b5bc352eb593aee3_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMy01LTEtMS0w_d6202b14-7c00-40bc-aa26-2ff85cfde273">546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dea9cf71d074399a074543cd69ce8c7_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMy0xMS0xLTEtMA_31a0a164-4d77-41b9-b7d0-39d02ee8811d">546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i846826e778c54bd7b5bc352eb593aee3_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfNC01LTEtMS0w_2e8df2bd-95de-4822-a379-155f691e9d2d">517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dea9cf71d074399a074543cd69ce8c7_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfNC0xMS0xLTEtMA_c3a5b543-90a9-4bea-8cce-f912a6b3934e">517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6201937a06d74f6d89fca534176e3345_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfNi05LTEtMS0w_1f034a06-1f06-4c4f-b42d-0635009a826c">51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dea9cf71d074399a074543cd69ce8c7_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfNi0xMS0xLTEtMA_e750e5c6-875e-42ef-92db-cede798271b8">51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i71bb35af2d12464b9a9e8594554ebb5f_D20210101-20210331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfNy03LTEtMS0w_07142dd6-7758-433f-a37c-c5dc1d737c9e">12,477</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dea9cf71d074399a074543cd69ce8c7_D20210101-20210331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfNy0xMS0xLTEtMA_5f78e920-3f64-4f82-af59-37d9976fd70e">12,477</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4f6c6875545040a48cde06a5f5b74823_I20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfOC0xLTEtMS0w_b03eef8d-f837-466b-8402-a4a3f67bfdd3">87,993,598</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f6c6875545040a48cde06a5f5b74823_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfOC0zLTEtMS0w_8ea02c53-0c99-4dee-94b5-1bb72207efa7">9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d560c291f0e4806b54ba5e47f9e4337_I20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfOC01LTEtMS0w_f1ca3ad3-2066-499c-96cb-c17e9747e738">168,442</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib50af716c597410c87b2e6c906cd80f9_I20210331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfOC03LTEtMS0w_7387af5b-2ffb-4b08-ab5d-e36123ba1512">118,442</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a52bc4a3c0d4c7cbfa5ea8a045321fa_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfOC05LTEtMS0w_127bb66d-0af5-4a79-a1e6-362f9a5ca129">32</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie38be6e4d7ba4275b47ca89d4c64b7f9_I20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfOC0xMS0xLTEtMA_1b1b840f-dca2-4bed-ae44-49b8b25d869d">50,041</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d4ca9f881df45978d9417d0ab7dc94e_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfOS01LTEtMS0w_183aa400-1359-43bc-a4af-5723b48a3c4f">764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac6b52ac45d04a2588c506176895e21f_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfOS0xMS0xLTEtMA_82798ddf-b76b-4f2d-a1f6-b67203eabce3">764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock-ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icc50c37ab44c4df39214039f0d7b1151_D20210401-20210630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTAtMS0xLTEtMA_8b9ba55c-0deb-441f-82bf-57c9c4230a5c">103,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d4ca9f881df45978d9417d0ab7dc94e_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTAtNS0xLTEtMA_d14b81aa-00a2-46cd-a833-9c26ae7ec6e7">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac6b52ac45d04a2588c506176895e21f_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTAtMTEtMS0xLTA_6e672720-2141-4cd0-9b05-292c2b924715">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ec0151a0c3948b38923be5743f1344a_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTEtOS0xLTEtMA_45268a20-3712-492d-9e8b-141c20e7a21c">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac6b52ac45d04a2588c506176895e21f_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTEtMTEtMS0xLTA_a0be2eb2-8732-4488-b8ff-08fdec71e932">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62ce8e911e4846bd9009ddd7272195ab_D20210401-20210630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTItNy0xLTEtMA_d248dd72-128a-49ec-9fb9-e7e3f535781d">14,269</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac6b52ac45d04a2588c506176895e21f_D20210401-20210630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTItMTEtMS0xLTA_f77ba16b-4cb3-4079-bfbb-f38b5a688c39">14,269</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i96f79fc5e863496fa7949c405ecc957f_I20210630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTMtMS0xLTEtMA_4c006952-b334-4bd8-8403-039a68c32593">88,096,694</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96f79fc5e863496fa7949c405ecc957f_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTMtMy0xLTEtMA_713fbaad-74d8-494c-bb14-1e5347c72595">9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id04667370fcb4287af7d78737a293eb4_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTMtNS0xLTEtMA_c9c52237-cf79-471b-9166-53d885e3da5d">169,337</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id42a638fb6864f9d9e37c2babc3b3899_I20210630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTMtNy0xLTEtMA_cd36eee1-3bc2-4467-a47c-a8cc59193b0b">132,711</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i992a828696e04df48d18d2f8bc76598e_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTMtOS0xLTEtMA_74f29b31-d221-4d0f-8ca9-55e99b083008">5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd96764703204097bea35e7a9db99a49_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTMtMTEtMS0xLTA_6cdb3d21-d96f-46d9-9210-fb535d56f87e">36,640</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dcdb6a39c9748148c55ed098113f458_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTQtNS0xLTEtMTA0NzQ_5013fdab-94aa-4265-9ad5-e75ac9e759bf">889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTQtMTEtMS0xLTEwNDc0_8c76c530-0373-4d96-ab7a-61d2519845ed">889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of restricted stock units and related repurchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i17d0ab6befad44789b59d2b647f01e28_D20210701-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTUtMS0xLTEtMTA0NzQ_6a71c532-3356-46bd-b5cc-851a8001bacb">11,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9dcdb6a39c9748148c55ed098113f458_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTUtNS0xLTEtMTA0NzQ_085ec888-a0c8-49bb-a1ab-900e65b38eeb">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTUtMTEtMS0xLTEwNDc0_e4fbdb8e-80be-46f0-999f-dffd31a9fa1e">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8045808dcb149df893c7a2d3e216476_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTYtOS0xLTEtMTA0NzQ_91350c24-2452-483d-8dd3-f4ba8a8a289f">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTYtMTEtMS0xLTEwNDc0_92bba50a-1f3c-4d10-a333-97183d1998b3">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b100964d44d428faaab570e10ff8900_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTctNy0xLTEtMTA0NzQ_957849b9-fc07-4ae5-ba92-b5ea6c16f889">23,531</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTctMTEtMS0xLTEwNDc0_f90f4659-a874-469d-bebc-dadb0f531575">23,531</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i978591bf15364b7ea2e8132edee5fb1c_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTgtMS0xLTEtMTA0NzQ_3e8cbc29-0cfa-41b5-a9af-c8bfa5d995bd">88,108,543</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i978591bf15364b7ea2e8132edee5fb1c_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTgtMy0xLTEtMTA0NzQ_19c4e388-46bd-4e06-aff1-f738d2590939">9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b8227feae1749778133a28312e507ba_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTgtNS0xLTEtMTA0NzQ_79a31b4a-fbd0-4063-b861-241ce6435740">170,217</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i290713ee60b04dd08da1a92f4da5adfd_I20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTgtNy0xLTEtMTA0NzQ_8e7eec6f-76ff-427b-a575-7d501248e4d9">156,242</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf9e5d3ecf814b9ab2f88960463e4dd8_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTgtOS0xLTEtMTA0NzQ_65f84a4c-eb98-420f-bb9f-bd627cd04d99">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTgtMTEtMS0xLTEwNDc0_b4fc36be-e647-4d3c-a337-2348fa8d230a">13,983</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except shares)</span></div></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.949%"><tr><td style="width:1.0%"></td><td style="width:35.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.188%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.086%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.997%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.153%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.364%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional Paid-in- Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Stockholders&#8217; Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibbd40097533240cc82bcab253f741f47_I20191231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMi0xLTEtMS0w_822df976-0356-45cb-a8c6-195ac3a87495">86,069,263</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbd40097533240cc82bcab253f741f47_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMi0zLTEtMS0w_cd0d709c-6c94-4b1e-b183-7b58a56b4628">9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i719acf51485c46e1b4361db7fe272812_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMi01LTEtMS0w_4f2dad57-3526-467c-b88a-13ec23fc9ca6">162,062</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d9766a167f349bb92052a2b44a794db_I20191231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMi03LTEtMS0w_2a6e9a32-e2ed-41f1-bf9a-84bbf66732b5">81,297</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifca2e3b16c794fc4a70ed80eb0c74b8d_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMi05LTEtMS0w_cd6b1cbe-2b9b-4454-8fed-3bb67d7136ab">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c58992375514840acc525804de3b5bf_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMi0xMS0xLTEtMA_ba5d511a-99ac-484c-acb9-22f2389f7741">80,747</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia27678044cb14d4281421247fb96281d_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfNC01LTEtMS0w_a7cde918-596b-4eac-844f-36a31a4fa615">441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab3dbd6a7f674d7083db2fa3c9db78a2_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfNC0xMS0xLTEtMA_b4ac2b01-d626-4eff-bb6a-d89c405851a9">441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i507ff9b7892843ad987a51c1c29c0a35_D20200101-20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfNS0xLTEtMS0w_70234307-2026-42f5-b3b1-8c036d2b1c63">1,081,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia27678044cb14d4281421247fb96281d_D20200101-20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfNS01LTEtMS0w_be381322-2e36-4f53-9b76-b7f177b94055">2,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab3dbd6a7f674d7083db2fa3c9db78a2_D20200101-20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfNS0xMS0xLTEtMA_c1e00c5d-8bb7-446f-bd1f-9b22db34cd91">2,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3e5273956124a8099431ab285dc59c1_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfNi05LTEtMS0w_185b3535-1b58-4c45-9e0e-fca7ec24d247">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab3dbd6a7f674d7083db2fa3c9db78a2_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfNi0xMS0xLTEtMA_7961d706-4e0a-4c46-89aa-1687669cf343">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6257175c451430abb2778376da96411_D20200101-20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfNy03LTEtMS0w_64bb9891-47b1-41e7-a636-52324fdcabe8">1,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab3dbd6a7f674d7083db2fa3c9db78a2_D20200101-20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfNy0xMS0xLTEtMA_97893093-b8d6-4630-adad-c9b5022659e2">1,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6575d7f8daec4ae4abac4b2ef1bb98b4_I20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfOC0xLTEtMS0w_4cf77f72-bbb3-4e3c-8510-51762a62a66d">87,150,447</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6575d7f8daec4ae4abac4b2ef1bb98b4_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfOC0zLTEtMS0w_f87d0734-be1b-4fe7-993c-e0fc0782040e">9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i602a59ce297c424b93795664859a8674_I20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfOC01LTEtMS0w_cdab5768-526e-45cb-a226-e9a031ba6d6f">165,269</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8b0e758c6064f6291d39bb97bb331c8_I20200331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfOC03LTEtMS0w_5fd806ba-77a5-405d-8855-79b2fc00a481">80,147</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a09fd187a41481abc00b2e5f81774d2_I20200331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfOC05LTEtMS0w_eabb8d19-5706-47bd-8650-7b4aeddee4b4">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71026660fee448b3b596180fe34cbeca_I20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfOC0xMS0xLTEtMA_808211fa-297b-4122-8fc5-237303352861">85,114</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff8d18ca423a4767b541788b25f1e8bf_D20200401-20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfOS0xLTEtMS0w_bdeadb23-dd2d-4e83-9bae-004f1af364f7">55,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0372b5960b948f488c30f66137194f2_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfOS01LTEtMS0w_d3eb4460-73cb-4999-9813-64ddc52969b9">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b2c76fc1f31458f93f96af1cff6f08f_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfOS0xMS0xLTEtMA_a8d72d93-7da2-498f-ad89-49816d2f5f9c">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0372b5960b948f488c30f66137194f2_D20200401-20200630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTAtNS0xLTEtMA_8787f108-9827-44be-aced-2a70480c65aa">544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b2c76fc1f31458f93f96af1cff6f08f_D20200401-20200630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTAtMTEtMS0xLTA_c4626a82-20d3-4925-bafd-380e0ec1ba1b">544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47fe6eddfdbe4eed90628172bad98597_D20200401-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTEtOS0xLTEtMA_5ea561c6-ee87-48c3-a12a-d28ac0c72db3">355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b2c76fc1f31458f93f96af1cff6f08f_D20200401-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTEtMTEtMS0xLTA_53aa6f81-8a21-47e4-a328-5624e65f5939">355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cb024c41379417ebfea69a16d594eb0_D20200401-20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTItNy0xLTEtMA_b52a18c6-0f09-4629-93c7-15aa1ce81195">4,311</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b2c76fc1f31458f93f96af1cff6f08f_D20200401-20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTItMTEtMS0xLTA_c241a4db-43d7-4d80-bbed-1a865ccd91f2">4,311</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2055279aba744bfa86fba3a79756df14_I20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTMtMS0xLTEtMA_a244dbba-2e76-4c13-b403-b821ac383aa2">87,206,346</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2055279aba744bfa86fba3a79756df14_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTMtMy0xLTEtMA_d2b4d335-63e7-4e96-8fd6-fce41eec967f">9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e64861bfb143a6a581ccee7a5ad430_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTMtNS0xLTEtMA_235c27c3-d8d0-4f09-aa23-92108521dbc0">165,863</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6db610d7a4604665833e6884c7e4d50c_I20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTMtNy0xLTEtMA_e94094b8-8ec3-42e4-bff7-b2ed0b08f29b">84,458</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9ef743ad4504fe6a4762417ee298525_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTMtOS0xLTEtMA_f9657b8a-1cbe-4901-9c26-face9e5d34b5">338</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f68996929254ee4bbba614e977012de_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTMtMTEtMS0xLTA_1ecfc9d4-9fdf-4f09-9c61-fa8fa43ab945">81,752</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of options</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTQtMS0xLTEtMTA1MDU_1c128f88-9334-45b5-86c5-54f72c228c0c">22,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTQtNS0xLTEtMTA1MDU_a98dc989-6746-4ccf-9ec0-473e2b1c0b49">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTQtMTEtMS0xLTEwNTA1_7b089b93-01ec-4d23-ba49-d6ba48d00a96">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d81767196a447c99e736999c49bbd94_D20200701-20200930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTUtNS0xLTEtMTA1MDU_149c6ca4-ea8a-41ba-9835-f05606c13ba8">617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTUtMTEtMS0xLTEwNTA1_8fb12e14-4d50-45d8-b673-43a49f552c58">617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d81767196a447c99e736999c49bbd94_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTYtNS0xLTEtMTA1MDU_461c2944-06c6-49a1-94d5-78cb59dd7509">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if22d9a712dc144118a697b351d62e799_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTYtOS0xLTEtMTA1MDU_de55a011-8adb-42cd-8cfd-b6b638a43950">138</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTYtMTEtMS0xLTEwNTA1_6b727e6f-994f-4af1-9a70-79eb0a0ac352">138</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42d47dd822a748b791c92e60630a2428_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTctNy0xLTEtMTA1MDU_6d0bc9f9-72a4-416d-a4ff-df75636f9f27">8,822</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTctMTEtMS0xLTEwNTA1_91640eb5-1806-4029-b3ed-7c9b65d1fc75">8,822</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i66eacee5840b45e29eab0ce41b30f033_I20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTgtMS0xLTEtMTA1MDU_c7a54f9a-d1c7-421c-ace7-4711aca72d10">87,228,586</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66eacee5840b45e29eab0ce41b30f033_I20200930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTgtMy0xLTEtMTA1MDU_a43543ef-754f-4f1b-8473-984010ecae7d">9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e35705736534c78843742303282feb9_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTgtNS0xLTEtMTA1MDU_33de88c9-46a0-4e11-b7c6-931735bf54d0">166,499</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i447f37e612cc480fb09d01d85dfe8a92_I20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTgtNy0xLTEtMTA1MDU_cae8b3ad-3ded-4a52-8522-a311477c8a13">93,280</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe0cf5fbf4e1438fb46d794ecd6487cc_I20200930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTgtOS0xLTEtMTA1MDU_fd0061af-b14f-448b-b2ae-61edfe439f47">200</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if042bb6dd7e349bab540c21e2b62d94c_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTgtMTEtMS0xLTEwNTA1_b27a1970-1016-4f18-aa6e-973ee5b541f3">73,428</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the unaudited condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i30c50c718dda42d28fbdd6dcd4fa2365_31"></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMy0xLTEtMS0w_29efdca3-8ca1-437a-b76f-ef59a29c0a41">50,277</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMy0zLTEtMS0w_bad12a7d-cc7e-49e9-a24c-38106096130c">11,983</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" name="us-gaap:DepreciationAmortizationAndAccretionNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfNS0xLTEtMS0w_74b165e7-e88d-48cf-b695-964994a440db">829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" name="us-gaap:DepreciationAmortizationAndAccretionNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfNS0zLTEtMS0w_af752ece-ff4a-4158-a862-714ebb7777d8">494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfNy0xLTEtMS0w_1fe41068-84be-456b-8aae-f425b34aae2d">489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfNy0zLTEtMS0w_354abf72-b551-48a1-a08a-6a13ea2ac945">518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfOC0xLTEtMS0w_485826bb-d5ed-44f3-9679-78afb88695ab">2,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfOC0zLTEtMS0w_fbc1a144-207f-4295-8e54-5a24aabf576f">1,603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of long-term debt issuance costs and fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfOS0xLTEtMS0w_3d4ef5dd-eab1-4525-8fb3-fb176870d3aa">213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfOS0zLTEtMS0w_de47e157-6473-4ac5-84a3-da885e0b0742">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMTAtMS0xLTEtMA_0e552c42-527b-49f2-8027-231b37eedd80">183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMTAtMy0xLTEtMA_8ea50365-17ab-4ad3-b15d-def6ba545a8c">202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMTEtMS0xLTEtMA_8515e02c-842d-49ef-9daa-84dbdc240e25">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMTEtMy0xLTEtMA_4673c247-a411-4280-b3da-0a9be331dc99">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMTItMS0xLTEtMA_340bafa8-8b94-481a-9582-e1939ce9b088">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMTItMy0xLTEtMA_b00e7984-1314-4507-bfca-b639a01467c1">343</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMTQtMS0xLTEtMA_0e13bc15-9b27-4403-8019-756070499a72">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMTQtMy0xLTEtMA_9a9e0c6b-e3b8-43a7-ba37-98a4b1a1c80c">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMTUtMS0xLTEtMA_6d0900c0-e5bb-4bd9-ae56-aa07e03dae32">922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMTUtMy0xLTEtMA_9ba10e78-6e14-4e96-9b4a-3bfe6c71f358">1,473</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMTYtMS0xLTEtMA_e73dd416-79bb-4266-b08d-62b27284057f">72</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMTYtMy0xLTEtMA_44069ba3-bdf2-411d-9069-69d406f43177">181</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMTctMS0xLTEtMA_9c6776c8-0182-42d1-9f33-1c0e697b6bc3">629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMTctMy0xLTEtMA_c646ec1f-d64f-4851-8bd3-9c733ea60070">535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMTgtMS0xLTEtMA_beb0d84b-2b76-430d-bf3d-5c9b244cd419">1,697</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMTgtMy0xLTEtMA_61732338-ec32-4942-aad7-8cc494daaffc">461</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMTktMS0xLTEtMA_1b5b6424-0ce2-4c0e-9454-8a60cbf42a61">22,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMTktMy0xLTEtMA_89b43888-5dee-4df1-a21d-f10732d8d7c1">16,351</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMjAtMS0xLTEtMA_a8380185-03e7-4076-9f4a-22963c20f9db">408</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMjAtMy0xLTEtMA_b11201ee-dbfd-416f-9d2c-c190ed11c6bd">119</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMjEtMS0xLTEtMA_7ef3df82-3f37-4fa5-8fc6-b3cc5e1a1fc6">21,022</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMjEtMy0xLTEtMA_71a18c57-0679-45ae-9d63-6da8441f9b18">27,463</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of available for sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMjMtMS0xLTEtMA_0bfe98b4-e162-4fb6-973f-a3c44745d1c4">6,497</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMjMtMy0xLTEtMA_58ad5975-7657-4d79-84b6-9a9a884bbb4b">47,349</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale or maturity of available for sale securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMjQtMS0xLTEtMA_fa8068fd-58e4-4748-b123-7836490735cb">46,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMjQtMy0xLTEtMA_343dd0a3-5abf-4a8e-a21c-656102b4b55b">47,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMjUtMS0xLTEtMA_6e556446-724c-4b86-921e-0ac2de1330e8">623</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMjUtMy0xLTEtMA_b047a4d0-315c-4792-aa59-5dd8c150ac71">3,074</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMjYtMS0xLTEtMA_2b8208fb-e7bd-44b5-8028-39ac16e04d22">38,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMjYtMy0xLTEtMA_dc800c10-8375-4806-8b7d-aad77abaa677">3,330</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from common stock offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMjgtMS0xLTEtMA_4710042b-3a1e-442e-ac42-f7be8d52e4cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMjgtMy0xLTEtMA_eb27973b-5c07-4eb5-9e46-58b05cb9d9ab">2,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of common stock financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="xcur:PaymentsOfCommonStockFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMjktMS0xLTEtMA_7e47aab6-8d4c-405a-81f2-c58a3edc818b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" name="xcur:PaymentsOfCommonStockFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMjktMy0xLTEtMA_9b8f46d0-6932-4f31-9946-b41e91354947"><ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" name="xcur:PaymentsOfCommonStockFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMjktMy0xLTEtMA_abf82239-d1b1-426d-abc1-a6a2255d858c">207</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from long-term borrowing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMzAtMS0xLTEtMA_e415c62c-16a4-43b9-a89f-2ed2c9a98be4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMzAtMy0xLTEtMA_154dbc42-51d9-4985-9a66-7997ac9af136">17,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of long-term debt fees and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMzEtMS0xLTEtMA_24de3a86-0c55-487c-8ca6-a997602e0db5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMzEtMy0xLTEtMA_072fe2d8-fb95-4516-8d9a-40cb81e9f72a">344</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMzItMS0xLTEtMA_09d41ca7-dcf0-47dd-84d0-be143eca8d7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMzItMy0xLTEtMA_08d4888f-ceb0-4fa5-9ccc-3315cf44a15a">4,999</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMzMtMS0xLTEtMA_882637b5-6fb4-4598-af54-9c7c08aa5220">131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMzMtMy0xLTEtMA_ea8030b1-8ffd-471a-ad81-8e42b45dc3db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of common stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMzQtMS0xLTEtMA_99f9b0fe-f882-438f-9b93-4cbe824cf776">546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMzQtMy0xLTEtMA_4aa08a47-6e79-4d85-994a-dcef9291243f">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for minimum statutory tax withholding related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMzUtMS0xLTEtMTA2NDM_e4d19822-d8db-4548-ba81-f32de156958c">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMzUtMy0xLTEtMTA2NDM_f11bdeb8-f6bb-41fe-9c3e-bdd30d244fc9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMzUtMS0xLTEtMA_8720dd48-e72f-43b1-ba45-009164c31626">668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMzUtMy0xLTEtMA_16b61e36-3a9f-41b4-9da2-142ae7366587">14,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMzctMS0xLTEtMA_4a883595-9492-438c-96b5-c6ef37c7d3f9">18,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMzctMy0xLTEtMA_0765c192-6062-4400-a61f-2bc13e3238fd">15,801</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash - beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMzgtMS0xLTEtMA_584831ac-8b09-4c7e-a6f4-6663c53c6cf8">34,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c58992375514840acc525804de3b5bf_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMzgtMy0xLTEtMA_c394b1d3-714c-4e3f-b125-7cbee4559f6b">48,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash - end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMzktMS0xLTEtMA_d101447d-64f0-4426-bde6-bd7c3c315bff">53,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if042bb6dd7e349bab540c21e2b62d94c_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMzktMy0xLTEtMA_c0cf7d4d-0709-4e74-aa3d-901bb80a30f4">32,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (continued)</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset acquired through operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjNjYzQ1NDRmZTZiOTRkZDRiZjdlOTliMmU4NDljYWEwL3RhYmxlcmFuZ2U6M2NjNDU0NGZlNmI5NGRkNGJmN2U5OWIyZTg0OWNhYTBfNC0xLTEtMS0w_e95db05f-8c97-4a6a-bbaa-8cee16c3d7ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjNjYzQ1NDRmZTZiOTRkZDRiZjdlOTliMmU4NDljYWEwL3RhYmxlcmFuZ2U6M2NjNDU0NGZlNmI5NGRkNGJmN2U5OWIyZTg0OWNhYTBfNC0zLTEtMS0w_e77b063b-3120-4e90-997e-0634886ecf25">8,147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures (accounts payable and accrued expenses)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjNjYzQ1NDRmZTZiOTRkZDRiZjdlOTliMmU4NDljYWEwL3RhYmxlcmFuZ2U6M2NjNDU0NGZlNmI5NGRkNGJmN2U5OWIyZTg0OWNhYTBfNi0xLTEtMS0w_664b707c-cb6a-4d4e-964e-ef374bb7ab73">303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjNjYzQ1NDRmZTZiOTRkZDRiZjdlOTliMmU4NDljYWEwL3RhYmxlcmFuZ2U6M2NjNDU0NGZlNmI5NGRkNGJmN2U5OWIyZTg0OWNhYTBfNi0zLTEtMS0w_56075a42-a1fc-46db-85db-ef25eda83e0b">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt fees (accrued expense and other noncurrent liabilities)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjNjYzQ1NDRmZTZiOTRkZDRiZjdlOTliMmU4NDljYWEwL3RhYmxlcmFuZ2U6M2NjNDU0NGZlNmI5NGRkNGJmN2U5OWIyZTg0OWNhYTBfOC0xLTEtMS0w_48f77469-7100-4b38-8118-38be7cc07487">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjNjYzQ1NDRmZTZiOTRkZDRiZjdlOTliMmU4NDljYWEwL3RhYmxlcmFuZ2U6M2NjNDU0NGZlNmI5NGRkNGJmN2U5OWIyZTg0OWNhYTBfOC0zLTEtMS0w_64179959-5b8f-4396-a083-ca58e616fa16">834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the unaudited condensed consolidated balance sheets that sum to the total of the amounts shown in the unaudited condensed consolidated statements of cash flows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjNjNWRjNTE4MTk1MDQyNzU5YmQxYzc3OTU1OGZiZjc4L3RhYmxlcmFuZ2U6M2M1ZGM1MTgxOTUwNDI3NTliZDFjNzc5NTU4ZmJmNzhfMS0xLTEtMS0w_c473202f-01c0-44f6-bd94-c8f16d27e930">51,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjNjNWRjNTE4MTk1MDQyNzU5YmQxYzc3OTU1OGZiZjc4L3RhYmxlcmFuZ2U6M2M1ZGM1MTgxOTUwNDI3NTliZDFjNzc5NTU4ZmJmNzhfMS0zLTEtMS0w_ef5ead5f-667f-4826-a42c-2278447cfc67">33,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjNjNWRjNTE4MTk1MDQyNzU5YmQxYzc3OTU1OGZiZjc4L3RhYmxlcmFuZ2U6M2M1ZGM1MTgxOTUwNDI3NTliZDFjNzc5NTU4ZmJmNzhfMi0xLTEtMS0w_0ccea7ef-7385-420b-9d22-181bb86822a4">1,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjNjNWRjNTE4MTk1MDQyNzU5YmQxYzc3OTU1OGZiZjc4L3RhYmxlcmFuZ2U6M2M1ZGM1MTgxOTUwNDI3NTliZDFjNzc5NTU4ZmJmNzhfMi0zLTEtMS0w_e59ac78d-fd49-4dcc-af0a-71d38678f7da">1,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash shown in the unaudited condensed consolidated statements of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjNjNWRjNTE4MTk1MDQyNzU5YmQxYzc3OTU1OGZiZjc4L3RhYmxlcmFuZ2U6M2M1ZGM1MTgxOTUwNDI3NTliZDFjNzc5NTU4ZmJmNzhfMy0xLTEtMS0w_cd6fc5a2-3bd0-485c-884d-334dec33503f">53,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjNjNWRjNTE4MTk1MDQyNzU5YmQxYzc3OTU1OGZiZjc4L3RhYmxlcmFuZ2U6M2M1ZGM1MTgxOTUwNDI3NTliZDFjNzc5NTU4ZmJmNzhfMy0zLTEtMS0w_60304fe8-2a4d-4ec8-8984-abb8e1a09a96">34,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">See accompanying notes to the unaudited condensed consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="i30c50c718dda42d28fbdd6dcd4fa2365_34"></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div id="i30c50c718dda42d28fbdd6dcd4fa2365_37"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zNy9mcmFnOmY5ZjRkZjg2YTk3NzRhZjM5NmYwYjEzOTAzN2M0NTE4L3RleHRyZWdpb246ZjlmNGRmODZhOTc3NGFmMzk2ZjBiMTM5MDM3YzQ1MThfMTE5MTE_30088a48-d707-408e-9c40-5e6fc83dc58c" continuedAt="ibef337c5ad0d4d9ca4ad14d1c5840e2e" escape="true">Description of Business and Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="ibef337c5ad0d4d9ca4ad14d1c5840e2e" continuedAt="i7fb6036fead64450aed170730e7caace"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exicure, Inc. (the &#8220;Company&#8221;) is a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases, and other genetic disorders based on its proprietary Spherical Nucleic Acid, or SNA&#8482;, technology. The Company believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. The Company is in preclinical development of XCUR-FXN, a lipid-nanoparticle SNA-based therapeutic candidate, for the intrathecal treatment of Friedreich&#8217;s ataxia (&#8220;FA&#8221;).  The Company&#8217;s therapeutic candidate cavrotolimod (AST-008) is in a Phase 1b/2 clinical trial in patients with advanced solid tumors. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes one of the key strengths of its proprietary SNAs is that they have the potential for increased cellular uptake compared to conventional linear oligonucleotides and as a result the potential to achieve higher efficacy at the same doses of oligonucleotide administered. The Company has shown in clinical and preclinical studies that SNAs may have therapeutic potential in immuno-oncology and dermatology.  In addition, the Company has shown in preclinical studies that SNAs may have therapeutic potential in neurology, ophthalmology, pulmonology, and gastroenterology. Accordingly, the Company has expanded its pipeline into neurology, for which investigational new drug application (&#8220;IND&#8221;)-enabling activities are ongoing for XCUR-FXN, and is concluding early stage research activities in ophthalmology, pulmonology, and gastroenterology. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout these unaudited condensed consolidated financial statements, the terms the &#8220;Company,&#8221;  &#8220;Exicure,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Exicure, Inc. and where appropriate, its wholly owned subsidiary, Exicure Operating Company.  Exicure Operating Company holds all material assets and conducts all business activities and operations of Exicure, Inc.&#160;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zNy9mcmFnOmY5ZjRkZjg2YTk3NzRhZjM5NmYwYjEzOTAzN2M0NTE4L3RleHRyZWdpb246ZjlmNGRmODZhOTc3NGFmMzk2ZjBiMTM5MDM3YzQ1MThfMTE5MDY_ad55f6bb-2c28-4c5a-ac83-0fda78025d80" continuedAt="i959fd25779684d9a8b375cb315429d1a" escape="true">Basis of Presentation</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i959fd25779684d9a8b375cb315429d1a">The accompanying unaudited condensed consolidated financial statements as of September&#160;30, 2021 and December 31, 2020, and for the nine months ended September&#160;30, 2021 and 2020, have been presented in conformity with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;).</ix:continuation>  </span></div><ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zNy9mcmFnOmY5ZjRkZjg2YTk3NzRhZjM5NmYwYjEzOTAzN2M0NTE4L3RleHRyZWdpb246ZjlmNGRmODZhOTc3NGFmMzk2ZjBiMTM5MDM3YzQ1MThfMTE5MTQ_dfb4b031-3c4f-4bf3-846b-cfff162b760a" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements include the accounts of Exicure and its wholly owned subsidiary, Exicure Operating Company. All intercompany transactions and accounts are eliminated in consolidation.</span></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Risks and Uncertainties</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Research and License Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, revenue recognized under the AbbVie Collaboration Agreement (as defined in Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Research and License Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for the three and nine months ended September 30, 2021 reflects the cumulative catchup adjustment (reduction) of revenue of $(<ix:nonFraction unitRef="usd" contextRef="i5ead1c261b0940cab128efb701608748_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="xcur:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zNy9mcmFnOmY5ZjRkZjg2YTk3NzRhZjM5NmYwYjEzOTAzN2M0NTE4L3RleHRyZWdpb246ZjlmNGRmODZhOTc3NGFmMzk2ZjBiMTM5MDM3YzQ1MThfMTA5OTUxMTY0NDIyMg_a26a21e1-cfad-4c18-9a0d-eb5eae3797d5">4,480</ix:nonFraction>) recorded in connection with a change in estimate that occurred during the third quarter of 2021.  The Company currently estimates significant additional efforts will be required to satisfy the performance obligation under the AbbVie Collaboration Agreement.  These increased estimated efforts in connection with the change in workplan resulted in less progress occurring relative to the increased estimate of total project hours to complete the research services during the three and nine months ended September 30, 2021 as compared to the amount of revenue recognized at both June 30, 2021 and December 31, 2020, which led to revenue reversals in each respective period.  Due to uncertainties inherent in the estimation process, it is at least reasonably possible that estimated efforts required to complete the research services under the AbbVie Collaboration Agreement will be further revised in the </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i7fb6036fead64450aed170730e7caace" continuedAt="i06b3eb3f997d4d65872b60df69d0fade"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">near-term which may result in additional adjustments (reductions of revenue) in future periods.  As discussed in Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Significant Accounting Policies &#8212; Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, determining the estimate of total project hours used to recognize revenue for our collaboration agreements requires significant judgment and any changes to those estimates may have a significant impact on the amount and timing of revenue recognition for the Ipsen Collaboration Agreement or the AbbVie Collaboration Agreement (each, as defined in Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Research and License Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) in future periods.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Risks and Uncertainties</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the ongoing COVID-19 pandemic, the Company has taken and continues to take active measures designed to address and mitigate the impact of the COVID-19 pandemic on its business, such as remote working policies, facilitating management&#8217;s routine communication to address employee and business concerns and providing frequent updates to the Company&#8217;s board of directors (the &#8220;Board&#8221;).  During the third quarter of 2021 and through the date of this report, the Company continues to operate under COVID-19 social distancing guidelines and has generally operated with approximately <ix:nonFraction unitRef="number" contextRef="ic4e83e9c6d3f41cba0167701375d65af_D20210701-20210930" decimals="2" name="xcur:ResearchAndDevelopmentStaffOnSitePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zNy9mcmFnOmY5ZjRkZjg2YTk3NzRhZjM5NmYwYjEzOTAzN2M0NTE4L3RleHRyZWdpb246ZjlmNGRmODZhOTc3NGFmMzk2ZjBiMTM5MDM3YzQ1MThfNDE2Mg_9cc03bbc-4713-4194-99ca-e6505591173b">100</ix:nonFraction>% of its R&amp;D staff on-site.  The Company&#8217;s office and general and administrative team is also working on-site approximately <ix:nonFraction unitRef="number" contextRef="ic4e83e9c6d3f41cba0167701375d65af_D20210701-20210930" decimals="2" name="xcur:OfficeAndGeneralAndAdministrativeStaffOnSitePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zNy9mcmFnOmY5ZjRkZjg2YTk3NzRhZjM5NmYwYjEzOTAzN2M0NTE4L3RleHRyZWdpb246ZjlmNGRmODZhOTc3NGFmMzk2ZjBiMTM5MDM3YzQ1MThfNDI4Nw_632a0616-f671-4e99-af08-5800073cd20c">50</ix:nonFraction>% of the time. The Company&#8217;s preclinical development program in Friedreich&#8217;s ataxia (&#8220;FA&#8221;) is ongoing and it began IND-enabling studies for XCUR-FXN in late 2020.  The Company also continues research and development activities with its collaboration partners, Ipsen Biopharm Limited (&#8220;Ipsen&#8221;) and AbbVie Inc. (&#8220;AbbVie&#8221;).  However, if the COVID-19 pandemic continues to persist for an extended period of time, the Company could experience further significant disruptions to its clinical and preclinical development timelines, which would adversely affect its business, financial condition, results of operations and growth prospects.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that the effects of the COVID-19 pandemic or its impact contributed to delays that began during the third quarter of 2020 and continued into the second half of 2021 in its enrollment plans and clinical trial site start-ups for the Phase 2 dose expansion phase of the Phase 1b/2 clinical trial for its cavrotolimod (AST-008) clinical program.  As a result of these delays, pending further delays or any additional unanticipated effects of the COVID-19 pandemic on its clinical development plans, the Company now expects to report overall response rate (&#8220;ORR&#8221;) results of cavrotolimod (AST-008) in the second half of 2022 as opposed to the previously reported first half of 2022. In the third quarter of 2020, the Company implemented, and continues to employ, additional measures to increase the enrollment of patients, including frequent interaction with its clinical trial sites currently open as well as increasing the number of clinical trial sites that potentially are activated for this trial so that the Company may continue to enroll patients as initially planned.  However, any additional delays may require the Company to further lengthen its clinical development timeline for cavrotolimod (AST-008).  The extent to which the COVID-19 pandemic or its impact or effects may continue to impact the Company&#8217;s business, its clinical development and regulatory efforts, its corporate development objectives and the value of and market for its common stock will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration or spread of the COVID-19 pandemic, its impact and effects, the possibility of additional periods of increases or spikes in the number of COVID-19 cases, the introduction and spread of new variants of the virus, travel restrictions, quarantines, social distancing, phased re-openings and business closure requirements in the United States and other countries, and the effectiveness of actions taken globally to contain and treat the disease including, without limitation, the effectiveness and timing of vaccination initiatives in the United States and worldwide.  The global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the COVID-19 pandemic could have a material adverse effect on the Company&#8217;s business, financial condition, results of operations and growth prospects. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is subject to other challenges and risks specific to its business and its ability to execute on its business plan and strategy, as well as risks and uncertainties common to companies in the biotechnology industry with research and development operations, including, without limitation, risks and uncertainties associated with: obtaining regulatory approval of its product candidates; delays or problems in obtaining clinical supply, loss of single source suppliers or failure to comply with manufacturing regulations; identifying, acquiring or in-licensing additional products or product candidates; product development and the </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i06b3eb3f997d4d65872b60df69d0fade" continuedAt="ia2517e62ff084895b174260b62acfe42"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inherent uncertainty of clinical success; and the challenges of protecting and enhancing its intellectual property rights; and the challenges of complying with applicable regulatory requirements.  In addition, to the extent the ongoing COVID-19 pandemic adversely affects the Company&#8217;s business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each reporting period, the Company evaluates whether there are conditions or events that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. The Company is required to make certain additional disclosures if it concludes substantial doubt exists and it is not alleviated by the Company&#8217;s plans or when its plans alleviate substantial doubt about the Company&#8217;s ability to continue as a going concern.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the Company has generated an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="xcur:RetainedEarningsAccumulatedDeficitInceptiontoDate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zNy9mcmFnOmY5ZjRkZjg2YTk3NzRhZjM5NmYwYjEzOTAzN2M0NTE4L3RleHRyZWdpb246ZjlmNGRmODZhOTc3NGFmMzk2ZjBiMTM5MDM3YzQ1MThfODE5MQ_dcf42449-3533-46e6-bfe1-e4417d9c17b5">175,079</ix:nonFraction> since inception and expects to incur significant expenses and negative cash flows for the foreseeable future. Based on the Company&#8217;s current operating plans and existing working capital at September 30, 2021, it is uncertain whether our current liquidity is sufficient to fund operations over the next twelve months from the date of the issuance of these condensed consolidated financial statements.  As a result, there is substantial doubt about our ability to continue as a going concern. The Company has no committed sources of additional capital at this time and substantial additional financing will be needed by the Company to fund its operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that it will be able to obtain additional funding through equity or debt financings, collaboration agreements, strategic partnerships and licensing arrangements, or other arrangements, such as its &#8220;at the market offering&#8221; program pursuant to its equity distribution agreement with BMO Capital Markets Corp., to fund its current operations and business strategy. However, there can be no assurance that such additional financing will be available and, if available, can be obtained on terms acceptable to the Company.  If the Company is unable to obtain such additional financing, the Company could be forced to delay, reduce or eliminate its research and development programs or clinical efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations.  The Company has historically principally raised capital through the public offerings of its securities.  However, the COVID-19 pandemic continues to rapidly evolve and has already resulted in a significant disruption of global financial markets.  If the disruption continues to persist and deepens, the Company could experience an inability to access additional capital, which could negatively affect its ability to raise capital and ultimately, its operations, liquidity and ability to continue as a going concern. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated interim financial statements have been prepared as though the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim condensed consolidated balance sheet as of September&#160;30, 2021, the interim condensed consolidated statements of operations for the three and nine months ended September&#160;30, 2021 and 2020, the interim condensed consolidated statements of comprehensive (loss) income for the three and nine months ended September&#160;30, 2021 and 2020, the interim condensed consolidated statements of changes in stockholders&#8217; equity for the three and nine months ended September&#160;30, 2021 and 2020, and the interim condensed consolidated statements of cash flows for the nine months ended September&#160;30, 2021 and 2020, are unaudited. The interim unaudited condensed consolidated financial statements have been prepared on the same basis as the annual audited financial statements; and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company&#8217;s financial position as of September&#160;30, 2021, the results of its operations for the three and nine months ended September&#160;30, 2021 and 2020, and the results of its cash flows for the nine months ended September&#160;30, 2021 and 2020. The financial data and other information disclosed in </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="ia2517e62ff084895b174260b62acfe42"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">these notes related to the three and nine months ended September&#160;30, 2021 and 2020 are unaudited. The results for the three and nine months ended September&#160;30, 2021 are not necessarily indicative of results to be expected for the year ending December&#160;31, 2021, or any other interim periods, or any future year or period.</span></div><ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zNy9mcmFnOmY5ZjRkZjg2YTk3NzRhZjM5NmYwYjEzOTAzN2M0NTE4L3RleHRyZWdpb246ZjlmNGRmODZhOTc3NGFmMzk2ZjBiMTM5MDM3YzQ1MThfMTE5MDg_bb73cc36-daf9-4bc8-88fd-d1aa6a418e24" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Management bases its estimates on certain assumptions which it believes are reasonable in the circumstances and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company&#8217;s financial position, results of operations or cash flows. Actual results in future periods could differ from those estimates.</span></div></ix:nonNumeric></ix:continuation><div id="i30c50c718dda42d28fbdd6dcd4fa2365_40"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80MC9mcmFnOjdjMzQxMzgzYWVmZjQ5M2NiNzI0NTNhMDMzOTM4ZmY1L3RleHRyZWdpb246N2MzNDEzODNhZWZmNDkzY2I3MjQ1M2EwMzM5MzhmZjVfMTk3Ng_5e772a4d-d4a4-414a-a193-220907729582" continuedAt="iffa5dabaacdc4850bfce8cac4defe214" escape="true">Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="iffa5dabaacdc4850bfce8cac4defe214" continuedAt="i17d858565181403192ddf7ed1d27452d"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant accounting policies are disclosed in the audited consolidated financial statements and the notes thereto, which are included in the in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020 filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March 11, 2021. Since the date of those audited consolidated financial statements, there have been no material changes to the Company&#8217;s significant accounting policies, except as noted below:</span></div><ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80MC9mcmFnOjdjMzQxMzgzYWVmZjQ5M2NiNzI0NTNhMDMzOTM4ZmY1L3RleHRyZWdpb246N2MzNDEzODNhZWZmNDkzY2I3MjQ1M2EwMzM5MzhmZjVfMjc0ODc3OTA4NTk0MQ_2086afc2-a18c-4370-8067-cda8fe20f121" continuedAt="i901614f4a6574ea6b7245b6135ee6960" escape="true"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue recognition</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2018, we adopted the provisions of Accounting Standards Codification, or ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> using the modified retrospective method for all contracts not completed as of the date of adoption.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 606, we recognize revenue when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC 606, we perform the following five steps:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt">Identify the contract with the customer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party&#8217;s rights and obligations regarding the goods or services to be transferred and identifies the related payment terms, (ii) the contract has commercial substance, and (iii) we determine that collection of substantially all consideration for goods and services that are transferred is probable based on the customer&#8217;s intent and ability to pay the promised consideration. We apply judgment in determining the customer&#8217;s intent and ability to pay, which is based on a variety of factors including the customer&#8217;s historical payment experience, or in the case of a new customer, published credit and financial information pertaining to the customer.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt">Identify the performance obligations in the contract.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Performance obligations promised in a contract are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the good or service either on its own or together with other available resources, and are distinct in the context of the contract, whereby the transfer of the good or service is separately identifiable from other promises in the contract. To the extent a contract includes multiple promised goods and services, we must apply judgment to determine whether promised goods and services are both capable of being distinct and distinct in the context of the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt">Determine the transaction price.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The transaction price is determined based on the consideration to which we will be entitled in exchange for transferring goods and services to the customer. To the extent the transaction price includes variable consideration, we estimate the amount of variable consideration that </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i17d858565181403192ddf7ed1d27452d" continuedAt="if3b2ba17aed94c3c8e22cbe75863a646"><ix:continuation id="i901614f4a6574ea6b7245b6135ee6960" continuedAt="id51c74cbb52f43989cab7896b491e1fb"><div style="margin-bottom:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">should be included in the transaction price utilizing either the expected value method or the most likely amount method, depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in our judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Any estimates, including the effect of the constraint on variable consideration, are evaluated at each reporting period for any changes. Determining the transaction price requires significant judgment.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt">Allocate the transaction price to performance obligations in the contract.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. However, if a series of distinct services that are substantially the same qualifies as a single performance obligation in a contract with variable consideration, we must determine if the variable consideration is attributable to the entire contract or to a specific part of the contract. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative standalone selling price basis unless the transaction price is variable and meets the criteria to be allocated entirely to a performance obligation or to a distinct service that forms part of a single performance obligation. The consideration to be received is allocated among the separate performance obligations based on relative standalone selling prices. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt">Recognize revenue when or as the Company satisfies a performance obligation.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We satisfy performance obligations either over time or at a point in time. Revenue is recognized over time if either (i) the customer simultaneously receives and consumes the benefits provided by the entity&#8217;s performance, (ii) the entity&#8217;s performance creates or enhances an asset that the customer controls as the asset is created or enhanced, or (iii) the entity&#8217;s performance does not create an asset with an alternative use to the entity and the entity has an enforceable right to payment for performance completed to date. If the entity does not satisfy a performance obligation over time, the related performance obligation is satisfied at a point in time by transferring the control of a promised good or service to a customer. Examples of control are using the asset to produce goods or services, enhance the value of other assets, or settle liabilities, and holding or selling the asset.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue allocated to performance obligations relating to provision of research and development activities is recognized as the performance obligations are satisfied using an input method to measure progress, based on an estimate of the percentage of completion of the project based on the actual hours incurred on the project as a percentage of the total expected project hours. The determination of the percentage of completion requires management to estimate the total expected project hours. A detailed estimate of the total expected project hours is re-assessed every reporting period based on the latest project plan and discussions with project teams. If a change in facts or circumstances occurs, the estimate will be adjusted and the revenue will be recognized based on the revised estimate. The difference between the cumulative revenue recognized based on the previous estimate and the revenue recognized based on the revised estimate would be recognized as an adjustment to revenue in the period in which the change in estimate occurs. Determining the estimate of total project hours requires significant judgment and may have a significant impact on the amount and timing of revenue recognition.  For example, as discussed in Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Research and License Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, revenue recognized under the AbbVie Collaboration Agreement (as defined in Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Research and License Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for the three and nine months ended September 30, 2021 reflects the cumulative catchup adjustment (reduction) of revenue of $(<ix:nonFraction unitRef="usd" contextRef="i5ead1c261b0940cab128efb701608748_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="xcur:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80MC9mcmFnOjdjMzQxMzgzYWVmZjQ5M2NiNzI0NTNhMDMzOTM4ZmY1L3RleHRyZWdpb246N2MzNDEzODNhZWZmNDkzY2I3MjQ1M2EwMzM5MzhmZjVfODI0NjMzNzIyMDM1Mw_a26a21e1-cfad-4c18-9a0d-eb5eae3797d5">4,480</ix:nonFraction>) recorded in connection with a change in estimate that occurred during the third quarter of 2021.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses of intellectual property</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from consideration allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the licenses. For licenses that are combined with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or&#160;at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing </span></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="if3b2ba17aed94c3c8e22cbe75863a646"><ix:continuation id="id51c74cbb52f43989cab7896b491e1fb"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revenue. We evaluate the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone payments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;At the inception of each arrangement that includes development milestone payments, we evaluate the probability of reaching the milestones and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur in the future, the associated milestone value is included in the transaction price. Milestone payments that are not within our control or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received and therefore revenue recognized is constrained as management is unable to assert that a reversal of revenue would not be possible. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues and earnings in the period of adjustment.  To date, we have not recognized any milestone payment revenue from any of its collaboration agreements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;For arrangements that include sales-based royalties, including milestone payments based on levels of sales, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, we have not recognized any royalty revenue resulting from any of its collaboration agreements.</span></div></ix:continuation><ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80MC9mcmFnOjdjMzQxMzgzYWVmZjQ5M2NiNzI0NTNhMDMzOTM4ZmY1L3RleHRyZWdpb246N2MzNDEzODNhZWZmNDkzY2I3MjQ1M2EwMzM5MzhmZjVfMTk3NA_d39bc909-86f1-406a-ba98-95a101eefc3c" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2016-13&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2016-13 is a new standard intended to improve reporting requirements specific to loans, receivables and other financial instruments. ASU 2016-13 requires that credit losses on financial assets measured at amortized cost be determined using an expected loss model, instead of the current incurred loss model, and requires that credit losses related to available-for-sale debt securities&#160;be recorded through an allowance for credit losses and limited to the amount by which carrying value exceeds fair value. ASU 2016-13 also requires enhanced disclosure of credit risk associated with financial assets. The effective date of ASU 2016-13 was deferred by ASU 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments&#8212;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842)&#8212;Effective Dates </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the annual period beginning after December 15, 2022 for companies that (i) meet the definition of an SEC filer and (ii) are eligible as &#8220;smaller reporting companies&#8221; as such term is defined by the SEC, with early adoption permitted. The Company is currently assessing the impact of adoption of ASU 2016-13 to its consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i30c50c718dda42d28fbdd6dcd4fa2365_43"></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTUzNTk_abed29d6-eaa2-4676-8868-702cc02c966a" continuedAt="i880b5c9810fc46af812bbed1a990756b" escape="true">Collaborative Research and License Agreements</ix:nonNumeric></span></div><ix:continuation id="i880b5c9810fc46af812bbed1a990756b" continuedAt="i5a4e041162054b3d90f60bb941feeb2c"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ipsen Collaboration Agreement</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Agreement</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2021 (the &#8220;Ipsen Effective Date&#8221;), the Company entered into a Collaboration, Option and License Agreement with Ipsen (the &#8220;Ipsen Collaboration Agreement&#8221;). Pursuant to the Ipsen Collaboration Agreement, the Company granted to Ipsen exclusive access and options to license SNA-based therapeutics arising from <ix:nonFraction unitRef="agreement" contextRef="i7c9b511297334f1596139d6ed967838a_D20210730-20210730" decimals="INF" format="ixt-sec:numwordsen" name="xcur:NumberofCollaborationPrograms" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfNTQ5NzU1ODE2NzY2OA_06168603-de76-4d8e-943a-1862f0c9c151">two</ix:nonFraction> collaboration programs related to the treatment of Huntington&#8217;s disease and Angelman syndrome (each, an &#8220;Ipsen Collaboration Program&#8221;), respectively. Each such license (obtained in connection with the exercise of an Ipsen Option, as defined and discussed further below) would grant to Ipsen exclusive, royalty-bearing, sublicensable, worldwide rights to develop, manufacture, use and commercialize such SNA therapeutics. Upon written notice to the Company, Ipsen may exercise its option during the corresponding collaboration program&#8217;s applicable option exercise period, (each, an &#8220;Ipsen Option Exercise Period&#8221;).</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the Ipsen Effective Date, the Company and Ipsen have agreed upon a development plan for each Ipsen Collaboration Program that describes the development activities and timelines required to advance each such Ipsen Collaboration Program through its first IND filing (each, an &#8220;Ipsen Development Plan&#8221;).  The activities described in the Ipsen Development Plans are conducted under the supervision of the Ipsen Joint Steering Committee (the &#8220;Ipsen JSC&#8221;) consisting of three members from each of the Company and Ipsen.  Under the terms of the Ipsen Collaboration Agreement, the Company will use commercially reasonable efforts to conduct discovery and development in <ix:nonFraction unitRef="agreement" contextRef="i7c9b511297334f1596139d6ed967838a_D20210730-20210730" decimals="INF" format="ixt-sec:numwordsen" name="xcur:NumberofCollaborationPrograms" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfNTQ5NzU1ODE2NzY4Mw_3d83dc76-5ef8-457f-b2b0-9d00dd4441a9">two</ix:nonFraction> collaboration programs for Huntington&#8217;s disease (the &#8220;HD Program&#8221;) and Angelman syndrome (the &#8220;AS Program&#8221;) (the &#8220;Ipsen Development Activities&#8221;) respectively. The Company shall be solely responsible for all costs and expenses of conducting each Ipsen Collaboration Program through the selection of SNA therapeutic candidates for further development (&#8220;Ipsen Selection&#8221;), and Ipsen shall be responsible for all costs and expenses of all activities that are necessary to enable the first filing of an  IND for each proposed product candidate.  In the event that Ipsen exercises an option, Ipsen will be responsible for further development from the license effective date and commercialization of the corresponding licensed product. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the completion of all Ipsen Development Activities for the Ipsen Selection (the &#8220;Ipsen First R&amp;D Term Activities&#8221;), the Company is required to deliver to Ipsen a report that describes the results of the Ipsen First R&amp;D Term Activities and identifies at least one SNA-based compound that satisfies certain criteria for such Ipsen Collaboration Program as determined by the Ipsen JSC (the &#8220;Ipsen First Option Data Package&#8221;).  Following the delivery of the Ipsen First Option Data Package for an Ipsen Collaboration Program, Ipsen will have the ability for a defined period of time (the &#8220;Ipsen First Option Exercise Period&#8221;) to exercise an option (each a &#8220;First Ipsen Option&#8221;) to obtain worldwide rights and license to the Company&#8217;s SNA technology and the Company&#8217;s interest in joint collaboration technology to make, have made, import, use, sell or offer for sale any product (each an &#8220;Ipsen Licensed Product&#8221;) that results from such Ipsen Collaboration Program during the term of the Ipsen Collaboration Agreement.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the event Ipsen (i) does not exercise the First Ipsen Option with respect to an Ipsen Collaboration Program, (ii) the Ipsen Collaboration Agreement has not expired or been terminated with respect to such Ipsen Collaboration Program, and (iii) Ipsen agrees to fully fund additional research activities for an Ipsen Collaboration Program through IND filing, the Company will be responsible for research and development activities for such Ipsen Collaboration Program through IND filing (the &#8220;Ipsen Second R&amp;D Term Activities&#8221;).  Following the completion of the Ipsen Second R&amp;D Term Activities, the Company is required to deliver to Ipsen a report that describes the results of the Ipsen Second R&amp;D Term Activities (the &#8220;Ipsen Second Option Data Package&#8221;).   Following the delivery of the Ipsen Second Option Data Package for an Ipsen Collaboration Program, Ipsen will have the ability for a defined period of time (the &#8220;Ipsen Second Option Exercise Period&#8221;) to exercise an option (each a &#8220;Second Ipsen Option&#8221; and together with the First Ipsen Option, the &#8220;Ipsen Options&#8221;) to obtain worldwide rights and license to the Company&#8217;s SNA technology and the Company&#8217;s interest in joint collaboration technology to make, have made, import, use, sell or offer for sale any Ipsen Licensed Product&#8221; that results from such Ipsen Collaboration Program during the term of the Ipsen Collaboration Agreement.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i5a4e041162054b3d90f60bb941feeb2c" continuedAt="i32c0ebfa58804325afff4b91d93aafc2"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After Ipsen&#8217;s exercise of an Ipsen Option for an Ipsen Collaboration Program, the Company shall supply to Ipsen the licensed SNAs under current Good Manufacturing Practice, at the Company&#8217;s manufacturing cost pursuant to a clinical supply agreement to be negotiated by the Company and Ipsen in good faith following the Ipsen Effective Date and executed within twelve (12) months after the Ipsen Effective Date (the &#8220;Ipsen Supply Agreement&#8221;). The Ipsen Supply Agreement will provide for the transfer by the Company to Ipsen of all documents and information, and the provision by the Company of technical assistance and support, for Ipsen to manufacture or have manufactured by a third party contractor engaged by Ipsen the applicable licensed SNA to the extent it is intended to be actually used in the development and manufacture of the applicable licensed products.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Ipsen Collaboration Agreement, the Company received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i7c9b511297334f1596139d6ed967838a_D20210730-20210730" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromCollaborators" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfNTQ5NzU1ODE2NzY1Ng_c4671c91-cea5-4517-8c64-462516a2217e">20,000</ix:nonFraction> (the &#8220;Ipsen Upfront Payment&#8221;).  If Ipsen exercises a First Ipsen Option, Ipsen is required to pay the Company the First Ipsen Option exercise fee of $<ix:nonFraction unitRef="usd" contextRef="i101b7a1d41f042c7be4608f1ec08064c_D20210730-20210730" decimals="-3" format="ixt:num-dot-decimal" name="xcur:CollaborationAgreementOptionExerciseFee" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfNTQ5NzU1ODE2NzcwMw_840ac499-256a-4156-a9a8-f7d67e2475f0">10,000</ix:nonFraction> for each Ipsen Collaboration Program.  If Ipsen exercises a Second Ipsen  Option, Ipsen is required to pay the Company the Second Ipsen Option exercise fee of $<ix:nonFraction unitRef="usd" contextRef="i3771528d3f494af69c08d167b87d572b_D20210730-20210730" decimals="-3" format="ixt:num-dot-decimal" name="xcur:CollaborationAgreementOptionExerciseFee" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfNTQ5NzU1ODE2NzcyMA_4be35bb2-55eb-4328-9268-156a39d91401">25,000</ix:nonFraction> for each Ipsen Collaboration Program. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ipsen will pay a pre-clinical milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i20b3f5cd0c964a8e9b2b710ca2d7aec4_I20210730" decimals="-3" format="ixt:num-dot-decimal" name="xcur:RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfNTQ5NzU1ODE2NzczNg_121e5cc1-6f93-42c7-8a4e-7470e619c592">5,000</ix:nonFraction> for each Ipsen Collaboration Program upon achievement of such milestone regardless of whether an Ipsen Option is exercised.  In addition to the option exercise fees and the pre-clinical milestones described above, if Ipsen exercises an Ipsen Option for an Ipsen Collaboration Program, development and regulatory milestones will be payable for that program upon the initiation of certain clinical trials and the filing for processing by the United States Food and Drug Administration (&#8220;FDA&#8221;) in the United States and by two additional regulators outside the United States of a marketing application for review, per the Ipsen Collaboration Program, with an aggregate total of up to $<ix:nonFraction unitRef="usd" contextRef="i20b3f5cd0c964a8e9b2b710ca2d7aec4_I20210730" decimals="-3" format="ixt:num-dot-decimal" name="xcur:RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfNTQ5NzU1ODE2Nzc1Mw_4f82b858-f6b4-434d-ad3f-9c9d5ab706b3">180,000</ix:nonFraction> if both Ipsen Options are exercised. Commercial milestones will be payable for that Ipsen Collaboration Program upon first commercial sale of a licensed product in certain jurisdictions and the achievement of specified aggregate sales thresholds for all licensed products from that program, with an aggregate total of up to $<ix:nonFraction unitRef="usd" contextRef="i20b3f5cd0c964a8e9b2b710ca2d7aec4_I20210730" decimals="-3" format="ixt:num-dot-decimal" name="xcur:RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfNTQ5NzU1ODE2Nzc3Mg_de8e3924-8a27-4bf2-b90f-4010a7408291">762,000</ix:nonFraction> if both Ipsen Options are exercised. In the event a therapeutic candidate subject to the Ipsen Collaboration Agreement results in commercial sales, the Company is eligible to receive tiered royalties at percentages ranging from the mid-single digits to the mid-teens on future net product sales of such commercialized therapeutic candidates. A percentage of the aforementioned payments will be due to Northwestern University upon receipt, pursuant to the terms of the Company&#8217;s existing license agreements with Northwestern University (see Note 13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitment and Contingencies,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information on the Northwestern University License Agreements (as defined below)). In connection with the receipt of the Ipsen Upfront Payment, the Company paid a $<ix:nonFraction unitRef="usd" contextRef="i7c9b511297334f1596139d6ed967838a_D20210730-20210730" decimals="-3" format="ixt:num-dot-decimal" name="xcur:CollaborationAgreementLicensingFeesIncurred" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfNTQ5NzU1ODE2Nzc4OQ_5fcca641-cfbe-4be5-8b12-891be4fdc6a4">3,000</ix:nonFraction> license fee to Northwestern University under the terms of the Northwestern License Agreements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s obligations to conduct activities defined in the Ipsen Development Plan under the Ipsen Collaboration Agreement commenced on July 30, 2021 and continues, unless earlier terminated, until (a) the expiration of the later-to-expire Ipsen Option Exercise Period, if Ipsen does not exercise either Ipsen Option, or (b) the expiration of the last-to-expire royalty term for any licensed product in such country on a licensed product-by-licensed product and country-by-country basis, if Ipsen exercises one or both Ipsen Options. Upon expiration of the royalty term with respect to a particular licensed product in a country, the license for such product in such country will convert to a fully-paid, irrevocable and perpetual license. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Ipsen Collaboration Agreement also contains customary provisions for termination by either party, including by Ipsen for any or no reason in its entirety upon (<ix:nonNumeric contextRef="i7c9b511297334f1596139d6ed967838a_D20210730-20210730" format="ixt-sec:durday" name="xcur:CollaborationAgreementTerminationNoticePeriod" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMjc0ODc3OTEyOTA1MQ_4f2c50c1-2013-4abc-8b47-2d6f98263d86">90</ix:nonNumeric>) days prior written notice and including in the event of breach of the Ipsen Collaboration Agreement, subject to cure, and by the Company upon a challenge of the licensed patents, subject, in certain cases, to customary reversion rights. Upon termination of the Ipsen Collaboration Agreement by the Company for Ipsen&#8217;s breach or bankruptcy, all licenses granted by the Company to Ipsen will terminate.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Ipsen Collaboration Agreement includes customary representations and warranties on behalf of both the Company and Ipsen. The Ipsen Collaboration Agreement also provides for customary mutual indemnities.  In addition, the Ipsen Collaboration Agreement imposes certain exclusivity obligations on Ipsen and the Company, </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i32c0ebfa58804325afff4b91d93aafc2" continuedAt="i56ab720a91db437495dca760c81a665c"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively, with respect to the development, use, manufacture and commercialization of oligonucleotide-based therapeutic targeting the same targets in the collaboration programs and/or certain other specific targets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Either party may assign the Ipsen Collaboration Agreement or delegate its obligations to an affiliate or to a successor to substantially all of the business to which the Ipsen Collaboration Agreement relates without the consent of the other party.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Analysis</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that Ipsen is a customer in this arrangement, and as such the arrangement falls within the scope of the revenue recognition guidance. Under the Ipsen Collaboration Agreement, the Company has identified two performance obligations, as follows: (1) the performance obligation related to the HD Program that includes (i) the Ipsen First R&amp;D Term Activities related to the HD Program (the &#8220;Ipsen HD Program R&amp;D Services&#8221;), (ii) Ipsen JSC services related to the HD Program during the Ipsen First Term (the &#8220;Ipsen HD Program JSC Services&#8221;), and (iii) activities related to the negotiation of the Ipsen Supply Agreement within twelve months of the Ipsen Effective Date; and (2) the performance obligation related to the AS Program that includes (i) the Ipsen First R&amp;D Term Activities related to the AS Program (the &#8220;Ipsen AS Program R&amp;D Services&#8221;), (ii) Ipsen JSC services related to the AS Program during the Ipsen First Term (the &#8220;Ipsen AS Program JSC Services&#8221;), (iii) and activities related to the negotiation of the Ipsen Supply Agreement within twelve months of the Ipsen Effective Date.  The Company has concluded that the Ipsen HD Program R&amp;D Services and the Ipsen AS Program R&amp;D Services are not distinct from the Ipsen HD Program JSC Services and the Ipsen AS Program JSC Services, respectively. The Company has also concluded that the Ipsen HD Program JSC Services and the Ipsen AS Program JSC Services are not distinct from the activities related to entering the Ipsen Supply Agreements for each respective program. The Ipsen JSC provides oversight and management of the overall Ipsen Collaboration Agreement, and the members of the Ipsen JSC from the Company have specialized industry knowledge, particularly as it relates to SNA technology. The Ipsen JSC is meant to facilitate the early stage research being performed and coordinate the activities of both the Company and Ipsen. Further, the Ipsen JSC services are critical to the ongoing evaluation of the Ipsen Collaboration Programs and the drafting and evaluation of the Ipsen First Option Data Package. The Ipsen JSC will also provide oversight and management of the activities to enter into the Ipsen Supply Agreement.  Accordingly, the Company&#8217;s participation on the Ipsen JSC is essential to Ipsen receiving value from the Ipsen HD Program R&amp;D Services and the Ipsen AS Program R&amp;D Services, and as such, (i) the Ipsen HD Program JSC Services, along with the Ipsen HD Program R&amp;D Services and the activities related to entering the Ipsen Supply Agreement within twelve months of the Ipsen Effective Date for that program are considered a single performance obligation (the &#8220;Ipsen HD Program Services&#8221;) and (ii) the Ipsen AS Program JSC Services along with the Ipsen AS Program R&amp;D Services and the activities related to entering the Ipsen Supply Agreement within twelve months of the Ipsen Effective Date for that program are considered a single performance obligation (the &#8220;Ipsen AS Program Services&#8221;). </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the Ipsen Effective Date, the total transaction price was determined to be $<ix:nonFraction unitRef="usd" contextRef="i20b3f5cd0c964a8e9b2b710ca2d7aec4_I20210730" decimals="-3" format="ixt:num-dot-decimal" name="xcur:CollaborationAgreementTransactionPrice" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfODc5NjA5MzA0OTk4NQ_c4a263b6-d8af-46c0-b06d-a651a9731867">20,000</ix:nonFraction>, consisting solely of the Ipsen Upfront Payment. The Company also utilized the most likely amount method to estimate any development and regulatory milestone payments to be received. As of the Ipsen Effective Date, there were no milestones included in the transaction price.&#160;The pre-clinical, development, regulatory, and commercial milestones were fully constrained due to the significant uncertainties surrounding such payments.&#160;The Company considered the stage of development and the risks associated with the remaining development required to achieve the milestone, as well as whether the achievement of the milestone is outside the control of the Company or Ipsen.  The Company has determined that any commercial milestones and sales-based royalties will be recognized when the related sales occur and therefore, they have also been excluded from the transaction price. The Company will re-evaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur.  As of September&#160;30, 2021, the Company determined that any pre-clinical, development, regulatory, or commercial milestones continue to be constrained and therefore the related milestone payments continue to be excluded from the transaction price at September&#160;30, 2021.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated the total transaction price to each of the two identified performance obligations under the Ipsen Collaboration Agreement based on an expected cost plus a margin approach, as follows: $<ix:nonFraction unitRef="usd" contextRef="ibd51ee58a09548a296ac27e125b6aaf5_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="xcur:CollaborationAgreementTransactionPrice" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTA5OTUxMTY3MjY2Mw_77c8fc61-514d-4fbd-b939-b5a1ada22e83">10,793</ix:nonFraction> of the </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i56ab720a91db437495dca760c81a665c" continuedAt="i54748f94cb034e3bbc4604c0cfede784"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transaction price allocated to the Ipsen HD Program Services and $<ix:nonFraction unitRef="usd" contextRef="i577ec678c36d41cb95beb6bb59053c95_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="xcur:CollaborationAgreementTransactionPrice" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTA5OTUxMTY3MjY3NA_f5695dd2-f23f-424d-b847-ea4897343000">9,207</ix:nonFraction> of the transaction price allocated to the Ipsen AS Program Services.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will recognize revenue related to each of Ipsen HD Program Services and the Ipsen AS Program Services as those performance obligations are satisfied using an input method to measure progress for each of those performance obligations. The Company believes the input method that most accurately depicts the measure of progress is the actual hours incurred to date relative to projected hours to complete the activities for the Ipsen HD Program Services and the Ipsen AS Program Services.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2021, the Company recognized revenue under the Ipsen Collaboration Agreement of approximately $<ix:nonFraction unitRef="usd" contextRef="ia146a37ad8c04dd3a46243658527ace5_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTA5OTUxMTY1Njc1OA_a6156d78-dfee-46ab-a3d5-17b25d543754"><ix:nonFraction unitRef="usd" contextRef="i6e7d092153af4ab295e43b76a46e94f7_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTA5OTUxMTY1Njc1OA_cd9a527e-86a9-4bfc-8696-5e601d2a1e8d">803</ix:nonFraction></ix:nonFraction>.  As of September&#160;30, 2021 , there was $<ix:nonFraction unitRef="usd" contextRef="i0eb88576f2154b229cc5f904054ddcaf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTA5OTUxMTY1Njc2OA_914c845f-27e8-4c8c-a608-3b46f4152ab9">19,197</ix:nonFraction> of deferred revenue related to the Ipsen Collaboration Agreement, of which is $<ix:nonFraction unitRef="usd" contextRef="i0eb88576f2154b229cc5f904054ddcaf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTA5OTUxMTY1Njc4MA_540aea04-1219-49d7-8fda-363800807f72">7,945</ix:nonFraction> is classified as current and $<ix:nonFraction unitRef="usd" contextRef="i0eb88576f2154b229cc5f904054ddcaf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTA5OTUxMTY1Njc5Mg_20aafacf-daee-420d-bcec-60237548675d">11,252</ix:nonFraction> is classified as noncurrent on the unaudited condensed consolidated balance sheet. Deferred revenue under the Ipsen Collaboration Agreement will be recognized as revenue in future periods as the Company satisfies its obligations under the Ipsen Collaboration Agreement, which the Company currently estimates to be over the next <ix:nonNumeric contextRef="id7d7e4233d934ae2905015e902539333_D20210101-20210930" format="ixt-sec:durmonth" name="xcur:CollaborationAgreementEstimatedTimingOfRevenueRecognition" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMjc0ODc3OTEyOTM5Ng_833efe4f-77a1-48f0-bf16-7faf9ad57e63">33</ix:nonNumeric> to <ix:nonNumeric contextRef="i8cc70e8bc70d42888c31d1910622f129_D20210101-20210930" format="ixt-sec:durmonth" name="xcur:CollaborationAgreementEstimatedTimingOfRevenueRecognition" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMjc0ODc3OTEyOTQzMA_69ec676d-3f1d-47d0-86ab-7680c9f448f8">42</ix:nonNumeric> months.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AbbVie Collaboration Agreement</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Agreement&#160;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 13, 2019 (the &#8220;AbbVie Effective Date&#8221;), the Company entered into a Collaboration, Option and License Agreement (the &#8220;AbbVie Collaboration Agreement&#8221;), with a wholly-owned subsidiary of Allergan plc, Allergan. On May 8, 2020, Allergan plc, including Allergan was acquired by AbbVie. Pursuant to the AbbVie Collaboration Agreement, the Company granted to AbbVie exclusive access and options to license SNA-based therapeutics arising from <ix:nonFraction unitRef="agreement" contextRef="i25a109363b9444d0b161c5f239e1f5d2_D20191113-20191113" decimals="INF" format="ixt-sec:numwordsen" name="xcur:NumberofCollaborationPrograms" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfNTQ4_8ea83143-4899-433a-a11f-874e1f5121f6">two</ix:nonFraction> collaboration programs related to the treatment of hair loss disorders (each, an &#8220;AbbVie Collaboration Program&#8221;). Under each such license (obtained in connection with the exercise of an AbbVie Option, as defined and discussed further below), the Company would grant to AbbVie exclusive, royalty-bearing, sublicensable, nontransferable, worldwide rights to develop, manufacture, use and commercialize such SNA therapeutics. Under the AbbVie Collaboration Agreement, the Company will use commercially reasonable efforts to conduct the AbbVie Collaboration Programs, each focused on one or more hair loss disorders to discover one or more SNA products that are directed to, bind to or inhibit one or more specific AbbVie Collaboration Program targets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the AbbVie Effective Date, the Company and AbbVie have agreed upon a development plan for each AbbVie Collaboration Program that describes the development activities and timelines required to advance such AbbVie Collaboration Program through its first IND filing (each, an &#8220;AbbVie Development Plan&#8221;).  The activities described in the AbbVie Development Plan are conducted under the supervision of the AbbVie Joint Development Committee (the &#8220;AbbVie JDC&#8221;) consisting of three members from each of the Company and AbbVie. The Company is primarily responsible for performing early-stage discovery and preclinical activities (the &#8220;AbbVie Collaboration Program Initial Development Activities&#8221;) set forth in the AbbVie Development Plan for each AbbVie Collaboration Program and will be solely responsible for all costs and expenses related to the AbbVie Collaboration Program Initial Development Activities. AbbVie may elect, in its sole discretion and at its sole cost and expense, to conduct formulation assessment and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> testing as set forth in an AbbVie Development Plan.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2021, the AbbVie JDC revised the AbbVie Initial Development Plan for each AbbVie Collaboration Program.  In connection with the revised workplan for each AbbVie Collaboration Program, the Company expects to perform additional early stage discovery and preclinical activities to those set forth in the AbbVie Development Plan.  As such, the Company currently estimates significant additional efforts will be required to satisfy the performance obligation under the AbbVie Collaboration Agreement due to the revised workplan for each AbbVie Collaboration Program.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i54748f94cb034e3bbc4604c0cfede784" continuedAt="i0ec2678b276f47a682c63b012cbc5a87"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the completion of all AbbVie Initial Development Activities, the Company is required to deliver to AbbVie a report that describes the results of the AbbVie Initial Development Activities and identifies at least one SNA-based compound that satisfies certain criteria for such AbbVie Collaboration Program as determined by the AbbVie JDC (the &#8220;AbbVie Initial Development Report&#8221;).  Following the delivery of the AbbVie Initial Development Report for an AbbVie Collaboration Program, AbbVie will have the ability for a defined period of time (the &#8220;AbbVie Initial Option Exercise Period&#8221;) to exercise an option (each an &#8220;AbbVie Option&#8221;) to obtain worldwide rights and license to the Company&#8217;s SNA technology and the Company&#8217;s interest in joint collaboration technology to make, have made, import, use, sell or offer for sale any product (each an &#8220;AbbVie Licensed Product&#8221;) that results from such AbbVie Collaboration Program during the term of the AbbVie Collaboration Agreement.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At AbbVie&#8217;s sole option, AbbVie may extend the AbbVie Initial Option Exercise Period (the &#8220;AbbVie Option Extension&#8221;) and require the Company to perform IND-enabling activities described in the AbbVie Development Plan (the &#8220;AbbVie IND-Enabling Activities&#8221;), subject to the payment of additional consideration (&#8220;AbbVie Extension Exercise&#8221;). If AbbVie exercises the AbbVie Option Extension, the Company would be responsible for conducting the AbbVie IND-Enabling Activities and would be solely responsible for all costs and expenses associated with such activities.  Upon completion of the AbbVie IND-Enabling Activities, the Company is required to deliver a report that describes the results of the AbbVie IND-Enabling Activities (the &#8220;AbbVie IND-Enabling Activities Data Package&#8221;) to AbbVie. Following the delivery of AbbVie IND-Enabling Activities Data Package, AbbVie will have the ability for a defined period of time (the &#8220;AbbVie Extended Option Exercise Period&#8221;) to exercise an AbbVie Option with respect to such AbbVie Collaboration Program. After the exercise of an AbbVie Option with respect to an AbbVie Collaboration Program, AbbVie will be responsible for all development, manufacturing and commercialization activities, and costs and expense associated with such activities in connection with AbbVie Licensed Products arising from such AbbVie Collaboration Program.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s obligation to conduct the activities defined in the AbbVie Development Plan under the AbbVie Collaboration Agreement commenced on November 13, 2019 and continues until the earlier of (i) the date AbbVie exercises an AbbVie Option, (ii) the date AbbVie abandons an AbbVie Collaboration Program and foregoes its AbbVie Option to that AbbVie Collaboration Program, or (iii) the fifth anniversary of the AbbVie Effective Date (the &#8220;AbbVie Research Term&#8221;). If the AbbVie Initial Option Exercise Period or AbbVie Extended Option Exercise Period is still in effect for an AbbVie Collaboration Program or if the Company has not delivered a complete AbbVie Initial Development Report or, if AbbVie made an AbbVie Extension Exercise for an AbbVie Collaboration Program, a complete AbbVie IND-Enabling Activities Data Package for such AbbVie Collaboration Program, as determined by the AbbVie JDC, then the AbbVie Research Term will automatically extend by one-year increments until such obligation is satisfied, but in no event past the seventh anniversary of the AbbVie Effective Date.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the AbbVie Collaboration Agreement, the Company received a $<ix:nonFraction unitRef="usd" contextRef="i25a109363b9444d0b161c5f239e1f5d2_D20191113-20191113" decimals="-3" format="ixt:num-dot-decimal" name="xcur:CollaborationAgreementUpfrontPayment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfNTQ0Mg_7ee0f4a5-4325-41f8-b6d8-bc141a3b7c2d">25,000</ix:nonFraction> upfront, non-refundable, non-creditable cash payment (the &#8220;AbbVie Upfront Payment&#8221;) related to the Company&#8217;s research and development costs for conducting the AbbVie Development Plan for <ix:nonFraction unitRef="agreement" contextRef="i25a109363b9444d0b161c5f239e1f5d2_D20191113-20191113" decimals="INF" format="ixt-sec:numwordsen" name="xcur:NumberofCollaborationPrograms" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfNTYyNQ_37da6eb4-095e-4387-8d68-2ebb7f10e519">two</ix:nonFraction> AbbVie Collaboration Programs, each focused on one or more targets, and certain options to obtain exclusive, worldwide licenses under certain intellectual property rights owned or controlled by the Company to develop, manufacture and commercialize certain products resulting from each such AbbVie Collaboration Programs.  The option exercise fee during the AbbVie Initial Option Exercise Period is $<ix:nonFraction unitRef="usd" contextRef="i25a109363b9444d0b161c5f239e1f5d2_D20191113-20191113" decimals="-3" format="ixt:num-dot-decimal" name="xcur:CollaborationAgreementOptionExerciseFee" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfNjAwNQ_0c539dd4-31ca-4f3d-bbce-2e9fc04458e9">10,000</ix:nonFraction> per AbbVie Collaboration Program.  If AbbVie elects to extend the AbbVie Initial Option Exercise Period, AbbVie is required to pay an additional fee of $<ix:nonFraction unitRef="usd" contextRef="i25a109363b9444d0b161c5f239e1f5d2_D20191113-20191113" decimals="-3" format="ixt:num-dot-decimal" name="xcur:CollaborationAgreementExtendedOptionAdditionalExerciseFee" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfNjE0Ng_b85163e2-2512-4621-9128-19a226a7224d">10,000</ix:nonFraction>.  If AbbVie elects to exercise its option during the AbbVie Extended Option Exercise Period, AbbVie must pay the Company the option exercise fee of $<ix:nonFraction unitRef="usd" contextRef="i62ddab29023047f19bcd9cdd54f54b72_D20191113-20191113" decimals="-3" format="ixt:num-dot-decimal" name="xcur:CollaborationAgreementOptionExerciseFee" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfNjI5MA_8dd8e2f4-d311-4dc4-8f72-d814c6e4e0c8">15,000</ix:nonFraction>.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the exercise by AbbVie of an AbbVie Option with respect to an AbbVie Collaboration Program, AbbVie would be required to make certain milestone payments to the Company upon the achievement of specified development, product approval and launch, and commercial events, on an AbbVie Licensed Product by AbbVie Licensed Product basis. On an AbbVie Licensed Product by AbbVie Licensed Product basis, for the first AbbVie Licensed Product to achieve the associated milestone event, the Company is eligible to receive up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="iadf638d109364478ada9ed12098f78a3_D20191113-20191113" decimals="-3" format="ixt:num-dot-decimal" name="xcur:RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfNjc4NA_e872aab0-5fa9-465b-83b1-61b6c219eaf6">55,000</ix:nonFraction> for development milestone payments and $<ix:nonFraction unitRef="usd" contextRef="iadf638d109364478ada9ed12098f78a3_D20191113-20191113" decimals="-3" format="ixt:num-dot-decimal" name="xcur:RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfNjgyNg_abea8a33-8f91-40df-a89b-561df28d7161">132,500</ix:nonFraction> for product approval and launch milestone payments. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i0ec2678b276f47a682c63b012cbc5a87" continuedAt="i463525324511496ba8e01bab12bdea40"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also eligible for up to $<ix:nonFraction unitRef="usd" contextRef="iadf638d109364478ada9ed12098f78a3_D20191113-20191113" decimals="-3" format="ixt:num-dot-decimal" name="xcur:RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfNjkyMA_44728eb1-66ef-4740-bfa6-988eb1c5b54b">175,000</ix:nonFraction> in sales milestone payments on an AbbVie Collaboration Program by AbbVie Collaboration Program basis, associated with aggregate worldwide sales. Certain product approval milestones are subject to certain reductions under specified circumstances, including for payments required to be made by AbbVie to obtain certain third-party intellectual property rights.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, to the extent there is any AbbVie Licensed Product, the Company would be entitled to receive tiered royalty payments of mid-single digits to the mid-teens percentage on future net worldwide product sales of such AbbVie Licensed Products, subject to certain reductions under specified circumstances. Royalties are due on a AbbVie Licensed Product by AbbVie Licensed Product and country by country basis from the date of the first commercial sale of each AbbVie Licensed Product in a country until the latest to occur of: (i) the expiration date in such country of the last to expire valid claim within the licensed intellectual property covering the manufacture, use or sale of such AbbVie Licensed Product in such country, (ii) the tenth anniversary of the first commercial sale of such AbbVie Licensed Product in such country, and (iii) the expiration of regulatory exclusivity for such AbbVie Licensed Product in such country.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie may terminate the AbbVie Collaboration Agreement for any reason or no reason, either in its entirety or on an AbbVie Collaboration Program by AbbVie Collaboration Program basis, at any time on <ix:nonNumeric contextRef="i25a109363b9444d0b161c5f239e1f5d2_D20191113-20191113" format="ixt-sec:durday" name="xcur:CollaborationAgreementTerminationPeriodUponWrittenNotice" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfODMzOA_4326b830-9b72-43ec-8168-1b9eb5b1841f">90</ix:nonNumeric> days&#8217; prior written notice to the Company. Unless earlier terminated, the term of the AbbVie Collaboration Agreement shall continue until (i) if both AbbVie Option Exercise Periods expire without AbbVie exercising either AbbVie Option, the expiration of the later to expire AbbVie Option Exercise Period, and (ii) if either or both AbbVie Options are exercised on an AbbVie Licensed Product by AbbVie Licensed Product and country-by-country basis, the expiration of the royalty term for such AbbVie Licensed Product in such country. Either party may terminate the AbbVie Collaboration Agreement if the other party has materially breached or defaulted in the performance of any of its material obligations and such breach or default continues after the specified cure period. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Termination of the AbbVie Collaboration Agreement for any reason will not release either party from any liability which, at the time of such termination, has already accrued to the other party or which is attributable to a period prior to such termination. In addition, termination of the AbbVie Collaboration Agreement will not preclude either party from pursuing any rights and remedies it may have under the agreement or at law or in equity with respect to any breach of the AbbVie Collaboration Agreement. If either party terminates the AbbVie Collaboration Agreement, the license and rights granted to AbbVie with respect to the terminated AbbVie Collaboration Program or AbbVie License Product shall terminate. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Analysis</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that AbbVie is a customer in this arrangement, and as such the arrangement falls within the scope of the revenue recognition guidance. Under the AbbVie Collaboration Agreement, the Company has identified a single performance obligation that includes (i) the research and development activities during the AbbVie Research Term (the &#8220;AbbVie R&amp;D Services&#8221;), and (ii) AbbVie Joint Development Committee services during the AbbVie Research Term (the &#8220;AbbVie JDC Services&#8221;). The Company has concluded that the AbbVie R&amp;D Services is not distinct from the AbbVie JDC Services during the AbbVie Research Term. The AbbVie JDC provides oversight and management of the overall AbbVie Collaboration Agreement, and the members of the AbbVie JDC from the Company have specialized industry knowledge, particularly as it relates to SNA technology. The AbbVie JDC is meant to facilitate the early-stage research being performed and coordinate the activities of both the Company and AbbVie. Further, the AbbVie JDC services are critical to the ongoing evaluation of an AbbVie Collaboration Program and the drafting and evaluation of the AbbVie Initial Development Report and the AbbVie IND-Enabling Data Package. Accordingly, the Company&#8217;s participation on the AbbVie JDC is essential to AbbVie receiving value from the AbbVie R&amp;D Services and as such, the AbbVie JDC Services along with the AbbVie R&amp;D Services are considered one performance obligation (the &#8220;AbbVie Collaboration Program Services&#8221;).  In addition, the Company has concluded that the option to purchase two development and commercialization licenses is considered a marketing offer as the options did not provide any discounts or other rights that would be considered a material right in the arrangement, and thus, not a performance obligation at the onset of the agreement.&#160;&#160;The consideration for these options will be accounted for when they are exercised.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i463525324511496ba8e01bab12bdea40" continuedAt="ided6fb19e10e47308fc389a8d8d32a2b"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the AbbVie Effective Date, the total transaction price was determined to be $<ix:nonFraction unitRef="usd" contextRef="i25a109363b9444d0b161c5f239e1f5d2_D20191113-20191113" decimals="-3" format="ixt:num-dot-decimal" name="xcur:CollaborationAgreementUpfrontPayment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTE3NDE_6f2ae343-9875-404a-b3a8-47c92f4a850a">25,000</ix:nonFraction>, consisting solely of the AbbVie Upfront Payment. The Company also utilized the most likely amount method to estimate any development and regulatory milestone payments to be received. As of the AbbVie Effective Date, there were no milestones included in the transaction price.&#160;The milestones were fully constrained due to the significant uncertainties surrounding such payments.&#160;The Company considered the stage of development and the risks associated with the remaining development required to achieve the milestone, as well as whether the achievement of the milestone is outside the control of the Company or AbbVie.  The Company has determined that any commercial milestones and sales-based royalties will be recognized when the related sales occur and therefore they have also been excluded from the transaction price. The Company will re-evaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur.  As of September&#160;30, 2021, the Company determined that any development, regulatory or commercial milestones continue to be constrained and therefore the related milestone payments continue to be excluded from the transaction price at September 30, 2021.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will recognize revenue related to the AbbVie Collaboration Program Services as the performance obligation is satisfied using an input method to measure progress. The Company believes the input method that most accurately depicts the measure of progress is the actual hours incurred to date relative to projected hours to complete the research service.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed above, during the third quarter of 2021, the AbbVie JDC revised the AbbVie Initial Development Plan for each AbbVie Collaboration Program.  As a result, the Company has increased its estimate of total hours to complete the research services, requiring an adjustment to cumulative revenue recognized (considered a change in estimate pursuant to ASC 606) as of September 30, 2021.  As such, during the third quarter of 2021, the Company recorded a cumulative catchup adjustment (reduction) of revenue of $(<ix:nonFraction unitRef="usd" contextRef="i5ead1c261b0940cab128efb701608748_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="xcur:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfODI0NjMzNzI0MDMzMA_a26a21e1-cfad-4c18-9a0d-eb5eae3797d5">4,480</ix:nonFraction>).</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2021, the Company recognized revenue under the AbbVie Collaboration Agreement of approximately $(<ix:nonFraction unitRef="usd" contextRef="i5ead1c261b0940cab128efb701608748_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="xcur:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTM0Nzk_a26a21e1-cfad-4c18-9a0d-eb5eae3797d5">4,480</ix:nonFraction>) and $(<ix:nonFraction unitRef="usd" contextRef="ie6c60cafc25843e7aa83623d15b8db40_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTM0ODY_889fbcd4-5652-43b1-b4ba-ed2ab877ebaf">3,404</ix:nonFraction>), respectively, reflecting the cumulative catchup adjustment (reduction) of revenue of $(<ix:nonFraction unitRef="usd" contextRef="i5ead1c261b0940cab128efb701608748_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="xcur:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfODI0NjMzNzI2Mjk1MA_a26a21e1-cfad-4c18-9a0d-eb5eae3797d5">4,480</ix:nonFraction>) discussed above due to a change in estimate.  The Company currently estimates significant additional efforts will be required to satisfy the performance obligation under the AbbVie Collaboration Agreement due to the revised workplan for each AbbVie Collaboration Program.  These increased estimated efforts in connection with the change in workplan resulted in less progress occurring relative to the increased estimate of total project hours to complete the research services during the three and nine months ended September 30, 2021 as compared to the amount of revenue recognized at both June 30, 2021 and December 31, 2020, which led to revenue reversals in each respective period.  During the three and nine months ended September&#160;30, 2020, the Company recognized revenue under the AbbVie Collaboration Agreement of approximately $<ix:nonFraction unitRef="usd" contextRef="i202fe08011f74b3bb586c3b5936aade6_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTQyMTU_1f115f63-906b-49b0-93e7-17e61a84b25d">2,402</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i334dc3567c6c404c81c2439542a6c976_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTQyMjI_8fca8067-3b83-4f94-a282-069e7e967ee1">16,351</ix:nonFraction>, respectively.  As of September&#160;30, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="ib58e437af4b84283a34ce171354bebca_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTA5OTUxMTY1NzI0OQ_70819ac9-77c1-4da1-8337-905a03efe21f">11,747</ix:nonFraction> of deferred revenue related to the AbbVie Collaboration Agreement, of which is $<ix:nonFraction unitRef="usd" contextRef="ib58e437af4b84283a34ce171354bebca_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTA5OTUxMTY1NzI1Ng_8feff2fb-b03b-4322-87a0-fa56a6970f80">6,070</ix:nonFraction> is classified as current and $<ix:nonFraction unitRef="usd" contextRef="ib58e437af4b84283a34ce171354bebca_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTA5OTUxMTY1NzI2Mw_2f69f543-d4a2-460d-a13b-5b29373ce88f">5,677</ix:nonFraction> is classified as noncurrent on the unaudited condensed consolidated balance sheet.  Deferred revenue under the AbbVie Collaboration Agreement will be recognized as revenue in future periods as the Company satisfies its obligations under the AbbVie Collaboration Agreement, which the Company currently estimates to be over the next <ix:nonNumeric contextRef="i9f46863e9a324f25a2a99c8d4fc202db_D20210101-20210930" format="ixt-sec:durmonth" name="xcur:CollaborationAgreementEstimatedTimingOfRevenueRecognition" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMjc0ODc3OTEyOTA2MQ_6a3405ff-6df1-4ab1-a4b0-691d7f13902f">24</ix:nonNumeric> to <ix:nonNumeric contextRef="ib068c60a143742cab222adf4b1fc4d6e_D20210101-20210930" format="ixt-sec:durmonth" name="xcur:CollaborationAgreementEstimatedTimingOfRevenueRecognition" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMjc0ODc3OTEyOTA4MA_aa991ba9-8e0f-41d2-847b-97d75afa3f47">27</ix:nonNumeric> months.  As of  December&#160;31, 2020, there was $<ix:nonFraction unitRef="usd" contextRef="ie0f5e47c15a04e01ae8607547bdbb25b_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTQyNzU_2ac05a0d-526c-4c98-ba38-888a64d530b0">8,343</ix:nonFraction> of deferred revenue related to the AbbVie Collaboration Agreement, which was classified as current on the unaudited condensed consolidated balance sheet based on the estimated contract completion date at that time.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dermelix Collaboration Agreement</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2019, Exicure entered into a License and Development Agreement (the &#8220;Dermelix Collaboration Agreement&#8221;) with Dermelix, LLC d/b/a Dermelix Biotherapeutics (&#8220;Dermelix&#8221;). Under the terms of the Dermelix Collaboration Agreement, Exicure received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ibe437bd3033d4b10b7ec04a3e962b1fa_D20190217-20190217" decimals="-3" format="ixt:num-dot-decimal" name="xcur:CollaborationAgreementUpfrontPayment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTQ2OTY_05db506c-b24e-4e95-8d85-ddb90b0654d2">1,000</ix:nonFraction>, to be applied against the initial $<ix:nonFraction unitRef="usd" contextRef="ibe437bd3033d4b10b7ec04a3e962b1fa_D20190217-20190217" decimals="-3" format="ixt:num-dot-decimal" name="xcur:CollaborationDevelopmentExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTQ3MzQ_3699d7e2-c167-4fec-87a0-cb738b0f4171">1,000</ix:nonFraction> of the Company&#8217;s development expenses.  </span></div><div style="margin-bottom:9pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company initially recorded the upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ibe437bd3033d4b10b7ec04a3e962b1fa_D20190217-20190217" decimals="-3" format="ixt:num-dot-decimal" name="xcur:CollaborationAgreementUpfrontPayment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTQ4MzI_fdc70b97-1640-487b-be02-12927616fc4a">1,000</ix:nonFraction> as deferred revenue related to its wholly unsatisfied performance obligation and reduced this balance to <ix:nonFraction unitRef="usd" contextRef="i1b1064f27e214d639fb5a6444e15afc9_I20191231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ContractWithCustomerLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTQ5NDA_4e68cbfa-4a53-4422-ab65-7a0f24ac9053">zero</ix:nonFraction> during 2019 by recognizing revenue as services </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="ided6fb19e10e47308fc389a8d8d32a2b"><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were provided.  The Company recognized <ix:nonFraction unitRef="usd" contextRef="ie7111ceb9bee457d80c964d377cc8997_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTUwMjk_326eae8b-5305-4fcc-abbd-0fd58b02f550"><ix:nonFraction unitRef="usd" contextRef="i9a7767cbe5314379a5bbad2a39574623_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTUwMjk_9bea6405-3690-4f9f-a65c-b76e65e118ad">no</ix:nonFraction></ix:nonFraction> revenue under the Dermelix Collaboration Agreement during the three and nine months ended September&#160;30, 2021. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="i1972cd63fd53468ca6ea728506874004_D20200701-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTUxNDc_05542d5a-c805-4cb8-98d4-ad8b0d0c1baf">41</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i6df20868c6bf4088a7c126fd9b4c448f_D20200101-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTUxNTQ_b56f8f7f-322b-40c4-9ac9-d77728a26029">122</ix:nonFraction> of revenue during the three and nine months ended September&#160;30, 2020 which reflected reimbursement by Dermelix for additional costs incurred by Exicure for early-stage development costs beyond the initial $<ix:nonFraction unitRef="usd" contextRef="ibe437bd3033d4b10b7ec04a3e962b1fa_D20190217-20190217" decimals="-3" format="ixt:num-dot-decimal" name="xcur:CollaborationAgreementUpfrontPayment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTUzMzc_15fa0289-b7c4-4ada-b222-75b8d0ddac93">1,000</ix:nonFraction> upfront payment.</span></div><div style="margin-bottom:9pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Contract Liabilities</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Up-front payments are recorded as deferred revenue upon receipt or when due until such time as the Company satisfies its performance obligations under these arrangements.</span></div><ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfNTQ5NzU1ODE2Nzc5Nw_bf0e3def-20f9-40e3-9872-e807cf6ba461" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in the balances of the Company&#8217;s contract liabilities (in thousands):</span></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.032%"><tr><td style="width:1.0%"></td><td style="width:30.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.559%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.972%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Revenue Balance at January 1, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue <br/>(Recognized) Reversed</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Revenue Balance at September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Collaboration Agreement</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8868537d91414e59b86b641af9be949f_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RhYmxlOjRmN2M5NjI5OTNlNTRiNzViOGQ1ZGViM2RkMmZiNTkyL3RhYmxlcmFuZ2U6NGY3Yzk2Mjk5M2U1NGI3NWI4ZDVkZWIzZGQyZmI1OTJfMS0yLTEtMS05ODEz_d18fa140-46c7-46c3-b275-305f85a9802d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i603ebaab9dc547c9b12a83e9eed30a32_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="xcur:ContractWithCustomerLiabilityAdditions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RhYmxlOjRmN2M5NjI5OTNlNTRiNzViOGQ1ZGViM2RkMmZiNTkyL3RhYmxlcmFuZ2U6NGY3Yzk2Mjk5M2U1NGI3NWI4ZDVkZWIzZGQyZmI1OTJfMS00LTEtMS05ODE1_68665c16-ccfd-49ae-9129-6ea3b28fe871">20,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i603ebaab9dc547c9b12a83e9eed30a32_D20210101-20210930" decimals="-3" name="xcur:ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RhYmxlOjRmN2M5NjI5OTNlNTRiNzViOGQ1ZGViM2RkMmZiNTkyL3RhYmxlcmFuZ2U6NGY3Yzk2Mjk5M2U1NGI3NWI4ZDVkZWIzZGQyZmI1OTJfMS02LTEtMS05ODE3_f0c5943a-c175-4abc-b28d-9212536520da">803</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2eeecde261e4327b21ed0de06f04e52_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RhYmxlOjRmN2M5NjI5OTNlNTRiNzViOGQ1ZGViM2RkMmZiNTkyL3RhYmxlcmFuZ2U6NGY3Yzk2Mjk5M2U1NGI3NWI4ZDVkZWIzZGQyZmI1OTJfMS04LTEtMS05ODE5_0fd979a0-8045-4950-b2f7-9d5d58796ec6">19,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbbVie Collaboration Agreement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a37c9da460c48809897a601836d2643_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RhYmxlOjRmN2M5NjI5OTNlNTRiNzViOGQ1ZGViM2RkMmZiNTkyL3RhYmxlcmFuZ2U6NGY3Yzk2Mjk5M2U1NGI3NWI4ZDVkZWIzZGQyZmI1OTJfMi0yLTEtMS05ODEz_87e0fef1-a7a8-4aaa-b578-dee9b1cfbd2d">8,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb811529c5b84fc488584f1160906a17_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="xcur:ContractWithCustomerLiabilityAdditions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RhYmxlOjRmN2M5NjI5OTNlNTRiNzViOGQ1ZGViM2RkMmZiNTkyL3RhYmxlcmFuZ2U6NGY3Yzk2Mjk5M2U1NGI3NWI4ZDVkZWIzZGQyZmI1OTJfMi00LTEtMS05ODE1_e80e17b6-7085-4443-a9f5-7d4c7f2540ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb811529c5b84fc488584f1160906a17_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="xcur:ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RhYmxlOjRmN2M5NjI5OTNlNTRiNzViOGQ1ZGViM2RkMmZiNTkyL3RhYmxlcmFuZ2U6NGY3Yzk2Mjk5M2U1NGI3NWI4ZDVkZWIzZGQyZmI1OTJfMi02LTEtMS05ODE3_6f124142-0bd1-4910-adef-92a9c6790d42">3,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbfce07014ab4a519300435d21964c4d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RhYmxlOjRmN2M5NjI5OTNlNTRiNzViOGQ1ZGViM2RkMmZiNTkyL3RhYmxlcmFuZ2U6NGY3Yzk2Mjk5M2U1NGI3NWI4ZDVkZWIzZGQyZmI1OTJfMi04LTEtMS05ODE5_5a2d1617-27fe-4f18-b56b-bf1dbb66e86d">11,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RhYmxlOjRmN2M5NjI5OTNlNTRiNzViOGQ1ZGViM2RkMmZiNTkyL3RhYmxlcmFuZ2U6NGY3Yzk2Mjk5M2U1NGI3NWI4ZDVkZWIzZGQyZmI1OTJfMy0yLTEtMS05ODEz_071d7622-5645-409d-b299-203bec368379">8,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="xcur:ContractWithCustomerLiabilityAdditions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RhYmxlOjRmN2M5NjI5OTNlNTRiNzViOGQ1ZGViM2RkMmZiNTkyL3RhYmxlcmFuZ2U6NGY3Yzk2Mjk5M2U1NGI3NWI4ZDVkZWIzZGQyZmI1OTJfMy00LTEtMS05ODE1_d4f248e4-8c10-48a2-a085-ea84b5238b14">20,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="xcur:ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RhYmxlOjRmN2M5NjI5OTNlNTRiNzViOGQ1ZGViM2RkMmZiNTkyL3RhYmxlcmFuZ2U6NGY3Yzk2Mjk5M2U1NGI3NWI4ZDVkZWIzZGQyZmI1OTJfMy02LTEtMS05ODE3_9028993b-9a83-46c8-8ffd-c0c8110d506d">2,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RhYmxlOjRmN2M5NjI5OTNlNTRiNzViOGQ1ZGViM2RkMmZiNTkyL3RhYmxlcmFuZ2U6NGY3Yzk2Mjk5M2U1NGI3NWI4ZDVkZWIzZGQyZmI1OTJfMy04LTEtMS05ODE5_9c9f39d9-bfd9-40f9-b63e-d69b9f4c7686">30,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i30c50c718dda42d28fbdd6dcd4fa2365_46"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RleHRyZWdpb246ODE1YmQzOGUzYWEwNGE0ZmE3NGU0ZDVmMDM2OGQxNGRfMzY1_50093ffb-71a7-4ff4-8469-797724eaee40" continuedAt="if78348d75bc64e09833f9dcb83dfd20f" escape="true">Supplemental Balance Sheet Information</ix:nonNumeric></span></div><ix:continuation id="if78348d75bc64e09833f9dcb83dfd20f" continuedAt="i6023e21ac0ca4933a5db71005956b39e"><ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RleHRyZWdpb246ODE1YmQzOGUzYWEwNGE0ZmE3NGU0ZDVmMDM2OGQxNGRfMzYw_e6004c0b-787a-4892-a512-87513ecb8d50" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid expenses and other current assets</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.711%"><tr><td style="width:1.0%"></td><td style="width:72.165%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.646%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical, contract research and manufacturing costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjNkN2ZjYWIwNzQzZDQ3NmRiNzkwZDQxZmVlNjI4MjI3L3RhYmxlcmFuZ2U6M2Q3ZmNhYjA3NDNkNDc2ZGI3OTBkNDFmZWU2MjgyMjdfMS0xLTEtMS0w_44efd144-c4a2-470a-9810-8f221ebc9e0f">2,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjNkN2ZjYWIwNzQzZDQ3NmRiNzkwZDQxZmVlNjI4MjI3L3RhYmxlcmFuZ2U6M2Q3ZmNhYjA3NDNkNDc2ZGI3OTBkNDFmZWU2MjgyMjdfMS0zLTEtMS0w_f6a5fad5-0184-45db-a5c0-4db8f007ad18">2,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" name="us-gaap:InterestReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjNkN2ZjYWIwNzQzZDQ3NmRiNzkwZDQxZmVlNjI4MjI3L3RhYmxlcmFuZ2U6M2Q3ZmNhYjA3NDNkNDc2ZGI3OTBkNDFmZWU2MjgyMjdfMi0xLTEtMS0w_9731dda8-5193-4705-bfe5-5de4a9c33b52">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" name="us-gaap:InterestReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjNkN2ZjYWIwNzQzZDQ3NmRiNzkwZDQxZmVlNjI4MjI3L3RhYmxlcmFuZ2U6M2Q3ZmNhYjA3NDNkNDc2ZGI3OTBkNDFmZWU2MjgyMjdfMi0zLTEtMS0w_d715f63b-195b-4de2-a475-2da2bdf71933">161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" name="us-gaap:PrepaidInsurance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjNkN2ZjYWIwNzQzZDQ3NmRiNzkwZDQxZmVlNjI4MjI3L3RhYmxlcmFuZ2U6M2Q3ZmNhYjA3NDNkNDc2ZGI3OTBkNDFmZWU2MjgyMjdfMy0xLTEtMS0w_bea88837-e20c-4e60-9fb9-f691cee33107">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" name="us-gaap:PrepaidInsurance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjNkN2ZjYWIwNzQzZDQ3NmRiNzkwZDQxZmVlNjI4MjI3L3RhYmxlcmFuZ2U6M2Q3ZmNhYjA3NDNkNDc2ZGI3OTBkNDFmZWU2MjgyMjdfMy0zLTEtMS0w_5b4c6c61-9837-424e-a407-ad1c489298e4">694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjNkN2ZjYWIwNzQzZDQ3NmRiNzkwZDQxZmVlNjI4MjI3L3RhYmxlcmFuZ2U6M2Q3ZmNhYjA3NDNkNDc2ZGI3OTBkNDFmZWU2MjgyMjdfNC0xLTEtMS0w_c1b41cdd-4a14-4ebf-8d10-aeb73a2b7e0d">1,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjNkN2ZjYWIwNzQzZDQ3NmRiNzkwZDQxZmVlNjI4MjI3L3RhYmxlcmFuZ2U6M2Q3ZmNhYjA3NDNkNDc2ZGI3OTBkNDFmZWU2MjgyMjdfNC0zLTEtMS0w_ce4a47a4-90de-490e-b930-cce096e7845f">1,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjNkN2ZjYWIwNzQzZDQ3NmRiNzkwZDQxZmVlNjI4MjI3L3RhYmxlcmFuZ2U6M2Q3ZmNhYjA3NDNkNDc2ZGI3OTBkNDFmZWU2MjgyMjdfNS0xLTEtMS0w_327d19d2-706c-49e5-9e7f-ede5a551cde2">3,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjNkN2ZjYWIwNzQzZDQ3NmRiNzkwZDQxZmVlNjI4MjI3L3RhYmxlcmFuZ2U6M2Q3ZmNhYjA3NDNkNDc2ZGI3OTBkNDFmZWU2MjgyMjdfNS0zLTEtMS0w_de6fc8f1-c5e4-401b-9d14-802d637cbc6a">4,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RleHRyZWdpb246ODE1YmQzOGUzYWEwNGE0ZmE3NGU0ZDVmMDM2OGQxNGRfMzY3_ba74598f-c94a-4557-8067-c74d9a15032b" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and equipment, net</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.230%"><tr><td style="width:1.0%"></td><td style="width:72.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.314%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.997%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scientific equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47cd4e78b2384bf799057776f855682a_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjFhNGEwMmI1NDk5YjQyNTliMjk4ODYyZGY3ZTM1ZDBjL3RhYmxlcmFuZ2U6MWE0YTAyYjU0OTliNDI1OWIyOTg4NjJkZjdlMzVkMGNfMS0xLTEtMS0w_79891888-4cff-4e90-a5ac-1f39e1c7a219">6,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0018e41fbb07474dba5b83bb48cc8e03_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjFhNGEwMmI1NDk5YjQyNTliMjk4ODYyZGY3ZTM1ZDBjL3RhYmxlcmFuZ2U6MWE0YTAyYjU0OTliNDI1OWIyOTg4NjJkZjdlMzVkMGNfMS0zLTEtMS0w_01e1218f-91d3-4b27-95f7-00186616d361">5,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib82780d8d54341299de5c10d925f31a6_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjFhNGEwMmI1NDk5YjQyNTliMjk4ODYyZGY3ZTM1ZDBjL3RhYmxlcmFuZ2U6MWE0YTAyYjU0OTliNDI1OWIyOTg4NjJkZjdlMzVkMGNfMi0xLTEtMS0w_72ae94eb-5fe7-4d7a-bb8b-ad1702caef34">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3ceab8c75694c4993355dcd2ae5c9fe_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjFhNGEwMmI1NDk5YjQyNTliMjk4ODYyZGY3ZTM1ZDBjL3RhYmxlcmFuZ2U6MWE0YTAyYjU0OTliNDI1OWIyOTg4NjJkZjdlMzVkMGNfMi0zLTEtMS0w_8a75cfc2-b76c-4dc9-bac4-9b2289941fd3">192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40174dd466594c3ab62a59e071f6cefd_I20210930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjFhNGEwMmI1NDk5YjQyNTliMjk4ODYyZGY3ZTM1ZDBjL3RhYmxlcmFuZ2U6MWE0YTAyYjU0OTliNDI1OWIyOTg4NjJkZjdlMzVkMGNfMy0xLTEtMS0w_2ea5ab26-7842-43bf-81fe-23f668720fd8">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d6ec4e189a747bd803d814ff65b5f44_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjFhNGEwMmI1NDk5YjQyNTliMjk4ODYyZGY3ZTM1ZDBjL3RhYmxlcmFuZ2U6MWE0YTAyYjU0OTliNDI1OWIyOTg4NjJkZjdlMzVkMGNfMy0zLTEtMS0w_656eb85d-1cb0-42b3-bf91-925a941865ac">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9c2eeac1b3a491ba5d5b4821b396ce8_I20210930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjFhNGEwMmI1NDk5YjQyNTliMjk4ODYyZGY3ZTM1ZDBjL3RhYmxlcmFuZ2U6MWE0YTAyYjU0OTliNDI1OWIyOTg4NjJkZjdlMzVkMGNfNC0xLTEtMS0w_f1ffcd5e-7f92-46e4-adc3-cb755111c0a0">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8817be1e21d4636989a972eaf99d676_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjFhNGEwMmI1NDk5YjQyNTliMjk4ODYyZGY3ZTM1ZDBjL3RhYmxlcmFuZ2U6MWE0YTAyYjU0OTliNDI1OWIyOTg4NjJkZjdlMzVkMGNfNC0zLTEtMS0w_4936673e-689b-4169-8291-8c42aeb369e5">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac3a1146a0b04454a629ec3468190f98_I20210930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjFhNGEwMmI1NDk5YjQyNTliMjk4ODYyZGY3ZTM1ZDBjL3RhYmxlcmFuZ2U6MWE0YTAyYjU0OTliNDI1OWIyOTg4NjJkZjdlMzVkMGNfNS0xLTEtMS0w_04755b2d-5905-4bfc-8b60-3af247033387">318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00fa9951d7744973a1c8d2aa533d73dc_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjFhNGEwMmI1NDk5YjQyNTliMjk4ODYyZGY3ZTM1ZDBjL3RhYmxlcmFuZ2U6MWE0YTAyYjU0OTliNDI1OWIyOTg4NjJkZjdlMzVkMGNfNS0zLTEtMS0w_c8321348-7d7c-45de-b020-0778f4b4d49e">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjFhNGEwMmI1NDk5YjQyNTliMjk4ODYyZGY3ZTM1ZDBjL3RhYmxlcmFuZ2U6MWE0YTAyYjU0OTliNDI1OWIyOTg4NjJkZjdlMzVkMGNfNi0xLTEtMS0w_acd46fe8-633f-4be1-9770-eb4df454ea1f">6,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjFhNGEwMmI1NDk5YjQyNTliMjk4ODYyZGY3ZTM1ZDBjL3RhYmxlcmFuZ2U6MWE0YTAyYjU0OTliNDI1OWIyOTg4NjJkZjdlMzVkMGNfNi0zLTEtMS0w_31839d56-d211-4991-939e-635c85a5fe9d">5,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjFhNGEwMmI1NDk5YjQyNTliMjk4ODYyZGY3ZTM1ZDBjL3RhYmxlcmFuZ2U6MWE0YTAyYjU0OTliNDI1OWIyOTg4NjJkZjdlMzVkMGNfNy0xLTEtMS0w_6b2ea2f1-20f5-47a5-96b6-0bb90e1de599">2,373</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjFhNGEwMmI1NDk5YjQyNTliMjk4ODYyZGY3ZTM1ZDBjL3RhYmxlcmFuZ2U6MWE0YTAyYjU0OTliNDI1OWIyOTg4NjJkZjdlMzVkMGNfNy0zLTEtMS0w_a59656a1-5903-45aa-9ec0-13498cad8dc9">1,740</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjFhNGEwMmI1NDk5YjQyNTliMjk4ODYyZGY3ZTM1ZDBjL3RhYmxlcmFuZ2U6MWE0YTAyYjU0OTliNDI1OWIyOTg4NjJkZjdlMzVkMGNfOC0xLTEtMS0w_5642c749-6942-4353-ab25-c5c83f33daad">4,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjFhNGEwMmI1NDk5YjQyNTliMjk4ODYyZGY3ZTM1ZDBjL3RhYmxlcmFuZ2U6MWE0YTAyYjU0OTliNDI1OWIyOTg4NjJkZjdlMzVkMGNfOC0zLTEtMS0w_8e3ab2be-9df8-4100-ae74-5d2c4baf0005">4,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense was $<ix:nonFraction unitRef="usd" contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930" decimals="-3" name="us-gaap:DepreciationAmortizationAndAccretionNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RleHRyZWdpb246ODE1YmQzOGUzYWEwNGE0ZmE3NGU0ZDVmMDM2OGQxNGRfMTY0_6f216bc2-a641-4bf4-afd5-5f9b9a716aed">283</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="-3" name="us-gaap:DepreciationAmortizationAndAccretionNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RleHRyZWdpb246ODE1YmQzOGUzYWEwNGE0ZmE3NGU0ZDVmMDM2OGQxNGRfMTcx_3c4b46fe-78d1-4b1a-9202-ff3ffc305857">159</ix:nonFraction> for the three months ended September 30, 2021 and 2020, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" name="us-gaap:DepreciationAmortizationAndAccretionNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RleHRyZWdpb246ODE1YmQzOGUzYWEwNGE0ZmE3NGU0ZDVmMDM2OGQxNGRfMjQz_3f9aba37-5e2b-4299-8cf3-221d5a37cfba">829</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" name="us-gaap:DepreciationAmortizationAndAccretionNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RleHRyZWdpb246ODE1YmQzOGUzYWEwNGE0ZmE3NGU0ZDVmMDM2OGQxNGRfMjUw_d22ad309-96d0-44d9-8e9d-c467bc411f93">494</ix:nonFraction> for the nine months ended September 30, 2021 and 2020, respectively.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i6023e21ac0ca4933a5db71005956b39e"><ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RleHRyZWdpb246ODE1YmQzOGUzYWEwNGE0ZmE3NGU0ZDVmMDM2OGQxNGRfMzYz_31d71642-37c4-4850-a872-7ef11703569c" escape="true"><div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued expenses and other current liabilities</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.551%"><tr><td style="width:1.0%"></td><td style="width:72.289%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.950%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical, contract research and manufacturing costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="xcur:AccruedClinicalContractResearchAndManufacturingCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjY2OWNlNTZhMzExMTQ0ODY4YThjZjQyMzMwOTdhNjk4L3RhYmxlcmFuZ2U6NjY5Y2U1NmEzMTExNDQ4NjhhOGNmNDIzMzA5N2E2OThfMS0xLTEtMS0w_8cc2406e-e07d-44e1-9604-737d1f81b9e7">2,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="xcur:AccruedClinicalContractResearchAndManufacturingCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjY2OWNlNTZhMzExMTQ0ODY4YThjZjQyMzMwOTdhNjk4L3RhYmxlcmFuZ2U6NjY5Y2U1NmEzMTExNDQ4NjhhOGNmNDIzMzA5N2E2OThfMS0zLTEtMS0w_2b9c13c7-18e6-4b45-ae90-78593b7940a3">1,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjY2OWNlNTZhMzExMTQ0ODY4YThjZjQyMzMwOTdhNjk4L3RhYmxlcmFuZ2U6NjY5Y2U1NmEzMTExNDQ4NjhhOGNmNDIzMzA5N2E2OThfMi0xLTEtMS0w_21e92a15-347b-4548-b0c7-05244847c595">1,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjY2OWNlNTZhMzExMTQ0ODY4YThjZjQyMzMwOTdhNjk4L3RhYmxlcmFuZ2U6NjY5Y2U1NmEzMTExNDQ4NjhhOGNmNDIzMzA5N2E2OThfMi0zLTEtMS0w_3123cd51-0e90-4072-adc0-5bc9a4b052e8">1,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjY2OWNlNTZhMzExMTQ0ODY4YThjZjQyMzMwOTdhNjk4L3RhYmxlcmFuZ2U6NjY5Y2U1NmEzMTExNDQ4NjhhOGNmNDIzMzA5N2E2OThfNS0xLTEtMS0w_e5458608-a56e-4e1e-ae46-96d4b4b0cb13">440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjY2OWNlNTZhMzExMTQ0ODY4YThjZjQyMzMwOTdhNjk4L3RhYmxlcmFuZ2U6NjY5Y2U1NmEzMTExNDQ4NjhhOGNmNDIzMzA5N2E2OThfNS0zLTEtMS0w_0185b2de-8c75-45f1-8e07-6d81cc5d552e">223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjY2OWNlNTZhMzExMTQ0ODY4YThjZjQyMzMwOTdhNjk4L3RhYmxlcmFuZ2U6NjY5Y2U1NmEzMTExNDQ4NjhhOGNmNDIzMzA5N2E2OThfNi0xLTEtMS0w_93b71cf2-ec9b-42ba-966f-577e5c175aec">911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjY2OWNlNTZhMzExMTQ0ODY4YThjZjQyMzMwOTdhNjk4L3RhYmxlcmFuZ2U6NjY5Y2U1NmEzMTExNDQ4NjhhOGNmNDIzMzA5N2E2OThfNi0zLTEtMS0w_7a293d27-e8b2-475f-891b-e1a89151993b">772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjY2OWNlNTZhMzExMTQ0ODY4YThjZjQyMzMwOTdhNjk4L3RhYmxlcmFuZ2U6NjY5Y2U1NmEzMTExNDQ4NjhhOGNmNDIzMzA5N2E2OThfNy0xLTEtMS0w_1260afa5-162f-49b8-aa0d-1ccb0c66d1a3">5,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjY2OWNlNTZhMzExMTQ0ODY4YThjZjQyMzMwOTdhNjk4L3RhYmxlcmFuZ2U6NjY5Y2U1NmEzMTExNDQ4NjhhOGNmNDIzMzA5N2E2OThfNy0zLTEtMS0w_80137896-e317-4c19-898f-e8d1dd581429">3,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:9pt;margin-top:1pt;text-align:center;text-indent:18pt"><span><br/></span></div><div id="i30c50c718dda42d28fbdd6dcd4fa2365_49"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RleHRyZWdpb246YzJhNzk3NmJiODUzNDMyOGI0MTJlMmJhMTA5NTI1NmVfMTIzNQ_5953c5ab-28cd-4a8f-a472-597313334556" continuedAt="i58d4d5a2224a4284b3fd738ed2d50d81" escape="true">Investments</ix:nonNumeric></span></div><ix:continuation id="i58d4d5a2224a4284b3fd738ed2d50d81" continuedAt="ic13f0da76a66497fad035ab64a06cd3b"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021 and December&#160;31, 2020, the Company primarily invested its excess cash in debt instruments of corporations, the U.S. Treasury, financial institutions, and U.S. government agencies with strong credit ratings and an investment grade rating at or above a long-term rating of Aa3/AA- and a short-term rating of P1/A1. The Company has established guidelines relative to diversification and maturities that maintain safety and liquidity. The Company periodically reviews and modifies these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity.</span></div><ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="us-gaap:InvestmentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RleHRyZWdpb246YzJhNzk3NmJiODUzNDMyOGI0MTJlMmJhMTA5NTI1NmVfMTIzNg_db166bcc-0eb1-4735-8841-5d127b84b76e" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the contract maturity of the available-for-sale securities the Company held as of September&#160;30, 2021:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:282.75pt"><tr><td style="width:1.0pt"></td><td style="width:211.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One year or less</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="2" name="xcur:DebtSecuritiesAvailableForSaleCurrentPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOjQwZDM3MjI5MDZhNDQzMTlhZjgyNWNjOGYyN2MxNTc4L3RhYmxlcmFuZ2U6NDBkMzcyMjkwNmE0NDMxOWFmODI1Y2M4ZjI3YzE1NzhfMC0xLTEtMS0w_85e9da8f-f937-4cbe-a00a-ffb285af69eb">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one year but within two years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="2" format="ixt:fixed-zero" name="xcur:DebtSecuritiesAvailableForSaleNoncurrentPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOjQwZDM3MjI5MDZhNDQzMTlhZjgyNWNjOGYyN2MxNTc4L3RhYmxlcmFuZ2U6NDBkMzcyMjkwNmE0NDMxOWFmODI1Y2M4ZjI3YzE1NzhfMS0xLTEtMS0w_a5855e8c-583a-4f44-9e4b-5f2cff06d0dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="2" name="xcur:DebtSecuritiesAvailableforSalePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOjQwZDM3MjI5MDZhNDQzMTlhZjgyNWNjOGYyN2MxNTc4L3RhYmxlcmFuZ2U6NDBkMzcyMjkwNmE0NDMxOWFmODI1Y2M4ZjI3YzE1NzhfMi0xLTEtMS0w_26016e68-9567-40f5-91c9-fe9352267a0e">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s available-for-sale securities are available to the Company for use in its current operations. As a result, the Company categorizes all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date.</span></div><ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RleHRyZWdpb246YzJhNzk3NmJiODUzNDMyOGI0MTJlMmJhMTA5NTI1NmVfMTIzNw_2fc5dc48-00d2-4fe8-8c09-0b08b3327eef" continuedAt="i8363088b72a8430889d89c882295c14f" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized holding gains, gross unrealized holding losses and fair value of cash equivalents and available-for-sale securities by type of security at&#160;September&#160;30, 2021&#160;and December&#160;31, 2020 were as follows:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.826%"><tr><td style="width:1.0%"></td><td style="width:45.147%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.672%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.672%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.290%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.672%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.295%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Holding Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Holding Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0053a355b9114313a12f8f7a031d65fc_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOjUyNzIwZjI1NDQ2NDQxZGU4Y2JiNTE0OGFhMDNlYmJkL3RhYmxlcmFuZ2U6NTI3MjBmMjU0NDY0NDFkZThjYmI1MTQ4YWEwM2ViYmRfMi0xLTEtMS0w_c799d8c8-2e93-46f1-b247-295a7af4ca22">6,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0053a355b9114313a12f8f7a031d65fc_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOjUyNzIwZjI1NDQ2NDQxZGU4Y2JiNTE0OGFhMDNlYmJkL3RhYmxlcmFuZ2U6NTI3MjBmMjU0NDY0NDFkZThjYmI1MTQ4YWEwM2ViYmRfMi0zLTEtMS0w_446e9fe6-13ec-4ee3-bea0-0b2fc7166d65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0053a355b9114313a12f8f7a031d65fc_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOjUyNzIwZjI1NDQ2NDQxZGU4Y2JiNTE0OGFhMDNlYmJkL3RhYmxlcmFuZ2U6NTI3MjBmMjU0NDY0NDFkZThjYmI1MTQ4YWEwM2ViYmRfMi01LTEtMS0w_74e3d5f3-00b9-4e1b-b937-0d2b3f995991">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0053a355b9114313a12f8f7a031d65fc_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOjUyNzIwZjI1NDQ2NDQxZGU4Y2JiNTE0OGFhMDNlYmJkL3RhYmxlcmFuZ2U6NTI3MjBmMjU0NDY0NDFkZThjYmI1MTQ4YWEwM2ViYmRfMi03LTEtMS0w_489fb3fe-5c4f-4680-b838-61e7bea9703a">6,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f345e6eb7f04fe4b6eab2801122fe23_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOjUyNzIwZjI1NDQ2NDQxZGU4Y2JiNTE0OGFhMDNlYmJkL3RhYmxlcmFuZ2U6NTI3MjBmMjU0NDY0NDFkZThjYmI1MTQ4YWEwM2ViYmRfMy0xLTEtMS0w_1f89aae0-1c1d-4d0a-a421-8450640bdc96">1,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f345e6eb7f04fe4b6eab2801122fe23_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOjUyNzIwZjI1NDQ2NDQxZGU4Y2JiNTE0OGFhMDNlYmJkL3RhYmxlcmFuZ2U6NTI3MjBmMjU0NDY0NDFkZThjYmI1MTQ4YWEwM2ViYmRfMy0zLTEtMS0w_f9ed4ed8-05ee-43ab-8bdf-14612ab368e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f345e6eb7f04fe4b6eab2801122fe23_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOjUyNzIwZjI1NDQ2NDQxZGU4Y2JiNTE0OGFhMDNlYmJkL3RhYmxlcmFuZ2U6NTI3MjBmMjU0NDY0NDFkZThjYmI1MTQ4YWEwM2ViYmRfMy01LTEtMS0w_0682f879-92c4-4956-8d34-4c4386d0437e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f345e6eb7f04fe4b6eab2801122fe23_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOjUyNzIwZjI1NDQ2NDQxZGU4Y2JiNTE0OGFhMDNlYmJkL3RhYmxlcmFuZ2U6NTI3MjBmMjU0NDY0NDFkZThjYmI1MTQ4YWEwM2ViYmRfMy03LTEtMS0w_eb91afc5-5fe7-4d48-a9b3-57d3f48bfbd7">1,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9282a032bc9d437cbb449818fa2c4843_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOjUyNzIwZjI1NDQ2NDQxZGU4Y2JiNTE0OGFhMDNlYmJkL3RhYmxlcmFuZ2U6NTI3MjBmMjU0NDY0NDFkZThjYmI1MTQ4YWEwM2ViYmRfNS0xLTEtMS0w_cbd91c8e-bd50-4f14-ae4d-b1472d77308f">1,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9282a032bc9d437cbb449818fa2c4843_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOjUyNzIwZjI1NDQ2NDQxZGU4Y2JiNTE0OGFhMDNlYmJkL3RhYmxlcmFuZ2U6NTI3MjBmMjU0NDY0NDFkZThjYmI1MTQ4YWEwM2ViYmRfNS0zLTEtMS0w_5f38f57f-5409-4b50-af9b-60ac06177b6e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9282a032bc9d437cbb449818fa2c4843_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOjUyNzIwZjI1NDQ2NDQxZGU4Y2JiNTE0OGFhMDNlYmJkL3RhYmxlcmFuZ2U6NTI3MjBmMjU0NDY0NDFkZThjYmI1MTQ4YWEwM2ViYmRfNS01LTEtMS0w_e9008db2-62b5-4f1e-b68b-ca268ad4fb22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9282a032bc9d437cbb449818fa2c4843_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOjUyNzIwZjI1NDQ2NDQxZGU4Y2JiNTE0OGFhMDNlYmJkL3RhYmxlcmFuZ2U6NTI3MjBmMjU0NDY0NDFkZThjYmI1MTQ4YWEwM2ViYmRfNS03LTEtMS0w_ef6d909e-2973-43b8-88d4-53f1cfa72d75">1,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOjUyNzIwZjI1NDQ2NDQxZGU4Y2JiNTE0OGFhMDNlYmJkL3RhYmxlcmFuZ2U6NTI3MjBmMjU0NDY0NDFkZThjYmI1MTQ4YWEwM2ViYmRfNi0xLTEtMS0w_6a0ae527-1695-47d3-a050-6219b214f366">8,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOjUyNzIwZjI1NDQ2NDQxZGU4Y2JiNTE0OGFhMDNlYmJkL3RhYmxlcmFuZ2U6NTI3MjBmMjU0NDY0NDFkZThjYmI1MTQ4YWEwM2ViYmRfNi0zLTEtMS0w_47ea8beb-ed6f-4f6d-a6fa-f14f55d9eb9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOjUyNzIwZjI1NDQ2NDQxZGU4Y2JiNTE0OGFhMDNlYmJkL3RhYmxlcmFuZ2U6NTI3MjBmMjU0NDY0NDFkZThjYmI1MTQ4YWEwM2ViYmRfNi01LTEtMS0w_627af70c-7f8d-44b8-a208-be99187ad431">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOjUyNzIwZjI1NDQ2NDQxZGU4Y2JiNTE0OGFhMDNlYmJkL3RhYmxlcmFuZ2U6NTI3MjBmMjU0NDY0NDFkZThjYmI1MTQ4YWEwM2ViYmRfNi03LTEtMS0w_3a4f2c6f-a23c-412f-a8ee-5bbe1b04fbe5">8,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="text-align:center;text-indent:18pt"><ix:continuation id="ic13f0da76a66497fad035ab64a06cd3b"><ix:continuation id="i8363088b72a8430889d89c882295c14f"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.025%"><tr><td style="width:1.0%"></td><td style="width:44.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.680%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.680%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.680%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Holding Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Holding Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23975282c1f34d05bda28777e4086e31_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOmMwMGFhZTEwMjYyOTRlYjU5ZGFlZjg2MWFiOTg3ODhhL3RhYmxlcmFuZ2U6YzAwYWFlMTAyNjI5NGViNTlkYWVmODYxYWI5ODc4OGFfMi0xLTEtMS0w_c8459f8d-4d00-4276-930f-0e06c76c04a2">15,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23975282c1f34d05bda28777e4086e31_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOmMwMGFhZTEwMjYyOTRlYjU5ZGFlZjg2MWFiOTg3ODhhL3RhYmxlcmFuZ2U6YzAwYWFlMTAyNjI5NGViNTlkYWVmODYxYWI5ODc4OGFfMi0zLTEtMS0w_78bdf0fb-b3db-4037-9027-46898d20f24a">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i23975282c1f34d05bda28777e4086e31_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOmMwMGFhZTEwMjYyOTRlYjU5ZGFlZjg2MWFiOTg3ODhhL3RhYmxlcmFuZ2U6YzAwYWFlMTAyNjI5NGViNTlkYWVmODYxYWI5ODc4OGFfMi01LTEtMS0w_c6b15843-75bb-4c53-b5ad-07fcd2075d07">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23975282c1f34d05bda28777e4086e31_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOmMwMGFhZTEwMjYyOTRlYjU5ZGFlZjg2MWFiOTg3ODhhL3RhYmxlcmFuZ2U6YzAwYWFlMTAyNjI5NGViNTlkYWVmODYxYWI5ODc4OGFfMi03LTEtMS0w_e61d8a44-d8e4-43c2-8b0e-f4ce760265da">15,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia247df9dcde04691921f7589b38fdf6a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOmMwMGFhZTEwMjYyOTRlYjU5ZGFlZjg2MWFiOTg3ODhhL3RhYmxlcmFuZ2U6YzAwYWFlMTAyNjI5NGViNTlkYWVmODYxYWI5ODc4OGFfMy0xLTEtMS0w_d8612ab6-7a56-421e-9bf2-ae3f71cb7c53">29,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia247df9dcde04691921f7589b38fdf6a_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOmMwMGFhZTEwMjYyOTRlYjU5ZGFlZjg2MWFiOTg3ODhhL3RhYmxlcmFuZ2U6YzAwYWFlMTAyNjI5NGViNTlkYWVmODYxYWI5ODc4OGFfMy0zLTEtMS0w_dafda7c4-757e-4f87-b0e0-1a8cde35b073">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia247df9dcde04691921f7589b38fdf6a_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOmMwMGFhZTEwMjYyOTRlYjU5ZGFlZjg2MWFiOTg3ODhhL3RhYmxlcmFuZ2U6YzAwYWFlMTAyNjI5NGViNTlkYWVmODYxYWI5ODc4OGFfMy01LTEtMS0w_9cfe91b2-7974-4c4a-8fdd-365e769643ab">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia247df9dcde04691921f7589b38fdf6a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOmMwMGFhZTEwMjYyOTRlYjU5ZGFlZjg2MWFiOTg3ODhhL3RhYmxlcmFuZ2U6YzAwYWFlMTAyNjI5NGViNTlkYWVmODYxYWI5ODc4OGFfMy03LTEtMS0w_1e416cc7-6de2-48ae-acf8-655027d84e41">29,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2705fb27647c4404a185735a84cd5bae_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOmMwMGFhZTEwMjYyOTRlYjU5ZGFlZjg2MWFiOTg3ODhhL3RhYmxlcmFuZ2U6YzAwYWFlMTAyNjI5NGViNTlkYWVmODYxYWI5ODc4OGFfNC0xLTEtMS0w_8aee06ff-12dd-40a8-8bde-1bfbc1ff8741">2,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2705fb27647c4404a185735a84cd5bae_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOmMwMGFhZTEwMjYyOTRlYjU5ZGFlZjg2MWFiOTg3ODhhL3RhYmxlcmFuZ2U6YzAwYWFlMTAyNjI5NGViNTlkYWVmODYxYWI5ODc4OGFfNC0zLTEtMS0w_400cd595-9b27-49ce-a62a-a25686de2ef6">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2705fb27647c4404a185735a84cd5bae_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOmMwMGFhZTEwMjYyOTRlYjU5ZGFlZjg2MWFiOTg3ODhhL3RhYmxlcmFuZ2U6YzAwYWFlMTAyNjI5NGViNTlkYWVmODYxYWI5ODc4OGFfNC01LTEtMS0w_44887ace-5b7e-4c78-88dc-59a0e869d879">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2705fb27647c4404a185735a84cd5bae_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOmMwMGFhZTEwMjYyOTRlYjU5ZGFlZjg2MWFiOTg3ODhhL3RhYmxlcmFuZ2U6YzAwYWFlMTAyNjI5NGViNTlkYWVmODYxYWI5ODc4OGFfNC03LTEtMS0w_74ba333d-6f7f-4a09-a1a4-18c28d29c550">2,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7567e0c7c5914bf5bde30bc572efc791_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOmMwMGFhZTEwMjYyOTRlYjU5ZGFlZjg2MWFiOTg3ODhhL3RhYmxlcmFuZ2U6YzAwYWFlMTAyNjI5NGViNTlkYWVmODYxYWI5ODc4OGFfNS0xLTEtMS0w_3bf0e5f0-b54c-4f31-af6e-1a6a97602849">1,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7567e0c7c5914bf5bde30bc572efc791_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOmMwMGFhZTEwMjYyOTRlYjU5ZGFlZjg2MWFiOTg3ODhhL3RhYmxlcmFuZ2U6YzAwYWFlMTAyNjI5NGViNTlkYWVmODYxYWI5ODc4OGFfNS0zLTEtMS0w_eb2ab05e-48c3-49c9-95f5-fe1fdf1c6bc9">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7567e0c7c5914bf5bde30bc572efc791_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOmMwMGFhZTEwMjYyOTRlYjU5ZGFlZjg2MWFiOTg3ODhhL3RhYmxlcmFuZ2U6YzAwYWFlMTAyNjI5NGViNTlkYWVmODYxYWI5ODc4OGFfNS01LTEtMS0w_1ea05b73-02cb-474b-b6f9-b37cb6965a08">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7567e0c7c5914bf5bde30bc572efc791_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOmMwMGFhZTEwMjYyOTRlYjU5ZGFlZjg2MWFiOTg3ODhhL3RhYmxlcmFuZ2U6YzAwYWFlMTAyNjI5NGViNTlkYWVmODYxYWI5ODc4OGFfNS03LTEtMS0w_fb726eb9-3fbb-4ac3-89ef-7948b87f9082">1,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOmMwMGFhZTEwMjYyOTRlYjU5ZGFlZjg2MWFiOTg3ODhhL3RhYmxlcmFuZ2U6YzAwYWFlMTAyNjI5NGViNTlkYWVmODYxYWI5ODc4OGFfNi0xLTEtMS0w_0c414ea8-fc25-4945-9bb7-27ade88e10e9">48,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOmMwMGFhZTEwMjYyOTRlYjU5ZGFlZjg2MWFiOTg3ODhhL3RhYmxlcmFuZ2U6YzAwYWFlMTAyNjI5NGViNTlkYWVmODYxYWI5ODc4OGFfNi0zLTEtMS0w_5fa6ca2b-0a46-41d0-85b5-1afc7a5c0505">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOmMwMGFhZTEwMjYyOTRlYjU5ZGFlZjg2MWFiOTg3ODhhL3RhYmxlcmFuZ2U6YzAwYWFlMTAyNjI5NGViNTlkYWVmODYxYWI5ODc4OGFfNi01LTEtMS0w_ecbbe779-f43c-4bb3-9151-d0a7761828ec">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOmMwMGFhZTEwMjYyOTRlYjU5ZGFlZjg2MWFiOTg3ODhhL3RhYmxlcmFuZ2U6YzAwYWFlMTAyNjI5NGViNTlkYWVmODYxYWI5ODc4OGFfNi03LTEtMS0w_f77955a4-83c2-4db6-91a6-11f463daa579">48,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div id="i30c50c718dda42d28fbdd6dcd4fa2365_52"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfNTYwNg_72d8fca4-4d7c-4765-98f5-2272f0d0e469" continuedAt="i9a0303135c094a8799c66697703a2941" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="i9a0303135c094a8799c66697703a2941" continuedAt="ib44163c51dbe42ae9ba085781c2c8040"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MidCap Credit Agreement</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2021, the Company entered into an amendment (&#8220;Amendment No. 3&#8221;) to the Company&#8217;s Credit and Security Agreement, dated as of September 25, 2020, as amended on October 21, 2020 and July 30, 2021, with MidCap Financial Trust, as agent (&#8220;MidCap&#8221;), and the lenders party thereto from time to time (as amended by Amendment No. 3, the &#8220;MidCap Credit Agreement&#8221;).</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MidCap Credit Agreement provides for a secured term loan facility in an aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="if6bd93e3d37e4fcb8e2b2027637863ed_I20200925" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfMzk0_f835ca36-70b2-46fd-9b38-78161f7bbc8b">25,000</ix:nonFraction> (the &#8220;MidCap Credit Facility&#8221;). The Company borrowed the first advance of $<ix:nonFraction unitRef="usd" contextRef="i7978f6f7e1b748cbabd1e2488f7447b7_D20200925-20200925" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfNDcx_2e42931f-9812-4e53-8f64-6e9917a0a042">17,500</ix:nonFraction> (&#8220;Tranche 1&#8221;) on September 25, 2020 (the &#8220;Closing Date&#8221;). Amendment No. 3 extends the availability of the second advance of $<ix:nonFraction unitRef="usd" contextRef="i34a25167a0434d11aa0d2091e882e0a7_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfNjAy_27b83ca4-809e-42c2-a089-e32611f015e1">7,500</ix:nonFraction> (&#8220;Tranche 2&#8221;) under the MidCap Credit Agreement from September 30, 2021 to December 31, 2021, subject to the Company&#8217;s satisfaction of certain applicable funding conditions as described in Amendment No. 3, including  the Company&#8217;s issuance of equity interests, subject to certain limitations, resulting in receipt by the Company of unrestricted net cash proceeds of at least $<ix:nonFraction unitRef="usd" contextRef="i34a25167a0434d11aa0d2091e882e0a7_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="xcur:DebtInstrumentFundingConditionRequiredProceedsFromEquityIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfNTQ5NzU1ODE1Mjk3Mg_23abd191-f729-4f8e-907a-b220729d7a7c">20,000</ix:nonFraction>, and the contribution by the Company, and receipt by Exicure Operating Company, of such cash proceeds to the capital of Exicure Operating Company.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Tranche 1 and if borrowed, Tranche 2, each bear interest at a floating rate equal to <ix:nonFraction unitRef="number" contextRef="if6bd93e3d37e4fcb8e2b2027637863ed_I20200925" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfMTEwOQ_2659edb6-c91b-47ea-9bc5-07848861abaf">6.25</ix:nonFraction>% per annum, plus the greater of (i) <ix:nonFraction unitRef="number" contextRef="ic8b146e3b6574d4ca6373ba4278baaa4_D20200925-20200925" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfMTE0Nw_9756f8c3-82b0-44c0-80ba-aa87a2d5d200">1.50</ix:nonFraction>% or (ii) one-month LIBOR. Interest on each loan advance is due and payable monthly in arrears. Principal on each loan advance is payable in <ix:nonFraction unitRef="installmentpayment" contextRef="i6c070a76443f46c79d54256b1cbf28fa_I20221001" decimals="INF" name="xcur:DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfMTI4OQ_efca28db-cbb5-4886-9b9b-98746073a5df">36</ix:nonFraction> equal monthly installments beginning October 1, 2022 until paid in full on October 1, 2025 (the &#8220;Maturity Date&#8221;). Prepayments of the loans under the MidCap Credit Agreement, in whole or in part, will be subject to early termination fees in an amount equal to <ix:nonFraction unitRef="number" contextRef="i89a02e4e5ce34167a93a3c5c5bff753f_I20210930" decimals="INF" name="xcur:DebtInstrumentEarlyTerminationFeePercentageOfPrincipal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfMTU1MQ_00b1f68f-4974-4d8c-a9c4-f054cd5d84e9">3.0</ix:nonFraction>% of principal prepaid if prepayment occurs on or prior to the first anniversary of the Closing Date and <ix:nonFraction unitRef="number" contextRef="i0d913806ddcd4fe38da350a6c3ed1feb_I20210930" decimals="INF" name="xcur:DebtInstrumentEarlyTerminationFeePercentageOfPrincipal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfMTY1Nw_24565742-a127-4196-88f1-25b7517fdd66">1.0</ix:nonFraction>% of principal prepaid if prepayment occurs after the first anniversary of the Closing Date and prior to the maturity date.  In connection with execution of the MidCap Credit Agreement, the Company paid MidCap a $<ix:nonFraction unitRef="usd" contextRef="ia9b3e45e1e944cbfa8d1c6fa857fb39c_D20200925-20200925" decimals="-3" name="us-gaap:LoanProcessingFee" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfMTg3MA_b189f921-41d3-4ce6-8bf2-a68292eb3001">125</ix:nonFraction> origination fee.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Maturity Date or on any earlier date on which all amounts advanced to the Company become due and payable in full, or are otherwise paid in full, the Company is required to pay an exit fee equal to <ix:nonFraction unitRef="number" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="INF" name="xcur:DebtInstrumentExitFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfMjA5NQ_dc42f5ba-f46f-4b83-a7e6-fb84be792633">3.75</ix:nonFraction>% of the principal amount of all loans advanced to the Company under the MidCap Credit Agreement. Upon the advance of Tranche 1, the Company accrued $<ix:nonFraction unitRef="usd" contextRef="ic85ffe60044641adbba3cef493f35219_I20200925" decimals="-3" name="us-gaap:DebtInstrumentFeeAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfMjI0NQ_b57ee90f-3c1e-4e03-93d9-a57d03cf68fa">656</ix:nonFraction> for the related exit fee.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s obligations under the MidCap Credit Agreement are secured by a security interest in substantially all of its assets, excluding intellectual property (which is subject to a negative pledge). Additionally, the Company&#8217;s future subsidiaries, if any, may be required to become co-borrowers or guarantors under the MidCap Credit Agreement.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MidCap Credit Agreement contains customary affirmative covenants and customary negative covenants limiting the Company&#8217;s ability and the ability of the Company&#8217;s subsidiaries, if any, to, among other things, dispose of assets, undergo a change in control, merge or consolidate, make acquisitions, incur debt, incur liens, pay dividends, repurchase stock and make investments, in each case subject to certain exceptions.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="ib44163c51dbe42ae9ba085781c2c8040"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MidCap Credit Agreement also contains customary events of default relating to, among other things, payment defaults, breaches of covenants, a material adverse change, delisting of the Company&#8217;s common stock, bankruptcy and insolvency, cross defaults with certain material indebtedness and certain material contracts, judgments, and inaccuracies of representations and warranties. Upon an event of default, the agent and the lenders may declare all or a portion of the Company&#8217;s outstanding obligations to be immediately due and payable and exercise other rights and remedies provided for under the agreement. During the existence of an event of default, interest on the obligations could be increased by <ix:nonFraction unitRef="number" contextRef="i77889ae6ab624d1295d8b058f98f0543_D20210101-20210930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfMzc1NQ_495110cd-6b15-4c09-80a8-13acca5925a3">2.0</ix:nonFraction>%.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total proceeds, net of fees and issuance costs, borrowed under Tranche 1 were $<ix:nonFraction unitRef="usd" contextRef="i7978f6f7e1b748cbabd1e2488f7447b7_D20200925-20200925" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfMzgzNw_d54af0c4-1dc1-42eb-b1c7-1ce8602c4775">16,512</ix:nonFraction>.  Fees and issuance costs of $<ix:nonFraction unitRef="usd" contextRef="ic85ffe60044641adbba3cef493f35219_I20200925" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfMzg2OQ_bdfdf06e-8399-44f8-8a42-95365a566e4c">332</ix:nonFraction>, as well as fees of $<ix:nonFraction unitRef="usd" contextRef="ic85ffe60044641adbba3cef493f35219_I20200925" decimals="-3" name="us-gaap:DebtInstrumentFeeAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfMzg5Mg_b57ee90f-3c1e-4e03-93d9-a57d03cf68fa">656</ix:nonFraction> that are payable to MidCap at maturity of Tranche 1, are recorded as a reduction to the carrying amount of long-term debt on the Company&#8217;s balance sheet and will be amortized to interest expense through the maturity date of October 1, 2025 using the effective interest method. Fees and issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i6126506f80104557ba998535d441061c_I20200925" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfNDE5OQ_c827bcb5-e345-43dd-b44b-7af7e89ccd3b">73</ix:nonFraction> attributed to the amount available to be borrowed under Tranche 2 were paid and recorded as deferred financing costs (other assets) and will be (i) recorded as a reduction in the carrying amount of long-term debt in future periods if amounts are borrowed under Tranche 2 or (ii) will be amortized and recorded to interest expense if amounts are not borrowed under Tranche 2. For the three and nine months ended September 30, 2021, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="ice5e4b94c8ca4a1c808b55cb400e24e7_D20210701-20210930" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfNDY1MA_b58ce5c0-6356-43d2-bf56-debaa0cf88a5">36</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i8f010890f93049f2ae4c474fd0f3290c_D20210101-20210930" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfMTA5OTUxMTY0MjExMw_6f810c06-46a0-4af0-a69e-0fd37e509ee7">73</ix:nonFraction>, respectively, as interest expense and <ix:nonFraction unitRef="usd" contextRef="i34a25167a0434d11aa0d2091e882e0a7_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfNDczNA_7bd66838-68d7-4c4b-867b-4d13baf27e0c">no</ix:nonFraction> balance of the deferred financing costs remains as of September 30, 2021.</span></div><div style="margin-bottom:9pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the aggregate carrying value of the Company&#8217;s long-term debt is $<ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfNDgzMg_32a03de6-5720-44e6-aabc-eb4500ef8bb5">16,801</ix:nonFraction>.</span></div><ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfNTYwOA_6c2aa4e4-7154-423d-8498-67f2ece1e2ef" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the principal maturities of the Company&#8217;s long-term debt were as follows:</span></div><div style="margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:76.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.249%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (remaining three months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RhYmxlOmI2ZTZiYWIyM2M1NzQ1OGFiMTFmM2UwNGQ3ZmM2NmEyL3RhYmxlcmFuZ2U6YjZlNmJhYjIzYzU3NDU4YWIxMWYzZTA0ZDdmYzY2YTJfMS0yLTEtMS0w_3db52d40-fda4-4b12-9491-dd07e1b6ee05">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RhYmxlOmI2ZTZiYWIyM2M1NzQ1OGFiMTFmM2UwNGQ3ZmM2NmEyL3RhYmxlcmFuZ2U6YjZlNmJhYjIzYzU3NDU4YWIxMWYzZTA0ZDdmYzY2YTJfMi0yLTEtMS0w_c770b5c8-93c2-46b3-92d3-b0f1f6464251">1,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RhYmxlOmI2ZTZiYWIyM2M1NzQ1OGFiMTFmM2UwNGQ3ZmM2NmEyL3RhYmxlcmFuZ2U6YjZlNmJhYjIzYzU3NDU4YWIxMWYzZTA0ZDdmYzY2YTJfMy0yLTEtMS0w_8698dac4-0a82-42af-a517-ee35da116d9d">5,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RhYmxlOmI2ZTZiYWIyM2M1NzQ1OGFiMTFmM2UwNGQ3ZmM2NmEyL3RhYmxlcmFuZ2U6YjZlNmJhYjIzYzU3NDU4YWIxMWYzZTA0ZDdmYzY2YTJfNC0yLTEtMS0w_6e70cb8a-9741-4f48-9780-76b1b4fb0b8d">5,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RhYmxlOmI2ZTZiYWIyM2M1NzQ1OGFiMTFmM2UwNGQ3ZmM2NmEyL3RhYmxlcmFuZ2U6YjZlNmJhYjIzYzU3NDU4YWIxMWYzZTA0ZDdmYzY2YTJfNS0yLTEtMS0w_c6c3e711-2350-4b74-9f25-8985d356155f">4,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal balance outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RhYmxlOmI2ZTZiYWIyM2M1NzQ1OGFiMTFmM2UwNGQ3ZmM2NmEyL3RhYmxlcmFuZ2U6YjZlNmJhYjIzYzU3NDU4YWIxMWYzZTA0ZDdmYzY2YTJfNi0yLTEtMS0w_8d3302fc-fea2-4f8a-8b66-5cc1dfe31281">17,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less: unamortized discount and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RhYmxlOmI2ZTZiYWIyM2M1NzQ1OGFiMTFmM2UwNGQ3ZmM2NmEyL3RhYmxlcmFuZ2U6YjZlNmJhYjIzYzU3NDU4YWIxMWYzZTA0ZDdmYzY2YTJfNy0yLTEtMS0w_e882c7be-8c3d-4a17-9ccd-6a632225822d">699</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RhYmxlOmI2ZTZiYWIyM2M1NzQ1OGFiMTFmM2UwNGQ3ZmM2NmEyL3RhYmxlcmFuZ2U6YjZlNmJhYjIzYzU3NDU4YWIxMWYzZTA0ZDdmYzY2YTJfOC0yLTEtMS0w_46eb27fa-a24c-4762-8106-350d1aea98d0">16,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RhYmxlOmI2ZTZiYWIyM2M1NzQ1OGFiMTFmM2UwNGQ3ZmM2NmEyL3RhYmxlcmFuZ2U6YjZlNmJhYjIzYzU3NDU4YWIxMWYzZTA0ZDdmYzY2YTJfOS0yLTEtMS0w_9ed6211d-b488-432a-b9da-027537213c0c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RhYmxlOmI2ZTZiYWIyM2M1NzQ1OGFiMTFmM2UwNGQ3ZmM2NmEyL3RhYmxlcmFuZ2U6YjZlNmJhYjIzYzU3NDU4YWIxMWYzZTA0ZDdmYzY2YTJfMTAtMi0xLTEtMA_03e02278-13d0-4bc4-bc5d-bbb4a30e8ee9">16,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid interest on the MidCap Credit Agreement of $<ix:nonFraction unitRef="usd" contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfNDk4Mg_9e3556ca-bbf2-450d-b90c-9e4210fb9091">344</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfNDk4OQ_87be2e3b-1837-45f5-8f10-80850ffa6ea8">1,041</ix:nonFraction> during the three and nine months ended September 30, 2021, respectively. The Company paid interest on the Hercules Loan Agreement (as discussed below) of $<ix:nonFraction unitRef="usd" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfNTEzNA_a5e2068b-b930-4a14-978b-6bad593450ee">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfNTE0MQ_d73012aa-8f73-4841-954a-a9fbaee95f57">142</ix:nonFraction> during the three and nine months ended September 30, 2020, respectively.</span></div><div style="margin-bottom:9pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hercules Loan Agreement</span></div><div style="margin-bottom:9pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 2, 2020, pursuant to the terms of the loan agreement with Hercules Technology Growth Capital (&#8220;Hercules&#8221;) and subsequent amendments thereto  (the &#8220;Hercules Loan Agreement&#8221;), the Company repaid all remaining outstanding obligations under the Hercules Loan Agreement as of the maturity date, including the outstanding principal balance of $<ix:nonFraction unitRef="usd" contextRef="i5116d3a6dd234ef8a2099862dd24c82b_D20200302-20200302" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfNTU3NA_8fd2c699-88e6-49a3-9d48-24ebb007e0dd">4,999</ix:nonFraction> and the end of term fee of $<ix:nonFraction unitRef="usd" contextRef="i5116d3a6dd234ef8a2099862dd24c82b_D20200302-20200302" decimals="-3" name="xcur:PaymentsForDebtEndTermFees" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfNTYwNA_ee0ba011-d2c1-4a91-81df-debc59e7814f">100</ix:nonFraction>.</span></div></ix:continuation><div id="i30c50c718dda42d28fbdd6dcd4fa2365_55"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RleHRyZWdpb246MDI5YjFmNDU1ZjU2NDIyMDk2Y2I5MjFiY2RhY2IwMmFfNDU1Ng_edb04c21-e9b1-49af-bc52-74723305b880" continuedAt="i4b03356e956a4d57bdc6b97531343887" escape="true">Leases</ix:nonNumeric></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4b03356e956a4d57bdc6b97531343887" continuedAt="i9b4757bb2a774683b4ed5fdc7816f94a">The Company&#8217;s lease arrangements at September 30, 2021 consist of (i) a lease for office and laboratory space at its headquarters in Chicago, Illinois that commenced in July 2020 (the &#8220;Chicago Lease&#8221;), (ii) a lease for office </ix:continuation></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i9b4757bb2a774683b4ed5fdc7816f94a" continuedAt="i8e19a8cbce3d44ffb6a6ca5d1888aa0f"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">space at a multi-tenant facility in Cambridge, Massachusetts that commenced in March 2019 and is cancelable at any time (the &#8220;Cambridge Lease&#8221;), and (iii) leases for office equipment (the &#8220;Office Equipment Leases&#8221;). Each of these leases are classified as operating leases.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the nature of the Cambridge Lease, the Company determined that this lease represented a short-term lease with an initial term of less than twelve months and, as such, the Cambridge Lease is not recorded on the balance sheet and related lease costs are recognized in the statement of operations as they are incurred. The Company has also elected to not record the Office Equipment Leases on the balance sheet since related payment amounts and lease costs are insignificant. Lease costs for the Office Equipment Leases are recognized in the statement of operations on a straight-line basis over the lease term.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s lease arrangement for office and laboratory space at its former headquarters in Skokie, Illinois ended in February 2021 in accordance with the terms of that lease arrangement. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Chicago Lease</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has approximately <ix:nonFraction unitRef="sqft" contextRef="i9576e645ea7c457ca92b31b2bdd21d44_D20200701-20200701" decimals="-3" format="ixt-sec:numwordsen" name="xcur:LesseeOperatingLeaseLeaseArea" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RleHRyZWdpb246MDI5YjFmNDU1ZjU2NDIyMDk2Y2I5MjFiY2RhY2IwMmFfMTM0OQ_d6211c0a-32d0-4300-9bf6-d3250ce448ef">thirty thousand</ix:nonFraction> square feet of office and laboratory space in Chicago, Illinois (the &#8220;Chicago Lease&#8221;). The original term (the &#8220;Original Term&#8221;) of the Chicago Lease is <ix:nonNumeric contextRef="i271a8511a8d74205a164612b6225fd65_I20200701" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RleHRyZWdpb246MDI5YjFmNDU1ZjU2NDIyMDk2Y2I5MjFiY2RhY2IwMmFfMTUwMw_d6cdc148-b36d-4abf-ad7f-c1e9ef5756a2">10</ix:nonNumeric> years, commencing on July 1, 2020 (the &#8220;Commencement Date&#8221;), which is the date the premises were ready for occupancy under the terms of the Chicago Lease.  The Company has options to extend the term of the Chicago Lease for&#160;<ix:nonFraction unitRef="extensionperiod" contextRef="i9576e645ea7c457ca92b31b2bdd21d44_D20200701-20200701" decimals="INF" format="ixt-sec:numwordsen" name="xcur:LesseeOperatingLeaseNumberOfExtensions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RleHRyZWdpb246MDI5YjFmNDU1ZjU2NDIyMDk2Y2I5MjFiY2RhY2IwMmFfMTcyNA_b141417a-4932-4126-b2ff-4dca4371fbb6">two</ix:nonFraction>&#160;additional successive periods of <ix:nonNumeric contextRef="i271a8511a8d74205a164612b6225fd65_I20200701" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RleHRyZWdpb246MDI5YjFmNDU1ZjU2NDIyMDk2Y2I5MjFiY2RhY2IwMmFfMTc2MA_fb3b8467-3855-465b-8c63-3110429a74ce">five years</ix:nonNumeric> each (the &#8220;Extension Periods&#8221;) at the then prevailing effective market rental rate.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial annual base rent during the Original Term is approximately $<ix:nonFraction unitRef="usd" contextRef="i271a8511a8d74205a164612b6225fd65_I20200701" decimals="-3" format="ixt:num-dot-decimal" name="xcur:LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RleHRyZWdpb246MDI5YjFmNDU1ZjU2NDIyMDk2Y2I5MjFiY2RhY2IwMmFfMTkxOA_2ff3191a-0079-4a7a-927c-bf1a3a9577ce">1,113</ix:nonFraction> for the first 12-month period of the Original Term, payable in monthly installments beginning on the Commencement Date. Base rent thereafter is subject to annual increases of <ix:nonFraction unitRef="number" contextRef="i271a8511a8d74205a164612b6225fd65_I20200701" decimals="2" name="xcur:LesseeOperatingLeaseBaseRentAnnualPercentageIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RleHRyZWdpb246MDI5YjFmNDU1ZjU2NDIyMDk2Y2I5MjFiY2RhY2IwMmFfMjA5Ng_4d3d78ee-c7cb-437b-af7f-a38e414e77c7">3</ix:nonFraction>%, for an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="i271a8511a8d74205a164612b6225fd65_I20200701" decimals="-3" format="ixt:num-dot-decimal" name="xcur:LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RleHRyZWdpb246MDI5YjFmNDU1ZjU2NDIyMDk2Y2I5MjFiY2RhY2IwMmFfMjEyNw_1849b9b4-0187-40da-82a3-7254c857899d">12,761</ix:nonFraction> over the Original Term. The Company must also pay its proportionate share of certain operating expenses and taxes for each calendar year during the term.  During the first 12-month period of the Original Term, the base rent and the Company&#8217;s proportionate share of operating expenses and taxes were subject to certain abatements. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Chicago Lease, the Company will maintain a letter of credit for the benefit of the landlord in an initial amount of $<ix:nonFraction unitRef="usd" contextRef="i271a8511a8d74205a164612b6225fd65_I20200701" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RleHRyZWdpb246MDI5YjFmNDU1ZjU2NDIyMDk2Y2I5MjFiY2RhY2IwMmFfMjU5OQ_0fc7ddee-31fc-48a1-99ad-979c9d1ff8dc">1,200</ix:nonFraction>, which amount is subject to reduction over time.  Upon execution of the Chicago Lease, the Company paid to the landlord the first installment of base rent and the estimated monthly amount of its pro rata share of taxes and its pro rata share of operating expenses in the aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="i9576e645ea7c457ca92b31b2bdd21d44_D20200701-20200701" decimals="-3" name="xcur:LesseeOperatingLeaseRentalPaymentAdjustedForAbatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RleHRyZWdpb246MDI5YjFmNDU1ZjU2NDIyMDk2Y2I5MjFiY2RhY2IwMmFfMjg5Mw_50949e86-b627-4274-a4d8-b4f3f208cdd2">87</ix:nonFraction> which amount had been adjusted for the abatement as set forth in the lease agreement. The Company also paid the landlord a net amount of $<ix:nonFraction unitRef="usd" contextRef="i9576e645ea7c457ca92b31b2bdd21d44_D20200701-20200701" decimals="-3" name="us-gaap:PaymentsForTenantImprovements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RleHRyZWdpb246MDI5YjFmNDU1ZjU2NDIyMDk2Y2I5MjFiY2RhY2IwMmFfMzAzMw_d264651a-98db-4cd9-b89d-f5b99c7ccd6d">697</ix:nonFraction> toward tenant improvements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the agreement for the Chicago Lease, the Company is required to maintain a&#160;standby letter of credit during the term of the lease, currently in the amount of $<ix:nonFraction unitRef="usd" contextRef="i271a8511a8d74205a164612b6225fd65_I20200701" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RleHRyZWdpb246MDI5YjFmNDU1ZjU2NDIyMDk2Y2I5MjFiY2RhY2IwMmFfMzIzMg_fddd2db6-c04f-44e3-ba59-dcf2396dfb5d">1,200</ix:nonFraction> and subject to reduction over time, which is secured by a restricted certificate of deposit account and presented within other noncurrent assets on the Company&#8217;s unaudited condensed consolidated balance sheet at September&#160;30, 2021.&#160;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized a right of use asset of $<ix:nonFraction unitRef="usd" contextRef="i271a8511a8d74205a164612b6225fd65_I20200701" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RleHRyZWdpb246MDI5YjFmNDU1ZjU2NDIyMDk2Y2I5MjFiY2RhY2IwMmFfMzQ5OQ_9602d3ca-6e83-44f1-9810-32cb673dcce7">8,931</ix:nonFraction> and a lease liability of $<ix:nonFraction unitRef="usd" contextRef="i271a8511a8d74205a164612b6225fd65_I20200701" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RleHRyZWdpb246MDI5YjFmNDU1ZjU2NDIyMDk2Y2I5MjFiY2RhY2IwMmFfMzUyNw_9b341a85-fa9e-42ac-b402-75d794cd417f">8,147</ix:nonFraction> on the Commencement Date. Because the rate implicit in the Chicago Lease is not readily determinable, the Company used its incremental borrowing rate of <ix:nonFraction unitRef="number" contextRef="i271a8511a8d74205a164612b6225fd65_I20200701" decimals="3" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RleHRyZWdpb246MDI5YjFmNDU1ZjU2NDIyMDk2Y2I5MjFiY2RhY2IwMmFfMzY4Mw_1022c574-e6fb-4cb4-9983-9bd262c370d3">8.3</ix:nonFraction>% on the Commencement Date to determine the present value of the lease payments over the Original Term. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease. As of September&#160;30, 2021, the Company determined it is not reasonably certain that the renewal option would be exercised.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i8e19a8cbce3d44ffb6a6ca5d1888aa0f"><div style="margin-bottom:9pt;text-indent:18pt"><ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="xcur:ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RleHRyZWdpb246MDI5YjFmNDU1ZjU2NDIyMDk2Y2I5MjFiY2RhY2IwMmFfNDU1Mg_0812bb14-983d-474e-975b-5ea749cdd153" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information related to the Company&#8217;s operating lease asset and related operating lease liabilities were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:76.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.249%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOjE4YmI1OWI4MDRkZjRmNmVhOGI3NDIwOTA1ZjI4MWRmL3RhYmxlcmFuZ2U6MThiYjU5YjgwNGRmNGY2ZWE4Yjc0MjA5MDVmMjgxZGZfMS0yLTEtMS0w_3587c467-f414-4ad4-adac-a165e39adb77">8.8</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOjE4YmI1OWI4MDRkZjRmNmVhOGI3NDIwOTA1ZjI4MWRmL3RhYmxlcmFuZ2U6MThiYjU5YjgwNGRmNGY2ZWE4Yjc0MjA5MDVmMjgxZGZfMi0yLTEtMS0w_c5246558-65d8-4b49-8ed7-b7c703cbfda4">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RleHRyZWdpb246MDI5YjFmNDU1ZjU2NDIyMDk2Y2I5MjFiY2RhY2IwMmFfNDU1NA_436cb9b9-cb9e-41e9-996b-ad1ba6421ca5" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes lease costs in the Company&#8217;s unaudited condensed consolidated statement of operations:</span></div><div style="margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmFhNTNlY2NlOGJmMzQ3YWU4NzFmZjQ3MTE1MzZjNmZmL3RhYmxlcmFuZ2U6YWE1M2VjY2U4YmYzNDdhZTg3MWZmNDcxMTUzNmM2ZmZfMi0xLTEtMS0w_a622f3c5-c53e-466c-b720-5a2a5c6eab1e">326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmFhNTNlY2NlOGJmMzQ3YWU4NzFmZjQ3MTE1MzZjNmZmL3RhYmxlcmFuZ2U6YWE1M2VjY2U4YmYzNDdhZTg3MWZmNDcxMTUzNmM2ZmZfMi0zLTEtMS0w_5fdcfd7e-3f6f-4022-8835-68271dbebd9f">333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmFhNTNlY2NlOGJmMzQ3YWU4NzFmZjQ3MTE1MzZjNmZmL3RhYmxlcmFuZ2U6YWE1M2VjY2U4YmYzNDdhZTg3MWZmNDcxMTUzNmM2ZmZfMi01LTEtMS0w_490738ca-ee72-4776-9e93-779ef715b82c">980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmFhNTNlY2NlOGJmMzQ3YWU4NzFmZjQ3MTE1MzZjNmZmL3RhYmxlcmFuZ2U6YWE1M2VjY2U4YmYzNDdhZTg3MWZmNDcxMTUzNmM2ZmZfMi03LTEtMS0w_21cb19de-2d6c-4daa-8f28-13c067f97124">712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmFhNTNlY2NlOGJmMzQ3YWU4NzFmZjQ3MTE1MzZjNmZmL3RhYmxlcmFuZ2U6YWE1M2VjY2U4YmYzNDdhZTg3MWZmNDcxMTUzNmM2ZmZfMy0xLTEtMS0w_f7969eb2-2da3-4bb5-80c7-82fc43870a8f">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmFhNTNlY2NlOGJmMzQ3YWU4NzFmZjQ3MTE1MzZjNmZmL3RhYmxlcmFuZ2U6YWE1M2VjY2U4YmYzNDdhZTg3MWZmNDcxMTUzNmM2ZmZfMy0zLTEtMS0w_d57d5eea-b70b-4b42-a40d-f97bb46c0e19">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmFhNTNlY2NlOGJmMzQ3YWU4NzFmZjQ3MTE1MzZjNmZmL3RhYmxlcmFuZ2U6YWE1M2VjY2U4YmYzNDdhZTg3MWZmNDcxMTUzNmM2ZmZfMy01LTEtMS0w_48280b7f-fc35-4086-9d3d-74530bc9d9ee">94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmFhNTNlY2NlOGJmMzQ3YWU4NzFmZjQ3MTE1MzZjNmZmL3RhYmxlcmFuZ2U6YWE1M2VjY2U4YmYzNDdhZTg3MWZmNDcxMTUzNmM2ZmZfMy03LTEtMS0w_13482e8a-8443-42f1-9cda-a49b9fe7d76e">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmFhNTNlY2NlOGJmMzQ3YWU4NzFmZjQ3MTE1MzZjNmZmL3RhYmxlcmFuZ2U6YWE1M2VjY2U4YmYzNDdhZTg3MWZmNDcxMTUzNmM2ZmZfNC0xLTEtMS0w_375dd16d-7026-4483-93f5-1c1644bc18a9">231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmFhNTNlY2NlOGJmMzQ3YWU4NzFmZjQ3MTE1MzZjNmZmL3RhYmxlcmFuZ2U6YWE1M2VjY2U4YmYzNDdhZTg3MWZmNDcxMTUzNmM2ZmZfNC0zLTEtMS0w_74a432cb-d034-47dd-86a5-79bd239d6a97">172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmFhNTNlY2NlOGJmMzQ3YWU4NzFmZjQ3MTE1MzZjNmZmL3RhYmxlcmFuZ2U6YWE1M2VjY2U4YmYzNDdhZTg3MWZmNDcxMTUzNmM2ZmZfNC01LTEtMS0w_0f4d47f6-dc23-4cb1-801f-144bc26c7501">803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmFhNTNlY2NlOGJmMzQ3YWU4NzFmZjQ3MTE1MzZjNmZmL3RhYmxlcmFuZ2U6YWE1M2VjY2U4YmYzNDdhZTg3MWZmNDcxMTUzNmM2ZmZfNC03LTEtMS0w_d7e5e88c-8615-4a55-b07f-c6c0e16944dc">322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease costs</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmFhNTNlY2NlOGJmMzQ3YWU4NzFmZjQ3MTE1MzZjNmZmL3RhYmxlcmFuZ2U6YWE1M2VjY2U4YmYzNDdhZTg3MWZmNDcxMTUzNmM2ZmZfNS0xLTEtMS0w_1272d9fc-3db2-4517-965e-d4e62ba0bb90">589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmFhNTNlY2NlOGJmMzQ3YWU4NzFmZjQ3MTE1MzZjNmZmL3RhYmxlcmFuZ2U6YWE1M2VjY2U4YmYzNDdhZTg3MWZmNDcxMTUzNmM2ZmZfNS0zLTEtMS0w_23699a22-28dc-4b96-aa10-ce9621ac7380">534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmFhNTNlY2NlOGJmMzQ3YWU4NzFmZjQ3MTE1MzZjNmZmL3RhYmxlcmFuZ2U6YWE1M2VjY2U4YmYzNDdhZTg3MWZmNDcxMTUzNmM2ZmZfNS01LTEtMS0w_79b3acf4-074f-429c-9700-5dfa75edb819">1,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmFhNTNlY2NlOGJmMzQ3YWU4NzFmZjQ3MTE1MzZjNmZmL3RhYmxlcmFuZ2U6YWE1M2VjY2U4YmYzNDdhZTg3MWZmNDcxMTUzNmM2ZmZfNS03LTEtMS0w_903bc186-d2a7-4575-a3c5-00b1b5f50e35">1,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company made cash payments for operating leases of $<ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RleHRyZWdpb246MDI5YjFmNDU1ZjU2NDIyMDk2Y2I5MjFiY2RhY2IwMmFfNDQwNw_552c6e47-22d2-45ff-9c29-a1b1d2f8c027">1,721</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RleHRyZWdpb246MDI5YjFmNDU1ZjU2NDIyMDk2Y2I5MjFiY2RhY2IwMmFfNDQxNA_41d9e148-6a7f-446f-8eea-578eafccd76c">1,717</ix:nonFraction> during the nine months ended September 30, 2021 and 2020, respectively.</span></div><ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RleHRyZWdpb246MDI5YjFmNDU1ZjU2NDIyMDk2Y2I5MjFiY2RhY2IwMmFfNDU1NQ_66c99610-13e8-445c-bc7a-8b81b22fa345" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of the Company&#8217;s lease liability as of September&#160;30, 2021 were as follows:</span></div><div style="margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:76.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.249%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (remaining three months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmMxNWQxYzE1YTJlYzQ3M2U5YWNmNjk2ZmQ0OTZiNWExL3RhYmxlcmFuZ2U6YzE1ZDFjMTVhMmVjNDczZTlhY2Y2OTZmZDQ5NmI1YTFfMS0yLTEtMS0w_5ba81c70-3624-49cc-8189-4b5a54ba728c">191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmMxNWQxYzE1YTJlYzQ3M2U5YWNmNjk2ZmQ0OTZiNWExL3RhYmxlcmFuZ2U6YzE1ZDFjMTVhMmVjNDczZTlhY2Y2OTZmZDQ5NmI1YTFfMi0yLTEtMS0w_0424b6e5-33cb-412c-9309-7467d2e51cc4">1,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmMxNWQxYzE1YTJlYzQ3M2U5YWNmNjk2ZmQ0OTZiNWExL3RhYmxlcmFuZ2U6YzE1ZDFjMTVhMmVjNDczZTlhY2Y2OTZmZDQ5NmI1YTFfMy0yLTEtMS0w_6e0028da-5b29-46ec-a2de-e5768ac50b1b">1,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmMxNWQxYzE1YTJlYzQ3M2U5YWNmNjk2ZmQ0OTZiNWExL3RhYmxlcmFuZ2U6YzE1ZDFjMTVhMmVjNDczZTlhY2Y2OTZmZDQ5NmI1YTFfNC0yLTEtMS0w_4a3edc12-4e5b-4c3d-ac33-b87808d46cc4">1,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmMxNWQxYzE1YTJlYzQ3M2U5YWNmNjk2ZmQ0OTZiNWExL3RhYmxlcmFuZ2U6YzE1ZDFjMTVhMmVjNDczZTlhY2Y2OTZmZDQ5NmI1YTFfNS0yLTEtMS0w_c9f03945-60a9-43db-9a1a-3f1de50ad449">1,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmMxNWQxYzE1YTJlYzQ3M2U5YWNmNjk2ZmQ0OTZiNWExL3RhYmxlcmFuZ2U6YzE1ZDFjMTVhMmVjNDczZTlhY2Y2OTZmZDQ5NmI1YTFfNi0yLTEtMS0w_058abd49-8d5a-4b99-b668-abfc2dcfbdab">1,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmMxNWQxYzE1YTJlYzQ3M2U5YWNmNjk2ZmQ0OTZiNWExL3RhYmxlcmFuZ2U6YzE1ZDFjMTVhMmVjNDczZTlhY2Y2OTZmZDQ5NmI1YTFfNy0yLTEtMS0w_5a7b589c-e6ec-4dcb-b66a-89471e5fd346">4,897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmMxNWQxYzE1YTJlYzQ3M2U5YWNmNjk2ZmQ0OTZiNWExL3RhYmxlcmFuZ2U6YzE1ZDFjMTVhMmVjNDczZTlhY2Y2OTZmZDQ5NmI1YTFfOC0yLTEtMS0w_74d842df-535f-40e6-a801-a04ca9e0c2e2">11,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmMxNWQxYzE1YTJlYzQ3M2U5YWNmNjk2ZmQ0OTZiNWExL3RhYmxlcmFuZ2U6YzE1ZDFjMTVhMmVjNDczZTlhY2Y2OTZmZDQ5NmI1YTFfOS0yLTEtMS0w_81f1fb9f-1541-4d6a-80b2-94a69152443b">3,275</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmMxNWQxYzE1YTJlYzQ3M2U5YWNmNjk2ZmQ0OTZiNWExL3RhYmxlcmFuZ2U6YzE1ZDFjMTVhMmVjNDczZTlhY2Y2OTZmZDQ5NmI1YTFfMTAtMi0xLTEtMA_e50abb43-b6fb-483d-abdb-f2d0fc1ff684">7,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmMxNWQxYzE1YTJlYzQ3M2U5YWNmNjk2ZmQ0OTZiNWExL3RhYmxlcmFuZ2U6YzE1ZDFjMTVhMmVjNDczZTlhY2Y2OTZmZDQ5NmI1YTFfMTItMi0xLTEtMA_f9641a22-e6f2-4bf0-997e-000fa0921735">440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent operating lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmMxNWQxYzE1YTJlYzQ3M2U5YWNmNjk2ZmQ0OTZiNWExL3RhYmxlcmFuZ2U6YzE1ZDFjMTVhMmVjNDczZTlhY2Y2OTZmZDQ5NmI1YTFfMTMtMi0xLTEtMA_1cf7d045-6c46-43d1-81bc-61590b5176fa">7,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmMxNWQxYzE1YTJlYzQ3M2U5YWNmNjk2ZmQ0OTZiNWExL3RhYmxlcmFuZ2U6YzE1ZDFjMTVhMmVjNDczZTlhY2Y2OTZmZDQ5NmI1YTFfMTQtMi0xLTEtMA_074d97a9-bfd6-4cd9-8e46-ef0092e43695">7,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="i30c50c718dda42d28fbdd6dcd4fa2365_58"></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMjcwMQ_94dabf56-6593-4031-9dd7-6fa863c1875b" continuedAt="if831f9f8ab10428ab8a3e831ab1e90ae" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="if831f9f8ab10428ab8a3e831ab1e90ae" continuedAt="ief25b1aa31d049faa66cca6884994b16"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021 and December&#160;31, 2020, the Company had <ix:nonFraction unitRef="shares" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfNzg_4e75251e-3a88-4f77-bfcd-15c51a818781"><ix:nonFraction unitRef="shares" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfNzg_5876cf99-416b-421c-aa11-dd12a2663f1b">10,000,000</ix:nonFraction></ix:nonFraction> shares of preferred stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMTE4_3340691a-b118-43e1-ba4c-17d492e4e961"><ix:nonFraction unitRef="usdPerShare" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMTE4_4d7e9a86-3c68-4a70-870c-226192ea3862">0.0001</ix:nonFraction></ix:nonFraction> authorized and <ix:nonFraction unitRef="shares" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMTM2_04b64c3f-3406-4ddd-b665-f97c914ff4c4"><ix:nonFraction unitRef="shares" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMTM2_c1b22335-9921-4289-af9d-612c6e42f5e2"><ix:nonFraction unitRef="shares" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMTM2_ceaa01aa-174f-4651-aaf6-5626fb48839c"><ix:nonFraction unitRef="shares" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMTM2_f11982f2-9530-406a-8c69-aeb2d5469d8f">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021 and December&#160;31, 2020, the Company had authorized <ix:nonFraction unitRef="shares" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMjI3_27b4e6b3-7d4d-4460-992e-b696f12c5b94"><ix:nonFraction unitRef="shares" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMjI3_736804ba-3618-4e39-a7e3-fc0bf2442785">200,000,000</ix:nonFraction></ix:nonFraction> shares of common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMjY0_dce3295a-ee4b-4d4d-85f0-f284a3567263"><ix:nonFraction unitRef="usdPerShare" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMjY0_ecd72e63-43e6-4773-8cd4-4723591521c7">0.0001</ix:nonFraction></ix:nonFraction>.  As of September&#160;30, 2021 and December&#160;31, 2020, the Company had <ix:nonFraction unitRef="shares" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMzAy_72c19139-e9af-454d-b0b5-5ef2fc4b28e4"><ix:nonFraction unitRef="shares" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMzAy_a8d5a2bc-8d25-433e-8a97-cce3c5ee640f">88,108,543</ix:nonFraction></ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMzE2_2650a44d-ddd4-4fb1-b1d1-2dd243401f55"><ix:nonFraction unitRef="shares" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMzE2_53e61338-21bb-48c8-9ed4-1950ceae7af3">87,651,352</ix:nonFraction></ix:nonFraction> shares issued and outstanding, respectively.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of shares of the Company&#8217;s common stock are entitled to <ix:nonFraction unitRef="votepershare" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="INF" format="ixt-sec:numwordsen" name="xcur:CommonStockVotingRightsForEachShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfNDM0_d304bcc1-f6d2-42c6-805f-b710b5f517a1">one</ix:nonFraction> vote per share on all matters to be voted upon by the Company&#8217;s stockholders and there are no cumulative rights. Subject to preferences that may be applicable to any outstanding preferred stock, the holders of shares of the Company&#8217;s common stock are entitled to receive ratably any dividends that may be declared from time to time by the Board out of funds legally available for that purpose. In the event of the Company&#8217;s liquidation, dissolution or winding up, the holders of shares of the Company&#8217;s common stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock then outstanding. The Company&#8217;s common stock has no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to the Company&#8217;s common stock. The outstanding shares of the Company&#8217;s common stock are fully paid and&#160;non-assessable.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Warrants</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of September&#160;30, 2021, <ix:nonFraction unitRef="shares" contextRef="i27fa1ea6e2df45148c9b25b975903963_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMTQyMQ_80c3341b-f060-4f6f-954b-76bfb6f2dbfe">no</ix:nonFraction> warrants were outstanding. As of December 31, 2020, warrants to purchase <ix:nonFraction unitRef="shares" contextRef="ibd76f03fda964ae290754abfcc474c0f_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMTQ5Nw_757df66a-72d5-4a61-ab26-00250256b564">413,320</ix:nonFraction> shares of common stock at a price of&#160;$<ix:nonFraction unitRef="usdPerShare" contextRef="ibd76f03fda964ae290754abfcc474c0f_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMTUzNw_527c6c01-dcd4-4ee3-bfb7-a3496c8f4696">3.00</ix:nonFraction>&#160;per share were outstanding.  The warrants expired unexercised as follows: <ix:nonFraction unitRef="shares" contextRef="i8169de03b9ae4915bce1475ec011bdcd_I20210327" decimals="INF" format="ixt:num-dot-decimal" name="xcur:ClassofWarrantorRightExpired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMTYxNA_850d4797-d8bf-49c1-9976-f2c78685bfb7">163,174</ix:nonFraction> warrants expired on March 27, 2021, <ix:nonFraction unitRef="shares" contextRef="i1c3f90d09e82457cb147316b3d91afa0_I20210428" decimals="INF" format="ixt:num-dot-decimal" name="xcur:ClassofWarrantorRightExpired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMTY1Mw_a893b5fe-64a0-4460-ac3f-63c736d3dd06">132,884</ix:nonFraction> expired on April 28, 2021, and <ix:nonFraction unitRef="shares" contextRef="if2dfcf33b3dd445fac1ae79f628e0c43_I20210503" decimals="INF" format="ixt:num-dot-decimal" name="xcur:ClassofWarrantorRightExpired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMTY4Nw_68652114-1a05-4d16-8a3b-506357da9dce">117,262</ix:nonFraction> expired on May 3, 2021.  The warrants were classified as a liability which was remeasured each period at fair value. See Note 12,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;for more information on the fair value of the common stock warrant liability.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="ief25b1aa31d049faa66cca6884994b16" continuedAt="id2c3f158bc84416aa50de0fdaa2d8389"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income (Loss)</span></div><ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMjY5OQ_d62c6254-ae82-45c3-ba80-c0d5a0495e15" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in each component of accumulated other comprehensive income (loss), net of tax, for&#160;2021:</span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.980%"><tr><td style="width:1.0%"></td><td style="width:57.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.754%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.757%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains (losses) on short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1d431f25394a5c823a69f4d9ab4c33_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmM2ODkxNjI5OTgyNjRiYzVhMWY4N2Q2NzY0ZGZlZmM3L3RhYmxlcmFuZ2U6YzY4OTE2Mjk5ODI2NGJjNWExZjg3ZDY3NjRkZmVmYzdfMS0yLTEtMS0w_b4f39ad8-81e2-4b0b-af65-93e844836610">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i501a27e325104650a73ad03cfcd4faa7_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmM2ODkxNjI5OTgyNjRiYzVhMWY4N2Q2NzY0ZGZlZmM3L3RhYmxlcmFuZ2U6YzY4OTE2Mjk5ODI2NGJjNWExZjg3ZDY3NjRkZmVmYzdfMS00LTEtMS0w_583b019f-efb3-4b9c-a5b0-6ff3e1719d3e">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic64e0711d9f74fb89ed048800885e19f_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmM2ODkxNjI5OTgyNjRiYzVhMWY4N2Q2NzY0ZGZlZmM3L3RhYmxlcmFuZ2U6YzY4OTE2Mjk5ODI2NGJjNWExZjg3ZDY3NjRkZmVmYzdfMi0yLTEtMS0w_40b130d7-3219-4f3e-a71c-3028aab7d716">51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dea9cf71d074399a074543cd69ce8c7_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmM2ODkxNjI5OTgyNjRiYzVhMWY4N2Q2NzY0ZGZlZmM3L3RhYmxlcmFuZ2U6YzY4OTE2Mjk5ODI2NGJjNWExZjg3ZDY3NjRkZmVmYzdfMi00LTEtMS0w_3d012cec-8850-469e-b394-800ef786e759">51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic64e0711d9f74fb89ed048800885e19f_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmM2ODkxNjI5OTgyNjRiYzVhMWY4N2Q2NzY0ZGZlZmM3L3RhYmxlcmFuZ2U6YzY4OTE2Mjk5ODI2NGJjNWExZjg3ZDY3NjRkZmVmYzdfMy0yLTEtMS0w_0b48f01a-b6c7-4389-a1aa-239cd841192b">51</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dea9cf71d074399a074543cd69ce8c7_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmM2ODkxNjI5OTgyNjRiYzVhMWY4N2Q2NzY0ZGZlZmM3L3RhYmxlcmFuZ2U6YzY4OTE2Mjk5ODI2NGJjNWExZjg3ZDY3NjRkZmVmYzdfMy00LTEtMS0w_0fe1a301-3476-4cce-8b4d-75c1f7ef2022">51</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53500ad38bdf4e52898d5f52b87b27ef_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmM2ODkxNjI5OTgyNjRiYzVhMWY4N2Q2NzY0ZGZlZmM3L3RhYmxlcmFuZ2U6YzY4OTE2Mjk5ODI2NGJjNWExZjg3ZDY3NjRkZmVmYzdfNC0yLTEtMS0w_1b46da42-e1ce-4bc0-9e78-251745d15707">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a52bc4a3c0d4c7cbfa5ea8a045321fa_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmM2ODkxNjI5OTgyNjRiYzVhMWY4N2Q2NzY0ZGZlZmM3L3RhYmxlcmFuZ2U6YzY4OTE2Mjk5ODI2NGJjNWExZjg3ZDY3NjRkZmVmYzdfNC00LTEtMS0w_90423c8b-09bf-4330-a730-7fc81f3ad975">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecc89148ecae49e08ec084733d34a7aa_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmM2ODkxNjI5OTgyNjRiYzVhMWY4N2Q2NzY0ZGZlZmM3L3RhYmxlcmFuZ2U6YzY4OTE2Mjk5ODI2NGJjNWExZjg3ZDY3NjRkZmVmYzdfNS0yLTEtMS0w_f3817cd2-f31f-47f1-9b90-79f34b234eee">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac6b52ac45d04a2588c506176895e21f_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmM2ODkxNjI5OTgyNjRiYzVhMWY4N2Q2NzY0ZGZlZmM3L3RhYmxlcmFuZ2U6YzY4OTE2Mjk5ODI2NGJjNWExZjg3ZDY3NjRkZmVmYzdfNS00LTEtMS0w_11c274e7-6276-4609-be7f-45171869abda">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecc89148ecae49e08ec084733d34a7aa_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmM2ODkxNjI5OTgyNjRiYzVhMWY4N2Q2NzY0ZGZlZmM3L3RhYmxlcmFuZ2U6YzY4OTE2Mjk5ODI2NGJjNWExZjg3ZDY3NjRkZmVmYzdfNy0yLTEtMS0w_fd62925d-f54a-4787-8a70-31002a27422c">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac6b52ac45d04a2588c506176895e21f_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmM2ODkxNjI5OTgyNjRiYzVhMWY4N2Q2NzY0ZGZlZmM3L3RhYmxlcmFuZ2U6YzY4OTE2Mjk5ODI2NGJjNWExZjg3ZDY3NjRkZmVmYzdfNy00LTEtMS0w_9158ac94-d17a-40ad-8c84-0c32315f5f73">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4c5418937146598e8abc57dcc888bc_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmM2ODkxNjI5OTgyNjRiYzVhMWY4N2Q2NzY0ZGZlZmM3L3RhYmxlcmFuZ2U6YzY4OTE2Mjk5ODI2NGJjNWExZjg3ZDY3NjRkZmVmYzdfOC0yLTEtMS0w_7f907d2b-091c-426b-b044-d6ccfe135547">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i992a828696e04df48d18d2f8bc76598e_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmM2ODkxNjI5OTgyNjRiYzVhMWY4N2Q2NzY0ZGZlZmM3L3RhYmxlcmFuZ2U6YzY4OTE2Mjk5ODI2NGJjNWExZjg3ZDY3NjRkZmVmYzdfOC00LTEtMS0w_d079fd0e-159b-4ea8-9ca4-b614e5387822">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0deb149ab1ef4764ab8d4cdbf04c52b6_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmM2ODkxNjI5OTgyNjRiYzVhMWY4N2Q2NzY0ZGZlZmM3L3RhYmxlcmFuZ2U6YzY4OTE2Mjk5ODI2NGJjNWExZjg3ZDY3NjRkZmVmYzdfOS0yLTEtMS0xMTY1OQ_4eac13e1-b8e6-4173-9394-a2b1968743d2">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmM2ODkxNjI5OTgyNjRiYzVhMWY4N2Q2NzY0ZGZlZmM3L3RhYmxlcmFuZ2U6YzY4OTE2Mjk5ODI2NGJjNWExZjg3ZDY3NjRkZmVmYzdfOS00LTEtMS0xMTY1OQ_b18596f9-8583-4161-8635-23961a8f6c15">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net losses (gains) reclassified from accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0deb149ab1ef4764ab8d4cdbf04c52b6_D20210701-20210930" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmM2ODkxNjI5OTgyNjRiYzVhMWY4N2Q2NzY0ZGZlZmM3L3RhYmxlcmFuZ2U6YzY4OTE2Mjk5ODI2NGJjNWExZjg3ZDY3NjRkZmVmYzdfMTAtMi0xLTEtMTE2NTk_c9051dd0-e20a-4dd1-a7be-98395d2f3b65">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmM2ODkxNjI5OTgyNjRiYzVhMWY4N2Q2NzY0ZGZlZmM3L3RhYmxlcmFuZ2U6YzY4OTE2Mjk5ODI2NGJjNWExZjg3ZDY3NjRkZmVmYzdfMTAtNC0xLTEtMTE2NTk_565993b2-7e43-4614-8830-7d21f75b9396">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0deb149ab1ef4764ab8d4cdbf04c52b6_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmM2ODkxNjI5OTgyNjRiYzVhMWY4N2Q2NzY0ZGZlZmM3L3RhYmxlcmFuZ2U6YzY4OTE2Mjk5ODI2NGJjNWExZjg3ZDY3NjRkZmVmYzdfMTEtMi0xLTEtMTE2NTk_8002994c-b3fe-4c7f-98a4-36a46e643543">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmM2ODkxNjI5OTgyNjRiYzVhMWY4N2Q2NzY0ZGZlZmM3L3RhYmxlcmFuZ2U6YzY4OTE2Mjk5ODI2NGJjNWExZjg3ZDY3NjRkZmVmYzdfMTEtNC0xLTEtMTE2NTk_1c4c6afa-f1a9-4fd1-9c46-7ae5470cb37f">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ed6144e7375437b82d12e674ba92210_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmM2ODkxNjI5OTgyNjRiYzVhMWY4N2Q2NzY0ZGZlZmM3L3RhYmxlcmFuZ2U6YzY4OTE2Mjk5ODI2NGJjNWExZjg3ZDY3NjRkZmVmYzdfMTItMi0xLTEtMTE2NTk_f0fa277d-759f-43b4-917f-1d882349ff15">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf9e5d3ecf814b9ab2f88960463e4dd8_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmM2ODkxNjI5OTgyNjRiYzVhMWY4N2Q2NzY0ZGZlZmM3L3RhYmxlcmFuZ2U6YzY4OTE2Mjk5ODI2NGJjNWExZjg3ZDY3NjRkZmVmYzdfMTItNC0xLTEtMTE2NTk_fc4f26f0-a575-4861-b38a-4163742534ba">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net gain reclassified from accumulated other comprehensive loss during the three months ended September 30, 2021 resulted from available-for-sale securities that were called prior to maturity and <ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMTA5OTUxMTYzMTMyNw_1b948017-58cd-442b-adb3-1819abfceff9"><ix:nonFraction unitRef="usd" contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMTA5OTUxMTYzMTMyNw_6538d25a-44c3-4e5c-bd77-b02b14a10169"><ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMTA5OTUxMTYzMTMyNw_7ae40dae-0ea3-4b45-b99f-b757f31872ff"><ix:nonFraction unitRef="usd" contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMTA5OTUxMTYzMTMyNw_8de5bef0-f0a1-42d0-b733-2de622176dfc">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> gains or losses were recognized for the three and nine months ended September 30, 2021. The basis on which the cost of the securities was determined was specific identification. Proceeds related to these sales were $<ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMTA5OTUxMTYzMTM1Mg_1957464f-f91f-4f8c-a99f-6feac10e9763">4,000</ix:nonFraction>.</span></div><div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in each component of accumulated other comprehensive income (loss), net of tax, for&#160;2020:</span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.980%"><tr><td style="width:1.0%"></td><td style="width:57.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.754%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.757%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains (losses) on short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73a5c9b5040b4db1b63fd576e252a033_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmUxOTU3M2YxMGUwZTRhZWY5YjI4ZWJlYzczNGRmYTMwL3RhYmxlcmFuZ2U6ZTE5NTczZjEwZTBlNGFlZjliMjhlYmVjNzM0ZGZhMzBfMS0yLTEtMS0w_cc22858a-b1cf-42e3-bc2b-1a59723cb6ab">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifca2e3b16c794fc4a70ed80eb0c74b8d_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmUxOTU3M2YxMGUwZTRhZWY5YjI4ZWJlYzczNGRmYTMwL3RhYmxlcmFuZ2U6ZTE5NTczZjEwZTBlNGFlZjliMjhlYmVjNzM0ZGZhMzBfMS00LTEtMS0w_42f30fe0-fbcc-47ba-a301-4ad2cae956e0">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4e62853255f45b2b31cd2904be103fe_D20200101-20200331" decimals="-3" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmUxOTU3M2YxMGUwZTRhZWY5YjI4ZWJlYzczNGRmYTMwL3RhYmxlcmFuZ2U6ZTE5NTczZjEwZTBlNGFlZjliMjhlYmVjNzM0ZGZhMzBfMi0yLTEtMS0w_6c16d7dd-428d-4352-a064-d5965c4d1faf">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab3dbd6a7f674d7083db2fa3c9db78a2_D20200101-20200331" decimals="-3" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmUxOTU3M2YxMGUwZTRhZWY5YjI4ZWJlYzczNGRmYTMwL3RhYmxlcmFuZ2U6ZTE5NTczZjEwZTBlNGFlZjliMjhlYmVjNzM0ZGZhMzBfMi00LTEtMS0w_dc41d0d1-2cb6-4c55-a010-2987d102974a">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4e62853255f45b2b31cd2904be103fe_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmUxOTU3M2YxMGUwZTRhZWY5YjI4ZWJlYzczNGRmYTMwL3RhYmxlcmFuZ2U6ZTE5NTczZjEwZTBlNGFlZjliMjhlYmVjNzM0ZGZhMzBfMy0yLTEtMS0w_6f32b186-c297-4eb7-b138-c043716d43d2">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab3dbd6a7f674d7083db2fa3c9db78a2_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmUxOTU3M2YxMGUwZTRhZWY5YjI4ZWJlYzczNGRmYTMwL3RhYmxlcmFuZ2U6ZTE5NTczZjEwZTBlNGFlZjliMjhlYmVjNzM0ZGZhMzBfMy00LTEtMS0w_8634841f-ebd1-48d3-8c54-74e841e20088">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57be8b97989949c89b339f60ea0c9c10_I20200331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmUxOTU3M2YxMGUwZTRhZWY5YjI4ZWJlYzczNGRmYTMwL3RhYmxlcmFuZ2U6ZTE5NTczZjEwZTBlNGFlZjliMjhlYmVjNzM0ZGZhMzBfNC0yLTEtMS0w_445603f1-2e6c-4904-928d-5943b539c519">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a09fd187a41481abc00b2e5f81774d2_I20200331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmUxOTU3M2YxMGUwZTRhZWY5YjI4ZWJlYzczNGRmYTMwL3RhYmxlcmFuZ2U6ZTE5NTczZjEwZTBlNGFlZjliMjhlYmVjNzM0ZGZhMzBfNC00LTEtMS0w_edf22077-37ac-4e57-8daa-244b3e1e3a92">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i078e9e8c3ffe4962a86e337d4adc40ed_D20200401-20200630" decimals="-3" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmUxOTU3M2YxMGUwZTRhZWY5YjI4ZWJlYzczNGRmYTMwL3RhYmxlcmFuZ2U6ZTE5NTczZjEwZTBlNGFlZjliMjhlYmVjNzM0ZGZhMzBfNS0yLTEtMS0w_19a6b936-2723-47c6-90ea-9feb30809db6">352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b2c76fc1f31458f93f96af1cff6f08f_D20200401-20200630" decimals="-3" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmUxOTU3M2YxMGUwZTRhZWY5YjI4ZWJlYzczNGRmYTMwL3RhYmxlcmFuZ2U6ZTE5NTczZjEwZTBlNGFlZjliMjhlYmVjNzM0ZGZhMzBfNS00LTEtMS0w_88d75a61-67f3-4096-b43c-439a56a7b64c">352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net losses (gains) reclassified from accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i078e9e8c3ffe4962a86e337d4adc40ed_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmUxOTU3M2YxMGUwZTRhZWY5YjI4ZWJlYzczNGRmYTMwL3RhYmxlcmFuZ2U6ZTE5NTczZjEwZTBlNGFlZjliMjhlYmVjNzM0ZGZhMzBfNi0yLTEtMS0w_842ecb03-aa27-4402-8082-041f1e6cf989">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b2c76fc1f31458f93f96af1cff6f08f_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmUxOTU3M2YxMGUwZTRhZWY5YjI4ZWJlYzczNGRmYTMwL3RhYmxlcmFuZ2U6ZTE5NTczZjEwZTBlNGFlZjliMjhlYmVjNzM0ZGZhMzBfNi00LTEtMS0w_60558914-04ac-4e5d-8fc7-2d9b8988a964">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i078e9e8c3ffe4962a86e337d4adc40ed_D20200401-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmUxOTU3M2YxMGUwZTRhZWY5YjI4ZWJlYzczNGRmYTMwL3RhYmxlcmFuZ2U6ZTE5NTczZjEwZTBlNGFlZjliMjhlYmVjNzM0ZGZhMzBfNy0yLTEtMS0w_b316d714-7b55-457e-bb20-1cab031c167b">355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b2c76fc1f31458f93f96af1cff6f08f_D20200401-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmUxOTU3M2YxMGUwZTRhZWY5YjI4ZWJlYzczNGRmYTMwL3RhYmxlcmFuZ2U6ZTE5NTczZjEwZTBlNGFlZjliMjhlYmVjNzM0ZGZhMzBfNy00LTEtMS0w_099fb607-5de1-4e99-9181-75fc379d8c2b">355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i284324b6f8f04a0a9d2178e2163abdef_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmUxOTU3M2YxMGUwZTRhZWY5YjI4ZWJlYzczNGRmYTMwL3RhYmxlcmFuZ2U6ZTE5NTczZjEwZTBlNGFlZjliMjhlYmVjNzM0ZGZhMzBfOC0yLTEtMS0w_c3c7a1d8-d236-48d0-b133-a8e5d14aa58a">338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9ef743ad4504fe6a4762417ee298525_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmUxOTU3M2YxMGUwZTRhZWY5YjI4ZWJlYzczNGRmYTMwL3RhYmxlcmFuZ2U6ZTE5NTczZjEwZTBlNGFlZjliMjhlYmVjNzM0ZGZhMzBfOC00LTEtMS0w_1bece6cb-2372-4713-821d-227125a2fd21">338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff67e94dbcb44135b28d7b8a3cc93f58_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmUxOTU3M2YxMGUwZTRhZWY5YjI4ZWJlYzczNGRmYTMwL3RhYmxlcmFuZ2U6ZTE5NTczZjEwZTBlNGFlZjliMjhlYmVjNzM0ZGZhMzBfOS0yLTEtMS0w_dc646bb2-5da0-489e-a5af-d3f84d064140">138</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmUxOTU3M2YxMGUwZTRhZWY5YjI4ZWJlYzczNGRmYTMwL3RhYmxlcmFuZ2U6ZTE5NTczZjEwZTBlNGFlZjliMjhlYmVjNzM0ZGZhMzBfOS00LTEtMS0xMjM5NA_3c98c588-961a-4159-9945-42d24df601c9">138</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff67e94dbcb44135b28d7b8a3cc93f58_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmUxOTU3M2YxMGUwZTRhZWY5YjI4ZWJlYzczNGRmYTMwL3RhYmxlcmFuZ2U6ZTE5NTczZjEwZTBlNGFlZjliMjhlYmVjNzM0ZGZhMzBfMTAtMi0xLTEtMA_2fdcf95f-417d-4573-aa94-476824e69116">138</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmUxOTU3M2YxMGUwZTRhZWY5YjI4ZWJlYzczNGRmYTMwL3RhYmxlcmFuZ2U6ZTE5NTczZjEwZTBlNGFlZjliMjhlYmVjNzM0ZGZhMzBfMTAtNC0xLTEtMTIzOTQ_9b787067-1be1-4151-b3a8-53bd46d9da03">138</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88948d106e48468baa525705927f987b_I20200930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmUxOTU3M2YxMGUwZTRhZWY5YjI4ZWJlYzczNGRmYTMwL3RhYmxlcmFuZ2U6ZTE5NTczZjEwZTBlNGFlZjliMjhlYmVjNzM0ZGZhMzBfMTEtMi0xLTEtMA_ec7a515c-d87d-4ed8-baa1-98bf666e9bc0">200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe0cf5fbf4e1438fb46d794ecd6487cc_I20200930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmUxOTU3M2YxMGUwZTRhZWY5YjI4ZWJlYzczNGRmYTMwL3RhYmxlcmFuZ2U6ZTE5NTczZjEwZTBlNGFlZjliMjhlYmVjNzM0ZGZhMzBfMTEtNC0xLTEtMTIzOTQ_7fbbff46-c0a9-4551-b215-a32b80de2503">200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id2c3f158bc84416aa50de0fdaa2d8389">The net loss reclassified from accumulated other comprehensive loss during the nine months ended September 30, 2020 resulted from sales of available-for-sale securities prior to maturity. The gross realized gains and gross realized losses of these sales were $<ix:nonFraction unitRef="usd" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMjQ5Mw_9995b7e7-76b5-4b2a-a5b1-339bb07476c4">23</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMjUwMA_1455dfd1-7797-4f4e-9631-e499d6acdb6c">6</ix:nonFraction>, respectively, for the three and nine months ended September 30, 2020. The basis on which the cost of the securities was determined was specific identification. Proceeds related to these sales were $<ix:nonFraction unitRef="usd" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMjY5NQ_bd5e0f3a-5235-44f7-a2a4-3735b7afd608">9,404</ix:nonFraction>.</ix:continuation></span></div><div id="i30c50c718dda42d28fbdd6dcd4fa2365_61"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfNjcxMw_03b44271-cd0d-4150-a398-57b882802e2d" continuedAt="i873134b7fc294bc5ba0692998b0c2f7d" escape="true">Equity-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i873134b7fc294bc5ba0692998b0c2f7d" continuedAt="i02574ef065e24650a0744736ddab0bd5"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 Equity Incentive Plan</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Awards that may be awarded under the 2017 Equity Incentive Plan include non-qualified and incentive stock options, stock appreciation rights, bonus shares, restricted stock, restricted stock units, performance units and cash-based awards. The number of shares of common stock reserved for issuance under the 2017 Equity Incentive Plan automatically increases on January 1 of each year, beginning on January 1, 2020, by the lesser of (i) <ix:nonFraction unitRef="shares" contextRef="if0c01f0c5533412a95c4f674b3fca01f_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfNDk4_94afb501-e9ba-4f44-824c-21b9ecb74288">4,600,000</ix:nonFraction> shares, (ii) <ix:nonFraction unitRef="number" contextRef="i9cf18d06bb4048079daf994c18213de9_I20210930" decimals="2" name="xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfNTE0_484d70da-febe-47fc-ae2c-25994bee8934">5</ix:nonFraction>% of the total number of shares of our capital stock outstanding on December 31 of the preceding calendar year, or (iii) a lesser number of shares determined by the Compensation Committee of the Board (the &#8220;Compensation Committee&#8221;). The Compensation Committee made the determination to increase the share reserve for the 2017 Equity Incentive Plan by <ix:nonFraction unitRef="shares" contextRef="iab7fc37403bc4ae2845774e5e03fe94c_D20210101-20210101" decimals="INF" format="ixt:num-dot-decimal" name="xcur:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfODM1_cb628883-1065-4fe7-9a71-e590f1704adf">4,382,567</ix:nonFraction> shares, effective January 1, 2021. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the aggregate number of equity awards available for grant under the 2017 Equity Incentive Plan was <ix:nonFraction unitRef="shares" contextRef="i9cf18d06bb4048079daf994c18213de9_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfOTgz_fba8a4ff-da65-47cf-9962-48ca9d2d3e9e">2,558,218</ix:nonFraction>.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inducement Grant</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company granted stock options to purchase up to <ix:nonFraction unitRef="shares" contextRef="id55f75e995434a9dbf67ef6793958099_D20210501-20210531" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfMTA2OQ_b1bc604e-c2a8-4fdd-a96d-a1f7d2e756c8">600,000</ix:nonFraction> shares of common stock as a material inducement to Brian C. Bock, the Company&#8217;s Chief Financial Officer, to enter into employment with the Company (the &#8220;Inducement Grant&#8221;).  The Inducement Grant, which was made pursuant to a stand-alone nonstatutory stock option agreement (the &#8220;Inducement Award Agreement&#8221;), was approved by the Compensation Committee, was awarded in accordance with Nasdaq Listing Rule 5635(c)(4) and outside of the Company&#8217;s 2017 Equity Incentive Plan and is subject to the terms and conditions of the Inducement Award Agreement.  As such, any shares underlying the Inducement Grant are not, upon forfeiture, cancellation or expiration, returned to a pool of shares reserved for future issuance.  As of September&#160;30, 2021, stock options to purchase up to <ix:nonFraction unitRef="shares" contextRef="ie212c3441c564ae7beb10ac73b3f5f39_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfMTg1NA_074d0c25-02cf-4fc9-8f63-57c7acd1c7fd">600,000</ix:nonFraction> shares of common stock remained outstanding under the Inducement Grant.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2017 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) was adopted by the Board in September 2017 and approved by the Company&#8217;s stockholders in September 2017. Through the ESPP, eligible employees may authorize payroll deductions of up to <ix:nonFraction unitRef="number" contextRef="i4c783d5073c74f03a909d7ebe8913ac0_I20170930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfMjE5Mw_b422e1e9-204b-4cf8-8348-fdbf80ace005">15</ix:nonFraction>% of their compensation to purchase common stock. The maximum number of shares that an employee may purchase on any exercise date in an offer period will be the smaller of (i) <ix:nonFraction unitRef="shares" contextRef="i4333b7976f584c9cb7edb39e5c5abebd_D20170901-20170930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfMjM3MA_ae0bcbd5-58a6-4627-8a23-2a07f6fa9542">7,500</ix:nonFraction> shares or (ii) such number of shares as has a fair market value (determined as of the offering date for such offer period) equal to $<ix:nonFraction unitRef="usd" contextRef="i4333b7976f584c9cb7edb39e5c5abebd_D20170901-20170930" decimals="INF" format="ixt:num-dot-decimal" name="xcur:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfMjUwNQ_4e49b61b-7967-4911-89dc-cf3c6dab8c54">25,000</ix:nonFraction> within one calendar year minus the fair market value of any other shares of common stock that are attributed to such calendar year. The purchase price per share at each purchase date is equal to <ix:nonFraction unitRef="number" contextRef="i4333b7976f584c9cb7edb39e5c5abebd_D20170901-20170930" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfMjcwMw_712b3eac-a877-4426-b1b1-86c0159bec41">85</ix:nonFraction>% of the lower of (i) the closing market price per share of Exicure common stock on the employee&#8217;s offering date or (ii) the closing market price per share of Exicure common stock on the exercise date. Each offering period is approximately <ix:nonNumeric contextRef="i4333b7976f584c9cb7edb39e5c5abebd_D20170901-20170930" format="ixt-sec:durwordsen" name="xcur:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfNjcxMA_b17c53a5-988f-43cb-9729-4eea1aa4ed2a">six-months</ix:nonNumeric> in duration and the first offering period began on November 16, 2020 and ended on May 14, 2021.  In connection with the end of the first offering period on May 14, 2021, the Company issued <ix:nonFraction unitRef="shares" contextRef="id8d6615560b5454ea9d90fe9e4254cc7_D20210514-20210514" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfMzE0Mw_1236aeb5-0eb4-4d6d-bbc2-d24b7c9e7eae">103,096</ix:nonFraction> shares of common stock that were purchased under the ESPP.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ESPP provides that the number of shares reserved and available for issuance will automatically increase each January 1, beginning on January 1, 2018 and each January 1 thereafter through January 1, 2027, by the least of (i) <ix:nonFraction unitRef="shares" contextRef="i4c783d5073c74f03a909d7ebe8913ac0_I20170930" decimals="INF" format="ixt:num-dot-decimal" name="xcur:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfMzQzMw_f36b42cc-6896-4d46-8e49-b34bb8cbc507">300,000</ix:nonFraction> shares; (ii) <ix:nonFraction unitRef="number" contextRef="i4333b7976f584c9cb7edb39e5c5abebd_D20170901-20170930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfMzQ0OQ_1c2d8be9-f4bb-4998-911d-7c5f5feaca47">0.3</ix:nonFraction>% of the outstanding shares of common stock on the last day of the immediately preceding calendar year; or (iii) a lesser number of shares determined by the Board. On January 1, 2021 and 2020, the number </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i02574ef065e24650a0744736ddab0bd5" continuedAt="i7ae62c742af54cdfaf88490b47487e9e"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of shares of common stock available for issuance under the ESPP increased by <ix:nonFraction unitRef="shares" contextRef="i5c0e7a1b94874bc79ecebefc5fac4988_D20210101-20210101" decimals="INF" format="ixt:num-dot-decimal" name="xcur:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfMzczMQ_c7c4e560-5206-401d-bfd6-9fbee5ff966d">258,207</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="i982ad11b02e442eabda7ce00ba0f8e6f_D20200101-20200101" decimals="INF" format="ixt:num-dot-decimal" name="xcur:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfMzc0NQ_24149269-ddfb-47ae-bf6a-405328263ff1">262,954</ix:nonFraction> shares, respectively. As of September&#160;30, 2021, there were <ix:nonFraction unitRef="shares" contextRef="if7a30565b6414f62b985b9824a0b50b0_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfMzgwMg_85d74788-14c9-434b-bf4c-79950c5e5833">1,100,791</ix:nonFraction> shares available for issuance under the ESPP.</span></div><ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfNjcxOQ_cc51abb9-5e0d-45c4-8766-17e018199156" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity-based compensation expense is classified in the statements of operations as follows:</span></div><div style="margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if808fd669ed14a3eb6ab7ba40be06723_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjZmMjM3NTEwNTBlOTQ1YmM4YzUxMjU4OTY4NDc4OTNhL3RhYmxlcmFuZ2U6NmYyMzc1MTA1MGU5NDViYzhjNTEyNTg5Njg0Nzg5M2FfMi0xLTEtMS0w_2bda6733-d5cf-4a00-8cfd-9942d360bd16">427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dd8d8dbeff24010a0f6b35ba5d055da_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjZmMjM3NTEwNTBlOTQ1YmM4YzUxMjU4OTY4NDc4OTNhL3RhYmxlcmFuZ2U6NmYyMzc1MTA1MGU5NDViYzhjNTEyNTg5Njg0Nzg5M2FfMi0zLTEtMS0w_56edec06-dccd-4a9c-8917-92594bd71456">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3196c46080b4a98afd913b13a6d4a34_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjZmMjM3NTEwNTBlOTQ1YmM4YzUxMjU4OTY4NDc4OTNhL3RhYmxlcmFuZ2U6NmYyMzc1MTA1MGU5NDViYzhjNTEyNTg5Njg0Nzg5M2FfMi01LTEtMS0w_8f22e6f6-53f2-4b24-be45-3c1aa45a3cb7">1,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i320897d327b3429885b686fa2ddd6d58_D20200101-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjZmMjM3NTEwNTBlOTQ1YmM4YzUxMjU4OTY4NDc4OTNhL3RhYmxlcmFuZ2U6NmYyMzc1MTA1MGU5NDViYzhjNTEyNTg5Njg0Nzg5M2FfMi03LTEtMS0w_18ead26b-ec02-4e76-a720-03bcd8fc5583">607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc041bea74db41bc8b34b9c2abac7ec1_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjZmMjM3NTEwNTBlOTQ1YmM4YzUxMjU4OTY4NDc4OTNhL3RhYmxlcmFuZ2U6NmYyMzc1MTA1MGU5NDViYzhjNTEyNTg5Njg0Nzg5M2FfMy0xLTEtMS0w_7b7052a9-9a3e-4519-8915-4fac6dff579e">462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i999eb37ba3c84d41978cdddb2073c9c0_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjZmMjM3NTEwNTBlOTQ1YmM4YzUxMjU4OTY4NDc4OTNhL3RhYmxlcmFuZ2U6NmYyMzc1MTA1MGU5NDViYzhjNTEyNTg5Njg0Nzg5M2FfMy0zLTEtMS0w_6549eb2f-b34e-496a-a5c3-b216f5950117">371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id73356acb7214cc990e0f0fdb073fe06_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjZmMjM3NTEwNTBlOTQ1YmM4YzUxMjU4OTY4NDc4OTNhL3RhYmxlcmFuZ2U6NmYyMzc1MTA1MGU5NDViYzhjNTEyNTg5Njg0Nzg5M2FfMy01LTEtMS0w_bb71fd23-293b-4622-afa4-f3b923890dcf">1,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3853bdccdca84ad7b18ecb46c72865db_D20200101-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjZmMjM3NTEwNTBlOTQ1YmM4YzUxMjU4OTY4NDc4OTNhL3RhYmxlcmFuZ2U6NmYyMzc1MTA1MGU5NDViYzhjNTEyNTg5Njg0Nzg5M2FfMy03LTEtMS0w_2dd085c1-4ea7-4bfb-82df-c33b44ec61ec">996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjZmMjM3NTEwNTBlOTQ1YmM4YzUxMjU4OTY4NDc4OTNhL3RhYmxlcmFuZ2U6NmYyMzc1MTA1MGU5NDViYzhjNTEyNTg5Njg0Nzg5M2FfNC0xLTEtMS0w_a7abc495-2f53-46f2-bbdd-0fff3bc48227">889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjZmMjM3NTEwNTBlOTQ1YmM4YzUxMjU4OTY4NDc4OTNhL3RhYmxlcmFuZ2U6NmYyMzc1MTA1MGU5NDViYzhjNTEyNTg5Njg0Nzg5M2FfNC0zLTEtMS0w_6cc91ef3-dc61-4319-86e3-6009a7177043">618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjZmMjM3NTEwNTBlOTQ1YmM4YzUxMjU4OTY4NDc4OTNhL3RhYmxlcmFuZ2U6NmYyMzc1MTA1MGU5NDViYzhjNTEyNTg5Njg0Nzg5M2FfNC01LTEtMS0w_756f0c24-6d25-4474-a405-d7a67ea85697">2,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjZmMjM3NTEwNTBlOTQ1YmM4YzUxMjU4OTY4NDc4OTNhL3RhYmxlcmFuZ2U6NmYyMzc1MTA1MGU5NDViYzhjNTEyNTg5Njg0Nzg5M2FfNC03LTEtMS0w_c3397842-61b4-4e4d-9b88-442e590a5f17">1,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized equity-based compensation expense at September&#160;30, 2021 was $<ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfNDAwMg_6348f315-073b-42ad-9d47-bd13818d1391">7,820</ix:nonFraction>, which is expected to be amortized over a weighted-average period of <ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfNDA3NA_9b865ee1-abbc-4c46-ade3-9826c2401b13">3.0</ix:nonNumeric> years. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the Black-Scholes option-pricing model to determine the fair value of common stock option grants. The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable.  The model also requires the input of highly subjective assumptions.  <ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfNjcyMw_47f529be-2262-40f5-8838-2d89bf65d7c3" continuedAt="i7230cf824a5c4e47b2d93ffba80f4b76" escape="true">In addition to an assumption on the expected term of the option grants as discussed below, application of the Black-Scholes model requires additional inputs for which we have assumed the values described in the table below:</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><ix:continuation id="i7230cf824a5c4e47b2d93ffba80f4b76" continuedAt="iccf851bedd174d8e835796ab983efb34"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.115%"><tr><td style="width:1.0%"></td><td style="width:56.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.857%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.625%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.858%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6aeb1a850cfb47d0a5ac9c85fe47090e_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjFjOWNiMjMxOWYzZTRiYWE4MzcyYTU2ZWM0ZGNmYzdhL3RhYmxlcmFuZ2U6MWM5Y2IyMzE5ZjNlNGJhYTgzNzJhNTZlYzRkY2ZjN2FfMi0xLTEtMS0wL3RleHRyZWdpb246ODFhZjU5MzBkNzkxNGFmM2E4NDYyYWUwZWRhNTRmY2NfNA_f57d0030-584f-4adb-b662-7179ff69801b">5.0</ix:nonNumeric> to <ix:nonNumeric contextRef="i6b82c3458cdf484196d37803505070a6_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjFjOWNiMjMxOWYzZTRiYWE4MzcyYTU2ZWM0ZGNmYzdhL3RhYmxlcmFuZ2U6MWM5Y2IyMzE5ZjNlNGJhYTgzNzJhNTZlYzRkY2ZjN2FfMi0xLTEtMS0wL3RleHRyZWdpb246ODFhZjU5MzBkNzkxNGFmM2E4NDYyYWUwZWRhNTRmY2NfMTA_273a22de-7405-4a0a-b1f4-ff53afb0661a">6.1</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia356a586489a48ba88f9458d0242cdf9_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjFjOWNiMjMxOWYzZTRiYWE4MzcyYTU2ZWM0ZGNmYzdhL3RhYmxlcmFuZ2U6MWM5Y2IyMzE5ZjNlNGJhYTgzNzJhNTZlYzRkY2ZjN2FfMi0zLTEtMS0wL3RleHRyZWdpb246OTc4NzM0Njg3Y2VkNGY5ZThkNjJlNDhhMGM5NGU3MWJfNA_f9d2aa98-c4c3-4ae5-b719-9fb0949c4ffa">5.2</ix:nonNumeric> to <ix:nonNumeric contextRef="i773b254eadab4295b1ffc8c03ceb00b8_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjFjOWNiMjMxOWYzZTRiYWE4MzcyYTU2ZWM0ZGNmYzdhL3RhYmxlcmFuZ2U6MWM5Y2IyMzE5ZjNlNGJhYTgzNzJhNTZlYzRkY2ZjN2FfMi0zLTEtMS0wL3RleHRyZWdpb246OTc4NzM0Njg3Y2VkNGY5ZThkNjJlNDhhMGM5NGU3MWJfMTA_160255c1-c4f0-4320-95b3-3469508d0d94">6.1</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjFjOWNiMjMxOWYzZTRiYWE4MzcyYTU2ZWM0ZGNmYzdhL3RhYmxlcmFuZ2U6MWM5Y2IyMzE5ZjNlNGJhYTgzNzJhNTZlYzRkY2ZjN2FfMy0xLTEtMS0wL3RleHRyZWdpb246MGU1MjUwNjFkYzQ0NGExNmFlYzM1ZWRmZjEzNjJmMWJfNA_2734277a-fa0c-413e-b031-4b25365c32a4">0.36</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjFjOWNiMjMxOWYzZTRiYWE4MzcyYTU2ZWM0ZGNmYzdhL3RhYmxlcmFuZ2U6MWM5Y2IyMzE5ZjNlNGJhYTgzNzJhNTZlYzRkY2ZjN2FfMy0xLTEtMS0wL3RleHRyZWdpb246MGU1MjUwNjFkYzQ0NGExNmFlYzM1ZWRmZjEzNjJmMWJfMTA_f4b94b2e-dd4b-468c-9224-78dfee377585">1.12</ix:nonFraction>%; weighted avg. <ix:nonFraction unitRef="number" contextRef="ic894455288284da09cf40a767a1e085c_D20210101-20210930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjFjOWNiMjMxOWYzZTRiYWE4MzcyYTU2ZWM0ZGNmYzdhL3RhYmxlcmFuZ2U6MWM5Y2IyMzE5ZjNlNGJhYTgzNzJhNTZlYzRkY2ZjN2FfMy0xLTEtMS0wL3RleHRyZWdpb246MGU1MjUwNjFkYzQ0NGExNmFlYzM1ZWRmZjEzNjJmMWJfMjg_d7a6106f-a36a-47b4-a9cb-63962a13b980">1.05</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjFjOWNiMjMxOWYzZTRiYWE4MzcyYTU2ZWM0ZGNmYzdhL3RhYmxlcmFuZ2U6MWM5Y2IyMzE5ZjNlNGJhYTgzNzJhNTZlYzRkY2ZjN2FfMy0zLTEtMS0wL3RleHRyZWdpb246MTVmYTZjZDIyYzE2NDcxNzhhOWIzNTJkZjBiMWQwOTFfNA_cfb932ef-e50e-4d05-af35-5ec2d2aae2cf">0.31</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjFjOWNiMjMxOWYzZTRiYWE4MzcyYTU2ZWM0ZGNmYzdhL3RhYmxlcmFuZ2U6MWM5Y2IyMzE5ZjNlNGJhYTgzNzJhNTZlYzRkY2ZjN2FfMy0zLTEtMS0wL3RleHRyZWdpb246MTVmYTZjZDIyYzE2NDcxNzhhOWIzNTJkZjBiMWQwOTFfMTA_3f31a3f4-8fa4-418e-886e-549d13703dc6">1.68</ix:nonFraction>%; weighted avg. <ix:nonFraction unitRef="number" contextRef="if589413bdfb14e7bbc638c0c928b54e3_D20200101-20200930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjFjOWNiMjMxOWYzZTRiYWE4MzcyYTU2ZWM0ZGNmYzdhL3RhYmxlcmFuZ2U6MWM5Y2IyMzE5ZjNlNGJhYTgzNzJhNTZlYzRkY2ZjN2FfMy0zLTEtMS0wL3RleHRyZWdpb246MTVmYTZjZDIyYzE2NDcxNzhhOWIzNTJkZjBiMWQwOTFfMjg_9f076083-1093-4088-9b89-a42ce2426c1e">0.61</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjFjOWNiMjMxOWYzZTRiYWE4MzcyYTU2ZWM0ZGNmYzdhL3RhYmxlcmFuZ2U6MWM5Y2IyMzE5ZjNlNGJhYTgzNzJhNTZlYzRkY2ZjN2FfNC0xLTEtMS0wL3RleHRyZWdpb246ZTExOTBmN2I0Y2I5NDQzN2E0Y2U1ZDg3Y2RlYTk0ODdfNA_4802583a-2001-4590-b950-8230f54cd26f">81.7</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjFjOWNiMjMxOWYzZTRiYWE4MzcyYTU2ZWM0ZGNmYzdhL3RhYmxlcmFuZ2U6MWM5Y2IyMzE5ZjNlNGJhYTgzNzJhNTZlYzRkY2ZjN2FfNC0xLTEtMS0wL3RleHRyZWdpb246ZTExOTBmN2I0Y2I5NDQzN2E0Y2U1ZDg3Y2RlYTk0ODdfMTA_f2699231-a0ec-424d-a617-cb240c282cac">83.6</ix:nonFraction>%; weighted avg. <ix:nonFraction unitRef="number" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjFjOWNiMjMxOWYzZTRiYWE4MzcyYTU2ZWM0ZGNmYzdhL3RhYmxlcmFuZ2U6MWM5Y2IyMzE5ZjNlNGJhYTgzNzJhNTZlYzRkY2ZjN2FfNC0xLTEtMS0wL3RleHRyZWdpb246ZTExOTBmN2I0Y2I5NDQzN2E0Y2U1ZDg3Y2RlYTk0ODdfMjg_805f6209-c65e-468a-b94d-59726e7f8398">82.6</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjFjOWNiMjMxOWYzZTRiYWE4MzcyYTU2ZWM0ZGNmYzdhL3RhYmxlcmFuZ2U6MWM5Y2IyMzE5ZjNlNGJhYTgzNzJhNTZlYzRkY2ZjN2FfNC0zLTEtMS0wL3RleHRyZWdpb246YjU1MzNjMWNmOTVmNDk3MWJhZjM0YTA1YzJhYTNhZjlfNA_98cfe527-7223-41a8-9372-f43c2963a59f">81.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjFjOWNiMjMxOWYzZTRiYWE4MzcyYTU2ZWM0ZGNmYzdhL3RhYmxlcmFuZ2U6MWM5Y2IyMzE5ZjNlNGJhYTgzNzJhNTZlYzRkY2ZjN2FfNC0zLTEtMS0wL3RleHRyZWdpb246YjU1MzNjMWNmOTVmNDk3MWJhZjM0YTA1YzJhYTNhZjlfMTA_aee604eb-a3db-4f73-b349-58cea6285490">85.8</ix:nonFraction>%; weighted avg. <ix:nonFraction unitRef="number" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjFjOWNiMjMxOWYzZTRiYWE4MzcyYTU2ZWM0ZGNmYzdhL3RhYmxlcmFuZ2U6MWM5Y2IyMzE5ZjNlNGJhYTgzNzJhNTZlYzRkY2ZjN2FfNC0zLTEtMS0wL3RleHRyZWdpb246YjU1MzNjMWNmOTVmNDk3MWJhZjM0YTA1YzJhYTNhZjlfMjg_92509b74-0273-4140-8ef8-08c73dabdbaf">83.8</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeiture rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="2" name="xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjFjOWNiMjMxOWYzZTRiYWE4MzcyYTU2ZWM0ZGNmYzdhL3RhYmxlcmFuZ2U6MWM5Y2IyMzE5ZjNlNGJhYTgzNzJhNTZlYzRkY2ZjN2FfNS0xLTEtMS0w_7676e5a3-777a-40d1-a3d5-c99bf5454f4b">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="2" name="xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjFjOWNiMjMxOWYzZTRiYWE4MzcyYTU2ZWM0ZGNmYzdhL3RhYmxlcmFuZ2U6MWM5Y2IyMzE5ZjNlNGJhYTgzNzJhNTZlYzRkY2ZjN2FfNS0zLTEtMS0w_c0ff12e0-7b90-41de-9758-cda9b9b2dfc6">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjFjOWNiMjMxOWYzZTRiYWE4MzcyYTU2ZWM0ZGNmYzdhL3RhYmxlcmFuZ2U6MWM5Y2IyMzE5ZjNlNGJhYTgzNzJhNTZlYzRkY2ZjN2FfNi0xLTEtMS0w_e5e41ca3-6329-4c6a-b694-86894488df3a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjFjOWNiMjMxOWYzZTRiYWE4MzcyYTU2ZWM0ZGNmYzdhL3RhYmxlcmFuZ2U6MWM5Y2IyMzE5ZjNlNGJhYTgzNzJhNTZlYzRkY2ZjN2FfNi0zLTEtMS0w_3fd8974f-bf1a-47de-b337-4cd289580d52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term is based upon the &#8220;simplified method&#8221; as described in Staff Accounting Bulletin Topic 14.D.2. Currently, the Company does not have sufficient experience to provide a reasonable estimate of an expected term of its common stock options. The Company will continue to use the &#8220;simplified method&#8221; until there is sufficient experience to provide a more reasonable estimate in conformance with ASC 718-10-30-25 through 30-26. The risk-free interest rate assumptions were based on the U.S. Treasury bond rate appropriate for the expected term in effect at the time of grant.  The expected volatility is based on calculated enterprise value volatilities for publicly traded companies in the same industry and general stage of development.  The estimated forfeiture rates were based on historical experience for similar classes of employees.  The dividend yield was based on expected dividends at the time of grant.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i7ae62c742af54cdfaf88490b47487e9e"><ix:continuation id="iccf851bedd174d8e835796ab983efb34"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the underlying common stock and the exercise price for the common stock options granted during the nine months ended September 30, 2021 and 2020 are summarized in the table below:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.833%"><tr><td style="width:1.0%"></td><td style="width:53.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.140%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.142%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock Options Granted During Period Ended:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value of Underlying Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price of Common Stock Option</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine months ended September 30, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i02e0beb6fe6341f7a29be934913d195d_I20210930" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOmRiMGRkMDBjNzYyYTRjMmRiOWNjMDQ4OWEzNDNjZjgzL3RhYmxlcmFuZ2U6ZGIwZGQwMGM3NjJhNGMyZGI5Y2MwNDg5YTM0M2NmODNfMS0xLTEtMS0wL3RleHRyZWdpb246MDE1ZjJjZDgxYmYzNGFlMjg3OTk3NjNhMTcyNWE1ZmZfNA_657c07b3-5526-495e-8be7-07c564349781">1.15</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="i1ddff9f5fe814e669c4e7af58af7e785_I20210930" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOmRiMGRkMDBjNzYyYTRjMmRiOWNjMDQ4OWEzNDNjZjgzL3RhYmxlcmFuZ2U6ZGIwZGQwMGM3NjJhNGMyZGI5Y2MwNDg5YTM0M2NmODNfMS0xLTEtMS0wL3RleHRyZWdpb246MDE1ZjJjZDgxYmYzNGFlMjg3OTk3NjNhMTcyNWE1ZmZfMTA_9e607d7e-5d7e-4dc0-b397-c018b8bde992">2.57</ix:nonFraction>; weighted avg. $<ix:nonFraction unitRef="usdPerShare" contextRef="iab9b918edd71485aaa8ea0f447186603_I20210930" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOmRiMGRkMDBjNzYyYTRjMmRiOWNjMDQ4OWEzNDNjZjgzL3RhYmxlcmFuZ2U6ZGIwZGQwMGM3NjJhNGMyZGI5Y2MwNDg5YTM0M2NmODNfMS0xLTEtMS0wL3RleHRyZWdpb246MDE1ZjJjZDgxYmYzNGFlMjg3OTk3NjNhMTcyNWE1ZmZfMjk_9f18fe3c-b8e7-4e9d-b793-2a8c850d8246">1.87</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i02e0beb6fe6341f7a29be934913d195d_I20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOmRiMGRkMDBjNzYyYTRjMmRiOWNjMDQ4OWEzNDNjZjgzL3RhYmxlcmFuZ2U6ZGIwZGQwMGM3NjJhNGMyZGI5Y2MwNDg5YTM0M2NmODNfMS0zLTEtMS0wL3RleHRyZWdpb246YTU4OTdhNjUyYWJkNDEwNmI2YjIxMTgxODQ5NWY1ZDdfNA_66eac5a3-fc47-4497-9673-3fc713d49a17">1.15</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="i1ddff9f5fe814e669c4e7af58af7e785_I20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOmRiMGRkMDBjNzYyYTRjMmRiOWNjMDQ4OWEzNDNjZjgzL3RhYmxlcmFuZ2U6ZGIwZGQwMGM3NjJhNGMyZGI5Y2MwNDg5YTM0M2NmODNfMS0zLTEtMS0wL3RleHRyZWdpb246YTU4OTdhNjUyYWJkNDEwNmI2YjIxMTgxODQ5NWY1ZDdfMTA_2bf064d3-d9a5-4b8a-a807-ecb946b54f13">2.57</ix:nonFraction>; weighted avg. $<ix:nonFraction unitRef="usdPerShare" contextRef="iab9b918edd71485aaa8ea0f447186603_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOmRiMGRkMDBjNzYyYTRjMmRiOWNjMDQ4OWEzNDNjZjgzL3RhYmxlcmFuZ2U6ZGIwZGQwMGM3NjJhNGMyZGI5Y2MwNDg5YTM0M2NmODNfMS0zLTEtMS0wL3RleHRyZWdpb246YTU4OTdhNjUyYWJkNDEwNmI2YjIxMTgxODQ5NWY1ZDdfMjk_96873492-6272-4e18-b53f-cceb90aa6c66">1.87</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine months ended September 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ic679721ac45b4f7fb6a4951133fb72b5_I20200930" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOmRiMGRkMDBjNzYyYTRjMmRiOWNjMDQ4OWEzNDNjZjgzL3RhYmxlcmFuZ2U6ZGIwZGQwMGM3NjJhNGMyZGI5Y2MwNDg5YTM0M2NmODNfMi0xLTEtMS0wL3RleHRyZWdpb246OWE5ZDRhYmE5NjRlNDMxZmI5MDAyZjFiOTk0ZmY5NmZfNA_3098955b-4b5f-4add-8435-54ea446430dd">1.19</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="i5da161d8e266400a93c4f383d423b29f_I20200930" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOmRiMGRkMDBjNzYyYTRjMmRiOWNjMDQ4OWEzNDNjZjgzL3RhYmxlcmFuZ2U6ZGIwZGQwMGM3NjJhNGMyZGI5Y2MwNDg5YTM0M2NmODNfMi0xLTEtMS0wL3RleHRyZWdpb246OWE5ZDRhYmE5NjRlNDMxZmI5MDAyZjFiOTk0ZmY5NmZfMTA_cd7a886e-09a6-4b46-b7e2-d8061f661cd7">2.80</ix:nonFraction>:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">weighted avg. $<ix:nonFraction unitRef="usdPerShare" contextRef="if76f066c63564146bf012992a98ddce9_I20200930" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOmRiMGRkMDBjNzYyYTRjMmRiOWNjMDQ4OWEzNDNjZjgzL3RhYmxlcmFuZ2U6ZGIwZGQwMGM3NjJhNGMyZGI5Y2MwNDg5YTM0M2NmODNfMi0xLTEtMS0wL3RleHRyZWdpb246OWE5ZDRhYmE5NjRlNDMxZmI5MDAyZjFiOTk0ZmY5NmZfMjg_f47ad8fc-9bda-4f85-9be1-65e515a41e0f">1.91</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ic679721ac45b4f7fb6a4951133fb72b5_I20200930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOmRiMGRkMDBjNzYyYTRjMmRiOWNjMDQ4OWEzNDNjZjgzL3RhYmxlcmFuZ2U6ZGIwZGQwMGM3NjJhNGMyZGI5Y2MwNDg5YTM0M2NmODNfMi0zLTEtMS0wL3RleHRyZWdpb246NDM0OWYxOGJmNzM5NDBkNGI4N2NiMmRlZGJjMTM2ODFfNA_39dbdff3-6a03-4628-8603-c6bc345ac202">1.19</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="i5da161d8e266400a93c4f383d423b29f_I20200930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOmRiMGRkMDBjNzYyYTRjMmRiOWNjMDQ4OWEzNDNjZjgzL3RhYmxlcmFuZ2U6ZGIwZGQwMGM3NjJhNGMyZGI5Y2MwNDg5YTM0M2NmODNfMi0zLTEtMS0wL3RleHRyZWdpb246NDM0OWYxOGJmNzM5NDBkNGI4N2NiMmRlZGJjMTM2ODFfMTA_a78879f8-ec92-48f1-acbf-196dd8fee202">2.80</ix:nonFraction>:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">weighted avg. $<ix:nonFraction unitRef="usdPerShare" contextRef="if76f066c63564146bf012992a98ddce9_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOmRiMGRkMDBjNzYyYTRjMmRiOWNjMDQ4OWEzNDNjZjgzL3RhYmxlcmFuZ2U6ZGIwZGQwMGM3NjJhNGMyZGI5Y2MwNDg5YTM0M2NmODNfMi0zLTEtMS0wL3RleHRyZWdpb246NDM0OWYxOGJmNzM5NDBkNGI4N2NiMmRlZGJjMTM2ODFfMjg_164de140-4654-434a-977c-9246015ccc63">1.94</ix:nonFraction></span></div></td></tr></table></div></ix:continuation><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of common stock options granted in the nine months ended September 30, 2021 and 2020 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfNTg5Ng_0636ec33-7989-42c3-8cea-5ccefe5116ef">1.30</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfNTkwMw_878c555a-5cb7-4c6d-b1fe-06d8e69dbd8f">1.33</ix:nonFraction> per common stock option, respectively.</span></div><ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfNjcyMA_92e162e3-67a2-4836-942d-bb7d7ba0591b" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of common stock option activity as of the periods indicated is as follows:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.551%"><tr><td style="width:1.0%"></td><td style="width:37.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.645%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.645%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.645%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjc0MzFkOTIyY2UzMjRkOGZhMjUzNWQ1M2QzZTRlNjA4L3RhYmxlcmFuZ2U6NzQzMWQ5MjJjZTMyNGQ4ZmEyNTM1ZDUzZDNlNGU2MDhfMS0xLTEtMS0w_717e1ab6-c5f6-452a-9122-27bcbfbd371c">7,227,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjc0MzFkOTIyY2UzMjRkOGZhMjUzNWQ1M2QzZTRlNjA4L3RhYmxlcmFuZ2U6NzQzMWQ5MjJjZTMyNGQ4ZmEyNTM1ZDUzZDNlNGU2MDhfMS0zLTEtMS0w_76f29e38-8289-40a0-96de-b98256a58974">2.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i597ea376c91548b4a05158f306bea587_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjc0MzFkOTIyY2UzMjRkOGZhMjUzNWQ1M2QzZTRlNjA4L3RhYmxlcmFuZ2U6NzQzMWQ5MjJjZTMyNGQ4ZmEyNTM1ZDUzZDNlNGU2MDhfMS01LTEtMS0w_64081227-9c3a-4144-ab52-f8375ddc1d56">6.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0041572b03444403ad89282293144d76_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjc0MzFkOTIyY2UzMjRkOGZhMjUzNWQ1M2QzZTRlNjA4L3RhYmxlcmFuZ2U6NzQzMWQ5MjJjZTMyNGQ4ZmEyNTM1ZDUzZDNlNGU2MDhfMS03LTEtMS0w_e24538c6-757c-40b5-9e8d-344fbbc84638">1,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjc0MzFkOTIyY2UzMjRkOGZhMjUzNWQ1M2QzZTRlNjA4L3RhYmxlcmFuZ2U6NzQzMWQ5MjJjZTMyNGQ4ZmEyNTM1ZDUzZDNlNGU2MDhfMi0xLTEtMS0w_9820e8dd-fca2-4afd-9522-c0e09e163539">4,427,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjc0MzFkOTIyY2UzMjRkOGZhMjUzNWQ1M2QzZTRlNjA4L3RhYmxlcmFuZ2U6NzQzMWQ5MjJjZTMyNGQ4ZmEyNTM1ZDUzZDNlNGU2MDhfMi0zLTEtMS0w_8f570792-87f5-4df7-9bc9-caa1e8d19684">1.87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjc0MzFkOTIyY2UzMjRkOGZhMjUzNWQ1M2QzZTRlNjA4L3RhYmxlcmFuZ2U6NzQzMWQ5MjJjZTMyNGQ4ZmEyNTM1ZDUzZDNlNGU2MDhfMy0xLTEtMS0w_3814d7bf-8faf-4605-990b-41f770f3e946">342,246</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjc0MzFkOTIyY2UzMjRkOGZhMjUzNWQ1M2QzZTRlNjA4L3RhYmxlcmFuZ2U6NzQzMWQ5MjJjZTMyNGQ4ZmEyNTM1ZDUzZDNlNGU2MDhfMy0zLTEtMS0w_bff6d57c-b4a9-4cc7-91d4-a335a0789988">1.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjc0MzFkOTIyY2UzMjRkOGZhMjUzNWQ1M2QzZTRlNjA4L3RhYmxlcmFuZ2U6NzQzMWQ5MjJjZTMyNGQ4ZmEyNTM1ZDUzZDNlNGU2MDhfNC0xLTEtMS0w_84b306d0-6f6b-48c7-8a90-55ac74941e32">252,681</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjc0MzFkOTIyY2UzMjRkOGZhMjUzNWQ1M2QzZTRlNjA4L3RhYmxlcmFuZ2U6NzQzMWQ5MjJjZTMyNGQ4ZmEyNTM1ZDUzZDNlNGU2MDhfNC0zLTEtMS0w_028dbd50-fcf4-4428-9844-4cbb05461d6d">2.38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjc0MzFkOTIyY2UzMjRkOGZhMjUzNWQ1M2QzZTRlNjA4L3RhYmxlcmFuZ2U6NzQzMWQ5MjJjZTMyNGQ4ZmEyNTM1ZDUzZDNlNGU2MDhfNS0xLTEtMS0w_30cc86ed-3756-4e37-ad83-7d6e650e0d44">11,059,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjc0MzFkOTIyY2UzMjRkOGZhMjUzNWQ1M2QzZTRlNjA4L3RhYmxlcmFuZ2U6NzQzMWQ5MjJjZTMyNGQ4ZmEyNTM1ZDUzZDNlNGU2MDhfNS0zLTEtMS0w_83cde1f6-1a69-4eeb-b57c-5bdd4c97b017">2.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjc0MzFkOTIyY2UzMjRkOGZhMjUzNWQ1M2QzZTRlNjA4L3RhYmxlcmFuZ2U6NzQzMWQ5MjJjZTMyNGQ4ZmEyNTM1ZDUzZDNlNGU2MDhfNS01LTEtMS0w_3f63d46a-a98a-4f48-abd2-40507e8d25b6">7.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjc0MzFkOTIyY2UzMjRkOGZhMjUzNWQ1M2QzZTRlNjA4L3RhYmxlcmFuZ2U6NzQzMWQ5MjJjZTMyNGQ4ZmEyNTM1ZDUzZDNlNGU2MDhfNS03LTEtMS0w_5ae76e72-654b-43d2-8db8-a3c9910f4e6b">397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable - September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjc0MzFkOTIyY2UzMjRkOGZhMjUzNWQ1M2QzZTRlNjA4L3RhYmxlcmFuZ2U6NzQzMWQ5MjJjZTMyNGQ4ZmEyNTM1ZDUzZDNlNGU2MDhfNi0xLTEtMS0w_c83d5523-ce05-48a9-8336-ed06b8f95de3">5,207,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjc0MzFkOTIyY2UzMjRkOGZhMjUzNWQ1M2QzZTRlNjA4L3RhYmxlcmFuZ2U6NzQzMWQ5MjJjZTMyNGQ4ZmEyNTM1ZDUzZDNlNGU2MDhfNi0zLTEtMS0w_6c0606a2-57f6-4efb-88ef-59fa3b138352">2.27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjc0MzFkOTIyY2UzMjRkOGZhMjUzNWQ1M2QzZTRlNjA4L3RhYmxlcmFuZ2U6NzQzMWQ5MjJjZTMyNGQ4ZmEyNTM1ZDUzZDNlNGU2MDhfNi01LTEtMS0w_9a6893f3-db84-43fd-b64a-308c4aefc678">5.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjc0MzFkOTIyY2UzMjRkOGZhMjUzNWQ1M2QzZTRlNjA4L3RhYmxlcmFuZ2U6NzQzMWQ5MjJjZTMyNGQ4ZmEyNTM1ZDUzZDNlNGU2MDhfNi03LTEtMS0w_e2f3f440-2c65-442e-a041-acc4ea009530">389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and Expected to Vest -<br/>September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjc0MzFkOTIyY2UzMjRkOGZhMjUzNWQ1M2QzZTRlNjA4L3RhYmxlcmFuZ2U6NzQzMWQ5MjJjZTMyNGQ4ZmEyNTM1ZDUzZDNlNGU2MDhfNy0xLTEtMS0w_13d89557-e92f-477a-b6ee-20c20f639f4e">10,630,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjc0MzFkOTIyY2UzMjRkOGZhMjUzNWQ1M2QzZTRlNjA4L3RhYmxlcmFuZ2U6NzQzMWQ5MjJjZTMyNGQ4ZmEyNTM1ZDUzZDNlNGU2MDhfNy0zLTEtMS0w_f512a49c-6852-4ed4-a87a-80b005405915">2.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjc0MzFkOTIyY2UzMjRkOGZhMjUzNWQ1M2QzZTRlNjA4L3RhYmxlcmFuZ2U6NzQzMWQ5MjJjZTMyNGQ4ZmEyNTM1ZDUzZDNlNGU2MDhfNy01LTEtMS0w_1a281bec-03b4-4f33-a7d8-076662c3245f">7.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjc0MzFkOTIyY2UzMjRkOGZhMjUzNWQ1M2QzZTRlNjA4L3RhYmxlcmFuZ2U6NzQzMWQ5MjJjZTMyNGQ4ZmEyNTM1ZDUzZDNlNGU2MDhfNy03LTEtMS0w_3bbd2e4b-5ad4-485f-b44a-88a26ad68220">396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of common stock options exercised during the nine months ended September 30, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfNjEzNg_6fd8e7f3-29b6-41eb-bf86-45074e034e71">243</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfNjE0Mw_102173cf-0a8a-420d-ae26-1b8cb873014c">74</ix:nonFraction>, respectively.</span></div><ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfNjcyNQ_5345ed9c-6fcc-4d48-ba9f-b54fd3e7ad64" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of restricted stock unit activity of the periods indicated is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.512%"><tr><td style="width:1.0%"></td><td style="width:58.218%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.672%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.674%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance - December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5719399e939a44d98b39d249c039d68d_I20201231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjQ4YWU0MDhiMzk5MjQzZmFhY2E4ZGU5NDVmNjllMzBlL3RhYmxlcmFuZ2U6NDhhZTQwOGIzOTkyNDNmYWFjYThkZTk0NWY2OWUzMGVfMS0xLTEtMS0w_303dea00-0f79-4fee-a60b-7942784315fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5719399e939a44d98b39d249c039d68d_I20201231" decimals="2" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjQ4YWU0MDhiMzk5MjQzZmFhY2E4ZGU5NDVmNjllMzBlL3RhYmxlcmFuZ2U6NDhhZTQwOGIzOTkyNDNmYWFjYThkZTk0NWY2OWUzMGVfMS0zLTEtMS0w_b9917088-3422-4dcd-a073-089cf14fba86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0e30264806374843a74cbde5714a8879_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjQ4YWU0MDhiMzk5MjQzZmFhY2E4ZGU5NDVmNjllMzBlL3RhYmxlcmFuZ2U6NDhhZTQwOGIzOTkyNDNmYWFjYThkZTk0NWY2OWUzMGVfMi0xLTEtMS0w_7efb0911-589b-4279-a4b1-650faf8664ab">575,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0e30264806374843a74cbde5714a8879_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjQ4YWU0MDhiMzk5MjQzZmFhY2E4ZGU5NDVmNjllMzBlL3RhYmxlcmFuZ2U6NDhhZTQwOGIzOTkyNDNmYWFjYThkZTk0NWY2OWUzMGVfMi0zLTEtMS0w_c6edb9af-c15e-4e12-a934-034cc75d16e9">1.58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0e30264806374843a74cbde5714a8879_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjQ4YWU0MDhiMzk5MjQzZmFhY2E4ZGU5NDVmNjllMzBlL3RhYmxlcmFuZ2U6NDhhZTQwOGIzOTkyNDNmYWFjYThkZTk0NWY2OWUzMGVfMy0xLTEtMS0w_c465ed1f-7339-4fa2-b41e-621168f3e5b3">17,875</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0e30264806374843a74cbde5714a8879_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjQ4YWU0MDhiMzk5MjQzZmFhY2E4ZGU5NDVmNjllMzBlL3RhYmxlcmFuZ2U6NDhhZTQwOGIzOTkyNDNmYWFjYThkZTk0NWY2OWUzMGVfMy0zLTEtMS0w_adea71a9-676f-471c-97c1-bd219aa6c5d5">1.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0e30264806374843a74cbde5714a8879_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjQ4YWU0MDhiMzk5MjQzZmFhY2E4ZGU5NDVmNjllMzBlL3RhYmxlcmFuZ2U6NDhhZTQwOGIzOTkyNDNmYWFjYThkZTk0NWY2OWUzMGVfNC0xLTEtMS0w_2018590f-7a06-4434-ad61-4433d9b17af0">10,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0e30264806374843a74cbde5714a8879_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjQ4YWU0MDhiMzk5MjQzZmFhY2E4ZGU5NDVmNjllMzBlL3RhYmxlcmFuZ2U6NDhhZTQwOGIzOTkyNDNmYWFjYThkZTk0NWY2OWUzMGVfNC0zLTEtMS0w_ad08ed11-1e9f-4e7e-8468-2c46e9e59d89">1.15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance - September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6d14cf3685554550979e56c0584d59a2_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjQ4YWU0MDhiMzk5MjQzZmFhY2E4ZGU5NDVmNjllMzBlL3RhYmxlcmFuZ2U6NDhhZTQwOGIzOTkyNDNmYWFjYThkZTk0NWY2OWUzMGVfNS0xLTEtMS0w_bc8216d4-de96-430c-a449-a2c839fae6e0">546,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6d14cf3685554550979e56c0584d59a2_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjQ4YWU0MDhiMzk5MjQzZmFhY2E4ZGU5NDVmNjllMzBlL3RhYmxlcmFuZ2U6NDhhZTQwOGIzOTkyNDNmYWFjYThkZTk0NWY2OWUzMGVfNS0zLTEtMS0w_8cc24032-6de9-42e3-b0a5-9f983670923e">1.57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value of restricted stock units is based on the Company&#8217;s closing stock price at the date of grant. At vesting, each outstanding restricted stock unit will be exchanged for <ix:nonFraction unitRef="shares" contextRef="i6d14cf3685554550979e56c0584d59a2_I20210930" decimals="INF" format="ixt-sec:numwordsen" name="xcur:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfNjQ0MA_671b2cc9-cfa6-40d8-b077-cb56bc9e4002">one</ix:nonFraction> share of the Company&#8217;s common stock. The restricted stock units granted during the 2021 period generally vest evenly on a quarterly basis over a period of <ix:nonNumeric contextRef="i0e30264806374843a74cbde5714a8879_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfNjU5OA_ce66e960-87c1-4d87-ac85-a1a883b0b10f">4</ix:nonNumeric> years in exchange for continued service provided by the restricted stock unit recipient during that vesting period.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="i30c50c718dda42d28fbdd6dcd4fa2365_64"></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82NC9mcmFnOjc2MDg0MzI2Yzg2ODQ0ODFhMTA1MjNkMTc1ZWY5MzRhL3RleHRyZWdpb246NzYwODQzMjZjODY4NDQ4MWExMDUyM2QxNzVlZjkzNGFfNDYy_8e2c6689-6253-48c0-92f2-ad907a3990d2" continuedAt="i811c9409bbc04f30b373d245c6f3ff5b" escape="true">Income Taxes</ix:nonNumeric></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i811c9409bbc04f30b373d245c6f3ff5b">The Company incurred a pretax loss in each of the three and nine months ended September 30, 2021 and 2020, which consists entirely of loss in the United States and resulted in <ix:nonFraction unitRef="usd" contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82NC9mcmFnOjc2MDg0MzI2Yzg2ODQ0ODFhMTA1MjNkMTc1ZWY5MzRhL3RleHRyZWdpb246NzYwODQzMjZjODY4NDQ4MWExMDUyM2QxNzVlZjkzNGFfMTg1_3893e5b1-f65e-4bd4-a6ad-685541843ffc"><ix:nonFraction unitRef="usd" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82NC9mcmFnOjc2MDg0MzI2Yzg2ODQ0ODFhMTA1MjNkMTc1ZWY5MzRhL3RleHRyZWdpb246NzYwODQzMjZjODY4NDQ4MWExMDUyM2QxNzVlZjkzNGFfMTg1_928e9918-99ef-40d2-a7c3-addd5603b525"><ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82NC9mcmFnOjc2MDg0MzI2Yzg2ODQ0ODFhMTA1MjNkMTc1ZWY5MzRhL3RleHRyZWdpb246NzYwODQzMjZjODY4NDQ4MWExMDUyM2QxNzVlZjkzNGFfMTg1_9e96b0a8-5114-45eb-8b5a-aafa2fafccc3"><ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82NC9mcmFnOjc2MDg0MzI2Yzg2ODQ0ODFhMTA1MjNkMTc1ZWY5MzRhL3RleHRyZWdpb246NzYwODQzMjZjODY4NDQ4MWExMDUyM2QxNzVlZjkzNGFfMTg1_c2c85d10-5d32-4fb6-90ea-ebda3dae7c68">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> provision for income tax expense during the periods then ended.  The effective tax rate is <ix:nonFraction unitRef="number" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82NC9mcmFnOjc2MDg0MzI2Yzg2ODQ0ODFhMTA1MjNkMTc1ZWY5MzRhL3RleHRyZWdpb246NzYwODQzMjZjODY4NDQ4MWExMDUyM2QxNzVlZjkzNGFfMjc5_4a5dd744-fc96-4562-9393-15ac4e068157"><ix:nonFraction unitRef="number" contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82NC9mcmFnOjc2MDg0MzI2Yzg2ODQ0ODFhMTA1MjNkMTc1ZWY5MzRhL3RleHRyZWdpb246NzYwODQzMjZjODY4NDQ4MWExMDUyM2QxNzVlZjkzNGFfMjc5_9cf361f2-58c1-4525-b7bc-33d30f4daa9c"><ix:nonFraction unitRef="number" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82NC9mcmFnOjc2MDg0MzI2Yzg2ODQ0ODFhMTA1MjNkMTc1ZWY5MzRhL3RleHRyZWdpb246NzYwODQzMjZjODY4NDQ4MWExMDUyM2QxNzVlZjkzNGFfMjc5_a64dd311-d57a-490d-8b32-808d6af7ea28"><ix:nonFraction unitRef="number" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82NC9mcmFnOjc2MDg0MzI2Yzg2ODQ0ODFhMTA1MjNkMTc1ZWY5MzRhL3RleHRyZWdpb246NzYwODQzMjZjODY4NDQ4MWExMDUyM2QxNzVlZjkzNGFfMjc5_d62c2df5-eca0-4086-8a2d-707c50186b3e">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>% in each of the three and nine months ended September 30, 2021 and 2020 because the Company has generated tax losses and has provided a full valuation allowance against its deferred tax assets.</ix:continuation> </span></div><div id="i30c50c718dda42d28fbdd6dcd4fa2365_67"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RleHRyZWdpb246MmE3Y2I4NTg5NzU1NGFmNmE3ZTZmMmQzOWE1ZmRmMzBfMTEzOA_9b01550e-dc88-4d23-816a-09a63ce59145" continuedAt="ia7ea7bdce2f24772a86ef421621a8a97" escape="true">Loss Per Common Share</ix:nonNumeric></span></div><ix:continuation id="ia7ea7bdce2f24772a86ef421621a8a97"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RleHRyZWdpb246MmE3Y2I4NTg5NzU1NGFmNmE3ZTZmMmQzOWE1ZmRmMzBfMTEzOQ_bf4ca112-e7a5-4f27-85b4-99b9fb3fffcf" escape="true">Basic loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per common share is calculated using the treasury share method by giving effect to all potentially dilutive securities that were outstanding.  Potentially dilutive options, restricted stock units and warrants to purchase common stock that were outstanding during the periods presented were excluded from the diluted loss per share calculation for the periods presented because such shares had an anti-dilutive effect due to the net loss reported in those periods.</ix:nonNumeric>  Therefore, basic and diluted loss per common share is the same for each of the three and nine months ended September 30, 2021 and 2020.</span></div><ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RleHRyZWdpb246MmE3Y2I4NTg5NzU1NGFmNmE3ZTZmMmQzOWE1ZmRmMzBfMTE0MA_386f8d0d-2a13-49ce-a03f-80c7ef5a3d80" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is the computation of loss per common share for the three and nine months ended September 30, 2021 and 2020:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.551%"><tr><td style="width:1.0%"></td><td style="width:37.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.645%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.645%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.645%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjQ5ZDljNDc2ZDYzNzQzMzM4Y2Q0Y2MyMmY0NjkyNTEyL3RhYmxlcmFuZ2U6NDlkOWM0NzZkNjM3NDMzMzhjZDRjYzIyZjQ2OTI1MTJfMi0xLTEtMS0w_f7943432-4fb6-4d16-ba6a-69fe01ce70f5">23,531</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjQ5ZDljNDc2ZDYzNzQzMzM4Y2Q0Y2MyMmY0NjkyNTEyL3RhYmxlcmFuZ2U6NDlkOWM0NzZkNjM3NDMzMzhjZDRjYzIyZjQ2OTI1MTJfMi0zLTEtMS0w_b9f8ec94-63ec-47a1-92e3-77c20db68caf">8,822</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjQ5ZDljNDc2ZDYzNzQzMzM4Y2Q0Y2MyMmY0NjkyNTEyL3RhYmxlcmFuZ2U6NDlkOWM0NzZkNjM3NDMzMzhjZDRjYzIyZjQ2OTI1MTJfMi01LTEtMS0w_c76bb9d5-e186-4c8b-90a1-87e5b135be13">50,277</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjQ5ZDljNDc2ZDYzNzQzMzM4Y2Q0Y2MyMmY0NjkyNTEyL3RhYmxlcmFuZ2U6NDlkOWM0NzZkNjM3NDMzMzhjZDRjYzIyZjQ2OTI1MTJfMi03LTEtMS0w_944dcf69-0d95-43a8-8e49-ea0a4edf6917">11,983</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic and diluted common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjQ5ZDljNDc2ZDYzNzQzMzM4Y2Q0Y2MyMmY0NjkyNTEyL3RhYmxlcmFuZ2U6NDlkOWM0NzZkNjM3NDMzMzhjZDRjYzIyZjQ2OTI1MTJfNC0xLTEtMS0w_6a32eb69-b3c4-4883-a9f8-24ec73d714b0"><ix:nonFraction unitRef="shares" contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjQ5ZDljNDc2ZDYzNzQzMzM4Y2Q0Y2MyMmY0NjkyNTEyL3RhYmxlcmFuZ2U6NDlkOWM0NzZkNjM3NDMzMzhjZDRjYzIyZjQ2OTI1MTJfNC0xLTEtMS0w_b5bb72be-5235-4905-baaf-f1cd4e6dd852">88,105,066</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjQ5ZDljNDc2ZDYzNzQzMzM4Y2Q0Y2MyMmY0NjkyNTEyL3RhYmxlcmFuZ2U6NDlkOWM0NzZkNjM3NDMzMzhjZDRjYzIyZjQ2OTI1MTJfNC0zLTEtMS0w_6e96028f-c740-4f7e-ab2d-52cb737a5ea2"><ix:nonFraction unitRef="shares" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjQ5ZDljNDc2ZDYzNzQzMzM4Y2Q0Y2MyMmY0NjkyNTEyL3RhYmxlcmFuZ2U6NDlkOWM0NzZkNjM3NDMzMzhjZDRjYzIyZjQ2OTI1MTJfNC0zLTEtMS0w_b2d241c0-355b-4bc1-ab64-e2b01f0b5db7">87,227,136</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjQ5ZDljNDc2ZDYzNzQzMzM4Y2Q0Y2MyMmY0NjkyNTEyL3RhYmxlcmFuZ2U6NDlkOWM0NzZkNjM3NDMzMzhjZDRjYzIyZjQ2OTI1MTJfNC01LTEtMS0w_d576c33f-a239-41d6-8a68-aa53b3c83431"><ix:nonFraction unitRef="shares" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjQ5ZDljNDc2ZDYzNzQzMzM4Y2Q0Y2MyMmY0NjkyNTEyL3RhYmxlcmFuZ2U6NDlkOWM0NzZkNjM3NDMzMzhjZDRjYzIyZjQ2OTI1MTJfNC01LTEtMS0w_d86f9092-0ac2-4430-9651-343836b66c77">88,001,222</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjQ5ZDljNDc2ZDYzNzQzMzM4Y2Q0Y2MyMmY0NjkyNTEyL3RhYmxlcmFuZ2U6NDlkOWM0NzZkNjM3NDMzMzhjZDRjYzIyZjQ2OTI1MTJfNC03LTEtMS0w_0119c157-1c20-41cd-a5c8-65f9a7909137"><ix:nonFraction unitRef="shares" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjQ5ZDljNDc2ZDYzNzQzMzM4Y2Q0Y2MyMmY0NjkyNTEyL3RhYmxlcmFuZ2U6NDlkOWM0NzZkNjM3NDMzMzhjZDRjYzIyZjQ2OTI1MTJfNC03LTEtMS0w_12b8bb9f-804d-424d-a048-7cd3d17797b5">87,160,520</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share - basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjQ5ZDljNDc2ZDYzNzQzMzM4Y2Q0Y2MyMmY0NjkyNTEyL3RhYmxlcmFuZ2U6NDlkOWM0NzZkNjM3NDMzMzhjZDRjYzIyZjQ2OTI1MTJfOC0xLTEtMS0w_5c818a51-eb86-4593-b214-a61baa199eb3"><ix:nonFraction unitRef="usdPerShare" contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjQ5ZDljNDc2ZDYzNzQzMzM4Y2Q0Y2MyMmY0NjkyNTEyL3RhYmxlcmFuZ2U6NDlkOWM0NzZkNjM3NDMzMzhjZDRjYzIyZjQ2OTI1MTJfOC0xLTEtMS0w_91b6fe31-b04e-486c-bbff-79c8a83a8179">0.27</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjQ5ZDljNDc2ZDYzNzQzMzM4Y2Q0Y2MyMmY0NjkyNTEyL3RhYmxlcmFuZ2U6NDlkOWM0NzZkNjM3NDMzMzhjZDRjYzIyZjQ2OTI1MTJfOC0zLTEtMS0w_239a3a28-39ee-42e8-bb43-23385b60e1e7"><ix:nonFraction unitRef="usdPerShare" contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjQ5ZDljNDc2ZDYzNzQzMzM4Y2Q0Y2MyMmY0NjkyNTEyL3RhYmxlcmFuZ2U6NDlkOWM0NzZkNjM3NDMzMzhjZDRjYzIyZjQ2OTI1MTJfOC0zLTEtMS0w_a8e25838-1079-476d-8596-bf4dc308c33c">0.10</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjQ5ZDljNDc2ZDYzNzQzMzM4Y2Q0Y2MyMmY0NjkyNTEyL3RhYmxlcmFuZ2U6NDlkOWM0NzZkNjM3NDMzMzhjZDRjYzIyZjQ2OTI1MTJfOC01LTEtMS0w_e3fb8312-8b42-4c2c-8911-acabed80a520"><ix:nonFraction unitRef="usdPerShare" contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjQ5ZDljNDc2ZDYzNzQzMzM4Y2Q0Y2MyMmY0NjkyNTEyL3RhYmxlcmFuZ2U6NDlkOWM0NzZkNjM3NDMzMzhjZDRjYzIyZjQ2OTI1MTJfOC01LTEtMS0w_e5b1bdfd-fd4a-4684-85a5-cdd7e3ef1478">0.57</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjQ5ZDljNDc2ZDYzNzQzMzM4Y2Q0Y2MyMmY0NjkyNTEyL3RhYmxlcmFuZ2U6NDlkOWM0NzZkNjM3NDMzMzhjZDRjYzIyZjQ2OTI1MTJfOC03LTEtMS0w_6d61adac-7543-44d5-a864-31eae859827c"><ix:nonFraction unitRef="usdPerShare" contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjQ5ZDljNDc2ZDYzNzQzMzM4Y2Q0Y2MyMmY0NjkyNTEyL3RhYmxlcmFuZ2U6NDlkOWM0NzZkNjM3NDMzMzhjZDRjYzIyZjQ2OTI1MTJfOC03LTEtMS0w_8bcb45f0-2ff0-4491-90b0-440aa1d98e6d">0.14</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RleHRyZWdpb246MmE3Y2I4NTg5NzU1NGFmNmE3ZTZmMmQzOWE1ZmRmMzBfMTE0MQ_a24dfb34-999d-42a5-baf4-5d9f129d6808" escape="true"><div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outstanding securities presented below were excluded from the calculation of loss per common share, for the periods presented, because such securities would have been anti-dilutive due to the Company&#8217;s loss per share during that period:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.294%"><tr><td style="width:1.0%"></td><td style="width:64.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.439%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.442%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i23729b7c757546618ffd14bfc2bf93dd_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjRlZDAzMzJmZDBhMzRkMDA5ZDFkOWQ0ZWUyZDVmZmI3L3RhYmxlcmFuZ2U6NGVkMDMzMmZkMGEzNGQwMDlkMWQ5ZDRlZTJkNWZmYjdfMi0xLTEtMS0w_cf703a17-30f4-4fa2-9142-c9db753d471f">11,059,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7f4cd3d9bdd4d918c745f1ede290f0d_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjRlZDAzMzJmZDBhMzRkMDA5ZDFkOWQ0ZWUyZDVmZmI3L3RhYmxlcmFuZ2U6NGVkMDMzMmZkMGEzNGQwMDlkMWQ5ZDRlZTJkNWZmYjdfMi0zLTEtMS0w_aa85e11d-f4c5-4b47-abbd-351d702499b6">7,739,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i78855d9d0c4747009459828fe157b733_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjRlZDAzMzJmZDBhMzRkMDA5ZDFkOWQ0ZWUyZDVmZmI3L3RhYmxlcmFuZ2U6NGVkMDMzMmZkMGEzNGQwMDlkMWQ5ZDRlZTJkNWZmYjdfMy0xLTEtMS0w_1f971647-1c07-4bff-b2e8-f874b1d57ffe">546,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3521ed35239b4892871886f1c9a86593_D20200101-20200930" decimals="0" format="ixt:fixed-zero" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjRlZDAzMzJmZDBhMzRkMDA5ZDFkOWQ0ZWUyZDVmZmI3L3RhYmxlcmFuZ2U6NGVkMDMzMmZkMGEzNGQwMDlkMWQ5ZDRlZTJkNWZmYjdfMy0zLTEtMS0w_5e47d1d1-e8fd-4126-8d58-e0861808bec5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic2c85780c2fe44a5a264af346e3d74fe_D20210101-20210930" decimals="0" format="ixt:fixed-zero" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjRlZDAzMzJmZDBhMzRkMDA5ZDFkOWQ0ZWUyZDVmZmI3L3RhYmxlcmFuZ2U6NGVkMDMzMmZkMGEzNGQwMDlkMWQ5ZDRlZTJkNWZmYjdfNC0xLTEtMS0w_6ec0dfca-9395-4bef-a32c-f7c014b0fe4f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8414c9548ccf4c85ba53fb4883723dac_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjRlZDAzMzJmZDBhMzRkMDA5ZDFkOWQ0ZWUyZDVmZmI3L3RhYmxlcmFuZ2U6NGVkMDMzMmZkMGEzNGQwMDlkMWQ5ZDRlZTJkNWZmYjdfNC0zLTEtMS0w_d0070fb1-778a-49d1-99f2-dab25ac750a2">413,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i30c50c718dda42d28fbdd6dcd4fa2365_70"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RleHRyZWdpb246ZTVmZjE5M2Q0OGI5NDk3MzhmYTc0OTY1NGViNGM2YWRfMTgxNQ_fe5cba10-9322-440b-8fba-f4c1cf251cb8" continuedAt="i2f76f48741cc48f4864095a6da6a45c0" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:18pt"><ix:continuation id="i2f76f48741cc48f4864095a6da6a45c0" continuedAt="if6094098f8134f8f84e74a1411e9abc3"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, as follows: Level 1 Inputs - unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date; Level 2 Inputs - other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3 Inputs - unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date. </span></ix:continuation></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="if6094098f8134f8f84e74a1411e9abc3" continuedAt="iff4def7227ff4aae8ee54fe48a9b5c39"><ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RleHRyZWdpb246ZTVmZjE5M2Q0OGI5NDk3MzhmYTc0OTY1NGViNGM2YWRfMTgxNg_22fd8ee6-f733-408b-b90f-8cefae6f5e36" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets measured at fair value on a recurring basis as of September&#160;30, 2021 are as follows:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.269%"><tr><td style="width:1.0%"></td><td style="width:42.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.487%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.487%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.478%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic82a774e2c8d4a41b3170db670ad8155_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfMy0xLTEtMS0w_c13372c5-57f3-4739-b909-387d2529649c">27,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7c24c0d5bd4c578f72a33ccc3c05bf_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfMy0zLTEtMS0w_3b2f463d-f93e-467d-981c-a4eebf0907a9">27,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i020262a33e8049ff9ab935e2b201f6fb_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfMy01LTEtMS0w_c785c82d-be16-4576-bcf9-a9f01889e81d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i439032d25541463e8e6c4621ef8fd111_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfMy03LTEtMS0w_6239e83c-6f81-446a-87bd-5c0b68af406e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a58bfb15835492ab090e8b81401af85_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfNC0xLTEtMS0xMjExOQ_fe868b4b-cceb-48f3-ba81-c9c8e946b04d">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ddced473eff483780d1373964171762_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfNC0zLTEtMS0xMjExOQ_c1bc6cd2-8caa-4a13-a688-d5afda20c881">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5731c03b9fc44849a8c3fb5ed3c6949a_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfNC01LTEtMS0xMjExOQ_a52af22e-3371-4f58-b355-779725074674">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56aca844fa034db2b2e2a7b18d0023e7_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfNC03LTEtMS0xMjExOQ_b26477d9-6f59-45e4-b3e9-2d5f00d9f15f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9718465693743c3b538b21283198504_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfNS0xLTEtMS0xMjExOQ_b95c8c01-472c-48e5-a5e3-4e6021fcf718">9,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313d98866f5747ea9ad78d453628370d_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfNS0zLTEtMS0xMjExOQ_f53a2636-024d-41ec-98c2-4294f9344811">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibda75316052d4dbe9d661f043c9b1956_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfNS01LTEtMS0xMjExOQ_4328d3f1-c7d4-43cb-8cbf-40a40206cfac">9,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib677e14bc757464bb5589291a71b4e61_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfNS03LTEtMS0xMjExOQ_3453b8e3-d44b-4335-9b77-19863cc5db96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d8d9676d98849f883d2748566593b17_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfNi0xLTEtMS0w_f789ddb8-a8f8-4492-8c3f-130ca3deb0eb">6,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0974ff1702c42d395bd413417d4a0d9_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfNi0zLTEtMS0w_8d064e33-512a-4bfd-a965-346fad759994">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c8552c18039495daa749078cb358e04_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfNi01LTEtMS0w_ed216515-1ee2-4553-a70c-3323a13c6925">6,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64760482c2c9480ea6bc6748d1d90ce7_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfNi03LTEtMS0w_70e9faaf-7bac-4b93-a006-17d4884abf4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icea87c7e3d6a4dfba48ae4131cda39e8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfNy0xLTEtMS0w_0d96e737-7a2b-4305-b192-0b195879ac66">1,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86c21c42f5cd42dfa1f7346b010764d4_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfNy0zLTEtMS0w_49a6e24e-cde2-411e-9e70-26cd07ccfa0b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62ff7db7da784f799e2dfe0c311b9e0f_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfNy01LTEtMS0w_6502d7ce-5a78-4af3-863d-33b4779a3cc4">1,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i965562b1554547d1a09c7766cedd87ae_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfNy03LTEtMS0w_6fd1ad28-1c3f-4a89-964f-2f27447b01cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9531f369bf98470ba15fba85df910ef3_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfOS0xLTEtMS0w_f71954c7-2178-4a62-9a74-34bf9f011350">1,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia886151578c443df8e7d2e02ad3a907b_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfOS0zLTEtMS0w_2065e226-fd68-4d3b-a250-1687f5e7c9b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied37c8b6308741fda6f2b2dcb570461d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfOS01LTEtMS0w_ad5388be-7ea3-46ab-ab7e-cdc8c4606ba6">1,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc5f1ed1d0574ff59b0f1eed86e46da0_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfOS03LTEtMS0w_b7fa76f4-0072-43c8-8e34-8f3c7528fc71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b19f1632fda44cfb2cbf056cb55773e_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfMTAtMS0xLTEtMA_7fcecaf9-9683-48f8-beaa-ce2127065745">48,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie60c424895d44cb6a873a2f566d9ba85_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfMTAtMy0xLTEtMA_2ecbc464-6678-4b4a-99b5-1fa3c933f889">27,641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id804d84aba2942da9b78003f9fa2d272_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfMTAtNS0xLTEtMA_8b69e25d-4508-4196-98a7-c558959953b8">20,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cb225e6af3547baa416759169909bcb_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfMTAtNy0xLTEtMA_2886d2f4-30f8-4b8f-9afe-3d614a50de53">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value on a recurring basis as of December 31, 2020 are as follows:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.557%"><tr><td style="width:1.0%"></td><td style="width:46.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.423%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cba3845e261446285d53d1b68bd1b2b_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfMy0xLTEtMS0w_68ae3814-b471-4e11-a1cd-e9da87aa1558">24,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i086920543bec4d90bb757a3cefcb83ef_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfMy0zLTEtMS0w_246096db-deb5-4989-9960-64806b1e6aaf">24,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic202372402d84018b4b88f88701033d0_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfMy01LTEtMS0w_7becc414-476e-4c28-a650-71d5c0ec8a83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83369fca8bab4aab90e8db725e903baf_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfMy03LTEtMS0w_dc984af5-bf3a-49dd-b11d-f0532c24378c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2996ac3939c042e3ab6d42a6553a235a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfNS0xLTEtMS0w_7a267783-351e-4208-90ea-116ab5316b6c">15,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8883903151f24f5fa017edecc72b8b35_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfNS0zLTEtMS0w_bc0ba760-1996-45ba-be87-49e7f0e79d3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i719acee816814d07916c8dfd5ca71de9_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfNS01LTEtMS0w_a482edbc-8482-4a33-8a85-818ec3bc0a7c">15,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca413f9b9054d00bbda5b1373b22305_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfNS03LTEtMS0w_ae779cb7-76d4-43a8-a9d4-b3e8a6a25175">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34fe6e6e209446768a2cf34d62dad6aa_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfNi0xLTEtMS0w_f408e05b-e36d-4f5c-818d-b843e9a2a6dc">29,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f9200c696c41d78a853e83862f647b_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfNi0zLTEtMS0w_183fcd63-5b70-4c29-8d4c-3e747f5583ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d5744490b0d4c738db4cd2bb4e0aa81_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfNi01LTEtMS0w_cd44aba7-208b-4414-933a-d491e475bdac">29,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfc85e952cc2497fbeee275f739aa825_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfNi03LTEtMS0w_082930d4-a905-4cb2-8b69-387f0ff65565">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ed86c954d924fc8a28507f2891286eb_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfNy0xLTEtMS0w_848f4695-6d3c-42e4-be4a-e1d60e8227c3">2,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaf0a15420cb4a7294217b68929d7235_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfNy0zLTEtMS0w_06142ded-fd1f-45ea-898c-560deac1b776">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1e7126375264b1c93061499c8d47b5e_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfNy01LTEtMS0w_ed8d1c35-6cbd-4f76-affb-6a7ad8d2e96f">2,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71bd3df32bb94d4fae58db8bff589a4e_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfNy03LTEtMS0w_ba734447-4943-4ccf-8815-27a13302f76a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic259c1b511b64ac2978a410b11be349b_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfOC0xLTEtMS0w_4da32faa-3348-4ee1-a31c-e08e3cdfa14d">1,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a439123584f4408a9d60d89e70d2703_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfOC0zLTEtMS0w_5a6bd6a2-28a0-4df6-993b-52cd4aca5dc2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0667ee8e62af460ca0b2e1c8843b72c2_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfOC01LTEtMS0w_2ec16774-0ef1-4a4d-b2a1-23503cf3060f">1,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64cfed00d63048338a59cf563ea272b8_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfOC03LTEtMS0w_9c86e67d-caa9-4c93-b349-96a3a65bd92b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1126e3e21a654b5fb23bb497bc28aa43_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfOS0xLTEtMS0w_b6e8b965-0440-4fd5-a1fc-51f5de6e106b">73,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c44bd27d0ac448590035ac735a75a7b_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfOS0zLTEtMS0w_a946d776-e6d8-4c36-a07b-546e35da7622">24,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b2c5cfdc76544d29619b3bd1e9955a8_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfOS01LTEtMS0w_150a9856-4539-4f43-b1e1-9e2d557b410f">48,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa0ce1eb50024db289d3b452e949a956_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfOS03LTEtMS0w_bf36df87-7f2c-4606-82de-224ead3c1105">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrant liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1126e3e21a654b5fb23bb497bc28aa43_I20201231" decimals="-3" name="xcur:CommonStockWarrantLiabilityFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfMTItMS0xLTEtMA_89946922-ce22-4b2e-980e-3ac8057209d5">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c44bd27d0ac448590035ac735a75a7b_I20201231" decimals="-3" format="ixt:fixed-zero" name="xcur:CommonStockWarrantLiabilityFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfMTItMy0xLTEtMA_795fd9a7-ffa6-48c9-9228-62a367eec91a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b2c5cfdc76544d29619b3bd1e9955a8_I20201231" decimals="-3" format="ixt:fixed-zero" name="xcur:CommonStockWarrantLiabilityFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfMTItNS0xLTEtMA_ed7f744c-ae1e-4393-aa04-77adbac8f3c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa0ce1eb50024db289d3b452e949a956_I20201231" decimals="-3" name="xcur:CommonStockWarrantLiabilityFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfMTItNy0xLTEtMA_b5d2f600-9279-41b6-a5f9-43586f6eca00">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1126e3e21a654b5fb23bb497bc28aa43_I20201231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfMTMtMS0xLTEtMA_df89731c-9293-4a4f-96b2-803b4edebef0">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c44bd27d0ac448590035ac735a75a7b_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfMTMtMy0xLTEtMA_63c17740-4574-497f-8e1c-897e4601e169">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b2c5cfdc76544d29619b3bd1e9955a8_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfMTMtNS0xLTEtMA_b1e9678d-c417-43c7-b5ab-cb53e4bda8a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa0ce1eb50024db289d3b452e949a956_I20201231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfMTMtNy0xLTEtMA_4211dcfe-c7c9-465b-8ba4-396e5f839d1d">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the market approach and Level 1 and Level 2 inputs to value its cash equivalents and Level 2 inputs to value its short-term investments.  The Company&#8217;s long-term debt bore interest at the prevailing market rates for instruments with similar characteristics and, accordingly, the carrying value for this instrument also approximates its fair value and the financial measurement is also classified within Level 2 of the fair value hierarchy.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the Company&#8217;s common stock warrant liability was $<ix:nonFraction unitRef="usd" contextRef="i27fa1ea6e2df45148c9b25b975903963_I20210930" decimals="INF" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RleHRyZWdpb246ZTVmZjE5M2Q0OGI5NDk3MzhmYTc0OTY1NGViNGM2YWRfMTUzOA_8b50b874-9083-4c90-aed4-027fac0a46bf">0</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i27fa1ea6e2df45148c9b25b975903963_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RleHRyZWdpb246ZTVmZjE5M2Q0OGI5NDk3MzhmYTc0OTY1NGViNGM2YWRfMTU0NQ_80c3341b-f060-4f6f-954b-76bfb6f2dbfe">no</ix:nonFraction> warrants were outstanding (refer to Note 8, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stockholders&#8217; Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for more information). <ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RleHRyZWdpb246ZTVmZjE5M2Q0OGI5NDk3MzhmYTc0OTY1NGViNGM2YWRfMTgxNw_bc2e252b-87d1-4ce6-9a35-1c3c1f51ad6e" continuedAt="ie27cac055d3a48509c8a889f3b9f5a14" escape="true">The following is a reconciliation of the Company&#8217;s liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3) for the three months ended September&#160;30, 2021:</ix:nonNumeric></span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXICURE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="iff4def7227ff4aae8ee54fe48a9b5c39"><ix:continuation id="ie27cac055d3a48509c8a889f3b9f5a14"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.237%"><tr><td style="width:1.0%"></td><td style="width:72.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock Warrant Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f8b49f540eb4a5f880bed694d3fd14d_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjRmMDFjYzU0NDE5MjQzNDRhMmIxNDFiNTM0ZWM4YjlhL3RhYmxlcmFuZ2U6NGYwMWNjNTQ0MTkyNDM0NGEyYjE0MWI1MzRlYzhiOWFfMi0xLTEtMS0w_cd19eb40-2e00-4d23-93ea-3429c5eb6a28">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03125214387d41b9a8017ffe8a649dac_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjRmMDFjYzU0NDE5MjQzNDRhMmIxNDFiNTM0ZWM4YjlhL3RhYmxlcmFuZ2U6NGYwMWNjNTQ0MTkyNDM0NGEyYjE0MWI1MzRlYzhiOWFfMy0xLTEtMS0w_cf13eb87-38ce-4b42-9a71-111bb9066f4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain included in other (expense) income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03125214387d41b9a8017ffe8a649dac_D20210101-20210930" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjRmMDFjYzU0NDE5MjQzNDRhMmIxNDFiNTM0ZWM4YjlhL3RhYmxlcmFuZ2U6NGYwMWNjNTQ0MTkyNDM0NGEyYjE0MWI1MzRlYzhiOWFfNC0xLTEtMS0w_c0d456ec-a6c4-498e-8551-5b5c646f5d95">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September&#160;30, 2021</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9361796fa9024b2182ac08a2f7e2bf59_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjRmMDFjYzU0NDE5MjQzNDRhMmIxNDFiNTM0ZWM4YjlhL3RhYmxlcmFuZ2U6NGYwMWNjNTQ0MTkyNDM0NGEyYjE0MWI1MzRlYzhiOWFfNS0xLTEtMS0w_b9028bad-371b-4802-bfdc-e2d66d55b925">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div id="i30c50c718dda42d28fbdd6dcd4fa2365_73"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83My9mcmFnOjEzYzhmZTIzYzNhMTQ5YjI4N2NkNTE3YjVlMzQxZjQwL3RleHRyZWdpb246MTNjOGZlMjNjM2ExNDliMjg3Y2Q1MTdiNWUzNDFmNDBfMjgyNw_34a7b6d8-86ad-4abb-9f9b-95c4e893b530" continuedAt="ia3ff36a653984c59922b5c198b7fa1a4" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="ia3ff36a653984c59922b5c198b7fa1a4" continuedAt="i35516386331d467eb3ccca8d110263e5"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 7,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for a discussion of the commitments associated with the Company&#8217;s lease agreements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Northwestern University License Agreements</span></div></ix:continuation><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i35516386331d467eb3ccca8d110263e5">On December 12, 2011, (1) AuraSense, LLC, the Company&#8217;s former parent, assigned to the Company all of its worldwide rights and interests under AuraSense, LLC&#8217;s 2009 license agreement with Northwestern University (&#8220;NU&#8221;) in the field of the use of nanoparticles, nanotechnology, microtechnology or nanomaterial-based constructs as therapeutics or accompanying therapeutics as a means of delivery, but expressly excluding diagnostics (the &#8220;assigned field&#8221;); (2)&#160;in accordance with the terms and conditions of this assignment, the Company assumed all liabilities and obligations of AuraSense, LLC as set forth in its license agreement in the assigned field; and (3)&#160;in order to secure this assignment and the patent rights from NU, the Company agreed (i) to pay NU an annual license fee, which may be credited against any royalties due to NU in the same year, (ii) to reimburse NU for expenses associated with the prosecution and maintenance of the license patent rights, (iii) to pay NU royalties based on any net revenue generated by the Company&#8217;s sale or transfer of any licensed product, (iv) to pay NU, in the event the Company grants a sublicense under the licensed patent rights, the greater of a percentage of all sublicensee royalties or a percentage of any net revenue generated by a sublicensee&#8217;s sale or transfer of any licensed product, and (v) to pay NU a percentage of all other sublicense payments received by the Company.  In August 2015, the Company entered into a restated license agreement with NU (the &#8220;Restated License Agreement&#8221;). In February 2016, the Company obtained exclusive license as to NU&#8217;s rights in certain SNA technology it jointly owns with NU (the &#8220;Co-owned Technology License&#8221;). The Company&#8217;s license to NU&#8217;s rights is limited to the assigned field, however the Company has no such limitation as to its own rights in this jointly owned technology. In June 2016, the Company entered into an exclusive license with NU to obtain worldwide rights to certain inhibitors of glucosylceramide synthase and their use in wound healing in diabetes (the &#8220;Wound Healing License&#8221;). The Company&#8217;s rights and obligations in the Co-owned Technology License and the Wound Healing License agreements&#160;are substantially the same as in the Restated License Agreement from August 2015 (collectively referred to as &#8220;the Northwestern University License Agreements&#8221;).  All pending patent applications under the Wound Healing License have been abandoned and the Wound Healing License has been terminated.  As of September&#160;30, 2021, the Company has paid to NU an aggregate of $<ix:nonFraction unitRef="usd" contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="xcur:AggregatePaymentsMadeToDateForLicenseAgreements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83My9mcmFnOjEzYzhmZTIzYzNhMTQ5YjI4N2NkNTE3YjVlMzQxZjQwL3RleHRyZWdpb246MTNjOGZlMjNjM2ExNDliMjg3Y2Q1MTdiNWUzNDFmNDBfMjc2Mw_f8b0d727-5eef-4843-859a-d77808c506f4">11,413</ix:nonFraction> in consideration of each of the obligations described above.</ix:continuation> </span></div><div id="i30c50c718dda42d28fbdd6dcd4fa2365_76"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83Ni9mcmFnOjQ3ZjEzODdjODc5ZjQ2ZTA4YTdkYjFlOGY1NzQwOWQ4L3RleHRyZWdpb246NDdmMTM4N2M4NzlmNDZlMDhhN2RiMWU4ZjU3NDA5ZDhfNDE2_24a03e06-213e-46db-8c18-8711b0cc57e0" continuedAt="i5439f32f802147db872722c6e06dd628" escape="true">Related-Party Transactions</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5439f32f802147db872722c6e06dd628">The Company received consulting services from, and paid fees to, one of its co-founders who is not an employee but, through April 30, 2021, served as a member of the Board. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="i8264fbfff9464a9baa8088b432d019fd_D20200101-20200930" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83Ni9mcmFnOjQ3ZjEzODdjODc5ZjQ2ZTA4YTdkYjFlOGY1NzQwOWQ4L3RleHRyZWdpb246NDdmMTM4N2M4NzlmNDZlMDhhN2RiMWU4ZjU3NDA5ZDhfMjMy_609a0b92-22db-4e83-9d28-a688e372ca6c"><ix:nonFraction unitRef="usd" contextRef="i18f420eacb594066840b698845eaa3a4_D20210101-20210930" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83Ni9mcmFnOjQ3ZjEzODdjODc5ZjQ2ZTA4YTdkYjFlOGY1NzQwOWQ4L3RleHRyZWdpb246NDdmMTM4N2M4NzlmNDZlMDhhN2RiMWU4ZjU3NDA5ZDhfMjMy_acba6b18-d371-44a7-ab31-f6e191857160">75</ix:nonFraction></ix:nonFraction> as an expense in each of the nine months ended September&#160;30, 2021 and 2020 in connection with these consulting services in the accompanying unaudited condensed consolidated statement of operations.  The consulting agreement with this co-founder and former Board member expired on September 30, 2021 under the terms of the agreement and was not renewed.</ix:continuation></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><div id="i30c50c718dda42d28fbdd6dcd4fa2365_82"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The following information should be read in conjunction with our unaudited condensed consolidated financial statements and the notes thereto included in this Quarterly Report on Form 10-Q and the audited financial information and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the Securities and Exchange Commission, or SEC, on March 11, 2021. This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">that involve significant risks and uncertainties. Our actual results, performance or experience could differ materially from what is indicated by any forward-looking statement due to various important factors, risks, uncertainties, assumptions and other factors including, but not limited to, those identified in this Quarterly Report on Form 10-Q and those set forth under the section titled &#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q and in our other SEC filings.  Such factors may be amplified by the COVID-19 pandemic and its current or future impact on our business and the global economy.</span></div><div id="i30c50c718dda42d28fbdd6dcd4fa2365_85"></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases, and other genetic disorders based on our proprietary Spherical Nucleic Acid, or SNA&#8482;, technology. We believe that our proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics.  We are in preclinical development of XCUR-FXN, a lipid-nanoparticle SNA-based therapeutic candidate, for the intrathecal treatment of Friedreich&#8217;s ataxia, or FA.  Our therapeutic candidate cavrotolimod (AST-008) is in a Phase 1b/2 clinical trial in patients with advanced solid tumors. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe one of the key strengths of our proprietary SNAs is that they have the potential for increased cellular uptake compared to conventional linear oligonucleotides and as a result the potential to achieve higher efficacy at the same doses of oligonucleotide administered.  We have shown in clinical and preclinical studies that SNAs may have therapeutic potential in immuno-oncology and dermatology. In addition, we have shown in preclinical studies that SNAs may have therapeutic potential in neurology, ophthalmology, pulmonology, and gastroenterology. As a consequence, we have expanded our pipeline into neurology, for which IND-enabling activities are ongoing for XCUR-FXN, and are conducting early stage research activities in ophthalmology, pulmonology, and gastroenterology.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below sets forth the current status of development of our SNA therapeutic candidates.</span></div><div style="text-align:center;text-indent:18pt"><img src="xcur-20210930_g1.jpg" alt="xcur-20210930_g1.jpg" style="height:283px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"/></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">___________</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)  Cavrotolimod is a TLR9 agonist.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)  In combination with checkpoint inhibitors.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating, financing, and cash flow considerations</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception in 2011, we have devoted substantial resources to the research and development of SNAs and the protection and enhancement of our intellectual property. We have no products approved for sale and have primarily funded our operations through sales of our securities and collaborations. Through September 30, 2021, we have raised gross proceeds of $190.1 million from the sale of common stock and preferred stock. We have also received $56.0 million in upfront payments from collaborations, including an upfront payment of $20.0 million we received in August 2021 in connection with the Ipsen Collaboration Agreement and an upfront payment of $25.0 million we received in November 2019 in connection with the AbbVie Collaboration Agreement.  On September 25, 2020, we also borrowed $17.5 million under the terms of a credit and security agreement with MidCap Financial Trust (as described further below). As of September 30, 2021, our cash, cash equivalents, short-term investments, and restricted cash were $62.0 million.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have incurred significant operating losses.  As of September 30, 2021, we have generated an accumulated deficit of $175.1 million. Substantially all of our operating losses resulted from expenses incurred in connection with our research programs and from general and administrative costs associated with our operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur losses for the foreseeable future. Our net losses may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially as we:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue research and development of XCUR-FXN and other neurological therapeutic candidates and advance preclinical product candidates into clinical development;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to advance the ongoing Phase 1b/2 clinical development for cavrotolimod (AST-008) for immuno-oncology applications;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance our SNA platform with our current and prospective suitable collaboration partners;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiate research and development, preclinical studies and clinical trials for any additional therapeutic candidates that we may pursue in the future;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance other therapeutic candidates through preclinical and clinical development;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increase our research and development activities to enhance our technology platform;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to manufacture increasing quantities of drug substance and drug product material for use in preclinical studies and clinical trials;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek regulatory approval for our therapeutic candidates that successfully complete clinical trials;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, expand and protect our intellectual property portfolio;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquire or in-license other approved drugs, drug candidates or technologies; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire additional operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts; and</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incur additional costs associated with operating as a public company.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not generated any revenue from commercial drug sales nor do we expect to generate substantial revenue from product sales unless or until we successfully complete development and obtain regulatory approval of and commercialize one or more of our therapeutic candidates. We do not anticipate generating revenue from drug sales for the next several years, if ever. If we obtain regulatory approval for any of our therapeutic candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">distribution. Other sources of revenue could include a combination of research and development payments, license fees and other upfront payments, milestone payments, and royalties in connection with our current and any future collaborations and licenses. Until such time, if ever, that we generate revenue from whatever source, we expect to finance our cash needs through a combination of public or private equity offerings, debt financings and research collaboration and license agreements. We may be unable to raise capital or enter into such other arrangements when needed or on favorable terms. Our failure to raise capital or enter into such other arrangements as and when needed would have a negative impact on our financial condition and our ability to develop our therapeutic candidates.</span></div><div id="i30c50c718dda42d28fbdd6dcd4fa2365_88"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Developments</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously reported, on November 9, 2021, the Audit Committee of our Board of Directors was notified of a claim made by a former Company senior researcher regarding alleged improprieties that researcher claims to have committed with respect to our XCUR-FXN preclinical program for the treatment of Friedreich&#8217;s ataxia. The Audit Committee has retained external counsel to conduct an internal investigation of the claim. We are currently unable to predict the timing or outcome of the investigation.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Therapeutic Development Program Updates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">XCUR-FXN, Friedreich&#8217;s ataxia</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing XCUR-FXN, an SNA-based therapeutic candidate for the treatment of FA. We remain committed to maintaining our development plans and to pursuing our business strategy in the best interests of our stockholders as well as the patients we look to serve; however, we acknowledge that, at this point in time, we are unable to determine the potential impact of the asserted claim referenced above on our research and development activities or the timing of completion of our current research and development of our XCUR-FXN preclinical program for the treatment of FA, as the investigation of the asserted claim referenced above remains ongoing.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cavrotolimod (AST-008)</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently evaluating cavrotolimod (AST-008) in a Phase 1b/2 clinical trial in patients with advanced solid tumors. As of November 4, 2021, we had 25 clinical trial sites activated for enrollment and 2 additional sites pending activation.  We expect to open approximately 27 sites in total for the Phase 2 stage of the clinical trial.  We anticipate all sites will be activated by the first half of 2022. As of November 4, 2021, we have dosed 37 patients with 32 mg of cavrotolimod (AST-008) in the Phase 2 portion of the clinical trial, including the primary and exploratory cohorts.  Including the six patients dosed with 32 mg of cavrotolimod (AST-008) in the Phase 1b portion of the clinical trial, a total of 43 patients have been dosed with 32 mg of cavrotolimod (AST-008) through November 4, 2021.  As of November 4, 2021, four of the 43 patients dosed with 32 mg of cavrotolimod (AST-008) have experienced serious adverse events, or SAEs, assessed as related to cavrotolimod by clinical trial investigators.  All of these patients were dosed in the Phase 2 stage of the clinical trial. The treatment-related SAEs experienced by these four patients were hypotension (n=2), flu-like symptoms (n=1), injection-related reaction (n=1), and injection site reaction (n=1). None of the 14 patients dosed in the Phase 1b portion of the clinical trial with doses of cavrotolimod (AST-008) less than 32 mg experienced a treatment-related SAE. In summary, as of November 4, 2021, in total, 4 of 57 patients treated with cavrotolimod (AST-008) have experienced a treatment-related SAE.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the impact of the ongoing COVID-19 pandemic continues to contribute to delays that began during the third quarter of 2020 and continued into the second half of 2021 in our enrollment plans and clinical trial site start-ups for the Phase 2 dose expansion phase of the Phase 1b/2 clinical trial for its cavrotolimod (AST-008) clinical program.  As a result of these delays, pending further delays or any additional unanticipated effects of the COVID-19 pandemic on our clinical development plans, we now expect to report ORR results of cavrotolimod (AST-008) in the second half of 2022 rather than the first half of 2022.  We will also continue to seek opportunities to advance this program through strategic collaborations or partnerships with the goal of maximizing stockholder value of the program and the full potential of our pipeline. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Update Regarding AbbVie Collaboration</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We previously granted to AbbVie, Inc., or AbbVie, exclusive access and options to license SNA-based therapeutics arising from two collaboration programs we are conducting related to the treatment of hair loss disorders. During the third quarter of 2021, the joint development committee for the AbbVie collaboration made the decision to revise the initial development plan for both of the AbbVie collaboration programs.  Due to these revised workplans, we expect significant additional efforts will be required to satisfy the performance obligation under our Collaboration, Option and License Agreement with AbbVie, or the AbbVie Collaboration Agreement, as we conduct additional early-stage discovery and preclinical activities than those originally set forth in the respective initial development plan.  These increased estimated efforts in connection with the change in workplan resulted in less progress occurring relative to the increased estimate of total project hours to complete the research services during the three and nine months ended September 30, 2021 as compared to the amount of revenue recognized at both June 30, 2021 and December 31, 2020, which led to revenue reversals in each respective period.  As such, we recorded a cumulative catchup adjustment (reduction) of revenue of $(4.5) million during the three and nine months ended September 30, 2021.  Refer to Note 3,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Collaborative Research and License Agreements,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the accompanying unaudited condensed consolidated financial statements for more information regarding the AbbVie Collaboration Agreement.</span></div><div id="i30c50c718dda42d28fbdd6dcd4fa2365_91"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Business Update</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the global spread of the COVID-19 pandemic continues to affect our economy and our industry, we continue to monitor closely the developments and continue to take active measures to protect the health of our employees and their families, our communities, as well as our clinical trial investigators, patients, and caregivers.  On June 11, 2021, Illinois moved into &#8220;Phase 5&#8221; of the Restore Illinois Plan, which is intended to permit businesses to operate at full capacity and permits fully vaccinated individuals to resume activities without wearing a mask except where required by federal, state, local, tribal, or territorial laws, rules and regulations, including local business and workplace guidance.  As of November 12, 2021, Illinois remains in &#8220;Phase 5&#8221; of the Restore Illinois Plan.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supply chain </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are working closely with our third-party manufacturers and other partners to manage our supply chain activities and mitigate potential disruptions as a result of the COVID-19 pandemic. We have observed minor delays in receipt of key chemicals, reagents and materials as certain manufacturers have had supply disruptions related to the COVID-19 pandemic. During the second half of 2021, we have experienced delays in the receipt of components needed for the manufacture of GMP drug product of cavrotolimod (AST-008) and XCUR-FXN.  We are actively exploring substitutions to, and alternative sources for, these components to minimize any potential delays in the manufacture of these GMP drug products. Delays in the manufacturing of GMP drug product could adversely impact our clinical development activities for those programs.  If the COVID-19 pandemic continues to persist for an extended period of time and impacts essential distribution systems such as FedEx and postal delivery, we could experience future disruptions to our supply chain and operations and associated delays in the manufacturing and our clinical supply, which would adversely impact our preclinical and clinical development activities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical operations</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the ongoing COVID-19 pandemic has affected our Phase 1b/2 clinical trial of cavrotolimod (AST-008). Namely, the COVID-19 pandemic or its impact has contributed to delays that began during the third quarter of 2020 and continued into the second half of 2021 in our enrollment plans and clinical trial site start-ups for the Phase 2 dose expansion phase of the clinical trial.  As a result of these delays, pending further delays or any additional unanticipated effects of the COVID-19 pandemic on our clinical development plans, we now expect to report ORR results of cavrotolimod (AST-008) in the second half of 2022 rather than the first half of 2022.  Beginning in third quarter of 2020, we implemented, and continue to employ, additional measures to increase the enrollment of patients, including frequent interaction with our clinical trial sites currently open as well as increasing the number of clinical trial sites that potentially are activated for this trial so that we may continue to enroll patients as initially planned.  However, any additional delays may require us to further lengthen our clinical development </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">timeline for cavrotolimod (AST-008) and could potentially delay our proposed clinical development timeline for XCUR-FXN.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We remain committed to maintaining our development plans for cavrotolimod (AST-008) and XCUR-FXN and continue to monitor and manage the rapidly evolving situation of the effects of the pandemic. We have taken and continue to take measures to implement remote and virtual approaches, including remote patient monitoring where possible, to maintain patient safety and trial continuity and to preserve study integrity. Should the COVID-19 pandemic or its impact or effects continue, our ability to maintain patient enrollment and our clinical development timeline could continue to be negatively impacted. We could also see an impact on our ability to supply study drug, report trial results, or interact with regulators, ethics committees or other important agencies due to limitations in regulatory authority employee resources or otherwise. In addition, we rely on contract research organizations or other third parties to assist us with clinical trials, and we cannot guarantee that they will continue to perform their contractual duties in a timely and satisfactory manner as a result of the COVID-19 pandemic. As the COVID-19 pandemic continues to persist for an extended period of time, we continue to be impacted and could experience additional delays in patient enrollment for our Phase 2 stage of the Phase 1b/2 clinical trial of cavrotolimod (AST-008). Any significant disruptions to our clinical development timelines would further delay our anticipated timeline for results and adversely affect our business, financial condition, results of operations and growth prospects. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div id="i30c50c718dda42d28fbdd6dcd4fa2365_94"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the revenue and expenses incurred during the reported periods. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not apparent from other sources. Changes in estimates are reflected in reported results for the period in which they become known. Actual results may differ from these estimates under different assumptions or conditions, including uncertainty in the current economic environment due to the ongoing COVID-19 pandemic.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our critical accounting policies require the most significant judgments and estimates in the preparation of our consolidated financial statements. There have been no significant changes to our critical accounting policies from those which were discussed in our Annual Report on Form 10-K for the year ended December 31, 2020, except as discussed in Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the accompanying notes to the unaudited condensed consolidated financial statements related to revenue recognition.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently adopted accounting pronouncements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent accounting pronouncements not yet adopted</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of the accompanying unaudited condensed consolidated financial statements for a description of recently accounting pronouncements not yet updated.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><div id="i30c50c718dda42d28fbdd6dcd4fa2365_97"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of the Three Months Ended September 30, 2021 and 2020</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of our operations for the three months ended September 30, 2021 and 2020:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.429%"><tr><td style="width:1.0%"></td><td style="width:41.953%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.136%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.308%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.392%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.140%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,677)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,120)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(251)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,677)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,443&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,120)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(251)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,563&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,081)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,120)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,961)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Dividend income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(197)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(455)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(428)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other (expense) income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/m</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other (expense) income, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(450)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(748)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(251)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,531)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,822)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,709)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,531)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,822)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,709)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue earned during the periods indicated:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.224%"><tr><td style="width:1.0%"></td><td style="width:45.258%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.028%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbbVie Collaboration Agreement</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,480)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,882)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(287)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Collaboration Agreement</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/m</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dermelix Collaboration Agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,677)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,443&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,120)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(251)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,677)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,443&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,120)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(251)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue was $(3.7) million during the three months ended September 30, 2021, reflecting a decrease of $6.1 million, or 251%, from collaboration revenue of $2.4 million for the three months ended September 30, 2020.  The decrease in collaboration revenue of $6.1 million is mostly due to a decrease in revenue related to the AbbVie Collaboration Agreement of $6.9 million partially offset by revenue related to the Ipsen Collaboration Agreement of $0.8 million.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed further in Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Research and License Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of the accompanying unaudited condensed consolidated financial statements, revenue recognized under the AbbVie Collaboration Agreement for the three months ended September 30, 2021 reflects the cumulative catchup adjustment (reduction) of revenue of $(4.5) million in connection with the change in estimate that resulted from a change in workplan during the third quarter of 2021.  We currently estimate significant additional efforts will be required to satisfy the performance obligation under the AbbVie Collaboration Agreement.  These increased estimated efforts in connection with the change in workplan resulted in less progress occurring relative to the increased estimate of total project hours to complete the research services during the three and nine months ended September 30, 2021 and compared to the amount of revenue recognized at both June 30, 2021 and December 31, 2020, which led to revenue reversals in each respective period.  As of September 30, 2021, deferred revenue under the AbbVie Collaboration Agreement was $11.7 million and is expected to be recognized as revenue over the next 24 to 27 months as we satisfy our obligations under the AbbVie Collaboration Agreement.   In August 2021, we received an upfront payment of $20.0 million in connection with the Ipsen Collaboration Agreement for which revenue has been deferred and will be recognized as revenue in future periods as we satisfy our obligations under the Ipsen Collaboration Agreement.  At September 30, 2021, deferred revenue under the Ipsen Collaboration Agreement was $19.2 million and is expected to be recognized as revenue over the next 33 to 42 months as we satisfy our obligations under the Ipsen Collaboration Agreement.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Research and License Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of the accompanying unaudited condensed consolidated financial statements for more information regarding revenue recognition for the AbbVie Collaboration Agreement and Ipsen Collaboration Agreement.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect to generate any product revenue for the foreseeable future. However, future revenue may include amounts attributable to partnership activities including, a combination of research and development payments, license fees and other upfront payments, milestone payments, product sales and royalties, and reimbursement of certain research and development expenses, in connection with the AbbVie Collaboration Agreement, the Ipsen Collaboration Agreement, the Dermelix Collaboration Agreement or any future collaboration and licenses.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expense</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our research and development expenses incurred during the periods indicated:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(dollars&#160;in&#160;thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical development programs expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,394&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,173&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and discovery-related expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee-related expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,432&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facilities, depreciation, and other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,457&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Full time employees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense was $16.5 million for the three months ended September 30, 2021, reflecting an increase of $7.3 million, or 80%, from research and development expense of $9.1 million for the three months ended September 30, 2020.  Since September 30, 2020, we have increased our headcount in research and development from 48 to 65 as of September 30, 2021. The increase in research and development expense for the three months ended September 30, 2021 of $7.3 million reflects this increased headcount and the related increase in research and development activities, to include increased clinical trial activities.  More specifically, the increase in research and development expense for the three months ended September 30, 2021 of $7.3 million was primarily due to a net increase in costs related to our clinical development programs of $4.2 million, higher platform and discovery-related expense of $1.6 million, and higher employee-related expenses of $1.3 million.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net increase in clinical development programs expense for the three months ended September 30, 2021 of $4.2 million was primarily due to manufacturing and toxicology study costs in connection with IND-enabling and Phase 1 clinical trial preparation activities for XCUR-FXN, in addition to higher clinical trial costs in connection with our Phase 1b/2 clinical trial for cavrotolimod (AST-008), partially offset by lower manufacturing costs for cavrotolimod (AST-008).</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in platform and discovery-related expense of $1.6 million was mostly due to the license fee paid to Northwestern University of $3.0 million in connection with the receipt of the upfront payment of $20.0 million from Ipsen, partially offset by lower costs for materials, reagents, supplies, and contract research organizations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in employee-related expense for the three months ended September 30, 2021 of $1.3 million was due to higher compensation and related costs in connection with the net increase in headcount during the period presented as well as certain salary increases in 2021 for existing employees. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our research and development expenses to continue to increase during 2021 as compared to 2020 as we broaden our pipeline of SNA-based therapeutic candidates, continue investment into our clinical development programs, and further develop our SNA technology platform.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expense</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(dollars&#160;in&#160;thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,947&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,424&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Full time employees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense was $2.9 million for the three months ended September 30, 2021, representing an increase of $0.5 million, or 22%, from $2.4 million for the three months ended September 30, 2020.  The increase for the three months ended September 30, 2021 was mostly due to higher compensation and related costs in connection with salary increases in 2021 and an increase in headcount, as well as higher legal costs.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest income</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in interest income of $0.2 million for the three months ended September 30, 2021 was primarily the result of lower average balances invested in available for sale securities during the three months ended September 30, 2021 as compared to the prior-year period.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in interest expense of $0.4 million for the three months ended September 30, 2021 was the result of a higher average debt balance during the three months ended September 30, 2021 as compared to the prior-year period.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of the Nine Months Ended September 30, 2021 and 2020</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of our operations for the nine months ended September 30, 2021 and 2020:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.429%"><tr><td style="width:1.0%"></td><td style="width:41.953%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.136%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.308%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.392%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.140%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,601)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,074)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,601)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,074)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,499&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,449&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,100)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,976)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,124)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Dividend income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(693)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,314)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,159)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other (expense) income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(278)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/m</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other (expense) income, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,177)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,170)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(219)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,277)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,983)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,294)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,277)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,983)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,294)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenue earned during the periods indicated:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.224%"><tr><td style="width:1.0%"></td><td style="width:45.258%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.028%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbbVie Collaboration Agreement</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,404)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,755)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Collaboration Agreement</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/m</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dermelix Collaboration Agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,601)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,074)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,601)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,473&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,074)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue was $(2.6) million during the nine months ended September 30, 2021, reflecting a decrease of $19.1 million, or 116%, from collaboration revenue of $16.5 million for the nine months ended September 30, 2020.  The decrease in collaboration revenue of $19.1 million was mostly due to a decrease in revenue related to the AbbVie Collaboration Agreement of $19.8 million partially offset by revenue related to the Ipsen Collaboration Agreement of $0.8 million. As discussed further above in the section titled &#8220;Comparison of the Three Months Ended September 30, 2021 and 2020,&#8221; revenue related to the AbbVie Collaboration Agreement for </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the nine months ended September 30, 2021 reflects the cumulative catchup adjustment (reduction) of revenue of $(4.5) million in connection with the change in estimate during the third quarter of 2021.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Refer to Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Research and License Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of the accompanying unaudited condensed consolidated financial statements for more information regarding revenue recognition for the AbbVie Collaboration Agreement and Ipsen Collaboration Agreement.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect to generate any product revenue for the foreseeable future. However, future revenue may include amounts attributable to partnership activities including, a combination of research and development payments, license fees and other upfront payments, milestone payments, product sales and royalties, and reimbursement of certain research and development expenses, in connection with the AbbVie Collaboration Agreement, the Ipsen Collaboration Agreement, the Dermelix Collaboration Agreement or any future collaboration and licenses.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expense</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our research and development expenses incurred during the periods indicated:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(dollars&#160;in&#160;thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical development programs expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,438&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and discovery-related expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee-related expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facilities, depreciation, and other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,562&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,340&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Full time employees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense was $37.6 million for the nine months ended September 30, 2021, reflecting an increase of $15.3 million, or 69%, from research and development expense of $22.2 million for the nine months ended September 30, 2020.  Since September 30, 2020, we have increased our headcount in research and development from 48 to 65 at September 30, 2021. The increase in research and development expense for the nine months ended September 30, 2021 of $15.3 million reflects this increased headcount and the related increase in research and development activities, to include increased clinical trial activities.  More specifically, the increase in research and development expense for the nine months ended September 30, 2021 of $15.3 million was primarily due to a net increase in costs related to our clinical development programs of $7.8 million, higher employee-related expenses of $4.0 million, higher platform and discovery-related expense of $2.3 million, and higher facilities, depreciation, and other expenses of $1.3 million.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net increase in clinical development programs expense for the nine months ended September 30, 2021 of $7.8 million was primarily due to manufacturing and toxicology study costs in connection with IND-enabling and Phase 1 clinical trial preparation activities for XCUR-FXN, in addition to higher clinical trial costs in connection with our Phase 1b/2 clinical trial for cavrotolimod (AST-008), partially offset by lower manufacturing costs for cavrotolimod (AST-008).</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in platform and discovery-related expense of $2.3 million was mostly due to the license fee paid to Northwestern University of $3.0 million in connection with the receipt of the upfront payment of $20.0 million from Ipsen, partially offset by lower costs for materials and reagents.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in employee-related expense for the nine months ended September 30, 2021 of $4.0 million was due to higher compensation and related costs in connection with the net increase in headcount during the period presented as well as certain salary increases in 2021 for existing employees. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in facilities, depreciation, and other expenses for the nine months ended September 30, 2021 of $1.3 million was mostly due to higher lease costs related to our Chicago lease that commenced on July 1, 2020 as well as higher depreciation expense in connection with the acquisition of additional scientific equipment that were placed in service since the prior-year period.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our research and development expenses to continue to increase during 2021 as compared to 2020 as we broaden our pipeline of SNA-based therapeutic candidates, continue investment into our clinical development programs, and further develop our SNA technology platform.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expense</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(dollars&#160;in&#160;thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,937&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,227&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,710&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Full time employees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense was $8.9 million for the nine months ended September 30, 2021, representing an increase of $1.7 million, or 24%, from $7.2 million for the nine months ended September 30, 2020.  The increase for the nine months ended September 30, 2021 is mostly due to higher compensation and related costs mostly due to salary increases in 2021 and an increase in headcount, recruiting costs, higher consulting and legal costs, and higher D&amp;O insurance premium costs.  This increase was partially offset by lower investor relations and franchise tax costs.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest income</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in interest income of $0.7 million for the nine months ended September 30, 2021 was primarily the result of lower average balances invested in available for sale securities during the nine months ended September 30, 2021 as compared to the prior-year period.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in interest expense of $1.2 million for the nine months ended September 30, 2021 was the result of a higher average debt balance during the nine months ended September 30, 2021 as compared to the prior-year period.</span></div><div id="i30c50c718dda42d28fbdd6dcd4fa2365_100"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have incurred significant operating losses. We have generated limited revenue to date from our collaboration agreements. We have not yet commercialized any of our product candidates, which are in various phases of preclinical development and clinical trials; and we do not expect to generate revenue from sales of any product for several years, if at all. We have funded our operations to date with proceeds received from equity financings and payments received in connection with collaboration agreements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, our cash, cash equivalents, short-term investments, and restricted cash were $62.0 million.  As of September&#160;30, 2021, we have generated an accumulated deficit of $175.1 million since inception and expect to incur significant expenses and negative cash flows for the foreseeable future.  Based on our current operating plans and existing working capital at September 30, 2021, it is uncertain whether our current liquidity is sufficient to fund operations over the next twelve months from the date of the issuance of the accompanying condensed consolidated financial statements.  As a result, there is substantial doubt about our ability to continue as a going concern. We have no committed sources of additional capital at this time and substantial additional financing will be needed by us to fund our operations.  Management believes that we will be able to obtain additional funding through equity or debt financings, collaboration agreements, strategic partnerships and licensing arrangements, or other arrangements, such as our &#8220;at the market offering&#8221; program pursuant to our equity distribution agreement with BMO Capital Markets Corp., or BMO, to fund our current operations and business strategy. However, there can be no assurance that such additional financing will be available and, if available, can be obtained on terms acceptable to </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">us.  If we are unable to obtain such additional financing, we could be forced to delay, reduce or eliminate its research and development programs or clinical efforts, which could adversely affect its business prospects, or we may be unable to continue operations.  We have historically principally raised capital through the sale of our securities.  However, the COVID-19 pandemic continues to rapidly evolve and has already resulted in a significant disruption of global financial markets.  If the disruption continues to persist and deepens, we could experience an inability to access additional capital, which could in the future negatively affect our ability to raise capital and ultimately, our operations.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MidCap Facility</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 30, 2021, we entered into an amendment, or Amendment No. 3, to our Credit and Security Agreement, dated as of September 25, 2020, as amended on October 21, 2020 and July 30, 2021, with MidCap Financial Trust, as agent, or MidCap, and the lenders party thereto from time to time, or as amended by Amendment No. 3, the MidCap Credit Agreement.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MidCap Credit Agreement provides for a secured term loan facility in an aggregate principal amount of up to $25.0 million, or the MidCap Credit Facility. We borrowed the first advance of $17.5 million, or Tranche 1, on September 25, 2020, or the Closing Date. Amendment No. 3 extends the availability of the second advance of $7.5 million,  or Tranche 2, under the MidCap Credit Agreement from September 30, 2021 to December 31, 2021, subject to our satisfaction of certain applicable funding conditions as described in Amendment No. 3, including our issuance of equity interests, subject to certain limitations, resulting in receipt by us of unrestricted net cash proceeds of at least $20.0&#160;million, and the contribution by us, and receipt by Exicure Operating Company, of such cash proceeds to the capital of Exicure Operating Company.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tranche 1 and if borrowed, Tranche 2, each bear interest at a floating rate equal to 6.25% per annum, plus the greater of (i) 1.50% or (ii) one-month LIBOR. Interest on each loan advance is due and payable monthly in arrears. Principal on each loan advance is payable in 36 equal monthly installments beginning October 1, 2022 until paid in full on October 1, 2025, or the Maturity Date. Prepayments of the loans under the MidCap Credit Agreement, in whole or in part, will be subject to early termination fees in an amount equal to 3.0% of principal prepaid if prepayment occurs on or prior to the first anniversary of the Closing Date and 1.0% of principal prepaid if prepayment occurs after the first anniversary of the Closing Date and prior to the maturity date. In connection with execution of the MidCap Credit Agreement, we paid MidCap a $125,000 origination fee.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Maturity Date or on any earlier date on which all amounts advanced to us become due and payable in full, or are otherwise paid in full, we are required to pay an exit fee equal to 3.75% of the principal amount of all loans advanced to us under the MidCap Credit Agreement.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations under the MidCap Credit Agreement are secured by a security interest in substantially all of our assets, excluding intellectual property (which is subject to a negative pledge). Additionally, our future subsidiaries, if any, may be required to become co-borrowers or guarantors under the MidCap Credit Agreement.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MidCap Credit Agreement contains customary affirmative covenants and customary negative covenants limiting our ability and the ability of our subsidiaries, if any, to, among other things, dispose of assets, undergo a change in control, merge or consolidate, make acquisitions, incur debt, incur liens, pay dividends, repurchase stock and make investments, in each case subject to certain exceptions.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MidCap Credit Agreement also contains customary events of default relating to, among other things, payment defaults, breaches of covenants, a material adverse change, delisting of our common stock, bankruptcy and insolvency, cross defaults with certain material indebtedness and certain material contracts, judgments, and inaccuracies of representations and warranties. Upon an event of default, the agent and the lenders may declare all or a portion of our outstanding obligations to be immediately due and payable and exercise other rights and remedies provided for under the MidCap Credit Agreement. During the existence of an event of default, interest on the obligations could be increased by 2.0%.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At-the-Market Facility Program</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we entered into an equity distribution agreement with BMO under which we may offer and sell in &#8220;at the market offerings&#8221; (as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended) from time to time at our sole discretion, shares of our common stock having an aggregate offering price of up to $50.0 million through BMO acting as our distribution agent pursuant to a prospectus supplement and a shelf registration statement on Form S-3 that was declared effective by the SEC on January 7, 2021. Through September 30, 2021, we have not sold any shares under the equity distribution agreement. </span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a summary of our cash flows for the nine months ended September 30, 2021 and 2020:</span></div><div style="margin-top:5pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.750%"><tr><td style="width:1.0%"></td><td style="width:67.447%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.654%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.654%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.774%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in&#160;thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,022)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,463)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,330)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net increase (decrease) in cash, cash equivalents, and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,623&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,801)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating activities</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $21.0 million and $27.5 million for the nine months ended September 30, 2021 and 2020, respectively. The decrease in cash used in operating activities for the nine months ended September 30, 2021 of $6.4 million was primarily due to the receipt of the upfront payment of $20.0 million from Ipsen in connection with the Ipsen Collaboration Agreement, partially offset by higher cash used for working capital and the license fee paid to Northwestern University of $3.0 million in connection with receipt of the Ipsen Upfront Payment.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing activities</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by (used in) investing activities was $39.0 million and $(3.3) million for the nine months ended September 30, 2021 and 2020, respectively. The increase in cash provided by investing activities of $42.3 million was primarily due to higher proceeds from the maturity, net of purchases, of available-for-sale securities, as well as a decrease in the purchase of scientific equipment of $2.5 million. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing activities</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities of $0.7 million&#160;for nine months ended September 30, 2021 is due to the proceeds received from the exercise of stock options and the issuance of common stock in connection with our employee stock purchase plan.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities of $15.0 million for the nine months ended September 30, 2020 was mostly due to the net proceeds we received of $17.3 million during the period in connection with the MidCap Credit Agreement (as discussed above), as well as the net proceeds received from the sale of shares of our common stock in the amount of $2.8 million pursuant to the partial exercise of the option to purchase additional shares by the underwriters from our December 2019 financing, partially offset by the repayment of the remaining outstanding obligations under the Hercules Loan Agreement in the amount of $5.0 million upon the loan&#8217;s maturity.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our primary uses of capital will continue to be third-party clinical and research and development services, compensation and related expenses, laboratory and related supplies, legal and other regulatory expenses and general overhead costs. Because of the numerous risks and uncertainties associated with research, development and commercialization of therapeutic candidates, we are unable to estimate the exact amount of our working capital requirements. Our future capital requirements are difficult to forecast and will depend on many factors, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">the terms and timing of any other collaboration, licensing and other arrangements that we may establish;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, progress, timing and completion of preclinical studies and clinical trials for our potential therapeutic candidates;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effects of health epidemics, including the ongoing COVID-19 pandemic, on our operations or the business or operations of our contract research organizations, or CROs, or other third parties with whom we conduct business;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">the number and characteristics of therapeutic candidates that we pursue;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">the progress, costs and results of our preclinical studies and clinical trials;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">the outcome, timing and cost of regulatory approvals;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">delays that may be caused by changing regulatory requirements;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">the cost and timing of hiring new employees to support our continued growth;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">unknown legal, administrative, regulatory, accounting, and information technology costs as well as additional costs associated with operating as a public company;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">the costs involved in filing and prosecuting patent applications and enforcing and defending patent claims;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of filing and prosecuting intellectual property rights and enforcing and defending any intellectual property-related claims;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">the costs and timing of procuring clinical and commercial supplies of our therapeutic candidates;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">the extent to which we acquire or in-license other therapeutic candidates and technologies; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">the extent to which we acquire or invest in other businesses, therapeutic candidates or technologies.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our current operating plans and existing working capital at September 30, 2021, it is uncertain whether our current liquidity is sufficient to fund operations over the next twelve months from the date of the issuance of the accompanying condensed consolidated financial statements.  As a result, there is substantial doubt about our ability to continue as a going concern. We have no committed sources of additional capital at this time and substantial additional financing will be needed by us to fund our operations.  We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our capital resources sooner than we expect. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, and marketing, distribution or licensing arrangements with third parties.  The COVID-19 pandemic continues to evolve and has resulted in a significant disruption of global financial markets.  If the disruption continues to persist and deepens, we could experience an inability to access additional capital, which could in the future negatively affect our operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we raise additional capital through future equity financings, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our existing common stockholders. If we raise additional funds through the issuance of debt securities, these securities could contain covenants that would restrict our operations. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, reduce or eliminate our product development efforts or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div id="i30c50c718dda42d28fbdd6dcd4fa2365_103"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations and Commitments</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our contractual obligations and commitments from those described in our Annual Report on Form 10-K for the year ended December 31, 2020.</span></div><div style="text-indent:18pt"><span><br/></span></div><div id="i30c50c718dda42d28fbdd6dcd4fa2365_106"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-balance Sheet Arrangements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</span></div><div style="text-indent:18pt"><span><br/></span></div><div id="i30c50c718dda42d28fbdd6dcd4fa2365_109"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JOBS Act</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Under the JOBS Act, an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, as an emerging growth company, we will not be required to provide an auditor&#8217;s attestation report on our internal control over financial reporting in future annual reports on Form 10-K as otherwise required by Section&#160;404(b) of the Sarbanes-Oxley Act of 2002, or Sarbanes-Oxley Act.  Our compliance with Section 404 of the Sarbanes-Oxley Act first became subject to management&#8217;s assessment regarding internal control over financial reporting in connection with the filing of our Annual Report on Form 10-K for the fiscal year ending December 31, 2018, and we will not be required to have an independent registered public accounting firm attest to the effectiveness of our internal control over financial reporting until the filing of our first Annual Report on Form 10-K after we lose emerging growth company status, which may not be until the 2023 Annual Report on Form 10-K.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we are also a smaller reporting company as defined in the Securities Exchange Act of 1934, as amended, or Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as (i) our voting and non-voting common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter or (ii) our annual revenue is less than $100.0 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><div id="i30c50c718dda42d28fbdd6dcd4fa2365_112"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3. Quantitative and Qualitative Disclosures about Market Risk.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act and in Item 10(f)(1) of Regulation S-K, we are electing scaled disclosure reporting obligations and therefore are not required to provide the information requested by this Item.</span></div><div style="text-indent:18pt"><span><br/></span></div><div id="i30c50c718dda42d28fbdd6dcd4fa2365_115"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4. Controls and Procedures.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic and current reports that we file with the SEC under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.  Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the end of the period covered by this Quarterly Report on Form 10-Q, we carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Exchange Act Rule 13a-15. Based upon, and as of the date of, this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective. Accordingly, management believes that the financial statements included in this report fairly present in all material respects our financial condition, results of operations and cash flows for the periods presented.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continuously seek to improve the efficiency and effectiveness of our internal controls. There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act during the fiscal quarter ended September 30, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="i30c50c718dda42d28fbdd6dcd4fa2365_118"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II &#8211; OTHER INFORMATION</span></div><div id="i30c50c718dda42d28fbdd6dcd4fa2365_121"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1. Legal Proceedings.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be subject to legal proceedings. We are not currently a party to or aware of any proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><div id="i30c50c718dda42d28fbdd6dcd4fa2365_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In addition to other information contained in this Quarterly Report on Form 10-Q, the following risks should be considered in evaluating our business and future prospects and an investment in our common stock. The risks and uncertainties described below are not the only ones we face. If any of the following risks and uncertainties develops into actual events, our business, financial condition, results of operations and cash flows could be materially adversely affected. In that case, the price of our common stock could decline and you may lose all or part of your investment. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Business</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our consolidated financial statements have been prepared assuming that we will continue as a going concern.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred recurring losses from operations since inception which raises substantial doubt about our ability to continue as a going concern. If we are unable to obtain sufficient funding, our business, prospects, financial condition and results of operations will be materially and adversely affected, and we may be unable to continue as a going concern. If we are unable to continue as a going concern, we may have to liquidate our assets and may receive less than the value at which those assets are carried on our audited financial statements, and it is likely that investors will lose all or a part of their investment. In addition, if there remains substantial doubt about our ability to continue as a going concern, investors or other financing sources may be unwilling to provide additional funding to us on commercially reasonable terms, or at all.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a clinical-stage biotechnology company with a history of losses. We expect to continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability, which could result in a decline in the market value of our common stock. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biotechnology company developing therapeutics for immuno-oncology, genetic disorders and other indications based on our proprietary SNA technology.  Since our inception in June 2011, we have devoted our resources to the development of SNA technology.  We have had significant operating losses since our inception.  As of September 30, 2021, we have generated an accumulated deficit of $175.1 million. For the nine months ended September 30, 2021 and 2020, our net loss was $50.3 million and $12.0 million, respectively. Substantially all of our losses have resulted from expenses incurred in connection with our research programs and from general and administrative costs associated with our operations. Our technology and therapeutic candidates are in early stages of development, and we are subject to the risks of failure inherent in the development of therapeutic candidates based on novel technologies. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not generated, and do not expect to generate, any product revenue for the foreseeable future, and we expect to continue to incur significant operating losses for the foreseeable future due to the cost of research and development, preclinical studies, clinical trials, and the regulatory approval process for therapeutic candidates. The amount of future losses is uncertain. Our ability to achieve profitability, if ever, will depend on, among other things, us, or any current or future collaborators, successfully developing therapeutic candidates, obtaining regulatory approvals to market and commercialize therapeutic candidates, manufacturing any approved products on commercially reasonable terms, establishing a sales and marketing organization or suitable third-party alternatives for any approved product and raising sufficient funds to finance business activities. If we, or any current or future collaborators, are unable to develop and commercialize one or more of our therapeutic candidates or if sales revenue from any therapeutic candidate that receives approval is insufficient, we will not achieve profitability, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has identified certain conditions or events, which, considered in the aggregate, raise substantial doubt about our ability to continue as a going concern, including the risk that we will be unable to raise adequate additional capital to fund our operations through at least the 12 months following the filing date of this Quarterly Report. Substantial doubt about our ability to continue as a going concern may create negative reactions to the price of our common stock. If we are unable to raise capital, we may be required to delay, reduce the scope of or eliminate research and development programs, or obtain funds through arrangements with collaborators or others that may require us to relinquish rights to certain drug candidates that we might otherwise seek to develop or commercialize independently. In addition, if we are unable to continue as a going concern, we may have to liquidate our assets and may receive less than the value at which those assets are carried on our financial statements, and it is likely that investors will lose all or a part of their investment. Further, the perception that we may be unable to continue as a going concern may impede our ability to pursue strategic opportunities or operate our business due to concerns regarding our ability to discharge our contractual obligations. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our approach to the discovery and development of innovative therapeutic treatments based on our technology is unproven and may not result in marketable products. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to develop a pipeline of therapeutic candidates based on our proprietary SNA technology. We believe that therapeutic candidates identified with our therapeutic discovery technology may offer an improved therapeutic approach compared to small molecules and antibodies, as well as several advantages over linear oligonucleotide-based therapeutics. However, the scientific research that forms the basis of our efforts to develop therapeutic candidates based on our SNA technology and the identification and optimization of SNA-based therapeutic candidates is relatively new. Further, the scientific evidence to support the feasibility of developing therapeutic treatments based on SNA technology is both preliminary and limited. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therapeutic candidates based on SNA technology have not been extensively tested in humans, and a number of clinical trials conducted by other companies using oligonucleotide technologies have not been successful. We may discover that the SNA-based therapeutic candidates do not possess certain properties required for therapeutic treatment to be effective, such as the ability to remain stable in the human body for the period of time required for the therapeutic candidate to reach the target tissue or the ability to cross the cell membrane and enter into cells within the target tissue for effective delivery. We currently have only limited data, and no conclusive evidence, to suggest that we can introduce these necessary drug-like properties into SNA-based therapeutic candidate. We may spend substantial funds attempting to introduce these properties and may never succeed in doing so. In addition, therapeutic candidates based on SNA technology may demonstrate different chemical and pharmacological properties in patients than they do in laboratory studies. Even if therapeutic candidates have successful results in animal studies, they may not demonstrate the same chemical and pharmacological properties in humans and may interact with human biological systems in unforeseen, ineffective or harmful ways. As a result, we may never succeed in developing a marketable therapeutic, we may not become profitable and the value of our common stock would decline. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the U.S. Food and Drug Administration, or FDA, and equivalent foreign regulatory authorities have limited experience with SNA-based therapeutics. No regulatory authority has granted approval to any person or entity, including us, to market and commercialize SNA-based therapeutics, which may increase the complexity, uncertainty and length of the regulatory approval process for our therapeutic candidates. We and any current or future collaborators may never receive approval to market and commercialize any therapeutic candidate. Even if we or a future collaborator obtain regulatory approval, the approval may be for disease indications or patient populations that are not as broad as we intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. We or a future collaborator may be required to perform additional or unanticipated clinical trials to obtain approval or be subject to post-marketing testing requirements to maintain regulatory approval. If our SNA technology proves to be ineffective, unsafe or commercially unviable, our technology and pipeline would have little, if any, value, which could have a material adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our therapeutic candidates are in early stages of development and may fail in development or suffer delays that materially and adversely affect their commercial viability. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no therapeutics on the market and all of our therapeutic candidates are in early stages of development. Our ability to achieve and sustain profitability depends on obtaining regulatory approvals, including an institutional review board, or IRB, approval to conduct clinical trials at particular sites for, and successfully commercializing, our therapeutic candidates, either alone or with third parties. Before obtaining regulatory approval for the commercial distribution of our therapeutic candidates, we or an existing or a future collaborator must conduct extensive preclinical studies and clinical trials to demonstrate the safety and efficacy in humans of our therapeutic candidates. Preclinical studies and clinical trials are expensive, difficult to design and implement, can take many years to complete and are uncertain as to outcome. The start or end of a clinical trial is often delayed or halted due to changing regulatory requirements, manufacturing challenges, required clinical trial administrative actions, slower than anticipated patient enrollment, changing standards of care, availability or prevalence of use of a comparative therapeutic or required prior therapy, clinical outcomes or financial constraints. For instance, delays or difficulties in patient enrollment or difficulties in retaining trial participants can result in increased costs, longer development times or termination of a clinical trial. Clinical trials of a new therapeutic candidate require the enrollment of a sufficient number of patients, including patients who are suffering from the disease the therapeutic candidate is intended to treat and who meet other eligibility criteria. Rates of patient enrollment are affected by many factors, including the size of the patient population, the eligibility criteria for the clinical trial, the age and condition of the patients, the stage and severity of disease, the nature of the protocol, the proximity of patients to clinical sites, the availability of effective treatments for the relevant disease, and COVID-19-related developments including the extent to which they may interact with any of the foregoing factors. For example, the continuing effects of the COVID-19 pandemic contributed to delays that began in the third quarter of 2020 and continued into the second half </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of 2021 in our enrollment plans and clinical trial site start-ups for the Phase 2 dose expansion phase of the Phase 1b/2 clinical trial for our cavrotolimod (AST-008) clinical program, and, as a result, we now expect to report ORR results of cavrotolimod (AST-008) in the second half of 2022 rather than the first half of 2022, pending further delays or any additional unanticipated effects of the COVID-19 pandemic on our clinical development plans.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A therapeutic candidate can unexpectedly fail at any stage of preclinical and clinical development. The historical failure rate for therapeutic candidates is high due to scientific feasibility, safety, efficacy, changing standards of medical care and other variables. The results from preclinical studies or early clinical trials of a therapeutic candidate may not predict the results that will be obtained in later phase clinical trials of the therapeutic candidate. We, the FDA, an IRB, an independent ethics committee, or other applicable regulatory authorities may suspend clinical trials of a therapeutic candidate at any time for various reasons, including a finding that subjects participating in such trials are being exposed to unreasonable and significant risk of illness or injury. Similarly, an IRB or ethics committee may suspend a clinical trial at a particular trial site. We may not have the financial resources to continue development of, or to enter into collaborations for, a therapeutic candidate if we experience any problems or other unforeseen events that delay or prevent regulatory approval of, or our ability to commercialize, therapeutic candidates, including: </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">negative or inconclusive results from our clinical trials or the clinical trials of others for therapeutic candidates similar to ours, leading to a decision or requirement to conduct additional preclinical testing or clinical trials or abandon a program; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">therapeutic-related side effects experienced by participants in our clinical trials or by individuals using therapeutics similar to our therapeutic candidates; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in submitting INDs or clinical trial applications, or CTAs, or comparable foreign applications or delays or failure in obtaining the necessary approvals from regulators or IRBs or ethics committees to commence a clinical trial, or a suspension or termination of a clinical trial once commenced; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conditions imposed by the FDA or comparable foreign authorities, such as the European Medicines Agency, or EMA, or European Union national competent authorities, regarding the scope or design of our clinical trials; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">further delays in enrolling research subjects in clinical trials; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">high drop-out rates of research subjects; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inadequate supply or quality of therapeutic candidate components or materials or other supplies necessary for the conduct of our clinical trials; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">greater than anticipated clinical trial costs; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">poor effectiveness of our therapeutic candidates during clinical trials; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unfavorable FDA or other regulatory agency inspection and review of a clinical trial site; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around clinical testing generally or with respect to our technology in particular, especially in light of the novelty of our therapeutic candidates;  </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">varying interpretations of data by the FDA and similar foreign regulatory agencies; or</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal of the FDA to accept data from clinical trials conducted outside the United States, or acceptance of these data subject to certain conditions by the FDA. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product development involves a lengthy and expensive process with an uncertain outcome, and results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing is expensive and generally takes many years to complete, and the outcome is inherently uncertain. Failure can occur at any time and at any stage during the clinical trial process. The results of preclinical studies and early clinical trials of our therapeutic candidates may not be predictive of the result of any subsequent clinical trials. Therapeutic candidates that have shown promising results in early stage clinical trials may still suffer significant setbacks in subsequent clinical trials. We will have to conduct trials in our proposed indications to verify the results obtained to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">date and to support any regulatory submissions for further clinical development. A number of companies in the biopharmaceutical industry have suffered significant setbacks in clinical trials due to&#160;lack of efficacy or adverse safety profiles despite promising results in earlier clinical trials. Moreover, clinical data is often susceptible to varying interpretations and analyses. We do not know whether Phase 1, Phase 2, Phase 3, or other clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety with respect to the proposed indication for use sufficient to receive regulatory approval or market our therapeutic candidates. &#160;If we experience delays in the completion of, or termination of, any clinical trial of our therapeutic candidates, the commercial prospects of our therapeutic candidates may be harmed, and our ability to generate product revenues from any of these therapeutic candidates will be delayed.&#160; In addition, any delays in completing clinical trials will increase our costs, slow down our therapeutic candidate development and approval process and jeopardize our ability to commence product sales and generate revenues.&#160; Any of these occurrences could materially and adversely affect our business, financial condition, results of operations or prospects.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, some of the clinical trials we conduct may be open-label in study design and may be conducted at a limited number of clinical sites on a limited number of patients. An &#8220;open-label&#8221; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. Moreover, patients selected for early clinical studies often include the most severe sufferers and their symptoms may have been bound to improve notwithstanding the new treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. Given that our planned open-label Phase 1b/2 clinical trial of cavrotolimod (AST-008) includes an open-label dosing design, the results from this clinical trial may not be predictive of future clinical trial results with this or other product candidates for which we conduct an open-label clinical trial when studied in a controlled environment with a placebo or active control.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A fast track designation by the FDA may not actually lead to a faster development or regulatory review or approval process and does not increase the likelihood that our therapeutic candidates will receive marketing approval.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a drug is intended for the treatment of a serious or life-threatening condition and the drug demonstrates the potential to address unmet medical needs for this condition, the drug sponsor may apply for FDA fast track designation. The FDA has broad discretion whether to grant this designation. We have obtained fast track designations from the FDA for (i) cavrotolimod in combination with anti-PD-1 or anti-PD-L1 therapy for the treatment of patients with locally advanced or metastatic MCC, refractory to prior anti-PD-(L)1 blockade and (ii) cavrotolimod in combination with anti-PD-1 therapy for the treatment of patients with locally advanced or metastatic CSCC, refractory to prior anti-PD-1 blockade. However, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw our fast track designation if the FDA believes that the designation is no longer supported by data from our clinical development program. Our fast track designation does not guarantee that we will qualify for or be able to take advantage of the FDA&#8217;s expedited review procedures. Many drugs that have received fast track designation have failed to obtain marketing approval. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need substantial additional funds to advance the development of our therapeutic candidates, and we cannot guarantee that we will have sufficient funds available in the future to develop and commercialize our current or future therapeutic candidates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our existing therapeutic candidates or our future therapeutic candidates enter and advance through preclinical studies and clinical trials, we will need substantial additional funds to expand our development, regulatory, manufacturing, marketing, and sales capabilities or contract with other organizations to provide these capabilities for us. We have used substantial funds to develop our therapeutic candidates and will require significant funds to conduct further research and development and preclinical studies and clinical trials of our therapeutic candidates, to seek regulatory approvals for our therapeutic candidates and to manufacture and market products, if any, that are approved for commercial sale.  As of September 30, 2021, we had $53.1 million in cash, cash equivalents, and restricted cash and $9.0 million in short-term investments. Based on our current operating plans and existing working capital at September 30, 2021, it is uncertain whether our current liquidity is sufficient to fund operations over the next twelve months from the date of the issuance of the accompanying condensed consolidated financial statements.  As a result, there is substantial doubt about our ability to continue as a going concern. We have no committed sources of additional capital at this time and substantial additional financing will be needed by us to fund our operations. Our future capital requirements and the period for which </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we expect our existing resources to support our operations may vary significantly from what we expect. Our monthly spending levels vary based on new and ongoing development and corporate activities. Since the length of time and activities associated with successful development of our therapeutic candidates is highly uncertain, we are unable to estimate the actual funds we will require for development and any approved marketing and commercialization activities. To execute our business plan, we will need, among other things: </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to obtain the human and financial resources necessary to develop, test, obtain regulatory approval for, manufacture and market our therapeutic candidates; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to build and maintain a strong intellectual property portfolio and avoid infringing the intellectual property of third parties; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to establish and maintain successful licenses, collaborations and alliances; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to satisfy the requirements of clinical trial protocols, including patient enrollment; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to establish and demonstrate the clinical efficacy and safety of our therapeutic candidates; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to obtain regulatory approvals; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to manage our spending as costs and expenses increase due to preclinical studies and clinical trials, regulatory approvals, and commercialization; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to obtain additional capital to support and expand our operations; and </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to market our products to achieve acceptance and use by the medical community in general. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are unable to obtain funding on a timely basis or on acceptable terms, we may have to delay, reduce or terminate our research and development programs and preclinical studies or clinical trials, if any, limit strategic opportunities or undergo reductions in our workforce or other corporate restructuring activities. We also could be required to seek funds through arrangements with collaborators or others that may require us to relinquish rights to some of our technology or therapeutic candidates that we would otherwise pursue on our own. We do not expect to realize revenue from product sales, milestone payments or royalties in the foreseeable future, if at all. Our revenue sources are, and will remain, extremely limited unless and until our therapeutic candidates are clinically tested, approved for commercialization and successfully marketed. To date, we have primarily financed our operations through the sale of equity securities, payments received in connection with our collaboration, option, and license agreement with AbbVie Inc., or AbbVie, our collaboration, option and license agreement with Ipsen Biopharm Limited, or Ipsen, our research collaboration, license, and option agreement with Purdue Pharma L.P., or Purdue, our license and development agreement with Dermelix LLC, or Dermelix, or as a primary contractor or as a subcontractor on government grants, proceeds from our credit and security agreement with MidCap Financial Trust, or MidCap, and proceeds from our loan agreement with Hercules Technology Growth Capital, or Hercules. We will be required to seek additional funding in the future and intend to do so through either collaborations, public or private equity offerings or debt financings, credit or loan facilities or a combination of one or more of these funding sources. Our ability to raise additional funds will depend on financial, economic and other factors, many of which are beyond our control. Additional funds may not be available to us on acceptable terms, or at all, and our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic. If we raise additional funds by issuing equity securities or by sales pursuant to our &#8220;at the market&#8221; program, our stockholders will suffer dilution and the terms of any financing may adversely affect the rights of our stockholders. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. Debt financing, if available, may involve restrictive covenants limiting our flexibility in conducting future business activities, and, in the event of insolvency, debt holders would be repaid before holders of equity securities received any distribution of corporate assets. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be adversely affected by the effects of health epidemics, including the global COVID&#8209;19 pandemic, in regions where we or third parties on which we rely have business operations and at our clinical trial sites, as well as the business or operations of our CROs or other third parties with whom we conduct business. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outbreak of the novel strain of coronavirus, SARS-CoV-2, which causes coronavirus disease 2019, or COVID-19, continues to negatively impact the global economy. Our business and operations could be adversely affected by the effects of health epidemics, including the ongoing COVID-19 pandemic, on our business activities performed by us or by third parties with whom we conduct business, including our third party manufacturers, contract research organizations, or CROs, shippers and others. Such effects could be more pronounced in regions where we have </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">concentrations of clinical trial sites or other business operations. Our company headquarters is located in Chicago, Illinois, our CROs are located globally, and our substance and drug product manufacturers are located in the United States and Europe.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 11, 2021, Illinois moved into &#8220;Phase 5&#8221; of the Restore Illinois Plan, which is intended to permit businesses to operate at full capacity and permits fully vaccinated individuals to resume activities without wearing a mask except where required by federal, state, local, tribal, or territorial laws, rules and regulations, including local business and workplace guidance.  As of November 12, 2021, Illinois remains in &#8220;Phase 5&#8221; of the Restore Illinois Plan.  Certain jurisdictions have begun re-opening only to return to restrictions in the face of increases in new COVID-19 cases. The extent of and timing for lifting of government restrictions remains uncertain as the COVID-19 pandemic continues to evolve. There is no guarantee that prior or new restrictions will not be reinstated in response to the continued spread of COVID-19 or the introduction and spread of new variants of SARS-CoV-2.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to current and prior public health directives and orders and to ensure the safety and wellbeing of our employees, we have implemented work-from-home policies to support the community efforts to reduce the transmission of COVID-19 and protect employees, complying with guidance from federal, state/provincial or municipal government and health authorities. We implemented a number of measures to ensure employee safety and business continuity.  Under social distancing guidelines for COVID-19, we were typically operating with less than 50% of our R&amp;D staff on-site at any one time through June 30, 2020. As of July 1, 2020, we took occupancy of approximately 30,000 square feet of laboratory and office space in our new headquarters in Chicago, Illinois.  Since then, we have operated under COVID-19 social distancing guidelines and have generally operated with approximately 100% of our R&amp;D staff on-site.  Our office and general and administrative team continues to generally work on site approximately 50% of the time.  We are managing laboratory staffing and taking other appropriate managerial actions to maintain progress on our preclinical and collaboration programs. Business travel has been restricted and we continue to take measures to secure our research and development project activities, while work in laboratories and facilities has been organized to reduce risk of COVID-19 transmission.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regions in which we operate are currently being affected by COVID-19 and have become subject to additional government-imposed mitigation measures to prevent the ongoing spread of COVID-19.  Further, timely enrollment in our clinical trials is dependent upon clinical trial sites which may be adversely affected by the COVID-19 pandemic or its impact or effects. During the third quarter of 2020 and through September 30, 2021, we have observed delays in our enrollment plans for the Phase 2 dose expansion phase of the Phase 1b/2 clinical trial for cavrotolimod (AST-008). We believe the effects of the COVID-19 pandemic or its impact have contributed to such delays. As a result, we lengthened our clinical development timeline for cavrotolimod (AST-008) and, pending further enrollment delays or any unanticipated effects of the COVID-19 pandemic on our clinical development plans, expect to report ORR results in the second half of 2022 rather than by the first half of 2022.  Quarantines, shelter-in-place, safer-at-home, social distancing requirements and similar government orders, business shutdowns and closures, phased re-openings or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could continue to occur, related to COVID-19 or other infectious diseases could impact personnel at third-party manufacturing facilities and CROs in the United States and other countries, or the availability or cost of materials, which would disrupt our supply chain. Additionally, our clinical trials may involve immunocompromised patients who are at higher risk for COVID-19 and who are therefore more likely to avoid hospitals or other high risk areas.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of the executive orders and our work-from-home policies may negatively impact productivity, disrupt our business and delay our clinical programs and timelines (for example, our timelines for any of our product candidates), the magnitude of which will continue to depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the COVID-19 outbreak, or similar pandemics, we may experience further disruptions that could severely impact our business, clinical trials and preclinical studies, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">further delays or difficulties in enrolling or maintaining patients in our clinical trials, including patients who may not be able to comply with clinical trial protocols if quarantines, shelter-in-place or safer-at-home restrictions, or social distancing practices or requirements, business shutdowns and closures, among other similar requirements or government orders, continue to impede patient movement or interrupt healthcare services;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased rates of patients withdrawing from our clinical trials following enrollment as a result of contracting COVID-19, being forced to quarantine, or being unable to visit clinical trial locations;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff who may have heightened exposure to COVID-19 or experience additional restrictions by their institutions, city, or state;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or disruptions in non-clinical experiments and investigational new drug application-enabling good laboratory practice standard toxicology studies due to unforeseen circumstances in supply chain;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion or prioritization of healthcare resources away from the conduct of clinical trials and towards the COVID-19 pandemic, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials, and because, who, as healthcare providers, may have heightened exposure to COVID-19 and adversely impact our clinical trial operations;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of our key clinical trial activities, such as clinical assessments at pre-specified time points during the trial and clinical trial site data monitoring, due to limitations on travel imposed or recommended by governmental entities, employers and others or interruption of clinical trial subject visits and study procedures (particularly any procedures that may be deemed non-essential), which may impact the integrity of subject data and clinical study endpoints;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption or delays in the operations of the FDA, European Medicines Agency, or EMA, and comparable foreign regulatory agencies or their refusal to accept data from clinical trials in affected geographies, which may impact approval timelines;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations in employee resources that would otherwise be focused on the conduct of our clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our clinical trials that we might conduct at sites outside the United States, in addition to the risks listed above, we may also experience the following adverse impacts, particularly in countries which are experiencing heightened impact from the COVID-19 pandemic:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in receiving approval from local regulatory authorities to initiate our planned clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption in global shipping that may affect the transport of clinical trial materials, such as investigational drug product and comparator drugs used in our clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in local regulations as part of a response to the ongoing COVID-19 pandemic which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the refusal of the FDA to accept data from clinical trials in these affected geographies.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The spread of COVID-19, which continues to cause broad global impact, may materially affect us economically. The trading price for our shares as well as the trading prices of other biopharmaceutical companies, as well as the broader equity and debt markets overall, have been highly volatile as a result of the COVID-19 pandemic and the resulting impact on U.S. economic activities. Although the potential economic impact brought by, and the duration or subsequent reoccurrence of, the COVID-19 pandemic may be difficult to assess or predict, a widespread and prolonged pandemic could continue to result in significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, even after the COVID-19 pandemic has subsided, a recession or market correction that has occurred or may occur in the future because of the COVID-19 could materially affect our business and the value of our common stock. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global outbreak of COVID-19 continues to rapidly evolve. The extent to which the COVID-19 pandemic or a similar pandemic will impact our business, preclinical studies and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration and severity of the outbreak, the possibility of additional periods of increases or spikes in the number of COVID-19 cases, the introduction and spread of new variants of the virus, limitations on our ability to conduct our business in the ordinary course, any reopening plans and additional closures, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions for us, our third party contractors and the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effectiveness of actions taken in the United States and other countries to contain and treat the disease, including, without limitation, the effectiveness and timing of vaccination initiatives in the United States and worldwide. The ultimate impact of the COVID-19 pandemic or a similar health pandemic is highly uncertain and subject to change; we continue to monitor the COVID-19 situation closely.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we continue to experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be further delayed or prevented.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to initiate or continue conducting clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the United States. Some of our competitors have ongoing clinical trials for product candidates that treat the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; product candidates. Patient enrollment is affected by other factors including:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size and nature of the patient population;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the severity of the disease under investigation;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the eligibility criteria for, and design of, the trial in question;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the perceived risks and benefits of the product candidate under study;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competition in recruiting and enrolling patients in clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efforts to facilitate timely enrollment in clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patient referral practices of physicians;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to monitor patients adequately during and after treatment;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the proximity and availability of clinical trial sites for prospective patients; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or difficulties due to the COVID-19 pandemic or its impact or effects.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays and could require us to abandon one or more clinical trials altogether. We may encounter further difficulties and/or delays in completing our planned enrollments. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, or the inability to complete development of our product candidates, which would cause the value of our company to decline, limit our ability to obtain additional financing, and materially impair our ability to generate revenues.  For example, the continuing effects of the COVID-19 pandemic contributed to delays that began in the third quarter of 2020 and continued into the second half of 2021 in our enrollment plans and clinical trial site start-ups for the Phase 2 dose expansion phase of the Phase 1b/2 clinical trial for our cavrotolimod (AST-008) clinical program, and, as a result, we now expect to report ORR results of cavrotolimod (AST-008) in the second half of 2022 rather than the first half of 2022, pending further delays or any additional unanticipated effects of the COVID-19 pandemic on our clinical development plans.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including:</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in the level of expense related to our therapeutic candidates or future development programs; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results of clinical trials, or the addition or termination of clinical trials or funding support by us, or a future collaborator or licensing partner; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our execution of any collaboration, licensing or similar arrangement, and the timing of payments we may make or receive under such existing or future arrangements or the termination or modification of any such existing or future arrangements;</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in estimates in total project hours in connection with the revenue recognition related to our collaboration agreements that may result in a significant adjustment of non-cash revenue;  </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any intellectual property infringement lawsuit or opposition, interference or cancellation proceeding in which we may become involved; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions and departures of key personnel; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether or not any of our therapeutic candidates receives regulatory approval, market acceptance and demand for such therapeutic candidates; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments affecting our therapeutic candidates or those of our competitors; and </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in general economic, industry, political and market conditions, including, but not limited to, the ongoing impact of the COVID-19 pandemic. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not successfully engage in strategic transactions, including any additional collaborations we seek, which could adversely affect our ability to develop and commercialize product candidates, impact our cash position, increase our expense and present significant distractions to our management.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may consider strategic transactions, such as collaborations, acquisitions of companies, asset purchases and&#160;out-&#160;or&#160;in-licensing&#160;of product candidates or technologies. In particular, in addition to our current arrangements with Ipsen, which began in July 2021, AbbVie, which began in November 2019, and Dermelix, which began in February 2019, and Purdue, with which there no active therapeutic candidates in development and which has not indicated any further interest in development, we will evaluate and, if strategically attractive, seek to enter into additional collaborations, including with major biotechnology or pharmaceutical companies. For example, on July 30, 2021, we entered into a collaboration, option, and licensing agreement with Ipsen. The competition for collaborators is intense, and the negotiation process is time-consuming and complex. Any new collaboration may be on terms that are not optimal for us, and we may be unable to maintain any new or existing collaboration if, for example, development or approval of a therapeutic candidate is delayed, sales of an approved product do not meet expectations or the collaborator terminates the collaboration. Any such collaboration, or other strategic transaction, may require us to incur&#160;non-recurring&#160;or other charges, increase our near- and long-term expenditures and pose significant integration or implementation challenges or disrupt our management or business. These transactions entail numerous operational and financial risks, including exposure to unknown liabilities, disruption of our business and diversion of our management&#8217;s time and attention in order to manage a collaboration or develop acquired products, product candidates or technologies, incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs, higher than expected collaboration, acquisition or integration costs, write-downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty and cost in facilitating the collaboration or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership and the inability to retain key employees of any acquired business. Accordingly, although there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, any transactions that we do complete may be subject to the foregoing or other risks and have a material adverse effect on our business, results of operations, financial condition and prospects. Conversely, any failure to enter any collaboration or other strategic transaction that would be beneficial to us could delay the development and potential commercialization of our product candidates and have a negative impact on the competitiveness of any product candidate that reaches market.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If third parties on which we depend to conduct our preclinical studies and clinical trials do not perform as contractually required, fail to satisfy regulatory or legal requirements, or miss expected deadlines, our development program could be delayed with materially adverse effects on our business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third-party clinical investigators, CROs, clinical data management organizations and consultants to design, conduct, supervise and monitor preclinical studies and clinical trials for our therapeutic candidates. Because we rely on third parties and do not have the ability to conduct preclinical studies or clinical trials independently, we have less control over the timing, quality and other aspects of preclinical studies and clinical trials than we would if we conducted them on our own. These investigators, CROs and consultants are not our employees and we have limited control over the amount of time and resources that they dedicate to our programs. These third parties may have contractual relationships with other entities, some of which may be our competitors, which may draw time and resources away from our programs. The third parties with which we contract might not be diligent, careful or timely in conducting our preclinical studies or clinical trials, resulting in the preclinical studies or clinical trials being delayed or unsuccessful. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we cannot contract with acceptable third parties on commercially reasonable terms, or at all, or if these third parties do not carry out their contractual duties, satisfy legal and regulatory requirements for the conduct of preclinical studies or clinical trials or meet expected deadlines, our clinical development programs could be delayed and otherwise adversely affected. In all events, we are responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. The FDA requires preclinical studies to be conducted in accordance with applicable good laboratory practices, or GLPs, and clinical trials to be conducted in accordance with applicable FDA regulations and good clinical practices, or GCPs, including requirements for conducting, recording and reporting the results of preclinical studies and clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are protected. Our reliance on third parties that we do not control does not relieve us of these responsibilities and requirements. Any adverse development or delay in our preclinical studies or clinical trials could have a material adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the operations of our CROs may be constrained or disrupted by the COVID-19 pandemic. Clinical site closure and other activities that require visits to clinical sites, have been and may continue to be delayed due to prioritization of hospital resources toward the COVID-19 pandemic or concerns among patients about participating in clinical trials during a pandemic. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our preclinical studies or clinical trials in accordance with regulatory requirements or our stated protocols, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms or in a timely manner. Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays could occur, which could compromise our ability to meet our desired development timelines. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we rely on third-party manufacturing and supply partners, our supply of research and development, preclinical studies and clinical trial materials may become limited or interrupted or may not be of satisfactory quantity or quality. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third-party partners to manufacture and supply the materials and components for our research and development, preclinical study and clinical trial supplies. We do not own manufacturing facilities or supply sources for such components and materials. Our manufacturing requirements include oligonucleotides and lipids. We procure our nonclinical toxicology and clinical development materials from a limited number of suppliers on a purchase order basis. There can be no assurance that our supply of research and development, preclinical study and clinical trial therapeutic candidates and other materials will not be limited, interrupted, restricted in certain geographic regions or of satisfactory quality or continue to be available at acceptable prices. In particular, any replacement of our drug product manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing process for a therapeutic candidate is subject to oversight by the FDA and foreign regulatory authorities. Suppliers and manufacturers must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory requirements, such as current good manufacturing practices, or cGMPs. In the event that any of our suppliers or manufacturers fails to comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third-party, which we may not be able to do on reasonable terms, if at all. In some cases, the technical skills or technology required to manufacture our therapeutic candidates may be unique or proprietary to the original manufacturer and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills or technology to another third-party and a feasible alternative may not exist. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third-party manufacture our therapeutic candidates. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop therapeutic candidates in a timely manner or within budget. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to rely on third-party manufacturers if we receive regulatory approval for any therapeutic candidate. To the extent that we have existing, or enter into future, manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance. If we are unable to obtain or maintain third-party manufacturing for therapeutic candidates, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our therapeutic candidates successfully. Our or a third-party&#8217;s failure to execute on our manufacturing requirements and comply with cGMPs could adversely affect our business in a number of ways, including: </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an inability to initiate or continue preclinical studies or clinical trials of our therapeutic candidates under development; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay in submitting regulatory applications, or receiving regulatory approvals, for therapeutic candidates; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of the cooperation of a future collaborator; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">subjecting manufacturing facilities of our therapeutic candidates to additional inspections by regulatory authorities; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requirements to cease distribution or to recall batches of our therapeutic candidates; and </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in the event of approval to market and commercialize a therapeutic candidate, an inability to meet commercial demands for our therapeutics. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our relationships with our manufacturers, suppliers or other vendors are terminated or scaled back as a result of the COVID-19 pandemic or other health epidemics or pandemics, we may not be able to enter into arrangements with alternative suppliers or vendors or do so on commercially reasonable terms or in a timely manner. Further, if the COVID-19 pandemic continues to persist for an extended period of time and impacts essential distribution systems such as FedEx and postal delivery, we could experience disruptions to our supply chain and operations, and associated delays in the manufacturing and supply of our product candidates. Switching or adding additional suppliers or vendors involves substantial cost and requires management time and focus. In addition, there is a natural transition period when a new supplier or vendor commences work. As a result, delays may occur, which could adversely impact our ability to meet our desired clinical development and any future commercialization timelines. Although we carefully manage our relationships with our suppliers and vendors, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not harm our business.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face competition from entities that have developed or may develop therapeutic candidates for our target disease indications, including companies developing novel treatments and technology platforms based on modalities and technology similar to ours. If these companies develop technologies, including delivery technologies, or therapeutic candidates more rapidly than we do or their technologies are more effective, our ability to develop and successfully commercialize therapeutic candidates may be adversely affected. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and commercialization of therapeutic candidates is highly competitive. We compete with a number of multinational pharmaceutical companies and specialized biotechnology companies, as well as technology being developed at universities and other research institutions. Our competitors have developed, are developing or will develop </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">therapeutic candidates and processes competitive with our therapeutic candidates. Competitive therapeutic treatments include those that have already been approved and accepted by the medical community and any new treatments that enter the market. We believe that a significant number of therapeutics are currently under development, and may become commercially available in the future, for the treatment of conditions for which we may try to develop therapeutic candidates. There is intense and rapidly evolving competition in the biotechnology, pharmaceutical and oligonucleotide therapeutics fields. While we believe that our SNA technology, its associated intellectual property and our scientific and technical know-how give us a competitive advantage in this space, competition from many sources remains. Our competitors include larger and better-funded pharmaceutical, biotechnology and oligonucleotide therapeutics companies. Moreover, we also compete with current and future therapeutics developed at universities and other research institutions. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of several companies that are developing oligonucleotide delivery platforms and oligonucleotide-based therapeutics. These competitors include Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Dicerna Pharmaceuticals, Inc., Arbutus Biopharma Corp., Wave Life Sciences Ltd., Arrowhead Pharmaceuticals, Inc., ProQR Therapeutics N.V., Stoke Therapeutics, Inc., Neubase Therapeutics, Inc., Idera Pharmaceuticals, Inc., Avidity Biosciences, Checkmate Pharmaceuticals, Inc., Dyne Therapeutics, Inc., Atalanta Therapeutics, Inc., PepGen, Inc. and others. These and other competitors compete with us in recruiting scientific and managerial talent, and for funding from pharmaceutical companies. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will partially depend on our ability to develop and protect therapeutics that are safer and more effective than competing therapeutics. Our commercial opportunity and success will be reduced or eliminated if competing therapeutics are safer, more effective, or less expensive than the therapeutics we develop. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our therapeutic candidates are approved for the indications we are currently pursuing, they will compete with a range of therapeutic treatments that are either in development or currently marketed. A number of therapeutics for treating psoriasis and cancers are on the market or in clinical development. For the treatment of psoriasis, marketed therapies range from small molecules like topical steroids to biologics, such as AbbVie&#8217;s adalimumab. In addition, numerous compounds are in clinical development for psoriasis treatment. With respect to immunogenic cancers such as melanoma, the most common treatments are chemotherapeutic compounds, radiation therapy and now immunotherapeutic antibodies such as ipilimumab, atezolizumab, pembrolizumab and others. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors have significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. If we successfully obtain approval for any therapeutic candidate, we will face competition based on many different factors, including the safety and effectiveness of our therapeutics, the ease with which our therapeutics can be administered and the extent to which patients accept relatively new routes of administration, the timing and scope of regulatory approvals for these therapeutics, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing therapeutics could present superior treatment alternatives, including by being more effective, safer, less expensive or marketed and sold more effectively than any therapeutics we may develop. Competitive therapeutics may make any therapeutics we develop obsolete or noncompetitive before we recover the expense of developing and commercializing our therapeutic candidates. Such competitors could also recruit our employees, which could negatively impact our level of expertise and our ability to execute our business plan. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market may not be receptive to our therapeutic candidates based on a novel therapeutic modality, and we may not generate any future revenue from the sale or licensing of therapeutic candidates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if approval is obtained for a therapeutic candidate, we may not generate or sustain revenue from sales of the product due to factors such as whether the product can be sold at a competitive cost and otherwise accepted in the market. The therapeutic candidates that we are developing are based on our SNA technology. Market participants with significant influence over acceptance of new treatments, such as physicians and third-party payors, may not adopt a treatment based on SNA technology, and we may not be able to convince the medical community and third-party payors to accept and use, or to provide favorable reimbursement for any therapeutic candidates developed by us or any current or future collaborators. Market acceptance of our therapeutic candidates will depend on, among other factors: </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of our receipt of any marketing and commercialization approvals; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms of any approvals and the countries in which approvals are obtained; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the safety and efficacy of our therapeutic candidates; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any adverse side effects associated with our therapeutic candidates; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations or warnings contained in any labeling approved by the FDA or other regulatory authority; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">relative convenience and ease of administration of our therapeutic candidates; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of patients to accept any new methods of administration; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our physician education programs; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of adequate government and third-party payor reimbursement; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the pricing of our products, particularly as compared to alternative treatments; and </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">availability of alternative effective treatments for indications our therapeutic candidates are intended to treat and the relative risks, benefits and costs of those treatments. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With our focus on SNAs, these risks may increase to the extent the space becomes more competitive or less favored in the commercial marketplace. Additional risks apply in relation to any disease indications we may pursue which are classified as rare diseases and allow for orphan drug designation by regulatory agencies in major commercial markets, such as the U.S., Europe and Japan. Because of the small patient population for a rare disease, if pricing is not approved or accepted in the market at an appropriate level for an approved product with orphan drug designation, such therapeutic may not generate enough revenue to offset costs of development, manufacturing, marketing and commercialization despite any benefits received from the orphan drug designation, such as market exclusivity, assistance in clinical trial design or a reduction in user fees or tax credits related to development expense. Market size is also a variable in disease indications not classified as rare. Our estimates regarding potential market size for any indication may be materially different from what we discover to exist at the time we commence commercialization, if any, for a therapeutic, which could result in significant changes in our business plan and have a material adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a therapeutic candidate that has orphan drug designation subsequently receives the first FDA approval for the indication for which it has such designation, the therapeutic candidate is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same therapeutic candidate for the same indication, except in very limited circumstances, for seven years. Orphan drug exclusivity, however, could also block the approval of one of our therapeutic candidates for seven years if a competitor obtains approval of the same therapeutic candidate as defined by the FDA or if our therapeutic candidate is determined to be contained within the competitor&#8217;s therapeutic candidate for the same indication or disease. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As in the U.S., we may apply for designation of a therapeutic candidate as an orphan drug for the treatment of a specific indication in the European Union before the application for marketing authorization is made.  Sponsors of orphan drugs in the European Union can enjoy economic and marketing benefits, including up to ten years of market exclusivity for the approved indication.  During such period, marketing applications for similar medicinal products will not be accepted, unless certain exceptions apply.  In the EU, a &#8220;similar medicinal product&#8221; is a medicinal product containing a similar active substance or substances as contained in a currently authorized orphan medicinal product, and which is intended for the same therapeutic indication.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we, or any future collaborators, obtain orphan drug designation for a therapeutic candidate, such as we obtained in March 2021 for cavrotolimod for the treatment of patients with Merkel cell carcinoma, that designation may not effectively protect the therapeutic candidate from competition because different drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective, or makes a major contribution to patient care.  </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any inability to attract and retain qualified key management and technical personnel would impair our ability to implement our business plan. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success largely depends on the continued service of key management and other specialized personnel, including David A. Giljohann, Ph.D., our Chief Executive Officer, Brian C. Bock, our Chief Financial Officer, Matthias G. Schroff, Ph.D., our Chief Operating Officer, Douglas E. Feltner, M.D., our Chief Medical Officer, and Elias D. Papadimas, our Chief Accounting Officer. The loss of one or more members of our management team or other key employees or advisors could delay our research and development programs or clinical trials and materially harm our business, financial condition, results of operations and prospects. The relationships that our key managers have cultivated within our industry make us particularly dependent upon their continued employment with us. We are dependent on the continued service of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our technical personnel because of the highly technical nature of our therapeutic candidates and our technology and the specialized nature of the regulatory approval process. Because our management team and key employees are not obligated to provide us with continued service, they could terminate their employment with us at any time without penalty. We do not maintain key person life insurance policies on any of our management team members or key employees. Our future success will depend in large part on our continued ability to attract and retain highly qualified scientific, technical and management personnel, as well as personnel with expertise in clinical testing, manufacturing, governmental regulation and commercialization. We face competition for personnel from other companies, universities, public and private research institutions, government entities and other organizations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to continue to increase the size of our organization, and we may experience difficulties in managing growth.</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, we had 77 employees. As our development and commercialization plans and strategies develop, and as we further develop as a public company, we expect to need additional managerial, operational, financial and other personnel, including personnel to support our product development and planned future commercialization efforts. Future growth will impose significant added responsibilities on members of management, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identifying, recruiting, integrating, maintaining and motivating additional employees;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">managing our internal development efforts effectively, including the clinical, FDA and EMA review processes for our product candidates; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">improving our operational, financial and management controls, reporting systems and procedures.</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future financial performance and our ability to commercialize our product candidates will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are not able to effectively expand our organization by hiring new employees, we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development and commercialization goals.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If any of our therapeutic candidates are approved for marketing and commercialization and we are unable to develop sales, marketing and distribution capabilities on our own or enter into agreements with third parties to perform these functions on acceptable terms, we will be unable to successfully commercialize any such future therapeutics. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have no sales, marketing or distribution capabilities or experience. If any of our therapeutic candidates is approved, we will need to develop internal sales, marketing and distribution capabilities to appropriately commercialize such therapeutics, which would be expensive and time-consuming, or enter into collaborations with third parties to perform these services. If we decide to market our approved therapeutics directly, we will need to commit significant financial and managerial resources to develop a marketing and sales force with technical expertise and supporting distribution, administration and compliance capabilities. If we rely on third parties with such capabilities to market our approved therapeutics or decide to co-promote therapeutics with collaborators, we will need to establish and maintain compliant marketing and distribution arrangements with third parties, and there can be no assurance that we will be able to enter into such arrangements on acceptable terms or at all. In entering into third-party marketing or distribution arrangements, any revenue we receive will depend upon the efforts of the third parties and there can be no assurance that such third parties will establish adequate sales and distribution capabilities or be successful in gaining market acceptance of any approved therapeutic. If we are not successful in commercializing any therapeutic approved in the future, either on our own or through third parties, our business, financial condition, results of operations and prospects could be materially and adversely affected.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with U.S. or foreign regulatory requirements, regulatory authorities could withhold marketing or commercialization approvals, limit or withdraw any marketing or commercialization approvals we may receive and subject us to other penalties that could materially harm our business. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our therapeutic candidates, as well as our suppliers, contract manufacturers, distributors, and contract testing laboratories are subject to extensive regulation by governmental authorities in the European Union, the U.S., and other countries, with the regulations differing from country to country. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or current or future collaborators, manufacturers or service providers fail to comply with applicable requirements, these regulatory authorities could refuse to issue necessary approvals for marketing and commercialization. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we receive marketing and commercialization approval of a therapeutic candidate, we and our third-party service providers will be subject to continuing regulatory requirements, including a broad array of regulations related to establishment registration and product listing, manufacturing processes, risk management measures, quality and pharmacovigilance systems, pre- and post-approval clinical data, labeling, advertising and promotional activities for such therapeutic, record keeping, distribution, and import and export of therapeutics for any therapeutic for which we obtain marketing approval. We are required to submit safety and other post market information and reports and are subject to continuing regulatory review, including in relation to adverse patient experiences with the therapeutic and clinical results that are reported after a therapeutic is made commercially available, both in the U.S. and any foreign jurisdiction in which we seek regulatory approval. The FDA and certain foreign regulatory authorities, such as the EMA, have significant post-market authority, including the authority to require labeling changes based on new safety information and to require post-market studies or clinical trials to evaluate safety risks related to the use of a therapeutic or to require withdrawal of the therapeutic from the market. The FDA also has the authority to require a Risk Evaluation and Mitigation Strategies, or REMS, plan either before or after approval, which may impose further requirements or restrictions on the distribution or use of an approved therapeutic. The EMA now routinely requires risk management plans, or RMPs, as part of the marketing authorization application process, and such plans must be continually modified and updated throughout the lifetime of the product as new information becomes available. In addition, for nationally authorized medicinal products, the relevant governmental authority of any European Union member state can request an RMP whenever there is a concern about the risk/benefit balance of the product. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturer and manufacturing facilities we use to make a future therapeutic, if any, will also be subject to periodic review and inspection by the FDA and other regulatory agencies, including for continued compliance with cGMP requirements. The discovery of any new or previously unknown problems with our third-party manufacturers, manufacturing processes or facilities may result in restrictions on the therapeutic, manufacturer or facility, including withdrawal of the therapeutic from the market. If we rely on third-party manufacturers, we will not have control over compliance with applicable rules and regulations by such manufacturers. Any product promotion and advertising will also be subject to regulatory requirements and continuing regulatory review. Although a physician may prescribe products for off-label use since the FDA and other regulatory agencies do not regulate a physician&#8217;s choice of drug treatment made in the physician&#8217;s independent medical judgment, they do restrict promotional communications from companies or their sales force with respect to off-label uses of products for which marketing clearance has not been issued. Companies may only share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA approved labeling. If we or our future collaborators, manufacturers or service providers fail to comply with applicable continuing regulatory requirements in the U.S. or foreign jurisdictions in which we seek to market our therapeutics, we or they may be subject to, among other things, fines, warning and untitled letters, clinical holds, delay or refusal by the FDA or foreign regulatory authorities to approve pending applications or supplements to approved applications, suspension, refusal to renew or withdrawal of regulatory approval, recalls, seizures or administrative detention of products, refusal to permit the import or export of therapeutics, operating restrictions, inability to participate in government programs including Medicare and Medicaid, and total or partial suspension of production or distribution, injunction, restitution, disgorgement, debarment, civil and criminal penalties and criminal prosecution. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Price controls imposed in foreign markets may adversely affect our future profitability. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some countries, particularly member states of the European Union, the pricing of prescription drugs is subject to governmental control at the national level, and in some cases also at the regional level. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a therapeutic. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing and reimbursement negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. In some countries, we or current or future collaborators may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our SNA therapeutic candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of any therapeutic candidate approved for marketing is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business, financial condition, results of operations or prospects could be adversely affected. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business entails a significant risk of product liability and our inability to obtain sufficient insurance coverage could have a material adverse effect on our business, financial condition, results of operations or prospects. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business exposes us to significant product liability risks inherent in the development, testing, manufacturing and marketing of therapeutic treatments. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing therapeutics, such claims could result in an investigation by certain regulatory authorities, such as the FDA or foreign regulatory authorities, of the safety and effectiveness of our therapeutics, our manufacturing processes and facilities or our marketing programs and potentially a recall of our therapeutics or more serious enforcement action, limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our therapeutics, injury to our reputation, costs to defend the related litigation, a diversion of management&#8217;s time and our resources, substantial monetary awards to trial participants or patients and a decline in our stock price. We currently have product liability insurance that we believe is appropriate for our stage of development and may need to obtain higher levels of product liability insurance prior to marketing any of our therapeutic candidates. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could have a material adverse effect on our business. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements which could have an adverse effect on our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include, but is not limited to, intentional failures to comply with FDA, the Centers for Medicare &amp; Medicaid Services, or CMS, the Department of Health and Human Services, or HHS, Office of Inspector General, or OIG, or other agency regulations, applicable laws, regulations, guidance or codes of conduct set by foreign governmental authorities or self-regulatory industry organizations, or provide accurate information to any governmental authorities, such as the FDA, comply with manufacturing standards we may establish, comply with federal and state healthcare fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities to us. For example, on November 9, 2021, the Audit Committee of our Board of Directors was notified of a claim made by a former Company senior researcher regarding alleged improprieties that researcher claims to have committed with respect to our XCUR-FXN preclinical program for the treatment of Friedreich&#8217;s ataxia. The Audit Committee has retained external counsel to conduct an internal investigation of the claim. We are currently unable to predict the timing or outcome of the investigation. We are unable to determine the potential impact of the asserted claim on our research and development activities or the timing of completion of our current research and development of our XCUR-FXN preclinical program for the treatment of FA, as the investigation of the asserted claim remains ongoing.  In connection with the ongoing investigation, securities class actions and other lawsuits may be filed against us, certain current and former directors, and certain current and former officers.  Any future investigations or lawsuits may also adversely affect our business, financial condition, results of operations and cash flows.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws, regulations, guidance and codes of conduct intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws, regulations, guidance and codes of conduct may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions, including, fines, debarment, or disqualification of those employees from participation in certain government-regulated activities, and serious harm to our reputation. This could include violations of the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, other U.S. federal and state law, and requirements of non-U.S. jurisdictions, including the European Union Data Protection Directive.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, regulations, guidance or codes of conduct. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including exclusion from participation in the U.S. federal healthcare programs, the imposition of significant fines or other sanctions.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compliance with governmental regulations regarding the treatment of animals used in research could increase our operating costs, which would adversely affect the commercialization of our technology. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Animal Welfare Act, or AWA, is the federal law that covers the treatment of certain animals used in research. Currently, the AWA imposes a wide variety of specific regulations that govern the humane handling, care, treatment and transportation of certain animals by producers and users of research animals, most notably relating to personnel, facilities, sanitation, cage size, and feeding, watering and shipping conditions. Third parties with whom we contract are subject to registration, inspections and reporting requirements under the AWA. Furthermore, some states have their own regulations, including general anti-cruelty legislation, which establish certain standards in handling animals. Comparable rules, regulations, and or obligations exist in many foreign jurisdictions. If we or our contractors fail to comply with regulations concerning the treatment of animals used in research, we may be subject to fines and penalties and adverse publicity, and our operations could be adversely affected. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our internal computer systems, or those of our CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our therapeutic development programs. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the implementation of security measures, our internal computer systems and those of our CROs and other contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Such events could cause interruptions of our operations. For instance, the loss of preclinical study or clinical trial data involving our therapeutic candidates could result in delays in our development and regulatory filing efforts and significantly increase our costs. In addition, theft or other exposure of data may interfere with our ability to protect our intellectual property, trade secrets, and other information critical to our operations. We can provide no assurances that certain sensitive and proprietary information relating to one or more of our therapeutic candidates has not been, or will not in the future be, compromised. Although we have invested resources to enhance the security of our computer systems, there can be no assurances we will not experience additional unauthorized intrusions into our computer systems, or those of our CROs and other contractors and consultants, that we will successfully detect future unauthorized intrusions in a timely manner, or that future unauthorized intrusions will not result in material adverse effects on our financial condition, reputation, or business prospects. Payments related to the elimination of ransomware may materially affect our financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain data breaches must also be reported to affected individuals and the government, and in some cases to the media, under provisions of HIPAA, as amended by HITECH, other U.S. federal and state law, and requirements of non-U.S. jurisdictions, including the European Union Data Protection Directive.  Financial penalties may also apply in some data breaches where noncompliance with the applicable law is identified.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that any disruption or security breach were to result in a loss of, or damage to, our data, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the development of our therapeutic candidates could be delayed. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research, development and manufacturing involve the use of hazardous materials and various chemicals. We maintain quantities of various flammable and toxic chemicals in our facilities in Chicago, Illinois that are required for our research, development and manufacturing activities. We are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. We believe our procedures for storing, handling and disposing these materials in our Chicago facilities comply with the relevant guidelines of Chicago, the state of Illinois, and the Occupational Safety and Health Administration of the U.S. Department of Labor. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards mandated by applicable regulations, the risk of accidental contamination or injury from these materials cannot be eliminated. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of animals and biohazardous materials. Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of these materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological or hazardous materials. Additional federal, state and local laws and regulations affecting our operations may be adopted in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or regulations. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our information technology systems could face serious disruptions that could adversely affect our business. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our information technology and other internal infrastructure systems, including corporate firewalls, servers, leased lines and connection to the Internet, face the risk of systemic failure that could disrupt our operations. A significant disruption in the availability of our information technology and other internal infrastructure systems could cause interruptions and delays in our research and development work. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Increasing scrutiny and changing expectations from customers, regulators, investors, and other stakeholders with respect to our environmental, social and governance practices may impose additional costs on us or expose us to new or additional risks.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companies are facing increasing scrutiny from customers, regulators, investors, and other stakeholders related to their environmental, social and governance practices. Investor advocacy groups, investment funds and influential investors are also increasingly focused on these practices, especially as they relate to the environment, health and safety, supply chain management, diversity and human rights. Failure to adapt to or comply with regulatory requirements or investor or stakeholder expectations and standards could negatively impact our reputation and the price of our ordinary shares.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the factors mentioned above, or the perception that we or our suppliers, or contract manufacturers or collaborators have not responded appropriately to the growing concern for such issues, regardless of whether we are legally required to do so, may damage our reputation and have a material adverse effect on our business, financial condition, results of operations cash flows and/or ordinary share price.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Natural disasters or other unexpected events may disrupt our operations, adversely affect our results of operations and financial condition, and may not be covered by insurance.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of one or more unexpected events, including fires, tornadoes, tsunamis, hurricanes, earthquakes, floods, and other forms of severe hazards in the United States or in other countries in which we or our suppliers or manufacturers operate or are located could adversely affect our operations and financial performance.  These types of unexpected events could result in physical damage to and complete or partial closure of one or more of the manufacturing facilities operated by our contract manufacturers, or the temporary or long-term disruption in the supply of products, and/or disruption of our ability to deliver products to customers. Further, the long-term effects of climate change on general economic conditions and the pharmaceutical manufacturing and distribution industry in particular are unclear, and changes in the supply, demand or available sources of energy and the regulatory and other costs associated with energy production and delivery may affect the availability or cost of goods and services, including natural resources, necessary to run our businesses. Existing insurance arrangements may not provide protection for the costs that may arise from such events, particularly if such events are catastrophic in nature or occur in combination. Any long-term disruption in our ability to service our customers from one or more distribution centers or outsourcing facilities could have a material adverse effect on our operations, our business, results of operations and stock price.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our current operations are concentrated in one location and any events affecting this location may have material adverse consequences. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current operations are located in our facilities situated in Chicago, Illinois. Any unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, medical epidemics, power shortage, telecommunication failure or other natural or man-made accidents or incidents that result in us being unable to fully utilize the facilities, may have a material adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of our therapeutic candidates or interruption of our business operations. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot assure you that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed. Any business interruption may have a material adverse effect on our business, financial position, results of operations and prospects. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The investment of our cash, cash equivalents and fixed income marketable securities is subject to risks which may cause losses and affect the liquidity of these investments. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, we had $53.1 million in cash, cash equivalents, and restricted cash and $9.0 million in short-term investments.  We historically have invested excess cash in certificates of deposit or money market mutual </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">funds that invest in securities issued or guaranteed by the U.S.&#160;government or U.S.&#160;government agencies, floating rate and variable rate demand notes of U.S.&#160;and foreign corporations, and commercial paper.  During the fourth quarter of 2019, we have made direct purchases, and expect to continue to make direct purchases of, U.S.&#160;government or U.S.&#160;government agency securities, floating rate and variable rate demand notes of U.S.&#160;and foreign corporations, and commercial paper.  These investments are subject to general credit, liquidity, market and interest rate risks, including potential future impacts similar to the impact of U.S.&#160;sub-prime mortgage defaults that have affected various sectors of the financial markets and caused credit and liquidity issues.  We may realize losses in the fair value of these investments, an inability to access cash in these investments for a potentially meaningful period, or a complete loss of these investments, which would have a negative effect on our financial statements. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, should our investments cease paying or reduce the amount of interest paid to us, our interest income would suffer. The market risks associated with our investment portfolio may have an adverse effect on our results of operations, liquidity and financial condition. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant losses since our inception and expect to incur continued losses in the future. We must obtain additional funds to finance our operations and to remain a going concern.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our recurring losses from operations raise substantial doubt about our ability to continue as a going concern. As a result, we included an explanatory paragraph in our consolidated financial statements for the period ended September 30, 2021 with respect to this uncertainty. Our ability to continue as a going concern will require us to obtain additional funding. Based on our current operating plans and existing working capital at September 30, 2021, it is uncertain whether our current liquidity is sufficient to fund operations over the next twelve months from the date of the issuance of the accompanying condensed consolidated financial statements. As a result, there is substantial doubt about our ability to continue as a going concern. We have no committed sources of additional capital at this time and substantial additional financing will be needed by us to fund our operations. We have based these estimates, however, on assumptions that may prove to be wrong, and we could spend our available financial resources much faster than we currently expect and need to raise additional funds sooner than we anticipate. The perception of our ability to continue as a going concern may make it more difficult for us to obtain financing for the continuation of our operations and could result in the loss of confidence by investors, suppliers and employees. If we are unable to raise capital when needed or on acceptable terms, we would be forced to delay, reduce or eliminate our research and development programs and commercialization efforts.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, the Sarbanes-Oxley Act of 2002, or Sarbanes-Oxley Act, and the rules&#160;and regulations of The Nasdaq Capital Market. Pursuant to Section&#160;404 of the Sarbanes-Oxley Act, or Section&#160;404, we are now required to perform system and process evaluation and testing of our internal control over financial reporting to allow our management to report on the effectiveness of our internal control over financial reporting. However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the evaluation and testing process, if we identify one or more material weaknesses in our internal control over financial reporting, we will be unable to assert that our internal control over financial reporting is effective. Further, we may in the future discover weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our financial statements. Moreover, our internal controls over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected. Moreover, we are aware that the remote working arrangements implemented in connection with the COVID-19 pandemic potentially present new areas of risk, and we continue to monitor carefully any impact to our internal controls and procedures.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to assert that our internal control over financial reporting is effective, investors could lose confidence in the reliability of our financial statements, the market price of our stock could decline and we could be subject to sanctions or investigations by The Nasdaq Capital Market, the SEC or other regulatory authorities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are not able to obtain and enforce patent protection for our technology or therapeutic candidates, development and commercialization of our therapeutic candidates may be adversely affected. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in part on our ability to obtain and maintain patents and other forms of intellectual property rights, including in-licenses of intellectual property rights of others, for our therapeutic candidates, methods used to manufacture our therapeutic candidates and methods for treating patients using our therapeutic candidates, as well as our ability to preserve our trade secrets, to prevent third parties from infringing upon our proprietary rights and to operate without infringing upon the proprietary rights of others. As of September 30, 2021, our patent portfolio consists of over 90 issued patents and allowed patent applications and 110 pending patent applications.  We may not be able to apply for patents on certain aspects of our therapeutic candidates in a timely fashion or at all. Our existing issued and granted patents and any future patents we obtain may not be sufficiently broad to prevent others from using our technology or from developing competing therapeutics and technology. There is no guarantee that any of our pending patent applications will result in issued or granted patents, that any of our issued or granted patents will not later be found to be invalid or unenforceable or that any issued or granted patents will include claims that are sufficiently broad to cover our therapeutic candidates or to provide meaningful protection from our competitors. Moreover, the patent position of pharmaceutical and biotechnology companies can be highly uncertain because it involves complex legal and factual questions. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our current and future proprietary technology and therapeutic candidates are covered by valid and enforceable patents or are effectively maintained as trade secrets. If third parties disclose or misappropriate our proprietary rights, it may materially and adversely impact our position in the market. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Patent and Trademark Office, or USPTO, and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case. The standards applied by the USPTO and foreign patent offices in granting patents are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in biotechnology and pharmaceutical patents. As such, we do not know the degree of future protection that we will have on our proprietary therapeutics and technology. While we will endeavor to try to protect our therapeutic candidates with intellectual property rights such as patents, as appropriate, the process of obtaining patents is time-consuming, expensive and sometimes unpredictable. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are numerous recent changes to the patent laws and proposed changes to the rules of the USPTO, which may have a significant impact on our ability to protect our technology and enforce our intellectual property rights. For example, the Leahy-Smith America Invents Act enacted in 2011 involves significant changes in patent legislation. The U.S. Supreme Court has ruled on several patent cases in recent years, some of which cases either narrow the scope of patent protection available in certain circumstances or weaken the rights of patent owners in certain situations. The 2013 decision by the Supreme Court in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Association for Molecular Pathology v. Myriad Genetics, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> precludes a claim to a nucleic acid having a stated nucleotide sequence that is identical to a sequence found in nature and unmodified. We currently are not aware of an immediate impact of this decision on our patents or patent applications because we are developing oligonucleotide therapeutics which contain modifications that we believe are not found in nature. However, this decision has yet to be clearly interpreted by courts and by the USPTO. We cannot assure you that the interpretations of this decision or subsequent rulings will not adversely impact our patents or patent applications. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that may weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once granted, patents may remain open to opposition, interference, re-examination, post-grant review, inter partes review, nullification or derivation action in court or before patent offices or similar proceedings for a given period after allowance or grant, during which time third parties can raise objections against such initial grant. In the course of such proceedings, which may continue for a protracted period of time, the patent owner may be compelled to limit the scope of the allowed or granted claims thus attacked, or may lose the allowed or granted claims altogether. In addition, there can be no assurance that: </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Others will not or may not be able to make, use or sell compounds that are the same as or similar to our therapeutic candidates but that are not covered by the claims of the patents that we own or license. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We or our licensors, or any current or future collaborators, are the first to make the inventions covered by each of our issued patents and pending patent applications that we own or license. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We or our licensors, or any current or future collaborators, are the first to file patent applications covering certain aspects of our inventions. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Others will not independently develop similar or alternative technologies or duplicate any of our technology without infringing our intellectual property rights. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A third-party will not challenge our patents and, if challenged, a court may not hold that our patents are valid, enforceable and infringed. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any issued patents that we own or have licensed will provide us with any competitive advantages, or will not be challenged by third parties. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will develop additional proprietary technologies that are patentable. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The patents of others will not have an adverse effect on our business. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our competitors will not conduct research and development activities in countries where we lack enforceable patent rights and then use the information learned from such activities to develop competitive therapeutics for sale in our major commercial markets. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent term may be inadequate to protect our competitive position on our future therapeutics for an adequate amount of time. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the amount of time required for the development, testing and regulatory review of new therapeutic candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. We expect to seek extensions of patent terms in the U.S. and, if available, in other countries where we have patents covering our product candidates. In the U.S., the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, the patent term extension or restoration cannot extend the remaining term of a patent beyond a total of 14 years from the approval date of the product candidate.&#160;Only one patent applicable to an approved product candidate is eligible for the extension and the application for extension must be made prior to expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we intend to apply for restorations of patent term for some of our currently owned or licensed patents to add patent life beyond their current expiration dates. However, the applicable authorities, including the FDA and the USPTO in the U.S., and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently license patent rights from Northwestern University and may in the future license patent rights from other third-party owners or licensees. If Northwestern University or such other owners or licensees do not properly or successfully obtain, maintain or enforce the patents underlying such licenses, or if they retain or license to others any competing rights, our competitive position and business prospects may be adversely affected. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do, and will continue to, rely on intellectual property rights licensed from third parties to protect our technology. We are a party to a number of licenses that give us rights to third-party intellectual property that is necessary or useful for our business. In particular, we have a license from Northwestern University, which provides us the exclusive worldwide right under certain patents and patent applications owned by Northwestern University to exploit therapeutics and processes using nanoparticles, nanotechnology, microtechnology and nanomaterial-based constructs as therapeutics or accompanying therapeutics as a means of administration. We may also license additional third-party intellectual property in the future. Our success will depend in part on the ability of our licensors to obtain, maintain and enforce patent protection for our licensed intellectual property, and in particular, for those patents to which we have secured exclusive rights. Our licensors may not successfully prosecute the patent applications licensed to us. Even if patents issue or are granted, our licensors may fail to maintain these patents, may determine not to pursue litigation against other companies that are infringing these patents, or may pursue litigation less aggressively than we would. Further, we may not obtain exclusive rights, which would allow for third parties to develop competing therapeutics. Without protection for, or exclusive rights to, the intellectual property we license, other companies might be able to offer substantially identical </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">therapeutics for sale, which could adversely affect our competitive business position and harm our business prospects. In addition, the U.S. government has certain rights to the inventions covered by the patent rights licensed to us by third parties and Northwestern University, as an academic research and medical center, has reserved the right to practice the patent rights it has licensed to us (i)&#160;for research, teaching and/or other educationally related purposes (including the right to distribute materials for such purposes) and (ii)&#160;for use in the field of diagnostics (including theradiagnostics) and in any field other than the field of use licensed to us. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently have Collaboration, Option and License Agreements with Ipsen and Allergan Pharmaceuticals International Limited, or Allergan, and may in the future have additional Collaboration, Option and License Agreements with other third-parties. If Ipsen or Allergan, or such other licensees do not properly or successfully collaborate to research and develop SNAs, our competitive position and business prospects may be adversely affected. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do, and will continue to, rely on collaboration with third parties to develop our technology. We are a party to a number of licenses that provide rights to a third-party that is necessary or useful for our business. In particular, we have a Collaboration, Option and License Agreement with Ipsen, to collaborate together to research and develop SNAs. We also have a Collaboration, Option and License Agreement with Allergan, to collaborate together to research, develop, and manufacture new nucleic acid therapeutics focusing on certain hair loss disorders. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also collaborate with additional third-parties in the future. Our success will depend in part on the ability of our licensees to research and develop SNAs based on our existing intellectual property. Without successful collaboration to research and develop SNAs, other companies might be able to offer substantially identical therapeutics for sale, which could adversely affect our competitive business position and harm our business prospects.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other companies or organizations may challenge our or our licensors&#8217; patent rights or may assert patent rights that prevent us from developing and commercializing our therapeutic candidates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oligonucleotide and SNA-based therapeutics are a relatively new scientific field. We have obtained grants and issuances of SNA therapeutic patents and have licensed many of these patents from a third-party on an exclusive basis for therapeutics applications. The issued patents and pending patent applications in the U.S. and in key markets around the world that we own or license claim many different methods, compositions and processes relating to the discovery, development, manufacture and commercialization of SNA therapeutics. Specifically, we own and have licensed a portfolio of patents, patent applications and other intellectual property covering SNA compositions of matter as well as their methods of use. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the field of SNA therapeutics matures, patent applications are being processed by national patent offices around the world. There is uncertainty about which patents will issue, and, if they do, as to when, to whom, and with what claims. In addition, third parties may attempt to invalidate our intellectual property rights. Even if our rights are not directly challenged, disputes could lead to the weakening of our intellectual property rights. Our defense against any attempt by third parties to circumvent or invalidate our intellectual property rights could be costly to us, could require significant time and attention of our management and could have a material adverse effect on our business and our ability to successfully compete. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are many issued and pending patents that claim aspects of oligonucleotide chemistry and modifications that we may need to apply to our SNA therapeutic candidates. There are also many issued patents that claim targeting genes or portions of genes that may be relevant for SNA therapeutics we wish to develop. Thus, it is possible that one or more organizations will hold patent rights to which we will need a license. If those organizations refuse to grant us a license to such patent rights on reasonable terms, we may not be able to market therapeutics or perform research and development or other activities covered by these patents. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to protect our intellectual property rights throughout the world. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining a valid and enforceable issued or granted patent covering our technology in the U.S. and worldwide can be extremely costly. In jurisdictions where we have not obtained patent protection, competitors may use our technology to develop their own therapeutics and, further, may export otherwise infringing therapeutics to territories where we have patent protection, but where it is more difficult to enforce a patent as compared to the U.S. Competitor therapeutics may compete with our future therapeutics in jurisdictions where we do not have issued or granted patents or where our issued or granted patent claims or other intellectual property rights are not sufficient to prevent competitor activities in these jurisdictions. The legal systems of certain countries, particularly certain developing countries, make it difficult to enforce patents and such countries may not recognize other types of intellectual property protection, particularly that relating to biotechnology and pharmaceuticals. This could make it difficult for us to prevent the infringement of our patents or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">marketing of competing therapeutics in violation of our proprietary rights generally in certain jurisdictions. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally file a provisional patent application first, also known as a priority filing, at the USPTO. An international application under the Patent Cooperation Treaty, or PCT, is usually filed within twelve months after the priority filing. Based on the PCT filing, national and regional patent applications may be filed in the U.S., European Union, Japan, Australia and Canada and, depending on the individual case, also in any or all of, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter alia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, China, India, South Korea, and Mexico. We have so far not filed for patent protection in all national and regional jurisdictions where such protection may be available. In addition, we may decide to abandon national and regional patent applications before grant or after grant by nonpayment of maintenance fees for the resulting patent. Finally, the grant proceeding of each national or regional patent is an independent proceeding which may lead to situations in which applications might in some jurisdictions be refused by the relevant registration authorities, while granted by others. It is also quite common that depending on the country, various scopes of patent protection may be granted on the same therapeutic candidate or technology. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws in the U.S., and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. If we or our licensors encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished and we may face additional competition from others in those jurisdictions. Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position in the relevant jurisdiction may be impaired and our business and results of operations may be adversely affected. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We or our licensors, or any current or future strategic partners, may become subject to third-party claims or litigation alleging infringement of patents or other proprietary rights or seeking to invalidate patents or other proprietary rights, and we may need to resort to litigation to protect or enforce our patents or other proprietary rights, all of which could be costly, time consuming, delay or prevent the development and commercialization of our therapeutic candidates, or put our patents and other proprietary rights at risk. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our licensors, or any current or future strategic partners, may be subject to third-party claims for infringement or misappropriation of patent or other proprietary rights. We are generally obligated under our license agreements to indemnify and hold harmless our licensors for damages arising from intellectual property infringement by us. If we or our licensors, or any current or future strategic partners, are found to infringe a third-party patent or other intellectual property rights, we could be required to pay damages, potentially including treble damages, if we are found to have willfully infringed. In addition, we or our licensors, or any current or future strategic partners, may choose to seek, or be required to seek, a license from a third-party, which may not be available on acceptable terms, if at all. Even if a license can be obtained on acceptable terms, the rights may be non-exclusive, which could give our competitors access to the same technology or intellectual property rights licensed to us. If we fail to obtain a required license, we or any current or future collaborator may be unable to effectively market therapeutic candidates based on our technology, which could limit our ability to generate revenue or achieve profitability and possibly prevent us from generating revenue sufficient to sustain our operations. In addition, we may find it necessary to pursue claims or initiate lawsuits to protect or enforce our patent or other intellectual property rights. The cost to us in defending or initiating any litigation or other proceeding relating to patent or other proprietary rights, even if resolved in our favor, could be substantial, and litigation would divert our management&#8217;s attention. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay our research and development efforts and limit our ability to continue our operations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we were to initiate legal proceedings against a third-party to enforce a patent covering one of our therapeutics or our technology, the defendant could counterclaim that our patent is invalid or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on one or more of our therapeutics or certain aspects of our technology. Such a loss of patent protection could have a material adverse impact on our business. Patents and other intellectual property rights also will not protect our technology if competitors design around our protected technology without legally infringing our patents or other intellectual property rights. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is also possible that we have failed to identify relevant third-party patents or applications. For example, U.S. applications filed before November&#160;29, 2000 and certain U.S. applications filed after that date that will not be filed outside the U.S. remain confidential until patents issue. Patent applications in the U.S. and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our therapeutics or technology could have been filed by others without our knowledge. Additionally, pending patent applications which have been published can, subject to certain limitations, be later amended in a manner that could cover our SNA technology, our therapeutics or the use of our therapeutics. Third-party intellectual property right holders may also actively bring infringement claims against us. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we are unable to successfully settle future claims on terms acceptable to us, we may be required to engage in or continue costly, unpredictable and time-consuming litigation and may be prevented from or experience substantial delays in marketing our therapeutics. If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing any of our therapeutic candidates that are held to be infringing. We might, if possible, also be forced to redesign therapeutic candidates so that we no longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also be subject to claims that former employees or other third parties have an ownership interest in our patents or other intellectual property. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and distraction to management and other employees.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations under any license, collaboration or other agreements, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our therapeutic candidates or we could lose certain rights to grant sublicenses. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current licenses impose, and any future licenses we enter into are likely to impose, various development, commercialization, funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement, and other obligations on us. If we breach any of these obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and the licensor may have the right to terminate the license, which could result in us being unable to develop, manufacture and sell therapeutics that are covered by the licensed technology or could enable a competitor to gain access to the licensed technology. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#8217;s rights in such unlicensed intellectual property. In addition, while we cannot currently determine the amount of the royalty obligations we would be required to pay on sales of future therapeutics, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in therapeutics that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize therapeutics, we may be unable to achieve or maintain profitability. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patent protection for certain aspects of our therapeutic candidates, we also consider trade secrets, including confidential and unpatented know-how important to the maintenance of our competitive position. We protect trade secrets and confidential and unpatented know-how, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to such knowledge, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants that </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obligate them to maintain confidentiality and assign their inventions to us. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts in the U.S. and certain foreign jurisdictions are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Northwestern University License Agreements, Northwestern University could publish research findings relating to the patent rights licensed to us by Northwestern University, which could have a material adverse effect on our business. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject both in the U.S. and outside the U.S. to various regulatory schemes regarding requests for the information we provide to regulatory authorities, which may include, in whole or in part, trade secrets or confidential commercial information. While we are likely to be notified in advance of any disclosure of such information and would likely object to such disclosure, there can be no assurance that our challenge to the request would be successful. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that we or our employees or consultants have wrongfully used or disclosed alleged trade secrets of our employees&#8217; or consultants&#8217; former employers or their clients. These claims may be costly to defend and if we do not successfully do so, we may be required to pay monetary damages and may lose valuable intellectual property rights or personnel. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our employees were previously employed at universities or pharmaceutical or biotechnology companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. A loss of key research personnel or their work product could hamper our ability to commercialize, or prevent us from commercializing, our therapeutic candidates, which could severely harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties may independently develop similar or superior technology. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that others will not independently develop, or have not already developed, similar or more advanced technologies than our technology; or that others will not design around, or have not already designed around, aspects of our technology and/or our trade secrets developed therefrom. If third parties develop technology similar or superior to our technology, or they successfully design around our current or future technology, our competitive position, business prospects, and results of operations could be materially and adversely affected. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The intellectual property which we have licensed from Northwestern University was discovered through government funded programs and thus may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements, and a preference for U.S. industry. Compliance with such regulations may limit our exclusive rights, subject us to expenditure of resources with respect to reporting requirements, and limit our ability to contract with non-U.S. manufacturers. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have licensed certain intellectual property from Northwestern University pursuant to the Northwestern University License Agreements. The Northwestern University License Agreements indicate that the rights licensed to us by Northwestern University are subject to the obligations to and the rights of the U.S. government, including those set&#160;forth in the Bayh-Dole Act of 1980, or Bayh-Dole Act. As a result, the U.S. government may have certain rights to intellectual property embodied in our current or future therapeutics based on the licensed Northwestern University intellectual </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">property. These U.S. government rights&#160;in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide&#160;license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us to grant exclusive, partially exclusive, or nonexclusive licenses to any of these inventions to a third-party if it determines that: (i)&#160;adequate steps have not been taken to commercialize the invention; (ii)&#160;government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations, also referred to as&#160;&#8220;march-in rights.&#8221; While the U.S. government has sparingly used, and to our knowledge never successfully exercised, such march-in rights, any exercise of the march-in rights by the U.S. government could harm our competitive position, business, financial condition, results of operations, and prospects. If the U.S. government exercises such march-in rights, we may receive compensation that is deemed reasonable by the U.S. government in its sole discretion, which may be less than what we might be able to obtain in the open market. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the U.S. government requires that any therapeutics embodying any invention generated through the use of U.S. government funding be manufactured substantially in the U.S. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. manufacturers may limit our ability to contract with non-U.S. therapeutic manufacturers for therapeutics covered by such intellectual property. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Government Regulation </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to obtain U.S. or foreign regulatory approval and, as a result, unable to commercialize our therapeutic candidates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our therapeutic candidates are subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, safety, efficacy, approval, recordkeeping, reporting, labeling, storage, packaging, advertising and promotion, pricing, marketing, sampling, and distribution of therapeutics. Rigorous preclinical testing and clinical trials and an extensive regulatory approval process are required to be successfully completed in the U.S. and in many foreign jurisdictions before a new therapeutic can be marketed. Satisfaction of these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. It is possible that none of the therapeutic candidates we may develop will obtain the regulatory approvals necessary for us or any current or future collaborators to begin selling them. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have very limited experience in conducting and managing the clinical trials necessary to obtain regulatory approvals, including approval by the FDA as well as foreign regulatory authorities, such as the EMA and European Union national competent authorities. The time required to obtain FDA and foreign regulatory approvals is unpredictable but typically takes many years following the commencement of clinical trials, depending upon the type, complexity and novelty of the therapeutic candidate. The standards that the FDA and its foreign counterparts use when regulating us are not always applied predictably or uniformly and can change. Any analysis we perform of data from preclinical and clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval. We may also encounter unexpected delays or increased costs due to new government regulations, for example, from future legislation or administrative action, or from changes in the policy of the FDA or foreign regulatory authorities during the period of therapeutic development, clinical trials and regulatory review by the FDA or foreign regulatory authorities. It is impossible to predict whether legislative changes will be enacted, or whether FDA or foreign laws, regulations, guidance or interpretations will be changed, or what the impact of such changes, if any, may be. In addition, unfavorable changes in our industry or the global economy, including as a result of the COVID-19 pandemic, could contribute to some of the events listed above and further impact our ability to progress our clinical trials, submit for marketing approval or commercialize our product candidates, if approved, as planned.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because the therapeutics we are developing may represent a new class of therapeutic, the FDA and its foreign counterparts have not yet established any definitive policies, practices or guidelines in relation to these therapeutics. While we believe the therapeutic candidates that we are currently developing are regulated as new drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, the FDA could decide to regulate them or other therapeutics we may develop as biologics under the Public Health Service Act. The lack of policies, practices or guidelines may hinder or slow review by the FDA or foreign regulatory authorities of any regulatory filings that we may submit. Moreover, the FDA may respond to these submissions by defining requirements we may not have anticipated. Such responses could lead to significant delays in the clinical development of our therapeutic candidates. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delay or failure in obtaining required approvals could have a material adverse effect on our ability to generate revenues from the particular therapeutic candidate for which we are seeking approval. Furthermore, any regulatory approval to market a therapeutic may be subject to limitations on the approved uses for which we may market the therapeutic or the labeling or other restrictions. Regulatory authorities also may impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the therapeutic. In addition, the FDA has the authority to require a REMS plan as part of a NDA or a Biologics License Application, or BLA, or after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug or biologic, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria and requiring treated patients to enroll in a registry. These limitations and restrictions may limit the size of the market for the therapeutic and affect coverage and reimbursement by third-party payors. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process varies among countries and may include all of the risks associated with FDA approval described above as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Moreover, the time required to obtain approval may differ from that required to obtain FDA approval. Approval by the FDA does not ensure approval by regulatory authorities outside the U.S. and vice versa. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain of our therapeutic candidates may require companion diagnostics in certain indications.  Failure to successfully develop, validate and obtain regulatory clearance or approval for such tests could harm our product development strategy or prevent us from realizing the full commercial potential of our therapeutic candidates.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our therapeutic candidates may require companion diagnostics to identify appropriate patients for those therapeutic candidates in certain indications.  Companion diagnostics are subject to regulation by the FDA and comparable foreign regulatory authorities as a medical device and may require separate regulatory authorization prior to commercialization.  We may rely on third parties for the design, development, testing and manufacturing of these companion diagnostics, the application for and receipt of any required regulatory authorization, and the commercial supply of these companion diagnostics.  If these parties are unable to successfully develop companion diagnostics for these therapeutic candidates, or experience delays in doing so, the development of our therapeutic candidates may be adversely affected and we may not be able to obtain marketing authorization for these therapeutic candidates.  Furthermore, our ability to market and sell, as well as the commercial success, of any of our therapeutic candidates that require a companion diagnostic will be tied to, and dependent upon, the receipt of required regulatory authorization and the continued ability of such third parties to make the companion diagnostic commercially available on reasonable terms in the relevant geographies.  Any failure to develop, validate, obtain and maintain marketing authorization for a companion diagnostic and supply such companion diagnostic will harm our business, results of operations and financial condition.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or current or future collaborators, manufacturers or service providers fail to comply with healthcare laws and regulations, we or they could be subject to enforcement actions, which could affect our ability to develop, market and sell our therapeutics and may harm our reputation. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we do not currently have any products on the market, our current and future business operations may subject us to additional healthcare statutory and regulatory requirements and enforcement by the federal, state and foreign governments of the jurisdictions in which we conduct our business. Healthcare providers, including physicians and third-party payors play a primary role in the recommendation and prescription of any therapeutic candidates for which we obtain marketing approval. Our arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we research, market, sell or distribute our therapeutic candidates for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations, include, but are not limited to, the following:</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from soliciting, receiving, offering or providing remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, to induce either the referral of an individual for a healthcare item or service, or the purchasing or ordering of an item or service, for which payment may be made, in whole or in part, under a federal healthcare program, such as Medicare or Medicaid. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand, and prescribers, purchasers and formulary managers, among others, on the other. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S.&#160;federal False Claims Act, which imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. For example, pharmaceutical companies have been prosecuted under the False Claims Act in connection with their alleged off-label promotion of drugs, purportedly concealing price concessions in the pricing information submitted to the government for government price reporting purposes, and allegedly providing free product to customers with the expectation that the customers would bill federal health care programs for the product. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal price reporting laws, which require manufacturers to calculate and report complex pricing metrics to government programs, where such reported prices may be used in the calculation of reimbursement and/or discounts on approved products;</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA includes a fraud and abuse provision sometimes referred to as the HIPAA All-Payor Fraud Law, which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program (i.e., not just federal healthcare programs), or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the HITECH, and its implementing regulations, which impose obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses and their business associates that perform certain services involving the use or disclosure of individually identifiable health information as well as their covered subcontractors, including mandatory contractual terms, with respect to safeguarding the privacy, security, and transmission of individually identifiable health information, and require notification to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the federal Physician Payments Sunshine Act and the implementing regulations, also referred to as &#8220;Open Payments,&#8221; issued under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, which require that certain manufacturers of pharmaceutical and biological drugs reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program report to CMS all consulting fees, travel reimbursements, research grants, and other payments, transfers of value or gifts made to U.S.-licensed physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and U.S. teaching hospitals with limited exceptions, as well as ownership and investment interests held by physicians and their immediate family members. Effective January 1, 2022, these reporting obligations will extend to include transfers of value and payments made during the previous year to physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists and certified nurse midwives; and </span></div><div><span><br/></span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">analogous state laws and regulations, such as, state anti-kickback and false claims laws potentially applicable to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; and some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures, state and local laws that require the registration of pharmaceutical sales representatives, and state laws governing the privacy and security of personal data (including personal health information) in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and state transparency laws that require the reporting of certain pricing information; among other state laws. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring that our future business arrangements with third-parties comply with applicable healthcare laws and regulations could involve substantial costs. If our operations are found to be in violation of any such requirements, we may be subject to penalties, including significant administrative, civil and/or criminal penalties, monetary damages, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disgorgement, fines, imprisonment, additional integrity reporting requirements and regulatory oversight, the curtailment or restructuring of our operations, or exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, any of which could adversely affect our financial results. Although an effective compliance program can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time and resources.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or current or future collaborators, manufacturers or service providers fail to comply with applicable federal, state or foreign laws or regulations, we could be subject to significant penalties and enforcement actions, which could affect our ability to develop, market and sell our therapeutics successfully and could harm our reputation and lead to reduced acceptance of our therapeutics by the market. These penalties and enforcement actions include, among others: </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse regulatory inspection findings; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">warning or untitled letters; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">voluntary product recalls or public notification or medical product safety alerts to healthcare professionals; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on, or prohibitions against, marketing our therapeutics; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on, or prohibitions against, importation or exportation of our therapeutics; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension of review or refusal to approve pending applications or supplements to approved applications; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exclusion from participation in government-funded healthcare programs; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exclusion from eligibility for the award of government contracts for our therapeutics; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">integrity oversight and reporting obligations;</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA debarment; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension or withdrawal of therapeutic approvals; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seizures or administrative detention of therapeutics; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions; and </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">civil and criminal penalties and fines. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any therapeutics we develop may become subject to unfavorable pricing regulations, third-party coverage and reimbursement practices or healthcare reform initiatives, thereby harming our business. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulations that govern marketing approvals, pricing and reimbursement for new therapeutics vary widely from country to country. Some countries require approval of the sale price of a therapeutic before it can be marketed. In many countries, the pricing review period begins after marketing or therapeutic licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. Although we intend to monitor these regulations, our programs are currently in the early stages of development and we will not be able to assess the impact of price regulations for a number of years. As a result, we might obtain regulatory approval for a therapeutic in a particular country, but then be subject to price regulations that delay our commercial launch of the therapeutic and negatively impact the revenues we are able to generate from the sale of the therapeutic in that country.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients who are prescribed therapeutics for the treatment of their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved therapeutics. Our ability to commercialize any therapeutics successfully also will depend in part on the extent to which coverage and reimbursement for these therapeutics and related treatments will be available from government health administration authorities, private health insurers and other organizations. However, there may be significant delays in obtaining coverage for newly-approved therapeutics. Moreover, eligibility for coverage does not necessarily signify that a therapeutic will be reimbursed in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution costs. Also, interim payments </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for new therapeutics, if applicable, may be insufficient to cover our costs and may not be made permanent. Thus, even if we succeed in bringing one or more therapeutics to the market, these therapeutics may not be considered cost-effective, and the amount reimbursed for any therapeutics may be insufficient to allow us to sell our therapeutics on a competitive basis. Because our programs are in the early stages of development, we are unable at this time to determine their cost effectiveness or the likely level or method of reimbursement. Increasingly, the third-party payors who reimburse patients or healthcare providers, such as government and private insurance plans, are seeking greater upfront discounts, additional rebates and other concessions to reduce the prices for therapeutics. If the price we are able to charge for any therapeutics we develop, or the reimbursement provided for such therapeutics, is inadequate in light of our development and other costs, our return on investment could be adversely affected.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently expect that some therapeutics we develop may need to be administered under the supervision of a physician on an outpatient basis. Under currently applicable U.S. law, certain therapeutics that are not usually self-administered (including injectable therapeutics) may be eligible for coverage under Medicare through Medicare Part B. Medicare Part B is part of original Medicare, the federal health care program that provides health care benefits to the aged and disabled, and covers outpatient services and supplies, including certain pharmaceutical products that are medically necessary to treat a beneficiary&#8217;s health condition. Specifically, Medicare Part B coverage may be available for eligible beneficiaries when the following, among other requirements, have been satisfied:</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product is reasonable and necessary for the diagnosis or treatment of the illness or injury for which the product is administered according to accepted standards of medical practice; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product is typically furnished incident to a physician&#8217;s services; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product has been approved by the FDA. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Medicaid Drug Rebate Statute, a manufacturer must participate in the Medicaid Drug Rebate Program in order to receive payment for its covered outpatient drugs under Medicare Part B (the Medicare program that generally covers physician-administered, outpatient drugs).  In addition, manufacturers who participate in the Medicaid Drug Rebate Program are also required to (1) sign the Pharmaceutical Pricing Agreement and participate in the 340B Drug Pricing Program, and (2) sign the VA Master Agreement for inclusion of the manufacturer&#8217;s drugs on the Federal Supply Schedule, or FSS. The Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the Secretary of HHS as a condition for states to receive federal matching funds for the manufacturer&#8217;s outpatient drugs furnished to Medicaid patients. Under the 340B Drug Pricing Program, the manufacturer must extend discounts to entities eligible to participate in the program. Average prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of therapeutics from countries where they may be sold at lower prices than in the U.S. Self-administered therapeutics are typically reimbursed under Medicare Part D, and therapeutics that are administered in an inpatient hospital setting are typically reimbursed under Medicare Part A under a bundled payment. On March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap for single source and innovator multiple source drugs, beginning January 1, 2024.  It is difficult for us to predict how Medicare coverage and reimbursement policies will be applied to our therapeutics in the future and coverage and reimbursement under different federal healthcare programs are not always consistent. Medicare reimbursement rates may also reflect budgetary constraints placed on the Medicare program.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial third-party payors often rely upon Medicare coverage policies and payment limitations in setting their own reimbursement rates. Our inability to promptly obtain coverage, and adequate reimbursement from both government-funded and private payors for new therapeutics we develop and for which we obtain regulatory approval could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our financial condition.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics. Additionally, if any companion diagnostic provider is unable to obtain reimbursement or is inadequately reimbursed, that may limit the availability of such companion diagnostic, which would negatively impact prescriptions for our product candidates, if approved.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the efforts of governments and third-party payors to contain or reduce the cost of healthcare, and specifically, therapeutics, and legislative and regulatory proposals to broaden the availability of healthcare will continue to affect the business and financial condition of pharmaceutical and biotechnology companies. A number of legislative and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory changes in the healthcare system in the U.S. and other major healthcare markets have been proposed. These developments could, directly or indirectly, affect our ability to sell our therapeutics, if approved, at a favorable price.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in the U.S., in 2010, the U.S. Congress passed the ACA, a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of health spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional policy reforms.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions of the ACA addressing coverage and reimbursement of pharmaceutical products that may be of importance to our potential therapeutic candidates include the following:</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increases to pharmaceutical manufacturer rebate liability under the Medicaid Drug Rebate Program due to an increase in the minimum basic Medicaid rebate on most branded prescription drugs and the application of Medicaid rebate liability to drugs used in risk-based Medicaid managed care plans.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The expansion of the 340B Drug Pricing Program to require discounts for &#8220;covered outpatient drugs&#8221; sold to certain children&#8217;s hospitals, critical access hospitals, freestanding cancer hospitals, rural referral centers, and sole community hospitals. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Requirements imposed on pharmaceutical companies to offer discounts on brand-name drugs to patients who fall within the Medicare Part D coverage gap, commonly referred to as the &#8220;Donut Hole.&#8221; In February 2018, Congress passed the Bipartisan Budget Act of 2018, which, effective as of 2019, increased the discount to be paid by pharmaceutical companies from 50% to 70% of a brand-name drug&#8217;s negotiated price and added biosimilars to the coverage gap discount program.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Requirements imposed on pharmaceutical companies to pay an annual non-tax-deductible fee to the federal government based on each company&#8217;s market share of prior year total sales of branded drugs to certain federal healthcare programs, such as Medicare, Medicaid, Department of Veterans Affairs, and Department of Defense. Since we currently expect our branded pharmaceutical sales to constitute a small portion of the total federal healthcare program pharmaceutical market, we do not currently expect this annual assessment to have a material impact on our financial condition. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For therapeutic candidates classified as biologics, marketing approval for a follow-on biologic therapeutic may not become effective until 12 years after the date on which the reference innovator biologic therapeutic was first licensed by the FDA, with a possible six-month extension for pediatric therapeutics. After this exclusivity ends, it may be possible for biosimilar manufacturers to enter the market, which is likely to reduce the pricing for such therapeutics and could affect our profitability if our therapeutics are classified as biologics. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, pursuant to certain health reform legislation and related initiatives, CMS is working with various healthcare providers to develop, refine, and implement Accountable Care Organizations, or ACOs, and other innovative models of care for Medicare and Medicaid beneficiaries, including the Bundled Payments for Care Improvement Initiative, the Financial Alignment Initiative Demonstration, and other models. The continued development and expansion of ACOs and other innovative models of care will have an uncertain impact on any future reimbursement we may receive for approved therapeutics administered by such organizations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been judicial, administrative, executive, and legislative challenges to certain aspects of the ACA. For example, on June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace, which began on February 15, 2021 and remained open through August 15, 2021. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. In addition, Congress is considering additional health reform measures as part of the budget reconciliation process. It is unclear how any such challenges and the healthcare reform measures of the Biden administration will impact the ACA and our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been increasing legislative and enforcement interest in the United States with respect to drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed federal and state </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that seek to implement several of the administration&#8217;s proposals. As a result, the FDA released a final rule on September 24, 2020, effective November 30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Medicare Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed until January 1, 2023.  On November 20, 2020, CMS issued an interim final rule implementing the Trump administration&#8217;s Most Favored Nation, or MFN, executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. As a result of litigation challenging the MFN model, on August 10, 2021, CMS published a proposed rule that seeks to rescind the MFN model interim final rule. Further, in July 2021, the Biden administration released an executive order that included multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform. The plan sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles.  No legislation or administrative actions have been finalized to implement these principles. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, individual states have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, to encourage importation from other countries and bulk purchasing.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, similar political, economic and regulatory developments may affect our ability to profitably commercialize our therapeutic candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the European Union or member state level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the European Union, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than European Union, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most European Union member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing European Union and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our therapeutic candidates, restrict or regulate post-approval activities and affect our ability to commercialize our therapeutic candidates, if approved. In markets outside of the United States and European Union, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, it is possible that additional governmental action is taken in response to the COVID-19 pandemic. We cannot predict the ultimate content, timing or effect of any healthcare reform legislation or the impact of potential legislation on us. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our current or any future therapeutic candidates we may develop may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potential liability related to the privacy and security of health information we obtain from clinical trials sponsored by us.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most healthcare providers, including research institutions from which we obtain patient health information, are subject to privacy and security regulations promulgated under HIPAA, as amended by the HITECH. We are not currently classified as a covered entity or business associate under HIPAA and thus are not directly subject to its requirements or penalties. However, any person may be prosecuted under HIPAA&#8217;s criminal provisions either directly or under aiding-and-abetting or conspiracy principles. Consequently, depending on the facts and circumstances, we could face substantial penalties if we receive or use individually identifiable health information from a HIPAA-covered healthcare provider or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research institution or business associate that has not satisfied HIPAA&#8217;s requirements for disclosure of individually identifiable health information. In addition, we may maintain sensitive personally identifiable information, including health information, that we receive throughout the clinical trial process, in the course of our research collaborations, and directly from individuals (or their healthcare providers) who enroll in our patient assistance programs. As such, we may be subject to state laws requiring notification of affected individuals and state regulators in the event of a breach of personal information, which is a broader class of information than the health information protected by HIPAA. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, certain health privacy laws, data security laws, data breach notification laws, consumer protection laws and genetic testing laws may apply directly to our operations and/or those of our collaborators and may impose restrictions on our collection, use and dissemination of individuals&#8217; health information. Patients about whom we or our collaborators obtain health information, as well as the providers who share this information with us, may have statutory or contractual rights that limit our ability to use and disclose the information. We may be required to expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data security laws. Claims that we have violated individuals&#8217; privacy rights or breached our contractual obligations, even if we are not found liable, could be expensive and time- consuming to defend and could result in adverse publicity that could harm our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or third-party manufacturers, CROs or other contractors or consultants fail to comply with applicable federal, state or local regulatory requirements, we could be subject to a range of regulatory actions that could affect our or our contractors&#8217; ability to develop and commercialize our therapeutic candidates and could harm or prevent sales of any affected therapeutics that we are able to commercialize, or could substantially increase the costs and expenses of developing, commercializing and marketing our therapeutics. Any threatened or actual government enforcement action could also generate adverse publicity and require that we devote substantial resources that could otherwise be used in other aspects of our business. Increasing use of social media could give rise to liability, breaches of data security or reputational damage.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to European data protection laws, including the European Union&#8217;s General Data Protection Regulation 2016/679, or GDPR. If we fail to comply with existing or future data protection regulations, our business, financial condition, results of operations and prospects may be materially adversely affected.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By virtue of our clinical trial activities in the United Kingdom and Europe, we are subject to European data protection laws, including the GDPR. The GDPR which came into effect on May 25, 2018, establishes new requirements applicable to the processing of personal data (i.e., data which identifies an individual or from which an individual is identifiable), affords new data protection rights to individuals (e.g., the right to erasure of personal data) and imposes penalties for serious breaches of up to 4% annual worldwide turnover or &#8364;20 million, whichever is greater. Individuals (e.g., study subjects) also have a right to compensation for financial or non-financial losses (e.g., distress). There may be circumstances under which a failure to comply with the GDPR, or the exercise of individual rights under the GDPR, would limit our ability to utilize clinical trial data collected on certain subjects. The GDPR imposes additional responsibility and liability in relation to our processing of personal data. This may be onerous and we may be unsuccessful in implementing all measures required by data protection authorities or courts in interpretation of the GDPR, which may materially adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to obtain services, reimbursement or funding from the federal government may be impacted by possible reductions in federal spending. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. federal government agencies currently face potentially significant spending reductions. The Budget Control Act of 2011, or BCA, established a Joint Select Committee on Deficit Reduction, which was tasked with achieving a reduction in the federal debt level of at least $1.2 trillion. That committee did not draft a proposal by the BCA&#8217;s deadline. As a result, automatic cuts, referred to as sequestration, in various federal programs were scheduled to take place. This includes reductions to Medicare payments to providers of 2% per fiscal year, that began in April 2013, and, due to subsequent legislative amendments, will remain in effect through 2030 unless additional Congressional action is taken. COVID-19 relief legislation, including the Coronavirus Aid, Relief and Economic Security Act, or CARES Act, which was signed into law in March 2020 , among other things, suspended the 2% Medicare sequester from May 1, 2020 through December 31, 2021.  </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These reductions may also impact the ability of relevant agencies to timely review and approve therapeutic research and development, manufacturing, and marketing activities, which may delay our ability to develop, market, and sell any therapeutics we may develop.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If any of our therapeutic candidates receives marketing approval and we or others later identify undesirable side effects caused by the therapeutic candidate, our ability to market and derive revenue from the therapeutic candidates could be compromised. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that any of our therapeutic candidates receive regulatory approval and we or others identify undesirable side effects, adverse events or other problems caused by one of our therapeutics, any of the following adverse events could occur, which could result in the loss of significant revenue to us and materially and adversely affect our results of operations and business: </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may withdraw their approval of the therapeutic or seize the therapeutic; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may need to recall the therapeutic or change the way the therapeutic is administered to patients; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional restrictions may be imposed on the marketing of the particular therapeutic or the manufacturing processes for the therapeutic or any component thereof; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be subject to fines, restitution or disgorgement of profits or revenues, injunctions, or the imposition of civil penalties or criminal prosecution; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require us to implement a REMS, or to conduct post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the therapeutic; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could be sued and held liable for harm caused to patients; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the therapeutic may become less competitive; and </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market price of our common stock has been, and is likely to continue to be, highly volatile, and you may not be able to resell your shares at or above the price you paid for them. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since July 31, 2019, our stock price has been volatile and it is likely that the trading price of our common stock will continue to be volatile. As a result of this volatility, investors may not be able to sell their common stock at or above the price paid for the shares. The market price for our common stock may be influenced by a variety of factors, including the other risks described in this section titled &#8220;Risk Factors&#8221; and the following:</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of competitive therapeutics or technologies; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results of our preclinical studies and clinical trials of our therapeutic candidates, or those of our competitors, or any current or future collaborators; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory or legal developments in the United States and other countries, especially changes in laws or regulations applicable to our therapeutics; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">introductions and announcements of new therapeutics by us, our future commercialization partners, or our competitors, and the timing of these introductions or announcements; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actions taken by regulatory agencies with respect to our therapeutics, clinical studies, manufacturing process or sales and marketing terms; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated variations in our financial results or those of companies that are perceived to be similar to us; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our efforts to acquire or in-license additional technologies, therapeutics or therapeutic candidates; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments concerning any current or future collaborations, including but not limited to those with our sources of manufacturing supply and our commercialization partners; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments or disputes concerning patents or other proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our therapeutics; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability or inability to raise additional capital and the terms on which we raise it; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the recruitment or departure of key personnel; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market conditions in the pharmaceutical and biotechnology sectors; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated changes in earnings estimates or changes in stock market analyst recommendations regarding our common stock, other comparable companies or our industry generally; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our failure or the failure of our competitors to meet analysts&#8217; projections or guidance that we or our competitors may give to the market; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in the valuation of companies perceived by investors to be comparable to us; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcement and expectation of additional financing efforts; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">speculation in the press or investment community; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trading volume of our common stock and overall fluctuations in U.S. equity markets, including as a result of the COVID-19 pandemic; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of our common stock by us or our stockholders; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the concentrated ownership of our common stock; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in accounting principles; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">terrorist acts, acts of war or periods of widespread civil unrest; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">natural disasters and other calamities; and </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic, industry, political and market conditions, including, but not limited to, the ongoing impact of the COVID-19 pandemic. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock markets in general, and the markets for pharmaceutical and biotechnology stocks in particular, have experienced extreme volatility that has been often unrelated to the operating performance of the issuer. These broad market and industry factors, such as those related to the COVID-19 pandemic, may seriously harm the market price of our common stock, regardless of our operating performance. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional funds by issuing securities may cause dilution to existing stockholders and raising funds through lending and licensing arrangements may restrict our operations or require us to relinquish proprietary rights.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, grants and license and development agreements in connection with any collaborations. We do not have any committed external source of funds. To the extent that we raise additional capital through the issuance of shares or other securities convertible into shares, our stockholders will be diluted.  Future issuances of our common stock or other equity securities, or the perception that such sales may occur, could adversely affect the prevailing market price of our common stock and impair our ability to raise capital through future offerings of equity or equity-linked securities.  For example, on December 23, 2019, we completed the sale of 10,000,000 shares of our common stock in the December 2019 Offering and on August 2, 2019 we completed the sale of 31,625,000 shares of our common stock in the August 2019 Offering.  The issuance of shares in both the December 2019 Offering and August 2019 Offering were pursuant to a shelf registration statement on Form S-3 that was declared effective by the SEC on July 24, 2019. The shelf registration statement allows us to sell from time-to-time up to $125.0 million of common stock, preferred stock, debt securities, warrants, or units comprised of any combination of these securities, for our own account in one or more offerings; the remaining amount available under this shelf registration after the December 2019 Offering </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(inclusive of the exercise of the underwriters&#8217; option in January 2020 to purchase additional shares at the public offering price in connection with the December 2019 Offering) is approximately $31.3 million. Further, in December 2020 we entered into an equity distribution agreement with BMO providing for the sale of up to $50.0 million of our common stock from time to time in &#8220;at the market offerings&#8221; (as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended) pursuant to a prospectus supplement and a shelf registration statement on Form S-3 that was declared effective by the SEC on January 7, 2021. The issuance of the shares pursuant to the December 2019 Offering and the August 2019 Offering and/or the resale of a substantial number of shares of our common stock in the public market or the sale of any shares of our common stock under the equity distribution agreement could adversely affect the market price for our common stock and make it more difficult for you to sell shares of our common stock at times and prices that you feel are appropriate. Adverse market and price pressures that may result from the December 2019 Offering or the August 2019 Offering or an offering pursuant to the shelf registration statement or such &#8216;at the market&#8217; offerings may continue for an extended period of time and continued negative pressure on the market price of our common stock could have a material adverse effect on our ability to raise additional equity capital.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. Any debt financing that we enter into may involve covenants that restrict our operations. These restrictive covenants may include limitations on additional borrowing and specific restrictions on the use of our assets as well as prohibitions on our ability to create liens, pay dividends, redeem our stock or make investments. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are an &#8220;emerging growth company&#8221; and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to investors. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an &#8220;emerging growth company&#8221; as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including (1)&#160;not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, (2)&#160;reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and (3)&#160;exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. In addition, as an emerging growth company, we are only required to provide two years of audited financial statements and two years of selected financial data. We could be an emerging growth company for up to five years, although circumstances could cause us to lose that status earlier, including if the market value of our common stock held by non-affiliates exceeds $700.0&#160;million as of any June&#160;30 before that time or if we have total annual gross revenue of $1.07&#160;billion or more during any fiscal year before that time, in which cases we would no longer be an emerging growth company as of the following December&#160;31, or if we issue more than $1.0&#160;billion in non-convertible debt during any three-year period before that time, in which case we would no longer be an emerging growth company immediately. Even after we no longer qualify as an emerging growth company, we may still qualify as a &#8220;smaller reporting company&#8221; which would allow us to take advantage of many of the same exemptions from disclosure requirements including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our share price may be more volatile. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the beneficial ownership of our common stock as of September 30, 2021, our executive officers and directors, together with holders of five percent or more of our outstanding common stock and their respective affiliates, will beneficially own approximately&#160;42% of our outstanding common stock. As a result, these stockholders, if acting together, will continue to have significant influence over the outcome of corporate actions requiring stockholder approval, including the election of directors, any merger, consolidation or sale of all or substantially all of our assets and any other significant corporate transaction. The interests of these stockholders may not be the same as or may even conflict with your interests. For example, these stockholders could delay or prevent a change of control of our Company, even if such a change of control would benefit our other stockholders, which could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of our company or our assets and might affect the prevailing market price of our common stock. The significant concentration of stock ownership may adversely affect the trading price of our common stock due to investors&#8217; perception that conflicts of interest may exist or arise. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our charter documents and under the General Corporation Law of the State of Delaware could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our management. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our amended and restated certificate of incorporation and our bylaws may delay or prevent an acquisition of us or a change in our management. These provisions include a classified board of directors, a prohibition on actions by written consent of our stockholders, and the ability of the Board to issue preferred stock without stockholder approval. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, or DGCL, which prohibits stockholders owning in excess of 15% of the outstanding combined organization voting stock from merging or combining with the combined organization. Although we believe these provisions collectively will provide for an opportunity to receive higher bids by requiring potential acquirers to negotiate with our Board, they would apply even if the offer may be considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove then-current management by making it more difficult for stockholders to replace members of the Board, which is responsible for appointing the members of management. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our charter documents could discourage, delay or prevent a change in control of us and may affect the trading price of our common stock. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate documents and the DGCL contain provisions that may enable our Board to resist a change in control of us even if a change in control were to be considered favorable by our stockholders. These provisions: </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">stagger the terms of our Board and require 66 and 2/3% stockholder voting to remove directors, who may only be removed for cause; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">authorize our Board to issue &#8220;blank check&#8221; preferred stock and to determine the rights and preferences of those shares, which may be senior to our common stock, without prior stockholder approval; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish advance notice requirements for nominating directors and proposing matters to be voted on by stockholders at stockholders&#8217; meetings; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prohibit our stockholders from calling a special meeting and prohibit stockholders from acting by written consent; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require 66 and 2/3% stockholder voting to effect certain amendments to our certificate of incorporation and bylaws; and </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prohibit cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions could discourage, delay or prevent a transaction involving a change in control of us. These provisions could also discourage proxy contests and make it more difficult for stockholders to elect directors of their choosing and cause us to take other corporate actions our stockholders desire. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated certificate of incorporation designates the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation provides that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any of the following types of actions or proceedings under Delaware statutory or common law: derivative action or proceeding brought on our behalf, any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, employees or agents to us or our stockholders, any action asserting a claim arising pursuant to any provision of the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws or any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein. This provision would not apply to suits brought to enforce a duty or liability created by the Securities Exchange Act of 1934, as amended, or any other claims for which a court or forum other than the Court of Chancery has exclusive jurisdiction or for which the Court of Chancery does not have subject matter jurisdiction. Furthermore, Section 22 of the Securities Act of 1933, as amended, or the Securities Act, creates concurrent jurisdiction for federal and state courts over all Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. Our amended and restated certificate of incorporation also provides that any person purchasing or otherwise acquiring any interest in any shares of our common stock shall be deemed to have notice of and to have consented to this provision of our amended and restated certificate of incorporation.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This choice of forum provision may limit our stockholders&#8217; ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, employees or agents, which may discourage such lawsuits against us and our directors, officers, employees and agents even though an action, if successful, might benefit our stockholders. Stockholders who do bring a claim in the Court of Chancery could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near Delaware. The Court of Chancery may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments or results may be more favorable to us than to our stockholders. If a court were to find this exclusive forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable in any action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could have a material adverse effect on our business, financial condition or results of operations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition&#160;or results of operations.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business operations and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act, or the Tax Act, enacted many significant changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to the Tax Act may affect us, and certain aspects of the Tax Act could be repealed or modified in future legislation. For example, the CARES Act modified certain provisions of the Tax Act. In addition, it is uncertain if and to what extent various states will conform to the Tax Act, the CARES Act, or any newly enacted federal tax legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses under the Tax Act or future reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future U.S. tax expense.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred substantial losses during our history and do not expect to become profitable in the near future and we may never achieve profitability. Our net operating loss, or NOL, carryforwards generated in tax years beginning on or before December 31, 2017, are only permitted to be carried forward for 20 years under applicable U.S. tax law. Under the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax Act, as modified by the CARES Act, our federal NOLs generated in tax years beginning after December 31, 2017, may be carried forward indefinitely, but the deductibility of such federal NOLs in tax years beginning after December 31, 2020, is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to the Tax Act, or the CARES Act. In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change NOL carryforwards, and other pre-change tax attributes (such as research tax credits) to offset its post-change income or taxes may be limited. We have experienced ownership changes in the past. In addition, we may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which are outside of our control. As a result, if we earn net taxable income, our ability to use our pre-change NOL carryforwards to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Risks Related to our Indebtedness</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:99%">Our indebtedness could adversely affect our business, financial condition and competitive position. </span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, we had $17.5 million of indebtedness outstanding, consisting of our borrowing under our MidCap Credit Facility. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to service this indebtedness and any additional indebtedness we may incur in the future, we need to generate cash. Our ability to generate cash is subject, to a certain extent, to our ability to successfully execute our business strategy, as well as general economic, financial, competitive, regulatory and other factors beyond our control. We cannot assure you that our business will be able to generate sufficient cash flow from operations or that future borrowings or other financing will be available to us in an amount sufficient to enable us to service our indebtedness and fund our other liquidity needs. To the extent we are required to use our cash flow from operations or the proceeds of any future financing to service our indebtedness instead of funding working capital, capital expenditures or other general corporate purposes, we will be less able to plan for, or react to, changes in our business, industry and in the economy generally. This will place us at a competitive disadvantage compared to our competitors that have less indebtedness.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the MidCap Credit Agreement contains, and any agreements evidencing or governing other future indebtedness may contain, certain restrictive covenants that limit our ability, among other things, to engage in certain activities that are in our long-term best interests, including our ability to:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incur additional indebtedness;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">create or incur liens;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">engage in certain fundamental changes, including mergers or consolidations;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make investments, loans, advances, guarantees and acquisitions;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sell or transfer assets;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pay dividends and distributions and repurchase capital stock;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">engage in certain transactions with affiliates;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enter into negative pledge clauses and clauses restricting subsidiary distributions;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">modify the terms of material documents.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> While we have not previously breached and are not in breach of any of these covenants, there can be no guarantee that we will not breach these covenants in the future.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to comply with these covenants and restrictions may be affected by events and factors beyond our control. Our failure to comply with any of these covenants or restrictions could result in an event of default under our MidCap Credit Facility. This would permit the lending banks under such facilities to take certain actions, including terminating all outstanding commitments and declaring all amounts due under our credit agreement, such as outstanding principal and accrued and unpaid interest thereon, to be immediately due and payable. In addition, the lenders would have the right to proceed against the collateral we have granted to them, which includes substantially all of our assets. The occurrence of any of these events could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:99%">We may not be able to secure additional financing on favorable terms, or at all, to meet our future capital needs.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the future, we may require additional capital to respond to business opportunities, challenges, acquisitions or unforeseen circumstances, and may determine to engage in equity or debt financings or enter into credit facilities or refinance existing indebtedness for other reasons. We may not be able to timely secure additional debt or equity financing on favorable terms, or at all. As discussed above, the credit agreements governing the MidCap Credit Facility contain restrictive covenants that limit our ability to incur additional indebtedness and engage in other capital-raising activities. Any debt financing obtained by us in the future could involve covenants that further restrict our capital raising activities and other financial and operational matters, which may make it more difficult for us to operate our business, obtain additional capital and pursue business opportunities, including potential acquisitions. Furthermore, if we raise additional funds through the issuance of equity or convertible debt or other equity-linked securities or through the sale of our common stock pursuant to our &#8220;at the market&#8221; program, our existing stockholders could suffer significant dilution. If we are unable to obtain adequate financing or financing on terms satisfactory to us, when we require it, our ability to continue to grow or support our business and to respond to business challenges could be significantly limited.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">General Risk Factors</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">FINRA sales practice requirements may limit a stockholder&#8217;s ability to buy and sell our stock.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Financial Industry Regulatory Authority, or FINRA, has adopted rules requiring that, in recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing that the investment is suitable for that customer. Prior to recommending speculative or low-priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer&#8217;s financial status, tax status, investment objectives and other information. Under interpretations of these rules, FINRA has indicated its belief that there is a high probability that speculative or low-priced securities will not be suitable for at least some customers. If these FINRA requirements are applicable to us or our securities, they may make it more difficult for broker-dealers to recommend that at least some of their customers buy our common stock, which may limit the ability of our stockholders to buy and sell our common stock and could have an adverse effect on the market for and price of our common stock.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline. </span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business.  Our research coverage by securities and industry analysts is currently limited.  In addition, because we did not become a reporting company by conducting an underwritten initial public offering of our common stock, security analysts of brokerage firms may not provide wider coverage of our Company.  In addition, investment banks may be less likely to agree to underwrite secondary offerings on our behalf than they might if we became a public reporting company by means of an underwritten initial public offering, because they may be less familiar with our Company as a result of more limited coverage by analysts and the media, and because we became public at an early stage in our development.  The failure to receive wider research coverage or support in the market for our shares will have an adverse effect on our ability to develop a liquid market for our common stock and the trading price for our stock would be negatively impacted.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event we obtain wider securities or industry analyst coverage, if any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our target studies and operating results fail to meet the expectations of analysts, our stock price would likely decline.  If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><div id="i30c50c718dda42d28fbdd6dcd4fa2365_127"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. </span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-indent:18pt"><span><br/></span></div><div id="i30c50c718dda42d28fbdd6dcd4fa2365_130"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-indent:18pt"><span><br/></span></div><div id="i30c50c718dda42d28fbdd6dcd4fa2365_133"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-indent:18pt"><span><br/></span></div><div id="i30c50c718dda42d28fbdd6dcd4fa2365_136"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 9, 2021, the Audit Committee of the Board of Directors of the Company was notified of a claim made by a former Company senior researcher regarding alleged improprieties that researcher claims to have committed with respect to the Company&#8217;s XCUR-FXN preclinical program for the treatment of Friedreich&#8217;s ataxia. The Audit Committee has retained external counsel to conduct an internal investigation of the claim. The Company is currently unable to predict the timing or outcome of the investigation.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><div id="i30c50c718dda42d28fbdd6dcd4fa2365_139"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary;margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.024%"><tr><td style="width:1.0%"></td><td style="width:13.071%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.528%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit</span></div><div style="margin-bottom:1.5pt;margin-top:3.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">No.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:3.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Description</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File No.</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex32.htm">Certificate of Amendment to Certificate of Incorporation, filed with the Secretary of State of the State of Delaware on September 26, 2017.</a></span></div><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/02/17</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;000-55764</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1698530/000169853021000031/exicureex33amendedandresta.htm">Amended and Restated Certificate of Incorporation, as filed with the Secretary of State of the State of Delaware on November 15, 2017.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/11/21</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-39011</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex34.htm">Amended and Restated Bylaws, as currently in effect.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/02/17</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:6pt;text-align:center;text-indent:-11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">000-55764</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001698530/000169853021000091/exicureexhibit104-63021.htm">Amendment No. 2 dated as of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001698530/000169853021000091/exicureexhibit104-63021.htm">July 30</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001698530/000169853021000091/exicureexhibit104-63021.htm">, 2021 to Credit and Security Agreement, dated as of September 25, 2020 by and among Exicure, Inc., Exicure Operating Company, the lenders party thereto from time to time and MidCap Financial Trust, as agent.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:-13.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/12/21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-39011</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1698530/000169853021000094/exhibit101.htm">Amendment No. 3 dated as of September 30, 2021 to Credit and Security Agreement, dated as of September 25, 2020 by and among Exicure, Inc., Exicure Operating Company, the lenders party thereto from time to time and MidCap Financial Trust, as agent.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/06/21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-39011</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3 &#8224; *</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exicureexhibit103-93021.htm">Collaboration, Option and License Agreement between Exicure, Inc. and Ipsen Biopharm Limited dated as of July 30, 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4 *</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exicureexhibit104-93021.htm">Side Agreement to Northwestern Agreements by and among Exicure Inc., Northwestern University and Ipsen Biopharm Limited dated as of July 30, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5 &#8224; *</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exicureexhibit105-93021.htm">Amendment Five to the Amended Restated License Agreement between Exicure OpCo and Northwestern University dated as of September 8, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exicureexhibit311-93021.htm">Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exicureexhibit312-93021.htm">Certification of Principal Financial Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary;margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.024%"><tr><td style="width:1.0%"></td><td style="width:13.071%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.528%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exicureexhibit321-93021.htm">Certifications of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;   Certain portions of the exhibit (indicated by asterisks) have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*   Filed herewith.</span></div><div style="margin-bottom:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**   The certification attached as Exhibit 32.1 that accompanies this Quarterly Report on Form 10-Q is not deemed filed with the SEC and is not to be incorporated by reference into any filing of Exicure, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of such Form 10-Q), irrespective of any general incorporation language contained in such filing.</span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><div id="i30c50c718dda42d28fbdd6dcd4fa2365_142"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i30c50c718dda42d28fbdd6dcd4fa2365_7">Table of Contents</a></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: November 19, 2021</span></div><div style="margin-bottom:9pt;text-align:right;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.551%"><tr><td style="width:1.0%"></td><td style="width:11.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.311%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXICURE, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Brian C. Bock</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brian C. Bock</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">( Principal Financial Officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Elias D. Papadimas</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elias D. Papadimas</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Accounting Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">( Principal Accounting Officer)</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>2
<FILENAME>exicureexhibit103-93021.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i9b16f1ba634f40d19a7a1b6dadea2dc9_38"></div><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.3</font></div><div style="text-align:right"><font><br></font></div><div style="margin-top:3.9pt;padding-right:21.95pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">EXECUTION VERSION</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.9pt;padding-right:21.95pt;text-align:right"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:165.67pt;padding-right:165.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:247%">COLLABORATION, OPTION</font></div><div style="padding-left:85.77pt;padding-right:85.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:247%">AND</font></div><div style="padding-left:85.77pt;padding-right:85.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:247%">LICENSE AGREEMENT</font></div><div style="padding-left:85.8pt;padding-right:85.8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:247%">by and between </font></div><div style="padding-left:108.25pt;padding-right:108.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:247%">EXICURE, INC.</font></div><div style="padding-left:108.25pt;padding-right:108.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:247%">and</font></div><div style="padding-left:85.82pt;padding-right:85.82pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:247%">IPSEN BIOPHARM LIMITED</font></div><div style="padding-left:85.82pt;padding-right:85.82pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:247%">dated </font></div><div style="padding-left:85.82pt;padding-right:85.82pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:247%">July 30, 2021</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><div id="i9b16f1ba634f40d19a7a1b6dadea2dc9_41"></div><hr style="page-break-after:always"><div style="min-height:92pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:80%">TABLE OF CONTENTS</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Page</font></div></div><div><font><br></font></div><div style="margin-top:11.1pt;padding-left:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">ARTICLE 1 DEFINITIONS&#160;&#160;&#160;&#160;1</font></div><div style="margin-top:5.95pt;padding-left:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">ARTICLE 2 R&#38;D TERM RESEARCH AND DEVELOPMENT&#160;&#160;&#160;&#160;14</font></div><div style="margin-top:6.1pt;padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">GOALS&#160;&#160;&#160;&#160;14</font></div><div style="margin-top:5.95pt;padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">R&#38;D TERM PLANS&#59; PERFORMANCE&#160;&#160;&#160;&#160;14</font></div><div style="margin-top:6.05pt;padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">OBLIGATIONS UNDER THE R&#38;D TERM PLANS&#160;&#160;&#160;&#160;15</font></div><div style="margin-top:5.95pt;padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">R&#38;D TERM RESEARCH AND DEVELOPMENT COSTS.&#160;&#160;&#160;&#160;16</font></div><div style="margin-top:6pt;padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">SUBCONTRACTORS FOR THE R&#38;D TERM PLANS&#160;&#160;&#160;&#160;17</font></div><div style="margin-top:6.05pt;padding-left:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">ARTICLE 3 OPTION GRANT&#59; OPTION DATA PACKAGES&#59; OPTION EXERCISE&#160;&#160;&#160;&#160;17</font></div><div style="margin-top:5.95pt;padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">FIRST OPTION GRANT&#160;&#160;&#160;&#160;17</font></div><div style="margin-top:6.1pt;padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">FIRST OPTION DATA PACKAGE&#160;&#160;&#160;&#160;17</font></div><div style="margin-top:5.95pt;padding-left:82.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">FIRST OPTION EXERCISE&#160;&#160;&#160;&#160;17</font></div><div style="margin-top:5.95pt;padding-left:82.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">SECOND OPTION GRANT&#160;&#160;&#160;&#160;17</font></div><div style="margin-top:6.05pt;padding-left:82.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">SECOND OPTION DATA PACKAGE&#160;&#160;&#160;&#160;17</font></div><div style="margin-top:5.95pt;padding-left:82.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">3.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">SECOND OPTION EXERCISE&#160;&#160;&#160;&#160;18</font></div><div style="margin-top:6.1pt;padding-left:82.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">3.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">EARLY SECOND OPTION EXERCISE&#160;&#160;&#160;&#160;18</font></div><div style="margin-top:5.95pt;padding-left:82.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">3.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">GOVERNMENT APPROVALS.&#160;&#160;&#160;&#160;18</font></div><div style="margin-top:5.95pt;padding-left:82.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">3.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">ASSISTANCE&#160;&#160;&#160;&#160;19</font></div><div style="margin-top:6.05pt;padding-left:10.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">ARTICLE 4 R&#38;D TERM GOVERNANCE&#160;&#160;&#160;&#160;19</font></div><div style="margin-top:5.95pt;padding-left:82.1pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">ALLIANCE MANAGER&#160;&#160;&#160;&#160;19</font></div><div style="margin-top:6.1pt;padding-left:82.1pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">JOINT STEERING COMMITTEE.&#160;&#160;&#160;&#160;19</font></div><div style="margin-top:5.95pt;padding-left:82.1pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">RESOLUTION OF JSC DISPUTES.&#160;&#160;&#160;&#160;20</font></div><div style="margin-top:6.1pt;padding-left:82.1pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">LIMITATION OF JSC AUTHORITY&#160;&#160;&#160;&#160;21</font></div><div style="margin-top:5.95pt;padding-left:82.1pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">4.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">DISCONTINUATION OF THE JSC&#160;&#160;&#160;&#160;21</font></div><div style="margin-top:5.95pt;padding-left:10.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">ARTICLE 5 DEVELOPMENT AND COMMERCIALIZATION&#160;&#160;&#160;&#160;21</font></div><div style="margin-top:6.05pt;padding-left:82.1pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">DEVELOPMENT&#160;&#160;&#160;&#160;21</font></div><div style="margin-top:5.95pt;padding-left:82.15pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">REGULATORY RESPONSIBILITIES.&#160;&#160;&#160;&#160;21</font></div><div style="margin-top:6.1pt;padding-left:82.15pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">REGULATORY INFORMATION SHARING&#160;&#160;&#160;&#160;22</font></div><div style="margin-top:5.95pt;padding-left:82.15pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">COMMERCIALIZATION&#160;&#160;&#160;&#160;22</font></div><div style="margin-top:5.95pt;padding-left:82.15pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">5.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">DILIGENCE&#160;&#160;&#160;&#160;22</font></div><div style="margin-top:6.05pt;padding-left:82.15pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">5.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">EXICURE COOPERATION&#160;&#160;&#160;&#160;23</font></div><div style="margin-top:5.95pt;padding-left:82.15pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">5.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">UPDATE MEETINGS&#160;&#160;&#160;&#160;23</font></div><div style="margin-top:7.2pt;padding-left:165.62pt;padding-right:165.62pt;text-align:center"><font><br></font></div><div style="height:63.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-i-</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><div id="i9b16f1ba634f40d19a7a1b6dadea2dc9_44"></div><hr style="page-break-after:always"><div style="min-height:92pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:80%">TABLE OF CONTENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(continued)</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Page</font></div></div><div style="margin-top:22.6pt;padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">5.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">REPORTS BY IPSEN&#160;&#160;&#160;&#160;23</font></div><div style="margin-top:5.95pt;padding-left:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">ARTICLE 6 MANUFACTURE AND SUPPLY&#160;&#160;&#160;&#160;23</font></div><div style="margin-top:6.1pt;padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">EXICURE MANUFACTURE AND SUPPLY&#160;&#160;&#160;&#160;23</font></div><div style="margin-top:5.95pt;padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">&#91;***&#93;&#160;&#160;&#160;&#160;23</font></div><div style="margin-top:6.05pt;padding-left:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">ARTICLE 7 LICENSES AND EXCLUSIVITY&#160;&#160;&#160;&#160;24</font></div><div style="margin-top:5.95pt;padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">LICENSES TO IPSEN UPON EXERCISE OF THE OPTION&#160;&#160;&#160;&#160;24</font></div><div style="margin-top:5.95pt;padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">EXICURE RETAINED RIGHTS&#59; LICENSES TO EXICURE.&#160;&#160;&#160;&#160;24</font></div><div style="margin-top:6.1pt;padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">SUBLICENSING.&#160;&#160;&#160;&#160;24</font></div><div style="margin-top:5.95pt;padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">7.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">NO IMPLIED LICENSES&#160;&#160;&#160;&#160;25</font></div><div style="margin-top:6.1pt;padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">7.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">TECHNOLOGY TRANSFER&#160;&#160;&#160;&#160;25</font></div><div style="margin-top:5.95pt;padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">7.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">EXCLUSIVITY&#160;&#160;&#160;&#160;25</font></div><div style="margin-top:5.95pt;padding-left:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">ARTICLE 8 FINANCIALS&#160;&#160;&#160;&#160;26</font></div><div style="margin-top:6.05pt;padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">UPFRONT PAYMENT&#160;&#160;&#160;&#160;26</font></div><div style="margin-top:5.95pt;padding-left:82.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">PREPARATION COSTS AND OPTION FEE&#160;&#160;&#160;&#160;26</font></div><div style="margin-top:6.1pt;padding-left:82.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">DEVELOPMENT MILESTONE PAYMENTS&#160;&#160;&#160;&#160;27</font></div><div style="margin-top:5.95pt;padding-left:82.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">8.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">COMMERCIAL MILESTONE PAYMENTS.&#160;&#160;&#160;&#160;28</font></div><div style="margin-top:5.95pt;padding-left:82.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">8.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">ROYALTIES.&#160;&#160;&#160;&#160;29</font></div><div style="margin-top:6.05pt;padding-left:82.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">8.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">TAXES&#160;&#160;&#160;&#160;31</font></div><div style="margin-top:5.95pt;padding-left:82.1pt;text-indent:-36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">8.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.35pt">CHANGE IN ACCOUNTING PERIODS&#160;&#160;&#160;&#160;32</font></div><div style="margin-top:6.1pt;padding-left:10.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">ARTICLE 9 INTELLECTUAL PROPERTY&#160;&#160;&#160;&#160;32</font></div><div style="margin-top:5.95pt;padding-left:82.1pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">OWNERSHIP OF IP.&#160;&#160;&#160;&#160;32</font></div><div style="margin-top:6.1pt;padding-left:82.1pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">PROSECUTION, MAINTENANCE &#38; ENFORCEMENT&#160;&#160;&#160;&#160;33</font></div><div style="margin-top:5.95pt;padding-left:82.1pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">9.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">DEFENSE AND SETTLEMENT OF THIRD PARTY CLAIMS&#160;&#160;&#160;&#160;34</font></div><div style="margin-top:5.95pt;padding-left:82.1pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">9.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">ENFORCEMENT.&#160;&#160;&#160;&#160;34</font></div><div style="margin-top:6.05pt;padding-left:82.1pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">9.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">TRADEMARKS&#160;&#160;&#160;&#160;35</font></div><div style="margin-top:5.85pt;padding-left:82.1pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">9.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">PATENT EXTENSIONS&#59; ORANGE BOOK LISTINGS&#59; PATENT</font></div><div style="margin-top:0.2pt;padding-left:82.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">CERTIFICATIONS&#160;&#160;&#160;&#160;35</font></div><div style="margin-top:5.95pt;padding-left:10.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">ARTICLE 10 REPRESENTATIONS, WARRANTIES AND COVENANTS&#160;&#160;&#160;&#160;36</font></div><div style="margin-top:5.95pt;padding-left:82.15pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">10.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:16.8pt">MUTUAL REPRESENTATIONS, WARRANTIES AND COVENANTS&#160;&#160;&#160;&#160;36</font></div><div style="margin-top:6.05pt;padding-left:82.15pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:16.8pt">REPRESENTATIONS, WARRANTIES AND COVENANTS BY EXICURE&#160;&#160;&#160;&#160;36</font></div><div style="margin-top:5.95pt;padding-left:82.15pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">10.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:16.8pt">NO OTHER REPRESENTATIONS OR WARRANTIES&#160;&#160;&#160;&#160;37</font></div><div style="margin-top:6.1pt;padding-left:10.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">ARTICLE 11 INDEMNIFICATION&#160;&#160;&#160;&#160;38</font></div><div style="margin-top:5.95pt;padding-left:82.15pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">11.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:16.8pt">INDEMNIFICATION BY EXICURE&#160;&#160;&#160;&#160;38</font></div><div style="height:60pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">-ii-</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><div id="i9b16f1ba634f40d19a7a1b6dadea2dc9_47"></div><hr style="page-break-after:always"><div style="min-height:92pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:80%">TABLE OF CONTENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(continued)</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Page</font></div></div><div style="margin-top:22.6pt;padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">11.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:16.8pt">INDEMNIFICATION BY IPSEN&#160;&#160;&#160;&#160;38</font></div><div style="margin-top:5.95pt;padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">11.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:16.8pt">INDEMNIFICATION PROCEDURES&#160;&#160;&#160;&#160;38</font></div><div style="margin-top:6.1pt;padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">11.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:16.8pt">LIMITATION OF LIABILITY&#160;&#160;&#160;&#160;39</font></div><div style="margin-top:5.95pt;padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">11.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:16.8pt">INSURANCE&#160;&#160;&#160;&#160;39</font></div><div style="margin-top:6.05pt;padding-left:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">ARTICLE 12 CONFIDENTIALITY&#160;&#160;&#160;&#160;39</font></div><div style="margin-top:5.95pt;padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">12.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:16.8pt">CONFIDENTIALITY&#59; EXCEPTIONS&#160;&#160;&#160;&#160;39</font></div><div style="margin-top:5.95pt;padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">12.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:16.8pt">AUTHORIZED DISCLOSURE&#160;&#160;&#160;&#160;40</font></div><div style="margin-top:6.1pt;padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">12.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:16.8pt">PRIOR AGREEMENT&#160;&#160;&#160;&#160;41</font></div><div style="margin-top:5.95pt;padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">12.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:16.8pt">PUBLICATIONS&#160;&#160;&#160;&#160;41</font></div><div style="margin-top:6.1pt;padding-left:82.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">12.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:16.8pt">ATTORNEY-CLIENT PRIVILEGE&#160;&#160;&#160;&#160;41</font></div><div style="margin-top:5.95pt;padding-left:10.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">ARTICLE 13 TERM AND TERMINATION&#160;&#160;&#160;&#160;41</font></div><div style="margin-top:5.95pt;padding-left:82.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">13.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:16.8pt">TERM&#160;&#160;&#160;&#160;41</font></div><div style="margin-top:6.05pt;padding-left:82.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">13.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:16.8pt">TERMINATION BY IPSEN&#160;&#160;&#160;&#160;41</font></div><div style="margin-top:5.95pt;padding-left:82.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">13.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:16.8pt">TERMINATION FOR BREACH OR INSOLVENCY&#160;&#160;&#160;&#160;41</font></div><div style="margin-top:6.1pt;padding-left:82.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">13.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:16.8pt">TERMINATION FOR PATENT CHALLENGE&#160;&#160;&#160;&#160;42</font></div><div style="margin-top:5.95pt;padding-left:82.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">13.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:16.8pt">EFFECTS OF TERMINATION&#160;&#160;&#160;&#160;43</font></div><div style="margin-top:5.95pt;padding-left:82.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">13.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:16.8pt">OTHER REMEDIES&#160;&#160;&#160;&#160;45</font></div><div style="margin-top:6.05pt;padding-left:82.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">13.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:16.8pt">RIGHTS IN BANKRUPTCY&#160;&#160;&#160;&#160;45</font></div><div style="margin-top:5.95pt;padding-left:82.1pt;text-indent:-36.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">13.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:16.85pt">SURVIVAL&#160;&#160;&#160;&#160;45</font></div><div style="margin-top:6.1pt;padding-left:10.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">ARTICLE 14 DISPUTE RESOLUTION&#160;&#160;&#160;&#160;46</font></div><div style="margin-top:5.95pt;padding-left:82.1pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">14.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:16.8pt">DISPUTE RESOLUTION&#160;&#160;&#160;&#160;46</font></div><div style="margin-top:6.1pt;padding-left:82.1pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">14.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:16.8pt">INJUNCTIVE RELIEF&#59; REMEDY FOR BREACH OF EXCLUSIVITY&#160;&#160;&#160;&#160;47</font></div><div style="margin-top:5.95pt;padding-left:82.1pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">14.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:16.8pt">PATENT AND TRADEMARK DISPUTES&#160;&#160;&#160;&#160;47</font></div><div style="margin-top:5.95pt;padding-left:10.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">ARTICLE 15 MISCELLANEOUS&#160;&#160;&#160;&#160;47</font></div><div style="margin-top:6.05pt;padding-left:82.1pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">15.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:16.8pt">ENTIRE AGREEMENT&#59; AMENDMENT&#160;&#160;&#160;&#160;47</font></div><div style="margin-top:5.95pt;padding-left:82.15pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">15.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:16.8pt">FORCE MAJEURE&#160;&#160;&#160;&#160;48</font></div><div style="margin-top:6.1pt;padding-left:82.15pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">15.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:16.8pt">NOTICES&#160;&#160;&#160;&#160;48</font></div><div style="margin-top:5.95pt;padding-left:82.15pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">15.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:16.8pt">NO STRICT CONSTRUCTION&#59; HEADINGS&#160;&#160;&#160;&#160;49</font></div><div style="margin-top:5.95pt;padding-left:82.15pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">15.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:16.8pt">INTERPRETATION&#160;&#160;&#160;&#160;49</font></div><div style="margin-top:6.05pt;padding-left:82.15pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">15.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:16.8pt">ASSIGNMENT&#160;&#160;&#160;&#160;49</font></div><div style="margin-top:5.95pt;padding-left:82.15pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">15.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:16.8pt">PERFORMANCE BY AFFILIATES&#160;&#160;&#160;&#160;49</font></div><div style="margin-top:6.1pt;padding-left:82.2pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">15.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:16.8pt">FURTHER ACTIONS&#160;&#160;&#160;&#160;49</font></div><div style="height:60pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">-iii-</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><div id="i9b16f1ba634f40d19a7a1b6dadea2dc9_50"></div><hr style="page-break-after:always"><div style="min-height:92pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:80%">TABLE OF CONTENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(continued)</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Page</font></div></div><div style="margin-top:22.6pt;padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">15.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:16.8pt">SEVERABILITY&#160;&#160;&#160;&#160;49</font></div><div style="margin-top:5.95pt;padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">15.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:11.3pt">WAIVER AND NON-EXCLUSION OF REMEDIES&#160;&#160;&#160;&#160;49</font></div><div style="margin-top:6.1pt;padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">15.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:11.3pt">INDEPENDENT CONTRACTORS&#160;&#160;&#160;&#160;50</font></div><div style="margin-top:5.95pt;padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">15.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:11.3pt">ENGLISH LANGUAGE&#160;&#160;&#160;&#160;50</font></div><div style="margin-top:6.05pt;padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">15.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:11.3pt">COUNTERPARTS&#160;&#160;&#160;&#160;50</font></div><div style="margin-top:5.95pt;padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">15.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:11.3pt">CHOICE OF LAW&#160;&#160;&#160;&#160;50</font></div><div style="height:60pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">-iv-</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><div id="i9b16f1ba634f40d19a7a1b6dadea2dc9_53"></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div><font><br></font></div><div style="margin-top:9.55pt;padding-left:74.7pt;padding-right:74.7pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">COLLABORATION, OPTION AND LICENSE AGREEMENT</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:46pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">THIS COLLABORATION, OPTION AND LICENSE AGREEMENT </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;) is</font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">entered into as of July 30, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;) by and between EXICURE, INC., a corporation organized and existing under the laws of Delaware and having a principal place of business at 2430 N. Halsted Street, Chicago, IL 60614, United States (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Exicure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;), and IPSEN BIOPHARM LIMITED, a company organized under the laws of England, located at Ash Road, Wrexham Industrial Estate, Wrexham LL13 9UF, United Kingdom (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Ipsen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;). Exicure and Ipsen are sometimes referred to herein individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; and collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.&#8221;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:165.67pt;padding-right:165.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">BACKGROUND</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Exicure owns or otherwise Controls certain materials, patents, patent applications, technology, know-how, scientific and technical information and other proprietary rights and information relating to spherical nucleic acids (such spherical nucleic acids, together with any modifications or derivatives thereof, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">SNAs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;).</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Ipsen is a global biopharmaceutical company that conducts research, development, manufacturing and commercialization of branded biopharmaceutical products.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Exicure and Ipsen desire to collaborate together to research and develop SNAs in accordance with the terms and conditions set forth herein.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The purpose of this Agreement is for Exicure to grant to Ipsen, and for Ipsen to receive from Exicure, on a Program-by-Program basis, exclusive options to obtain exclusive and non-exclusive licenses  to &#91;***&#93;.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">NOW THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement, the Parties agree as follows&#58;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:213.52pt;padding-right:213.52pt;text-align:center;text-indent:-0.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:233%">ARTICLE 1 DEFINITIONS</font></div><div style="padding-left:46pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:108%">As used in this Agreement, the following initially capitalized terms, whether used in the singular</font></div><div style="margin-top:0.05pt;padding-left:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">or plural form, will have the meanings set forth in this Article 1.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:9.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Accounting Standards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means United States GAAP or International Financial Reporting Standards (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">IFRS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;), as applicable, which principles or standards are currently used at the relevant time and consistently applied by the applicable Party. All accounting terms used herein with respect to Ipsen that are not specifically defined herein should be determined in accordance with IFRS accounting principles, as consistently applied by Ipsen.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:9.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, with respect to a particular Person, a person, corporation, partnership, or other entity that controls, is controlled by or is under common control with such Person. For the purposes of this definition, the word &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; (including, with correlative meaning, the terms &#8220;controlled by&#8221; or &#8220;under the common control with&#8221;) means the actual power, either directly or indirectly through one or more intermediaries, to direct or cause the direction of the management and policies of such Person, whether by the ownership of &#91;***&#93; of the voting stock or other equity interests of such Person, or by contract or otherwise.</font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><div id="i9b16f1ba634f40d19a7a1b6dadea2dc9_56"></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:10.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in the preamble to this Agreement.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:9.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Alliance Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 4.1.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:9.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">ANDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means an Abbreviated New Drug Application pursuant to 21 U.S.C. &#167; 355(j) and 21 C.F.R. &#167; 314.3.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:9.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Applicable Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means the applicable laws, rules, regulations, guidelines and other requirements of Governmental Authorities, including Regulatory Authorities, that may be in effect from time to time, including GLP, GMP and the Foreign Corrupt Practices Act of 1977, as amended.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:9.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">A-S Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means the program of Research or Development of SNAs targeting &#91;***&#93; that Exicure engages in under this Agreement pursuant to the applicable R&#38;D Term Plans.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:9.5pt">&#8220;&#91;***&#93;&#8221; has the meaning set forth in Section 7.6(a)(ii).</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:9.5pt">&#8220;&#91;***&#93;&#8221; has the meaning set forth in Section 7.6(a)(ii).</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;&#91;***&#93;&#8221; means &#91;***&#93;.</font></div><div style="margin-top:0.45pt;padding-left:10pt;padding-right:21.7pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Bankrupt Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 13.7.</font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Bankruptcy Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means Title 11, United States Code, as amended.</font></div><div style="margin-top:0.45pt;padding-left:10pt;padding-right:21.7pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Breaching Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 13.3(a).</font></div><div style="margin-top:0.55pt;padding-left:10pt;padding-right:21.7pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Budget</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 4.2(b)(iii).</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means a day other than a Saturday or a Sunday or a bank or other public holiday in Chicago, Illinois or Paris, France.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Calendar Quarter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Calendar Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means each successive period of twelve (12) months commencing on January 1 and ending on December 31.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, with respect to a Party, (a) completion of a merger, reorganization, amalgamation, arrangement, share exchange, consolidation, tender or exchange offer, private purchase, business combination, recapitalization or other transaction involving a Party as a result of which the stockholders of such Party immediately preceding such transaction hold &#91;***&#93; of the outstanding shares, or &#91;***&#93; of the outstanding voting power, respectively, of the ultimate company or entity resulting from such transaction immediately after consummation thereof (including a company or entity which as a result of such transaction owns the then- outstanding securities of a Party or all or substantially all of a Party&#8217;s assets, either directly or through one or more subsidiaries), (b) the adoption of a plan relating to the liquidation or dissolution of a Party, other than &#91;***&#93; (without limitation of clause (a), above)&#59; (c) any sale, lease, exchange, contribution or other transfer (in one transaction or a series of related transactions) to a Third Party of all or substantially all the assets of a Party (determined on a consolidated basis)&#59; or (d) the sale or disposition to a Third Party of assets or businesses that constitute &#91;***&#93; of the total revenue or assets of a Party (determined on a consolidated basis).</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 11.1.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div style="padding-left:10pt;padding-right:21.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means any clinical trial in humans that is designed to generate data in support or maintenance of an IND or MAA, or other similar marketing application, including any Phase I Clinical Trial, Phase I&#47;II Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial, Pivotal Clinical Trial, or Phase IV Clinical Trial.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Combination Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means (a) a Licensed Product that, in addition to containing a Licensed SNA as an active component, also contains at least one other active pharmaceutical ingredient that is not a Licensed SNA (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Other API</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;)&#59; or (b) any sale of a Licensed Product with another product(s) or service(s) for a single invoice price (each such Other API, other product or other service, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Other Component</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;).</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Combination Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 1.110.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Commercialize</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, together with all correlative meanings, the import, export, marketing, promotion, sale or distribution of a product, including commercial activities conducted in preparation for a product launch. Commercialization shall expressly exclude (a) Research,</font></div><div style="margin-top:0.2pt;padding-left:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b) Development and (c) Manufacture.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Commercially Reasonable Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, with respect to the efforts to be expended, or considerations to be undertaken, by a Party with respect to any objective or activity to be undertaken hereunder, reasonable, good faith efforts to accomplish such objective or activity as such Party would normally use to accomplish a similar objective or activity under similar circumstances, it being understood and agreed that with respect to the Development, Manufacture, seeking and obtaining Regulatory Approval, or Commercialization of any Licensed Product, such efforts and resources will be consistent with those efforts and resources commonly used by biopharmaceutical companies of similar size to such Party under similar circumstances for similar compounds or products owned by it or to which it has similar rights, which compound or product, as applicable, is at a similar stage in its development or product life and is of similar market potential, taking into account&#58; (a) issues of efficacy, safety, tolerability and expected and actual approved labeling, (b) &#91;***&#93;, (c) the expected and actual product profile of the Licensed Product, (d) the expected and actual patent and other proprietary position of the Licensed Products, (e) &#91;***&#93;, (f) the expected and actual profitability and return on investment of the Licensed Product, or other compounds or products in such Party&#8217;s portfolio of compounds or products, taking into consideration, among other factors, expected and actual (i) &#91;***&#93;, (ii) &#91;***&#93;, and (iii) &#91;***&#93;.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:10.05pt;padding-right:21.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">1.25.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:3.95pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:118%">Competitive Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#8221; means the &#91;***&#93; or the &#91;***&#93;, as applicable.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:10.05pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.26.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3.95pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 12.1.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9.95pt;padding-right:21.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.27.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4.1pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Controlled</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, with respect to any materials, compounds, Information, Patents, Regulatory Materials or Regulatory Approvals, the possession (whether by ownership or license, but other than pursuant to this Agreement) by a Party or its Affiliates of the ability or right to grant to the other Party a license, sublicense or access as provided herein to such item, without violating the terms of any agreement or other arrangement with any Third Party, in existence as of the time such Party or its Affiliates would first be required hereunder to grant the other Party such license, sublicense or access&#59; provided that, any New Affiliate of a Party shall not be considered an Affiliate of such Party for the purposes of this definition, but only if such Party, such New Affiliate and such Party&#8217;s other Affiliates are not in &#91;***&#93; of the provisos in Sections 7.6(b)(i) and 7.6(b)(ii).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.28.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Cover</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">,&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Covering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means&#58; (a) with respect to a Patent, that, in the absence of a license granted to a Person under an issued Valid Claim included in such Patent, the practice by such Person of the subject matter at issue would infringe such Valid Claim, or (b) with respect to an application for Patents, that, in the absence of a license granted to a Person under a pending Valid Claim included in such application, the practice by such Person of the subject matter at issue would infringe such Valid Claim if such Patent application were to issue as a Patent including such Valid Claim as an issued Valid Claim.</font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">3</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div><font><br></font></div><div style="padding-left:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.29.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">CPA Firm</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 8.5(e)(i).</font></div><div style="padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.30.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Criteria</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 4.2(b)(iv).</font></div><div style="margin-top:0.45pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.31.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Cure Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 13.3(a).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:10pt;padding-right:18.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.32.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Develop</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, together with all correlative meanings, pre-clinical and clinical drug development activities, conducted before or after obtaining Regulatory Approval that are &#91;***&#93; related to or leading to the development, preparation, and submission of data and information to a Regulatory Authority for the purpose of obtaining, supporting or expanding Regulatory Approval or to the appropriate body for obtaining, supporting or expanding pricing and reimbursement approval, including without limitation, all activities related to preclinical testing, assay development and validation, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">in vivo </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">testing, biomarker development and validation, toxicology, pharmacokinetic profiling, design and conduct of Clinical Trials and any other clinical trials or studies, regulatory affairs, statistical analysis, report writing, and Regulatory Material creation and submission (including the services of outside advisors and consultants in connection therewith). Development expressly excludes (a) Research, (b) Commercialization and (c) the Manufacture and accumulation of commercial inventory of a product.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.33.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 14.1(a).</font></div><div style="padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.34.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">DOJ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 3.8(b).</font></div><div style="margin-top:0.45pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.35.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in the preamble to this Agreement.</font></div><div style="margin-top:0.45pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.36.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">EMA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means the European Medicines Agency or its successor.</font></div><div style="margin-top:0.45pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">1.37.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Executive Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#8221; means (a) in the case of Ipsen, the Chief Business Officer of Ipsen, and (b) in the case of Exicure, the chief executive officer of Exicure, who, in each case of (a) and (b), will not be a member of the JSC.</font></div><div style="margin-top:0.2pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.38.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Exicure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in the preamble to this Agreement.</font></div><div style="margin-top:0.35pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.45pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">1.39.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Exicure Background Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#8221; means, on a Program-by-Program basis, any and all Patents and Information Controlled by Exicure or any of its Affiliates &#91;***&#93; or that comes  into the Control of Exicure during the Term for such Program (other than pursuant to this Agreement), in each case related to such Program.</font></div><div style="margin-top:0.15pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.40.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Exicure Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 11.2.</font></div><div style="margin-top:0.3pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">1.41.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Exicure Licensed Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#8221; means, on a Program-by-Program basis, the Exicure SNA Technology, the Exicure Background Technology, and the Exicure Other Technology, in each case with respect to such Program.</font></div><div style="margin-top:0.2pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.42.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Exicure Other IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 9.1(c).</font></div><div style="margin-top:0.45pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.43.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Exicure Other Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, on a Program-by-Program basis, any and all Patents and Information that comes into the Control of Exicure or any of its Affiliates during the Term for such Program pursuant to this Agreement and relates to such Program, including Patents Covering, and Information claiming or covering, the R&#38;D Term IP, the Exicure Other IP, or Exicure&#8217;s interest in the Joint Other IP Invented in such Program, in each case other than &#91;***&#93;.</font></div><div style="margin-top:0.55pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.44.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Exicure SNA Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 9.2(c)(i).</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.45.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Exicure SNA Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, on a Program-by-Program basis, any and all Information claiming or covering, and any and all Patents Covering the Inventions or Results within the </font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">4</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div style="padding-left:10pt;padding-right:21.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">R&#38;D Term IP, the Exicure Other IP, or Exicure&#8217;s interest in the Joint Other IP Invented in such Program &#91;***&#93;.</font></div><div><font><br></font></div><div style="padding-left:10pt;padding-right:21.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.46.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4.05pt">&#8220;&#91;***&#93;&#8221; means the &#91;***&#93;, made &#91;***&#93;, by and between &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.47.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;&#91;***&#93;&#8221; means the &#91;***&#93;, made with effect from  &#91;***&#93;, by and between &#91;***&#93; and &#91;***&#93;, and the &#91;***&#93;,  made &#91;***&#93; and effective as of &#91;***&#93;, by and between &#91;***&#93; and &#91;***&#93;, each as amended from time to time.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.48.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Exploit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Exploitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, collectively, to make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported, export, have exported and otherwise exploit and have exploited, including to Research, Develop, Manufacture and Commercialize.</font></div><div style="margin-top:0.1pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.49.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means the United States Food and Drug Administration or its successor.</font></div><div style="margin-top:0.45pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.50.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">FD&#38;C Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means the United States Federal Food, Drug and Cosmetic Act, as amended.</font></div><div style="margin-top:0.45pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.51.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;&#91;***&#93;&#8221; has the meaning set forth in Section 6.2.</font></div><div style="margin-top:0.45pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.52.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">First Commercial Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, (a) with respect to a Licensed Product and a country, the first sale to a Third Party of such Licensed Product in such country after all Regulatory Approvals (excluding, for the avoidance of doubt, any pricing or reimbursement approvals, as applicable, except &#91;***&#93;) have been obtained in such country, or (b) with respect to a &#91;***&#93; and a country, the first sale of such &#91;***&#93; as a pharmaceutical product in such country after all Regulatory Approvals (excluding, for the avoidance of doubt, any pricing or reimbursement approvals, as applicable, except &#91;***&#93;) have been obtained in such country, but with respect to and (b), First Commercial Sale excludes &#91;***&#93;.</font></div><div style="margin-top:0.45pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.53.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">First Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 3.1.</font></div><div style="margin-top:0.3pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.54.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">First Option Data Package</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, on a Program-by-Program basis, (a) &#91;***&#93;, (b) &#91;***&#93;, (c) &#91;***&#93;, (d) &#91;***&#93;, and (e) &#91;***&#93; all activities undertaken by or on behalf of Exicure during the First R&#38;D Term in preparation for the Second R&#38;D Term for such Program (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Preparation Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;).</font></div><div style="margin-top:0.5pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.55.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">First Option Exercise Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, on a Program-by-Program basis, the date on which the First Option Exercise Notice for such Program is delivered by Ipsen to Exicure.</font></div><div style="margin-top:0.5pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">1.56.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">First Option Exercise Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#8221; means, on a Program-by-Program basis, the written notice to exercise the First Option for such Program delivered by Ipsen to Exicure, effective on the date on which the written notice is delivered.</font></div><div style="margin-top:0.2pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.57.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">First Option Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 8.2.</font></div><div style="margin-top:0.3pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.58.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">First Option Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, on a Program-by-Program basis, the period beginning on &#91;***&#93;, and ending on &#91;***&#93;.</font></div><div style="padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.59.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">First R&#38;D Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, on a Program-by-Program basis, the period beginning on &#91;***&#93; and ending on &#91;***&#93;.</font></div><div style="padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.60.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">First R&#38;D Term Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 2.2.</font></div><div style="margin-top:0.45pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.61.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">FTC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 3.8(b).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9.95pt;padding-right:18.1pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.62.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4.1pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">FTE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means the equivalent of a full-time employee&#8217;s work time for a twelve (12) month period, where such employee is an appropriately qualified and trained person and where &#8220;full-time&#8221; is determined by &#91;***&#93; hours per year. In the event that any employee who works full-time during a given fiscal year works partially on Licensed SNAs or Licensed Products or in furtherance of the applicable </font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">5</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div style="margin-top:0.05pt;padding-left:9.95pt;padding-right:18.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Program and partially on other work outside the Program in the fiscal year, then the full-time equivalent to be attributed to such employee&#8217;s work hereunder for such fiscal year will be equal to the percentage of such employee&#8217;s total work time in such fiscal year that such employee spent working on Licensed SNAs or Licensed Products or in furtherance of the Program, as recorded monthly in an appropriate hourly time-sheet system. FTE efforts will not include the work of general corporate or administrative personnel or Third Party consultants or contractors&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, that FTE efforts will include Exicure&#8217;s project management functions as specified in the applicable R&#38;D Term Plan.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:13.35pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.63.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">FTE Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means &#91;***&#93; per FTE per Calendar Year, which amount shall &#91;***&#93;&#59; provided, however,  in no event shall the FTE Rate per Calendar Year exceed &#91;***&#93;.</font></div><div style="margin-top:0.5pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.64.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">GAAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means U.S. generally accepted accounting principles.</font></div><div style="margin-top:0.4pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">1.65.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%;padding-left:4pt">&#8220;&#91;***&#93;&#8221; means, with respect to a &#91;***&#93; in a country in the Territory, the &#91;***&#93; in which the &#91;***&#93; of the &#91;***&#93; in such country  occurred.</font></div><div style="margin-top:0.05pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.66.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;&#91;***&#93;&#8221; means, with respect to a particular &#91;***&#93; in a country, &#91;***&#93; in such country by a Regulatory Authority through an &#91;***&#93; , or any &#91;***&#93;, or pursuant to any similar &#91;***&#93; in any countries in the Territory&#59; or (b) (i) contains the same &#91;***&#93;&#59; and (ii) is approved for use in such country by a &#91;***&#93;, or &#91;***&#93;, first submitted by Ipsen or its Affiliates or Sublicensees for obtaining Regulatory Approval for such Licensed Product, in each case other than &#91;***&#93;.</font></div><div style="margin-top:0.5pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.67.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Good Laboratory Practices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">GLP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means the then-current practices and procedures set forth in Title 21, United States Code of Federal Regulations, Part 58 (as amended), and any other regulations, guidelines or guidance documents relating to good laboratory practices, or any foreign equivalents thereof in the country in which such studies or clinical trials are conducted.</font></div><div style="margin-top:0.55pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;padding-right:19pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.68.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Good Manufacturing Practices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">GMP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means the then-current practices and procedures set forth in Title 21, United States Code of Federal Regulations, Parts 210 &#8211; 211, ICH Guideline Q7A, and any other regulations, guidelines or guidance documents relating to good manufacturing practices, or any foreign equivalents thereof in the country in which such manufacturing activities are conducted.</font></div><div style="margin-top:0.4pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.69.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Governmental Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means any multi-national, federal, state, local, municipal or other government authority of any nature (including any governmental division, subdivision, department, agency, bureau, branch, office, commission, council, court or other tribunal).</font></div><div style="padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.70.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;&#91;***&#93;&#8221; has the meaning set forth in Section 7.6(a)(i).</font></div><div style="margin-top:0.45pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">1.71.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">HD Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#8221; means the program of Research or Development of SNAs targeting the &#91;***&#93; (collectively, &#8220;&#91;***&#93;&#8221;) that Exicure engages in under this Agreement pursuant to the applicable R&#38;D Term Plan(s).</font></div><div style="margin-top:0.2pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.72.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;&#91;***&#93;&#8221; has the meaning set forth in Section 7.6(a)(i).</font></div><div style="margin-top:0.3pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">1.73.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">HSR Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#8221; means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules and regulations promulgated thereunder, or any successor statute, rules and regulations thereto.</font></div><div style="margin-top:0.2pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.74.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;&#91;***&#93;&#8221; has the meaning set forth in Section 1.71.</font></div><div style="margin-top:0.55pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.75.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">ICC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 14.1(b).</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.76.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4.05pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">IND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means (a) an Investigational New Drug Application as defined in the FD&#38;C Act and applicable regulations promulgated thereunder by the FDA, or (b) a clinical trial application or similar </font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">6</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div style="padding-left:10pt;padding-right:21.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">equivalent application or submission to the equivalent Regulatory Authority in any other regulatory jurisdiction, the filing of which is necessary to initiate or conduct clinical testing of a pharmaceutical product in humans in such jurisdiction.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">1.77.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">IND Filing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#8221; means, on a Program-by-Program basis, the filing of an IND by or on behalf of Exicure for a Licensed SNA or Licensed Product in such Program under the Second R&#38;D Term Plan for such Program, at the sole discretion of Exicure (unless Ipsen exercises its rights under Section 3.7).</font></div><div style="margin-top:0.2pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.78.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 11.3.</font></div><div style="margin-top:0.55pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.79.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Indemnifying Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 11.3.</font></div><div style="margin-top:0.45pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.80.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;&#91;***&#93;&#8221; has the meaning set forth in Section 1.110.</font></div><div style="margin-top:0.45pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.81.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means any &#91;***&#93;.</font></div><div style="margin-top:0.35pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">1.82.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:118%">Initiation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#8221; means, together with all correlative meanings, the first dosing of the first subject or patient in a Clinical Trial.</font></div><div style="margin-top:0.1pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.83.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;&#91;***&#93;&#8221; has the meaning set forth in Section 6.2.</font></div><div style="padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.84.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Interim Report</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 2.3(a).</font></div><div style="margin-top:0.45pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.85.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;&#91;***&#93;&#8221; has the meaning set forth in Section 6.2.</font></div><div style="margin-top:0.45pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.86.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Invented</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 9.1(b).</font></div><div style="margin-top:0.45pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">1.87.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#8221; mean all inventions, discoveries, improvements, modifications, enhancements or creations, in each case whether or not patentable, and any intellectual property rights (including Information and Patents) arising from any of the foregoing.</font></div><div style="margin-top:0.2pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.88.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Ipsen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in the preamble to this Agreement.</font></div><div style="margin-top:0.45pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.89.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Ipsen Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 11.1.</font></div><div style="margin-top:0.3pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">1.90.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Ipsen Licensed Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#8221; means any and all Patents and Information that comes into the Control of Ipsen or any of its Affiliates pursuant to this Agreement, including Patents Covering, and Information claiming or covering, the Ipsen Other IP or Ipsen&#8217;s interest in the Joint Other IP.</font></div><div style="margin-top:0.2pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.91.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Ipsen Other IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 9.1(c).</font></div><div style="margin-top:0.55pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.92.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Ipsen R&#38;D Term Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 9.1(b).</font></div><div style="margin-top:0.35pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.93.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Ipsen Reversion IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, on a Program-by-Program basis, any Patents or Information that (a) (i) are included in the Ipsen Licensed Technology with respect to such Program, or (ii) claim or cover any &#91;***&#93; in such Program or its method of manufacture or use &#91;***&#93;, (b) are Controlled by Ipsen or any of its Affiliates &#91;***&#93;, and (c) were used or are being used by Ipsen or any of its Affiliates to Research, Develop, Manufacture or Commercialize the &#91;***&#93;.</font></div><div style="padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.94.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Joint Other IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 9.1(c).</font></div><div style="margin-top:0.4pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.95.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Joint R&#38;D Term Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 9.1(b).</font></div><div style="margin-top:0.55pt;padding-left:10pt;text-indent:36pt"><font><br></font></div><div style="padding-left:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.96.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Joint Steering Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">JSC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 4.2(a).</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">7</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div style="margin-top:0.05pt;padding-right:21.6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.97.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Licensed A-S Program SNA(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means any SNA that (a) has been tested by Exicure during the First R&#38;D Term for the A-S Program as targeting &#91;***&#93;, (b) is Controlled by Exicure during such First R&#38;D Term, and (c) is Selected by the JSC pursuant to Section 4.2(b)(v) for identification in the First Option Data Package for the A-S Program.</font></div><div style="margin-top:0.5pt;text-indent:36pt"><font><br></font></div><div style="padding-right:21.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.98.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Licensed HD Program SNA(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means any SNA that (a) has been tested by Exicure during the First R&#38;D Term for the HD Program as targeting &#91;***&#93;, (b) is Controlled by Exicure during such First R&#38;D Term, and (c) is Selected by the JSC pursuant to Section 4.2(b)(v) for identification in the First Option Data Package for the HD Program.</font></div><div style="margin-top:0.4pt;text-indent:36pt"><font><br></font></div><div style="margin-top:0.05pt;padding-right:21.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">1.99.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:14pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:118%">Licensed Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#8221; means any product containing a &#91;***&#93;. For clarity, a  Licensed Product includes any &#91;***&#93;.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-right:21.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">1.100.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:8.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:118%">Licensed SNA(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#8221; means the &#91;***&#93; or the &#91;***&#93;, as applicable.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-right:21.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">1.101.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%;padding-left:8.5pt">&#8220;&#91;***&#93;&#8221; means a condition where, with respect to &#91;***&#93; in a particular country in the Territory, one or more &#91;***&#93; in such country by a Third Party.</font></div><div style="margin-top:0.1pt;text-indent:36pt"><font><br></font></div><div style="padding-right:18.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">1.102.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:8.5pt">&#8220;&#91;***&#93;&#8221; means each of the &#91;***&#93;.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="margin-top:0.05pt;padding-right:21.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.103.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:8.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Manufacture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Manufacturing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, with respect to a product, those manufacturing activities involved in or relating to (a) manufacturing process development, (b) CMC activities including analytical development and qualification, formulation development, solubility testing, bulk drug substance manufacturing, stability testing and scale-up activities, bulk drug product manufacturing and stability testing, (c) quality assurance and quality control activities including validation testing, qualification and audit of clinical and commercial manufacturing facilities, and (d) in the case of either a clinical or commercial supply of such product or supply of such product for any non-clinical study, the manufacturing, processing, formulating, packaging, labeling, shipping, holding, quality control testing and release of such product. When used as a noun, &#8220;Manufacturing&#8221; means any of the foregoing activities. &#8220;Manufacturing&#8221; refers to both nonclinical and clinical Manufacturing for Research and Development, and Manufacturing for Commercialization.</font></div><div style="margin-top:0.45pt;text-indent:36pt"><font><br></font></div><div style="padding-right:21.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.104.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:8.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Manufacturing Cost</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, with respect to a particular Licensed SNA (whether as active pharmaceutical ingredient or finished form) supplied by Exicure pursuant to Section 6.1, &#91;***&#93; of (a) if Exicure or its Affiliate Manufactures the applicable Licensed SNA, the &#91;***&#93; of such Licensed SNA (as determined &#91;***&#93;)&#59; or (b) if a Third Party Manufactures such Licensed SNA, &#91;***&#93;, in either case &#91;***&#93;, and supported by &#91;***&#93; and auditable by Ipsen to be further described in the Supply Agreement.</font></div><div style="margin-top:0.5pt;text-indent:36pt"><font><br></font></div><div style="margin-top:0.05pt;padding-right:21.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.105.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:8.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Manufacturing Technology Transfer Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 6.2.</font></div><div style="margin-top:0.5pt;text-indent:36pt"><font><br></font></div><div style="padding-right:21.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.106.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:8.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Marketing Authorization Application</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">MAA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means any biologics license application or other marketing authorization application, in each case, filed with the applicable Regulatory Authority in a country or other regulatory jurisdiction, &#91;***&#93;, including all Biologics License Applications or equivalent submitted to the FDA or any analogous application or submission with any Regulatory Authority outside of the United States.</font></div><div style="margin-top:0.4pt;text-indent:36pt"><font><br></font></div><div style="margin-top:0.05pt;padding-right:21.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.107.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:8.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means &#91;***&#93;.</font></div><div style="margin-top:0.05pt;text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.108.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:8.5pt">&#8220;&#91;***&#93;&#8221; has the meaning set forth in Section 1.110.</font></div><div style="margin-top:0.35pt;text-indent:36pt"><font><br></font></div><div style="padding-right:21.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">1.109.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%;padding-left:8.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">NDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#8221; means a New Drug Application, as defined in the FD&#38;C Act and applicable regulations promulgated thereunder by the FDA, or any analogous application or submission with any Regulatory Authority outside of the United States.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">8</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.65pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.110.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, with respect to a Licensed Product in a country in the Territory, the gross amount &#91;***&#93; Ipsen, its Affiliates or Sublicensees to Third Parties (including distributors, resellers, wholesalers, Government Authorities, benefit management organizations, health insurance carriers, hospitals, group purchasing organizations, other institutions, and end users), less the following deductions &#91;***&#93;&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.65pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">customary discounts in the trade for quantity purchased, cash discounts, &#91;***&#93; payment, in each case actually paid, granted or accrued on the Licensed Product, or retro-active price reductions and charge-back payments, and rebates granted to wholesalers, distributors, government authorities, benefit management organizations, health insurance carriers, hospitals, and group purchasing organizations&#59;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9.95pt;padding-right:21.65pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%;padding-left:13.23pt">credits or allowances actually given or made for credit rejections, recalls, rebates, chargebacks, billing errors, or refunds for price adjustments, claims, returns that do not exceed the original invoice amount&#59;</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.75pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.85pt">any sales, use, excise turnover, inventory, value-added, import, export, consumption, or similar taxes, customs, or other duties and compulsory payments to Governmental Authorities and any other governmental charges imposed relating to the sale of such Licensed Product to Third Parties, as adjusted for reimbursement, rebates and refunds of or on such taxes, duties or governmental charges from any Third Party, including pharmaceutical excise taxes&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.18pt">amounts written off as uncollectible, if and when actually written off or allowed, after &#91;***&#93; have been exhausted (&#91;***&#93;)&#59; provided that any such amounts will be added back to Net Sales if and when collected&#59; and</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.75pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.85pt">freight, insurance and other transportation charges incurred and separately invoiced in shipping a Licensed Product to Third Parties&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">in each case to the extent such deductions&#58; &#91;***&#93;.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Sales and other transfer of a Licensed Product between any of Ipsen, its Affiliates and Sublicensees will not give rise to Net Sales &#91;***&#93;,  but rather the Net Sales will be deemed to have arisen upon the subsequent sale of the Licensed Product to Third Parties.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Net Sales will include the transfer of Licensed Products to non-Sublicensee Third Parties by Ipsen, its Affiliates or Sublicensees in connection with Clinical Trials, compassionate use or expanded access programs, indigent programs, promotional sampling or technology transfer activities, in each case, for monetary or other financial consideration no less than &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">With respect to any sale of any Licensed Product in any country for any substantive consideration other than &#91;***&#93;, for purposes of calculating the Net Sales under this Agreement, such Licensed Product shall be deemed to be sold &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">In the event that any Licensed Product is sold as a Combination Product (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Combination Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;), the Net Sales amount for such Licensed Product sold in such a Combination Sale in any period and country shall be &#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, if the calculation of Net Sales resulting from a Combination Sale cannot be determined by the foregoing method, the calculation of Net Sales for such Combination Sale shall be calculated &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.111.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:8.55pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Net Sales Royalty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 8.5(a).</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.112.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:8.55pt">&#8220;&#91;***&#93;&#8221; has the meaning set forth in Section 8.5(a).</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">9</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.113.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">New Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means a Third Party that becomes an Affiliate of a Party after &#91;***&#93; (a) through a Change of Control of such Party, or (b) because such Party acquires such Third Party or a portion of the business of such Third Party (whether by merger, stock purchase, purchase of assets, reorganization, consolidation or otherwise).</font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.114.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;&#91;***&#93;&#8221; has the meaning set forth in Section 7.3(b).</font></div><div style="margin-top:0.45pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.115.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Non-Breaching Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 13.3(a).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.116.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, on a Program-by-Program basis, the First Option or the Second Option, as applicable.</font></div><div style="margin-top:0.4pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">1.117.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:118%">Option Exercise Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#8221; means, on a Program-by-Program basis, the First Option Exercise Date or the Second Option Exercise Date for such Program, as applicable.</font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">1.118.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:118%">Option Exercise Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#8221; means, on a Program-by-Program basis, the First Option Exercise Notice or the Second Option Exercise Notice for such Program, as applicable.</font></div><div style="margin-top:0.15pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.119.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Option Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 8.2.</font></div><div style="margin-top:0.3pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">1.120.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:118%">Option Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#8221; means, on a Program-by-Program basis, the First Option Period or the Second Option Period for such Program, as applicable.</font></div><div style="margin-top:0.1pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.121.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Orange Book</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 9.6(b).</font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.122.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Other API</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 1.21.</font></div><div style="margin-top:0.45pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.123.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;&#91;***&#93;&#8221; has the meaning set forth in Section 7.6(a)(ii).</font></div><div style="margin-top:0.45pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.124.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Other Component</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 1.21.</font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.125.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;&#91;***&#93;&#8221; has the meaning set forth in 7.6(a)(ii).</font></div><div style="margin-top:0.45pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.126.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Other IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 9.1(c).</font></div><div style="margin-top:0.45pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.127.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in the preamble to this Agreement.</font></div><div style="margin-top:0.3pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.128.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Patent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means (a) any national, regional or international patent or patent application, including any provisional patent application, (b) any patent application filed either from such a patent, patent application or provisional application or from an application claiming priority from any of these, including any divisional, continuation, continuation-in-part, provisional, converted provisional, and continued prosecution application, (c) any patent that has issued or in the future issues from any of the foregoing patent applications (in each case (a) and (b)), including any utility model, petty patent, design patent and certificate of invention, (d) any extension or restoration by existing or future extension or restoration mechanisms, including any revalidation, reissue, re-examination and extension (including any supplementary protection certificate and the like) of any of the foregoing patents or patent applications (in each case (a), (b) and (c)), and (e) any similar rights, including so-called pipeline protection, or any importation, revalidation, confirmation or introduction patent or registration patent or patent of additions to any such foregoing patent application or patent.</font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.129.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Patent Challenge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 13.4.</font></div><div style="margin-top:0.45pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.130.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture or other similar entity or organization, including a government or political subdivision, department or agency of a government.</font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">10</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">1.131.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Phase I Clinical Trial(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#8221; means a human clinical trial(s) of a product, the principal purpose of which is a determination of initial tolerance or safety of such product in healthy volunteers or the target patient population, as described in 21 CFR 312.21(a) (as amended or any replacement thereof), or a similar clinical trial prescribed by the Regulatory Authority in a country other than the United States.</font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.132.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Phase I&#47;II Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means a Clinical Trial (or any arm thereof) of a pharmaceutical or biologic product with the endpoint of determining initial tolerance, safety, metabolism, pharmacokinetic or pharmacodynamic information in single dose, single ascending dose, multiple dose, or multiple ascending dose regimens, and evaluating its effectiveness for a particular indication or indications in one or more specified doses or its short term tolerance and safety, as well as its pharmacokinetic and pharmacodynamic information in patients with the indications under study, that is prospectively designed to generate sufficient data (if successful) to commence a Pivotal Clinical Trial for such product, and that satisfies the requirements of U.S. federal regulation 21 C.F.R. &#167;&#167; 312.21(a) and (b) and its successor regulation or equivalents in other jurisdictions.</font></div><div style="margin-top:0.5pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.133.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Phase II Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means a human clinical trial of a product, the principal purpose of which is a determination of safety and efficacy in the target patient population, as described in 21 C.F.R. 312.21(b) (as amended or any replacement thereof), or a similar clinical trial prescribed by the Regulatory Authority in a country other than the United States.</font></div><div style="margin-top:0.4pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.134.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Phase III Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means a human clinical trial of a product, the design of which is acknowledged by the FDA to be sufficient for such clinical trial to satisfy the requirements of 21 C.F.R. 312.21(c) (as amended or any replacement thereof), or a similar human clinical trial prescribed by the Regulatory Authority in a country other than the United States, the design of which is acknowledged by such Regulatory Authority to be sufficient for such clinical trial to satisfy the requirements of a pivotal efficacy and safety clinical trial.</font></div><div style="margin-top:0.5pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.135.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Phase IV Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means any study of a product following the first Regulatory Approval for the sale of such product whether or not required by a Governmental Authority. Phase IV Clinical Trials may include epidemiological studies, modeling and pharmacoeconomic studies, post- marketing surveillance studies and clinical or other research studies.</font></div><div style="margin-top:0.5pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.136.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Pivotal Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means any (a) &#91;***&#93; of a pharmaceutical or biologic product on a sufficient number of patients, the results of which, together with prior data and information concerning such product, are &#91;***&#93; in any particular jurisdiction and that is intended to support, or otherwise supports, the filing of an MAA by a &#91;***&#93; in such jurisdiction (including any bridging study). Notwithstanding any provision to the contrary set forth in this Agreement, treatment of patients as part of &#91;***&#93;, in each case, will &#91;***&#93;.</font></div><div style="margin-top:0.4pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">1.137.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:3pt">&#8220;&#91;***&#93;&#8221; means the &#91;***&#93; or its successor.</font></div><div style="margin-top:0.15pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.138.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Preparation Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 1.54.</font></div><div style="margin-top:0.45pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.139.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Preparation Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means the FTEs and &#91;***&#93; in  performing the Preparation Activities with respect to a Program&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, (a) such FTE time shall not exceed &#91;***&#93;, and &#91;***&#93;, (b) in the event of termination of this Agreement with respect to a Program under Sections 13.1, 13.2 or 13.3, any Preparation Costs incurred with respect to &#91;***&#93; for such Program shall be applied to the other Program at Ipsen&#8217;s request if such Preparation Costs have not at such time been incurred for such other Program, and (c) if this Agreement terminates in its entirety pursuant to Sections 13.1, 13.2 or 13.3, and Exicure &#91;***&#93;.</font></div><div style="margin-top:0.45pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.140.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means the HD Program or the A-S Program, as applicable. For clarity, following exercise of the First Option or Second Option, as applicable, references in this Agreement to </font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">11</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Licensed SNA(s) or Licensed Products that are in, for, or with respect to, a specific Program are referring to the Licensed SNA(s) or Licensed Products that had been Selected from such Program.</font></div><div style="margin-top:0.4pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">1.141.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:118%">Program Fields</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#8221; means the treatment, cure, maintenance or palliation of either &#91;***&#93;.</font></div><div style="margin-top:0.15pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.142.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;&#91;***&#93;&#8221; has the meaning set forth in Section 6.1.</font></div><div style="margin-top:0.3pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">1.143.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:118%">R&#38;D Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#8221; means, on a Program-by-Program basis, the First R&#38;D Term or the Second R&#38;D Term, as applicable.</font></div><div style="margin-top:0.1pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.144.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">R&#38;D Term IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 9.1(b).</font></div><div style="margin-top:0.45pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.145.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">R&#38;D Term Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, on a Program-by-Program basis, the First R&#38;D Term Plan or the Second R&#38;D Term Plan, as applicable.</font></div><div style="margin-top:0.55pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="margin-top:0.3pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.146.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 2.3(b).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font></div><div style="margin-top:0.3pt;padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.147.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Regulatory Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means all approvals necessary for the Manufacture, marketing, importation and sale of a product for one or more indications in a country or regulatory jurisdiction, which may include satisfaction of all applicable regulatory and notification requirements, including any pricing and reimbursement approvals. Regulatory Approvals include approvals by Regulatory Authorities of INDs, MAAs, or NDAs.</font></div><div style="margin-top:0.45pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.148.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Regulatory Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, in a particular country or regulatory jurisdiction, any applicable Governmental Authority involved in granting Regulatory Approval or, &#91;***&#93;, pricing or reimbursement approval of a product in such country or regulatory jurisdiction, including (a) the FDA, (b) the EMA, and (c) the &#91;***&#93;.</font></div><div style="margin-top:0.55pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.149.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Regulatory Exclusivity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means any exclusive marketing rights or data exclusivity rights conferred by any Regulatory Authority with respect to a Licensed Product other than &#91;***&#93;, including, without limitation, rights conferred in the U.S. under the Hatch-Waxman Act or the FDA Modernization Act of 1997 (including pediatric exclusivity), orphan drug exclusivity, or rights similar thereto outside the U.S.</font></div><div style="margin-top:0.45pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.150.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Regulatory Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means regulatory applications, submissions, notifications, registrations, or other filings made to or with a Regulatory Authority that are necessary or reasonably desirable in order to Develop, Manufacture, market, sell or otherwise Commercialize a Licensed Product in a particular country or regulatory jurisdiction. Regulatory Materials include INDs, MAAs and NDAs (as applications, but not the approvals with respect thereto).</font></div><div style="margin-top:0.45pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.151.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Research</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, together with all correlative meanings, with respect to a specific SNA, activities related to &#91;***&#93;. Research shall expressly exclude (a) Development, (b) Commercialization and (c) Manufacture, and (d) on a Program-by-Program basis, with respect to any activities undertaken by Ipsen after exercising the Option for such Program pursuant to Sections 3.3, 3.6, or 3.7, including &#8220;Research&#8221; as set forth in Section 7.5, the discovery, identification or profiling of SNAs.</font></div><div style="margin-top:0.5pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.152.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Results</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means &#91;***&#93; pursuant to this Agreement during the applicable R&#38;D Term.</font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.153.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Reversion Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 13.5(b)(i).</font></div><div style="margin-top:0.45pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.154.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Reversion Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means any product containing a Reversion SNA.</font></div><div style="margin-top:0.3pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.155.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Reversion SNA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, on a Program-by-Program basis, (a) all Licensed SNAs in such Program, and (b) other SNAs comprising the nucleic acid sequences in the Licensed SNAs, modifications thereto or derivatives thereof.</font></div><div style="margin-top:0.1pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">12</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.156.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, as applicable.</font></div><div style="margin-top:0.5pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.157.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Royalty Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 8.5(a).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font></div><div style="margin-top:0.3pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.158.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, on a Program-by-Program, country-by-country and Licensed Product-by-Licensed Product basis, the period commencing upon &#91;***&#93; and ending upon the later to occur of (a) &#91;***&#93;, (b) &#91;***&#93;, or (c) &#91;***&#93;&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided, however, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">in no event shall the Royalty Term for such Licensed Product in the Territory exceed &#91;***&#93; from &#91;***&#93;.</font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.159.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Rules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 14.1(b).</font></div><div style="margin-top:0.45pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.160.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means the U.S. Securities and Exchange Commission.</font></div><div style="margin-top:0.45pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.161.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Second Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 3.4.</font></div><div style="margin-top:0.45pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.162.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Second Option Data Package</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, on a Program-by-Program basis, (a) &#91;***&#93;, and</font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b) &#91;***&#93;.</font></div><div style="margin-top:0.4pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.163.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Second Option Exercise Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, on a Program-by-Program basis, the date on which the Second Option Exercise Notice for such Program is delivered by Ipsen to Exicure and such Second Option Exercise Notice takes effect.</font></div><div style="margin-top:0.45pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">1.164.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:118%">Second Option Exercise Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#8221; means, on a Program-by-Program basis, the written notice to exercise the Second Option for such Program delivered by Ipsen to Exicure.</font></div><div style="margin-top:0.15pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.165.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Second Option Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 8.2.</font></div><div style="margin-top:0.45pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.166.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Second Option Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, on a Program-by-Program basis and only in the event Ipsen did not exercise the First Option with respect to such Program and this Agreement has not expired or been terminated with respect to such Program, the period beginning on &#91;***&#93;, and ending on &#91;***&#93;.</font></div><div style="margin-top:0.5pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.167.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Second R&#38;D Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, on a Program-by-Program basis and only in the event Ipsen did not exercise the First Option with respect to such Program but agreed to fund Exicure&#8217;s activities under the Second R&#38;D Term Plan for the Program during the First Option Period for such Program, the period beginning on &#91;***&#93; and ending on &#91;***&#93;.</font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.168.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Second R&#38;D Term Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 2.2.</font></div><div style="margin-top:0.45pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.169.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Selection</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 4.2(b)(v).</font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.170.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">SNAs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in the recitals of this Agreement.</font></div><div style="margin-top:0.3pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.171.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Sublicensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means any Third Party granted a sublicense by Ipsen under the rights licensed to Ipsen pursuant to Article 7 hereof&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">a &#8220;Sublicensee&#8221; does not include any of Ipsen&#8217;s Affiliates, subcontractors, consultants and agents providing goods or services on behalf of Ipsen with respect to Licensed SNAs or Licensed Products, including contract manufacturing organizations, contract research organizations or clinical trial sites, or wholesale distributors of Ipsen, its Affiliates or Sublicensees who purchase Licensed Products from Ipsen, or such Affiliates or Sublicensee in an &#91;***&#93; transaction  and who have no other obligation, including a &#91;***&#93;, to Ipsen, such Affiliates or Sublicensees,  with respect to any subsequent use or disposition of such Licensed Products, but only to the extent that the  rights of such Affiliates, subcontractors, consultants and agents with respect to Licensed SNAs or Licensed  Products are limited to providing goods or services on behalf of Ipsen, its Affiliates or Sublicensee under this Agreement.</font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.172.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Supply Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 6.1.</font></div><div style="margin-top:0.45pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">13</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.173.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means &#91;***&#93; or &#91;***&#93;, as applicable.</font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.174.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 13.1.</font></div><div style="margin-top:0.45pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.175.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means worldwide.</font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.176.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means any Person other than Exicure or Ipsen or their respective Affiliates.</font></div><div style="margin-top:0.3pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.177.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Third Party Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means any &#91;***&#93; agreement between Exicure (or any of its Affiliates) and any Third Party (a) related to the Research of any Licensed SNA or Licensed Product, or (b) otherwise including a license from or to such Third Party to any Exicure Licensed Technology (or Information or Patents that would be Exicure Licensed Technology if Controlled by Exicure or its Affiliate), to the extent related to the HD Program or the A-S Program.</font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.178.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Transition Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 13.5(b).</font></div><div style="margin-top:0.45pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.179.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Transition Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 13.5(b).</font></div><div style="margin-top:0.45pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.180.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">U.S.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">United States</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means the United States of America and its possessions and territories, including Puerto Rico.</font></div><div style="margin-top:0.5pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.181.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">U.S. CPI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, the consumer price index as published by the Bureau of Labor Statistics,</font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">U.S. Department of Labor, or any replacement index published by a U.S. Governmental Authority, if applicable.</font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.182.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">USD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">$</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means United States Dollars, the lawful currency of the United States.</font></div><div style="margin-top:0.35pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.183.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Valid Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means a claim of any pending Patent application or any issued, unexpired United States or granted foreign Patent that has not been dedicated to the public, disclaimed, abandoned or held invalid or unenforceable by a court or other body of competent jurisdiction from which no further appeal can be taken, and that has not been explicitly disclaimed, or admitted in writing to be invalid or unenforceable or of a scope not Covering a particular product or service through reissue, disclaimer or otherwise, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">if a particular claim has not issued within &#91;***&#93; of its initial filing, it shall not be considered a Valid Claim for purposes of this Agreement unless and until such claim is included in an issued or granted Patent, notwithstanding the foregoing definition.</font></div><div style="margin-top:0.45pt;padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1.184.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:3pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">VAT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 8.6.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:165.72pt;padding-right:165.72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">ARTICLE 2</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:74.7pt;padding-right:74.7pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">R&#38;D TERM RESEARCH AND DEVELOPMENT</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.25pt;text-decoration:underline">Goals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. The objective for the First R&#38;D Term is, on a Program-by-Program basis, for Exicure to perform certain Research activities in order to permit Ipsen to evaluate whether to exercise the First Option with respect to such Program. The objective for the Second R&#38;D Term is, on a Program-by- Program basis and only in the event Ipsen did not exercise the First Option with respect to such Program but did decide to fully fund the Research and Development activities during the Second R&#38;D Term, for Exicure to perform such Research and Development activities in order to permit Ipsen to evaluate whether to exercise the Second Option with respect to such Program.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.25pt;text-decoration:underline">R&#38;D Term Plans&#59; Performance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. On a Program-by-Program basis, during the First R&#38;D Term for such Program, the Research activities of Exicure will follow a research plan designed to obtain Results in such Program necessary for the JSC to make the Selection for such Program, which includes&#58;</font></div><div style="margin-top:0.1pt;padding-left:9.95pt;padding-right:21.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.85pt">the responsibilities of Exicure, and (b) an intended timeline showing the key activities and anticipated timeframes in which such activities are expected to be completed (including the Selection) </font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">14</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div style="margin-top:0.1pt;padding-left:9.95pt;padding-right:21.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">First R&#38;D Term Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;). </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> sets forth background information and outline for the HD Program. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> set forth background information and outline for the &#91;***&#93;. The First R&#38;D Term Plan for the HD Program is set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Exhibit A1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> and the First R&#38;D Term Plan for the A-S Program is set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Exhibit B1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. On a Program-by-Program basis, during the First R&#38;D Term for each Program, Exicure shall have the right to modify or amend the First R&#38;D Term Plan for such Program, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, that any modifications or amendments to the First R&#38;D Term Plan (x) will be subject to review and comment by the JSC pursuant to Section 4.2(b) and (y) will not modify the Criteria, or the definition of &#91;***&#93; set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Exhibit A1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Exhibit B1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, as applicable. On a Program-by-Program basis, during the Second R&#38;D Term for such Program, if any, Research and Development activities of Exicure will follow a research and development plan designed to enable the filing of an IND with respect to such Program which includes (i) the responsibilities of Exicure, (ii) an estimated budget for both FTE number and &#91;***&#93;, and (iii) a general timeline showing the key activities (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Second R&#38;D Term Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;). An &#91;***&#93;, high-level version of the Second R&#38;D Term Plan for the HD Program is set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Exhibit A2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> and a refined version shall be included in the First Option Data Package for the HD Program, and an &#91;***&#93;, high-level version of the Second R&#38;D Term Plan for the A-S Program is set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Exhibit B2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> and a refined version shall be included in the First Option Data Package for the A-S Program. On a Program-by-Program basis, during the Second R&#38;D Term for such Program, if any, Exicure shall have the right to modify or amend the Second R&#38;D Term Plan, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, that any modifications or amendments to the Second R&#38;D Term Plan will be subject to review and comment by the JSC pursuant to Section 4.2(b).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9.95pt;padding-right:21.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.3pt;text-decoration:underline">Obligations Under the R&#38;D Term Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. On a Program-by-Program basis, Exicure will perform and &#91;***&#93; complete (itself or through its Affiliates or by permitted subcontracting) its obligations under the applicable R&#38;D Term Plans. Without limiting the generality of the foregoing, on a Program-by-Program basis, Exicure will &#91;***&#93; (a) obtain Results in such Program necessary for the JSC to make the Selection for such Program within &#91;***&#93; after the Effective Date and (b) in the event Ipsen does not exercise the First Option with respect to such Program, submit the IND Filing for the first Licensed SNA for such Program within the timelines in the applicable Second R&#38;D Term Plan (&#91;***&#93;). The Parties agree that, notwithstanding anything in this Agreement to the contrary, on a Program-by-Program basis, so long as Exicure has performed and &#91;***&#93; complete its activities under the First R&#38;D Term Plan, in the event the JSC has determined &#91;***&#93;, this Agreement shall automatically expire with respect to such Program upon the expiration of the &#91;***&#93; period&#59; provided, however, in the event the JSC cannot agree upon whether an SNA has met the Criteria, such period will be extended &#91;***&#93;. Exicure will not be required to perform activities under the Second R&#38;D Term Plan for a Program &#91;***&#93;. In addition, Exicure will not be required to perform any work which is not contemplated by any R&#38;D Term Plan, &#91;***&#93;. For the avoidance of doubt, Ipsen shall be responsible for the Preparation Costs in accordance with the Budget, regardless of whether the Preparation Activities may be considered additional work, by &#91;***&#93; paying Exicure any and all Preparation Costs in accordance with the Budget as they are incurred, in each case &#91;***&#93;.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.65pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.85pt;text-decoration:underline">Interim Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. During the applicable R&#38;D Term, at each meeting of the JSC, Exicure shall provide to the JSC a written report which shall detail all activities undertaken and all accomplishments achieved under the applicable R&#38;D Term Plan, planned activities for the subsequent &#91;***&#93; , progress against any timelines and any other aspects that the JSC may &#91;***&#93; request, if any, since the previous report, in sufficient detail and in a good scientific manner (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Interim Report</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;). During the applicable R&#38;D Term for each Program, Exicure shall &#91;***&#93; notify Ipsen with respect to &#91;***&#93; generated by or for Exicure and Controlled by Exicure relating to the SNAs (including Licensed SNAs) being Researched and Developed under such Program. Without limiting the foregoing, periodically (but at least once every six weeks) during the applicable R&#38;D Term, Exicure will host informal data review meetings to update Ipsen with respect to Exicure&#8217;s recent activities under the applicable R&#38;D Term Plan. Such data review meetings may be conducted telephonically. Should Ipsen request that a meeting be held in person at its premises or outside Exicure&#8217;s premises, such meeting will be organized by Ipsen and &#91;***&#93; shall be paid by and be borne by Ipsen.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">15</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.18pt;text-decoration:underline">Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. During the applicable R&#38;D Term, Exicure will maintain, or cause to be maintained, records and laboratory notebooks with respect to its performance of activities under the applicable R&#38;D Term Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;) in sufficient detail and in a good scientific manner and format appropriate for (i) scientific purposes, (ii) inclusion in Regulatory Materials, and (iii) obtaining and maintaining intellectual property rights and protections, in each case ((i)-(iii)) for a period of &#91;***&#93; after the expiration or termination of the applicable R&#38;D Term. Such Records shall be complete and accurate in all material respects and shall fully and properly reflect all work done, data and developments made, and results achieved under the applicable R&#38;D Term Plan.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.65pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt;text-decoration:underline">Ownership&#59; Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Exicure shall own all rights, title and interest (including all intellectual property rights) in and to the Results, the Records and the content of each Interim Report generated by or for it during all R&#38;D Terms. The Results, the Records and the content of each Interim Report shall in each case be subject to the rights and obligations of the Parties under this Agreement, including Article 12 and the licenses granted under Article 7.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9.95pt;padding-right:21.65pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.28pt">The Parties agree that, notwithstanding anything in this Agreement to the contrary, on a Program-by-Program basis, in the event no IND Filing has occurred in such Program by the end of &#91;***&#93; after the Second R&#38;D Term begins (&#91;***&#93;), Exicure will deliver a written report of all activities undertaken and all accomplishments achieved by or on behalf Exicure in connection with the Second R&#38;D Term Plan for such Program, and all of Exicure&#8217;s Results in such Program during the Second R&#38;D Term for such Program, in each case &#91;***&#93; in sufficient detail and in a good scientific manner. Within &#91;***&#93; after receiving the report, Ipsen shall notify Exicure in writing whether Ipsen wishes to continue with the activities under the Second R&#38;D Term Plan. If Ipsen notifies Exicure in writing that Ipsen does not wish to continue with the activities under the Second R&#38;D Term Plan, the Second R&#38;D Term shall automatically terminate upon the delivery of such written notice. If Ipsen notifies Exicure in writing that Ipsen wishes to continue with the activities under the Second R&#38;D Term Plan, Exicure may, upon receipt of such written notice, elect to (i) continue &#91;***&#93; complete its remaining obligations under the Second R&#38;D Term Plan&#59; or (ii) have Ipsen assume Exicure&#8217;s remaining obligations under the Second R&#38;D Term Plan, in each case by delivering a written notice to Ipsen. In the event Exicure elects to have Ipsen assume Exicure&#8217;s remaining obligations under the Second R&#38;D Term Plan, Ipsen hereby agrees to, &#91;***&#93;, (i) assume such obligations immediately upon Ipsen&#8217;s receipt (A) of Exicure&#8217;s written election, and (B) from Exicure of such materials, including quantities of Selected SNAs, necessary to continue such obligations, (ii) &#91;***&#93; complete such obligations, and (iii) keep Exicure fully and timely informed of all activities (on the same basis as Exicure had kept Ipsen informed of its activities) undertaken and all accomplishments achieved (including all Results obtained) by or on behalf Ipsen in connection with performing such obligations. Exicure may terminate this Agreement with respect to such Program by delivering written notice to Ipsen, such termination to be effective upon &#91;***&#93; following the date of such notice, in the event that Ipsen has assumed Exicure&#8217;s remaining obligations under the Second R&#38;D Term Plan but Ipsen or any of its Affiliates fails to conduct any &#91;***&#93; under the Second R&#38;D Term Plan with respect to such Program for a continuous period of longer than &#91;***&#93;.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt">R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">&#38;D Term Research and Development Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:10pt;padding-right:21.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%;padding-left:13.8pt;text-decoration:underline">First R&#38;D Term Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">. Exicure shall bear &#91;***&#93; incurred in connection with its activities under each First R&#38;D Term Plan.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:10pt;padding-right:21.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%;padding-left:13.18pt;text-decoration:underline">Second R&#38;D Term Plan FTE Support</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">. During the Second R&#38;D Term for each Program, Ipsen will pay Exicure for FTE hours actually worked at the applicable FTE Rate so long as &#91;***&#93;&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:117%">provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%"> (i) Ipsen&#8217;s obligation to compensate Exicure shall be subject to &#91;***&#93;&#59; and (ii) for the avoidance of doubt, any delay of Exicure in relation to invoicing Ipsen for a payment under this Section 2.4(b) by no more than &#91;***&#93; shall not prejudice the rights of Exicure to receive the payment and shall only be relevant to the timing of receipt of such payment. Within &#91;***&#93; after the end of each &#91;***&#93; during the Second R&#38;D Term, Exicure shall send a &#91;***&#93; to Ipsen, which shall include &#91;***&#93;. &#91;***&#93;, Ipsen will make payment &#91;***&#93;. &#91;***&#93; shall be approved by the JSC. For clarity, the FTE Rate shall apply only to </font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">16</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div style="margin-top:4.55pt;padding-left:10pt;padding-right:21.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">employees of Exicure.  &#91;***&#93; shall be paid in accordance with Section 2.4(c). Exicure shall use the Research and Development funding it receives from Ipsen under this Agreement solely to carry out its activities under the applicable Program in accordance with the applicable Second R&#38;D Term Plan and the terms and conditions of this Agreement and for no other purposes.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.65pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt;text-decoration:underline">Second R&#38;D Term Plan Payment for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#91;***&#93;. For each &#91;***&#93; during the Second R&#38;D Term for each Program, Ipsen will &#91;***&#93;, so long as &#91;***&#93;. &#91;***&#93; Ipsen will pay &#91;***&#93;. &#91;***&#93; shall be approved  by the JSC. Exicure shall be solely responsible for managing the performance of its subcontractors. Exicure agrees to provide Ipsen with full transparency &#91;***&#93; with respect to the Second R&#38;D Term Plan.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.3pt;text-decoration:underline">Subcontractors for the R&#38;D Term Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Subject to the remainder of this Section 2.5, Exicure may engage subcontractors to perform its obligations under the applicable R&#38;D Term Plan. In all cases, Exicure shall ensure that (a) it remains responsible for the work allocated to such subcontractors to the same extent it would if it had done such work itself, (b) the subcontractor undertakes in writing obligations of &#91;***&#93;, and (c) the  subcontractor undertakes in writing to &#91;***&#93;. Without limiting the generality of the foregoing, Exicure may subcontract any of its obligations under the applicable R&#38;D Term Plan to a university or academic institution &#91;***&#93;, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, &#91;***&#93;. The engagement of any subcontractor in compliance with this Section 2.5 shall not relieve Exicure of its obligations under the applicable R&#38;D Term Plan or this Agreement.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:78.27pt;padding-right:78.27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">ARTICLE 3</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:78.27pt;padding-right:78.27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">OPTION GRANT&#59; OPTION DATA PACKAGES&#59; OPTION EXERCISE</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.25pt;text-decoration:underline">First Option Grant. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">On a Program-by-Program basis, Exicure hereby grants to Ipsen the right, but not the obligation, to exercise an exclusive option during the First Option Period for such Program to obtain the licenses set forth in Section 7.1 with respect to such Program (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">First Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;).</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt;text-decoration:underline">First Option Data Package</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:9.95pt;padding-right:21.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">On a Program-by-Program basis, no later than &#91;***&#93; after the later of (a) the Selection by the JSC for such Program pursuant to Section 4.2(b)(v) or (b) the approval by the JSC of the Budget pursuant to Section 4.2(b)(iii), Exicure will (i) provide to Ipsen the First Option Data Package for such Program, and (ii) afford &#91;***&#93; access during normal business hours to Exicure&#8217;s personnel by Ipsen and its representatives as Ipsen may &#91;***&#93; request to assist Ipsen in deciding whether to exercise the First Option. In addition, during the First Option Period, Exicure will &#91;***&#93; provide any additional Information regarding the First Option Data Package for such Program &#91;***&#93;, provided Ipsen makes such request &#91;***&#93; upon discovering the need for such additional Information and such additional Information is limited to Information already in Exicure&#8217;s Control and does not require Exicure to undertake any further activity in connection with the First R&#38;D Term Plan. For the avoidance of doubt, such request for additional Information does not prejudice the status of the First Option Data Package being &#8220;complete&#8221; for purposes of Section 1.58.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.25pt;text-decoration:underline">First Option Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. On a Program-by-Program basis, Ipsen may exercise the First Option with respect to such Program by delivering a First Option Exercise Notice in respect of such First Option to Exicure at any time during the First Option Period for such Program. Following such delivery, Ipsen will pay the First Option Fee to Exicure in accordance with Section 8.1. For clarity, on a Program- by-Program basis, after &#91;***&#93;, Ipsen will be responsible and have authority for all Research, Development, Manufacturing and Commercialization of all Licensed SNA(s) and Licensed Products in such Program. On a Program-by-Program basis, during the First Option Period for such Program, if Ipsen (a) does not exercise the First Option with respect to such Program, (b) does not agree in writing to fund Exicure&#8217;s activities under the Second R&#38;D Term Plan for such Program in accordance with the Budget pursuant to Section 2.4(b), or (c) &#91;***&#93;, this Agreement will expire with respect to such Program upon the expiration of the First Option Period.</font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">17</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.25pt;text-decoration:underline">Second Option Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. On a Program-by-Program basis, and only in the event Ipsen did not exercise the First Option with respect to such Program and this Agreement has not expired or been terminated with respect to such Program, Exicure hereby grants to Ipsen the right, but not the obligation, to exercise an exclusive option during the Second Option Period to obtain the licenses set forth in Section 7.1 with respect to such Program (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Second Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.25pt;text-decoration:underline">Second Option Data Package</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. On a Program-by-Program basis, and only in the event Ipsen did not exercise the First Option with respect to such Program, no later than &#91;***&#93; after the IND Filing for such Program in &#91;***&#93;, Exicure will (a) provide to Ipsen the Second Option Data Package for such Program, and (b) afford &#91;***&#93; access during normal business hours to Exicure&#8217;s personnel by Ipsen and its representatives as Ipsen may &#91;***&#93; request to assist Ipsen in deciding whether to exercise the Second Option.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">3.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.3pt;text-decoration:underline">Second Option Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. On a Program-by-Program basis, and only in the event Ipsen did not exercise the First Option with respect to such Program and this Agreement has not expired or been terminated with respect to such Program, Ipsen may exercise the Second Option with respect to such Program by delivering a Second Option Exercise Notice in respect of such Second Option to Exicure at any time during the Second Option Period for such Program. Following such delivery, Ipsen will pay the Second Option Fee to Exicure in accordance with Section 8.2. For clarity, on a Program-by-Program basis, after &#91;***&#93;, Ipsen will be responsible and have sole authority for all Research, Development, Manufacturing and Commercialization of all Licensed SNA(s) and Licensed Products for such Program.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">3.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.3pt;text-decoration:underline">Early Second Option Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Notwithstanding the foregoing, Ipsen shall have the right &#91;***&#93; to obtain a Second Option Data Package and to exercise the Second Option with respect to a program by delivering a Second Option Exercise Notice with respect to such Program &#91;***&#93;. Exicure will so prepare and deliver such Second Option Data Package within &#91;***&#93; of the request of Ipsen. After early exercise of the Second Option, Ipsen will be responsible and have authority for all Research, Development, Manufacturing and Commercialization of all Licensed SNA(s) and Licensed Products for such Program.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9.95pt;padding-right:21.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">For clarity, any request by Ipsen for the Second Option Data Package in and of itself shall not constitute an exercise of the Second Option, nor does failure to deliver a Second Option Exercise Notice pursuant to this Section 3.7 constitute a waiver of Ipsen&#8217;s rights to obtain a Second Option Data Package pursuant to Section 3.4 and to exercise its Second Option following the relevant IND Filing.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">3.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt;text-decoration:underline">Government Approvals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:9.95pt;padding-right:21.65pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.85pt;text-decoration:underline">Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Following the exercise of the Option for a Program, Exicure, at the request of Ipsen, will collaborate with Ipsen, and the Parties will &#91;***&#93; eliminate any concern on the part of any Governmental Authority regarding the legality of the licenses granted hereunder including, if required by federal or state antitrust authorities, &#91;***&#93; taking all steps to secure government antitrust clearance, including cooperating in &#91;***&#93; with any government investigation including the &#91;***&#93; production of documents and information demanded by a second request for documents and of witnesses if requested. Notwithstanding anything to the contrary in this Agreement, this Section 3.8(a) and the term &#8220;&#91;***&#93;&#8221; does not require that either Party (a) offer, negotiate, commit to or effect, by consent decree, hold separate order, trust or otherwise, the sale, divestiture, license or other disposition of any capital stock, assets, rights, products or businesses of Exicure, Ipsen or their respective Affiliates, (b) agree to any restrictions on the businesses of Exicure, Ipsen or their respective Affiliates, or (c) pay any amount or take any other action to prevent, effect the dissolution of, vacate, or lift any decree, order, judgment, injunction, temporary restraining order, or other order in any suit or proceeding that would otherwise have the effect of preventing or delaying the transactions contemplated by this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.65pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.23pt;text-decoration:underline">HSR Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. If the exercise of the Option for a Program requires clearance under the HSR Act, Ipsen and Exicure will, within &#91;***&#93; after delivery of the applicable Option Exercise Notice </font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">18</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div style="padding-left:9.95pt;padding-right:21.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(or such later time as may be agreed to in writing by the Parties) file with the U.S. Federal  Trade Commission (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">FTC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;) and the Antitrust Division of the U.S. Department of Justice (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">DOJ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;) any HSR Filing required of it under the HSR Act &#91;***&#93; with respect to the licenses granted hereunder. In such circumstances, Exicure, at the request of Ipsen, will collaborate with Ipsen, &#91;***&#93;, and &#91;***&#93;. Ipsen shall be responsible for &#91;***&#93;. In the event that Ipsen makes an HSR Filing under this Section 3.8(b), the licenses granted under Section 7.1 shall not be effective &#91;***&#93;. As used herein&#58; (x) &#8220;HSR Clearance Date&#8221; means the earliest date on which the Parties have actual knowledge that all applicable waiting periods under the HSR Act with respect to the transactions contemplated by exercise of the Option have expired or have been terminated&#59; and (y) &#8220;HSR Filing&#8221; means a filing by Ipsen with the FTC and the DOJ of a Notification and Report Form for Certain Mergers and Acquisitions (as that term is defined in the HSR Act) with respect to the matters set forth herein, together with all required documentary attachments thereto. In the event that clearance under the HSR Act is not obtained in connection with the exercise of an Option for a Program, Exicure may terminate this Agreement with respect to such Program with immediate effect.</font></div><div><font><br></font></div><div style="padding-left:10pt;padding-right:21.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt;text-decoration:underline">Information Exchange</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Each of Exicure and Ipsen will, in connection with any HSR Filing, to the extent permitted by Applicable Law and not prohibited by the Governmental Authority,</font></div><div style="margin-top:0.05pt;padding-left:9.95pt;padding-right:21.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%;padding-left:13.85pt">cooperate with each other in connection with any communication, filing or submission and in connection with any investigation or other inquiry, including any proceeding initiated by a private party&#59; (b) keep the other Party and&#47;or its counsel informed of any communication received by such Party from, or given by such Party to, the FTC, the DOJ or any other U.S. or other Governmental Authority and of any communication received or given in connection with any proceeding by a private party, in each case regarding the transactions contemplated hereunder&#59; (c) &#91;***&#93; in advance of any meeting or conference with the FTC, the DOJ or any other Governmental Authority or, in connection with any proceeding by a private party, with any other Person, and to the extent permitted by the FTC, the DOJ or such other Governmental Authority or other Person, give the Parties and&#47;or their counsel the opportunity to &#91;***&#93;&#59; and (d) permit the other Party and&#47;or its counsel to review in advance any submission, filing or communication (and documents submitted therewith) intended to be given by it to the FTC, the DOJ or any other Governmental Authority&#59; provided, that materials may be redacted to remove references concerning the valuation of the business of Exicure. Exicure and Ipsen, as each deems advisable and necessary, may &#91;***&#93; designate any competitively sensitive material to be provided to the other under this Section 3.8(c) as &#8220;Antitrust Counsel Only Material.&#8221; Such materials and the information contained therein shall be given only to the outside antitrust counsel of the recipient and will not be disclosed by such outside counsel to employees, officers or directors of the recipient &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">3.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.25pt;text-decoration:underline">Assistance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Subject to this Section 3.9, following the exercise of the Option, Exicure shall cooperate with Ipsen whom will &#91;***&#93; make all other registrations, filings and applications, to give all notices and to obtain as soon as practicable all governmental or other consents, transfers, approvals, orders, qualifications, authorizations, permits and waivers, if any, and to do all other things necessary or desirable for the consummation of the transactions as contemplated hereby.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:165.7pt;padding-right:165.7pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">ARTICLE 4</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:165.62pt;padding-right:165.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">R&#38;D TERM GOVERNANCE</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.3pt;text-decoration:underline">Alliance Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Within &#91;***&#93; of the Effective Date, each Party will appoint an individual (from such Party or from an Affiliate of such Party) who possesses a general understanding of Research issues to act as the facilitator of the meetings of the JSC and the first point of contact between the Parties with regard to questions relating to this Agreement or the overall business relationship and related matters between the Parties (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Alliance Managers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;). Each Party may replace its Alliance Manager at any time upon written notice to the other Party. The Alliance Managers&#58;</font></div><div><font><br></font></div><div style="padding-left:10pt;padding-right:21.75pt;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.85pt">will &#91;***&#93; collaborate, organize and attend all meetings of the JSC, as a non-voting member&#59; and</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">19</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div style="padding-left:9.95pt;padding-right:21.7pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:13.23pt">may bring any matter to the attention of the JSC where such Alliance Manager &#91;***&#93; believes that such matter requires attention.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt;text-decoration:underline">Joint Steering Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9.95pt;padding-right:13.35pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.85pt;text-decoration:underline">Formation&#59; Composition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Within &#91;***&#93; of the Effective Date, the Parties will establish a joint steering committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Joint Steering Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">JSC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;) comprised of &#91;***&#93; representatives from each Party (or appointed representatives of an Affiliate of such Party) with sufficient seniority and experience to fulfill the scope of the JSC&#8217;s responsibilities. Each Party may replace its JSC representatives at any time upon notice to the other Party. The JSC may invite non-members to &#91;***&#93;. Each meeting of the JSC will be co-chaired by a representative of Exicure and a representative of Ipsen. The role of the chairpersons will be to convene and preside at meetings of the JSC. The chairpersons will have no additional powers or rights beyond those held by the other JSC representatives. The Alliance Managers will work with the chairpersons to prepare and circulate agendas and to ensure the preparation of minutes.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:118pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.23pt;text-decoration:underline">Specific Responsibilities During the R&#38;D Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. The JSC will, on a Program-by-</font></div><div style="margin-top:0.05pt;padding-left:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Program basis&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:15.68pt">review and comment on, and oversee the performance of, the First R&#38;D Term Plan for such Program and, if applicable, the Second R&#38;D Term Plan for such Program&#59;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.58pt">review the progress of activities under the First R&#38;D Term Plan and, if applicable, the Second R&#38;D Term Plan and advise regarding any amendments thereto, including any amendment to the timelines or activities under such R&#38;D Term Plan(s)&#59;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:9.95pt;padding-right:21.75pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:9.58pt">review and approve &#91;***&#93; to be included as &#91;***&#93;, collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Budget</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;&#59;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.65pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:10.23pt">modify the acceptance criteria for a Licensed SNA in such Program (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:118%">Criteria</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#8221;), if necessary, the &#91;***&#93;version of which is set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;text-decoration:underline">Exhibit A1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;text-decoration:underline">Exhibit B1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">, as applicable&#59;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:10pt;padding-right:21.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:13.23pt">select SNA(s) identified by Exicure during the First R&#38;D Term for such Program that meet or exceed the Criteria (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:118%">Selection</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#8221;)&#59;</font></div><div><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:10.18pt">establish subcommittees to perform specific duties of the JSC, direct each such subcommittee to perform the functions for which it is established, and oversee each subcommittee, including resolution of disputes raised to the JSC by any subcommittee, provided that the subcommittees shall have no decision-making authority&#59; and</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.85pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:7.08pt">perform such other functions as appropriate, to further the purposes of this Agreement, in each case as agreed in writing by the Parties.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:118pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.85pt;text-decoration:underline">Meetings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:9.95pt;padding-right:21.65pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:15.68pt">During the applicable R&#38;D Term, the JSC will meet &#91;***&#93;  per &#91;***&#93;. No later than &#91;***&#93;, the Alliance Managers will jointly prepare and circulate an agenda for such meeting&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, that either Party may propose additional topics to be included on such agenda, &#91;***&#93;. Either Party may also call a special meeting of the JSC (by videoconference, teleconference or in person) by providing at least &#91;***&#93; prior notice to the other Party if &#91;***&#93;, in which event such Party will work with the chairpersons of the JSC to provide the members of the JSC no later than &#91;***&#93; with an agenda for the meeting and materials &#91;***&#93;. The JSC may meet in person, by videoconference or by teleconference. In-person JSC meetings will be held at locations mutually agreed upon by Exicure and Ipsen. Each Party will bear &#91;***&#93;.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9.95pt;padding-right:21.65pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.63pt">The Alliance Managers will be responsible for preparing &#91;***&#93; written minutes of all JSC meetings that reflect topics discussed and action items identified at such meetings. The </font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">20</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div style="margin-top:0.05pt;padding-left:9.95pt;padding-right:21.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Alliance Managers will send draft meeting minutes to each member of the JSC for review and approval within &#91;***&#93; after each JSC meeting. Such minutes will be deemed approved &#91;***&#93;. Upon any such objection, the members shall work together &#91;***&#93; to &#91;***&#93; revise such minutes &#91;***&#93;. Minutes will be officially endorsed by the JSC at the next JSC meeting.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%;padding-left:13.18pt;text-decoration:underline">Decision-Making</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">. The representatives from each Party on the JSC will have, collectively, one (1) vote on behalf of that Party, and all decision-making will be by consensus. Disputes at the JSC will be handled in accordance with Section 4.3.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt;text-decoration:underline">Resolution of JSC Disputes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:9.95pt;padding-right:21.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.85pt;text-decoration:underline">Within the JSC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Subject to the exception specified below in this Section 4.3(a), all decisions within the JSC will be made by consensus. If the JSC is unable to reach consensus on any issue for which it is responsible, within &#91;***&#93; after a Party affirmatively states that a decision needs to    be made, either Party may elect to submit such issue to the Parties&#8217; Executive Officers, in accordance with Section 4.3(b).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.23pt;text-decoration:underline">Referral to Executive Officers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. If a Party makes an election under Section 4.3(a) to refer a matter to the Executive Officers, the Executive Officers will &#91;***&#93; to resolve &#91;***&#93; such matter, which &#91;***&#93; will include at least &#91;***&#93; in-person, video or telephonic meeting between such Executive Officers within &#91;***&#93; after the submission of such matter to them. If the Executive Officers are unable to reach consensus on any such matter within &#91;***&#93; after its submission to them, then (a) any matter set forth in Sections 4.2(b)(iii), 4.2(b)(iv), and 4.2(b)(v) will be resolved pursuant to Section 14.1(c), (b) &#91;***&#93; will be decided by Exicure, and (c) &#91;***&#93; will be decided by Ipsen&#59; except that any matter relating solely to the day-to-day conduct of the Second R&#38;D Term Plan or any application of Exicure Background Technology shall be decided by Exicure.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9.95pt;padding-right:21.65pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.85pt;text-decoration:underline">Good Faith</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. In conducting themselves on the JSC, and in exercising their rights under this Section 4.3, all representatives of both Parties will consider &#91;***&#93; all input  received from the other Party. In exercising any decision-making authority granted to it under Sections 4.2 and 4.3, each Party will act based on its &#91;***&#93; taking into consideration the best interests of the Licensed SNAs, the Licensed Products and the applicable Program.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.25pt;text-decoration:underline">Limitation of JSC Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. The JSC shall only have the powers expressly assigned to it in this Article 4 and elsewhere in this Agreement and shall not have the authority to&#58; (a) modify or amend the terms or conditions of this Agreement&#59; (b) waive or determine either Party&#8217;s compliance with the terms or conditions of this Agreement&#59; (c) decide any issue in a manner that would conflict with the &#91;***&#93; terms  or conditions of this Agreement&#59; or (d) bind either Party in any way, without prior written consent of such Party.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9.95pt;padding-right:18.1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">4.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.3pt;text-decoration:underline">Discontinuation of the JSC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. The activities to be performed by the JSC shall solely relate to governance under this Agreement, and are not intended to be or involve the delivery of services. &#91;***&#93;, the JSC shall continue to exist &#91;***&#93;. Thereafter, the JSC shall have no further obligations under this Agreement, and each Party shall designate a contact person for the exchange of information relevant to the JSC under this Agreement. Once the JSC is disbanded, any references in this Agreement to decisions of the JSC will automatically become references to decisions of (a) Ipsen with respect to the Research, Development, Manufacture or Commercialization of the Licensed SNAs and Licensed Products in the applicable Program in the Territory&#59; or (b) Exicure with respect to any other decisions.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:165.7pt;padding-right:165.7pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">ARTICLE 5</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:74.75pt;padding-right:74.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">DEVELOPMENT AND COMMERCIALIZATION</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.25pt;text-decoration:underline">Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. On a Program-by-Program basis, after &#91;***&#93;, Ipsen will have sole authority and responsibility for and, subject to Section 5.3, sole decision- making over, the Development of all </font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">21</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Licensed SNAs and Licensed Products in such Program in the Territory, and shall be responsible for &#91;***&#93;.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt;text-decoration:underline">Regulatory Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:118pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.85pt;text-decoration:underline">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:10pt;padding-right:21.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:15.68pt">During the R&#38;D Terms and the Option Periods, the Parties acknowledge and agree that the Parties shall not conduct any regulatory activities for any Licensed SNAs or Licensed Products except as set forth in Section 5.2(b)(i).</font></div><div><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.7pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.63pt">On a Program-by-Program basis, after &#91;***&#93;, Ipsen will have sole responsibility for and, subject to Section 5.3, sole authority and decision- making over all regulatory activities for the Licensed SNAs and Licensed Products in such Program in the Territory, both before and after obtaining Regulatory Approval, and shall be responsible for &#91;***&#93;.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:118pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.23pt;text-decoration:underline">Regulatory Materials&#59; Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. On a Program-by-Program basis&#58;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:15.68pt">during the Second R&#38;D Term for such Program, Exicure may prepare and file documents and information to a Regulatory Authority in connection with the IND Filing in such Program, and conduct all other communications with the Regulatory Authority, including all meetings, conferences and discussions (including any pre-IND (or equivalent) meetings and advisory committee meetings), in each case as the holder of such IND&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided, that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Exicure shall provide to Ipsen copies of any such documents to be filed with a Regulatory Authority &#91;***&#93; and consider &#91;***&#93; comments from Ipsen, and to &#91;***&#93;&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.55pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.58pt">after &#91;***&#93;&#58; (A) Ipsen will lead and have sole control over preparing and submitting all Regulatory Materials related to the Licensed SNAs and Licensed Products in such Program, including all applications for Regulatory Approval, subject to Section 5.3&#59; and (B) Ipsen will own any and all applications for Regulatory Approvals, the Regulatory Approvals, and other Regulatory Materials related to such Licensed SNAs and Licensed Products, which will be held in the name of Ipsen or its designees&#59; and</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.55pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:9.58pt">&#91;***&#93;, Exicure shall transfer and assign to Ipsen IND sponsorship (if applicable) and all documents and information in Exicure&#8217;s Control, including all Regulatory Materials, in each case in connection with the IND Filing in such Program &#91;***&#93;. All such documentation is to be provided in English.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.65pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt;text-decoration:underline">Interactions with Regulatory Authorities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. On a Program-by-Program basis, after the &#91;***&#93; for such Program, Ipsen will have the sole right to conduct all communications with Regulatory Authorities, including all meetings, conferences and discussions (including advisory committee meetings), with regard to the Licensed SNAs and Licensed Products in such Program in the Territory&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, if Ipsen &#91;***&#93; requests that Exicure conduct any communications or otherwise interact with a Regulatory Authority, Exicure will engage in such communications or other interaction with such Regulatory Authority&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided, further that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, Exicure may &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.25pt;text-decoration:underline">Regulatory Information Sharing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Notwithstanding anything herein to the contrary, Ipsen shall (a) keep Exicure informed of any &#91;***&#93; relating to the Licensed Products received by Ipsen from the Regulatory Authorities in the Territory&#59; and (b)(i) provide Exicure with &#91;***&#93; for Exicure&#8217;s review and comment, in connection with obtaining or maintaining Regulatory Approval for Licensed Products in the &#91;***&#93;, &#91;***&#93;, (ii) allow Exicure reasonable time to translate, review and provide comment, and (iii) consider Exicure&#8217;s comments &#91;***&#93; in the &#91;***&#93; submitted to the applicable Regulatory Authorities, &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.25pt;text-decoration:underline">Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Subject to Section 5.5, on a Program-by-Program basis, after the &#91;***&#93; for each Program, Ipsen will have sole authority and responsibility for and sole decision-making over all </font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">22</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Commercialization activities for the Licensed SNAs and Licensed Products in such Program in the Territory, and will be solely responsible for &#91;***&#93;.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">5.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt;text-decoration:underline">Diligence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:9.95pt;padding-right:21.65pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.85pt">On a Program-by-Program basis, during the &#91;***&#93;, Exicure shall perform &#91;***&#93; complete (itself or through its Affiliates or by permitted subcontracting) its obligations under the applicable R&#38;D Term Plan, in accordance with the scientific standards customary for the industry using its latest applicable technology, and in accordance with Applicable Law. Ipsen will cooperate with and provide &#91;***&#93; support through the JSC to Exicure in Exicure&#8217;s performance of its responsibilities under the R&#38;D Term Plans.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.23pt">On a Program-by-Program basis, after the &#91;***&#93; for such Program,     Ipsen will itself, or through its Affiliates or Sublicensees, &#91;***&#93; Develop at least &#91;***&#93; Licensed Product in such Program. In addition, Ipsen will &#91;***&#93; Commercialize at least &#91;***&#93; Licensed Product in such Program in &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">5.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.25pt;text-decoration:underline">Exicure Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. On a Program-by-Program basis, &#91;***&#93;, Exicure will &#91;***&#93;. Ipsen will &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9.95pt;padding-right:21.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">5.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.3pt;text-decoration:underline">Update Meetings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. On a Program-by-Program basis, commencing after the &#91;***&#93; for such Program, and continuing &#91;***&#93;, from time to time upon written request by Exicure, &#91;***&#93; per &#91;***&#93;, the Parties will &#91;***&#93;, during which time Ipsen will provide Exicure with an update on the Development of the Licensed SNAs and Licensed Products in such Program to enable Exicure to understand the current status and future plans for such Licensed SNAs and Licensed Products and to enable a scientific discussion between representatives of the Parties&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, that such discussions will not impose any additional obligations on Ipsen beyond those expressly set forth in this Agreement. Each Party will bear &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">5.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.25pt;text-decoration:underline">Reports by Ipsen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. On a Program-by-Program basis, commencing after the &#91;***&#93; for such Program, and continuing &#91;***&#93;, Ipsen will prepare, and will cause its Affiliates and Sublicensees to prepare, &#91;***&#93; reports for Exicure summarizing its or their Development activities with respect to the Licensed SNAs and Licensed Products in the Program in the Territory.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:165.7pt;padding-right:165.7pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">ARTICLE 6 </font></div><div style="padding-right:171.65pt"><font><br></font></div><div style="padding-left:74.75pt;padding-right:74.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">MANUFACTURE AND SUPPLY</font></div><div style="padding-left:85.82pt;padding-right:85.82pt;text-align:center"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.3pt;text-decoration:underline">Exicure Manufacture and Supply</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. On a Program-by-Program basis, after &#91;***&#93;, but before &#91;***&#93;, Exicure shall supply to Ipsen the Licensed SNAs under GMP, at &#91;***&#93;, in order for Ipsen to conduct any Clinical Trial of the Licensed SNAs for obtaining any Regulatory Approval in the Territory, pursuant to a clinical supply agreement to be negotiated by the Parties in &#91;***&#93; following the Effective Date and executed within &#91;***&#93; after the Effective Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Supply Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;). Ipsen acknowledges, understands and agrees that any supply of Licensed SNAs after the &#91;***&#93; GMP batch of Licensed SNAs for Phase I Clinical Trial is subject to &#91;***&#93;. The Supply Agreement shall also include, without limitation, &#91;***&#93;, &#91;***&#93;, and &#91;***&#93;. Additionally, following the &#91;***&#93;, the Parties shall negotiate &#91;***&#93;. Each such &#91;***&#93; shall set forth, among other things, &#91;***&#93; and &#91;***&#93;, and shall grant Ipsen access to &#91;***&#93;. On a Program-by-Program basis,    Ipsen shall be &#91;***&#93; and have &#91;***&#93; for Manufacturing the Licensed SNAs and Licensed Products for the Development and Commercialization thereof in the Territory &#91;***&#93;, in each case subject to the licenses granted to Ipsen under Article 7. For clarity, Ipsen shall not have the right to Manufacture or have Manufactured any Licensed SNA and Licensed Products for clinical or commercial use &#91;***&#93;.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.3pt;text-decoration:underline">Manufacturing Technology Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. The Parties shall enter into a Manufacturing technology transfer agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Manufacturing Technology Transfer Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;) &#91;***&#93;, &#91;***&#93;, </font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">23</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div style="padding-left:9.95pt;padding-right:21.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">providing for &#91;***&#93;. During the term of the Supply Agreement, &#91;***&#93;, following the delivery of the  &#91;***&#93; GMP batch of the Licensed SNAs to Ipsen for Phase I Clinical Trial use with respect thereto, Exicure  shall within &#91;***&#93; initiate and provide, and Ipsen will accept and &#91;***&#93; implement, &#91;***&#93;, &#91;***&#93;, it being acknowledged, understood and agreed that the &#91;***&#93; shall be deemed complete &#91;***&#93;. During &#91;***&#93;, any &#91;***&#93; will be made by Exicure (or its subcontractor), with Ipsen&#8217;s &#91;***&#93; cooperation and assistance. Exicure shall be responsible for &#91;***&#93;, and such Information or assistance shall be provided on a &#91;***&#93; basis, &#91;***&#93;. Ipsen may, &#91;***&#93;, initiate  &#91;***&#93;, and upon Ipsen&#8217;s written request, Exicure will provide such assistance and cooperation &#91;***&#93; in completing such &#91;***&#93;&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Exicure will not be required  to provide any assistance or cooperation that was not  &#91;***&#93;&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided further that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#91;***&#93;. Notwithstanding anything herein to the contrary, Exicure shall not be responsible for any  &#91;***&#93;.</font></div><div><font><br></font></div><div style="padding-left:74.75pt;padding-right:74.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">ARTICLE 7 </font></div><div style="padding-left:40.37pt;padding-right:40.37pt;text-align:center"><font><br></font></div><div style="padding-left:40.37pt;padding-right:40.37pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">LICENSES AND EXCLUSIVITY</font></div><div style="padding-left:40.37pt;padding-right:40.37pt;text-align:center"><font><br></font></div><div style="padding-left:82pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:108%">7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:108%;padding-left:22.3pt;text-decoration:underline">Licenses to Ipsen Upon Exercise of the Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:108%">. On a Program-by-Program basis, only upon</font></div><div style="padding-left:9.95pt;padding-right:21.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">the exercise of the First Option (pursuant to Section 3.1) or the Second Option (pursuant to Section 3.6), and in each case subject to the terms and conditions of this Agreement, including Section 3.8, &#91;***&#93;, Exicure agrees to grant and hereby grants to Ipsen the following royalty-bearing licenses&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9.95pt;padding-right:21.55pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.85pt">a non-transferable (subject to Section 15.6), exclusive &#91;***&#93;, under Exicure&#8217;s interest in the Exicure SNA Technology and the Exicure Other Technology with respect to such Program, to &#91;***&#93;&#59; and</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.23pt">a non-transferable (subject to Section 15.6), non-exclusive license, with the right to sublicense through multiple tiers (as permitted in accordance with Section 7.3), under Exicure&#8217;s interest in the Exicure Background Technology, in each case with respect to such Program, to &#91;***&#93;.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">For the avoidance of doubt, in the event any Licensed Product is a Combination Product, the licenses granted herein are limited to the Licensed SNA(s) in such Combination Product, and do not cover any Other API in such Combination Product.</font></div><div style="margin-top:10.75pt;padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt;text-decoration:underline">Exicure Retained Rights&#59; Licenses to Exicure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:10pt;padding-right:21.65pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.85pt">Notwithstanding the exclusive license granted to Ipsen pursuant to Section 7.1(a), Exicure hereby retains the right under the Exicure SNA Technology and the Exicure Other Technology solely to (i) perform (or to have performed) the activities assigned to or contemplated to be carried out by Exicure under this Agreement, including &#91;***&#93;&#59; and (ii)      subject to Section 7.6, discover, &#91;***&#93;.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.23pt">Notwithstanding any provision to the contrary in this Agreement, Ipsen acknowledges and agrees that the rights and licenses granted to Ipsen pursuant to Section 7.1 are subject to the applicable terms of &#91;***&#93; with respect to the &#91;***&#93; that is being sublicensed thereunder.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.85pt">Subject to the terms and conditions of this Agreement, Ipsen hereby grants to Exicure (i) a non-exclusive, non-transferable, sublicensable (as permitted in accordance with Section 7.3), royalty-free, fully-paid license, under the Ipsen Licensed Technology, solely to perform &#91;***&#93;&#59; and (ii) on a Program-by- Program basis, a non-exclusive license and right of reference with respect to &#91;***&#93;, to the extent &#91;***&#93;.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt;text-decoration:underline">Sublicensing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div><font><br></font></div><div style="margin-top:4.6pt;padding-left:118pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.85pt;text-decoration:underline">Scope of Permissible Sublicensing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:15.68pt">The licenses granted by Exicure to Ipsen in Section 7.1 may be sublicensed (through multiple tiers) by Ipsen to&#58; (A) Affiliates of Ipsen, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">any such sublicense to an </font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">24</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div style="margin-top:4.55pt;padding-left:10pt;padding-right:21.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Affiliate of Ipsen will immediately terminate if and when such party ceases to be an Affiliate of Ipsen, or (B) Sublicensees, on the following conditions&#58; (1) &#91;***&#93;, and (2) &#91;***&#93;. Ipsen agrees to (x) notify Exicure in writing no later than &#91;***&#93;, and (y) provide Exicure with a copy of such executed sublicense agreement with a Sublicensee within &#91;***&#93; after the effective date of such agreement (subject to &#91;***&#93; redaction as Ipsen &#91;***&#93; believes appropriate to comply with confidentiality obligations, including financial provisions and sensitive information as applicable).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.23pt">The licenses granted by Ipsen to Exicure in Section 7.2(b) may be sublicensed by Exicure to (A) Affiliates of Exicure without any requirement of consent, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">any such sublicense to an Affiliate of Exicure will immediately terminate if and when such party ceases to be an Affiliate of Exicure, or (B) Third Party contract research organizations to perform Exicure&#8217;s responsibilities assigned or contemplated under this Agreement, in each case upon &#91;***&#93; written notice to Ipsen&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(1) &#91;***&#93;, (2) &#91;***&#93;, and (3) Exicure will provide Ipsen with a copy of the executed sublicense agreement with a non-Affiliate Third Party within &#91;***&#93; after the effective date of such agreement (subject to &#91;***&#93; redaction as Exicure &#91;***&#93; believes appropriate to comply with confidentiality obligations, including financial provisions and sensitive information as applicable).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:18.9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.23pt;text-decoration:underline">Survival of Sublicenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Upon termination of this Agreement for any reason, all sublicenses granted pursuant to Section 7.3(a) shall automatically terminate. Upon the request of any Sublicensee not then in breach of its sublicense agreement or the terms of this Agreement applicable to such Sublicensee, Exicure shall &#91;***&#93;. Under any such &#91;***&#93;, &#91;***&#93;. Under such &#91;***&#93;,  &#91;***&#93;.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.85pt">Ipsen, its Affiliates and Sublicensees may, following exercise of the applicable Options, engage subcontractors to perform activities on their behalf in their &#91;***&#93;. In all cases, Ipsen shall ensure that (a) &#91;***&#93;, and (b) &#91;***&#93;.</font></div><div><font><br></font></div><div style="padding-left:10pt;padding-right:21.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">7.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.25pt;text-decoration:underline">No Implied Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Except as explicitly set forth in this Agreement, neither Party grants to the other Party any license or other rights, express or implied, under any intellectual property rights (whether by implication, estoppel or otherwise). Without limiting the generality of the foregoing, Ipsen agrees not to use any &#91;***&#93; outside the scope of the licenses granted under Section 7.1, and Exicure agrees not to use any of the &#91;***&#93; outside of the scope of the rights and licenses granted under Section 7.2.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">7.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.25pt;text-decoration:underline">Technology Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. On a Program-by-Program basis&#58;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9.95pt;padding-right:21.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.85pt">&#91;***&#93; following the receipt of the Option Fee for such Program, Exicure will provide to Ipsen with (i) &#91;***&#93;&#59; (ii) &#91;***&#93;&#59; and (iii) &#91;***&#93;&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9.95pt;padding-right:21.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.23pt">following the receipt of the Option Fee for such Program, from time to time during the Term for such Program, &#91;***&#93;, Exicure will provide to Ipsen &#91;***&#93;&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.85pt">following the receipt of the Option Fee for such Program, during the Term for such Program, Exicure will &#91;***&#93; cooperate with Ipsen to facilitate the technology transfer of &#91;***&#93; to Ipsen to enable the &#91;***&#93; and &#91;***&#93; in the Territory. Such cooperation will include providing Ipsen with &#91;***&#93;. Ipsen will &#91;***&#93;&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9.95pt;padding-right:21.6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.23pt">following the receipt of the First Option Fee for such Program following &#91;***&#93;, Exicure shall, &#91;***&#93;, either (i) &#91;***&#93;&#59; (ii) &#91;***&#93;&#59; or (iii) &#91;***&#93;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">that, in the event  Ipsen has been adjudicated by a court of competent jurisdiction to lack standing to enforce any such agreement or contract against any Third Party subcontractor or vendor despite Ipsen&#8217;s best efforts to assert and defend such standing, Exicure shall enforce such agreement or contract against such Third Party subcontract or vendor as directed by Ipsen. Exicure&#8217;s obligation under clauses (ii) and (iii) above in connection with enforcement activities pursuant to this Section 7.5(d) shall in no event exceed &#91;***&#93; hours of FTE time in the aggregate. To the extent Exicure remains a party to an agreement or contract it had entered into in connection with its &#91;***&#93;, it agrees to maintain in full force and effect such agreement or contract in order to fulfill its obligations thereunder in connection with this Agreement.</font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">25</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div><font><br></font></div><div style="padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">7.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt;text-decoration:underline">Exclusivity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:118pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.85pt;text-decoration:underline">Exclusivity Covenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9.95pt;padding-right:18.7pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:15.68pt">&#91;***&#93;.  &#91;***&#93;, with respect to the &#91;***&#93;, Ipsen will not, directly or indirectly, whether by itself or through an Affiliate&#58; (A) &#91;***&#93;&#59;</font></div><div style="padding-left:9.95pt;padding-right:18.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:11.4pt">&#91;***&#93;&#59; (C) &#91;***&#93;&#59; or (D) for clarity, &#91;***&#93;, Exicure will not, directly or indirectly, whether by itself or through an Affiliate&#58; (a) &#91;***&#93;&#59; (b) &#91;***&#93;&#59; (c) &#91;***&#93;&#59; or (d) &#91;***&#93;. &#91;***&#93;, with respect to the &#91;***&#93;,      Exicure will not, directly or indirectly, whether by itself or through an Affiliate (X) &#91;***&#93;&#59; (Y) &#91;***&#93;&#59; or (Z) &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9.95pt;padding-right:21.65pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%;padding-left:12.63pt">&#91;***&#93;.  &#91;***&#93;, with respect to the &#91;***&#93;, Ipsen will not, directly or indirectly, whether by itself or through an Affiliate&#58; (A) &#91;***&#93;&#59; (B) &#91;***&#93;&#59; (C) &#91;***&#93;&#59; or (D) for clarity, &#91;***&#93;. During the Term with respect to the &#91;***&#93;, Exicure will not, directly or indirectly, whether by itself or through an Affiliate&#58; (a) &#91;***&#93;&#59; (b) &#91;***&#93;&#59; (c) &#91;***&#93;&#59; or (d) for clarity, &#91;***&#93;. &#91;***&#93;, with respect to the &#91;***&#93;, Exicure will not, directly or indirectly, whether by itself or through an Affiliate (X) &#91;***&#93;&#59; (Y) &#91;***&#93;&#59; or (Z) &#91;***&#93;.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:9.53pt;text-decoration:underline">Meaning of &#8220;Known&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. For purposes of this Section 7.6(a), &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Known</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, with respect to any &#91;***&#93; that is licensed, sublicensed and acquired by a Party or an Affiliate, that either (A) such Party or its Affiliate has &#91;***&#93; or (B) credible information is generally publicly available, that &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.7pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:10.18pt">&#91;***&#93;. Notwithstanding the foregoing provisions of this Section 7.6(a), nothing herein shall prohibit either Party or its Affiliates from, either itself, or together with or through enabling (including through a grant of rights to) any Third Party, Exploiting any &#91;***&#93; that (A) &#91;***&#93;, and (B) &#91;***&#93;, nor prohibit Exicure or any of its Affiliates from, either itself, or together with or through enabling (including through a grant of rights to) any Third Party, Exploiting any &#91;***&#93; for &#91;***&#93;. Notwithstanding anything to the contrary herein, any off-label use of any such &#91;***&#93; by any Person that is not supported (financially or in-kind) by a Party, its Affiliates or sublicensees (in Exicure&#8217;s case) or Sublicensees (in Ipsen&#8217;s case) shall not constitute a breach by such Party of this Section 7.6. &#8220;&#91;***&#93;&#8221; means, &#91;***&#93;.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:118pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.23pt;text-decoration:underline">Exceptions to Exclusivity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:10pt;padding-right:21.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:15.68pt">Any New Affiliate shall not be bound by the exclusivity conditions set forth in Section 7.6(a)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, on a Program-by-Program basis, during the Term with respect to the applicable Program, any such New Affiliate shall not directly or indirectly use or practice any Exicure Licensed Technology, Ipsen Licensed Technology or Confidential Information of Exicure or Ipsen in Researching, Developing, Manufacturing or Commercializing a &#91;***&#93; (in the case of the HD Program) or a &#91;***&#93; (in the case of the A-S Program).</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:10pt;padding-right:21.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.63pt">Notwithstanding Section 7.6(a), in the event that a Party or its Affiliate acquires a Third Party or a portion of the assets or business of a Third Party (whether by merger, stock purchase, purchase of assets, reorganization, consolidation or otherwise) that is, &#91;***&#93;, conducting a Research, Development or Commercialization program that, if conducted by such Party at such time, would be a breach of such Party&#8217;s exclusivity obligation in Section 7.6(a), such Party or its Affiliate shall either (A) comply with the obligations set forth in Section 7.6(b)(i) to the extent permitted therein&#59; (B) &#91;***&#93; divest the applicable Competitive Product &#91;***&#93;, and &#91;***&#93; after the closing of such acquisition&#59; provided that (1) such &#91;***&#93; time period shall be extended  if at the expiration of such time period (and any extensions thereto) such Party provides competent evidence of &#91;***&#93;&#59; provided, however, such extension shall not exceed &#91;***&#93; following the end of such &#91;***&#93; period, (2) such Party or its Affiliate shall comply with the obligations set forth in Section 7.6(b)(i) during such &#91;***&#93; time period or any extension to the time period pursuant to clause (1) above, and (3) such Party or its Affiliate shall &#91;***&#93; if such Party or its Affiliate has not &#91;***&#93;&#59; or (C) suspend the Research, Development and </font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">26</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div style="margin-top:4.6pt;padding-left:10pt;padding-right:21.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Commercialization activities with respect to such Competitive Product &#91;***&#93;&#59; and in either case for clauses (B) or (C), such Party or its Affiliate shall not be deemed in breach of Section 7.6(a) with respect to such Competitive Product so long as &#91;***&#93;.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:74.75pt;padding-right:74.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">ARTICLE 8 </font></div><div style="padding-left:40.37pt;padding-right:40.37pt;text-align:center"><font><br></font></div><div style="padding-left:40.37pt;padding-right:40.37pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">FINANCIALS</font></div><div style="padding-left:40.37pt;padding-right:40.37pt;text-align:center"><font><br></font></div><div style="padding-left:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:106%">8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:106%;padding-left:12.25pt;text-decoration:underline">Upfront Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:106%">. Within &#91;***&#93; after the Effective Date, in consideration for the</font></div><div style="padding-left:10pt;padding-right:21.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">rights granted to Ipsen hereunder, Ipsen will pay Exicure a &#91;***&#93;, non-refundable, non-creditable upfront payment of Twenty Million Dollars (US$20,000,000).</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.25pt;text-decoration:underline">Preparation Costs and Option Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. On a Program-by-Program basis, during the First Option Period for such Program, Ipsen will &#91;***&#93;, regardless of whether Ipsen exercises the First Option for such Program. On a Program-by-Program basis, &#91;***&#93; Ipsen will pay to Exicure a &#91;***&#93;, non-refundable, non-creditable payment of (a) Ten Million Dollars (US$10,000,000) &#91;***&#93;, in the event the Option Exercise Notice is the First Option Exercise Notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">First Option Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;), or (b) Twenty-Five Million Dollars (US$25,000,000) &#91;***&#93;, in the event the Option Exercise Notice is the Second Option Exercise Notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Second Option Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;&#59; together with the First Option Fee, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Option Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided, however, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">if HSR or other clearance is required by a Governmental Authority pursuant to Section 3.8 in order to comply with Applicable Law, such &#91;***&#93; period shall only begin and such payment shall be made only after obtaining such clearance. Any Option Fee will be made by wire transfer of immediately available funds into an account designated in writing by Exicure. If Ipsen fails to deliver any Option Fee within such &#91;***&#93; period, then the applicable Option, and all licenses and other rights granted under such Option, shall be deemed terminated, null and void.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%;padding-left:12.3pt;text-decoration:underline">Development Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">. On a Program-by-Program basis, in consideration for the rights granted to Ipsen under this Agreement, Ipsen will make the following Development milestone payments to Exicure upon the occurrence of each of the following milestone events for such Program&#58;</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">27</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div style="padding-left:5.55pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.600%"><tr><td style="width:1.0%"></td><td style="width:8.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.862%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:68.466%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt;padding-right:13.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Development Milestone Events</font></div></td><td colspan="3" style="border-left:0.5pt dotted #000000;border-right:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%">Development Milestone Payments (US$)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)</font></td><td colspan="3" style="border-left:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt;padding-right:4.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt dotted #000000;border-right:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Five Million Dollars ($5,000,000)</font></td></tr><tr><td colspan="3" style="border-left:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)</font></td><td colspan="3" style="border-left:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt;padding-right:4.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt dotted #000000;border-right:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3)</font></td><td colspan="3" style="border-left:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:106%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt dotted #000000;border-right:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt;padding-right:4.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4)</font></td><td colspan="3" style="border-left:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt;padding-right:4.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt dotted #000000;border-right:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(5)</font></td><td colspan="3" style="border-left:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt;padding-right:4.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt dotted #000000;border-right:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt dotted #000000;border-left:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(6)</font></td><td colspan="3" style="border-bottom:0.5pt dotted #000000;border-left:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt;padding-right:4.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:0.5pt dotted #000000;border-left:0.5pt dotted #000000;border-right:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:118pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.85pt;text-decoration:underline">Clarification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:10pt;padding-right:18.1pt;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:15.68pt">For the avoidance of doubt, and for illustration purposes only, assume that Ipsen has not yet made any payments to Exicure for any Development milestone events and then a first Licensed Product achieves the first three (3) milestone events and immediately after &#91;***&#93;, Ipsen decides to cease Development of such Licensed Product. Ipsen would pay Exicure the first three (3) milestone payments upon the attainment of such Development milestone events by such Licensed Product. Then, assume that a second Licensed Product achieves the first four (4) Development milestone events. With respect to the second Licensed Product, Ipsen would pay Exicure only the fourth (4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:115%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">) milestone amount as a result of the attainment of the fourth (4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:115%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">) Development milestone event by such Licensed Product.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.7pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.63pt">For clarity, the Development milestone payments under this Section 8.3 will each be payable only once and be owed and payable to Exicure whether the Development milestone event triggering such Development milestone payment was achieved by Ipsen or any of its Affiliates or Sublicensees. The &#8220;first Licensed Product&#8221; referenced in the applicable Development milestone event in </font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">28</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div style="padding-left:9.95pt;padding-right:21.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">this Section 8.3 does not mean the same Licensed Product, but refers to the first Licensed Product that achieves the applicable Development milestone event.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:9.95pt;padding-right:13.35pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:9.58pt">For clarity, if a Development milestone event under this Section 8.3 is achieved and any Development milestone payment with respect to any previous Development milestone event under (1)-(3) of this Section 8.3 has not been paid, then Ipsen shall pay &#91;***&#93; within &#91;***&#93; of achievement of such subsequent Development milestone event, regardless of whether the prior Development milestone event has been achieved.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.23pt;text-decoration:underline">Notice&#59; Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Exicure will provide Ipsen with written notice of the achievement of the first (1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:115%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">) Development milestone event set forth in this Section 8.3 within &#91;***&#93; after the achievement of such Development milestone event, &#91;***&#93;. Ipsen will provide Exicure with written notice of the achievement of each of the other Development milestone events set forth in this Section 8.3 within &#91;***&#93; after the achievement of the applicable Development milestone event by Ipsen or its Affiliate, or within &#91;***&#93; after Ipsen has notification of the achievement of the applicable milestone event by a Sublicensee, which notification Ipsen shall ensure that the Sublicensee will provide &#91;***&#93;. &#91;***&#93;. Ipsen shall pay the applicable Development milestone payment &#91;***&#93;. For the avoidance of doubt, any failure or delay of Exicure in relation to invoicing Ipsen for a Development milestone payment under this Section 8.3 shall not prejudice the rights of Exicure to receive the relevant Development milestone payment and shall only be relevant to the timing of receipt of such Development milestone payment. Each such payment will be made by wire transfer of immediately available funds into an account designated by Exicure.</font></div><div><font><br></font></div><div style="padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">8.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt;text-decoration:underline">Commercial Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:10pt;padding-right:21.8pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%;padding-left:13.85pt">On a Program-by-Program basis, Ipsen will make the following &#91;***&#93; commercial milestone payments to Exicure upon the occurrence of each of the following commercial milestone events for such Program&#58;</font></div><div style="margin-top:4.6pt;padding-left:81.95pt;padding-right:21.8pt"><font><br></font></div><div style="padding-left:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.450%"><tr><td style="width:1.0%"></td><td style="width:9.363%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.643%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:4.6pt;padding-left:2.75pt;padding-right:24.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Commercial Milestone Events</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:4.6pt;padding-left:2.75pt;padding-right:24.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Commercial Milestone Payments (US$)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:4.6pt;padding-left:2.75pt;padding-right:24.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">(1)</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:4.6pt;padding-left:2.75pt;padding-right:24.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:4.6pt;padding-left:2.75pt;padding-right:24.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:4.6pt;padding-left:2.75pt;padding-right:24.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">(2)</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:4.6pt;padding-left:2.75pt;padding-right:24.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:4.6pt;padding-left:2.75pt;padding-right:24.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:4.6pt;padding-left:2.75pt;padding-right:24.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">(3)</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:4.6pt;padding-left:2.75pt;padding-right:24.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:4.6pt;padding-left:2.75pt;padding-right:24.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:4.6pt;padding-left:2.75pt;padding-right:24.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">(4)</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:4.6pt;padding-left:2.75pt;padding-right:24.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:4.6pt;padding-left:2.75pt;padding-right:24.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:4.6pt;padding-left:2.75pt;padding-right:24.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">(5)</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:4.6pt;padding-left:2.75pt;padding-right:24.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:4.6pt;padding-left:2.75pt;padding-right:24.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:4.6pt;padding-left:2.75pt;padding-right:24.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">(6)</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:4.6pt;padding-left:2.75pt;padding-right:24.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:4.6pt;padding-left:2.75pt;padding-right:24.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:4.6pt;padding-left:2.75pt;padding-right:24.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">(7)</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:4.6pt;padding-left:2.75pt;padding-right:24.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:4.6pt;padding-left:2.75pt;padding-right:24.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:4.6pt;padding-left:2.75pt;padding-right:24.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">(8)</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:4.6pt;padding-left:2.75pt;padding-right:24.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:4.6pt;padding-left:2.75pt;padding-right:24.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#91;***&#93;</font></div></td></tr></table></div><div style="margin-top:4.55pt;padding-left:9.95pt;padding-right:21.6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.23pt;text-decoration:underline">Clarification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. For clarity, the commercial milestone payments will each be payable only once and shall be additive such that if multiple commercial milestone events are achieved in the same &#91;***&#93;, then the commercial milestone payments for all such commercial milestone events shall be payable. The &#8220;first Licensed Product&#8221; referenced in the applicable commercial milestone event in this Section 8.4 does not mean the same Licensed Product, but refers to the first Licensed Product that achieves the applicable commercial milestone event.</font></div><div><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.85pt;text-decoration:underline">Notice&#59; Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Ipsen will provide Exicure with written notice of the achievement of each of commercial milestone &#91;***&#93; set forth in this Section 8.4 within &#91;***&#93; after such achievement by Ipsen or its Affiliates or Sublicensees. Ipsen will provide Exicure with written notice of the achievement of each of commercial milestone events &#91;***&#93; set forth in this Section 8.4 within &#91;***&#93; after the end of </font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">29</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div style="padding-left:9.95pt;padding-right:21.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#91;***&#93; in which the applicable milestone event was achieved by Ipsen or its Affiliates or Sublicensees. &#91;***&#93; Ipsen shall pay the associated commercial milestone payment &#91;***&#93;. For the avoidance of doubt, any failure or delay of Exicure in relation to invoicing Ipsen for a commercial milestone payment under this Section 8.4 shall not prejudice the rights of Exicure to receive the relevant commercial milestone payment and shall only be relevant to the timing of receipt of such commercial milestone payment. Each such commercial milestone payment will be made by wire transfer of immediately available funds into an account designated by Exicure.</font></div><div><font><br></font></div><div style="padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">8.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt;text-decoration:underline">Royalties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:10pt;padding-right:21.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%;padding-left:13.8pt;text-decoration:underline">Net Sales Royalty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">. On a Program-by-Program basis, Ipsen will pay to Exicure royalties on &#91;***&#93; and &#91;***&#93; basis on &#91;***&#93; worldwide Net Sales for all Licensed Products in such Program during the applicable Royalty Term at the royalty rates (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Royalty Rates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#8221;) set forth below (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:117%">Net Sales Royalty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">&#8221;)&#58;</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.800%"><tr><td style="width:1.0%"></td><td style="width:88.089%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.711%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:114%;text-decoration:underline">worldwide Net Sales of all Licensed Products in the Program</font></div></td><td colspan="3" style="border-left:0.5pt dotted #000000;border-right:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.35pt;padding-right:3.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">Royalty Rate</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt dotted #000000;border-right:0.5pt dotted #000000;border-top:2.5pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.27pt;padding-right:8.27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:90%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt dotted #000000;border-right:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.27pt;padding-right:8.27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt dotted #000000;border-right:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.27pt;padding-right:8.27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt dotted #000000;border-right:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.27pt;padding-right:8.27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt dotted #000000;border-right:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.27pt;padding-right:8.27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt dotted #000000;border-left:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt dotted #000000;border-left:0.5pt dotted #000000;border-right:0.5pt dotted #000000;border-top:0.5pt dotted #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:8.27pt;padding-right:8.27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:114%">&#91;***&#93;</font></div></td></tr></table></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">30</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><div id="i9b16f1ba634f40d19a7a1b6dadea2dc9_59"></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The applicable Net Sales Royalty shall be calculated by reference to the &#91;***&#93; worldwide Net Sales of all Licensed Products in such Program in &#91;***&#93;. By way of example, in the first &#91;***&#93; of the &#91;***&#93;, if the worldwide Net Sales of all Licensed Products in such Program for which royalties are due under this Section 8.5(a) were &#91;***&#93;, the following royalty payment for the &#91;***&#93; would be payable under this Section 8.5(a)&#58; (&#91;***&#93;) + (&#91;***&#93;) + (&#91;***&#93;) + (&#91;***&#93;)</font></div><div style="padding-left:9.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">+ (&#91;***&#93;) &#61; &#91;***&#93;.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">For clarity, once Ipsen&#8217;s royalty obligations for &#91;***&#93;, the &#91;***&#93; will be excluded from royalty calculations (including thresholds and ceilings). The Net Sales Royalty calculation will be delivered in writing by Ipsen to Exicure within &#91;***&#93; of each applicable &#91;***&#93; and will include, on a Program-by-Program basis, &#91;***&#93;. &#91;***&#93; Ipsen shall pay the associated payment &#91;***&#93;. For the avoidance of doubt, any failure or delay of Exicure in relation to invoicing Ipsen for a payment under this Section 8.5(a) shall not prejudice the rights of Exicure to receive the payment and shall only be relevant to the timing of receipt of such payment. Ipsen will pay the Net Sales Royalty in United States dollars by wire transfer to an account designated in writing by Exicure.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:118pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.23pt;text-decoration:underline">True-Up&#59; Adjustments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:15.63pt;text-decoration:underline">True-Up</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. On a Program-by-Program basis, during the Term for such Program, on &#91;***&#93; basis, following the first &#91;***&#93; in which the First Commercial Sale for such Program occurs, Ipsen shall perform a &#8220;true up&#8221; reconciliation (and shall provide Exicure with a written report of such reconciliation) of the &#91;***&#93; in the definition of &#8220;Net Sales.&#8221; The reconciliation shall be based on &#91;***&#93;. If the foregoing reconciliation report shows an underpayment by Ipsen, Ipsen shall pay the shortfall to Exicure within &#91;***&#93; after the date of delivery of such report. If the foregoing reconciliation report shows &#91;***&#93;, the amount of the difference shall be offset against &#91;***&#93;.</font></div><div><font><br></font></div><div style="padding-left:10pt;padding-right:21.75pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.58pt;text-decoration:underline">Adjustments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. On a Program-by-Program basis, within &#91;***&#93; after the termination or expiration of this Agreement with respect to such Program, Ipsen shall perform a &#8220;true-up&#8221; reconciliation (and shall provide Exicure with a written report of such reconciliation) of the &#91;***&#93; outlined in the definition of &#8220;Net Sales.&#8221; If the foregoing reconciliation report shows either an underpayment or an overpayment between the Parties, the Party owing payment to the other Party shall pay &#91;***&#93; within &#91;***&#93; after the date of delivery of such report.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:118pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.85pt;text-decoration:underline">Reductions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.65pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:15.63pt">If Ipsen, an Affiliate or a Sublicensee makes a royalty payment under any agreement with a Third Party pursuant to which Ipsen or such Affiliate or a Sublicensee obtains a license under a Patent in a specific country owned or controlled by such Third Party, absent which license the sale of a Licensed Product in such country would constitute infringement of such Patent in such country, then during the term of such license, Ipsen may offset against the royalties due to Exicure for Net Sales of such Licensed Product in such country an amount equal to &#91;***&#93;, subject to Section 8.5(c)(iv)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, in the event that such license can be used for products other than &#91;***&#93;, any upfront and milestone payments may be offset to the extent such payments is allocated to the Licensed Products&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided further that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">in the event of a Dispute regarding such allocation, the matter shall be finally resolved under Section 14.1(c).</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.55pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.63pt">If, pursuant to Section 8.5(a), any royalties are payable on Net Sales of a Licensed Product attributable to the United States where there is no Patent within the Exicure Licensed Technology, in each case that contains a Valid Claim covering &#91;***&#93; of such Licensed Product in the United States (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, royalties are payable on Net Sales of such Licensed Product in the United States only on the basis of clause (b) or (c) in the definition of Royalty Term in Section 1.158), then the Royalty Rates applicable to those Net Sales of such Licensed Product for the United States will be reduced by &#91;***&#93; percent (&#91;***&#93;) from those set forth in Section 8.5(a), subject to Section 8.5(c)(iv).</font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">31</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.65pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:9.58pt">Subject to Section 8.5(c)(iv), on a Licensed Product-by-Licensed Product and country-by-country basis, if during any &#91;***&#93;, there is &#91;***&#93; for such  Licensed Product in such country and the aggregate Net Sales of such Licensed Product in such country during any &#91;***&#93; following the &#91;***&#93; are at least &#91;***&#93; percent (&#91;***&#93;)  lower than the aggregate Net Sales of such Licensed Product in such country &#91;***&#93;, then the Royalty Rate applicable to Net Sales of such Licensed Product in such country in such &#91;***&#93; will be reduced by &#91;***&#93; percent (&#91;***&#93;) of the applicable Royalty Rate that would otherwise be owed on such Net Sales of such Licensed Product in such country under Section 8.5(a)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, that if the aggregate Net Sales of such Licensed Product in that country during any &#91;***&#93; following the &#91;***&#93; are at least &#91;***&#93; percent (&#91;***&#93;) lower than the aggregate Net Sales of such Licensed Product in such country &#91;***&#93;, then the Royalty Rate applicable to Net Sales of such Licensed Product in such country in such &#91;***&#93; will be reduced by &#91;***&#93; percent (&#91;***&#93;) of the applicable Royalty Rate that would otherwise be owed on such Net Sales of such Licensed Product in such country under Section 8.5(a). Ipsen will &#91;***&#93; notify Exicure of the occurrence of &#91;***&#93;, which notice will specify &#91;***&#93;.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:10.23pt">Notwithstanding Sections 8.5(c)(i), 8.5(c)(ii) and 8.5(c)(iii), in no event shall any &#91;***&#93; decrease the Net Sales Royalties otherwise due to Exicure by more than &#91;***&#93; percent (&#91;***&#93;) of the Net Sales Royalties that would have been payable &#91;***&#93;.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9.95pt;padding-right:21.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.23pt;text-decoration:underline">Payment Method and Currency Exchange</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.&#160;&#160;&#160;&#160;All payments due to a Party hereunder shall be made via wire transfer of immediately available USD funds to an account designated in writing by that Party to the other Party. The account information for the upfront payment in Section 8.1 is set forth in Schedule 8.5(d). For any currency conversion required in determining the amount of payments due hereunder, such conversion shall be made as follows&#58; (a) when calculating Net Sales, the amount of such sales in foreign currencies shall be converted into USD using &#91;***&#93; and (b) when calculating all other sums due under this Agreement, the amount in foreign currencies shall be converted into USD using &#91;***&#93;.</font></div><div><font><br></font></div><div style="padding-left:118pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.85pt;text-decoration:underline">Net Sales Audit Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:15.68pt">Exicure will have the right to engage, &#91;***&#93;, subject to this Section 8.5, an independent internationally recognized public accounting firm chosen by Exicure and &#91;***&#93; (which accounting firm will not be the external auditor of Exicure, will not have been hired or paid on a contingency basis and will have experience auditing pharmaceutical companies) (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">CPA Firm</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;) to conduct an audit of Ipsen for the purposes of confirming Ipsen&#8217;s compliance with the Net Sales Royalty provisions of this Agreement.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.65pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.58pt">The CPA Firm will be given access to and will be permitted to examine such books and records of Ipsen as it will &#91;***&#93; request, upon &#91;***&#93; prior written notice having been given by Exicure, during regular business hours, for the sole purpose of determining compliance with the Net Sales Royalty provisions of this Agreement. &#91;***&#93;, the CPA Firm will enter into a confidentiality agreement &#91;***&#93; with respect to the Information to which it is given access and will not contain in its report or otherwise disclose to Exicure or any Third Party any information labeled by Ipsen as being confidential customer information regarding pricing or other competitively sensitive proprietary information.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.55pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:9.58pt">Within &#91;***&#93; after completion of the CPA Firm&#8217;s audit, Ipsen will pay to Exicure &#91;***&#93;. If the report of the CPA Firm shows that Ipsen overpaid, then Ipsen will &#91;***&#93;. If no royalty is then owed to Exicure, then Exicure will remit such overpayment to Ipsen. If the report of the CPA Firm shows a discrepancy between &#91;***&#93; and &#91;***&#93;, and such discrepancy exceeds &#91;***&#93; percent (&#91;***&#93;) of the amount audited, then in addition to the payment &#91;***&#93;, &#91;***&#93; will be paid by Ipsen.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:154pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:20.18pt">Exicure&#8217;s exercise of its audit rights under this Section 8.5(d) may not</font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">32</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div style="padding-left:10pt;padding-right:21.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(A) be conducted for any &#91;***&#93; more than &#91;***&#93; after the end of such &#91;***&#93; to which such books and records pertain, (B) be conducted more than once in any &#91;***&#93; period  (&#91;***&#93;), or (C) be repeated for any &#91;***&#93;.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">8.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.25pt;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Any payment payable by Ipsen to Exicure under this Agreement shall be paid exclusive of any and all taxes, including any withholding taxes, value-added or similar taxes (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">VAT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;), sales taxes, turnover taxes or any comparable taxes required by Applicable Law. The Parties agree to pay for any value-added taxes, sales taxes, turnover taxes or any comparable taxes according to their national law in addition to prices set forth in this Agreement. &#91;***&#93;. Ipsen shall deliver to Exicure an original version of the receipt issued by the competent authority in relation to the payment of this tax. In case a double tax treaty would provide for &#91;***&#93;, Ipsen shall give written notice of its intention to withhold and allow Exicure sufficient time to furnish any documentation or forms to the applicable Governmental Authority to minimize or eliminate such withholding. In the event the aforementioned documentation or forms is not provided to Ipsen by Exicure, at Ipsen&#8217;s option, Ipsen shall either (i) postpone the payment &#91;***&#93;, or (ii) pay &#91;***&#93; after applying tax withholdings required by Applicable Law and borne by Exicure. Ipsen shall provide Exicure with receipts from the appropriate taxing authority for all payments of taxes withheld and paid by Ipsen to such authorities on behalf of Exicure. Exicure shall have the right to appeal to the appropriate taxing authority any such withholding and payment of such taxes. Notwithstanding anything in this Agreement to the contrary, (i) if an assignment or sublicense of Ipsen&#8217;s rights or obligations under this Agreement, or failure to comply with Applicable Laws or filing or record retention requirements by Ipsen leads to the imposition  or increase of withholding tax or other tax liability on Exicure that would not have been imposed in the absence of such action that cannot be avoided by furnishing the relevant documentation or forms to the applicable Governmental Authority to minimize or eliminate such withholding, then &#91;***&#93;, (ii) otherwise, the sum payable by Ipsen (in respect of which such deduction or withholding is required to be made) shall be &#91;***&#93;. Each Party will provide the other with timely and &#91;***&#93; assistance to enable the recovery, as permitted by Applicable Law, of withholding taxes, VAT, or similar obligations resulting from payments made under this Agreement, such recovery to be for the benefit of the Party effectively bearing such withholding tax or VAT. If &#91;***&#93;, and if Exicure subsequently obtains a tax credit or deduction on account of any such withholding tax, VAT or similar payment obligation paid by Ipsen (or any fraction thereof), Exicure shall &#91;***&#93;.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">8.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.25pt;text-decoration:underline">Change in Accounting Periods</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. From time to time, either Party may change &#91;***&#93;. If a Party notifies the other of a change in &#91;***&#93;, then thereafter, beginning with the period specified in the notice, the payment, reporting and other obligations hereunder related to Calendar Quarters and Calendar Years will be deemed satisfied by compliance therewith in accordance with the new reporting periods (fiscal reporting periods or calendar reporting periods, as the case may be) instead of the previously utilized reporting periods. The Parties will cooperate &#91;***&#93; to minimize any disruption caused by any such change.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:74.75pt;padding-right:74.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">ARTICLE 9</font></div><div style="padding-left:40.37pt;padding-right:40.37pt;text-align:center"><font><br></font></div><div style="padding-left:74.75pt;padding-right:74.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">INTELLECTUAL PROPERTY</font></div><div style="padding-left:90.05pt;padding-right:90.05pt;text-align:center"><font><br></font></div><div style="padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:108%">9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:108%;padding-left:22.3pt;text-decoration:underline">Ownership of IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:108%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:10pt;padding-right:18.05pt;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%;padding-left:13.85pt">Exicure shall own all rights, title and interest (including intellectual property rights) in and to the Materials and Information supplied by Exicure to Ipsen under this Agreement. Ipsen shall not imply or represent to any Person that it is the owner of such Materials or Information.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.65pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.23pt">On a Program-by-Program basis, as between the Parties, Exicure will solely own all rights, title and interest (including intellectual property rights) in and to all Inventions and Results in such Program created or conceived (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Invented</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;) during the R&#38;D Terms or the Option Periods for such Program (&#91;***&#93;) (i) solely by or on behalf of Ipsen pursuant to this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Ipsen R&#38;D Term Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;), (ii) solely by or on behalf of Exicure pursuant to this Agreement, or (iii) jointly by or on behalf of Ipsen and Exicure pursuant to this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Joint R&#38;D Term Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;) ((i)-(iii) </font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">33</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div style="padding-left:9.95pt;padding-right:21.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">R&#38;D Term IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;). For the avoidance of doubt, in the event an Invention or Result is conceived &#91;***&#93; but finally created &#91;***&#93;, this Section 9.1(b) controls the ownership of rights, title and interest in and to it. Ipsen will &#91;***&#93; disclose to Exicure any and all Ipsen R&#38;D Term Inventions and Joint R&#38;D Term Inventions, and will provide Exicure such documentation regarding the same as &#91;***&#93;. Ipsen, for itself and on behalf of its Affiliates, licensees and Sublicensees, and employees, subcontractors, consultants and agents of any of the foregoing, hereby assigns (and to the extent such assignment can only be made in the future hereby agrees to assign), to Exicure all Ipsen&#8217;s right, title and interest in and to the Ipsen R&#38;D Term Inventions and the Joint R&#38;D Term Inventions. Ipsen will &#91;***&#93; cooperate, and will cause the foregoing Persons and entities to &#91;***&#93; cooperate, with Exicure to effectuate and perfect the foregoing ownership, including by &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt">On a Program-by-Program basis, ownership of rights, title and interest in and to all Inventions and Results in such Program Invented by or on behalf one or both of the Parties pursuant to this Agreement solely after &#91;***&#93; for such Program, if any (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Other IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;), shall follow inventorship, with inventorship being determined in accordance with United States patent laws (regardless of where the applicable activities occurred)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">inventorship with respect to any Patent shall be determined in accordance with the patent laws of the specific country or other jurisdiction in which such Patent was applied for. Without limiting the generality of the foregoing, as between the Parties, Other IP Invented solely by or on behalf of Exicure after &#91;***&#93; will be solely owned by Exicure (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Exicure Other IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;), Other IP Invented solely by or on behalf of Ipsen after &#91;***&#93; will be solely owned by Ipsen (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Ipsen Other IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;), and Other IP Invented jointly by on or behalf of Exicure and Ipsen after the Option Exercise Date will be jointly owned by both Parties (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Joint Other IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;). Each Party will have &#91;***&#93;.  Each Party, for itself and on behalf of its Affiliates, licensees and sublicensees, and employees, subcontractors, consultants and agents of any of the foregoing, hereby assigns (and to the extent such assignment can only be made in the future hereby agrees to assign), to the other Party &#91;***&#93; Joint Other IP.</font></div><div><font><br></font></div><div style="padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt;text-decoration:underline">Prosecution, Maintenance &#38; Enforcement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:10pt;padding-right:21.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt;text-decoration:underline">Ipsen Other IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Ipsen will &#91;***&#93; file, prosecute (including the defense of any oppositions, interferences, reissue proceedings, re-examinations and other post-grant proceedings originating in a patent office), maintain and enforce intellectual property rights pertaining to the Ipsen Other IP &#91;***&#93;.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.23pt;text-decoration:underline">R&#38;D Term IP, Exicure Other IP, and Joint Other IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Subject to Section 9.2(c), Exicure will &#91;***&#93; to file, prosecute (including the defense of any oppositions, interferences, reissue proceedings, re-examinations and other post-grant proceedings originating in a patent office), maintain and enforce intellectual property rights pertaining to the R&#38;D Term IP, the Exicure Other IP, and the Joint Other IP &#91;***&#93;.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:118pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:23.85pt;text-decoration:underline">Exicure Licensed Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div><font><br></font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:18.85pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:15.68pt">Notwithstanding the provisions in Section 9.2(b), Exicure will control the preparation, filing for, and prosecution and maintenance of (including the defense of any oppositions, interferences, reissue proceedings, re-examinations and other post-grant proceedings originating in a patent office) all Patents (A) in the Exicure SNA Technology, and (B) in the Exicure Other Technology (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Exicure SNA Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;), &#91;***&#93;, as well as filing for any patent term extensions or similar protections, subject to Section 9.6, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Exicure shall consider diligently, &#91;***&#93; all input received from Ipsen regarding such prosecution and maintenance. Without limiting the generality of the foregoing, Exicure will (v) provide Ipsen copies of and a reasonable opportunity to review and comment upon &#91;***&#93;, (w) provide Ipsen with a copy of each &#91;***&#93;, (x) keep Ipsen advised of the status of all &#91;***&#93;, (y) give Ipsen copies of and a reasonable opportunity to review and comment on &#91;***&#93;, and (z) &#91;***&#93; consider &#91;***&#93; Ipsen&#8217;s comments on &#91;***&#93;. Ipsen will provide  Exicure any cooperation or assistance &#91;***&#93; in connection with &#91;***&#93;, and Ipsen will &#91;***&#93;. Notwithstanding the foregoing, Exicure&#8217;s obligations under this Section 9.2(c)(i) with respect to Patents in the Exicure Other Technology shall be limited to &#91;***&#93;.</font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">34</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.55pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.58pt">On a Program-by-Program basis, if Exicure declines to file for, prosecute or maintain (including defending or prosecuting office actions, prosecutions or interferences) any Exicure SNA Patent with respect to such Program after &#91;***&#93;, it will give Ipsen &#91;***&#93; notice thereof and thereafter, Ipsen may, upon written notice to Exicure and &#91;***&#93;, control the filing for, prosecution and maintenance of such Exicure SNA Patent thereafter. Without limiting the generality of the foregoing, within &#91;***&#93; after receiving the written notice from Ipsen, Exicure will (to the extent not previously provided) (x) provide Ipsen, &#91;***&#93;, with copies of all documents (including file histories and then current dockets) for such Exicure SNA Patent for which Ipsen has the right to file, prosecute and maintain, pursuant to this Section 9.2(c)(ii) and that are in the file maintained by Exicure&#8217;s in-house or outside patent counsel for such Exicure SNA Patent or otherwise available to Exicure, including any communications, filings and drafts as well as written notice of any pending deadlines or communications for such Exicure SNA Patent (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, that Exicure  will provide notice of pending deadlines &#91;***&#93; after receiving the written notice from Ipsen so as to ensure adequate time and coordination with respect to such deadlines), and (y) execute and deliver any legal papers &#91;***&#93; to effectuate transfer of control of the filing, prosecution and maintenance of such Exicure SNA Patent (excluding papers that transfer any right, title or  interest in or to the Exicure SNA Patent other than such control).</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.65pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:9.53pt">Each Party will &#91;***&#93; cooperate with the other Party in the filing, prosecution, defense, and maintenance of the Exicure SNA Patents. Such cooperation includes &#91;***&#93; executing all documents, requiring inventors to be available to discuss and review applications and other filings, and requiring inventors, subcontractors, employees and consultants and agents of such Party and its Affiliates, and for Ipsen and its Affiliates and Sublicensees, to execute all documents, &#91;***&#93; so as to enable the prosecution and maintenance of any such Exicure SNA Patents.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9.95pt;padding-right:21.6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">9.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.3pt;text-decoration:underline">Defense and Settlement of Third Party Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. On a Program-by-Program basis, from and after &#91;***&#93;, if a Third Party asserts that a Patent or other right owned by it is infringed by the Exploitation of any Licensed SNA or Licensed Product in the Territory, Ipsen will have the first right to defend against any such assertions &#91;***&#93;. Ipsen will have the first right to control the defense of any such Third Party claims &#91;***&#93; and to elect to settle such claims (except as set forth below). Exicure will assist Ipsen and cooperate in any such litigation at Ipsen&#8217;s request, and Ipsen will &#91;***&#93;. Exicure may join any defense pursuant to this Section 9.3, with its own counsel, &#91;***&#93;. Ipsen may settle or consent to the entry of any judgment in any enforcement action hereunder without Exicure&#8217;s prior written consent so long as such settlement or judgment does not impose any liability (financial or otherwise) on, or otherwise &#91;***&#93;. Should Ipsen fail to defend against any such assertion &#91;***&#93;, Exicure will have the right to do so, &#91;***&#93;. Ipsen will assist Exicure and &#91;***&#93; cooperate in any such litigation at Exicure&#8217;s request. Ipsen may join any such defense brought by Exicure pursuant to this Section 9.3, with its own counsel, &#91;***&#93;. Exicure will not settle or consent to the entry of any judgment in any enforcement action hereunder without Ipsen&#8217;s prior written consent, &#91;***&#93;. Exicure will give Ipsen &#91;***&#93; written notice of any allegation by any Third Party that a Patent or other right owned by it is infringed by the Exploitation of any Licensed SNA or Licensed Product. Each Party will pay any amounts due to the other Party under this Section 9.3 &#91;***&#93;. If Ipsen is obligated under Section 11.1 to indemnify Exicure (including any Exicure Indemnitee) with respect to such claim, then the process described in Section 11.3 of this Agreement shall govern the procedure for defending against such claim rather than this Section 9.3. Except as otherwise provided in Article 11, any settlement or license fees incurred by Ipsen to the Third Party under this Section 9.3 will be allocated in accordance with the principle set forth in Section 8.5(c)(i) to the extent that the Patent that is the subject of such settlement license would be infringed by the sale of the Licensed Product in the relevant country.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">9.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:22.3pt;text-decoration:underline">Enforcement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:9.95pt;padding-right:21.65pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.85pt">On a Program-by-Program basis, from and after &#91;***&#93; for such Program, in the event that (i) Exicure or Ipsen becomes aware of any actual or suspected infringement of any Exicure SNA Patent with respect to such Program by a product primarily targeting the Target in such Program, (ii) any such Exicure SNA Patent is challenged in any action or proceeding (other than &#91;***&#93;) or (iii) Exicure </font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">35</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div style="margin-top:4.55pt;padding-left:9.95pt;padding-right:21.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">or Ipsen receives a Notice of Paragraph IV Patent certification as described in Section 9.6(c), such Party will notify the other Party &#91;***&#93;, and following such notification, the Parties will confer. Ipsen will have the sole right, but will not be obligated, to defend any such action or proceeding or bring an infringement action with respect to such infringement &#91;***&#93;, in its own name and entirely under its own direction and control, or, subject to Exicure&#8217;s prior written consent, &#91;***&#93;, conditioned or delayed, settle any such action or proceeding by sublicense (including, &#91;***&#93;, granting a sublicense, covenant not to sue or other right with respect to a compound or product (including a &#91;***&#93;) in the Territory). Exicure will &#91;***&#93; assist Ipsen in any action or proceeding being defended or prosecuted if so requested, and will be named in or join such action or proceeding if requested by Ipsen. If Exicure elects to be represented by legal counsel it will bear &#91;***&#93;&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided, that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, Ipsen will bear &#91;***&#93;.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9.95pt;padding-right:21.65pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.28pt;text-decoration:underline">Damages</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. In the event that Ipsen exercises the rights conferred in this Section 9.4 and recovers any damages, payments or other sums in such action or proceeding or in settlement thereof, such damages or other sums recovered will first be applied to &#91;***&#93;. If such recovery is insufficient to cover &#91;***&#93;, the Parties will be paid &#91;***&#93;. If after &#91;***&#93; any funds will remain from such damages or other sums recovered, such funds will be allocated between the Parties as follows&#58; the remaining recovery (up to &#91;***&#93; determined in the action or proceeding or as agreed in the settlement or &#91;***&#93;) will be treated as Net Sales hereunder and subject to &#91;***&#93;, and all the remaining recovery other than &#91;***&#93; will be paid &#91;***&#93; percent (&#91;***&#93;) to Ipsen and &#91;***&#93; percent (&#91;***&#93;) to Exicure.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">9.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.25pt;text-decoration:underline">Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Subject to the remainder of this Section 9.5, on a Program-by-Program basis, from and after &#91;***&#93;, Ipsen will solely own all right, title and interest in and to any trademarks adopted for use with the Licensed Products in such Program in the Territory, and will be responsible and have sole authority for the registration, filing, maintenance and enforcement thereof. Neither Party will do or authorize to be done any act or thing which &#91;***&#93; impair the rights of the other Party in any of the other Party&#8217;s trademarks (or the registrations or applications therefor), including adopting, using or claiming any right of interest in or to any of the other Party&#8217;s trademarks (or the registrations or applications therefor) or any confusingly similar trademarks (or the registrations or applications therefor) in a manner that might amount to infringement, dilution, unfair competition or passing off of any of the other Party&#8217;s trademarks (or the registrations or applications therefor), in each case without the other Party&#8217;s consent.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">9.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.25pt;text-decoration:underline">Patent Extensions&#59; Orange Book Listings&#59; Patent Certifications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. On a Program-by-Program basis, from and after &#91;***&#93;&#58;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.65pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.85pt;text-decoration:underline">Patent Term Extension</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. If elections with respect to obtaining patent term extension or supplemental protection certificates or their equivalents in any country with respect to any Licensed Product in such Program becomes available, upon Regulatory Approval or otherwise, Ipsen will have the sole right to file for patent term extension or supplemental protection certificates or their equivalents and to determine &#91;***&#93;, in each case in the Territory, except that Exicure shall have the sole right with respect to Exicure Background Technology to file for patent term extension or supplemental protection certificates or their equivalents and to determine &#91;***&#93;. Exicure will &#91;***&#93; cooperate with Ipsen so as to enable Ipsen to exercise its rights under this Section 9.6(a). Such cooperation includes &#91;***&#93; executing all documents, requiring inventors to be available to discuss and review any filings, and requiring inventors, subcontractors, employees, consultants and agents of Ipsen and its Affiliates to execute all documents, &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.23pt;text-decoration:underline">Regulatory Exclusivity and Orange Book Listings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. With respect to &#91;***&#93;, Ipsen shall have the sole right to seek and maintain all such &#91;***&#93; that may be available for the Licensed Products in such Program in the Territory, in consultation with Exicure. Ipsen shall have the sole right to make all filings in the FDA&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">Approved Drug Products with Therapeutic Equivalence Evaluations </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Orange Book</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;) and all equivalents in any country in the Territory with respect to the Licensed Products in the Territory.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt;text-decoration:underline">Notification of Patent Certification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Exicure and Ipsen will each notify and provide the other Party with copies of any notice of a Paragraph IV Patent Certification (including any associated </font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">36</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">documents) with respect to any Exicure SNA Patent with respect to such Program by a Third Party filing an ANDA, an application under &#167; 505(b)(2) of the FD&#38;C Act (as amended or any replacement thereof), or any other similar patent certification by a Third Party, and any foreign equivalent thereof. Such notification and copies will be provided to the other Party within &#91;***&#93; after receipt of such notification and will be sent to the address set forth in Section 15.3.</font></div><div id="i9b16f1ba634f40d19a7a1b6dadea2dc9_62"></div><div><font><br></font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:74.75pt;padding-right:74.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">ARTICLE 10</font></div><div style="padding-left:40.37pt;padding-right:40.37pt;text-align:center"><font><br></font></div><div style="padding-left:74.75pt;padding-right:74.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">REPRESENTATIONS, WARRANTIES AND COVENANTS</font></div><div style="padding-left:55.67pt;padding-right:55.67pt;text-align:center"><font><br></font></div><div style="padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:106%">10.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:106%;padding-left:16.8pt;text-decoration:underline">Mutual Representations, Warranties and Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:106%">. Each Party hereby represents and</font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:18.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">warrants to the other Party &#91;***&#93;, and covenants, as applicable, as a &#91;***&#93; inducement  for such other Party&#8217;s entry into this Agreement, as follows&#58;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt;text-decoration:underline">Corporate Existence and Power</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. It is a company or corporation duly organized, validly existing, and in good standing under the laws of the jurisdiction in which it is incorporated, and has full corporate power and authority and the legal right to own and operate its property and assets and to carry on its business as it is now being conducted and as contemplated in this Agreement, including the right to grant the licenses granted by it hereunder.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.18pt;text-decoration:underline">Authority and Binding Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. (i) It has the corporate power and authority and the legal right to enter into this Agreement and perform its obligations hereunder&#59; (ii) it has taken all necessary corporate action on its part required to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder&#59; and (iii) this Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, and binding obligation of such Party that is enforceable against it in accordance with its terms.</font></div><div><font><br></font></div><div style="padding-left:10pt;padding-right:21.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%;padding-left:13.8pt;text-decoration:underline">No Conflict</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">. It is not a party to and will not enter into any agreement that would prevent it from granting the rights or exclusivity granted or intended to be granted to the other Party under this Agreement or performing its obligations under this Agreement.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.18pt;text-decoration:underline">Bankruptcy&#59; Insolvency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. It is not aware of any action or petition, pending or otherwise, for bankruptcy or insolvency of such Party or its Affiliates or subsidiaries in any state, country or other jurisdiction, and it is not aware of any facts or circumstances that could result in such Party becoming or being declared insolvent, bankrupt or otherwise incapable of meeting its obligations under this Agreement as they become due in the ordinary course of business.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt;text-decoration:underline">No Debarment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Such Party is not debarred, has not been convicted, and is not subject to debarment or conviction pursuant to Section 306 of the FD&#38;C Act or any foreign equivalents thereof. In the course of the Research or Development of Licensed SNAs or Licensed Products, such Party has not, to its knowledge, used &#91;***&#93;, and will not use, during the Term, any employee, consultant, agent or independent contractor who has been debarred by any Regulatory Authority, or, to such Party&#8217;s knowledge, is the subject of debarment proceedings by a Regulatory Authority or has been convicted pursuant to Section 306 of the FD&#38;C Act or any foreign equivalent thereof.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.65pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:15.02pt;text-decoration:underline">Compliance with Applicable Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Each Party will comply with the Applicable Law in the course of performing its obligations or exercising its rights pursuant to this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%;padding-left:6.75pt;text-decoration:underline">Representations, Warranties and Covenants by Exicure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">. Exicure hereby represents, warrants and covenants to Ipsen &#91;***&#93;, and covenants to Ipsen, as applicable, as &#91;***&#93; inducement for Ipsen&#8217;s entry into this Agreement, as follows&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt;text-decoration:underline">No IP Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Neither Exicure nor any of its Affiliates has entered into any agreement (other than &#91;***&#93;) granting any right, interest or claim in or to, any Exicure Licensed </font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">37</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div style="padding-left:10pt;padding-right:21.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Technology to any Third Party that would conflict with the licenses and other rights granted to Ipsen under this Agreement.</font></div><div id="i9b16f1ba634f40d19a7a1b6dadea2dc9_65"></div><div><font><br></font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.18pt;text-decoration:underline">No Notice of Infringement or Misappropriation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Exicure has not received and is not aware of any written notice from any Third Party asserting or alleging that any Exploitation of Exicure Licensed Technology, Licensed SNAs or Licensed Products has infringed or misappropriated, or would infringe or misappropriate, the intellectual property rights of any Third Party.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt;text-decoration:underline">No Misappropriation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. To the best knowledge of Exicure, (i) the development, creation, conception and reduction to practice of any inventions and the use, development, creation, conception and reduction to practice of any other Information within Exicure Licensed Technology have not constituted or involved the misappropriation of trade secrets or other rights or property of any Third Party, and (ii) no employee, consultant, agent or independent contractor of Exicure, or Third Party, has misappropriated any Exicure Licensed Technology. To the knowledge of Exicure, no issued or granted Patent of a Third Party would be infringed, or with respect to any Patent other than &#91;***&#93;, would be &#91;***&#93; infringed upon issuance or grant, by the Exploitation of the Licensed SNAs or Licensed Products in accordance with the terms and conditions of this Agreement.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.23pt;text-decoration:underline">Employee Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. &#91;***&#93;, Exicure has secured from all employees, consultants, contractors and other Persons who have contributed to the development, creation, conception or invention of any of the Exicure Licensed Technology a written agreement assigning to Exicure or its Affiliates all rights to such developments, creations, conceptions or inventions, and such Affiliates have assigned such rights to Exicure, and neither Exicure nor any of its Affiliates has received any written communication challenging Exicure&#8217;s ownership or right to the Exicure Licensed Technology, &#91;***&#93;.</font></div><div><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt;text-decoration:underline">Conduct of Research and Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. &#91;***&#93;, Exicure has conducted all Research and Development of SNAs in accordance with all Applicable Law.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:15.07pt;text-decoration:underline">Third Party Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Other than &#91;***&#93;, Exicure is not a party to any Third Party Agreement. Exicure has disclosed to Ipsen a full complete and correct copy of the Existing In-License Agreements, including any amendments or modifications thereto. The Existing In-License Agreements are in full force and effect, Exicure is in full compliance with the Existing In-License Agreements, and neither Exicure nor its Affiliates has received any notice that is or would become with the passage of time an event of default under either of the Existing In-License Agreements. Exicure will maintain the Existing In-License Agreements in full force and effect, will fully perform its obligations thereunder, and will not terminate the Existing In-License Agreements or amend or modify the Existing In-License Agreements in a manner that would &#91;***&#93; affect the rights of Ipsen under this Agreement. Exicure will &#91;***&#93; furnish Ipsen with true and complete copies of all amendments, modifications, consents and waivers to the Existing In-License Agreements to the extent related to either Party&#8217;s performance of its obligations or exercise of its rights hereunder. Exicure will furnish Ipsen with copies of all notices received by Exicure or its Affiliates relating to any alleged breach or default by Exicure or its Affiliates under the Existing In-License Agreements within &#91;***&#93; after receipt thereof. Exicure represents and warrants to Ipsen that the agreements listed in Schedule 10.2(f) provide that &#91;***&#93;.</font></div><div><font><br></font></div><div style="padding-left:10pt;padding-right:21.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">10.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:6.75pt;text-decoration:underline">No Other Representations or Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. EXCEPT AS EXPRESSLY STATED IN THIS Article 10, NO REPRESENTATIONS OR WARRANTIES WHATSOEVER, WHETHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, OR NON-MISAPPROPRIATION OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS, IS MADE OR GIVEN BY OR ON BEHALF OF A PARTY.</font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">38</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><div id="i9b16f1ba634f40d19a7a1b6dadea2dc9_68"></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div><font><br></font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9.95pt;padding-right:21.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT, ALL REPRESENTATIONS AND WARRANTIES, WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE, ARE HEREBY EXPRESSLY EXCLUDED.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:74.75pt;padding-right:74.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">ARTICLE 11</font></div><div style="padding-left:40.37pt;padding-right:40.37pt;text-align:center"><font><br></font></div><div style="padding-left:74.75pt;padding-right:74.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">INDEMNIFICATION</font></div><div style="padding-left:101.57pt;padding-right:101.57pt;text-align:center"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">11.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:6.85pt;text-decoration:underline">Indemnification by Exicure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Subject to the remainder of this Article 11, Exicure will defend, indemnify, and hold Ipsen, its Affiliates, subcontractors and Sublicensees, and its and their respective officers, directors, employees, and agents (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Ipsen Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;) harmless from and against any and all liabilities, losses, costs, damages, fees, expenses or other amounts payable to a Third Party claimant, as well as any &#91;***&#93;, all to the extent resulting from claims, suits, proceedings or causes of action (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;) brought by or on behalf of such Third Party against such Ipsen Indemnitee that arise from or are based on&#58; (a) a breach of any of Exicure&#8217;s representations, warranties or obligations under this Agreement&#59; (b) the willful misconduct or grossly negligent acts of Exicure or its Affiliates&#59; (c) violation of Applicable Law by any Exicure Indemnitees&#59; or (d) the Exploitation of Reversion SNAs or Reversion Products by Exicure or its Affiliates or any of their respective sublicensees in the Territory&#59; excluding, in each case ((a), (b), (c) and (d)), any damages or other amounts for which Ipsen has an obligation to indemnify any Exicure Indemnitee pursuant to Section 11.2.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">11.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:6.85pt;text-decoration:underline">Indemnification by Ipsen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Subject to the remainder of this Article 11, Ipsen will defend, indemnify, and hold Exicure, its Affiliates, subcontractors, licensees and sublicensees, and each of their respective officers, directors, employees, and agents (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Exicure Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;) harmless from and against any and all damages or other amounts payable to a Third Party claimant, as well as any &#91;***&#93;, all to the extent resulting from any Claims brought by such Third Party against such Exicure Indemnitee that arise from or are based on&#58; (a) the Exploitation of Licensed SNAs or Licensed Products by Ipsen or its Affiliates in the Territory&#59; (b) a breach of any of Ipsen&#8217;s representations, warranties or obligations under this Agreement&#59; (c) the willful misconduct or grossly negligent acts of Ipsen or its Affiliates&#59; or (d) violation of Applicable Law by any Ipsen Indemnitees&#59; excluding, in each case ((a), (b), (c) and (d)), any damages or other amounts for which Exicure has an obligation to indemnify any Ipsen Indemnitee pursuant to Section 11.1.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9.95pt;padding-right:21.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">11.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:6.85pt;text-decoration:underline">Indemnification Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. The Party claiming indemnity under this Article 11 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;) will give written notice to the Party from whom indemnity is being sought (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Indemnifying Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;) &#91;***&#93; after learning of the Claim. The Indemnifying Party&#8217;s obligation to defend, indemnify, and hold harmless pursuant to Section 11.1 or Section 11.2, as applicable, will be reduced to the extent the Indemnified Party&#8217;s delay in providing notification pursuant to the previous sentence results in &#91;***&#93;&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, that the failure by an Indemnified Party to give such notice or otherwise meet its obligations under this Section 11.3 will not relieve the Indemnifying Party of its indemnification obligation under this Agreement. At its option, the Indemnifying Party may assume the defense and have exclusive control, &#91;***&#93;, of any Claim for which indemnity is being sought by giving written notice to the Indemnified Party within &#91;***&#93; after receipt of the notice of the Claim, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a) the Claim involves only money damages and does not seek an injunction or other equitable relief against the Indemnified Party&#59; (b) the Claim does not relate to any criminal or regulatory enforcement proceeding&#59; and (c) the Indemnifying Party conducts the defense of the Claim diligently. The Indemnified Party will provide the Indemnifying Party with &#91;***&#93;, &#91;***&#93;, in connection with the defense. The Indemnified Party may &#91;***&#93;&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, the Indemnifying Party will have the right to assume and conduct the defense of the Claim with counsel of its choice. The Indemnifying Party will not settle any Claim without the prior written consent of the Indemnified Party, &#91;***&#93;, &#91;***&#93;. The Indemnified Party will not settle any such Claim without the prior written consent of the Indemnifying Party, &#91;***&#93;. If the Indemnifying Party does not assume and conduct the defense of the Claim as provided above, (x) the Indemnified Party may defend against, and consent to the entry of any judgment or enter into any settlement with respect to the </font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">39</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div style="margin-top:0.05pt;padding-left:9.95pt;padding-right:21.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Claim in any manner the Indemnified Party may &#91;***&#93; (&#91;***&#93;), and (y) the Indemnified Party reserves any right it may have under this Article 11 to obtain indemnification from the Indemnifying Party.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">11.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:6.8pt;text-decoration:underline">Limitation of Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, EXEMPLARY OR INDIRECT DAMAGES OF ANY KIND ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT OR ANY CLAIMS ARISING HEREUNDER, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY (WHETHER IN CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY OR OTHERWISE), REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 11.4 IS INTENDED TO OR WILL LIMIT OR RESTRICT (A) THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER SECTION 11.1 OR SECTION 11.2, (B) DAMAGES AVAILABLE IN THE CASE OF A PARTY&#8217;S FRAUD, GROSS NEGLIGENCE OR INTENTIONAL MISCONDUCT, OR (C) DAMAGES AVAILABLE TO A PARTY FOR A BREACH BY THE OTHER PARTY OF THE CONFIDENTIALITY OBLIGATIONS UNDER ARTICLE 12.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">11.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:6.8pt;text-decoration:underline">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. During the Term, (a) Ipsen will obtain and maintain, &#91;***&#93;, the following minimum required insurance&#58; comprehensive general liability insurance, products liability insurance and clinical trials insurance, each with minimum limits of &#91;***&#93; Dollars (US$&#91;***&#93;) per occurrence and &#91;***&#93; (US$&#91;***&#93;) &#91;***&#93; aggregate&#59; and Exicure will obtain and maintain, &#91;***&#93; general liability insurance with a minimum limit of &#91;***&#93; Dollars (US$&#91;***&#93;) per occurrence and &#91;***&#93; Dollars (US&#91;***&#93;) &#91;***&#93; aggregate. Each Party shall also maintain any mandatory insurance, including but not limited to workers compensation coverage or its applicable foreign equivalent, in accordance with all Applicable Laws and regulations. Commercial insurance shall be obtained from reputable and financially secure insurance carriers having a minimum A.M. Best rating (or equivalent) of A-. Each Party shall ensure continuity of coverage for claims which may be presented during the &#91;***&#93; period following the expiration or termination of this Agreement. Each Party will furnish to the other Party certificates of insurance evidencing the minimum required insurance, including notice of cancellation to be provided in accordance with the terms of the insurance policies. Each Party further agrees to provide written notice to the other within &#91;***&#93; of becoming aware of any &#91;***&#93; which prevents compliance with the foregoing insurance obligations. A Party&#8217;s failure to maintain minimum required insurance will be deemed a &#91;***&#93;.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:197.35pt;padding-right:197.35pt;text-align:center;text-indent:-0.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:233%">ARTICLE 12 CONFIDENTIALITY</font></div><div style="padding-left:82pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:106%">12.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:106%;padding-left:16.8pt;text-decoration:underline">Confidentiality&#59; Exceptions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:106%">. Except to the extent expressly authorized by this Agreement</font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">or otherwise agreed in writing, the Parties agree that the receiving Party will keep confidential and will not publish or otherwise disclose or use for any purpose other than as provided for in this Agreement any information and materials furnished to it by or on behalf of the other Party or its Affiliates in connection with this Agreement (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;). For clarity, Confidential Information of a Party or its Affiliates will include, without limitation, all information and materials disclosed by such Party or its Affiliates or their respective designees that (a) is marked as &#8220;Confidential,&#8221; &#8220;Proprietary&#8221; or with similar designation at the time of disclosure or (b) by its nature can &#91;***&#93; be expected to be considered Confidential Information by the recipient. Information disclosed orally will not be required to be identified as such to be considered Confidential Information. The terms of this Agreement shall be deemed to be the Confidential Information of both Parties. During the Term and at all times thereafter, information relating to the Exicure Background Technology, Exicure SNA Technology and Exicure Other Technology shall be deemed to be the Confidential Information of Exicure. &#91;***&#93;, Exicure SNA Technology, Results, Records, the content of Interim Reports, and Licensed SNAs and Licensed Products with respect to such Program shall be deemed to be the Confidential Information of Exicure. Upon exercise of an Option for a Program, Results, Records and the content of Interim Reports, and Licensed SNAs and Licensed Products with respect to such Program shall be deemed to be the Confidential Information of both Parties. During the Term and at all times thereafter, Ipsen Licensed Technology or Ipsen Reversion IP shall be deemed to be the Confidential Information of Ipsen. Notwithstanding the </font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">40</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">foregoing, Confidential Information will not include any information to the extent that it can be established by written documentation by the receiving Party that such information&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.85pt">was already known to the receiving Party, other than under an obligation of confidentiality (except to the extent such obligation has expired or an exception is applicable under the relevant agreement pursuant to which such obligation was established), at the time of disclosure&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.23pt">was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving Party&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9.95pt;padding-right:21.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.85pt">became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving Party in breach of this Agreement&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.23pt">was independently developed by the receiving Party as demonstrated by written documentation prepared contemporaneously with such independent development&#59; or</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.85pt">was disclosed to the receiving Party, other than under an obligation of confidentiality (except to the extent such obligation has expired or an exception is applicable under the relevant agreement pursuant to which such obligation was established), by a Third Party who had no obligation to the disclosing Party not to disclose such information to others.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9.95pt;padding-right:21.6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">12.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:6.8pt;text-decoration:underline">Authorized Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Except as expressly provided otherwise in this Agreement, each Party may use and disclose Confidential Information of the other Party solely as follows&#58; (a) under appropriate confidentiality provisions substantially equivalent to those in this Agreement (but of shorter duration if customary)&#58; (i) in connection with the performance of its obligations or as &#91;***&#93; in the exercise of its rights under this Agreement, including the right to grant licenses or sublicenses as permitted hereunder, (ii) to the extent such disclosure is &#91;***&#93; necessary or useful in conducting Clinical Trials under this Agreement&#59; or (iii) to actual or potential (sub)licensees, acquirers or assignees, collaborators, investment bankers, investors or lenders, or&#59; (b) to the extent such disclosure is to a Governmental Authority as &#91;***&#93; in filing or prosecuting Patent, copyright or trademark applications in accordance with this Agreement, prosecuting or defending litigation related to this Agreement, or Exicure Licensed Technology, Licensed SNAs or Licensed Products as provided under Article 9, complying with applicable governmental regulations with respect to performance under this Agreement, obtaining Regulatory Approval or fulfilling post-approval regulatory obligations for the Licensed SNAs or Licensed Products, or otherwise required by Applicable Law&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, that if a Party is required by Applicable Law or the rules of any securities exchange or automated quotation system to make any such disclosure of the other Party&#8217;s Confidential Information it will, except where impracticable for necessary disclosures (for example, in the event of medical emergency), give &#91;***&#93; notice to the other Party of such disclosure requirement and, in each of the foregoing, will &#91;***&#93; secure confidential treatment of such Confidential Information required to be disclosed and will only disclose that Confidential Information that is required to be disclosed&#59; (c) to advisors (including lawyers and accountants) on a need to know basis, in each case under appropriate confidentiality provisions or professional standards of confidentiality substantially equivalent to those of this Agreement, or (d) to the extent mutually agreed to by the Parties. The Parties agree to issue a mutually agreed joint press release &#91;***&#93; after &#91;***&#93;, in the form set forth in Exhibit C&#59; thereafter, Exicure and Ipsen may each disclose to Third Parties the information contained in such press release without the need for further approval by the other. Each Party acknowledges and agrees that the other Party may submit this Agreement to the SEC if required by Applicable Law, and if a Party does submit this Agreement to the SEC, such Party agrees to &#91;***&#93;. If a Party is required by Applicable Law to make a disclosure of the terms of this Agreement in a filing with or other submission to the SEC, and (x) such Party has provided copies of the disclosure to the other Party as far in advance of such filing or other disclosure &#91;***&#93;, (y) such Party has &#91;***&#93; notified the other Party in writing of such requirement and any respective timing constraints, and (z) such Party has given the other Party &#91;***&#93; to comment upon, request confidential treatment or approve such disclosure, then such Party will have the right to make such public disclosure at the time and in the manner &#91;***&#93; to be required by Applicable Law. Notwithstanding </font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">41</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div style="margin-top:0.05pt;padding-left:9.95pt;padding-right:21.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">anything to the contrary herein, it is hereby understood and agreed that if a Party seeks to make a disclosure to the SEC as set forth in this Section 12.2, and the other Party provides comments within the respective time periods or constraints specified herein or within the respective notice, the Party seeking to make such disclosure or its counsel, as the case may be, will &#91;***&#93;. Each Party will have the right to issue additional press releases or to make public disclosures with the prior written agreement of the other Party.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">12.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:6.75pt;text-decoration:underline">Prior Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. This Agreement supersedes the Existing Confidentiality Agreement. All confidential information exchanged between the Parties under the Existing Confidentiality Agreement will be deemed Confidential Information of the disclosing Party and will be subject to the terms of this Agreement, provided that confidential information disclosed by Ipsen Bioscience, Inc. under the Existing Confidentiality Agreement will be deemed Confidential Information of Ipsen under this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">12.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:6.8pt;text-decoration:underline">Publications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. &#91;***&#93;, Ipsen may not publish peer reviewed manuscripts, or provide other forms of public disclosure, including abstracts and presentations, of results of Development activities carried out under this Agreement, or otherwise pertaining to the Licensed SNAs, the Licensed Products or Information contained in Exicure Licensed Technology (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;), without the prior written consent of Exicure, &#91;***&#93;. Following Option exercise with respect to a Program, Ipsen may publish or otherwise publicly disclose Publications&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided that, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#91;***&#93;, (a) Ipsen will provide to Exicure the opportunity to review such Publication&#59; (b) Exicure will designate a person or persons who will be responsible for reviewing such Publications&#59; and (c) such designated person will respond in writing &#91;***&#93;. Ipsen will remove such Exicure Confidential Information &#91;***&#93;, provided that if Ipsen requests Exicure will &#91;***&#93;.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9.95pt;padding-right:21.6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">12.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:6.8pt;text-decoration:underline">Attorney-Client Privilege</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Neither Party is waiving, nor will be deemed to have waived or diminished, any of its attorney work product protections, attorney-client privileges or similar protections and privileges as a result of disclosing information pursuant to this Agreement, or any of its Confidential Information (including Confidential Information related to pending or threatened litigation) to the receiving Party, regardless of whether the disclosing Party has asserted, or is or may be entitled to assert, such privileges and protections. The Parties&#58; (a) share a common legal and commercial interest in such disclosure that is subject to such privileges and protections&#59; (b) are or may become joint defendants in proceedings to which the information covered by such protections and privileges relates&#59; (c) intend that such privileges and protections remain intact should either Party become subject to any actual or threatened proceeding to which the disclosing Party&#8217;s Confidential Information covered by such protections and privileges relates&#59; and (d) intend that after &#91;***&#93; both the receiving Party and the disclosing Party will have the right to assert such protections and privileges.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:165.7pt;padding-right:165.7pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">ARTICLE 13</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:165.72pt;padding-right:165.72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">TERM AND TERMINATION</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">13.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:6.8pt;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. This Agreement will commence on the Effective Date and will expire, on a Program- by-Program basis, on the last day of the Second Option Period for such Program, unless earlier terminated pursuant to this Article 13, or &#91;***&#93;. If Ipsen exercises either the First Option or the Second Option, this Agreement, unless earlier terminated pursuant to this Article 13, will expire on a country-by-country and Licensed Product-by-Licensed Product basis at the end of the applicable Royalty Term (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;). Following the end of the Term for any such Licensed Product and in such country by expiration (but not termination), the licenses granted to Ipsen under Section 7.1 with respect to such Licensed Product and such country will become perpetual, irrevocable, fully paid-up and royalty-free.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">13.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%;padding-left:6.8pt;text-decoration:underline">Termination by Ipsen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">. On a Program-by-Program basis, Ipsen will have the right for any or no reason to terminate this Agreement in its entirety with respect to such Program upon &#91;***&#93; prior written notice to Exicure.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">13.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:16.8pt;text-decoration:underline">Termination for Breach or Insolvency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">42</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div style="margin-top:4.55pt;padding-left:10pt;padding-right:21.65pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.8pt;text-decoration:underline">Termination for Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Each Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Non-Breaching Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;) will have the right to terminate this Agreement in its entirety if a material breach is applicable to the Agreement taken as a whole, or with respect to a Program, if a material breach is applicable solely with respect to such Program, upon written notice to the other Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Breaching Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;) if the Breaching Party materially breaches its obligations under this Agreement and, after receiving written notice from the Non-Breaching Party identifying such material breach by the Breaching Party&#91;***&#93;, fails to cure such material breach within &#91;***&#93; from &#91;***&#93; (or, if such breach cannot be cured within &#91;***&#93; from &#91;***&#93;, if the Breaching Party has not commenced or is not diligently continuing &#91;***&#93; to cure such breach&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, in any event, such breach must be cured  within &#91;***&#93; from the date of such notice) (such &#91;***&#93; or &#91;***&#93; period, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Cure Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;).</font></div><div><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.55pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.23pt;text-decoration:underline">Disputes Regarding Material Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. If the Parties &#91;***&#93; disagree as to whether there has been a material breach, then the Breaching Party that disputes whether there has been a material breach may contest the allegation in accordance with Article 14, and the applicable Cure Period will be tolled upon the initiation of such dispute resolution procedures. If, as a result of such dispute resolution process, it is finally determined pursuant to Article 14 that the Breaching Party committed a material breach of this Agreement, then the applicable Cure Period will resume and &#91;***&#93;, this Agreement will terminate (in its entirety or with respect to the Program as to which the material breach relates, as applicable) &#91;***&#93;. This Agreement will remain in full force and effect during the pendency of any such dispute resolution proceeding and all Cure Periods. Any such dispute resolution proceeding will not suspend any obligations of either Party hereunder and each Party will &#91;***&#93; mitigate any damages. Any payments that are made by one Party to the other Party pursuant to this Agreement pending resolution of the dispute will be &#91;***&#93; refunded if it is determined &#91;***&#93;. If, as a result of such dispute resolution proceeding, it is determined that &#91;***&#93;, then no termination of this Agreement will be effective, and this Agreement will continue in full force and effect.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.85pt;text-decoration:underline">Termination for Insolvency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. To the extent permitted by Applicable Law, either Party may terminate this Agreement in its entirety upon providing written notice to the other Party on or after the time that such other Party files or institutes a bankruptcy, reorganization, liquidation, or receivership proceeding or upon the appointment of a receiver or trustee over all or substantially all property of the other Party, or upon an assignment of a substantial portion of the assets of the other Party for the benefit of creditors&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, that in the case of any involuntary bankruptcy proceeding, such right to terminate will only become effective if the other Party consents to the involuntary bankruptcy or such proceeding is not dismissed within &#91;***&#93; after the filing thereof.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">13.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:6.8pt;text-decoration:underline">Termination for Patent Challenge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. If Ipsen or any of its Affiliates or Sublicensees, directly or indirectly through any Third Party, commences any interference or opposition proceeding with respect to, challenges the validity or enforceability of any Patent with the Exicure Licensed Technology (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Patent Challenge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;), then Exicure will have the right to terminate this Agreement, either in its entirety or with respect to the applicable Program to which a challenge relates, on &#91;***&#93; written notice to Ipsen&#59; such termination to be effective immediately following such notice period&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">if Ipsen or its Affiliate or Sublicensee withdraws (or causes to be withdrawn) such Patent Challenge within &#91;***&#93; after being requested to do so by Exicure in writing (which termination notice will be deemed a request), then Exicure will have no right to terminate this Agreement pursuant to this Section 13.4. For clarity, Exicure may not terminate this Agreement pursuant to this Section 13.4 if Ipsen or its Affiliate or Sublicensee is required by legal process to be joined as a party in any Patent Challenge by a Third Party. In addition, notwithstanding the foregoing, Exicure will have no right to terminate this Agreement pursuant to this Section 13.4 with respect to&#58; (a) any affirmative defense or other validity, enforceability, or non- infringement challenge, whether in the same action or in any other agency or forum of competent jurisdiction, advanced by Ipsen, or any of its Affiliates or Sublicensees in response to any claim or action brought in the first instance by, or on behalf of, Exicure or any Third Party, or (b) any Patent Challenge that is commenced by a Sublicensee, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Ipsen demands that such Sublicensee withdraw such Patent Challenge &#91;***&#93; and terminates the sublicense agreement with the applicable Sublicensee if such Sublicensee does not withdraw such Patent Challenge within &#91;***&#93; after receipt of notice from Ipsen.</font></div><div><font><br></font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">43</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div style="padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">13.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:16.8pt;text-decoration:underline">Effects of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:10pt;padding-right:21.7pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:13.8pt;text-decoration:underline">Effects of Termination Generally</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">. Subject to Section 13.5(c), on a Program-by- Program basis, upon termination of this Agreement in its entirety or with respect to such Program&#58;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:9.95pt;padding-right:21.75pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:15.68pt;text-decoration:underline">Licenses and Exclusivity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. All licenses granted in Article 7 with respect to such Program will terminate&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">such licenses will continue as necessary for the Parties to complete the orderly wind-down of their activities under this Agreement in accordance with Applicable Law and as otherwise required in accordance with Section 13.5(a)(ii). With the exception of such wind-down activities, Ipsen shall immediately &#91;***&#93;. The exclusivity obligations set forth in Section 7.5 with respect to such Program will also terminate.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.58pt;text-decoration:underline">Wind-Down</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. &#91;***&#93;, the Parties will begin to wind-down their respective activities under this Agreement with respect to such Program. The JSC, if applicable, will coordinate the wind-down of each Party&#8217;s efforts under this Agreement, and, if the JSC has disbanded, then the Parties will establish an appropriate committee to coordinate such wind-down. &#91;***&#93;, if Exicure elects to continue to Exploit any Licensed Products in such Program, then, Exicure will not be required to wind down its efforts under this Agreement with respect to such Program.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:9.53pt;text-decoration:underline">Confidential Information and Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Each Party will &#91;***&#93; return to the other Party (or as directed by such other Party destroy and certify to such other Party in writing as to such destruction) all of such other Party&#8217;s Confidential Information and Materials provided by or on behalf of such other Party hereunder that is in the possession or Control of such Party (or any of its Affiliates, sublicensees or subcontractors) (or if this Agreement is terminated with respect to such Program only but not in its entirety, all such Confidential Information and Materials of such other Party that solely relate to such Program), except that such Party will have the right to retain one (1) copy of intangible Confidential Information of such other Party for legal purposes and any Confidential Information of such other Party that forms part of a permanent electronic backup or archive system.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.65pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.18pt;text-decoration:underline">Reversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. On a Program-by-Program basis, in the event of a termination of this Agreement in its entirety or with respect to such Program by Ipsen pursuant to Section 13.2, or by Exicure pursuant to Sections 13.3 or 13.4, after &#91;***&#93;, the following will occur&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.75pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:15.63pt">Ipsen shall, and does hereby, grant to Exicure, &#91;***&#93;, a worldwide, perpetual, exclusive license, with the right to grant sublicenses through multiple tiers, under the Ipsen Reversion IP for the sole purpose of Researching, Developing, Manufacturing or Commercializing the Reversion SNAs or Reversion Products in such Program in the Territory. The license agreement will include consideration, including without limitation milestone and royalty payments, &#91;***&#93;. In the event that the Parties are unable to agree upon &#91;***&#93; within &#91;***&#93; following the date of termination of this Agreement, either Party may require that all remaining unresolved issues with respect to such terms (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Reversion Disputes&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">) be resolved in accordance with Sections 14.1(a) and 14.1(c), it being understood that &#91;***&#93;, the licenses, assignments and any obligations of Ipsen related thereto under this Section 13.5(b) shall not take effect&#59;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.65pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.58pt">Ipsen shall, and does hereby, grant to Exicure a fully paid-up, royalty-free, worldwide, transferable, sublicensable (through multiple tiers), perpetual, and irrevocable license under trademarks Controlled by Ipsen or its Affiliates and &#91;***&#93; for the purpose of Commercializing the Reversion SNAs and the Reversion Products&#59;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:9.95pt;padding-right:21.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:9.63pt">Ipsen shall, and does hereby, assign to Exicure any Regulatory Materials and Regulatory Approvals that are Controlled by Ipsen or its Affiliates or Sublicensees that are solely related to the Licensed SNAs or Licensed Products in such Program (and shall take all actions necessary or desirable to vest in Exicure such Regulatory Materials and Regulatory Approvals)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">if any such Licensed SNA or Licensed Product is a Combination Product, then any corresponding Regulatory Materials or Regulatory Approvals shall be limited to the Licensed SNA for such Licensed Product&#59; </font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">44</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div style="margin-top:0.05pt;padding-left:9.95pt;padding-right:21.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided, further that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">to the extent such assignment is delayed or is not permitted by the applicable Regulatory Authority, Ipsen shall permit Exicure to cross-reference and rely upon any Regulatory Materials and Regulatory Approvals filed by Ipsen or its Affiliates or Sublicensees with respect to any such Licensed SNAs or Licensed Products. Ipsen will &#91;***&#93; transfer, or will cause its Affiliates and Sublicensees to transfer, ownership of all such assigned Regulatory Materials and Regulatory Approvals to Exicure, including submitting to each applicable Regulatory Authority a letter or other necessary documentation (with a copy to Exicure) notifying such Regulatory Authority of the transfer of such ownership of each of such Regulatory Materials and Regulatory Approvals&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.55pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:10.23pt">Ipsen shall, and does hereby, grant to Exicure a non-exclusive right of reference (A) under Regulatory Materials and Regulatory Approvals that are Controlled by Ipsen or its Affiliates or Sublicensees, that are not solely related to the Licensed SNAs or Licensed Products, or (B) with respect to CMC and clinical safety results sections of the Regulatory Materials and Regulatory Approvals that are Controlled by Ipsen or its Affiliates or Sublicensees, in each case of (A) and (B) &#91;***&#93;&#59;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.65pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.28pt">&#91;***&#93;, at Exicure&#8217;s written request, Ipsen will and hereby does, and will cause its Affiliates and its Sublicensees to, transfer control of all Clinical Trials involving any Licensed SNAs or Licensed Products in such Program, which Clinical Trials are being conducted by or on behalf of Ipsen, its Affiliate or a Sublicensee &#91;***&#93;, to Exicure or its Affiliates or a Third Party that is designated in writing by Exicure. Either in connection with such transfer or separately, at Exicure&#8217;s written request, Ipsen shall, and does hereby, assign to Exicure all clinical synopses, protocols, operation analyses and plans and any and all other documents and Information in connection with such Clinical Trials that are Controlled by Ipsen or its Affiliates or Sublicensees, and will &#91;***&#93; transfer, or will cause its Affiliates and Sublicensees to transfer, ownership of all such assigned documents and Information to Exicure. Ipsen will continue to conduct such Clinical Trials, &#91;***&#93;, &#91;***&#93;&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Exicure will not have any obligation to continue any Clinical Trial &#91;***&#93;. Exicure will pay &#91;***&#93;&#59;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.8pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%;padding-left:10.18pt">Exicure will have the right, &#91;***&#93;, to purchase from Ipsen any or all of the inventory of the Licensed SNAs or Licensed Products in such Program and, in each case held by  Ipsen or its Affiliates &#91;***&#93;&#59;</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9.95pt;padding-right:21.7pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:7.13pt">at Exicure&#8217;s written request, Ipsen will continue &#91;***&#93; Manufacture or cause to be Manufactured and to supply or cause to be supplied to Exicure such quantities of Licensed SNAs or Licensed Products in such Program (in bulk drug substance, bulk drug product, or finished drug product form, in each case to the extent Ipsen Manufactures or has Manufactured such form(s) at the time of termination) as Exicure indicates in written forecasts and orders therefor from time to time &#91;***&#93;, &#91;***&#93;. Exicure acknowledges and agrees that &#91;***&#93; will be subject to &#91;***&#93;&#59; and</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9.95pt;padding-right:21.65pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:4.08pt">Ipsen will, and will cause its Affiliates and Sublicensees to, provide any other assistance or take any other actions, &#91;***&#93;, as necessary to transfer to Exicure the Exploitation of the Licensed SNAs or Licensed Products in such Program, and will execute all documents &#91;***&#93; in order to give effect to this Section 13.5(b)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">to the extent that &#91;***&#93;, Exicure&#8217;s licenses and rights will be subject to Exicure&#8217;s performance of all obligations under &#91;***&#93;.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The Parties agree to negotiate &#91;***&#93; a written agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Transition Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;) that will memorialize &#91;***&#93;. In the event that the Parties cannot reach agreement on &#91;***&#93; within &#91;***&#93; after the date of termination, either Party may require that the matter (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Transition Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;) be resolved pursuant to Section 14.1(c). Notwithstanding the previous sentence, the provisions of this Section 13.5(b) will have effect regardless of whether the Transition Agreement is entered into by the Parties.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9.95pt;padding-right:21.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.85pt;text-decoration:underline">Termination by Ipsen Due to Material Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Notwithstanding the termination of this Agreement or with respect to a Program by Ipsen pursuant to Section 13.3(a), upon such termination, at Ipsen&#8217;s election, (i) if such termination occurs during the Second R&#38;D Term or Second Option Period for such Program, Ipsen shall immediately have the right to exercise the Second Option for such Program, and (ii) in the event Ipsen has, by the time the termination becomes effective or pursuant to the preceding </font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">45</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div style="margin-top:0.05pt;padding-left:9.95pt;padding-right:21.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">clause (i), exercised the Option for such Program, the license granted to Ipsen under Section 7.1(a) for such Program will become exclusive, perpetual, and irrevocable, and the license granted to Ipsen under Section 7.1(b) for such Program will become non-exclusive, perpetual, and irrevocable. In the event Ipsen makes the election pursuant to the immediately preceding sentence, (x) Ipsen&#8217;s payment obligations under Article 8 shall survive the termination but shall automatically be reduced by &#91;***&#93; percent (&#91;***&#93;), (y) &#91;***&#93;, and (z) Ipsen would fully and forever release and discharge Exicure and its Affiliates, from any and all claims, demands, liabilities, obligations, responsibilities, suits, actions and causes of action, known or unknown, past, present or future, or otherwise, arising out of or relating to such uncured material breach.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:9.95pt;padding-right:21.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%;padding-left:13.23pt;text-decoration:underline">Conduct During Termination Notice Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:117%">. Following any notice of termination permitted under this Article 13, other than &#91;***&#93;, during any applicable termination notice period, (i) each Party will continue to perform all of its obligations under this Agreement then in effect in accordance with the terms and conditions of this Agreement&#59; and (ii) neither Party will make any statement to any Person, whether written, verbal, electronic or otherwise, that disparages any Licensed SNA or Licensed Product, the work performed by either Party under this Agreement, or the other Party.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.4pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.85pt;text-decoration:underline">Termination by Ipsen </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#91;***&#93;. In the event Ipsen terminates this Agreement with respect to a Program under Section 13.2 &#91;***&#93;, Exicure may &#91;***&#93; elect to continue Research and Development activities directed towards achievement of such Development milestone event. If such Development milestone event is achieved &#91;***&#93;, Ipsen shall pay &#91;***&#93;. Exicure will notify Ipsen regarding whether it intends to continue pursuing the Development milestone event (1) in Section 8.3, and provide Ipsen with &#91;***&#93; estimate of the date it expects such Development milestone event to be achieved.</font></div><div><font><br></font></div><div style="padding-left:10pt;padding-right:21.6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">13.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:6.75pt;text-decoration:underline">Other Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Termination or expiration of this Agreement for any reason will not release either Party from any liability or obligation that already has accrued prior to such expiration or termination, nor affect the survival of any provision hereof to the extent it is expressly stated to survive such termination. Termination or expiration of this Agreement for any reason will not constitute a waiver or release of, or otherwise &#91;***&#93;, any rights, remedies or claims, whether for damages or otherwise, that a Party may have hereunder or that may arise out of or in connection with such termination or expiration.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">13.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:6.75pt;text-decoration:underline">Rights in Bankruptcy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. All rights and licenses granted under or pursuant to this Agreement by Exicure and Ipsen are, and will otherwise be deemed to be, for purposes of Section 365(n) of the Bankruptcy Code, licenses of right to &#8220;intellectual property&#8221; as defined under Section 101 of the Bankruptcy Code. The Parties agree that each Party, as licensee of certain rights under this Agreement, will retain and may fully exercise all of its rights and elections under the Bankruptcy Code. The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against a Party (such Party, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Bankrupt Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;) under the Bankruptcy Code, the other Party will be entitled to a complete duplicate of (or complete access to, as appropriate) any intellectual property licensed to such other Party and all embodiments of such intellectual property, which, if not already in such other Party&#8217;s possession, will be &#91;***&#93; delivered to it (a) upon any such commencement of a bankruptcy proceeding upon such other Party&#8217;s written request therefor, &#91;***&#93;. The Parties acknowledge and agree that of the milestones and royalties to be paid pursuant to Article 8, only the royalties contained in Section 8.5 will constitute royalties within the meaning of Bankruptcy Code &#167; 365(n) with respect to the licenses of intellectual property hereunder.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">13.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:6.75pt;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Termination or expiration of this Agreement will not affect rights or obligations of the Parties under this Agreement that have accrued prior to the date of termination or expiration of this Agreement. Notwithstanding anything to the contrary, the following provisions will survive and apply after expiration or termination of this Agreement in its entirety or with respect to a Program, as the case may be&#58; Sections 7.3(b), 8.6, 9.1, 9.4(b), 9.5, 10.3, 13.1, 13.5, 13.6, 13.7 and this 13.8 and Articles 1, 11, 12, 14 and</font></div><div style="padding-left:9.9pt;padding-right:21.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">15. In addition, the other applicable provisions of Article 8 will survive such expiration or termination of this Agreement in its entirety or with respect to a Program to the extent required to make final reimbursements, reconciliations or other payments incurred or accrued prior to the date of termination or expiration. For any surviving provisions requiring action or decision by the JSC or an Executive Officer, </font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">46</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div style="padding-left:9.9pt;padding-right:21.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">each Party will be responsible for all actions or decisions of such Party. All provisions not surviving in accordance with the foregoing will terminate upon expiration or termination of this Agreement and be of no further force and effect.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:74.75pt;padding-right:74.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">ARTICLE 14 </font></div><div style="padding-left:40.37pt;padding-right:40.37pt;text-align:center"><font><br></font></div><div style="padding-left:40.37pt;padding-right:40.37pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">DISPUTE RESOLUTION</font></div><div style="padding-left:40.37pt;padding-right:40.37pt;text-align:center"><font><br></font></div><div style="padding-left:82pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:111%">14.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:111%;padding-left:16.8pt;text-decoration:underline">Dispute Resolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:111%">.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:9.95pt;padding-right:21.45pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.85pt">In the event of any dispute between the Parties under, arising out of, or otherwise in connection with, this Agreement (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;), the Parties will first attempt &#91;***&#93; to resolve such Dispute by negotiation and consultation between themselves. In the event that such Dispute is not resolved on an informal basis within &#91;***&#93;, either Party may refer the matter to the Parties&#8217; Executive Officers for attempted resolution, whereupon the Parties&#8217; Executive Officers will meet in person if requested by either such Executive Officers and attempt &#91;***&#93; to resolve such Dispute by negotiation and consultation for a &#91;***&#93; period following such referral. If the Executive Officers do not resolve such Dispute within such &#91;***&#93; period, either Party may commence arbitration pursuant to Section 14.1(b) or Section 14.1(c), as applicable, with respect to the subject matter of the Dispute and with respect to any other claims it may have, and thereafter neither Party shall have any further obligation under this Section 14.1(a). Any Dispute concerning the propriety of the commencement of the arbitration or the applicability of this Agreement to arbitrate shall be finally settled by the arbitral tribunal.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.65pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.23pt;text-decoration:underline">General Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Subject to Section 14.1(a), all Disputes, including with respect to existence, validity, interpretation, performance, breach or termination of this Agreement, &#91;***&#93;, Disputes over matters set forth in Sections 4.2(b)(iii), 4.2(b)(iv), 4.2(b)(v), or 8.5(c)(i), Reversion Disputes and Transition Disputes, shall be submitted to and finally resolved by arbitration administered by the International Court of Arbitration of the International Chamber of Commerce (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">ICC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;) under the Rules of Arbitration of the International Chamber of Commerce (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Rules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;). The seat of arbitration shall be Boston, Massachusetts. The language of the arbitration shall be English.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:15.73pt">The arbitration shall be conducted by a tribunal of three (3) arbitrators. Each Party shall nominate one (1) arbitrator, and the two (2) Party-nominated arbitrators shall jointly nominate, within &#91;***&#93; of the second arbitrator&#8217;s appointment, the third (3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:115%;position:relative;top:-3.85pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">) arbitrator who shall serve as the presiding arbitrator and shall be of neutral nationality. Each arbitrator must have significant business or legal experience in the pharmaceutical business. An arbitrator shall be deemed to meet this qualification &#91;***&#93;. Discovery of information and evidence that is or might be relevant to the claims, defenses, and issues in the Dispute, including by means of discovery in the form of requests for documents (including electronically stored information), may be allowed, but only for good cause shown. After conducting any hearing and taking any evidence deemed appropriate for consideration, the arbitrators shall render their award within &#91;***&#93; of the final arbitration hearing or the final post-hearing submissions &#91;***&#93;. The arbitral tribunal shall not have the power to award damages excluded pursuant to Section 11.4, and any arbitral ward that purports to award such damages is expressly prohibited.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.68pt">The arbitral award shall be final and binding, and the Parties undertake to carry out the award without delay. Judgement on the award so rendered may be entered in any court of competent jurisdiction. Notwithstanding any provision in the Rules, (x) the arbitral tribunal shall not be empowered to allocate, assess, or award costs or fees (whether at the conclusion of the proceedings or at any other time)&#59; each Party shall bear &#91;***&#93;, and (y) each Party shall bear &#91;***&#93;. The existence and content of the arbitral proceedings and any rulings or awards shall be kept confidential by the Parties and members of the arbitral tribunal except (A) to the extent that disclosure may be required of a Party to fulfill a legal duty, protect or pursue a legal right, or enforce or challenge an award in bona fide legal proceedings before a state court or other judicial authority, (B) with the consent of both Parties, (C) where needed for the preparation or presentation of a claim or defense in this arbitration, (D) where such </font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">47</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div style="padding-left:9.95pt;padding-right:21.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">information is already in the public domain other than &#91;***&#93;,  or (E) by order of the arbitral tribunal upon application of a Party.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9.95pt;padding-right:21.55pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.85pt;text-decoration:underline">Baseball Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Subject to Section 14.1(a), any Disputes over any amounts &#91;***&#93;, disputes over matters set forth in Sections 4.2(b)(iii), 4.2(b)(iv), 4.2(b)(v), or 8.5(c)(i), Reversion Disputes and Transition Disputes shall be submitted to and finally resolved by the following provisions in this Section 14.1(c) (the &#8220;baseball-style&#8221; arbitration). The Parties shall &#91;***&#93; designate in writing a single mutually acceptable arbitrator experienced in the licensing, development, and commercialization of pharmaceutical products, who is independent of each Party (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, not a current or former employee, consultant, officer, or director or current stockholder of either Party or their respective Affiliates and who does not otherwise have any current or previous business relationship with either Party or their respective Affiliates). If the Parties cannot agree on an arbitrator within &#91;***&#93; after referral of such matter, the arbitrator shall be selected in accordance with the Rules. The arbitration shall be conducted in accordance with the Rules to the extent consistent with this Section 14.1(c). Within &#91;***&#93; of the arbitrator&#8217;s appointment, each Party shall prepare and deliver to both the arbitrator and the other Party its last, best offer for the applicable unresolved terms and a memorandum in support thereof. The Parties shall also provide the arbitrator with a copy of the relevant provisions of this Agreement. Each Party may submit to the arbitrator (with a copy to the other Party) a rebuttal to the other Party&#8217;s support memorandum and will at such time have the opportunity to amend its last such offer based on any new information contained in the other Party&#8217;s support memorandum. Within &#91;***&#93; after the arbitrator&#8217;s appointment, the arbitrator will select from the two (2) proposals provided by the Parties the proposal such arbitrator believes is the most consistent with the intent of the Parties when this Agreement was entered into&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided, however, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">the arbitrator may not select any compromise or combination of the two (2) proposals and may not alter the terms of this Agreement. The decision of the arbitrator shall be final and binding on the Parties. The foregoing &#8220;baseball-style&#8221; arbitration shall be the exclusive remedy of either Party if the Parties cannot agree on any Disputes over any amounts &#91;***&#93;, disputes over matters set forth in Sections 4.2(b)(iii), 4.2(b)(iv), 4.2(b)(v), or 8.5(c)(i), Reversion Disputes and Transition Disputes.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.55pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:13.23pt">During the pendency of any Dispute initiated before the end of any applicable Cure Period, (i) this Agreement will remain in full force and effect, (ii) the provisions of this Agreement relating to termination for material breach will not be effective, (iii) the time periods for cure under Section 13.3(a) or Section 13.3(b) as to any termination notice given prior to the initiation of the proceeding will be tolled, and (iv) neither Party will issue a notice of termination pursuant to this Agreement based on the subject matter of the arbitration (and no effect will be given to previously issued termination notices) &#91;***&#93;.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.55pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">14.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:6.8pt;text-decoration:underline">Injunctive Relief&#59; Remedy for Breach of Exclusivity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Nothing in this Article 14 will preclude either Party from seeking equitable relief or interim or provisional relief from a court of competent jurisdiction, including a temporary restraining order, preliminary injunction or other interim equitable relief, concerning a Dispute either prior to or during any arbitration if necessary to protect the interests of such Party or to preserve the status quo pending the arbitration. Therefore, in addition to its rights and remedies otherwise available at law, including the recovery of damages for breach of this Agreement, upon an adequate showing of material breach, and without further proof of irreparable harm other than this acknowledgement, the Non-Breaching Party will &#91;***&#93;.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">14.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:6.75pt;text-decoration:underline">Patent and Trademark Disputes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Notwithstanding any provision to the contrary set forth in this Agreement, any and all issues regarding the scope, construction, validity, and enforceability of any Patent or trademark relating to a Licensed SNA or Licensed Product will be determined in a court or other tribunal, as the case may be, of competent jurisdiction under the applicable patent or trademark laws of the country or other jurisdiction in which such Patent or trademark rights were granted or arose.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:74.75pt;padding-right:74.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">ARTICLE 15 </font></div><div style="padding-left:40.37pt;padding-right:40.37pt;text-align:center"><font><br></font></div><div style="padding-left:40.37pt;padding-right:40.37pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MISCELLANEOUS</font></div><div style="padding-left:40.37pt;padding-right:40.37pt;text-align:center"><font><br></font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">48</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div style="padding-left:82pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:106%">15.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:106%;padding-left:16.8pt;text-decoration:underline">Entire Agreement&#59; Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:106%">. This Agreement, including the Exhibits hereto, set forth</font></div><div style="margin-top:0.1pt;padding-left:10pt;padding-right:21.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">the complete, final and exclusive agreement and all the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings between the Parties &#91;***&#93; with respect to the subject matter hereof. In the event of any inconsistency between any plan hereunder (including any R&#38;D Term Plan) and this Agreement, the terms of this Agreement will prevail. There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties with respect to the subject matter hereof other than as set forth herein. No subsequent alteration, amendment, change or addition to this Agreement will be binding upon the Parties unless reduced to writing specifically referencing this Agreement and signed by an authorized officer of each Party.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9.95pt;padding-right:21.6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">15.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:6.8pt;text-decoration:underline">Force Majeure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Both Parties will be excused from the performance of their obligations under this Agreement to the extent that such performance is prevented or delayed by force majeure and the nonperforming Party &#91;***&#93; provides notice of the prevention to the other Party. Such excuse will be continued so long as the condition constituting force majeure continues and the nonperforming Party &#91;***&#93; remove the condition&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, that if the condition constituting force majeure continues for more than &#91;***&#93; consecutive days, the other Party will have the option to terminate this Agreement immediately upon written notice. For purposes of this Agreement, force majeure will mean conditions &#91;***&#93;, including an act of God, war, civil commotion, terrorist act, labor strike or lock-out, pandemic, epidemic, failure or default of public utilities or common carriers, destruction of production facilities or materials by fire, earthquake, storm or like catastrophe, and failure of plant or machinery (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">such failure could not have been prevented by the exercise of skill, diligence, and prudence that would be &#91;***&#93; expected from a skilled and experienced person engaged in the same type of undertaking under the same or similar circumstances). Notwithstanding the foregoing, a Party will not be excused from making payments owed hereunder because of a force majeure affecting such Party, &#91;***&#93;.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">15.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:6.75pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Any notice required or permitted to be given under this Agreement will be in writing, will specifically refer to this Agreement, and will be addressed to the appropriate Party at the address specified below or such other address as may be specified by such Party in writing in accordance with this Section 15.3, and will be deemed to have been given for all purposes (a) when received, if hand- delivered or sent by a reputable international expedited delivery service, or (b) &#91;***&#93; after mailing, if mailed by first class certified or registered mail, postage prepaid, return receipt requested. This Section 15.3 is not intended to govern the day-to-day business communications necessary between the Parties in performing their obligations under the terms of this Agreement.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:46pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">If to Exicure&#58;&#160;&#160;&#160;&#160;Exicure, Inc.</font></div><div style="padding-left:189.95pt;padding-right:208.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">2430 N. Halsted Street Chicago, IL 60614 United States</font></div><div style="margin-top:0.05pt;padding-left:189.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Attn&#58; &#91;***&#93;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:45.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">With a copy to (which will not constitute notice)&#58;</font></div><div style="padding-left:189.95pt;padding-right:211.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Goodwin Procter LLP 100 Northern Avenue</font></div><div style="padding-left:189.95pt;padding-right:178.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Boston, Massachusetts 02210 United States</font></div><div style="padding-left:189.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Attention&#58; Kingsley L. Taft, Esq.&#47;Can Cui, Esq.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:189.95pt;padding-right:201.65pt;text-indent:-144.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">If to Ipsen&#58;&#160;&#160;&#160;&#160;Ipsen Biopharm Limited c&#47;o Ipsen Pharma SAS 65 quai Georges Gorse</font></div><div style="margin-top:0.1pt;padding-left:189.95pt;padding-right:182.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">92100 Boulogne-Billancourt France</font></div><div style="padding-left:189.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Attn&#58; &#91;***&#93;</font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">49</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:45.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">With a copy to (which will not constitute notice)&#58;</font></div><div style="padding-left:189.95pt;padding-right:184.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Faber Daeufer &#38; Itrato PC 890 Winter Street, Suite 315</font></div><div style="padding-left:189.95pt;padding-right:190.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Waltham, MA 02451 Attn&#58; Mark J. Cooper, Esq.</font></div><div><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">15.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:6.75pt;text-decoration:underline">No Strict Construction&#59; Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. This Agreement has been prepared jointly and will not be strictly construed against either Party. Ambiguities, if any, in this Agreement will not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision. The headings of each Article and Section in this Agreement have been inserted for convenience of reference only and are not intended to limit or expand on the meaning of the language contained in the particular Article or Section.</font></div><div><font><br></font></div><div style="padding-left:10pt;padding-right:21.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">15.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:6.75pt;text-decoration:underline">Interpretation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Whenever any provision of this Agreement uses the term &#8220;including&#8221; (or &#8220;includes&#8221;), such term will be deemed to mean &#8220;including without limitation&#8221; (or &#8220;includes without limitations&#8221;). &#8220;Herein,&#8221; &#8220;hereby,&#8221; &#8220;hereunder,&#8221; &#8220;hereof&#8221; and other equivalent words refer to this Agreement as an entirety and not solely to the particular portion of this Agreement in which any such word is used. The term &#8220;or&#8221; means &#8220;and&#47;or&#8221; hereunder. The terms &#8220;will&#8221; and &#8220;shall&#8221; are used interchangeably hereunder. All definitions set forth herein will be deemed applicable whether the words defined are used herein in the singular or the plural. Unless otherwise provided, all references to Sections and Exhibits in this Agreement are to Sections and Exhibits of this Agreement. References to any Sections include Sections and subsections that are part of the related Section (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, a section numbered &#8220;Section 3.2&#8221; would be part of &#8220;Section 3&#8221;, and references to &#8220;Section 3.2&#8221; would also refer to material contained in the subsection described as &#8220;Section 3.2(a)&#8221;). Unless otherwise stated, dollar amounts set forth in this Agreement are U.S. dollars.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9.95pt;padding-right:21.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">15.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:6.8pt;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Neither Party may assign or transfer (whether by operation of Applicable Law or otherwise) this Agreement or any rights or obligations hereunder without the prior written consent of the other Party, except that either Party may make such an assignment without the other Party&#8217;s consent to an Affiliate of such Party or to a successor to substantially all of the business to which this Agreement relates, whether in a merger, sale of stock, sale of assets, reorganization or other transaction. Any permitted successor or assignee of rights or obligations hereunder will expressly assume performance of such rights or obligations (and in any event, any Party assigning this Agreement to an Affiliate will remain bound by the terms and conditions hereof). Any permitted assignment will be binding on and inure to the benefit of the successors of the assigning Party. Any assignment or attempted assignment by either Party in violation of &#91;***&#93; will be null, void and of no legal effect.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">15.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:6.75pt;text-decoration:underline">Performance by Affiliates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Each Party may discharge any obligations and exercise any right hereunder through any of its Affiliates. Each Party hereby guarantees the performance by its Affiliates of such Party&#8217;s obligations under this Agreement, and will cause its Affiliates to comply with the provisions of this Agreement in connection with such performance. Any breach by a Party&#8217;s Affiliate of any of such Party&#8217;s obligations under this Agreement will be deemed a breach by such Party, and the other Party may proceed directly against such Party without any obligation to first proceed against such Party&#8217;s Affiliate.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">15.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:6.75pt;text-decoration:underline">Further Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">15.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:6.75pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. If any one or more of the provisions of this Agreement is held to be invalid or unenforceable by an arbitrator or by any court of competent jurisdiction from which no appeal can be or is taken, the provision will be considered severed from this Agreement and will not serve to invalidate any remaining provisions hereof. The Parties will &#91;***&#93; replace any invalid or unenforceable provision with a </font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">50</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">EXECUTION VERSION</font></div></div><div style="padding-left:10pt;padding-right:21.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">valid and enforceable one such that the objectives contemplated by the Parties when entering into this Agreement may be realized.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:21.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">15.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:1.3pt;text-decoration:underline">Waiver and Non-Exclusion of Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Any term or condition of this Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but no such waiver will be effective &#91;***&#93;. The waiver by either Party of any right hereunder or of the failure to perform or of a breach by the other Party will not be deemed a waiver of any other right hereunder or of any other breach or failure by such other Party whether of a similar nature or otherwise. The rights and remedies provided herein are cumulative and do not exclude any other right or remedy provided by Applicable Law or otherwise available except as expressly set forth herein.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:10pt;padding-right:21.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">15.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:1.25pt;text-decoration:underline">Independent Contractors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Each Party will act solely as an independent contractor, and nothing in this Agreement will be construed to give either Party the power or authority to act for, bind, or commit the other Party in any way. Nothing herein will be construed to create the relationship of partners, principal and agent, or joint-venture partners between the Parties. All Persons employed by a Party will be employees of that Party and not of the other Party and all expenses and obligations incurred by reason of such employment will be for the account and expense of such Party.</font></div><div><font><br></font></div><div style="padding-left:10pt;padding-right:21.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">15.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:1.25pt;text-decoration:underline">English Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. This Agreement will be written and executed in, and all other communications under or in connection with this Agreement, will be in the English language. Any translation into any other language will not be an official version thereof, and in the event of any conflict in interpretation between the English version and such translation, the English version will control.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:10pt;padding-right:21.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">15.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:1.25pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. This Agreement may be executed in one (1) or more counterparts, by facsimile, pdf or another electronic format, each of which will be deemed an original, but all of which together will constitute one and the same instrument.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:9.95pt;padding-right:21.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">15.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:1.3pt;text-decoration:underline">Choice of Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. This Agreement will be governed by, and enforced and construed in accordance with, the laws of the State of New York, without regard to its conflicts of law provisions. Notwithstanding any other provision in this Agreement, the Parties expressly reject the application to this Agreement, all transactions and activities contemplated hereby, and all Disputes of (a) the United Nations Convention on Contracts for the International Sale Of Goods, and (b) the 1974 Convention on the Limitation Period in the International Sale of Goods, as amended by that certain Protocol, concluded at Vienna, Austria on April 11, 1980.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:165.7pt;padding-right:165.7pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">&#91;Signature Page Follows&#93;</font></div><div style="height:48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">51</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><div id="i9b16f1ba634f40d19a7a1b6dadea2dc9_71"></div><hr style="page-break-after:always"><div style="min-height:109pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:0.55pt;padding-left:1pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, the Parties have executed this Agreement by their duly authorized representatives as of the Effective Date.</font></div><div><font><br></font></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.650%"><tr><td style="width:1.0%"></td><td style="width:14.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.050%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">XICURE,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">.</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; David Giljohann</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">David Giljohann</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.950%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Signature Page to Collaboration, Option and License Agreement</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:80%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><div id="i9b16f1ba634f40d19a7a1b6dadea2dc9_74"></div><hr style="page-break-after:always"><div style="min-height:109pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.55pt;padding-left:1pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, the Parties have executed this Agreement by their duly authorized representatives as of the Effective Date.</font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:261.95pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.650%"><tr><td style="width:1.0%"></td><td style="width:14.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.050%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IPSEN BIOPHARM LIMITED</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; Asad Ali</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Asad Ali</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Director</font></td></tr></table></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.950%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Signature Page to Collaboration, Option and License Agreement</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:80%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><div id="i9b16f1ba634f40d19a7a1b6dadea2dc9_77"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:165.7pt;padding-right:165.7pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">EXHIBIT A</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:78.27pt;padding-right:78.27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">BACKGROUND AND OUTLINE FOR THE HD PROGRAM</font></div><div style="padding-left:78.27pt;padding-right:78.27pt;text-align:center"><font><br></font></div><div style="padding-left:78.27pt;padding-right:78.27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div><div style="height:27.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><div id="i9b16f1ba634f40d19a7a1b6dadea2dc9_80"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:13.47pt;padding-right:13.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">EXHIBIT A1</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:13.17pt;padding-right:13.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">FIRST R&#38;D TERM PLAN FOR THE HD PROGRAM</font></div><div style="padding-left:13.17pt;padding-right:13.17pt;text-align:center"><font><br></font></div><div style="padding-left:13.17pt;padding-right:13.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div><div style="height:36.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.&#160;&#160;&#160;&#160;</font></div></div></div><div id="i9b16f1ba634f40d19a7a1b6dadea2dc9_83"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:13.47pt;padding-right:13.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">EXHIBIT A2</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:13.12pt;padding-right:13.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">INITIAL VERSION OF THE SECOND R&#38;D TERM PLAN FOR THE HD PROGRAM</font></div><div style="padding-left:13.12pt;padding-right:13.12pt;text-align:center"><font><br></font></div><div style="padding-left:13.12pt;padding-right:13.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div><div style="height:36.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.&#160;&#160;&#160;&#160;</font></div></div></div><div id="i9b16f1ba634f40d19a7a1b6dadea2dc9_86"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:13.6pt;padding-right:13.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">EXHIBIT B</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:13.02pt;padding-right:13.02pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">BACKGROUND AND OUTLINE FOR THE A-S PROGRAM</font></div><div style="padding-left:13.02pt;padding-right:13.02pt;text-align:center"><font><br></font></div><div style="padding-left:13.02pt;padding-right:13.02pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div><div style="height:36.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.&#160;&#160;&#160;&#160;</font></div></div></div><div id="i9b16f1ba634f40d19a7a1b6dadea2dc9_89"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:6.65pt;padding-right:6.65pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">EXHIBIT B1</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:6.82pt;padding-right:6.82pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">FIRST R&#38;D TERM PLAN FOR THE A-S PROGRAM</font></div><div style="padding-left:6.82pt;padding-right:6.82pt;text-align:center"><font><br></font></div><div style="padding-left:6.82pt;padding-right:6.82pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div><div style="height:36.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.&#160;&#160;&#160;&#160;</font></div></div></div><div id="i9b16f1ba634f40d19a7a1b6dadea2dc9_92"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:6.65pt;padding-right:6.65pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">EXHIBIT B2</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:31.82pt;padding-right:31.82pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">INITIAL VERSION OF THE SECOND R&#38;D TERM PLAN FOR THE A-S PROGRAM</font></div><div style="padding-left:31.82pt;padding-right:31.82pt;text-align:center"><font><br></font></div><div style="padding-left:31.82pt;padding-right:31.82pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div><div style="height:36.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.&#160;&#160;&#160;&#160;</font></div></div></div><div id="i9b16f1ba634f40d19a7a1b6dadea2dc9_95"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:197.3pt;padding-right:197.3pt;text-align:center;text-indent:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:225%">EXHIBIT C PRESS RELEASE</font></div><div style="height:36.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.&#160;&#160;&#160;&#160;</font></div></div></div><div id="i9b16f1ba634f40d19a7a1b6dadea2dc9_98"></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.033%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Disclaimer&#58; Intended for international media and investor audiences only</font></div></td></tr></table></div></div><div><font><br></font></div><div style="padding-left:5.3pt"><img alt="image_1a.jpg" src="image_1a.jpg" style="height:49px;margin-bottom:5pt;vertical-align:text-bottom;width:169px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><img alt="image_2a.jpg" src="image_2a.jpg" style="height:35px;margin-bottom:5pt;vertical-align:text-bottom;width:151px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font><img alt="image_3a.jpg" src="image_3a.jpg" style="height:66px;margin-bottom:5pt;vertical-align:text-bottom;width:305px"></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:37.07pt;padding-right:37.07pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:118%">Ipsen and Exicure enter into exclusive collaboration targeting rare neurodegenerative disorders</font></div><div style="margin-top:7.55pt;padding-left:75.3pt;padding-right:18.1pt;text-indent:-38.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:115%;padding-left:35.13pt">Ipsen obtains exclusive options to Spherical Nucleic Acids (SNAs</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">TM</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:115%">) currently under discovery evaluation for Huntington&#8217;s disease and Angelman syndrome</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:75.3pt;padding-right:18.1pt;text-indent:-38.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:115%;padding-left:35.13pt">Exicure will be responsible for discovery and certain pre-clinical development activities. In the event Ipsen exercises its option to the two programs, Ipsen will be responsible for further development and worldwide commercialization</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:75.3pt;padding-right:18.1pt;text-indent:-38.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:114%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:114%;padding-left:35.13pt">Exicure will receive a $20m upfront payment and is eligible to receive up to $1B in option exercise fees and milestone payments should Ipsen opt into both programs, as well as tiered royalties</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:6.35pt;padding-left:16pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Paris (France), and Chicago, IL, Cambridge, MA (USA) Monday 2 August 2021 &#8211; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Ipsen (Euronext&#58; IPN&#59; ADR&#58; IPSEY) and Exicure Inc. (NASDAQ&#58; XCUR) have signed an exclusive collaboration agreement to research, develop, and commercialize novel Spherical Nucleic Acids (SNAs) as potential investigational treatments for Huntington&#8217;s disease and Angelman syndrome.</font></div><div><font><br></font></div><div style="padding-left:16pt;padding-right:5.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Oligonucleotides are synthetic structures of nucleic acids that can be used to modulate gene expression via a range of processes, including gene activation, inhibition, and splice-modulation. These molecules have demonstrated potential in many different therapeutic areas.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Achieving efficient oligonucleotide delivery to target organs and tissues, including the brain, remains a major limitation to their use.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">1,2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Exicure&#8217;s SNAs provide distinct chemical and biochemical properties to oligonucleotides. In preclinical models, SNAs have been shown to enhance the cell penetration, biodistribution and organ persistence properties of oligonucleotides,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">3,4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> which may potentially enhance drug delivery to previously inaccessible target tissues, including deep brain regions.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5,6</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:16pt;padding-right:5.7pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Philippe Lopes-Fernandes, Chief Business Officer at Ipsen, said &#8220;Neuroscience is deeply rooted within Ipsen as a key strategic driver for our business. We are pleased to partner with Exicure to progress development of investigational treatment options for Huntington&#8217;s disease and Angelman syndrome, two areas of significant unmet need. This collaboration marks an important step in maximizing the potential of this novel technology, bringing together the expertise of Exicure and the robust heritage of Ipsen in neuroscience. With this new collaboration we will deepen our commitment to people living with neurological conditions around the world.&#8221;</font></div><div><font><br></font></div><div style="padding-left:16pt;padding-right:5.8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;We are thrilled to partner with Ipsen, a leading global company with significant expertise and commitment to developing treatments for patients with rare neurological diseases,&#8221; said David Giljohann, Ph.D., Chief Executive Officer, Exicure, Inc. &#8220;In collaboration with Ipsen, we have the opportunity to apply our technology to Huntington's disease and Angelman syndrome, both indications requiring deep brain penetration and technological advances to reach previously hard-to-drug targets. We believe our platform technology with its deep penetration and persistence of medicinal effect will allow Exicure and Ipsen to overcome challenges from first-generation oligonucleotides and bring new medicines to patients in need.&#34;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:16pt;padding-right:7.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the agreement, Ipsen will receive exclusive options to license SNA-based therapeutics arising from two collaboration programs for Huntington&#8217;s disease and Angelman syndrome. Ipsen will pay Exicure a cash upfront payment of $20m upon closing and Exicure will be responsible for discovery and certain pre-clinical development activities. In the event Ipsen exercises its option, Ipsen will be responsible for further development and commercialization of the licensed products. Exicure will receive a $20m upfront payment and is eligible to receive up to $1B in option exercise fees and milestone payments should Ipsen opt into both programs, as well as tiered royalties.</font></div><div><font><br></font></div><div style="margin-top:6.9pt;padding-left:37.05pt;padding-right:37.05pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ENDS</font></div><div style="height:74pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.&#160;&#160;&#160;&#160;</font></div></div></div><div id="i9b16f1ba634f40d19a7a1b6dadea2dc9_101"></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.033%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Disclaimer&#58; Intended for international media and investor audiences only</font></div></td></tr></table></div></div><div style="margin-top:4.15pt;padding-left:16pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Huntington&#8217;s disease</font></div><div style="padding-left:16pt;padding-right:5.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Huntington&#8217;s disease (HD) is a progressive, fatal neurodegenerative disorder and the most common monogenic neurological disorder in the developed world, affecting about 40,000 individuals in the US.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> HD is caused by an expanded CAG trinucleotide repetition in the huntingtin </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(HTT) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">gene in chromosome 4. HD is characterized by involuntary movements, psychiatric disorders, cognitive deterioration, and early mortality, with death often occurring within 10 to 20 years after motor symptoms appear. Mean age of onset of motor symptoms is around 40 years of age, with longer CAG repeats causing earlier disease onset. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> There is currently no approved therapy to address the underlying molecular cause of HD to slow or stop disease progression.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">9</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:16pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Angelman syndrome</font></div><div style="padding-left:16pt;padding-right:5.7pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Angelman syndrome (AS) is a severe neurodevelopmental disorder. The prevalence of Angelman syndrome is estimated to be 1 in 12,000-20,000 people in the general population.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The disorder is characterized by severe intellectual deficit, speech impairment, epilepsy, ataxic movements and behavioral abnormalities. AS results from loss of function of the maternally inherited copy of the ubiquitin-protein ligase E3A (UBE3A) gene on chromosome</font></div><div style="padding-left:16pt;padding-right:5.55pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%">11 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Disruption of UBE3A function in neurons prevents synapse formation and remodeling, leading to significant neurodevelopmental disability. There is currently no approved disease-modifying therapy for AS and standard- of-care treatment is supportive, such as medications for seizures and behavioral abnormalities.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">12</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:16pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Ipsen</font></div><div style="padding-left:16pt;padding-right:5.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Ipsen is a global, mid-sized biopharmaceutical company focused on transformative medicines in Oncology, Rare Disease and Neuroscience&#59; it also has a well-established Consumer Healthcare business. With Total Sales of over &#8364;2.5bn in FY 2020, Ipsen sells more than 20 medicines in over 115 countries, with a direct commercial presence in more than 30 countries. The Company&#8217;s research and development efforts are focused on its innovative and differentiated technological platforms located in the heart of leading biotechnological and life- science hubs&#58; Paris-Saclay, France&#59; Oxford, U.K.&#59; Cambridge, U.S.&#59; Shanghai, China. Ipsen has c.5,700 colleagues worldwide and is listed in Paris (Euronext&#58; IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR&#58; IPSEY). For more information, visit </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">ipsen.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.65pt;padding-left:16pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exicure, Inc.</font></div><div style="padding-left:16pt;padding-right:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases, and other genetic disorders based on its proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure is in preclinical development of XCUR-FXN a lipid-nanoparticle SNA&#8211;based therapeutic candidate, for the intrathecal treatment of Friedreich&#8217;s ataxia (FA). Exicure&#8217;s therapeutic candidate cavrotolimod (AST-008) is in a Phase 1b&#47;2 clinical trial in patients with advanced solid tumors. Exicure is based in Chicago, IL and in Cambridge, MA.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:6.9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.748%"><tr><td style="width:1.0%"></td><td style="width:51.686%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Ipsen contacts</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Investors</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.35pt;padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Craig Marks</font></div><div style="padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Vice President, Investor Relations</font></div><div style="padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">+44 7584 349 193</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.35pt;padding-left:81.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Adrien Dupin de Saint-Cyr</font></div><div style="padding-left:81.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Investor Relations Manager</font></div><div style="padding-left:81.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">+33 6 64 26 17 49</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Media</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.3pt;padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Jess Smith</font></div><div style="padding-left:10pt;padding-right:122.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Senior Director, Global Communications, R&#38;D and Business Development</font></div><div style="margin-top:0.05pt;padding-left:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">+44 7557 267 634</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:16pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exicure contact</font></div><div style="padding-left:16pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Karen Sharma</font></div><div style="padding-left:16pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">+1 781-235-3060</font></div><div style="padding-left:16pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div><div style="height:74pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.&#160;&#160;&#160;&#160;</font></div></div></div><div id="i9b16f1ba634f40d19a7a1b6dadea2dc9_104"></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.033%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Disclaimer&#58; Intended for international media and investor audiences only</font></div></td></tr></table></div></div><div style="margin-top:4.15pt;padding-left:16pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Ipsen&#8217;s forward-looking statements</font></div><div style="padding-left:16pt;padding-right:5.65pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The forward-looking statements, objectives and targets contained herein are based on Ipsen&#8217;s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen&#8217;s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words &#8216;believes&#8217;, &#8216;anticipates&#8217; and &#8216;expects&#8217; and similar expressions are intended to identify forward-looking statements, including Ipsen&#8217;s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising product in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic products that might translate into a loss of market share. Furthermore, the Research and Development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. There can be no guarantees a product will receive the necessary regulatory approvals or that the product will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition&#59; general economic factors, including interest rate and currency exchange rate fluctuations&#59; the impact of pharmaceutical industry regulation and health care legislation&#59; global trends toward health care cost containment&#59; technological advances, new products and patents attained by competitors&#59; challenges inherent in new product development, including obtaining regulatory approval&#59; Ipsen's ability to accurately predict future market conditions&#59; manufacturing difficulties or delays&#59; financial instability of international economies and sovereign risk&#59; dependence on the effectiveness of Ipsen&#8217;s patents and other protections for innovative products&#59; and the exposure to litigation, including patent litigation, and&#47;or regulatory actions. Ipsen also depends on third parties to develop and market some of its products which could potentially generate substantial royalties&#59; these partners could behave in such ways which could cause damage to Ipsen&#8217;s activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen&#8217;s partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen&#8217;s business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen&#8217;s business is subject to the risk factors outlined in its registration documents filed with the French Autorit&#233; des March&#233;s Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen&#8217;s 2020 Registration Document, available on </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">ipsen.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.7pt;padding-left:16pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exicure&#8217;s forward-looking statements</font></div><div style="padding-left:16pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical fact could be deemed forward looking including, but not limited to, statements regarding the company&#8217;s exclusive collaboration with Ipsen&#59; the ability of SNAs to potentially enhance drug delivery to previously inaccessible target tissues and other benefits of SNAs including as potential treatment options for Huntington&#8217;s disease and Angelman syndrome&#59; the ability of the company&#8217;s technology to overcome challenges from first-generation oligonucleotides and bring new drugs to patients in need&#59; the ability of the company to realize contingent milestone payments and royalties under the collaboration agreement with Ipsen&#59; and the advancement, timing and success of the company&#8217;s preclinical and clinical programs. The forward-looking statements in this press release speak only as of the date of this press release, and the company undertakes no obligation to update these forward-looking statements. Forward-looking statements are based on management&#8217;s current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation&#58; the risks that the ongoing COVID-19 pandemic may disrupt the company&#8217;s business and&#47;or the global healthcare system more severely than it has to date or more severely than anticipated&#59; unexpected costs, charges or expenses that reduce the company&#8217;s capital resources&#59; the company&#8217;s preclinical or clinical programs do not advance or result in approved products on a timely or cost </font></div><div style="height:74pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.033%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.7pt;padding-left:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Disclaimer&#58; Intended for international media and investor audiences only</font></div></td></tr></table></div></div><div style="padding-left:16pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">effective basis or at all&#59; the results of early clinical trials are not always being predictive of future results&#59; the cost, timing and results of clinical trials&#59; that many drug candidates do not become approved drugs on a timely or cost effective basis or at all&#59; the ability to enroll patients in clinical trials&#59; possible safety and efficacy concerns&#59; the ability of the company to collaborate successfully with strategic partners&#59; regulatory developments&#59; exposure to litigation, including patent litigation, and&#47;or regulatory actions&#59; and the ability of the company to protect its intellectual property rights. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the company&#8217;s actual results to differ from those contained in the forward-looking statements, see the section titled &#8220;Risk Factors&#8221; in the company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, as updated by the company&#8217;s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the company undertakes no duty to update this information, except as required by law.</font></div><div><font><br></font></div><div style="margin-top:9.4pt;padding-left:16pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">References</font></div><div style="margin-top:0.05pt"><img alt="image_4a.jpg" src="image_4a.jpg" style="height:1px;margin-bottom:5pt;vertical-align:text-bottom;width:192px"></div><div style="margin-top:5.1pt;padding-left:16pt;padding-right:31.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Nature Reviews Drug Discovery </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2020&#59;19&#58;673&#8211;694. Available here&#58; </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">https&#58;&#47;&#47;www.nature.com&#47;articles&#47;s41573-020-0075-7</font></div><div style="padding-left:16pt;padding-right:9.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Crawford L, Rosch J, Putnam D. Concepts, technologies, and practices for drug delivery past the blood&#8211;brain barrier to the central nervous system. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Journal of Controlled Release. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2016&#59;240&#58; 251-266. Available here&#58; </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">https&#58;&#47;&#47;www.sciencedirect.com&#47;science&#47;article&#47;pii&#47;S0168365915302923&#63;via%3Dihub#bb0020</font></div><div style="padding-left:16pt;padding-right:31.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:118%;position:relative;top:-3.5pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:118%"> </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:118%;text-decoration:underline">https&#58;&#47;&#47;investors.exicuretx.com&#47;news&#47;news-details&#47;2019&#47;Exicure-Announces-Preclinical-Data-Supporting-</font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:118%"> </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:118%;text-decoration:underline">Development-of-SNA-Technology-in-the-Central-Nervous-System&#47;default.aspx</font></div><div style="padding-left:16pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:113%;position:relative;top:-3.5pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:113%"> </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:113%;text-decoration:underline">https&#58;&#47;&#47;s1.q4cdn.com&#47;907903764&#47;files&#47;doc_news&#47;archive&#47;b984683d-76f4-4759-9add-d2c65150ebb6.pdf</font></div><div style="padding-left:16pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Rosi NL, Giljohann DA, Thaxton S, et al. Oligonucleotide-modified gold nanoparticles for intracellular gene regulation. Science 2006&#59;312(5776)&#58;1027&#8211;1030. Available here&#58; </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">https&#58;&#47;&#47;science.sciencemag.org&#47;content&#47;312&#47;5776&#47;1027&#63;ijkey&#61;8fbfd37b2763498a2658cc0dfaa5dc15df0e81a0&#38;</font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">keytype2&#61;tf_ipsecsha</font></div><div style="padding-left:16pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">https&#58;&#47;&#47;www.news-medical.net&#47;life-sciences&#47;What-is-an-Oligonucleotide.aspx</font></div><div style="padding-left:16pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Yohrling et al., Huntington Study Group 2019 Annual Meeting</font></div><div style="padding-left:16pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Bates et al., Nature Reviews Disease Primers, 2015</font></div><div style="padding-left:16pt;padding-right:16.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Tabrizi et al., Nature Reviews Neurology, 2020 Available here&#58; </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">https&#58;&#47;&#47;www.nature.com&#47;articles&#47;s41582-020-</font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">0389-4&#63;proof&#61;t</font></div><div style="padding-left:16pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> NORD. </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">https&#58;&#47;&#47;rarediseases.org&#47;rare-diseases&#47;angelman-syndrome&#47;</font></div><div style="padding-left:16pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">11</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Buiting et al., Nature Reviews Neurology, 2016&#59; US Census Data</font></div><div style="padding-left:16pt;padding-right:33.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">12</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> NIH, National Institute of Neurological Disorders and Stroke, accessed on July 27, 2021 Available here&#58; </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">https&#58;&#47;&#47;www.ninds.nih.gov&#47;Disorders&#47;All-Disorders&#47;Angelman-Syndrome-Information-Page</font></div><div id="i9b16f1ba634f40d19a7a1b6dadea2dc9_107"></div><div style="margin-top:4.15pt;padding-left:16pt;padding-right:5.95pt;text-align:justify"><font><br></font></div><div style="height:74pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.&#160;&#160;&#160;&#160;</font></div></div></div><div id="i9b16f1ba634f40d19a7a1b6dadea2dc9_110"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:143.07pt;padding-right:143.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">SCHEDULE </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">7.6(a)(i)</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div><div style="margin-top:4.55pt;padding-left:151.4pt"><font><br></font></div><div style="padding-left:41pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.5pt">&#91;***&#93;</font></div><div style="margin-top:0.1pt;padding-left:41pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.5pt">&#91;***&#93;</font></div><div style="padding-left:41pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.5pt">&#91;***&#93;</font></div><div style="margin-top:0.05pt;padding-left:41pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.5pt">&#91;***&#93;</font></div><div style="padding-left:41pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.5pt">&#91;***&#93;</font></div><div style="padding-left:41pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.5pt">&#91;***&#93;</font></div><div style="margin-top:0.1pt;padding-left:41pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.5pt">&#91;***&#93;</font></div><div style="padding-left:41pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.5pt">&#91;***&#93;</font></div><div style="margin-top:0.05pt;padding-left:41pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.5pt">&#91;***&#93;</font></div><div style="height:36.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.&#160;&#160;&#160;&#160;</font></div></div></div><div id="i9b16f1ba634f40d19a7a1b6dadea2dc9_113"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:143.07pt;padding-right:143.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">SCHEDULE </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">7.6(a)(ii)</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.55pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">&#91;***&#93;</font></div><div style="padding-left:41pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.5pt">&#91;***&#93;</font></div><div style="margin-top:0.1pt;padding-left:41pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.5pt">&#91;***&#93;</font></div><div style="height:36.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.&#160;&#160;&#160;&#160;</font></div></div></div><div id="i9b16f1ba634f40d19a7a1b6dadea2dc9_116"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:143.02pt;padding-right:143.02pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">SCHEDULE 8.5(d)</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:143.15pt;padding-right:143.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Wire Instructions for Upfront Payment</font></div><div style="margin-top:4.6pt;padding-left:143.15pt;padding-right:143.15pt;text-align:center"><font><br></font></div><div style="margin-top:4.6pt;padding-left:143.15pt;padding-right:143.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div><div style="height:36.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.&#160;&#160;&#160;&#160;</font></div></div></div><div id="i9b16f1ba634f40d19a7a1b6dadea2dc9_119"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:143.05pt;padding-right:143.05pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">SCHEDULE 10.2(f)</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Exicure&#8217;s agreements with the following service vendors&#58;</font></div><div><font><br></font></div><div style="margin-top:10.8pt;padding-left:41pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.5pt">&#91;***&#93;</font></div><div style="padding-left:41pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.5pt">&#91;***&#93;</font></div><div style="height:36.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.&#160;&#160;&#160;&#160;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>3
<FILENAME>exicureexhibit104-93021.htm
<DESCRIPTION>EX-10.4
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i7ebe7dd0ed954d04b9a200bbd57b472c_58"></div><div style="min-height:92pt;width:100%"><div style="margin-top:0.6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:80%">Exhibit 10.4</font></div><div style="text-align:right"><font><br></font></div><div style="margin-top:0.6pt"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:39px;margin-bottom:5pt;vertical-align:text-bottom;width:178px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:80%">&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.544%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:0.9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2430 N. Halsted St., 4th Floor</font></div><div style="margin-top:0.05pt;padding-right:0.9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Chicago, IL 60614</font></div><div style="padding-right:0.9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Ph&#58; 847-673-1700, Fax&#58; 847-556-6411</font></div></td></tr></table></div></div><div><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">CONFIDENTIAL</font></div><div><font><br></font></div><div style="padding-left:5.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">July 30, 2021</font></div><div><font><br></font></div><div style="padding-left:5.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Alicia L&#246;ffler, Ph.D.</font></div><div style="padding-left:5.35pt;padding-right:293.15pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Executive Director, Associate Provost for Innovation and New Ventures, and Associate Vice President for Research Northwestern University</font></div><div style="padding-left:5.35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">1800 Sherman Avenue</font></div><div style="padding-left:5.35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Evanston, IL 60202</font></div><div><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:37.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Re&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">Side Agreement to &#8220;Northwestern Agreements&#8221; in Relation to Ipsen Sublicense</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:5.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Dear Dr. L&#246;ffler&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5.35pt;padding-right:8.6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Reference is hereby made to that certain License Agreement effective as of May 27, 2014, as amended on June 11, 2018 and November 13, 2019 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">2014 Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;), and that certain Restated License Agreement restated on August 15, 2015 and effective as of December 12, 2011, as amended on September 27, 2016, November 30, 2017 and January 1, 2019 and November 30, 2019 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">2011 Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;), in each case, by and between Northwestern University, an Illinois not-for-profit corporation with a principal place of business at 633 Clark Street, Evanston, Illinois, 60208 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Northwestern</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;), and Exicure, Inc., a Delaware corporation with a principal place of business at 8045 Lamon Avenue, Skokie, Illinois, 60077 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Exicure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;). The &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Northwestern Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, collectively, the 2011 Agreement and the 2014 Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5.4pt;padding-right:8.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">pursuant to the Northwestern Agreements, Northwestern has granted Exicure an exclusive license to certain Patent Rights, and a non-exclusive license to certain Know-How (each as defined in the Northwestern Agreements) and other rights (in total, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Exicure Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;)&#59;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5.4pt;padding-right:8.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Exicure is granting an option to sublicense certain of the Exicure Rights to IPSEN BIOPHARM LIMITED, a company organized under the laws of England, located at Ash Road, Wrexham Industrial Estate, Wrexham LL13 9UF, United Kingdom (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Ipsen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;) pursuant to the Collaboration, Option and License Agreement, dated on the date hereof, between Exicure and Ipsen (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Sublicense Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;), upon the execution of which Ipsen would become a Sublicensee (as defined under the Northwestern Agreements).</font></div><div><font><br></font></div><div style="padding-left:5.4pt;padding-right:8.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">NOW THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, in order to clarify certain provisions of the Northwestern Agreements, including the consequences to Ipsen in the event of a termination by Northwestern of some or all of the Exicure Rights pursuant to Section 10 of the Northwestern Agreements, Exicure, Northwestern and Ipsen hereby enter into this side agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Side Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;). Unless otherwise expressly stated in this Side Agreement, all provisions of the Northwestern Agreements and of the Sublicense Agreement remain unchanged and in full force and effect. Unless defined in this Side Agreement or otherwise indicated, all capitalized terms shall have the meanings assigned to them in the Sublicense Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.4pt;padding-right:8.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Exicure, Northwestern and Ipsen, each intending to be legally bound by this Side Agreement, hereby agree to the following&#58;</font></div><div style="height:68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:92pt;width:100%"><div style="margin-top:0.6pt"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:39px;margin-bottom:5pt;vertical-align:text-bottom;width:178px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:80%">&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.544%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:0.9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2430 N. Halsted St., 4th Floor</font></div><div style="margin-top:0.05pt;padding-right:0.9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Chicago, IL 60614</font></div><div style="padding-right:0.9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Ph&#58; 847-673-1700, Fax&#58; 847-556-6411</font></div></td></tr></table></div></div><div style="margin-top:4.6pt;padding-left:41.4pt;padding-right:8.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;Northwestern hereby consents and agrees that, notwithstanding Section 2.7 of the Northwestern Agreements, Northwestern hereby consents to the grant of sublicenses by Ipsen as follows&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41.4pt;padding-right:8.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:20.23pt">Ipsen may grant sublicenses (through multiple tiers) of each license granted to Ipsen under Section 7.1 of the Sublicense Agreement to&#58; (A) Affiliates of Ipsen, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">any such sublicense to an Affiliate of Ipsen will immediately terminate if and when such party ceases to be an Affiliate of Ipsen, or (B) Sublicensees, on the following conditions&#58; (1) Exicure&#8217;s obligations to such sublicensed Affiliate or Sublicensee will be no broader than Exicure&#8217;s obligations were to Ipsen under the Sublicense Agreement prior to Ipsen&#8217;s grant of such a sublicense, and (2) Ipsen will be liable for any act or omission of any such sublicensed Affiliate or Sublicensee that is a breach of any of Ipsen&#8217;s obligations under the Sublicense Agreement as though the same were a breach by Ipsen. Ipsen agrees to (x) notify Exicure in writing no later than twenty-four (24) hours prior to entering into a sublicense agreement with a Sublicensee, and (y) provide Exicure with a copy of such executed sublicense agreement with a Sublicensee within thirty (30) days after the effective date of such agreement (subject to reasonable redaction as Ipsen reasonably believes appropriate to comply with confidentiality obligations, including financial provisions and sensitive information as applicable). Notwithstanding the foregoing, in the event Ipsen intends to grant a sublicense to an Affiliate or Third Party that constitutes a Restricted Party, Ipsen shall provide prior written notice to Northwestern, and Ipsen may not grant such sublicense without Northwestern&#8217;s prior written consent, not to be unreasonably withheld, conditioned or delayed&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">that Northwestern&#8217;s prior written consent shall be deemed to be granted if Northwestern does not provide written notice of any objection to Ipsen within ten (10) Business Days of such notice from Ipsen. For purposes of this Section (a)(i) a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Restricted Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; shall mean any third party with whom, in Ipsen&#8217;s good faith determination, it would be inappropriate for Northwestern to contract or affiliate with taking into consideration (a) Northwestern&#8217;s status and obligations as an educational institution and (b) the negative impact such relationship will likely have on Northwestern&#8217;s reputation with the general public. Without limiting the foregoing, &#8220;Restricted Party&#8221; shall include any person or entity for which the U.S. government maintains restrictions on certain exports, reexports or transfers of items, including any person or entity appearing on the Consolidated Screening List maintained by the International Trade Administration of the United States Department of Commerce. In addition, for each sublicense granted by Ipsen to a Third Party other than a subcontractor of Ipsen, Ipsen (a) shall promptly notify Exicure of the granting of each sublicense, (b) shall provide to Exicure a written copy of each sublicense agreement (which copy may be reasonably redacted as necessary to protect confidential or commercially sensitive information) and (c) shall ensure that the terms of any sublicense agreement (i) are subject to and subordinate to the Sublicense Agreement and (ii) without limiting the foregoing, contain provisions requiring that the Sublicensee (A) comply with the confidentiality and non-use provisions of Article 12 of the Sublicense Agreement with respect to Exicure&#8217;s Confidential Information and (B) submit applicable sales or other reports to Ipsen to the extent necessary or relevant to the reports required to be made or records required to be maintained under the Sublicense Agreement. For the avoidance of doubt, except as otherwise set forth in this Side Agreement, all obligations of &#8220;Licensee&#8221; and &#8220;Sublicensee&#8221; (as those terms are used in Section 2.7 of the Northwestern Agreements) are still in effect.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:41.4pt;padding-right:8.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:17.18pt">Ipsen may transfer the Sublicense Agreement and Ipsen&#8217;s sublicensees may transfer their sublicense agreements, in each case, including by direct assignment or further sublicensing, or indirectly by operation of law or transfer of voting control of Ipsen or such </font></div><div style="height:68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92pt;width:100%"><div style="margin-top:0.6pt"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:39px;margin-bottom:5pt;vertical-align:text-bottom;width:178px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:80%">&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.544%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:0.9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2430 N. Halsted St., 4th Floor</font></div><div style="margin-top:0.05pt;padding-right:0.9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Chicago, IL 60614</font></div><div style="padding-right:0.9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Ph&#58; 847-673-1700, Fax&#58; 847-556-6411</font></div></td></tr></table></div></div><div style="padding-left:41.4pt;padding-right:8.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">sublicensees, without the prior written approval of Northwestern, except no transfer is permitted to a Restricted Party without Northwestern&#8217;s prior written consent.</font></div><div style="padding-left:5.4pt;padding-right:8.7pt;text-align:justify;text-indent:54pt"><font><br></font></div><div style="padding-left:41.4pt;padding-right:8.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.13pt">Northwestern acknowledges and agrees that the Sublicense Agreement is consistent with all terms and conditions of the Northwestern Agreements.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5.4pt;padding-right:8.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:17.78pt">Notwithstanding Section 2.7 of the Northwestern Agreements, in the event of (i) a termination of either or both of the Northwestern Agreements for any reason, or (ii) the rejection of either or both of the Northwestern Agreements in any bankruptcy proceeding pursuant to 11 U.S.C. &#167; 365&#58;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:41.4pt;padding-right:8.55pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:20.23pt">Northwestern, after receiving or providing notice, as applicable, of such termination or rejection, shall promptly notify Ipsen in writing of such termination or rejection, as applicable (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Termination Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;). Unless Ipsen is then in material breach of the Sublicense Agreement, Ipsen may provide written notice to Northwestern within thirty (30) days of the Termination Notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Springing Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;), and Ipsen, automatically and without further required action, shall be granted the same rights (including the grant of licenses) of Exicure under the Northwestern Agreements to the extent of the sublicensed rights granted to Ipsen pursuant to the Sublicense Agreement (or that would be granted to Ipsen pursuant to the Sublicense Agreement following exercise of the Option (as defined therein)) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Direct License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;), and Northwestern hereby grants such Direct License to Ipsen effective upon receipt of such Springing Notice retroactively to the date of such termination or rejection. For clarity, if Northwestern grants a Direct License to Ipsen, then all sublicenses granted by Ipsen pursuant to Section (a)(i) shall survive such termination or rejection of either or both of the Northwestern Agreements. By sending the foregoing Springing Notice, Ipsen will be deemed to have assumed the same rights and responsibilities of Exicure under the Northwestern Agreements, to the extent arising out of the practice of the sublicensed rights granted by Exicure to Ipsen under the Sublicense Agreement. Notwithstanding the foregoing, (a) the scope of the rights and obligations of Ipsen pursuant to the Direct License shall not in any respect exceed the scope and limitations of the rights and obligations of Ipsen under the Sublicense Agreement, (b) Ipsen shall not be responsible for any obligations (financial or otherwise) arising out of the activities of any sublicensee of Exicure other than Ipsen and its Affiliates and sublicensees and (c) Ipsen shall not be responsible for any obligations (financial or otherwise), including, without limitation, one-time or annual license fees, that have already accrued or been satisfied by Exicure prior to the termination or rejection of the Northwestern Agreements. For the sake of clarity, as part of assuming the rights and responsibilities of Exicure, Ipsen will pay Northwestern any annual license fee that may thereafter become payable to Northwestern under Section 5.4 of the 2011 Agreement or Section 5.3(b) of the 2014 Agreement, such amount to be pro-rated based on the then-current number of sublicenses granted by Exicure under each Northwestern Agreement that become direct licenses from Northwestern after such termination or rejection, as applicable. For clarity, any such annual license fee paid by Ipsen under this Section (b)(i) shall, in accordance with Section 5.4 of the 2011 Agreement or Section 5.3(b) of the 2014 Agreement, as applicable, be creditable against future royalties payable to Northwestern by Ipsen pursuant to the Direct License. As between Northwestern and Exicure, Exicure shall have no responsibility with respect to any obligations of Ipsen that accrue after the effective date of any such termination or rejection.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41.4pt;padding-right:6.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:17.18pt">In the event of a Direct License, if the Sublicense Agreement remains in effect, Ipsen shall remain fully responsible for making all payments to Exicure as required under the Sublicense Agreement, but shall be entitled to deduct 100% of the payments that are made </font></div><div style="height:68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92pt;width:100%"><div style="margin-top:0.6pt"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:39px;margin-bottom:5pt;vertical-align:text-bottom;width:178px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:80%">&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.544%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:0.9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2430 N. Halsted St., 4th Floor</font></div><div style="margin-top:0.05pt;padding-right:0.9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Chicago, IL 60614</font></div><div style="padding-right:0.9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Ph&#58; 847-673-1700, Fax&#58; 847-556-6411</font></div></td></tr></table></div></div><div style="padding-left:41.4pt;padding-right:6.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">directly to Northwestern pursuant to the Direct License from the payments that are owed to Exicure under the Sublicense Agreement. Such set-off right shall be without limitation of any other rights or remedies that Ipsen may have under the Sublicense Agreement, at law or in equity.</font></div><div style="padding-left:5.4pt;padding-right:6.05pt;text-align:justify;text-indent:54pt"><font><br></font></div><div style="padding-left:41.4pt;padding-right:6.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.13pt">Each party shall perform, or cause to be performed, all such further acts, and shall execute and deliver all such other agreements and documents, as the other parties may reasonably request in order to carry out the intent and purposes of this Section (b), including the execution and delivery of any instruments or documents requested by Ipsen to evidence the grant of a Direct License.</font></div><div style="margin-top:0.45pt;padding-left:0.05pt"><font><br></font></div><div style="padding-left:5.4pt;padding-right:8.6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:18.4pt">Notwithstanding Section 6.2 of the Northwestern Agreements, Northwestern agrees that Ipsen may only be audited directly by or on behalf of Exicure pursuant to the terms of the Sublicense Agreement, and the results of such audit may be shared with Northwestern subject to treatment as Confidential Information of Exicure under the Northwestern Agreements. As between Exicure and Northwestern, Northwestern shall have the right to&#58; (i) request Exicure to exercise its right to audit Ipsen under Section 8.5(e) of the Sublicense Agreement, at Exicure&#8217;s (or, if applicable pursuant to Section 8.5(e)(iii) of the Sublicense Agreement, Ipsen&#8217;s) cost, and (ii) approve Exicure&#8217;s selection of an independent public accounting firm of internationally recognized standing for purposes of such audit.</font></div><div style="margin-top:0.45pt;padding-left:0.05pt"><font><br></font></div><div style="padding-left:5.4pt;padding-right:8.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:17.78pt">With respect to Article 8 of the Northwestern Agreements, Exicure may, upon written notice to Northwestern, permit Ipsen or Ipsen&#8217;s sublicensees to directly exercise any of Exicure&#8217;s rights thereunder. In addition, notwithstanding anything to the contrary in Article 8 of the Northwestern Agreements, on a Program-by-Program basis, from and after the Option Exercise Date for such Program, in the event that (i) Exicure or Ipsen becomes aware of any actual or suspected infringement of any Exicure SNA Patent with respect to such Program by a product primarily targeting the Target in such Program, (ii) any such Exicure SNA Patent is challenged in any action or proceeding (other than any interferences, oppositions, reissue proceedings or re-examinations) or (iii) Exicure or Ipsen receives a Notice of Paragraph IV Patent certification, such party will notify the other party promptly, and following such notification, Exicure and Ipsen will confer. Ipsen will have the sole right, but will not be obligated, to defend any such action or proceeding or bring an infringement action with respect to such infringement at its own expense, in its own name and entirely under its own direction and control. Upon Ipsen&#8217;s request, Northwestern shall join any such action at Ipsen&#8217;s reasonable cost and expense, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">that, if such action is not an enforcement action brought under the Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. ch. 9 &#167; 301&#59; 21 U.S.C. ch. 9, subch. V &#167;&#167; 355 &#38; 360cc (or its successor or equivalent law) or under the Biologics Price Competition and Innovation Act (or its successor or equivalent law), as applicable, such joinder shall be subject to Northwestern&#8217;s prior written consent, not to be unreasonably withheld, conditioned or delayed. Northwestern will not exercise its right under Sections 8.2 and 8.4 of the Northwestern Agreements to enforce or defend (as applicable) the applicable Patent with respect to an infringement if Ipsen notifies Exicure and Northwestern of a strategic rationale in good faith for non-enforcement of the applicable Patent. Notwithstanding Section 8.3 of the Northwestern Agreements, Ipsen shall also have the right to, subject to Exicure&#8217;s prior written consent, not to be unreasonably withheld, conditioned or delayed, settle any such action or proceeding by sublicense (including, at Ipsen&#8217;s sole discretion, granting a sublicense, covenant not to sue or other right with respect to a compound or product (including a Generic Product) in the Territory), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">that any settlement that (A) imposes any costs or liability on, or involves any admission (including any admission of infringement or invalidity or unenforceability) by Northwestern, or (B) imposes restrictions or obligations not otherwise permitted </font></div><div style="height:68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92pt;width:100%"><div style="margin-top:0.6pt"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:39px;margin-bottom:5pt;vertical-align:text-bottom;width:178px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:80%">&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.544%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:0.9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2430 N. Halsted St., 4th Floor</font></div><div style="margin-top:0.05pt;padding-right:0.9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Chicago, IL 60614</font></div><div style="padding-right:0.9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Ph&#58; 847-673-1700, Fax&#58; 847-556-6411</font></div></td></tr></table></div></div><div style="padding-left:5.4pt;padding-right:8.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">by the applicable Northwestern Agreement on Northwestern, or (C) admits the invalidity or unenforceability (in whole or in part) of any Patent Right (as defined in the Northwestern Agreements)&#59; shall, in each case, be subject to the express written consent of Northwestern, which consent shall not be unreasonably withheld, conditioned or delayed. Ipsen shall keep Exicure and Northwestern reasonably informed of any material steps taken in connection with any action under this Section (d), and shall consider in good faith any comments from Exicure or Northwestern with respect thereto.</font></div><div style="padding-right:8.7pt;text-align:justify;text-indent:54pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:5.4pt;padding-right:8.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:18.45pt">In the event that Exicure&#8217;s licenses under either Northwestern Agreement would be rendered non-exclusive under Section 10.4 of such Northwestern Agreement, other than as a result of an act or omission on the part of Ipsen or any of its Affiliates or sublicensees, Northwestern agrees that, subject to Ipsen&#8217;s continued compliance with its obligations under the Sublicense Agreement and this Side Agreement, the licenses granted to Exicure will remain exclusive with respect to the field of the licenses granted to Ipsen under the Sublicense Agreement.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:5.35pt;padding-right:8.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:19.67pt">Notwithstanding the last sentence of Section 2.7 of the Northwestern Agreements&#58; (i) Northwestern shall only be a third party beneficiary of the Sublicense Agreement with regard to Section 7.3 of the Sublicense Agreement, pertaining to Ipsen&#8217;s compliance with its obligations as a sublicensee under the Northwestern Agreements&#59; and (ii) with respect to any further sublicenses granted by Ipsen, Northwestern shall only be a third party beneficiary of such further sublicense agreements to the same extent as set forth in the preceding sentence with respect to the Sublicense Agreement</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5.35pt;padding-right:8.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:17.88pt">Northwestern waives any right to receive notice of or audit Ipsen&#8217;s or its Affiliates&#8217; or sublicensees&#8217; subcontractors under Section 2.6 of the Northwestern Agreements.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.35pt;padding-right:8.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:17.83pt">Notwithstanding Article 3 of the Northwestern Agreements, Exicure may disclose to Ipsen any documents or information provided by Northwestern pursuant to Article 7 or Article 8 of the Northwestern Agreements, in order to consult with and receive input from Ipsen regarding the exercise of Exicure&#8217;s rights thereunder.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:5.35pt;padding-right:8.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:20.28pt">No party may assign or transfer this Side Agreement without the prior written consent of each other party, except that (i) Ipsen may assign this Side Agreement without such consent solely to a permitted assignee of the Sublicense Agreement and (ii) Exicure may assign this Side Agreement without such consent solely to a permitted assignee of each of the Sublicense Agreement, the 2011 Agreement and the 2014 Agreement. Any purported assignment, delegation or transfer in contravention of this Section </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">(i) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">will be null and void. This Side Agreement will be binding on and inure to the sole benefit of the parties and their permitted successors and assigns.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5.35pt;padding-right:8.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:20.28pt">In the event any provision of this Side Agreement is held to be invalid or unenforceable, the valid or enforceable portion thereof in any other jurisdiction and the remaining provisions of this Side Agreement will remain in full force and effect. The parties desire the terms herein to be valid and enforced to the maximum extent not prohibited by law, regulation or court order in a given jurisdiction and as such, any invalid or unenforceable terms will be promptly reformed by the parties to effectuate the intent of the parties as evidenced on the date hereof.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5.35pt;padding-right:8.6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:17.83pt">This Side Agreement is not intended to, nor shall it be deemed to, and does not, (a) grant Ipsen any right with respect to Exicure not granted by Exicure under the Sublicense Agreement, or (b) impose any obligation on Exicure not imposed by the Sublicense Agreement or the </font></div><div style="height:68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:92pt;width:100%"><div style="margin-top:0.6pt"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:39px;margin-bottom:5pt;vertical-align:text-bottom;width:178px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:80%">&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.544%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:0.9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2430 N. Halsted St., 4th Floor</font></div><div style="margin-top:0.05pt;padding-right:0.9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Chicago, IL 60614</font></div><div style="padding-right:0.9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Ph&#58; 847-673-1700, Fax&#58; 847-556-6411</font></div></td></tr></table></div></div><div style="padding-left:5.35pt;padding-right:8.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Northwestern Agreements. As between Ipsen and Exicure, to the extent of any conflict between this Side Agreement and the Sublicense Agreement, the Sublicense Agreement shall govern and control. This Side Agreement, together with the Sublicense Agreement, the 2011 Agreement and the 2014 Agreement, constitutes the entire, final, complete and exclusive agreement among the parties and supersedes all previous agreements or representations, written or oral. This Side Agreement may not be modified or amended except in a writing signed by a duly authorized representative of each party. Each party acknowledges that it was provided an opportunity to seek advice of counsel and as such this Side Agreement shall not be construed for or against the drafter.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:5.35pt;padding-right:8.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:20.28pt">Any waiver (express or implied) by any party of any term of this Side Agreement shall not constitute a waiver of any other or subsequent breach. The delay or failure to assert a right or to insist upon compliance with any term of this Side Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition. A valid waiver must be executed in writing and signed by the party granting the waiver.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5.3pt;padding-right:8.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">(m) &#160;&#160;&#160;&#160;This Side Agreement may be executed in counterparts with the same force and effect as if each of the signatories had executed the same instrument.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:160.97pt;padding-right:160.97pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#91;Signature page follows&#93;</font></div><div style="height:68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6</font></div></div></div><div id="i7ebe7dd0ed954d04b9a200bbd57b472c_76"></div><hr style="page-break-after:always"><div style="min-height:74pt;width:100%"><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:39px;margin-bottom:5pt;vertical-align:text-bottom;width:178px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:80%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.051%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:0.9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2430 N. Halsted St., 4th Floor</font></div><div style="margin-top:0.05pt;padding-right:0.9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Chicago, IL 60614</font></div><div style="padding-right:0.9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Ph&#58; 847-673-1700, Fax&#58; 847-556-6411</font></div></td></tr></table></div></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">In witness whereof, the parties have executed this Side Agreement by their duly authorized representatives on the date first written above.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.05pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.160%"><tr><td style="width:1.0%"></td><td style="width:19.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.814%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NORTHWESTERN UNIVERSITY</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; Alicia L&#246;ffler, Ph.D.</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt 0 3.77pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Alicia L&#246;ffler, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt 0 3.77pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Executive Director, Associate Provost for Innovation and New Ventures, and Associate Vice President for Research</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXICURE, INC.</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; David Giljohann, Ph.D.</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt 0 3.77pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">David Giljohann, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt 0 3.77pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">IPSEN BIOPHARM LIMITED</font></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:5.4pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:36.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:4.5pt;padding-left:154.12pt;padding-right:154.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#91;Signature page to Side Agreement&#93;</font></div></div></div><div id="i7ebe7dd0ed954d04b9a200bbd57b472c_227"></div><hr style="page-break-after:always"><div style="min-height:74pt;width:100%"><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:39px;margin-bottom:5pt;vertical-align:text-bottom;width:178px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:80%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.051%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:0.9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2430 N. Halsted St., 4th Floor</font></div><div style="margin-top:0.05pt;padding-right:0.9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Chicago, IL 60614</font></div><div style="padding-right:0.9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Ph&#58; 847-673-1700, Fax&#58; 847-556-6411</font></div></td></tr></table></div></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">In witness whereof, the parties have executed this Side Agreement by their duly authorized representatives on the date first written above.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.05pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.160%"><tr><td style="width:1.0%"></td><td style="width:19.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.814%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NORTHWESTERN UNIVERSITY</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt 0 3.77pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Alicia L&#246;ffler, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt 0 3.77pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Executive Director, Associate Provost for Innovation and New Ventures, and Associate Vice President for Research</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EXICURE, INC.</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt 0 3.77pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">David Giljohann, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt 0 3.77pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">IPSEN BIOPHARM LIMITED</font></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; Asad Ali</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Asad Ali</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Director</font></td></tr></table></div><div style="padding-left:5.4pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:36.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:4.5pt;padding-left:154.12pt;padding-right:154.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#91;Signature page to Side Agreement&#93;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>4
<FILENAME>exicureexhibit105-93021.htm
<DESCRIPTION>EX-10.5
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i0e3169650f5a44dc875a487e4efc637f_58"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.5</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">FIFTH AMENDMENT TO THE LICENSE AGREEMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">BY AND BETWEEN</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">NORTHWESTERN UNIVERSITY AND EXICURE OPERATING COMPANY.</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">FIFTH </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">AMENDMENT (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;), effective as of September 8, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Fifth Amendment Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;), is entered into by and between NORTHWESTERN UNIVERSITY, an Illinois not-for-profit corporation having a principal office located at 633 Clark Street, Evanston, Illinois 60208 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Northwestern</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;) and Exicure Operating Company having a principal office located at 2430 N. Halsted Street, Chicago, IL 60614 (&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#34;).</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">RECITALS</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">WHEREAS, Northwestern and Licensee entered into that certain License Agreement dated December 12, 2011 pursuant to which Northwestern granted an exclusive license to Licensee for the purpose of commercializing certain Patent Rights (hereinafter, the &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Original</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#34;)&#59; </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">WHERAS, thereafter, Northwestern and Licensee entered into that certain document titled &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">First Amendment to the License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; dated September 27, 2016 pursuant to which Northwestern and Licensee restated the terms of the Original License. </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">WHEREAS, thereafter, Northwestern and Licensee entered into that certain document titled &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Second Amendment to the License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; dated November 30, 2017 pursuant to which Northwestern and Licensee restated the terms of the Original License. </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">WHEREAS, thereafter, Northwestern and Licensee entered into that certain document titled &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Third Amendment to the License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; dated January 1, 2019 pursuant to which Northwestern and Licensee restated the terms of the Original License.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">WHEREAS, thereafter, Northwestern and Licensee entered into that certain document titled &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Fourth Amendment to the License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; dated November 13, 2019 pursuant to which Northwestern and Licensee restated the terms of the Original License. </font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">WHERAS, the Original License, together with the First Amendment to the License Agreement, the Second Amendment to the License Agreement, the Third Amendment to the License Agreement, and the Fourth Amendment to the License Agreement shall be referred to as the License. Northwestern and Licensee wish to further amend the License with regard to updating the licensed Patent Rights and restating the patent prosecution and reimbursement terms.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">NOW, THEREFORE, in consideration of the mutual promises and covenants set forth below, IT IS AGREED&#58;</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">ARTICLE 5 &#8211; PAYMENT AND REPORTS</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Section 5.8 shall be replaced in its entirety with the following</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The patent applications and patents within the Patent Rights in existence as the Fifth Amendment Effective Date have been listed in Appendix A. After the Effective Date and during the term of the Agreement, the parties contemplate several changes of status for the rights listed on Appendix A including that&#58; (a) patent applications within the Patent Rights may be filed therefrom&#59; (b) the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">reimbursement status of any given patent application or patent of the Patent Rights may change. The parties agree that Licensee is obligated to reimburse all unreimbursed patent expenses incurred by Northwestern to prepare, file, prosecute and maintain the Patent Rights even in the event an Appendix A attached hereto does not reflect the then-current status of the rights. In the event that Licensee makes a Partial Assignment pursuant to Article 11, Licensee is not required to assign, but may expressly include an obligation to assume, the payment obligations in this Section 5.8 (including Sections 5.8.1 and 5.8.2) with respect to all or any portion of the Patent Rights that are the subject of such Partial Assignment.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;5.8.1 Licensee agrees to pay to Northwestern for the reimbursement of&#58; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(a) 100% of  Northwestern&#8217;s out of pocket patent expenses to date to prepare, file, and prosecute Patent Rights included in Appendix A plus, commencing on the Fifth Amendment Effective Date, a &#91;***&#93; percent (&#91;***&#93;%) processing fee, the total of such expenses and fees to be provided by Northwestern&#8217;s outside patent counsel upon request by Licensee. Any outstanding patent expenses incurred by Northwestern, shall be reimbursed by Licensee. All future patent costs for the preparation, filing, prosecution, and maintenance of the Patent Rights, including without limitation any interference or other proceeding before the United States Patent and Trademark Office, shall be borne by Licensee in addition to a &#91;***&#93; percent (&#91;***&#93;%) processing fee. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(b) &#91;***&#93;% of the patent expenses during the term of this Agreement to prepare, file, prosecute, maintain, enforce and defend the Patent Rights set forth in Appendix B unless modified by the terms of Articles 7 and 8.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;5.8.2 Intentionally Omitted</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;text-decoration:underline">ARTICLE 7 &#8211; PATENT PROSECUTION</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Section 7.1 shall be replaced in its entirety with the following</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Payment of all fees and costs relating to the filing, prosecution, and maintenance of Patent Rights prior to the Effective Date shall be reimbursed by Licensee as set forth in Section 5.8.  Payment of all fees and costs relating to the filing, prosecution, and maintenance of Patent Rights incurred after the Effective Date by Licensee or by Northwestern at the request of Licensee shall be the sole responsibility of Licensee.  Any payments of such fees and costs by Northwestern shall be reimbursed by Licensee within thirty (30) days of Licensee&#8217;s receipt of an invoice from Northwestern or Northwestern&#8217;s patent counsel. For the avoidance of doubt, Licensee shall reimburse Northwestern for any expenses incurred by Northwestern in addition to a &#91;***&#93; percent (&#91;***&#93;%) processing fee as outlined in Section 5.8 if Licensee chooses not to exercise its right to utilize its own patent counsel for the filing, prosecution, and&#47;or maintenance of Patent Rights as set forth below.</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Section 7.2 shall be replaced in its entirety with the following</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Northwestern hereby grants Licensee the right to apply for, seek prompt issuance of, and maintain during the term of this Agreement the Patent Rights listed in Appendix A in Northwestern&#8217;s name, in the United States and in foreign countries.  Appendix A may be amended by verbal agreement of both Parties, such agreement to be confirmed in writing. The Parties agree to use reasonable efforts to update Appendix A on an annual basis as new applications are filed and prosecution status changes.  Licensee shall have the right to select patent counsel reasonably acceptable to Northwestern, such acceptance not to be unreasonably withheld, and to take such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">7</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">other actions, at its own expense, as it deems are necessary or appropriate to obtain patent protection with respect to any Patent Rights in the Territory. Licensee shall keep Northwestern informed in all matters of filing and prosecution, shall give Northwestern reasonable opportunities to consult with and advise Licensee concerning Licensee's prosecution, filing and maintenance activities by notifying Northwestern thirty (30) days in advance of any such activity if Licensee has been given such notice, and shall provide Northwestern with copies of all documents related to patent filing, prosecution, and maintenance.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Section 7.3 shall be replaced in its entirety with the following</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Licensee through its patent counsel will take the lead on patent prosecution for additional filings falling within the scope of the Patent Rights listed in Appendix A for which it pays the prosecution costs, keeping Northwestern informed with opportunity to consult as described above. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Section 7.4 shall be replaced in its entirety with the following&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">In the event that Licensee elects (i) not to file a United States patent application which may claim priority from a patent application filed in another jurisdiction included within the Patent Rights, (ii) not to file a PCT application which may claim priority from a United States patent application included within the Patent Rights, or (iii) to abandon a patent or patent application included within the Patent Rights in a specific country, it shall promptly notify Northwestern in writing, no later than ten (10) business days prior to the date by which an action must be taken to avoid a) abandonment of the patent or patent application included within the Patent Rights or b) payment of extension fees.  In the event that Licensee notifies Northwestern of its decision not to file a non-provisional patent application claiming priority to a provisional patent application listed in Appendix A or to abandon a U.S. patent or patent application covering any potentially patentable subject matter relating to the Patent Rights, Northwestern shall have the right, but not the obligation, to file, prosecute, or maintain such patent or patent application  at its sole discretion, control and expense and such patent or patent application shall be removed from the Patent Rights licensed hereunder.  In the event that Licensee notifies Northwestern of its decision to abandon or not to file a PCT or national phase patent or patent application in any foreign country based on a U. S. provisional or utility application in the Patent Rights, Northwestern shall have the right, but not the obligation, to file, prosecute, or maintain such PCT or foreign patent or patent application at its sole discretion and control. </font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Appendix A shall be replaced in its entirety with the updated and amended Appendix A attached hereto and incorporated by reference.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Except as set forth herein, all terms and conditions of the License shall remain in full force and effect. Unless otherwise defined in this Amendment, capitalized terms used in this Amendment shall have the same meaning as set forth in the License. This Amendment, together with the License, constitute the entire agreement of the Parties with respect to the subject matter hereof, and supersedes any other agreements, promises, representations or discussions, written or oral, concerning such subject matter</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">This Amendment may be executed in counterparts, each of which shall be deemed an original, and all of which taken together shall constitute one and the same document. Execution of the Amendment by a facsimile signature or other electronic delivery of an image file (e.g., PDF) shall be deemed an original signature. IN WITNESS WHEREOF, the Northwestern and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">7</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Licensee acknowledge their acceptance of this Amendment effective as of the date and year first set forth above.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.191%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.008%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.495%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">EXICURE OPERATING COMPANY</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">NORTHWESTERN</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; David Giljohann</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; Alicia Loffler</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">David Giljohann</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Alicia Loffler</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Executive Director, Associate Provost for Innovation and New Ventures, Assoc. Vice President, Research</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 8, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 8, 2021</font></td></tr></table></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">7</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Appendix A</font></div><div style="text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.065%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.702%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.852%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">TECH ID</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Title</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Serial Number</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Patent Number</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Country</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">File Date</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Prosecution Lead</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">7</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.065%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.702%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.852%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">7</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Appendix B</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">Intentionally Omitted</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Page </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">7</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#91;***&#93; - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>exicureexhibit311-93021.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ia1324ba34db543eb9e4b3026b85baed2_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1 </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, David A. Giljohann, Ph.D., certify that&#58; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q of Exicure, Inc.&#59; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November 19, 2021 </font></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.470%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; David A. Giljohann</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">David A. Giljohann, Ph.D.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>exicureexhibit312-93021.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i2a9f5697781941ca8453581c2a7632d2_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2 </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Brian C. Bock, certify that&#58; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q of Exicure, Inc.&#59; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November 19, 2021 </font></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.470%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Brian C. Bock</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Brian C. Bock</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>exicureexhibit321-93021.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i3346c8ade2f64bd3892f296f2c20e1a9_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1 </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 1350 CERTIFICATIONS* </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167; 1350), David A. Giljohann, Ph. D., President and Chief Executive Officer of Exicure, Inc. (the &#8220;Company&#8221;), and Brian C. Bock, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge&#58;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. The Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, to which this Certification is attached as Exhibit 32.1 (the &#8220;Quarterly Report&#8221;), fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act&#59; and </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; November 19, 2021</font></div><div style="margin-top:5pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.910%"><tr><td style="width:1.0%"></td><td style="width:44.896%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.898%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; David A. Giljohann</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Brian C. Bock</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">David A. Giljohann, Ph.D.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Brian C. Bock</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(Principal Executive Officer)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(Principal Financial Officer)</font></div></td></tr></table></div><div style="margin-bottom:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.073%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This certification accompanies the Quarterly Report on Form 10-Q, to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Quarterly Report on Form 10-Q), irrespective of any general incorporation language contained in such filing.</font></td></tr></table></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>xcur-20210930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:ec2cf3ab-02c5-4899-a9f4-a2b651188a5f,g:ebea5fae-f5ab-4d4a-8517-3fed58ff79ef-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xcur="http://www.exicuretx.com/20210930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.exicuretx.com/20210930">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xcur-20210930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xcur-20210930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xcur-20210930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xcur-20210930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.exicuretx.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>1003004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME" roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME">
        <link:definition>1004005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY">
        <link:definition>1005006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1006007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical" roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical">
        <link:definition>1007008 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandBasisofPresentation" roleURI="http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentation">
        <link:definition>2101101 - Disclosure - Description of Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandBasisofPresentationDetails" roleURI="http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails">
        <link:definition>2402401 - Disclosure - Description of Business and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPolicies" roleURI="http://www.exicuretx.com/role/SignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesPolicies" roleURI="http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesDetails" roleURI="http://www.exicuretx.com/role/SignificantAccountingPoliciesDetails">
        <link:definition>2405402 - Disclosure - Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeResearchandLicenseAgreements" roleURI="http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreements">
        <link:definition>2106103 - Disclosure - Collaborative Research and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeResearchandLicenseAgreementsTables" roleURI="http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsTables">
        <link:definition>2307301 - Disclosure - Collaborative Research and License Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeResearchandLicenseAgreementsDetails" roleURI="http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails">
        <link:definition>2408403 - Disclosure - Collaborative Research and License Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeResearchandLicenseAgreementsOtherCurrentLiabilitiesDetails" roleURI="http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsOtherCurrentLiabilitiesDetails">
        <link:definition>2409404 - Disclosure - Collaborative Research and License Agreements - Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalBalanceSheetInformation" roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformation">
        <link:definition>2110104 - Disclosure - Supplemental Balance Sheet Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalBalanceSheetInformationTables" roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables">
        <link:definition>2311302 - Disclosure - Supplemental Balance Sheet Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails" roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails">
        <link:definition>2412405 - Disclosure - Supplemental Balance Sheet Information - Prepaid expenses and other current assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails" roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails">
        <link:definition>2413406 - Disclosure - Supplemental Balance Sheet Information - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails" roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails">
        <link:definition>2414407 - Disclosure - Supplemental Balance Sheet Information - Accrued Expense and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.exicuretx.com/role/Investments">
        <link:definition>2115105 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://www.exicuretx.com/role/InvestmentsTables">
        <link:definition>2316303 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsDetails" roleURI="http://www.exicuretx.com/role/InvestmentsDetails">
        <link:definition>2417408 - Disclosure - Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsAvailableforsaleSecuritiesDetails" roleURI="http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails">
        <link:definition>2418409 - Disclosure - Investments - Available-for-sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.exicuretx.com/role/Debt">
        <link:definition>2119106 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.exicuretx.com/role/DebtTables">
        <link:definition>2320304 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://www.exicuretx.com/role/DebtNarrativeDetails">
        <link:definition>2421410 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtPrincipalMaturitiesofLongTermDebtDetails" roleURI="http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails">
        <link:definition>2422411 - Disclosure - Debt - Principal Maturities of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtPrincipalMaturitiesofLongTermDebtDetails_1" roleURI="http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails_1">
        <link:definition>2422411 - Disclosure - Debt - Principal Maturities of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.exicuretx.com/role/Leases">
        <link:definition>2123107 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.exicuretx.com/role/LeasesTables">
        <link:definition>2324305 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.exicuretx.com/role/LeasesNarrativeDetails">
        <link:definition>2425412 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesRightofUseAssetInformationDetails" roleURI="http://www.exicuretx.com/role/LeasesRightofUseAssetInformationDetails">
        <link:definition>2426413 - Disclosure - Leases - Right of Use Asset Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseCostsDetails" roleURI="http://www.exicuretx.com/role/LeasesLeaseCostsDetails">
        <link:definition>2427414 - Disclosure - Leases - Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofFutureMinimumRentalPaymentsDetails" roleURI="http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails">
        <link:definition>2428415 - Disclosure - Leases - Schedule of Future Minimum Rental Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofFutureMinimumRentalPaymentsDetails_1" roleURI="http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails_1">
        <link:definition>2428415 - Disclosure - Leases - Schedule of Future Minimum Rental Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.exicuretx.com/role/StockholdersEquity">
        <link:definition>2129108 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.exicuretx.com/role/StockholdersEquityTables">
        <link:definition>2330306 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityCurrentCapitalizationDetails" roleURI="http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails">
        <link:definition>2431416 - Disclosure - Stockholders' Equity - Current Capitalization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityCommonStockWarrantsDetails" roleURI="http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails">
        <link:definition>2432417 - Disclosure - Stockholders' Equity - Common Stock Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityAccumulatedOtherComprehensiveLossDetails" roleURI="http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails">
        <link:definition>2433418 - Disclosure - Stockholders' Equity - Accumulated Other Comprehensive Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensation" roleURI="http://www.exicuretx.com/role/EquityBasedCompensation">
        <link:definition>2134109 - Disclosure - Equity-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationTables" roleURI="http://www.exicuretx.com/role/EquityBasedCompensationTables">
        <link:definition>2335307 - Disclosure - Equity-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationNarrativeDetails" roleURI="http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails">
        <link:definition>2436419 - Disclosure - Equity-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationScheduleofCompensationExpenseDetails" roleURI="http://www.exicuretx.com/role/EquityBasedCompensationScheduleofCompensationExpenseDetails">
        <link:definition>2437420 - Disclosure - Equity-Based Compensation - Schedule of Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails" roleURI="http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails">
        <link:definition>2438421 - Disclosure - Equity-Based Compensation - Assumptions Used for Fair Value Measurement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails" roleURI="http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails">
        <link:definition>2439422 - Disclosure - Equity-Based Compensation - Fair Value of Underlying Common Stock and Exercise Price of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" roleURI="http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails">
        <link:definition>2440423 - Disclosure - Equity-Based Compensation - Schedule of Stock Options Rollforward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityBasedCompensationRSUActivityDetails" roleURI="http://www.exicuretx.com/role/EquityBasedCompensationRSUActivityDetails">
        <link:definition>2441424 - Disclosure - Equity-Based Compensation - RSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.exicuretx.com/role/IncomeTaxes">
        <link:definition>2142110 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.exicuretx.com/role/IncomeTaxesDetails">
        <link:definition>2443425 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShare" roleURI="http://www.exicuretx.com/role/LossPerCommonShare">
        <link:definition>2144111 - Disclosure - Loss Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShareTables" roleURI="http://www.exicuretx.com/role/LossPerCommonShareTables">
        <link:definition>2345308 - Disclosure - Loss Per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShareComputationofEarningsPerShareDetails" roleURI="http://www.exicuretx.com/role/LossPerCommonShareComputationofEarningsPerShareDetails">
        <link:definition>2446426 - Disclosure - Loss Per Common Share - Computation of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShareAntidilutiveSecuritiesDetails" roleURI="http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails">
        <link:definition>2447427 - Disclosure - Loss Per Common Share - Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.exicuretx.com/role/FairValueMeasurements">
        <link:definition>2148112 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.exicuretx.com/role/FairValueMeasurementsTables">
        <link:definition>2349309 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails" roleURI="http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails">
        <link:definition>2450428 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>2451429 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>2452430 - Disclosure - Fair Value Measurements - Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingencies" roleURI="http://www.exicuretx.com/role/CommitmentandContingencies">
        <link:definition>2153113 - Disclosure - Commitment and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesDetails" roleURI="http://www.exicuretx.com/role/CommitmentandContingenciesDetails">
        <link:definition>2454431 - Disclosure - Commitment and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.exicuretx.com/role/RelatedPartyTransactions">
        <link:definition>2155114 - Disclosure - Related-Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.exicuretx.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2456432 - Disclosure - Related-Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="xcur_CollaborationAgreementUpfrontPayment" abstract="false" name="CollaborationAgreementUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_AbbVieCollaborationMember" abstract="true" name="AbbVieCollaborationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xcur_MidCapCreditAgreementMember" abstract="true" name="MidCapCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xcur_IpsenCollaborationMember" abstract="true" name="IpsenCollaborationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xcur_RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment" abstract="false" name="RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_ComputersandSoftwareMember" abstract="true" name="ComputersandSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xcur_DebtInstrumentFundingConditionRequiredProceedsFromEquityIssuance" abstract="false" name="DebtInstrumentFundingConditionRequiredProceedsFromEquityIssuance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths" abstract="false" name="LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_CollaborationDevelopmentExpenses" abstract="false" name="CollaborationDevelopmentExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_DebtSecuritiesAvailableforSalePercent" abstract="false" name="DebtSecuritiesAvailableforSalePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment" abstract="false" name="RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_CollaborationAgreementOptionExerciseFee" abstract="false" name="CollaborationAgreementOptionExerciseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_LesseeOperatingLeaseLeaseArea" abstract="false" name="LesseeOperatingLeaseLeaseArea" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="xcur_CollaborationAgreementLicensingFeesIncurred" abstract="false" name="CollaborationAgreementLicensingFeesIncurred" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_ExercisePeriodTwoMember" abstract="true" name="ExercisePeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xcur_CollaborationAgreementEstimatedTimingOfRevenueRecognition" abstract="false" name="CollaborationAgreementEstimatedTimingOfRevenueRecognition" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="xcur_CommonStockWarrantLiabilityFairValueDisclosure" abstract="false" name="CommonStockWarrantLiabilityFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_ArrangementNameDomain" abstract="true" name="ArrangementNameDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xcur_PaymentsOfCommonStockFinancingCosts" abstract="false" name="PaymentsOfCommonStockFinancingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment" abstract="false" name="RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent" abstract="false" name="DebtSecuritiesAvailableForSaleNoncurrentPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="xcur_WarrantLiabilityMember" abstract="true" name="WarrantLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xcur_MidCapCreditAgreementTranche2Member" abstract="true" name="MidCapCreditAgreementTranche2Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xcur_SupplementalBalanceSheetInformationAbstract" abstract="true" name="SupplementalBalanceSheetInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="xcur_DebtInstrumentExitFeePercentage" abstract="false" name="DebtInstrumentExitFeePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment" abstract="false" name="RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_DebtSecuritiesAvailableForSaleCurrentPercent" abstract="false" name="DebtSecuritiesAvailableForSaleCurrentPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="xcur_RevenueFromContractWithCustomerNetOfCumulativeCatchUpAdjustment" abstract="false" name="RevenueFromContractWithCustomerNetOfCumulativeCatchUpAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_COVID19Member" abstract="true" name="COVID19Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xcur_ExicureInc.2017EquityIncentivePlanMember" abstract="true" name="ExicureInc.2017EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xcur_PaymentsForDebtEndTermFees" abstract="false" name="PaymentsForDebtEndTermFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="xcur_ExercisePeriodOneMember" abstract="true" name="ExercisePeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xcur_DevelopmentandCommercializationLicenseMember" abstract="true" name="DevelopmentandCommercializationLicenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xcur_LesseeOperatingLeaseBaseRentAnnualPercentageIncrease" abstract="false" name="LesseeOperatingLeaseBaseRentAnnualPercentageIncrease" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="xcur_IpsenHDMember" abstract="true" name="IpsenHDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xcur_MidCapCreditAgreementTranche1Member" abstract="true" name="MidCapCreditAgreementTranche1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xcur_ExercisePeriodAxis" abstract="true" name="ExercisePeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent" abstract="false" name="AccruedClinicalContractResearchAndManufacturingCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_ResearchAndDevelopmentStaffOnSitePercentage" abstract="false" name="ResearchAndDevelopmentStaffOnSitePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="xcur_HerculesTechnologyGrowthCapitalMember" abstract="true" name="HerculesTechnologyGrowthCapitalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xcur_IpsenASMember" abstract="true" name="IpsenASMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment" abstract="false" name="RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_DermelixLicenseAgreementMember" abstract="true" name="DermelixLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee" abstract="false" name="CollaborationAgreementExtendedOptionAdditionalExerciseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_ClassofWarrantorRightExpired" abstract="false" name="ClassofWarrantorRightExpired" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="xcur_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance" abstract="false" name="ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice" abstract="false" name="CollaborationAgreementTerminationPeriodUponWrittenNotice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="xcur_CollaborationAgreementPerformanceObligationDomain" abstract="true" name="CollaborationAgreementPerformanceObligationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xcur_NumberofCollaborationPrograms" abstract="false" name="NumberofCollaborationPrograms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="xcur_LesseeOperatingLeaseRentalPaymentAdjustedForAbatement" abstract="false" name="LesseeOperatingLeaseRentalPaymentAdjustedForAbatement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_LesseeOperatingLeaseNumberOfExtensions" abstract="false" name="LesseeOperatingLeaseNumberOfExtensions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="xcur_CommonStockVotingRightsForEachShare" abstract="false" name="CommonStockVotingRightsForEachShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="xcur_ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock" abstract="false" name="ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="xcur_CollaborationAgreementPerformanceObligationAxis" abstract="true" name="CollaborationAgreementPerformanceObligationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="xcur_LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm" abstract="false" name="LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments" abstract="false" name="DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="xcur_CollaborationAgreementTerminationNoticePeriod" abstract="false" name="CollaborationAgreementTerminationNoticePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="xcur_AggregatePaymentsMadeToDateForLicenseAgreements" abstract="false" name="AggregatePaymentsMadeToDateForLicenseAgreements" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_ConsultingServicesMember" abstract="true" name="ConsultingServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xcur_ContractWithCustomerLiabilityAdditions" abstract="false" name="ContractWithCustomerLiabilityAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate" abstract="false" name="RetainedEarningsAccumulatedDeficitInceptiontoDate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_CollaborationAgreementTransactionPrice" abstract="false" name="CollaborationAgreementTransactionPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_DebtInstrumentEarlyTerminationFeePercentageOfPrincipal" abstract="false" name="DebtInstrumentEarlyTerminationFeePercentageOfPrincipal" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="xcur_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate" abstract="false" name="ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_OfficeAndGeneralAndAdministrativeStaffOnSitePercentage" abstract="false" name="OfficeAndGeneralAndAdministrativeStaffOnSitePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="xcur_ArrangementNameAxis" abstract="true" name="ArrangementNameAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="xcur_RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment" abstract="false" name="RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="xcur_ChicagoMember" abstract="true" name="ChicagoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="xcur_ExercisePeriodDomain" abstract="true" name="ExercisePeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>xcur-20210930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:ec2cf3ab-02c5-4899-a9f4-a2b651188a5f,g:ebea5fae-f5ab-4d4a-8517-3fed58ff79ef-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="xcur-20210930.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_da675fe0-1fe0-4814-a6c4-e015cbc7b8f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_cbb6e805-cd59-4329-bd23-8c9a5b15e3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_da675fe0-1fe0-4814-a6c4-e015cbc7b8f3" xlink:to="loc_us-gaap_CommonStockValue_cbb6e805-cd59-4329-bd23-8c9a5b15e3a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_1a7f7c66-0729-4aa6-aa15-e5c5900e2c60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_da675fe0-1fe0-4814-a6c4-e015cbc7b8f3" xlink:to="loc_us-gaap_AdditionalPaidInCapital_1a7f7c66-0729-4aa6-aa15-e5c5900e2c60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_2d8e070d-5c4a-4807-8ff3-d57a9b8e87f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_da675fe0-1fe0-4814-a6c4-e015cbc7b8f3" xlink:to="loc_us-gaap_PreferredStockValue_2d8e070d-5c4a-4807-8ff3-d57a9b8e87f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_97c9f90e-38de-450a-beaf-7ffe7c71ab59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_da675fe0-1fe0-4814-a6c4-e015cbc7b8f3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_97c9f90e-38de-450a-beaf-7ffe7c71ab59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f17688b4-de04-42cf-b510-9bc721bd694a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_da675fe0-1fe0-4814-a6c4-e015cbc7b8f3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f17688b4-de04-42cf-b510-9bc721bd694a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_1e8c7a42-ee2b-4493-b186-c6f3869e2c81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_fa10688a-541c-473f-8bf8-2a90085e3e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1e8c7a42-ee2b-4493-b186-c6f3869e2c81" xlink:to="loc_us-gaap_AssetsCurrent_fa10688a-541c-473f-8bf8-2a90085e3e4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7cf0ae7c-948b-45ad-94ca-f0f3ad6bf172" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1e8c7a42-ee2b-4493-b186-c6f3869e2c81" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7cf0ae7c-948b-45ad-94ca-f0f3ad6bf172" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_bf6ae495-d09a-4dbc-ab08-54144ecbb893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1e8c7a42-ee2b-4493-b186-c6f3869e2c81" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_bf6ae495-d09a-4dbc-ab08-54144ecbb893" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8540e7ce-b3e1-4c70-8866-52acc31af6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1e8c7a42-ee2b-4493-b186-c6f3869e2c81" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8540e7ce-b3e1-4c70-8866-52acc31af6e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ded331db-3333-45fe-b9d4-bc403907ae78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_aec7b1fe-bb60-4920-9f37-8b80fcb3262c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ded331db-3333-45fe-b9d4-bc403907ae78" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_aec7b1fe-bb60-4920-9f37-8b80fcb3262c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1512d066-2653-4aae-b285-7e0369c0cfbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ded331db-3333-45fe-b9d4-bc403907ae78" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1512d066-2653-4aae-b285-7e0369c0cfbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_6db0a01b-2fba-46e3-a46f-fd7b79e9a407" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ded331db-3333-45fe-b9d4-bc403907ae78" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_6db0a01b-2fba-46e3-a46f-fd7b79e9a407" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d9e211f3-f607-40fd-8e58-8335edf59bce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ded331db-3333-45fe-b9d4-bc403907ae78" xlink:to="loc_us-gaap_LiabilitiesCurrent_d9e211f3-f607-40fd-8e58-8335edf59bce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_17de1098-15b4-43ee-9990-6b178ff16e57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_ded331db-3333-45fe-b9d4-bc403907ae78" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_17de1098-15b4-43ee-9990-6b178ff16e57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_977bd86f-6d45-4b18-ba21-f8a5c1fca199" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_fd364f29-7c4d-4796-b6de-503497030a48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_977bd86f-6d45-4b18-ba21-f8a5c1fca199" xlink:to="loc_us-gaap_AccountsPayableCurrent_fd364f29-7c4d-4796-b6de-503497030a48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3a1560f5-1c47-4275-b59c-295b5dad865a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_977bd86f-6d45-4b18-ba21-f8a5c1fca199" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_3a1560f5-1c47-4275-b59c-295b5dad865a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d71019a9-cc4d-448f-a831-b63a7f7716c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_977bd86f-6d45-4b18-ba21-f8a5c1fca199" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d71019a9-cc4d-448f-a831-b63a7f7716c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_e4b4845b-498d-4896-9817-9adfd7710b63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_07524deb-7561-4ab0-81bc-ea47437c14d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e4b4845b-498d-4896-9817-9adfd7710b63" xlink:to="loc_us-gaap_Liabilities_07524deb-7561-4ab0-81bc-ea47437c14d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d1307246-7d93-4e6a-ab24-2572da100c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e4b4845b-498d-4896-9817-9adfd7710b63" xlink:to="loc_us-gaap_StockholdersEquity_d1307246-7d93-4e6a-ab24-2572da100c6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f65151b4-819e-40b4-bea5-52c4448c6533" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_c73df9ee-0774-4b3a-8ce6-ac271c59db14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f65151b4-819e-40b4-bea5-52c4448c6533" xlink:to="loc_us-gaap_ShortTermInvestments_c73df9ee-0774-4b3a-8ce6-ac271c59db14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_888600d8-6d07-4a96-8137-9e66cd98fb57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f65151b4-819e-40b4-bea5-52c4448c6533" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_888600d8-6d07-4a96-8137-9e66cd98fb57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3d4db001-10be-45c9-9190-50eee96b3b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f65151b4-819e-40b4-bea5-52c4448c6533" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3d4db001-10be-45c9-9190-50eee96b3b5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d2cc55c4-f4ab-4bdc-b3eb-d4b3e2d29f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f65151b4-819e-40b4-bea5-52c4448c6533" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d2cc55c4-f4ab-4bdc-b3eb-d4b3e2d29f7c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="xcur-20210930.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_38b92797-10f6-45cd-a9a2-b07933c28010" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5a0a73f1-abcf-482e-9bcb-cd4dda835720" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_38b92797-10f6-45cd-a9a2-b07933c28010" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5a0a73f1-abcf-482e-9bcb-cd4dda835720" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_95637a99-fada-46f3-ad58-51d5bd05ab8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_38b92797-10f6-45cd-a9a2-b07933c28010" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_95637a99-fada-46f3-ad58-51d5bd05ab8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_4d890138-0c63-449c-b3fa-f79066987698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeDividend_99ffa72e-2a9d-46b7-9481-8f626fc98d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeDividend"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_4d890138-0c63-449c-b3fa-f79066987698" xlink:to="loc_us-gaap_InvestmentIncomeDividend_99ffa72e-2a9d-46b7-9481-8f626fc98d5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_04ced5ab-0f6a-4366-9adc-b3306f7be0b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_4d890138-0c63-449c-b3fa-f79066987698" xlink:to="loc_us-gaap_InvestmentIncomeInterest_04ced5ab-0f6a-4366-9adc-b3306f7be0b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_a844a5b7-2a74-4fad-a908-5216da0ce17b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_4d890138-0c63-449c-b3fa-f79066987698" xlink:to="loc_us-gaap_InterestExpense_a844a5b7-2a74-4fad-a908-5216da0ce17b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_31d0db8e-ee62-4a3f-9806-22e1b722e9b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_4d890138-0c63-449c-b3fa-f79066987698" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_31d0db8e-ee62-4a3f-9806-22e1b722e9b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5d631e81-b245-4f0a-bffd-687842e527c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ceab5751-0840-4519-af31-f9d337bea81d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5d631e81-b245-4f0a-bffd-687842e527c8" xlink:to="loc_us-gaap_Revenues_ceab5751-0840-4519-af31-f9d337bea81d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d586fbd5-24cb-46e4-93ea-194e98dc717d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5d631e81-b245-4f0a-bffd-687842e527c8" xlink:to="loc_us-gaap_OperatingExpenses_d586fbd5-24cb-46e4-93ea-194e98dc717d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_85efb179-2bf7-4e45-899a-55d4b464d08b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueFromContractWithCustomerNetOfCumulativeCatchUpAdjustment_9730d85f-f286-4a8e-8c49-4148b3598d51" xlink:href="xcur-20210930.xsd#xcur_RevenueFromContractWithCustomerNetOfCumulativeCatchUpAdjustment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_85efb179-2bf7-4e45-899a-55d4b464d08b" xlink:to="loc_xcur_RevenueFromContractWithCustomerNetOfCumulativeCatchUpAdjustment_9730d85f-f286-4a8e-8c49-4148b3598d51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_2ac18a4a-1fb5-4066-b953-9029f02a52a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d2c3b099-cfc4-4a4d-b212-026b689013ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_2ac18a4a-1fb5-4066-b953-9029f02a52a0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d2c3b099-cfc4-4a4d-b212-026b689013ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_211da739-331f-44c8-a2ea-cad22a8525ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_2ac18a4a-1fb5-4066-b953-9029f02a52a0" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_211da739-331f-44c8-a2ea-cad22a8525ae" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME" xlink:type="simple" xlink:href="xcur-20210930.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5453fdc0-d082-499d-9953-8086633fead0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e499be6e-82cb-42ce-a708-32d7f1873da8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5453fdc0-d082-499d-9953-8086633fead0" xlink:to="loc_us-gaap_NetIncomeLoss_e499be6e-82cb-42ce-a708-32d7f1873da8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_906f6a8b-3cc0-4826-b102-59116acb2002" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5453fdc0-d082-499d-9953-8086633fead0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_906f6a8b-3cc0-4826-b102-59116acb2002" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_36074490-fd0f-41d7-aeca-186862e522be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1a049b19-051b-445f-b21b-aa2a9c7cb17e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_36074490-fd0f-41d7-aeca-186862e522be" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1a049b19-051b-445f-b21b-aa2a9c7cb17e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="xcur-20210930.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4f94e819-6b75-4ad7-a34c-955ee2a14cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_57a07a87-01f8-4a06-963f-cc959c8e1b80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4f94e819-6b75-4ad7-a34c-955ee2a14cd9" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_57a07a87-01f8-4a06-963f-cc959c8e1b80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_71a0b0e2-b4ac-46d5-8bf5-7190ce7bd354" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4f94e819-6b75-4ad7-a34c-955ee2a14cd9" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_71a0b0e2-b4ac-46d5-8bf5-7190ce7bd354" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_41384e31-2ff5-4db9-9057-231a6b10006c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4f94e819-6b75-4ad7-a34c-955ee2a14cd9" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_41384e31-2ff5-4db9-9057-231a6b10006c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74643ba2-00f0-4dac-9375-ec3b8d733059" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8b139151-ad94-4641-9267-12e5cdb36d67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74643ba2-00f0-4dac-9375-ec3b8d733059" xlink:to="loc_us-gaap_NetIncomeLoss_8b139151-ad94-4641-9267-12e5cdb36d67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_b84ea8f0-5860-40b5-a22f-1b70e9348140" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74643ba2-00f0-4dac-9375-ec3b8d733059" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_b84ea8f0-5860-40b5-a22f-1b70e9348140" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_db9796a8-4fc4-476e-a93a-2b61705a1618" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74643ba2-00f0-4dac-9375-ec3b8d733059" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_db9796a8-4fc4-476e-a93a-2b61705a1618" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_585a29e3-dce0-4de2-aa13-213dd8bac8e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74643ba2-00f0-4dac-9375-ec3b8d733059" xlink:to="loc_us-gaap_ShareBasedCompensation_585a29e3-dce0-4de2-aa13-213dd8bac8e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_1cde100a-1434-48a7-a0b7-f337c3bf873b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74643ba2-00f0-4dac-9375-ec3b8d733059" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_1cde100a-1434-48a7-a0b7-f337c3bf873b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_723fab30-faae-4738-872d-59cb0b6cc06d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74643ba2-00f0-4dac-9375-ec3b8d733059" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_723fab30-faae-4738-872d-59cb0b6cc06d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0f44b1aa-b9a7-41d4-ac98-e8bfdeb9ab08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74643ba2-00f0-4dac-9375-ec3b8d733059" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0f44b1aa-b9a7-41d4-ac98-e8bfdeb9ab08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2c42a28d-7287-466a-9d86-262073369ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74643ba2-00f0-4dac-9375-ec3b8d733059" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2c42a28d-7287-466a-9d86-262073369ae0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_eb087a61-12c1-4160-8aae-e108c3fa654a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74643ba2-00f0-4dac-9375-ec3b8d733059" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_eb087a61-12c1-4160-8aae-e108c3fa654a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_50453069-edef-4a0a-b62f-d5557fd516c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74643ba2-00f0-4dac-9375-ec3b8d733059" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_50453069-edef-4a0a-b62f-d5557fd516c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_49f0db4a-5628-4971-bcab-eec2f6039dea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74643ba2-00f0-4dac-9375-ec3b8d733059" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_49f0db4a-5628-4971-bcab-eec2f6039dea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_f5de162f-00e1-436c-a056-99b154a3fd5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74643ba2-00f0-4dac-9375-ec3b8d733059" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_f5de162f-00e1-436c-a056-99b154a3fd5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_a43718a7-7595-412c-90c8-3b3149bb00ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74643ba2-00f0-4dac-9375-ec3b8d733059" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_a43718a7-7595-412c-90c8-3b3149bb00ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_5cc1d8dd-c14a-4efe-9232-f59ae4bb3941" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74643ba2-00f0-4dac-9375-ec3b8d733059" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_5cc1d8dd-c14a-4efe-9232-f59ae4bb3941" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_475c8233-6568-4f9a-a302-69f71d9ae67c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_74643ba2-00f0-4dac-9375-ec3b8d733059" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_475c8233-6568-4f9a-a302-69f71d9ae67c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c8cc8e4c-8176-4f21-928d-1e31c9a8a936" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_PaymentsOfCommonStockFinancingCosts_d873c6f6-e852-4f88-88c3-4c58f2c74627" xlink:href="xcur-20210930.xsd#xcur_PaymentsOfCommonStockFinancingCosts"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c8cc8e4c-8176-4f21-928d-1e31c9a8a936" xlink:to="loc_xcur_PaymentsOfCommonStockFinancingCosts_d873c6f6-e852-4f88-88c3-4c58f2c74627" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_4f6afc7f-e06f-4f7b-be73-ad2771b62777" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c8cc8e4c-8176-4f21-928d-1e31c9a8a936" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_4f6afc7f-e06f-4f7b-be73-ad2771b62777" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_68cedd67-2121-4723-b9f4-226be05e2954" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c8cc8e4c-8176-4f21-928d-1e31c9a8a936" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_68cedd67-2121-4723-b9f4-226be05e2954" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_35018dda-1ecc-4be2-b991-ce003045b911" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c8cc8e4c-8176-4f21-928d-1e31c9a8a936" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_35018dda-1ecc-4be2-b991-ce003045b911" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0c6e7b63-a189-48b4-ab60-cdd2a212b80d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c8cc8e4c-8176-4f21-928d-1e31c9a8a936" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0c6e7b63-a189-48b4-ab60-cdd2a212b80d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_1cbf28bd-8de2-4b49-9453-c5341e6d6e85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c8cc8e4c-8176-4f21-928d-1e31c9a8a936" xlink:to="loc_us-gaap_ProceedsFromStockPlans_1cbf28bd-8de2-4b49-9453-c5341e6d6e85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_7cf9f07c-6ae0-4a05-b04f-4d8070b8e012" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c8cc8e4c-8176-4f21-928d-1e31c9a8a936" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_7cf9f07c-6ae0-4a05-b04f-4d8070b8e012" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4bb1495e-b9e4-455e-8d2a-6aa11b5a8b05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c8cc8e4c-8176-4f21-928d-1e31c9a8a936" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4bb1495e-b9e4-455e-8d2a-6aa11b5a8b05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b70bfe3a-b209-4242-b4ec-8f69b6669c82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6fb41bf8-742f-497c-8df6-7a4fc0e24bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b70bfe3a-b209-4242-b4ec-8f69b6669c82" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6fb41bf8-742f-497c-8df6-7a4fc0e24bf2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_89871145-2cd8-4636-8319-805b88eb7b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b70bfe3a-b209-4242-b4ec-8f69b6669c82" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_89871145-2cd8-4636-8319-805b88eb7b2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_72cf012a-c573-4545-b351-3f7a896f6b82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b70bfe3a-b209-4242-b4ec-8f69b6669c82" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_72cf012a-c573-4545-b351-3f7a896f6b82" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical" xlink:type="simple" xlink:href="xcur-20210930.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_90a62e65-65e4-4c31-bd7b-f314ddacbaee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_39b8be18-06d6-49ee-8cfa-6f36cc6da639" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_90a62e65-65e4-4c31-bd7b-f314ddacbaee" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_39b8be18-06d6-49ee-8cfa-6f36cc6da639" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4a66ea05-92ec-4886-a5e4-717ea5a39610" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_90a62e65-65e4-4c31-bd7b-f314ddacbaee" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4a66ea05-92ec-4886-a5e4-717ea5a39610" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_29100813-54a6-4e91-8281-bfc6fdde1ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_dbfa39bc-dcf6-4db6-aed4-6e9a201c0e17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_29100813-54a6-4e91-8281-bfc6fdde1ddc" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_dbfa39bc-dcf6-4db6-aed4-6e9a201c0e17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_8878bda1-90d5-4a5b-bec1-a6dec7322cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_29100813-54a6-4e91-8281-bfc6fdde1ddc" xlink:to="loc_us-gaap_InterestReceivable_8878bda1-90d5-4a5b-bec1-a6dec7322cc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_46d22041-4960-4f1c-a8ca-ed6dc0d55b18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_29100813-54a6-4e91-8281-bfc6fdde1ddc" xlink:to="loc_us-gaap_PrepaidInsurance_46d22041-4960-4f1c-a8ca-ed6dc0d55b18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_993809da-ca43-4000-9e2d-511ddc34a954" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_29100813-54a6-4e91-8281-bfc6fdde1ddc" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_993809da-ca43-4000-9e2d-511ddc34a954" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0b914de0-c93d-4cfd-81df-cafeded0572a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_e8b67cdf-77e7-4794-aecb-0631d44a19d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_0b914de0-c93d-4cfd-81df-cafeded0572a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_e8b67cdf-77e7-4794-aecb-0631d44a19d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b1d3c5e3-3ea6-4510-b53d-d72cf9d866ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_0b914de0-c93d-4cfd-81df-cafeded0572a" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b1d3c5e3-3ea6-4510-b53d-d72cf9d866ec" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_6e0f4e4f-0a6b-4885-884f-8a14ddb235bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_15b8fe1c-b318-4f2f-93ae-f5cac6f3c2e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_6e0f4e4f-0a6b-4885-884f-8a14ddb235bc" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_15b8fe1c-b318-4f2f-93ae-f5cac6f3c2e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent_794ac88f-5d41-4411-a656-958a296248f1" xlink:href="xcur-20210930.xsd#xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_6e0f4e4f-0a6b-4885-884f-8a14ddb235bc" xlink:to="loc_xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent_794ac88f-5d41-4411-a656-958a296248f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ff92cd4d-6706-4712-9fb4-25a790a79b99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_6e0f4e4f-0a6b-4885-884f-8a14ddb235bc" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ff92cd4d-6706-4712-9fb4-25a790a79b99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3354dbda-7ad0-4953-a32d-d630d28d129c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_6e0f4e4f-0a6b-4885-884f-8a14ddb235bc" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3354dbda-7ad0-4953-a32d-d630d28d129c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/InvestmentsDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#InvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/InvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DebtSecuritiesAvailableforSalePercent_5b5a7951-dcad-4d7e-af10-b50aeef3c458" xlink:href="xcur-20210930.xsd#xcur_DebtSecuritiesAvailableforSalePercent"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DebtSecuritiesAvailableForSaleCurrentPercent_7ddad5a9-6fc7-42fe-89b6-018c574dc168" xlink:href="xcur-20210930.xsd#xcur_DebtSecuritiesAvailableForSaleCurrentPercent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_xcur_DebtSecuritiesAvailableforSalePercent_5b5a7951-dcad-4d7e-af10-b50aeef3c458" xlink:to="loc_xcur_DebtSecuritiesAvailableForSaleCurrentPercent_7ddad5a9-6fc7-42fe-89b6-018c574dc168" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent_f00cce2f-85a4-431d-96fd-fe204a8520f4" xlink:href="xcur-20210930.xsd#xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_xcur_DebtSecuritiesAvailableforSalePercent_5b5a7951-dcad-4d7e-af10-b50aeef3c458" xlink:to="loc_xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent_f00cce2f-85a4-431d-96fd-fe204a8520f4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#InvestmentsAvailableforsaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e81fe83a-869b-4c3c-82d1-d5c7becc3328" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8df22d05-0209-4855-92d6-e25120477a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e81fe83a-869b-4c3c-82d1-d5c7becc3328" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8df22d05-0209-4855-92d6-e25120477a1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_aacccf96-fa60-491f-9840-8defaf28f2d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e81fe83a-869b-4c3c-82d1-d5c7becc3328" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_aacccf96-fa60-491f-9840-8defaf28f2d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e9eb711b-9e77-4840-b72c-177b7c619b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e81fe83a-869b-4c3c-82d1-d5c7becc3328" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e9eb711b-9e77-4840-b72c-177b7c619b2f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#DebtPrincipalMaturitiesofLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_817dd2f5-b543-4470-abd7-72c9f84f5a25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_2820df80-e077-45c9-a84e-af392c7f6891" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_817dd2f5-b543-4470-abd7-72c9f84f5a25" xlink:to="loc_us-gaap_LongTermDebtCurrent_2820df80-e077-45c9-a84e-af392c7f6891" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_cf333bd6-759b-4fb6-81ac-a76c435114e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_817dd2f5-b543-4470-abd7-72c9f84f5a25" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_cf333bd6-759b-4fb6-81ac-a76c435114e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_3b7985f4-af4e-4e16-9b8c-3c5e08c812d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_a16ae84e-5097-496c-90fb-e3b424d64503" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_3b7985f4-af4e-4e16-9b8c-3c5e08c812d6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_a16ae84e-5097-496c-90fb-e3b424d64503" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_fdc382c4-db57-46f7-8a3b-c606b7132db4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_3b7985f4-af4e-4e16-9b8c-3c5e08c812d6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_fdc382c4-db57-46f7-8a3b-c606b7132db4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_611236a0-d422-4df5-b0a1-1ec1c1bc7e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_3b7985f4-af4e-4e16-9b8c-3c5e08c812d6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_611236a0-d422-4df5-b0a1-1ec1c1bc7e6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1c37fd4f-50a3-435a-b270-e9a331e1ff64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_3b7985f4-af4e-4e16-9b8c-3c5e08c812d6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1c37fd4f-50a3-435a-b270-e9a331e1ff64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_a8a52430-9d69-4277-bc1d-39c8a619db3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_3b7985f4-af4e-4e16-9b8c-3c5e08c812d6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_a8a52430-9d69-4277-bc1d-39c8a619db3c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails_1" xlink:type="simple" xlink:href="xcur-20210930.xsd#DebtPrincipalMaturitiesofLongTermDebtDetails_1"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_58bb903b-8d2b-4b9a-ad14-5ff592a07d25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ca252a61-8263-4cb8-9944-62d6307b6c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_58bb903b-8d2b-4b9a-ad14-5ff592a07d25" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_ca252a61-8263-4cb8-9944-62d6307b6c0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_7a913c3d-8351-45cc-851d-82c0b380120f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_58bb903b-8d2b-4b9a-ad14-5ff592a07d25" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_7a913c3d-8351-45cc-851d-82c0b380120f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LeasesLeaseCostsDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#LeasesLeaseCostsDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/LeasesLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_0b50f640-4935-4fa3-93a0-bb033338acb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_a7731ef3-81ed-4abb-b61e-58bfc3396493" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_0b50f640-4935-4fa3-93a0-bb033338acb4" xlink:to="loc_us-gaap_OperatingLeaseCost_a7731ef3-81ed-4abb-b61e-58bfc3396493" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_02e680cf-34a6-4dcd-86ae-53e1c14cc6cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_0b50f640-4935-4fa3-93a0-bb033338acb4" xlink:to="loc_us-gaap_ShortTermLeaseCost_02e680cf-34a6-4dcd-86ae-53e1c14cc6cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_1335c126-dccc-404a-a3a8-cc98bef13ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_0b50f640-4935-4fa3-93a0-bb033338acb4" xlink:to="loc_us-gaap_VariableLeaseCost_1335c126-dccc-404a-a3a8-cc98bef13ed7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#LeasesScheduleofFutureMinimumRentalPaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5ec32c60-07b5-4ad2-a5b3-a26bfd895139" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2e75d09e-06f6-467f-810a-62fbf743e2a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5ec32c60-07b5-4ad2-a5b3-a26bfd895139" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2e75d09e-06f6-467f-810a-62fbf743e2a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_af8ca70d-9efc-4d93-bc06-ac9838e96eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5ec32c60-07b5-4ad2-a5b3-a26bfd895139" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_af8ca70d-9efc-4d93-bc06-ac9838e96eb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ee0c3c3d-07bb-49f3-9b1d-6b0f7671590e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5ec32c60-07b5-4ad2-a5b3-a26bfd895139" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ee0c3c3d-07bb-49f3-9b1d-6b0f7671590e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6887566c-4b13-418c-933b-28ef853fc76b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5ec32c60-07b5-4ad2-a5b3-a26bfd895139" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6887566c-4b13-418c-933b-28ef853fc76b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_7e96b74f-c669-4b6a-9d38-d7a0748d03d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5ec32c60-07b5-4ad2-a5b3-a26bfd895139" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_7e96b74f-c669-4b6a-9d38-d7a0748d03d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_652378a9-2d20-4901-9983-9458ffe24860" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5ec32c60-07b5-4ad2-a5b3-a26bfd895139" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_652378a9-2d20-4901-9983-9458ffe24860" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b4dada28-ccb0-4148-a8e8-2443870af9b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5ec32c60-07b5-4ad2-a5b3-a26bfd895139" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b4dada28-ccb0-4148-a8e8-2443870af9b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_76990bf2-ace4-4f8c-9c65-504182b1dd81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f3c88d86-2cad-4173-a430-63f2c160fcc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_76990bf2-ace4-4f8c-9c65-504182b1dd81" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f3c88d86-2cad-4173-a430-63f2c160fcc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4a82f994-370b-4ad0-8b23-f4e8794ea317" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_76990bf2-ace4-4f8c-9c65-504182b1dd81" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4a82f994-370b-4ad0-8b23-f4e8794ea317" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails_1" xlink:type="simple" xlink:href="xcur-20210930.xsd#LeasesScheduleofFutureMinimumRentalPaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_801a4074-1d87-44ee-9833-1f7ee471e97d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_c051bbda-b720-4d7a-9f70-c36fe0402dce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_801a4074-1d87-44ee-9833-1f7ee471e97d" xlink:to="loc_us-gaap_OperatingLeaseLiability_c051bbda-b720-4d7a-9f70-c36fe0402dce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_77d5c15a-8f23-4047-ab4d-2a7688102da8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_801a4074-1d87-44ee-9833-1f7ee471e97d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_77d5c15a-8f23-4047-ab4d-2a7688102da8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#StockholdersEquityAccumulatedOtherComprehensiveLossDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_55f3447c-4093-4a22-acd8-cc6041266abe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_d7dc5a6d-5a60-4390-8814-73d835815aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_55f3447c-4093-4a22-acd8-cc6041266abe" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_d7dc5a6d-5a60-4390-8814-73d835815aa2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_4ee074c4-71cc-4682-9ef0-a6cc34de0ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_55f3447c-4093-4a22-acd8-cc6041266abe" xlink:to="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_4ee074c4-71cc-4682-9ef0-a6cc34de0ef2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_b7bdb844-775d-4203-b5a7-6fa1d8dcf141" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_25b59c4e-0d67-49be-91c7-21bf3647c45a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_b7bdb844-775d-4203-b5a7-6fa1d8dcf141" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_25b59c4e-0d67-49be-91c7-21bf3647c45a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_48808248-e359-4542-96ab-01900db969db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_b7bdb844-775d-4203-b5a7-6fa1d8dcf141" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_48808248-e359-4542-96ab-01900db969db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_3435b944-b8f4-49b2-97ae-94bb44289ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CommonStockWarrantLiabilityFairValueDisclosure_e6292aef-1066-417a-b502-90c9ab9c20a1" xlink:href="xcur-20210930.xsd#xcur_CommonStockWarrantLiabilityFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_3435b944-b8f4-49b2-97ae-94bb44289ad9" xlink:to="loc_xcur_CommonStockWarrantLiabilityFairValueDisclosure_e6292aef-1066-417a-b502-90c9ab9c20a1" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>xcur-20210930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:ec2cf3ab-02c5-4899-a9f4-a2b651188a5f,g:ebea5fae-f5ab-4d4a-8517-3fed58ff79ef-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="xcur-20210930.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended" id="id00bf36f2aeb4c32acf447c217f09c5e_UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_edcf3de5-2409-4bd7-b503-e9903473735b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dcae9ab8-47a1-404c-b004-9edb1b82f350" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_edcf3de5-2409-4bd7-b503-e9903473735b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dcae9ab8-47a1-404c-b004-9edb1b82f350" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_afee37b4-bc77-4af8-8597-9b9f38914c63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dcae9ab8-47a1-404c-b004-9edb1b82f350" xlink:to="loc_us-gaap_SharesOutstanding_afee37b4-bc77-4af8-8597-9b9f38914c63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_22121799-f2eb-4f68-93f5-7f0a0dc67e02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dcae9ab8-47a1-404c-b004-9edb1b82f350" xlink:to="loc_us-gaap_StockholdersEquity_22121799-f2eb-4f68-93f5-7f0a0dc67e02" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6049fff6-0d5e-4cf3-a066-70a3562f7d90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dcae9ab8-47a1-404c-b004-9edb1b82f350" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6049fff6-0d5e-4cf3-a066-70a3562f7d90" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d5c36276-815f-4c94-b8c9-7a2a4486ea1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dcae9ab8-47a1-404c-b004-9edb1b82f350" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d5c36276-815f-4c94-b8c9-7a2a4486ea1e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_101f3560-2a34-447b-adb0-4af6aa98aa67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dcae9ab8-47a1-404c-b004-9edb1b82f350" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_101f3560-2a34-447b-adb0-4af6aa98aa67" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_9d31581c-a14a-403b-9440-e3c1c95dcafb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dcae9ab8-47a1-404c-b004-9edb1b82f350" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_9d31581c-a14a-403b-9440-e3c1c95dcafb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_b0bff7ca-18a5-45f5-a44f-b870855c687b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dcae9ab8-47a1-404c-b004-9edb1b82f350" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_b0bff7ca-18a5-45f5-a44f-b870855c687b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0e1f577f-6c0d-42a3-bedf-9766113e5b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dcae9ab8-47a1-404c-b004-9edb1b82f350" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0e1f577f-6c0d-42a3-bedf-9766113e5b3f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_803908f7-316d-4f3f-bb48-fa6194251d44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dcae9ab8-47a1-404c-b004-9edb1b82f350" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_803908f7-316d-4f3f-bb48-fa6194251d44" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_01ce9719-8f19-4b4c-b178-4b58c2ab4a29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dcae9ab8-47a1-404c-b004-9edb1b82f350" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_01ce9719-8f19-4b4c-b178-4b58c2ab4a29" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a17dc5f2-7187-41b0-8131-e1dfd4d6ce3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dcae9ab8-47a1-404c-b004-9edb1b82f350" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a17dc5f2-7187-41b0-8131-e1dfd4d6ce3f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4a7998aa-ed60-4fce-a36a-3e8ab3dc39fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dcae9ab8-47a1-404c-b004-9edb1b82f350" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4a7998aa-ed60-4fce-a36a-3e8ab3dc39fe" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_00d87bb1-3de1-4d90-bbb4-27aca5ac7cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dcae9ab8-47a1-404c-b004-9edb1b82f350" xlink:to="loc_us-gaap_NetIncomeLoss_00d87bb1-3de1-4d90-bbb4-27aca5ac7cc9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_b02b9245-53f1-4e4e-acd7-5bc19d47f35d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_003c3dd4-b7ac-4005-96f3-27058f2c5c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_13b8c0a4-d255-4b4f-87a2-48b1006eafeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_edcf3de5-2409-4bd7-b503-e9903473735b" xlink:to="loc_us-gaap_StatementTable_13b8c0a4-d255-4b4f-87a2-48b1006eafeb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9f50d16b-1d76-4547-9b98-e560c76daf5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_13b8c0a4-d255-4b4f-87a2-48b1006eafeb" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9f50d16b-1d76-4547-9b98-e560c76daf5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9f50d16b-1d76-4547-9b98-e560c76daf5b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9f50d16b-1d76-4547-9b98-e560c76daf5b" xlink:to="loc_us-gaap_EquityComponentDomain_9f50d16b-1d76-4547-9b98-e560c76daf5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_025fcd1f-5b92-451b-b63f-c064f4f659bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9f50d16b-1d76-4547-9b98-e560c76daf5b" xlink:to="loc_us-gaap_EquityComponentDomain_025fcd1f-5b92-451b-b63f-c064f4f659bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5554a875-b592-4fc5-b179-9cfb74149447" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_025fcd1f-5b92-451b-b63f-c064f4f659bf" xlink:to="loc_us-gaap_CommonStockMember_5554a875-b592-4fc5-b179-9cfb74149447" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_e30d8d88-b7cb-48b8-aec0-c4c17977834a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_025fcd1f-5b92-451b-b63f-c064f4f659bf" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_e30d8d88-b7cb-48b8-aec0-c4c17977834a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_4c132729-df00-40cf-9544-340706aae81b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_025fcd1f-5b92-451b-b63f-c064f4f659bf" xlink:to="loc_us-gaap_RetainedEarningsMember_4c132729-df00-40cf-9544-340706aae81b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3c75d2c5-5a33-4429-9d4e-ece11958254d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_025fcd1f-5b92-451b-b63f-c064f4f659bf" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3c75d2c5-5a33-4429-9d4e-ece11958254d" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#DescriptionofBusinessandBasisofPresentationDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails" xlink:type="extended" id="id22e6deae4a6436a9885cf98ebaa5557_DescriptionofBusinessandBasisofPresentationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_08b52c74-17a9-42d3-9883-760777f52f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_08d8b912-4bb6-455e-ade0-1e9a0accc66b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_08b52c74-17a9-42d3-9883-760777f52f1f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_08d8b912-4bb6-455e-ade0-1e9a0accc66b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ResearchAndDevelopmentStaffOnSitePercentage_7a0e9589-c287-4075-81e5-86b9ce18eabc" xlink:href="xcur-20210930.xsd#xcur_ResearchAndDevelopmentStaffOnSitePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_08b52c74-17a9-42d3-9883-760777f52f1f" xlink:to="loc_xcur_ResearchAndDevelopmentStaffOnSitePercentage_7a0e9589-c287-4075-81e5-86b9ce18eabc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_OfficeAndGeneralAndAdministrativeStaffOnSitePercentage_c2c30e9f-e173-47ec-bcd1-f47f96c7f1cf" xlink:href="xcur-20210930.xsd#xcur_OfficeAndGeneralAndAdministrativeStaffOnSitePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_08b52c74-17a9-42d3-9883-760777f52f1f" xlink:to="loc_xcur_OfficeAndGeneralAndAdministrativeStaffOnSitePercentage_c2c30e9f-e173-47ec-bcd1-f47f96c7f1cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate_5e4d703a-39f2-4e29-b2e2-b05352f12cc5" xlink:href="xcur-20210930.xsd#xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_08b52c74-17a9-42d3-9883-760777f52f1f" xlink:to="loc_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate_5e4d703a-39f2-4e29-b2e2-b05352f12cc5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate_89768ec7-395a-45e9-bff0-f72ddfbf56fd" xlink:href="xcur-20210930.xsd#xcur_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_08b52c74-17a9-42d3-9883-760777f52f1f" xlink:to="loc_xcur_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate_89768ec7-395a-45e9-bff0-f72ddfbf56fd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualRiskOrUncertaintyTable_92d564d8-b520-4e37-90ff-2f8a6cfbc6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_08b52c74-17a9-42d3-9883-760777f52f1f" xlink:to="loc_us-gaap_UnusualRiskOrUncertaintyTable_92d564d8-b520-4e37-90ff-2f8a6cfbc6f2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameAxis_cf5d4e19-d463-47a7-85e9-7b7da711283c" xlink:href="xcur-20210930.xsd#xcur_ArrangementNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyTable_92d564d8-b520-4e37-90ff-2f8a6cfbc6f2" xlink:to="loc_xcur_ArrangementNameAxis_cf5d4e19-d463-47a7-85e9-7b7da711283c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameDomain_cf5d4e19-d463-47a7-85e9-7b7da711283c_default" xlink:href="xcur-20210930.xsd#xcur_ArrangementNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_xcur_ArrangementNameAxis_cf5d4e19-d463-47a7-85e9-7b7da711283c" xlink:to="loc_xcur_ArrangementNameDomain_cf5d4e19-d463-47a7-85e9-7b7da711283c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameDomain_0d9b9d52-11b5-4cd5-8bc4-4c890c8ca540" xlink:href="xcur-20210930.xsd#xcur_ArrangementNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_xcur_ArrangementNameAxis_cf5d4e19-d463-47a7-85e9-7b7da711283c" xlink:to="loc_xcur_ArrangementNameDomain_0d9b9d52-11b5-4cd5-8bc4-4c890c8ca540" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_AbbVieCollaborationMember_7c0de014-4a71-4c14-9c4f-d5bcd007faac" xlink:href="xcur-20210930.xsd#xcur_AbbVieCollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xcur_ArrangementNameDomain_0d9b9d52-11b5-4cd5-8bc4-4c890c8ca540" xlink:to="loc_xcur_AbbVieCollaborationMember_7c0de014-4a71-4c14-9c4f-d5bcd007faac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6ee6a405-1d1b-42b3-aad4-08f77d0f13a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyTable_92d564d8-b520-4e37-90ff-2f8a6cfbc6f2" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6ee6a405-1d1b-42b3-aad4-08f77d0f13a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ee6a405-1d1b-42b3-aad4-08f77d0f13a4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6ee6a405-1d1b-42b3-aad4-08f77d0f13a4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ee6a405-1d1b-42b3-aad4-08f77d0f13a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13715268-965e-4a1e-b5a3-abc7b3998f77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6ee6a405-1d1b-42b3-aad4-08f77d0f13a4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13715268-965e-4a1e-b5a3-abc7b3998f77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_02dc04c2-e1bc-4ff5-a544-1ba27781f167" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13715268-965e-4a1e-b5a3-abc7b3998f77" xlink:to="loc_us-gaap_CollaborativeArrangementMember_02dc04c2-e1bc-4ff5-a544-1ba27781f167" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis_1b097525-62f8-4189-906d-8379e17b5d16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyTable_92d564d8-b520-4e37-90ff-2f8a6cfbc6f2" xlink:to="loc_us-gaap_UnusualOrInfrequentItemAxis_1b097525-62f8-4189-906d-8379e17b5d16" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_1b097525-62f8-4189-906d-8379e17b5d16_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_1b097525-62f8-4189-906d-8379e17b5d16" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_1b097525-62f8-4189-906d-8379e17b5d16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_3071d732-f7aa-41ed-9c10-8156e72f74ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_1b097525-62f8-4189-906d-8379e17b5d16" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_3071d732-f7aa-41ed-9c10-8156e72f74ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_COVID19Member_b6473162-2df1-4eba-98da-58e9ea3967de" xlink:href="xcur-20210930.xsd#xcur_COVID19Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain_3071d732-f7aa-41ed-9c10-8156e72f74ed" xlink:to="loc_xcur_COVID19Member_b6473162-2df1-4eba-98da-58e9ea3967de" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#SignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/SignificantAccountingPoliciesDetails" xlink:type="extended" id="i2ce7ebcde9984e55808d95e311fa141b_SignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_15620f39-e3e1-4119-b464-f64b714c521f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_e6dc5147-bca9-46d8-a418-9876ea2155a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_15620f39-e3e1-4119-b464-f64b714c521f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_e6dc5147-bca9-46d8-a418-9876ea2155a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualRiskOrUncertaintyTable_7fe81fe9-fa63-46ce-8cd6-2e6307c6cb94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_15620f39-e3e1-4119-b464-f64b714c521f" xlink:to="loc_us-gaap_UnusualRiskOrUncertaintyTable_7fe81fe9-fa63-46ce-8cd6-2e6307c6cb94" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameAxis_9ba8a5b8-0816-4760-b9d4-df88b366e1af" xlink:href="xcur-20210930.xsd#xcur_ArrangementNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyTable_7fe81fe9-fa63-46ce-8cd6-2e6307c6cb94" xlink:to="loc_xcur_ArrangementNameAxis_9ba8a5b8-0816-4760-b9d4-df88b366e1af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameDomain_9ba8a5b8-0816-4760-b9d4-df88b366e1af_default" xlink:href="xcur-20210930.xsd#xcur_ArrangementNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_xcur_ArrangementNameAxis_9ba8a5b8-0816-4760-b9d4-df88b366e1af" xlink:to="loc_xcur_ArrangementNameDomain_9ba8a5b8-0816-4760-b9d4-df88b366e1af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameDomain_998ccde8-8c1e-4df3-83cd-caabcdd353a6" xlink:href="xcur-20210930.xsd#xcur_ArrangementNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_xcur_ArrangementNameAxis_9ba8a5b8-0816-4760-b9d4-df88b366e1af" xlink:to="loc_xcur_ArrangementNameDomain_998ccde8-8c1e-4df3-83cd-caabcdd353a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_AbbVieCollaborationMember_29adf08d-6dc8-4cf6-8a53-441b26b3a1d9" xlink:href="xcur-20210930.xsd#xcur_AbbVieCollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xcur_ArrangementNameDomain_998ccde8-8c1e-4df3-83cd-caabcdd353a6" xlink:to="loc_xcur_AbbVieCollaborationMember_29adf08d-6dc8-4cf6-8a53-441b26b3a1d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_20b4cd6a-9a9b-4983-975e-9d333662ad18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyTable_7fe81fe9-fa63-46ce-8cd6-2e6307c6cb94" xlink:to="loc_us-gaap_TypeOfArrangementAxis_20b4cd6a-9a9b-4983-975e-9d333662ad18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_20b4cd6a-9a9b-4983-975e-9d333662ad18_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_20b4cd6a-9a9b-4983-975e-9d333662ad18" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_20b4cd6a-9a9b-4983-975e-9d333662ad18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6a36198e-ff53-4e04-aa1e-9be983ec85c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_20b4cd6a-9a9b-4983-975e-9d333662ad18" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6a36198e-ff53-4e04-aa1e-9be983ec85c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_56ca7d0d-5807-4ea0-b6fa-c6cd27c8c68f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6a36198e-ff53-4e04-aa1e-9be983ec85c1" xlink:to="loc_us-gaap_CollaborativeArrangementMember_56ca7d0d-5807-4ea0-b6fa-c6cd27c8c68f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#CollaborativeResearchandLicenseAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails" xlink:type="extended" id="if3019c1df00844a9ba141ddf76d2affd_CollaborativeResearchandLicenseAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_NumberofCollaborationPrograms_5f4e8c95-a856-43ae-a7fd-6535875d6342" xlink:href="xcur-20210930.xsd#xcur_NumberofCollaborationPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_xcur_NumberofCollaborationPrograms_5f4e8c95-a856-43ae-a7fd-6535875d6342" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_fb955fac-52a3-403e-a5cb-707f973cde5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_us-gaap_ProceedsFromCollaborators_fb955fac-52a3-403e-a5cb-707f973cde5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementOptionExerciseFee_25e1267b-6232-4a75-b538-155090cf4a68" xlink:href="xcur-20210930.xsd#xcur_CollaborationAgreementOptionExerciseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_xcur_CollaborationAgreementOptionExerciseFee_25e1267b-6232-4a75-b538-155090cf4a68" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment_bff9e620-071d-48b6-ad55-6a15b47922f7" xlink:href="xcur-20210930.xsd#xcur_RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_xcur_RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment_bff9e620-071d-48b6-ad55-6a15b47922f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment_cbe278c2-c9bb-4f18-9992-529389f8a175" xlink:href="xcur-20210930.xsd#xcur_RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_xcur_RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment_cbe278c2-c9bb-4f18-9992-529389f8a175" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment_db3decd3-172b-4398-994e-ed7b2c37ce5c" xlink:href="xcur-20210930.xsd#xcur_RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_xcur_RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment_db3decd3-172b-4398-994e-ed7b2c37ce5c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementLicensingFeesIncurred_11235e1e-9a07-4df6-939f-2799d766dd92" xlink:href="xcur-20210930.xsd#xcur_CollaborationAgreementLicensingFeesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_xcur_CollaborationAgreementLicensingFeesIncurred_11235e1e-9a07-4df6-939f-2799d766dd92" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementTerminationNoticePeriod_34d4d552-1f8e-4211-a471-27f6d7825a36" xlink:href="xcur-20210930.xsd#xcur_CollaborationAgreementTerminationNoticePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_xcur_CollaborationAgreementTerminationNoticePeriod_34d4d552-1f8e-4211-a471-27f6d7825a36" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementTransactionPrice_7260b2ca-2701-4711-9718-4334f82e40ef" xlink:href="xcur-20210930.xsd#xcur_CollaborationAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_xcur_CollaborationAgreementTransactionPrice_7260b2ca-2701-4711-9718-4334f82e40ef" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_028185b0-4b4f-47e0-8024-357b8fa60416" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_028185b0-4b4f-47e0-8024-357b8fa60416" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_92425b21-4395-4b10-864b-80351db53b79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_us-gaap_ContractWithCustomerLiability_92425b21-4395-4b10-864b-80351db53b79" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2ac32118-2776-42a0-83b5-ac9bd637bc70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2ac32118-2776-42a0-83b5-ac9bd637bc70" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_264f6c8f-89fc-4512-bfad-89df391dde48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_264f6c8f-89fc-4512-bfad-89df391dde48" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementEstimatedTimingOfRevenueRecognition_edc851d5-0b2a-4902-98fc-a17e6c1fb5a7" xlink:href="xcur-20210930.xsd#xcur_CollaborationAgreementEstimatedTimingOfRevenueRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_xcur_CollaborationAgreementEstimatedTimingOfRevenueRecognition_edc851d5-0b2a-4902-98fc-a17e6c1fb5a7" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementUpfrontPayment_61daddd9-461b-4354-9e84-53bdb31d38ef" xlink:href="xcur-20210930.xsd#xcur_CollaborationAgreementUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_xcur_CollaborationAgreementUpfrontPayment_61daddd9-461b-4354-9e84-53bdb31d38ef" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee_d62593e7-3f59-491e-b6f8-4d20af93e906" xlink:href="xcur-20210930.xsd#xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee_d62593e7-3f59-491e-b6f8-4d20af93e906" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment_1702d03b-6cbf-462c-82bd-9aded39ac3e5" xlink:href="xcur-20210930.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment_1702d03b-6cbf-462c-82bd-9aded39ac3e5" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment_9eab8db9-9af8-480b-bdd9-c44d8bc0bc26" xlink:href="xcur-20210930.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment_9eab8db9-9af8-480b-bdd9-c44d8bc0bc26" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment_abea5603-36a0-43be-9767-211e8f10f571" xlink:href="xcur-20210930.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment_abea5603-36a0-43be-9767-211e8f10f571" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice_0e145734-1630-4cb4-a572-80431111be99" xlink:href="xcur-20210930.xsd#xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice_0e145734-1630-4cb4-a572-80431111be99" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_3aa1ece1-d657-428e-b495-361eb373c166" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_3aa1ece1-d657-428e-b495-361eb373c166" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationDevelopmentExpenses_93bfaa3a-ba18-4549-8aeb-33b2b6d8aeb3" xlink:href="xcur-20210930.xsd#xcur_CollaborationDevelopmentExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_xcur_CollaborationDevelopmentExpenses_93bfaa3a-ba18-4549-8aeb-33b2b6d8aeb3" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate_8eec450a-c52c-4cfd-8cd3-2f97df6d02a8" xlink:href="xcur-20210930.xsd#xcur_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_xcur_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate_8eec450a-c52c-4cfd-8cd3-2f97df6d02a8" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ceb255b0-a182-4a68-adb5-0885960f7a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ceb255b0-a182-4a68-adb5-0885960f7a0c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_30045909-6bb9-4b95-b00d-669a5631da89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ceb255b0-a182-4a68-adb5-0885960f7a0c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_30045909-6bb9-4b95-b00d-669a5631da89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_30045909-6bb9-4b95-b00d-669a5631da89_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_30045909-6bb9-4b95-b00d-669a5631da89" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_30045909-6bb9-4b95-b00d-669a5631da89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b02e136e-decb-41c2-8ac2-26067f048622" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_30045909-6bb9-4b95-b00d-669a5631da89" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b02e136e-decb-41c2-8ac2-26067f048622" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_18c3380a-d237-468e-86f9-2815655338f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b02e136e-decb-41c2-8ac2-26067f048622" xlink:to="loc_us-gaap_CollaborativeArrangementMember_18c3380a-d237-468e-86f9-2815655338f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameAxis_1e7e158b-b729-4a27-bdd3-cb1231f836da" xlink:href="xcur-20210930.xsd#xcur_ArrangementNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ceb255b0-a182-4a68-adb5-0885960f7a0c" xlink:to="loc_xcur_ArrangementNameAxis_1e7e158b-b729-4a27-bdd3-cb1231f836da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameDomain_1e7e158b-b729-4a27-bdd3-cb1231f836da_default" xlink:href="xcur-20210930.xsd#xcur_ArrangementNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_xcur_ArrangementNameAxis_1e7e158b-b729-4a27-bdd3-cb1231f836da" xlink:to="loc_xcur_ArrangementNameDomain_1e7e158b-b729-4a27-bdd3-cb1231f836da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameDomain_05751be3-e2b7-4dcc-813f-3c2b7aaff43e" xlink:href="xcur-20210930.xsd#xcur_ArrangementNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_xcur_ArrangementNameAxis_1e7e158b-b729-4a27-bdd3-cb1231f836da" xlink:to="loc_xcur_ArrangementNameDomain_05751be3-e2b7-4dcc-813f-3c2b7aaff43e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_IpsenCollaborationMember_947d9e5b-b6bc-4af1-9068-4747cc7ff58a" xlink:href="xcur-20210930.xsd#xcur_IpsenCollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xcur_ArrangementNameDomain_05751be3-e2b7-4dcc-813f-3c2b7aaff43e" xlink:to="loc_xcur_IpsenCollaborationMember_947d9e5b-b6bc-4af1-9068-4747cc7ff58a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_AbbVieCollaborationMember_c25be32b-1004-4476-9b39-ca536616e3c5" xlink:href="xcur-20210930.xsd#xcur_AbbVieCollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xcur_ArrangementNameDomain_05751be3-e2b7-4dcc-813f-3c2b7aaff43e" xlink:to="loc_xcur_AbbVieCollaborationMember_c25be32b-1004-4476-9b39-ca536616e3c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DermelixLicenseAgreementMember_933bccd0-a43a-4bbf-ab2c-0253911cca22" xlink:href="xcur-20210930.xsd#xcur_DermelixLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xcur_ArrangementNameDomain_05751be3-e2b7-4dcc-813f-3c2b7aaff43e" xlink:to="loc_xcur_DermelixLicenseAgreementMember_933bccd0-a43a-4bbf-ab2c-0253911cca22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ExercisePeriodAxis_927d2160-a5b1-4ac5-ad0b-92227813c4c7" xlink:href="xcur-20210930.xsd#xcur_ExercisePeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ceb255b0-a182-4a68-adb5-0885960f7a0c" xlink:to="loc_xcur_ExercisePeriodAxis_927d2160-a5b1-4ac5-ad0b-92227813c4c7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ExercisePeriodDomain_927d2160-a5b1-4ac5-ad0b-92227813c4c7_default" xlink:href="xcur-20210930.xsd#xcur_ExercisePeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_xcur_ExercisePeriodAxis_927d2160-a5b1-4ac5-ad0b-92227813c4c7" xlink:to="loc_xcur_ExercisePeriodDomain_927d2160-a5b1-4ac5-ad0b-92227813c4c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ExercisePeriodDomain_056868eb-92a0-4137-a39a-170f17a8cc15" xlink:href="xcur-20210930.xsd#xcur_ExercisePeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_xcur_ExercisePeriodAxis_927d2160-a5b1-4ac5-ad0b-92227813c4c7" xlink:to="loc_xcur_ExercisePeriodDomain_056868eb-92a0-4137-a39a-170f17a8cc15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ExercisePeriodOneMember_4b83ee94-2a56-46ac-a195-44c18aeeb7b6" xlink:href="xcur-20210930.xsd#xcur_ExercisePeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xcur_ExercisePeriodDomain_056868eb-92a0-4137-a39a-170f17a8cc15" xlink:to="loc_xcur_ExercisePeriodOneMember_4b83ee94-2a56-46ac-a195-44c18aeeb7b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ExercisePeriodTwoMember_04cedacc-baac-4f0b-b038-4d60520463a2" xlink:href="xcur-20210930.xsd#xcur_ExercisePeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xcur_ExercisePeriodDomain_056868eb-92a0-4137-a39a-170f17a8cc15" xlink:to="loc_xcur_ExercisePeriodTwoMember_04cedacc-baac-4f0b-b038-4d60520463a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementPerformanceObligationAxis_22ab10b8-ef3d-4ab6-8fa1-5bde7a6c2cdc" xlink:href="xcur-20210930.xsd#xcur_CollaborationAgreementPerformanceObligationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ceb255b0-a182-4a68-adb5-0885960f7a0c" xlink:to="loc_xcur_CollaborationAgreementPerformanceObligationAxis_22ab10b8-ef3d-4ab6-8fa1-5bde7a6c2cdc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementPerformanceObligationDomain_22ab10b8-ef3d-4ab6-8fa1-5bde7a6c2cdc_default" xlink:href="xcur-20210930.xsd#xcur_CollaborationAgreementPerformanceObligationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_xcur_CollaborationAgreementPerformanceObligationAxis_22ab10b8-ef3d-4ab6-8fa1-5bde7a6c2cdc" xlink:to="loc_xcur_CollaborationAgreementPerformanceObligationDomain_22ab10b8-ef3d-4ab6-8fa1-5bde7a6c2cdc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementPerformanceObligationDomain_cfe0bce5-cadb-4d90-b020-11a06eaa844e" xlink:href="xcur-20210930.xsd#xcur_CollaborationAgreementPerformanceObligationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_xcur_CollaborationAgreementPerformanceObligationAxis_22ab10b8-ef3d-4ab6-8fa1-5bde7a6c2cdc" xlink:to="loc_xcur_CollaborationAgreementPerformanceObligationDomain_cfe0bce5-cadb-4d90-b020-11a06eaa844e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_IpsenHDMember_1ae9f9ad-0622-429a-8370-48eca3281c06" xlink:href="xcur-20210930.xsd#xcur_IpsenHDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xcur_CollaborationAgreementPerformanceObligationDomain_cfe0bce5-cadb-4d90-b020-11a06eaa844e" xlink:to="loc_xcur_IpsenHDMember_1ae9f9ad-0622-429a-8370-48eca3281c06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_IpsenASMember_25961050-281c-4ddf-8d39-7d49b07f523a" xlink:href="xcur-20210930.xsd#xcur_IpsenASMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xcur_CollaborationAgreementPerformanceObligationDomain_cfe0bce5-cadb-4d90-b020-11a06eaa844e" xlink:to="loc_xcur_IpsenASMember_25961050-281c-4ddf-8d39-7d49b07f523a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c091e62d-4cbe-43f5-a074-97c42a62d1d8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ceb255b0-a182-4a68-adb5-0885960f7a0c" xlink:to="loc_srt_RangeAxis_c091e62d-4cbe-43f5-a074-97c42a62d1d8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c091e62d-4cbe-43f5-a074-97c42a62d1d8_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c091e62d-4cbe-43f5-a074-97c42a62d1d8" xlink:to="loc_srt_RangeMember_c091e62d-4cbe-43f5-a074-97c42a62d1d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e4e74bbb-a7ac-4646-a192-2b6267c927fe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c091e62d-4cbe-43f5-a074-97c42a62d1d8" xlink:to="loc_srt_RangeMember_e4e74bbb-a7ac-4646-a192-2b6267c927fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c355d940-d010-433c-b171-ff3057ce8c73" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e4e74bbb-a7ac-4646-a192-2b6267c927fe" xlink:to="loc_srt_MinimumMember_c355d940-d010-433c-b171-ff3057ce8c73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_69bb5235-01f9-4580-b753-f7bf173d4518" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e4e74bbb-a7ac-4646-a192-2b6267c927fe" xlink:to="loc_srt_MaximumMember_69bb5235-01f9-4580-b753-f7bf173d4518" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_9cfd07a6-254c-4a72-9cef-74969dee139d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ceb255b0-a182-4a68-adb5-0885960f7a0c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_9cfd07a6-254c-4a72-9cef-74969dee139d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9cfd07a6-254c-4a72-9cef-74969dee139d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_9cfd07a6-254c-4a72-9cef-74969dee139d" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9cfd07a6-254c-4a72-9cef-74969dee139d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_71d55105-9a8e-4ec3-ace3-697f08c9f463" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_9cfd07a6-254c-4a72-9cef-74969dee139d" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_71d55105-9a8e-4ec3-ace3-697f08c9f463" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DevelopmentandCommercializationLicenseMember_e5831ad4-1125-4e8d-83ff-84aec8dbeec2" xlink:href="xcur-20210930.xsd#xcur_DevelopmentandCommercializationLicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_71d55105-9a8e-4ec3-ace3-697f08c9f463" xlink:to="loc_xcur_DevelopmentandCommercializationLicenseMember_e5831ad4-1125-4e8d-83ff-84aec8dbeec2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#CollaborativeResearchandLicenseAgreementsOtherCurrentLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsOtherCurrentLiabilitiesDetails" xlink:type="extended" id="ida8adf7315474bfa9b891983de09992d_CollaborativeResearchandLicenseAgreementsOtherCurrentLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2d32abd8-14bc-437b-b3dd-139d1c8b53fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInDeferredRevenueRollForward_0e29e285-6283-4161-9498-24228c908f76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInDeferredRevenueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2d32abd8-14bc-437b-b3dd-139d1c8b53fa" xlink:to="loc_us-gaap_MovementInDeferredRevenueRollForward_0e29e285-6283-4161-9498-24228c908f76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_bdfe0ddb-4c6e-45a7-b91a-b279b7c054db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInDeferredRevenueRollForward_0e29e285-6283-4161-9498-24228c908f76" xlink:to="loc_us-gaap_ContractWithCustomerLiability_bdfe0ddb-4c6e-45a7-b91a-b279b7c054db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ContractWithCustomerLiabilityAdditions_72f46bf2-3d43-4578-b0d0-0f0f2b1f8f17" xlink:href="xcur-20210930.xsd#xcur_ContractWithCustomerLiabilityAdditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInDeferredRevenueRollForward_0e29e285-6283-4161-9498-24228c908f76" xlink:to="loc_xcur_ContractWithCustomerLiabilityAdditions_72f46bf2-3d43-4578-b0d0-0f0f2b1f8f17" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance_c4a289ee-cf3b-43a9-a99a-a9d75865431a" xlink:href="xcur-20210930.xsd#xcur_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInDeferredRevenueRollForward_0e29e285-6283-4161-9498-24228c908f76" xlink:to="loc_xcur_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance_c4a289ee-cf3b-43a9-a99a-a9d75865431a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_2c50260a-a533-4a66-8c8e-7a9c057e87bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_093aa2db-d4a8-451b-bd1e-f20c54832901" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2d32abd8-14bc-437b-b3dd-139d1c8b53fa" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_093aa2db-d4a8-451b-bd1e-f20c54832901" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameAxis_af9bc8d1-bfaf-4e93-91a1-bb2c4cea183c" xlink:href="xcur-20210930.xsd#xcur_ArrangementNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_093aa2db-d4a8-451b-bd1e-f20c54832901" xlink:to="loc_xcur_ArrangementNameAxis_af9bc8d1-bfaf-4e93-91a1-bb2c4cea183c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameDomain_af9bc8d1-bfaf-4e93-91a1-bb2c4cea183c_default" xlink:href="xcur-20210930.xsd#xcur_ArrangementNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_xcur_ArrangementNameAxis_af9bc8d1-bfaf-4e93-91a1-bb2c4cea183c" xlink:to="loc_xcur_ArrangementNameDomain_af9bc8d1-bfaf-4e93-91a1-bb2c4cea183c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameDomain_786e5d32-c474-48f7-a4bb-225c235c5986" xlink:href="xcur-20210930.xsd#xcur_ArrangementNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_xcur_ArrangementNameAxis_af9bc8d1-bfaf-4e93-91a1-bb2c4cea183c" xlink:to="loc_xcur_ArrangementNameDomain_786e5d32-c474-48f7-a4bb-225c235c5986" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_IpsenCollaborationMember_8247e63c-5357-42f6-ad1b-50b472df78a7" xlink:href="xcur-20210930.xsd#xcur_IpsenCollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xcur_ArrangementNameDomain_786e5d32-c474-48f7-a4bb-225c235c5986" xlink:to="loc_xcur_IpsenCollaborationMember_8247e63c-5357-42f6-ad1b-50b472df78a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_AbbVieCollaborationMember_f7b9faf6-8ea7-47b1-ac38-c45eb815b2f2" xlink:href="xcur-20210930.xsd#xcur_AbbVieCollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xcur_ArrangementNameDomain_786e5d32-c474-48f7-a4bb-225c235c5986" xlink:to="loc_xcur_AbbVieCollaborationMember_f7b9faf6-8ea7-47b1-ac38-c45eb815b2f2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails" xlink:type="extended" id="ia0042af5354b44258e382146e3156669_SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_53ddeb5f-a59f-4d28-b16a-32832ad2104c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_33c35575-fada-4b9e-b6ba-a9530c1648f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_53ddeb5f-a59f-4d28-b16a-32832ad2104c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_33c35575-fada-4b9e-b6ba-a9530c1648f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c1fc15ef-b2f7-49df-85ba-53c970e16e16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_53ddeb5f-a59f-4d28-b16a-32832ad2104c" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c1fc15ef-b2f7-49df-85ba-53c970e16e16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_badf8d3a-ce59-4d59-90ae-873ea3a5bc71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_53ddeb5f-a59f-4d28-b16a-32832ad2104c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_badf8d3a-ce59-4d59-90ae-873ea3a5bc71" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_d8073073-f0d5-4098-854b-b753449ed28f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_53ddeb5f-a59f-4d28-b16a-32832ad2104c" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_d8073073-f0d5-4098-854b-b753449ed28f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4454f53a-3b60-424b-a715-cda4a82199c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_53ddeb5f-a59f-4d28-b16a-32832ad2104c" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4454f53a-3b60-424b-a715-cda4a82199c3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bd5d6644-9c1c-4c0a-9883-cac86c68479a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4454f53a-3b60-424b-a715-cda4a82199c3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bd5d6644-9c1c-4c0a-9883-cac86c68479a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bd5d6644-9c1c-4c0a-9883-cac86c68479a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bd5d6644-9c1c-4c0a-9883-cac86c68479a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bd5d6644-9c1c-4c0a-9883-cac86c68479a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_693de6f3-0797-4d73-b26c-57b86762c0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bd5d6644-9c1c-4c0a-9883-cac86c68479a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_693de6f3-0797-4d73-b26c-57b86762c0a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_c0f33dbf-8e51-4fad-8634-61cdcbdc64ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_693de6f3-0797-4d73-b26c-57b86762c0a5" xlink:to="loc_us-gaap_EquipmentMember_c0f33dbf-8e51-4fad-8634-61cdcbdc64ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_cd7d83fc-a6e2-4d16-a79d-c6f85f77afdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_693de6f3-0797-4d73-b26c-57b86762c0a5" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_cd7d83fc-a6e2-4d16-a79d-c6f85f77afdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ComputersandSoftwareMember_8560217e-0421-4de8-9ea3-6bd7506bea70" xlink:href="xcur-20210930.xsd#xcur_ComputersandSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_693de6f3-0797-4d73-b26c-57b86762c0a5" xlink:to="loc_xcur_ComputersandSoftwareMember_8560217e-0421-4de8-9ea3-6bd7506bea70" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_de813ed9-3862-446b-b96d-f43017932195" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_693de6f3-0797-4d73-b26c-57b86762c0a5" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_de813ed9-3862-446b-b96d-f43017932195" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_9cff61b4-256c-4da9-9508-41c2cb6cb7ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_693de6f3-0797-4d73-b26c-57b86762c0a5" xlink:to="loc_us-gaap_ConstructionInProgressMember_9cff61b4-256c-4da9-9508-41c2cb6cb7ce" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#InvestmentsAvailableforsaleSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails" xlink:type="extended" id="icf580ca9785c48748c5b18c9996e0c30_InvestmentsAvailableforsaleSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fde0354d-72a3-4c62-9915-9dd0f0b4c682" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d4b3eb57-eb9c-4dc1-86d9-25bf1dd09077" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fde0354d-72a3-4c62-9915-9dd0f0b4c682" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d4b3eb57-eb9c-4dc1-86d9-25bf1dd09077" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_edfeeac8-2b1c-4128-88aa-5b33f2dd44b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fde0354d-72a3-4c62-9915-9dd0f0b4c682" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_edfeeac8-2b1c-4128-88aa-5b33f2dd44b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d528c3e5-4338-4ff6-a460-93daf73cdea2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fde0354d-72a3-4c62-9915-9dd0f0b4c682" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d528c3e5-4338-4ff6-a460-93daf73cdea2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b89107f9-df09-414a-97b9-213506b0b0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fde0354d-72a3-4c62-9915-9dd0f0b4c682" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b89107f9-df09-414a-97b9-213506b0b0aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ca1bcbc1-1ada-4c10-8819-9a116169056a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fde0354d-72a3-4c62-9915-9dd0f0b4c682" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ca1bcbc1-1ada-4c10-8819-9a116169056a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_92164bd8-1565-4bff-82ce-862da3e0a5a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ca1bcbc1-1ada-4c10-8819-9a116169056a" xlink:to="loc_us-gaap_FinancialInstrumentAxis_92164bd8-1565-4bff-82ce-862da3e0a5a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92164bd8-1565-4bff-82ce-862da3e0a5a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_92164bd8-1565-4bff-82ce-862da3e0a5a9" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92164bd8-1565-4bff-82ce-862da3e0a5a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b453c3ea-f39d-49ae-9dcd-29b2dd80818f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_92164bd8-1565-4bff-82ce-862da3e0a5a9" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b453c3ea-f39d-49ae-9dcd-29b2dd80818f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_184e08dc-76e8-4111-bb92-0e29b4c6fa0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b453c3ea-f39d-49ae-9dcd-29b2dd80818f" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_184e08dc-76e8-4111-bb92-0e29b4c6fa0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_ec4dcab3-7d70-4d6e-9e73-11de077a9747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b453c3ea-f39d-49ae-9dcd-29b2dd80818f" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_ec4dcab3-7d70-4d6e-9e73-11de077a9747" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_4a20d548-82ce-465a-a7c4-bb4b5edd408f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b453c3ea-f39d-49ae-9dcd-29b2dd80818f" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_4a20d548-82ce-465a-a7c4-bb4b5edd408f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_8810e896-da35-45b4-8bb6-be9c51091ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b453c3ea-f39d-49ae-9dcd-29b2dd80818f" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_8810e896-da35-45b4-8bb6-be9c51091ff4" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#DebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/DebtNarrativeDetails" xlink:type="extended" id="i0606f7ff51454c94b74f377a999c345f_DebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_8d6fc72f-745d-4e7d-aac1-6da45540bbd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_bc5d4edc-8284-41df-9670-486016a7cf46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8d6fc72f-745d-4e7d-aac1-6da45540bbd5" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_bc5d4edc-8284-41df-9670-486016a7cf46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_719e0e3d-09bf-49f3-a15b-ed869046914f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8d6fc72f-745d-4e7d-aac1-6da45540bbd5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_719e0e3d-09bf-49f3-a15b-ed869046914f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DebtInstrumentFundingConditionRequiredProceedsFromEquityIssuance_df21abeb-892d-447d-a13b-68af56ff0eac" xlink:href="xcur-20210930.xsd#xcur_DebtInstrumentFundingConditionRequiredProceedsFromEquityIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8d6fc72f-745d-4e7d-aac1-6da45540bbd5" xlink:to="loc_xcur_DebtInstrumentFundingConditionRequiredProceedsFromEquityIssuance_df21abeb-892d-447d-a13b-68af56ff0eac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5d86244d-ca8b-44a3-8835-cb43a49deb7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8d6fc72f-745d-4e7d-aac1-6da45540bbd5" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5d86244d-ca8b-44a3-8835-cb43a49deb7e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7d70d368-48b7-46eb-8ad5-67a8b80a3798" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8d6fc72f-745d-4e7d-aac1-6da45540bbd5" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7d70d368-48b7-46eb-8ad5-67a8b80a3798" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments_7ab76b1a-5727-4af0-a63b-08150dc2d22d" xlink:href="xcur-20210930.xsd#xcur_DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8d6fc72f-745d-4e7d-aac1-6da45540bbd5" xlink:to="loc_xcur_DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments_7ab76b1a-5727-4af0-a63b-08150dc2d22d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DebtInstrumentEarlyTerminationFeePercentageOfPrincipal_a4c3af8d-2c20-4da5-b155-62151b873fe3" xlink:href="xcur-20210930.xsd#xcur_DebtInstrumentEarlyTerminationFeePercentageOfPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8d6fc72f-745d-4e7d-aac1-6da45540bbd5" xlink:to="loc_xcur_DebtInstrumentEarlyTerminationFeePercentageOfPrincipal_a4c3af8d-2c20-4da5-b155-62151b873fe3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoanProcessingFee_5556e104-6448-43de-9e11-0f335999d7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoanProcessingFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8d6fc72f-745d-4e7d-aac1-6da45540bbd5" xlink:to="loc_us-gaap_LoanProcessingFee_5556e104-6448-43de-9e11-0f335999d7c6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DebtInstrumentExitFeePercentage_21266753-ef6e-43a1-86c2-758ffc6661e1" xlink:href="xcur-20210930.xsd#xcur_DebtInstrumentExitFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8d6fc72f-745d-4e7d-aac1-6da45540bbd5" xlink:to="loc_xcur_DebtInstrumentExitFeePercentage_21266753-ef6e-43a1-86c2-758ffc6661e1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_a9c565d0-43a3-43f7-8af7-72d9422b0639" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8d6fc72f-745d-4e7d-aac1-6da45540bbd5" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_a9c565d0-43a3-43f7-8af7-72d9422b0639" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_8c6635b0-c363-4f53-a8ff-7816b942c71f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8d6fc72f-745d-4e7d-aac1-6da45540bbd5" xlink:to="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_8c6635b0-c363-4f53-a8ff-7816b942c71f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_a21a7b05-c995-4cdd-8c4b-5558f6f44cba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8d6fc72f-745d-4e7d-aac1-6da45540bbd5" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_a21a7b05-c995-4cdd-8c4b-5558f6f44cba" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_0996ec38-929a-4b0b-bbcb-2056305fa2a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8d6fc72f-745d-4e7d-aac1-6da45540bbd5" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_0996ec38-929a-4b0b-bbcb-2056305fa2a1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_eebfd756-87ee-478c-9982-4dc45a2d47dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8d6fc72f-745d-4e7d-aac1-6da45540bbd5" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_eebfd756-87ee-478c-9982-4dc45a2d47dd" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_230a4da3-8953-4dfe-aa62-f4f6eb91c938" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8d6fc72f-745d-4e7d-aac1-6da45540bbd5" xlink:to="loc_us-gaap_LongTermDebt_230a4da3-8953-4dfe-aa62-f4f6eb91c938" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_e7e5eb99-5373-46dc-960a-5853e9162866" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8d6fc72f-745d-4e7d-aac1-6da45540bbd5" xlink:to="loc_us-gaap_InterestPaidNet_e7e5eb99-5373-46dc-960a-5853e9162866" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_62136a95-73da-4654-b31a-cea3f95d4b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8d6fc72f-745d-4e7d-aac1-6da45540bbd5" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_62136a95-73da-4654-b31a-cea3f95d4b0d" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_PaymentsForDebtEndTermFees_8bdd5e7c-84ae-4e88-96ce-814c76e6c60c" xlink:href="xcur-20210930.xsd#xcur_PaymentsForDebtEndTermFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8d6fc72f-745d-4e7d-aac1-6da45540bbd5" xlink:to="loc_xcur_PaymentsForDebtEndTermFees_8bdd5e7c-84ae-4e88-96ce-814c76e6c60c" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_018cae0b-f98f-4d16-8e6c-9ee84c963ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8d6fc72f-745d-4e7d-aac1-6da45540bbd5" xlink:to="loc_us-gaap_DebtInstrumentTable_018cae0b-f98f-4d16-8e6c-9ee84c963ccc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a1fed48c-25c4-44d0-8e2e-4da2133fc40a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_018cae0b-f98f-4d16-8e6c-9ee84c963ccc" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a1fed48c-25c4-44d0-8e2e-4da2133fc40a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a1fed48c-25c4-44d0-8e2e-4da2133fc40a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a1fed48c-25c4-44d0-8e2e-4da2133fc40a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a1fed48c-25c4-44d0-8e2e-4da2133fc40a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_da4bd1c8-71df-42f6-beef-e371525ef1a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a1fed48c-25c4-44d0-8e2e-4da2133fc40a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_da4bd1c8-71df-42f6-beef-e371525ef1a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_27cad2a8-1b80-4b84-9894-3ec88feb21fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_da4bd1c8-71df-42f6-beef-e371525ef1a6" xlink:to="loc_us-gaap_SecuredDebtMember_27cad2a8-1b80-4b84-9894-3ec88feb21fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_a349a4ab-2972-4d3e-9a8f-83ca401e143a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_da4bd1c8-71df-42f6-beef-e371525ef1a6" xlink:to="loc_us-gaap_LoansPayableMember_a349a4ab-2972-4d3e-9a8f-83ca401e143a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_a7058a3d-c888-4491-ade6-cd820e7e5646" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_018cae0b-f98f-4d16-8e6c-9ee84c963ccc" xlink:to="loc_us-gaap_CreditFacilityAxis_a7058a3d-c888-4491-ade6-cd820e7e5646" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_a7058a3d-c888-4491-ade6-cd820e7e5646_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_a7058a3d-c888-4491-ade6-cd820e7e5646" xlink:to="loc_us-gaap_CreditFacilityDomain_a7058a3d-c888-4491-ade6-cd820e7e5646_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_912069b2-19b8-44c1-b41c-b33375bdc2e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_a7058a3d-c888-4491-ade6-cd820e7e5646" xlink:to="loc_us-gaap_CreditFacilityDomain_912069b2-19b8-44c1-b41c-b33375bdc2e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_e9a8a727-acc6-46d1-ad43-9fb1ea5f8483" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_912069b2-19b8-44c1-b41c-b33375bdc2e7" xlink:to="loc_us-gaap_SecuredDebtMember_e9a8a727-acc6-46d1-ad43-9fb1ea5f8483" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_451d301f-9ebc-4e73-a780-3d5b02897ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_018cae0b-f98f-4d16-8e6c-9ee84c963ccc" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_451d301f-9ebc-4e73-a780-3d5b02897ce3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_451d301f-9ebc-4e73-a780-3d5b02897ce3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_451d301f-9ebc-4e73-a780-3d5b02897ce3" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_451d301f-9ebc-4e73-a780-3d5b02897ce3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_2e0ab6d5-6987-4322-afff-8748756d407c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_451d301f-9ebc-4e73-a780-3d5b02897ce3" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_2e0ab6d5-6987-4322-afff-8748756d407c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_HerculesTechnologyGrowthCapitalMember_133243b9-ce26-4f55-b071-ab36f3f1f5c4" xlink:href="xcur-20210930.xsd#xcur_HerculesTechnologyGrowthCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_2e0ab6d5-6987-4322-afff-8748756d407c" xlink:to="loc_xcur_HerculesTechnologyGrowthCapitalMember_133243b9-ce26-4f55-b071-ab36f3f1f5c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_acd84c4f-fff4-4895-9fb3-e685fed97e32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_018cae0b-f98f-4d16-8e6c-9ee84c963ccc" xlink:to="loc_us-gaap_DebtInstrumentAxis_acd84c4f-fff4-4895-9fb3-e685fed97e32" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_acd84c4f-fff4-4895-9fb3-e685fed97e32_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_acd84c4f-fff4-4895-9fb3-e685fed97e32" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_acd84c4f-fff4-4895-9fb3-e685fed97e32_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_433b33b7-026c-4db2-80b1-754acf311853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_acd84c4f-fff4-4895-9fb3-e685fed97e32" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_433b33b7-026c-4db2-80b1-754acf311853" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_MidCapCreditAgreementMember_a1c07b91-7910-488d-89c5-df9a5e75d49e" xlink:href="xcur-20210930.xsd#xcur_MidCapCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_433b33b7-026c-4db2-80b1-754acf311853" xlink:to="loc_xcur_MidCapCreditAgreementMember_a1c07b91-7910-488d-89c5-df9a5e75d49e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_MidCapCreditAgreementTranche1Member_3fe3cff3-f5c1-4d9d-aade-deafebe22cfe" xlink:href="xcur-20210930.xsd#xcur_MidCapCreditAgreementTranche1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xcur_MidCapCreditAgreementMember_a1c07b91-7910-488d-89c5-df9a5e75d49e" xlink:to="loc_xcur_MidCapCreditAgreementTranche1Member_3fe3cff3-f5c1-4d9d-aade-deafebe22cfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_MidCapCreditAgreementTranche2Member_36bf78c6-f207-419a-a22e-f682e55ca414" xlink:href="xcur-20210930.xsd#xcur_MidCapCreditAgreementTranche2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_xcur_MidCapCreditAgreementMember_a1c07b91-7910-488d-89c5-df9a5e75d49e" xlink:to="loc_xcur_MidCapCreditAgreementTranche2Member_36bf78c6-f207-419a-a22e-f682e55ca414" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_52bcb67d-badc-444c-86ee-68b062e2c904" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_018cae0b-f98f-4d16-8e6c-9ee84c963ccc" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_52bcb67d-badc-444c-86ee-68b062e2c904" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_52bcb67d-badc-444c-86ee-68b062e2c904_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_52bcb67d-badc-444c-86ee-68b062e2c904" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_52bcb67d-badc-444c-86ee-68b062e2c904_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_92fc5d1c-8a70-4bf0-a7e0-483d1daf884c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_52bcb67d-badc-444c-86ee-68b062e2c904" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_92fc5d1c-8a70-4bf0-a7e0-483d1daf884c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_827507e6-ff7a-47c3-b21f-28ac8b6a079b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_92fc5d1c-8a70-4bf0-a7e0-483d1daf884c" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_827507e6-ff7a-47c3-b21f-28ac8b6a079b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_275b9ac2-7362-4706-895e-3570a4ca9727" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_92fc5d1c-8a70-4bf0-a7e0-483d1daf884c" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_275b9ac2-7362-4706-895e-3570a4ca9727" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_a4ff2db5-51ea-4380-bbd6-e1df839f758d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_018cae0b-f98f-4d16-8e6c-9ee84c963ccc" xlink:to="loc_srt_StatementScenarioAxis_a4ff2db5-51ea-4380-bbd6-e1df839f758d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_a4ff2db5-51ea-4380-bbd6-e1df839f758d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_a4ff2db5-51ea-4380-bbd6-e1df839f758d" xlink:to="loc_srt_ScenarioUnspecifiedDomain_a4ff2db5-51ea-4380-bbd6-e1df839f758d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_35f47db5-3017-4fa0-a739-b8e095b96047" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_a4ff2db5-51ea-4380-bbd6-e1df839f758d" xlink:to="loc_srt_ScenarioUnspecifiedDomain_35f47db5-3017-4fa0-a739-b8e095b96047" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_7898653d-7d5a-4e83-9a66-8e70e33363b7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_35f47db5-3017-4fa0-a739-b8e095b96047" xlink:to="loc_srt_ScenarioForecastMember_7898653d-7d5a-4e83-9a66-8e70e33363b7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i85c564ff3df443439188857058c6cba3_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_b63f7f1f-54d1-4cb2-a189-7cf379ec9f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseLeaseArea_270f6f15-6798-4400-9526-650bbd766e81" xlink:href="xcur-20210930.xsd#xcur_LesseeOperatingLeaseLeaseArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b63f7f1f-54d1-4cb2-a189-7cf379ec9f5b" xlink:to="loc_xcur_LesseeOperatingLeaseLeaseArea_270f6f15-6798-4400-9526-650bbd766e81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_a5ae965c-2c88-483f-a40d-30cb16ebde84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b63f7f1f-54d1-4cb2-a189-7cf379ec9f5b" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_a5ae965c-2c88-483f-a40d-30cb16ebde84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseNumberOfExtensions_42a36145-edf6-40e0-817e-de87c04a2a95" xlink:href="xcur-20210930.xsd#xcur_LesseeOperatingLeaseNumberOfExtensions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b63f7f1f-54d1-4cb2-a189-7cf379ec9f5b" xlink:to="loc_xcur_LesseeOperatingLeaseNumberOfExtensions_42a36145-edf6-40e0-817e-de87c04a2a95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_d33ab224-a6e0-49a4-9510-c479425051e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b63f7f1f-54d1-4cb2-a189-7cf379ec9f5b" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_d33ab224-a6e0-49a4-9510-c479425051e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths_b5833951-3bb3-44ec-a815-936325a62c6f" xlink:href="xcur-20210930.xsd#xcur_LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b63f7f1f-54d1-4cb2-a189-7cf379ec9f5b" xlink:to="loc_xcur_LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths_b5833951-3bb3-44ec-a815-936325a62c6f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseBaseRentAnnualPercentageIncrease_d14848fd-09ac-4833-a2a5-4b4931657742" xlink:href="xcur-20210930.xsd#xcur_LesseeOperatingLeaseBaseRentAnnualPercentageIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b63f7f1f-54d1-4cb2-a189-7cf379ec9f5b" xlink:to="loc_xcur_LesseeOperatingLeaseBaseRentAnnualPercentageIncrease_d14848fd-09ac-4833-a2a5-4b4931657742" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm_478f61f6-bb58-4dd1-a574-c6985c82d8d7" xlink:href="xcur-20210930.xsd#xcur_LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b63f7f1f-54d1-4cb2-a189-7cf379ec9f5b" xlink:to="loc_xcur_LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm_478f61f6-bb58-4dd1-a574-c6985c82d8d7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_6e75ee8b-cc8c-4036-8031-311c86485595" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b63f7f1f-54d1-4cb2-a189-7cf379ec9f5b" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_6e75ee8b-cc8c-4036-8031-311c86485595" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseRentalPaymentAdjustedForAbatement_b0c94b07-1795-453c-9a87-62947f512323" xlink:href="xcur-20210930.xsd#xcur_LesseeOperatingLeaseRentalPaymentAdjustedForAbatement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b63f7f1f-54d1-4cb2-a189-7cf379ec9f5b" xlink:to="loc_xcur_LesseeOperatingLeaseRentalPaymentAdjustedForAbatement_b0c94b07-1795-453c-9a87-62947f512323" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForTenantImprovements_39449f09-3950-4ec2-800d-61b3efe31d12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForTenantImprovements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b63f7f1f-54d1-4cb2-a189-7cf379ec9f5b" xlink:to="loc_us-gaap_PaymentsForTenantImprovements_39449f09-3950-4ec2-800d-61b3efe31d12" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6f05fb63-2fbf-4850-8f03-338bc1386d93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b63f7f1f-54d1-4cb2-a189-7cf379ec9f5b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6f05fb63-2fbf-4850-8f03-338bc1386d93" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_ecf76ede-4d17-437b-a2e9-ee23d7b353b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b63f7f1f-54d1-4cb2-a189-7cf379ec9f5b" xlink:to="loc_us-gaap_OperatingLeaseLiability_ecf76ede-4d17-437b-a2e9-ee23d7b353b0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_4932b3f8-93c6-4096-9f06-e91a3d6feed6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b63f7f1f-54d1-4cb2-a189-7cf379ec9f5b" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_4932b3f8-93c6-4096-9f06-e91a3d6feed6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_5eb6d611-9131-4ff4-adc6-e44820330cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b63f7f1f-54d1-4cb2-a189-7cf379ec9f5b" xlink:to="loc_us-gaap_OperatingLeasePayments_5eb6d611-9131-4ff4-adc6-e44820330cbc" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_5b5a11b5-2d1b-496f-b4d9-df4e8fb7e0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b63f7f1f-54d1-4cb2-a189-7cf379ec9f5b" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_5b5a11b5-2d1b-496f-b4d9-df4e8fb7e0d8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_fd3256f3-d7a8-4c9e-9014-06acbe4f9e12" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_5b5a11b5-2d1b-496f-b4d9-df4e8fb7e0d8" xlink:to="loc_srt_StatementGeographicalAxis_fd3256f3-d7a8-4c9e-9014-06acbe4f9e12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_fd3256f3-d7a8-4c9e-9014-06acbe4f9e12_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_fd3256f3-d7a8-4c9e-9014-06acbe4f9e12" xlink:to="loc_srt_SegmentGeographicalDomain_fd3256f3-d7a8-4c9e-9014-06acbe4f9e12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_532c44df-ed6d-4a4b-90bb-1e2f6727031b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_fd3256f3-d7a8-4c9e-9014-06acbe4f9e12" xlink:to="loc_srt_SegmentGeographicalDomain_532c44df-ed6d-4a4b-90bb-1e2f6727031b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ChicagoMember_f4c72208-f97c-49dc-8788-44822a5e8fb9" xlink:href="xcur-20210930.xsd#xcur_ChicagoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_532c44df-ed6d-4a4b-90bb-1e2f6727031b" xlink:to="loc_xcur_ChicagoMember_f4c72208-f97c-49dc-8788-44822a5e8fb9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#StockholdersEquityCommonStockWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails" xlink:type="extended" id="i2caaab0ab3084ff68c211f17a42c570b_StockholdersEquityCommonStockWarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_ed94bef4-f89c-4ab4-86e8-ce46a9de1a72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_d1368db8-2b5b-45e4-8319-9d0613d67049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ed94bef4-f89c-4ab4-86e8-ce46a9de1a72" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_d1368db8-2b5b-45e4-8319-9d0613d67049" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c17358fe-d896-4a2c-a040-ddc9e149d8da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ed94bef4-f89c-4ab4-86e8-ce46a9de1a72" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c17358fe-d896-4a2c-a040-ddc9e149d8da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ClassofWarrantorRightExpired_bd97811c-6598-404c-b72b-b85b7c9f932f" xlink:href="xcur-20210930.xsd#xcur_ClassofWarrantorRightExpired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ed94bef4-f89c-4ab4-86e8-ce46a9de1a72" xlink:to="loc_xcur_ClassofWarrantorRightExpired_bd97811c-6598-404c-b72b-b85b7c9f932f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_5dc30d14-4ea4-4ee1-a34c-1f2371e95553" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ed94bef4-f89c-4ab4-86e8-ce46a9de1a72" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_5dc30d14-4ea4-4ee1-a34c-1f2371e95553" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_bd9fea73-5024-4f05-b39f-eb28c57287ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_5dc30d14-4ea4-4ee1-a34c-1f2371e95553" xlink:to="loc_us-gaap_StatementClassOfStockAxis_bd9fea73-5024-4f05-b39f-eb28c57287ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_bd9fea73-5024-4f05-b39f-eb28c57287ca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_bd9fea73-5024-4f05-b39f-eb28c57287ca" xlink:to="loc_us-gaap_ClassOfStockDomain_bd9fea73-5024-4f05-b39f-eb28c57287ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ccc30b79-a9c9-476a-9eeb-aef21273a66a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_bd9fea73-5024-4f05-b39f-eb28c57287ca" xlink:to="loc_us-gaap_ClassOfStockDomain_ccc30b79-a9c9-476a-9eeb-aef21273a66a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_88a961a9-2829-48db-bd95-74d1e3993590" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ccc30b79-a9c9-476a-9eeb-aef21273a66a" xlink:to="loc_us-gaap_CommonStockMember_88a961a9-2829-48db-bd95-74d1e3993590" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#StockholdersEquityAccumulatedOtherComprehensiveLossDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails" xlink:type="extended" id="if3441099ee2345a6a2906a4545f6bf65_StockholdersEquityAccumulatedOtherComprehensiveLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_c00d04a7-0689-4267-967e-1be9301fb58e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_e658b9f3-6edd-4781-95af-4d5a170dea3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_c00d04a7-0689-4267-967e-1be9301fb58e" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_e658b9f3-6edd-4781-95af-4d5a170dea3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_27f833dd-0123-4398-8b3a-4f20cb6f7a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_e658b9f3-6edd-4781-95af-4d5a170dea3a" xlink:to="loc_us-gaap_StockholdersEquity_27f833dd-0123-4398-8b3a-4f20cb6f7a3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_da76d413-92f9-4b1b-a3ef-7343151de7de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_e658b9f3-6edd-4781-95af-4d5a170dea3a" xlink:to="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_da76d413-92f9-4b1b-a3ef-7343151de7de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_4810f0fb-4547-4721-b2b8-4cbc0891f730" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_e658b9f3-6edd-4781-95af-4d5a170dea3a" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_4810f0fb-4547-4721-b2b8-4cbc0891f730" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3168a9a5-dac0-44c1-b683-a2cb48a0412a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_e658b9f3-6edd-4781-95af-4d5a170dea3a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3168a9a5-dac0-44c1-b683-a2cb48a0412a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0d338c08-b62a-4dce-afc6-1fe7482679e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_07f53aef-b95e-496b-b010-97167abe4aba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_c00d04a7-0689-4267-967e-1be9301fb58e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_07f53aef-b95e-496b-b010-97167abe4aba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_8e4319e2-bd1f-4837-b825-ba0645b7a30c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_c00d04a7-0689-4267-967e-1be9301fb58e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_8e4319e2-bd1f-4837-b825-ba0645b7a30c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_025b6c78-97ef-4147-8f86-5ba3596e2d87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_c00d04a7-0689-4267-967e-1be9301fb58e" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_025b6c78-97ef-4147-8f86-5ba3596e2d87" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_6f559d27-055b-4c27-8ac0-e144d4289097" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_c00d04a7-0689-4267-967e-1be9301fb58e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_6f559d27-055b-4c27-8ac0-e144d4289097" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_cbe860e5-fd49-4347-a035-3d4658e95591" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_6f559d27-055b-4c27-8ac0-e144d4289097" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_cbe860e5-fd49-4347-a035-3d4658e95591" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cbe860e5-fd49-4347-a035-3d4658e95591_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cbe860e5-fd49-4347-a035-3d4658e95591" xlink:to="loc_us-gaap_EquityComponentDomain_cbe860e5-fd49-4347-a035-3d4658e95591_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1404c391-190c-44f5-be4e-367cadb40c56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cbe860e5-fd49-4347-a035-3d4658e95591" xlink:to="loc_us-gaap_EquityComponentDomain_1404c391-190c-44f5-be4e-367cadb40c56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_22b1038d-9f3b-4481-82d3-2acc771bdde0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1404c391-190c-44f5-be4e-367cadb40c56" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_22b1038d-9f3b-4481-82d3-2acc771bdde0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_edf0d563-0cff-44c5-ae93-22f5fce8ca8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1404c391-190c-44f5-be4e-367cadb40c56" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_edf0d563-0cff-44c5-ae93-22f5fce8ca8f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#EquityBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" xlink:type="extended" id="i08c81712b7074ac5a54e43d219d53771_EquityBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02949e86-86d4-4061-90a8-eddd53480274" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares_abb4c7d7-963b-48c4-a7dc-d11d67b15464" xlink:href="xcur-20210930.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02949e86-86d4-4061-90a8-eddd53480274" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares_abb4c7d7-963b-48c4-a7dc-d11d67b15464" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding_f3e5d3d2-d01d-49b6-9b7f-a06ca9576328" xlink:href="xcur-20210930.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02949e86-86d4-4061-90a8-eddd53480274" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding_f3e5d3d2-d01d-49b6-9b7f-a06ca9576328" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant_d1dddeae-2370-4856-ad0f-d55ac96dbfad" xlink:href="xcur-20210930.xsd#xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02949e86-86d4-4061-90a8-eddd53480274" xlink:to="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant_d1dddeae-2370-4856-ad0f-d55ac96dbfad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2d4a22b6-702c-4021-af13-21ca213607cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02949e86-86d4-4061-90a8-eddd53480274" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2d4a22b6-702c-4021-af13-21ca213607cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_35e843e9-1928-4ea1-92e3-0039fb8dc643" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02949e86-86d4-4061-90a8-eddd53480274" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_35e843e9-1928-4ea1-92e3-0039fb8dc643" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_575fa083-49a1-422c-b95d-50317a91d78e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02949e86-86d4-4061-90a8-eddd53480274" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_575fa083-49a1-422c-b95d-50317a91d78e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_4bcaba96-7ad5-4bc4-8d85-66165af10f36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02949e86-86d4-4061-90a8-eddd53480274" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_4bcaba96-7ad5-4bc4-8d85-66165af10f36" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_c8f685b0-06fa-4f88-8691-3f27747fff8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02949e86-86d4-4061-90a8-eddd53480274" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_c8f685b0-06fa-4f88-8691-3f27747fff8a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_62210925-4167-44f2-97c1-bb36334a814a" xlink:href="xcur-20210930.xsd#xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02949e86-86d4-4061-90a8-eddd53480274" xlink:to="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_62210925-4167-44f2-97c1-bb36334a814a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_10a0f0d1-d59e-4f26-8cb1-da45c88783c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02949e86-86d4-4061-90a8-eddd53480274" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_10a0f0d1-d59e-4f26-8cb1-da45c88783c2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_e3a45df3-848c-4d12-9c29-1f59a189b7b6" xlink:href="xcur-20210930.xsd#xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02949e86-86d4-4061-90a8-eddd53480274" xlink:to="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_e3a45df3-848c-4d12-9c29-1f59a189b7b6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_bb0e09cb-4cf2-4f18-8d48-4ed23a79f51d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02949e86-86d4-4061-90a8-eddd53480274" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_bb0e09cb-4cf2-4f18-8d48-4ed23a79f51d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_611571d0-8a2c-469f-92f4-695332838392" xlink:href="xcur-20210930.xsd#xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02949e86-86d4-4061-90a8-eddd53480274" xlink:to="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_611571d0-8a2c-469f-92f4-695332838392" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_710de42a-be30-463f-9cf9-122811437ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02949e86-86d4-4061-90a8-eddd53480274" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_710de42a-be30-463f-9cf9-122811437ea3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1bb6957c-fd76-4a69-a91a-c877be391a97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02949e86-86d4-4061-90a8-eddd53480274" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1bb6957c-fd76-4a69-a91a-c877be391a97" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_da02cea5-3402-4b72-888b-630cf013bda2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02949e86-86d4-4061-90a8-eddd53480274" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_da02cea5-3402-4b72-888b-630cf013bda2" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_53a424c5-b062-499d-9edd-f87ce3a6ff86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02949e86-86d4-4061-90a8-eddd53480274" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_53a424c5-b062-499d-9edd-f87ce3a6ff86" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_602701be-51b5-4ddf-9ced-a471aee23945" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02949e86-86d4-4061-90a8-eddd53480274" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_602701be-51b5-4ddf-9ced-a471aee23945" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting_8fa0d7ba-cf25-4874-bdb7-6f06912cd920" xlink:href="xcur-20210930.xsd#xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02949e86-86d4-4061-90a8-eddd53480274" xlink:to="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting_8fa0d7ba-cf25-4874-bdb7-6f06912cd920" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_bff66e1a-bd5f-4aa0-b26c-5afdb6ed0551" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02949e86-86d4-4061-90a8-eddd53480274" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_bff66e1a-bd5f-4aa0-b26c-5afdb6ed0551" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e6bf4706-c646-4119-b48f-0c5e9610074b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02949e86-86d4-4061-90a8-eddd53480274" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e6bf4706-c646-4119-b48f-0c5e9610074b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_956a4256-79b5-4f99-a5e4-928be4ea581e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e6bf4706-c646-4119-b48f-0c5e9610074b" xlink:to="loc_us-gaap_AwardTypeAxis_956a4256-79b5-4f99-a5e4-928be4ea581e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_956a4256-79b5-4f99-a5e4-928be4ea581e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_956a4256-79b5-4f99-a5e4-928be4ea581e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_956a4256-79b5-4f99-a5e4-928be4ea581e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d25263d3-5b54-4b70-8cb3-3ad68fa6063e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_956a4256-79b5-4f99-a5e4-928be4ea581e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d25263d3-5b54-4b70-8cb3-3ad68fa6063e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d96c801b-e702-4ce8-8871-f9fa52c5cd6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d25263d3-5b54-4b70-8cb3-3ad68fa6063e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d96c801b-e702-4ce8-8871-f9fa52c5cd6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_cbb0c4b7-76eb-461d-a02c-9253e496f839" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d25263d3-5b54-4b70-8cb3-3ad68fa6063e" xlink:to="loc_us-gaap_EmployeeStockMember_cbb0c4b7-76eb-461d-a02c-9253e496f839" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_fa1bce99-ec12-4b11-a05c-81db43b4d422" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d25263d3-5b54-4b70-8cb3-3ad68fa6063e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_fa1bce99-ec12-4b11-a05c-81db43b4d422" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_3bdc3164-bbb9-4d4a-b04c-124763624eae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e6bf4706-c646-4119-b48f-0c5e9610074b" xlink:to="loc_us-gaap_PlanNameAxis_3bdc3164-bbb9-4d4a-b04c-124763624eae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3bdc3164-bbb9-4d4a-b04c-124763624eae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_3bdc3164-bbb9-4d4a-b04c-124763624eae" xlink:to="loc_us-gaap_PlanNameDomain_3bdc3164-bbb9-4d4a-b04c-124763624eae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_1853fbc1-ae4c-41f6-85f2-28c81e7c2deb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_3bdc3164-bbb9-4d4a-b04c-124763624eae" xlink:to="loc_us-gaap_PlanNameDomain_1853fbc1-ae4c-41f6-85f2-28c81e7c2deb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ExicureInc.2017EquityIncentivePlanMember_3dbfdb50-d3e3-40e7-b27a-ef9b31dcc837" xlink:href="xcur-20210930.xsd#xcur_ExicureInc.2017EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1853fbc1-ae4c-41f6-85f2-28c81e7c2deb" xlink:to="loc_xcur_ExicureInc.2017EquityIncentivePlanMember_3dbfdb50-d3e3-40e7-b27a-ef9b31dcc837" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_7421dc56-2b08-4c8f-a7c0-b4e05430b0d0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e6bf4706-c646-4119-b48f-0c5e9610074b" xlink:to="loc_srt_TitleOfIndividualAxis_7421dc56-2b08-4c8f-a7c0-b4e05430b0d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7421dc56-2b08-4c8f-a7c0-b4e05430b0d0_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_7421dc56-2b08-4c8f-a7c0-b4e05430b0d0" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7421dc56-2b08-4c8f-a7c0-b4e05430b0d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_293aa914-2ee6-4370-905d-d96b0c26854f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_7421dc56-2b08-4c8f-a7c0-b4e05430b0d0" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_293aa914-2ee6-4370-905d-d96b0c26854f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefFinancialOfficerMember_afc56496-b849-4c27-b550-17bfb8814d9c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefFinancialOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_293aa914-2ee6-4370-905d-d96b0c26854f" xlink:to="loc_srt_ChiefFinancialOfficerMember_afc56496-b849-4c27-b550-17bfb8814d9c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationScheduleofCompensationExpenseDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#EquityBasedCompensationScheduleofCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationScheduleofCompensationExpenseDetails" xlink:type="extended" id="i093c250a7cad4cc59843bfcf02f83a10_EquityBasedCompensationScheduleofCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fee0e0d-2ebf-4ed4-8132-2cc2ff4683b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_8af9ac3d-d56b-4b6c-9fb4-1e19538194df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fee0e0d-2ebf-4ed4-8132-2cc2ff4683b2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_8af9ac3d-d56b-4b6c-9fb4-1e19538194df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be3ec500-b93f-4e5e-bd90-7ae73dd936cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fee0e0d-2ebf-4ed4-8132-2cc2ff4683b2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be3ec500-b93f-4e5e-bd90-7ae73dd936cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ef38ee43-6bb4-4190-839c-b25ae6d69dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be3ec500-b93f-4e5e-bd90-7ae73dd936cc" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ef38ee43-6bb4-4190-839c-b25ae6d69dc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ef38ee43-6bb4-4190-839c-b25ae6d69dc8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ef38ee43-6bb4-4190-839c-b25ae6d69dc8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ef38ee43-6bb4-4190-839c-b25ae6d69dc8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d2c7f48f-393e-4b04-bb83-0365118e6676" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ef38ee43-6bb4-4190-839c-b25ae6d69dc8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d2c7f48f-393e-4b04-bb83-0365118e6676" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_072e6797-4cb1-47fb-aa95-4866fb16ad57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d2c7f48f-393e-4b04-bb83-0365118e6676" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_072e6797-4cb1-47fb-aa95-4866fb16ad57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_5cd7a3f4-da44-4f78-8c79-934a1780880f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d2c7f48f-393e-4b04-bb83-0365118e6676" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_5cd7a3f4-da44-4f78-8c79-934a1780880f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails" xlink:type="extended" id="if13c43ab02d547f88a9f40aace59744d_EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_489a7105-a7a4-4d2d-9e91-0f2d60b63126" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b67723ae-818f-4a61-b838-fdd6e1b7ec60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_489a7105-a7a4-4d2d-9e91-0f2d60b63126" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b67723ae-818f-4a61-b838-fdd6e1b7ec60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_db8ef8e3-3d2b-415a-a63f-184c99cdbbb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_489a7105-a7a4-4d2d-9e91-0f2d60b63126" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_db8ef8e3-3d2b-415a-a63f-184c99cdbbb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_e8233eba-c06a-4209-9477-6e4bfb8bc3eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_489a7105-a7a4-4d2d-9e91-0f2d60b63126" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_e8233eba-c06a-4209-9477-6e4bfb8bc3eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ff363c8b-178d-49f1-ae89-3d0aa29cbf61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_489a7105-a7a4-4d2d-9e91-0f2d60b63126" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ff363c8b-178d-49f1-ae89-3d0aa29cbf61" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_1f651c0d-959a-4769-9eaa-84ed0f180d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_489a7105-a7a4-4d2d-9e91-0f2d60b63126" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_1f651c0d-959a-4769-9eaa-84ed0f180d9b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_7fc78707-6c6b-4d3a-b021-c7fb02382eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_489a7105-a7a4-4d2d-9e91-0f2d60b63126" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_7fc78707-6c6b-4d3a-b021-c7fb02382eb3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_3dd0b5cc-24fc-46f1-abf8-cd5c29b0b3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_489a7105-a7a4-4d2d-9e91-0f2d60b63126" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_3dd0b5cc-24fc-46f1-abf8-cd5c29b0b3ec" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_d7c4fa89-8d71-4396-b40f-6ad947763610" xlink:href="xcur-20210930.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_489a7105-a7a4-4d2d-9e91-0f2d60b63126" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_d7c4fa89-8d71-4396-b40f-6ad947763610" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_93edc795-8e43-4608-8682-d62902a0c5af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_489a7105-a7a4-4d2d-9e91-0f2d60b63126" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_93edc795-8e43-4608-8682-d62902a0c5af" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f546cead-b6a4-4b0d-b708-d36648f273f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_489a7105-a7a4-4d2d-9e91-0f2d60b63126" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f546cead-b6a4-4b0d-b708-d36648f273f7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_094c1172-582c-4851-8a8e-f1b65ce8a7d1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f546cead-b6a4-4b0d-b708-d36648f273f7" xlink:to="loc_srt_RangeAxis_094c1172-582c-4851-8a8e-f1b65ce8a7d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_094c1172-582c-4851-8a8e-f1b65ce8a7d1_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_094c1172-582c-4851-8a8e-f1b65ce8a7d1" xlink:to="loc_srt_RangeMember_094c1172-582c-4851-8a8e-f1b65ce8a7d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_48327ade-724f-44c8-be6d-86b5107f5d78" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_094c1172-582c-4851-8a8e-f1b65ce8a7d1" xlink:to="loc_srt_RangeMember_48327ade-724f-44c8-be6d-86b5107f5d78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_28dad1b7-2daf-4c75-8a83-65d92f5d4280" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_48327ade-724f-44c8-be6d-86b5107f5d78" xlink:to="loc_srt_MinimumMember_28dad1b7-2daf-4c75-8a83-65d92f5d4280" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_34366ce2-0248-41ce-ae2f-5bd5b7292f04" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_48327ade-724f-44c8-be6d-86b5107f5d78" xlink:to="loc_srt_MaximumMember_34366ce2-0248-41ce-ae2f-5bd5b7292f04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_8837419d-b242-4f8b-be91-524d4eea50d7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_48327ade-724f-44c8-be6d-86b5107f5d78" xlink:to="loc_srt_WeightedAverageMember_8837419d-b242-4f8b-be91-524d4eea50d7" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails" xlink:type="extended" id="idca16b1c4e434affa09c81c7c5f24596_EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09defaf0-776d-4c80-91b6-c0b60139d9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_84ce78f7-6148-421e-8ac6-d107397df258" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09defaf0-776d-4c80-91b6-c0b60139d9bb" xlink:to="loc_us-gaap_SharePrice_84ce78f7-6148-421e-8ac6-d107397df258" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_5d84a6f5-db55-45a2-81b0-576ab00778a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09defaf0-776d-4c80-91b6-c0b60139d9bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_5d84a6f5-db55-45a2-81b0-576ab00778a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d27ec2b-f1a8-4479-9425-58b04afbc120" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09defaf0-776d-4c80-91b6-c0b60139d9bb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d27ec2b-f1a8-4479-9425-58b04afbc120" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2740d4c1-7f61-426a-a37f-b706465c1fe0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d27ec2b-f1a8-4479-9425-58b04afbc120" xlink:to="loc_srt_RangeAxis_2740d4c1-7f61-426a-a37f-b706465c1fe0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2740d4c1-7f61-426a-a37f-b706465c1fe0_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2740d4c1-7f61-426a-a37f-b706465c1fe0" xlink:to="loc_srt_RangeMember_2740d4c1-7f61-426a-a37f-b706465c1fe0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_52bf40c0-48ec-4b7d-96ff-f670a09eed55" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2740d4c1-7f61-426a-a37f-b706465c1fe0" xlink:to="loc_srt_RangeMember_52bf40c0-48ec-4b7d-96ff-f670a09eed55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4a1568d4-b5f3-4ee0-b75c-1de4e392e947" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_52bf40c0-48ec-4b7d-96ff-f670a09eed55" xlink:to="loc_srt_MinimumMember_4a1568d4-b5f3-4ee0-b75c-1de4e392e947" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2829fa45-3526-4dc1-af06-89c4720b3c34" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_52bf40c0-48ec-4b7d-96ff-f670a09eed55" xlink:to="loc_srt_MaximumMember_2829fa45-3526-4dc1-af06-89c4720b3c34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_c9534358-9aa4-4c48-a83c-316f9c71e556" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_52bf40c0-48ec-4b7d-96ff-f670a09eed55" xlink:to="loc_srt_WeightedAverageMember_c9534358-9aa4-4c48-a83c-316f9c71e556" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationRSUActivityDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#EquityBasedCompensationRSUActivityDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationRSUActivityDetails" xlink:type="extended" id="i409ece760581491f958a97164da08785_EquityBasedCompensationRSUActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_975e45fd-e1ca-4637-831b-557ce07ec8c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_b03395c2-aba0-4265-af0e-2759c6293e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_975e45fd-e1ca-4637-831b-557ce07ec8c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_b03395c2-aba0-4265-af0e-2759c6293e0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b98acb5f-e6a9-4951-b607-e3366662f9fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_b03395c2-aba0-4265-af0e-2759c6293e0d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b98acb5f-e6a9-4951-b607-e3366662f9fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8b9ee2e0-49b0-41b6-ab55-db9080cfe23a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_b03395c2-aba0-4265-af0e-2759c6293e0d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8b9ee2e0-49b0-41b6-ab55-db9080cfe23a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_78ce8b4c-6e60-49dc-a9e9-32f6bb118bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_b03395c2-aba0-4265-af0e-2759c6293e0d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_78ce8b4c-6e60-49dc-a9e9-32f6bb118bf8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0c114a20-53aa-4140-8200-58c2de5d232d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_b03395c2-aba0-4265-af0e-2759c6293e0d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0c114a20-53aa-4140-8200-58c2de5d232d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_42d621cf-7da5-46aa-8528-2c8dbbabe943" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_174d70e3-6603-4d29-afe8-d459105ee0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_975e45fd-e1ca-4637-831b-557ce07ec8c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_174d70e3-6603-4d29-afe8-d459105ee0a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_43e525fa-bdb2-42a6-b6fd-4b859f976f32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_174d70e3-6603-4d29-afe8-d459105ee0a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_43e525fa-bdb2-42a6-b6fd-4b859f976f32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_78a80b78-4387-46d6-b81b-3ed1e66617c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_174d70e3-6603-4d29-afe8-d459105ee0a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_78a80b78-4387-46d6-b81b-3ed1e66617c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_670c98c2-0060-411a-9aa1-ae0e87bf35c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_174d70e3-6603-4d29-afe8-d459105ee0a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_670c98c2-0060-411a-9aa1-ae0e87bf35c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4abc284e-b53b-48b4-8ce3-5894da0d9f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_174d70e3-6603-4d29-afe8-d459105ee0a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4abc284e-b53b-48b4-8ce3-5894da0d9f6e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d5d90f83-aa1a-4323-b4e4-bbee94c02a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d98c603-b2a1-4d6a-bcc8-6ecfd14bce98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_975e45fd-e1ca-4637-831b-557ce07ec8c5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d98c603-b2a1-4d6a-bcc8-6ecfd14bce98" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_fa198179-b5ad-4430-89c1-e920e52d0217" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d98c603-b2a1-4d6a-bcc8-6ecfd14bce98" xlink:to="loc_us-gaap_AwardTypeAxis_fa198179-b5ad-4430-89c1-e920e52d0217" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fa198179-b5ad-4430-89c1-e920e52d0217_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_fa198179-b5ad-4430-89c1-e920e52d0217" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fa198179-b5ad-4430-89c1-e920e52d0217_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_acd94516-68b1-44f2-ac2e-b59cef82e783" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_fa198179-b5ad-4430-89c1-e920e52d0217" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_acd94516-68b1-44f2-ac2e-b59cef82e783" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b64b9e2e-8e94-47e9-804c-bf550a61f362" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_acd94516-68b1-44f2-ac2e-b59cef82e783" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b64b9e2e-8e94-47e9-804c-bf550a61f362" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#LossPerCommonShareAntidilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="extended" id="i255f38094f7244d383b3d1ac6217d92b_LossPerCommonShareAntidilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_df34eb60-76d6-4cf1-bc39-4ccbfb080614" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9519419b-abf7-45ec-b78f-44506efb3b25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_df34eb60-76d6-4cf1-bc39-4ccbfb080614" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9519419b-abf7-45ec-b78f-44506efb3b25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_95e4fe9d-75bf-4eaf-9215-f34a7d2e5ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_df34eb60-76d6-4cf1-bc39-4ccbfb080614" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_95e4fe9d-75bf-4eaf-9215-f34a7d2e5ed0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c0d13473-efb6-4f58-9147-a58c7f1a462b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_95e4fe9d-75bf-4eaf-9215-f34a7d2e5ed0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c0d13473-efb6-4f58-9147-a58c7f1a462b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c0d13473-efb6-4f58-9147-a58c7f1a462b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c0d13473-efb6-4f58-9147-a58c7f1a462b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c0d13473-efb6-4f58-9147-a58c7f1a462b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_edfdb8d8-cdfc-453c-82e3-821f54af6cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c0d13473-efb6-4f58-9147-a58c7f1a462b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_edfdb8d8-cdfc-453c-82e3-821f54af6cc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a77c3ff7-b50f-4bad-8106-2559369ac9e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_edfdb8d8-cdfc-453c-82e3-821f54af6cc5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a77c3ff7-b50f-4bad-8106-2559369ac9e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_9b93539e-114e-4170-a8a2-24cb42d25845" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_edfdb8d8-cdfc-453c-82e3-821f54af6cc5" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_9b93539e-114e-4170-a8a2-24cb42d25845" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_37c13a68-ca86-4bae-bf4a-6f0b27e49087" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_edfdb8d8-cdfc-453c-82e3-821f54af6cc5" xlink:to="loc_us-gaap_WarrantMember_37c13a68-ca86-4bae-bf4a-6f0b27e49087" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended" id="i9a4ad011cdea4439abf6c252ebbb7769_FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b4d27005-4366-486b-9c32-574d267f48a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_446a1d4e-e23e-4a08-89ff-8b42607749c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b4d27005-4366-486b-9c32-574d267f48a9" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_446a1d4e-e23e-4a08-89ff-8b42607749c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1e9a6a5a-01aa-4c5a-a7e2-ac8059c50802" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b4d27005-4366-486b-9c32-574d267f48a9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1e9a6a5a-01aa-4c5a-a7e2-ac8059c50802" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_e8b28ef0-6cee-40ba-b4b6-5322fb9d1951" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b4d27005-4366-486b-9c32-574d267f48a9" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_e8b28ef0-6cee-40ba-b4b6-5322fb9d1951" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CommonStockWarrantLiabilityFairValueDisclosure_c0e86f32-7bbc-476f-b33d-919da167e08e" xlink:href="xcur-20210930.xsd#xcur_CommonStockWarrantLiabilityFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b4d27005-4366-486b-9c32-574d267f48a9" xlink:to="loc_xcur_CommonStockWarrantLiabilityFairValueDisclosure_c0e86f32-7bbc-476f-b33d-919da167e08e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_95f5baab-470d-4906-ab8a-9fff72810d91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b4d27005-4366-486b-9c32-574d267f48a9" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_95f5baab-470d-4906-ab8a-9fff72810d91" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ddfca826-dbc2-4574-bded-0bd42a565b50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b4d27005-4366-486b-9c32-574d267f48a9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ddfca826-dbc2-4574-bded-0bd42a565b50" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_335976ba-d2d3-4db3-a550-acf36bffa597" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ddfca826-dbc2-4574-bded-0bd42a565b50" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_335976ba-d2d3-4db3-a550-acf36bffa597" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_335976ba-d2d3-4db3-a550-acf36bffa597_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_335976ba-d2d3-4db3-a550-acf36bffa597" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_335976ba-d2d3-4db3-a550-acf36bffa597_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0dfae113-525b-40fb-90a4-16e3d872cfa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_335976ba-d2d3-4db3-a550-acf36bffa597" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0dfae113-525b-40fb-90a4-16e3d872cfa7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_f4166ec1-f503-4ed9-9d8c-94000d5f99b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0dfae113-525b-40fb-90a4-16e3d872cfa7" xlink:to="loc_us-gaap_MoneyMarketFundsMember_f4166ec1-f503-4ed9-9d8c-94000d5f99b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_5f4af087-6596-4276-a90f-28ebdbd23dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0dfae113-525b-40fb-90a4-16e3d872cfa7" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_5f4af087-6596-4276-a90f-28ebdbd23dc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_b6bb5f9d-6b94-404c-83a5-440c889b723e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0dfae113-525b-40fb-90a4-16e3d872cfa7" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_b6bb5f9d-6b94-404c-83a5-440c889b723e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d609ae64-462d-49fc-9139-24ca951f1dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ddfca826-dbc2-4574-bded-0bd42a565b50" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d609ae64-462d-49fc-9139-24ca951f1dc8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d609ae64-462d-49fc-9139-24ca951f1dc8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d609ae64-462d-49fc-9139-24ca951f1dc8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d609ae64-462d-49fc-9139-24ca951f1dc8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f7ae1264-d032-4c00-b73c-fe4ef558f929" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d609ae64-462d-49fc-9139-24ca951f1dc8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f7ae1264-d032-4c00-b73c-fe4ef558f929" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_71a93610-4972-4da4-b408-da51bb0f056d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f7ae1264-d032-4c00-b73c-fe4ef558f929" xlink:to="loc_us-gaap_CommercialPaperMember_71a93610-4972-4da4-b408-da51bb0f056d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_d5b8accb-f495-4488-9007-8e0602229993" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f7ae1264-d032-4c00-b73c-fe4ef558f929" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_d5b8accb-f495-4488-9007-8e0602229993" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_43caa640-6ce4-4faa-a3aa-a24026b1dc4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f7ae1264-d032-4c00-b73c-fe4ef558f929" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_43caa640-6ce4-4faa-a3aa-a24026b1dc4e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_ce33a896-5c1c-4ea3-9040-506b01e5b44e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f7ae1264-d032-4c00-b73c-fe4ef558f929" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_ce33a896-5c1c-4ea3-9040-506b01e5b44e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c05a4828-5cb7-4f16-a5f5-fb9cff81e38a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ddfca826-dbc2-4574-bded-0bd42a565b50" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c05a4828-5cb7-4f16-a5f5-fb9cff81e38a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c05a4828-5cb7-4f16-a5f5-fb9cff81e38a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c05a4828-5cb7-4f16-a5f5-fb9cff81e38a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c05a4828-5cb7-4f16-a5f5-fb9cff81e38a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5cd864ed-5999-49b8-96b5-1a6f68305730" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c05a4828-5cb7-4f16-a5f5-fb9cff81e38a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5cd864ed-5999-49b8-96b5-1a6f68305730" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_99b65e3d-6979-49ce-8f1e-1abf905ddf7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_5cd864ed-5999-49b8-96b5-1a6f68305730" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_99b65e3d-6979-49ce-8f1e-1abf905ddf7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ae772053-f8fa-4f87-94ff-4ac56440e3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ddfca826-dbc2-4574-bded-0bd42a565b50" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ae772053-f8fa-4f87-94ff-4ac56440e3ac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ae772053-f8fa-4f87-94ff-4ac56440e3ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ae772053-f8fa-4f87-94ff-4ac56440e3ac" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ae772053-f8fa-4f87-94ff-4ac56440e3ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3681e950-bf1c-4383-ac27-42978581a0d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ae772053-f8fa-4f87-94ff-4ac56440e3ac" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3681e950-bf1c-4383-ac27-42978581a0d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_7d3bcb02-e26d-4eb0-b28c-eff262c04d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3681e950-bf1c-4383-ac27-42978581a0d5" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_7d3bcb02-e26d-4eb0-b28c-eff262c04d9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_88b0e7f3-0f71-4f7b-9def-449ede8a4ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3681e950-bf1c-4383-ac27-42978581a0d5" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_88b0e7f3-0f71-4f7b-9def-449ede8a4ac0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1279b0bc-62bd-45f6-b844-7d3a6c1e1d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3681e950-bf1c-4383-ac27-42978581a0d5" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1279b0bc-62bd-45f6-b844-7d3a6c1e1d4a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" id="i8cb091bb09cc4ca9b3f4c23567bfe5c8_FairValueMeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fbaa731a-77cc-40e3-bbb4-e7986f9bc361" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_1d702b49-37a2-4d68-9200-a1e8eb36cbbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fbaa731a-77cc-40e3-bbb4-e7986f9bc361" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_1d702b49-37a2-4d68-9200-a1e8eb36cbbe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_5191c01d-a988-43d2-8707-6db5e0e7db49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fbaa731a-77cc-40e3-bbb4-e7986f9bc361" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_5191c01d-a988-43d2-8707-6db5e0e7db49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_381ac895-0b1a-4e21-aeaf-eec92baea163" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fbaa731a-77cc-40e3-bbb4-e7986f9bc361" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_381ac895-0b1a-4e21-aeaf-eec92baea163" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_64e06c85-6e9b-4ed6-84b2-90d2ebdc4f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_381ac895-0b1a-4e21-aeaf-eec92baea163" xlink:to="loc_us-gaap_StatementClassOfStockAxis_64e06c85-6e9b-4ed6-84b2-90d2ebdc4f1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_64e06c85-6e9b-4ed6-84b2-90d2ebdc4f1e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_64e06c85-6e9b-4ed6-84b2-90d2ebdc4f1e" xlink:to="loc_us-gaap_ClassOfStockDomain_64e06c85-6e9b-4ed6-84b2-90d2ebdc4f1e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_997c3485-5a50-4d12-91f6-7197803ed572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_64e06c85-6e9b-4ed6-84b2-90d2ebdc4f1e" xlink:to="loc_us-gaap_ClassOfStockDomain_997c3485-5a50-4d12-91f6-7197803ed572" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_76c7d31f-2993-4a02-afbc-1869af84a4e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_997c3485-5a50-4d12-91f6-7197803ed572" xlink:to="loc_us-gaap_CommonStockMember_76c7d31f-2993-4a02-afbc-1869af84a4e7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended" id="i8b2cf4f0a18a40a489945f34a73695e3_FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_b27fe806-da43-4189-8a12-99022ccb4b99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e1d65760-ecc9-4154-b514-35355e9cd518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_b27fe806-da43-4189-8a12-99022ccb4b99" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e1d65760-ecc9-4154-b514-35355e9cd518" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_d23ba965-9ddc-4c87-ab49-83f5f1c284be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e1d65760-ecc9-4154-b514-35355e9cd518" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_d23ba965-9ddc-4c87-ab49-83f5f1c284be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_6bede204-0879-4905-b28a-8c412971d173" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e1d65760-ecc9-4154-b514-35355e9cd518" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_6bede204-0879-4905-b28a-8c412971d173" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_d1913b3b-ad1d-4124-bdae-c904ccf66d45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e1d65760-ecc9-4154-b514-35355e9cd518" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_d1913b3b-ad1d-4124-bdae-c904ccf66d45" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_eb4f1cae-b5f1-460f-a48b-b17c1f672102" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e533adba-79a3-4933-b88f-37f78018a815" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_b27fe806-da43-4189-8a12-99022ccb4b99" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e533adba-79a3-4933-b88f-37f78018a815" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7cb1b87f-3bc8-4461-8ffc-2750fc8fab87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e533adba-79a3-4933-b88f-37f78018a815" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7cb1b87f-3bc8-4461-8ffc-2750fc8fab87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7cb1b87f-3bc8-4461-8ffc-2750fc8fab87_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7cb1b87f-3bc8-4461-8ffc-2750fc8fab87" xlink:to="loc_us-gaap_ClassOfStockDomain_7cb1b87f-3bc8-4461-8ffc-2750fc8fab87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3b6e1001-edb7-49ac-8561-03e08e8d875b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7cb1b87f-3bc8-4461-8ffc-2750fc8fab87" xlink:to="loc_us-gaap_ClassOfStockDomain_3b6e1001-edb7-49ac-8561-03e08e8d875b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2fe9fcec-aa7b-44aa-a4ae-35bde9d67b98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3b6e1001-edb7-49ac-8561-03e08e8d875b" xlink:to="loc_us-gaap_CommonStockMember_2fe9fcec-aa7b-44aa-a4ae-35bde9d67b98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_d5ade988-c2be-4cd5-a5d2-38d1f129c0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e533adba-79a3-4933-b88f-37f78018a815" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_d5ade988-c2be-4cd5-a5d2-38d1f129c0a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_d5ade988-c2be-4cd5-a5d2-38d1f129c0a7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_d5ade988-c2be-4cd5-a5d2-38d1f129c0a7" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_d5ade988-c2be-4cd5-a5d2-38d1f129c0a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ef9127f1-0c2d-4bc8-a671-facb6bf3704a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_d5ade988-c2be-4cd5-a5d2-38d1f129c0a7" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ef9127f1-0c2d-4bc8-a671-facb6bf3704a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_WarrantLiabilityMember_b24b73b2-acdd-4620-8f12-d0b5df770ce0" xlink:href="xcur-20210930.xsd#xcur_WarrantLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ef9127f1-0c2d-4bc8-a671-facb6bf3704a" xlink:to="loc_xcur_WarrantLiabilityMember_b24b73b2-acdd-4620-8f12-d0b5df770ce0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.exicuretx.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" id="ied7dce51fd444937be4a065a5a9eb41d_RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_6aeac265-e63a-4c28-8c49-97de24c90a11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_57b0d5d3-b14f-4b7f-be66-e8e806d79ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6aeac265-e63a-4c28-8c49-97de24c90a11" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_57b0d5d3-b14f-4b7f-be66-e8e806d79ffe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c2ca1802-2b3c-498c-b894-49313a9866e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6aeac265-e63a-4c28-8c49-97de24c90a11" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c2ca1802-2b3c-498c-b894-49313a9866e9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e9ea5841-bb3d-426a-bb2c-1d4ff851b805" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c2ca1802-2b3c-498c-b894-49313a9866e9" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e9ea5841-bb3d-426a-bb2c-1d4ff851b805" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e9ea5841-bb3d-426a-bb2c-1d4ff851b805_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e9ea5841-bb3d-426a-bb2c-1d4ff851b805" xlink:to="loc_us-gaap_RelatedPartyDomain_e9ea5841-bb3d-426a-bb2c-1d4ff851b805_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_176372ef-7be4-4a91-9968-ae66f2eb53ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e9ea5841-bb3d-426a-bb2c-1d4ff851b805" xlink:to="loc_us-gaap_RelatedPartyDomain_176372ef-7be4-4a91-9968-ae66f2eb53ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_28f2a35e-0bea-4ad0-936c-4bab65f56fee" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_176372ef-7be4-4a91-9968-ae66f2eb53ed" xlink:to="loc_srt_DirectorMember_28f2a35e-0bea-4ad0-936c-4bab65f56fee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_b1f872d0-a0f3-4297-847b-31bd7e5a144f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c2ca1802-2b3c-498c-b894-49313a9866e9" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_b1f872d0-a0f3-4297-847b-31bd7e5a144f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_b1f872d0-a0f3-4297-847b-31bd7e5a144f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_b1f872d0-a0f3-4297-847b-31bd7e5a144f" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_b1f872d0-a0f3-4297-847b-31bd7e5a144f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_d646a1dd-7deb-4151-ae75-c7ab4b373ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_b1f872d0-a0f3-4297-847b-31bd7e5a144f" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_d646a1dd-7deb-4151-ae75-c7ab4b373ec8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ConsultingServicesMember_c482a501-ac1a-4ab8-8e43-48fd03029c05" xlink:href="xcur-20210930.xsd#xcur_ConsultingServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_d646a1dd-7deb-4151-ae75-c7ab4b373ec8" xlink:to="loc_xcur_ConsultingServicesMember_c482a501-ac1a-4ab8-8e43-48fd03029c05" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>xcur-20210930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:ec2cf3ab-02c5-4899-a9f4-a2b651188a5f,g:ebea5fae-f5ab-4d4a-8517-3fed58ff79ef-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_e7a9550c-1eb6-414b-b6f9-5ed26029607a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on short-term investments</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_2694acf6-5169-47ca-916f-b763009b148e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_93cb1093-ff06-4cba-9618-22795e25186b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6080848e-895d-461d-8964-06389ded0d25_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_c2f36a7c-06d2-4569-ad18-f3e6a3e7523a_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_2e721d64-f6f2-493f-bf22-81aab18b3b36_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_e3754056-0188-4004-a38c-d0cb747a9db4_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_3e59d3fe-6edd-4c97-adbd-745fb9146bf4_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_6766948e-b7e2-4c9a-adf1-4821b9ec28aa_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_ed200742-c2a8-4242-9ade-d459deaadb80_terseLabel_en-US" xlink:label="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum contribution amount</link:label>
    <link:label id="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_label_en-US" xlink:label="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount</link:label>
    <link:label id="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_documentation_en-US" xlink:label="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:href="xcur-20210930.xsd#xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:to="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_d9bee876-4620-4610-9c43-db5949c89feb_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_2927b675-f17f-46a6-9967-56f9365c8981_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll-related expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_DebtSecuritiesAvailableForSaleCurrentPercent_36e7e9a0-ff77-4048-986c-50a626f1f2a8_terseLabel_en-US" xlink:label="lab_xcur_DebtSecuritiesAvailableForSaleCurrentPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One year or less</link:label>
    <link:label id="lab_xcur_DebtSecuritiesAvailableForSaleCurrentPercent_label_en-US" xlink:label="lab_xcur_DebtSecuritiesAvailableForSaleCurrentPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available For Sale, Current, Percent</link:label>
    <link:label id="lab_xcur_DebtSecuritiesAvailableForSaleCurrentPercent_documentation_en-US" xlink:label="lab_xcur_DebtSecuritiesAvailableForSaleCurrentPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available For Sale, Current, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DebtSecuritiesAvailableForSaleCurrentPercent" xlink:href="xcur-20210930.xsd#xcur_DebtSecuritiesAvailableForSaleCurrentPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_DebtSecuritiesAvailableForSaleCurrentPercent" xlink:to="lab_xcur_DebtSecuritiesAvailableForSaleCurrentPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_c0d06494-3fae-46f1-b431-cace5b993e7d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_a876cb92-f452-41d7-b552-4e424e8c8535_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_dbdfd08f-71ef-4c0d-8898-411b5de901c1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_eb85787d-59f8-4144-8142-d897d30b42c2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Maturities of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b7245e95-61f2-47fc-a44a-5ba287a15ea0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_335b6fbc-5c13-44bf-93a7-959f968b5246_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum number of shares per employee in purchase period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_1681b8b8-7363-4032-b9e1-ec6fe9a798dc_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Of The Company's Contract Liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_d09939d9-ff28-47f2-8442-725a009c1f9b_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_96696f8d-352d-4e7f-b4f6-96ed6b52ef1e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_56ad6cdc-e72c-40a2-831a-2af3587f44ce_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_03231ccb-ba55-4909-9888-1330d6127c6f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b9d4826-70f3-49d6-a900-de488c2279b6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8b5b4a95-e1b9-4153-af1d-210bb25917a0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8dfd2681-aa80-4d39-90f9-31a1744d57e8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9d13b830-a442-4db8-8a89-f71e2791b0d3_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_73849191-4f01-48de-b6e1-d95a42b68ff6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_63584579-c137-4833-b5f7-076fd3f4de1e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_58f92e4d-b5ad-451f-b0b8-3e875e065178_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_57ea8cab-9bed-4534-bbd7-43a85a7882d6_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses from transactions with related party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c054ed85-f230-42d3-98b1-e5067c48537a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain included in other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0feacba3-a3d8-474c-a0c5-bc45a4751d5e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, stock options, exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_1f04b44f-8242-4890-8a2e-72fb89869d64_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale or maturity of available for sale securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_55e79c18-4cd8-4399-b2d3-b01180240f4c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_2ae97b83-8dd4-4906-863e-ed754686079e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 (remaining three months)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_ba5eb989-bc49-4bd8-a6e7-ae1b5ed156e0_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_PaymentsForDebtEndTermFees_9b3c5e2d-2e70-48f0-b760-f82a056434ec_terseLabel_en-US" xlink:label="lab_xcur_PaymentsForDebtEndTermFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for debt end term fees</link:label>
    <link:label id="lab_xcur_PaymentsForDebtEndTermFees_label_en-US" xlink:label="lab_xcur_PaymentsForDebtEndTermFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Debt End Term Fees</link:label>
    <link:label id="lab_xcur_PaymentsForDebtEndTermFees_documentation_en-US" xlink:label="lab_xcur_PaymentsForDebtEndTermFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Debt End Term Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_PaymentsForDebtEndTermFees" xlink:href="xcur-20210930.xsd#xcur_PaymentsForDebtEndTermFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_PaymentsForDebtEndTermFees" xlink:to="lab_xcur_PaymentsForDebtEndTermFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_87c11ab1-ba65-417e-be1b-8f18b5788044_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_dd283e46-d818-4ece-b2bd-fa06479a824e_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease costs</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_24fa6800-7bbc-46c5-baf7-08f24be396e2_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potentially dilutive shares excluded from computation of weighted-average diluted common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_40a08b33-43bd-4455-8718-e85c1597e585_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_3d89f261-af1e-4194-8f9b-0320a455d081_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_39f1c7d2-dffb-4d19-8205-9c38414dcdd3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_00a2129a-1fa7-4bb7-b813-c63c8ed25ffd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_CollaborationAgreementPerformanceObligationDomain_d16c78db-020d-44d9-865d-72c7da0c7f02_terseLabel_en-US" xlink:label="lab_xcur_CollaborationAgreementPerformanceObligationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Performance Obligation [Domain]</link:label>
    <link:label id="lab_xcur_CollaborationAgreementPerformanceObligationDomain_label_en-US" xlink:label="lab_xcur_CollaborationAgreementPerformanceObligationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Performance Obligation [Domain]</link:label>
    <link:label id="lab_xcur_CollaborationAgreementPerformanceObligationDomain_documentation_en-US" xlink:label="lab_xcur_CollaborationAgreementPerformanceObligationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Performance Obligation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementPerformanceObligationDomain" xlink:href="xcur-20210930.xsd#xcur_CollaborationAgreementPerformanceObligationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CollaborationAgreementPerformanceObligationDomain" xlink:to="lab_xcur_CollaborationAgreementPerformanceObligationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_97e664ac-b22e-4ca1-969f-c934758ac372_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_d74f6bb1-2a97-4ced-a8f2-d8e095cc3921_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (losses) gains on available for sale securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2cc1d6a-1b15-4284-b1d2-3335898b4f20_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_666372b4-eccd-400c-9098-12979d0e45d7_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_3663a407-9fc5-4456-af08-bcc6bfcb94b8_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_573bc7a1-2c83-4a80-8ab7-2d623c6aa1c1_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e568700c-1c36-4605-95d8-e4d24ef5fda1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_493463f7-577f-4c29-918d-cdc3ca28d77e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ResearchAndDevelopmentStaffOnSitePercentage_9a2172cf-1d33-41a2-baed-aa0c84181673_terseLabel_en-US" xlink:label="lab_xcur_ResearchAndDevelopmentStaffOnSitePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of R&amp;D staff on site</link:label>
    <link:label id="lab_xcur_ResearchAndDevelopmentStaffOnSitePercentage_label_en-US" xlink:label="lab_xcur_ResearchAndDevelopmentStaffOnSitePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Staff on Site, Percentage</link:label>
    <link:label id="lab_xcur_ResearchAndDevelopmentStaffOnSitePercentage_documentation_en-US" xlink:label="lab_xcur_ResearchAndDevelopmentStaffOnSitePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Staff on Site, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ResearchAndDevelopmentStaffOnSitePercentage" xlink:href="xcur-20210930.xsd#xcur_ResearchAndDevelopmentStaffOnSitePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ResearchAndDevelopmentStaffOnSitePercentage" xlink:to="lab_xcur_ResearchAndDevelopmentStaffOnSitePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_bd477d05-b0eb-46c2-a17e-fdb08b62bc07_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_a62ee6ff-070f-445e-a78c-091f92a5f0b6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, weighted-average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8088834d-a2e1-452e-ba37-a0575b99ac9d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_3aae6146-ad3e-4dd3-b155-441d7685f8e0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value per share; 10,000,000 shares authorized, no shares issued and outstanding, September&#160;30, 2021 and December&#160;31, 2020</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_15a750dc-f429-42d8-b4b1-8a925a219b53_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0b383cf4-92ef-482d-bd5d-e4672b3e0220_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9f8caab1-f3f3-4a03-930a-81989918f83e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_6f17c1eb-ac01-4fdc-af77-c4dcf53791b4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_05c72271-3c04-4eea-803e-ef2a0129edf4_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_acdbe003-ee49-4fcf-b51f-2ba52a96cf77_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ecbb2ebf-5e38-47af-bd05-13a728e7dd4e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e5d05167-a25e-4bb3-a1f4-9f27549c200f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3fe57a15-21c8-47f9-b94c-0a1feb5afb79_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_19ad97a2-aeeb-4d3c-bf01-8b8877baeafc_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from collaborators</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Collaborators</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollaborators" xlink:to="lab_us-gaap_ProceedsFromCollaborators" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1eb2d9f4-de6e-488a-b82f-6e7e98a81deb_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_980b2aae-070d-41d6-9dc7-57bf71acfe3c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_c6e504d9-2dea-4a75-9539-4d9727eaaa06_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_c5a98564-2963-4608-86e3-64f1f7255d1c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_4be415c1-992c-47f5-a3c3-19ea6261c42b_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures (accounts payable and accrued expenses)</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_AbbVieCollaborationMember_d6cee2d7-7ab4-463c-8d67-395453ac4b65_terseLabel_en-US" xlink:label="lab_xcur_AbbVieCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbbVie Collaboration</link:label>
    <link:label id="lab_xcur_AbbVieCollaborationMember_label_en-US" xlink:label="lab_xcur_AbbVieCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbbVie Collaboration [Member]</link:label>
    <link:label id="lab_xcur_AbbVieCollaborationMember_documentation_en-US" xlink:label="lab_xcur_AbbVieCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allergan Collaboration [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_AbbVieCollaborationMember" xlink:href="xcur-20210930.xsd#xcur_AbbVieCollaborationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_AbbVieCollaborationMember" xlink:to="lab_xcur_AbbVieCollaborationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_63896446-aada-43be-8b0e-296b34790885_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset acquired through operating leases</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_LesseeOperatingLeaseRentalPaymentAdjustedForAbatement_0cea54ba-2860-4a6e-8a8c-b5ca9e96b6aa_terseLabel_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseRentalPaymentAdjustedForAbatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental payment adjusted for abatement</link:label>
    <link:label id="lab_xcur_LesseeOperatingLeaseRentalPaymentAdjustedForAbatement_label_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseRentalPaymentAdjustedForAbatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Rental Payment Adjusted For Abatement</link:label>
    <link:label id="lab_xcur_LesseeOperatingLeaseRentalPaymentAdjustedForAbatement_documentation_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseRentalPaymentAdjustedForAbatement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Rental Payment Adjusted For Abatement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseRentalPaymentAdjustedForAbatement" xlink:href="xcur-20210930.xsd#xcur_LesseeOperatingLeaseRentalPaymentAdjustedForAbatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_LesseeOperatingLeaseRentalPaymentAdjustedForAbatement" xlink:to="lab_xcur_LesseeOperatingLeaseRentalPaymentAdjustedForAbatement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_3ae4c2c2-968a-4e21-829c-372df1bc91ea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum ESPP contribution rate as a percentage of compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_MidCapCreditAgreementMember_41fb5a98-3d2b-4c6b-9827-1b93109f83cb_terseLabel_en-US" xlink:label="lab_xcur_MidCapCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MidCap Credit Agreement</link:label>
    <link:label id="lab_xcur_MidCapCreditAgreementMember_label_en-US" xlink:label="lab_xcur_MidCapCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MidCap Credit Agreement [Member]</link:label>
    <link:label id="lab_xcur_MidCapCreditAgreementMember_documentation_en-US" xlink:label="lab_xcur_MidCapCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MidCap Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_MidCapCreditAgreementMember" xlink:href="xcur-20210930.xsd#xcur_MidCapCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_MidCapCreditAgreementMember" xlink:to="lab_xcur_MidCapCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_ddc98815-874a-4e22-9f8b-a5740fde6bc1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_669ecfa7-532f-421b-b18c-b22852d2d6ca_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_DebtInstrumentFundingConditionRequiredProceedsFromEquityIssuance_644ecb34-310b-4c71-86ab-a522bd280ad3_terseLabel_en-US" xlink:label="lab_xcur_DebtInstrumentFundingConditionRequiredProceedsFromEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding condition, required proceeds from equity issuance</link:label>
    <link:label id="lab_xcur_DebtInstrumentFundingConditionRequiredProceedsFromEquityIssuance_label_en-US" xlink:label="lab_xcur_DebtInstrumentFundingConditionRequiredProceedsFromEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Funding Condition, Required Proceeds From Equity Issuance</link:label>
    <link:label id="lab_xcur_DebtInstrumentFundingConditionRequiredProceedsFromEquityIssuance_documentation_en-US" xlink:label="lab_xcur_DebtInstrumentFundingConditionRequiredProceedsFromEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Funding Condition, Required Proceeds From Equity Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DebtInstrumentFundingConditionRequiredProceedsFromEquityIssuance" xlink:href="xcur-20210930.xsd#xcur_DebtInstrumentFundingConditionRequiredProceedsFromEquityIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_DebtInstrumentFundingConditionRequiredProceedsFromEquityIssuance" xlink:to="lab_xcur_DebtInstrumentFundingConditionRequiredProceedsFromEquityIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_caa86e50-a685-4c17-8d26-69d17065e3be_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_f3ad7e9f-46ac-46d9-9b7a-b0688f2a4db4_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_f3919ab8-d7c9-4816-8ad3-84ed9a0fe3a4_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (loss) earnings per common share (USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_56dde4e3-0ec4-4298-9474-30a8ff3ae874_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) earnings per basic common share (USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_CommonStockVotingRightsForEachShare_e6231fe5-0dd5-47b4-85f3-ca15fc718720_terseLabel_en-US" xlink:label="lab_xcur_CommonStockVotingRightsForEachShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, voting rights for each share</link:label>
    <link:label id="lab_xcur_CommonStockVotingRightsForEachShare_label_en-US" xlink:label="lab_xcur_CommonStockVotingRightsForEachShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Voting Rights For Each Share</link:label>
    <link:label id="lab_xcur_CommonStockVotingRightsForEachShare_documentation_en-US" xlink:label="lab_xcur_CommonStockVotingRightsForEachShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Voting Rights For Each Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CommonStockVotingRightsForEachShare" xlink:href="xcur-20210930.xsd#xcur_CommonStockVotingRightsForEachShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CommonStockVotingRightsForEachShare" xlink:to="lab_xcur_CommonStockVotingRightsForEachShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_db8cabbe-a08f-4eda-923b-ddd09e7e23ca_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_IpsenHDMember_b8a22f8e-c58e-4197-b722-215b08b5fea0_terseLabel_en-US" xlink:label="lab_xcur_IpsenHDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen HD</link:label>
    <link:label id="lab_xcur_IpsenHDMember_label_en-US" xlink:label="lab_xcur_IpsenHDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen HD [Member]</link:label>
    <link:label id="lab_xcur_IpsenHDMember_documentation_en-US" xlink:label="lab_xcur_IpsenHDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen HD</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_IpsenHDMember" xlink:href="xcur-20210930.xsd#xcur_IpsenHDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_IpsenHDMember" xlink:to="lab_xcur_IpsenHDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualRiskOrUncertaintyTable_d67f823e-928b-4291-b50c-4937d0b9e4d4_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualRiskOrUncertaintyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual Risk or Uncertainty [Table]</link:label>
    <link:label id="lab_us-gaap_UnusualRiskOrUncertaintyTable_label_en-US" xlink:label="lab_us-gaap_UnusualRiskOrUncertaintyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual Risk or Uncertainty [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualRiskOrUncertaintyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyTable" xlink:to="lab_us-gaap_UnusualRiskOrUncertaintyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeDividend_28f51ed8-d0a5-4add-8f4a-bc9d6fe22ed6_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeDividend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeDividend_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeDividend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Dividend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeDividend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeDividend" xlink:to="lab_us-gaap_InvestmentIncomeDividend" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_24f6d621-0808-4534-aaaf-d641876e7655_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December 31, 2020</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_54d22b72-31d9-4b54-8bf9-4a9c9a63d810_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at September&#160;30, 2021</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7fbce36a-c8da-4743-a704-f7e92c0e048f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested balance - beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d657ff56-c659-453b-afd5-0c9a03ba9bbc_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested balance - end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_c29a18dd-6509-4000-8490-d7ae2443f875_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_a8d26031-36b6-422b-a101-4c1a14f9475f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_f6ba717e-ce98-4cff-acbe-98f3fb4a4ce6_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid clinical, contract research and manufacturing costs</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm_b797f4b0-1132-43e5-af24-a89b3f817b1b_terseLabel_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated rental payment over original term</link:label>
    <link:label id="lab_xcur_LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm_label_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Estimated Rental Payment Over Original Term</link:label>
    <link:label id="lab_xcur_LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm_documentation_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Estimated Rental Payment Over Original Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm" xlink:href="xcur-20210930.xsd#xcur_LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm" xlink:to="lab_xcur_LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_7158bc4b-0c24-4417-bf39-e7aabc3887b5_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_18115b32-b07f-41c9-80bd-e80808c79f6b_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_aa566909-c41a-4149-a3d7-520fbf298b68_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, cash payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_890e54d7-eae8-462d-a123-a5f511033272_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative catch-up adjustment to revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_a9830ccf-54a7-4586-b27c-eb2bd94366ce_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash included in other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_eb0b870a-0af0-4346-8395-3eb680a258e5_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal balance outstanding</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_6a524291-c986-455c-bf28-cb6f1fe7bd89_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After first anniversary</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_74dc4e6a-a425-4930-b298-13a1ddd9973d_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_aadd8d8a-54d2-4377-8976-670251effccb_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_2643a9b3-e6a9-4989-9f7f-277c57f8b77c_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting_8eff9479-d0e3-4036-a694-8dece0eceaf9_terseLabel_en-US" xlink:label="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued for each vested restricted stock unit (in shares)</link:label>
    <link:label id="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting_label_en-US" xlink:label="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Of Common Stock Issuable Upon Vesting</link:label>
    <link:label id="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting_documentation_en-US" xlink:label="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Of Common Stock Issuable Upon Vesting</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting" xlink:href="xcur-20210930.xsd#xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting" xlink:to="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_a4d46b7d-19ad-4abc-a8ca-bd3a8ffa3acb_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total financial assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_9950a16d-c933-4751-9b2d-d4310ae067e4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a2381b64-90ea-4231-888e-f6b443e21326_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1e8a113a-bd58-494e-ada1-652cad3c54c2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_1d3a1c10-99a9-42ac-9125-c575203267d8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_8f5d9f80-3325-442a-a4e6-ba1c44fa638f_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_f0c7c0a9-c655-4ad3-9a64-e7031b0e2ff5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_CollaborationAgreementPerformanceObligationAxis_5c44adc3-7593-4833-8324-50a0b6e2c5c8_terseLabel_en-US" xlink:label="lab_xcur_CollaborationAgreementPerformanceObligationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Performance Obligation [Axis]</link:label>
    <link:label id="lab_xcur_CollaborationAgreementPerformanceObligationAxis_label_en-US" xlink:label="lab_xcur_CollaborationAgreementPerformanceObligationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Performance Obligation [Axis]</link:label>
    <link:label id="lab_xcur_CollaborationAgreementPerformanceObligationAxis_documentation_en-US" xlink:label="lab_xcur_CollaborationAgreementPerformanceObligationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Performance Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementPerformanceObligationAxis" xlink:href="xcur-20210930.xsd#xcur_CollaborationAgreementPerformanceObligationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CollaborationAgreementPerformanceObligationAxis" xlink:to="lab_xcur_CollaborationAgreementPerformanceObligationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_95a0f7ec-34a4-4bef-bfc3-c929f7be0037_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_0b875700-4f5a-45cf-b148-ed47db7173d9_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_3dd531a0-bfde-4f72-a4c4-ccde0d0c7377_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued other expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_e907c233-9d9a-4a73-9c15-3026be0ca06b_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_321456d7-53e3-4055-87e8-e018cc6276c1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_f0cee5d1-05f8-4d08-8cbc-edfdf3d289ca_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_584df551-d919-4336-a864-32afd8e4ea19_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_a44bee20-5388-46a6-9669-06263e744262_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_b3282591-31f4-4ac4-9e2f-987f18416503_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Government agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_32103502-5687-4050-866c-61486f1022f2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForTenantImprovements_18e53950-436a-4800-b01a-16b7cc59d8ac_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for tenant improvements</link:label>
    <link:label id="lab_us-gaap_PaymentsForTenantImprovements_label_en-US" xlink:label="lab_us-gaap_PaymentsForTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Tenant Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForTenantImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForTenantImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForTenantImprovements" xlink:to="lab_us-gaap_PaymentsForTenantImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e3df9ffd-054a-4579-b342-b21a4584a932_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_06127ef3-a662-439e-9042-b2fd6e657e5d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_325c1a66-4cef-44b2-9285-13debe892a62_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_CollaborationAgreementTerminationNoticePeriod_60985758-b441-4391-9af8-f1e7d5861c7b_terseLabel_en-US" xlink:label="lab_xcur_CollaborationAgreementTerminationNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement, termination notice period</link:label>
    <link:label id="lab_xcur_CollaborationAgreementTerminationNoticePeriod_label_en-US" xlink:label="lab_xcur_CollaborationAgreementTerminationNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Termination Notice Period</link:label>
    <link:label id="lab_xcur_CollaborationAgreementTerminationNoticePeriod_documentation_en-US" xlink:label="lab_xcur_CollaborationAgreementTerminationNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Termination Notice Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementTerminationNoticePeriod" xlink:href="xcur-20210930.xsd#xcur_CollaborationAgreementTerminationNoticePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CollaborationAgreementTerminationNoticePeriod" xlink:to="lab_xcur_CollaborationAgreementTerminationNoticePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_169ff07f-7827-479a-a331-eccbf5b9c713_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_6a958985-e7d0-4930-b636-19c7da7b57e4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_75d1bc7d-b8d4-47af-8fd4-d4f5cefa550a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d571c36c-be81-4856-80ba-4404c6f77b68_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_d9c548b0-8c0f-4cda-861e-3276414c8940_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_df4ac2bf-310a-4030-97f4-3a03283018fe_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross realized gains, available for sale securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d53b303e-1cda-42b5-ae2f-d9cf545ae121_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_1b6455d3-f18f-4a23-964a-9db97d550b65_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_IpsenASMember_1b560831-7529-4b5e-aefc-b9e85fb3539e_terseLabel_en-US" xlink:label="lab_xcur_IpsenASMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen AS</link:label>
    <link:label id="lab_xcur_IpsenASMember_label_en-US" xlink:label="lab_xcur_IpsenASMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen AS [Member]</link:label>
    <link:label id="lab_xcur_IpsenASMember_documentation_en-US" xlink:label="lab_xcur_IpsenASMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen AS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_IpsenASMember" xlink:href="xcur-20210930.xsd#xcur_IpsenASMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_IpsenASMember" xlink:to="lab_xcur_IpsenASMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_7743821f-ce94-41fa-b476-d8c07591be38_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_f3caf8a8-ac89-477e-b599-db8f073fa150_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_98544fbd-e9ab-4979-b234-896d2b536377_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7b24e4a6-45f9-4c6d-8988-b9d153ee0c4f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Holding Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_CollaborationAgreementLicensingFeesIncurred_dc483110-a31b-410d-84e2-5ecfaf4a2623_terseLabel_en-US" xlink:label="lab_xcur_CollaborationAgreementLicensingFeesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement, licensing fees incurred</link:label>
    <link:label id="lab_xcur_CollaborationAgreementLicensingFeesIncurred_label_en-US" xlink:label="lab_xcur_CollaborationAgreementLicensingFeesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Licensing Fees Incurred</link:label>
    <link:label id="lab_xcur_CollaborationAgreementLicensingFeesIncurred_documentation_en-US" xlink:label="lab_xcur_CollaborationAgreementLicensingFeesIncurred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Licensing Fees Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementLicensingFeesIncurred" xlink:href="xcur-20210930.xsd#xcur_CollaborationAgreementLicensingFeesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CollaborationAgreementLicensingFeesIncurred" xlink:to="lab_xcur_CollaborationAgreementLicensingFeesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_9a2284ac-dc45-4745-b1e0-c353953ccfa8_terseLabel_en-US" xlink:label="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares allowable annually under the plan (in shares)</link:label>
    <link:label id="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_label_en-US" xlink:label="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Allowable Under The Plan</link:label>
    <link:label id="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_documentation_en-US" xlink:label="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Allowable Under The Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:href="xcur-20210930.xsd#xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:to="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_eda26bf9-b41d-42e1-85ea-9c50b9a84ff9_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_c549b784-4e25-441d-8c65-21ed75fabadc_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_a4c38e53-d144-499b-a145-b84eac93875f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_d9c7b2cd-6740-4e86-bf77-e28c6dddb29e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_5214b4e5-dfe5-497c-a522-4081c6817aca_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_0f421718-ac73-4fd8-8acb-111fcc2101d6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_9fa43b5d-aa9a-470a-9bab-2afe1946efa3_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_3c30096c-bc6c-4818-a338-0f480aeeed4f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_56de174a-c486-40c5-9790-75051a3afb62_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_015209d2-1c9b-4a3b-be4c-3b20094b927f_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_cb6135e5-d646-4e11-ad55-742ea8bffd45_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, weighted-average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6752eb7c-da5e-4e55-a2c6-2b9fe0d145ee_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_a9990c80-476d-4a7d-aa34-e75f11f420f2_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_a2ac85f7-f44d-4695-84b7-52235686c2db_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_dfffc149-7613-46b9-a68a-68cd0ec956ab_terseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt fees (accrued expense and other noncurrent liabilities)</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6ecb298e-df91-4598-84ec-34a0e45e0f5c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_789e65e4-518f-4559-a33f-18c760dc1bb0_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_CollaborationAgreementUpfrontPayment_d3fea078-f16c-41e9-a7e3-966090afb046_terseLabel_en-US" xlink:label="lab_xcur_CollaborationAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable upfront payment received for research agreement</link:label>
    <link:label id="lab_xcur_CollaborationAgreementUpfrontPayment_label_en-US" xlink:label="lab_xcur_CollaborationAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Upfront Payment</link:label>
    <link:label id="lab_xcur_CollaborationAgreementUpfrontPayment_documentation_en-US" xlink:label="lab_xcur_CollaborationAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementUpfrontPayment" xlink:href="xcur-20210930.xsd#xcur_CollaborationAgreementUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CollaborationAgreementUpfrontPayment" xlink:to="lab_xcur_CollaborationAgreementUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_6e429a7f-e3f3-43af-a23b-c6d8a2d3e515_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_472bd2bd-1f66-4074-8c9c-b5a9d23fb97c_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_9e2b1ed8-3638-4d9c-8c76-5ea4b5a0a56b_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of credit outstanding</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment_6cd48400-2ea5-48e1-baff-9005e4d81e10_terseLabel_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development milestone payment</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment_label_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Development Milestone Payment</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment_documentation_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Development Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment" xlink:href="xcur-20210930.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment" xlink:to="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_21500dfc-4d0b-4c60-88c4-48183230ac48_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value per share; 200,000,000 shares authorized, 88,108,543 issued and outstanding, September&#160;30, 2021; 87,651,352 issued and outstanding, December&#160;31, 2020</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_c65aaee5-4bff-46b7-9526-84efeb8e43c6_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_685d5133-8837-407c-a7b9-42da84c2830e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation expense recognition period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_23519f88-7263-4493-97e4-e754f97875d2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested balance - beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1199de42-c2e2-47b8-9501-a125740e3629_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested balance - end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_59cc1f56-c24a-48d6-8206-cefc4aecc292_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_f0d07786-d1b1-41ea-9b02-1ae871b5e3e1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_CollaborationAgreementTransactionPrice_bbf2ba37-194b-4720-94c6-c9fad0c4aec8_terseLabel_en-US" xlink:label="lab_xcur_CollaborationAgreementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction price allocated</link:label>
    <link:label id="lab_xcur_CollaborationAgreementTransactionPrice_label_en-US" xlink:label="lab_xcur_CollaborationAgreementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Transaction Price</link:label>
    <link:label id="lab_xcur_CollaborationAgreementTransactionPrice_documentation_en-US" xlink:label="lab_xcur_CollaborationAgreementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Transaction Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementTransactionPrice" xlink:href="xcur-20210930.xsd#xcur_CollaborationAgreementTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CollaborationAgreementTransactionPrice" xlink:to="lab_xcur_CollaborationAgreementTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b79ca086-c902-4fa1-981c-bc07d9c1cf08_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_5bd7dbeb-04e6-4d53-9c50-6ca22e623ca9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from debt, net of fees and issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_29da6331-4d05-460d-ba06-17c00687940f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 (remaining three months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_f95f9b40-a352-4c44-92ae-c42407e437a6_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of long-term debt fees and issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6a972ccf-5367-418c-8925-23be014ca419_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumptions Used to Determine Fair Value of Common Stock Option Grants</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_c4b7c118-cebb-4e4d-bb88-298f0a238e4b_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_1611b87b-8ec5-4015-9c75-67b7dc68feec_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_d124f07a-4be3-476d-83c4-921994045b7d_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_b58377a8-e00d-4e73-8337-8f48f601a5b7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_LesseeOperatingLeaseNumberOfExtensions_f6ee18c3-2ee5-44d0-a52a-4ab8fc55e8e2_terseLabel_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseNumberOfExtensions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of extensions</link:label>
    <link:label id="lab_xcur_LesseeOperatingLeaseNumberOfExtensions_label_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseNumberOfExtensions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number of Extensions</link:label>
    <link:label id="lab_xcur_LesseeOperatingLeaseNumberOfExtensions_documentation_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseNumberOfExtensions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number of Extensions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseNumberOfExtensions" xlink:href="xcur-20210930.xsd#xcur_LesseeOperatingLeaseNumberOfExtensions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_LesseeOperatingLeaseNumberOfExtensions" xlink:to="lab_xcur_LesseeOperatingLeaseNumberOfExtensions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_039ead6c-d371-4f48-9eaa-91fcecaef630_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_7c309d35-29d9-4224-9431-f8ed7da9ade9_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ea69fbd0-d3dd-46bd-bd8c-5513997ba15d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_HerculesTechnologyGrowthCapitalMember_8a4e13ce-0a32-412e-baf1-17166de09d07_terseLabel_en-US" xlink:label="lab_xcur_HerculesTechnologyGrowthCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hercules Technology Growth Capital</link:label>
    <link:label id="lab_xcur_HerculesTechnologyGrowthCapitalMember_label_en-US" xlink:label="lab_xcur_HerculesTechnologyGrowthCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hercules Technology Growth Capital [Member]</link:label>
    <link:label id="lab_xcur_HerculesTechnologyGrowthCapitalMember_documentation_en-US" xlink:label="lab_xcur_HerculesTechnologyGrowthCapitalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hercules Technology Growth Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_HerculesTechnologyGrowthCapitalMember" xlink:href="xcur-20210930.xsd#xcur_HerculesTechnologyGrowthCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_HerculesTechnologyGrowthCapitalMember" xlink:to="lab_xcur_HerculesTechnologyGrowthCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_864976be-643e-41ca-a038-d8606c0f598a_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f51273f9-ae70-4d6e-adc8-a9698522e595_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_99eeae81-c32a-4d16-b527-2b4d2cb0a9ee_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualRiskOrUncertaintyLineItems_588d1f43-de15-472f-90e0-ca56eb1e05b4_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualRiskOrUncertaintyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual Risk or Uncertainty [Line Items]</link:label>
    <link:label id="lab_us-gaap_UnusualRiskOrUncertaintyLineItems_label_en-US" xlink:label="lab_us-gaap_UnusualRiskOrUncertaintyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual Risk or Uncertainty [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualRiskOrUncertaintyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems" xlink:to="lab_us-gaap_UnusualRiskOrUncertaintyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_51713ff7-8812-40cb-9e83-0d0970b39fae_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_b77cc238-5b1f-4fed-97ea-691caaed8104_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3c81cf91-7f1a-4379-8b39-e078d33ef7f2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_d541aafd-53cc-4d73-94de-be624c4735b9_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_f6a82377-c48a-4d92-86b2-39dd41e92f46_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_744d7161-57d8-48fc-a5c5-4b911c3d9897_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_9298a6e9-092f-4799-809c-01ebb7183748_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_3bcd0d8e-f5d6-4fff-a68a-53a0ffc97c7d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_38d95b97-9456-4abb-9962-4b20c0f59687_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_CollaborationDevelopmentExpenses_bc074676-994d-4fe3-ae2a-e276cec71b8d_terseLabel_en-US" xlink:label="lab_xcur_CollaborationDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration development expenses</link:label>
    <link:label id="lab_xcur_CollaborationDevelopmentExpenses_label_en-US" xlink:label="lab_xcur_CollaborationDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Development Expenses</link:label>
    <link:label id="lab_xcur_CollaborationDevelopmentExpenses_documentation_en-US" xlink:label="lab_xcur_CollaborationDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Development Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationDevelopmentExpenses" xlink:href="xcur-20210930.xsd#xcur_CollaborationDevelopmentExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CollaborationDevelopmentExpenses" xlink:to="lab_xcur_CollaborationDevelopmentExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_6a5165f3-bbda-4eb8-acfc-752a030406ea_terseLabel_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) before reclassifications</link:label>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, before Reclassifications, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:to="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_ba06f345-0ae8-4c49-b85b-6a4a7b868d82_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5655c6bd-9122-4d87-b3c0-a3d95815f514_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8a7d2de0-87e3-45a3-b348-bf53465c2d8e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_92438757-73c9-43dc-8e1a-498e7e94221b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_d782831f-f6b6-45e4-bc45-0d9c9db125ba_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_AggregatePaymentsMadeToDateForLicenseAgreements_4237ff3a-36f8-4aec-a79e-0b50ce14a2f1_terseLabel_en-US" xlink:label="lab_xcur_AggregatePaymentsMadeToDateForLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate consideration paid to NU for agreement obligations</link:label>
    <link:label id="lab_xcur_AggregatePaymentsMadeToDateForLicenseAgreements_label_en-US" xlink:label="lab_xcur_AggregatePaymentsMadeToDateForLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Payments Made To Date For License Agreements</link:label>
    <link:label id="lab_xcur_AggregatePaymentsMadeToDateForLicenseAgreements_documentation_en-US" xlink:label="lab_xcur_AggregatePaymentsMadeToDateForLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Payments Made To Date For License Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_AggregatePaymentsMadeToDateForLicenseAgreements" xlink:href="xcur-20210930.xsd#xcur_AggregatePaymentsMadeToDateForLicenseAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_AggregatePaymentsMadeToDateForLicenseAgreements" xlink:to="lab_xcur_AggregatePaymentsMadeToDateForLicenseAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_767f6b77-a500-420e-8caa-febca525385a_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Holding Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_7fed2cb8-7a58-4131-bcc8-ee4e678fa52a_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Research and License Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_87efacb2-eb2a-445c-af8c-3215e2de23f8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_b62dbc15-2d56-4109-bb0a-a08ed7626428_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_31e9210c-9a32-4b30-87a2-94a97cbfe7c5_terseLabel_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_label_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:to="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ArrangementNameAxis_8f2e8450-73f3-4682-aaf3-23c113184c69_terseLabel_en-US" xlink:label="lab_xcur_ArrangementNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangement, Name [Axis]</link:label>
    <link:label id="lab_xcur_ArrangementNameAxis_label_en-US" xlink:label="lab_xcur_ArrangementNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangement, Name [Axis]</link:label>
    <link:label id="lab_xcur_ArrangementNameAxis_documentation_en-US" xlink:label="lab_xcur_ArrangementNameAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangement, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameAxis" xlink:href="xcur-20210930.xsd#xcur_ArrangementNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ArrangementNameAxis" xlink:to="lab_xcur_ArrangementNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_215febaa-17e0-4420-ab42-c38f3204f6e4_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in- Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_d524d0e4-f7dc-454a-bb9e-dd51384d1f13_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ChicagoMember_999c92a9-9d8f-445c-bcdb-335cdee9cbe3_terseLabel_en-US" xlink:label="lab_xcur_ChicagoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chicago</link:label>
    <link:label id="lab_xcur_ChicagoMember_label_en-US" xlink:label="lab_xcur_ChicagoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chicago [Member]</link:label>
    <link:label id="lab_xcur_ChicagoMember_documentation_en-US" xlink:label="lab_xcur_ChicagoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chicago</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ChicagoMember" xlink:href="xcur-20210930.xsd#xcur_ChicagoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ChicagoMember" xlink:to="lab_xcur_ChicagoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_07a3b420-ddcb-4e2a-9ce1-fd56a07ae937_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_fcca2180-445d-48a3-8b79-7a16e059b1f6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_9adbce43-1fa2-4fa2-ba2c-50b3943ce8ae_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of available for sale securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b9378d51-3935-4370-81ac-8e82f03b68db_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment_a48f8691-f127-4b7e-b1a2-e0bafd074dcc_terseLabel_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and regulatory milestone payment amount</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment_label_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Development And Regulatory Milestone Payment</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment_documentation_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Development And Regulatory Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment" xlink:href="xcur-20210930.xsd#xcur_RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment" xlink:to="lab_xcur_RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c6ebcf31-d0a3-4e9a-9d2c-90c8d8ed32e6_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares called by warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_61cc0186-cb11-48a1-8cd0-a386ea9f48c7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_8b357fca-a53e-422e-acf2-7429aa86d0c6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidInsurance_371a36ec-13f4-4986-98f3-6518b3e96c1b_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid insurance</link:label>
    <link:label id="lab_us-gaap_PrepaidInsurance_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6cca764c-2a5c-4757-a502-0a7e021f9aac_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_PaymentsOfCommonStockFinancingCosts_7917d1b0-f41a-4d73-a8d7-5dbb044848bf_negatedLabel_en-US" xlink:label="lab_xcur_PaymentsOfCommonStockFinancingCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of common stock financing costs</link:label>
    <link:label id="lab_xcur_PaymentsOfCommonStockFinancingCosts_label_en-US" xlink:label="lab_xcur_PaymentsOfCommonStockFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Common Stock Financing Costs</link:label>
    <link:label id="lab_xcur_PaymentsOfCommonStockFinancingCosts_documentation_en-US" xlink:label="lab_xcur_PaymentsOfCommonStockFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Common Stock Financing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_PaymentsOfCommonStockFinancingCosts" xlink:href="xcur-20210930.xsd#xcur_PaymentsOfCommonStockFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_PaymentsOfCommonStockFinancingCosts" xlink:to="lab_xcur_PaymentsOfCommonStockFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_07b6a12d-e4d9-44b8-940c-3151ff560da0_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5dfb2197-0515-46de-ae8f-a3ab32c3a1fb_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_da38e5cf-aeac-49b5-8c75-af551d767841_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_eed1d2b7-128c-4af8-954b-fb1f4d446893_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_08ef0fda-c541-448c-a3d3-6d3b6f26437b_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_b715efe6-e92d-4172-8da8-4d3777aa67ac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares_cde91956-2283-4899-89dc-e0407c5fbc33_terseLabel_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares authorized, potential maximum additional shares (in shares)</link:label>
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares_label_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Potential Maximum Additional Shares</link:label>
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares_documentation_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Potential Maximum Additional Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares" xlink:href="xcur-20210930.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares" xlink:to="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ExercisePeriodAxis_a9bf36f3-2900-4dcb-9d1a-5827ba917d0b_terseLabel_en-US" xlink:label="lab_xcur_ExercisePeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Period [Axis]</link:label>
    <link:label id="lab_xcur_ExercisePeriodAxis_label_en-US" xlink:label="lab_xcur_ExercisePeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Period [Axis]</link:label>
    <link:label id="lab_xcur_ExercisePeriodAxis_documentation_en-US" xlink:label="lab_xcur_ExercisePeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ExercisePeriodAxis" xlink:href="xcur-20210930.xsd#xcur_ExercisePeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ExercisePeriodAxis" xlink:to="lab_xcur_ExercisePeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3469e3ec-b02b-49ef-a91e-fa4f027956f4_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_40230adf-8f0e-4315-b388-ee3349d8d418_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Rental Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_d2029ccd-9a05-4e67-9059-2974bec6d34d_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_107628dc-443f-4e66-88b6-b29ef7e46b7c_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_0533c68b-d629-4c7c-af76-8adf76671b96_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_cd12ac5b-d443-42a4-9807-d604be29c30b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_4e69b1af-176a-4e02-be23-f81946967be0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_dece0c74-5055-402a-a7d4-971e5ec940c7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_160c1978-12b2-4e66-a9a0-539b4143c6b4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_COVID19Member_c43ef575-1cac-4eb1-a0eb-235cce810d28_terseLabel_en-US" xlink:label="lab_xcur_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19</link:label>
    <link:label id="lab_xcur_COVID19Member_label_en-US" xlink:label="lab_xcur_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 [Member]</link:label>
    <link:label id="lab_xcur_COVID19Member_documentation_en-US" xlink:label="lab_xcur_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_COVID19Member" xlink:href="xcur-20210930.xsd#xcur_COVID19Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_COVID19Member" xlink:to="lab_xcur_COVID19Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_d017c8c2-7924-46d0-ad3f-6f9851ece46c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross realized losses, available for sale securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_331ca2ab-f4da-4979-8005-a40e81f450e3_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_547be0f5-90a5-4611-9f04-318a3e0cb34f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ContractWithCustomerLiabilityAdditions_b0afb53e-2d69-4268-8fe9-b162f76c541d_terseLabel_en-US" xlink:label="lab_xcur_ContractWithCustomerLiabilityAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_xcur_ContractWithCustomerLiabilityAdditions_label_en-US" xlink:label="lab_xcur_ContractWithCustomerLiabilityAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Additions</link:label>
    <link:label id="lab_xcur_ContractWithCustomerLiabilityAdditions_documentation_en-US" xlink:label="lab_xcur_ContractWithCustomerLiabilityAdditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ContractWithCustomerLiabilityAdditions" xlink:href="xcur-20210930.xsd#xcur_ContractWithCustomerLiabilityAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ContractWithCustomerLiabilityAdditions" xlink:to="lab_xcur_ContractWithCustomerLiabilityAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1cf8d215-a8dd-4a56-ad40-0db90ee75f76_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_IpsenCollaborationMember_d4198693-6f57-4a8d-b3fa-c0d608147e4a_terseLabel_en-US" xlink:label="lab_xcur_IpsenCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Collaboration</link:label>
    <link:label id="lab_xcur_IpsenCollaborationMember_label_en-US" xlink:label="lab_xcur_IpsenCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Collaboration [Member]</link:label>
    <link:label id="lab_xcur_IpsenCollaborationMember_documentation_en-US" xlink:label="lab_xcur_IpsenCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_IpsenCollaborationMember" xlink:href="xcur-20210930.xsd#xcur_IpsenCollaborationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_IpsenCollaborationMember" xlink:to="lab_xcur_IpsenCollaborationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_8b8eb196-0ece-4890-a711-745ddd9b7f44_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability, noncurrent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_ed03f485-d8d3-48ba-b06a-e9045b694d4b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_db199041-633f-4b2a-8500-25736118fcb8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_55a89332-b5af-4a85-a42d-4866cc9556b5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_880678b2-42f5-474e-ad74-6ddf92948af5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_2eb5eed3-562d-4cc3-b0b3-098fb6ce435c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_WarrantLiabilityMember_9315f7ca-1a96-4145-b03c-d291d7fb2246_terseLabel_en-US" xlink:label="lab_xcur_WarrantLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability</link:label>
    <link:label id="lab_xcur_WarrantLiabilityMember_label_en-US" xlink:label="lab_xcur_WarrantLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability [Member]</link:label>
    <link:label id="lab_xcur_WarrantLiabilityMember_documentation_en-US" xlink:label="lab_xcur_WarrantLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_WarrantLiabilityMember" xlink:href="xcur-20210930.xsd#xcur_WarrantLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_WarrantLiabilityMember" xlink:to="lab_xcur_WarrantLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_688e9953-8641-4610-9145-d5becda32188_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_f83dc731-ac36-4cc1-a490-a792611cbca9_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of underlying common stock (dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_10ec1681-7945-4e23-852e-7834ca1113d2_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_13308a49-3436-460e-94c8-5776c0c2530e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_db1b6c4b-f75b-409a-af38-25c8a09c81ac_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment_8bdc7aee-510c-4c6f-b469-7854c20dca20_terseLabel_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial milestone payment amount</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment_label_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Commercial Milestone Payment</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment_documentation_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Commercial Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment" xlink:href="xcur-20210930.xsd#xcur_RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment" xlink:to="lab_xcur_RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_e0da5055-6235-47a2-ae99-b41fe41eb265_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_454a69bc-2b3a-4cf6-a89b-f55b9d8acb4b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock-ESPP (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_23ecc272-ecd1-4378-ac0b-410ecc74818c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_669c1e2a-ea3f-4607-9a65-6ac1b150f829_terseLabel_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeiture rate</link:label>
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_label_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate</link:label>
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_documentation_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:href="xcur-20210930.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:to="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_2e3cb40b-8464-4e9f-998c-0c1ae2d31701_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasuries</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_232318b0-66e7-4a34-862b-e911a7d5be89_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_e13acf7c-534c-41d0-b40a-db1ed7458974_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_df6ba783-0d84-4153-b2ff-5caf2f10ae5b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoanProcessingFee_846bd25f-f826-48f3-9814-5cdf0ed172f8_terseLabel_en-US" xlink:label="lab_us-gaap_LoanProcessingFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Origination fee</link:label>
    <link:label id="lab_us-gaap_LoanProcessingFee_label_en-US" xlink:label="lab_us-gaap_LoanProcessingFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Processing Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoanProcessingFee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoanProcessingFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoanProcessingFee" xlink:to="lab_us-gaap_LoanProcessingFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_14a325af-49fa-41ed-a5aa-b8ddc8ebe5fe_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of common stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_4594aca1-b151-4c30-9f19-3cfbcf1f5470_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_7c684eb9-e932-44c4-89dc-bcac4050a893_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_96b0e6ad-9387-46d0-a043-c9c0dae09c10_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent_d1a69cc5-272e-4d7f-9bd2-ae3d57947221_terseLabel_en-US" xlink:label="lab_xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After one year but within two years</link:label>
    <link:label id="lab_xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent_label_en-US" xlink:label="lab_xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available For Sale, Noncurrent, Percent</link:label>
    <link:label id="lab_xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent_documentation_en-US" xlink:label="lab_xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available For Sale, Noncurrent, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent" xlink:href="xcur-20210930.xsd#xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent" xlink:to="lab_xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_79c1e4c8-1298-4158-aec5-6ec7bbb69ddc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_1d454fc0-b491-415f-85f1-f56e276fa748_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_5b5314cd-6494-4a7c-a1c9-dec9e1820641_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from long-term borrowing</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_CollaborationAgreementEstimatedTimingOfRevenueRecognition_7447ae58-f64d-4763-a6d9-b9c8c3983fc8_terseLabel_en-US" xlink:label="lab_xcur_CollaborationAgreementEstimatedTimingOfRevenueRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated timing of revenue recognition</link:label>
    <link:label id="lab_xcur_CollaborationAgreementEstimatedTimingOfRevenueRecognition_label_en-US" xlink:label="lab_xcur_CollaborationAgreementEstimatedTimingOfRevenueRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Estimated Timing Of Revenue Recognition</link:label>
    <link:label id="lab_xcur_CollaborationAgreementEstimatedTimingOfRevenueRecognition_documentation_en-US" xlink:label="lab_xcur_CollaborationAgreementEstimatedTimingOfRevenueRecognition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Estimated Timing Of Revenue Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementEstimatedTimingOfRevenueRecognition" xlink:href="xcur-20210930.xsd#xcur_CollaborationAgreementEstimatedTimingOfRevenueRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CollaborationAgreementEstimatedTimingOfRevenueRecognition" xlink:to="lab_xcur_CollaborationAgreementEstimatedTimingOfRevenueRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_bf1eba32-ab92-4e1c-9788-aad1c5aa1216_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_1eb35ee3-4af5-4880-92ca-1a19aca41cd6_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_81e63ce8-b1cf-48e7-95d7-284ebc306e42_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e6c5a59c-380c-43f9-92e2-ae34d943d2a3_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_e13a814f-6518-49c7-9a61-d347145d06b4_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_97685960-d9d2-47e0-a2d8-e39f748bd951_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4c6157fa-c3db-409f-82d4-2e93de156737_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_5b156782-6abe-46df-adbe-a008b52b6e2e_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f7258386-a5fd-45b8-aabd-5631ddfe3dd9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_65096dc3-1a17-41ed-96c3-3d21fd66645f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate increase</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:to="lab_us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_f9963634-7b42-445e-a665-04370f6ba49e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_NumberofCollaborationPrograms_e79b088f-33ee-45e0-98c3-0cd6b44d92f5_terseLabel_en-US" xlink:label="lab_xcur_NumberofCollaborationPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of collaboration programs</link:label>
    <link:label id="lab_xcur_NumberofCollaborationPrograms_label_en-US" xlink:label="lab_xcur_NumberofCollaborationPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Collaboration Programs</link:label>
    <link:label id="lab_xcur_NumberofCollaborationPrograms_documentation_en-US" xlink:label="lab_xcur_NumberofCollaborationPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Collaboration Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_NumberofCollaborationPrograms" xlink:href="xcur-20210930.xsd#xcur_NumberofCollaborationPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_NumberofCollaborationPrograms" xlink:to="lab_xcur_NumberofCollaborationPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_997badc6-df21-4297-83af-fe25ad2b828a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_fe3a93f2-1ee7-4547-92c1-195e7541b7d4_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_ed895eb9-9894-4b90-80b2-1acc185ce4f0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_0acc2f64-5831-4ad6-80ec-7e0c34ae4ad1_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_c79e6d50-ff73-4010-82e6-6e6c56bd9ada_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_496ca634-fcd3-45b6-9de9-3aefc91ac880_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment_0a2317c2-ee43-4a30-97a0-d1a0d5967176_terseLabel_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-clinical milestone payment amount</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment_label_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Collaboration Agreement, Pre-Clinical Milestone Payment</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment_documentation_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Collaboration Agreement, Pre-Clinical Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment" xlink:href="xcur-20210930.xsd#xcur_RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment" xlink:to="lab_xcur_RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_RevenueFromContractWithCustomerNetOfCumulativeCatchUpAdjustment_30811ef0-efb4-407d-ad68-80a4a94be7e8_terseLabel_en-US" xlink:label="lab_xcur_RevenueFromContractWithCustomerNetOfCumulativeCatchUpAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue</link:label>
    <link:label id="lab_xcur_RevenueFromContractWithCustomerNetOfCumulativeCatchUpAdjustment_label_en-US" xlink:label="lab_xcur_RevenueFromContractWithCustomerNetOfCumulativeCatchUpAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contract With Customer, Net Of Cumulative Catch-Up Adjustment</link:label>
    <link:label id="lab_xcur_RevenueFromContractWithCustomerNetOfCumulativeCatchUpAdjustment_documentation_en-US" xlink:label="lab_xcur_RevenueFromContractWithCustomerNetOfCumulativeCatchUpAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contract With Customer, Net Of Cumulative Catch-Up Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueFromContractWithCustomerNetOfCumulativeCatchUpAdjustment" xlink:href="xcur-20210930.xsd#xcur_RevenueFromContractWithCustomerNetOfCumulativeCatchUpAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_RevenueFromContractWithCustomerNetOfCumulativeCatchUpAdjustment" xlink:to="lab_xcur_RevenueFromContractWithCustomerNetOfCumulativeCatchUpAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7477167d-df27-417c-89c4-e2d9890a48fe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_28bde35e-f7d8-48d8-bcd6-dda9cd3ac96b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_ba176e36-ea06-4c8b-9d71-0a1ee1ae66e9_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short term lease costs</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_79dbfd37-2e17-4bdb-b3b5-a2acf0c08257_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_95454e70-1aa6-41d9-8ab2-f2bb0678f02c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_6738c224-7fcc-4a69-ba06-b75b962730dc_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAbstract_10a3a97b-5cb8-4458-a597-9b0a3b4612a3_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_5d78f433-3de8-45f3-be1f-0abb585a7b96_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_3e391c4c-669e-42a7-a3ce-dc049a74a2e5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1db13e8e-37f5-4365-bab0-6e1bf97fb232_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_61ed7d01-ec9f-4f83-ae48-107c0fbf2191_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_d1067dea-a8ea-4b63-b0b3-06055d4d76a0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted stock units and related repurchases</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_17b4e3c0-28ff-4da5-b0e3-a31b50a1e50c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-Based Compensation Expense Classification in Statement of Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_01e18865-655a-4ffd-acdc-e914b3aaccb1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9352e820-1593-4d00-a696-b269f4753e69_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments:</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_a948c938-d061-463d-bfba-a33d30f5b612_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b731fc3b-84f8-4166-98ee-703106dc904b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_6f236bc2-edc1-43ed-92ba-ded3a58a09de_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_a81c5ea2-7b85-4a60-b936-14abca4c1da2_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_4ee721d2-bc70-42d5-aa21-65ff9fa5993f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_24f0b73b-a394-4b1e-8fdd-b51d14251b73_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP purchase price as a percentage of market price</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_94c6e925-95f0-4582-a2d5-3872aa10411e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9eb33b30-da43-4055-8ce0-7b180e3a9e50_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_7ed707a9-9ce2-45c1-aca5-f826ac4f8cce_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, noncurrent</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ArrangementNameDomain_1f5a7841-244b-4322-b271-a896e0ae8af7_terseLabel_en-US" xlink:label="lab_xcur_ArrangementNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangement, Name [Domain]</link:label>
    <link:label id="lab_xcur_ArrangementNameDomain_label_en-US" xlink:label="lab_xcur_ArrangementNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangement, Name [Domain]</link:label>
    <link:label id="lab_xcur_ArrangementNameDomain_documentation_en-US" xlink:label="lab_xcur_ArrangementNameDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Arrangement, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameDomain" xlink:href="xcur-20210930.xsd#xcur_ArrangementNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ArrangementNameDomain" xlink:to="lab_xcur_ArrangementNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1a0528a7-a5b8-49ab-95cd-93740f934e19_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Costs</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_bd46147c-f5d3-482a-b27e-750582b49bcf_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_af1bca7c-8a84-4f04-bf80-e696beb1505a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computation of loss per common share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_fd08b007-2dd5-4a4e-9ff2-ad3f679ebabe_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_297091f8-3151-4ffb-b902-af94b9f747b9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_157398a3-2a66-4c8a-8c38-6f6412f85d44_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_a24b38cc-4377-4c8e-92d0-630d64c02326_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2dd8b814-c22e-448f-89e0-69c889c34ea7_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e0f73dee-a161-4e7e-94c6-ba26b61fe2a8_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_9df7ac66-1ecf-4d33-9888-6d01b0e2c8d9_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_LesseeOperatingLeaseLeaseArea_4ca484fd-54c4-4e1f-808b-47e611298f85_terseLabel_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseLeaseArea" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease area</link:label>
    <link:label id="lab_xcur_LesseeOperatingLeaseLeaseArea_label_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseLeaseArea" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Area</link:label>
    <link:label id="lab_xcur_LesseeOperatingLeaseLeaseArea_documentation_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseLeaseArea" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Area</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseLeaseArea" xlink:href="xcur-20210930.xsd#xcur_LesseeOperatingLeaseLeaseArea"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_LesseeOperatingLeaseLeaseArea" xlink:to="lab_xcur_LesseeOperatingLeaseLeaseArea" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_DebtInstrumentEarlyTerminationFeePercentageOfPrincipal_f9042cc2-9586-457b-9284-d4dfb80b946a_terseLabel_en-US" xlink:label="lab_xcur_DebtInstrumentEarlyTerminationFeePercentageOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early termination fee</link:label>
    <link:label id="lab_xcur_DebtInstrumentEarlyTerminationFeePercentageOfPrincipal_label_en-US" xlink:label="lab_xcur_DebtInstrumentEarlyTerminationFeePercentageOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Early Termination Fee, Percentage of Principal</link:label>
    <link:label id="lab_xcur_DebtInstrumentEarlyTerminationFeePercentageOfPrincipal_documentation_en-US" xlink:label="lab_xcur_DebtInstrumentEarlyTerminationFeePercentageOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Early Termination Fee, Percentage of Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DebtInstrumentEarlyTerminationFeePercentageOfPrincipal" xlink:href="xcur-20210930.xsd#xcur_DebtInstrumentEarlyTerminationFeePercentageOfPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_DebtInstrumentEarlyTerminationFeePercentageOfPrincipal" xlink:to="lab_xcur_DebtInstrumentEarlyTerminationFeePercentageOfPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_6f707496-e0db-42e0-a0a2-dfd42d016fc2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from common stock offering</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_76bd387d-41ab-4cd3-abc7-d24a961576b9_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_b6426367-a01b-4c23-838f-c4b039ba96be_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board of Directors</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_9abcde63-cab9-4b5c-ae0e-5d58c0714525_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_492cbbed-d109-4eeb-a046-41ab4e65eac4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_477a2e64-cab8-4bfb-8de8-807f513d6281_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_013e2d15-b556-4d23-a8d2-2679c2bd148c_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid on debt</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_696051e6-fb03-4f85-9408-af70c20d9f62_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_12330437-f0fd-41f1-bfc9-8e5617ba25ae_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_617907bf-3e90-48ee-9830-e0634b4647d2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_b73a4376-3e6e-4ef4-a0c1-98c31efe2de5_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_1e3168e3-dcd7-44f5-83e3-7a0cd192cdd9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_986996d4-eb1a-42b5-b923-f85f02627c62_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d85edbf-d7bd-4419-ac52-b7bd50b8a436_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_e9221c17-715a-43a4-8e9f-77848308c7c5_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_da8491fe-e9c5-40d2-a4c5-329dc20da2e2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_f7636623-aa86-4631-b4b6-cb4d98d70663_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance_5cd37827-9d27-462e-a4fb-093719d682ca_negatedTerseLabel_en-US" xlink:label="lab_xcur_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue (Recognized) Reversed</link:label>
    <link:label id="lab_xcur_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance_label_en-US" xlink:label="lab_xcur_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized, Including Opening Balance</link:label>
    <link:label id="lab_xcur_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance_documentation_en-US" xlink:label="lab_xcur_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized, Including Opening Balance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance" xlink:href="xcur-20210930.xsd#xcur_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance" xlink:to="lab_xcur_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ab80e3c8-8faa-4436-a046-d1674078d738_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_98b90234-5b70-4c52-88f6-3c1d4baf4428_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_42dae9ab-c11a-482f-8ede-866829a2d114_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lease Costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_fbf9a3c7-9fac-4a0c-a291-719b9d387c61_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_123656d4-cf61-43d7-81f2-161cfb67b22c_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_SupplementalBalanceSheetInformationAbstract_51ee30cb-8e4d-4b40-8d65-1d893b75bc24_terseLabel_en-US" xlink:label="lab_xcur_SupplementalBalanceSheetInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information [Abstract]</link:label>
    <link:label id="lab_xcur_SupplementalBalanceSheetInformationAbstract_label_en-US" xlink:label="lab_xcur_SupplementalBalanceSheetInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information [Abstract]</link:label>
    <link:label id="lab_xcur_SupplementalBalanceSheetInformationAbstract_documentation_en-US" xlink:label="lab_xcur_SupplementalBalanceSheetInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SupplementalBalanceSheetInformationAbstract" xlink:href="xcur-20210930.xsd#xcur_SupplementalBalanceSheetInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract" xlink:to="lab_xcur_SupplementalBalanceSheetInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_00be84cb-e742-4920-923d-0ed1df9864f3_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_29e12876-8b2e-48b5-92bc-627b9d19d64e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fee amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFeeAmount" xlink:to="lab_us-gaap_DebtInstrumentFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_07868f58-af2c-4700-95c0-bdabed275784_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average basic common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_5c30daab-3501-4ba1-bdd6-b3e2156bf35e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (loss) earnings per common share (USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_cdcd7bfb-1a42-495b-b23b-c84b07e01a06_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) earnings per diluted common share (USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_0dad2b4d-3968-44ca-b4bf-34b7924e3d0e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_4774d65d-bf40-44cc-8d75-78e4f7f9358c_totalLabel_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total financial liabilities</link:label>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding_be11591e-977c-49ce-9e11-4f826b9d16f2_terseLabel_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares authorized, percentage of common stock outstanding</link:label>
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding_label_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Percentage of Common Stock Outstanding</link:label>
    <link:label id="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding_documentation_en-US" xlink:label="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Percentage of Common Stock Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding" xlink:href="xcur-20210930.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding" xlink:to="lab_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee_47896138-ebae-4660-8f0b-bf506fd0bada_terseLabel_en-US" xlink:label="lab_xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration option exercise fee</link:label>
    <link:label id="lab_xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee_label_en-US" xlink:label="lab_xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Extended Option, Additional Exercise Fee</link:label>
    <link:label id="lab_xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee_documentation_en-US" xlink:label="lab_xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Extended Option, Additional Exercise Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee" xlink:href="xcur-20210930.xsd#xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee" xlink:to="lab_xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant_148db689-2999-43c7-842b-b9a381e86776_terseLabel_en-US" xlink:label="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in number of shares available for grant (in shares)</link:label>
    <link:label id="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Available for Grant</link:label>
    <link:label id="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant_documentation_en-US" xlink:label="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant" xlink:href="xcur-20210930.xsd#xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant" xlink:to="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_74b9fc17-047d-4e1f-ab5d-1038c77c52e9_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_64c2756a-293a-4bfd-946e-03d74bbed4e6_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_37a38dc9-c580-4fd1-99f9-ab02d1924299_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Balance at January 1, 2021</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_e1e0c04e-9e6b-4642-83ca-0b60beee4e93_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Balance at September 30, 2021</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff611b3c-cfd4-4a56-a3cc-e60a0d0401a3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_de4b6355-b6e4-4e4e-90b5-9758898766df_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income, net of taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_LesseeOperatingLeaseBaseRentAnnualPercentageIncrease_a1642e4a-de79-4aaa-a174-14334baba5fc_terseLabel_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseBaseRentAnnualPercentageIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base rent annual percentage increase</link:label>
    <link:label id="lab_xcur_LesseeOperatingLeaseBaseRentAnnualPercentageIncrease_label_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseBaseRentAnnualPercentageIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Base Rent Annual Percentage Increase</link:label>
    <link:label id="lab_xcur_LesseeOperatingLeaseBaseRentAnnualPercentageIncrease_documentation_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseBaseRentAnnualPercentageIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Base Rent Annual Percentage Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseBaseRentAnnualPercentageIncrease" xlink:href="xcur-20210930.xsd#xcur_LesseeOperatingLeaseBaseRentAnnualPercentageIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_LesseeOperatingLeaseBaseRentAnnualPercentageIncrease" xlink:to="lab_xcur_LesseeOperatingLeaseBaseRentAnnualPercentageIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_e6f9a462-0931-4c0b-a4ad-7227a80dca74_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6acf240a-f784-4a8f-bccc-be4ddaa8ee5d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ChiefFinancialOfficerMember_d9a98ae0-bea3-4aed-9ec0-8d46492c9a21_terseLabel_en-US" xlink:label="lab_srt_ChiefFinancialOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Financial Officer</link:label>
    <link:label id="lab_srt_ChiefFinancialOfficerMember_label_en-US" xlink:label="lab_srt_ChiefFinancialOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Financial Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefFinancialOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefFinancialOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefFinancialOfficerMember" xlink:to="lab_srt_ChiefFinancialOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableMember_e07102ae-d144-40fe-8846-7a0e2e9837d5_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths_05248e38-a9e6-47e4-886d-377f2dd71c00_terseLabel_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual rent payment initial twelve months</link:label>
    <link:label id="lab_xcur_LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths_label_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Annual Rent Payment Initial Twelve Months</link:label>
    <link:label id="lab_xcur_LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths_documentation_en-US" xlink:label="lab_xcur_LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Annual Rent Payment Initial Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths" xlink:href="xcur-20210930.xsd#xcur_LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths" xlink:to="lab_xcur_LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_9827af72-7fd1-444b-92c9-25b4ded06d07_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Unit Awards Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_3039653a-788e-4d40-beba-6aff474b0956_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate notes/bonds</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_293d431e-ff2b-4894-9da9-b494df49ffc1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_7ea8bc25-d41f-4987-a14c-0fc020b95de6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_label_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossAttributableToParent" xlink:to="lab_us-gaap_IncomeLossAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_3c9a3c2c-2c4c-42c8-bfe4-f8c6e5e85cdd_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_b86e5ece-86b3-4bc2-b3ee-982cea48b834_terseLabel_en-US" xlink:label="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering period duration</link:label>
    <link:label id="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_label_en-US" xlink:label="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period</link:label>
    <link:label id="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_documentation_en-US" xlink:label="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:href="xcur-20210930.xsd#xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:to="lab_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_6c7328a9-a562-4546-8605-ac6f3c9bf3ae_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate_1a8489c2-2321-42b0-81b6-cc9d2619c97c_terseLabel_en-US" xlink:label="lab_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit generated, since inception</link:label>
    <link:label id="lab_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate_label_en-US" xlink:label="lab_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit), Inception to Date</link:label>
    <link:label id="lab_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate_documentation_en-US" xlink:label="lab_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit), Inception to Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate" xlink:href="xcur-20210930.xsd#xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate" xlink:to="lab_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_db784922-673d-40ad-a639-c6a0e4c24e2c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_80a394e3-0359-490b-8901-2f046ef5a476_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_607cdcbf-1c86-4113-94c0-cdcec7ec49f9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8d318940-089b-489c-8c73-33766ed7d913_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_DebtSecuritiesAvailableforSalePercent_934b54e4-72ca-46f7-a30f-ffeae86c77c6_totalLabel_en-US" xlink:label="lab_xcur_DebtSecuritiesAvailableforSalePercent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_xcur_DebtSecuritiesAvailableforSalePercent_label_en-US" xlink:label="lab_xcur_DebtSecuritiesAvailableforSalePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available for Sale, Percent</link:label>
    <link:label id="lab_xcur_DebtSecuritiesAvailableforSalePercent_documentation_en-US" xlink:label="lab_xcur_DebtSecuritiesAvailableforSalePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available for Sale, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DebtSecuritiesAvailableforSalePercent" xlink:href="xcur-20210930.xsd#xcur_DebtSecuritiesAvailableforSalePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_DebtSecuritiesAvailableforSalePercent" xlink:to="lab_xcur_DebtSecuritiesAvailableforSalePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_OfficeAndGeneralAndAdministrativeStaffOnSitePercentage_1eccdd10-bc87-425b-9b3a-7b8703f461d4_terseLabel_en-US" xlink:label="lab_xcur_OfficeAndGeneralAndAdministrativeStaffOnSitePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of time that office and general and administrative staff are on site</link:label>
    <link:label id="lab_xcur_OfficeAndGeneralAndAdministrativeStaffOnSitePercentage_label_en-US" xlink:label="lab_xcur_OfficeAndGeneralAndAdministrativeStaffOnSitePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office And General And Administrative Staff On Site, Percentage</link:label>
    <link:label id="lab_xcur_OfficeAndGeneralAndAdministrativeStaffOnSitePercentage_documentation_en-US" xlink:label="lab_xcur_OfficeAndGeneralAndAdministrativeStaffOnSitePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office And General And Administrative Staff On Site, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_OfficeAndGeneralAndAdministrativeStaffOnSitePercentage" xlink:href="xcur-20210930.xsd#xcur_OfficeAndGeneralAndAdministrativeStaffOnSitePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_OfficeAndGeneralAndAdministrativeStaffOnSitePercentage" xlink:to="lab_xcur_OfficeAndGeneralAndAdministrativeStaffOnSitePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_80c7120c-f602-4856-9f45-9bc36bdba5e6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ExercisePeriodOneMember_b48cc677-9740-4dbe-b5e8-07e30b95719c_terseLabel_en-US" xlink:label="lab_xcur_ExercisePeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Exercise Period after the Selection</link:label>
    <link:label id="lab_xcur_ExercisePeriodOneMember_label_en-US" xlink:label="lab_xcur_ExercisePeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Period One [Member]</link:label>
    <link:label id="lab_xcur_ExercisePeriodOneMember_documentation_en-US" xlink:label="lab_xcur_ExercisePeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Period One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ExercisePeriodOneMember" xlink:href="xcur-20210930.xsd#xcur_ExercisePeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ExercisePeriodOneMember" xlink:to="lab_xcur_ExercisePeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment_d16c7af3-a27e-4719-96d0-d57194eca9a0_terseLabel_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product approval and launch milestone payment</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment_label_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Product Approval and Launch Milestone Payment</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment_documentation_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Product Approval and Launch Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment" xlink:href="xcur-20210930.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment" xlink:to="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_f9190214-ee4e-48e1-b56f-a213060213b2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted stock units and related repurchases (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemDomain_ccc7c63b-9ffb-4452-9049-ad3d1eea6056_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Domain]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemDomain_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain" xlink:to="lab_us-gaap_UnusualOrInfrequentItemDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ClassofWarrantorRightExpired_48a13511-66b5-4da6-81bb-16790afc2641_terseLabel_en-US" xlink:label="lab_xcur_ClassofWarrantorRightExpired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant expirations (in shares)</link:label>
    <link:label id="lab_xcur_ClassofWarrantorRightExpired_label_en-US" xlink:label="lab_xcur_ClassofWarrantorRightExpired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Expired</link:label>
    <link:label id="lab_xcur_ClassofWarrantorRightExpired_documentation_en-US" xlink:label="lab_xcur_ClassofWarrantorRightExpired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Expired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ClassofWarrantorRightExpired" xlink:href="xcur-20210930.xsd#xcur_ClassofWarrantorRightExpired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ClassofWarrantorRightExpired" xlink:to="lab_xcur_ClassofWarrantorRightExpired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_91e93941-dd12-4a17-8719-57a444cc011b_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_9f9afb7e-ae48-4ca5-af88-72a7c6ac7778_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInDeferredRevenueRollForward_febbbadf-9756-4852-b8e2-ff41c6a10795_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInDeferredRevenueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Movement in Deferred Revenue [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInDeferredRevenueRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInDeferredRevenueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Movement in Deferred Revenue [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInDeferredRevenueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInDeferredRevenueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInDeferredRevenueRollForward" xlink:to="lab_us-gaap_MovementInDeferredRevenueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_814aebd5-9420-4c6b-ae73-683a0f093c81_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ExercisePeriodDomain_6752f7ce-76b7-424e-a7ae-d45599603a12_terseLabel_en-US" xlink:label="lab_xcur_ExercisePeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Period [Domain]</link:label>
    <link:label id="lab_xcur_ExercisePeriodDomain_label_en-US" xlink:label="lab_xcur_ExercisePeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Period [Domain]</link:label>
    <link:label id="lab_xcur_ExercisePeriodDomain_documentation_en-US" xlink:label="lab_xcur_ExercisePeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ExercisePeriodDomain" xlink:href="xcur-20210930.xsd#xcur_ExercisePeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ExercisePeriodDomain" xlink:to="lab_xcur_ExercisePeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fca83992-d5e5-493a-b3e9-16d801b9ce98_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate_f7a5815d-8f62-450e-87f5-948735f29bca_terseLabel_en-US" xlink:label="lab_xcur_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative catch-up adjustments to revenue, change in estimate</link:label>
    <link:label id="lab_xcur_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate_label_en-US" xlink:label="lab_xcur_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Cumulative Catch-up Adjustments To Revenue, Change In Estimate</link:label>
    <link:label id="lab_xcur_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate_documentation_en-US" xlink:label="lab_xcur_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Cumulative Catch-up Adjustments To Revenue, Change In Estimate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate" xlink:href="xcur-20210930.xsd#xcur_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate" xlink:to="lab_xcur_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_1d5a16d8-06a1-4de6-bf73-2f65ef942ab3_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease costs</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_1a5a1fa1-9f1e-4897-b330-0b9146a8f35f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_5a8d4c5b-e728-43a2-83c7-354f3b1d37bb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_1bb53960-e53f-41b2-9612-96cd88501bba_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_DevelopmentandCommercializationLicenseMember_f44cc24f-2a86-4a18-8968-e0f3b3922a47_terseLabel_en-US" xlink:label="lab_xcur_DevelopmentandCommercializationLicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and Commercialization License</link:label>
    <link:label id="lab_xcur_DevelopmentandCommercializationLicenseMember_label_en-US" xlink:label="lab_xcur_DevelopmentandCommercializationLicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and Commercialization License [Member]</link:label>
    <link:label id="lab_xcur_DevelopmentandCommercializationLicenseMember_documentation_en-US" xlink:label="lab_xcur_DevelopmentandCommercializationLicenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and Commercialization License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DevelopmentandCommercializationLicenseMember" xlink:href="xcur-20210930.xsd#xcur_DevelopmentandCommercializationLicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_DevelopmentandCommercializationLicenseMember" xlink:to="lab_xcur_DevelopmentandCommercializationLicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivable_79fea03c-5212-48d2-a12a-1257e5c2086f_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivable_label_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivable" xlink:to="lab_us-gaap_InterestReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_bd4d8ae0-3505-4763-87b1-9dcf5c91e7f5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_96881382-9dac-448d-b9fd-062690457597_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_ee771aa0-7886-42ee-a899-80cbb6cb4cb9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_ba8ec869-9c03-4865-a4bf-062c33188c28_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_54479d6e-c4f6-407e-82ca-f4bb518c22d7_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ExercisePeriodTwoMember_eaa2a6b0-180f-4cbb-94af-e3db1917059a_terseLabel_en-US" xlink:label="lab_xcur_ExercisePeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Exercise Period that begins after the first Option Exercise Period</link:label>
    <link:label id="lab_xcur_ExercisePeriodTwoMember_label_en-US" xlink:label="lab_xcur_ExercisePeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Period Two [Member]</link:label>
    <link:label id="lab_xcur_ExercisePeriodTwoMember_documentation_en-US" xlink:label="lab_xcur_ExercisePeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Period Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ExercisePeriodTwoMember" xlink:href="xcur-20210930.xsd#xcur_ExercisePeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ExercisePeriodTwoMember" xlink:to="lab_xcur_ExercisePeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_9633e996-6ca2-4f17-aabb-86815b4cb99a_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_d749ce00-5ade-4d92-a450-5694897b655a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_53e64791-40a0-484e-a99c-07e63ce0c915_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_4f9d2565-ff37-4907-a1e5-d26b8d224d0d_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_0137f358-b73d-4e58-a259-3d809c2d388f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_1372989c-2c08-4790-abc4-f645a3ca1a6e_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_0f969b60-8645-42d0-bca3-e3c1752c18b5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_38aa814c-62a5-430d-b68f-cea4da2846d1_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_4b328c2b-25e4-4bcf-8934-1eb3b6769a59_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_c0dc12e3-a9a1-49e7-ad7b-0d4d9308a3d0_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_84f8d71c-cfc6-4f8b-a269-b235d70ed45e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_dbaf7f42-6311-406b-942d-eb352e8f784c_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scientific equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_DebtInstrumentExitFeePercentage_b5b75042-739c-46f6-9c77-83685bce2b17_terseLabel_en-US" xlink:label="lab_xcur_DebtInstrumentExitFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit fee percentage</link:label>
    <link:label id="lab_xcur_DebtInstrumentExitFeePercentage_label_en-US" xlink:label="lab_xcur_DebtInstrumentExitFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Exit Fee, Percentage</link:label>
    <link:label id="lab_xcur_DebtInstrumentExitFeePercentage_documentation_en-US" xlink:label="lab_xcur_DebtInstrumentExitFeePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Exit Fee, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DebtInstrumentExitFeePercentage" xlink:href="xcur-20210930.xsd#xcur_DebtInstrumentExitFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_DebtInstrumentExitFeePercentage" xlink:to="lab_xcur_DebtInstrumentExitFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_df588780-5923-4dab-9a03-de88428c53ae_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_22dfbb86-f6c1-43fd-bbbc-dcfb1fddbce6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of debt securities, available-for-sale</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_55367909-09e7-4cce-81bd-18a74a104554_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants to purchase common stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a2434538-d3ab-4e98-8ec3-a36f474e839a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1400997a-23bc-407b-afdb-0d0b3bcc19fc_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_87fb02c5-e993-41b5-9924-f869cce3db14_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_deccb135-a80f-4f27-9768-48ae06c8762e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_51f04f2b-b9eb-43ba-a637-ac4ee1faa695_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsFinancingActivitiesAbstract_d2440cf6-eae5-403d-a5d6-d22add93ac54_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash financing activities:</link:label>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Cash Flow Elements, Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalCashFlowElementsFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalCashFlowElementsFinancingActivitiesAbstract" xlink:to="lab_us-gaap_AdditionalCashFlowElementsFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bdb9667b-5b00-4b75-9afa-68d6fec77b44_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_74bd0ff7-36d8-417f-bea9-74eeba9eb7cf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of common stock option (dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_83a0ee34-f634-42f5-8fe9-6ef6da309be6_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ComputersandSoftwareMember_f8341527-8157-40ad-a14b-346e9d96aaea_terseLabel_en-US" xlink:label="lab_xcur_ComputersandSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computers and software</link:label>
    <link:label id="lab_xcur_ComputersandSoftwareMember_label_en-US" xlink:label="lab_xcur_ComputersandSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computers and Software [Member]</link:label>
    <link:label id="lab_xcur_ComputersandSoftwareMember_documentation_en-US" xlink:label="lab_xcur_ComputersandSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computers and Software [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ComputersandSoftwareMember" xlink:href="xcur-20210930.xsd#xcur_ComputersandSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ComputersandSoftwareMember" xlink:to="lab_xcur_ComputersandSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemAxis_f2013a0f-d625-4f33-9e9c-2d403ce6352f_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Axis]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemAxis_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis" xlink:to="lab_us-gaap_UnusualOrInfrequentItemAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_863f2af6-9963-4032-99ff-1025f552d1de_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, weighted-average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_CollaborationAgreementOptionExerciseFee_2379b45b-7892-4938-abde-eca9e612ef54_terseLabel_en-US" xlink:label="lab_xcur_CollaborationAgreementOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration option exercise fee</link:label>
    <link:label id="lab_xcur_CollaborationAgreementOptionExerciseFee_label_en-US" xlink:label="lab_xcur_CollaborationAgreementOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Option, Exercise Fee</link:label>
    <link:label id="lab_xcur_CollaborationAgreementOptionExerciseFee_documentation_en-US" xlink:label="lab_xcur_CollaborationAgreementOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Option, Exercise Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementOptionExerciseFee" xlink:href="xcur-20210930.xsd#xcur_CollaborationAgreementOptionExerciseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CollaborationAgreementOptionExerciseFee" xlink:to="lab_xcur_CollaborationAgreementOptionExerciseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6dfb0e08-0da0-4d60-80b9-8e5668dd12af_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_28760ea2-fed5-44e8-be12-15161d84896f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_7846986a-3bf5-4740-907a-8455f4fea60d_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f4961eeb-cd23-421d-8796-52c77867a11f_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_CommonStockWarrantLiabilityFairValueDisclosure_50214c58-40a8-47ff-9641-249b46b000f7_terseLabel_en-US" xlink:label="lab_xcur_CommonStockWarrantLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock warrant liability</link:label>
    <link:label id="lab_xcur_CommonStockWarrantLiabilityFairValueDisclosure_label_en-US" xlink:label="lab_xcur_CommonStockWarrantLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrant Liability, Fair Value Disclosure</link:label>
    <link:label id="lab_xcur_CommonStockWarrantLiabilityFairValueDisclosure_documentation_en-US" xlink:label="lab_xcur_CommonStockWarrantLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrant Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CommonStockWarrantLiabilityFairValueDisclosure" xlink:href="xcur-20210930.xsd#xcur_CommonStockWarrantLiabilityFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CommonStockWarrantLiabilityFairValueDisclosure" xlink:to="lab_xcur_CommonStockWarrantLiabilityFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_05d2d014-82a9-43a1-8ba5-25c442c8c12a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of investments</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice_5d3096bf-f1e5-4268-bf65-0b6ee4c2b21b_terseLabel_en-US" xlink:label="lab_xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination period upon written notice</link:label>
    <link:label id="lab_xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice_label_en-US" xlink:label="lab_xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Termination Period Upon Written Notice</link:label>
    <link:label id="lab_xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice_documentation_en-US" xlink:label="lab_xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Termination Period Upon Written Notice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice" xlink:href="xcur-20210930.xsd#xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice" xlink:to="lab_xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_5ada624e-ec6d-4848-9bf9-93e11adbf74a_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of long-term debt issuance costs and fees</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_878bafa0-597d-4c91-aeda-e79ecb52021b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value (thousands)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_c5dac05a-414e-4e11-9d4a-c1d0d8c2519f_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in process</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a7d8084b-cebe-4c85-a82b-2be5d9a969bf_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash - beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_eab73985-28f0-471c-bf75-35525581e36d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash - end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_356d183a-1b39-4f99-998b-b3104c736f3d_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents, and restricted cash shown in the unaudited condensed consolidated statements of cash flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_ab5e14e4-2ed7-4b59-9fda-638f78ff7d24_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_80e0eab9-89af-4398-9080-0312e6de7679_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a30ff4d0-3255-48d0-999f-caa492db1572_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_04dea727-94dc-48e9-a19e-9962ddd3d78c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_ea5fe584-1315-4804-8234-9893f5dfb47d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior to first anniversary</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_0a2e1f70-8919-4c58-927b-9be89d7079ac_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_5496cc44-2a4b-4e83-b275-10ee3cff872a_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock_7fba1135-48cb-4ec9-afd8-dfb886951d77_terseLabel_en-US" xlink:label="lab_xcur_ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leases, Additional Information</link:label>
    <link:label id="lab_xcur_ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock_label_en-US" xlink:label="lab_xcur_ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leases, Additional Information [Table Text Block]</link:label>
    <link:label id="lab_xcur_ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock_documentation_en-US" xlink:label="lab_xcur_ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leases, Additional Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock" xlink:href="xcur-20210930.xsd#xcur_ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock" xlink:to="lab_xcur_ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_d9a22a2f-1f5b-4fc6-a820-1e08f3324638_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_7d0edb54-be66-4806-9f8c-bed05cdfd695_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_19c25a23-6537-48c2-b6ab-5600e36c7d48_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents:</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_72443ab7-5d97-4b94-a629-cf7469d2ee9e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net losses (gains) reclassified from accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from AOCI, Current Period, before Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_73732454-07d6-42c6-af1e-49410861cb57_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_798f216b-4baf-40a4-9071-3ae892c56269_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_35db2ecc-28d0-4236-956e-4c3a960a5202_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average diluted common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_0b415f28-91ed-4aaf-9d15-a19f4a431a35_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock warrant liability</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_3660a8f2-ba05-4b62-b3e8-630f4db3078b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_7071c533-0d2a-4c00-a9d8-07fb81d03ce0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_1087f689-e941-4d96-8930-b08b38d89da9_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_3a9ffff3-ac59-4a42-8889-b6aecb100bf3_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_e7334358-c4ba-4ca6-8159-52734f26d5ab_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_99a02580-f369-4d96-8c78-ede1dcd46164_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_c1736f7a-dfe1-4035-b095-054f0526c250_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_eccfaa77-59d5-44af-9ebe-52adfdb42c7b_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract_5c3f7e28-3144-40a3-b9fd-a23e3a3fbaa3_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash investing activities:</link:label>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Cash Flow Elements, Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract" xlink:to="lab_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_083f872d-911b-4c47-b77c-7ce62f8a1cf0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent_49cdd4e8-0ddd-49fb-837b-8126ef652a79_terseLabel_en-US" xlink:label="lab_xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical, contract research and manufacturing costs</link:label>
    <link:label id="lab_xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent_label_en-US" xlink:label="lab_xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical, Contract Research And Manufacturing Costs, Current</link:label>
    <link:label id="lab_xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent_documentation_en-US" xlink:label="lab_xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical, Contract Research And Manufacturing Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent" xlink:href="xcur-20210930.xsd#xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent" xlink:to="lab_xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_67b24086-4630-4840-b465-87200bb1beb2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_070fb381-da1f-4db3-b106-e57e62e99eb0_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income, net:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_db597e2c-a1a3-495c-abff-822377fb8374_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental borrowing rate</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_DermelixLicenseAgreementMember_0484af01-7aac-4f51-9296-1a16f3af1c61_terseLabel_en-US" xlink:label="lab_xcur_DermelixLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dermelix License Agreement</link:label>
    <link:label id="lab_xcur_DermelixLicenseAgreementMember_label_en-US" xlink:label="lab_xcur_DermelixLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dermelix License Agreement [Member]</link:label>
    <link:label id="lab_xcur_DermelixLicenseAgreementMember_documentation_en-US" xlink:label="lab_xcur_DermelixLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dermelix License Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DermelixLicenseAgreementMember" xlink:href="xcur-20210930.xsd#xcur_DermelixLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_DermelixLicenseAgreementMember" xlink:to="lab_xcur_DermelixLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_da3fbb47-9eca-4427-a5c1-0ec0cf8c5bae_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_cf1bc7fc-b77b-48ef-9579-b0670353b686_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_855e2ed0-698a-4999-93c8-d0430e4fdfd2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_292f9c8f-5cab-4962-be05-12ece3fa7c6d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_ce16ae33-33a0-4817-a1fa-07c8d13a45b2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock-ESPP</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_MidCapCreditAgreementTranche1Member_c5acb133-0bea-406c-bba2-2cc2caee9052_terseLabel_en-US" xlink:label="lab_xcur_MidCapCreditAgreementTranche1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MidCap Credit Agreement - Tranche 1</link:label>
    <link:label id="lab_xcur_MidCapCreditAgreementTranche1Member_label_en-US" xlink:label="lab_xcur_MidCapCreditAgreementTranche1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MidCap Credit Agreement - Tranche 1 [Member]</link:label>
    <link:label id="lab_xcur_MidCapCreditAgreementTranche1Member_documentation_en-US" xlink:label="lab_xcur_MidCapCreditAgreementTranche1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MidCap Credit Agreement - Tranche 1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_MidCapCreditAgreementTranche1Member" xlink:href="xcur-20210930.xsd#xcur_MidCapCreditAgreementTranche1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_MidCapCreditAgreementTranche1Member" xlink:to="lab_xcur_MidCapCreditAgreementTranche1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_a63f3e0f-f67c-4a7b-a8cd-2b8ac474438b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3d114478-d801-4783-8ea8-a1af26edfa3d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f9f9c480-7e80-4c2c-807d-0278615e2830_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment_dd487e80-c498-481c-8642-af11517434d7_terseLabel_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales milestone payment</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment_label_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Sales Milestone Payment</link:label>
    <link:label id="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment_documentation_en-US" xlink:label="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Sales Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment" xlink:href="xcur-20210930.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment" xlink:to="lab_xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_1adc0d54-64c7-4f22-ad21-e133b5552667_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_9a451791-486f-401b-a41a-de20e33216c3_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f539cb56-4232-4547-ad40-cbeae445d8e6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_f932a472-502d-4b65-8160-9c70d694819e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_300d5337-94f6-474a-ae9a-ae7f67207217_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_cf9b647b-df8f-410c-93bc-dead902232d0_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_cb3fb107-5991-49ed-9cde-745a51395e93_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for minimum statutory tax withholding related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ConsultingServicesMember_6f4e907f-fe45-4912-ba69-f13c38bc708a_terseLabel_en-US" xlink:label="lab_xcur_ConsultingServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting services</link:label>
    <link:label id="lab_xcur_ConsultingServicesMember_label_en-US" xlink:label="lab_xcur_ConsultingServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting Services [Member]</link:label>
    <link:label id="lab_xcur_ConsultingServicesMember_documentation_en-US" xlink:label="lab_xcur_ConsultingServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ConsultingServicesMember" xlink:href="xcur-20210930.xsd#xcur_ConsultingServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ConsultingServicesMember" xlink:to="lab_xcur_ConsultingServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_d7a4e0d3-3b83-497c-913a-6c72cf774b5a_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_f301b80a-3463-40af-8142-29b8dc0b90fd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value (thousands)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_7581bdce-94a7-47ef-8558-346d9cf42da2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_b39779a6-127c-4e37-bbd7-2aa8d1421b6f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of outstanding shares allowable as annual increase</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_2fdfbf13-81c3-47b7-abd1-2128d156705b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">less: unamortized discount and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments_6b419dd5-6b6d-4553-a7b7-90acb5a3319a_terseLabel_en-US" xlink:label="lab_xcur_DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of monthly installment payments</link:label>
    <link:label id="lab_xcur_DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments_label_en-US" xlink:label="lab_xcur_DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Principal Payment, Number of Monthly Installment Payments</link:label>
    <link:label id="lab_xcur_DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments_documentation_en-US" xlink:label="lab_xcur_DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Principal Payment, Number of Monthly Installment Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments" xlink:href="xcur-20210930.xsd#xcur_DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments" xlink:to="lab_xcur_DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_da207abd-3ed7-4caf-950a-0f2fe286db1e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_ff5a449b-15fa-4bc5-8e10-7779cceab3ce_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_b18e4bb2-7d7a-4754-9083-c838db08ff04_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_baccda24-fd99-438b-bc4c-0d754533c4a3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e58eaad8-cb4b-4647-b93d-65e5a17c4154_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ff284493-3bbf-4267-86f1-14df0a19cdd2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_MidCapCreditAgreementTranche2Member_962d6295-3fe2-4b06-82e4-9210689bb7dc_terseLabel_en-US" xlink:label="lab_xcur_MidCapCreditAgreementTranche2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MidCap Credit Agreement - Tranche 2</link:label>
    <link:label id="lab_xcur_MidCapCreditAgreementTranche2Member_label_en-US" xlink:label="lab_xcur_MidCapCreditAgreementTranche2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MidCap Credit Agreement - Tranche 2 [Member]</link:label>
    <link:label id="lab_xcur_MidCapCreditAgreementTranche2Member_documentation_en-US" xlink:label="lab_xcur_MidCapCreditAgreementTranche2Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MidCap Credit Agreement - Tranche 2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_MidCapCreditAgreementTranche2Member" xlink:href="xcur-20210930.xsd#xcur_MidCapCreditAgreementTranche2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_MidCapCreditAgreementTranche2Member" xlink:to="lab_xcur_MidCapCreditAgreementTranche2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTableTextBlock_6c14d9fc-069d-4e62-a00d-faced5edb04b_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTableTextBlock" xlink:to="lab_us-gaap_InvestmentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_98f513c2-1f8c-494d-9dd1-c790bcf1e5fe_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_85f95258-33f3-4fd8-ac7b-5f3771ae92f8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4e45848b-3928-4f60-8760-1b0e376834a6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation cost not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_aad42b32-a654-4482-a4a8-020207ea4626_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_7204afdf-448f-4362-a217-47c5eff18312_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAmortizationAndAccretionNet_d0b81ac0-3b31-41c5-89cf-a8d3a7ff7487_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAmortizationAndAccretionNet_87adc168-7a47-4eae-9298-56c8bfc946e7_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAmortizationAndAccretionNet_label_en-US" xlink:label="lab_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Amortization and Accretion, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:to="lab_us-gaap_DepreciationAmortizationAndAccretionNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_920eb55d-82c6-4fea-9430-7193b21c3377_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_db837224-fe6c-4061-be98-4a1e7afc4709_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_1bb6ed9a-912f-4a94-b44b-5ec81684baa5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_38291e83-6b6a-4a85-808c-2b9eb420873f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_xcur_ExicureInc.2017EquityIncentivePlanMember_c44ce09b-1792-4919-8c49-c2e42e02e83f_terseLabel_en-US" xlink:label="lab_xcur_ExicureInc.2017EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exicure, Inc. 2017 Equity Incentive Plan</link:label>
    <link:label id="lab_xcur_ExicureInc.2017EquityIncentivePlanMember_label_en-US" xlink:label="lab_xcur_ExicureInc.2017EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exicure, Inc. 2017 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_xcur_ExicureInc.2017EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_xcur_ExicureInc.2017EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exicure, Inc. 2017 Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ExicureInc.2017EquityIncentivePlanMember" xlink:href="xcur-20210930.xsd#xcur_ExicureInc.2017EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_xcur_ExicureInc.2017EquityIncentivePlanMember" xlink:to="lab_xcur_ExicureInc.2017EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_35b4d55d-2be2-4f67-8a45-6df0f7279459_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related-Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_d4f84791-a647-4af2-9f8a-a4de7a1a4597_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fe20ddba-8fb6-4675-a528-8943e4c3eeba_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>xcur-20210930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:ec2cf3ab-02c5-4899-a9f4-a2b651188a5f,g:ebea5fae-f5ab-4d4a-8517-3fed58ff79ef-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exicuretx.com/role/CoverPage" xlink:type="simple" xlink:href="xcur-20210930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_cb62dc53-2cdf-4a93-90f3-217e83e41eaa" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_d3117c77-fa14-4263-aa20-382ef0d067bb" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb62dc53-2cdf-4a93-90f3-217e83e41eaa" xlink:to="loc_dei_DocumentType_d3117c77-fa14-4263-aa20-382ef0d067bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_49a1373c-74d6-4788-bb32-7e30e67d71ed" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb62dc53-2cdf-4a93-90f3-217e83e41eaa" xlink:to="loc_dei_DocumentQuarterlyReport_49a1373c-74d6-4788-bb32-7e30e67d71ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_c6f481c0-16db-45a9-a021-394906fcc6ce" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb62dc53-2cdf-4a93-90f3-217e83e41eaa" xlink:to="loc_dei_DocumentPeriodEndDate_c6f481c0-16db-45a9-a021-394906fcc6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_5322a15f-0025-4d04-9851-59eb2c5c52a8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb62dc53-2cdf-4a93-90f3-217e83e41eaa" xlink:to="loc_dei_DocumentTransitionReport_5322a15f-0025-4d04-9851-59eb2c5c52a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_0756e3b9-1e85-4e7b-b361-43a724051aa7" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb62dc53-2cdf-4a93-90f3-217e83e41eaa" xlink:to="loc_dei_EntityFileNumber_0756e3b9-1e85-4e7b-b361-43a724051aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_bdf27bb9-2c0f-48d2-83a2-fd1dff8eb191" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb62dc53-2cdf-4a93-90f3-217e83e41eaa" xlink:to="loc_dei_EntityRegistrantName_bdf27bb9-2c0f-48d2-83a2-fd1dff8eb191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_88a2a9c3-2fd5-4fa4-9adf-ab4dee528f42" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb62dc53-2cdf-4a93-90f3-217e83e41eaa" xlink:to="loc_dei_EntityIncorporationStateCountryCode_88a2a9c3-2fd5-4fa4-9adf-ab4dee528f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_145f3f44-8566-42e7-81f4-ec04205c9d8d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb62dc53-2cdf-4a93-90f3-217e83e41eaa" xlink:to="loc_dei_EntityTaxIdentificationNumber_145f3f44-8566-42e7-81f4-ec04205c9d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_bdbbd02a-45f8-4315-a40c-4d1883f0f10e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb62dc53-2cdf-4a93-90f3-217e83e41eaa" xlink:to="loc_dei_EntityAddressAddressLine1_bdbbd02a-45f8-4315-a40c-4d1883f0f10e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_d7a08c08-0cc6-4b09-87ce-06039ce7a47c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb62dc53-2cdf-4a93-90f3-217e83e41eaa" xlink:to="loc_dei_EntityAddressCityOrTown_d7a08c08-0cc6-4b09-87ce-06039ce7a47c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_fe8e3868-42ee-4390-b53d-a2bc67b4cd8d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb62dc53-2cdf-4a93-90f3-217e83e41eaa" xlink:to="loc_dei_EntityAddressStateOrProvince_fe8e3868-42ee-4390-b53d-a2bc67b4cd8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_4c28eaa1-b230-4dc8-881f-e623fc2a2447" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb62dc53-2cdf-4a93-90f3-217e83e41eaa" xlink:to="loc_dei_EntityAddressPostalZipCode_4c28eaa1-b230-4dc8-881f-e623fc2a2447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_c41cabb2-5c79-4a07-a54c-8604ae2980ba" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb62dc53-2cdf-4a93-90f3-217e83e41eaa" xlink:to="loc_dei_CityAreaCode_c41cabb2-5c79-4a07-a54c-8604ae2980ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_402cbc1e-6328-49d9-877a-67531b9d68ae" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb62dc53-2cdf-4a93-90f3-217e83e41eaa" xlink:to="loc_dei_LocalPhoneNumber_402cbc1e-6328-49d9-877a-67531b9d68ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_f9c255f6-e072-42a4-b2e6-8703fc747abb" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb62dc53-2cdf-4a93-90f3-217e83e41eaa" xlink:to="loc_dei_Security12bTitle_f9c255f6-e072-42a4-b2e6-8703fc747abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_066ab4fb-0024-43e5-8786-d6508e31da04" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb62dc53-2cdf-4a93-90f3-217e83e41eaa" xlink:to="loc_dei_TradingSymbol_066ab4fb-0024-43e5-8786-d6508e31da04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_a5b44615-6036-444d-a56a-a7dbf24dc26d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb62dc53-2cdf-4a93-90f3-217e83e41eaa" xlink:to="loc_dei_SecurityExchangeName_a5b44615-6036-444d-a56a-a7dbf24dc26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_52aedc8d-9b3f-47d8-8cd7-01ceec56c534" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb62dc53-2cdf-4a93-90f3-217e83e41eaa" xlink:to="loc_dei_EntityCurrentReportingStatus_52aedc8d-9b3f-47d8-8cd7-01ceec56c534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_b44c71c5-d601-4f21-bb7e-2481fc1ca66c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb62dc53-2cdf-4a93-90f3-217e83e41eaa" xlink:to="loc_dei_EntityInteractiveDataCurrent_b44c71c5-d601-4f21-bb7e-2481fc1ca66c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_6b46feed-cc54-4f36-a3b2-82aaf9d197e8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb62dc53-2cdf-4a93-90f3-217e83e41eaa" xlink:to="loc_dei_EntityFilerCategory_6b46feed-cc54-4f36-a3b2-82aaf9d197e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_1891f0c9-2a1b-4a5b-8f45-3d39c63d1c46" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb62dc53-2cdf-4a93-90f3-217e83e41eaa" xlink:to="loc_dei_EntitySmallBusiness_1891f0c9-2a1b-4a5b-8f45-3d39c63d1c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_1de52f0f-04a4-4491-b464-facad921298d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb62dc53-2cdf-4a93-90f3-217e83e41eaa" xlink:to="loc_dei_EntityEmergingGrowthCompany_1de52f0f-04a4-4491-b464-facad921298d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_1a52e15d-a953-442a-b23b-b8def8097fda" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb62dc53-2cdf-4a93-90f3-217e83e41eaa" xlink:to="loc_dei_EntityExTransitionPeriod_1a52e15d-a953-442a-b23b-b8def8097fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_cf7b2c70-c7a6-4695-92c5-a9ef2c6a739f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb62dc53-2cdf-4a93-90f3-217e83e41eaa" xlink:to="loc_dei_EntityShellCompany_cf7b2c70-c7a6-4695-92c5-a9ef2c6a739f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_12dfe516-afa3-445f-b9da-0499cca10345" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb62dc53-2cdf-4a93-90f3-217e83e41eaa" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_12dfe516-afa3-445f-b9da-0499cca10345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_48f77003-2cad-4122-9900-669157303c1d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb62dc53-2cdf-4a93-90f3-217e83e41eaa" xlink:to="loc_dei_EntityCentralIndexKey_48f77003-2cad-4122-9900-669157303c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_352de842-18d6-46fa-b309-87f30a858fec" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb62dc53-2cdf-4a93-90f3-217e83e41eaa" xlink:to="loc_dei_CurrentFiscalYearEndDate_352de842-18d6-46fa-b309-87f30a858fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_3e53e3f6-2ff6-4f7b-adfd-cf8bdb1d94eb" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb62dc53-2cdf-4a93-90f3-217e83e41eaa" xlink:to="loc_dei_DocumentFiscalYearFocus_3e53e3f6-2ff6-4f7b-adfd-cf8bdb1d94eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_d7281ac6-756e-4cf6-8a8c-93e736612d0c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb62dc53-2cdf-4a93-90f3-217e83e41eaa" xlink:to="loc_dei_DocumentFiscalPeriodFocus_d7281ac6-756e-4cf6-8a8c-93e736612d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_5025fc0b-aef3-401c-adff-b38d5ceb13c2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cb62dc53-2cdf-4a93-90f3-217e83e41eaa" xlink:to="loc_dei_AmendmentFlag_5025fc0b-aef3-401c-adff-b38d5ceb13c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="xcur-20210930.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_57e8131f-2c1b-433e-a724-fa5574b95c93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_1a50f573-3a7a-4a95-a35f-0d88a5153a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_57e8131f-2c1b-433e-a724-fa5574b95c93" xlink:to="loc_us-gaap_AssetsAbstract_1a50f573-3a7a-4a95-a35f-0d88a5153a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_c8582ca3-c8e1-4cc1-bf6e-f422547687f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1a50f573-3a7a-4a95-a35f-0d88a5153a5c" xlink:to="loc_us-gaap_AssetsCurrentAbstract_c8582ca3-c8e1-4cc1-bf6e-f422547687f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2b74630a-102e-4b4b-a67a-4a22d7262283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c8582ca3-c8e1-4cc1-bf6e-f422547687f6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2b74630a-102e-4b4b-a67a-4a22d7262283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_b917db44-8271-4e47-a2bc-660513966a71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c8582ca3-c8e1-4cc1-bf6e-f422547687f6" xlink:to="loc_us-gaap_ShortTermInvestments_b917db44-8271-4e47-a2bc-660513966a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_456ab452-42c7-4c08-89ec-6ee75a793cab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c8582ca3-c8e1-4cc1-bf6e-f422547687f6" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_456ab452-42c7-4c08-89ec-6ee75a793cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_fd5d11dc-b3e4-4fe4-b071-141507d8421f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c8582ca3-c8e1-4cc1-bf6e-f422547687f6" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_fd5d11dc-b3e4-4fe4-b071-141507d8421f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4f570967-100d-4af8-809a-933eb5406b00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c8582ca3-c8e1-4cc1-bf6e-f422547687f6" xlink:to="loc_us-gaap_AssetsCurrent_4f570967-100d-4af8-809a-933eb5406b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b80b496e-9289-4c38-8b19-125092b4720d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1a50f573-3a7a-4a95-a35f-0d88a5153a5c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b80b496e-9289-4c38-8b19-125092b4720d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_65050e15-5bdc-4756-8d88-d20e962b6800" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1a50f573-3a7a-4a95-a35f-0d88a5153a5c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_65050e15-5bdc-4756-8d88-d20e962b6800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_beee28f0-ea8b-4391-b927-dabdd9e823fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1a50f573-3a7a-4a95-a35f-0d88a5153a5c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_beee28f0-ea8b-4391-b927-dabdd9e823fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_88d2ded0-a4f3-4316-ba5a-fc58d47c6fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1a50f573-3a7a-4a95-a35f-0d88a5153a5c" xlink:to="loc_us-gaap_Assets_88d2ded0-a4f3-4316-ba5a-fc58d47c6fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6f9c670a-ee4f-4574-a6c1-b3c4a73eb23b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_57e8131f-2c1b-433e-a724-fa5574b95c93" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6f9c670a-ee4f-4574-a6c1-b3c4a73eb23b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_bef9b58a-1f91-49ae-8827-a821415f9d14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6f9c670a-ee4f-4574-a6c1-b3c4a73eb23b" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_bef9b58a-1f91-49ae-8827-a821415f9d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_6529d91b-5f79-41be-8cde-f9dda6042abe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bef9b58a-1f91-49ae-8827-a821415f9d14" xlink:to="loc_us-gaap_AccountsPayableCurrent_6529d91b-5f79-41be-8cde-f9dda6042abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_42f6594a-cec2-49e3-a7a3-998618e3c077" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bef9b58a-1f91-49ae-8827-a821415f9d14" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_42f6594a-cec2-49e3-a7a3-998618e3c077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_0bd681bd-c7c8-40d3-8b60-4e993bdf32bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bef9b58a-1f91-49ae-8827-a821415f9d14" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_0bd681bd-c7c8-40d3-8b60-4e993bdf32bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e0fcffc5-1bc3-4f6b-9d2c-49a5833b38c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bef9b58a-1f91-49ae-8827-a821415f9d14" xlink:to="loc_us-gaap_LiabilitiesCurrent_e0fcffc5-1bc3-4f6b-9d2c-49a5833b38c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1084dc66-355e-452b-b1cd-0f8f59bd6423" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6f9c670a-ee4f-4574-a6c1-b3c4a73eb23b" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_1084dc66-355e-452b-b1cd-0f8f59bd6423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_fd4dd077-3ee3-4c23-96f2-f7e2fdbd0019" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6f9c670a-ee4f-4574-a6c1-b3c4a73eb23b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_fd4dd077-3ee3-4c23-96f2-f7e2fdbd0019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_19330507-5bd6-4c87-8e8f-9386e9469b05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6f9c670a-ee4f-4574-a6c1-b3c4a73eb23b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_19330507-5bd6-4c87-8e8f-9386e9469b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_a404cd4d-7721-40e8-b7ee-4a108619e4d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6f9c670a-ee4f-4574-a6c1-b3c4a73eb23b" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_a404cd4d-7721-40e8-b7ee-4a108619e4d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_eaa0d4ea-01c0-4bce-85f2-68b2fe922dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6f9c670a-ee4f-4574-a6c1-b3c4a73eb23b" xlink:to="loc_us-gaap_Liabilities_eaa0d4ea-01c0-4bce-85f2-68b2fe922dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_e8bd134b-a941-41c6-b5d6-afa98c01ead4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6f9c670a-ee4f-4574-a6c1-b3c4a73eb23b" xlink:to="loc_us-gaap_StockholdersEquityAbstract_e8bd134b-a941-41c6-b5d6-afa98c01ead4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_848ea3a9-d63c-402d-a883-45149fefb90a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e8bd134b-a941-41c6-b5d6-afa98c01ead4" xlink:to="loc_us-gaap_PreferredStockValue_848ea3a9-d63c-402d-a883-45149fefb90a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_c8b2a72b-bf5c-4f15-891f-8b834af4e3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e8bd134b-a941-41c6-b5d6-afa98c01ead4" xlink:to="loc_us-gaap_CommonStockValue_c8b2a72b-bf5c-4f15-891f-8b834af4e3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_094e6652-211e-4c49-ad0e-401d1528dd91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e8bd134b-a941-41c6-b5d6-afa98c01ead4" xlink:to="loc_us-gaap_AdditionalPaidInCapital_094e6652-211e-4c49-ad0e-401d1528dd91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_85ff7206-b3d8-42ea-817e-0b6fbcd2da94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e8bd134b-a941-41c6-b5d6-afa98c01ead4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_85ff7206-b3d8-42ea-817e-0b6fbcd2da94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_64c89a65-bbc0-4c4e-9553-51d522320b52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e8bd134b-a941-41c6-b5d6-afa98c01ead4" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_64c89a65-bbc0-4c4e-9553-51d522320b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dbbb3ced-c26b-4d29-822b-83a0c195ae81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_e8bd134b-a941-41c6-b5d6-afa98c01ead4" xlink:to="loc_us-gaap_StockholdersEquity_dbbb3ced-c26b-4d29-822b-83a0c195ae81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4deb3b0c-5755-4b63-bd35-1ba1e6a07427" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6f9c670a-ee4f-4574-a6c1-b3c4a73eb23b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_4deb3b0c-5755-4b63-bd35-1ba1e6a07427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="xcur-20210930.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_5621db67-3195-45c1-95ff-3ae9b9f5860e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_409520ba-e3ac-400c-aa5a-83e12593168d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5621db67-3195-45c1-95ff-3ae9b9f5860e" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_409520ba-e3ac-400c-aa5a-83e12593168d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_e0324206-d4dd-443b-941c-0de3e8769d19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5621db67-3195-45c1-95ff-3ae9b9f5860e" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_e0324206-d4dd-443b-941c-0de3e8769d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_2fbb6b7b-b8a1-49c0-855e-d9dfe5782628" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5621db67-3195-45c1-95ff-3ae9b9f5860e" xlink:to="loc_us-gaap_PreferredStockSharesIssued_2fbb6b7b-b8a1-49c0-855e-d9dfe5782628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_4a093d59-ac39-478d-8658-39aab0a01d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5621db67-3195-45c1-95ff-3ae9b9f5860e" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_4a093d59-ac39-478d-8658-39aab0a01d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_f1327d92-09c6-4caf-9939-06325ffd7009" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5621db67-3195-45c1-95ff-3ae9b9f5860e" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_f1327d92-09c6-4caf-9939-06325ffd7009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_32bab3b6-2d3b-4c8d-9a1a-f868023326c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5621db67-3195-45c1-95ff-3ae9b9f5860e" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_32bab3b6-2d3b-4c8d-9a1a-f868023326c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_11566067-0607-4c77-a760-43dc92ba08f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5621db67-3195-45c1-95ff-3ae9b9f5860e" xlink:to="loc_us-gaap_CommonStockSharesIssued_11566067-0607-4c77-a760-43dc92ba08f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4ce6bf8e-48a5-448a-b51c-f134258db2ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5621db67-3195-45c1-95ff-3ae9b9f5860e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4ce6bf8e-48a5-448a-b51c-f134258db2ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="xcur-20210930.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_011af17e-461c-4907-ac5a-f4956ea0c699" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_a6b999f0-ceb7-4501-bc2d-1759cce70d06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_011af17e-461c-4907-ac5a-f4956ea0c699" xlink:to="loc_us-gaap_RevenuesAbstract_a6b999f0-ceb7-4501-bc2d-1759cce70d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueFromContractWithCustomerNetOfCumulativeCatchUpAdjustment_b02747f8-dd44-4598-b0a0-ca93dffd6ed7" xlink:href="xcur-20210930.xsd#xcur_RevenueFromContractWithCustomerNetOfCumulativeCatchUpAdjustment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_a6b999f0-ceb7-4501-bc2d-1759cce70d06" xlink:to="loc_xcur_RevenueFromContractWithCustomerNetOfCumulativeCatchUpAdjustment_b02747f8-dd44-4598-b0a0-ca93dffd6ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_cb838c3d-ec5d-4b2f-b005-ae8bc39c0b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_a6b999f0-ceb7-4501-bc2d-1759cce70d06" xlink:to="loc_us-gaap_Revenues_cb838c3d-ec5d-4b2f-b005-ae8bc39c0b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_8d39fa64-86dc-4f99-9d72-2d5f7a13ae88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_011af17e-461c-4907-ac5a-f4956ea0c699" xlink:to="loc_us-gaap_OperatingExpensesAbstract_8d39fa64-86dc-4f99-9d72-2d5f7a13ae88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7ffbd98e-8c93-4063-a6b3-bff9216ffd96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8d39fa64-86dc-4f99-9d72-2d5f7a13ae88" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7ffbd98e-8c93-4063-a6b3-bff9216ffd96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_4c2d58ab-cd70-4449-a267-0cbfc44c430f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8d39fa64-86dc-4f99-9d72-2d5f7a13ae88" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_4c2d58ab-cd70-4449-a267-0cbfc44c430f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_c2cbd691-1b16-4813-a84d-51332a9bcda9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8d39fa64-86dc-4f99-9d72-2d5f7a13ae88" xlink:to="loc_us-gaap_OperatingExpenses_c2cbd691-1b16-4813-a84d-51332a9bcda9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e9327fc1-83cf-4461-8291-aa65474772d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_011af17e-461c-4907-ac5a-f4956ea0c699" xlink:to="loc_us-gaap_OperatingIncomeLoss_e9327fc1-83cf-4461-8291-aa65474772d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f1c5a229-13d9-4bbf-a150-e54667be6712" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_011af17e-461c-4907-ac5a-f4956ea0c699" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f1c5a229-13d9-4bbf-a150-e54667be6712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeDividend_4393105d-73b7-4fc1-9117-cd9150364a94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeDividend"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f1c5a229-13d9-4bbf-a150-e54667be6712" xlink:to="loc_us-gaap_InvestmentIncomeDividend_4393105d-73b7-4fc1-9117-cd9150364a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_8b0fe55c-57ff-4dbb-95ed-904a6035f6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f1c5a229-13d9-4bbf-a150-e54667be6712" xlink:to="loc_us-gaap_InvestmentIncomeInterest_8b0fe55c-57ff-4dbb-95ed-904a6035f6fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_8ad212af-d4b0-4765-aeb4-3f202327ad20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f1c5a229-13d9-4bbf-a150-e54667be6712" xlink:to="loc_us-gaap_InterestExpense_8ad212af-d4b0-4765-aeb4-3f202327ad20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_76fd210c-ca49-4b52-89ad-b13bee4dedd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f1c5a229-13d9-4bbf-a150-e54667be6712" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_76fd210c-ca49-4b52-89ad-b13bee4dedd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_eb54006e-5e7e-487c-ba32-d18784d8f0b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f1c5a229-13d9-4bbf-a150-e54667be6712" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_eb54006e-5e7e-487c-ba32-d18784d8f0b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_ac5bd433-70f3-43b6-aa00-d6ad8946f6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_011af17e-461c-4907-ac5a-f4956ea0c699" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_ac5bd433-70f3-43b6-aa00-d6ad8946f6ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_93113432-ba93-414b-a10d-ede006485b49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_011af17e-461c-4907-ac5a-f4956ea0c699" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_93113432-ba93-414b-a10d-ede006485b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_51db157d-0661-4fab-be54-69e0068146be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_011af17e-461c-4907-ac5a-f4956ea0c699" xlink:to="loc_us-gaap_NetIncomeLoss_51db157d-0661-4fab-be54-69e0068146be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_0cc35d9b-d47b-44fa-9c8e-ac7c57bde414" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_011af17e-461c-4907-ac5a-f4956ea0c699" xlink:to="loc_us-gaap_EarningsPerShareBasic_0cc35d9b-d47b-44fa-9c8e-ac7c57bde414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f9952a56-8d7a-4cb2-8f2b-d9169e27a127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_011af17e-461c-4907-ac5a-f4956ea0c699" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f9952a56-8d7a-4cb2-8f2b-d9169e27a127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_268ee200-4520-4588-bc58-f47a9e4fca10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_011af17e-461c-4907-ac5a-f4956ea0c699" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_268ee200-4520-4588-bc58-f47a9e4fca10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4b1767ac-f5ab-4d70-9b62-53236f9d4561" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_011af17e-461c-4907-ac5a-f4956ea0c699" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4b1767ac-f5ab-4d70-9b62-53236f9d4561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME" xlink:type="simple" xlink:href="xcur-20210930.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1d3b5409-6d70-4df2-b283-3a459ab519e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_87aa1268-4500-4f96-82cc-1452703ca92e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1d3b5409-6d70-4df2-b283-3a459ab519e3" xlink:to="loc_us-gaap_NetIncomeLoss_87aa1268-4500-4f96-82cc-1452703ca92e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_881219b5-2045-4fd1-b26c-f6e9438e7efd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1d3b5409-6d70-4df2-b283-3a459ab519e3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_881219b5-2045-4fd1-b26c-f6e9438e7efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_3c5c9f75-0d98-4ceb-897b-af4332ed2ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_881219b5-2045-4fd1-b26c-f6e9438e7efd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_3c5c9f75-0d98-4ceb-897b-af4332ed2ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5fe658da-b276-4d2c-b3f1-92a4cfea5d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_881219b5-2045-4fd1-b26c-f6e9438e7efd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5fe658da-b276-4d2c-b3f1-92a4cfea5d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_42878c41-b1c4-4281-8a11-7b3898822f28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1d3b5409-6d70-4df2-b283-3a459ab519e3" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_42878c41-b1c4-4281-8a11-7b3898822f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="xcur-20210930.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_65abe642-d906-4a00-b7ea-bbad7d56db2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_13b8c0a4-d255-4b4f-87a2-48b1006eafeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_65abe642-d906-4a00-b7ea-bbad7d56db2a" xlink:to="loc_us-gaap_StatementTable_13b8c0a4-d255-4b4f-87a2-48b1006eafeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9f50d16b-1d76-4547-9b98-e560c76daf5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_13b8c0a4-d255-4b4f-87a2-48b1006eafeb" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9f50d16b-1d76-4547-9b98-e560c76daf5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_025fcd1f-5b92-451b-b63f-c064f4f659bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9f50d16b-1d76-4547-9b98-e560c76daf5b" xlink:to="loc_us-gaap_EquityComponentDomain_025fcd1f-5b92-451b-b63f-c064f4f659bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5554a875-b592-4fc5-b179-9cfb74149447" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_025fcd1f-5b92-451b-b63f-c064f4f659bf" xlink:to="loc_us-gaap_CommonStockMember_5554a875-b592-4fc5-b179-9cfb74149447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_e30d8d88-b7cb-48b8-aec0-c4c17977834a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_025fcd1f-5b92-451b-b63f-c064f4f659bf" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_e30d8d88-b7cb-48b8-aec0-c4c17977834a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_4c132729-df00-40cf-9544-340706aae81b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_025fcd1f-5b92-451b-b63f-c064f4f659bf" xlink:to="loc_us-gaap_RetainedEarningsMember_4c132729-df00-40cf-9544-340706aae81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3c75d2c5-5a33-4429-9d4e-ece11958254d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_025fcd1f-5b92-451b-b63f-c064f4f659bf" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3c75d2c5-5a33-4429-9d4e-ece11958254d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_edcf3de5-2409-4bd7-b503-e9903473735b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_13b8c0a4-d255-4b4f-87a2-48b1006eafeb" xlink:to="loc_us-gaap_StatementLineItems_edcf3de5-2409-4bd7-b503-e9903473735b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dcae9ab8-47a1-404c-b004-9edb1b82f350" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_edcf3de5-2409-4bd7-b503-e9903473735b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dcae9ab8-47a1-404c-b004-9edb1b82f350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_afee37b4-bc77-4af8-8597-9b9f38914c63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dcae9ab8-47a1-404c-b004-9edb1b82f350" xlink:to="loc_us-gaap_SharesOutstanding_afee37b4-bc77-4af8-8597-9b9f38914c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_22121799-f2eb-4f68-93f5-7f0a0dc67e02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dcae9ab8-47a1-404c-b004-9edb1b82f350" xlink:to="loc_us-gaap_StockholdersEquity_22121799-f2eb-4f68-93f5-7f0a0dc67e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6049fff6-0d5e-4cf3-a066-70a3562f7d90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dcae9ab8-47a1-404c-b004-9edb1b82f350" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6049fff6-0d5e-4cf3-a066-70a3562f7d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d5c36276-815f-4c94-b8c9-7a2a4486ea1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dcae9ab8-47a1-404c-b004-9edb1b82f350" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d5c36276-815f-4c94-b8c9-7a2a4486ea1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_101f3560-2a34-447b-adb0-4af6aa98aa67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dcae9ab8-47a1-404c-b004-9edb1b82f350" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_101f3560-2a34-447b-adb0-4af6aa98aa67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_9d31581c-a14a-403b-9440-e3c1c95dcafb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dcae9ab8-47a1-404c-b004-9edb1b82f350" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_9d31581c-a14a-403b-9440-e3c1c95dcafb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_b0bff7ca-18a5-45f5-a44f-b870855c687b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dcae9ab8-47a1-404c-b004-9edb1b82f350" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_b0bff7ca-18a5-45f5-a44f-b870855c687b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0e1f577f-6c0d-42a3-bedf-9766113e5b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dcae9ab8-47a1-404c-b004-9edb1b82f350" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0e1f577f-6c0d-42a3-bedf-9766113e5b3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_803908f7-316d-4f3f-bb48-fa6194251d44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dcae9ab8-47a1-404c-b004-9edb1b82f350" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_803908f7-316d-4f3f-bb48-fa6194251d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_01ce9719-8f19-4b4c-b178-4b58c2ab4a29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dcae9ab8-47a1-404c-b004-9edb1b82f350" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_01ce9719-8f19-4b4c-b178-4b58c2ab4a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a17dc5f2-7187-41b0-8131-e1dfd4d6ce3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dcae9ab8-47a1-404c-b004-9edb1b82f350" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a17dc5f2-7187-41b0-8131-e1dfd4d6ce3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4a7998aa-ed60-4fce-a36a-3e8ab3dc39fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dcae9ab8-47a1-404c-b004-9edb1b82f350" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4a7998aa-ed60-4fce-a36a-3e8ab3dc39fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_00d87bb1-3de1-4d90-bbb4-27aca5ac7cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dcae9ab8-47a1-404c-b004-9edb1b82f350" xlink:to="loc_us-gaap_NetIncomeLoss_00d87bb1-3de1-4d90-bbb4-27aca5ac7cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_b02b9245-53f1-4e4e-acd7-5bc19d47f35d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dcae9ab8-47a1-404c-b004-9edb1b82f350" xlink:to="loc_us-gaap_SharesOutstanding_b02b9245-53f1-4e4e-acd7-5bc19d47f35d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_003c3dd4-b7ac-4005-96f3-27058f2c5c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dcae9ab8-47a1-404c-b004-9edb1b82f350" xlink:to="loc_us-gaap_StockholdersEquity_003c3dd4-b7ac-4005-96f3-27058f2c5c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="xcur-20210930.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_dd0c36a7-5195-40fc-842d-9be7ccab93da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4d352282-23f5-4c0a-b446-3d71b4cdaba2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_dd0c36a7-5195-40fc-842d-9be7ccab93da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4d352282-23f5-4c0a-b446-3d71b4cdaba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_61361ca2-12c1-4710-b7ac-1aae73e0899a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4d352282-23f5-4c0a-b446-3d71b4cdaba2" xlink:to="loc_us-gaap_NetIncomeLoss_61361ca2-12c1-4710-b7ac-1aae73e0899a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a01c6a6-8d7c-4bdc-9621-8801499c11d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4d352282-23f5-4c0a-b446-3d71b4cdaba2" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a01c6a6-8d7c-4bdc-9621-8801499c11d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_527384d2-13c6-49cd-8918-a26690e6d7e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a01c6a6-8d7c-4bdc-9621-8801499c11d2" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_527384d2-13c6-49cd-8918-a26690e6d7e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_28ddceb4-1edd-466f-9edd-349d8827d3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a01c6a6-8d7c-4bdc-9621-8801499c11d2" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_28ddceb4-1edd-466f-9edd-349d8827d3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f202d134-5ca7-4a75-b5ad-be41c99f37a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a01c6a6-8d7c-4bdc-9621-8801499c11d2" xlink:to="loc_us-gaap_ShareBasedCompensation_f202d134-5ca7-4a75-b5ad-be41c99f37a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_3eba7ab4-d76d-44c9-bfe7-3cabf7c7fcb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a01c6a6-8d7c-4bdc-9621-8801499c11d2" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_3eba7ab4-d76d-44c9-bfe7-3cabf7c7fcb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_2620dec5-60a6-4f69-a994-748503509a80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a01c6a6-8d7c-4bdc-9621-8801499c11d2" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_2620dec5-60a6-4f69-a994-748503509a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_cfd4d0ba-a599-4649-a10f-70739acd1268" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a01c6a6-8d7c-4bdc-9621-8801499c11d2" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_cfd4d0ba-a599-4649-a10f-70739acd1268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_a523e74d-2a1b-4a6e-b4c8-2e0fdbba77a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a01c6a6-8d7c-4bdc-9621-8801499c11d2" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_a523e74d-2a1b-4a6e-b4c8-2e0fdbba77a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e59eeac1-0ed3-4025-a920-82655749fcb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3a01c6a6-8d7c-4bdc-9621-8801499c11d2" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e59eeac1-0ed3-4025-a920-82655749fcb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_64232361-466a-476f-bfed-9ee4799812c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e59eeac1-0ed3-4025-a920-82655749fcb6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_64232361-466a-476f-bfed-9ee4799812c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_cf9d0f1f-5e6b-49cd-bf0d-456e2d84b80d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e59eeac1-0ed3-4025-a920-82655749fcb6" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_cf9d0f1f-5e6b-49cd-bf0d-456e2d84b80d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_28ff5805-7844-4263-958f-ddb8731d32e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e59eeac1-0ed3-4025-a920-82655749fcb6" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_28ff5805-7844-4263-958f-ddb8731d32e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6e155d34-22d3-4122-acd2-72347dd67b18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e59eeac1-0ed3-4025-a920-82655749fcb6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6e155d34-22d3-4122-acd2-72347dd67b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_d62aaccf-aaf1-40b2-be58-97b3629f401a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e59eeac1-0ed3-4025-a920-82655749fcb6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_d62aaccf-aaf1-40b2-be58-97b3629f401a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8573cd41-4354-42e3-8517-93a5ef581fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e59eeac1-0ed3-4025-a920-82655749fcb6" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8573cd41-4354-42e3-8517-93a5ef581fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_54e5b202-1fa6-4d4f-9aa9-437c9859efdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e59eeac1-0ed3-4025-a920-82655749fcb6" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_54e5b202-1fa6-4d4f-9aa9-437c9859efdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b904d3f4-9629-419c-9899-4409cedddb6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4d352282-23f5-4c0a-b446-3d71b4cdaba2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b904d3f4-9629-419c-9899-4409cedddb6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a1d0b641-80b5-4617-8b3f-1192d3c86c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_dd0c36a7-5195-40fc-842d-9be7ccab93da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a1d0b641-80b5-4617-8b3f-1192d3c86c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_7612aa15-850c-467d-bca0-d37c375538b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a1d0b641-80b5-4617-8b3f-1192d3c86c0f" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_7612aa15-850c-467d-bca0-d37c375538b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_a57e5a68-f364-4bf6-b5b8-84abd353ed33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a1d0b641-80b5-4617-8b3f-1192d3c86c0f" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_a57e5a68-f364-4bf6-b5b8-84abd353ed33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f595d881-84c6-428a-9ee8-398f80f2b4f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a1d0b641-80b5-4617-8b3f-1192d3c86c0f" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f595d881-84c6-428a-9ee8-398f80f2b4f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_86828548-a0e1-4040-905d-e995c05f48cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a1d0b641-80b5-4617-8b3f-1192d3c86c0f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_86828548-a0e1-4040-905d-e995c05f48cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a177b411-53c3-4c43-8abd-d0c1544d0a57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_dd0c36a7-5195-40fc-842d-9be7ccab93da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a177b411-53c3-4c43-8abd-d0c1544d0a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_626a2ccb-df21-4d0f-8564-928586d9a45f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a177b411-53c3-4c43-8abd-d0c1544d0a57" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_626a2ccb-df21-4d0f-8564-928586d9a45f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_PaymentsOfCommonStockFinancingCosts_7c2b12d3-2668-4b7b-9c4c-05de4d5021eb" xlink:href="xcur-20210930.xsd#xcur_PaymentsOfCommonStockFinancingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a177b411-53c3-4c43-8abd-d0c1544d0a57" xlink:to="loc_xcur_PaymentsOfCommonStockFinancingCosts_7c2b12d3-2668-4b7b-9c4c-05de4d5021eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_c6cf5e1b-5540-4b00-a391-e8bac080f774" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a177b411-53c3-4c43-8abd-d0c1544d0a57" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_c6cf5e1b-5540-4b00-a391-e8bac080f774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_1f0182e4-d565-4608-9824-7ff4d2f35b86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a177b411-53c3-4c43-8abd-d0c1544d0a57" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_1f0182e4-d565-4608-9824-7ff4d2f35b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_f969573c-2e49-4250-8ded-fb5c44d5637a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a177b411-53c3-4c43-8abd-d0c1544d0a57" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_f969573c-2e49-4250-8ded-fb5c44d5637a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_476c2a90-f2c8-441c-b896-6cb24eb03d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a177b411-53c3-4c43-8abd-d0c1544d0a57" xlink:to="loc_us-gaap_ProceedsFromStockPlans_476c2a90-f2c8-441c-b896-6cb24eb03d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_04260b5b-9b1b-4d7d-934d-6fdd1b7c69a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a177b411-53c3-4c43-8abd-d0c1544d0a57" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_04260b5b-9b1b-4d7d-934d-6fdd1b7c69a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_fc2e4577-8fa3-4ece-a802-41da8e4a690b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a177b411-53c3-4c43-8abd-d0c1544d0a57" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_fc2e4577-8fa3-4ece-a802-41da8e4a690b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_155d180e-fafe-4e3e-b9ef-f3d81b8660b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a177b411-53c3-4c43-8abd-d0c1544d0a57" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_155d180e-fafe-4e3e-b9ef-f3d81b8660b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c964ad2d-edf3-4c28-bcd9-d49e809b0b24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_dd0c36a7-5195-40fc-842d-9be7ccab93da" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c964ad2d-edf3-4c28-bcd9-d49e809b0b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f1526a17-f26b-4795-8c6b-4aa74f4d9136" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_dd0c36a7-5195-40fc-842d-9be7ccab93da" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f1526a17-f26b-4795-8c6b-4aa74f4d9136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_56239009-3683-4620-9a4a-6fb038749722" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_dd0c36a7-5195-40fc-842d-9be7ccab93da" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_56239009-3683-4620-9a4a-6fb038749722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_607b5444-f8ad-4fcf-86cd-dcc066afc515" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_dd0c36a7-5195-40fc-842d-9be7ccab93da" xlink:to="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_607b5444-f8ad-4fcf-86cd-dcc066afc515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_786d9314-f975-4dff-b239-85edb3869c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_607b5444-f8ad-4fcf-86cd-dcc066afc515" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_786d9314-f975-4dff-b239-85edb3869c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract_2b151b82-823f-48de-93a8-fdc4b84d1fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_607b5444-f8ad-4fcf-86cd-dcc066afc515" xlink:to="loc_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract_2b151b82-823f-48de-93a8-fdc4b84d1fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_a8a90066-a647-419e-82da-715e77154e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract_2b151b82-823f-48de-93a8-fdc4b84d1fb9" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_a8a90066-a647-419e-82da-715e77154e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsFinancingActivitiesAbstract_44a82278-e4f6-48ce-b9d6-d52dd4bbb69d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalCashFlowElementsFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_607b5444-f8ad-4fcf-86cd-dcc066afc515" xlink:to="loc_us-gaap_AdditionalCashFlowElementsFinancingActivitiesAbstract_44a82278-e4f6-48ce-b9d6-d52dd4bbb69d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_647a8473-6b50-4690-854f-4946460a7198" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsFinancingActivitiesAbstract_44a82278-e4f6-48ce-b9d6-d52dd4bbb69d" xlink:to="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_647a8473-6b50-4690-854f-4946460a7198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical" xlink:type="simple" xlink:href="xcur-20210930.xsd#UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_b4670eda-482e-4658-ab64-ca7a3fb67cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dd8c4dfb-ed78-4ea9-b18a-717849485dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b4670eda-482e-4658-ab64-ca7a3fb67cf0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dd8c4dfb-ed78-4ea9-b18a-717849485dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_f475e4b8-fb34-482c-8f33-2936da5cc51d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b4670eda-482e-4658-ab64-ca7a3fb67cf0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_f475e4b8-fb34-482c-8f33-2936da5cc51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bd031695-3d01-4516-a254-315bde26f713" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b4670eda-482e-4658-ab64-ca7a3fb67cf0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bd031695-3d01-4516-a254-315bde26f713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentation" xlink:type="simple" xlink:href="xcur-20210930.xsd#DescriptionofBusinessandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_244274fd-7cd9-4515-bd33-637eb58bb5d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_e764a8bc-b17a-46b5-8046-454e178444d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_244274fd-7cd9-4515-bd33-637eb58bb5d6" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_e764a8bc-b17a-46b5-8046-454e178444d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#DescriptionofBusinessandBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_39eb535a-3345-4ef8-9c5b-d06f5249a5f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualRiskOrUncertaintyTable_92d564d8-b520-4e37-90ff-2f8a6cfbc6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_39eb535a-3345-4ef8-9c5b-d06f5249a5f0" xlink:to="loc_us-gaap_UnusualRiskOrUncertaintyTable_92d564d8-b520-4e37-90ff-2f8a6cfbc6f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameAxis_cf5d4e19-d463-47a7-85e9-7b7da711283c" xlink:href="xcur-20210930.xsd#xcur_ArrangementNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyTable_92d564d8-b520-4e37-90ff-2f8a6cfbc6f2" xlink:to="loc_xcur_ArrangementNameAxis_cf5d4e19-d463-47a7-85e9-7b7da711283c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameDomain_0d9b9d52-11b5-4cd5-8bc4-4c890c8ca540" xlink:href="xcur-20210930.xsd#xcur_ArrangementNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_ArrangementNameAxis_cf5d4e19-d463-47a7-85e9-7b7da711283c" xlink:to="loc_xcur_ArrangementNameDomain_0d9b9d52-11b5-4cd5-8bc4-4c890c8ca540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_AbbVieCollaborationMember_7c0de014-4a71-4c14-9c4f-d5bcd007faac" xlink:href="xcur-20210930.xsd#xcur_AbbVieCollaborationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_ArrangementNameDomain_0d9b9d52-11b5-4cd5-8bc4-4c890c8ca540" xlink:to="loc_xcur_AbbVieCollaborationMember_7c0de014-4a71-4c14-9c4f-d5bcd007faac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6ee6a405-1d1b-42b3-aad4-08f77d0f13a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyTable_92d564d8-b520-4e37-90ff-2f8a6cfbc6f2" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6ee6a405-1d1b-42b3-aad4-08f77d0f13a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13715268-965e-4a1e-b5a3-abc7b3998f77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6ee6a405-1d1b-42b3-aad4-08f77d0f13a4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13715268-965e-4a1e-b5a3-abc7b3998f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_02dc04c2-e1bc-4ff5-a544-1ba27781f167" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13715268-965e-4a1e-b5a3-abc7b3998f77" xlink:to="loc_us-gaap_CollaborativeArrangementMember_02dc04c2-e1bc-4ff5-a544-1ba27781f167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis_1b097525-62f8-4189-906d-8379e17b5d16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyTable_92d564d8-b520-4e37-90ff-2f8a6cfbc6f2" xlink:to="loc_us-gaap_UnusualOrInfrequentItemAxis_1b097525-62f8-4189-906d-8379e17b5d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_3071d732-f7aa-41ed-9c10-8156e72f74ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_1b097525-62f8-4189-906d-8379e17b5d16" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_3071d732-f7aa-41ed-9c10-8156e72f74ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_COVID19Member_b6473162-2df1-4eba-98da-58e9ea3967de" xlink:href="xcur-20210930.xsd#xcur_COVID19Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain_3071d732-f7aa-41ed-9c10-8156e72f74ed" xlink:to="loc_xcur_COVID19Member_b6473162-2df1-4eba-98da-58e9ea3967de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_08b52c74-17a9-42d3-9883-760777f52f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyTable_92d564d8-b520-4e37-90ff-2f8a6cfbc6f2" xlink:to="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_08b52c74-17a9-42d3-9883-760777f52f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_08d8b912-4bb6-455e-ade0-1e9a0accc66b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_08b52c74-17a9-42d3-9883-760777f52f1f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_08d8b912-4bb6-455e-ade0-1e9a0accc66b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ResearchAndDevelopmentStaffOnSitePercentage_7a0e9589-c287-4075-81e5-86b9ce18eabc" xlink:href="xcur-20210930.xsd#xcur_ResearchAndDevelopmentStaffOnSitePercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_08b52c74-17a9-42d3-9883-760777f52f1f" xlink:to="loc_xcur_ResearchAndDevelopmentStaffOnSitePercentage_7a0e9589-c287-4075-81e5-86b9ce18eabc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_OfficeAndGeneralAndAdministrativeStaffOnSitePercentage_c2c30e9f-e173-47ec-bcd1-f47f96c7f1cf" xlink:href="xcur-20210930.xsd#xcur_OfficeAndGeneralAndAdministrativeStaffOnSitePercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_08b52c74-17a9-42d3-9883-760777f52f1f" xlink:to="loc_xcur_OfficeAndGeneralAndAdministrativeStaffOnSitePercentage_c2c30e9f-e173-47ec-bcd1-f47f96c7f1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate_5e4d703a-39f2-4e29-b2e2-b05352f12cc5" xlink:href="xcur-20210930.xsd#xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_08b52c74-17a9-42d3-9883-760777f52f1f" xlink:to="loc_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate_5e4d703a-39f2-4e29-b2e2-b05352f12cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate_89768ec7-395a-45e9-bff0-f72ddfbf56fd" xlink:href="xcur-20210930.xsd#xcur_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_08b52c74-17a9-42d3-9883-760777f52f1f" xlink:to="loc_xcur_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate_89768ec7-395a-45e9-bff0-f72ddfbf56fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SignificantAccountingPolicies" xlink:type="simple" xlink:href="xcur-20210930.xsd#SignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7fdcc709-29b1-4dad-8301-bdc8c11eb81e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_78d0bea9-0353-494e-b9cb-063937e05e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7fdcc709-29b1-4dad-8301-bdc8c11eb81e" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_78d0bea9-0353-494e-b9cb-063937e05e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="xcur-20210930.xsd#SignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_095be96b-0024-407b-ac7e-6f4401f851ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ee5a791b-4ecd-4984-81ef-2239308e3821" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_095be96b-0024-407b-ac7e-6f4401f851ca" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ee5a791b-4ecd-4984-81ef-2239308e3821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_e4345400-61be-4c47-8154-3df87a799926" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_095be96b-0024-407b-ac7e-6f4401f851ca" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_e4345400-61be-4c47-8154-3df87a799926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_9d5b3a6f-32ef-4826-90ed-c2cf425c9171" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_095be96b-0024-407b-ac7e-6f4401f851ca" xlink:to="loc_us-gaap_UseOfEstimates_9d5b3a6f-32ef-4826-90ed-c2cf425c9171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_cd91007e-88cf-4bdd-9767-dfcf53629a63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_095be96b-0024-407b-ac7e-6f4401f851ca" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_cd91007e-88cf-4bdd-9767-dfcf53629a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_acc890ba-768b-4e93-a767-fd3c721d7827" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_095be96b-0024-407b-ac7e-6f4401f851ca" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_acc890ba-768b-4e93-a767-fd3c721d7827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_278792d6-b8a3-4924-bdc8-ad088aa5cac7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_095be96b-0024-407b-ac7e-6f4401f851ca" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_278792d6-b8a3-4924-bdc8-ad088aa5cac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#SignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ff23bf92-294f-4bd0-b318-9ed8fbb1a86f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualRiskOrUncertaintyTable_7fe81fe9-fa63-46ce-8cd6-2e6307c6cb94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ff23bf92-294f-4bd0-b318-9ed8fbb1a86f" xlink:to="loc_us-gaap_UnusualRiskOrUncertaintyTable_7fe81fe9-fa63-46ce-8cd6-2e6307c6cb94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameAxis_9ba8a5b8-0816-4760-b9d4-df88b366e1af" xlink:href="xcur-20210930.xsd#xcur_ArrangementNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyTable_7fe81fe9-fa63-46ce-8cd6-2e6307c6cb94" xlink:to="loc_xcur_ArrangementNameAxis_9ba8a5b8-0816-4760-b9d4-df88b366e1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameDomain_998ccde8-8c1e-4df3-83cd-caabcdd353a6" xlink:href="xcur-20210930.xsd#xcur_ArrangementNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_ArrangementNameAxis_9ba8a5b8-0816-4760-b9d4-df88b366e1af" xlink:to="loc_xcur_ArrangementNameDomain_998ccde8-8c1e-4df3-83cd-caabcdd353a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_AbbVieCollaborationMember_29adf08d-6dc8-4cf6-8a53-441b26b3a1d9" xlink:href="xcur-20210930.xsd#xcur_AbbVieCollaborationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_ArrangementNameDomain_998ccde8-8c1e-4df3-83cd-caabcdd353a6" xlink:to="loc_xcur_AbbVieCollaborationMember_29adf08d-6dc8-4cf6-8a53-441b26b3a1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_20b4cd6a-9a9b-4983-975e-9d333662ad18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyTable_7fe81fe9-fa63-46ce-8cd6-2e6307c6cb94" xlink:to="loc_us-gaap_TypeOfArrangementAxis_20b4cd6a-9a9b-4983-975e-9d333662ad18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6a36198e-ff53-4e04-aa1e-9be983ec85c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_20b4cd6a-9a9b-4983-975e-9d333662ad18" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6a36198e-ff53-4e04-aa1e-9be983ec85c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_56ca7d0d-5807-4ea0-b6fa-c6cd27c8c68f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6a36198e-ff53-4e04-aa1e-9be983ec85c1" xlink:to="loc_us-gaap_CollaborativeArrangementMember_56ca7d0d-5807-4ea0-b6fa-c6cd27c8c68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_15620f39-e3e1-4119-b464-f64b714c521f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyTable_7fe81fe9-fa63-46ce-8cd6-2e6307c6cb94" xlink:to="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_15620f39-e3e1-4119-b464-f64b714c521f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_e6dc5147-bca9-46d8-a418-9876ea2155a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualRiskOrUncertaintyLineItems_15620f39-e3e1-4119-b464-f64b714c521f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_e6dc5147-bca9-46d8-a418-9876ea2155a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreements" xlink:type="simple" xlink:href="xcur-20210930.xsd#CollaborativeResearchandLicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_d2f0bd10-f1e0-4afe-a95a-4a36a99c2252" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_89dbcee0-06eb-4a68-a59c-4232fd04e9fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_d2f0bd10-f1e0-4afe-a95a-4a36a99c2252" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_89dbcee0-06eb-4a68-a59c-4232fd04e9fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsTables" xlink:type="simple" xlink:href="xcur-20210930.xsd#CollaborativeResearchandLicenseAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_4e93967c-f04e-432d-a91b-f120401eab17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_78a21e3f-5e8c-48e2-9b86-9b155566d2f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_4e93967c-f04e-432d-a91b-f120401eab17" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_78a21e3f-5e8c-48e2-9b86-9b155566d2f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#CollaborativeResearchandLicenseAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_2d0cac32-671c-4ef6-be04-c78fc9446e71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ceb255b0-a182-4a68-adb5-0885960f7a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_2d0cac32-671c-4ef6-be04-c78fc9446e71" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ceb255b0-a182-4a68-adb5-0885960f7a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_30045909-6bb9-4b95-b00d-669a5631da89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ceb255b0-a182-4a68-adb5-0885960f7a0c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_30045909-6bb9-4b95-b00d-669a5631da89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b02e136e-decb-41c2-8ac2-26067f048622" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_30045909-6bb9-4b95-b00d-669a5631da89" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b02e136e-decb-41c2-8ac2-26067f048622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_18c3380a-d237-468e-86f9-2815655338f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b02e136e-decb-41c2-8ac2-26067f048622" xlink:to="loc_us-gaap_CollaborativeArrangementMember_18c3380a-d237-468e-86f9-2815655338f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameAxis_1e7e158b-b729-4a27-bdd3-cb1231f836da" xlink:href="xcur-20210930.xsd#xcur_ArrangementNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ceb255b0-a182-4a68-adb5-0885960f7a0c" xlink:to="loc_xcur_ArrangementNameAxis_1e7e158b-b729-4a27-bdd3-cb1231f836da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameDomain_05751be3-e2b7-4dcc-813f-3c2b7aaff43e" xlink:href="xcur-20210930.xsd#xcur_ArrangementNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_ArrangementNameAxis_1e7e158b-b729-4a27-bdd3-cb1231f836da" xlink:to="loc_xcur_ArrangementNameDomain_05751be3-e2b7-4dcc-813f-3c2b7aaff43e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_IpsenCollaborationMember_947d9e5b-b6bc-4af1-9068-4747cc7ff58a" xlink:href="xcur-20210930.xsd#xcur_IpsenCollaborationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_ArrangementNameDomain_05751be3-e2b7-4dcc-813f-3c2b7aaff43e" xlink:to="loc_xcur_IpsenCollaborationMember_947d9e5b-b6bc-4af1-9068-4747cc7ff58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_AbbVieCollaborationMember_c25be32b-1004-4476-9b39-ca536616e3c5" xlink:href="xcur-20210930.xsd#xcur_AbbVieCollaborationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_ArrangementNameDomain_05751be3-e2b7-4dcc-813f-3c2b7aaff43e" xlink:to="loc_xcur_AbbVieCollaborationMember_c25be32b-1004-4476-9b39-ca536616e3c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DermelixLicenseAgreementMember_933bccd0-a43a-4bbf-ab2c-0253911cca22" xlink:href="xcur-20210930.xsd#xcur_DermelixLicenseAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_ArrangementNameDomain_05751be3-e2b7-4dcc-813f-3c2b7aaff43e" xlink:to="loc_xcur_DermelixLicenseAgreementMember_933bccd0-a43a-4bbf-ab2c-0253911cca22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ExercisePeriodAxis_927d2160-a5b1-4ac5-ad0b-92227813c4c7" xlink:href="xcur-20210930.xsd#xcur_ExercisePeriodAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ceb255b0-a182-4a68-adb5-0885960f7a0c" xlink:to="loc_xcur_ExercisePeriodAxis_927d2160-a5b1-4ac5-ad0b-92227813c4c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ExercisePeriodDomain_056868eb-92a0-4137-a39a-170f17a8cc15" xlink:href="xcur-20210930.xsd#xcur_ExercisePeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_ExercisePeriodAxis_927d2160-a5b1-4ac5-ad0b-92227813c4c7" xlink:to="loc_xcur_ExercisePeriodDomain_056868eb-92a0-4137-a39a-170f17a8cc15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ExercisePeriodOneMember_4b83ee94-2a56-46ac-a195-44c18aeeb7b6" xlink:href="xcur-20210930.xsd#xcur_ExercisePeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_ExercisePeriodDomain_056868eb-92a0-4137-a39a-170f17a8cc15" xlink:to="loc_xcur_ExercisePeriodOneMember_4b83ee94-2a56-46ac-a195-44c18aeeb7b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ExercisePeriodTwoMember_04cedacc-baac-4f0b-b038-4d60520463a2" xlink:href="xcur-20210930.xsd#xcur_ExercisePeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_ExercisePeriodDomain_056868eb-92a0-4137-a39a-170f17a8cc15" xlink:to="loc_xcur_ExercisePeriodTwoMember_04cedacc-baac-4f0b-b038-4d60520463a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementPerformanceObligationAxis_22ab10b8-ef3d-4ab6-8fa1-5bde7a6c2cdc" xlink:href="xcur-20210930.xsd#xcur_CollaborationAgreementPerformanceObligationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ceb255b0-a182-4a68-adb5-0885960f7a0c" xlink:to="loc_xcur_CollaborationAgreementPerformanceObligationAxis_22ab10b8-ef3d-4ab6-8fa1-5bde7a6c2cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementPerformanceObligationDomain_cfe0bce5-cadb-4d90-b020-11a06eaa844e" xlink:href="xcur-20210930.xsd#xcur_CollaborationAgreementPerformanceObligationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_CollaborationAgreementPerformanceObligationAxis_22ab10b8-ef3d-4ab6-8fa1-5bde7a6c2cdc" xlink:to="loc_xcur_CollaborationAgreementPerformanceObligationDomain_cfe0bce5-cadb-4d90-b020-11a06eaa844e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_IpsenHDMember_1ae9f9ad-0622-429a-8370-48eca3281c06" xlink:href="xcur-20210930.xsd#xcur_IpsenHDMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_CollaborationAgreementPerformanceObligationDomain_cfe0bce5-cadb-4d90-b020-11a06eaa844e" xlink:to="loc_xcur_IpsenHDMember_1ae9f9ad-0622-429a-8370-48eca3281c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_IpsenASMember_25961050-281c-4ddf-8d39-7d49b07f523a" xlink:href="xcur-20210930.xsd#xcur_IpsenASMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_CollaborationAgreementPerformanceObligationDomain_cfe0bce5-cadb-4d90-b020-11a06eaa844e" xlink:to="loc_xcur_IpsenASMember_25961050-281c-4ddf-8d39-7d49b07f523a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c091e62d-4cbe-43f5-a074-97c42a62d1d8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ceb255b0-a182-4a68-adb5-0885960f7a0c" xlink:to="loc_srt_RangeAxis_c091e62d-4cbe-43f5-a074-97c42a62d1d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e4e74bbb-a7ac-4646-a192-2b6267c927fe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c091e62d-4cbe-43f5-a074-97c42a62d1d8" xlink:to="loc_srt_RangeMember_e4e74bbb-a7ac-4646-a192-2b6267c927fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c355d940-d010-433c-b171-ff3057ce8c73" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e4e74bbb-a7ac-4646-a192-2b6267c927fe" xlink:to="loc_srt_MinimumMember_c355d940-d010-433c-b171-ff3057ce8c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_69bb5235-01f9-4580-b753-f7bf173d4518" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e4e74bbb-a7ac-4646-a192-2b6267c927fe" xlink:to="loc_srt_MaximumMember_69bb5235-01f9-4580-b753-f7bf173d4518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_9cfd07a6-254c-4a72-9cef-74969dee139d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ceb255b0-a182-4a68-adb5-0885960f7a0c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_9cfd07a6-254c-4a72-9cef-74969dee139d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_71d55105-9a8e-4ec3-ace3-697f08c9f463" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_9cfd07a6-254c-4a72-9cef-74969dee139d" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_71d55105-9a8e-4ec3-ace3-697f08c9f463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DevelopmentandCommercializationLicenseMember_e5831ad4-1125-4e8d-83ff-84aec8dbeec2" xlink:href="xcur-20210930.xsd#xcur_DevelopmentandCommercializationLicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_71d55105-9a8e-4ec3-ace3-697f08c9f463" xlink:to="loc_xcur_DevelopmentandCommercializationLicenseMember_e5831ad4-1125-4e8d-83ff-84aec8dbeec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ceb255b0-a182-4a68-adb5-0885960f7a0c" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_NumberofCollaborationPrograms_5f4e8c95-a856-43ae-a7fd-6535875d6342" xlink:href="xcur-20210930.xsd#xcur_NumberofCollaborationPrograms"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_xcur_NumberofCollaborationPrograms_5f4e8c95-a856-43ae-a7fd-6535875d6342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_fb955fac-52a3-403e-a5cb-707f973cde5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_us-gaap_ProceedsFromCollaborators_fb955fac-52a3-403e-a5cb-707f973cde5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementOptionExerciseFee_25e1267b-6232-4a75-b538-155090cf4a68" xlink:href="xcur-20210930.xsd#xcur_CollaborationAgreementOptionExerciseFee"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_xcur_CollaborationAgreementOptionExerciseFee_25e1267b-6232-4a75-b538-155090cf4a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment_bff9e620-071d-48b6-ad55-6a15b47922f7" xlink:href="xcur-20210930.xsd#xcur_RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_xcur_RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment_bff9e620-071d-48b6-ad55-6a15b47922f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment_cbe278c2-c9bb-4f18-9992-529389f8a175" xlink:href="xcur-20210930.xsd#xcur_RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_xcur_RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment_cbe278c2-c9bb-4f18-9992-529389f8a175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment_db3decd3-172b-4398-994e-ed7b2c37ce5c" xlink:href="xcur-20210930.xsd#xcur_RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_xcur_RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment_db3decd3-172b-4398-994e-ed7b2c37ce5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementLicensingFeesIncurred_11235e1e-9a07-4df6-939f-2799d766dd92" xlink:href="xcur-20210930.xsd#xcur_CollaborationAgreementLicensingFeesIncurred"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_xcur_CollaborationAgreementLicensingFeesIncurred_11235e1e-9a07-4df6-939f-2799d766dd92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementTerminationNoticePeriod_34d4d552-1f8e-4211-a471-27f6d7825a36" xlink:href="xcur-20210930.xsd#xcur_CollaborationAgreementTerminationNoticePeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_xcur_CollaborationAgreementTerminationNoticePeriod_34d4d552-1f8e-4211-a471-27f6d7825a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementTransactionPrice_7260b2ca-2701-4711-9718-4334f82e40ef" xlink:href="xcur-20210930.xsd#xcur_CollaborationAgreementTransactionPrice"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_xcur_CollaborationAgreementTransactionPrice_7260b2ca-2701-4711-9718-4334f82e40ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_028185b0-4b4f-47e0-8024-357b8fa60416" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_028185b0-4b4f-47e0-8024-357b8fa60416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_92425b21-4395-4b10-864b-80351db53b79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_us-gaap_ContractWithCustomerLiability_92425b21-4395-4b10-864b-80351db53b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2ac32118-2776-42a0-83b5-ac9bd637bc70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2ac32118-2776-42a0-83b5-ac9bd637bc70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_264f6c8f-89fc-4512-bfad-89df391dde48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_264f6c8f-89fc-4512-bfad-89df391dde48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementEstimatedTimingOfRevenueRecognition_edc851d5-0b2a-4902-98fc-a17e6c1fb5a7" xlink:href="xcur-20210930.xsd#xcur_CollaborationAgreementEstimatedTimingOfRevenueRecognition"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_xcur_CollaborationAgreementEstimatedTimingOfRevenueRecognition_edc851d5-0b2a-4902-98fc-a17e6c1fb5a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementUpfrontPayment_61daddd9-461b-4354-9e84-53bdb31d38ef" xlink:href="xcur-20210930.xsd#xcur_CollaborationAgreementUpfrontPayment"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_xcur_CollaborationAgreementUpfrontPayment_61daddd9-461b-4354-9e84-53bdb31d38ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee_d62593e7-3f59-491e-b6f8-4d20af93e906" xlink:href="xcur-20210930.xsd#xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee_d62593e7-3f59-491e-b6f8-4d20af93e906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment_1702d03b-6cbf-462c-82bd-9aded39ac3e5" xlink:href="xcur-20210930.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment_1702d03b-6cbf-462c-82bd-9aded39ac3e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment_9eab8db9-9af8-480b-bdd9-c44d8bc0bc26" xlink:href="xcur-20210930.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment_9eab8db9-9af8-480b-bdd9-c44d8bc0bc26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment_abea5603-36a0-43be-9767-211e8f10f571" xlink:href="xcur-20210930.xsd#xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment_abea5603-36a0-43be-9767-211e8f10f571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice_0e145734-1630-4cb4-a572-80431111be99" xlink:href="xcur-20210930.xsd#xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice_0e145734-1630-4cb4-a572-80431111be99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_3aa1ece1-d657-428e-b495-361eb373c166" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_3aa1ece1-d657-428e-b495-361eb373c166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CollaborationDevelopmentExpenses_93bfaa3a-ba18-4549-8aeb-33b2b6d8aeb3" xlink:href="xcur-20210930.xsd#xcur_CollaborationDevelopmentExpenses"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_xcur_CollaborationDevelopmentExpenses_93bfaa3a-ba18-4549-8aeb-33b2b6d8aeb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate_8eec450a-c52c-4cfd-8cd3-2f97df6d02a8" xlink:href="xcur-20210930.xsd#xcur_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4501c96d-b9e8-4891-8ee9-0785f427870a" xlink:to="loc_xcur_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate_8eec450a-c52c-4cfd-8cd3-2f97df6d02a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#CollaborativeResearchandLicenseAgreementsOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_a5cb278c-14e9-49be-9eaa-25aa85221a04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_093aa2db-d4a8-451b-bd1e-f20c54832901" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_a5cb278c-14e9-49be-9eaa-25aa85221a04" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_093aa2db-d4a8-451b-bd1e-f20c54832901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameAxis_af9bc8d1-bfaf-4e93-91a1-bb2c4cea183c" xlink:href="xcur-20210930.xsd#xcur_ArrangementNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_093aa2db-d4a8-451b-bd1e-f20c54832901" xlink:to="loc_xcur_ArrangementNameAxis_af9bc8d1-bfaf-4e93-91a1-bb2c4cea183c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ArrangementNameDomain_786e5d32-c474-48f7-a4bb-225c235c5986" xlink:href="xcur-20210930.xsd#xcur_ArrangementNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_ArrangementNameAxis_af9bc8d1-bfaf-4e93-91a1-bb2c4cea183c" xlink:to="loc_xcur_ArrangementNameDomain_786e5d32-c474-48f7-a4bb-225c235c5986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_IpsenCollaborationMember_8247e63c-5357-42f6-ad1b-50b472df78a7" xlink:href="xcur-20210930.xsd#xcur_IpsenCollaborationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_ArrangementNameDomain_786e5d32-c474-48f7-a4bb-225c235c5986" xlink:to="loc_xcur_IpsenCollaborationMember_8247e63c-5357-42f6-ad1b-50b472df78a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_AbbVieCollaborationMember_f7b9faf6-8ea7-47b1-ac38-c45eb815b2f2" xlink:href="xcur-20210930.xsd#xcur_AbbVieCollaborationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_ArrangementNameDomain_786e5d32-c474-48f7-a4bb-225c235c5986" xlink:to="loc_xcur_AbbVieCollaborationMember_f7b9faf6-8ea7-47b1-ac38-c45eb815b2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2d32abd8-14bc-437b-b3dd-139d1c8b53fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_093aa2db-d4a8-451b-bd1e-f20c54832901" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2d32abd8-14bc-437b-b3dd-139d1c8b53fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInDeferredRevenueRollForward_0e29e285-6283-4161-9498-24228c908f76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInDeferredRevenueRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2d32abd8-14bc-437b-b3dd-139d1c8b53fa" xlink:to="loc_us-gaap_MovementInDeferredRevenueRollForward_0e29e285-6283-4161-9498-24228c908f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_bdfe0ddb-4c6e-45a7-b91a-b279b7c054db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInDeferredRevenueRollForward_0e29e285-6283-4161-9498-24228c908f76" xlink:to="loc_us-gaap_ContractWithCustomerLiability_bdfe0ddb-4c6e-45a7-b91a-b279b7c054db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ContractWithCustomerLiabilityAdditions_72f46bf2-3d43-4578-b0d0-0f0f2b1f8f17" xlink:href="xcur-20210930.xsd#xcur_ContractWithCustomerLiabilityAdditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInDeferredRevenueRollForward_0e29e285-6283-4161-9498-24228c908f76" xlink:to="loc_xcur_ContractWithCustomerLiabilityAdditions_72f46bf2-3d43-4578-b0d0-0f0f2b1f8f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance_c4a289ee-cf3b-43a9-a99a-a9d75865431a" xlink:href="xcur-20210930.xsd#xcur_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInDeferredRevenueRollForward_0e29e285-6283-4161-9498-24228c908f76" xlink:to="loc_xcur_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance_c4a289ee-cf3b-43a9-a99a-a9d75865431a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_2c50260a-a533-4a66-8c8e-7a9c057e87bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInDeferredRevenueRollForward_0e29e285-6283-4161-9498-24228c908f76" xlink:to="loc_us-gaap_ContractWithCustomerLiability_2c50260a-a533-4a66-8c8e-7a9c057e87bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformation" xlink:type="simple" xlink:href="xcur-20210930.xsd#SupplementalBalanceSheetInformation"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SupplementalBalanceSheetInformationAbstract_1a35f9f5-303f-443d-b3fd-5532bcd7d929" xlink:href="xcur-20210930.xsd#xcur_SupplementalBalanceSheetInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_a6620213-8308-4361-b2be-2b37bd4e964a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_1a35f9f5-303f-443d-b3fd-5532bcd7d929" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_a6620213-8308-4361-b2be-2b37bd4e964a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables" xlink:type="simple" xlink:href="xcur-20210930.xsd#SupplementalBalanceSheetInformationTables"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SupplementalBalanceSheetInformationAbstract_db217ae2-0ce5-464e-8797-2c4ba76bacdf" xlink:href="xcur-20210930.xsd#xcur_SupplementalBalanceSheetInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_37ea15ca-26ae-419e-ab42-63c11f0b4619" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_db217ae2-0ce5-464e-8797-2c4ba76bacdf" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_37ea15ca-26ae-419e-ab42-63c11f0b4619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_2c17c13c-81ff-4403-ab6e-a6354d0c6c25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_db217ae2-0ce5-464e-8797-2c4ba76bacdf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_2c17c13c-81ff-4403-ab6e-a6354d0c6c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_f555998d-9d2e-454f-a9c9-381b1ed8d254" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_db217ae2-0ce5-464e-8797-2c4ba76bacdf" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_f555998d-9d2e-454f-a9c9-381b1ed8d254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SupplementalBalanceSheetInformationAbstract_37f60737-9b75-4cbb-8918-2026f3aab63a" xlink:href="xcur-20210930.xsd#xcur_SupplementalBalanceSheetInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_22a70c4a-db5c-4555-8469-c2d5093bbd33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_37f60737-9b75-4cbb-8918-2026f3aab63a" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_22a70c4a-db5c-4555-8469-c2d5093bbd33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_e15180be-18fd-4da7-aa0d-a2c6bba93b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_37f60737-9b75-4cbb-8918-2026f3aab63a" xlink:to="loc_us-gaap_InterestReceivable_e15180be-18fd-4da7-aa0d-a2c6bba93b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_1b2d8a6d-7202-4607-b735-ca1a39b30a46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_37f60737-9b75-4cbb-8918-2026f3aab63a" xlink:to="loc_us-gaap_PrepaidInsurance_1b2d8a6d-7202-4607-b735-ca1a39b30a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_bb1b6fc4-9d45-450c-ac02-42dbce649598" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_37f60737-9b75-4cbb-8918-2026f3aab63a" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_bb1b6fc4-9d45-450c-ac02-42dbce649598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9cd095d2-7e13-4a58-983d-091e51127056" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_37f60737-9b75-4cbb-8918-2026f3aab63a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9cd095d2-7e13-4a58-983d-091e51127056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SupplementalBalanceSheetInformationAbstract_10bd738f-b484-430a-9d22-9157c80ec081" xlink:href="xcur-20210930.xsd#xcur_SupplementalBalanceSheetInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4454f53a-3b60-424b-a715-cda4a82199c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_10bd738f-b484-430a-9d22-9157c80ec081" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4454f53a-3b60-424b-a715-cda4a82199c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bd5d6644-9c1c-4c0a-9883-cac86c68479a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4454f53a-3b60-424b-a715-cda4a82199c3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bd5d6644-9c1c-4c0a-9883-cac86c68479a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_693de6f3-0797-4d73-b26c-57b86762c0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bd5d6644-9c1c-4c0a-9883-cac86c68479a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_693de6f3-0797-4d73-b26c-57b86762c0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_c0f33dbf-8e51-4fad-8634-61cdcbdc64ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_693de6f3-0797-4d73-b26c-57b86762c0a5" xlink:to="loc_us-gaap_EquipmentMember_c0f33dbf-8e51-4fad-8634-61cdcbdc64ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_cd7d83fc-a6e2-4d16-a79d-c6f85f77afdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_693de6f3-0797-4d73-b26c-57b86762c0a5" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_cd7d83fc-a6e2-4d16-a79d-c6f85f77afdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ComputersandSoftwareMember_8560217e-0421-4de8-9ea3-6bd7506bea70" xlink:href="xcur-20210930.xsd#xcur_ComputersandSoftwareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_693de6f3-0797-4d73-b26c-57b86762c0a5" xlink:to="loc_xcur_ComputersandSoftwareMember_8560217e-0421-4de8-9ea3-6bd7506bea70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_de813ed9-3862-446b-b96d-f43017932195" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_693de6f3-0797-4d73-b26c-57b86762c0a5" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_de813ed9-3862-446b-b96d-f43017932195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_9cff61b4-256c-4da9-9508-41c2cb6cb7ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_693de6f3-0797-4d73-b26c-57b86762c0a5" xlink:to="loc_us-gaap_ConstructionInProgressMember_9cff61b4-256c-4da9-9508-41c2cb6cb7ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_53ddeb5f-a59f-4d28-b16a-32832ad2104c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4454f53a-3b60-424b-a715-cda4a82199c3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_53ddeb5f-a59f-4d28-b16a-32832ad2104c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_33c35575-fada-4b9e-b6ba-a9530c1648f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_53ddeb5f-a59f-4d28-b16a-32832ad2104c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_33c35575-fada-4b9e-b6ba-a9530c1648f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c1fc15ef-b2f7-49df-85ba-53c970e16e16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_53ddeb5f-a59f-4d28-b16a-32832ad2104c" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c1fc15ef-b2f7-49df-85ba-53c970e16e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_badf8d3a-ce59-4d59-90ae-873ea3a5bc71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_53ddeb5f-a59f-4d28-b16a-32832ad2104c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_badf8d3a-ce59-4d59-90ae-873ea3a5bc71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAmortizationAndAccretionNet_d8073073-f0d5-4098-854b-b753449ed28f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_53ddeb5f-a59f-4d28-b16a-32832ad2104c" xlink:to="loc_us-gaap_DepreciationAmortizationAndAccretionNet_d8073073-f0d5-4098-854b-b753449ed28f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SupplementalBalanceSheetInformationAbstract_cbf7a7ec-b22c-4762-bf69-d4b90057d2a0" xlink:href="xcur-20210930.xsd#xcur_SupplementalBalanceSheetInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent_b9a393ef-b003-488e-a3ac-06c72d889018" xlink:href="xcur-20210930.xsd#xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_cbf7a7ec-b22c-4762-bf69-d4b90057d2a0" xlink:to="loc_xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent_b9a393ef-b003-488e-a3ac-06c72d889018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_168c143f-7fe0-4e46-be97-23303b0536de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_cbf7a7ec-b22c-4762-bf69-d4b90057d2a0" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_168c143f-7fe0-4e46-be97-23303b0536de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4dc9a9d4-1512-4805-9cf7-4018264e33b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_cbf7a7ec-b22c-4762-bf69-d4b90057d2a0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4dc9a9d4-1512-4805-9cf7-4018264e33b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_952a1055-51d4-4214-9ff8-06d6e8ee2066" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_cbf7a7ec-b22c-4762-bf69-d4b90057d2a0" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_952a1055-51d4-4214-9ff8-06d6e8ee2066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_92d60aab-ff68-4b4f-aa8b-171c4c26a50d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_SupplementalBalanceSheetInformationAbstract_cbf7a7ec-b22c-4762-bf69-d4b90057d2a0" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_92d60aab-ff68-4b4f-aa8b-171c4c26a50d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/Investments" xlink:type="simple" xlink:href="xcur-20210930.xsd#Investments"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_1e87c5a8-999f-4201-8276-8b3034f8bde1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_708ecaa2-f1b7-4929-a6bd-51dc83c683f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_1e87c5a8-999f-4201-8276-8b3034f8bde1" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_708ecaa2-f1b7-4929-a6bd-51dc83c683f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/InvestmentsTables" xlink:type="simple" xlink:href="xcur-20210930.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_60d80aa5-b310-4014-b9db-150efd932fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTableTextBlock_0dc42b2c-f17e-4bbe-817b-42ff04cde0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_60d80aa5-b310-4014-b9db-150efd932fcd" xlink:to="loc_us-gaap_InvestmentTableTextBlock_0dc42b2c-f17e-4bbe-817b-42ff04cde0cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_4a3f41ae-62e8-4c8f-a05c-1e8a7f131d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_60d80aa5-b310-4014-b9db-150efd932fcd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_4a3f41ae-62e8-4c8f-a05c-1e8a7f131d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/InvestmentsDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#InvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/InvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_f64ec0c5-3d98-4b16-94ee-3057da280769" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DebtSecuritiesAvailableForSaleCurrentPercent_43dfde17-6be8-4ddc-a20a-6cd6c696ec23" xlink:href="xcur-20210930.xsd#xcur_DebtSecuritiesAvailableForSaleCurrentPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_f64ec0c5-3d98-4b16-94ee-3057da280769" xlink:to="loc_xcur_DebtSecuritiesAvailableForSaleCurrentPercent_43dfde17-6be8-4ddc-a20a-6cd6c696ec23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent_37b0b92d-f17d-42a4-812c-83ba35549b1f" xlink:href="xcur-20210930.xsd#xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_f64ec0c5-3d98-4b16-94ee-3057da280769" xlink:to="loc_xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent_37b0b92d-f17d-42a4-812c-83ba35549b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DebtSecuritiesAvailableforSalePercent_ee412f9a-221d-47a1-b6b0-6749e46d554a" xlink:href="xcur-20210930.xsd#xcur_DebtSecuritiesAvailableforSalePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_f64ec0c5-3d98-4b16-94ee-3057da280769" xlink:to="loc_xcur_DebtSecuritiesAvailableforSalePercent_ee412f9a-221d-47a1-b6b0-6749e46d554a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#InvestmentsAvailableforsaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAbstract_6c42fdc6-78da-4973-98d7-582e76ddad3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ca1bcbc1-1ada-4c10-8819-9a116169056a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAbstract_6c42fdc6-78da-4973-98d7-582e76ddad3b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ca1bcbc1-1ada-4c10-8819-9a116169056a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_92164bd8-1565-4bff-82ce-862da3e0a5a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ca1bcbc1-1ada-4c10-8819-9a116169056a" xlink:to="loc_us-gaap_FinancialInstrumentAxis_92164bd8-1565-4bff-82ce-862da3e0a5a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b453c3ea-f39d-49ae-9dcd-29b2dd80818f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_92164bd8-1565-4bff-82ce-862da3e0a5a9" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b453c3ea-f39d-49ae-9dcd-29b2dd80818f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_184e08dc-76e8-4111-bb92-0e29b4c6fa0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b453c3ea-f39d-49ae-9dcd-29b2dd80818f" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_184e08dc-76e8-4111-bb92-0e29b4c6fa0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_ec4dcab3-7d70-4d6e-9e73-11de077a9747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b453c3ea-f39d-49ae-9dcd-29b2dd80818f" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_ec4dcab3-7d70-4d6e-9e73-11de077a9747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_4a20d548-82ce-465a-a7c4-bb4b5edd408f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b453c3ea-f39d-49ae-9dcd-29b2dd80818f" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_4a20d548-82ce-465a-a7c4-bb4b5edd408f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_8810e896-da35-45b4-8bb6-be9c51091ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b453c3ea-f39d-49ae-9dcd-29b2dd80818f" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_8810e896-da35-45b4-8bb6-be9c51091ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fde0354d-72a3-4c62-9915-9dd0f0b4c682" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ca1bcbc1-1ada-4c10-8819-9a116169056a" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fde0354d-72a3-4c62-9915-9dd0f0b4c682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d4b3eb57-eb9c-4dc1-86d9-25bf1dd09077" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fde0354d-72a3-4c62-9915-9dd0f0b4c682" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d4b3eb57-eb9c-4dc1-86d9-25bf1dd09077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_edfeeac8-2b1c-4128-88aa-5b33f2dd44b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fde0354d-72a3-4c62-9915-9dd0f0b4c682" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_edfeeac8-2b1c-4128-88aa-5b33f2dd44b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d528c3e5-4338-4ff6-a460-93daf73cdea2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fde0354d-72a3-4c62-9915-9dd0f0b4c682" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d528c3e5-4338-4ff6-a460-93daf73cdea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b89107f9-df09-414a-97b9-213506b0b0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fde0354d-72a3-4c62-9915-9dd0f0b4c682" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b89107f9-df09-414a-97b9-213506b0b0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/Debt" xlink:type="simple" xlink:href="xcur-20210930.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2f6c3d26-56e2-4895-ba78-8560f69eb045" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_4190114f-ced0-4228-93d1-26b539d73f33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2f6c3d26-56e2-4895-ba78-8560f69eb045" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_4190114f-ced0-4228-93d1-26b539d73f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/DebtTables" xlink:type="simple" xlink:href="xcur-20210930.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_62344b8b-3871-467d-911f-8684f0671725" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_fa65bed1-7acb-478f-a599-370c0b144d17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_62344b8b-3871-467d-911f-8684f0671725" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_fa65bed1-7acb-478f-a599-370c0b144d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#DebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e2969070-2ae5-4748-a5d6-f9a61880bba9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_018cae0b-f98f-4d16-8e6c-9ee84c963ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e2969070-2ae5-4748-a5d6-f9a61880bba9" xlink:to="loc_us-gaap_DebtInstrumentTable_018cae0b-f98f-4d16-8e6c-9ee84c963ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a1fed48c-25c4-44d0-8e2e-4da2133fc40a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_018cae0b-f98f-4d16-8e6c-9ee84c963ccc" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a1fed48c-25c4-44d0-8e2e-4da2133fc40a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_da4bd1c8-71df-42f6-beef-e371525ef1a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a1fed48c-25c4-44d0-8e2e-4da2133fc40a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_da4bd1c8-71df-42f6-beef-e371525ef1a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_27cad2a8-1b80-4b84-9894-3ec88feb21fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_da4bd1c8-71df-42f6-beef-e371525ef1a6" xlink:to="loc_us-gaap_SecuredDebtMember_27cad2a8-1b80-4b84-9894-3ec88feb21fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_a349a4ab-2972-4d3e-9a8f-83ca401e143a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_da4bd1c8-71df-42f6-beef-e371525ef1a6" xlink:to="loc_us-gaap_LoansPayableMember_a349a4ab-2972-4d3e-9a8f-83ca401e143a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_a7058a3d-c888-4491-ade6-cd820e7e5646" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_018cae0b-f98f-4d16-8e6c-9ee84c963ccc" xlink:to="loc_us-gaap_CreditFacilityAxis_a7058a3d-c888-4491-ade6-cd820e7e5646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_912069b2-19b8-44c1-b41c-b33375bdc2e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_a7058a3d-c888-4491-ade6-cd820e7e5646" xlink:to="loc_us-gaap_CreditFacilityDomain_912069b2-19b8-44c1-b41c-b33375bdc2e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_e9a8a727-acc6-46d1-ad43-9fb1ea5f8483" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_912069b2-19b8-44c1-b41c-b33375bdc2e7" xlink:to="loc_us-gaap_SecuredDebtMember_e9a8a727-acc6-46d1-ad43-9fb1ea5f8483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_451d301f-9ebc-4e73-a780-3d5b02897ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_018cae0b-f98f-4d16-8e6c-9ee84c963ccc" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_451d301f-9ebc-4e73-a780-3d5b02897ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_2e0ab6d5-6987-4322-afff-8748756d407c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_451d301f-9ebc-4e73-a780-3d5b02897ce3" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_2e0ab6d5-6987-4322-afff-8748756d407c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_HerculesTechnologyGrowthCapitalMember_133243b9-ce26-4f55-b071-ab36f3f1f5c4" xlink:href="xcur-20210930.xsd#xcur_HerculesTechnologyGrowthCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_2e0ab6d5-6987-4322-afff-8748756d407c" xlink:to="loc_xcur_HerculesTechnologyGrowthCapitalMember_133243b9-ce26-4f55-b071-ab36f3f1f5c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_acd84c4f-fff4-4895-9fb3-e685fed97e32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_018cae0b-f98f-4d16-8e6c-9ee84c963ccc" xlink:to="loc_us-gaap_DebtInstrumentAxis_acd84c4f-fff4-4895-9fb3-e685fed97e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_433b33b7-026c-4db2-80b1-754acf311853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_acd84c4f-fff4-4895-9fb3-e685fed97e32" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_433b33b7-026c-4db2-80b1-754acf311853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_MidCapCreditAgreementMember_a1c07b91-7910-488d-89c5-df9a5e75d49e" xlink:href="xcur-20210930.xsd#xcur_MidCapCreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_433b33b7-026c-4db2-80b1-754acf311853" xlink:to="loc_xcur_MidCapCreditAgreementMember_a1c07b91-7910-488d-89c5-df9a5e75d49e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_MidCapCreditAgreementTranche1Member_3fe3cff3-f5c1-4d9d-aade-deafebe22cfe" xlink:href="xcur-20210930.xsd#xcur_MidCapCreditAgreementTranche1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_MidCapCreditAgreementMember_a1c07b91-7910-488d-89c5-df9a5e75d49e" xlink:to="loc_xcur_MidCapCreditAgreementTranche1Member_3fe3cff3-f5c1-4d9d-aade-deafebe22cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_MidCapCreditAgreementTranche2Member_36bf78c6-f207-419a-a22e-f682e55ca414" xlink:href="xcur-20210930.xsd#xcur_MidCapCreditAgreementTranche2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_xcur_MidCapCreditAgreementMember_a1c07b91-7910-488d-89c5-df9a5e75d49e" xlink:to="loc_xcur_MidCapCreditAgreementTranche2Member_36bf78c6-f207-419a-a22e-f682e55ca414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_52bcb67d-badc-444c-86ee-68b062e2c904" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_018cae0b-f98f-4d16-8e6c-9ee84c963ccc" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_52bcb67d-badc-444c-86ee-68b062e2c904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_92fc5d1c-8a70-4bf0-a7e0-483d1daf884c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_52bcb67d-badc-444c-86ee-68b062e2c904" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_92fc5d1c-8a70-4bf0-a7e0-483d1daf884c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_827507e6-ff7a-47c3-b21f-28ac8b6a079b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_92fc5d1c-8a70-4bf0-a7e0-483d1daf884c" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_827507e6-ff7a-47c3-b21f-28ac8b6a079b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_275b9ac2-7362-4706-895e-3570a4ca9727" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_92fc5d1c-8a70-4bf0-a7e0-483d1daf884c" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_275b9ac2-7362-4706-895e-3570a4ca9727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_a4ff2db5-51ea-4380-bbd6-e1df839f758d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_018cae0b-f98f-4d16-8e6c-9ee84c963ccc" xlink:to="loc_srt_StatementScenarioAxis_a4ff2db5-51ea-4380-bbd6-e1df839f758d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_35f47db5-3017-4fa0-a739-b8e095b96047" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_a4ff2db5-51ea-4380-bbd6-e1df839f758d" xlink:to="loc_srt_ScenarioUnspecifiedDomain_35f47db5-3017-4fa0-a739-b8e095b96047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_7898653d-7d5a-4e83-9a66-8e70e33363b7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_35f47db5-3017-4fa0-a739-b8e095b96047" xlink:to="loc_srt_ScenarioForecastMember_7898653d-7d5a-4e83-9a66-8e70e33363b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_8d6fc72f-745d-4e7d-aac1-6da45540bbd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_018cae0b-f98f-4d16-8e6c-9ee84c963ccc" xlink:to="loc_us-gaap_DebtInstrumentLineItems_8d6fc72f-745d-4e7d-aac1-6da45540bbd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_bc5d4edc-8284-41df-9670-486016a7cf46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8d6fc72f-745d-4e7d-aac1-6da45540bbd5" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_bc5d4edc-8284-41df-9670-486016a7cf46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_719e0e3d-09bf-49f3-a15b-ed869046914f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8d6fc72f-745d-4e7d-aac1-6da45540bbd5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_719e0e3d-09bf-49f3-a15b-ed869046914f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DebtInstrumentFundingConditionRequiredProceedsFromEquityIssuance_df21abeb-892d-447d-a13b-68af56ff0eac" xlink:href="xcur-20210930.xsd#xcur_DebtInstrumentFundingConditionRequiredProceedsFromEquityIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8d6fc72f-745d-4e7d-aac1-6da45540bbd5" xlink:to="loc_xcur_DebtInstrumentFundingConditionRequiredProceedsFromEquityIssuance_df21abeb-892d-447d-a13b-68af56ff0eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5d86244d-ca8b-44a3-8835-cb43a49deb7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8d6fc72f-745d-4e7d-aac1-6da45540bbd5" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5d86244d-ca8b-44a3-8835-cb43a49deb7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7d70d368-48b7-46eb-8ad5-67a8b80a3798" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8d6fc72f-745d-4e7d-aac1-6da45540bbd5" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7d70d368-48b7-46eb-8ad5-67a8b80a3798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments_7ab76b1a-5727-4af0-a63b-08150dc2d22d" xlink:href="xcur-20210930.xsd#xcur_DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8d6fc72f-745d-4e7d-aac1-6da45540bbd5" xlink:to="loc_xcur_DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments_7ab76b1a-5727-4af0-a63b-08150dc2d22d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DebtInstrumentEarlyTerminationFeePercentageOfPrincipal_a4c3af8d-2c20-4da5-b155-62151b873fe3" xlink:href="xcur-20210930.xsd#xcur_DebtInstrumentEarlyTerminationFeePercentageOfPrincipal"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8d6fc72f-745d-4e7d-aac1-6da45540bbd5" xlink:to="loc_xcur_DebtInstrumentEarlyTerminationFeePercentageOfPrincipal_a4c3af8d-2c20-4da5-b155-62151b873fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoanProcessingFee_5556e104-6448-43de-9e11-0f335999d7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoanProcessingFee"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8d6fc72f-745d-4e7d-aac1-6da45540bbd5" xlink:to="loc_us-gaap_LoanProcessingFee_5556e104-6448-43de-9e11-0f335999d7c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_DebtInstrumentExitFeePercentage_21266753-ef6e-43a1-86c2-758ffc6661e1" xlink:href="xcur-20210930.xsd#xcur_DebtInstrumentExitFeePercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8d6fc72f-745d-4e7d-aac1-6da45540bbd5" xlink:to="loc_xcur_DebtInstrumentExitFeePercentage_21266753-ef6e-43a1-86c2-758ffc6661e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_a9c565d0-43a3-43f7-8af7-72d9422b0639" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8d6fc72f-745d-4e7d-aac1-6da45540bbd5" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_a9c565d0-43a3-43f7-8af7-72d9422b0639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_8c6635b0-c363-4f53-a8ff-7816b942c71f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8d6fc72f-745d-4e7d-aac1-6da45540bbd5" xlink:to="loc_us-gaap_DebtInstrumentInterestRateIncreaseDecrease_8c6635b0-c363-4f53-a8ff-7816b942c71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_a21a7b05-c995-4cdd-8c4b-5558f6f44cba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8d6fc72f-745d-4e7d-aac1-6da45540bbd5" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_a21a7b05-c995-4cdd-8c4b-5558f6f44cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_0996ec38-929a-4b0b-bbcb-2056305fa2a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8d6fc72f-745d-4e7d-aac1-6da45540bbd5" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_0996ec38-929a-4b0b-bbcb-2056305fa2a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_eebfd756-87ee-478c-9982-4dc45a2d47dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8d6fc72f-745d-4e7d-aac1-6da45540bbd5" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_eebfd756-87ee-478c-9982-4dc45a2d47dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_230a4da3-8953-4dfe-aa62-f4f6eb91c938" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8d6fc72f-745d-4e7d-aac1-6da45540bbd5" xlink:to="loc_us-gaap_LongTermDebt_230a4da3-8953-4dfe-aa62-f4f6eb91c938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_e7e5eb99-5373-46dc-960a-5853e9162866" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8d6fc72f-745d-4e7d-aac1-6da45540bbd5" xlink:to="loc_us-gaap_InterestPaidNet_e7e5eb99-5373-46dc-960a-5853e9162866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_62136a95-73da-4654-b31a-cea3f95d4b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8d6fc72f-745d-4e7d-aac1-6da45540bbd5" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_62136a95-73da-4654-b31a-cea3f95d4b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_PaymentsForDebtEndTermFees_8bdd5e7c-84ae-4e88-96ce-814c76e6c60c" xlink:href="xcur-20210930.xsd#xcur_PaymentsForDebtEndTermFees"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8d6fc72f-745d-4e7d-aac1-6da45540bbd5" xlink:to="loc_xcur_PaymentsForDebtEndTermFees_8bdd5e7c-84ae-4e88-96ce-814c76e6c60c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#DebtPrincipalMaturitiesofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_500079c3-1ce2-4c2c-bf67-1c4432894f20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_fbc4f9fe-8b43-4f20-8b4f-823caa79f720" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_500079c3-1ce2-4c2c-bf67-1c4432894f20" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_fbc4f9fe-8b43-4f20-8b4f-823caa79f720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_00e03375-d894-4d39-9183-27ba7494ac52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_500079c3-1ce2-4c2c-bf67-1c4432894f20" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_00e03375-d894-4d39-9183-27ba7494ac52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_3b5a0102-676b-4023-949d-1055676a6511" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_500079c3-1ce2-4c2c-bf67-1c4432894f20" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_3b5a0102-676b-4023-949d-1055676a6511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_581f075b-b8c9-4807-8258-df07a10ff28c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_500079c3-1ce2-4c2c-bf67-1c4432894f20" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_581f075b-b8c9-4807-8258-df07a10ff28c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_6491db64-bf77-4871-aab1-569469559452" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_500079c3-1ce2-4c2c-bf67-1c4432894f20" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_6491db64-bf77-4871-aab1-569469559452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_3b1579ca-1321-47a3-95f4-1759f94b067b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_500079c3-1ce2-4c2c-bf67-1c4432894f20" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_3b1579ca-1321-47a3-95f4-1759f94b067b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_75bb30d8-6159-482b-a5f4-8f5e0c236345" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_500079c3-1ce2-4c2c-bf67-1c4432894f20" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_75bb30d8-6159-482b-a5f4-8f5e0c236345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_e41bd353-90a5-419b-a81e-eb4ccc309d88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_500079c3-1ce2-4c2c-bf67-1c4432894f20" xlink:to="loc_us-gaap_LongTermDebt_e41bd353-90a5-419b-a81e-eb4ccc309d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_be5999a6-27f8-4f4e-a4a4-b37e8b60b5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_500079c3-1ce2-4c2c-bf67-1c4432894f20" xlink:to="loc_us-gaap_LongTermDebtCurrent_be5999a6-27f8-4f4e-a4a4-b37e8b60b5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_fdf51f8d-63af-4f95-be76-9efa861b59e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_500079c3-1ce2-4c2c-bf67-1c4432894f20" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_fdf51f8d-63af-4f95-be76-9efa861b59e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails_1" xlink:type="simple" xlink:href="xcur-20210930.xsd#DebtPrincipalMaturitiesofLongTermDebtDetails_1"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/Leases" xlink:type="simple" xlink:href="xcur-20210930.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_35b2af62-8e53-4dbe-8b90-c3fb9c509407" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_17571cca-df8a-4552-a8dd-8bf6b171f9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_35b2af62-8e53-4dbe-8b90-c3fb9c509407" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_17571cca-df8a-4552-a8dd-8bf6b171f9ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LeasesTables" xlink:type="simple" xlink:href="xcur-20210930.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e8400ee5-0fdc-4bf7-bae6-3bc53a73637a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock_14523de1-77b2-49d5-98c1-281ee659ec1b" xlink:href="xcur-20210930.xsd#xcur_ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e8400ee5-0fdc-4bf7-bae6-3bc53a73637a" xlink:to="loc_xcur_ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock_14523de1-77b2-49d5-98c1-281ee659ec1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_c31705ef-57cd-4a8b-bb13-cbb6960f41b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e8400ee5-0fdc-4bf7-bae6-3bc53a73637a" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_c31705ef-57cd-4a8b-bb13-cbb6960f41b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_bbf348af-6d60-4ca7-ad34-e0967b8b5c60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e8400ee5-0fdc-4bf7-bae6-3bc53a73637a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_bbf348af-6d60-4ca7-ad34-e0967b8b5c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_eb2e1cba-3e0d-497d-86b1-511a311a99c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_5b5a11b5-2d1b-496f-b4d9-df4e8fb7e0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_eb2e1cba-3e0d-497d-86b1-511a311a99c1" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_5b5a11b5-2d1b-496f-b4d9-df4e8fb7e0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_fd3256f3-d7a8-4c9e-9014-06acbe4f9e12" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_5b5a11b5-2d1b-496f-b4d9-df4e8fb7e0d8" xlink:to="loc_srt_StatementGeographicalAxis_fd3256f3-d7a8-4c9e-9014-06acbe4f9e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_532c44df-ed6d-4a4b-90bb-1e2f6727031b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_fd3256f3-d7a8-4c9e-9014-06acbe4f9e12" xlink:to="loc_srt_SegmentGeographicalDomain_532c44df-ed6d-4a4b-90bb-1e2f6727031b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ChicagoMember_f4c72208-f97c-49dc-8788-44822a5e8fb9" xlink:href="xcur-20210930.xsd#xcur_ChicagoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_532c44df-ed6d-4a4b-90bb-1e2f6727031b" xlink:to="loc_xcur_ChicagoMember_f4c72208-f97c-49dc-8788-44822a5e8fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_b63f7f1f-54d1-4cb2-a189-7cf379ec9f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_5b5a11b5-2d1b-496f-b4d9-df4e8fb7e0d8" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_b63f7f1f-54d1-4cb2-a189-7cf379ec9f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseLeaseArea_270f6f15-6798-4400-9526-650bbd766e81" xlink:href="xcur-20210930.xsd#xcur_LesseeOperatingLeaseLeaseArea"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b63f7f1f-54d1-4cb2-a189-7cf379ec9f5b" xlink:to="loc_xcur_LesseeOperatingLeaseLeaseArea_270f6f15-6798-4400-9526-650bbd766e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_a5ae965c-2c88-483f-a40d-30cb16ebde84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b63f7f1f-54d1-4cb2-a189-7cf379ec9f5b" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_a5ae965c-2c88-483f-a40d-30cb16ebde84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseNumberOfExtensions_42a36145-edf6-40e0-817e-de87c04a2a95" xlink:href="xcur-20210930.xsd#xcur_LesseeOperatingLeaseNumberOfExtensions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b63f7f1f-54d1-4cb2-a189-7cf379ec9f5b" xlink:to="loc_xcur_LesseeOperatingLeaseNumberOfExtensions_42a36145-edf6-40e0-817e-de87c04a2a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_d33ab224-a6e0-49a4-9510-c479425051e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b63f7f1f-54d1-4cb2-a189-7cf379ec9f5b" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_d33ab224-a6e0-49a4-9510-c479425051e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths_b5833951-3bb3-44ec-a815-936325a62c6f" xlink:href="xcur-20210930.xsd#xcur_LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b63f7f1f-54d1-4cb2-a189-7cf379ec9f5b" xlink:to="loc_xcur_LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths_b5833951-3bb3-44ec-a815-936325a62c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseBaseRentAnnualPercentageIncrease_d14848fd-09ac-4833-a2a5-4b4931657742" xlink:href="xcur-20210930.xsd#xcur_LesseeOperatingLeaseBaseRentAnnualPercentageIncrease"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b63f7f1f-54d1-4cb2-a189-7cf379ec9f5b" xlink:to="loc_xcur_LesseeOperatingLeaseBaseRentAnnualPercentageIncrease_d14848fd-09ac-4833-a2a5-4b4931657742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm_478f61f6-bb58-4dd1-a574-c6985c82d8d7" xlink:href="xcur-20210930.xsd#xcur_LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b63f7f1f-54d1-4cb2-a189-7cf379ec9f5b" xlink:to="loc_xcur_LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm_478f61f6-bb58-4dd1-a574-c6985c82d8d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_6e75ee8b-cc8c-4036-8031-311c86485595" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b63f7f1f-54d1-4cb2-a189-7cf379ec9f5b" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_6e75ee8b-cc8c-4036-8031-311c86485595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_LesseeOperatingLeaseRentalPaymentAdjustedForAbatement_b0c94b07-1795-453c-9a87-62947f512323" xlink:href="xcur-20210930.xsd#xcur_LesseeOperatingLeaseRentalPaymentAdjustedForAbatement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b63f7f1f-54d1-4cb2-a189-7cf379ec9f5b" xlink:to="loc_xcur_LesseeOperatingLeaseRentalPaymentAdjustedForAbatement_b0c94b07-1795-453c-9a87-62947f512323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForTenantImprovements_39449f09-3950-4ec2-800d-61b3efe31d12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForTenantImprovements"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b63f7f1f-54d1-4cb2-a189-7cf379ec9f5b" xlink:to="loc_us-gaap_PaymentsForTenantImprovements_39449f09-3950-4ec2-800d-61b3efe31d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6f05fb63-2fbf-4850-8f03-338bc1386d93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b63f7f1f-54d1-4cb2-a189-7cf379ec9f5b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6f05fb63-2fbf-4850-8f03-338bc1386d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_ecf76ede-4d17-437b-a2e9-ee23d7b353b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b63f7f1f-54d1-4cb2-a189-7cf379ec9f5b" xlink:to="loc_us-gaap_OperatingLeaseLiability_ecf76ede-4d17-437b-a2e9-ee23d7b353b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_4932b3f8-93c6-4096-9f06-e91a3d6feed6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b63f7f1f-54d1-4cb2-a189-7cf379ec9f5b" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_4932b3f8-93c6-4096-9f06-e91a3d6feed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_5eb6d611-9131-4ff4-adc6-e44820330cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b63f7f1f-54d1-4cb2-a189-7cf379ec9f5b" xlink:to="loc_us-gaap_OperatingLeasePayments_5eb6d611-9131-4ff4-adc6-e44820330cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LeasesRightofUseAssetInformationDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#LeasesRightofUseAssetInformationDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/LeasesRightofUseAssetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ce2736c5-baa4-4536-8094-6123e006fc49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5fdc9982-009c-4006-a538-9087ffb33a03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ce2736c5-baa4-4536-8094-6123e006fc49" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5fdc9982-009c-4006-a538-9087ffb33a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9ef88e4d-a243-49a4-a345-5cd3113c5870" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ce2736c5-baa4-4536-8094-6123e006fc49" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9ef88e4d-a243-49a4-a345-5cd3113c5870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LeasesLeaseCostsDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#LeasesLeaseCostsDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/LeasesLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_14e3502c-1c83-4009-918f-478896e7cd17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_571216fd-e805-4cb5-9462-a9e91a199a49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_14e3502c-1c83-4009-918f-478896e7cd17" xlink:to="loc_us-gaap_OperatingLeaseCost_571216fd-e805-4cb5-9462-a9e91a199a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_d1dd1747-4db6-41e7-82c2-147d03235a08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_14e3502c-1c83-4009-918f-478896e7cd17" xlink:to="loc_us-gaap_ShortTermLeaseCost_d1dd1747-4db6-41e7-82c2-147d03235a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_0ab4a2b5-ddc5-44fe-bc47-04536af93bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_14e3502c-1c83-4009-918f-478896e7cd17" xlink:to="loc_us-gaap_VariableLeaseCost_0ab4a2b5-ddc5-44fe-bc47-04536af93bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_59e8019e-4169-4e3d-8c48-5a075a0b8108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_14e3502c-1c83-4009-918f-478896e7cd17" xlink:to="loc_us-gaap_LeaseCost_59e8019e-4169-4e3d-8c48-5a075a0b8108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#LeasesScheduleofFutureMinimumRentalPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3dc4be92-51be-495e-b5c6-9299d25952e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_688fd89c-9f89-47d3-a7e6-307ef1b4ea4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3dc4be92-51be-495e-b5c6-9299d25952e6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_688fd89c-9f89-47d3-a7e6-307ef1b4ea4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ccd17ac9-c8ec-410d-a658-6ff9b6b68d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3dc4be92-51be-495e-b5c6-9299d25952e6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ccd17ac9-c8ec-410d-a658-6ff9b6b68d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f33b51a6-288d-4e36-a356-2cc8f533cea8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3dc4be92-51be-495e-b5c6-9299d25952e6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f33b51a6-288d-4e36-a356-2cc8f533cea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_33fab057-72b8-45c9-b14c-5c685a631676" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3dc4be92-51be-495e-b5c6-9299d25952e6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_33fab057-72b8-45c9-b14c-5c685a631676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_699712aa-bc23-4e47-87b1-dcba3e250eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3dc4be92-51be-495e-b5c6-9299d25952e6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_699712aa-bc23-4e47-87b1-dcba3e250eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_76e6495d-c8ff-4e60-8668-806db7b3102f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3dc4be92-51be-495e-b5c6-9299d25952e6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_76e6495d-c8ff-4e60-8668-806db7b3102f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_ed08804a-03b2-42f5-8977-82a4b61d440d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3dc4be92-51be-495e-b5c6-9299d25952e6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_ed08804a-03b2-42f5-8977-82a4b61d440d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7e98419e-aa29-405c-84e1-a661f92feafa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3dc4be92-51be-495e-b5c6-9299d25952e6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7e98419e-aa29-405c-84e1-a661f92feafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_08d7b561-c3a5-4b3e-8583-9f9b2534cb37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3dc4be92-51be-495e-b5c6-9299d25952e6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_08d7b561-c3a5-4b3e-8583-9f9b2534cb37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b58f1749-eced-4071-a694-54a1f1b8a677" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3dc4be92-51be-495e-b5c6-9299d25952e6" xlink:to="loc_us-gaap_OperatingLeaseLiability_b58f1749-eced-4071-a694-54a1f1b8a677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f6e4cf66-ec8a-41c2-900a-1db3aaa15db2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3dc4be92-51be-495e-b5c6-9299d25952e6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f6e4cf66-ec8a-41c2-900a-1db3aaa15db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e427b629-4e41-484f-a0eb-1fef9aa0ae8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3dc4be92-51be-495e-b5c6-9299d25952e6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e427b629-4e41-484f-a0eb-1fef9aa0ae8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails_1" xlink:type="simple" xlink:href="xcur-20210930.xsd#LeasesScheduleofFutureMinimumRentalPaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquity" xlink:type="simple" xlink:href="xcur-20210930.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_85b08509-51dd-4095-85a1-7645b107fa54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_532373fb-376c-42ba-b07f-f189cc31c4f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_85b08509-51dd-4095-85a1-7645b107fa54" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_532373fb-376c-42ba-b07f-f189cc31c4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="xcur-20210930.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_07f0d4e9-fd8a-4b6c-b283-30949a617123" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_a2b68ae0-0ffc-4431-8e4b-c6271bd398b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_07f0d4e9-fd8a-4b6c-b283-30949a617123" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_a2b68ae0-0ffc-4431-8e4b-c6271bd398b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#StockholdersEquityCurrentCapitalizationDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f6f445a9-5234-4494-a9b0-f19bb2372a07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_eb67fbd3-9bd4-4ebd-8cf9-8ad7f9ee49b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f6f445a9-5234-4494-a9b0-f19bb2372a07" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_eb67fbd3-9bd4-4ebd-8cf9-8ad7f9ee49b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6657aa55-a203-4fc0-a2e0-187f29a9f92c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f6f445a9-5234-4494-a9b0-f19bb2372a07" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6657aa55-a203-4fc0-a2e0-187f29a9f92c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_74b2edce-e104-4297-8974-e93fc72ed6b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f6f445a9-5234-4494-a9b0-f19bb2372a07" xlink:to="loc_us-gaap_PreferredStockSharesIssued_74b2edce-e104-4297-8974-e93fc72ed6b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_b084c5b3-dae9-4c18-ab6b-d8999de4c7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f6f445a9-5234-4494-a9b0-f19bb2372a07" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_b084c5b3-dae9-4c18-ab6b-d8999de4c7cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_e2701c76-36b8-44ec-8838-1c7c688fce68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f6f445a9-5234-4494-a9b0-f19bb2372a07" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_e2701c76-36b8-44ec-8838-1c7c688fce68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_77c44e82-9434-4d98-89fd-c3b0f8d2247a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f6f445a9-5234-4494-a9b0-f19bb2372a07" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_77c44e82-9434-4d98-89fd-c3b0f8d2247a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_5dff07fe-cad6-417e-bd3a-e3bfaf0acca4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f6f445a9-5234-4494-a9b0-f19bb2372a07" xlink:to="loc_us-gaap_CommonStockSharesIssued_5dff07fe-cad6-417e-bd3a-e3bfaf0acca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_381aa031-4d8a-4b32-bf7f-aac8bab3fa1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f6f445a9-5234-4494-a9b0-f19bb2372a07" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_381aa031-4d8a-4b32-bf7f-aac8bab3fa1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CommonStockVotingRightsForEachShare_ae81339d-40f4-4abc-a577-7793d6ebf116" xlink:href="xcur-20210930.xsd#xcur_CommonStockVotingRightsForEachShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f6f445a9-5234-4494-a9b0-f19bb2372a07" xlink:to="loc_xcur_CommonStockVotingRightsForEachShare_ae81339d-40f4-4abc-a577-7793d6ebf116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#StockholdersEquityCommonStockWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_490e6c53-ea63-4703-8b33-bacb8ec6c2c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_5dc30d14-4ea4-4ee1-a34c-1f2371e95553" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_490e6c53-ea63-4703-8b33-bacb8ec6c2c3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_5dc30d14-4ea4-4ee1-a34c-1f2371e95553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_bd9fea73-5024-4f05-b39f-eb28c57287ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_5dc30d14-4ea4-4ee1-a34c-1f2371e95553" xlink:to="loc_us-gaap_StatementClassOfStockAxis_bd9fea73-5024-4f05-b39f-eb28c57287ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ccc30b79-a9c9-476a-9eeb-aef21273a66a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_bd9fea73-5024-4f05-b39f-eb28c57287ca" xlink:to="loc_us-gaap_ClassOfStockDomain_ccc30b79-a9c9-476a-9eeb-aef21273a66a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_88a961a9-2829-48db-bd95-74d1e3993590" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ccc30b79-a9c9-476a-9eeb-aef21273a66a" xlink:to="loc_us-gaap_CommonStockMember_88a961a9-2829-48db-bd95-74d1e3993590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_ed94bef4-f89c-4ab4-86e8-ce46a9de1a72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_5dc30d14-4ea4-4ee1-a34c-1f2371e95553" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_ed94bef4-f89c-4ab4-86e8-ce46a9de1a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_d1368db8-2b5b-45e4-8319-9d0613d67049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ed94bef4-f89c-4ab4-86e8-ce46a9de1a72" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_d1368db8-2b5b-45e4-8319-9d0613d67049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c17358fe-d896-4a2c-a040-ddc9e149d8da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ed94bef4-f89c-4ab4-86e8-ce46a9de1a72" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c17358fe-d896-4a2c-a040-ddc9e149d8da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ClassofWarrantorRightExpired_bd97811c-6598-404c-b72b-b85b7c9f932f" xlink:href="xcur-20210930.xsd#xcur_ClassofWarrantorRightExpired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_ed94bef4-f89c-4ab4-86e8-ce46a9de1a72" xlink:to="loc_xcur_ClassofWarrantorRightExpired_bd97811c-6598-404c-b72b-b85b7c9f932f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#StockholdersEquityAccumulatedOtherComprehensiveLossDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e491c396-d9c6-40ed-8f4b-b9410da7067a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_6f559d27-055b-4c27-8ac0-e144d4289097" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e491c396-d9c6-40ed-8f4b-b9410da7067a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_6f559d27-055b-4c27-8ac0-e144d4289097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_cbe860e5-fd49-4347-a035-3d4658e95591" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_6f559d27-055b-4c27-8ac0-e144d4289097" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_cbe860e5-fd49-4347-a035-3d4658e95591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1404c391-190c-44f5-be4e-367cadb40c56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cbe860e5-fd49-4347-a035-3d4658e95591" xlink:to="loc_us-gaap_EquityComponentDomain_1404c391-190c-44f5-be4e-367cadb40c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_22b1038d-9f3b-4481-82d3-2acc771bdde0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1404c391-190c-44f5-be4e-367cadb40c56" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_22b1038d-9f3b-4481-82d3-2acc771bdde0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_edf0d563-0cff-44c5-ae93-22f5fce8ca8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1404c391-190c-44f5-be4e-367cadb40c56" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_edf0d563-0cff-44c5-ae93-22f5fce8ca8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_c00d04a7-0689-4267-967e-1be9301fb58e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_6f559d27-055b-4c27-8ac0-e144d4289097" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_c00d04a7-0689-4267-967e-1be9301fb58e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_e658b9f3-6edd-4781-95af-4d5a170dea3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_c00d04a7-0689-4267-967e-1be9301fb58e" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_e658b9f3-6edd-4781-95af-4d5a170dea3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_27f833dd-0123-4398-8b3a-4f20cb6f7a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_e658b9f3-6edd-4781-95af-4d5a170dea3a" xlink:to="loc_us-gaap_StockholdersEquity_27f833dd-0123-4398-8b3a-4f20cb6f7a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_da76d413-92f9-4b1b-a3ef-7343151de7de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_e658b9f3-6edd-4781-95af-4d5a170dea3a" xlink:to="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_da76d413-92f9-4b1b-a3ef-7343151de7de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_4810f0fb-4547-4721-b2b8-4cbc0891f730" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_e658b9f3-6edd-4781-95af-4d5a170dea3a" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_4810f0fb-4547-4721-b2b8-4cbc0891f730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3168a9a5-dac0-44c1-b683-a2cb48a0412a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_e658b9f3-6edd-4781-95af-4d5a170dea3a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3168a9a5-dac0-44c1-b683-a2cb48a0412a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0d338c08-b62a-4dce-afc6-1fe7482679e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_e658b9f3-6edd-4781-95af-4d5a170dea3a" xlink:to="loc_us-gaap_StockholdersEquity_0d338c08-b62a-4dce-afc6-1fe7482679e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_07f53aef-b95e-496b-b010-97167abe4aba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_c00d04a7-0689-4267-967e-1be9301fb58e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_07f53aef-b95e-496b-b010-97167abe4aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_8e4319e2-bd1f-4837-b825-ba0645b7a30c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_c00d04a7-0689-4267-967e-1be9301fb58e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_8e4319e2-bd1f-4837-b825-ba0645b7a30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_025b6c78-97ef-4147-8f86-5ba3596e2d87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_c00d04a7-0689-4267-967e-1be9301fb58e" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_025b6c78-97ef-4147-8f86-5ba3596e2d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensation" xlink:type="simple" xlink:href="xcur-20210930.xsd#EquityBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f692c76e-9406-407d-adc4-578434e8c465" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ac411af0-1869-4d75-b654-ad877c73bad9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f692c76e-9406-407d-adc4-578434e8c465" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ac411af0-1869-4d75-b654-ad877c73bad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationTables" xlink:type="simple" xlink:href="xcur-20210930.xsd#EquityBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1dc40bdf-2d25-4f3b-92fa-ba0d874a5b14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_feaa91b3-5102-4db5-9fed-00317c47a73e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1dc40bdf-2d25-4f3b-92fa-ba0d874a5b14" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_feaa91b3-5102-4db5-9fed-00317c47a73e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f4688e0b-6e39-407d-b89d-e3bd45691de7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1dc40bdf-2d25-4f3b-92fa-ba0d874a5b14" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f4688e0b-6e39-407d-b89d-e3bd45691de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_32416d87-1757-415d-acdd-c7980f56e8e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1dc40bdf-2d25-4f3b-92fa-ba0d874a5b14" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_32416d87-1757-415d-acdd-c7980f56e8e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_35b64e49-0941-4bf1-a23f-a46f39953ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1dc40bdf-2d25-4f3b-92fa-ba0d874a5b14" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_35b64e49-0941-4bf1-a23f-a46f39953ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#EquityBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c09c895e-07c9-49d2-8a43-1a26f0ca3f41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e6bf4706-c646-4119-b48f-0c5e9610074b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c09c895e-07c9-49d2-8a43-1a26f0ca3f41" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e6bf4706-c646-4119-b48f-0c5e9610074b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_956a4256-79b5-4f99-a5e4-928be4ea581e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e6bf4706-c646-4119-b48f-0c5e9610074b" xlink:to="loc_us-gaap_AwardTypeAxis_956a4256-79b5-4f99-a5e4-928be4ea581e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d25263d3-5b54-4b70-8cb3-3ad68fa6063e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_956a4256-79b5-4f99-a5e4-928be4ea581e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d25263d3-5b54-4b70-8cb3-3ad68fa6063e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d96c801b-e702-4ce8-8871-f9fa52c5cd6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d25263d3-5b54-4b70-8cb3-3ad68fa6063e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d96c801b-e702-4ce8-8871-f9fa52c5cd6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_cbb0c4b7-76eb-461d-a02c-9253e496f839" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d25263d3-5b54-4b70-8cb3-3ad68fa6063e" xlink:to="loc_us-gaap_EmployeeStockMember_cbb0c4b7-76eb-461d-a02c-9253e496f839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_fa1bce99-ec12-4b11-a05c-81db43b4d422" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d25263d3-5b54-4b70-8cb3-3ad68fa6063e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_fa1bce99-ec12-4b11-a05c-81db43b4d422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_3bdc3164-bbb9-4d4a-b04c-124763624eae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e6bf4706-c646-4119-b48f-0c5e9610074b" xlink:to="loc_us-gaap_PlanNameAxis_3bdc3164-bbb9-4d4a-b04c-124763624eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_1853fbc1-ae4c-41f6-85f2-28c81e7c2deb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_3bdc3164-bbb9-4d4a-b04c-124763624eae" xlink:to="loc_us-gaap_PlanNameDomain_1853fbc1-ae4c-41f6-85f2-28c81e7c2deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ExicureInc.2017EquityIncentivePlanMember_3dbfdb50-d3e3-40e7-b27a-ef9b31dcc837" xlink:href="xcur-20210930.xsd#xcur_ExicureInc.2017EquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1853fbc1-ae4c-41f6-85f2-28c81e7c2deb" xlink:to="loc_xcur_ExicureInc.2017EquityIncentivePlanMember_3dbfdb50-d3e3-40e7-b27a-ef9b31dcc837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_7421dc56-2b08-4c8f-a7c0-b4e05430b0d0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e6bf4706-c646-4119-b48f-0c5e9610074b" xlink:to="loc_srt_TitleOfIndividualAxis_7421dc56-2b08-4c8f-a7c0-b4e05430b0d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_293aa914-2ee6-4370-905d-d96b0c26854f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_7421dc56-2b08-4c8f-a7c0-b4e05430b0d0" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_293aa914-2ee6-4370-905d-d96b0c26854f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefFinancialOfficerMember_afc56496-b849-4c27-b550-17bfb8814d9c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefFinancialOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_293aa914-2ee6-4370-905d-d96b0c26854f" xlink:to="loc_srt_ChiefFinancialOfficerMember_afc56496-b849-4c27-b550-17bfb8814d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02949e86-86d4-4061-90a8-eddd53480274" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e6bf4706-c646-4119-b48f-0c5e9610074b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02949e86-86d4-4061-90a8-eddd53480274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares_abb4c7d7-963b-48c4-a7dc-d11d67b15464" xlink:href="xcur-20210930.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02949e86-86d4-4061-90a8-eddd53480274" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares_abb4c7d7-963b-48c4-a7dc-d11d67b15464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding_f3e5d3d2-d01d-49b6-9b7f-a06ca9576328" xlink:href="xcur-20210930.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02949e86-86d4-4061-90a8-eddd53480274" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding_f3e5d3d2-d01d-49b6-9b7f-a06ca9576328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant_d1dddeae-2370-4856-ad0f-d55ac96dbfad" xlink:href="xcur-20210930.xsd#xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02949e86-86d4-4061-90a8-eddd53480274" xlink:to="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant_d1dddeae-2370-4856-ad0f-d55ac96dbfad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2d4a22b6-702c-4021-af13-21ca213607cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02949e86-86d4-4061-90a8-eddd53480274" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2d4a22b6-702c-4021-af13-21ca213607cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_35e843e9-1928-4ea1-92e3-0039fb8dc643" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02949e86-86d4-4061-90a8-eddd53480274" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_35e843e9-1928-4ea1-92e3-0039fb8dc643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_575fa083-49a1-422c-b95d-50317a91d78e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02949e86-86d4-4061-90a8-eddd53480274" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_575fa083-49a1-422c-b95d-50317a91d78e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_4bcaba96-7ad5-4bc4-8d85-66165af10f36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02949e86-86d4-4061-90a8-eddd53480274" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_4bcaba96-7ad5-4bc4-8d85-66165af10f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_c8f685b0-06fa-4f88-8691-3f27747fff8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02949e86-86d4-4061-90a8-eddd53480274" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_c8f685b0-06fa-4f88-8691-3f27747fff8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_62210925-4167-44f2-97c1-bb36334a814a" xlink:href="xcur-20210930.xsd#xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02949e86-86d4-4061-90a8-eddd53480274" xlink:to="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_62210925-4167-44f2-97c1-bb36334a814a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_10a0f0d1-d59e-4f26-8cb1-da45c88783c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02949e86-86d4-4061-90a8-eddd53480274" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_10a0f0d1-d59e-4f26-8cb1-da45c88783c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_e3a45df3-848c-4d12-9c29-1f59a189b7b6" xlink:href="xcur-20210930.xsd#xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02949e86-86d4-4061-90a8-eddd53480274" xlink:to="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_e3a45df3-848c-4d12-9c29-1f59a189b7b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_bb0e09cb-4cf2-4f18-8d48-4ed23a79f51d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02949e86-86d4-4061-90a8-eddd53480274" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_bb0e09cb-4cf2-4f18-8d48-4ed23a79f51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_611571d0-8a2c-469f-92f4-695332838392" xlink:href="xcur-20210930.xsd#xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02949e86-86d4-4061-90a8-eddd53480274" xlink:to="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan_611571d0-8a2c-469f-92f4-695332838392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_710de42a-be30-463f-9cf9-122811437ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02949e86-86d4-4061-90a8-eddd53480274" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_710de42a-be30-463f-9cf9-122811437ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1bb6957c-fd76-4a69-a91a-c877be391a97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02949e86-86d4-4061-90a8-eddd53480274" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1bb6957c-fd76-4a69-a91a-c877be391a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_da02cea5-3402-4b72-888b-630cf013bda2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02949e86-86d4-4061-90a8-eddd53480274" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_da02cea5-3402-4b72-888b-630cf013bda2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_53a424c5-b062-499d-9edd-f87ce3a6ff86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02949e86-86d4-4061-90a8-eddd53480274" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_53a424c5-b062-499d-9edd-f87ce3a6ff86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_602701be-51b5-4ddf-9ced-a471aee23945" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02949e86-86d4-4061-90a8-eddd53480274" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_602701be-51b5-4ddf-9ced-a471aee23945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting_8fa0d7ba-cf25-4874-bdb7-6f06912cd920" xlink:href="xcur-20210930.xsd#xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02949e86-86d4-4061-90a8-eddd53480274" xlink:to="loc_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting_8fa0d7ba-cf25-4874-bdb7-6f06912cd920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_bff66e1a-bd5f-4aa0-b26c-5afdb6ed0551" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02949e86-86d4-4061-90a8-eddd53480274" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_bff66e1a-bd5f-4aa0-b26c-5afdb6ed0551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationScheduleofCompensationExpenseDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#EquityBasedCompensationScheduleofCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationScheduleofCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e3ffe917-7c10-43e7-960e-f6c9fa3d24dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be3ec500-b93f-4e5e-bd90-7ae73dd936cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e3ffe917-7c10-43e7-960e-f6c9fa3d24dd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be3ec500-b93f-4e5e-bd90-7ae73dd936cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ef38ee43-6bb4-4190-839c-b25ae6d69dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be3ec500-b93f-4e5e-bd90-7ae73dd936cc" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ef38ee43-6bb4-4190-839c-b25ae6d69dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d2c7f48f-393e-4b04-bb83-0365118e6676" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ef38ee43-6bb4-4190-839c-b25ae6d69dc8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d2c7f48f-393e-4b04-bb83-0365118e6676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_072e6797-4cb1-47fb-aa95-4866fb16ad57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d2c7f48f-393e-4b04-bb83-0365118e6676" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_072e6797-4cb1-47fb-aa95-4866fb16ad57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_5cd7a3f4-da44-4f78-8c79-934a1780880f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d2c7f48f-393e-4b04-bb83-0365118e6676" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_5cd7a3f4-da44-4f78-8c79-934a1780880f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fee0e0d-2ebf-4ed4-8132-2cc2ff4683b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_be3ec500-b93f-4e5e-bd90-7ae73dd936cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fee0e0d-2ebf-4ed4-8132-2cc2ff4683b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_8af9ac3d-d56b-4b6c-9fb4-1e19538194df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fee0e0d-2ebf-4ed4-8132-2cc2ff4683b2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_8af9ac3d-d56b-4b6c-9fb4-1e19538194df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d9cebfb2-6269-49aa-8fee-6966c8a8eba6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f546cead-b6a4-4b0d-b708-d36648f273f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d9cebfb2-6269-49aa-8fee-6966c8a8eba6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f546cead-b6a4-4b0d-b708-d36648f273f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_094c1172-582c-4851-8a8e-f1b65ce8a7d1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f546cead-b6a4-4b0d-b708-d36648f273f7" xlink:to="loc_srt_RangeAxis_094c1172-582c-4851-8a8e-f1b65ce8a7d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_48327ade-724f-44c8-be6d-86b5107f5d78" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_094c1172-582c-4851-8a8e-f1b65ce8a7d1" xlink:to="loc_srt_RangeMember_48327ade-724f-44c8-be6d-86b5107f5d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_28dad1b7-2daf-4c75-8a83-65d92f5d4280" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_48327ade-724f-44c8-be6d-86b5107f5d78" xlink:to="loc_srt_MinimumMember_28dad1b7-2daf-4c75-8a83-65d92f5d4280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_34366ce2-0248-41ce-ae2f-5bd5b7292f04" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_48327ade-724f-44c8-be6d-86b5107f5d78" xlink:to="loc_srt_MaximumMember_34366ce2-0248-41ce-ae2f-5bd5b7292f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_8837419d-b242-4f8b-be91-524d4eea50d7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_48327ade-724f-44c8-be6d-86b5107f5d78" xlink:to="loc_srt_WeightedAverageMember_8837419d-b242-4f8b-be91-524d4eea50d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_489a7105-a7a4-4d2d-9e91-0f2d60b63126" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f546cead-b6a4-4b0d-b708-d36648f273f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_489a7105-a7a4-4d2d-9e91-0f2d60b63126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b67723ae-818f-4a61-b838-fdd6e1b7ec60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_489a7105-a7a4-4d2d-9e91-0f2d60b63126" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b67723ae-818f-4a61-b838-fdd6e1b7ec60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_db8ef8e3-3d2b-415a-a63f-184c99cdbbb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_489a7105-a7a4-4d2d-9e91-0f2d60b63126" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_db8ef8e3-3d2b-415a-a63f-184c99cdbbb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_e8233eba-c06a-4209-9477-6e4bfb8bc3eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_489a7105-a7a4-4d2d-9e91-0f2d60b63126" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_e8233eba-c06a-4209-9477-6e4bfb8bc3eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ff363c8b-178d-49f1-ae89-3d0aa29cbf61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_489a7105-a7a4-4d2d-9e91-0f2d60b63126" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ff363c8b-178d-49f1-ae89-3d0aa29cbf61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_1f651c0d-959a-4769-9eaa-84ed0f180d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_489a7105-a7a4-4d2d-9e91-0f2d60b63126" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_1f651c0d-959a-4769-9eaa-84ed0f180d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_7fc78707-6c6b-4d3a-b021-c7fb02382eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_489a7105-a7a4-4d2d-9e91-0f2d60b63126" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_7fc78707-6c6b-4d3a-b021-c7fb02382eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_3dd0b5cc-24fc-46f1-abf8-cd5c29b0b3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_489a7105-a7a4-4d2d-9e91-0f2d60b63126" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_3dd0b5cc-24fc-46f1-abf8-cd5c29b0b3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_d7c4fa89-8d71-4396-b40f-6ad947763610" xlink:href="xcur-20210930.xsd#xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_489a7105-a7a4-4d2d-9e91-0f2d60b63126" xlink:to="loc_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate_d7c4fa89-8d71-4396-b40f-6ad947763610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_93edc795-8e43-4608-8682-d62902a0c5af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_489a7105-a7a4-4d2d-9e91-0f2d60b63126" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_93edc795-8e43-4608-8682-d62902a0c5af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2c1ed416-f1e4-4050-8d33-fb40200ddffc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d27ec2b-f1a8-4479-9425-58b04afbc120" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2c1ed416-f1e4-4050-8d33-fb40200ddffc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d27ec2b-f1a8-4479-9425-58b04afbc120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2740d4c1-7f61-426a-a37f-b706465c1fe0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d27ec2b-f1a8-4479-9425-58b04afbc120" xlink:to="loc_srt_RangeAxis_2740d4c1-7f61-426a-a37f-b706465c1fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_52bf40c0-48ec-4b7d-96ff-f670a09eed55" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2740d4c1-7f61-426a-a37f-b706465c1fe0" xlink:to="loc_srt_RangeMember_52bf40c0-48ec-4b7d-96ff-f670a09eed55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4a1568d4-b5f3-4ee0-b75c-1de4e392e947" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_52bf40c0-48ec-4b7d-96ff-f670a09eed55" xlink:to="loc_srt_MinimumMember_4a1568d4-b5f3-4ee0-b75c-1de4e392e947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2829fa45-3526-4dc1-af06-89c4720b3c34" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_52bf40c0-48ec-4b7d-96ff-f670a09eed55" xlink:to="loc_srt_MaximumMember_2829fa45-3526-4dc1-af06-89c4720b3c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_c9534358-9aa4-4c48-a83c-316f9c71e556" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_52bf40c0-48ec-4b7d-96ff-f670a09eed55" xlink:to="loc_srt_WeightedAverageMember_c9534358-9aa4-4c48-a83c-316f9c71e556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09defaf0-776d-4c80-91b6-c0b60139d9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d27ec2b-f1a8-4479-9425-58b04afbc120" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09defaf0-776d-4c80-91b6-c0b60139d9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_84ce78f7-6148-421e-8ac6-d107397df258" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09defaf0-776d-4c80-91b6-c0b60139d9bb" xlink:to="loc_us-gaap_SharePrice_84ce78f7-6148-421e-8ac6-d107397df258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_5d84a6f5-db55-45a2-81b0-576ab00778a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09defaf0-776d-4c80-91b6-c0b60139d9bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_5d84a6f5-db55-45a2-81b0-576ab00778a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3642a947-6d86-4b00-a423-df3222cf5a19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_91d0fc8c-f289-4e0a-b22e-39c69bf755b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3642a947-6d86-4b00-a423-df3222cf5a19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_91d0fc8c-f289-4e0a-b22e-39c69bf755b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e06ec8d3-27a4-4e6a-8d77-1c1bc172334c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_91d0fc8c-f289-4e0a-b22e-39c69bf755b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e06ec8d3-27a4-4e6a-8d77-1c1bc172334c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_04e0eb51-8b90-40b0-94e6-3c9d2bdf2ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_91d0fc8c-f289-4e0a-b22e-39c69bf755b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_04e0eb51-8b90-40b0-94e6-3c9d2bdf2ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_79a82e1c-a5ac-49cd-8010-0f9ad272dc44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_91d0fc8c-f289-4e0a-b22e-39c69bf755b9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_79a82e1c-a5ac-49cd-8010-0f9ad272dc44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d2567d70-7e28-44bc-a696-801f1f50999d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_91d0fc8c-f289-4e0a-b22e-39c69bf755b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d2567d70-7e28-44bc-a696-801f1f50999d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b33b6a3e-87d5-426b-94a6-6f98949c8e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_91d0fc8c-f289-4e0a-b22e-39c69bf755b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b33b6a3e-87d5-426b-94a6-6f98949c8e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6bef19cc-7c0b-462f-8e10-b648cd34882b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3642a947-6d86-4b00-a423-df3222cf5a19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6bef19cc-7c0b-462f-8e10-b648cd34882b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_cb928465-774b-44f5-8f94-fbfac81fdff4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3642a947-6d86-4b00-a423-df3222cf5a19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_cb928465-774b-44f5-8f94-fbfac81fdff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bfe6f56a-1aad-4769-ac76-4dbcaf3a34c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3642a947-6d86-4b00-a423-df3222cf5a19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bfe6f56a-1aad-4769-ac76-4dbcaf3a34c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_36976665-3ac4-4110-aea9-cf694358fac8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bfe6f56a-1aad-4769-ac76-4dbcaf3a34c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_36976665-3ac4-4110-aea9-cf694358fac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_966575bc-32e2-45ab-a1af-9b8f04c118ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bfe6f56a-1aad-4769-ac76-4dbcaf3a34c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_966575bc-32e2-45ab-a1af-9b8f04c118ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d862d13e-e845-4bef-94da-831314fb3fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bfe6f56a-1aad-4769-ac76-4dbcaf3a34c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d862d13e-e845-4bef-94da-831314fb3fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_aa975320-d206-4c7e-ae35-20b55248060c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bfe6f56a-1aad-4769-ac76-4dbcaf3a34c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_aa975320-d206-4c7e-ae35-20b55248060c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_da29a6c1-2184-4e5c-a38d-b58ce46b6955" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_bfe6f56a-1aad-4769-ac76-4dbcaf3a34c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_da29a6c1-2184-4e5c-a38d-b58ce46b6955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_6327a32e-c844-4c58-b6f5-0f99872809bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3642a947-6d86-4b00-a423-df3222cf5a19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_6327a32e-c844-4c58-b6f5-0f99872809bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_ba7b094c-fc7e-4aad-9d1e-05b62dd6a29d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3642a947-6d86-4b00-a423-df3222cf5a19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_ba7b094c-fc7e-4aad-9d1e-05b62dd6a29d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_533ea52c-b2a2-42a2-8f27-1269e4822b81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3642a947-6d86-4b00-a423-df3222cf5a19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_533ea52c-b2a2-42a2-8f27-1269e4822b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6d3766cc-4a67-42e6-af75-29f555153dad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_533ea52c-b2a2-42a2-8f27-1269e4822b81" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6d3766cc-4a67-42e6-af75-29f555153dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_dadc1d7f-4559-4945-ae7f-ce01b4a2effc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_533ea52c-b2a2-42a2-8f27-1269e4822b81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_dadc1d7f-4559-4945-ae7f-ce01b4a2effc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_04f78a3b-0dd9-4129-8d17-3ff9cf867087" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_533ea52c-b2a2-42a2-8f27-1269e4822b81" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_04f78a3b-0dd9-4129-8d17-3ff9cf867087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7388b843-6ac6-4b69-bec7-304b07189848" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_533ea52c-b2a2-42a2-8f27-1269e4822b81" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7388b843-6ac6-4b69-bec7-304b07189848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_ebe9fdf1-2ee6-4c84-810f-94c9f54d35a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_533ea52c-b2a2-42a2-8f27-1269e4822b81" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_ebe9fdf1-2ee6-4c84-810f-94c9f54d35a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_f59dd204-b858-4c27-8405-6c6d9796b3c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_533ea52c-b2a2-42a2-8f27-1269e4822b81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_f59dd204-b858-4c27-8405-6c6d9796b3c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/EquityBasedCompensationRSUActivityDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#EquityBasedCompensationRSUActivityDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/EquityBasedCompensationRSUActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_20f49a64-1f28-4b3b-87b3-b36aac8ef842" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d98c603-b2a1-4d6a-bcc8-6ecfd14bce98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_20f49a64-1f28-4b3b-87b3-b36aac8ef842" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d98c603-b2a1-4d6a-bcc8-6ecfd14bce98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_fa198179-b5ad-4430-89c1-e920e52d0217" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d98c603-b2a1-4d6a-bcc8-6ecfd14bce98" xlink:to="loc_us-gaap_AwardTypeAxis_fa198179-b5ad-4430-89c1-e920e52d0217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_acd94516-68b1-44f2-ac2e-b59cef82e783" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_fa198179-b5ad-4430-89c1-e920e52d0217" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_acd94516-68b1-44f2-ac2e-b59cef82e783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b64b9e2e-8e94-47e9-804c-bf550a61f362" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_acd94516-68b1-44f2-ac2e-b59cef82e783" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b64b9e2e-8e94-47e9-804c-bf550a61f362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_975e45fd-e1ca-4637-831b-557ce07ec8c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d98c603-b2a1-4d6a-bcc8-6ecfd14bce98" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_975e45fd-e1ca-4637-831b-557ce07ec8c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_b03395c2-aba0-4265-af0e-2759c6293e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_975e45fd-e1ca-4637-831b-557ce07ec8c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_b03395c2-aba0-4265-af0e-2759c6293e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b98acb5f-e6a9-4951-b607-e3366662f9fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_b03395c2-aba0-4265-af0e-2759c6293e0d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b98acb5f-e6a9-4951-b607-e3366662f9fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8b9ee2e0-49b0-41b6-ab55-db9080cfe23a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_b03395c2-aba0-4265-af0e-2759c6293e0d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8b9ee2e0-49b0-41b6-ab55-db9080cfe23a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_78ce8b4c-6e60-49dc-a9e9-32f6bb118bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_b03395c2-aba0-4265-af0e-2759c6293e0d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_78ce8b4c-6e60-49dc-a9e9-32f6bb118bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0c114a20-53aa-4140-8200-58c2de5d232d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_b03395c2-aba0-4265-af0e-2759c6293e0d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0c114a20-53aa-4140-8200-58c2de5d232d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_42d621cf-7da5-46aa-8528-2c8dbbabe943" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_b03395c2-aba0-4265-af0e-2759c6293e0d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_42d621cf-7da5-46aa-8528-2c8dbbabe943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_174d70e3-6603-4d29-afe8-d459105ee0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_975e45fd-e1ca-4637-831b-557ce07ec8c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_174d70e3-6603-4d29-afe8-d459105ee0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_43e525fa-bdb2-42a6-b6fd-4b859f976f32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_174d70e3-6603-4d29-afe8-d459105ee0a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_43e525fa-bdb2-42a6-b6fd-4b859f976f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_78a80b78-4387-46d6-b81b-3ed1e66617c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_174d70e3-6603-4d29-afe8-d459105ee0a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_78a80b78-4387-46d6-b81b-3ed1e66617c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_670c98c2-0060-411a-9aa1-ae0e87bf35c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_174d70e3-6603-4d29-afe8-d459105ee0a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_670c98c2-0060-411a-9aa1-ae0e87bf35c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4abc284e-b53b-48b4-8ce3-5894da0d9f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_174d70e3-6603-4d29-afe8-d459105ee0a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4abc284e-b53b-48b4-8ce3-5894da0d9f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d5d90f83-aa1a-4323-b4e4-bbee94c02a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_174d70e3-6603-4d29-afe8-d459105ee0a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d5d90f83-aa1a-4323-b4e4-bbee94c02a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/IncomeTaxes" xlink:type="simple" xlink:href="xcur-20210930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5caeb824-564a-4b15-af2d-1127f63abb47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_b496a186-5735-4d43-9122-22d35e2c1c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5caeb824-564a-4b15-af2d-1127f63abb47" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_b496a186-5735-4d43-9122-22d35e2c1c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d926ce4d-946a-4801-a0b8-121bfe6fa3f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e49483f6-4781-4c0c-983a-c85152c425b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d926ce4d-946a-4801-a0b8-121bfe6fa3f8" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e49483f6-4781-4c0c-983a-c85152c425b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7ee10c17-a562-415c-9e11-1aa736271aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d926ce4d-946a-4801-a0b8-121bfe6fa3f8" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7ee10c17-a562-415c-9e11-1aa736271aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShare" xlink:type="simple" xlink:href="xcur-20210930.xsd#LossPerCommonShare"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_57cd77ef-9483-486f-9b56-377c38f57858" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_9c2d064c-ffb8-4f7e-a215-6889b816b869" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_57cd77ef-9483-486f-9b56-377c38f57858" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_9c2d064c-ffb8-4f7e-a215-6889b816b869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShareTables" xlink:type="simple" xlink:href="xcur-20210930.xsd#LossPerCommonShareTables"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_60a68444-e74b-4697-8aa8-a9932884515d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_21ebb988-cabc-45c3-947b-b63fb5b9ea51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_60a68444-e74b-4697-8aa8-a9932884515d" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_21ebb988-cabc-45c3-947b-b63fb5b9ea51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_79de064c-4bfd-4aec-ac94-3735ffac9449" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_60a68444-e74b-4697-8aa8-a9932884515d" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_79de064c-4bfd-4aec-ac94-3735ffac9449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShareComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#LossPerCommonShareComputationofEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShareComputationofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6d43ae7b-20d4-4bf3-ac8e-4f3532072ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1a328b5f-cd2d-448e-ab6e-bcdeef1f05f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6d43ae7b-20d4-4bf3-ac8e-4f3532072ba4" xlink:to="loc_us-gaap_NetIncomeLoss_1a328b5f-cd2d-448e-ab6e-bcdeef1f05f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_10590341-f957-4179-a5c8-d5a101b4b2b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6d43ae7b-20d4-4bf3-ac8e-4f3532072ba4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_10590341-f957-4179-a5c8-d5a101b4b2b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0e7a0be1-118d-4ca4-b97e-caec980e8588" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6d43ae7b-20d4-4bf3-ac8e-4f3532072ba4" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0e7a0be1-118d-4ca4-b97e-caec980e8588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_f79a4377-bd5f-42f2-a1af-8b3a639c4554" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6d43ae7b-20d4-4bf3-ac8e-4f3532072ba4" xlink:to="loc_us-gaap_EarningsPerShareBasic_f79a4377-bd5f-42f2-a1af-8b3a639c4554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f5561ff4-507c-449d-a7d5-7395b5cbcbb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6d43ae7b-20d4-4bf3-ac8e-4f3532072ba4" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f5561ff4-507c-449d-a7d5-7395b5cbcbb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#LossPerCommonShareAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_003efe81-5529-4005-bf11-05c7516c4da4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_95e4fe9d-75bf-4eaf-9215-f34a7d2e5ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_003efe81-5529-4005-bf11-05c7516c4da4" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_95e4fe9d-75bf-4eaf-9215-f34a7d2e5ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c0d13473-efb6-4f58-9147-a58c7f1a462b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_95e4fe9d-75bf-4eaf-9215-f34a7d2e5ed0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c0d13473-efb6-4f58-9147-a58c7f1a462b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_edfdb8d8-cdfc-453c-82e3-821f54af6cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c0d13473-efb6-4f58-9147-a58c7f1a462b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_edfdb8d8-cdfc-453c-82e3-821f54af6cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a77c3ff7-b50f-4bad-8106-2559369ac9e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_edfdb8d8-cdfc-453c-82e3-821f54af6cc5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a77c3ff7-b50f-4bad-8106-2559369ac9e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_9b93539e-114e-4170-a8a2-24cb42d25845" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_edfdb8d8-cdfc-453c-82e3-821f54af6cc5" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_9b93539e-114e-4170-a8a2-24cb42d25845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_37c13a68-ca86-4bae-bf4a-6f0b27e49087" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_edfdb8d8-cdfc-453c-82e3-821f54af6cc5" xlink:to="loc_us-gaap_WarrantMember_37c13a68-ca86-4bae-bf4a-6f0b27e49087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_df34eb60-76d6-4cf1-bc39-4ccbfb080614" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_95e4fe9d-75bf-4eaf-9215-f34a7d2e5ed0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_df34eb60-76d6-4cf1-bc39-4ccbfb080614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9519419b-abf7-45ec-b78f-44506efb3b25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_df34eb60-76d6-4cf1-bc39-4ccbfb080614" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9519419b-abf7-45ec-b78f-44506efb3b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="xcur-20210930.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_656e41f5-1e5d-4293-a340-c8ada2dc7a66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_d447ea56-f11a-4b2b-a458-64c624a0250f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_656e41f5-1e5d-4293-a340-c8ada2dc7a66" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_d447ea56-f11a-4b2b-a458-64c624a0250f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="xcur-20210930.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6d310ac2-273b-4c50-9bc5-de308032146b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_e30f64b6-6965-438e-91a0-f7d71a0f3bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6d310ac2-273b-4c50-9bc5-de308032146b" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_e30f64b6-6965-438e-91a0-f7d71a0f3bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1edd2de9-758c-41dc-becb-ad47cf4ac060" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6d310ac2-273b-4c50-9bc5-de308032146b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1edd2de9-758c-41dc-becb-ad47cf4ac060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1eb1e53c-5bdc-4f4c-8c20-9eb684a9d608" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ddfca826-dbc2-4574-bded-0bd42a565b50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1eb1e53c-5bdc-4f4c-8c20-9eb684a9d608" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ddfca826-dbc2-4574-bded-0bd42a565b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_335976ba-d2d3-4db3-a550-acf36bffa597" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ddfca826-dbc2-4574-bded-0bd42a565b50" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_335976ba-d2d3-4db3-a550-acf36bffa597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0dfae113-525b-40fb-90a4-16e3d872cfa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_335976ba-d2d3-4db3-a550-acf36bffa597" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0dfae113-525b-40fb-90a4-16e3d872cfa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_f4166ec1-f503-4ed9-9d8c-94000d5f99b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0dfae113-525b-40fb-90a4-16e3d872cfa7" xlink:to="loc_us-gaap_MoneyMarketFundsMember_f4166ec1-f503-4ed9-9d8c-94000d5f99b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_5f4af087-6596-4276-a90f-28ebdbd23dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0dfae113-525b-40fb-90a4-16e3d872cfa7" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_5f4af087-6596-4276-a90f-28ebdbd23dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_b6bb5f9d-6b94-404c-83a5-440c889b723e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0dfae113-525b-40fb-90a4-16e3d872cfa7" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_b6bb5f9d-6b94-404c-83a5-440c889b723e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d609ae64-462d-49fc-9139-24ca951f1dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ddfca826-dbc2-4574-bded-0bd42a565b50" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d609ae64-462d-49fc-9139-24ca951f1dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f7ae1264-d032-4c00-b73c-fe4ef558f929" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d609ae64-462d-49fc-9139-24ca951f1dc8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f7ae1264-d032-4c00-b73c-fe4ef558f929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_71a93610-4972-4da4-b408-da51bb0f056d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f7ae1264-d032-4c00-b73c-fe4ef558f929" xlink:to="loc_us-gaap_CommercialPaperMember_71a93610-4972-4da4-b408-da51bb0f056d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_d5b8accb-f495-4488-9007-8e0602229993" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f7ae1264-d032-4c00-b73c-fe4ef558f929" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_d5b8accb-f495-4488-9007-8e0602229993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_43caa640-6ce4-4faa-a3aa-a24026b1dc4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f7ae1264-d032-4c00-b73c-fe4ef558f929" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_43caa640-6ce4-4faa-a3aa-a24026b1dc4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_ce33a896-5c1c-4ea3-9040-506b01e5b44e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f7ae1264-d032-4c00-b73c-fe4ef558f929" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_ce33a896-5c1c-4ea3-9040-506b01e5b44e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c05a4828-5cb7-4f16-a5f5-fb9cff81e38a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ddfca826-dbc2-4574-bded-0bd42a565b50" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c05a4828-5cb7-4f16-a5f5-fb9cff81e38a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5cd864ed-5999-49b8-96b5-1a6f68305730" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c05a4828-5cb7-4f16-a5f5-fb9cff81e38a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5cd864ed-5999-49b8-96b5-1a6f68305730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_99b65e3d-6979-49ce-8f1e-1abf905ddf7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_5cd864ed-5999-49b8-96b5-1a6f68305730" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_99b65e3d-6979-49ce-8f1e-1abf905ddf7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ae772053-f8fa-4f87-94ff-4ac56440e3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ddfca826-dbc2-4574-bded-0bd42a565b50" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ae772053-f8fa-4f87-94ff-4ac56440e3ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3681e950-bf1c-4383-ac27-42978581a0d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ae772053-f8fa-4f87-94ff-4ac56440e3ac" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3681e950-bf1c-4383-ac27-42978581a0d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_7d3bcb02-e26d-4eb0-b28c-eff262c04d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3681e950-bf1c-4383-ac27-42978581a0d5" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_7d3bcb02-e26d-4eb0-b28c-eff262c04d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_88b0e7f3-0f71-4f7b-9def-449ede8a4ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3681e950-bf1c-4383-ac27-42978581a0d5" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_88b0e7f3-0f71-4f7b-9def-449ede8a4ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1279b0bc-62bd-45f6-b844-7d3a6c1e1d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3681e950-bf1c-4383-ac27-42978581a0d5" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1279b0bc-62bd-45f6-b844-7d3a6c1e1d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b4d27005-4366-486b-9c32-574d267f48a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ddfca826-dbc2-4574-bded-0bd42a565b50" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b4d27005-4366-486b-9c32-574d267f48a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_446a1d4e-e23e-4a08-89ff-8b42607749c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b4d27005-4366-486b-9c32-574d267f48a9" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_446a1d4e-e23e-4a08-89ff-8b42607749c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1e9a6a5a-01aa-4c5a-a7e2-ac8059c50802" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b4d27005-4366-486b-9c32-574d267f48a9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1e9a6a5a-01aa-4c5a-a7e2-ac8059c50802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_e8b28ef0-6cee-40ba-b4b6-5322fb9d1951" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b4d27005-4366-486b-9c32-574d267f48a9" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_e8b28ef0-6cee-40ba-b4b6-5322fb9d1951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_CommonStockWarrantLiabilityFairValueDisclosure_c0e86f32-7bbc-476f-b33d-919da167e08e" xlink:href="xcur-20210930.xsd#xcur_CommonStockWarrantLiabilityFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b4d27005-4366-486b-9c32-574d267f48a9" xlink:to="loc_xcur_CommonStockWarrantLiabilityFairValueDisclosure_c0e86f32-7bbc-476f-b33d-919da167e08e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_95f5baab-470d-4906-ab8a-9fff72810d91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b4d27005-4366-486b-9c32-574d267f48a9" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_95f5baab-470d-4906-ab8a-9fff72810d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_71b2021d-157a-4902-a400-dcb08c4bee4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_381ac895-0b1a-4e21-aeaf-eec92baea163" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_71b2021d-157a-4902-a400-dcb08c4bee4b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_381ac895-0b1a-4e21-aeaf-eec92baea163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_64e06c85-6e9b-4ed6-84b2-90d2ebdc4f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_381ac895-0b1a-4e21-aeaf-eec92baea163" xlink:to="loc_us-gaap_StatementClassOfStockAxis_64e06c85-6e9b-4ed6-84b2-90d2ebdc4f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_997c3485-5a50-4d12-91f6-7197803ed572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_64e06c85-6e9b-4ed6-84b2-90d2ebdc4f1e" xlink:to="loc_us-gaap_ClassOfStockDomain_997c3485-5a50-4d12-91f6-7197803ed572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_76c7d31f-2993-4a02-afbc-1869af84a4e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_997c3485-5a50-4d12-91f6-7197803ed572" xlink:to="loc_us-gaap_CommonStockMember_76c7d31f-2993-4a02-afbc-1869af84a4e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fbaa731a-77cc-40e3-bbb4-e7986f9bc361" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_381ac895-0b1a-4e21-aeaf-eec92baea163" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fbaa731a-77cc-40e3-bbb4-e7986f9bc361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_1d702b49-37a2-4d68-9200-a1e8eb36cbbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fbaa731a-77cc-40e3-bbb4-e7986f9bc361" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_1d702b49-37a2-4d68-9200-a1e8eb36cbbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_5191c01d-a988-43d2-8707-6db5e0e7db49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fbaa731a-77cc-40e3-bbb4-e7986f9bc361" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_5191c01d-a988-43d2-8707-6db5e0e7db49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0b347e15-c667-49f7-a594-511a563edc5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e533adba-79a3-4933-b88f-37f78018a815" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0b347e15-c667-49f7-a594-511a563edc5d" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e533adba-79a3-4933-b88f-37f78018a815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7cb1b87f-3bc8-4461-8ffc-2750fc8fab87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e533adba-79a3-4933-b88f-37f78018a815" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7cb1b87f-3bc8-4461-8ffc-2750fc8fab87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3b6e1001-edb7-49ac-8561-03e08e8d875b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7cb1b87f-3bc8-4461-8ffc-2750fc8fab87" xlink:to="loc_us-gaap_ClassOfStockDomain_3b6e1001-edb7-49ac-8561-03e08e8d875b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2fe9fcec-aa7b-44aa-a4ae-35bde9d67b98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3b6e1001-edb7-49ac-8561-03e08e8d875b" xlink:to="loc_us-gaap_CommonStockMember_2fe9fcec-aa7b-44aa-a4ae-35bde9d67b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_d5ade988-c2be-4cd5-a5d2-38d1f129c0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e533adba-79a3-4933-b88f-37f78018a815" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_d5ade988-c2be-4cd5-a5d2-38d1f129c0a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ef9127f1-0c2d-4bc8-a671-facb6bf3704a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_d5ade988-c2be-4cd5-a5d2-38d1f129c0a7" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ef9127f1-0c2d-4bc8-a671-facb6bf3704a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_WarrantLiabilityMember_b24b73b2-acdd-4620-8f12-d0b5df770ce0" xlink:href="xcur-20210930.xsd#xcur_WarrantLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ef9127f1-0c2d-4bc8-a671-facb6bf3704a" xlink:to="loc_xcur_WarrantLiabilityMember_b24b73b2-acdd-4620-8f12-d0b5df770ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_b27fe806-da43-4189-8a12-99022ccb4b99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e533adba-79a3-4933-b88f-37f78018a815" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_b27fe806-da43-4189-8a12-99022ccb4b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e1d65760-ecc9-4154-b514-35355e9cd518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_b27fe806-da43-4189-8a12-99022ccb4b99" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e1d65760-ecc9-4154-b514-35355e9cd518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_d23ba965-9ddc-4c87-ab49-83f5f1c284be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e1d65760-ecc9-4154-b514-35355e9cd518" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_d23ba965-9ddc-4c87-ab49-83f5f1c284be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_6bede204-0879-4905-b28a-8c412971d173" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e1d65760-ecc9-4154-b514-35355e9cd518" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_6bede204-0879-4905-b28a-8c412971d173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_d1913b3b-ad1d-4124-bdae-c904ccf66d45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e1d65760-ecc9-4154-b514-35355e9cd518" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_d1913b3b-ad1d-4124-bdae-c904ccf66d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_eb4f1cae-b5f1-460f-a48b-b17c1f672102" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e1d65760-ecc9-4154-b514-35355e9cd518" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_eb4f1cae-b5f1-460f-a48b-b17c1f672102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/CommitmentandContingencies" xlink:type="simple" xlink:href="xcur-20210930.xsd#CommitmentandContingencies"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/CommitmentandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_dd8d0da4-92c2-45c9-902d-e7f1ecef728a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_999453d7-67ac-4e0e-8cef-87cf4c3a1d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_dd8d0da4-92c2-45c9-902d-e7f1ecef728a" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_999453d7-67ac-4e0e-8cef-87cf4c3a1d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/CommitmentandContingenciesDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#CommitmentandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/CommitmentandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_11fdd8f5-ec66-48e7-90d4-66713548de59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_AggregatePaymentsMadeToDateForLicenseAgreements_bbb60555-de52-4b76-a01d-4ec98f330939" xlink:href="xcur-20210930.xsd#xcur_AggregatePaymentsMadeToDateForLicenseAgreements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_11fdd8f5-ec66-48e7-90d4-66713548de59" xlink:to="loc_xcur_AggregatePaymentsMadeToDateForLicenseAgreements_bbb60555-de52-4b76-a01d-4ec98f330939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="xcur-20210930.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_4cbe4d7e-0ae7-44e5-a477-28ecb281b8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_61af439d-f80a-4da6-a81f-fbeb3aadf207" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_4cbe4d7e-0ae7-44e5-a477-28ecb281b8f0" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_61af439d-f80a-4da6-a81f-fbeb3aadf207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exicuretx.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="xcur-20210930.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.exicuretx.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_1419ce8a-b5d8-4827-8a8e-c976a01f60c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c2ca1802-2b3c-498c-b894-49313a9866e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_1419ce8a-b5d8-4827-8a8e-c976a01f60c7" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c2ca1802-2b3c-498c-b894-49313a9866e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e9ea5841-bb3d-426a-bb2c-1d4ff851b805" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c2ca1802-2b3c-498c-b894-49313a9866e9" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e9ea5841-bb3d-426a-bb2c-1d4ff851b805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_176372ef-7be4-4a91-9968-ae66f2eb53ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e9ea5841-bb3d-426a-bb2c-1d4ff851b805" xlink:to="loc_us-gaap_RelatedPartyDomain_176372ef-7be4-4a91-9968-ae66f2eb53ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_28f2a35e-0bea-4ad0-936c-4bab65f56fee" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_176372ef-7be4-4a91-9968-ae66f2eb53ed" xlink:to="loc_srt_DirectorMember_28f2a35e-0bea-4ad0-936c-4bab65f56fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_b1f872d0-a0f3-4297-847b-31bd7e5a144f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c2ca1802-2b3c-498c-b894-49313a9866e9" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_b1f872d0-a0f3-4297-847b-31bd7e5a144f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_d646a1dd-7deb-4151-ae75-c7ab4b373ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_b1f872d0-a0f3-4297-847b-31bd7e5a144f" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_d646a1dd-7deb-4151-ae75-c7ab4b373ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_xcur_ConsultingServicesMember_c482a501-ac1a-4ab8-8e43-48fd03029c05" xlink:href="xcur-20210930.xsd#xcur_ConsultingServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_d646a1dd-7deb-4151-ae75-c7ab4b373ec8" xlink:to="loc_xcur_ConsultingServicesMember_c482a501-ac1a-4ab8-8e43-48fd03029c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_6aeac265-e63a-4c28-8c49-97de24c90a11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c2ca1802-2b3c-498c-b894-49313a9866e9" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_6aeac265-e63a-4c28-8c49-97de24c90a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_57b0d5d3-b14f-4b7f-be66-e8e806d79ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6aeac265-e63a-4c28-8c49-97de24c90a11" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_57b0d5d3-b14f-4b7f-be66-e8e806d79ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
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MQB;/6)'=YD*Y<<JM$"B JR&Y. 'Y*P\6(S)WUL$85;6SLEZ_9>MVMDN%0ZZ
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M1W2?'CC@3R?SZA+Y=<F*">.^N[@RAJ=E__[]W+7];1+T<L7!&Y17M14KF)
MLPDF.J:3[;/CZ;881;8,.35JC(P:H4/7,$'#T)&>Z#1NBE? T&2=H+5WAVDY
M\=B.ENX\JS9N;\^G,0X\L.$2#9J!2!>N, R.SL+$[-Y4]^O&'&AC-2%_R]//
MO5;<T:!]D3RF#P89CA3#.$AR$H041H44_&KG\@&_/#TZJ48??KBWA \[>)5"
M)Q3T(>4@)6HD:SKYM!T=[1<I]$=W/-?H'MJVP'??'^H6'-^^) IJA D&+D;S
MO6A=+&0G8 2+ N1W=Z&5Q\U!_U%SJ,[I*R!QEB&*T:W%%794#SAD8RI<'5+Y
MGG"!I(^?>)K!LW#E'2Z_BG%AIR]E*3%()ND2#)JMQ-CK;4(O<*Q6R5!JIQUK
M,W' JDW/!_H_PE;=(\8WRJF-[MAM($AB>C,?WW#MD$>6;MJ9W> W3%][&ZB1
MM5]503(V?.X%+E,^ XL7+[&)#3475 =:Y:@YN)BCM":/0>M*K'QTS.33W((_
M#CDU:HRSJI'#GV*[U;?PJ5V'#Q_QEXW!_/6H:!X3<D*D6Q+$^"#E@XPM3@@I
M%U^]ZK:V=2K5J6BU$PHZZC8!U83$)=/B5=!184+0V=%H[^T#@K1^T\G-\B?5
M:/J<%;2@6;TQNZ^6\$9IZ*SHT,"H%=)#7S7E-X.IX6UGP49CK+C];D*NP'W1
M? XBXLP)AFA_ .IDZ! S*;I@]:]98=,"W32D#B[FPYA7R_=$"5&C YI5A.2F
MC(1<C8\Y!-W%1Y>MNO>WK9YZ]C6J--D.57V/H$,A.700#N93\E'UPXA5T@EO
MN/L-_3_^N!D+ )X7/_[X4WKZ]HXU]\KQ#;ZZ.]C4:J%Z$U>U@4VN+>V[R:TL
M?>'-,UWJ>WMV6Q,J79?,BX6=?6.KMC;E/H$C1X]U*1N*9\X$H] T2PR=BXAV
MBJ!#/(L%O<N5M2U<4JRM\6^G1KTBXT@AAHL10E)P5,.T&=7HYQ7>F3-;>1,,
M@EJ;J-FD,!@A1(>-O? J&!?&]J=?MG-1*O/!"51U/K/SB8]A?-SBT0JDM+^;
M^N67YW&<7:OPZJMO,1TT6DK:Q)HK/#&[/Y4Y'#Q,^73DX@+Q</68AE<B-3IQ
MXD29.M"!#A]+V=@XX55!BM#3>%[/8V/Y7-S**\^]U/15L9N<??L/E%RI@QKA
MLG%:->JNC3K>;,NCWW[G?;ESW"XE"2%FY2+MO>5Y7"\R$*+DI,VCNB23<%<4
MB]$=S[S<\/K]GWU>VK7*)IN8+^Y$&5449RI(MM(F@PY%<!]D17J)/_;*:ZU6
MSN!4#GQUZ,J^]\OQC:7IS<7Z$G_]!CY])YNZPQN_3:Y>WVOD U]]<YK9R-^B
MS9F!5YMX6F^GEWO[)5__X%Q/XCHK6QY_D9+1L?&G52,7&UUPZZ;L-G\P<FK4
M&&=5(UK6UFUHZ2QDS*0EC:F10TY37G/1RHW9;=HDE?IPC#4L?!45J&_G!ATR
M25FS\1&+J($5=U$_R9Q B-3HE=?>=LI1"ZH 5-W.;3BEA!V-YPADJ;@4Q:1H
M[\3P$VT^,6I@R-BY-D^97=#MK.Y@#2=C@CD8T\ZBQY*T$'_IM7>SVS0=6Q[9
M;I?*2!&57[0PIHU/XF(UQE=C;)6-"3LDC68C/4,C/MFW_Z>??JH:,(_F3 L3
MI633(8-K0(\H(:G"Q#@8VE]==,.Z#;]; =GJO/#V?BFU3DJN%1.K?'6KO55+
MW=4KQ?[K._2_TV>L'#GO[*GG'4_^PVJ66Z*]J5C0G@AK-]_45%UKP)B%=G_B
M9S724<U 0<\(D@KN#(2_+4^OMPPY-6J,1M1(ARBV08T*.Q@OO/1V=K/FY,N#
MWW!7I2C.H-!"<YWDU9/G7 CP/:@V=P73P=R]I^5.5+H8;M_TH"L0;>>N+.B4
MLGDJP->!6=R5M"^!\7I1A_CM&[?\;X,:S5NXQBXJ&&?0_KH\;ZQ 3I'H"-LP
M"!)=:MI$9>&Y[9AI"SR_\TW(,%QR[+1J!#9OV9W9;9J4>4LWT#(J,8X+2=)7
M8^52>>B(O!J+)^B4=%3IE5?2@V\<-6D.Z=&<8@*5](!^QH7!:$DC)</*&Q9T
M=I8^>M+2['=O;59O>;.T=J.OZG8AOJKSH#L*C 4.<Z'37,Q7K>Z<OOW^[6=?
M@/[I5U\6U.J87NY,*1:E%ZZ5W;?C3$7FSY$?#AWR7S\P\[6?7HV&CUN0W>:/
M1TZ-&N.L:D2+H?V?M6@T<]>#_R@(F(VI$3CG?L/F9+=IJWSQY4%?3W"&$2NG
MN/P&.H*'"^-,F/8E+8Q*L*&^@]'INI= D%X9']Z>+6O/A2R"FL<IJ*:0)T0R
M83LHF!PMZ1)K^?J %\R)$R<Z]:FS<I6D@'([FHMF3(5L-W/&L*;5WI3=IDF!
M2+_OB.F4V-O&]<;EAGUS938Q!,,IWQ,DV33!I"BIPNX+TKZ@E2USH/.R%((#
MOZ 3?-S*&#8&'2$<B8WX[KLF.">I"8&NTG?V_7QJL=N8%^B[HB0^1ZY?6EJW
ME$_,]Z07! 8N__# [_K)X:.'O_SNX)X#>]_:\_YS[[RV9>?VM4_<>^M#=W8:
M5>U,E.4%N]L3H:)ZL^/(OD<O>HW&<R^\2<DQ&SI;18/AVO#\&1.,C,%OPL\\
M=W*"](],3HT:X]?=KQG+U&(VT**&ALDQ,=(C-/1HBU02^87A4Y<X.J70$79@
M&35JZ-4TAR9^BN7$]J=>RV[3AC$&3*9*C<O<%;2$CHG"(5X4$E8A81.3I)SJ
M$1P)M_N2;[_[0>BF4Z4J[D?/E&R9W44D&R&\08>@6-A*H]_4XR=.'#MV_.C1
M8VW2&CCYXX\__31Z^G)G![,Q->H6''JTF0^"^^K@-]V"];0<M(D5F!3"Y3 F
MA:U<T.XS<6^*8*H(H0_&]W9UC-JX<AI&&@N1ET:+IL6K@]GE9.<;!K]__A57
MFYMOOOW^ZH&WR37+?+7+_74KBLQ9?,U"+C%/2M_*UBT,]%^T_HE_S-RX>MB"
M:8DI0\I&)ZX=I7KK>]AT.4_I:#6NM"9*_ZX)EZJ=7/4A0KL.BUY'QX,VL_QR
M_8;[7[S8?6RSYM].2B8(TFG5J&OEX-/6#/ZCD5.CQCBK&AE])V6W:4X@\NN3
M&IO/1QM3HXX]^L%XS+CE!N_WJP]L@P8Q^J(U]]H[QG"?D>=&)UEG:J7'VWDA
M^TSB8H(6]$_V'KCDQ5??Q810GE"1+P8QGX))"H'.#3(H%OEQ&QMBNU5W#0[I
M$[^Q6Y]!UX5'71,>V:;LVHIAO<(C>U0.OR8\JEMX5._$)*9'?7LFBA9Y_[R*
M@<C,WF#HD8Q66)K<O0<],6M6=K[RAJ^;:1=,&/:DB$Y@@GM0W"EM\YJ8UZ1E
M$)ZPC4U24@TN5%B9WK20M/-)S*V[^*2W-/+$#G0B0UOC]?<^*C&G,*E9_GZ+
MW(F;Y?X+"^/3F)I93.V,DKI)^6KUWZ,>:T+*BW6Z(M;Q;TGNOV,E_R=6]-<:
M[K],[O\+%_U9]_Y)]?P_3?Q;O-.EP8"]ND^>VO-O%5>[!AG!&6.S_]CY\../
M/X;-FW!1IWS@:C4T;H40F$V(@<&MOVGVZNPV?TAR:M08OZSP;K",W] ;J@0U
M_&;<M.79;9J3K[[^ABZ-VWQQ=+Q%ID 1A6;G5 BL[:QI9V)\I_INO897&A.Z
M]NI?IHXJUT;WK 1G..)4#]FZUKUBZ+6AD155DZ7KZJ_P5-*E"8Q!IQS@K&[U
M1&VB3L"8E4T(&>]_^-E+5FUXV![0VW'E>4(EU4'/YX+Y)>44J]AY%?>$['[#
MR@0I6<USEQ?YXG9(,D2C39F34XLA(F8B:.V<9%IXS2+H5A$%Q:=5(U+0'WRD
M)7S]_0]O=TKHG \KHX*1HI[GKB2Y)"6D;'"U@F;QQG"^RNZ/8%P9J!'-)TFO
MZ?;5+ES>1M?)W/'0CM+^"[W)F>[XS<6QZ6+]+9ZJF>ZJ&<6I2:!&%JWFLJCW
MTDC)WQ7YKU'YO_7B_TEY_RM>\O^2[O]KL&"7IZ0_:9[_BO)_,3N2J9Y6XQI0
M(RS6YW+S!KPZN.^S_=E_[YPY>/ [WU7U<+LSDW*G4:-[MF17"_YCDE.CQCBK
M&LU?VJ*C<N>K;U(=4^W11SZ]&H%!Y$JZPYY G"@I<_$1RJ.X^&SWV.I6'$@1
M7@7//+[-YR*XK(,480RJ>69Q*XX.*2NO6KBHLT-JUBV;+ADS]7:<2V$">F0'
M_1+-<F2> )/063F5@)N1.>S+RD<P^%[$V,FG?&W&[&P<C$(K%,Q,?HWD)]-K
M-73GD$&2I] HR8V .83$LC5H_48+,'WV;0Y.*_17D2SZ2I&A"T,/(=$S23:-
M<VE,4L%PUJ"]1B&G#1@\K=5+=#?&X 7K P-F>ZJF<G4SBY-3W%73V-J93.TT
MINZF@G3?*Y1K+M6*_JP6_-F4_EOE_L<H^HM>=&F4 ?N+5H),9?^B\I=%A?9&
MX/)XY[^J':^(=;]"[Y9O]' E>BU[X,*77[_U]AXG7Y-1(Q6B#9LW9)?"#CF2
MQQA6/D[[8J^^L2N[S1^2,Z@1*9EM4(UZ1\:#V[()(5R*H >K:,J]!=0(3>DC
M$T/(,LIT^Z86<AH-;+SW44("MYS(%"@R*#[ZJZ$SIAO<B-)0M0A#AV!%;."H
MI6SWV.I&LS&PC,>#SA:F^+"=4\"<?-0EJ@173HE!6@I30GC$Q&67J+6S3ZM&
M-D^$8*.X$+$)89L000N3X#70B4_Y>ZUK-!,'H]"2N=^K42:.R%A&C;B3:D2Q
MQJ29Z[-O?O-PXL2/M8/G68O#=B%V!C6RB5%:3!1*53UZ#?JJ93=[GSN'#A^I
M'+^$J9I4DIS,U-Q<DIK*U<[RI*>[TU.\=1/I>/JR</>_1@M C?X:]_TE)O\M
MX?E[W'.%(8!=%F>0F=)EIGQ%5,1BG=K%.O]-Z]@NWJ.=V:.]ULT:[AJ^<7#V
MGSQGMFU_G6;2#6I$P'?+10FN@N0K2;F*D%.%'9,'OFBNLGC_7N34J#'.JD:/
M//YL=IOF9.[BM6=3H^A)-1)^5B,1TH9L]]CJ]CLUXG]5(XH).W@%9\M(H9(2
M0Y083O:?=4G7BI&9Y8P@,^CQ+QK,Z(D9W'B-0@\\=!L7M7$J=%923-@XP\Y%
MVI3AD%"#->37\/G19XYF5D!JZ"ZR)C)(=2'; ^-1PC=@U"W9-[_9^&3?9U?U
MKG-*O_:AS*-(% M I) );:K:>?2BCC5<)^.=?_XKNWV;X=7W]WA3XPK,D5S?
M*>[:206I\6S=%(<YBDB/+N@_SF:6M5-!70)$^DIWO^L# RO*1NI5-]:-FGGC
MS4OG+M^T<O/6NQ][8<?.MU][9_>N#S[>?=7$Y!6)SI?%.UX6[XS%KK+J5[KZ
M]M[[Q04NW;SKWF= VM%Z7"&*LQ&7S\#92JN[S";&\UA=[%%S^,C1[#9_2')J
MU!@9-6J0HH9=\VB^EQ0KD7$FS<>>?;%%%[!-G+:0$E,$G_AY"8.2L8QS1A-W
M!JHCBA9<J)ENCV:DK:)A%=53/63KVL\KB=2,06>+-NS! %DAX()1T1QT-S%1
MOTZ?> E[==_3JA'&JC8F:O&&\[UA*ZM@Z 5Q7(C3;+A-&<9IR/@H&-ZP@913
M""Y*LBK)ZB1C(&/1V$/&J4XY5C6@10OQOO;F>S0?:DR-\AG3V;&^75%PQ=H'
MLENV)59M>9*MGL#63&3K)CL38UV)<5S]M(+$V,(!-W$CIJQY;,OS_WS]S8]V
M?7A@[Q??'CQ\]"R'PETWJ1:DZ*]ZX&]&AP8UNDSK]-AK%UAD?<7J1W]1(ZLG
M6. W[1+T@2 F)@A?JCPYL:DVV/Z[\V^G1C>$Q[4%-7)*B3??>3^[37,R?-RL
M,ZL1.MB;!XO:>,W*FV 60;<(T5,]9.N:C=<S%LV88D/7K&9,0ULR>-3]K%S4
MPD8[]AEQB;,TBHM! GE&I>$4WH8UCG:_28D:+6A.R72*D&0H!!.DN##&&VW*
M;)G#ZE%%1;0:$E*0*,6J%*M3C$DQ<8I)D&!LC&!-@H-!J#HD3?VY+%(+\--/
M/XV;O-8.&7=#E\J(4&8?;IQH,,8D6=/E2UVGC/SBRS8Z30<,6[61&SS96S.N
M(#'<E1Y97#O&W7=446J()S4L.')&]JO/1GCF8&MUERM,\3*=OS0F_5GE_Z8'
M5C[^NR)^Y\XMRQ[ N3@F&J!&)$1D$O1;-%]WA4>!F#&4GI#=X(_*@!$SSJ!&
MJS9LS6[0JAP[=KQGY9B652-4,C53-37SY8CE%!@7*_&G/_JDV1?B_I8!PZ=0
M8I+@,VOJ?MGWBN8/(2M":[X)/@)='7D\5J.8& W&1L!.]9"M;&(0F1#&A B2
M3P&&)#),C))^E#-!!( .TN,BXG5]+R'ET&G5R(K2C@@MZ@6^>(%LVGF5YL)V
M02&E>)LR EF,1#NJ=+NH.\ $PR'$''S"P:<<?)4=3$C20@*Z-2T:Q1T3URL#
M6VREP*U+'H1K()B&W=2G42.*B^.,;G%'BCNFM.H)%WG4=#-Q_,2)[J.G%]2,
M+DR.*$J.<->/+TB/I,S^A<DA8M^QT\Z_5$?EC(%_U^6_:UR[F'QYTO<W4VZ?
MZC+\MKG9KSLW9M]Z]Z]JQ"L$B[9Y.R08"7%GISJ]W]3L!G]4AHR>=08U6K[N
MX>P&K<K1H\>N*1]U!C6:/+O)BI6<68V\'6J;Y.S=<Z=^R$UG5B-:4NVBBCR>
M8#KXI!-,4,%.]9"M;+X(,CE*RG!M&BEK1,8:U B^\ ;73<EZ\96I2TB?;A.C
MF54,/QO\*(7SV3ZT'#+[3GKRF5>V[7CQB:=>V/XTV//;X1]MR9YX"J[MQ89_
M/_D[>['!?G[E\]N??@YLVU,[7WCEK68ZZ"B+9YY[NT"L*2@UT-)$M%140?,
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MUR$D#"4B1H/A$">\$9.GPNR.D(P<T"=DBXV^^^Y8K^@P*Q\FO HNR#@*Y@X
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MA>I4$EP53E41'C&?K>8[#-ER]BS[1L-S6[8ZO$&R5,5X"?.$<1H5J;%RZ9A
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MRG1'-=W*Q$%P6K/142<=9LM"VW=DX4CR7]C[V3YW.YA(LK%8,I6H=KX&H\/
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M%:2@\ (>M&78X*HD@"Q\BM$=M/LT7]>:]1M>S'S3W^&\V.@DZ@_['-56LO'
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M&^-L$[+Y ^ 56&@1L1$-$TQQ"#%0SB0/SF[80E=B%-QGL.EK0'!PF,XDF"L
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5?P;R$T?3'%SB     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_1a.jpg
<TEXT>
begin 644 image_1a.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M$'_QZBN[^SL5_P ^V<?U_#?SHZ']K[X$:I\7/"^@:[X6,7_":^#[X:KI44Q
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M-J:=CMQ'7R.W_!*KX8EB5\2^+%'93<VIQ_Y+TW_AU1\,_P#H9O%?_?\ M?\
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M;7C'PY^(FO\ PE\;:=XG\.W;6.K6$FY21\KKT:.1>ZL,@C^M?I7_ ,$L<_\
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M!G&7Q*U_/5:GA]%%%?6GS>A^TV:^6O$VA_;_ -M#16U\;[(V(FTQ9.4+1HQ
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7"O#/_@FE_P#DFBBBK^M5OYA?5:78_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_2a.jpg
<TEXT>
begin 644 image_2a.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M/I52_P!0MM+LY;J[N8;2VB7<\T\@1$'J6/ %<IH/QJ\ ^*=4;3-'\9Z%J>H
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MQ]BNLY$JXZ*Q_(_6C"RC6A]7J?)^8ZD7&7/'YGZ>>E?%O_!0;]J?_A6_AM_
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M=_\ "1MX/L*]_P#^&3_VM_\ H:+[_P *R3_&N"_:2TN\_9S_ &U;GQ%';O\
M91J\'B2SP,"6)W#R*O\ P(2K7ZS^$_$^G>-/#NG:[I-TMYI>H6Z7-O-&<AD8
M9'X]B.Q!%>_B,3.G"$H)--=4>;2I1FY*3U1^:W_#)_[7/_0T7W_A5R?XT?\
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M,O\ QG%>_P#88L__ $)*67_Q)>@\1\*]3]<])A%OI=I$. D**/P4"KM06?\
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M^.QC6O+@WKS/T(O6VLCPG]HS]OOQ/\<8G\'> =+O-#T:^;[.Y3]YJ.H \>6
MF=BGNJY)]<<5]4?L#?L[^+?@EX#N[SQ7J=Y;W6K!7B\-F7,%@O7<R\@2MWQT
M'!R>GK'PE_9C^&_P182^%/#%O:Z@5VMJ5RQGNF'?]XY)'T7 KU7MUQ6=;$0<
M/9THVC^+*ITY*7--W8V2-9$*L,JPP1ZU^27[5WP5\4?LL?&Y?'7A436N@W5]
M]OTW4(5)2UG)W- _8<YP#P0<=J_6[M69XB\.Z7XLT>YTK6;&WU/3+I#'-:W4
M8>.1?0@UEAL0Z$KVNGNBZE/VBMU/COX._P#!3?P/X@TFWMO']O<^%M910LMU
M!"UQ:2GNPV LF?0@X]:]!\3?\%$/@EH.GM<6OB:?7)P,I:Z=8S%V/IEU51^)
MKF/&W_!,CX5>)KA[K1;C6?";N<^197"S0#Z+(&(_!JYO2?\ @E-X&M[I7U'Q
MCX@OX <F*)(82?;=M:NM_4Y/FNUY&/[^.FC/E;X\_M#>,OVSO'FE>'M#T>:#
M3%GVZ9H=N?,=G/'FRL."<?@HK],/V8?@E!\!/A)I?AK<LNI8-SJ$Z='G;[V/
M8=!]*N_!W]F_P!\"[5U\(Z!#9W<J[9M0G8S7,H]#(W./88'M7J%8XC$QJ15*
MDK11=*DXMSF[MC:_(+]J;_D^*\_[#%G_ .A)7Z_>E>$>,OV,?ACX\^(TGC?5
M]/OY=?>>.Y:2._D2/>A!7Y <=AQ4X6M&A)M]58JM3=1*Q[G;_P#'K%_N#^53
M4R.,1HJCHHP*=7&;F7XC\/V'BO0[_1M5MDN].OH6M[B!QD.C#!%?DE\6/A7X
M^_86^,D/B3PW-,=%,I;3M5$9:":(GFWG'3.."#UP"*_7[]16=X@\.Z9XKTFY
MTK6;&WU/3;A=DUK=1B2-Q[@UU8?$.BVFKQ>Z,:E-5%V:/D_X1_\ !2WX;^+M
M-AC\9&?P7K  $OFQ//:N?59$!('LP&/4UZ%KG[=WP0T.Q:X_X3JUU!E&1#I\
M,L\C>P 7^9%<1XY_X)G?"7Q1<R7.D'5_"DCG/E:?<B2 ?1)0Q'T!%<?I_P#P
M2B\%PW >\\;:]<09YCCB@C)'^]M/\JZ;8.3YKM>1E>NM+)GCG[2O_!0S6/BY
MIMQX1^'NFWFAZ-??Z/->2?-?WJMQY:*F?+#=" 2QSCBO;?V!OV.[OX7J/B!X
MVLC;^)[B(QZ=ILH^:PA8?,[^DC#C'\(XZDX]V^#_ .R'\+_@C=1WWA[P^LVL
M(,#5=2D-S<K_ +I;A/\ @(%>SU-7%04/9459=>['"E+FYYN['9HI:*\TZ@HH
MHI@%%%% !1110 4444 %%%% !1110 ROF[]OJ.?_ (4+-/"?EAOX&D&<97YA
M_,BBBNS NV*AZHY<5K1EZ&7_ ,$\;B*Y^"MY*HPYU24.<=\+C],5]3XHHJ\P
M;>*J>HL)I1CZ"T445P'6%%%% !1110 4444 %%%% !1110 4444 %%%% "4M
1%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_3a.jpg
<TEXT>
begin 644 image_3a.jpg
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"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_4a.jpg
<TEXT>
begin 644 image_4a.jpg
MB5!.1PT*&@H    -24A$4@   ^D    $" (   !];>GI    ,DE$051X7NW6
M,0T   @$,?R;?L** DC:\11<%0  <%Z2G0  @(.\.P  _##O'@  X(,&#6>X
1XF.&!^,     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>xcur-20210930_g1.jpg
<TEXT>
begin 644 xcur-20210930_g1.jpg
M_]C_X  02D9)1@ ! @$ R #(  #_X@I024-#7U!23T9)3$4  0$   I 041"
M10)   !M;G1R4D="(%A96B 'WP ) !4 #@ $ "!A8W-P35-&5     !$14Q,
M                        ]M8  0    #3+41%3$QM':Y$VU;J;O9-['O4
M\BCC                                          ID97-C    _
M (1C<')T   !@    #AW='!T   !N    !1R6%E:   !S    !1G6%E:   !
MX    !1B6%E:   !]    !1R5%)#   ""   " QG5%)#   ""   " QB5%)#
M   ""   " QC:&%D   *%    "QD97-C         "I$14Q,(%4R-S$W1"!#
M;VQO<B!0<F]F:6QE+$0V-3 P
M
M                      !T97AT     $-O<'ER:6=H=" H8RD@,C Q-2!$
M96QL($EN8RX                          %A96B        #VU@ !
M -,M6%E:(        'PN  ! "   !=)865H@        65(  +*B   =QEA9
M6B         A5P  #58  *^58W5R=@        0     !0 *  \ %  9 !X
M(P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R '< ? "! (8 BP"0
M )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -  U0#; .  Y0#K /  ]@#[ 0$!
M!P$- 1,!&0$? 24!*P$R 3@!/@%% 4P!4@%9 6 !9P%N 74!? &# 8L!D@&:
M :$!J0&Q ;D!P0') =$!V0'A >D!\@'Z @,"# (4 AT")@(O C@"00)+ E0"
M70)G G$">@*$ HX"F *B JP"M@+! LL"U0+@ NL"]0,  PL#%@,A RT#. -#
M T\#6@-F W(#?@.* Y8#H@.N [H#QP/3 ^ #[ /Y! 8$$P0@!"T$.P1(!%4$
M8P1Q!'X$C 2:!*@$M@3$!-,$X03P!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F
M!;4%Q075!>4%]@8&!A8&)P8W!D@&609J!GL&C :=!J\&P ;1!N,&]0<'!QD'
M*P<]!T\'80=T!X8'F0>L![\'T@?E!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2
M".<(^PD0"24).@E/"60)>0F/":0)N@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*
MQ0K<"O,+"PLB"SD+40MI"X +F NP"\@+X0OY#!(,*@Q##%P,=0R.#*<,P S9
M#/,-#0TF#4 -6@UT#8X-J0W##=X-^ X3#BX.20YD#G\.FPZV#M(.[@\)#R4/
M00]>#WH/E@^S#\\/[! )$"800Q!A$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')
M$>@2!Q(F$D429!*$$J,2PQ+C$P,3(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4
MK13.%/ 5$A4T%585>!6;%;T5X!8#%B86219L%H\6LA;6%OH7'1=!%V47B1>N
M%](7]Q@;&$ 891B*&*\8U1CZ&2 911EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;
M%!L[&V,;BANR&]H< APJ'%(<>QRC',P<]1T>'4<=<!V9'<,=[!X6'D >:AZ4
M'KX>Z1\3'SX?:1^4'[\?ZB 5($$@;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B
M@B*O(MTC"B,X(V8CE"/"(_ D'R1-)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:'
M)K<FZ"<8)TDG>B>K)]PH#2@_*'$HHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K
M BLV*VDKG2O1+ 4L.2QN+*(LURT,+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1
M+\<O_C U,&PPI##;,1(Q2C&",;HQ\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4T
MGC38-1,U336'-<(U_38W-G(VKC;I-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\
M.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\93RD/.,](CUA/:$]X#X@/F ^H#[@/R$_
M83^B/^) (T!D0*9 YT$I06I!K$'N0C!"<D*U0O=#.D-]0\!$ T1'1(I$SD42
M155%FD7>1B)&9T:K1O!'-4=[1\!(!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+
M4TN:2^),*DQR3+I- DU*39--W$XE3FY.MT\ 3TE/DT_=4"=0<5"[40914%&;
M4>92,5)\4L=3$U-?4ZI3]E1"5(]4VU4H5755PE8/5EQ6J5;W5T17DE?@6"]8
M?5C+61I9:5FX6@=:5EJF6O5;15N56^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A
M7[-@!6!78*I@_&%/8:)A]6))8IQB\&-#8Y=CZV1 9)1DZ64]99)EYV8]9I)F
MZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK
M;L1O'F]X;]%P*W"&<.!Q.G&5<?!R2W*F<P%S77.X=!1T<'3,=2AUA77A=CYV
MFW;X=U9WLW@1>&YXS'DJ>8EYYWI&>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["
M?R-_A'_E@$> J($*@6N!S8(P@I*"](-7@[J$'82 A..%1X6KA@Z&<H;7ASN'
MGX@$B&F(SHDSB9F)_HIDBLJ+,(N6B_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!N
MD-:1/Y&HDA&2>I+CDTV3MI0@E(J4])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9
M_)IHFM6;0INOG!R<B9SWG62=TIY GJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-V
MH^:D5J3'I3BEJ:8:IHNF_:=NI^"H4JC$J3>IJ:H<JH^K JMUJ^FL7*S0K42M
MN*XMKJ&O%J^+L "P=;#JL6"QUK)+LL*S.+.NM"6TG+43M8JV ;9YMO"W:+?@
MN%FXT;E*N<*Z.[JUNRZ[I[PAO)N]%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"
MV\-8P]3$4<3.Q4O%R,9&QL/'0<>_R#W(O,DZR;G*.,JWRS;+MLPUS+7--<VU
MSC;.ML\WS[C0.="ZT3S1OM(_TL'31-/&U$G4R]5.U='65=;8UUS7X-ADV.C9
M;-GQVG;:^]N W 7<BMT0W9;>'-ZBWRG?K^ VX+WA1.',XE/BV^-CX^OD<^3\
MY83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q
M<O'_\HSS&?.G]#3TPO50]=[V;?;[]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ
M_DO^W/]M__]S9C,R       !#$0   7?___S)@  !Y0  /V/___[H?___:(
M  /;  # =?_N  Y!9&]B90!D      '_VP!#  P("!L*&R(1%R0J)!P;("0K
M*"@@)"DE)3$O)2DN*BLK.2LJ+B\T-34U-"\[.SL[.SL[.SL[.SL[.SL[.SL[
M.SO_VP!# 0T+"Q .$!L4&R0R*"$H,CLT,C(R.SL[.SL[.SL[.SL[.SL[.SM
M0$! 0#M 0$! 0$! 0$! 0$! 0$! 0$! 0$#_VP!# @T+"Q .$!L4&R0R*"$H
M,CLT,C(R.SL[.SL[.SL[.SL[.SL[.SM 0$! 0#M 0$! 0$! 0$! 0$! 0$!
M0$! 0$#_P  1" 1R"<L# "(  1$! A$"_\0 'P   04! 0$! 0$
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M?VLGH?T_QH O451_M9/0_I_C1_:R>A_3_&@"]15'^UD]#^G^-']K)Z']/\:
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M?VLGH?T_QH O451_M9/0_I_C1_:R>A_3_&@"]15'^UD]#^G^-']K)Z']/\:
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MC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4
M1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/
MR%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1
M]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D
M_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T
M4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^
MZ/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\
MA1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?
M9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%
M2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F
M3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_N
MC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4
M1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/
MR%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1
M]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D
M_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T
M4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^
MZ/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\
MA1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?
M9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%
M2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F
M3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_N
MC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4
M1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/
MR%2T4 1?9D_NC\A1]F3^Z/R%2T4 1?9D_NC\A1]F3^Z/R%2T4 9>JQ!-N !U
MZ#'I5_[,G]T?D*I:Q_#^/]*TJ (OLR?W1^0H^S)_='Y"I:* (OLR?W1^0H^S
M)_='Y"I:* (OLR?W1^0H^S)_='Y"I:* (OLR?W1^0H^S)_='Y"I:* (OLR?W
M1^0H^S)_='Y"I:* (OLR?W1^0H^S)_='Y"I:* (OLR?W1^0H^S)_='Y"I:*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH S=8_A_'^E:59NL?P_C_2M*@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S;W_
M %J?\!_G6E6;>_ZU/^ _SK2H **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ K-_Y;_Y_NUI5F_\ +?\ S_=H TJ*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH S='_B_#^M:59NC_P 7X?UK2H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *S='_ (OP_K6E6;H_\7X?UH TJ*** "J.K?<'^]_0U>JC
MJWW!_O?T- %FV^XO^Z/Y5+45M]Q?]T?RJ6@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0'4@JP!!!R"#T(-8/A_QK#KLA@B5PRJ6^<*!@$#LQ]:2387.@HHK%\1^*XM
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M?-M&S"_Q=<@'H,@<D XKHJ&FMP3N%9O_ "W_ ,_W:TJS?^6_^?[M(9I4444
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MNPZ GDCIZX%)*XS1HJEHVJKJT2W,8(5\X#8!X)7L3Z>M7:&K %%%% !1110
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MQ'\,1;1^;:%G9<ED;!)'^S@#D>G?MSP:LG&-W86MV9D4:2:JHLL;/.4C8<#
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M=ZSK*V]H]XC8!BW(V.[#Y#@CN2.H^M9'Q,T\7%H9N-T+*0<9.&.TC/;J"?7
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M -:IJ* (?[8_V?U_^M1_;'^S^O\ ]:IJ* (?[8_V?U_^M1_;'^S^O_UJFHH
MA_MC_9_7_P"M1_;'^S^O_P!:IJ* (?[8_P!G]?\ ZU']L?[/Z_\ UJFHH A_
MMC_9_7_ZU']L?[/Z_P#UJFHH A_MC_9_7_ZU']L?[/Z__6J:B@"'^V/]G]?_
M *U']L?[/Z__ %JFHH A_MC_ &?U_P#K4?VQ_L_K_P#6J:B@"'^V/]G]?_K4
M?VQ_L_K_ /6J:B@"'^V/]G]?_K4?VQ_L_K_]:IJ* (?[8_V?U_\ K4?VQ_L_
MK_\ 6J:B@"'^V/\ 9_7_ .M1_;'^S^O_ -:IJ* (?[8_V?U_^M1_;'^S^O\
M]:IJ* (?[8_V?U_^M1_;'^S^O_UJFHH A_MC_9_7_P"M1_;'^S^O_P!:IJ*
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MO_UJFHH A_MC_9_7_P"M1_;'^S^O_P!:IJ* (?[8_P!G]?\ ZU']L?[/Z_\
MUJFHH A_MC_9_7_ZU']L?[/Z_P#UJFHH A_MC_9_7_ZU']L?[/Z__6J:B@"'
M^V/]G]?_ *U']L?[/Z__ %JFHH A_MC_ &?U_P#K4?VQ_L_K_P#6J:B@"'^V
M/]G]?_K4?VQ_L_K_ /6J:B@"'^V/]G]?_K4?VQ_L_K_]:IJ* (?[8_V?U_\
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MV?U_^M4U% $/]L?[/Z__ %J/[8_V?U_^M4U% $/]L?[/Z_\ UJ/[8_V?U_\
MK5-10!#_ &Q_L_K_ /6H_MC_ &?U_P#K5-10!#_;'^S^O_UJ/[8_V?U_^M4U
M% $/]L?[/Z__ %J/[8_V?U_^M4U% $/]L?[/Z_\ UJ/[8_V?U_\ K5-10!0F
MO/-<28Z8XSZ'-6?[8_V?U_\ K5-10!#_ &Q_L_K_ /6H_MC_ &?U_P#K5-10
M!#_;'^S^O_UJ/[8_V?U_^M4U% $/]L?[/Z__ %J/[8_V?U_^M4U% $/]L?[/
MZ_\ UJ/[8_V?U_\ K5-10!#_ &Q_L_K_ /6H_MC_ &?U_P#K5-10!#_;'^S^
MO_UJ/[8_V?U_^M4U% $/]L?[/Z__ %J/[8_V?U_^M4U% $/]L?[/Z_\ UJ/[
M8_V?U_\ K5-10!#_ &Q_L_K_ /6H_MC_ &?U_P#K5-10!#_;'^S^O_UJ/[8_
MV?U_^M4U% $/]L?[/Z__ %J/[8_V?U_^M4U% $/]L?[/Z_\ UJ/[8_V?U_\
MK5-10!#_ &Q_L_K_ /6H_MC_ &?U_P#K5-10!#_;'^S^O_UJ/[8_V?U_^M4U
M% $/]L?[/Z__ %J/[8_V?U_^M4U% $/]L?[/Z_\ UJ/[8_V?U_\ K5-10!#_
M &Q_L_K_ /6H_MC_ &?U_P#K5-10!#_;'^S^O_UJ/[8_V?U_^M4U% $/]L?[
M/Z__ %J/[8_V?U_^M4U% $/]L?[/Z_\ UJ/[8_V?U_\ K5-10!#_ &Q_L_K_
M /6JM]L_>>;C\,^V*OT4 0_VQ_L_K_\ 6H_MC_9_7_ZU344 0_VQ_L_K_P#6
MH_MC_9_7_P"M4U% $/\ ;'^S^O\ ]:C^V/\ 9_7_ .M4U% $/]L?[/Z__6H_
MMC_9_7_ZU344 0_VQ_L_K_\ 6H_MC_9_7_ZU344 0_VQ_L_K_P#6H_MC_9_7
M_P"M4U% $/\ ;'^S^O\ ]:C^V/\ 9_7_ .M4U% $/]L?[/Z__6H_MC_9_7_Z
MU344 0_VQ_L_K_\ 6H_MC_9_7_ZU344 0_VQ_L_K_P#6H_MC_9_7_P"M4U%
M$/\ ;'^S^O\ ]:C^V/\ 9_7_ .M4U% $/]L?[/Z__6H_MC_9_7_ZU344 0_V
MQ_L_K_\ 6H_MC_9_7_ZU344 0_VQ_L_K_P#6H_MC_9_7_P"M4U% $/\ ;'^S
M^O\ ]:C^V/\ 9_7_ .M4U% $/]L?[/Z__6H_MC_9_7_ZU344 0_VQ_L_K_\
M6H_MC_9_7_ZU344 0_VQ_L_K_P#6H_MC_9_7_P"M4U% %"SO/LV>,YQWQTJS
M_;'^S^O_ -:IJ* (?[8_V?U_^M1_;'^S^O\ ]:IJ* (?[8_V?U_^M1_;'^S^
MO_UJFHH A_MC_9_7_P"M1_;'^S^O_P!:IJ* (?[8_P!G]?\ ZU']L?[/Z_\
MUJFHH A_MC_9_7_ZU']L?[/Z_P#UJFHH A_MC_9_7_ZU']L?[/Z__6J:B@"'
M^V/]G]?_ *U']L?[/Z__ %JFHH A_MC_ &?U_P#K4?VQ_L_K_P#6J:B@"'^V
M/]G]?_K4?VQ_L_K_ /6J:B@"'^V/]G]?_K4?VQ_L_K_]:IJ* (?[8_V?U_\
MK4?VQ_L_K_\ 6J:B@"'^V/\ 9_7_ .M1_;'^S^O_ -:IJ* (?[8_V?U_^M1_
M;'^S^O\ ]:IJ* (?[8_V?U_^M1_;'^S^O_UJFHH A_MC_9_7_P"M1_;'^S^O
M_P!:IJ* (?[8_P!G]?\ ZU']L?[/Z_\ UJFHH A_MC_9_7_ZU']L?[/Z_P#U
MJFHH A_MC_9_7_ZU']L?[/Z__6J:B@"'^V/]G]?_ *U&C_Q?A_6IJAT?^+\/
MZT :5%%% !5'5ON#_>_H:O51U;[@_P![^AH 2'[H^@I],A^Z/H*XCQUXEN-+
MG6*%]JF,$C:IY+,.X/I51BY.PF['=45A>#M?_MB#<Y'FH</T'T; /<?09!P,
M"H?'6K2Z7 LL+;6,@!. >"K'N#Z4<CYK!?2YT=%9'V]_L7VG/[S[-OS@?>\O
M=G&,=?;%<3I6O:GJN[R&W;,9^6(8SG'W@/0TXTV[B<K'IM%<#_Q.?\^173^&
M/M/EG[9_K-YQ]S[N!C[G'7/O2E"RW0U*YKT5PNE^);B?4#:,^8A)*-NU>BAL
M<XSQ@=Z[JB47$$[A17"ZIXEN(-0%HKXB,D0V[5Z,%SSC/.3WK7\=:M+I<"RP
MMM8R $X!X*L>X/I3]F[KS#F6IT=%><V%_JU^@FB.4;.#B$="0>" >HIM[KVI
MZ-MDN,;22,,J%2<="4P1ZCD9QW -/V3VNA<YZ116?H6L+J\2W"<9X(R"01U'
M'YCID$' S61XM\9KH_[F+#3'&0?NJ/?!')[#\3VS*BV[#NK7.GHKS]+G6+G]
MXH*AB< K$N.>F'^;Z9YQZU8T/QXZR?9KY0AP!N*E2#C^('IGU  'I@Y#]F_4
M7,CN**KW]\MA&T[_ '4!)Z?D,XY/0>IK@U\67VNN19J%"#) VGKCJS\=<X
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "H='_B_#^M35#H_P#%^']: -*BBB@ JCJW
MW!_O?T-7JHZM]P?[W]#0 D/W1]!7)^(M!FO+V"YC7,<?E[CN48VR%CP3GI[5
MUD/W1]!3Z<9<K$U<*\PU;P+<QR.ENI,)8%?G4#IP,,V?ER1D\]3WKT^BG";B
M#BF9'V!_L7V;'[S[-LQD?>\O;C.<=??%<3I6@ZGI6[R%V[\9^:(YQG'WB?4U
MZ;13C4:N)QN<#_Q.?\^16_X5^V_/]N_V=GW/?=]S\.OX5OT4.=U:R&HV.0\6
M^!CJK_:(2%D. P<G:<# (P#@\8QT/L<YS/(UC;Y?.,8^]%NQC'WL[L^^<]\Y
MKT*BA5&E;<3BCD/"7@UK%_MER<S') !)P6'S$GNW)'<=\G(Q<\=:3+JD"Q0K
MN82 D9 X"L.Y'K71T4N=\UQ\JM8R/"=@]A;1PRC#KNR,@]78CD$CH:A\8Z!_
M;$&U /-0Y3H/JN2.X^@R!DX%;M%',[W"VECF/!%K<V"&VN$PB\H<H>I)8':Q
M/4Y''KD]!1XM\&+K'[Z+"S#&2?NL/? /(['\#VQT]%'.^:X<JM8\_2VUBV_=
MJ2P4G!+1-GGKE_F^F><>E6-#\!NTGVF^8.< [2Q8DX_B)ZX] 2#ZX&#W%%/V
MC]!<J*NIZ<FI1M;R9VN.<'!X.0?P(SZ>O%<"GA&_T5]UJP8$G[K <#@;E? /
M!X^]@]^AKTBBE&;B-Q3/.[C0]4UC]U.P5 /XF4*>1P1'G/3(R,#%=AX?\/QZ
M+'Y2<L?O,>K'^@'8=O<DDZE%.4VU8%%(YCQ;X,76/WT6%F&,D_=8>^ >1V/X
M'MC$-GJ\*F$$E1D;M\9)!SR&8[_IT(]J]"HH51I6W$XHXOPSX&>VD%Y=,&<$
MMM^]\Q'5F/4@D].^"&K1\=:3+JD"Q0KN82 D9 X"L.Y'K71T4<[;N/E5K&1X
M3L'L+:.&48==V1D'J[$<@D=#7"Z9X:U'2V,L*;6(P3NB/!(/<GTKU&BA5&K^
M8G&YP/\ Q.?\^16OX8_M#S#]L_U>PX_U?WLC'W.>F?:NGHH<[K9 HG(?V#-_
M:?VW;^Y_O;E_YY;>F<]>.E=7<0+<*T3C*N"".F01@]*DHJ7)NPTK'E%SX%O$
M)C52R*S;3O0 ]MVTMQD >_3TKU62,2 JP!!!!!&00>HQ3J*J<W(%%(X&_P#
M]QITAN+!L#C"[L-U&5Y^5E[_ #'D<')'->ZT75-7Q%.<)SG+(%]>1'R>0,<'
M!].:]&HI^U8N1&1X:\.+H<9C!W,QRS8 SZ#OP/J>23WKE/$GAJ[GO&NX$R 4
M*MN3JJKV8]B.XKT*BDIM.XW%-6.!_P")S_GR*L:?_:WF)YO^KWKO_P!3]W(W
M=.>GIS7;44>T\D+E\PHHHJ"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_0U>JCJWW!_O?T- %FV^XO\ NC^52U%;?<7_ '1_*I: "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *HZM]P?[W]#5ZJ.K?<'^]_0T 6;;[B_[H_E4M16WW%_W1_*I: "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML',CLZ*XS_A:MK_<E_[Y3_XNC_A:MK_<E_[Y3_XNCV<NP<R.SHKC/^%JVO\
M<E_[Y3_XNC_A:MK_ ')?^^4_^+H]G+L',CLZ*XS_ (6K:_W)?^^4_P#BZ/\
MA:MK_<E_[Y3_ .+H]G+L',CLZ*XS_A:MK_<E_P"^4_\ BZ/^%JVO]R7_ +Y3
M_P"+H]G+L',CLZ*XS_A:MK_<E_[Y3_XNC_A:MK_<E_[Y3_XNCV<NP<R.SHKD
MK+XFVMRZQD.FXXW.%"CZD,<?7H.^!S76U+BUN--,****0PHHHH **** "BBB
M@ HHHH **** "J7_ "U_SZ5=JE_RU_SZ4 7:*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH I:;W_  _K5VJ6F]_P_K5V@ HHHH **** "BBB@ HHHH ****
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MBBN@\%>'X]=F:"4L%6,M\A .0RCN#ZTF[*X)7.?HK6\+:4NK7*6TA(5]V2N
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MQM&5PHHHJ1A1110 4444 %%%% !1110 52_Y:_Y]*NU2_P"6O^?2@"[1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% %+3>_X?UJ[5+3>_P"']:NT %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %9NC_Q?A_6M*LW1_P"+\/ZT :5%%% !
M5'5ON#_>_H:O51U;[@_WOZ&@"S;?<7_='\JEJ*V^XO\ NC^52T %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\*O^/I_^N+?^AI757'Q*M$C,B,6?;D)M8')[$XVC'<Y/MGC/._"BP8RR7/\
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M]WL\O;_%NSNW?[(QC%7_ !+I\5];R)-@*%9MQ!.TJ"=X YX]!U&1T-:=>?\
MQ+UYG*Z9#R7P7 &XG)&Q!C)SD9(QG[N#@D5G%<TM-"GHM3A_#MFEY<10RG".
MX!X)SZ+Q@C<>,]LY[5[M'&(@$4 *H   P !T %>7>(/ 9L+2.=%)E0$S8YX;
MG/WB/DZ':.1\QP!79^"?$1UN ,Y'FH=KXP/HV >X^@R#@8%75?,KK8F&FAYS
MX=T'^U[>YVC,D7ELF!R<;]R]">1T ZL%KJO#NN?VCIL\+??@A=3_ +NQMAZ
M=!CN>,GK5?X1?\O'_;+_ -GK)\36K>&+F0QC]U<Q2  <#$@(*_=P-K8( _AV
M@GFKE[TG'[A+1)G3_"K_ (]7_P"NS?\ H"5TNK?<'^]_0US7PJ_X]7_Z[-_Z
M E=+JWW!_O?T-8U/B9<=D6;;[B_[H_E4M16WW%_W1_*I:@H**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P ./$;-G3)\[X\[-QP<+@&/!P<KR0.>,C@**<K\GGU!6YO(QOBK_P ?2?\
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MB@ HHHH **** "BBB@ HHHH **** "NT^%7_ !]/_P!<6_\ 0TKBZ[3X5?\
M'T__ %Q;_P!#2HJ?"QQW1G?#[_C^B_X'_P"BVK?$@UXW.CN0)%GE>%F/&0Y)
M7 P3U;^]P2<?*,X'P^_X_HO^!_\ HMJJ:O>O97LTT1*NL\A!'^^?\D=".#4R
M5Y?(:=D;WPNC,5W(C AEA8$$8((=,@BLSX??\?T7_ __ $6U=WX<MX[V<:K
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M98TG6['79$MI+98F+J4*[,$KD[6.U>&QMQ@YSV.#7.^.;9;:\ECC4*HV8"@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "LW1_XOP_K6E6;H_P#%^']:
M -*BBB@ JCJWW!_O?T-7JHZM]P?[W]#0!9MON+_NC^52U%;?<7_='\JEH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *R=5\+6VK,)9TW,%V@[F' )./E(]36M133:"PV.,1
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MM]P?[W]#5ZJ.K?<'^]_0TF[@6;;[B_[H_E4M16WW%_W1_*I: "BBB@ HHHH
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MYB3C@<9QWK1HHYG:PK(I:IHT.JKLG0.!TSU'0\,,$9P,X//>J47@VTB1H%B
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MHHH **** "BBB@ HHHH **** "M3P_X@DT*0SQ!2S*5^<$C!(/8CTK+HI-7
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MN5PHHHK0D**** "BBB@ HHHH **** "BBB@ HHHH **** "GQQF4A%!+,0
M,DD] !1'&92$4$LQ   R23T %>L^"?!(T<"XF ,[#ZA >P]_4_@.,EHG-10X
MQN'@GP2-' N)@#.P^H0'L/?U/X#C);K:**Y)2<G=FR5@HHHI#"BBB@ HHHH
M**** "BBB@ JE_RU_P ^E7:I?\M?\^E %VBBB@ HHHH **** "BBB@ HHHH
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MKZG]/\*M44 5?[/7U/Z?X4?V>OJ?T_PJU10!5_L]?4_I_A1_9Z^I_3_"K5%
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M3^G^%6J* *O]GKZG]/\ "C^SU]3^G^%6J* *O]GKZG]/\*/[/7U/Z?X5:HH
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M_9Z^I_3_  JU10!5_L]?4_I_A1_9Z^I_3_"K5% %7^SU]3^G^%']GKZG]/\
M"K5% %7^SU]3^G^%5_LXW^7V_P#K9K2JE_RU_P ^E #_ .SU]3^G^%']GKZG
M]/\ "K5% %7^SU]3^G^%']GKZG]/\*M44 5?[/7U/Z?X4?V>OJ?T_P *M44
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M_9Z^I_3_  JU10!5_L]?4_I_A1_9Z^I_3_"K5% %7^SU]3^G^%']GKZG]/\
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MH **** "BBB@ HHHH **** "BBB@#G?'-Z]C;M-&<.N,' /5E!X.1T->=_\
M"P;[_GK_ ..1_P#Q-=[\1_\ CT?_ (#_ .AK7C]=%&*<3.HVF='_ ,+!OO\
MGK_XY'_\31_PL&^_YZ_^.1__ !-<Y16O)'L1S,Z/_A8-]_SU_P#'(_\ XFC_
M (6#??\ /7_QR/\ ^)KG**.2/8.9G1_\+!OO^>O_ (Y'_P#$T?\ "P;[_GK_
M ..1_P#Q-<Y11R1[!S,Z/_A8-]_SU_\ '(__ (FC_A8-]_SU_P#'(_\ XFN<
MHHY(]@YF='_PL&^_YZ_^.1__ !-'_"P;[_GK_P".1_\ Q-<Y11R1[!S,Z/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !6;H_P#%^']:TJS='_B_#^M &E11
M10 51U;[@_WOZ&KU4=6^X/\ >_H: +-M]Q?]T?RJ6HK;[B_[H_E4M !1110
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M[B_[H_E4M16WW%_W1_*I:D84444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 =!X1\7/H+X.6A8_,O_LP]_P!".#V(]BLKU+U%FB(9&&01_G\Q
MU!X-?/M=3X UZ6QG6V0%HYF 9>>,_P 8],#D]B!ST!&-6G?7J7"5M#V"BBBN
M8U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *I?\M?\^E7:I?\ +7_/I0!=HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@"EIO?\/ZU=JEIO?\ #^M7: "BBB@ HHHH **** "BBB@
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MBA<XZ9P!ZTV3289'\]HT,F0=Q12V1T.<9XQQ5>T7,WW%RZ)'FOQ5_P"/I/\
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M,-F=\4:(Q&,HBJ<>F0*TE4337<E1=T>:Z#_R&&_Z[7'\GHU[_D,+_P!=K?\
MDE>E1Z3#&_GK&@DR3N"*&R>ISC/.>:)-)AD?SVC0R9!W%%+9'0YQGC'%'M5>
M_E8.30Y?XJ_\>J?]=E_] >M'X??\>,7_  /_ -&-6W=V4=X-DJ*Z@YPZAAGU
MP:=;VRVRB.-0JCH%  &>>@J>;W;%6UN<W\1_^/1_^ _^AK7C]>P?$?\ X]'_
M . _^AK7C];4/A,ZFX4445L0%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !114]E9/>NL,0+.QP /\_F>@')H +*R>]=88@6=C@ ?Y_,] .37L7A'
MPBF@IDX:9A\S?^RCV_4GD]@#PCX1304R<-,P^9O_ &4>WZD\GL!T%<M6KS:+
M8UA"VH4445D6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 52_Y:_P"?2KM4O^6O^?2@"[1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% %+3>_X?UJ[5+3>_X?UJ[0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5FZ/_ !?A_6M*LW1_XOP_K0!I4444 %4=6^X/
M][^AJ]5'5ON#_>_H: +-M]Q?]T?RJ6HK;[B_[H_E4M !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %4=6^X/][^AJ]5'5ON#_>_H: +-M]Q?]T?RJ6HK;[B_P"Z/Y5+0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_?M/\*/^$<M?^>$7_?M/\*/K"[![-G@]%>\?\(Y:_P#/"+_OVG^%'_".6O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ JE_RU_P ^E7:I?\M?\^E %VBBB@ HHHH **** "BBB@ HHHH
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M_L]?4_I_A1_9Z^I_3_"@ _M!?0_I_C1_:"^A_3_&C^SU]3^G^%']GKZG]/\
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M7U/Z?X4?V>OJ?T_PH /[07T/Z?XT?V@OH?T_QH_L]?4_I_A1_9Z^I_3_  H
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M_L]?4_I_A1_9Z^I_3_"@ _M!?0_I_C1_:"^A_3_&C^SU]3^G^%']GKZG]/\
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M?4_I_A1_9Z^I_3_"@ _M!?0_I_C1_:"^A_3_ !H_L]?4_I_A1_9Z^I_3_"@
M_M!?0_I_C1_:"^A_3_&C^SU]3^G^%']GKZG]/\* #^T%]#^G^-']H+Z']/\
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M7U/Z?X4?V>OJ?T_PH /[07T/Z?XT?V@OH?T_QH_L]?4_I_A1_9Z^I_3_  H
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ML]?4_I_A1_9Z^I_3_"@ _M!?0_I_C1_:"^A_3_&C^SU]3^G^%']GKZG]/\*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M17@__"1W7_/>7_OX_P#C1_PD=U_SWE_[^/\ XT?5WW#VB/>**\'_ .$CNO\
MGO+_ -_'_P :/^$CNO\ GO+_ -_'_P :/J[[A[1'O%%>#_\ "1W7_/>7_OX_
M^-'_  D=U_SWE_[^/_C1]7?</:(]XHKP?_A([K_GO+_W\?\ QH_X2.Z_Y[R_
M]_'_ ,:/J[[A[1'O%%>#_P#"1W7_ #WE_P"_C_XT?\)'=?\ />7_ +^/_C1]
M7?</:(]XHKP?_A([K_GO+_W\?_&C_A([K_GO+_W\?_&CZN^X>T1[7=?ZQ?P_
MG5VO!CX@N3R9I,_]=&_QI?\ A([K_GO+_P!_'_QH^KON'M$>\45X/_PD=U_S
MWE_[^/\ XT?\)'=?\]Y?^_C_ .-'U=]P]HCWBBO!_P#A([K_ )[R_P#?Q_\
M&C_A([K_ )[R_P#?Q_\ &CZN^X>T1[Q17@__  D=U_SWE_[^/_C1_P )'=?\
M]Y?^_C_XT?5WW#VB/>**\.LO%MU:NLHE=MIZ.[,I]B"?_K]P0>:];\.>(X]=
MC\V/AA@.A/*G^H/8]_8@@3.DXE1FF:U%%%9E!1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5+_
M ):_Y]*NU2_Y:_Y]* +M%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4M-[_
M (?UJ[5+3>_X?UJ[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5FZ/\
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MD1X# $ JS%AU."...W SDFHP<G8')(]3HKA_&7CA$MU%I)\\W0[6!"992P)
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M (?UJ[5+3>_X?UJ[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5FZ/\
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M*".G.<]QG..1G1@NM*UYEWIY#C;D<(C8R2N1\N/<A6/ ![5K>)/%L^DS>7-
M#:MP6Y;<&SW.%!QU0CL><$&N.ULQ:_*JZ? RL1\V !G) 'R@E5 [G@9//J7&
M[2Z>8GHS5^*=VR2168)\M(PW)))))7)))S@+P3SR>>:H:[K-A=6XMX(F61-N
M'*1J3MX.YE.3D9/NV#6UXX\)3SQPW"YDDCB6.0*2Q./X@,9/).3UZ''4TYOB
MF98E2*(FY8@8QE,Y[ '<<]AQC/4XY(_"K:@]V:O@#41=V.)20L1="Q<CY0-V
M=W!7:&P.> ,@CMS\.JZ99J;2*%IV;(#,@+,6' #'#+Z<*,=0">3TFK17&M:<
MXDC"3,H;8"23M(;IC()P<+R1P"<YQR?@WQ+_ &,DMH(6:X9F*[4R20N-K+PV
M%()XSU/ [J*O=^>PWT0[X4R$7,B9.TPDD9XR&7!Q[9./J:@^(,307WG3*6B.
MPJ"2 RJ!N4$=.<Y[C.<<C,_PUC-G>R0R85Q&ZX)'WE=<@>O0].P)KH/$GBV?
M29O+F@!M6X+<MN#9[G"@XZH1V/."#3;:J:=A+X3)@NM*UYEWIY#C;D<(C8R2
MN1\N/<A6/ ![5#\4[MDDBLP3Y:1AN22222N223G 7@GGD\\UE:V8M?E5=/@9
M6(^;  SD@#Y02J@=SP,GGU/0>./"4\\<-PN9)(XECD"DL3C^(#&3R3D]>AQU
M--64E^H:M,Q==UFPNK<6\$3+(FW#E(U)V\'<RG)R,GW;!KM?AOJ!N[0*V<Q,
MR9)SD###Z8#8 ]!^%8S?%,RQ*D41-RQ QC*9SV .XY[#C&>IQSV>AW<MW$LE
MP@C=A]T$GMU((^7/]WD@8R<Y BI?EM8J.YB_$?\ X]'_ . _^AK7C]>P?$?_
M (]'_P" _P#H:UX_5T/A)J;A1116Q 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !72^ +2>:Z5X,A4(\P_P[">5/KNQP/7GC&10\.>')-=D
M\J/A1@NY'"C^I/8=_8 D>S:1I$>DQBWA&%'4]R>[$]R?_K#  %95:B2L7"-]
M2[1117*:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %4O\ EK_GTJ[5+_EK_GTH NT444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!2TWO\ A_6KM4M-[_A_6KM !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#EOB/_P >C_\  ?\ T-:\?KV?QS9/
M?6[0QC+MC R!T92>3@=!7G?_  KZ^_YY?^/Q_P#Q5=%&243.HFV<Y171_P#"
MOK[_ )Y?^/Q__%4?\*^OO^>7_C\?_P 56O/'N1RLYRBNC_X5]??\\O\ Q^/_
M .*H_P"%?7W_ #R_\?C_ /BJ.>/<.5G.45T?_"OK[_GE_P"/Q_\ Q5'_  KZ
M^_YY?^/Q_P#Q5'/'N'*SG**Z/_A7U]_SR_\ 'X__ (JC_A7U]_SR_P#'X_\
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4O^6O^?2KM4O^6O\
MGTH NT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!2TWO^']:NU2TWO^']:N
MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %9NC_Q?A_6M*LW1_XOP_K0
M!I4444 %4=6^X/\ >_H:O51U;[@_WOZ&@"S;?<7_ '1_*I:I07RJH'/ '\J?
M_:"^A_3_ !H M455_M!?0_I_C1_:"^A_3_&@"U157^T%]#^G^-']H+Z']/\
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MC0!:HJK_ &@OH?T_QH_M!?0_I_C0!:HJK_:"^A_3_&C^T%]#^G^- %JBJO\
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MT%]#^G^- %JBJO\ :"^A_3_&C^T%]#^G^- %JBJO]H+Z']/\:/[07T/Z?XT
M,NO]8OX?SJ[6;-<!V#CH,?SJQ_:"^A_3_&@"U157^T%]#^G^-']H+Z']/\:
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M4 0?8T]/U-'V-/3]34]% $'V-/3]31]C3T_4U/10!!]C3T_4T?8T]/U-3T4
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M4 0?8T]/U-'V-/3]34]% $'V-/3]31]C3T_4U/10!!]C3T_4T?8T]/U-3T4
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MH @^QIZ?J:/L:>GZFIZ* (/L:>GZFC[&GI^IJ>B@"#[&GI^IH^QIZ?J:GHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P">O_CD?_Q-<Y11R1[!S,Z/_A8-]_SU_P#'(_\ XFC_ (6#??\ /7_QR/\
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MF_\ BJ] T_56N;1;P@;C$6P,XSC-5.C*&XH58SV-6BO*O^%LW'_/./\ )O\
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MEIO?\/ZU=JEIO?\ #^M7: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L
MW1_XOP_K6E6;H_\ %^']: -*BBB@ JCJWW!_O?T-7JHZM]P?[W]#0!9MON+_
M +H_E4M16WW%_P!T?RJ6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** /*M!_P"0PW_7:X_D]>B>(_\
MCUG_ .N,G_H!KSO0?^0PW_7:X_D]>B>(_P#CUG_ZXR?^@&M:GQ(B.S.,^$7_
M "\?]LO_ &>NNC\56TCO#Y@#19W[@5 PP4_,P ZD#K]*Y'X1?\O'_;+_ -GK
M#M=,34]4>WESL:>;(!QG:6;&??'/?'0BJE%2G*XD[)'HEEXVL[UUACE!9S@
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M-@Y=SQ_Q'J%KK12.QMV67/.U0,@ G 1"0>N2<9 '<=.MN_"<UWIJ6;G,\7S
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M94]M:&?V'K5JWTW'+_D*O 8XK.53L4HC8HA$-HI]%%9%A1110 4444 %%%%
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MZ/Y5+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !5'5ON#_>_H:O51U;[@_P![^AH LVWW%_W1
M_*I:BMON+_NC^52T %%%% !1110 4444 %%%% !1110 4444 %%%% !2$9XI
M:* *\EBC]L?3_.*B;2P>A/X\_P"%7:*I2:%9&?\ V5_M?I_]>GKI8'4G\./\
M:NT4<\@Y45X[%$[9^O\ G%3@8XI:*3;8[!1112 **** "BBB@ HHHH ****
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MQ3R?K]WT]:O^'?#4>C*=N6D?[[MRQ/\ A_D\ULT53FVK$J"3N%%%%24%%%%
M!144EP$(0]34M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %4O^6O^?2KM4O\ EK_GTH NT444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
M2TWO^']:NU2TWO\ A_6KM !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6
M;H_\7X?UK2K-T?\ B_#^M &E1110 51U;[@_WOZ&KU4=6^X/][^AH ;#?[5
MQT [_P#UJ?\ VE[?K_\ 6J6WA4JIP/NCM[5)Y"^@_(4 5O[2]OU_^M1_:7M^
MO_UJL^0OH/R%'D+Z#\A0!6_M+V_7_P"M1_:7M^O_ -:K/D+Z#\A1Y"^@_(4
M5O[2]OU_^M1_:7M^O_UJL^0OH/R%'D+Z#\A0!6_M+V_7_P"M1_:7M^O_ -:K
M/D+Z#\A1Y"^@_(4 5O[2]OU_^M1_:7M^O_UJL^0OH/R%'D+Z#\A0!6_M+V_7
M_P"M1_:7M^O_ -:K/D+Z#\A1Y"^@_(4 5O[2]OU_^M1_:7M^O_UJL^0OH/R%
M'D+Z#\A0!6_M+V_7_P"M1_:7M^O_ -:K/D+Z#\A1Y"^@_(4 5O[2]OU_^M1_
M:7M^O_UJL^0OH/R%'D+Z#\A0!6_M+V_7_P"M1_:7M^O_ -:K/D+Z#\A1Y"^@
M_(4 5O[2]OU_^M1_:7M^O_UJL^0OH/R%'D+Z#\A0!6_M+V_7_P"M1_:7M^O_
M -:K/D+Z#\A1Y"^@_(4 5O[2]OU_^M1_:7M^O_UJL^0OH/R%'D+Z#\A0!6_M
M+V_7_P"M1_:7M^O_ -:K/D+Z#\A1Y"^@_(4 5O[2]OU_^M1_:7M^O_UJL^0O
MH/R%'D+Z#\A0!6_M+V_7_P"M1_:7M^O_ -:K/D+Z#\A1Y"^@_(4 5O[2]OU_
M^M1_:7M^O_UJL^0OH/R%'D+Z#\A0!6_M+V_7_P"M1_:7M^O_ -:K/D+Z#\A1
MY"^@_(4 5O[2]OU_^M1_:7M^O_UJL^0OH/R%'D+Z#\A0!6_M+V_7_P"M1_:7
MM^O_ -:K/D+Z#\A1Y"^@_(4 5O[2]OU_^M1_:7M^O_UJL^0OH/R%'D+Z#\A0
M!6_M+V_7_P"M1_:7M^O_ -:K/D+Z#\A1Y"^@_(4 5O[2]OU_^M1_:7M^O_UJ
ML^0OH/R%'D+Z#\A0!6_M+V_7_P"M1_:7M^O_ -:K/D+Z#\A1Y"^@_(4 5O[2
M]OU_^M1_:7M^O_UJL^0OH/R%'D+Z#\A0!6_M+V_7_P"M1_:7M^O_ -:K/D+Z
M#\A1Y"^@_(4 5O[2]OU_^M4%W<_:!MQCG/K6AY"^@_(54U- B@@8Y[?0T )%
M?[ %QT '7T_"G_VE[?K_ /6J:WA4JI('0=O:G^0OH/R% %;^TO;]?_K4?VE[
M?K_]:K/D+Z#\A1Y"^@_(4 5O[2]OU_\ K4?VE[?K_P#6JSY"^@_(4>0OH/R%
M %;^TO;]?_K4?VE[?K_]:K/D+Z#\A1Y"^@_(4 5O[2]OU_\ K4?VE[?K_P#6
MJSY"^@_(4>0OH/R% %;^TO;]?_K4?VE[?K_]:K/D+Z#\A1Y"^@_(4 5O[2]O
MU_\ K4?VE[?K_P#6JSY"^@_(4>0OH/R% %;^TO;]?_K4?VE[?K_]:K/D+Z#\
MA1Y"^@_(4 5O[2]OU_\ K4?VE[?K_P#6JSY"^@_(4>0OH/R% %;^TO;]?_K4
M?VE[?K_]:K/D+Z#\A1Y"^@_(4 5O[2]OU_\ K4?VE[?K_P#6JSY"^@_(4>0O
MH/R% %;^TO;]?_K4?VE[?K_]:K/D+Z#\A1Y"^@_(4 5O[2]OU_\ K4?VE[?K
M_P#6JSY"^@_(4>0OH/R% %;^TO;]?_K4?VE[?K_]:K/D+Z#\A1Y"^@_(4 5O
M[2]OU_\ K4?VE[?K_P#6JSY"^@_(4>0OH/R% %;^TO;]?_K4?VE[?K_]:K/D
M+Z#\A1Y"^@_(4 5O[2]OU_\ K4?VE[?K_P#6JSY"^@_(4>0OH/R% %;^TO;]
M?_K4?VE[?K_]:K/D+Z#\A1Y"^@_(4 5O[2]OU_\ K4?VE[?K_P#6JSY"^@_(
M4>0OH/R% %;^TO;]?_K4?VE[?K_]:K/D+Z#\A1Y"^@_(4 5O[2]OU_\ K4?V
ME[?K_P#6JSY"^@_(4>0OH/R% %;^TO;]?_K4?VE[?K_]:K/D+Z#\A1Y"^@_(
M4 5O[2]OU_\ K4?VE[?K_P#6JSY"^@_(4>0OH/R% %;^TO;]?_K4?VE[?K_]
M:K/D+Z#\A1Y"^@_(4 5O[2]OU_\ K4?VE[?K_P#6JSY"^@_(4>0OH/R% %;^
MTO;]?_K4?VE[?K_]:K/D+Z#\A1Y"^@_(4 5O[2]OU_\ K4?VE[?K_P#6JSY"
M^@_(4>0OH/R% %;^TO;]?_K4?VE[?K_]:K/D+Z#\A1Y"^@_(4 5O[2]OU_\
MK4?VE[?K_P#6JSY"^@_(4>0OH/R% %;^TO;]?_K4?VE[?K_]:K/D+Z#\A1Y"
M^@_(4 5O[2]OU_\ K4?VE[?K_P#6JSY"^@_(4>0OH/R% %;^TO;]?_K4?VE[
M?K_]:K/D+Z#\A1Y"^@_(4 5O[2]OU_\ K4?VE[?K_P#6JSY"^@_(4>0OH/R%
M %;^TO;]?_K4?VE[?K_]:K/D+Z#\A1Y"^@_(4 5O[2]OU_\ K4?VE[?K_P#6
MJSY"^@_(4>0OH/R% %;^TO;]?_K4?VE[?K_]:K/D+Z#\A1Y"^@_(4 5O[2]O
MU_\ K4?VE[?K_P#6JSY"^@_(4>0OH/R% %;^TO;]?_K4?VE[?K_]:K/D+Z#\
MA1Y"^@_(4 5O[2]OU_\ K4?VE[?K_P#6JSY"^@_(4>0OH/R% %;^TO;]?_K4
M?VE[?K_]:K/D+Z#\A1Y"^@_(4 5O[2]OU_\ K4?VE[?K_P#6JSY"^@_(4>0O
MH/R% %;^TO;]?_K4?VE[?K_]:K/D+Z#\A1Y"^@_(4 5O[2]OU_\ K4?VE[?K
M_P#6JSY"^@_(4>0OH/R% %;^TO;]?_K4?VE[?K_]:K/D+Z#\A1Y"^@_(4 5O
M[2]OU_\ K4?VE[?K_P#6JSY"^@_(4>0OH/R% %;^TO;]?_K4?VE[?K_]:K/D
M+Z#\A1Y"^@_(4 5O[2]OU_\ K4?VE[?K_P#6JSY"^@_(4>0OH/R% %;^TO;]
M?_K4?VE[?K_]:K/D+Z#\A1Y"^@_(4 5O[2]OU_\ K4?VE[?K_P#6JSY"^@_(
M4>0OH/R% %;^TO;]?_K4?VE[?K_]:K/D+Z#\A1Y"^@_(4 9]S<^=CC&*G_M+
MV_7_ .M3;] N,#'7I^%6_(7T'Y"@"M_:7M^O_P!:C^TO;]?_ *U6?(7T'Y"C
MR%]!^0H K?VE[?K_ /6H_M+V_7_ZU6?(7T'Y"CR%]!^0H K?VE[?K_\ 6H_M
M+V_7_P"M5GR%]!^0H\A?0?D* *W]I>WZ_P#UJ/[2]OU_^M5GR%]!^0H\A?0?
MD* *W]I>WZ__ %J/[2]OU_\ K59\A?0?D*/(7T'Y"@"M_:7M^O\ ]:C^TO;]
M?_K59\A?0?D*/(7T'Y"@"M_:7M^O_P!:C^TO;]?_ *U6?(7T'Y"CR%]!^0H
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M@_(4>0OH/R% %;^TO;]?_K4?VE[?K_\ 6JSY"^@_(4>0OH/R% %;^TO;]?\
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M 5O[2]OU_P#K4?VE[?K_ /6JSY"^@_(4>0OH/R% %;^TO;]?_K4?VE[?K_\
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M?0?D*/(7T'Y"@"M_:7M^O_UJ/[2]OU_^M5GR%]!^0H\A?0?D* *W]I>WZ_\
MUJBT?^+\/ZU>\A?0?D*HZ/\ Q?A_6@#2HHHH *HZM]P?[W]#5ZJ.K?<'^]_0
MT 6;;[B_[H_E4M16WW%_W1_*I: "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *HZM]P?[W]#5ZJ
M.K?<'^]_0T 6;;[B_P"Z/Y5+45M]Q?\ ='\JEH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M84444 02VV]@^>F/T-3T44 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\LQ_(5T6LZJNDQ-<R E4QD+@GDA>Y'KZT.#073+M%<I+\2K2-%E^8E_X  7
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"EIO?\/ZU=JEIO?\/ZU=H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *S='_B_#^M:59NC_ ,7X?UH
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MT\H=RC')"Y/09.<=C1=)FCU4SM&XC\Z<[BC!<$/@YQCG/%/1.3[H.B)/BY&
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MTYZ4GM'U!=2I\*;)!#)<8'F&0KN[[0JG'MR>?7C/05@^'8Q%JY10 JS3@ #
M  ?  KJ_AI926=LZ2HR,9F.'4J<;4YP:P=%TF:/53.T;B/SISN*,%P0^#G&.
M<\47UF%M$>EUA^*(+6_3[+=2*G(89D5&&,C(W?B.01U[UN5RGCSPDVMJLD./
M-CSU.-RXSMSCKG[N2 ,G/6LH6N7+8Y^?X?7FE@M9S$@@9"L8F)SZ9VG .<EA
MWX];_@?QG->3-97?+G=M)7:P*]4(  Z GG&,$<Y&*$?B/5;1/LYA9F4%=YB=
MFXXSN!VMCL<$'J<][O@KPC,LQU.ZRKDLP7C)+@Y8@=/O'C@YZXQ@ZR^%\UB%
MOH-^*VD%UCO5'W?D<\YP>5]@ <C/') Y[4O'^O?;[:V7*DRKYCA3D@A=N.IP
M,EASW&,\&N^U[3!JD$EMQEU.,D@;ARI..>& /]#7EW@FT.L7,*-@+:KNXX)"
MR%QZ_P ;\]/E]Z*;3C?L$EKZEWQ_I@TN"SMN,HLF<$D;CL+$9YY8D_T%=1#I
MT<.E%548:U+GC.6,>[=SWSR/3 QC K.^*.FRWOD>4C/M\S.Q2V,[,9P#Z5O?
M9F_L[RMIW_9-NW!W9\K&,=<YXQ2<O=CZC2U9S/PB_P"7C_ME_P"SUE_#N,:E
M>M-, S!6DR1_&77YL#CN<>AY'(%;GPNTV6R\_P U&3=Y>-ZE<XWYQD#UJA)H
M-UX4NC=6L9DA8D84%CM8YV$<L,8X;D=,]2M4VN:2[B2T0?%BR2)XIE #R!PQ
M'?;MVY^F>O7&!V%3^,O^07:_]L?_ $4U4/%D%]KP6Y:!DC4[4C +/\V=S$ ;
MNJ]P!]W .23K^+--EGTZVB1&9U\G*JI+#$3 Y &1@\4+110=RW\/-#A^RQW#
M(K2,S-N95)!5BHP<9&-N?KDUS8_XGFK>7/RJRNH'48B#$#!SP=OS#OD],UV_
M@:V:VLXHY%*L-^0P((R['H:Y_P 4>%9[:Y_M2R )!#,H.#N&=W QD,!R 2S$
MGCFI4O>D-K1&G\2K!;BT:5OO1,I4\9^9@I&<=#G/'<#TKC+N_:[TI%?GRKK8
M#SG C9AU/;=@>@ %;6M7E[XI5;-+=H5W L7+ $#@9)5>!G)&&)P"!Q4GB?PP
MUEI\5I"A=UE5GV*6))5MQX .,G )'3 -.'NI)]Q/6[-7X>:=&+)6VC,V_?D9
MW89E .>V.,=.OJ:X[X9627-T2X!\N,LN>S!E /X9X]#SU KOO ULUM9Q1R*5
M8;\A@01EV/0UR7PTTF:SN7>6-T4PL,NC*,[DXR123^,+?"4OBG&$NE( !:%2
M<#J=S#)]> !] *G^*]PS3QQ$_*L6X#W9B"?QVC\JF^)>DS7ERCQ1NZB%1E$9
MAG<_&0*VO'_A!]8"W$ !E0;2I.-RYR,$G VDGTR">> #49)<H-/4P]=U*;5+
M<60LI4";=A_>-MV\#C8,_+D<GOGK73?#Q)8K413(4,;L%#*5)!PV<'W8C\*Q
M&\4ZE/$L"6[K,2 92AP>>NUEVKGC))QUX'&.ST,3B)?M17S<<[!C''?D@GU(
MP,\ 8&3$](V''<Q?B/\ \>C_ / ?_0UKQ^O8/B/_ ,>C_P# ?_0UKQ^M*'PD
MU-PHHHK8@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J>RLGO76
M&(%G8X '^?S/0#DT65D]ZZPQ L['  _S^9Z <FO8O"/A%-!3)PTS#YF_]E'M
M^I/)[ 14J*"*C&YIZ-:R6L*13/OD5<,WK_CCID\G&3R:NT45QO4V"D)Q2TA&
M: *TMX>D:ES^2_\ ?1_ID^U8E_I2QJ9[IP$SGRUR(\_3.6)_#Z5TM<DL?]N7
MC"3_ %5OT7L3G'ZG/X#%;T.KV2U;ZG-B':RW;=DNGS+EI>R7VU5'D0G&WCYF
M]AQA?;N>U;5M9K;?=')ZD\D_4GDU))")048 J>H/2L2/43I<ZV4IS',"8F/)
M!'5">_L>O8Y/-0Y<VVGD:QAR;ZON;U<1\6?^/:/_ *[#_P!!:NWKB/BS_P >
MT?\ UV'_ *"U%#^(@K? SRJO:M$_Y!R?]>Y_]!->*U[5HG_(.3_KW/\ Z":Z
ML7LO4Y\-N_0\5KH_"&OW&D^9]GB\S?MW?*S8QG'W?7-<Y7H_PAZ3_P#;/_V:
MM:[2@VU<SHIN:Z#?^$]U#_GV_P#(<G^-8_B36+[7E6*2%E53G"QOR<8[Y]:]
M?HKC5:,7=11UNE)JSD>#VOA>ZNB$6%^?52H_,X%>N1^&$ELUTZ7D! "1ZCG(
M_&MRBE4KRG;I8*=%0N>9R_"-P?EF7'NI!_0FG1?"V>'A9P/H&'\C74GQ_9#C
MS1_WR_\ \32?\+ L?^>H_P"^7_\ B:OVE?\ I$^SI?TSEYOAM=J"5N,D#@9<
M9_'-<-_:$J'[[Y'^T?\ &O7YOB'9("PDR0.@5LGVY KQB1MQ)]36U!SE?F7X
M&-91C;E9Z=\,?$4M]YEM,Q?8 RECDXS@C/?MBO-[_P#UC_[[?S-=M\)(2997
M[! ,^Y.?Z5Q-_P#ZQ_\ ?;^9JJ:2J2MY"FVZ<;FIX3T*3696BB?RR$)SSTR!
MCCZUU7_"M+G_ )^/_0_\:Y_P#KL>CW!DF.$9"N0"<'(/0<]J]$_X6#8_\]?_
M !Q__B:SK2J*6BT]"Z,:;CKOZE#P[X#?3Y1/-,7V]%&0,^IR>?I6IXZ_X\IO
M]T?^A"HO^%@V/_/7_P <?_XFHO$^IQZGI\LT)W(1C.".C#/4"L/?<TVNIM[J
MBTCG_A#UG^D?_L];WCCP>-:3S8QB=!Q_M#^Z?Z&L'X0]9_I'_P"SUZ13K2<:
MK:%2BI4DF?.LD9C)5A@@X(/4$5Z%\//&FW%A.?:-C_Z ?Z?EZ5>^('@O[<#>
MP#]X!\RC^(#N/]H?J/?KY;TKJ3C7@<[4J,CL_BM_Q]+_ -<5_P#0GKTO0_\
MCWA_ZY)_Z"*\/U76)-4*/*<LB!,]R 203[\U[AH?_'O#_P!<D_\ 016&(BXP
MBC:C)2G)EZBBBN4Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ JE_RU_SZ5=JE_RU_P ^E %VBBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** *6F]_P_K5VJ6F]_P_K5V@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M K-T?^+\/ZUI5FZ/_%^']: -*BBB@ JCJWW!_O?T-7JHZM]P?[W]#0!9MON+
M_NC^52U%;?<7_='\JEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JCJWW!_O?T-7JHZM]P?[W
M]#0!9MON+_NC^52U%;?<7_='\JEH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M./9%:PTV/3U\J%0J^@'Z^]8LGP]LI"6,?).3\[]_^!5T=%)3DMF-Q3Z'-?\
M"NK'_GG_ ./O_P#%4?\ "NK'_GG_ ./O_P#%5TM%/VL^[%[./9'-?\*ZL?\
MGG_X^_\ \56E'X;@C@-B%_<MG*[CW.>N<]?>M.BDZDGU8*$5T,O1O#<&C;C
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M\/ZU=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S='_ (OP_K6E6;H_
M\7X?UH TJ*** "J.K?<'^]_0U>JCJWW!_O?T- %FV^XO^Z/Y5+69%?,H XX
MIW]H-Z#]?\: -&BL[^T&]!^O^-']H-Z#]?\ &@#1HK._M!O0?K_C1_:#>@_7
M_&@#1HK._M!O0?K_ (T?V@WH/U_QH T:*SO[0;T'Z_XT?V@WH/U_QH T:*SO
M[0;T'Z_XT?V@WH/U_P : -&BL[^T&]!^O^-']H-Z#]?\: -&BL[^T&]!^O\
MC1_:#>@_7_&@#1HK._M!O0?K_C1_:#>@_7_&@#1HK._M!O0?K_C1_:#>@_7_
M !H T:*SO[0;T'Z_XT?V@WH/U_QH T:*SO[0;T'Z_P"-']H-Z#]?\: -&BL[
M^T&]!^O^-']H-Z#]?\: -&BL[^T&]!^O^-']H-Z#]?\ &@#1HK._M!O0?K_C
M1_:#>@_7_&@#1HK._M!O0?K_ (T?V@WH/U_QH T:*SO[0;T'Z_XT?V@WH/U_
MQH T:*SO[0;T'Z_XT?V@WH/U_P : -&BL[^T&]!^O^-']H-Z#]?\: -&BL[^
MT&]!^O\ C1_:#>@_7_&@#1HK._M!O0?K_C1_:#>@_7_&@#1HK._M!O0?K_C1
M_:#>@_7_ !H T:*SO[0;T'Z_XT?V@WH/U_QH T:*SO[0;T'Z_P"-']H-Z#]?
M\: -&BL[^T&]!^O^-']H-Z#]?\: -&BL[^T&]!^O^-']H-Z#]?\ &@#1HK._
MM!O0?K_C1_:#>@_7_&@#1JCJWW!_O?T-,_M!O0?K_C45Q<&<;3ZYXH T;;[B
M_P"Z/Y5+6:E\R *,<#%+_:#>@_7_ !H T:*SO[0;T'Z_XT?V@WH/U_QH T:*
MSO[0;T'Z_P"-']H-Z#]?\: -&BL[^T&]!^O^-']H-Z#]?\: -&BL[^T&]!^O
M^-']H-Z#]?\ &@#1HK._M!O0?K_C1_:#>@_7_&@#1HK._M!O0?K_ (T?V@WH
M/U_QH T:*SO[0;T'Z_XT?V@WH/U_QH T:*SO[0;T'Z_XT?V@WH/U_P : -&B
ML[^T&]!^O^-']H-Z#]?\: -&BL[^T&]!^O\ C1_:#>@_7_&@#1HK._M!O0?K
M_C1_:#>@_7_&@#1HK._M!O0?K_C1_:#>@_7_ !H T:*SO[0;T'Z_XT?V@WH/
MU_QH T:*SO[0;T'Z_P"-']H-Z#]?\: -&BL[^T&]!^O^-']H-Z#]?\: -&BL
M[^T&]!^O^-']H-Z#]?\ &@#1HK._M!O0?K_C1_:#>@_7_&@#1HK._M!O0?K_
M (T?V@WH/U_QH T:*SO[0;T'Z_XT?V@WH/U_QH T:*SO[0;T'Z_XT?V@WH/U
M_P : -&BL[^T&]!^O^-']H-Z#]?\: -&BL[^T&]!^O\ C1_:#>@_7_&@#1HK
M._M!O0?K_C1_:#>@_7_&@#1HK._M!O0?K_C1_:#>@_7_ !H T:*SO[0;T'Z_
MXT?V@WH/U_QH T:*SO[0;T'Z_P"-']H-Z#]?\: -&BL[^T&]!^O^-']H-Z#]
M?\: -&BL[^T&]!^O^-']H-Z#]?\ &@#1HK._M!O0?K_C1_:#>@_7_&@#1HK.
M_M!O0?K_ (T?V@WH/U_QH T:*SO[0;T'Z_XT?V@WH/U_QH T:*SO[0;T'Z_X
MT?V@WH/U_P : -&BL[^T&]!^O^-']H-Z#]?\: -&BL[^T&]!^O\ C1_:#>@_
M7_&@#1HK._M!O0?K_C1_:#>@_7_&@#1HK._M!O0?K_C1_:#>@_7_ !H T:*S
MO[0;T'Z_XT?V@WH/U_QH T:*SO[0;T'Z_P"-']H-Z#]?\: -&BL[^T&]!^O^
M-']H-Z#]?\: -&BL[^T&]!^O^-']H-Z#]?\ &@#1HK._M!O0?K_C1_:#>@_7
M_&@#1HK._M!O0?K_ (T?V@WH/U_QH T:*SO[0;T'Z_XT?V@WH/U_QH T:*SO
M[0;T'Z_XT?V@WH/U_P : -&BL[^T&]!^O^-']H-Z#]?\: -&BL[^T&]!^O\
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M[0;T'Z_XT?V@WH/U_P : -&BL[^T&]!^O^-']H-Z#]?\: -&BL[^T&]!^O\
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M* (_(7T'Y"CR%]!^0J2B@"/R%]!^0H\A?0?D*DHH C\A?0?D*/(7T'Y"I**
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M% $?D+Z#\A1Y"^@_(5)10!'Y"^@_(4>0OH/R%244 1^0OH/R%'D+Z#\A4E%
M$?D+Z#\A1Y"^@_(5)10!'Y"^@_(4>0OH/R%244 1^0OH/R%'D+Z#\A4E% $?
MD+Z#\A1Y"^@_(5)10!'Y"^@_(4>0OH/R%244 1^0OH/R%'D+Z#\A4E% $?D+
MZ#\A1Y"^@_(5)10!'Y"^@_(4>0OH/R%244 4+A '4 <<?SJWY"^@_(56NO\
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M4 1^0OH/R%'D+Z#\A4E% $?D+Z#\A1Y"^@_(5)10!'Y"^@_(4>0OH/R%244
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M* (_(7T'Y"CR%]!^0J2B@"/R%]!^0H\A?0?D*DHH C\A?0?D*/(7T'Y"I**
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M%17-PMLK2N<*BEB>N !DGB@"6J.K?<'^]_0TS2/$,&L;O(?=LQGY67&[./O
M>AI^K?<'^]_0T-6 LVWW%_W1_*I:BMON+_NC^52T %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1_\ @/\ Z&M>/UTT/A,JFX4445L0%%%% !1110 4444 %%%% !1110 4444
M%%%% !7>>!?'7V7%E<G]WT1S_#Z*3_=]#_#T/R_=X.BIE%25F-.Q]$T5YEX%
M\=?9<65R?W?1'/\ #Z*3_=]#_#T/R_=]-KDG!Q=C:,KA1114C"BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 51U;[@_P![^AJ]5'5ON#_>_H: (HKYE '' %._M!O0?K_C4L'W1]!_*GT
M5_[0;T'Z_P"-']H-Z#]?\:L44 5_[0;T'Z_XT?V@WH/U_P :L44 5_[0;T'Z
M_P"-']H-Z#]?\:L44 5_[0;T'Z_XT?V@WH/U_P :L44 5_[0;T'Z_P"-']H-
MZ#]?\:L44 5_[0;T'Z_XT?V@WH/U_P :L44 5_[0;T'Z_P"-']H-Z#]?\:L4
M4 5_[0;T'Z_XT?V@WH/U_P :L44 5_[0;T'Z_P"-']H-Z#]?\:L44 5_[0;T
M'Z_XT?V@WH/U_P :L44 5_[0;T'Z_P"-']H-Z#]?\:L44 5_[0;T'Z_XT?V@
MWH/U_P :L44 5_[0;T'Z_P"-']H-Z#]?\:L44 5_[0;T'Z_XT?V@WH/U_P :
ML44 5_[0;T'Z_P"-']H-Z#]?\:L44 5_[0;T'Z_XT?V@WH/U_P :L44 5_[0
M;T'Z_P"-']H-Z#]?\:L44 5_[0;T'Z_XT?V@WH/U_P :L44 5_[0;T'Z_P"-
M']H-Z#]?\:L44 5_[0;T'Z_XT?V@WH/U_P :L44 5_[0;T'Z_P"-']H-Z#]?
M\:L44 5_[0;T'Z_XT?V@WH/U_P :L44 5_[0;T'Z_P"-']H-Z#]?\:L44 5_
M[0;T'Z_XT?V@WH/U_P :L44 5_[0;T'Z_P"-']H-Z#]?\:L44 5_[0;T'Z_X
MT?V@WH/U_P :L44 5_[0;T'Z_P"-17%P9QM/KGBKM% %9+YD 48X&*7^T&]!
M^O\ C5BB@"O_ &@WH/U_QH_M!O0?K_C5BB@"O_:#>@_7_&C^T&]!^O\ C5BB
M@"O_ &@WH/U_QH_M!O0?K_C5BB@"O_:#>@_7_&C^T&]!^O\ C5BB@"O_ &@W
MH/U_QH_M!O0?K_C5BB@"O_:#>@_7_&C^T&]!^O\ C5BB@"O_ &@WH/U_QH_M
M!O0?K_C5BB@"O_:#>@_7_&C^T&]!^O\ C5BB@"O_ &@WH/U_QH_M!O0?K_C5
MBB@"O_:#>@_7_&C^T&]!^O\ C5BB@"O_ &@WH/U_QH_M!O0?K_C5BB@"O_:#
M>@_7_&C^T&]!^O\ C5BB@"O_ &@WH/U_QH_M!O0?K_C5BB@"O_:#>@_7_&C^
MT&]!^O\ C5BB@"O_ &@WH/U_QH_M!O0?K_C5BB@"O_:#>@_7_&C^T&]!^O\
MC5BB@"O_ &@WH/U_QH_M!O0?K_C5BB@"O_:#>@_7_&C^T&]!^O\ C5BB@"O_
M &@WH/U_QH_M!O0?K_C5BB@"O_:#>@_7_&C^T&]!^O\ C5BB@"O_ &@WH/U_
MQH_M!O0?K_C5BB@"O_:#>@_7_&C^T&]!^O\ C5BB@"O_ &@WH/U_QH_M!O0?
MK_C5BB@"O_:#>@_7_&C^T&]!^O\ C5BB@"O_ &@WH/U_QH_M!O0?K_C5BB@"
MO_:#>@_7_&C^T&]!^O\ C5BB@"O_ &@WH/U_QH_M!O0?K_C5BB@"O_:#>@_7
M_&C^T&]!^O\ C5BB@"O_ &@WH/U_QH_M!O0?K_C5BB@"O_:#>@_7_&C^T&]!
M^O\ C5BB@"O_ &@WH/U_QH_M!O0?K_C5BB@"O_:#>@_7_&C^T&]!^O\ C5BB
M@"O_ &@WH/U_QH_M!O0?K_C5BB@"O_:#>@_7_&C^T&]!^O\ C5BB@"O_ &@W
MH/U_QH_M!O0?K_C5BB@"O_:#>@_7_&C^T&]!^O\ C5BB@"O_ &@WH/U_QH_M
M!O0?K_C5BB@"O_:#>@_7_&C^T&]!^O\ C5BB@"O_ &@WH/U_QH_M!O0?K_C5
MBB@"O_:#>@_7_&C^T&]!^O\ C5BB@"O_ &@WH/U_QH_M!O0?K_C5BB@"O_:#
M>@_7_&C^T&]!^O\ C5BB@"O_ &@WH/U_QH_M!O0?K_C5BB@"O_:#>@_7_&C^
MT&]!^O\ C5BB@"O_ &@WH/U_QH_M!O0?K_C5BB@"O_:#>@_7_&C^T&]!^O\
MC5BB@"O_ &@WH/U_QH_M!O0?K_C5BB@"O_:#>@_7_&C^T&]!^O\ C5BB@"O_
M &@WH/U_QH_M!O0?K_C5BB@"G/<&;&>WI4G]H-Z#]?\ &K%% %?^T&]!^O\
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MH-Z#]?\ &C^T&]!^O^-6** *_P#:#>@_7_&C^T&]!^O^-6** *_]H-Z#]?\
M&H_M!W>9W_\ K8JY10!7_M!O0?K_ (T?V@WH/U_QJQ10!7_M!O0?K_C1_:#>
M@_7_ !JQ10!7_M!O0?K_ (T?V@WH/U_QJQ10!7_M!O0?K_C1_:#>@_7_ !JQ
M10!7_M!O0?K_ (T?V@WH/U_QJQ10!7_M!O0?K_C1_:#>@_7_ !JQ10!7_M!O
M0?K_ (T?V@WH/U_QJQ10!7_M!O0?K_C1_:#>@_7_ !JQ10!7_M!O0?K_ (T?
MV@WH/U_QJQ10!7_M!O0?K_C1_:#>@_7_ !JQ10!7_M!O0?K_ (T?V@WH/U_Q
MJQ10!7_M!O0?K_C1_:#>@_7_ !JQ10!7_M!O0?K_ (T?V@WH/U_QJQ10!7_M
M!O0?K_C1_:#>@_7_ !JQ10!7_M!O0?K_ (T?V@WH/U_QJQ10!7_M!O0?K_C1
M_:#>@_7_ !JQ10!7_M!O0?K_ (T?V@WH/U_QJQ10!7_M!O0?K_C1_:#>@_7_
M !JQ10!3@N##G'?UJ3^T&]!^O^-6** *_P#:#>@_7_&C^T&]!^O^-6** *_]
MH-Z#]?\ &C^T&]!^O^-6** *_P#:#>@_7_&C^T&]!^O^-6** *_]H-Z#]?\
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M_>CD4?AM;;V_#\,GK71269O+-8EZF),?4 $#MUQBDX^SC%/I($^9MKL4_!,
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MXC-&XMUN%,;C*MU!J.SL([(;8U"CVZGZD\GK46KZD-.C,AZ]%&,Y)''X>O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3_[.C]/U/^-']G1^GZG_ !H 9YZ^H_,4>>OJ/S%/_LZ/T_4_XT?V='Z?J?\
M&@!GGKZC\Q1YZ^H_,4_^SH_3]3_C1_9T?I^I_P : &>>OJ/S%'GKZC\Q3_[.
MC]/U/^-']G1^GZG_ !H 9YZ^H_,4>>OJ/S%/_LZ/T_4_XT?V='Z?J?\ &@!G
MGKZC\Q1YZ^H_,4_^SH_3]3_C574;185!48.?4^AH G\]?4?F*//7U'YBB"P1
ME!(Y('<^GUI_]G1^GZG_ !H 9YZ^H_,4>>OJ/S%/_LZ/T_4_XT?V='Z?J?\
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MSH_3]3_C1_9T?I^I_P : &>>OJ/S%'GKZC\Q3_[.C]/U/^-']G1^GZG_ !H
M9YZ^H_,4>>OJ/S%/_LZ/T_4_XT?V='Z?J?\ &@!GGKZC\Q1YZ^H_,4_^SH_3
M]3_C1_9T?I^I_P : &>>OJ/S%'GKZC\Q3_[.C]/U/^-']G1^GZG_ !H 9YZ^
MH_,4>>OJ/S%/_LZ/T_4_XT?V='Z?J?\ &@!GGKZC\Q1YZ^H_,4_^SH_3]3_C
M1_9T?I^I_P : &>>OJ/S%'GKZC\Q3_[.C]/U/^-']G1^GZG_ !H 9YZ^H_,4
M>>OJ/S%/_LZ/T_4_XT?V='Z?J?\ &@!GGKZC\Q1YZ^H_,4_^SH_3]3_C1_9T
M?I^I_P : &>>OJ/S%'GKZC\Q3_[.C]/U/^-']G1^GZG_ !H 9YZ^H_,4>>OJ
M/S%/_LZ/T_4_XT?V='Z?J?\ &@!GGKZC\Q1YZ^H_,4_^SH_3]3_C1_9T?I^I
M_P : &>>OJ/S%'GKZC\Q3_[.C]/U/^-']G1^GZG_ !H 9YZ^H_,4>>OJ/S%/
M_LZ/T_4_XT?V='Z?J?\ &@!GGKZC\Q1YZ^H_,4_^SH_3]3_C1_9T?I^I_P :
M &>>OJ/S%'GKZC\Q3_[.C]/U/^-']G1^GZG_ !H 9YZ^H_,4>>OJ/S%/_LZ/
MT_4_XT?V='Z?J?\ &@!GGKZC\Q1YZ^H_,4_^SH_3]3_C1_9T?I^I_P : &>>
MOJ/S%'GKZC\Q3_[.C]/U/^-']G1^GZG_ !H 9YZ^H_,4>>OJ/S%/_LZ/T_4_
MXT?V='Z?J?\ &@!GGKZC\Q1YZ^H_,4_^SH_3]3_C1_9T?I^I_P : &>>OJ/S
M%'GKZC\Q3_[.C]/U/^-']G1^GZG_ !H 9YZ^H_,4>>OJ/S%/_LZ/T_4_XT?V
M='Z?J?\ &@!GGKZC\Q1YZ^H_,4_^SH_3]3_C1_9T?I^I_P : &>>OJ/S%'GK
MZC\Q3_[.C]/U/^-']G1^GZG_ !H 9YZ^H_,4>>OJ/S%/_LZ/T_4_XT?V='Z?
MJ?\ &@!GGKZC\Q1YZ^H_,4_^SH_3]3_C1_9T?I^I_P : &>>OJ/S%'GKZC\Q
M3_[.C]/U/^-']G1^GZG_ !H 9YZ^H_,4>>OJ/S%/_LZ/T_4_XT?V='Z?J?\
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MQH 9YZ^H_,4>>OJ/S%/_ +.C]/U/^-']G1^GZG_&@!GGKZC\Q1YZ^H_,4_\
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MSH_3]3_C1_9T?I^I_P : &>>OJ/S%'GKZC\Q3_[.C]/U/^-']G1^GZG_ !H
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M3_[.C]/U/^-']G1^GZG_ !H 9YZ^H_,4>>OJ/S%/_LZ/T_4_XT?V='Z?J?\
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MH *HZM]P?[W]#5ZJ.K?<'^]_0T 6;;[B_P"Z/Y5+45M]Q?\ ='\JEH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1_QH^JON'MD=O17$?VA+_?;_ +Z/^-']H2_WV_[Z/^-'U5]P]LCMZI?\M?\
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M10 4444 %%%% !1110 4444 %%%% !6;H_\ %^']:TJS='_B_#^M &E1110
M51U;[@_WOZ&KU4=6^X/][^AH LVWW%_W1_*I:BMON+_NC^52T %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 51U;[@_WOZ&KU4=6^X/][^AH LVWW%_W1_*I:BMON+_ +H_E4M
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MM_#4C),AVOW'?;T*DX!'//<>Q&*TNO>76R([/I=D&F7ZQ7@DA!".^-IP/O\
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M[) P&3SQ\P) X)P,?B:75/\ D(#_ *Z1?R6MW0-:FU)B6C C[-R/7CG[Q^F
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MN;**,F5@PR ""&."Q.1C .,GC@9..*L> 7 ,JYY(0X[\;L_S%;U5:G->??\
M$S@[SBS*\+Z8NH3;).5522.>>@QD$8ZY_"M?Q@!811VL0Q&2Q(R>Q!QR>F6S
MSWQ5/P+_ *]O^N9_]"6MSQ=I#7\8=!EHR>/4'K@=SP/UZG%%2=JZ3>@1C^[=
MMQNG^'(9;95VC=(@.XC+ L <@\<#T_/J:O:'HW]E(8PQ;)R<@ 9]AUZ8ZD].
MU<]!XO\ LL'D%2)47:.F!C@$YYR.XP<D=L\;_AZ:>:/=<#!SQE=K8]3_ "'
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M9A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %*JEC@<D^E"J6.!R3Z5U.C:,+0>8_+G]/;Z^I_ >\5*B
M@BHQ<F7;!'2-1(<L!SW^GZ58HHK@;N[G2@HHHI %%%% !1110 4444 %%%%
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M[_X\O^-']@S?W?\ QY?\:/:0[H.5]C/HK0_L&;^[_P"/+_C1_8,W]W_QY?\
M&CVD.Z#E?8SZ*T/[!F_N_P#CR_XT?V#-_=_\>7_&CVD.Z#E?8SZ*T/[!F_N_
M^/+_ (T?V#-_=_\ 'E_QH]I#N@Y7V,^BM#^P9O[O_CR_XT?V#-_=_P#'E_QH
M]I#N@Y7V,^BM#^P9O[O_ (\O^-']@S?W?_'E_P :/:0[H.5]C/HK0_L&;^[_
M ./+_C1_8,W]W_QY?\:/:0[H.5]C/HK0_L&;^[_X\O\ C1_8,W]W_P >7_&C
MVD.Z#E?8SZ*T/[!F_N_^/+_C1_8,W]W_ ,>7_&CVD.Z#E?8SZ*T/[!F_N_\
MCR_XT?V#-_=_\>7_ !H]I#N@Y7V,^BM#^P9O[O\ X\O^-,_L>7.S;S]1_C1[
M2'=!ROL4J*T/[!F_N_\ CR_XT?V#-_=_\>7_ !H]I#N@Y7V,^BM#^P9O[O\
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MH.5]C/HK0_L&;^[_ ./+_C1_8,W]W_QY?\:/:0[H.5]C/HK0_L&;^[_X\O\
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M3^M<YXZ_UZ_]<Q_Z$U7/'W_++_@?_LM:QC?V2VW);MSG11W26B())%^Z,,S
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M7L-S=W;H=/5:;4HH3L=U!'4%@#^1-<UI7B)Q:RL<F2+&&)R?G. <G.2#GMC
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MK_\ 6H OT50_M3_9_7_ZU']J?[/Z_P#UJ +]%4/[4_V?U_\ K4?VI_L_K_\
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MG]?_ *U %^BJ']J?[/Z__6H_M3_9_7_ZU %^BJ']J?[/Z_\ UJ/[4_V?U_\
MK4 7Z*H?VI_L_K_]:C^U/]G]?_K4 7Z*H?VI_L_K_P#6H_M3_9_7_P"M0!?H
MJA_:G^S^O_UJ/[4_V?U_^M0!?HJA_:G^S^O_ -:C^U/]G]?_ *U %^BJ']J?
M[/Z__6H_M3_9_7_ZU %^BJ']J?[/Z_\ UJ/[4_V?U_\ K4 7Z*H?VI_L_K_]
M:C^U/]G]?_K4 7Z*H?VI_L_K_P#6H_M3_9_7_P"M0!?HJA_:G^S^O_UJ/[4_
MV?U_^M0!?HJA_:G^S^O_ -:C^U/]G]?_ *U %^BJ']J?[/Z__6H_M3_9_7_Z
MU %^BJ']J?[/Z_\ UJ/[4_V?U_\ K4 7Z*H?VI_L_K_]:C^U/]G]?_K4 7Z*
MH?VI_L_K_P#6H_M3_9_7_P"M0!?HJA_:G^S^O_UJ/[4_V?U_^M0!?HJA_:G^
MS^O_ -:C^U/]G]?_ *U %^BJ']J?[/Z__6H_M3_9_7_ZU %^BJ']J?[/Z_\
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M7M^O_P!:@"[15+^TO;]?_K4?VE[?K_\ 6H NT52_M+V_7_ZU']I>WZ__ %J
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M40PK^]90&^4[OE^9CG!R,KTSP/3&*V/ O^H;_KH?_05K<BL(X@55% 88("@
M_7CGK2V]FEMGRU5<]=J@9Q]*)UXR@XI/5W'&FTTSFO%.=.GBOD'L<#&<>IYY
M921Z@#CVE\%VY<27;_>D;J1CW)!]"3VXR/RZ&>V6X&UU##.<, 1^M.AA6$;$
M  '0 8'Y"I=:]/EZ]_(%3]ZYQ&J?\A ?]=(OY+77:O8_;XGAZ%AQ]0<CL>,C
MGVJ5["-V\PHI?(.XJ,\=.<9XJ>B=;FY;=$.,+7\SB_#&LKI6^WN,ISN&5.<D
M#((Z],$<>O/2H;O_ (J.Z&P'RUPN[!'RC)))YP3SMS[9'6NTN+-+G'F*K8Z;
ME!QGZT^&%81L0  = !@?D*OZQ%-R2]YD^S=K7T.*\=(1,K8X,8&>W#'/\Q6U
MK 37;=FA.[8V1@$9*CD8(R>#Q[XK9GMEN!M=0PSG# $?K1!;+;C:BA1G.%
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M HHHH **** "BBB@ HHHH **** "J.K?<'^]_0U>JCJWW!_O?T- %FV^XO\
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M0U7^'\?Z5?H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1KI/$FF17R#S'$94_*Q(QSU&"1G./KQ]<IQ@E3;7>X[R;E8R8Y=0\M;D,&!
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MB0'8_<@9R/<9'/OZ<>F-JBDJLU+FOJ')&UNAQ7B71/L42RN[22%PNYB>F&.
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_*I:BMON+_NC^52T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 51U;[@_WOZ&KU4=6^X/][^AH
M LVWW%_W1_*I:BMON+_NC^52T %%%% !1110 4444 %%%% !1110 4444 %%
M%% "$9XJO)8*W(X_E5FB@#.>P8=.:B:V9>Q_#G^5:U% &1Y#>A_(TJVS-V/X
M\?SK6HH SH[!FZ\?K5B*Q5.O)JS10 @&.*6BB@ HHHH **** "BBB@ HHHH
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MJEYH[+YK*P8'' P<=1P%/&0?\FG]5E>UU=B]JO,[.BN4FOKVYC-VFU(P"0N
M6*CG=\P/;Z9QD#D9T?#&N'4T(<?/'C)['.<'Z\<]O3T$RH2C%RTTW&JB;L;5
M%<Y))>WSL8L1(IP X&3CO]UOTX]">34'A_Q#-),;2?DY89P,@KVXP,<'L>?:
MG[!V;NM ]HKV+T\=Y<R/M81(HPG"MN]">I&?TXX/)J;PUJK:E%O?[RL5)'?
M!SCMU_STJIKUZUZXTZ'.XD>8PZ!3U'Y')Y'9><D5M6-DMDBPI]U1WY/J3^)H
MG905TKO;T_X(1^(S_$GW/\^HKEZZCQ)]S_/J*Y>ML+\#]3.KN%%%%;F84444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !71Z)HGE8FD'S=@>WN??\ E]>AHFB>5B:0?-V![>Y]_P"7UZ;E
M<M:M?W4;4Z?5A1117,:A1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 5FZ/_%^']:TJS='_B_#^M &E1110 51
MU;[@_P![^AJ]5'5ON#_>_H: +-M]Q?\ ='\JEJ*V^XO^Z/Y5+0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !5'5ON#_>_H:O51U;[@_P![^AH LVWW%_W1_*I:BMON+_NC^52T
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@"AJO\/X_TJ_5#5?X?Q_I5^@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH I77^L7\/YU=JE=?ZQ?P_G5V@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "J7_+7_/I5VJ7_+7_ #Z4 7:*** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH I:;W_#^M7:I:;W_#^M7: "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "LW1_XOP_K6E6;H_\7X?UH TJ*** "J.K?<'^]_0U
M>JCJWW!_O?T- $EO=JJ@$] .Q]*?]L3U_0U4BM0P!YZ"G_9![T 6/MB>OZ&C
M[8GK^AJO]D'O1]D'O0!8^V)Z_H:/MB>OZ&J_V0>]'V0>] %C[8GK^AH^V)Z_
MH:K_ &0>]'V0>] %C[8GK^AH^V)Z_H:K_9![T?9![T 6/MB>OZ&C[8GK^AJO
M]D'O1]D'O0!8^V)Z_H:/MB>OZ&J_V0>]'V0>] %C[8GK^AH^V)Z_H:K_ &0>
M]'V0>] %C[8GK^AH^V)Z_H:K_9![T?9![T 6/MB>OZ&C[8GK^AJO]D'O1]D'
MO0!8^V)Z_H:/MB>OZ&J_V0>]'V0>] %C[8GK^AH^V)Z_H:K_ &0>]'V0>] %
MC[8GK^AH^V)Z_H:K_9![T?9![T 6/MB>OZ&C[8GK^AJO]D'O1]D'O0!8^V)Z
M_H:/MB>OZ&J_V0>]'V0>] %C[8GK^AH^V)Z_H:K_ &0>]'V0>] %C[8GK^AH
M^V)Z_H:K_9![T?9![T 6/MB>OZ&C[8GK^AJO]D'O1]D'O0!8^V)Z_H:/MB>O
MZ&J_V0>]'V0>] %C[8GK^AH^V)Z_H:K_ &0>]'V0>] %C[8GK^AH^V)Z_H:K
M_9![T?9![T 6/MB>OZ&C[8GK^AJO]D'O1]D'O0!8^V)Z_H:/MB>OZ&J_V0>]
M'V0>] %C[8GK^AH^V)Z_H:K_ &0>]'V0>] %C[8GK^AH^V)Z_H:K_9![T?9!
M[T 6/MB>OZ&C[8GK^AJO]D'O1]D'O0!8^V)Z_H:/MB>OZ&J_V0>]'V0>] %C
M[8GK^AJKJ,PF4!>3G^AIWV0>]'V0>] $L%TJJ 3R .Q]*?\ ;$]?T-5_L@]Z
M/L@]Z +'VQ/7]#1]L3U_0U7^R#WH^R#WH L?;$]?T-'VQ/7]#5?[(/>C[(/>
M@"Q]L3U_0T?;$]?T-5_L@]Z/L@]Z +'VQ/7]#1]L3U_0U7^R#WH^R#WH L?;
M$]?T-'VQ/7]#5?[(/>C[(/>@"Q]L3U_0T?;$]?T-5_L@]Z/L@]Z +'VQ/7]#
M1]L3U_0U7^R#WH^R#WH L?;$]?T-'VQ/7]#5?[(/>C[(/>@"Q]L3U_0T?;$]
M?T-5_L@]Z/L@]Z +'VQ/7]#1]L3U_0U7^R#WH^R#WH L?;$]?T-'VQ/7]#5?
M[(/>C[(/>@"Q]L3U_0T?;$]?T-5_L@]Z/L@]Z +'VQ/7]#1]L3U_0U7^R#WH
M^R#WH L?;$]?T-'VQ/7]#5?[(/>C[(/>@"Q]L3U_0T?;$]?T-5_L@]Z/L@]Z
M +'VQ/7]#1]L3U_0U7^R#WH^R#WH L?;$]?T-'VQ/7]#5?[(/>C[(/>@"Q]L
M3U_0T?;$]?T-5_L@]Z/L@]Z +'VQ/7]#1]L3U_0U7^R#WH^R#WH L?;$]?T-
M'VQ/7]#5?[(/>C[(/>@"Q]L3U_0T?;$]?T-5_L@]Z/L@]Z +'VQ/7]#1]L3U
M_0U7^R#WH^R#WH L?;$]?T-'VQ/7]#5?[(/>C[(/>@"Q]L3U_0T?;$]?T-5_
ML@]Z/L@]Z +'VQ/7]#1]L3U_0U7^R#WH^R#WH L?;$]?T-'VQ/7]#5?[(/>C
M[(/>@"Q]L3U_0T?;$]?T-5_L@]Z/L@]Z +'VQ/7]#1]L3U_0U7^R#WH^R#WH
M L?;$]?T-'VQ/7]#5?[(/>C[(/>@"Q]L3U_0T?;$]?T-5_L@]Z/L@]Z +'VQ
M/7]#1]L3U_0U7^R#WH^R#WH L?;$]?T-'VQ/7]#5?[(/>C[(/>@"Q]L3U_0T
M?;$]?T-5_L@]Z/L@]Z +'VQ/7]#1]L3U_0U7^R#WH^R#WH L?;$]?T-'VQ/7
M]#5?[(/>C[(/>@"Q]L3U_0T?;$]?T-5_L@]Z/L@]Z +'VQ/7]#1]L3U_0U7^
MR#WH^R#WH L?;$]?T-'VQ/7]#5?[(/>C[(/>@"Q]L3U_0T?;$]?T-5_L@]Z/
ML@]Z +'VQ/7]#1]L3U_0U7^R#WH^R#WH L?;$]?T-'VQ/7]#5?[(/>C[(/>@
M"Q]L3U_0T?;$]?T-5_L@]Z/L@]Z +'VQ/7]#1]L3U_0U7^R#WH^R#WH L?;$
M]?T-'VQ/7]#5?[(/>C[(/>@"Q]L3U_0T?;$]?T-5_L@]Z/L@]Z +'VQ/7]#1
M]L3U_0U7^R#WH^R#WH L?;$]?T-'VQ/7]#5?[(/>C[(/>@"Q]L3U_0T?;$]?
MT-5_L@]Z/L@]Z +'VQ/7]#1]L3U_0U7^R#WH^R#WH 9?RB7&WG&?Z5;^V)Z_
MH:K_ &0>]'V0>] %C[8GK^AH^V)Z_H:K_9![T?9![T 6/MB>OZ&C[8GK^AJO
M]D'O1]D'O0!8^V)Z_H:/MB>OZ&J_V0>]'V0>] %C[8GK^AH^V)Z_H:K_ &0>
M]'V0>] %C[8GK^AH^V)Z_H:K_9![T?9![T 6/MB>OZ&C[8GK^AJO]D'O1]D'
MO0!8^V)Z_H:/MB>OZ&J_V0>]'V0>] %C[8GK^AH^V)Z_H:K_ &0>]'V0>] %
MC[8GK^AH^V)Z_H:K_9![T?9![T 6/MB>OZ&C[8GK^AJO]D'O1]D'O0!8^V)Z
M_H:/MB>OZ&J_V0>]'V0>] %C[8GK^AH^V)Z_H:K_ &0>]'V0>] %C[8GK^AH
M^V)Z_H:K_9![T?9![T 6/MB>OZ&C[8GK^AJO]D'O1]D'O0!8^V)Z_H:/MB>O
MZ&J_V0>]'V0>] %C[8GK^AH^V)Z_H:K_ &0>]'V0>] #9Y@SAAT&/YU:^V)Z
M_H:K_9![T?9![T 6/MB>OZ&C[8GK^AJO]D'O1]D'O0!8^V)Z_H:/MB>OZ&J_
MV0>]'V0>] %C[8GK^AH^V)Z_H:K_ &0>]'V0>] %C[8GK^AH^V)Z_H:K_9![
MT?9![T 6/MB>OZ&C[8GK^AJO]D'O1]D'O0!8^V)Z_H:/MB>OZ&J_V0>]'V0>
M] %C[8GK^AH^V)Z_H:K_ &0>]'V0>] %C[8GK^AH^V)Z_H:K_9![T?9![T 6
M/MB>OZ&C[8GK^AJO]D'O1]D'O0!8^V)Z_H:/MB>OZ&J_V0>]'V0>] %C[8GK
M^AH^V)Z_H:K_ &0>]'V0>] %C[8GK^AH^V)Z_H:K_9![T?9![T 6/MB>OZ&C
M[8GK^AJO]D'O1]D'O0!8^V)Z_H:/MB>OZ&J_V0>]'V0>] %C[8GK^AH^V)Z_
MH:K_ &0>]'V0>] %C[8GK^AH^V)Z_H:K_9![T?9![T 6/MB>OZ&C[8GK^AJO
M]D'O1]D'O0!8^V)Z_H:/MB>OZ&J_V0>]'V0>] %C[8GK^AH^V)Z_H:K_ &0>
M]'V0>] %C[8GK^AH^V)Z_H:K_9![T?9![T 6/MB>OZ&JOG#S-_;_ .M3OL@]
MZ/L@]Z +'VQ/7]#1]L3U_0U7^R#WH^R#WH L?;$]?T-'VQ/7]#5?[(/>C[(/
M>@"Q]L3U_0T?;$]?T-5_L@]Z/L@]Z +'VQ/7]#1]L3U_0U7^R#WH^R#WH L?
M;$]?T-'VQ/7]#5?[(/>C[(/>@"Q]L3U_0T?;$]?T-5_L@]Z/L@]Z +'VQ/7]
M#1]L3U_0U7^R#WH^R#WH L?;$]?T-'VQ/7]#5?[(/>C[(/>@"Q]L3U_0T?;$
M]?T-5_L@]Z/L@]Z +'VQ/7]#1]L3U_0U7^R#WH^R#WH L?;$]?T-'VQ/7]#5
M?[(/>C[(/>@"Q]L3U_0T?;$]?T-5_L@]Z/L@]Z +'VQ/7]#1]L3U_0U7^R#W
MH^R#WH L?;$]?T-'VQ/7]#5?[(/>C[(/>@"Q]L3U_0T?;$]?T-5_L@]Z/L@]
MZ +'VQ/7]#1]L3U_0U7^R#WH^R#WH L?;$]?T-'VQ/7]#5?[(/>C[(/>@"Q]
ML3U_0T?;$]?T-5_L@]Z/L@]Z &V4PBSGOBK7VQ/7]#5?[(/>C[(/>@"Q]L3U
M_0T?;$]?T-5_L@]Z/L@]Z +'VQ/7]#1]L3U_0U7^R#WH^R#WH L?;$]?T-'V
MQ/7]#5?[(/>C[(/>@"Q]L3U_0T?;$]?T-5_L@]Z/L@]Z +'VQ/7]#1]L3U_0
MU7^R#WH^R#WH L?;$]?T-'VQ/7]#5?[(/>C[(/>@"Q]L3U_0T?;$]?T-5_L@
M]Z/L@]Z +'VQ/7]#1]L3U_0U7^R#WH^R#WH L?;$]?T-'VQ/7]#5?[(/>C[(
M/>@"Q]L3U_0T?;$]?T-5_L@]Z/L@]Z +'VQ/7]#1]L3U_0U7^R#WH^R#WH L
M?;$]?T-'VQ/7]#5?[(/>C[(/>@"Q]L3U_0T?;$]?T-5_L@]Z/L@]Z +'VQ/7
M]#1]L3U_0U7^R#WH^R#WH L?;$]?T-'VQ/7]#5?[(/>C[(/>@"Q]L3U_0T?;
M$]?T-5_L@]Z/L@]Z +'VQ/7]#1]L3U_0U7^R#WH^R#WH L?;$]?T-'VQ/7]#
M5?[(/>C[(/>@"Q]L3U_0U4T?^+\/ZT_[(/>F:/\ Q?A_6@#2HHHH *HZM]P?
M[W]#5ZJ.K?<'^]_0T .@^Z/H/Y4^F0?='T'\JK7FJK:'8P.2,\8_QIJ+;LA-
MV+E%9?\ PD,?HWY#_&K-KJ:7/RJ>3V/!_P *ITY+H"DF6Z*;+)Y0+GH 3^59
MO_"0Q^C?D/\ &E&$I; Y)&I167_PD,?HWY#_ !J[9W@NQO7. <<T.$DKM I)
MD]%9TNNI$2A#9!(Z#M^-,_X2&/T;\A_C3]E/L+G1J456L]02[^Z>1V/6I+FX
M%NID/0>GN<5/*[VZCNK7):*I6FK)=-L&0<=\?XU<9MO)Z"AQ:=F":8M%9T6N
MI*0@#9) Z#O^-:-$HN.X)IA15>]OEM "W<]!C-,LM26\R%R"/7'^-/E=K] N
MKV+=%-ED\H%ST )_*LW_ (2&/T;\A_C1&$I; Y)&I167_P )#'Z-^0_QJU9:
M@MYG:#\N.N._XGTH=.25V@4DRU14<]PMN-S' J@WB",<88_@/\:(PE+9 Y)&
MG15>UOTNONGG'0\&II9/*!<] "?RI--.P[CJ*JV6H+>9V@_+CKCO^)]*M4--
M.S!.X4457NK]+7[QYQT')H2;!NQ8HK,7Q!&>,,/P'^-7X+A;@;E.13E"4=T)
M23)***IW6K1V_!.3Z+S_ /6_K246]@;2+E%9J:_&QP<CW(_P)K01PXR#D>HY
MIR@X[@FF.HJA#K*2L(\$$G'S #GTZU?I2BX[@FF%%4KO5DM6V')..V/\:MHV
M\ ],CH>M#BTKA=#J***0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *K:/\ Q?A_6K-5M'_B_#^M &E1110 51U;[@_WOZ&KU4=6^X/]
M[^AH =!]T?0?RK!\0_ZP?[H_F:WH/NCZ#^58/B'_ %@_W1_,UKA_C(J?";7V
M&/\ N+_WR*QM8L/LI$J< GMV/7C_ #Q705E^(?\ 5C_>'\C11D^9!-*Q8:?[
M1 7]4.?K@Y_6L[0(%EW[@#C;U /K5FS_ ./8_P"Z_P#6LS3=-^VYYQMQVSUS
M[CTJXI*,E>VI+>J.@^PQ_P!Q?^^14L<0BX4 #V&*Q_\ A&_]O_QW_P"O6G96
MWV9!'G.,\].IS64[6T=RU?L8EN@>X((R-S\'GUK;^PQ_W%_[Y%<^8FEF94.&
M+-@Y(]?2GWL<UIC<QP>X8X^E;SAS-:VT(B[)Z %%M<!4Z!@/7KP1^N*U]9_U
M3?A_,55T6R3_ %P))!(Y&,?AS_/O5K6?]4WX?S%1*2<XKL-+W68UH/LS12]F
MSDGIU*G]*V]6F\J)CZC'/OQ_*LJ6#?;*_=2?R+$?SQ3]1NOMBQQC&7P3UZ_=
M_+.:J2YI)]FQ)V314A@\EXO5MI_-N/TKJ*P]00)/$HZ (!^#&MF>80J7/0"H
MK/FY65!6N8>J.;R80CH#CCGKU/X?TH4_8+CT5CZ8&&_H#_*F:.X,AED(!&>I
MQR>_\ZEUXI+M=2">AP<GU''YUILU#I8CIS&XR[N#T-5+RS148A5R%;^$>E2:
M?<_:$#]\<_4=:6^_U;_[K?RKG5XRL:NS1DZ! LN_< <;>H!]:VHX%B^Z ,^@
M K(\-_Q_\!_K6U5UV^=DTU[J.==O[4FVY.P9QCL!W_&MI-/C08"C\1G]36+X
M?;$A]U/\Q714ZS<6HK85-75SG]4L_L#+)'D9_0CW]_3ZUJR7 N(6D'=&_D<U
M6\0M\@'?=_0T6?\ Q['_ '7_ *TW[T(M[W!:2:(?#?\ '_P'^M;58OAO^/\
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MN7R >"R_KT_+-%.U16?3\@E>+NNI;TBU-VYG?G!]>_\ @/\ "MZF00B%0@Z
M4^LZD^9E1C9!1114%!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MV@"W153RYO\ .VCRYO\ .V@"W153RYO\[:/+F_SMH MT54\N;_.VCRYO\[:
M+=%5/+F_SMH\N;_.V@"W153RYO\ .VCRYO\ .V@"W153RYO\[:/+F_SMH MT
M54\N;_.VCRYO\[: +=%5/+F_SMH\N;_.V@"W153RYO\ .VCRYO\ .V@"W153
MRYO\[:/+F_SMH MT54\N;_.VCRYO\[: +=%5/+F_SMH\N;_.V@"W153RYO\
M.VCRYO\ .V@"W153RYO\[:/+F_SMH MT54\N;_.VCRYO\[: +=%5/+F_SMH\
MN;_.V@"W153RYO\ .VCRYO\ .V@"W153RYO\[:9NESL[_A0!>HJIY<W^=M'E
MS?YVT 6Z*J>7-_G;1Y<W^=M %NBJGES?YVT>7-_G;0!;HJIY<W^=M'ES?YVT
M 6Z*J>7-_G;1Y<W^=M %NBJGES?YVT>7-_G;0!;HJIY<W^=M'ES?YVT 6Z*J
M>7-_G;1Y<W^=M %NBJGES?YVT>7-_G;0!;HJIY<W^=M'ES?YVT 6Z*J>7-_G
M;1Y<W^=M %NBJGES?YVT>7-_G;0!;HJIY<W^=M'ES?YVT 6Z*J>7-_G;1Y<W
M^=M %NBJGES?YVT>7-_G;0!;HJIY<W^=M'ES?YVT 6Z*J>7-_G;1Y<W^=M %
MNBJGES?YVT>7-_G;0!;HJC&TLO3M]*?Y<W^=M %NBJGES?YVT>7-_G;0!;HJ
MIY<W^=M'ES?YVT 6Z*J>7-_G;1Y<W^=M %NBJGES?YVT>7-_G;0!;HJIY<W^
M=M'ES?YVT 6Z*J>7-_G;1Y<W^=M %NBJGES?YVT>7-_G;0!;HJIY<W^=M'ES
M?YVT 6Z*J>7-_G;1Y<W^=M %NBJGES?YVT>7-_G;0!;HJIY<W^=M'ES?YVT
M6Z*J>7-_G;1Y<W^=M %NBJGES?YVT>7-_G;0!;HJIY<W^=M'ES?YVT 6Z*J>
M7-_G;1Y<W^=M %NBJGES?YVT>7-_G;0!;HJIY<W^=M'ES?YVT 6Z*J>7-_G;
M1Y<W^=M %NJVC_Q?A_6F^7-_G;3M'_B_#^M &E1110 51U;[@_WOZ&KU4=6^
MX/\ >_H: +-M]Q?]T?RJ6HK;[B_[H_E4M !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4=6^X/
M][^AJ]5'5ON#_>_H: +-M]Q?]T?RJ6HK;[B_[H_E4M !1110 4444 %%%% !
M1110 4444 %5[NX\H8'4_P"<U.3CFLF>7S26H 91110 4UW"#<>@IU9DK_;F
MQTC7J?6@"O>7;7'(X7/ ]:UK52J@-UQ5*QB\]O-Q\J\*/\_YS6E0 55O+SR/
ME'+'H*=>70MUSW/053P;93,_,C=,]O\ /_UJ *_V8S-L)RQY8]<>W^?I6U&@
M0!1T%5["V\E<G[S<FDOKHQX1?O-0!'>WI'[M.O<^E1Z0K<MGY3^I]:B>WVD0
M+]YN6/\ 2M:.,1@*.@H <#CFM.UG\T<]1UK,I\$OE$-0!KT4@.>:6@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"-8WVJ,8 H O6J_:W,QZ+PM,FN%>7YC\J?S_ ,_RJ_:Q>4H7T'_ZZQ;1//D
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"EIO?\
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MP*#<R3]"3]/_ *U;JMNY'>H+R[%L,XSF@#($,B<@,/IFDDO'8;">/<5HSZF
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M=_RI044VGN#N[6-+3+B8DQS+T_BX'O\ 0_AT[UI5A:1JCE_L\O)Y&>^1V)_
M^IS6[6=56E_D5!W1S/B;_6#_ '!_,UTK*&&#R#7->)O]8/\ <'\S72LP49/
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MW^L'^X/YFKC"+E%VW0G)I,T--FG<^9+@1E2?X<>HZ'(X]:JIJ4VH.1#\JCU
M_,G!Y/H/\36S?*6C<#DE&_E6-X689<=_E_3-3%IQE*R&[W2*&L.[.!*,,J@9
M'0\GG\?\XZ5O:QJWV$ +@LWKT ]?7Z?_ %JR?$K R@#L@S^9I?$ZGS%/;9_(
MFKLI<ER;M7)YKBYM%$S$$''&.F1WP!C\^M:0OO.A,Z\'8Q'?!&?ZBJ$NCLRY
M:<E#CK]WVZMBK$5B+.!U#;@58YQCJOU-1+E:7>_8I71FVVJW%T/+3EADD_*.
M.!CG Z_C6C?:F]A&FX R,.?3C&>A]^W'?VJKX6_C_P" _P!:OZQ9)<J-[!2#
MP2>.>HY(]*)N*G:V@1ORW**/=[1,""#SMP,XZ^@Z^QS6O9RM*H9UVMW']?\
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M^8 _*O3JPO!_A9/#D/D*=SL<NW3)_P !V_\ KUNU%22E)M M@HHHJ!A1110
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M %FP7+?05HU3TY>"?4_R_P#UU<H **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU) L["*4#D-PI/J&Z8]CS]>M=D\8D!5AD$8(/(-<9JWPEL[TETW1$]D(V_\
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M/<!L\ ^F/H:[N.,1@*HP , #H .U:2G%+W>HDAU%%%9#/'-#_P"0ZW_7>?\
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MV[YAC' ';Z5NU#M<84444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** *6F]_P_K5VJ6F]_P /ZU=H **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH HZD,X_'^E3?8$]/U/\ C46I=OQ_I5VFFT%BO]@3
MT_4_XT?8$]/U/^-6**.9BLBO]@3T_4_XT?8$]/U/^-6**.9A9%?[ GI^I_QH
M^P)Z?J?\:L44<S"R*_V!/3]3_C1]@3T_4_XU8HHYF%D5_L">GZG_ !H^P)Z?
MJ?\ &K%%',PLBO\ 8$]/U/\ C1]@3T_4_P"-6**.9A9%?[ GI^I_QH^P)Z?J
M?\:L44<S"R*_V!/3]3_C1]@3T_4_XU8HHYF%D5_L">GZG_&C[ GI^I_QJQ11
MS,+(K_8$]/U/^-'V!/3]3_C5BBCF8617^P)Z?J?\:/L">GZG_&K%%',PLBO]
M@3T_4_XT?8$]/U/^-6**.9A9%?[ GI^I_P :/L">GZG_ !JQ11S,+(K_ &!/
M3]3_ (T?8$]/U/\ C5BBCF8617^P)Z?J?\:/L">GZG_&K%%',PLBO]@3T_4_
MXT?8$]/U/^-6**.9A9&;/;*KA0.#CU]:M?8$]/U/^-177^L7\/YU=HYF%D5_
ML">GZG_&C[ GI^I_QJQ11S,+(K_8$]/U/^-'V!/3]3_C5BBCF8617^P)Z?J?
M\:/L">GZG_&K%%',PLBO]@3T_4_XT?8$]/U/^-6**.9A9%?[ GI^I_QH^P)Z
M?J?\:L44<S"R*_V!/3]3_C1]@3T_4_XU8HHYF%D5_L">GZG_ !H^P)Z?J?\
M&K%%',PLBO\ 8$]/U/\ C1]@3T_4_P"-6**.9A9%?[ GI^I_QH^P)Z?J?\:L
M44<S"R&H@08'04ZBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "J7_ "U_SZ5=JE_RU_SZ4 7:*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH I:;W_  _K5VJ6F]_P_K5V@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ K-T?\ B_#^M:59NC_Q?A_6@#2HHHH *K7UN9UVCUSS5FB@#,%C
M*. WZFE^Q2_WO_'C6E10!F_8I?[W_CQH^Q2_WO\ QXUI44 9OV*7^]_X\:/L
M4O\ >_\ 'C6E10!F_8I?[W_CQH^Q2_WO_'C6E10!F_8I?[W_ (\:/L4O][_Q
MXUI44 9OV*7^]_X\:/L4O][_ ,>-:5% &;]BE_O?^/&C[%+_ 'O_ !XUI44
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M8I?[W_CQK2HH S?L4O\ >_\ 'C1]BE_O?^/&M*B@#-^Q2_WO_'C1]BE_O?\
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M\:TJ* ,W[%+_ 'O_ !XT?8I?[W_CQK2HH S?L4O][_QXT?8I?[W_ (\:TJ*
M,W[%+_>_\>--_L^3.=W/KD_X5J44 9OV*7^]_P"/&C[%+_>_\>-:5% &;]BE
M_O?^/&C[%+_>_P#'C6E10!F_8I?[W_CQH^Q2_P![_P >-:5% &;]BE_O?^/&
MC[%+_>_\>-:5% &;]BE_O?\ CQH^Q2_WO_'C6E10!F_8I?[W_CQH^Q2_WO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4C+NX-%% &-1110 4444 %%%%
M!1110 5LJNW@444 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
944 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>xcur-20210930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xcur="http://www.exicuretx.com/20210930"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="xcur-20210930.xsd" xlink:type="simple"/>
    <context id="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i04b6fc849e294cd184b4de031b935e57_I20211112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <instant>2021-11-12</instant>
        </period>
    </context>
    <context id="ia9d6ec897790429f9fceaa0150f61e3d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0041572b03444403ad89282293144d76_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7508d7c37391421a854292655f2865a7_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id1a551c230f14800abc2fa41ca7ad2a3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i889966d2ad0d48b1a39ab264208b8278_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i77adf0b70cbf4775bddca74d6b334c92_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i501a27e325104650a73ad03cfcd4faa7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iae971ef694a140e68a703e4451c6c2e3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i846826e778c54bd7b5bc352eb593aee3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3dea9cf71d074399a074543cd69ce8c7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6201937a06d74f6d89fca534176e3345_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i71bb35af2d12464b9a9e8594554ebb5f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4f6c6875545040a48cde06a5f5b74823_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4d560c291f0e4806b54ba5e47f9e4337_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib50af716c597410c87b2e6c906cd80f9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4a52bc4a3c0d4c7cbfa5ea8a045321fa_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie38be6e4d7ba4275b47ca89d4c64b7f9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0d4ca9f881df45978d9417d0ab7dc94e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iac6b52ac45d04a2588c506176895e21f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icc50c37ab44c4df39214039f0d7b1151_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2ec0151a0c3948b38923be5743f1344a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i62ce8e911e4846bd9009ddd7272195ab_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i96f79fc5e863496fa7949c405ecc957f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id04667370fcb4287af7d78737a293eb4_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id42a638fb6864f9d9e37c2babc3b3899_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i992a828696e04df48d18d2f8bc76598e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="idd96764703204097bea35e7a9db99a49_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9dcdb6a39c9748148c55ed098113f458_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i17d0ab6befad44789b59d2b647f01e28_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie8045808dcb149df893c7a2d3e216476_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7b100964d44d428faaab570e10ff8900_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i978591bf15364b7ea2e8132edee5fb1c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6b8227feae1749778133a28312e507ba_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i290713ee60b04dd08da1a92f4da5adfd_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="idf9e5d3ecf814b9ab2f88960463e4dd8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ibbd40097533240cc82bcab253f741f47_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i719acf51485c46e1b4361db7fe272812_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6d9766a167f349bb92052a2b44a794db_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifca2e3b16c794fc4a70ed80eb0c74b8d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0c58992375514840acc525804de3b5bf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia27678044cb14d4281421247fb96281d_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iab3dbd6a7f674d7083db2fa3c9db78a2_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i507ff9b7892843ad987a51c1c29c0a35_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic3e5273956124a8099431ab285dc59c1_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie6257175c451430abb2778376da96411_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6575d7f8daec4ae4abac4b2ef1bb98b4_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i602a59ce297c424b93795664859a8674_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="id8b0e758c6064f6291d39bb97bb331c8_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i6a09fd187a41481abc00b2e5f81774d2_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i71026660fee448b3b596180fe34cbeca_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="iff8d18ca423a4767b541788b25f1e8bf_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic0372b5960b948f488c30f66137194f2_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9b2c76fc1f31458f93f96af1cff6f08f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i47fe6eddfdbe4eed90628172bad98597_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3cb024c41379417ebfea69a16d594eb0_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2055279aba744bfa86fba3a79756df14_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i38e64861bfb143a6a581ccee7a5ad430_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i6db610d7a4604665833e6884c7e4d50c_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ib9ef743ad4504fe6a4762417ee298525_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i9f68996929254ee4bbba614e977012de_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i2d81767196a447c99e736999c49bbd94_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if22d9a712dc144118a697b351d62e799_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i42d47dd822a748b791c92e60630a2428_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i66eacee5840b45e29eab0ce41b30f033_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7e35705736534c78843742303282feb9_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i447f37e612cc480fb09d01d85dfe8a92_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ibe0cf5fbf4e1438fb46d794ecd6487cc_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if042bb6dd7e349bab540c21e2b62d94c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5ead1c261b0940cab128efb701608748_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic4e83e9c6d3f41cba0167701375d65af_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">xcur:COVID19Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7c9b511297334f1596139d6ed967838a_D20210730-20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:IpsenCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-07-30</endDate>
        </period>
    </context>
    <context id="i101b7a1d41f042c7be4608f1ec08064c_D20210730-20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:IpsenCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ExercisePeriodAxis">xcur:ExercisePeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-07-30</endDate>
        </period>
    </context>
    <context id="i3771528d3f494af69c08d167b87d572b_D20210730-20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:IpsenCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ExercisePeriodAxis">xcur:ExercisePeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-07-30</endDate>
        </period>
    </context>
    <context id="i20b3f5cd0c964a8e9b2b710ca2d7aec4_I20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:IpsenCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-30</instant>
        </period>
    </context>
    <context id="ibd51ee58a09548a296ac27e125b6aaf5_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:IpsenCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:CollaborationAgreementPerformanceObligationAxis">xcur:IpsenHDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i577ec678c36d41cb95beb6bb59053c95_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:IpsenCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:CollaborationAgreementPerformanceObligationAxis">xcur:IpsenASMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia146a37ad8c04dd3a46243658527ace5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:IpsenCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6e7d092153af4ab295e43b76a46e94f7_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:IpsenCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0eb88576f2154b229cc5f904054ddcaf_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:IpsenCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id7d7e4233d934ae2905015e902539333_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:IpsenCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8cc70e8bc70d42888c31d1910622f129_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:IpsenCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i25a109363b9444d0b161c5f239e1f5d2_D20191113-20191113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-13</startDate>
            <endDate>2019-11-13</endDate>
        </period>
    </context>
    <context id="i62ddab29023047f19bcd9cdd54f54b72_D20191113-20191113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">xcur:DevelopmentandCommercializationLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-13</startDate>
            <endDate>2019-11-13</endDate>
        </period>
    </context>
    <context id="iadf638d109364478ada9ed12098f78a3_D20191113-20191113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-13</startDate>
            <endDate>2019-11-13</endDate>
        </period>
    </context>
    <context id="ie6c60cafc25843e7aa83623d15b8db40_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i202fe08011f74b3bb586c3b5936aade6_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i334dc3567c6c404c81c2439542a6c976_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib58e437af4b84283a34ce171354bebca_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9f46863e9a324f25a2a99c8d4fc202db_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib068c60a143742cab222adf4b1fc4d6e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie0f5e47c15a04e01ae8607547bdbb25b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibe437bd3033d4b10b7ec04a3e962b1fa_D20190217-20190217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:DermelixLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-17</startDate>
            <endDate>2019-02-17</endDate>
        </period>
    </context>
    <context id="i1b1064f27e214d639fb5a6444e15afc9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:DermelixLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie7111ceb9bee457d80c964d377cc8997_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:DermelixLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9a7767cbe5314379a5bbad2a39574623_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:DermelixLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1972cd63fd53468ca6ea728506874004_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:DermelixLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6df20868c6bf4088a7c126fd9b4c448f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:DermelixLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8868537d91414e59b86b641af9be949f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:IpsenCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i603ebaab9dc547c9b12a83e9eed30a32_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:IpsenCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie2eeecde261e4327b21ed0de06f04e52_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:IpsenCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6a37c9da460c48809897a601836d2643_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icb811529c5b84fc488584f1160906a17_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibbfce07014ab4a519300435d21964c4d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="xcur:ArrangementNameAxis">xcur:AbbVieCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i47cd4e78b2384bf799057776f855682a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0018e41fbb07474dba5b83bb48cc8e03_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib82780d8d54341299de5c10d925f31a6_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie3ceab8c75694c4993355dcd2ae5c9fe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i40174dd466594c3ab62a59e071f6cefd_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xcur:ComputersandSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5d6ec4e189a747bd803d814ff65b5f44_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xcur:ComputersandSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id9c2eeac1b3a491ba5d5b4821b396ce8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib8817be1e21d4636989a972eaf99d676_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iac3a1146a0b04454a629ec3468190f98_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i00fa9951d7744973a1c8d2aa533d73dc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0053a355b9114313a12f8f7a031d65fc_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4f345e6eb7f04fe4b6eab2801122fe23_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9282a032bc9d437cbb449818fa2c4843_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i23975282c1f34d05bda28777e4086e31_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia247df9dcde04691921f7589b38fdf6a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2705fb27647c4404a185735a84cd5bae_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7567e0c7c5914bf5bde30bc572efc791_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if6bd93e3d37e4fcb8e2b2027637863ed_I20200925">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-25</instant>
        </period>
    </context>
    <context id="i7978f6f7e1b748cbabd1e2488f7447b7_D20200925-20200925">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementTranche1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-25</startDate>
            <endDate>2020-09-25</endDate>
        </period>
    </context>
    <context id="i34a25167a0434d11aa0d2091e882e0a7_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementTranche2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic8b146e3b6574d4ca6373ba4278baaa4_D20200925-20200925">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-25</startDate>
            <endDate>2020-09-25</endDate>
        </period>
    </context>
    <context id="i6c070a76443f46c79d54256b1cbf28fa_I20221001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-01</instant>
        </period>
    </context>
    <context id="i89a02e4e5ce34167a93a3c5c5bff753f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0d913806ddcd4fe38da350a6c3ed1feb_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia9b3e45e1e944cbfa8d1c6fa857fb39c_D20200925-20200925">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <startDate>2020-09-25</startDate>
            <endDate>2020-09-25</endDate>
        </period>
    </context>
    <context id="ic85ffe60044641adbba3cef493f35219_I20200925">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementTranche1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-25</instant>
        </period>
    </context>
    <context id="i77889ae6ab624d1295d8b058f98f0543_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6126506f80104557ba998535d441061c_I20200925">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementTranche2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-25</instant>
        </period>
    </context>
    <context id="ice5e4b94c8ca4a1c808b55cb400e24e7_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementTranche2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8f010890f93049f2ae4c474fd0f3290c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xcur:MidCapCreditAgreementTranche2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5116d3a6dd234ef8a2099862dd24c82b_D20200302-20200302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">xcur:HerculesTechnologyGrowthCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-02</startDate>
            <endDate>2020-03-02</endDate>
        </period>
    </context>
    <context id="i9576e645ea7c457ca92b31b2bdd21d44_D20200701-20200701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">xcur:ChicagoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-01</endDate>
        </period>
    </context>
    <context id="i271a8511a8d74205a164612b6225fd65_I20200701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">xcur:ChicagoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-01</instant>
        </period>
    </context>
    <context id="i27fa1ea6e2df45148c9b25b975903963_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ibd76f03fda964ae290754abfcc474c0f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8169de03b9ae4915bce1475ec011bdcd_I20210327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-27</instant>
        </period>
    </context>
    <context id="i1c3f90d09e82457cb147316b3d91afa0_I20210428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-28</instant>
        </period>
    </context>
    <context id="if2dfcf33b3dd445fac1ae79f628e0c43_I20210503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-03</instant>
        </period>
    </context>
    <context id="i7b1d431f25394a5c823a69f4d9ab4c33_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic64e0711d9f74fb89ed048800885e19f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i53500ad38bdf4e52898d5f52b87b27ef_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iecc89148ecae49e08ec084733d34a7aa_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0c4c5418937146598e8abc57dcc888bc_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0deb149ab1ef4764ab8d4cdbf04c52b6_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0ed6144e7375437b82d12e674ba92210_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i73a5c9b5040b4db1b63fd576e252a033_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia4e62853255f45b2b31cd2904be103fe_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i57be8b97989949c89b339f60ea0c9c10_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i078e9e8c3ffe4962a86e337d4adc40ed_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i284324b6f8f04a0a9d2178e2163abdef_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iff67e94dbcb44135b28d7b8a3cc93f58_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i88948d106e48468baa525705927f987b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if0c01f0c5533412a95c4f674b3fca01f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xcur:ExicureInc.2017EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9cf18d06bb4048079daf994c18213de9_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xcur:ExicureInc.2017EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iab7fc37403bc4ae2845774e5e03fe94c_D20210101-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xcur:ExicureInc.2017EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="id55f75e995434a9dbf67ef6793958099_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="ie212c3441c564ae7beb10ac73b3f5f39_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4c783d5073c74f03a909d7ebe8913ac0_I20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-30</instant>
        </period>
    </context>
    <context id="i4333b7976f584c9cb7edb39e5c5abebd_D20170901-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="id8d6615560b5454ea9d90fe9e4254cc7_D20210514-20210514">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-14</startDate>
            <endDate>2021-05-14</endDate>
        </period>
    </context>
    <context id="i5c0e7a1b94874bc79ecebefc5fac4988_D20210101-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i982ad11b02e442eabda7ce00ba0f8e6f_D20200101-20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-01</endDate>
        </period>
    </context>
    <context id="if7a30565b6414f62b985b9824a0b50b0_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if808fd669ed14a3eb6ab7ba40be06723_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7dd8d8dbeff24010a0f6b35ba5d055da_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if3196c46080b4a98afd913b13a6d4a34_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i320897d327b3429885b686fa2ddd6d58_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icc041bea74db41bc8b34b9c2abac7ec1_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i999eb37ba3c84d41978cdddb2073c9c0_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id73356acb7214cc990e0f0fdb073fe06_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3853bdccdca84ad7b18ecb46c72865db_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6aeb1a850cfb47d0a5ac9c85fe47090e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6b82c3458cdf484196d37803505070a6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia356a586489a48ba88f9458d0242cdf9_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i773b254eadab4295b1ffc8c03ceb00b8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic894455288284da09cf40a767a1e085c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if589413bdfb14e7bbc638c0c928b54e3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i02e0beb6fe6341f7a29be934913d195d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1ddff9f5fe814e669c4e7af58af7e785_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iab9b918edd71485aaa8ea0f447186603_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic679721ac45b4f7fb6a4951133fb72b5_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5da161d8e266400a93c4f383d423b29f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if76f066c63564146bf012992a98ddce9_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i597ea376c91548b4a05158f306bea587_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5719399e939a44d98b39d249c039d68d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0e30264806374843a74cbde5714a8879_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6d14cf3685554550979e56c0584d59a2_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i23729b7c757546618ffd14bfc2bf93dd_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia7f4cd3d9bdd4d918c745f1ede290f0d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i78855d9d0c4747009459828fe157b733_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3521ed35239b4892871886f1c9a86593_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic2c85780c2fe44a5a264af346e3d74fe_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8414c9548ccf4c85ba53fb4883723dac_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic82a774e2c8d4a41b3170db670ad8155_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="icf7c24c0d5bd4c578f72a33ccc3c05bf_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i020262a33e8049ff9ab935e2b201f6fb_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i439032d25541463e8e6c4621ef8fd111_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8a58bfb15835492ab090e8b81401af85_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8ddced473eff483780d1373964171762_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5731c03b9fc44849a8c3fb5ed3c6949a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i56aca844fa034db2b2e2a7b18d0023e7_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id9718465693743c3b538b21283198504_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i313d98866f5747ea9ad78d453628370d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ibda75316052d4dbe9d661f043c9b1956_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib677e14bc757464bb5589291a71b4e61_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i7d8d9676d98849f883d2748566593b17_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib0974ff1702c42d395bd413417d4a0d9_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4c8552c18039495daa749078cb358e04_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i64760482c2c9480ea6bc6748d1d90ce7_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="icea87c7e3d6a4dfba48ae4131cda39e8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i86c21c42f5cd42dfa1f7346b010764d4_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i62ff7db7da784f799e2dfe0c311b9e0f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i965562b1554547d1a09c7766cedd87ae_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9531f369bf98470ba15fba85df910ef3_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia886151578c443df8e7d2e02ad3a907b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ied37c8b6308741fda6f2b2dcb570461d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ibc5f1ed1d0574ff59b0f1eed86e46da0_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5b19f1632fda44cfb2cbf056cb55773e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie60c424895d44cb6a873a2f566d9ba85_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id804d84aba2942da9b78003f9fa2d272_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3cb225e6af3547baa416759169909bcb_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2cba3845e261446285d53d1b68bd1b2b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i086920543bec4d90bb757a3cefcb83ef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic202372402d84018b4b88f88701033d0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i83369fca8bab4aab90e8db725e903baf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2996ac3939c042e3ab6d42a6553a235a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8883903151f24f5fa017edecc72b8b35_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i719acee816814d07916c8dfd5ca71de9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5ca413f9b9054d00bbda5b1373b22305_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i34fe6e6e209446768a2cf34d62dad6aa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i62f9200c696c41d78a853e83862f647b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4d5744490b0d4c738db4cd2bb4e0aa81_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibfc85e952cc2497fbeee275f739aa825_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5ed86c954d924fc8a28507f2891286eb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifaf0a15420cb4a7294217b68929d7235_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia1e7126375264b1c93061499c8d47b5e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i71bd3df32bb94d4fae58db8bff589a4e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic259c1b511b64ac2978a410b11be349b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7a439123584f4408a9d60d89e70d2703_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0667ee8e62af460ca0b2e1c8843b72c2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i64cfed00d63048338a59cf563ea272b8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1126e3e21a654b5fb23bb497bc28aa43_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2c44bd27d0ac448590035ac735a75a7b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0b2c5cfdc76544d29619b3bd1e9955a8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifa0ce1eb50024db289d3b452e949a956_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2f8b49f540eb4a5f880bed694d3fd14d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i03125214387d41b9a8017ffe8a649dac_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9361796fa9024b2182ac08a2f7e2bf59_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">xcur:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8264fbfff9464a9baa8088b432d019fd_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">xcur:ConsultingServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i18f420eacb594066840b698845eaa3a4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001698530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">xcur:ConsultingServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="agreement">
        <measure>xcur:agreement</measure>
    </unit>
    <unit id="installmentpayment">
        <measure>xcur:installmentPayment</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="extensionperiod">
        <measure>xcur:extensionPeriod</measure>
    </unit>
    <unit id="votepershare">
        <measure>xcur:votePerShare</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80L2ZyYWc6YmE0MTA1MzBkZTU1NGZjOTk5OWY3NDdlNzM1MmY4NTUvdGFibGU6Mjk2OTc4OTIwNjRhNGJlMTg0YjM3NWNlMmNkZmM4MGUvdGFibGVyYW5nZToyOTY5Nzg5MjA2NGE0YmUxODRiMzc1Y2UyY2RmYzgwZV8zLTEtMS0xLTA_82d314e4-3f14-487b-b2bf-e07f60d91f41">0001698530</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80L2ZyYWc6YmE0MTA1MzBkZTU1NGZjOTk5OWY3NDdlNzM1MmY4NTUvdGFibGU6Mjk2OTc4OTIwNjRhNGJlMTg0YjM3NWNlMmNkZmM4MGUvdGFibGVyYW5nZToyOTY5Nzg5MjA2NGE0YmUxODRiMzc1Y2UyY2RmYzgwZV80LTEtMS0xLTA_622dc1ce-fe28-4afc-aff7-c408efa6114b">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80L2ZyYWc6YmE0MTA1MzBkZTU1NGZjOTk5OWY3NDdlNzM1MmY4NTUvdGFibGU6Mjk2OTc4OTIwNjRhNGJlMTg0YjM3NWNlMmNkZmM4MGUvdGFibGVyYW5nZToyOTY5Nzg5MjA2NGE0YmUxODRiMzc1Y2UyY2RmYzgwZV81LTEtMS0xLTA_dc226eb0-015a-427f-93b0-7266a8c9b006">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80L2ZyYWc6YmE0MTA1MzBkZTU1NGZjOTk5OWY3NDdlNzM1MmY4NTUvdGFibGU6Mjk2OTc4OTIwNjRhNGJlMTg0YjM3NWNlMmNkZmM4MGUvdGFibGVyYW5nZToyOTY5Nzg5MjA2NGE0YmUxODRiMzc1Y2UyY2RmYzgwZV82LTEtMS0xLTA_24bab51d-75b6-425a-8cbc-99836ca768d6">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80L2ZyYWc6YmE0MTA1MzBkZTU1NGZjOTk5OWY3NDdlNzM1MmY4NTUvdGFibGU6Mjk2OTc4OTIwNjRhNGJlMTg0YjM3NWNlMmNkZmM4MGUvdGFibGVyYW5nZToyOTY5Nzg5MjA2NGE0YmUxODRiMzc1Y2UyY2RmYzgwZV83LTEtMS0xLTA_5c0f7dee-a865-4e3c-a629-1114fbdb99ea">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGV4dHJlZ2lvbjo2MWFiMTkzYzUyMTk0ZjJmYWY1NWI3MGJiZDc4ODA0Ml8yMzk2_d83ce2ee-1088-4770-9276-fa58e55cafc8">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGV4dHJlZ2lvbjo2MWFiMTkzYzUyMTk0ZjJmYWY1NWI3MGJiZDc4ODA0Ml8yNDA1_0091e9b1-b920-461a-bacd-fbfb433d9dce">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGV4dHJlZ2lvbjo2MWFiMTkzYzUyMTk0ZjJmYWY1NWI3MGJiZDc4ODA0Ml8zMjk4NTM0ODg1NzUz_ae8d7262-ada4-4894-a218-6137d5ac32d5">2021-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGV4dHJlZ2lvbjo2MWFiMTkzYzUyMTk0ZjJmYWY1NWI3MGJiZDc4ODA0Ml8yMzk4_73344343-0d46-4df3-9954-f520f56ecb28">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGV4dHJlZ2lvbjo2MWFiMTkzYzUyMTk0ZjJmYWY1NWI3MGJiZDc4ODA0Ml8yMzky_2bfbcab9-080e-4ea4-bc89-ce14c621bec0">001-39011</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGV4dHJlZ2lvbjo2MWFiMTkzYzUyMTk0ZjJmYWY1NWI3MGJiZDc4ODA0Ml8yNDAz_1a35f61b-50e4-48d7-b79d-c50504cf7bff">EXICURE, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGFibGU6YWUzOGVhMzVkMjkyNDUyZjg3MWVhNDViYTc2ODYyODIvdGFibGVyYW5nZTphZTM4ZWEzNWQyOTI0NTJmODcxZWE0NWJhNzY4NjI4Ml8wLTAtMS0xLTA_9936fe16-26ef-40a5-bf0f-7b6294dfe381">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGFibGU6YWUzOGVhMzVkMjkyNDUyZjg3MWVhNDViYTc2ODYyODIvdGFibGVyYW5nZTphZTM4ZWEzNWQyOTI0NTJmODcxZWE0NWJhNzY4NjI4Ml8wLTItMS0xLTA_94d58e1b-aec5-4f3c-98b4-b887cabb33be">81-5333008</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGV4dHJlZ2lvbjo2MWFiMTkzYzUyMTk0ZjJmYWY1NWI3MGJiZDc4ODA0Ml8yMzkz_265c7caa-6dc2-4deb-acca-e728b17ceaf7">2430 N. Halsted St.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGV4dHJlZ2lvbjo2MWFiMTkzYzUyMTk0ZjJmYWY1NWI3MGJiZDc4ODA0Ml8yNDA2_36c16d1d-0799-49a9-add1-0bcb5b43a11c">Chicago</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGV4dHJlZ2lvbjo2MWFiMTkzYzUyMTk0ZjJmYWY1NWI3MGJiZDc4ODA0Ml8yNDA3_07af11cb-1cb6-48a8-8ff7-ed0add1899cf">IL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGV4dHJlZ2lvbjo2MWFiMTkzYzUyMTk0ZjJmYWY1NWI3MGJiZDc4ODA0Ml8yMzk5_7c08a4a1-ccb0-4b2c-8b81-2f3994fb71f5">60614</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGV4dHJlZ2lvbjo2MWFiMTkzYzUyMTk0ZjJmYWY1NWI3MGJiZDc4ODA0Ml8yNDAx_ab375b35-660e-49bd-8ec7-74e70b2d8c0c">(847)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGV4dHJlZ2lvbjo2MWFiMTkzYzUyMTk0ZjJmYWY1NWI3MGJiZDc4ODA0Ml8yNDAy_55713e8f-8ba6-4157-a9a4-552a38f9493c">673-1700</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGFibGU6ZmY3Y2E3M2VlZjY4NDA3YzkxYjgyZTE0OTZlYmMwNmIvdGFibGVyYW5nZTpmZjdjYTczZWVmNjg0MDdjOTFiODJlMTQ5NmViYzA2Yl8xLTAtMS0xLTA_eb0c7624-c229-45c0-add5-cb36e1140695">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGFibGU6ZmY3Y2E3M2VlZjY4NDA3YzkxYjgyZTE0OTZlYmMwNmIvdGFibGVyYW5nZTpmZjdjYTczZWVmNjg0MDdjOTFiODJlMTQ5NmViYzA2Yl8xLTItMS0xLTA_3f06ac78-f2f2-45dd-9f3e-649b5ae2e4aa">XCUR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGFibGU6ZmY3Y2E3M2VlZjY4NDA3YzkxYjgyZTE0OTZlYmMwNmIvdGFibGVyYW5nZTpmZjdjYTczZWVmNjg0MDdjOTFiODJlMTQ5NmViYzA2Yl8xLTQtMS0xLTA_9fd95f69-1aff-4d56-8bef-9cc3389cb4b7">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGV4dHJlZ2lvbjo2MWFiMTkzYzUyMTk0ZjJmYWY1NWI3MGJiZDc4ODA0Ml8yMzk0_f7112e49-3f40-42fa-9a7e-9713f85fbb5a">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGV4dHJlZ2lvbjo2MWFiMTkzYzUyMTk0ZjJmYWY1NWI3MGJiZDc4ODA0Ml8yNDA4_24419e3d-5a3e-4e67-a5ab-71ac66e8ce84">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGFibGU6YzllOTNiNDJkMGQ0NGU5YmFmZjZiZTgwMDcyZDJkMzUvdGFibGVyYW5nZTpjOWU5M2I0MmQwZDQ0ZTliYWZmNmJlODAwNzJkMmQzNV8xLTAtMS0xLTA_40b5cbb4-322d-4ab2-ab41-bf6af1e3b0a4">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGFibGU6YzllOTNiNDJkMGQ0NGU5YmFmZjZiZTgwMDcyZDJkMzUvdGFibGVyYW5nZTpjOWU5M2I0MmQwZDQ0ZTliYWZmNmJlODAwNzJkMmQzNV8xLTQtMS0xLTA_410e2118-de13-4c5d-843e-dff989a6e75a">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGFibGU6YzllOTNiNDJkMGQ0NGU5YmFmZjZiZTgwMDcyZDJkMzUvdGFibGVyYW5nZTpjOWU5M2I0MmQwZDQ0ZTliYWZmNmJlODAwNzJkMmQzNV8yLTQtMS0xLTA_1bce75d0-057c-43ad-b5ab-6d0d998ed680">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGV4dHJlZ2lvbjo2MWFiMTkzYzUyMTk0ZjJmYWY1NWI3MGJiZDc4ODA0Ml8yMzk1_50cacafe-6741-4590-9655-f2e0b3808168">true</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGV4dHJlZ2lvbjo2MWFiMTkzYzUyMTk0ZjJmYWY1NWI3MGJiZDc4ODA0Ml8yNDA5_9ec6d1eb-de5e-44f6-a07c-2c2253089953">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i04b6fc849e294cd184b4de031b935e57_I20211112"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xL2ZyYWc6NjFhYjE5M2M1MjE5NGYyZmFmNTViNzBiYmQ3ODgwNDIvdGV4dHJlZ2lvbjo2MWFiMTkzYzUyMTk0ZjJmYWY1NWI3MGJiZDc4ODA0Ml8yMzA3_f22406d8-c548-4a98-83e3-8634edfe170d"
      unitRef="shares">88120951</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfNC0xLTEtMS0w_c473202f-01c0-44f6-bd94-c8f16d27e930"
      unitRef="usd">51885000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfNC0zLTEtMS0w_ef5ead5f-667f-4826-a42c-2278447cfc67"
      unitRef="usd">33262000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfNS0xLTEtMS0w_33e360f1-0ee8-411e-abe9-bddc30cdb0b4"
      unitRef="usd">8953000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfNS0zLTEtMS0w_68e49fe8-8909-4d53-a210-69f76f90b029"
      unitRef="usd">48818000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfNi0xLTEtMS0w_f54d07fc-0706-4bdc-a2bc-694313de286a"
      unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfNi0zLTEtMS0w_2a0e150c-c809-4ade-8154-aacc6f504d24"
      unitRef="usd">11000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfOC0xLTEtMS0w_505ed6bf-2c7e-4900-8f87-80ff6f173313"
      unitRef="usd">3309000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfOC0zLTEtMS0w_b93c3cb3-6cc2-4425-b918-715477ff8c2c"
      unitRef="usd">4231000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfOS0xLTEtMS0w_6d495a78-59ff-4c29-bebb-5b374aaf2798"
      unitRef="usd">64147000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfOS0zLTEtMS0w_9d328223-4ce3-4f11-ba55-80f2af93ba1d"
      unitRef="usd">86322000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMTAtMS0xLTEtMA_06288101-94ab-4fae-8427-824ee9ef7911"
      unitRef="usd">4171000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMTAtMy0xLTEtMA_bf3f3747-ca4e-41c3-ade0-96a1af2e656f"
      unitRef="usd">4123000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMTEtMS0xLTEtMA_b332521b-58b4-4643-8466-89f82cf7c4c2"
      unitRef="usd">8117000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMTEtMy0xLTEtMA_b5f6b81c-a610-492e-89ac-dc8a594f193c"
      unitRef="usd">8606000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMTItMS0xLTEtMA_227b0497-6f68-43d5-872f-e2a0a1fd244d"
      unitRef="usd">1465000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMTItMy0xLTEtMA_ef1a4f53-24bd-48d0-a2cb-2251093e66f2"
      unitRef="usd">1393000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMTMtMS0xLTEtMA_8e6bfb47-ca2b-49e8-9083-bd18b9d7d0b7"
      unitRef="usd">77900000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMTMtMy0xLTEtMA_ffdbd6f6-3b35-4f1d-b9cb-9446b06c3b23"
      unitRef="usd">100444000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMTctMS0xLTEtMA_87c430ff-8be9-4450-94bb-c658332e196e"
      unitRef="usd">2485000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMTctMy0xLTEtMA_32171fba-16be-4d41-b8a2-62b9e2137500"
      unitRef="usd">1866000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMTgtMS0xLTEtMA_278e7b4c-4bcb-4f7d-9791-0e3d077a186f"
      unitRef="usd">5480000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMTgtMy0xLTEtMA_9b7ebf16-08dd-41b7-8834-3740adca3124"
      unitRef="usd">3525000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMTktMS0xLTEtMA_c9b2cb2a-5d18-42cf-a2d3-cd28c35a6634"
      unitRef="usd">14015000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMTktMy0xLTEtMA_5a47a0c9-d8ba-4bd1-a8a4-cdd43220616f"
      unitRef="usd">8343000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMjAtMS0xLTEtMA_01f1033f-0ff0-47d3-be6a-bdfa7994e193"
      unitRef="usd">21980000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMjAtMy0xLTEtMA_8708f8c8-a677-4ba9-881b-deaca33fcb89"
      unitRef="usd">13734000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMjEtMS0xLTEtMA_669d13a8-f91d-4d56-8ea1-a3b8cd4bb112"
      unitRef="usd">16801000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMjEtMy0xLTEtMA_ec74842d-dd21-4ae7-9f41-a9b1652e2f8f"
      unitRef="usd">16589000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMjMtMS0xLTEtMA_bd5f3981-2a0a-43c6-affa-4e233e30d57d"
      unitRef="usd">16929000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMjMtMy0xLTEtMA_452609a0-e915-4e29-8c77-969f1841c35b"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMjQtMS0xLTEtMA_5f314675-8210-46dd-86b0-56e388adcf86"
      unitRef="usd">7551000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMjQtMy0xLTEtMA_0aed3e66-ee80-4b53-b13e-97ae41021bbf"
      unitRef="usd">7959000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMjUtMS0xLTEtMA_a4684aa1-0aee-44aa-afc4-fb31b4c05fbf"
      unitRef="usd">656000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMjUtMy0xLTEtMA_d2ab32a5-7e92-497d-8c24-9811a66233b3"
      unitRef="usd">656000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMjctMS0xLTEtMA_dddd4a9e-57cc-4143-be55-d3a65fe65f21"
      unitRef="usd">63917000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMjctMy0xLTEtMA_90c10f08-d666-437f-aff4-f692aff294b7"
      unitRef="usd">38938000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjkxZTE0YTFkMzEwOTRhOTU5YjJlNzgyM2Y0N2JjZjVlXzIx_41c967ae-c3ed-4c2a-a7d1-683156fea705"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjkxZTE0YTFkMzEwOTRhOTU5YjJlNzgyM2Y0N2JjZjVlXzIx_516665e8-23a0-4f5f-a7e5-eeb3e9242b5a"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjkxZTE0YTFkMzEwOTRhOTU5YjJlNzgyM2Y0N2JjZjVlXzQ1_56cfb601-18c5-452d-90c9-013faed00344"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjkxZTE0YTFkMzEwOTRhOTU5YjJlNzgyM2Y0N2JjZjVlXzQ1_ec13fe0c-97c8-4241-8724-b7c9436ecdfb"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjkxZTE0YTFkMzEwOTRhOTU5YjJlNzgyM2Y0N2JjZjVlXzY3_0d29349d-87d9-4d38-bdfa-b42fe4bfacad"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjkxZTE0YTFkMzEwOTRhOTU5YjJlNzgyM2Y0N2JjZjVlXzY3_7a7e57ad-9538-4603-9c09-8143eed4ce88"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjkxZTE0YTFkMzEwOTRhOTU5YjJlNzgyM2Y0N2JjZjVlXzY3_9d5a51be-1b8a-4582-8943-71dd2986f785"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjkxZTE0YTFkMzEwOTRhOTU5YjJlNzgyM2Y0N2JjZjVlXzY3_bab0e058-655f-4fbe-bba3-e7f804520daf"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzAtMS0xLTEtMA_f3bd872b-a801-448a-a315-a4e9c82794a8"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzAtMy0xLTEtMA_d8463d02-8c62-47a8-9e11-0e1f54b2ff83"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjEwYmRjOTQwMzM1NzQyODBiZmFiMzYyN2Q0Zjk3OWRkXzE5_67e18e89-9a42-422e-a147-c07cac871486"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjEwYmRjOTQwMzM1NzQyODBiZmFiMzYyN2Q0Zjk3OWRkXzE5_ba995eb9-690b-4c02-8cba-483aeb9dd470"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjEwYmRjOTQwMzM1NzQyODBiZmFiMzYyN2Q0Zjk3OWRkXzQz_96e23a82-ecd4-4254-8c0e-31184f4de851"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjEwYmRjOTQwMzM1NzQyODBiZmFiMzYyN2Q0Zjk3OWRkXzQz_bbf9e719-b434-46a1-a880-45b6bdfa7fd3"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjEwYmRjOTQwMzM1NzQyODBiZmFiMzYyN2Q0Zjk3OWRkXzY1_9a52432a-4ae1-4b89-adc2-d69ad8f11631"
      unitRef="shares">88108543</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjEwYmRjOTQwMzM1NzQyODBiZmFiMzYyN2Q0Zjk3OWRkXzY1_ce5c4972-d716-479b-a3e0-4bc6e5a54622"
      unitRef="shares">88108543</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjEwYmRjOTQwMzM1NzQyODBiZmFiMzYyN2Q0Zjk3OWRkXzk2_2650a44d-ddd4-4fb1-b1d1-2dd243401f55"
      unitRef="shares">87651352</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjEwYmRjOTQwMzM1NzQyODBiZmFiMzYyN2Q0Zjk3OWRkXzk2_53e61338-21bb-48c8-9ed4-1950ceae7af3"
      unitRef="shares">87651352</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzEtMS0xLTEtMA_dc207781-e2b5-4c9c-b36c-baaa82cd2d5a"
      unitRef="usd">9000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzEtMy0xLTEtMA_4b698081-b2d1-47df-bff8-95d190ca484c"
      unitRef="usd">9000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzItMS0xLTEtMA_028c1e53-eb46-4b0c-a693-0d59db4bf4ad"
      unitRef="usd">170217000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzItMy0xLTEtMA_e0fbd84b-a331-426a-a4d7-e1771f64b37d"
      unitRef="usd">167379000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzMtMS0xLTEtMA_9a71d086-94c0-41ae-8673-2a3f51a34b69"
      unitRef="usd">-1000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzMtMy0xLTEtMA_f665e1cd-cf85-49f1-88df-dd04e0708e95"
      unitRef="usd">83000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzQtMS0xLTEtMA_06ae3b34-5aef-4191-8c9c-45d19035d870"
      unitRef="usd">-156242000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzQtMy0xLTEtMA_22c620c9-e35d-49c9-9a86-876301d8488d"
      unitRef="usd">-105965000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzUtMS0xLTEtMA_dc67d9a3-3afa-45fc-b906-11f9b1ed5cf8"
      unitRef="usd">13983000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzUtMy0xLTEtMA_ddd686a3-bc8e-4ccb-bfca-1521435a1ac1"
      unitRef="usd">61506000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzYtMS0xLTEtMA_593d0963-5f61-4a77-b66d-32d5ae4899d8"
      unitRef="usd">77900000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8xOS9mcmFnOmVlNDhiYzI4Mzc1YTQwOGRhMWM0MGEyMDE0M2FlMDgzL3RhYmxlOmQ0NmU5MDc5MzU2MjQ2MjU5YzQ5NTRiY2FmOGQ2ZWI3L3RhYmxlcmFuZ2U6ZDQ2ZTkwNzkzNTYyNDYyNTljNDk1NGJjYWY4ZDZlYjdfMzYtMy0xLTEtMA_935f8ccd-5003-4d7f-95a2-614b329c2099"
      unitRef="usd">100444000</us-gaap:LiabilitiesAndStockholdersEquity>
    <xcur:RevenueFromContractWithCustomerNetOfCumulativeCatchUpAdjustment
      contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMy0xLTEtMS0w_249d54e0-92d8-44d1-b544-2ae77ef046f1"
      unitRef="usd">-3677000</xcur:RevenueFromContractWithCustomerNetOfCumulativeCatchUpAdjustment>
    <xcur:RevenueFromContractWithCustomerNetOfCumulativeCatchUpAdjustment
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMy0zLTEtMS0w_b3a7faaa-6336-40c1-8814-bfdab5f2b272"
      unitRef="usd">2443000</xcur:RevenueFromContractWithCustomerNetOfCumulativeCatchUpAdjustment>
    <xcur:RevenueFromContractWithCustomerNetOfCumulativeCatchUpAdjustment
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMy01LTEtMS0w_2290b48d-a8fd-4ea8-8867-4b6e81a94299"
      unitRef="usd">-2601000</xcur:RevenueFromContractWithCustomerNetOfCumulativeCatchUpAdjustment>
    <xcur:RevenueFromContractWithCustomerNetOfCumulativeCatchUpAdjustment
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMy03LTEtMS0w_f48c6a98-5ce1-41cd-a408-972d80f8834d"
      unitRef="usd">16473000</xcur:RevenueFromContractWithCustomerNetOfCumulativeCatchUpAdjustment>
    <us-gaap:Revenues
      contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfNC0xLTEtMS0w_2382fdca-2fd6-48d1-975e-40c3a8fe356a"
      unitRef="usd">-3677000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfNC0zLTEtMS0w_b4f53199-cfe1-4951-87e7-e81af2c1907f"
      unitRef="usd">2443000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfNC01LTEtMS0w_e7fad401-ddd3-4b32-a033-b18e26591c1b"
      unitRef="usd">-2601000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfNC03LTEtMS0w_c3bb0339-3e60-4577-a320-9cbab109c22b"
      unitRef="usd">16473000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfNi0xLTEtMS0w_ec5b7421-0f66-4188-b38f-1d42bfa8565b"
      unitRef="usd">16457000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfNi0zLTEtMS0w_17330122-71cb-4727-a90d-1e5e73f410ad"
      unitRef="usd">9139000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfNi01LTEtMS0w_d43b9c21-87fe-42f6-aa3d-3ddf998013fa"
      unitRef="usd">37562000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfNi03LTEtMS0w_a52b8461-8492-454b-8214-b8b8a02c78db"
      unitRef="usd">22222000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfNy0xLTEtMS0w_648a153a-b32e-4e25-bf5b-b0f804346b8d"
      unitRef="usd">2947000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfNy0zLTEtMS0w_552e89f5-0c2f-4175-9a98-ce731c771bce"
      unitRef="usd">2424000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfNy01LTEtMS0w_6522fdb5-41bd-483a-a492-6b6d9a92bf6c"
      unitRef="usd">8937000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfNy03LTEtMS0w_1237860d-f9a2-415c-b561-063eda495507"
      unitRef="usd">7227000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfOC0xLTEtMS0w_c1a9a44e-8d79-4a24-bddb-d98ba37e2433"
      unitRef="usd">19404000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfOC0zLTEtMS0w_a38e041e-fa58-4e4a-b9ce-5e3cd559bf46"
      unitRef="usd">11563000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfOC01LTEtMS0w_4254547d-97ed-49db-aec1-c2ec74daea68"
      unitRef="usd">46499000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfOC03LTEtMS0w_22ff2b9f-196f-40aa-9779-0a162eef7c97"
      unitRef="usd">29449000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfOS0xLTEtMS0w_95c0a346-9302-46e8-a0b1-f718505e4927"
      unitRef="usd">-23081000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfOS0zLTEtMS0w_ac9447eb-eee6-44c4-9901-c1953f9f8515"
      unitRef="usd">-9120000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfOS01LTEtMS0w_414de35a-d686-4285-bdba-dbf1b65d07b7"
      unitRef="usd">-49100000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfOS03LTEtMS0w_f4069a75-9705-4da0-8156-523b38b59096"
      unitRef="usd">-12976000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeDividend
      contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTEtMS0xLTEtMA_da43a2c7-01bf-4c57-b5b8-9e351db6ce32"
      unitRef="usd">2000</us-gaap:InvestmentIncomeDividend>
    <us-gaap:InvestmentIncomeDividend
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTEtMy0xLTEtMA_23c108d9-8218-4ecc-ae23-5e616bcd77ad"
      unitRef="usd">2000</us-gaap:InvestmentIncomeDividend>
    <us-gaap:InvestmentIncomeDividend
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTEtNS0xLTEtMA_c4da4e9b-8079-441f-8695-276c5154859f"
      unitRef="usd">5000</us-gaap:InvestmentIncomeDividend>
    <us-gaap:InvestmentIncomeDividend
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTEtNy0xLTEtMA_d88e87ab-2ce8-4f24-8ed0-18ee8e523597"
      unitRef="usd">45000</us-gaap:InvestmentIncomeDividend>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTItMS0xLTEtMA_ad366147-93c6-428c-a995-61e5e09cd3f6"
      unitRef="usd">8000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTItMy0xLTEtMA_e9b41c78-a7a3-4a8a-be2f-89beeaa905a6"
      unitRef="usd">205000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTItNS0xLTEtMA_06fa4fe4-a8b4-499d-98e5-c2084412398e"
      unitRef="usd">139000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTItNy0xLTEtMA_1b0da67c-7601-40f2-96f0-3551b257d828"
      unitRef="usd">832000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTMtMS0xLTEtMA_3704e49d-98fb-4c7a-b0a4-5968f7bc88bb"
      unitRef="usd">455000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTMtMy0xLTEtMA_a3ede132-aa87-447d-bf4a-b023efb8baae"
      unitRef="usd">27000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTMtNS0xLTEtMA_7b5a58bd-32bf-4f5f-a31d-de7a10e67f47"
      unitRef="usd">1314000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTMtNy0xLTEtMA_97a64e2a-53d1-44c7-a250-99c0b7a0049c"
      unitRef="usd">155000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTQtMS0xLTEtMA_74d04947-dae6-4185-ad9b-cb05b8fa7645"
      unitRef="usd">-5000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTQtMy0xLTEtMA_58c1d99a-9bee-4cc5-a173-98a79e38d992"
      unitRef="usd">118000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTQtNS0xLTEtMA_a437fb42-bcf0-4d64-966b-bb8d6d180abd"
      unitRef="usd">-7000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTQtNy0xLTEtMA_eaf84def-6d0c-41e8-b78f-982f09af5529"
      unitRef="usd">271000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTUtMS0xLTEtMA_5a89ec35-4a40-4d4b-8017-aea94e572f9a"
      unitRef="usd">-450000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTUtMy0xLTEtMA_ae485cae-797c-4584-87c9-1869a09bbc5a"
      unitRef="usd">298000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTUtNS0xLTEtMA_a9b98f11-4bd2-4c5f-8d89-1648b7740e52"
      unitRef="usd">-1177000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTUtNy0xLTEtMA_08eeec07-73f1-42f6-96e1-e5e66fe19558"
      unitRef="usd">993000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTYtMS0xLTEtMA_ec30eacc-dea9-4517-9cb4-a3ad427b5c78"
      unitRef="usd">-23531000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTYtMy0xLTEtMA_c77a60e8-315b-425f-9a26-5535c4773177"
      unitRef="usd">-8822000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTYtNS0xLTEtMA_b336d545-9d78-4222-bb80-d91f8aff8e35"
      unitRef="usd">-50277000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTYtNy0xLTEtMA_cf247959-7699-45ba-89c7-b66a82233314"
      unitRef="usd">-11983000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTctMS0xLTEtMA_c2fb6856-0835-4288-be30-b9830bd2ee93"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTctMy0xLTEtMA_72deaf70-7398-4fcc-8fff-4deb10e26942"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTctNS0xLTEtMA_2ea88444-c1f9-4581-a19e-2ecaaff8ac8e"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTctNy0xLTEtMA_3ed3c6d8-612f-40e5-b61b-6336a1761e43"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTgtMS0xLTEtMA_94a29fdd-367b-4ea9-a730-bc9f21efb427"
      unitRef="usd">-23531000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTgtMy0xLTEtMA_37af539d-ed77-4a03-8288-fe40d50e4262"
      unitRef="usd">-8822000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTgtNS0xLTEtMA_474119c7-0fe9-456e-b2a9-2df09cea4e08"
      unitRef="usd">-50277000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMTgtNy0xLTEtMA_f8b22b3b-deab-466d-a1fe-5d331c8966e0"
      unitRef="usd">-11983000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMjAtMS0xLTEtMA_5c818a51-eb86-4593-b214-a61baa199eb3"
      unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMjAtMS0xLTEtMA_91b6fe31-b04e-486c-bbff-79c8a83a8179"
      unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMjAtMy0xLTEtMA_239a3a28-39ee-42e8-bb43-23385b60e1e7"
      unitRef="usdPerShare">-0.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMjAtMy0xLTEtMA_a8e25838-1079-476d-8596-bf4dc308c33c"
      unitRef="usdPerShare">-0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMjAtNS0xLTEtMA_e3fb8312-8b42-4c2c-8911-acabed80a520"
      unitRef="usdPerShare">-0.57</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMjAtNS0xLTEtMA_e5b1bdfd-fd4a-4684-85a5-cdd7e3ef1478"
      unitRef="usdPerShare">-0.57</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMjAtNy0xLTEtMA_6d61adac-7543-44d5-a864-31eae859827c"
      unitRef="usdPerShare">-0.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMjAtNy0xLTEtMA_8bcb45f0-2ff0-4491-90b0-440aa1d98e6d"
      unitRef="usdPerShare">-0.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMjMtMS0xLTEtMA_6a32eb69-b3c4-4883-a9f8-24ec73d714b0"
      unitRef="shares">88105066</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMjMtMS0xLTEtMA_b5bb72be-5235-4905-baaf-f1cd4e6dd852"
      unitRef="shares">88105066</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMjMtMy0xLTEtMA_6e96028f-c740-4f7e-ab2d-52cb737a5ea2"
      unitRef="shares">87227136</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMjMtMy0xLTEtMA_b2d241c0-355b-4bc1-ab64-e2b01f0b5db7"
      unitRef="shares">87227136</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMjMtNS0xLTEtMA_d576c33f-a239-41d6-8a68-aa53b3c83431"
      unitRef="shares">88001222</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMjMtNS0xLTEtMA_d86f9092-0ac2-4430-9651-343836b66c77"
      unitRef="shares">88001222</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMjMtNy0xLTEtMA_0119c157-1c20-41cd-a5c8-65f9a7909137"
      unitRef="shares">87160520</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yMi9mcmFnOmZjYzFhNWQ3ZjVjZTRkNGZiNmNlNzIwZTE0NWEyMGY2L3RhYmxlOjNmZGEyMDU5YjA4NTRkNDRiYWZiNmZiNzYxYTE4MDg4L3RhYmxlcmFuZ2U6M2ZkYTIwNTliMDg1NGQ0NGJhZmI2ZmI3NjFhMTgwODhfMjMtNy0xLTEtMA_12b8bb9f-804d-424d-a048-7cd3d17797b5"
      unitRef="shares">87160520</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yNS9mcmFnOjk3MWQxY2Y0NDlhMzRlYzJhYWYyMTY0NTk0ZGFmMDJmL3RhYmxlOjU0YWRlZWQwMDlmMzRjODlhYzAzMjBmZWMxNDcwM2U0L3RhYmxlcmFuZ2U6NTRhZGVlZDAwOWYzNGM4OWFjMDMyMGZlYzE0NzAzZTRfMi0xLTEtMS0w_b0ca7db5-9d0a-4a85-a48d-b33f7f460f70"
      unitRef="usd">-23531000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yNS9mcmFnOjk3MWQxY2Y0NDlhMzRlYzJhYWYyMTY0NTk0ZGFmMDJmL3RhYmxlOjU0YWRlZWQwMDlmMzRjODlhYzAzMjBmZWMxNDcwM2U0L3RhYmxlcmFuZ2U6NTRhZGVlZDAwOWYzNGM4OWFjMDMyMGZlYzE0NzAzZTRfMi0zLTEtMS0w_9a1a8380-ed4f-4631-814c-babfc2d8a322"
      unitRef="usd">-8822000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yNS9mcmFnOjk3MWQxY2Y0NDlhMzRlYzJhYWYyMTY0NTk0ZGFmMDJmL3RhYmxlOjU0YWRlZWQwMDlmMzRjODlhYzAzMjBmZWMxNDcwM2U0L3RhYmxlcmFuZ2U6NTRhZGVlZDAwOWYzNGM4OWFjMDMyMGZlYzE0NzAzZTRfMi01LTEtMS0w_700df0c4-edfe-43fc-a7b0-876281da6e8d"
      unitRef="usd">-50277000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yNS9mcmFnOjk3MWQxY2Y0NDlhMzRlYzJhYWYyMTY0NTk0ZGFmMDJmL3RhYmxlOjU0YWRlZWQwMDlmMzRjODlhYzAzMjBmZWMxNDcwM2U0L3RhYmxlcmFuZ2U6NTRhZGVlZDAwOWYzNGM4OWFjMDMyMGZlYzE0NzAzZTRfMi03LTEtMS0w_95aa02fc-1db0-48ae-9d3a-c8954ad86c41"
      unitRef="usd">-11983000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yNS9mcmFnOjk3MWQxY2Y0NDlhMzRlYzJhYWYyMTY0NTk0ZGFmMDJmL3RhYmxlOjU0YWRlZWQwMDlmMzRjODlhYzAzMjBmZWMxNDcwM2U0L3RhYmxlcmFuZ2U6NTRhZGVlZDAwOWYzNGM4OWFjMDMyMGZlYzE0NzAzZTRfNC0xLTEtMS0w_e72866d5-505e-467d-97ec-1147132eb1a2"
      unitRef="usd">-6000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yNS9mcmFnOjk3MWQxY2Y0NDlhMzRlYzJhYWYyMTY0NTk0ZGFmMDJmL3RhYmxlOjU0YWRlZWQwMDlmMzRjODlhYzAzMjBmZWMxNDcwM2U0L3RhYmxlcmFuZ2U6NTRhZGVlZDAwOWYzNGM4OWFjMDMyMGZlYzE0NzAzZTRfNC0zLTEtMS0w_41f3f9fe-0767-440c-aacd-48b792b88ae5"
      unitRef="usd">-138000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yNS9mcmFnOjk3MWQxY2Y0NDlhMzRlYzJhYWYyMTY0NTk0ZGFmMDJmL3RhYmxlOjU0YWRlZWQwMDlmMzRjODlhYzAzMjBmZWMxNDcwM2U0L3RhYmxlcmFuZ2U6NTRhZGVlZDAwOWYzNGM4OWFjMDMyMGZlYzE0NzAzZTRfNC01LTEtMS0w_85f70d23-5585-46d6-91bd-c4706faddc29"
      unitRef="usd">-84000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yNS9mcmFnOjk3MWQxY2Y0NDlhMzRlYzJhYWYyMTY0NTk0ZGFmMDJmL3RhYmxlOjU0YWRlZWQwMDlmMzRjODlhYzAzMjBmZWMxNDcwM2U0L3RhYmxlcmFuZ2U6NTRhZGVlZDAwOWYzNGM4OWFjMDMyMGZlYzE0NzAzZTRfNC03LTEtMS0w_d22b2542-272d-468c-b265-91bbaf961bd6"
      unitRef="usd">227000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yNS9mcmFnOjk3MWQxY2Y0NDlhMzRlYzJhYWYyMTY0NTk0ZGFmMDJmL3RhYmxlOjU0YWRlZWQwMDlmMzRjODlhYzAzMjBmZWMxNDcwM2U0L3RhYmxlcmFuZ2U6NTRhZGVlZDAwOWYzNGM4OWFjMDMyMGZlYzE0NzAzZTRfNS0xLTEtMS0w_e520c06a-8c7e-40ce-8487-bd7a4ffc9793"
      unitRef="usd">-6000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yNS9mcmFnOjk3MWQxY2Y0NDlhMzRlYzJhYWYyMTY0NTk0ZGFmMDJmL3RhYmxlOjU0YWRlZWQwMDlmMzRjODlhYzAzMjBmZWMxNDcwM2U0L3RhYmxlcmFuZ2U6NTRhZGVlZDAwOWYzNGM4OWFjMDMyMGZlYzE0NzAzZTRfNS0zLTEtMS0w_7304b25b-8cdd-4a93-afe2-33f438bd080d"
      unitRef="usd">-138000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yNS9mcmFnOjk3MWQxY2Y0NDlhMzRlYzJhYWYyMTY0NTk0ZGFmMDJmL3RhYmxlOjU0YWRlZWQwMDlmMzRjODlhYzAzMjBmZWMxNDcwM2U0L3RhYmxlcmFuZ2U6NTRhZGVlZDAwOWYzNGM4OWFjMDMyMGZlYzE0NzAzZTRfNS01LTEtMS0w_df281670-f09e-4190-9b8f-b2c0ed898828"
      unitRef="usd">-84000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yNS9mcmFnOjk3MWQxY2Y0NDlhMzRlYzJhYWYyMTY0NTk0ZGFmMDJmL3RhYmxlOjU0YWRlZWQwMDlmMzRjODlhYzAzMjBmZWMxNDcwM2U0L3RhYmxlcmFuZ2U6NTRhZGVlZDAwOWYzNGM4OWFjMDMyMGZlYzE0NzAzZTRfNS03LTEtMS0w_b9037294-b57d-4c83-82df-451a283c2170"
      unitRef="usd">227000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yNS9mcmFnOjk3MWQxY2Y0NDlhMzRlYzJhYWYyMTY0NTk0ZGFmMDJmL3RhYmxlOjU0YWRlZWQwMDlmMzRjODlhYzAzMjBmZWMxNDcwM2U0L3RhYmxlcmFuZ2U6NTRhZGVlZDAwOWYzNGM4OWFjMDMyMGZlYzE0NzAzZTRfNi0xLTEtMS0w_07720176-df55-42e9-a4e7-a8a5686033a1"
      unitRef="usd">-23537000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yNS9mcmFnOjk3MWQxY2Y0NDlhMzRlYzJhYWYyMTY0NTk0ZGFmMDJmL3RhYmxlOjU0YWRlZWQwMDlmMzRjODlhYzAzMjBmZWMxNDcwM2U0L3RhYmxlcmFuZ2U6NTRhZGVlZDAwOWYzNGM4OWFjMDMyMGZlYzE0NzAzZTRfNi0zLTEtMS0w_ccb5853a-4a77-4cb3-9b84-b08501e3b48a"
      unitRef="usd">-8960000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yNS9mcmFnOjk3MWQxY2Y0NDlhMzRlYzJhYWYyMTY0NTk0ZGFmMDJmL3RhYmxlOjU0YWRlZWQwMDlmMzRjODlhYzAzMjBmZWMxNDcwM2U0L3RhYmxlcmFuZ2U6NTRhZGVlZDAwOWYzNGM4OWFjMDMyMGZlYzE0NzAzZTRfNi01LTEtMS0w_6c0f4fe9-864d-477b-b14c-5883c0056581"
      unitRef="usd">-50361000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yNS9mcmFnOjk3MWQxY2Y0NDlhMzRlYzJhYWYyMTY0NTk0ZGFmMDJmL3RhYmxlOjU0YWRlZWQwMDlmMzRjODlhYzAzMjBmZWMxNDcwM2U0L3RhYmxlcmFuZ2U6NTRhZGVlZDAwOWYzNGM4OWFjMDMyMGZlYzE0NzAzZTRfNi03LTEtMS0w_dc48a6e3-d4ee-456e-afcb-5e09734bd9e8"
      unitRef="usd">-11756000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="id1a551c230f14800abc2fa41ca7ad2a3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMi0xLTEtMS0w_60bdbeaf-7563-4f3a-a280-e47f820b1a2b"
      unitRef="shares">87651352</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id1a551c230f14800abc2fa41ca7ad2a3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMi0zLTEtMS0w_f632e6cd-4546-4b45-8cbc-9da760050008"
      unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i889966d2ad0d48b1a39ab264208b8278_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMi01LTEtMS0w_dec40d7f-3b15-4fa4-a127-4527fb37ddb2"
      unitRef="usd">167379000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i77adf0b70cbf4775bddca74d6b334c92_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMi03LTEtMS0w_a6625123-8ee4-42d1-ae49-fc7e17d913da"
      unitRef="usd">-105965000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i501a27e325104650a73ad03cfcd4faa7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMi05LTEtMS0w_60a12930-25a9-42fd-9fef-8fa9969dc0fa"
      unitRef="usd">83000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMi0xMS0xLTEtMA_b26ded8f-9fc0-4289-b984-06d2b3c16d42"
      unitRef="usd">61506000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iae971ef694a140e68a703e4451c6c2e3_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMy0xLTEtMS0w_131ae5fe-538d-45ed-b06b-36763e73ef3e"
      unitRef="shares">342246</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i846826e778c54bd7b5bc352eb593aee3_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMy01LTEtMS0w_d6202b14-7c00-40bc-aa26-2ff85cfde273"
      unitRef="usd">546000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i3dea9cf71d074399a074543cd69ce8c7_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMy0xMS0xLTEtMA_31a0a164-4d77-41b9-b7d0-39d02ee8811d"
      unitRef="usd">546000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i846826e778c54bd7b5bc352eb593aee3_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfNC01LTEtMS0w_2e8df2bd-95de-4822-a379-155f691e9d2d"
      unitRef="usd">517000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3dea9cf71d074399a074543cd69ce8c7_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfNC0xMS0xLTEtMA_c3a5b543-90a9-4bea-8cce-f912a6b3934e"
      unitRef="usd">517000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i6201937a06d74f6d89fca534176e3345_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfNi05LTEtMS0w_1f034a06-1f06-4c4f-b42d-0635009a826c"
      unitRef="usd">-51000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i3dea9cf71d074399a074543cd69ce8c7_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfNi0xMS0xLTEtMA_e750e5c6-875e-42ef-92db-cede798271b8"
      unitRef="usd">-51000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i71bb35af2d12464b9a9e8594554ebb5f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfNy03LTEtMS0w_07142dd6-7758-433f-a37c-c5dc1d737c9e"
      unitRef="usd">-12477000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3dea9cf71d074399a074543cd69ce8c7_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfNy0xMS0xLTEtMA_5f78e920-3f64-4f82-af59-37d9976fd70e"
      unitRef="usd">-12477000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i4f6c6875545040a48cde06a5f5b74823_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfOC0xLTEtMS0w_b03eef8d-f837-466b-8402-a4a3f67bfdd3"
      unitRef="shares">87993598</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i4f6c6875545040a48cde06a5f5b74823_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfOC0zLTEtMS0w_8ea02c53-0c99-4dee-94b5-1bb72207efa7"
      unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4d560c291f0e4806b54ba5e47f9e4337_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfOC01LTEtMS0w_f1ca3ad3-2066-499c-96cb-c17e9747e738"
      unitRef="usd">168442000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib50af716c597410c87b2e6c906cd80f9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfOC03LTEtMS0w_7387af5b-2ffb-4b08-ab5d-e36123ba1512"
      unitRef="usd">-118442000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4a52bc4a3c0d4c7cbfa5ea8a045321fa_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfOC05LTEtMS0w_127bb66d-0af5-4a79-a1e6-362f9a5ca129"
      unitRef="usd">32000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie38be6e4d7ba4275b47ca89d4c64b7f9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfOC0xMS0xLTEtMA_1b1b840f-dca2-4bed-ae44-49b8b25d869d"
      unitRef="usd">50041000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0d4ca9f881df45978d9417d0ab7dc94e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfOS01LTEtMS0w_183aa400-1359-43bc-a4af-5723b48a3c4f"
      unitRef="usd">764000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iac6b52ac45d04a2588c506176895e21f_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfOS0xMS0xLTEtMA_82798ddf-b76b-4f2d-a1f6-b67203eabce3"
      unitRef="usd">764000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="icc50c37ab44c4df39214039f0d7b1151_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTAtMS0xLTEtMA_8b9ba55c-0deb-441f-82bf-57c9c4230a5c"
      unitRef="shares">103096</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i0d4ca9f881df45978d9417d0ab7dc94e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTAtNS0xLTEtMA_d14b81aa-00a2-46cd-a833-9c26ae7ec6e7"
      unitRef="usd">131000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="iac6b52ac45d04a2588c506176895e21f_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTAtMTEtMS0xLTA_6e672720-2141-4cd0-9b05-292c2b924715"
      unitRef="usd">131000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i2ec0151a0c3948b38923be5743f1344a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTEtOS0xLTEtMA_45268a20-3712-492d-9e8b-141c20e7a21c"
      unitRef="usd">-27000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="iac6b52ac45d04a2588c506176895e21f_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTEtMTEtMS0xLTA_a0be2eb2-8732-4488-b8ff-08fdec71e932"
      unitRef="usd">-27000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i62ce8e911e4846bd9009ddd7272195ab_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTItNy0xLTEtMA_d248dd72-128a-49ec-9fb9-e7e3f535781d"
      unitRef="usd">-14269000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iac6b52ac45d04a2588c506176895e21f_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTItMTEtMS0xLTA_f77ba16b-4cb3-4079-bfbb-f38b5a688c39"
      unitRef="usd">-14269000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i96f79fc5e863496fa7949c405ecc957f_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTMtMS0xLTEtMA_4c006952-b334-4bd8-8403-039a68c32593"
      unitRef="shares">88096694</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i96f79fc5e863496fa7949c405ecc957f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTMtMy0xLTEtMA_713fbaad-74d8-494c-bb14-1e5347c72595"
      unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id04667370fcb4287af7d78737a293eb4_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTMtNS0xLTEtMA_c9c52237-cf79-471b-9166-53d885e3da5d"
      unitRef="usd">169337000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id42a638fb6864f9d9e37c2babc3b3899_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTMtNy0xLTEtMA_cd36eee1-3bc2-4467-a47c-a8cc59193b0b"
      unitRef="usd">-132711000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i992a828696e04df48d18d2f8bc76598e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTMtOS0xLTEtMA_74f29b31-d221-4d0f-8ca9-55e99b083008"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idd96764703204097bea35e7a9db99a49_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTMtMTEtMS0xLTA_6cdb3d21-d96f-46d9-9210-fb535d56f87e"
      unitRef="usd">36640000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9dcdb6a39c9748148c55ed098113f458_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTQtNS0xLTEtMTA0NzQ_5013fdab-94aa-4265-9ad5-e75ac9e759bf"
      unitRef="usd">889000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTQtMTEtMS0xLTEwNDc0_8c76c530-0373-4d96-ab7a-61d2519845ed"
      unitRef="usd">889000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i17d0ab6befad44789b59d2b647f01e28_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTUtMS0xLTEtMTA0NzQ_6a71c532-3356-46bd-b5cc-851a8001bacb"
      unitRef="shares">11849</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i9dcdb6a39c9748148c55ed098113f458_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTUtNS0xLTEtMTA0NzQ_085ec888-a0c8-49bb-a1ab-900e65b38eeb"
      unitRef="usd">-9000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTUtMTEtMS0xLTEwNDc0_e4fbdb8e-80be-46f0-999f-dffd31a9fa1e"
      unitRef="usd">-9000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ie8045808dcb149df893c7a2d3e216476_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTYtOS0xLTEtMTA0NzQ_91350c24-2452-483d-8dd3-f4ba8a8a289f"
      unitRef="usd">-6000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTYtMTEtMS0xLTEwNDc0_92bba50a-1f3c-4d10-a333-97183d1998b3"
      unitRef="usd">-6000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i7b100964d44d428faaab570e10ff8900_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTctNy0xLTEtMTA0NzQ_957849b9-fc07-4ae5-ba92-b5ea6c16f889"
      unitRef="usd">-23531000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTctMTEtMS0xLTEwNDc0_f90f4659-a874-469d-bebc-dadb0f531575"
      unitRef="usd">-23531000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i978591bf15364b7ea2e8132edee5fb1c_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTgtMS0xLTEtMTA0NzQ_3e8cbc29-0cfa-41b5-a9af-c8bfa5d995bd"
      unitRef="shares">88108543</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i978591bf15364b7ea2e8132edee5fb1c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTgtMy0xLTEtMTA0NzQ_19c4e388-46bd-4e06-aff1-f738d2590939"
      unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6b8227feae1749778133a28312e507ba_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTgtNS0xLTEtMTA0NzQ_79a31b4a-fbd0-4063-b861-241ce6435740"
      unitRef="usd">170217000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i290713ee60b04dd08da1a92f4da5adfd_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTgtNy0xLTEtMTA0NzQ_8e7eec6f-76ff-427b-a575-7d501248e4d9"
      unitRef="usd">-156242000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idf9e5d3ecf814b9ab2f88960463e4dd8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTgtOS0xLTEtMTA0NzQ_65f84a4c-eb98-420f-bb9f-bd627cd04d99"
      unitRef="usd">-1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmY1YmEwOTBjZTkwMTRlZDJiNDkxZTVkMmIxYTE0OTk5L3RhYmxlcmFuZ2U6ZjViYTA5MGNlOTAxNGVkMmI0OTFlNWQyYjFhMTQ5OTlfMTgtMTEtMS0xLTEwNDc0_b4fc36be-e647-4d3c-a337-2348fa8d230a"
      unitRef="usd">13983000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ibbd40097533240cc82bcab253f741f47_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMi0xLTEtMS0w_822df976-0356-45cb-a8c6-195ac3a87495"
      unitRef="shares">86069263</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ibbd40097533240cc82bcab253f741f47_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMi0zLTEtMS0w_cd0d709c-6c94-4b1e-b183-7b58a56b4628"
      unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i719acf51485c46e1b4361db7fe272812_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMi01LTEtMS0w_4f2dad57-3526-467c-b88a-13ec23fc9ca6"
      unitRef="usd">162062000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6d9766a167f349bb92052a2b44a794db_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMi03LTEtMS0w_2a6e9a32-e2ed-41f1-bf9a-84bbf66732b5"
      unitRef="usd">-81297000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifca2e3b16c794fc4a70ed80eb0c74b8d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMi05LTEtMS0w_cd6b1cbe-2b9b-4454-8fed-3bb67d7136ab"
      unitRef="usd">-27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0c58992375514840acc525804de3b5bf_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMi0xMS0xLTEtMA_ba5d511a-99ac-484c-acb9-22f2389f7741"
      unitRef="usd">80747000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia27678044cb14d4281421247fb96281d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfNC01LTEtMS0w_a7cde918-596b-4eac-844f-36a31a4fa615"
      unitRef="usd">441000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iab3dbd6a7f674d7083db2fa3c9db78a2_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfNC0xMS0xLTEtMA_b4ac2b01-d626-4eff-bb6a-d89c405851a9"
      unitRef="usd">441000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i507ff9b7892843ad987a51c1c29c0a35_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfNS0xLTEtMS0w_70234307-2026-42f5-b3b1-8c036d2b1c63"
      unitRef="shares">1081184</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia27678044cb14d4281421247fb96281d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfNS01LTEtMS0w_be381322-2e36-4f53-9b76-b7f177b94055"
      unitRef="usd">2766000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iab3dbd6a7f674d7083db2fa3c9db78a2_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfNS0xMS0xLTEtMA_c1e00c5d-8bb7-446f-bd1f-9b22db34cd91"
      unitRef="usd">2766000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ic3e5273956124a8099431ab285dc59c1_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfNi05LTEtMS0w_185b3535-1b58-4c45-9e0e-fca7ec24d247"
      unitRef="usd">10000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="iab3dbd6a7f674d7083db2fa3c9db78a2_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfNi0xMS0xLTEtMA_7961d706-4e0a-4c46-89aa-1687669cf343"
      unitRef="usd">10000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="ie6257175c451430abb2778376da96411_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfNy03LTEtMS0w_64bb9891-47b1-41e7-a636-52324fdcabe8"
      unitRef="usd">1150000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iab3dbd6a7f674d7083db2fa3c9db78a2_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfNy0xMS0xLTEtMA_97893093-b8d6-4630-adad-c9b5022659e2"
      unitRef="usd">1150000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i6575d7f8daec4ae4abac4b2ef1bb98b4_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfOC0xLTEtMS0w_4cf77f72-bbb3-4e3c-8510-51762a62a66d"
      unitRef="shares">87150447</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i6575d7f8daec4ae4abac4b2ef1bb98b4_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfOC0zLTEtMS0w_f87d0734-be1b-4fe7-993c-e0fc0782040e"
      unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i602a59ce297c424b93795664859a8674_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfOC01LTEtMS0w_cdab5768-526e-45cb-a226-e9a031ba6d6f"
      unitRef="usd">165269000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id8b0e758c6064f6291d39bb97bb331c8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfOC03LTEtMS0w_5fd806ba-77a5-405d-8855-79b2fc00a481"
      unitRef="usd">-80147000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6a09fd187a41481abc00b2e5f81774d2_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfOC05LTEtMS0w_eabb8d19-5706-47bd-8650-7b4aeddee4b4"
      unitRef="usd">-17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i71026660fee448b3b596180fe34cbeca_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfOC0xMS0xLTEtMA_808211fa-297b-4122-8fc5-237303352861"
      unitRef="usd">85114000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iff8d18ca423a4767b541788b25f1e8bf_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfOS0xLTEtMS0w_bdeadb23-dd2d-4e83-9bae-004f1af364f7"
      unitRef="shares">55899</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic0372b5960b948f488c30f66137194f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfOS01LTEtMS0w_d3eb4460-73cb-4999-9813-64ddc52969b9"
      unitRef="usd">50000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i9b2c76fc1f31458f93f96af1cff6f08f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfOS0xMS0xLTEtMA_a8d72d93-7da2-498f-ad89-49816d2f5f9c"
      unitRef="usd">50000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic0372b5960b948f488c30f66137194f2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTAtNS0xLTEtMA_8787f108-9827-44be-aced-2a70480c65aa"
      unitRef="usd">544000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9b2c76fc1f31458f93f96af1cff6f08f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTAtMTEtMS0xLTA_c4626a82-20d3-4925-bafd-380e0ec1ba1b"
      unitRef="usd">544000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i47fe6eddfdbe4eed90628172bad98597_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTEtOS0xLTEtMA_5ea561c6-ee87-48c3-a12a-d28ac0c72db3"
      unitRef="usd">355000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i9b2c76fc1f31458f93f96af1cff6f08f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTEtMTEtMS0xLTA_53aa6f81-8a21-47e4-a328-5624e65f5939"
      unitRef="usd">355000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i3cb024c41379417ebfea69a16d594eb0_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTItNy0xLTEtMA_b52a18c6-0f09-4629-93c7-15aa1ce81195"
      unitRef="usd">-4311000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9b2c76fc1f31458f93f96af1cff6f08f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTItMTEtMS0xLTA_c241a4db-43d7-4d80-bbed-1a865ccd91f2"
      unitRef="usd">-4311000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i2055279aba744bfa86fba3a79756df14_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTMtMS0xLTEtMA_a244dbba-2e76-4c13-b403-b821ac383aa2"
      unitRef="shares">87206346</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i2055279aba744bfa86fba3a79756df14_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTMtMy0xLTEtMA_d2b4d335-63e7-4e96-8fd6-fce41eec967f"
      unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i38e64861bfb143a6a581ccee7a5ad430_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTMtNS0xLTEtMA_235c27c3-d8d0-4f09-aa23-92108521dbc0"
      unitRef="usd">165863000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6db610d7a4604665833e6884c7e4d50c_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTMtNy0xLTEtMA_e94094b8-8ec3-42e4-bff7-b2ed0b08f29b"
      unitRef="usd">-84458000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib9ef743ad4504fe6a4762417ee298525_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTMtOS0xLTEtMA_f9657b8a-1cbe-4901-9c26-face9e5d34b5"
      unitRef="usd">338000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9f68996929254ee4bbba614e977012de_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTMtMTEtMS0xLTA_1ecfc9d4-9fdf-4f09-9c61-fa8fa43ab945"
      unitRef="usd">81752000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTQtMS0xLTEtMTA1MDU_1c128f88-9334-45b5-86c5-54f72c228c0c"
      unitRef="shares">22240</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTQtNS0xLTEtMTA1MDU_a98dc989-6746-4ccf-9ec0-473e2b1c0b49"
      unitRef="usd">19000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTQtMTEtMS0xLTEwNTA1_7b089b93-01ec-4d23-ba49-d6ba48d00a96"
      unitRef="usd">19000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2d81767196a447c99e736999c49bbd94_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTUtNS0xLTEtMTA1MDU_149c6ca4-ea8a-41ba-9835-f05606c13ba8"
      unitRef="usd">617000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTUtMTEtMS0xLTEwNTA1_8fb12e14-4d50-45d8-b673-43a49f552c58"
      unitRef="usd">617000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i2d81767196a447c99e736999c49bbd94_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTYtNS0xLTEtMTA1MDU_461c2944-06c6-49a1-94d5-78cb59dd7509"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="if22d9a712dc144118a697b351d62e799_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTYtOS0xLTEtMTA1MDU_de55a011-8adb-42cd-8cfd-b6b638a43950"
      unitRef="usd">-138000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTYtMTEtMS0xLTEwNTA1_6b727e6f-994f-4af1-9a70-79eb0a0ac352"
      unitRef="usd">-138000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i42d47dd822a748b791c92e60630a2428_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTctNy0xLTEtMTA1MDU_6d0bc9f9-72a4-416d-a4ff-df75636f9f27"
      unitRef="usd">-8822000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTctMTEtMS0xLTEwNTA1_91640eb5-1806-4029-b3ed-7c9b65d1fc75"
      unitRef="usd">-8822000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i66eacee5840b45e29eab0ce41b30f033_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTgtMS0xLTEtMTA1MDU_c7a54f9a-d1c7-421c-ace7-4711aca72d10"
      unitRef="shares">87228586</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i66eacee5840b45e29eab0ce41b30f033_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTgtMy0xLTEtMTA1MDU_a43543ef-754f-4f1b-8473-984010ecae7d"
      unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7e35705736534c78843742303282feb9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTgtNS0xLTEtMTA1MDU_33de88c9-46a0-4e11-b7c6-931735bf54d0"
      unitRef="usd">166499000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i447f37e612cc480fb09d01d85dfe8a92_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTgtNy0xLTEtMTA1MDU_cae8b3ad-3ded-4a52-8522-a311477c8a13"
      unitRef="usd">-93280000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibe0cf5fbf4e1438fb46d794ecd6487cc_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTgtOS0xLTEtMTA1MDU_fd0061af-b14f-448b-b2ae-61edfe439f47"
      unitRef="usd">200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if042bb6dd7e349bab540c21e2b62d94c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8yOC9mcmFnOmU3MzdmY2Q5NWEzZjRhMGFiMDIxZDNkYWZlNGI3OWJlL3RhYmxlOmYzNzhkYTgwYWJkNTQxNDZhNmRmYmI5MDdmMjAxNjhmL3RhYmxlcmFuZ2U6ZjM3OGRhODBhYmQ1NDE0NmE2ZGZiYjkwN2YyMDE2OGZfMTgtMTEtMS0xLTEwNTA1_b27a1970-1016-4f18-aa6e-973ee5b541f3"
      unitRef="usd">73428000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMy0xLTEtMS0w_29efdca3-8ca1-437a-b76f-ef59a29c0a41"
      unitRef="usd">-50277000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMy0zLTEtMS0w_bad12a7d-cc7e-49e9-a24c-38106096130c"
      unitRef="usd">-11983000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAmortizationAndAccretionNet
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfNS0xLTEtMS0w_74b165e7-e88d-48cf-b695-964994a440db"
      unitRef="usd">829000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:DepreciationAmortizationAndAccretionNet
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfNS0zLTEtMS0w_af752ece-ff4a-4158-a862-714ebb7777d8"
      unitRef="usd">494000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfNy0xLTEtMS0w_1fe41068-84be-456b-8aae-f425b34aae2d"
      unitRef="usd">489000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfNy0zLTEtMS0w_354abf72-b551-48a1-a08a-6a13ea2ac945"
      unitRef="usd">518000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfOC0xLTEtMS0w_485826bb-d5ed-44f3-9679-78afb88695ab"
      unitRef="usd">2170000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfOC0zLTEtMS0w_fbc1a144-207f-4295-8e54-5a24aabf576f"
      unitRef="usd">1603000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfOS0xLTEtMS0w_3d4ef5dd-eab1-4525-8fb3-fb176870d3aa"
      unitRef="usd">213000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfOS0zLTEtMS0w_de47e157-6473-4ac5-84a3-da885e0b0742"
      unitRef="usd">39000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMTAtMS0xLTEtMA_0e552c42-527b-49f2-8027-231b37eedd80"
      unitRef="usd">-183000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMTAtMy0xLTEtMA_8ea50365-17ab-4ad3-b15d-def6ba545a8c"
      unitRef="usd">-202000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMTEtMS0xLTEtMA_8515e02c-842d-49ef-9daa-84dbdc240e25"
      unitRef="usd">6000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMTEtMy0xLTEtMA_4673c247-a411-4280-b3da-0a9be331dc99"
      unitRef="usd">67000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMTItMS0xLTEtMA_340bafa8-8b94-481a-9582-e1939ce9b088"
      unitRef="usd">-15000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMTItMy0xLTEtMA_b00e7984-1314-4507-bfca-b639a01467c1"
      unitRef="usd">-343000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMTQtMS0xLTEtMA_0e13bc15-9b27-4403-8019-756070499a72"
      unitRef="usd">-11000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMTQtMy0xLTEtMA_9a9e0c6b-e3b8-43a7-ba37-98a4b1a1c80c"
      unitRef="usd">10000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMTUtMS0xLTEtMA_6d0900c0-e5bb-4bd9-ae56-aa07e03dae32"
      unitRef="usd">-922000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMTUtMy0xLTEtMA_9ba10e78-6e14-4e96-9b4a-3bfe6c71f358"
      unitRef="usd">1473000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMTYtMS0xLTEtMA_e73dd416-79bb-4266-b08d-62b27284057f"
      unitRef="usd">72000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMTYtMy0xLTEtMA_44069ba3-bdf2-411d-9069-69d406f43177"
      unitRef="usd">181000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMTctMS0xLTEtMA_9c6776c8-0182-42d1-9f33-1c0e697b6bc3"
      unitRef="usd">629000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMTctMy0xLTEtMA_c646ec1f-d64f-4851-8bd3-9c733ea60070"
      unitRef="usd">535000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMTgtMS0xLTEtMA_beb0d84b-2b76-430d-bf3d-5c9b244cd419"
      unitRef="usd">1697000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMTgtMy0xLTEtMA_61732338-ec32-4942-aad7-8cc494daaffc"
      unitRef="usd">-461000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMTktMS0xLTEtMA_1b5b6424-0ce2-4c0e-9454-8a60cbf42a61"
      unitRef="usd">22601000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMTktMy0xLTEtMA_89b43888-5dee-4df1-a21d-f10732d8d7c1"
      unitRef="usd">-16351000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMjAtMS0xLTEtMA_a8380185-03e7-4076-9f4a-22963c20f9db"
      unitRef="usd">-408000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMjAtMy0xLTEtMA_b11201ee-dbfd-416f-9d2c-c190ed11c6bd"
      unitRef="usd">-119000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMjEtMS0xLTEtMA_7ef3df82-3f37-4fa5-8fc6-b3cc5e1a1fc6"
      unitRef="usd">-21022000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMjEtMy0xLTEtMA_71a18c57-0679-45ae-9d63-6da8441f9b18"
      unitRef="usd">-27463000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMjMtMS0xLTEtMA_0bfe98b4-e162-4fb6-973f-a3c44745d1c4"
      unitRef="usd">6497000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMjMtMy0xLTEtMA_58ad5975-7657-4d79-84b6-9a9a884bbb4b"
      unitRef="usd">47349000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMjQtMS0xLTEtMA_fa8068fd-58e4-4748-b123-7836490735cb"
      unitRef="usd">46097000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMjQtMy0xLTEtMA_343dd0a3-5abf-4a8e-a21c-656102b4b55b"
      unitRef="usd">47093000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMjUtMS0xLTEtMA_6e556446-724c-4b86-921e-0ac2de1330e8"
      unitRef="usd">623000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMjUtMy0xLTEtMA_b047a4d0-315c-4792-aa59-5dd8c150ac71"
      unitRef="usd">3074000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMjYtMS0xLTEtMA_2b8208fb-e7bd-44b5-8028-39ac16e04d22"
      unitRef="usd">38977000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMjYtMy0xLTEtMA_dc800c10-8375-4806-8b7d-aad77abaa677"
      unitRef="usd">-3330000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMjgtMS0xLTEtMA_4710042b-3a1e-442e-ac42-f7be8d52e4cf"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMjgtMy0xLTEtMA_eb27973b-5c07-4eb5-9e46-58b05cb9d9ab"
      unitRef="usd">2973000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <xcur:PaymentsOfCommonStockFinancingCosts
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMjktMS0xLTEtMA_7e47aab6-8d4c-405a-81f2-c58a3edc818b"
      unitRef="usd">0</xcur:PaymentsOfCommonStockFinancingCosts>
    <xcur:PaymentsOfCommonStockFinancingCosts
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMjktMy0xLTEtMA_9b8f46d0-6932-4f31-9946-b41e91354947"
      unitRef="usd">207000</xcur:PaymentsOfCommonStockFinancingCosts>
    <xcur:PaymentsOfCommonStockFinancingCosts
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMjktMy0xLTEtMA_abf82239-d1b1-426d-abc1-a6a2255d858c"
      unitRef="usd">207000</xcur:PaymentsOfCommonStockFinancingCosts>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMzAtMS0xLTEtMA_e415c62c-16a4-43b9-a89f-2ed2c9a98be4"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMzAtMy0xLTEtMA_154dbc42-51d9-4985-9a66-7997ac9af136"
      unitRef="usd">17500000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMzEtMS0xLTEtMA_24de3a86-0c55-487c-8ca6-a997602e0db5"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMzEtMy0xLTEtMA_072fe2d8-fb95-4516-8d9a-40cb81e9f72a"
      unitRef="usd">344000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMzItMS0xLTEtMA_09d41ca7-dcf0-47dd-84d0-be143eca8d7f"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMzItMy0xLTEtMA_08d4888f-ceb0-4fa5-9ccc-3315cf44a15a"
      unitRef="usd">4999000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMzMtMS0xLTEtMA_882637b5-6fb4-4598-af54-9c7c08aa5220"
      unitRef="usd">131000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMzMtMy0xLTEtMA_ea8030b1-8ffd-471a-ad81-8e42b45dc3db"
      unitRef="usd">0</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMzQtMS0xLTEtMA_99f9b0fe-f882-438f-9b93-4cbe824cf776"
      unitRef="usd">546000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMzQtMy0xLTEtMA_4aa08a47-6e79-4d85-994a-dcef9291243f"
      unitRef="usd">69000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMzUtMS0xLTEtMTA2NDM_e4d19822-d8db-4548-ba81-f32de156958c"
      unitRef="usd">9000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMzUtMy0xLTEtMTA2NDM_f11bdeb8-f6bb-41fe-9c3e-bdd30d244fc9"
      unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMzUtMS0xLTEtMA_8720dd48-e72f-43b1-ba45-009164c31626"
      unitRef="usd">668000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMzUtMy0xLTEtMA_16b61e36-3a9f-41b4-9da2-142ae7366587"
      unitRef="usd">14992000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMzctMS0xLTEtMA_4a883595-9492-438c-96b5-c6ef37c7d3f9"
      unitRef="usd">18623000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMzctMy0xLTEtMA_0765c192-6062-4400-a61f-2bc13e3238fd"
      unitRef="usd">-15801000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMzgtMS0xLTEtMA_584831ac-8b09-4c7e-a6f4-6663c53c6cf8"
      unitRef="usd">34462000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0c58992375514840acc525804de3b5bf_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMzgtMy0xLTEtMA_c394b1d3-714c-4e3f-b125-7cbee4559f6b"
      unitRef="usd">48460000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMzktMS0xLTEtMA_d101447d-64f0-4426-bde6-bd7c3c315bff"
      unitRef="usd">53085000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if042bb6dd7e349bab540c21e2b62d94c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjUxY2M3NTVkNWQwZjQyZDg5MGYxYmNkZmE4YTE5ZGQyL3RhYmxlcmFuZ2U6NTFjYzc1NWQ1ZDBmNDJkODkwZjFiY2RmYThhMTlkZDJfMzktMy0xLTEtMA_c0cf7d4d-0709-4e74-aa3d-901bb80a30f4"
      unitRef="usd">32659000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjNjYzQ1NDRmZTZiOTRkZDRiZjdlOTliMmU4NDljYWEwL3RhYmxlcmFuZ2U6M2NjNDU0NGZlNmI5NGRkNGJmN2U5OWIyZTg0OWNhYTBfNC0xLTEtMS0w_e95db05f-8c97-4a6a-bbaa-8cee16c3d7ab"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjNjYzQ1NDRmZTZiOTRkZDRiZjdlOTliMmU4NDljYWEwL3RhYmxlcmFuZ2U6M2NjNDU0NGZlNmI5NGRkNGJmN2U5OWIyZTg0OWNhYTBfNC0zLTEtMS0w_e77b063b-3120-4e90-997e-0634886ecf25"
      unitRef="usd">8147000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjNjYzQ1NDRmZTZiOTRkZDRiZjdlOTliMmU4NDljYWEwL3RhYmxlcmFuZ2U6M2NjNDU0NGZlNmI5NGRkNGJmN2U5OWIyZTg0OWNhYTBfNi0xLTEtMS0w_664b707c-cb6a-4d4e-964e-ef374bb7ab73"
      unitRef="usd">303000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjNjYzQ1NDRmZTZiOTRkZDRiZjdlOTliMmU4NDljYWEwL3RhYmxlcmFuZ2U6M2NjNDU0NGZlNmI5NGRkNGJmN2U5OWIyZTg0OWNhYTBfNi0zLTEtMS0w_56075a42-a1fc-46db-85db-ef25eda83e0b"
      unitRef="usd">13000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjNjYzQ1NDRmZTZiOTRkZDRiZjdlOTliMmU4NDljYWEwL3RhYmxlcmFuZ2U6M2NjNDU0NGZlNmI5NGRkNGJmN2U5OWIyZTg0OWNhYTBfOC0xLTEtMS0w_48f77469-7100-4b38-8118-38be7cc07487"
      unitRef="usd">0</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjNjYzQ1NDRmZTZiOTRkZDRiZjdlOTliMmU4NDljYWEwL3RhYmxlcmFuZ2U6M2NjNDU0NGZlNmI5NGRkNGJmN2U5OWIyZTg0OWNhYTBfOC0zLTEtMS0w_64179959-5b8f-4396-a083-ca58e616fa16"
      unitRef="usd">834000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjNjNWRjNTE4MTk1MDQyNzU5YmQxYzc3OTU1OGZiZjc4L3RhYmxlcmFuZ2U6M2M1ZGM1MTgxOTUwNDI3NTliZDFjNzc5NTU4ZmJmNzhfMS0xLTEtMS0w_c473202f-01c0-44f6-bd94-c8f16d27e930"
      unitRef="usd">51885000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjNjNWRjNTE4MTk1MDQyNzU5YmQxYzc3OTU1OGZiZjc4L3RhYmxlcmFuZ2U6M2M1ZGM1MTgxOTUwNDI3NTliZDFjNzc5NTU4ZmJmNzhfMS0zLTEtMS0w_ef5ead5f-667f-4826-a42c-2278447cfc67"
      unitRef="usd">33262000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjNjNWRjNTE4MTk1MDQyNzU5YmQxYzc3OTU1OGZiZjc4L3RhYmxlcmFuZ2U6M2M1ZGM1MTgxOTUwNDI3NTliZDFjNzc5NTU4ZmJmNzhfMi0xLTEtMS0w_0ccea7ef-7385-420b-9d22-181bb86822a4"
      unitRef="usd">1200000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjNjNWRjNTE4MTk1MDQyNzU5YmQxYzc3OTU1OGZiZjc4L3RhYmxlcmFuZ2U6M2M1ZGM1MTgxOTUwNDI3NTliZDFjNzc5NTU4ZmJmNzhfMi0zLTEtMS0w_e59ac78d-fd49-4dcc-af0a-71d38678f7da"
      unitRef="usd">1200000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjNjNWRjNTE4MTk1MDQyNzU5YmQxYzc3OTU1OGZiZjc4L3RhYmxlcmFuZ2U6M2M1ZGM1MTgxOTUwNDI3NTliZDFjNzc5NTU4ZmJmNzhfMy0xLTEtMS0w_cd6fc5a2-3bd0-485c-884d-334dec33503f"
      unitRef="usd">53085000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zMS9mcmFnOjY4ZTQyY2ZiNGNjNTQzZjg4ZjVmYzViYTA1NTE4OTVjL3RhYmxlOjNjNWRjNTE4MTk1MDQyNzU5YmQxYzc3OTU1OGZiZjc4L3RhYmxlcmFuZ2U6M2M1ZGM1MTgxOTUwNDI3NTliZDFjNzc5NTU4ZmJmNzhfMy0zLTEtMS0w_60304fe8-2a4d-4ec8-8984-abb8e1a09a96"
      unitRef="usd">34462000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zNy9mcmFnOmY5ZjRkZjg2YTk3NzRhZjM5NmYwYjEzOTAzN2M0NTE4L3RleHRyZWdpb246ZjlmNGRmODZhOTc3NGFmMzk2ZjBiMTM5MDM3YzQ1MThfMTE5MTE_30088a48-d707-408e-9c40-5e6fc83dc58c">Description of Business and Basis of Presentation&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exicure, Inc. (the &#x201c;Company&#x201d;) is a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases, and other genetic disorders based on its proprietary Spherical Nucleic Acid, or SNA&#x2122;, technology. The Company believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. The Company is in preclinical development of XCUR-FXN, a lipid-nanoparticle SNA-based therapeutic candidate, for the intrathecal treatment of Friedreich&#x2019;s ataxia (&#x201c;FA&#x201d;).  The Company&#x2019;s therapeutic candidate cavrotolimod (AST-008) is in a Phase 1b/2 clinical trial in patients with advanced solid tumors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes one of the key strengths of its proprietary SNAs is that they have the potential for increased cellular uptake compared to conventional linear oligonucleotides and as a result the potential to achieve higher efficacy at the same doses of oligonucleotide administered. The Company has shown in clinical and preclinical studies that SNAs may have therapeutic potential in immuno-oncology and dermatology.  In addition, the Company has shown in preclinical studies that SNAs may have therapeutic potential in neurology, ophthalmology, pulmonology, and gastroenterology. Accordingly, the Company has expanded its pipeline into neurology, for which investigational new drug application (&#x201c;IND&#x201d;)-enabling activities are ongoing for XCUR-FXN, and is concluding early stage research activities in ophthalmology, pulmonology, and gastroenterology. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Throughout these unaudited condensed consolidated financial statements, the terms the &#x201c;Company,&#x201d;  &#x201c;Exicure,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; and &#x201c;our&#x201d; refer to Exicure, Inc. and where appropriate, its wholly owned subsidiary, Exicure Operating Company.  Exicure Operating Company holds all material assets and conducts all business activities and operations of Exicure, Inc.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements as of September&#160;30, 2021 and December 31, 2020, and for the nine months ended September&#160;30, 2021 and 2020, have been presented in conformity with generally accepted accounting principles in the United States (&#x201c;GAAP&#x201d;).  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements include the accounts of Exicure and its wholly owned subsidiary, Exicure Operating Company. All intercompany transactions and accounts are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Research and License Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, revenue recognized under the AbbVie Collaboration Agreement (as defined in Note 3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Research and License Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) for the three and nine months ended September 30, 2021 reflects the cumulative catchup adjustment (reduction) of revenue of $(4,480) recorded in connection with a change in estimate that occurred during the third quarter of 2021.  The Company currently estimates significant additional efforts will be required to satisfy the performance obligation under the AbbVie Collaboration Agreement.  These increased estimated efforts in connection with the change in workplan resulted in less progress occurring relative to the increased estimate of total project hours to complete the research services during the three and nine months ended September 30, 2021 as compared to the amount of revenue recognized at both June 30, 2021 and December 31, 2020, which led to revenue reversals in each respective period.  Due to uncertainties inherent in the estimation process, it is at least reasonably possible that estimated efforts required to complete the research services under the AbbVie Collaboration Agreement will be further revised in the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;near-term which may result in additional adjustments (reductions of revenue) in future periods.  As discussed in Note 2, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Significant Accounting Policies &#x2014; Revenue Recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, determining the estimate of total project hours used to recognize revenue for our collaboration agreements requires significant judgment and any changes to those estimates may have a significant impact on the amount and timing of revenue recognition for the Ipsen Collaboration Agreement or the AbbVie Collaboration Agreement (each, as defined in Note 3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Research and License Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;COVID-19 Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In response to the ongoing COVID-19 pandemic, the Company has taken and continues to take active measures designed to address and mitigate the impact of the COVID-19 pandemic on its business, such as remote working policies, facilitating management&#x2019;s routine communication to address employee and business concerns and providing frequent updates to the Company&#x2019;s board of directors (the &#x201c;Board&#x201d;).  During the third quarter of 2021 and through the date of this report, the Company continues to operate under COVID-19 social distancing guidelines and has generally operated with approximately 100% of its R&amp;amp;D staff on-site.  The Company&#x2019;s office and general and administrative team is also working on-site approximately 50% of the time. The Company&#x2019;s preclinical development program in Friedreich&#x2019;s ataxia (&#x201c;FA&#x201d;) is ongoing and it began IND-enabling studies for XCUR-FXN in late 2020.  The Company also continues research and development activities with its collaboration partners, Ipsen Biopharm Limited (&#x201c;Ipsen&#x201d;) and AbbVie Inc. (&#x201c;AbbVie&#x201d;).  However, if the COVID-19 pandemic continues to persist for an extended period of time, the Company could experience further significant disruptions to its clinical and preclinical development timelines, which would adversely affect its business, financial condition, results of operations and growth prospects.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that the effects of the COVID-19 pandemic or its impact contributed to delays that began during the third quarter of 2020 and continued into the second half of 2021 in its enrollment plans and clinical trial site start-ups for the Phase 2 dose expansion phase of the Phase 1b/2 clinical trial for its cavrotolimod (AST-008) clinical program.  As a result of these delays, pending further delays or any additional unanticipated effects of the COVID-19 pandemic on its clinical development plans, the Company now expects to report overall response rate (&#x201c;ORR&#x201d;) results of cavrotolimod (AST-008) in the second half of 2022 as opposed to the previously reported first half of 2022. In the third quarter of 2020, the Company implemented, and continues to employ, additional measures to increase the enrollment of patients, including frequent interaction with its clinical trial sites currently open as well as increasing the number of clinical trial sites that potentially are activated for this trial so that the Company may continue to enroll patients as initially planned.  However, any additional delays may require the Company to further lengthen its clinical development timeline for cavrotolimod (AST-008).  The extent to which the COVID-19 pandemic or its impact or effects may continue to impact the Company&#x2019;s business, its clinical development and regulatory efforts, its corporate development objectives and the value of and market for its common stock will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration or spread of the COVID-19 pandemic, its impact and effects, the possibility of additional periods of increases or spikes in the number of COVID-19 cases, the introduction and spread of new variants of the virus, travel restrictions, quarantines, social distancing, phased re-openings and business closure requirements in the United States and other countries, and the effectiveness of actions taken globally to contain and treat the disease including, without limitation, the effectiveness and timing of vaccination initiatives in the United States and worldwide.  The global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the COVID-19 pandemic could have a material adverse effect on the Company&#x2019;s business, financial condition, results of operations and growth prospects. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company is subject to other challenges and risks specific to its business and its ability to execute on its business plan and strategy, as well as risks and uncertainties common to companies in the biotechnology industry with research and development operations, including, without limitation, risks and uncertainties associated with: obtaining regulatory approval of its product candidates; delays or problems in obtaining clinical supply, loss of single source suppliers or failure to comply with manufacturing regulations; identifying, acquiring or in-licensing additional products or product candidates; product development and the &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;inherent uncertainty of clinical success; and the challenges of protecting and enhancing its intellectual property rights; and the challenges of complying with applicable regulatory requirements.  In addition, to the extent the ongoing COVID-19 pandemic adversely affects the Company&#x2019;s business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Going Concern&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At each reporting period, the Company evaluates whether there are conditions or events that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued. The Company is required to make certain additional disclosures if it concludes substantial doubt exists and it is not alleviated by the Company&#x2019;s plans or when its plans alleviate substantial doubt about the Company&#x2019;s ability to continue as a going concern.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, the Company has generated an accumulated deficit of $175,079 since inception and expects to incur significant expenses and negative cash flows for the foreseeable future. Based on the Company&#x2019;s current operating plans and existing working capital at September 30, 2021, it is uncertain whether our current liquidity is sufficient to fund operations over the next twelve months from the date of the issuance of these condensed consolidated financial statements.  As a result, there is substantial doubt about our ability to continue as a going concern. The Company has no committed sources of additional capital at this time and substantial additional financing will be needed by the Company to fund its operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management believes that it will be able to obtain additional funding through equity or debt financings, collaboration agreements, strategic partnerships and licensing arrangements, or other arrangements, such as its &#x201c;at the market offering&#x201d; program pursuant to its equity distribution agreement with BMO Capital Markets Corp., to fund its current operations and business strategy. However, there can be no assurance that such additional financing will be available and, if available, can be obtained on terms acceptable to the Company.  If the Company is unable to obtain such additional financing, the Company could be forced to delay, reduce or eliminate its research and development programs or clinical efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations.  The Company has historically principally raised capital through the public offerings of its securities.  However, the COVID-19 pandemic continues to rapidly evolve and has already resulted in a significant disruption of global financial markets.  If the disruption continues to persist and deepens, the Company could experience an inability to access additional capital, which could negatively affect its ability to raise capital and ultimately, its operations, liquidity and ability to continue as a going concern. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated interim financial statements have been prepared as though the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Interim Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim condensed consolidated balance sheet as of September&#160;30, 2021, the interim condensed consolidated statements of operations for the three and nine months ended September&#160;30, 2021 and 2020, the interim condensed consolidated statements of comprehensive (loss) income for the three and nine months ended September&#160;30, 2021 and 2020, the interim condensed consolidated statements of changes in stockholders&#x2019; equity for the three and nine months ended September&#160;30, 2021 and 2020, and the interim condensed consolidated statements of cash flows for the nine months ended September&#160;30, 2021 and 2020, are unaudited. The interim unaudited condensed consolidated financial statements have been prepared on the same basis as the annual audited financial statements; and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company&#x2019;s financial position as of September&#160;30, 2021, the results of its operations for the three and nine months ended September&#160;30, 2021 and 2020, and the results of its cash flows for the nine months ended September&#160;30, 2021 and 2020. The financial data and other information disclosed in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;these notes related to the three and nine months ended September&#160;30, 2021 and 2020 are unaudited. The results for the three and nine months ended September&#160;30, 2021 are not necessarily indicative of results to be expected for the year ending December&#160;31, 2021, or any other interim periods, or any future year or period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Management bases its estimates on certain assumptions which it believes are reasonable in the circumstances and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company&#x2019;s financial position, results of operations or cash flows. Actual results in future periods could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zNy9mcmFnOmY5ZjRkZjg2YTk3NzRhZjM5NmYwYjEzOTAzN2M0NTE4L3RleHRyZWdpb246ZjlmNGRmODZhOTc3NGFmMzk2ZjBiMTM5MDM3YzQ1MThfMTE5MDY_ad55f6bb-2c28-4c5a-ac83-0fda78025d80">Basis of PresentationThe accompanying unaudited condensed consolidated financial statements as of September&#160;30, 2021 and December 31, 2020, and for the nine months ended September&#160;30, 2021 and 2020, have been presented in conformity with generally accepted accounting principles in the United States (&#x201c;GAAP&#x201d;).</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zNy9mcmFnOmY5ZjRkZjg2YTk3NzRhZjM5NmYwYjEzOTAzN2M0NTE4L3RleHRyZWdpb246ZjlmNGRmODZhOTc3NGFmMzk2ZjBiMTM5MDM3YzQ1MThfMTE5MTQ_dfb4b031-3c4f-4bf3-846b-cfff162b760a">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements include the accounts of Exicure and its wholly owned subsidiary, Exicure Operating Company. All intercompany transactions and accounts are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <xcur:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate
      contextRef="i5ead1c261b0940cab128efb701608748_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zNy9mcmFnOmY5ZjRkZjg2YTk3NzRhZjM5NmYwYjEzOTAzN2M0NTE4L3RleHRyZWdpb246ZjlmNGRmODZhOTc3NGFmMzk2ZjBiMTM5MDM3YzQ1MThfMTA5OTUxMTY0NDIyMg_a26a21e1-cfad-4c18-9a0d-eb5eae3797d5"
      unitRef="usd">-4480000</xcur:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate>
    <xcur:ResearchAndDevelopmentStaffOnSitePercentage
      contextRef="ic4e83e9c6d3f41cba0167701375d65af_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zNy9mcmFnOmY5ZjRkZjg2YTk3NzRhZjM5NmYwYjEzOTAzN2M0NTE4L3RleHRyZWdpb246ZjlmNGRmODZhOTc3NGFmMzk2ZjBiMTM5MDM3YzQ1MThfNDE2Mg_9cc03bbc-4713-4194-99ca-e6505591173b"
      unitRef="number">1</xcur:ResearchAndDevelopmentStaffOnSitePercentage>
    <xcur:OfficeAndGeneralAndAdministrativeStaffOnSitePercentage
      contextRef="ic4e83e9c6d3f41cba0167701375d65af_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zNy9mcmFnOmY5ZjRkZjg2YTk3NzRhZjM5NmYwYjEzOTAzN2M0NTE4L3RleHRyZWdpb246ZjlmNGRmODZhOTc3NGFmMzk2ZjBiMTM5MDM3YzQ1MThfNDI4Nw_632a0616-f671-4e99-af08-5800073cd20c"
      unitRef="number">0.50</xcur:OfficeAndGeneralAndAdministrativeStaffOnSitePercentage>
    <xcur:RetainedEarningsAccumulatedDeficitInceptiontoDate
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zNy9mcmFnOmY5ZjRkZjg2YTk3NzRhZjM5NmYwYjEzOTAzN2M0NTE4L3RleHRyZWdpb246ZjlmNGRmODZhOTc3NGFmMzk2ZjBiMTM5MDM3YzQ1MThfODE5MQ_dcf42449-3533-46e6-bfe1-e4417d9c17b5"
      unitRef="usd">-175079000</xcur:RetainedEarningsAccumulatedDeficitInceptiontoDate>
    <us-gaap:UseOfEstimates
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV8zNy9mcmFnOmY5ZjRkZjg2YTk3NzRhZjM5NmYwYjEzOTAzN2M0NTE4L3RleHRyZWdpb246ZjlmNGRmODZhOTc3NGFmMzk2ZjBiMTM5MDM3YzQ1MThfMTE5MDg_bb73cc36-daf9-4bc8-88fd-d1aa6a418e24">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Management bases its estimates on certain assumptions which it believes are reasonable in the circumstances and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company&#x2019;s financial position, results of operations or cash flows. Actual results in future periods could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80MC9mcmFnOjdjMzQxMzgzYWVmZjQ5M2NiNzI0NTNhMDMzOTM4ZmY1L3RleHRyZWdpb246N2MzNDEzODNhZWZmNDkzY2I3MjQ1M2EwMzM5MzhmZjVfMTk3Ng_5e772a4d-d4a4-414a-a193-220907729582">Significant Accounting Policies&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s significant accounting policies are disclosed in the audited consolidated financial statements and the notes thereto, which are included in the in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2020 filed with the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March 11, 2021. Since the date of those audited consolidated financial statements, there have been no material changes to the Company&#x2019;s significant accounting policies, except as noted below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2018, we adopted the provisions of Accounting Standards Codification, or ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; using the modified retrospective method for all contracts not completed as of the date of adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC 606, we recognize revenue when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC 606, we perform the following five steps:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Identify the contract with the customer.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party&#x2019;s rights and obligations regarding the goods or services to be transferred and identifies the related payment terms, (ii) the contract has commercial substance, and (iii) we determine that collection of substantially all consideration for goods and services that are transferred is probable based on the customer&#x2019;s intent and ability to pay the promised consideration. We apply judgment in determining the customer&#x2019;s intent and ability to pay, which is based on a variety of factors including the customer&#x2019;s historical payment experience, or in the case of a new customer, published credit and financial information pertaining to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Identify the performance obligations in the contract.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  Performance obligations promised in a contract are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the good or service either on its own or together with other available resources, and are distinct in the context of the contract, whereby the transfer of the good or service is separately identifiable from other promises in the contract. To the extent a contract includes multiple promised goods and services, we must apply judgment to determine whether promised goods and services are both capable of being distinct and distinct in the context of the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Determine the transaction price.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  The transaction price is determined based on the consideration to which we will be entitled in exchange for transferring goods and services to the customer. To the extent the transaction price includes variable consideration, we estimate the amount of variable consideration that &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;should be included in the transaction price utilizing either the expected value method or the most likely amount method, depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in our judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Any estimates, including the effect of the constraint on variable consideration, are evaluated at each reporting period for any changes. Determining the transaction price requires significant judgment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Allocate the transaction price to performance obligations in the contract.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. However, if a series of distinct services that are substantially the same qualifies as a single performance obligation in a contract with variable consideration, we must determine if the variable consideration is attributable to the entire contract or to a specific part of the contract. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative standalone selling price basis unless the transaction price is variable and meets the criteria to be allocated entirely to a performance obligation or to a distinct service that forms part of a single performance obligation. The consideration to be received is allocated among the separate performance obligations based on relative standalone selling prices. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Recognize revenue when or as the Company satisfies a performance obligation.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We satisfy performance obligations either over time or at a point in time. Revenue is recognized over time if either (i) the customer simultaneously receives and consumes the benefits provided by the entity&#x2019;s performance, (ii) the entity&#x2019;s performance creates or enhances an asset that the customer controls as the asset is created or enhanced, or (iii) the entity&#x2019;s performance does not create an asset with an alternative use to the entity and the entity has an enforceable right to payment for performance completed to date. If the entity does not satisfy a performance obligation over time, the related performance obligation is satisfied at a point in time by transferring the control of a promised good or service to a customer. Examples of control are using the asset to produce goods or services, enhance the value of other assets, or settle liabilities, and holding or selling the asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue allocated to performance obligations relating to provision of research and development activities is recognized as the performance obligations are satisfied using an input method to measure progress, based on an estimate of the percentage of completion of the project based on the actual hours incurred on the project as a percentage of the total expected project hours. The determination of the percentage of completion requires management to estimate the total expected project hours. A detailed estimate of the total expected project hours is re-assessed every reporting period based on the latest project plan and discussions with project teams. If a change in facts or circumstances occurs, the estimate will be adjusted and the revenue will be recognized based on the revised estimate. The difference between the cumulative revenue recognized based on the previous estimate and the revenue recognized based on the revised estimate would be recognized as an adjustment to revenue in the period in which the change in estimate occurs. Determining the estimate of total project hours requires significant judgment and may have a significant impact on the amount and timing of revenue recognition.  For example, as discussed in Note 3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Research and License Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, revenue recognized under the AbbVie Collaboration Agreement (as defined in Note 3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Research and License Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) for the three and nine months ended September 30, 2021 reflects the cumulative catchup adjustment (reduction) of revenue of $(4,480) recorded in connection with a change in estimate that occurred during the third quarter of 2021.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses of intellectual property&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from consideration allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the licenses. For licenses that are combined with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or&#160;at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;revenue. We evaluate the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone payments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;At the inception of each arrangement that includes development milestone payments, we evaluate the probability of reaching the milestones and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur in the future, the associated milestone value is included in the transaction price. Milestone payments that are not within our control or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received and therefore revenue recognized is constrained as management is unable to assert that a reversal of revenue would not be possible. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues and earnings in the period of adjustment.  To date, we have not recognized any milestone payment revenue from any of its collaboration agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;For arrangements that include sales-based royalties, including milestone payments based on levels of sales, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, we have not recognized any royalty revenue resulting from any of its collaboration agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;None.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2016-13&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2016-13 is a new standard intended to improve reporting requirements specific to loans, receivables and other financial instruments. ASU 2016-13 requires that credit losses on financial assets measured at amortized cost be determined using an expected loss model, instead of the current incurred loss model, and requires that credit losses related to available-for-sale debt securities&#160;be recorded through an allowance for credit losses and limited to the amount by which carrying value exceeds fair value. ASU 2016-13 also requires enhanced disclosure of credit risk associated with financial assets. The effective date of ASU 2016-13 was deferred by ASU 2019-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842)&#x2014;Effective Dates &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to the annual period beginning after December 15, 2022 for companies that (i) meet the definition of an SEC filer and (ii) are eligible as &#x201c;smaller reporting companies&#x201d; as such term is defined by the SEC, with early adoption permitted. The Company is currently assessing the impact of adoption of ASU 2016-13 to its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80MC9mcmFnOjdjMzQxMzgzYWVmZjQ5M2NiNzI0NTNhMDMzOTM4ZmY1L3RleHRyZWdpb246N2MzNDEzODNhZWZmNDkzY2I3MjQ1M2EwMzM5MzhmZjVfMjc0ODc3OTA4NTk0MQ_2086afc2-a18c-4370-8067-cda8fe20f121">&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2018, we adopted the provisions of Accounting Standards Codification, or ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; using the modified retrospective method for all contracts not completed as of the date of adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC 606, we recognize revenue when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC 606, we perform the following five steps:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Identify the contract with the customer.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party&#x2019;s rights and obligations regarding the goods or services to be transferred and identifies the related payment terms, (ii) the contract has commercial substance, and (iii) we determine that collection of substantially all consideration for goods and services that are transferred is probable based on the customer&#x2019;s intent and ability to pay the promised consideration. We apply judgment in determining the customer&#x2019;s intent and ability to pay, which is based on a variety of factors including the customer&#x2019;s historical payment experience, or in the case of a new customer, published credit and financial information pertaining to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Identify the performance obligations in the contract.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  Performance obligations promised in a contract are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the good or service either on its own or together with other available resources, and are distinct in the context of the contract, whereby the transfer of the good or service is separately identifiable from other promises in the contract. To the extent a contract includes multiple promised goods and services, we must apply judgment to determine whether promised goods and services are both capable of being distinct and distinct in the context of the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Determine the transaction price.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  The transaction price is determined based on the consideration to which we will be entitled in exchange for transferring goods and services to the customer. To the extent the transaction price includes variable consideration, we estimate the amount of variable consideration that &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;should be included in the transaction price utilizing either the expected value method or the most likely amount method, depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in our judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Any estimates, including the effect of the constraint on variable consideration, are evaluated at each reporting period for any changes. Determining the transaction price requires significant judgment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Allocate the transaction price to performance obligations in the contract.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. However, if a series of distinct services that are substantially the same qualifies as a single performance obligation in a contract with variable consideration, we must determine if the variable consideration is attributable to the entire contract or to a specific part of the contract. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative standalone selling price basis unless the transaction price is variable and meets the criteria to be allocated entirely to a performance obligation or to a distinct service that forms part of a single performance obligation. The consideration to be received is allocated among the separate performance obligations based on relative standalone selling prices. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Recognize revenue when or as the Company satisfies a performance obligation.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We satisfy performance obligations either over time or at a point in time. Revenue is recognized over time if either (i) the customer simultaneously receives and consumes the benefits provided by the entity&#x2019;s performance, (ii) the entity&#x2019;s performance creates or enhances an asset that the customer controls as the asset is created or enhanced, or (iii) the entity&#x2019;s performance does not create an asset with an alternative use to the entity and the entity has an enforceable right to payment for performance completed to date. If the entity does not satisfy a performance obligation over time, the related performance obligation is satisfied at a point in time by transferring the control of a promised good or service to a customer. Examples of control are using the asset to produce goods or services, enhance the value of other assets, or settle liabilities, and holding or selling the asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue allocated to performance obligations relating to provision of research and development activities is recognized as the performance obligations are satisfied using an input method to measure progress, based on an estimate of the percentage of completion of the project based on the actual hours incurred on the project as a percentage of the total expected project hours. The determination of the percentage of completion requires management to estimate the total expected project hours. A detailed estimate of the total expected project hours is re-assessed every reporting period based on the latest project plan and discussions with project teams. If a change in facts or circumstances occurs, the estimate will be adjusted and the revenue will be recognized based on the revised estimate. The difference between the cumulative revenue recognized based on the previous estimate and the revenue recognized based on the revised estimate would be recognized as an adjustment to revenue in the period in which the change in estimate occurs. Determining the estimate of total project hours requires significant judgment and may have a significant impact on the amount and timing of revenue recognition.  For example, as discussed in Note 3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Research and License Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, revenue recognized under the AbbVie Collaboration Agreement (as defined in Note 3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Research and License Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) for the three and nine months ended September 30, 2021 reflects the cumulative catchup adjustment (reduction) of revenue of $(4,480) recorded in connection with a change in estimate that occurred during the third quarter of 2021.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses of intellectual property&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from consideration allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the licenses. For licenses that are combined with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or&#160;at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;revenue. We evaluate the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone payments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;At the inception of each arrangement that includes development milestone payments, we evaluate the probability of reaching the milestones and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur in the future, the associated milestone value is included in the transaction price. Milestone payments that are not within our control or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received and therefore revenue recognized is constrained as management is unable to assert that a reversal of revenue would not be possible. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues and earnings in the period of adjustment.  To date, we have not recognized any milestone payment revenue from any of its collaboration agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;For arrangements that include sales-based royalties, including milestone payments based on levels of sales, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, we have not recognized any royalty revenue resulting from any of its collaboration agreements.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <xcur:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate
      contextRef="i5ead1c261b0940cab128efb701608748_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80MC9mcmFnOjdjMzQxMzgzYWVmZjQ5M2NiNzI0NTNhMDMzOTM4ZmY1L3RleHRyZWdpb246N2MzNDEzODNhZWZmNDkzY2I3MjQ1M2EwMzM5MzhmZjVfODI0NjMzNzIyMDM1Mw_a26a21e1-cfad-4c18-9a0d-eb5eae3797d5"
      unitRef="usd">-4480000</xcur:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80MC9mcmFnOjdjMzQxMzgzYWVmZjQ5M2NiNzI0NTNhMDMzOTM4ZmY1L3RleHRyZWdpb246N2MzNDEzODNhZWZmNDkzY2I3MjQ1M2EwMzM5MzhmZjVfMTk3NA_d39bc909-86f1-406a-ba98-95a101eefc3c">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;None.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2016-13&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2016-13 is a new standard intended to improve reporting requirements specific to loans, receivables and other financial instruments. ASU 2016-13 requires that credit losses on financial assets measured at amortized cost be determined using an expected loss model, instead of the current incurred loss model, and requires that credit losses related to available-for-sale debt securities&#160;be recorded through an allowance for credit losses and limited to the amount by which carrying value exceeds fair value. ASU 2016-13 also requires enhanced disclosure of credit risk associated with financial assets. The effective date of ASU 2016-13 was deferred by ASU 2019-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842)&#x2014;Effective Dates &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to the annual period beginning after December 15, 2022 for companies that (i) meet the definition of an SEC filer and (ii) are eligible as &#x201c;smaller reporting companies&#x201d; as such term is defined by the SEC, with early adoption permitted. The Company is currently assessing the impact of adoption of ASU 2016-13 to its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTUzNTk_abed29d6-eaa2-4676-8868-702cc02c966a">Collaborative Research and License Agreements&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Ipsen Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 30, 2021 (the &#x201c;Ipsen Effective Date&#x201d;), the Company entered into a Collaboration, Option and License Agreement with Ipsen (the &#x201c;Ipsen Collaboration Agreement&#x201d;). Pursuant to the Ipsen Collaboration Agreement, the Company granted to Ipsen exclusive access and options to license SNA-based therapeutics arising from two collaboration programs related to the treatment of Huntington&#x2019;s disease and Angelman syndrome (each, an &#x201c;Ipsen Collaboration Program&#x201d;), respectively. Each such license (obtained in connection with the exercise of an Ipsen Option, as defined and discussed further below) would grant to Ipsen exclusive, royalty-bearing, sublicensable, worldwide rights to develop, manufacture, use and commercialize such SNA therapeutics. Upon written notice to the Company, Ipsen may exercise its option during the corresponding collaboration program&#x2019;s applicable option exercise period, (each, an &#x201c;Ipsen Option Exercise Period&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of the Ipsen Effective Date, the Company and Ipsen have agreed upon a development plan for each Ipsen Collaboration Program that describes the development activities and timelines required to advance each such Ipsen Collaboration Program through its first IND filing (each, an &#x201c;Ipsen Development Plan&#x201d;).  The activities described in the Ipsen Development Plans are conducted under the supervision of the Ipsen Joint Steering Committee (the &#x201c;Ipsen JSC&#x201d;) consisting of three members from each of the Company and Ipsen.  Under the terms of the Ipsen Collaboration Agreement, the Company will use commercially reasonable efforts to conduct discovery and development in two collaboration programs for Huntington&#x2019;s disease (the &#x201c;HD Program&#x201d;) and Angelman syndrome (the &#x201c;AS Program&#x201d;) (the &#x201c;Ipsen Development Activities&#x201d;) respectively. The Company shall be solely responsible for all costs and expenses of conducting each Ipsen Collaboration Program through the selection of SNA therapeutic candidates for further development (&#x201c;Ipsen Selection&#x201d;), and Ipsen shall be responsible for all costs and expenses of all activities that are necessary to enable the first filing of an  IND for each proposed product candidate.  In the event that Ipsen exercises an option, Ipsen will be responsible for further development from the license effective date and commercialization of the corresponding licensed product. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following the completion of all Ipsen Development Activities for the Ipsen Selection (the &#x201c;Ipsen First R&amp;amp;D Term Activities&#x201d;), the Company is required to deliver to Ipsen a report that describes the results of the Ipsen First R&amp;amp;D Term Activities and identifies at least one SNA-based compound that satisfies certain criteria for such Ipsen Collaboration Program as determined by the Ipsen JSC (the &#x201c;Ipsen First Option Data Package&#x201d;).  Following the delivery of the Ipsen First Option Data Package for an Ipsen Collaboration Program, Ipsen will have the ability for a defined period of time (the &#x201c;Ipsen First Option Exercise Period&#x201d;) to exercise an option (each a &#x201c;First Ipsen Option&#x201d;) to obtain worldwide rights and license to the Company&#x2019;s SNA technology and the Company&#x2019;s interest in joint collaboration technology to make, have made, import, use, sell or offer for sale any product (each an &#x201c;Ipsen Licensed Product&#x201d;) that results from such Ipsen Collaboration Program during the term of the Ipsen Collaboration Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In the event Ipsen (i) does not exercise the First Ipsen Option with respect to an Ipsen Collaboration Program, (ii) the Ipsen Collaboration Agreement has not expired or been terminated with respect to such Ipsen Collaboration Program, and (iii) Ipsen agrees to fully fund additional research activities for an Ipsen Collaboration Program through IND filing, the Company will be responsible for research and development activities for such Ipsen Collaboration Program through IND filing (the &#x201c;Ipsen Second R&amp;amp;D Term Activities&#x201d;).  Following the completion of the Ipsen Second R&amp;amp;D Term Activities, the Company is required to deliver to Ipsen a report that describes the results of the Ipsen Second R&amp;amp;D Term Activities (the &#x201c;Ipsen Second Option Data Package&#x201d;).   Following the delivery of the Ipsen Second Option Data Package for an Ipsen Collaboration Program, Ipsen will have the ability for a defined period of time (the &#x201c;Ipsen Second Option Exercise Period&#x201d;) to exercise an option (each a &#x201c;Second Ipsen Option&#x201d; and together with the First Ipsen Option, the &#x201c;Ipsen Options&#x201d;) to obtain worldwide rights and license to the Company&#x2019;s SNA technology and the Company&#x2019;s interest in joint collaboration technology to make, have made, import, use, sell or offer for sale any Ipsen Licensed Product&#x201d; that results from such Ipsen Collaboration Program during the term of the Ipsen Collaboration Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;After Ipsen&#x2019;s exercise of an Ipsen Option for an Ipsen Collaboration Program, the Company shall supply to Ipsen the licensed SNAs under current Good Manufacturing Practice, at the Company&#x2019;s manufacturing cost pursuant to a clinical supply agreement to be negotiated by the Company and Ipsen in good faith following the Ipsen Effective Date and executed within twelve (12) months after the Ipsen Effective Date (the &#x201c;Ipsen Supply Agreement&#x201d;). The Ipsen Supply Agreement will provide for the transfer by the Company to Ipsen of all documents and information, and the provision by the Company of technical assistance and support, for Ipsen to manufacture or have manufactured by a third party contractor engaged by Ipsen the applicable licensed SNA to the extent it is intended to be actually used in the development and manufacture of the applicable licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Ipsen Collaboration Agreement, the Company received an upfront payment of $20,000 (the &#x201c;Ipsen Upfront Payment&#x201d;).  If Ipsen exercises a First Ipsen Option, Ipsen is required to pay the Company the First Ipsen Option exercise fee of $10,000 for each Ipsen Collaboration Program.  If Ipsen exercises a Second Ipsen  Option, Ipsen is required to pay the Company the Second Ipsen Option exercise fee of $25,000 for each Ipsen Collaboration Program. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ipsen will pay a pre-clinical milestone payment of $5,000 for each Ipsen Collaboration Program upon achievement of such milestone regardless of whether an Ipsen Option is exercised.  In addition to the option exercise fees and the pre-clinical milestones described above, if Ipsen exercises an Ipsen Option for an Ipsen Collaboration Program, development and regulatory milestones will be payable for that program upon the initiation of certain clinical trials and the filing for processing by the United States Food and Drug Administration (&#x201c;FDA&#x201d;) in the United States and by two additional regulators outside the United States of a marketing application for review, per the Ipsen Collaboration Program, with an aggregate total of up to $180,000 if both Ipsen Options are exercised. Commercial milestones will be payable for that Ipsen Collaboration Program upon first commercial sale of a licensed product in certain jurisdictions and the achievement of specified aggregate sales thresholds for all licensed products from that program, with an aggregate total of up to $762,000 if both Ipsen Options are exercised. In the event a therapeutic candidate subject to the Ipsen Collaboration Agreement results in commercial sales, the Company is eligible to receive tiered royalties at percentages ranging from the mid-single digits to the mid-teens on future net product sales of such commercialized therapeutic candidates. A percentage of the aforementioned payments will be due to Northwestern University upon receipt, pursuant to the terms of the Company&#x2019;s existing license agreements with Northwestern University (see Note 13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Commitment and Contingencies,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for more information on the Northwestern University License Agreements (as defined below)). In connection with the receipt of the Ipsen Upfront Payment, the Company paid a $3,000 license fee to Northwestern University under the terms of the Northwestern License Agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s obligations to conduct activities defined in the Ipsen Development Plan under the Ipsen Collaboration Agreement commenced on July 30, 2021 and continues, unless earlier terminated, until (a) the expiration of the later-to-expire Ipsen Option Exercise Period, if Ipsen does not exercise either Ipsen Option, or (b) the expiration of the last-to-expire royalty term for any licensed product in such country on a licensed product-by-licensed product and country-by-country basis, if Ipsen exercises one or both Ipsen Options. Upon expiration of the royalty term with respect to a particular licensed product in a country, the license for such product in such country will convert to a fully-paid, irrevocable and perpetual license. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Ipsen Collaboration Agreement also contains customary provisions for termination by either party, including by Ipsen for any or no reason in its entirety upon (90) days prior written notice and including in the event of breach of the Ipsen Collaboration Agreement, subject to cure, and by the Company upon a challenge of the licensed patents, subject, in certain cases, to customary reversion rights. Upon termination of the Ipsen Collaboration Agreement by the Company for Ipsen&#x2019;s breach or bankruptcy, all licenses granted by the Company to Ipsen will terminate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Ipsen Collaboration Agreement includes customary representations and warranties on behalf of both the Company and Ipsen. The Ipsen Collaboration Agreement also provides for customary mutual indemnities.  In addition, the Ipsen Collaboration Agreement imposes certain exclusivity obligations on Ipsen and the Company, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;respectively, with respect to the development, use, manufacture and commercialization of oligonucleotide-based therapeutic targeting the same targets in the collaboration programs and/or certain other specific targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Either party may assign the Ipsen Collaboration Agreement or delegate its obligations to an affiliate or to a successor to substantially all of the business to which the Ipsen Collaboration Agreement relates without the consent of the other party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting Analysis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company concluded that Ipsen is a customer in this arrangement, and as such the arrangement falls within the scope of the revenue recognition guidance. Under the Ipsen Collaboration Agreement, the Company has identified two performance obligations, as follows: (1) the performance obligation related to the HD Program that includes (i) the Ipsen First R&amp;amp;D Term Activities related to the HD Program (the &#x201c;Ipsen HD Program R&amp;amp;D Services&#x201d;), (ii) Ipsen JSC services related to the HD Program during the Ipsen First Term (the &#x201c;Ipsen HD Program JSC Services&#x201d;), and (iii) activities related to the negotiation of the Ipsen Supply Agreement within twelve months of the Ipsen Effective Date; and (2) the performance obligation related to the AS Program that includes (i) the Ipsen First R&amp;amp;D Term Activities related to the AS Program (the &#x201c;Ipsen AS Program R&amp;amp;D Services&#x201d;), (ii) Ipsen JSC services related to the AS Program during the Ipsen First Term (the &#x201c;Ipsen AS Program JSC Services&#x201d;), (iii) and activities related to the negotiation of the Ipsen Supply Agreement within twelve months of the Ipsen Effective Date.  The Company has concluded that the Ipsen HD Program R&amp;amp;D Services and the Ipsen AS Program R&amp;amp;D Services are not distinct from the Ipsen HD Program JSC Services and the Ipsen AS Program JSC Services, respectively. The Company has also concluded that the Ipsen HD Program JSC Services and the Ipsen AS Program JSC Services are not distinct from the activities related to entering the Ipsen Supply Agreements for each respective program. The Ipsen JSC provides oversight and management of the overall Ipsen Collaboration Agreement, and the members of the Ipsen JSC from the Company have specialized industry knowledge, particularly as it relates to SNA technology. The Ipsen JSC is meant to facilitate the early stage research being performed and coordinate the activities of both the Company and Ipsen. Further, the Ipsen JSC services are critical to the ongoing evaluation of the Ipsen Collaboration Programs and the drafting and evaluation of the Ipsen First Option Data Package. The Ipsen JSC will also provide oversight and management of the activities to enter into the Ipsen Supply Agreement.  Accordingly, the Company&#x2019;s participation on the Ipsen JSC is essential to Ipsen receiving value from the Ipsen HD Program R&amp;amp;D Services and the Ipsen AS Program R&amp;amp;D Services, and as such, (i) the Ipsen HD Program JSC Services, along with the Ipsen HD Program R&amp;amp;D Services and the activities related to entering the Ipsen Supply Agreement within twelve months of the Ipsen Effective Date for that program are considered a single performance obligation (the &#x201c;Ipsen HD Program Services&#x201d;) and (ii) the Ipsen AS Program JSC Services along with the Ipsen AS Program R&amp;amp;D Services and the activities related to entering the Ipsen Supply Agreement within twelve months of the Ipsen Effective Date for that program are considered a single performance obligation (the &#x201c;Ipsen AS Program Services&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of the Ipsen Effective Date, the total transaction price was determined to be $20,000, consisting solely of the Ipsen Upfront Payment. The Company also utilized the most likely amount method to estimate any development and regulatory milestone payments to be received. As of the Ipsen Effective Date, there were no milestones included in the transaction price.&#160;The pre-clinical, development, regulatory, and commercial milestones were fully constrained due to the significant uncertainties surrounding such payments.&#160;The Company considered the stage of development and the risks associated with the remaining development required to achieve the milestone, as well as whether the achievement of the milestone is outside the control of the Company or Ipsen.  The Company has determined that any commercial milestones and sales-based royalties will be recognized when the related sales occur and therefore, they have also been excluded from the transaction price. The Company will re-evaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur.  As of September&#160;30, 2021, the Company determined that any pre-clinical, development, regulatory, or commercial milestones continue to be constrained and therefore the related milestone payments continue to be excluded from the transaction price at September&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allocated the total transaction price to each of the two identified performance obligations under the Ipsen Collaboration Agreement based on an expected cost plus a margin approach, as follows: $10,793 of the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;transaction price allocated to the Ipsen HD Program Services and $9,207 of the transaction price allocated to the Ipsen AS Program Services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will recognize revenue related to each of Ipsen HD Program Services and the Ipsen AS Program Services as those performance obligations are satisfied using an input method to measure progress for each of those performance obligations. The Company believes the input method that most accurately depicts the measure of progress is the actual hours incurred to date relative to projected hours to complete the activities for the Ipsen HD Program Services and the Ipsen AS Program Services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September&#160;30, 2021, the Company recognized revenue under the Ipsen Collaboration Agreement of approximately $803.  As of September&#160;30, 2021 , there was $19,197 of deferred revenue related to the Ipsen Collaboration Agreement, of which is $7,945 is classified as current and $11,252 is classified as noncurrent on the unaudited condensed consolidated balance sheet. Deferred revenue under the Ipsen Collaboration Agreement will be recognized as revenue in future periods as the Company satisfies its obligations under the Ipsen Collaboration Agreement, which the Company currently estimates to be over the next 33 to 42 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;AbbVie Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of Agreement&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 13, 2019 (the &#x201c;AbbVie Effective Date&#x201d;), the Company entered into a Collaboration, Option and License Agreement (the &#x201c;AbbVie Collaboration Agreement&#x201d;), with a wholly-owned subsidiary of Allergan plc, Allergan. On May 8, 2020, Allergan plc, including Allergan was acquired by AbbVie. Pursuant to the AbbVie Collaboration Agreement, the Company granted to AbbVie exclusive access and options to license SNA-based therapeutics arising from two collaboration programs related to the treatment of hair loss disorders (each, an &#x201c;AbbVie Collaboration Program&#x201d;). Under each such license (obtained in connection with the exercise of an AbbVie Option, as defined and discussed further below), the Company would grant to AbbVie exclusive, royalty-bearing, sublicensable, nontransferable, worldwide rights to develop, manufacture, use and commercialize such SNA therapeutics. Under the AbbVie Collaboration Agreement, the Company will use commercially reasonable efforts to conduct the AbbVie Collaboration Programs, each focused on one or more hair loss disorders to discover one or more SNA products that are directed to, bind to or inhibit one or more specific AbbVie Collaboration Program targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of the AbbVie Effective Date, the Company and AbbVie have agreed upon a development plan for each AbbVie Collaboration Program that describes the development activities and timelines required to advance such AbbVie Collaboration Program through its first IND filing (each, an &#x201c;AbbVie Development Plan&#x201d;).  The activities described in the AbbVie Development Plan are conducted under the supervision of the AbbVie Joint Development Committee (the &#x201c;AbbVie JDC&#x201d;) consisting of three members from each of the Company and AbbVie. The Company is primarily responsible for performing early-stage discovery and preclinical activities (the &#x201c;AbbVie Collaboration Program Initial Development Activities&#x201d;) set forth in the AbbVie Development Plan for each AbbVie Collaboration Program and will be solely responsible for all costs and expenses related to the AbbVie Collaboration Program Initial Development Activities. AbbVie may elect, in its sole discretion and at its sole cost and expense, to conduct formulation assessment and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;in vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; testing as set forth in an AbbVie Development Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the third quarter of 2021, the AbbVie JDC revised the AbbVie Initial Development Plan for each AbbVie Collaboration Program.  In connection with the revised workplan for each AbbVie Collaboration Program, the Company expects to perform additional early stage discovery and preclinical activities to those set forth in the AbbVie Development Plan.  As such, the Company currently estimates significant additional efforts will be required to satisfy the performance obligation under the AbbVie Collaboration Agreement due to the revised workplan for each AbbVie Collaboration Program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following the completion of all AbbVie Initial Development Activities, the Company is required to deliver to AbbVie a report that describes the results of the AbbVie Initial Development Activities and identifies at least one SNA-based compound that satisfies certain criteria for such AbbVie Collaboration Program as determined by the AbbVie JDC (the &#x201c;AbbVie Initial Development Report&#x201d;).  Following the delivery of the AbbVie Initial Development Report for an AbbVie Collaboration Program, AbbVie will have the ability for a defined period of time (the &#x201c;AbbVie Initial Option Exercise Period&#x201d;) to exercise an option (each an &#x201c;AbbVie Option&#x201d;) to obtain worldwide rights and license to the Company&#x2019;s SNA technology and the Company&#x2019;s interest in joint collaboration technology to make, have made, import, use, sell or offer for sale any product (each an &#x201c;AbbVie Licensed Product&#x201d;) that results from such AbbVie Collaboration Program during the term of the AbbVie Collaboration Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At AbbVie&#x2019;s sole option, AbbVie may extend the AbbVie Initial Option Exercise Period (the &#x201c;AbbVie Option Extension&#x201d;) and require the Company to perform IND-enabling activities described in the AbbVie Development Plan (the &#x201c;AbbVie IND-Enabling Activities&#x201d;), subject to the payment of additional consideration (&#x201c;AbbVie Extension Exercise&#x201d;). If AbbVie exercises the AbbVie Option Extension, the Company would be responsible for conducting the AbbVie IND-Enabling Activities and would be solely responsible for all costs and expenses associated with such activities.  Upon completion of the AbbVie IND-Enabling Activities, the Company is required to deliver a report that describes the results of the AbbVie IND-Enabling Activities (the &#x201c;AbbVie IND-Enabling Activities Data Package&#x201d;) to AbbVie. Following the delivery of AbbVie IND-Enabling Activities Data Package, AbbVie will have the ability for a defined period of time (the &#x201c;AbbVie Extended Option Exercise Period&#x201d;) to exercise an AbbVie Option with respect to such AbbVie Collaboration Program. After the exercise of an AbbVie Option with respect to an AbbVie Collaboration Program, AbbVie will be responsible for all development, manufacturing and commercialization activities, and costs and expense associated with such activities in connection with AbbVie Licensed Products arising from such AbbVie Collaboration Program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s obligation to conduct the activities defined in the AbbVie Development Plan under the AbbVie Collaboration Agreement commenced on November 13, 2019 and continues until the earlier of (i) the date AbbVie exercises an AbbVie Option, (ii) the date AbbVie abandons an AbbVie Collaboration Program and foregoes its AbbVie Option to that AbbVie Collaboration Program, or (iii) the fifth anniversary of the AbbVie Effective Date (the &#x201c;AbbVie Research Term&#x201d;). If the AbbVie Initial Option Exercise Period or AbbVie Extended Option Exercise Period is still in effect for an AbbVie Collaboration Program or if the Company has not delivered a complete AbbVie Initial Development Report or, if AbbVie made an AbbVie Extension Exercise for an AbbVie Collaboration Program, a complete AbbVie IND-Enabling Activities Data Package for such AbbVie Collaboration Program, as determined by the AbbVie JDC, then the AbbVie Research Term will automatically extend by one-year increments until such obligation is satisfied, but in no event past the seventh anniversary of the AbbVie Effective Date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the AbbVie Collaboration Agreement, the Company received a $25,000 upfront, non-refundable, non-creditable cash payment (the &#x201c;AbbVie Upfront Payment&#x201d;) related to the Company&#x2019;s research and development costs for conducting the AbbVie Development Plan for two AbbVie Collaboration Programs, each focused on one or more targets, and certain options to obtain exclusive, worldwide licenses under certain intellectual property rights owned or controlled by the Company to develop, manufacture and commercialize certain products resulting from each such AbbVie Collaboration Programs.  The option exercise fee during the AbbVie Initial Option Exercise Period is $10,000 per AbbVie Collaboration Program.  If AbbVie elects to extend the AbbVie Initial Option Exercise Period, AbbVie is required to pay an additional fee of $10,000.  If AbbVie elects to exercise its option during the AbbVie Extended Option Exercise Period, AbbVie must pay the Company the option exercise fee of $15,000.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following the exercise by AbbVie of an AbbVie Option with respect to an AbbVie Collaboration Program, AbbVie would be required to make certain milestone payments to the Company upon the achievement of specified development, product approval and launch, and commercial events, on an AbbVie Licensed Product by AbbVie Licensed Product basis. On an AbbVie Licensed Product by AbbVie Licensed Product basis, for the first AbbVie Licensed Product to achieve the associated milestone event, the Company is eligible to receive up to an aggregate of $55,000 for development milestone payments and $132,500 for product approval and launch milestone payments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also eligible for up to $175,000 in sales milestone payments on an AbbVie Collaboration Program by AbbVie Collaboration Program basis, associated with aggregate worldwide sales. Certain product approval milestones are subject to certain reductions under specified circumstances, including for payments required to be made by AbbVie to obtain certain third-party intellectual property rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, to the extent there is any AbbVie Licensed Product, the Company would be entitled to receive tiered royalty payments of mid-single digits to the mid-teens percentage on future net worldwide product sales of such AbbVie Licensed Products, subject to certain reductions under specified circumstances. Royalties are due on a AbbVie Licensed Product by AbbVie Licensed Product and country by country basis from the date of the first commercial sale of each AbbVie Licensed Product in a country until the latest to occur of: (i) the expiration date in such country of the last to expire valid claim within the licensed intellectual property covering the manufacture, use or sale of such AbbVie Licensed Product in such country, (ii) the tenth anniversary of the first commercial sale of such AbbVie Licensed Product in such country, and (iii) the expiration of regulatory exclusivity for such AbbVie Licensed Product in such country.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AbbVie may terminate the AbbVie Collaboration Agreement for any reason or no reason, either in its entirety or on an AbbVie Collaboration Program by AbbVie Collaboration Program basis, at any time on 90 days&#x2019; prior written notice to the Company. Unless earlier terminated, the term of the AbbVie Collaboration Agreement shall continue until (i) if both AbbVie Option Exercise Periods expire without AbbVie exercising either AbbVie Option, the expiration of the later to expire AbbVie Option Exercise Period, and (ii) if either or both AbbVie Options are exercised on an AbbVie Licensed Product by AbbVie Licensed Product and country-by-country basis, the expiration of the royalty term for such AbbVie Licensed Product in such country. Either party may terminate the AbbVie Collaboration Agreement if the other party has materially breached or defaulted in the performance of any of its material obligations and such breach or default continues after the specified cure period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Termination of the AbbVie Collaboration Agreement for any reason will not release either party from any liability which, at the time of such termination, has already accrued to the other party or which is attributable to a period prior to such termination. In addition, termination of the AbbVie Collaboration Agreement will not preclude either party from pursuing any rights and remedies it may have under the agreement or at law or in equity with respect to any breach of the AbbVie Collaboration Agreement. If either party terminates the AbbVie Collaboration Agreement, the license and rights granted to AbbVie with respect to the terminated AbbVie Collaboration Program or AbbVie License Product shall terminate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting Analysis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company concluded that AbbVie is a customer in this arrangement, and as such the arrangement falls within the scope of the revenue recognition guidance. Under the AbbVie Collaboration Agreement, the Company has identified a single performance obligation that includes (i) the research and development activities during the AbbVie Research Term (the &#x201c;AbbVie R&amp;amp;D Services&#x201d;), and (ii) AbbVie Joint Development Committee services during the AbbVie Research Term (the &#x201c;AbbVie JDC Services&#x201d;). The Company has concluded that the AbbVie R&amp;amp;D Services is not distinct from the AbbVie JDC Services during the AbbVie Research Term. The AbbVie JDC provides oversight and management of the overall AbbVie Collaboration Agreement, and the members of the AbbVie JDC from the Company have specialized industry knowledge, particularly as it relates to SNA technology. The AbbVie JDC is meant to facilitate the early-stage research being performed and coordinate the activities of both the Company and AbbVie. Further, the AbbVie JDC services are critical to the ongoing evaluation of an AbbVie Collaboration Program and the drafting and evaluation of the AbbVie Initial Development Report and the AbbVie IND-Enabling Data Package. Accordingly, the Company&#x2019;s participation on the AbbVie JDC is essential to AbbVie receiving value from the AbbVie R&amp;amp;D Services and as such, the AbbVie JDC Services along with the AbbVie R&amp;amp;D Services are considered one performance obligation (the &#x201c;AbbVie Collaboration Program Services&#x201d;).  In addition, the Company has concluded that the option to purchase two development and commercialization licenses is considered a marketing offer as the options did not provide any discounts or other rights that would be considered a material right in the arrangement, and thus, not a performance obligation at the onset of the agreement.&#160;&#160;The consideration for these options will be accounted for when they are exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of the AbbVie Effective Date, the total transaction price was determined to be $25,000, consisting solely of the AbbVie Upfront Payment. The Company also utilized the most likely amount method to estimate any development and regulatory milestone payments to be received. As of the AbbVie Effective Date, there were no milestones included in the transaction price.&#160;The milestones were fully constrained due to the significant uncertainties surrounding such payments.&#160;The Company considered the stage of development and the risks associated with the remaining development required to achieve the milestone, as well as whether the achievement of the milestone is outside the control of the Company or AbbVie.  The Company has determined that any commercial milestones and sales-based royalties will be recognized when the related sales occur and therefore they have also been excluded from the transaction price. The Company will re-evaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur.  As of September&#160;30, 2021, the Company determined that any development, regulatory or commercial milestones continue to be constrained and therefore the related milestone payments continue to be excluded from the transaction price at September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will recognize revenue related to the AbbVie Collaboration Program Services as the performance obligation is satisfied using an input method to measure progress. The Company believes the input method that most accurately depicts the measure of progress is the actual hours incurred to date relative to projected hours to complete the research service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed above, during the third quarter of 2021, the AbbVie JDC revised the AbbVie Initial Development Plan for each AbbVie Collaboration Program.  As a result, the Company has increased its estimate of total hours to complete the research services, requiring an adjustment to cumulative revenue recognized (considered a change in estimate pursuant to ASC 606) as of September 30, 2021.  As such, during the third quarter of 2021, the Company recorded a cumulative catchup adjustment (reduction) of revenue of $(4,480).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September&#160;30, 2021, the Company recognized revenue under the AbbVie Collaboration Agreement of approximately $(4,480) and $(3,404), respectively, reflecting the cumulative catchup adjustment (reduction) of revenue of $(4,480) discussed above due to a change in estimate.  The Company currently estimates significant additional efforts will be required to satisfy the performance obligation under the AbbVie Collaboration Agreement due to the revised workplan for each AbbVie Collaboration Program.  These increased estimated efforts in connection with the change in workplan resulted in less progress occurring relative to the increased estimate of total project hours to complete the research services during the three and nine months ended September 30, 2021 as compared to the amount of revenue recognized at both June 30, 2021 and December 31, 2020, which led to revenue reversals in each respective period.  During the three and nine months ended September&#160;30, 2020, the Company recognized revenue under the AbbVie Collaboration Agreement of approximately $2,402 and $16,351, respectively.  As of September&#160;30, 2021, there was $11,747 of deferred revenue related to the AbbVie Collaboration Agreement, of which is $6,070 is classified as current and $5,677 is classified as noncurrent on the unaudited condensed consolidated balance sheet.  Deferred revenue under the AbbVie Collaboration Agreement will be recognized as revenue in future periods as the Company satisfies its obligations under the AbbVie Collaboration Agreement, which the Company currently estimates to be over the next 24 to 27 months.  As of  December&#160;31, 2020, there was $8,343 of deferred revenue related to the AbbVie Collaboration Agreement, which was classified as current on the unaudited condensed consolidated balance sheet based on the estimated contract completion date at that time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Dermelix Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 17, 2019, Exicure entered into a License and Development Agreement (the &#x201c;Dermelix Collaboration Agreement&#x201d;) with Dermelix, LLC d/b/a Dermelix Biotherapeutics (&#x201c;Dermelix&#x201d;). Under the terms of the Dermelix Collaboration Agreement, Exicure received an upfront payment of $1,000, to be applied against the initial $1,000 of the Company&#x2019;s development expenses.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company initially recorded the upfront payment of $1,000 as deferred revenue related to its wholly unsatisfied performance obligation and reduced this balance to zero during 2019 by recognizing revenue as services &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;were provided.  The Company recognized no revenue under the Dermelix Collaboration Agreement during the three and nine months ended September&#160;30, 2021. The Company recognized $41 and $122 of revenue during the three and nine months ended September&#160;30, 2020 which reflected reimbursement by Dermelix for additional costs incurred by Exicure for early-stage development costs beyond the initial $1,000 upfront payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Contract Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Up-front payments are recorded as deferred revenue upon receipt or when due until such time as the Company satisfies its performance obligations under these arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents changes in the balances of the Company&#x2019;s contract liabilities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.032%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred Revenue Balance at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue &lt;br/&gt;(Recognized) Reversed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred Revenue Balance at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ipsen Collaboration Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(803)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AbbVie Collaboration Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <xcur:NumberofCollaborationPrograms
      contextRef="i7c9b511297334f1596139d6ed967838a_D20210730-20210730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfNTQ5NzU1ODE2NzY2OA_06168603-de76-4d8e-943a-1862f0c9c151"
      unitRef="agreement">2</xcur:NumberofCollaborationPrograms>
    <xcur:NumberofCollaborationPrograms
      contextRef="i7c9b511297334f1596139d6ed967838a_D20210730-20210730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfNTQ5NzU1ODE2NzY4Mw_3d83dc76-5ef8-457f-b2b0-9d00dd4441a9"
      unitRef="agreement">2</xcur:NumberofCollaborationPrograms>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i7c9b511297334f1596139d6ed967838a_D20210730-20210730"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfNTQ5NzU1ODE2NzY1Ng_c4671c91-cea5-4517-8c64-462516a2217e"
      unitRef="usd">20000000</us-gaap:ProceedsFromCollaborators>
    <xcur:CollaborationAgreementOptionExerciseFee
      contextRef="i101b7a1d41f042c7be4608f1ec08064c_D20210730-20210730"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfNTQ5NzU1ODE2NzcwMw_840ac499-256a-4156-a9a8-f7d67e2475f0"
      unitRef="usd">10000000</xcur:CollaborationAgreementOptionExerciseFee>
    <xcur:CollaborationAgreementOptionExerciseFee
      contextRef="i3771528d3f494af69c08d167b87d572b_D20210730-20210730"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfNTQ5NzU1ODE2NzcyMA_4be35bb2-55eb-4328-9268-156a39d91401"
      unitRef="usd">25000000</xcur:CollaborationAgreementOptionExerciseFee>
    <xcur:RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment
      contextRef="i20b3f5cd0c964a8e9b2b710ca2d7aec4_I20210730"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfNTQ5NzU1ODE2NzczNg_121e5cc1-6f93-42c7-8a4e-7470e619c592"
      unitRef="usd">5000000</xcur:RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment>
    <xcur:RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment
      contextRef="i20b3f5cd0c964a8e9b2b710ca2d7aec4_I20210730"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfNTQ5NzU1ODE2Nzc1Mw_4f82b858-f6b4-434d-ad3f-9c9d5ab706b3"
      unitRef="usd">180000000</xcur:RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment>
    <xcur:RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment
      contextRef="i20b3f5cd0c964a8e9b2b710ca2d7aec4_I20210730"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfNTQ5NzU1ODE2Nzc3Mg_de8e3924-8a27-4bf2-b90f-4010a7408291"
      unitRef="usd">762000000</xcur:RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment>
    <xcur:CollaborationAgreementLicensingFeesIncurred
      contextRef="i7c9b511297334f1596139d6ed967838a_D20210730-20210730"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfNTQ5NzU1ODE2Nzc4OQ_5fcca641-cfbe-4be5-8b12-891be4fdc6a4"
      unitRef="usd">3000000</xcur:CollaborationAgreementLicensingFeesIncurred>
    <xcur:CollaborationAgreementTerminationNoticePeriod
      contextRef="i7c9b511297334f1596139d6ed967838a_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMjc0ODc3OTEyOTA1MQ_4f2c50c1-2013-4abc-8b47-2d6f98263d86">P90D</xcur:CollaborationAgreementTerminationNoticePeriod>
    <xcur:CollaborationAgreementTransactionPrice
      contextRef="i20b3f5cd0c964a8e9b2b710ca2d7aec4_I20210730"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfODc5NjA5MzA0OTk4NQ_c4a263b6-d8af-46c0-b06d-a651a9731867"
      unitRef="usd">20000000</xcur:CollaborationAgreementTransactionPrice>
    <xcur:CollaborationAgreementTransactionPrice
      contextRef="ibd51ee58a09548a296ac27e125b6aaf5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTA5OTUxMTY3MjY2Mw_77c8fc61-514d-4fbd-b939-b5a1ada22e83"
      unitRef="usd">10793000</xcur:CollaborationAgreementTransactionPrice>
    <xcur:CollaborationAgreementTransactionPrice
      contextRef="i577ec678c36d41cb95beb6bb59053c95_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTA5OTUxMTY3MjY3NA_f5695dd2-f23f-424d-b847-ea4897343000"
      unitRef="usd">9207000</xcur:CollaborationAgreementTransactionPrice>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia146a37ad8c04dd3a46243658527ace5_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTA5OTUxMTY1Njc1OA_a6156d78-dfee-46ab-a3d5-17b25d543754"
      unitRef="usd">803000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6e7d092153af4ab295e43b76a46e94f7_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTA5OTUxMTY1Njc1OA_cd9a527e-86a9-4bfc-8696-5e601d2a1e8d"
      unitRef="usd">803000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i0eb88576f2154b229cc5f904054ddcaf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTA5OTUxMTY1Njc2OA_914c845f-27e8-4c8c-a608-3b46f4152ab9"
      unitRef="usd">19197000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i0eb88576f2154b229cc5f904054ddcaf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTA5OTUxMTY1Njc4MA_540aea04-1219-49d7-8fda-363800807f72"
      unitRef="usd">7945000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i0eb88576f2154b229cc5f904054ddcaf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTA5OTUxMTY1Njc5Mg_20aafacf-daee-420d-bcec-60237548675d"
      unitRef="usd">11252000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <xcur:CollaborationAgreementEstimatedTimingOfRevenueRecognition
      contextRef="id7d7e4233d934ae2905015e902539333_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMjc0ODc3OTEyOTM5Ng_833efe4f-77a1-48f0-bf16-7faf9ad57e63">P33M</xcur:CollaborationAgreementEstimatedTimingOfRevenueRecognition>
    <xcur:CollaborationAgreementEstimatedTimingOfRevenueRecognition
      contextRef="i8cc70e8bc70d42888c31d1910622f129_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMjc0ODc3OTEyOTQzMA_69ec676d-3f1d-47d0-86ab-7680c9f448f8">P42M</xcur:CollaborationAgreementEstimatedTimingOfRevenueRecognition>
    <xcur:NumberofCollaborationPrograms
      contextRef="i25a109363b9444d0b161c5f239e1f5d2_D20191113-20191113"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfNTQ4_8ea83143-4899-433a-a11f-874e1f5121f6"
      unitRef="agreement">2</xcur:NumberofCollaborationPrograms>
    <xcur:CollaborationAgreementUpfrontPayment
      contextRef="i25a109363b9444d0b161c5f239e1f5d2_D20191113-20191113"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfNTQ0Mg_7ee0f4a5-4325-41f8-b6d8-bc141a3b7c2d"
      unitRef="usd">25000000</xcur:CollaborationAgreementUpfrontPayment>
    <xcur:NumberofCollaborationPrograms
      contextRef="i25a109363b9444d0b161c5f239e1f5d2_D20191113-20191113"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfNTYyNQ_37da6eb4-095e-4387-8d68-2ebb7f10e519"
      unitRef="agreement">2</xcur:NumberofCollaborationPrograms>
    <xcur:CollaborationAgreementOptionExerciseFee
      contextRef="i25a109363b9444d0b161c5f239e1f5d2_D20191113-20191113"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfNjAwNQ_0c539dd4-31ca-4f3d-bbce-2e9fc04458e9"
      unitRef="usd">10000000</xcur:CollaborationAgreementOptionExerciseFee>
    <xcur:CollaborationAgreementExtendedOptionAdditionalExerciseFee
      contextRef="i25a109363b9444d0b161c5f239e1f5d2_D20191113-20191113"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfNjE0Ng_b85163e2-2512-4621-9128-19a226a7224d"
      unitRef="usd">10000000</xcur:CollaborationAgreementExtendedOptionAdditionalExerciseFee>
    <xcur:CollaborationAgreementOptionExerciseFee
      contextRef="i62ddab29023047f19bcd9cdd54f54b72_D20191113-20191113"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfNjI5MA_8dd8e2f4-d311-4dc4-8f72-d814c6e4e0c8"
      unitRef="usd">15000000</xcur:CollaborationAgreementOptionExerciseFee>
    <xcur:RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment
      contextRef="iadf638d109364478ada9ed12098f78a3_D20191113-20191113"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfNjc4NA_e872aab0-5fa9-465b-83b1-61b6c219eaf6"
      unitRef="usd">55000000</xcur:RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment>
    <xcur:RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment
      contextRef="iadf638d109364478ada9ed12098f78a3_D20191113-20191113"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfNjgyNg_abea8a33-8f91-40df-a89b-561df28d7161"
      unitRef="usd">132500000</xcur:RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment>
    <xcur:RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment
      contextRef="iadf638d109364478ada9ed12098f78a3_D20191113-20191113"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfNjkyMA_44728eb1-66ef-4740-bfa6-988eb1c5b54b"
      unitRef="usd">175000000</xcur:RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment>
    <xcur:CollaborationAgreementTerminationPeriodUponWrittenNotice
      contextRef="i25a109363b9444d0b161c5f239e1f5d2_D20191113-20191113"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfODMzOA_4326b830-9b72-43ec-8168-1b9eb5b1841f">P90D</xcur:CollaborationAgreementTerminationPeriodUponWrittenNotice>
    <xcur:CollaborationAgreementUpfrontPayment
      contextRef="i25a109363b9444d0b161c5f239e1f5d2_D20191113-20191113"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTE3NDE_6f2ae343-9875-404a-b3a8-47c92f4a850a"
      unitRef="usd">25000000</xcur:CollaborationAgreementUpfrontPayment>
    <xcur:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate
      contextRef="i5ead1c261b0940cab128efb701608748_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfODI0NjMzNzI0MDMzMA_a26a21e1-cfad-4c18-9a0d-eb5eae3797d5"
      unitRef="usd">-4480000</xcur:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate>
    <xcur:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate
      contextRef="i5ead1c261b0940cab128efb701608748_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTM0Nzk_a26a21e1-cfad-4c18-9a0d-eb5eae3797d5"
      unitRef="usd">-4480000</xcur:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="ie6c60cafc25843e7aa83623d15b8db40_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTM0ODY_889fbcd4-5652-43b1-b4ba-ed2ab877ebaf"
      unitRef="usd">-3404000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <xcur:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate
      contextRef="i5ead1c261b0940cab128efb701608748_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfODI0NjMzNzI2Mjk1MA_a26a21e1-cfad-4c18-9a0d-eb5eae3797d5"
      unitRef="usd">-4480000</xcur:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i202fe08011f74b3bb586c3b5936aade6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTQyMTU_1f115f63-906b-49b0-93e7-17e61a84b25d"
      unitRef="usd">2402000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i334dc3567c6c404c81c2439542a6c976_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTQyMjI_8fca8067-3b83-4f94-a282-069e7e967ee1"
      unitRef="usd">16351000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ib58e437af4b84283a34ce171354bebca_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTA5OTUxMTY1NzI0OQ_70819ac9-77c1-4da1-8337-905a03efe21f"
      unitRef="usd">11747000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ib58e437af4b84283a34ce171354bebca_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTA5OTUxMTY1NzI1Ng_8feff2fb-b03b-4322-87a0-fa56a6970f80"
      unitRef="usd">6070000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ib58e437af4b84283a34ce171354bebca_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTA5OTUxMTY1NzI2Mw_2f69f543-d4a2-460d-a13b-5b29373ce88f"
      unitRef="usd">5677000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <xcur:CollaborationAgreementEstimatedTimingOfRevenueRecognition
      contextRef="i9f46863e9a324f25a2a99c8d4fc202db_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMjc0ODc3OTEyOTA2MQ_6a3405ff-6df1-4ab1-a4b0-691d7f13902f">P24M</xcur:CollaborationAgreementEstimatedTimingOfRevenueRecognition>
    <xcur:CollaborationAgreementEstimatedTimingOfRevenueRecognition
      contextRef="ib068c60a143742cab222adf4b1fc4d6e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMjc0ODc3OTEyOTA4MA_aa991ba9-8e0f-41d2-847b-97d75afa3f47">P27M</xcur:CollaborationAgreementEstimatedTimingOfRevenueRecognition>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ie0f5e47c15a04e01ae8607547bdbb25b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTQyNzU_2ac05a0d-526c-4c98-ba38-888a64d530b0"
      unitRef="usd">8343000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <xcur:CollaborationAgreementUpfrontPayment
      contextRef="ibe437bd3033d4b10b7ec04a3e962b1fa_D20190217-20190217"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTQ2OTY_05db506c-b24e-4e95-8d85-ddb90b0654d2"
      unitRef="usd">1000000</xcur:CollaborationAgreementUpfrontPayment>
    <xcur:CollaborationDevelopmentExpenses
      contextRef="ibe437bd3033d4b10b7ec04a3e962b1fa_D20190217-20190217"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTQ3MzQ_3699d7e2-c167-4fec-87a0-cb738b0f4171"
      unitRef="usd">1000000</xcur:CollaborationDevelopmentExpenses>
    <xcur:CollaborationAgreementUpfrontPayment
      contextRef="ibe437bd3033d4b10b7ec04a3e962b1fa_D20190217-20190217"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTQ4MzI_fdc70b97-1640-487b-be02-12927616fc4a"
      unitRef="usd">1000000</xcur:CollaborationAgreementUpfrontPayment>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i1b1064f27e214d639fb5a6444e15afc9_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTQ5NDA_4e68cbfa-4a53-4422-ab65-7a0f24ac9053"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie7111ceb9bee457d80c964d377cc8997_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTUwMjk_326eae8b-5305-4fcc-abbd-0fd58b02f550"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9a7767cbe5314379a5bbad2a39574623_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTUwMjk_9bea6405-3690-4f9f-a65c-b76e65e118ad"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1972cd63fd53468ca6ea728506874004_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTUxNDc_05542d5a-c805-4cb8-98d4-ad8b0d0c1baf"
      unitRef="usd">41000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6df20868c6bf4088a7c126fd9b4c448f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTUxNTQ_b56f8f7f-322b-40c4-9ac9-d77728a26029"
      unitRef="usd">122000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <xcur:CollaborationAgreementUpfrontPayment
      contextRef="ibe437bd3033d4b10b7ec04a3e962b1fa_D20190217-20190217"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfMTUzMzc_15fa0289-b7c4-4ada-b222-75b8d0ddac93"
      unitRef="usd">1000000</xcur:CollaborationAgreementUpfrontPayment>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RleHRyZWdpb246MWNmMjE3NzU5NDFiNGE4NmJkOWIzMzcwOTAxMmQ0ZTlfNTQ5NzU1ODE2Nzc5Nw_bf0e3def-20f9-40e3-9872-e807cf6ba461">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents changes in the balances of the Company&#x2019;s contract liabilities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.032%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred Revenue Balance at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue &lt;br/&gt;(Recognized) Reversed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred Revenue Balance at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ipsen Collaboration Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(803)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AbbVie Collaboration Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i8868537d91414e59b86b641af9be949f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RhYmxlOjRmN2M5NjI5OTNlNTRiNzViOGQ1ZGViM2RkMmZiNTkyL3RhYmxlcmFuZ2U6NGY3Yzk2Mjk5M2U1NGI3NWI4ZDVkZWIzZGQyZmI1OTJfMS0yLTEtMS05ODEz_d18fa140-46c7-46c3-b275-305f85a9802d"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <xcur:ContractWithCustomerLiabilityAdditions
      contextRef="i603ebaab9dc547c9b12a83e9eed30a32_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RhYmxlOjRmN2M5NjI5OTNlNTRiNzViOGQ1ZGViM2RkMmZiNTkyL3RhYmxlcmFuZ2U6NGY3Yzk2Mjk5M2U1NGI3NWI4ZDVkZWIzZGQyZmI1OTJfMS00LTEtMS05ODE1_68665c16-ccfd-49ae-9129-6ea3b28fe871"
      unitRef="usd">20000000</xcur:ContractWithCustomerLiabilityAdditions>
    <xcur:ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance
      contextRef="i603ebaab9dc547c9b12a83e9eed30a32_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RhYmxlOjRmN2M5NjI5OTNlNTRiNzViOGQ1ZGViM2RkMmZiNTkyL3RhYmxlcmFuZ2U6NGY3Yzk2Mjk5M2U1NGI3NWI4ZDVkZWIzZGQyZmI1OTJfMS02LTEtMS05ODE3_f0c5943a-c175-4abc-b28d-9212536520da"
      unitRef="usd">803000</xcur:ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ie2eeecde261e4327b21ed0de06f04e52_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RhYmxlOjRmN2M5NjI5OTNlNTRiNzViOGQ1ZGViM2RkMmZiNTkyL3RhYmxlcmFuZ2U6NGY3Yzk2Mjk5M2U1NGI3NWI4ZDVkZWIzZGQyZmI1OTJfMS04LTEtMS05ODE5_0fd979a0-8045-4950-b2f7-9d5d58796ec6"
      unitRef="usd">19197000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i6a37c9da460c48809897a601836d2643_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RhYmxlOjRmN2M5NjI5OTNlNTRiNzViOGQ1ZGViM2RkMmZiNTkyL3RhYmxlcmFuZ2U6NGY3Yzk2Mjk5M2U1NGI3NWI4ZDVkZWIzZGQyZmI1OTJfMi0yLTEtMS05ODEz_87e0fef1-a7a8-4aaa-b578-dee9b1cfbd2d"
      unitRef="usd">8343000</us-gaap:ContractWithCustomerLiability>
    <xcur:ContractWithCustomerLiabilityAdditions
      contextRef="icb811529c5b84fc488584f1160906a17_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RhYmxlOjRmN2M5NjI5OTNlNTRiNzViOGQ1ZGViM2RkMmZiNTkyL3RhYmxlcmFuZ2U6NGY3Yzk2Mjk5M2U1NGI3NWI4ZDVkZWIzZGQyZmI1OTJfMi00LTEtMS05ODE1_e80e17b6-7085-4443-a9f5-7d4c7f2540ca"
      unitRef="usd">0</xcur:ContractWithCustomerLiabilityAdditions>
    <xcur:ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance
      contextRef="icb811529c5b84fc488584f1160906a17_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RhYmxlOjRmN2M5NjI5OTNlNTRiNzViOGQ1ZGViM2RkMmZiNTkyL3RhYmxlcmFuZ2U6NGY3Yzk2Mjk5M2U1NGI3NWI4ZDVkZWIzZGQyZmI1OTJfMi02LTEtMS05ODE3_6f124142-0bd1-4910-adef-92a9c6790d42"
      unitRef="usd">-3404000</xcur:ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ibbfce07014ab4a519300435d21964c4d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RhYmxlOjRmN2M5NjI5OTNlNTRiNzViOGQ1ZGViM2RkMmZiNTkyL3RhYmxlcmFuZ2U6NGY3Yzk2Mjk5M2U1NGI3NWI4ZDVkZWIzZGQyZmI1OTJfMi04LTEtMS05ODE5_5a2d1617-27fe-4f18-b56b-bf1dbb66e86d"
      unitRef="usd">11747000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RhYmxlOjRmN2M5NjI5OTNlNTRiNzViOGQ1ZGViM2RkMmZiNTkyL3RhYmxlcmFuZ2U6NGY3Yzk2Mjk5M2U1NGI3NWI4ZDVkZWIzZGQyZmI1OTJfMy0yLTEtMS05ODEz_071d7622-5645-409d-b299-203bec368379"
      unitRef="usd">8343000</us-gaap:ContractWithCustomerLiability>
    <xcur:ContractWithCustomerLiabilityAdditions
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RhYmxlOjRmN2M5NjI5OTNlNTRiNzViOGQ1ZGViM2RkMmZiNTkyL3RhYmxlcmFuZ2U6NGY3Yzk2Mjk5M2U1NGI3NWI4ZDVkZWIzZGQyZmI1OTJfMy00LTEtMS05ODE1_d4f248e4-8c10-48a2-a085-ea84b5238b14"
      unitRef="usd">20000000</xcur:ContractWithCustomerLiabilityAdditions>
    <xcur:ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RhYmxlOjRmN2M5NjI5OTNlNTRiNzViOGQ1ZGViM2RkMmZiNTkyL3RhYmxlcmFuZ2U6NGY3Yzk2Mjk5M2U1NGI3NWI4ZDVkZWIzZGQyZmI1OTJfMy02LTEtMS05ODE3_9028993b-9a83-46c8-8ffd-c0c8110d506d"
      unitRef="usd">-2601000</xcur:ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80My9mcmFnOjFjZjIxNzc1OTQxYjRhODZiZDliMzM3MDkwMTJkNGU5L3RhYmxlOjRmN2M5NjI5OTNlNTRiNzViOGQ1ZGViM2RkMmZiNTkyL3RhYmxlcmFuZ2U6NGY3Yzk2Mjk5M2U1NGI3NWI4ZDVkZWIzZGQyZmI1OTJfMy04LTEtMS05ODE5_9c9f39d9-bfd9-40f9-b63e-d69b9f4c7686"
      unitRef="usd">30944000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RleHRyZWdpb246ODE1YmQzOGUzYWEwNGE0ZmE3NGU0ZDVmMDM2OGQxNGRfMzY1_50093ffb-71a7-4ff4-8469-797724eaee40">Supplemental Balance Sheet Information&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.711%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.165%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid clinical, contract research and manufacturing costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.230%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.314%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Scientific equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computers and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,373)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,740)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense was $283 and $159 for the three months ended September 30, 2021 and 2020, respectively, and $829 and $494 for the nine months ended September 30, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.551%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.289%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.950%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical, contract research and manufacturing costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RleHRyZWdpb246ODE1YmQzOGUzYWEwNGE0ZmE3NGU0ZDVmMDM2OGQxNGRfMzYw_e6004c0b-787a-4892-a512-87513ecb8d50">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.711%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.165%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid clinical, contract research and manufacturing costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjNkN2ZjYWIwNzQzZDQ3NmRiNzkwZDQxZmVlNjI4MjI3L3RhYmxlcmFuZ2U6M2Q3ZmNhYjA3NDNkNDc2ZGI3OTBkNDFmZWU2MjgyMjdfMS0xLTEtMS0w_44efd144-c4a2-470a-9810-8f221ebc9e0f"
      unitRef="usd">2133000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjNkN2ZjYWIwNzQzZDQ3NmRiNzkwZDQxZmVlNjI4MjI3L3RhYmxlcmFuZ2U6M2Q3ZmNhYjA3NDNkNDc2ZGI3OTBkNDFmZWU2MjgyMjdfMS0zLTEtMS0w_f6a5fad5-0184-45db-a5c0-4db8f007ad18"
      unitRef="usd">2336000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:InterestReceivable
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjNkN2ZjYWIwNzQzZDQ3NmRiNzkwZDQxZmVlNjI4MjI3L3RhYmxlcmFuZ2U6M2Q3ZmNhYjA3NDNkNDc2ZGI3OTBkNDFmZWU2MjgyMjdfMi0xLTEtMS0w_9731dda8-5193-4705-bfe5-5de4a9c33b52"
      unitRef="usd">27000</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjNkN2ZjYWIwNzQzZDQ3NmRiNzkwZDQxZmVlNjI4MjI3L3RhYmxlcmFuZ2U6M2Q3ZmNhYjA3NDNkNDc2ZGI3OTBkNDFmZWU2MjgyMjdfMi0zLTEtMS0w_d715f63b-195b-4de2-a475-2da2bdf71933"
      unitRef="usd">161000</us-gaap:InterestReceivable>
    <us-gaap:PrepaidInsurance
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjNkN2ZjYWIwNzQzZDQ3NmRiNzkwZDQxZmVlNjI4MjI3L3RhYmxlcmFuZ2U6M2Q3ZmNhYjA3NDNkNDc2ZGI3OTBkNDFmZWU2MjgyMjdfMy0xLTEtMS0w_bea88837-e20c-4e60-9fb9-f691cee33107"
      unitRef="usd">40000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjNkN2ZjYWIwNzQzZDQ3NmRiNzkwZDQxZmVlNjI4MjI3L3RhYmxlcmFuZ2U6M2Q3ZmNhYjA3NDNkNDc2ZGI3OTBkNDFmZWU2MjgyMjdfMy0zLTEtMS0w_5b4c6c61-9837-424e-a407-ad1c489298e4"
      unitRef="usd">694000</us-gaap:PrepaidInsurance>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjNkN2ZjYWIwNzQzZDQ3NmRiNzkwZDQxZmVlNjI4MjI3L3RhYmxlcmFuZ2U6M2Q3ZmNhYjA3NDNkNDc2ZGI3OTBkNDFmZWU2MjgyMjdfNC0xLTEtMS0w_c1b41cdd-4a14-4ebf-8d10-aeb73a2b7e0d"
      unitRef="usd">1109000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjNkN2ZjYWIwNzQzZDQ3NmRiNzkwZDQxZmVlNjI4MjI3L3RhYmxlcmFuZ2U6M2Q3ZmNhYjA3NDNkNDc2ZGI3OTBkNDFmZWU2MjgyMjdfNC0zLTEtMS0w_ce4a47a4-90de-490e-b930-cce096e7845f"
      unitRef="usd">1040000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjNkN2ZjYWIwNzQzZDQ3NmRiNzkwZDQxZmVlNjI4MjI3L3RhYmxlcmFuZ2U6M2Q3ZmNhYjA3NDNkNDc2ZGI3OTBkNDFmZWU2MjgyMjdfNS0xLTEtMS0w_327d19d2-706c-49e5-9e7f-ede5a551cde2"
      unitRef="usd">3309000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjNkN2ZjYWIwNzQzZDQ3NmRiNzkwZDQxZmVlNjI4MjI3L3RhYmxlcmFuZ2U6M2Q3ZmNhYjA3NDNkNDc2ZGI3OTBkNDFmZWU2MjgyMjdfNS0zLTEtMS0w_de6fc8f1-c5e4-401b-9d14-802d637cbc6a"
      unitRef="usd">4231000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RleHRyZWdpb246ODE1YmQzOGUzYWEwNGE0ZmE3NGU0ZDVmMDM2OGQxNGRfMzY3_ba74598f-c94a-4557-8067-c74d9a15032b">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.230%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.314%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Scientific equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computers and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,373)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,740)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i47cd4e78b2384bf799057776f855682a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjFhNGEwMmI1NDk5YjQyNTliMjk4ODYyZGY3ZTM1ZDBjL3RhYmxlcmFuZ2U6MWE0YTAyYjU0OTliNDI1OWIyOTg4NjJkZjdlMzVkMGNfMS0xLTEtMS0w_79891888-4cff-4e90-a5ac-1f39e1c7a219"
      unitRef="usd">6136000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0018e41fbb07474dba5b83bb48cc8e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjFhNGEwMmI1NDk5YjQyNTliMjk4ODYyZGY3ZTM1ZDBjL3RhYmxlcmFuZ2U6MWE0YTAyYjU0OTliNDI1OWIyOTg4NjJkZjdlMzVkMGNfMS0zLTEtMS0w_01e1218f-91d3-4b27-95f7-00186616d361"
      unitRef="usd">5476000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib82780d8d54341299de5c10d925f31a6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjFhNGEwMmI1NDk5YjQyNTliMjk4ODYyZGY3ZTM1ZDBjL3RhYmxlcmFuZ2U6MWE0YTAyYjU0OTliNDI1OWIyOTg4NjJkZjdlMzVkMGNfMi0xLTEtMS0w_72ae94eb-5fe7-4d7a-bb8b-ad1702caef34"
      unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie3ceab8c75694c4993355dcd2ae5c9fe_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjFhNGEwMmI1NDk5YjQyNTliMjk4ODYyZGY3ZTM1ZDBjL3RhYmxlcmFuZ2U6MWE0YTAyYjU0OTliNDI1OWIyOTg4NjJkZjdlMzVkMGNfMi0zLTEtMS0w_8a75cfc2-b76c-4dc9-bac4-9b2289941fd3"
      unitRef="usd">192000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i40174dd466594c3ab62a59e071f6cefd_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjFhNGEwMmI1NDk5YjQyNTliMjk4ODYyZGY3ZTM1ZDBjL3RhYmxlcmFuZ2U6MWE0YTAyYjU0OTliNDI1OWIyOTg4NjJkZjdlMzVkMGNfMy0xLTEtMS0w_2ea5ab26-7842-43bf-81fe-23f668720fd8"
      unitRef="usd">60000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5d6ec4e189a747bd803d814ff65b5f44_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjFhNGEwMmI1NDk5YjQyNTliMjk4ODYyZGY3ZTM1ZDBjL3RhYmxlcmFuZ2U6MWE0YTAyYjU0OTliNDI1OWIyOTg4NjJkZjdlMzVkMGNfMy0zLTEtMS0w_656eb85d-1cb0-42b3-bf91-925a941865ac"
      unitRef="usd">46000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id9c2eeac1b3a491ba5d5b4821b396ce8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjFhNGEwMmI1NDk5YjQyNTliMjk4ODYyZGY3ZTM1ZDBjL3RhYmxlcmFuZ2U6MWE0YTAyYjU0OTliNDI1OWIyOTg4NjJkZjdlMzVkMGNfNC0xLTEtMS0w_f1ffcd5e-7f92-46e4-adc3-cb755111c0a0"
      unitRef="usd">30000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib8817be1e21d4636989a972eaf99d676_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjFhNGEwMmI1NDk5YjQyNTliMjk4ODYyZGY3ZTM1ZDBjL3RhYmxlcmFuZ2U6MWE0YTAyYjU0OTliNDI1OWIyOTg4NjJkZjdlMzVkMGNfNC0zLTEtMS0w_4936673e-689b-4169-8291-8c42aeb369e5"
      unitRef="usd">30000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iac3a1146a0b04454a629ec3468190f98_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjFhNGEwMmI1NDk5YjQyNTliMjk4ODYyZGY3ZTM1ZDBjL3RhYmxlcmFuZ2U6MWE0YTAyYjU0OTliNDI1OWIyOTg4NjJkZjdlMzVkMGNfNS0xLTEtMS0w_04755b2d-5905-4bfc-8b60-3af247033387"
      unitRef="usd">318000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i00fa9951d7744973a1c8d2aa533d73dc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjFhNGEwMmI1NDk5YjQyNTliMjk4ODYyZGY3ZTM1ZDBjL3RhYmxlcmFuZ2U6MWE0YTAyYjU0OTliNDI1OWIyOTg4NjJkZjdlMzVkMGNfNS0zLTEtMS0w_c8321348-7d7c-45de-b020-0778f4b4d49e"
      unitRef="usd">119000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjFhNGEwMmI1NDk5YjQyNTliMjk4ODYyZGY3ZTM1ZDBjL3RhYmxlcmFuZ2U6MWE0YTAyYjU0OTliNDI1OWIyOTg4NjJkZjdlMzVkMGNfNi0xLTEtMS0w_acd46fe8-633f-4be1-9770-eb4df454ea1f"
      unitRef="usd">6544000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjFhNGEwMmI1NDk5YjQyNTliMjk4ODYyZGY3ZTM1ZDBjL3RhYmxlcmFuZ2U6MWE0YTAyYjU0OTliNDI1OWIyOTg4NjJkZjdlMzVkMGNfNi0zLTEtMS0w_31839d56-d211-4991-939e-635c85a5fe9d"
      unitRef="usd">5863000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjFhNGEwMmI1NDk5YjQyNTliMjk4ODYyZGY3ZTM1ZDBjL3RhYmxlcmFuZ2U6MWE0YTAyYjU0OTliNDI1OWIyOTg4NjJkZjdlMzVkMGNfNy0xLTEtMS0w_6b2ea2f1-20f5-47a5-96b6-0bb90e1de599"
      unitRef="usd">2373000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjFhNGEwMmI1NDk5YjQyNTliMjk4ODYyZGY3ZTM1ZDBjL3RhYmxlcmFuZ2U6MWE0YTAyYjU0OTliNDI1OWIyOTg4NjJkZjdlMzVkMGNfNy0zLTEtMS0w_a59656a1-5903-45aa-9ec0-13498cad8dc9"
      unitRef="usd">1740000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjFhNGEwMmI1NDk5YjQyNTliMjk4ODYyZGY3ZTM1ZDBjL3RhYmxlcmFuZ2U6MWE0YTAyYjU0OTliNDI1OWIyOTg4NjJkZjdlMzVkMGNfOC0xLTEtMS0w_5642c749-6942-4353-ab25-c5c83f33daad"
      unitRef="usd">4171000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjFhNGEwMmI1NDk5YjQyNTliMjk4ODYyZGY3ZTM1ZDBjL3RhYmxlcmFuZ2U6MWE0YTAyYjU0OTliNDI1OWIyOTg4NjJkZjdlMzVkMGNfOC0zLTEtMS0w_8e3ab2be-9df8-4100-ae74-5d2c4baf0005"
      unitRef="usd">4123000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAmortizationAndAccretionNet
      contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RleHRyZWdpb246ODE1YmQzOGUzYWEwNGE0ZmE3NGU0ZDVmMDM2OGQxNGRfMTY0_6f216bc2-a641-4bf4-afd5-5f9b9a716aed"
      unitRef="usd">283000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:DepreciationAmortizationAndAccretionNet
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RleHRyZWdpb246ODE1YmQzOGUzYWEwNGE0ZmE3NGU0ZDVmMDM2OGQxNGRfMTcx_3c4b46fe-78d1-4b1a-9202-ff3ffc305857"
      unitRef="usd">159000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:DepreciationAmortizationAndAccretionNet
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RleHRyZWdpb246ODE1YmQzOGUzYWEwNGE0ZmE3NGU0ZDVmMDM2OGQxNGRfMjQz_3f9aba37-5e2b-4299-8cf3-221d5a37cfba"
      unitRef="usd">829000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:DepreciationAmortizationAndAccretionNet
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RleHRyZWdpb246ODE1YmQzOGUzYWEwNGE0ZmE3NGU0ZDVmMDM2OGQxNGRfMjUw_d22ad309-96d0-44d9-8e9d-c467bc411f93"
      unitRef="usd">494000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RleHRyZWdpb246ODE1YmQzOGUzYWEwNGE0ZmE3NGU0ZDVmMDM2OGQxNGRfMzYz_31d71642-37c4-4850-a872-7ef11703569c">&lt;div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.551%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.289%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.950%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical, contract research and manufacturing costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <xcur:AccruedClinicalContractResearchAndManufacturingCostsCurrent
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjY2OWNlNTZhMzExMTQ0ODY4YThjZjQyMzMwOTdhNjk4L3RhYmxlcmFuZ2U6NjY5Y2U1NmEzMTExNDQ4NjhhOGNmNDIzMzA5N2E2OThfMS0xLTEtMS0w_8cc2406e-e07d-44e1-9604-737d1f81b9e7"
      unitRef="usd">2741000</xcur:AccruedClinicalContractResearchAndManufacturingCostsCurrent>
    <xcur:AccruedClinicalContractResearchAndManufacturingCostsCurrent
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjY2OWNlNTZhMzExMTQ0ODY4YThjZjQyMzMwOTdhNjk4L3RhYmxlcmFuZ2U6NjY5Y2U1NmEzMTExNDQ4NjhhOGNmNDIzMzA5N2E2OThfMS0zLTEtMS0w_2b9c13c7-18e6-4b45-ae90-78593b7940a3"
      unitRef="usd">1372000</xcur:AccruedClinicalContractResearchAndManufacturingCostsCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjY2OWNlNTZhMzExMTQ0ODY4YThjZjQyMzMwOTdhNjk4L3RhYmxlcmFuZ2U6NjY5Y2U1NmEzMTExNDQ4NjhhOGNmNDIzMzA5N2E2OThfMi0xLTEtMS0w_21e92a15-347b-4548-b0c7-05244847c595"
      unitRef="usd">1388000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjY2OWNlNTZhMzExMTQ0ODY4YThjZjQyMzMwOTdhNjk4L3RhYmxlcmFuZ2U6NjY5Y2U1NmEzMTExNDQ4NjhhOGNmNDIzMzA5N2E2OThfMi0zLTEtMS0w_3123cd51-0e90-4072-adc0-5bc9a4b052e8"
      unitRef="usd">1158000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjY2OWNlNTZhMzExMTQ0ODY4YThjZjQyMzMwOTdhNjk4L3RhYmxlcmFuZ2U6NjY5Y2U1NmEzMTExNDQ4NjhhOGNmNDIzMzA5N2E2OThfNS0xLTEtMS0w_e5458608-a56e-4e1e-ae46-96d4b4b0cb13"
      unitRef="usd">440000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjY2OWNlNTZhMzExMTQ0ODY4YThjZjQyMzMwOTdhNjk4L3RhYmxlcmFuZ2U6NjY5Y2U1NmEzMTExNDQ4NjhhOGNmNDIzMzA5N2E2OThfNS0zLTEtMS0w_0185b2de-8c75-45f1-8e07-6d81cc5d552e"
      unitRef="usd">223000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjY2OWNlNTZhMzExMTQ0ODY4YThjZjQyMzMwOTdhNjk4L3RhYmxlcmFuZ2U6NjY5Y2U1NmEzMTExNDQ4NjhhOGNmNDIzMzA5N2E2OThfNi0xLTEtMS0w_93b71cf2-ec9b-42ba-966f-577e5c175aec"
      unitRef="usd">911000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjY2OWNlNTZhMzExMTQ0ODY4YThjZjQyMzMwOTdhNjk4L3RhYmxlcmFuZ2U6NjY5Y2U1NmEzMTExNDQ4NjhhOGNmNDIzMzA5N2E2OThfNi0zLTEtMS0w_7a293d27-e8b2-475f-891b-e1a89151993b"
      unitRef="usd">772000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjY2OWNlNTZhMzExMTQ0ODY4YThjZjQyMzMwOTdhNjk4L3RhYmxlcmFuZ2U6NjY5Y2U1NmEzMTExNDQ4NjhhOGNmNDIzMzA5N2E2OThfNy0xLTEtMS0w_1260afa5-162f-49b8-aa0d-1ccb0c66d1a3"
      unitRef="usd">5480000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80Ni9mcmFnOjgxNWJkMzhlM2FhMDRhNGZhNzRlNGQ1ZjAzNjhkMTRkL3RhYmxlOjY2OWNlNTZhMzExMTQ0ODY4YThjZjQyMzMwOTdhNjk4L3RhYmxlcmFuZ2U6NjY5Y2U1NmEzMTExNDQ4NjhhOGNmNDIzMzA5N2E2OThfNy0zLTEtMS0w_80137896-e317-4c19-898f-e8d1dd581429"
      unitRef="usd">3525000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RleHRyZWdpb246YzJhNzk3NmJiODUzNDMyOGI0MTJlMmJhMTA5NTI1NmVfMTIzNQ_5953c5ab-28cd-4a8f-a472-597313334556">Investments&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021 and December&#160;31, 2020, the Company primarily invested its excess cash in debt instruments of corporations, the U.S. Treasury, financial institutions, and U.S. government agencies with strong credit ratings and an investment grade rating at or above a long-term rating of Aa3/AA- and a short-term rating of P1/A1. The Company has established guidelines relative to diversification and maturities that maintain safety and liquidity. The Company periodically reviews and modifies these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the contract maturity of the available-for-sale securities the Company held as of September&#160;30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:282.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:211.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;One year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After one year but within two years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company&#x2019;s available-for-sale securities are available to the Company for use in its current operations. As a result, the Company categorizes all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortized cost, gross unrealized holding gains, gross unrealized holding losses and fair value of cash equivalents and available-for-sale securities by type of security at&#160;September&#160;30, 2021&#160;and December&#160;31, 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.826%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.687%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Holding Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Holding Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.025%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.680%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.680%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.680%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Holding Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Holding Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:InvestmentTableTextBlock
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RleHRyZWdpb246YzJhNzk3NmJiODUzNDMyOGI0MTJlMmJhMTA5NTI1NmVfMTIzNg_db166bcc-0eb1-4735-8841-5d127b84b76e">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the contract maturity of the available-for-sale securities the Company held as of September&#160;30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:282.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:211.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;One year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After one year but within two years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentTableTextBlock>
    <xcur:DebtSecuritiesAvailableForSaleCurrentPercent
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOjQwZDM3MjI5MDZhNDQzMTlhZjgyNWNjOGYyN2MxNTc4L3RhYmxlcmFuZ2U6NDBkMzcyMjkwNmE0NDMxOWFmODI1Y2M4ZjI3YzE1NzhfMC0xLTEtMS0w_85e9da8f-f937-4cbe-a00a-ffb285af69eb"
      unitRef="number">1</xcur:DebtSecuritiesAvailableForSaleCurrentPercent>
    <xcur:DebtSecuritiesAvailableForSaleNoncurrentPercent
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOjQwZDM3MjI5MDZhNDQzMTlhZjgyNWNjOGYyN2MxNTc4L3RhYmxlcmFuZ2U6NDBkMzcyMjkwNmE0NDMxOWFmODI1Y2M4ZjI3YzE1NzhfMS0xLTEtMS0w_a5855e8c-583a-4f44-9e4b-5f2cff06d0dc"
      unitRef="number">0</xcur:DebtSecuritiesAvailableForSaleNoncurrentPercent>
    <xcur:DebtSecuritiesAvailableforSalePercent
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOjQwZDM3MjI5MDZhNDQzMTlhZjgyNWNjOGYyN2MxNTc4L3RhYmxlcmFuZ2U6NDBkMzcyMjkwNmE0NDMxOWFmODI1Y2M4ZjI3YzE1NzhfMi0xLTEtMS0w_26016e68-9567-40f5-91c9-fe9352267a0e"
      unitRef="number">1</xcur:DebtSecuritiesAvailableforSalePercent>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RleHRyZWdpb246YzJhNzk3NmJiODUzNDMyOGI0MTJlMmJhMTA5NTI1NmVfMTIzNw_2fc5dc48-00d2-4fe8-8c09-0b08b3327eef">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortized cost, gross unrealized holding gains, gross unrealized holding losses and fair value of cash equivalents and available-for-sale securities by type of security at&#160;September&#160;30, 2021&#160;and December&#160;31, 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.826%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.687%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Holding Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Holding Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.025%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.680%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.680%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.680%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Holding Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Holding Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0053a355b9114313a12f8f7a031d65fc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOjUyNzIwZjI1NDQ2NDQxZGU4Y2JiNTE0OGFhMDNlYmJkL3RhYmxlcmFuZ2U6NTI3MjBmMjU0NDY0NDFkZThjYmI1MTQ4YWEwM2ViYmRfMi0xLTEtMS0w_c799d8c8-2e93-46f1-b247-295a7af4ca22"
      unitRef="usd">6498000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0053a355b9114313a12f8f7a031d65fc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOjUyNzIwZjI1NDQ2NDQxZGU4Y2JiNTE0OGFhMDNlYmJkL3RhYmxlcmFuZ2U6NTI3MjBmMjU0NDY0NDFkZThjYmI1MTQ4YWEwM2ViYmRfMi0zLTEtMS0w_446e9fe6-13ec-4ee3-bea0-0b2fc7166d65"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0053a355b9114313a12f8f7a031d65fc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOjUyNzIwZjI1NDQ2NDQxZGU4Y2JiNTE0OGFhMDNlYmJkL3RhYmxlcmFuZ2U6NTI3MjBmMjU0NDY0NDFkZThjYmI1MTQ4YWEwM2ViYmRfMi01LTEtMS0w_74e3d5f3-00b9-4e1b-b937-0d2b3f995991"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0053a355b9114313a12f8f7a031d65fc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOjUyNzIwZjI1NDQ2NDQxZGU4Y2JiNTE0OGFhMDNlYmJkL3RhYmxlcmFuZ2U6NTI3MjBmMjU0NDY0NDFkZThjYmI1MTQ4YWEwM2ViYmRfMi03LTEtMS0w_489fb3fe-5c4f-4680-b838-61e7bea9703a"
      unitRef="usd">6497000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4f345e6eb7f04fe4b6eab2801122fe23_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOjUyNzIwZjI1NDQ2NDQxZGU4Y2JiNTE0OGFhMDNlYmJkL3RhYmxlcmFuZ2U6NTI3MjBmMjU0NDY0NDFkZThjYmI1MTQ4YWEwM2ViYmRfMy0xLTEtMS0w_1f89aae0-1c1d-4d0a-a421-8450640bdc96"
      unitRef="usd">1205000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4f345e6eb7f04fe4b6eab2801122fe23_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOjUyNzIwZjI1NDQ2NDQxZGU4Y2JiNTE0OGFhMDNlYmJkL3RhYmxlcmFuZ2U6NTI3MjBmMjU0NDY0NDFkZThjYmI1MTQ4YWEwM2ViYmRfMy0zLTEtMS0w_f9ed4ed8-05ee-43ab-8bdf-14612ab368e1"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4f345e6eb7f04fe4b6eab2801122fe23_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOjUyNzIwZjI1NDQ2NDQxZGU4Y2JiNTE0OGFhMDNlYmJkL3RhYmxlcmFuZ2U6NTI3MjBmMjU0NDY0NDFkZThjYmI1MTQ4YWEwM2ViYmRfMy01LTEtMS0w_0682f879-92c4-4956-8d34-4c4386d0437e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4f345e6eb7f04fe4b6eab2801122fe23_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOjUyNzIwZjI1NDQ2NDQxZGU4Y2JiNTE0OGFhMDNlYmJkL3RhYmxlcmFuZ2U6NTI3MjBmMjU0NDY0NDFkZThjYmI1MTQ4YWEwM2ViYmRfMy03LTEtMS0w_eb91afc5-5fe7-4d48-a9b3-57d3f48bfbd7"
      unitRef="usd">1205000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9282a032bc9d437cbb449818fa2c4843_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOjUyNzIwZjI1NDQ2NDQxZGU4Y2JiNTE0OGFhMDNlYmJkL3RhYmxlcmFuZ2U6NTI3MjBmMjU0NDY0NDFkZThjYmI1MTQ4YWEwM2ViYmRfNS0xLTEtMS0w_cbd91c8e-bd50-4f14-ae4d-b1472d77308f"
      unitRef="usd">1251000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9282a032bc9d437cbb449818fa2c4843_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOjUyNzIwZjI1NDQ2NDQxZGU4Y2JiNTE0OGFhMDNlYmJkL3RhYmxlcmFuZ2U6NTI3MjBmMjU0NDY0NDFkZThjYmI1MTQ4YWEwM2ViYmRfNS0zLTEtMS0w_5f38f57f-5409-4b50-af9b-60ac06177b6e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9282a032bc9d437cbb449818fa2c4843_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOjUyNzIwZjI1NDQ2NDQxZGU4Y2JiNTE0OGFhMDNlYmJkL3RhYmxlcmFuZ2U6NTI3MjBmMjU0NDY0NDFkZThjYmI1MTQ4YWEwM2ViYmRfNS01LTEtMS0w_e9008db2-62b5-4f1e-b68b-ca268ad4fb22"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9282a032bc9d437cbb449818fa2c4843_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOjUyNzIwZjI1NDQ2NDQxZGU4Y2JiNTE0OGFhMDNlYmJkL3RhYmxlcmFuZ2U6NTI3MjBmMjU0NDY0NDFkZThjYmI1MTQ4YWEwM2ViYmRfNS03LTEtMS0w_ef6d909e-2973-43b8-88d4-53f1cfa72d75"
      unitRef="usd">1251000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOjUyNzIwZjI1NDQ2NDQxZGU4Y2JiNTE0OGFhMDNlYmJkL3RhYmxlcmFuZ2U6NTI3MjBmMjU0NDY0NDFkZThjYmI1MTQ4YWEwM2ViYmRfNi0xLTEtMS0w_6a0ae527-1695-47d3-a050-6219b214f366"
      unitRef="usd">8954000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOjUyNzIwZjI1NDQ2NDQxZGU4Y2JiNTE0OGFhMDNlYmJkL3RhYmxlcmFuZ2U6NTI3MjBmMjU0NDY0NDFkZThjYmI1MTQ4YWEwM2ViYmRfNi0zLTEtMS0w_47ea8beb-ed6f-4f6d-a6fa-f14f55d9eb9a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOjUyNzIwZjI1NDQ2NDQxZGU4Y2JiNTE0OGFhMDNlYmJkL3RhYmxlcmFuZ2U6NTI3MjBmMjU0NDY0NDFkZThjYmI1MTQ4YWEwM2ViYmRfNi01LTEtMS0w_627af70c-7f8d-44b8-a208-be99187ad431"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOjUyNzIwZjI1NDQ2NDQxZGU4Y2JiNTE0OGFhMDNlYmJkL3RhYmxlcmFuZ2U6NTI3MjBmMjU0NDY0NDFkZThjYmI1MTQ4YWEwM2ViYmRfNi03LTEtMS0w_3a4f2c6f-a23c-412f-a8ee-5bbe1b04fbe5"
      unitRef="usd">8953000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i23975282c1f34d05bda28777e4086e31_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOmMwMGFhZTEwMjYyOTRlYjU5ZGFlZjg2MWFiOTg3ODhhL3RhYmxlcmFuZ2U6YzAwYWFlMTAyNjI5NGViNTlkYWVmODYxYWI5ODc4OGFfMi0xLTEtMS0w_c8459f8d-4d00-4276-930f-0e06c76c04a2"
      unitRef="usd">15992000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i23975282c1f34d05bda28777e4086e31_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOmMwMGFhZTEwMjYyOTRlYjU5ZGFlZjg2MWFiOTg3ODhhL3RhYmxlcmFuZ2U6YzAwYWFlMTAyNjI5NGViNTlkYWVmODYxYWI5ODc4OGFfMi0zLTEtMS0w_78bdf0fb-b3db-4037-9027-46898d20f24a"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i23975282c1f34d05bda28777e4086e31_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOmMwMGFhZTEwMjYyOTRlYjU5ZGFlZjg2MWFiOTg3ODhhL3RhYmxlcmFuZ2U6YzAwYWFlMTAyNjI5NGViNTlkYWVmODYxYWI5ODc4OGFfMi01LTEtMS0w_c6b15843-75bb-4c53-b5ad-07fcd2075d07"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i23975282c1f34d05bda28777e4086e31_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOmMwMGFhZTEwMjYyOTRlYjU5ZGFlZjg2MWFiOTg3ODhhL3RhYmxlcmFuZ2U6YzAwYWFlMTAyNjI5NGViNTlkYWVmODYxYWI5ODc4OGFfMi03LTEtMS0w_e61d8a44-d8e4-43c2-8b0e-f4ce760265da"
      unitRef="usd">15991000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia247df9dcde04691921f7589b38fdf6a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOmMwMGFhZTEwMjYyOTRlYjU5ZGFlZjg2MWFiOTg3ODhhL3RhYmxlcmFuZ2U6YzAwYWFlMTAyNjI5NGViNTlkYWVmODYxYWI5ODc4OGFfMy0xLTEtMS0w_d8612ab6-7a56-421e-9bf2-ae3f71cb7c53"
      unitRef="usd">29227000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia247df9dcde04691921f7589b38fdf6a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOmMwMGFhZTEwMjYyOTRlYjU5ZGFlZjg2MWFiOTg3ODhhL3RhYmxlcmFuZ2U6YzAwYWFlMTAyNjI5NGViNTlkYWVmODYxYWI5ODc4OGFfMy0zLTEtMS0w_dafda7c4-757e-4f87-b0e0-1a8cde35b073"
      unitRef="usd">72000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia247df9dcde04691921f7589b38fdf6a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOmMwMGFhZTEwMjYyOTRlYjU5ZGFlZjg2MWFiOTg3ODhhL3RhYmxlcmFuZ2U6YzAwYWFlMTAyNjI5NGViNTlkYWVmODYxYWI5ODc4OGFfMy01LTEtMS0w_9cfe91b2-7974-4c4a-8fdd-365e769643ab"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia247df9dcde04691921f7589b38fdf6a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOmMwMGFhZTEwMjYyOTRlYjU5ZGFlZjg2MWFiOTg3ODhhL3RhYmxlcmFuZ2U6YzAwYWFlMTAyNjI5NGViNTlkYWVmODYxYWI5ODc4OGFfMy03LTEtMS0w_1e416cc7-6de2-48ae-acf8-655027d84e41"
      unitRef="usd">29296000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2705fb27647c4404a185735a84cd5bae_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOmMwMGFhZTEwMjYyOTRlYjU5ZGFlZjg2MWFiOTg3ODhhL3RhYmxlcmFuZ2U6YzAwYWFlMTAyNjI5NGViNTlkYWVmODYxYWI5ODc4OGFfNC0xLTEtMS0w_8aee06ff-12dd-40a8-8bde-1bfbc1ff8741"
      unitRef="usd">2251000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2705fb27647c4404a185735a84cd5bae_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOmMwMGFhZTEwMjYyOTRlYjU5ZGFlZjg2MWFiOTg3ODhhL3RhYmxlcmFuZ2U6YzAwYWFlMTAyNjI5NGViNTlkYWVmODYxYWI5ODc4OGFfNC0zLTEtMS0w_400cd595-9b27-49ce-a62a-a25686de2ef6"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2705fb27647c4404a185735a84cd5bae_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOmMwMGFhZTEwMjYyOTRlYjU5ZGFlZjg2MWFiOTg3ODhhL3RhYmxlcmFuZ2U6YzAwYWFlMTAyNjI5NGViNTlkYWVmODYxYWI5ODc4OGFfNC01LTEtMS0w_44887ace-5b7e-4c78-88dc-59a0e869d879"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2705fb27647c4404a185735a84cd5bae_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOmMwMGFhZTEwMjYyOTRlYjU5ZGFlZjg2MWFiOTg3ODhhL3RhYmxlcmFuZ2U6YzAwYWFlMTAyNjI5NGViNTlkYWVmODYxYWI5ODc4OGFfNC03LTEtMS0w_74ba333d-6f7f-4a09-a1a4-18c28d29c550"
      unitRef="usd">2253000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7567e0c7c5914bf5bde30bc572efc791_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOmMwMGFhZTEwMjYyOTRlYjU5ZGFlZjg2MWFiOTg3ODhhL3RhYmxlcmFuZ2U6YzAwYWFlMTAyNjI5NGViNTlkYWVmODYxYWI5ODc4OGFfNS0xLTEtMS0w_3bf0e5f0-b54c-4f31-af6e-1a6a97602849"
      unitRef="usd">1265000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7567e0c7c5914bf5bde30bc572efc791_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOmMwMGFhZTEwMjYyOTRlYjU5ZGFlZjg2MWFiOTg3ODhhL3RhYmxlcmFuZ2U6YzAwYWFlMTAyNjI5NGViNTlkYWVmODYxYWI5ODc4OGFfNS0zLTEtMS0w_eb2ab05e-48c3-49c9-95f5-fe1fdf1c6bc9"
      unitRef="usd">13000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7567e0c7c5914bf5bde30bc572efc791_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOmMwMGFhZTEwMjYyOTRlYjU5ZGFlZjg2MWFiOTg3ODhhL3RhYmxlcmFuZ2U6YzAwYWFlMTAyNjI5NGViNTlkYWVmODYxYWI5ODc4OGFfNS01LTEtMS0w_1ea05b73-02cb-474b-b6f9-b37cb6965a08"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7567e0c7c5914bf5bde30bc572efc791_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOmMwMGFhZTEwMjYyOTRlYjU5ZGFlZjg2MWFiOTg3ODhhL3RhYmxlcmFuZ2U6YzAwYWFlMTAyNjI5NGViNTlkYWVmODYxYWI5ODc4OGFfNS03LTEtMS0w_fb726eb9-3fbb-4ac3-89ef-7948b87f9082"
      unitRef="usd">1278000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOmMwMGFhZTEwMjYyOTRlYjU5ZGFlZjg2MWFiOTg3ODhhL3RhYmxlcmFuZ2U6YzAwYWFlMTAyNjI5NGViNTlkYWVmODYxYWI5ODc4OGFfNi0xLTEtMS0w_0c414ea8-fc25-4945-9bb7-27ade88e10e9"
      unitRef="usd">48735000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOmMwMGFhZTEwMjYyOTRlYjU5ZGFlZjg2MWFiOTg3ODhhL3RhYmxlcmFuZ2U6YzAwYWFlMTAyNjI5NGViNTlkYWVmODYxYWI5ODc4OGFfNi0zLTEtMS0w_5fa6ca2b-0a46-41d0-85b5-1afc7a5c0505"
      unitRef="usd">89000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOmMwMGFhZTEwMjYyOTRlYjU5ZGFlZjg2MWFiOTg3ODhhL3RhYmxlcmFuZ2U6YzAwYWFlMTAyNjI5NGViNTlkYWVmODYxYWI5ODc4OGFfNi01LTEtMS0w_ecbbe779-f43c-4bb3-9151-d0a7761828ec"
      unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV80OS9mcmFnOmMyYTc5NzZiYjg1MzQzMjhiNDEyZTJiYTEwOTUyNTZlL3RhYmxlOmMwMGFhZTEwMjYyOTRlYjU5ZGFlZjg2MWFiOTg3ODhhL3RhYmxlcmFuZ2U6YzAwYWFlMTAyNjI5NGViNTlkYWVmODYxYWI5ODc4OGFfNi03LTEtMS0w_f77955a4-83c2-4db6-91a6-11f463daa579"
      unitRef="usd">48818000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfNTYwNg_72d8fca4-4d7c-4765-98f5-2272f0d0e469">Debt&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;MidCap Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 30, 2021, the Company entered into an amendment (&#x201c;Amendment No. 3&#x201d;) to the Company&#x2019;s Credit and Security Agreement, dated as of September 25, 2020, as amended on October 21, 2020 and July 30, 2021, with MidCap Financial Trust, as agent (&#x201c;MidCap&#x201d;), and the lenders party thereto from time to time (as amended by Amendment No. 3, the &#x201c;MidCap Credit Agreement&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The MidCap Credit Agreement provides for a secured term loan facility in an aggregate principal amount of up to $25,000 (the &#x201c;MidCap Credit Facility&#x201d;). The Company borrowed the first advance of $17,500 (&#x201c;Tranche 1&#x201d;) on September 25, 2020 (the &#x201c;Closing Date&#x201d;). Amendment No. 3 extends the availability of the second advance of $7,500 (&#x201c;Tranche 2&#x201d;) under the MidCap Credit Agreement from September 30, 2021 to December 31, 2021, subject to the Company&#x2019;s satisfaction of certain applicable funding conditions as described in Amendment No. 3, including  the Company&#x2019;s issuance of equity interests, subject to certain limitations, resulting in receipt by the Company of unrestricted net cash proceeds of at least $20,000, and the contribution by the Company, and receipt by Exicure Operating Company, of such cash proceeds to the capital of Exicure Operating Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Tranche 1 and if borrowed, Tranche 2, each bear interest at a floating rate equal to 6.25% per annum, plus the greater of (i) 1.50% or (ii) one-month LIBOR. Interest on each loan advance is due and payable monthly in arrears. Principal on each loan advance is payable in 36 equal monthly installments beginning October 1, 2022 until paid in full on October 1, 2025 (the &#x201c;Maturity Date&#x201d;). Prepayments of the loans under the MidCap Credit Agreement, in whole or in part, will be subject to early termination fees in an amount equal to 3.0% of principal prepaid if prepayment occurs on or prior to the first anniversary of the Closing Date and 1.0% of principal prepaid if prepayment occurs after the first anniversary of the Closing Date and prior to the maturity date.  In connection with execution of the MidCap Credit Agreement, the Company paid MidCap a $125 origination fee.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the Maturity Date or on any earlier date on which all amounts advanced to the Company become due and payable in full, or are otherwise paid in full, the Company is required to pay an exit fee equal to 3.75% of the principal amount of all loans advanced to the Company under the MidCap Credit Agreement. Upon the advance of Tranche 1, the Company accrued $656 for the related exit fee.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s obligations under the MidCap Credit Agreement are secured by a security interest in substantially all of its assets, excluding intellectual property (which is subject to a negative pledge). Additionally, the Company&#x2019;s future subsidiaries, if any, may be required to become co-borrowers or guarantors under the MidCap Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The MidCap Credit Agreement contains customary affirmative covenants and customary negative covenants limiting the Company&#x2019;s ability and the ability of the Company&#x2019;s subsidiaries, if any, to, among other things, dispose of assets, undergo a change in control, merge or consolidate, make acquisitions, incur debt, incur liens, pay dividends, repurchase stock and make investments, in each case subject to certain exceptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The MidCap Credit Agreement also contains customary events of default relating to, among other things, payment defaults, breaches of covenants, a material adverse change, delisting of the Company&#x2019;s common stock, bankruptcy and insolvency, cross defaults with certain material indebtedness and certain material contracts, judgments, and inaccuracies of representations and warranties. Upon an event of default, the agent and the lenders may declare all or a portion of the Company&#x2019;s outstanding obligations to be immediately due and payable and exercise other rights and remedies provided for under the agreement. During the existence of an event of default, interest on the obligations could be increased by 2.0%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total proceeds, net of fees and issuance costs, borrowed under Tranche 1 were $16,512.  Fees and issuance costs of $332, as well as fees of $656 that are payable to MidCap at maturity of Tranche 1, are recorded as a reduction to the carrying amount of long-term debt on the Company&#x2019;s balance sheet and will be amortized to interest expense through the maturity date of October 1, 2025 using the effective interest method. Fees and issuance costs of $73 attributed to the amount available to be borrowed under Tranche 2 were paid and recorded as deferred financing costs (other assets) and will be (i) recorded as a reduction in the carrying amount of long-term debt in future periods if amounts are borrowed under Tranche 2 or (ii) will be amortized and recorded to interest expense if amounts are not borrowed under Tranche 2. For the three and nine months ended September 30, 2021, the Company recognized $36 and $73, respectively, as interest expense and no balance of the deferred financing costs remains as of September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, the aggregate carrying value of the Company&#x2019;s long-term debt is $16,801.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, the principal maturities of the Company&#x2019;s long-term debt were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.749%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 (remaining three months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal balance outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;less: unamortized discount and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(699)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company paid interest on the MidCap Credit Agreement of $344 and $1,041 during the three and nine months ended September 30, 2021, respectively. The Company paid interest on the Hercules Loan Agreement (as discussed below) of $0 and $142 during the three and nine months ended September 30, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Hercules Loan Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 2, 2020, pursuant to the terms of the loan agreement with Hercules Technology Growth Capital (&#x201c;Hercules&#x201d;) and subsequent amendments thereto  (the &#x201c;Hercules Loan Agreement&#x201d;), the Company repaid all remaining outstanding obligations under the Hercules Loan Agreement as of the maturity date, including the outstanding principal balance of $4,999 and the end of term fee of $100.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="if6bd93e3d37e4fcb8e2b2027637863ed_I20200925"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfMzk0_f835ca36-70b2-46fd-9b38-78161f7bbc8b"
      unitRef="usd">25000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i7978f6f7e1b748cbabd1e2488f7447b7_D20200925-20200925"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfNDcx_2e42931f-9812-4e53-8f64-6e9917a0a042"
      unitRef="usd">17500000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i34a25167a0434d11aa0d2091e882e0a7_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfNjAy_27b83ca4-809e-42c2-a089-e32611f015e1"
      unitRef="usd">7500000</us-gaap:DebtInstrumentFaceAmount>
    <xcur:DebtInstrumentFundingConditionRequiredProceedsFromEquityIssuance
      contextRef="i34a25167a0434d11aa0d2091e882e0a7_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfNTQ5NzU1ODE1Mjk3Mg_23abd191-f729-4f8e-907a-b220729d7a7c"
      unitRef="usd">20000000</xcur:DebtInstrumentFundingConditionRequiredProceedsFromEquityIssuance>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if6bd93e3d37e4fcb8e2b2027637863ed_I20200925"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfMTEwOQ_2659edb6-c91b-47ea-9bc5-07848861abaf"
      unitRef="number">0.0625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ic8b146e3b6574d4ca6373ba4278baaa4_D20200925-20200925"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfMTE0Nw_9756f8c3-82b0-44c0-80ba-aa87a2d5d200"
      unitRef="number">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <xcur:DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments
      contextRef="i6c070a76443f46c79d54256b1cbf28fa_I20221001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfMTI4OQ_efca28db-cbb5-4886-9b9b-98746073a5df"
      unitRef="installmentpayment">36</xcur:DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments>
    <xcur:DebtInstrumentEarlyTerminationFeePercentageOfPrincipal
      contextRef="i89a02e4e5ce34167a93a3c5c5bff753f_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfMTU1MQ_00b1f68f-4974-4d8c-a9c4-f054cd5d84e9"
      unitRef="number">0.030</xcur:DebtInstrumentEarlyTerminationFeePercentageOfPrincipal>
    <xcur:DebtInstrumentEarlyTerminationFeePercentageOfPrincipal
      contextRef="i0d913806ddcd4fe38da350a6c3ed1feb_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfMTY1Nw_24565742-a127-4196-88f1-25b7517fdd66"
      unitRef="number">0.010</xcur:DebtInstrumentEarlyTerminationFeePercentageOfPrincipal>
    <us-gaap:LoanProcessingFee
      contextRef="ia9b3e45e1e944cbfa8d1c6fa857fb39c_D20200925-20200925"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfMTg3MA_b189f921-41d3-4ce6-8bf2-a68292eb3001"
      unitRef="usd">125000</us-gaap:LoanProcessingFee>
    <xcur:DebtInstrumentExitFeePercentage
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfMjA5NQ_dc42f5ba-f46f-4b83-a7e6-fb84be792633"
      unitRef="number">0.0375</xcur:DebtInstrumentExitFeePercentage>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="ic85ffe60044641adbba3cef493f35219_I20200925"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfMjI0NQ_b57ee90f-3c1e-4e03-93d9-a57d03cf68fa"
      unitRef="usd">656000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="i77889ae6ab624d1295d8b058f98f0543_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfMzc1NQ_495110cd-6b15-4c09-80a8-13acca5925a3"
      unitRef="number">0.020</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="i7978f6f7e1b748cbabd1e2488f7447b7_D20200925-20200925"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfMzgzNw_d54af0c4-1dc1-42eb-b1c7-1ce8602c4775"
      unitRef="usd">16512000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="ic85ffe60044641adbba3cef493f35219_I20200925"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfMzg2OQ_bdfdf06e-8399-44f8-8a42-95365a566e4c"
      unitRef="usd">332000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="ic85ffe60044641adbba3cef493f35219_I20200925"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfMzg5Mg_b57ee90f-3c1e-4e03-93d9-a57d03cf68fa"
      unitRef="usd">656000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i6126506f80104557ba998535d441061c_I20200925"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfNDE5OQ_c827bcb5-e345-43dd-b44b-7af7e89ccd3b"
      unitRef="usd">73000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="ice5e4b94c8ca4a1c808b55cb400e24e7_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfNDY1MA_b58ce5c0-6356-43d2-bf56-debaa0cf88a5"
      unitRef="usd">36000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i8f010890f93049f2ae4c474fd0f3290c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfMTA5OTUxMTY0MjExMw_6f810c06-46a0-4af0-a69e-0fd37e509ee7"
      unitRef="usd">73000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i34a25167a0434d11aa0d2091e882e0a7_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfNDczNA_7bd66838-68d7-4c4b-867b-4d13baf27e0c"
      unitRef="usd">0</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfNDgzMg_32a03de6-5720-44e6-aabc-eb4500ef8bb5"
      unitRef="usd">16801000</us-gaap:LongTermDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfNTYwOA_6c2aa4e4-7154-423d-8498-67f2ece1e2ef">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, the principal maturities of the Company&#x2019;s long-term debt were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.749%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 (remaining three months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal balance outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;less: unamortized discount and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(699)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RhYmxlOmI2ZTZiYWIyM2M1NzQ1OGFiMTFmM2UwNGQ3ZmM2NmEyL3RhYmxlcmFuZ2U6YjZlNmJhYjIzYzU3NDU4YWIxMWYzZTA0ZDdmYzY2YTJfMS0yLTEtMS0w_3db52d40-fda4-4b12-9491-dd07e1b6ee05"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RhYmxlOmI2ZTZiYWIyM2M1NzQ1OGFiMTFmM2UwNGQ3ZmM2NmEyL3RhYmxlcmFuZ2U6YjZlNmJhYjIzYzU3NDU4YWIxMWYzZTA0ZDdmYzY2YTJfMi0yLTEtMS0w_c770b5c8-93c2-46b3-92d3-b0f1f6464251"
      unitRef="usd">1459000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RhYmxlOmI2ZTZiYWIyM2M1NzQ1OGFiMTFmM2UwNGQ3ZmM2NmEyL3RhYmxlcmFuZ2U6YjZlNmJhYjIzYzU3NDU4YWIxMWYzZTA0ZDdmYzY2YTJfMy0yLTEtMS0w_8698dac4-0a82-42af-a517-ee35da116d9d"
      unitRef="usd">5833000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RhYmxlOmI2ZTZiYWIyM2M1NzQ1OGFiMTFmM2UwNGQ3ZmM2NmEyL3RhYmxlcmFuZ2U6YjZlNmJhYjIzYzU3NDU4YWIxMWYzZTA0ZDdmYzY2YTJfNC0yLTEtMS0w_6e70cb8a-9741-4f48-9780-76b1b4fb0b8d"
      unitRef="usd">5833000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RhYmxlOmI2ZTZiYWIyM2M1NzQ1OGFiMTFmM2UwNGQ3ZmM2NmEyL3RhYmxlcmFuZ2U6YjZlNmJhYjIzYzU3NDU4YWIxMWYzZTA0ZDdmYzY2YTJfNS0yLTEtMS0w_c6c3e711-2350-4b74-9f25-8985d356155f"
      unitRef="usd">4375000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RhYmxlOmI2ZTZiYWIyM2M1NzQ1OGFiMTFmM2UwNGQ3ZmM2NmEyL3RhYmxlcmFuZ2U6YjZlNmJhYjIzYzU3NDU4YWIxMWYzZTA0ZDdmYzY2YTJfNi0yLTEtMS0w_8d3302fc-fea2-4f8a-8b66-5cc1dfe31281"
      unitRef="usd">17500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RhYmxlOmI2ZTZiYWIyM2M1NzQ1OGFiMTFmM2UwNGQ3ZmM2NmEyL3RhYmxlcmFuZ2U6YjZlNmJhYjIzYzU3NDU4YWIxMWYzZTA0ZDdmYzY2YTJfNy0yLTEtMS0w_e882c7be-8c3d-4a17-9ccd-6a632225822d"
      unitRef="usd">699000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RhYmxlOmI2ZTZiYWIyM2M1NzQ1OGFiMTFmM2UwNGQ3ZmM2NmEyL3RhYmxlcmFuZ2U6YjZlNmJhYjIzYzU3NDU4YWIxMWYzZTA0ZDdmYzY2YTJfOC0yLTEtMS0w_46eb27fa-a24c-4762-8106-350d1aea98d0"
      unitRef="usd">16801000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RhYmxlOmI2ZTZiYWIyM2M1NzQ1OGFiMTFmM2UwNGQ3ZmM2NmEyL3RhYmxlcmFuZ2U6YjZlNmJhYjIzYzU3NDU4YWIxMWYzZTA0ZDdmYzY2YTJfOS0yLTEtMS0w_9ed6211d-b488-432a-b9da-027537213c0c"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RhYmxlOmI2ZTZiYWIyM2M1NzQ1OGFiMTFmM2UwNGQ3ZmM2NmEyL3RhYmxlcmFuZ2U6YjZlNmJhYjIzYzU3NDU4YWIxMWYzZTA0ZDdmYzY2YTJfMTAtMi0xLTEtMA_03e02278-13d0-4bc4-bc5d-bbb4a30e8ee9"
      unitRef="usd">16801000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:InterestPaidNet
      contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfNDk4Mg_9e3556ca-bbf2-450d-b90c-9e4210fb9091"
      unitRef="usd">344000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfNDk4OQ_87be2e3b-1837-45f5-8f10-80850ffa6ea8"
      unitRef="usd">1041000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfNTEzNA_a5e2068b-b930-4a14-978b-6bad593450ee"
      unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfNTE0MQ_d73012aa-8f73-4841-954a-a9fbaee95f57"
      unitRef="usd">142000</us-gaap:InterestPaidNet>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i5116d3a6dd234ef8a2099862dd24c82b_D20200302-20200302"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfNTU3NA_8fd2c699-88e6-49a3-9d48-24ebb007e0dd"
      unitRef="usd">4999000</us-gaap:RepaymentsOfLongTermDebt>
    <xcur:PaymentsForDebtEndTermFees
      contextRef="i5116d3a6dd234ef8a2099862dd24c82b_D20200302-20200302"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81Mi9mcmFnOjdlNWYzMWQ1OTQ3MjRhYTBiY2RjNTgzOWE4NjYxYWM3L3RleHRyZWdpb246N2U1ZjMxZDU5NDcyNGFhMGJjZGM1ODM5YTg2NjFhYzdfNTYwNA_ee0ba011-d2c1-4a91-81df-debc59e7814f"
      unitRef="usd">100000</xcur:PaymentsForDebtEndTermFees>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RleHRyZWdpb246MDI5YjFmNDU1ZjU2NDIyMDk2Y2I5MjFiY2RhY2IwMmFfNDU1Ng_edb04c21-e9b1-49af-bc52-74723305b880">LeasesThe Company&#x2019;s lease arrangements at September 30, 2021 consist of (i) a lease for office and laboratory space at its headquarters in Chicago, Illinois that commenced in July 2020 (the &#x201c;Chicago Lease&#x201d;), (ii) a lease for office &lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;space at a multi-tenant facility in Cambridge, Massachusetts that commenced in March 2019 and is cancelable at any time (the &#x201c;Cambridge Lease&#x201d;), and (iii) leases for office equipment (the &#x201c;Office Equipment Leases&#x201d;). Each of these leases are classified as operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the nature of the Cambridge Lease, the Company determined that this lease represented a short-term lease with an initial term of less than twelve months and, as such, the Cambridge Lease is not recorded on the balance sheet and related lease costs are recognized in the statement of operations as they are incurred. The Company has also elected to not record the Office Equipment Leases on the balance sheet since related payment amounts and lease costs are insignificant. Lease costs for the Office Equipment Leases are recognized in the statement of operations on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s lease arrangement for office and laboratory space at its former headquarters in Skokie, Illinois ended in February 2021 in accordance with the terms of that lease arrangement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Chicago Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has approximately thirty thousand square feet of office and laboratory space in Chicago, Illinois (the &#x201c;Chicago Lease&#x201d;). The original term (the &#x201c;Original Term&#x201d;) of the Chicago Lease is 10 years, commencing on July 1, 2020 (the &#x201c;Commencement Date&#x201d;), which is the date the premises were ready for occupancy under the terms of the Chicago Lease.  The Company has options to extend the term of the Chicago Lease for&#160;two&#160;additional successive periods of five years each (the &#x201c;Extension Periods&#x201d;) at the then prevailing effective market rental rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The initial annual base rent during the Original Term is approximately $1,113 for the first 12-month period of the Original Term, payable in monthly installments beginning on the Commencement Date. Base rent thereafter is subject to annual increases of 3%, for an aggregate amount of $12,761 over the Original Term. The Company must also pay its proportionate share of certain operating expenses and taxes for each calendar year during the term.  During the first 12-month period of the Original Term, the base rent and the Company&#x2019;s proportionate share of operating expenses and taxes were subject to certain abatements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Chicago Lease, the Company will maintain a letter of credit for the benefit of the landlord in an initial amount of $1,200, which amount is subject to reduction over time.  Upon execution of the Chicago Lease, the Company paid to the landlord the first installment of base rent and the estimated monthly amount of its pro rata share of taxes and its pro rata share of operating expenses in the aggregate amount of $87 which amount had been adjusted for the abatement as set forth in the lease agreement. The Company also paid the landlord a net amount of $697 toward tenant improvements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the agreement for the Chicago Lease, the Company is required to maintain a&#160;standby letter of credit during the term of the lease, currently in the amount of $1,200 and subject to reduction over time, which is secured by a restricted certificate of deposit account and presented within other noncurrent assets on the Company&#x2019;s unaudited condensed consolidated balance sheet at September&#160;30, 2021.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized a right of use asset of $8,931 and a lease liability of $8,147 on the Commencement Date. Because the rate implicit in the Chicago Lease is not readily determinable, the Company used its incremental borrowing rate of 8.3% on the Commencement Date to determine the present value of the lease payments over the Original Term. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease. As of September&#160;30, 2021, the Company determined it is not reasonably certain that the renewal option would be exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information related to the Company&#x2019;s operating lease asset and related operating lease liabilities were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.749%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes lease costs in the Company&#x2019;s unaudited condensed consolidated statement of operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short term lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company made cash payments for operating leases of $1,721 and $1,717 during the nine months ended September 30, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of the Company&#x2019;s lease liability as of September&#160;30, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.749%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 (remaining three months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,275)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <xcur:LesseeOperatingLeaseLeaseArea
      contextRef="i9576e645ea7c457ca92b31b2bdd21d44_D20200701-20200701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RleHRyZWdpb246MDI5YjFmNDU1ZjU2NDIyMDk2Y2I5MjFiY2RhY2IwMmFfMTM0OQ_d6211c0a-32d0-4300-9bf6-d3250ce448ef"
      unitRef="sqft">30000</xcur:LesseeOperatingLeaseLeaseArea>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i271a8511a8d74205a164612b6225fd65_I20200701"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RleHRyZWdpb246MDI5YjFmNDU1ZjU2NDIyMDk2Y2I5MjFiY2RhY2IwMmFfMTUwMw_d6cdc148-b36d-4abf-ad7f-c1e9ef5756a2">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <xcur:LesseeOperatingLeaseNumberOfExtensions
      contextRef="i9576e645ea7c457ca92b31b2bdd21d44_D20200701-20200701"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RleHRyZWdpb246MDI5YjFmNDU1ZjU2NDIyMDk2Y2I5MjFiY2RhY2IwMmFfMTcyNA_b141417a-4932-4126-b2ff-4dca4371fbb6"
      unitRef="extensionperiod">2</xcur:LesseeOperatingLeaseNumberOfExtensions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i271a8511a8d74205a164612b6225fd65_I20200701"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RleHRyZWdpb246MDI5YjFmNDU1ZjU2NDIyMDk2Y2I5MjFiY2RhY2IwMmFfMTc2MA_fb3b8467-3855-465b-8c63-3110429a74ce">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <xcur:LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths
      contextRef="i271a8511a8d74205a164612b6225fd65_I20200701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RleHRyZWdpb246MDI5YjFmNDU1ZjU2NDIyMDk2Y2I5MjFiY2RhY2IwMmFfMTkxOA_2ff3191a-0079-4a7a-927c-bf1a3a9577ce"
      unitRef="usd">1113000</xcur:LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths>
    <xcur:LesseeOperatingLeaseBaseRentAnnualPercentageIncrease
      contextRef="i271a8511a8d74205a164612b6225fd65_I20200701"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RleHRyZWdpb246MDI5YjFmNDU1ZjU2NDIyMDk2Y2I5MjFiY2RhY2IwMmFfMjA5Ng_4d3d78ee-c7cb-437b-af7f-a38e414e77c7"
      unitRef="number">0.03</xcur:LesseeOperatingLeaseBaseRentAnnualPercentageIncrease>
    <xcur:LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm
      contextRef="i271a8511a8d74205a164612b6225fd65_I20200701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RleHRyZWdpb246MDI5YjFmNDU1ZjU2NDIyMDk2Y2I5MjFiY2RhY2IwMmFfMjEyNw_1849b9b4-0187-40da-82a3-7254c857899d"
      unitRef="usd">12761000</xcur:LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i271a8511a8d74205a164612b6225fd65_I20200701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RleHRyZWdpb246MDI5YjFmNDU1ZjU2NDIyMDk2Y2I5MjFiY2RhY2IwMmFfMjU5OQ_0fc7ddee-31fc-48a1-99ad-979c9d1ff8dc"
      unitRef="usd">1200000</us-gaap:LettersOfCreditOutstandingAmount>
    <xcur:LesseeOperatingLeaseRentalPaymentAdjustedForAbatement
      contextRef="i9576e645ea7c457ca92b31b2bdd21d44_D20200701-20200701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RleHRyZWdpb246MDI5YjFmNDU1ZjU2NDIyMDk2Y2I5MjFiY2RhY2IwMmFfMjg5Mw_50949e86-b627-4274-a4d8-b4f3f208cdd2"
      unitRef="usd">87000</xcur:LesseeOperatingLeaseRentalPaymentAdjustedForAbatement>
    <us-gaap:PaymentsForTenantImprovements
      contextRef="i9576e645ea7c457ca92b31b2bdd21d44_D20200701-20200701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RleHRyZWdpb246MDI5YjFmNDU1ZjU2NDIyMDk2Y2I5MjFiY2RhY2IwMmFfMzAzMw_d264651a-98db-4cd9-b89d-f5b99c7ccd6d"
      unitRef="usd">697000</us-gaap:PaymentsForTenantImprovements>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i271a8511a8d74205a164612b6225fd65_I20200701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RleHRyZWdpb246MDI5YjFmNDU1ZjU2NDIyMDk2Y2I5MjFiY2RhY2IwMmFfMzIzMg_fddd2db6-c04f-44e3-ba59-dcf2396dfb5d"
      unitRef="usd">1200000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i271a8511a8d74205a164612b6225fd65_I20200701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RleHRyZWdpb246MDI5YjFmNDU1ZjU2NDIyMDk2Y2I5MjFiY2RhY2IwMmFfMzQ5OQ_9602d3ca-6e83-44f1-9810-32cb673dcce7"
      unitRef="usd">8931000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="i271a8511a8d74205a164612b6225fd65_I20200701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RleHRyZWdpb246MDI5YjFmNDU1ZjU2NDIyMDk2Y2I5MjFiY2RhY2IwMmFfMzUyNw_9b341a85-fa9e-42ac-b402-75d794cd417f"
      unitRef="usd">8147000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="i271a8511a8d74205a164612b6225fd65_I20200701"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RleHRyZWdpb246MDI5YjFmNDU1ZjU2NDIyMDk2Y2I5MjFiY2RhY2IwMmFfMzY4Mw_1022c574-e6fb-4cb4-9983-9bd262c370d3"
      unitRef="number">0.083</us-gaap:LesseeOperatingLeaseDiscountRate>
    <xcur:ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RleHRyZWdpb246MDI5YjFmNDU1ZjU2NDIyMDk2Y2I5MjFiY2RhY2IwMmFfNDU1Mg_0812bb14-983d-474e-975b-5ea749cdd153">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information related to the Company&#x2019;s operating lease asset and related operating lease liabilities were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.749%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</xcur:ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOjE4YmI1OWI4MDRkZjRmNmVhOGI3NDIwOTA1ZjI4MWRmL3RhYmxlcmFuZ2U6MThiYjU5YjgwNGRmNGY2ZWE4Yjc0MjA5MDVmMjgxZGZfMS0yLTEtMS0w_3587c467-f414-4ad4-adac-a165e39adb77">P8Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOjE4YmI1OWI4MDRkZjRmNmVhOGI3NDIwOTA1ZjI4MWRmL3RhYmxlcmFuZ2U6MThiYjU5YjgwNGRmNGY2ZWE4Yjc0MjA5MDVmMjgxZGZfMi0yLTEtMS0w_c5246558-65d8-4b49-8ed7-b7c703cbfda4"
      unitRef="number">0.083</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RleHRyZWdpb246MDI5YjFmNDU1ZjU2NDIyMDk2Y2I5MjFiY2RhY2IwMmFfNDU1NA_436cb9b9-cb9e-41e9-996b-ad1ba6421ca5">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes lease costs in the Company&#x2019;s unaudited condensed consolidated statement of operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short term lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmFhNTNlY2NlOGJmMzQ3YWU4NzFmZjQ3MTE1MzZjNmZmL3RhYmxlcmFuZ2U6YWE1M2VjY2U4YmYzNDdhZTg3MWZmNDcxMTUzNmM2ZmZfMi0xLTEtMS0w_a622f3c5-c53e-466c-b720-5a2a5c6eab1e"
      unitRef="usd">326000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmFhNTNlY2NlOGJmMzQ3YWU4NzFmZjQ3MTE1MzZjNmZmL3RhYmxlcmFuZ2U6YWE1M2VjY2U4YmYzNDdhZTg3MWZmNDcxMTUzNmM2ZmZfMi0zLTEtMS0w_5fdcfd7e-3f6f-4022-8835-68271dbebd9f"
      unitRef="usd">333000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmFhNTNlY2NlOGJmMzQ3YWU4NzFmZjQ3MTE1MzZjNmZmL3RhYmxlcmFuZ2U6YWE1M2VjY2U4YmYzNDdhZTg3MWZmNDcxMTUzNmM2ZmZfMi01LTEtMS0w_490738ca-ee72-4776-9e93-779ef715b82c"
      unitRef="usd">980000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmFhNTNlY2NlOGJmMzQ3YWU4NzFmZjQ3MTE1MzZjNmZmL3RhYmxlcmFuZ2U6YWE1M2VjY2U4YmYzNDdhZTg3MWZmNDcxMTUzNmM2ZmZfMi03LTEtMS0w_21cb19de-2d6c-4daa-8f28-13c067f97124"
      unitRef="usd">712000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmFhNTNlY2NlOGJmMzQ3YWU4NzFmZjQ3MTE1MzZjNmZmL3RhYmxlcmFuZ2U6YWE1M2VjY2U4YmYzNDdhZTg3MWZmNDcxMTUzNmM2ZmZfMy0xLTEtMS0w_f7969eb2-2da3-4bb5-80c7-82fc43870a8f"
      unitRef="usd">32000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmFhNTNlY2NlOGJmMzQ3YWU4NzFmZjQ3MTE1MzZjNmZmL3RhYmxlcmFuZ2U6YWE1M2VjY2U4YmYzNDdhZTg3MWZmNDcxMTUzNmM2ZmZfMy0zLTEtMS0w_d57d5eea-b70b-4b42-a40d-f97bb46c0e19"
      unitRef="usd">29000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmFhNTNlY2NlOGJmMzQ3YWU4NzFmZjQ3MTE1MzZjNmZmL3RhYmxlcmFuZ2U6YWE1M2VjY2U4YmYzNDdhZTg3MWZmNDcxMTUzNmM2ZmZfMy01LTEtMS0w_48280b7f-fc35-4086-9d3d-74530bc9d9ee"
      unitRef="usd">94000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmFhNTNlY2NlOGJmMzQ3YWU4NzFmZjQ3MTE1MzZjNmZmL3RhYmxlcmFuZ2U6YWE1M2VjY2U4YmYzNDdhZTg3MWZmNDcxMTUzNmM2ZmZfMy03LTEtMS0w_13482e8a-8443-42f1-9cda-a49b9fe7d76e"
      unitRef="usd">96000</us-gaap:ShortTermLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmFhNTNlY2NlOGJmMzQ3YWU4NzFmZjQ3MTE1MzZjNmZmL3RhYmxlcmFuZ2U6YWE1M2VjY2U4YmYzNDdhZTg3MWZmNDcxMTUzNmM2ZmZfNC0xLTEtMS0w_375dd16d-7026-4483-93f5-1c1644bc18a9"
      unitRef="usd">231000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmFhNTNlY2NlOGJmMzQ3YWU4NzFmZjQ3MTE1MzZjNmZmL3RhYmxlcmFuZ2U6YWE1M2VjY2U4YmYzNDdhZTg3MWZmNDcxMTUzNmM2ZmZfNC0zLTEtMS0w_74a432cb-d034-47dd-86a5-79bd239d6a97"
      unitRef="usd">172000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmFhNTNlY2NlOGJmMzQ3YWU4NzFmZjQ3MTE1MzZjNmZmL3RhYmxlcmFuZ2U6YWE1M2VjY2U4YmYzNDdhZTg3MWZmNDcxMTUzNmM2ZmZfNC01LTEtMS0w_0f4d47f6-dc23-4cb1-801f-144bc26c7501"
      unitRef="usd">803000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmFhNTNlY2NlOGJmMzQ3YWU4NzFmZjQ3MTE1MzZjNmZmL3RhYmxlcmFuZ2U6YWE1M2VjY2U4YmYzNDdhZTg3MWZmNDcxMTUzNmM2ZmZfNC03LTEtMS0w_d7e5e88c-8615-4a55-b07f-c6c0e16944dc"
      unitRef="usd">322000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmFhNTNlY2NlOGJmMzQ3YWU4NzFmZjQ3MTE1MzZjNmZmL3RhYmxlcmFuZ2U6YWE1M2VjY2U4YmYzNDdhZTg3MWZmNDcxMTUzNmM2ZmZfNS0xLTEtMS0w_1272d9fc-3db2-4517-965e-d4e62ba0bb90"
      unitRef="usd">589000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmFhNTNlY2NlOGJmMzQ3YWU4NzFmZjQ3MTE1MzZjNmZmL3RhYmxlcmFuZ2U6YWE1M2VjY2U4YmYzNDdhZTg3MWZmNDcxMTUzNmM2ZmZfNS0zLTEtMS0w_23699a22-28dc-4b96-aa10-ce9621ac7380"
      unitRef="usd">534000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmFhNTNlY2NlOGJmMzQ3YWU4NzFmZjQ3MTE1MzZjNmZmL3RhYmxlcmFuZ2U6YWE1M2VjY2U4YmYzNDdhZTg3MWZmNDcxMTUzNmM2ZmZfNS01LTEtMS0w_79b3acf4-074f-429c-9700-5dfa75edb819"
      unitRef="usd">1877000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmFhNTNlY2NlOGJmMzQ3YWU4NzFmZjQ3MTE1MzZjNmZmL3RhYmxlcmFuZ2U6YWE1M2VjY2U4YmYzNDdhZTg3MWZmNDcxMTUzNmM2ZmZfNS03LTEtMS0w_903bc186-d2a7-4575-a3c5-00b1b5f50e35"
      unitRef="usd">1130000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RleHRyZWdpb246MDI5YjFmNDU1ZjU2NDIyMDk2Y2I5MjFiY2RhY2IwMmFfNDQwNw_552c6e47-22d2-45ff-9c29-a1b1d2f8c027"
      unitRef="usd">1721000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RleHRyZWdpb246MDI5YjFmNDU1ZjU2NDIyMDk2Y2I5MjFiY2RhY2IwMmFfNDQxNA_41d9e148-6a7f-446f-8eea-578eafccd76c"
      unitRef="usd">1717000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RleHRyZWdpb246MDI5YjFmNDU1ZjU2NDIyMDk2Y2I5MjFiY2RhY2IwMmFfNDU1NQ_66c99610-13e8-445c-bc7a-8b81b22fa345">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of the Company&#x2019;s lease liability as of September&#160;30, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.749%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 (remaining three months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,275)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmMxNWQxYzE1YTJlYzQ3M2U5YWNmNjk2ZmQ0OTZiNWExL3RhYmxlcmFuZ2U6YzE1ZDFjMTVhMmVjNDczZTlhY2Y2OTZmZDQ5NmI1YTFfMS0yLTEtMS0w_5ba81c70-3624-49cc-8189-4b5a54ba728c"
      unitRef="usd">191000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmMxNWQxYzE1YTJlYzQ3M2U5YWNmNjk2ZmQ0OTZiNWExL3RhYmxlcmFuZ2U6YzE1ZDFjMTVhMmVjNDczZTlhY2Y2OTZmZDQ5NmI1YTFfMi0yLTEtMS0w_0424b6e5-33cb-412c-9309-7467d2e51cc4"
      unitRef="usd">1163000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmMxNWQxYzE1YTJlYzQ3M2U5YWNmNjk2ZmQ0OTZiNWExL3RhYmxlcmFuZ2U6YzE1ZDFjMTVhMmVjNDczZTlhY2Y2OTZmZDQ5NmI1YTFfMy0yLTEtMS0w_6e0028da-5b29-46ec-a2de-e5768ac50b1b"
      unitRef="usd">1198000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmMxNWQxYzE1YTJlYzQ3M2U5YWNmNjk2ZmQ0OTZiNWExL3RhYmxlcmFuZ2U6YzE1ZDFjMTVhMmVjNDczZTlhY2Y2OTZmZDQ5NmI1YTFfNC0yLTEtMS0w_4a3edc12-4e5b-4c3d-ac33-b87808d46cc4"
      unitRef="usd">1235000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmMxNWQxYzE1YTJlYzQ3M2U5YWNmNjk2ZmQ0OTZiNWExL3RhYmxlcmFuZ2U6YzE1ZDFjMTVhMmVjNDczZTlhY2Y2OTZmZDQ5NmI1YTFfNS0yLTEtMS0w_c9f03945-60a9-43db-9a1a-3f1de50ad449"
      unitRef="usd">1272000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmMxNWQxYzE1YTJlYzQ3M2U5YWNmNjk2ZmQ0OTZiNWExL3RhYmxlcmFuZ2U6YzE1ZDFjMTVhMmVjNDczZTlhY2Y2OTZmZDQ5NmI1YTFfNi0yLTEtMS0w_058abd49-8d5a-4b99-b668-abfc2dcfbdab"
      unitRef="usd">1310000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmMxNWQxYzE1YTJlYzQ3M2U5YWNmNjk2ZmQ0OTZiNWExL3RhYmxlcmFuZ2U6YzE1ZDFjMTVhMmVjNDczZTlhY2Y2OTZmZDQ5NmI1YTFfNy0yLTEtMS0w_5a7b589c-e6ec-4dcb-b66a-89471e5fd346"
      unitRef="usd">4897000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmMxNWQxYzE1YTJlYzQ3M2U5YWNmNjk2ZmQ0OTZiNWExL3RhYmxlcmFuZ2U6YzE1ZDFjMTVhMmVjNDczZTlhY2Y2OTZmZDQ5NmI1YTFfOC0yLTEtMS0w_74d842df-535f-40e6-a801-a04ca9e0c2e2"
      unitRef="usd">11266000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmMxNWQxYzE1YTJlYzQ3M2U5YWNmNjk2ZmQ0OTZiNWExL3RhYmxlcmFuZ2U6YzE1ZDFjMTVhMmVjNDczZTlhY2Y2OTZmZDQ5NmI1YTFfOS0yLTEtMS0w_81f1fb9f-1541-4d6a-80b2-94a69152443b"
      unitRef="usd">3275000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmMxNWQxYzE1YTJlYzQ3M2U5YWNmNjk2ZmQ0OTZiNWExL3RhYmxlcmFuZ2U6YzE1ZDFjMTVhMmVjNDczZTlhY2Y2OTZmZDQ5NmI1YTFfMTAtMi0xLTEtMA_e50abb43-b6fb-483d-abdb-f2d0fc1ff684"
      unitRef="usd">7991000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmMxNWQxYzE1YTJlYzQ3M2U5YWNmNjk2ZmQ0OTZiNWExL3RhYmxlcmFuZ2U6YzE1ZDFjMTVhMmVjNDczZTlhY2Y2OTZmZDQ5NmI1YTFfMTItMi0xLTEtMA_f9641a22-e6f2-4bf0-997e-000fa0921735"
      unitRef="usd">440000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmMxNWQxYzE1YTJlYzQ3M2U5YWNmNjk2ZmQ0OTZiNWExL3RhYmxlcmFuZ2U6YzE1ZDFjMTVhMmVjNDczZTlhY2Y2OTZmZDQ5NmI1YTFfMTMtMi0xLTEtMA_1cf7d045-6c46-43d1-81bc-61590b5176fa"
      unitRef="usd">7551000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81NS9mcmFnOjAyOWIxZjQ1NWY1NjQyMjA5NmNiOTIxYmNkYWNiMDJhL3RhYmxlOmMxNWQxYzE1YTJlYzQ3M2U5YWNmNjk2ZmQ0OTZiNWExL3RhYmxlcmFuZ2U6YzE1ZDFjMTVhMmVjNDczZTlhY2Y2OTZmZDQ5NmI1YTFfMTQtMi0xLTEtMA_074d97a9-bfd6-4cd9-8e46-ef0092e43695"
      unitRef="usd">7991000</us-gaap:OperatingLeaseLiability>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMjcwMQ_94dabf56-6593-4031-9dd7-6fa863c1875b">Stockholders&#x2019; Equity&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021 and December&#160;31, 2020, the Company had 10,000,000 shares of preferred stock, par value $0.0001 authorized and no shares issued and outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021 and December&#160;31, 2020, the Company had authorized 200,000,000 shares of common stock, par value $0.0001.  As of September&#160;30, 2021 and December&#160;31, 2020, the Company had 88,108,543 shares and 87,651,352 shares issued and outstanding, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The holders of shares of the Company&#x2019;s common stock are entitled to one vote per share on all matters to be voted upon by the Company&#x2019;s stockholders and there are no cumulative rights. Subject to preferences that may be applicable to any outstanding preferred stock, the holders of shares of the Company&#x2019;s common stock are entitled to receive ratably any dividends that may be declared from time to time by the Board out of funds legally available for that purpose. In the event of the Company&#x2019;s liquidation, dissolution or winding up, the holders of shares of the Company&#x2019;s common stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock then outstanding. The Company&#x2019;s common stock has no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to the Company&#x2019;s common stock. The outstanding shares of the Company&#x2019;s common stock are fully paid and&#160;non-assessable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; As of September&#160;30, 2021, no warrants were outstanding. As of December 31, 2020, warrants to purchase 413,320 shares of common stock at a price of&#160;$3.00&#160;per share were outstanding.  The warrants expired unexercised as follows: 163,174 warrants expired on March 27, 2021, 132,884 expired on April 28, 2021, and 117,262 expired on May 3, 2021.  The warrants were classified as a liability which was remeasured each period at fair value. See Note 12,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;for more information on the fair value of the common stock warrant liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accumulated Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in each component of accumulated other comprehensive income (loss), net of tax, for&#160;2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.980%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.754%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized gains (losses) on short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net losses (gains) reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net gain reclassified from accumulated other comprehensive loss during the three months ended September 30, 2021 resulted from available-for-sale securities that were called prior to maturity and no gains or losses were recognized for the three and nine months ended September 30, 2021. The basis on which the cost of the securities was determined was specific identification. Proceeds related to these sales were $4,000.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in each component of accumulated other comprehensive income (loss), net of tax, for&#160;2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.980%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.754%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized gains (losses) on short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net losses (gains) reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The net loss reclassified from accumulated other comprehensive loss during the nine months ended September 30, 2020 resulted from sales of available-for-sale securities prior to maturity. The gross realized gains and gross realized losses of these sales were $23 and $6, respectively, for the three and nine months ended September 30, 2020. The basis on which the cost of the securities was determined was specific identification. Proceeds related to these sales were $9,404.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfNzg_4e75251e-3a88-4f77-bfcd-15c51a818781"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfNzg_5876cf99-416b-421c-aa11-dd12a2663f1b"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMTE4_3340691a-b118-43e1-ba4c-17d492e4e961"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMTE4_4d7e9a86-3c68-4a70-870c-226192ea3862"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMTM2_04b64c3f-3406-4ddd-b665-f97c914ff4c4"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMTM2_c1b22335-9921-4289-af9d-612c6e42f5e2"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMTM2_ceaa01aa-174f-4651-aaf6-5626fb48839c"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMTM2_f11982f2-9530-406a-8c69-aeb2d5469d8f"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMjI3_27b4e6b3-7d4d-4460-992e-b696f12c5b94"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMjI3_736804ba-3618-4e39-a7e3-fc0bf2442785"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMjY0_dce3295a-ee4b-4d4d-85f0-f284a3567263"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMjY0_ecd72e63-43e6-4773-8cd4-4723591521c7"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMzAy_72c19139-e9af-454d-b0b5-5ef2fc4b28e4"
      unitRef="shares">88108543</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMzAy_a8d5a2bc-8d25-433e-8a97-cce3c5ee640f"
      unitRef="shares">88108543</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMzE2_2650a44d-ddd4-4fb1-b1d1-2dd243401f55"
      unitRef="shares">87651352</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMzE2_53e61338-21bb-48c8-9ed4-1950ceae7af3"
      unitRef="shares">87651352</us-gaap:CommonStockSharesIssued>
    <xcur:CommonStockVotingRightsForEachShare
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfNDM0_d304bcc1-f6d2-42c6-805f-b710b5f517a1"
      unitRef="votepershare">1</xcur:CommonStockVotingRightsForEachShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i27fa1ea6e2df45148c9b25b975903963_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMTQyMQ_80c3341b-f060-4f6f-954b-76bfb6f2dbfe"
      unitRef="shares">0</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ibd76f03fda964ae290754abfcc474c0f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMTQ5Nw_757df66a-72d5-4a61-ab26-00250256b564"
      unitRef="shares">413320</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ibd76f03fda964ae290754abfcc474c0f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMTUzNw_527c6c01-dcd4-4ee3-bfb7-a3496c8f4696"
      unitRef="usdPerShare">3.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <xcur:ClassofWarrantorRightExpired
      contextRef="i8169de03b9ae4915bce1475ec011bdcd_I20210327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMTYxNA_850d4797-d8bf-49c1-9976-f2c78685bfb7"
      unitRef="shares">163174</xcur:ClassofWarrantorRightExpired>
    <xcur:ClassofWarrantorRightExpired
      contextRef="i1c3f90d09e82457cb147316b3d91afa0_I20210428"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMTY1Mw_a893b5fe-64a0-4460-ac3f-63c736d3dd06"
      unitRef="shares">132884</xcur:ClassofWarrantorRightExpired>
    <xcur:ClassofWarrantorRightExpired
      contextRef="if2dfcf33b3dd445fac1ae79f628e0c43_I20210503"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMTY4Nw_68652114-1a05-4d16-8a3b-506357da9dce"
      unitRef="shares">117262</xcur:ClassofWarrantorRightExpired>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMjY5OQ_d62c6254-ae82-45c3-ba80-c0d5a0495e15">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in each component of accumulated other comprehensive income (loss), net of tax, for&#160;2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.980%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.754%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized gains (losses) on short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net losses (gains) reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net gain reclassified from accumulated other comprehensive loss during the three months ended September 30, 2021 resulted from available-for-sale securities that were called prior to maturity and no gains or losses were recognized for the three and nine months ended September 30, 2021. The basis on which the cost of the securities was determined was specific identification. Proceeds related to these sales were $4,000.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in each component of accumulated other comprehensive income (loss), net of tax, for&#160;2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.980%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.754%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized gains (losses) on short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net losses (gains) reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquity
      contextRef="i7b1d431f25394a5c823a69f4d9ab4c33_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmM2ODkxNjI5OTgyNjRiYzVhMWY4N2Q2NzY0ZGZlZmM3L3RhYmxlcmFuZ2U6YzY4OTE2Mjk5ODI2NGJjNWExZjg3ZDY3NjRkZmVmYzdfMS0yLTEtMS0w_b4f39ad8-81e2-4b0b-af65-93e844836610"
      unitRef="usd">83000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i501a27e325104650a73ad03cfcd4faa7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmM2ODkxNjI5OTgyNjRiYzVhMWY4N2Q2NzY0ZGZlZmM3L3RhYmxlcmFuZ2U6YzY4OTE2Mjk5ODI2NGJjNWExZjg3ZDY3NjRkZmVmYzdfMS00LTEtMS0w_583b019f-efb3-4b9c-a5b0-6ff3e1719d3e"
      unitRef="usd">83000</us-gaap:StockholdersEquity>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="ic64e0711d9f74fb89ed048800885e19f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmM2ODkxNjI5OTgyNjRiYzVhMWY4N2Q2NzY0ZGZlZmM3L3RhYmxlcmFuZ2U6YzY4OTE2Mjk5ODI2NGJjNWExZjg3ZDY3NjRkZmVmYzdfMi0yLTEtMS0w_40b130d7-3219-4f3e-a71c-3028aab7d716"
      unitRef="usd">-51000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i3dea9cf71d074399a074543cd69ce8c7_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmM2ODkxNjI5OTgyNjRiYzVhMWY4N2Q2NzY0ZGZlZmM3L3RhYmxlcmFuZ2U6YzY4OTE2Mjk5ODI2NGJjNWExZjg3ZDY3NjRkZmVmYzdfMi00LTEtMS0w_3d012cec-8850-469e-b394-800ef786e759"
      unitRef="usd">-51000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ic64e0711d9f74fb89ed048800885e19f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmM2ODkxNjI5OTgyNjRiYzVhMWY4N2Q2NzY0ZGZlZmM3L3RhYmxlcmFuZ2U6YzY4OTE2Mjk5ODI2NGJjNWExZjg3ZDY3NjRkZmVmYzdfMy0yLTEtMS0w_0b48f01a-b6c7-4389-a1aa-239cd841192b"
      unitRef="usd">-51000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i3dea9cf71d074399a074543cd69ce8c7_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmM2ODkxNjI5OTgyNjRiYzVhMWY4N2Q2NzY0ZGZlZmM3L3RhYmxlcmFuZ2U6YzY4OTE2Mjk5ODI2NGJjNWExZjg3ZDY3NjRkZmVmYzdfMy00LTEtMS0w_0fe1a301-3476-4cce-8b4d-75c1f7ef2022"
      unitRef="usd">-51000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="i53500ad38bdf4e52898d5f52b87b27ef_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmM2ODkxNjI5OTgyNjRiYzVhMWY4N2Q2NzY0ZGZlZmM3L3RhYmxlcmFuZ2U6YzY4OTE2Mjk5ODI2NGJjNWExZjg3ZDY3NjRkZmVmYzdfNC0yLTEtMS0w_1b46da42-e1ce-4bc0-9e78-251745d15707"
      unitRef="usd">32000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4a52bc4a3c0d4c7cbfa5ea8a045321fa_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmM2ODkxNjI5OTgyNjRiYzVhMWY4N2Q2NzY0ZGZlZmM3L3RhYmxlcmFuZ2U6YzY4OTE2Mjk5ODI2NGJjNWExZjg3ZDY3NjRkZmVmYzdfNC00LTEtMS0w_90423c8b-09bf-4330-a730-7fc81f3ad975"
      unitRef="usd">32000</us-gaap:StockholdersEquity>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="iecc89148ecae49e08ec084733d34a7aa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmM2ODkxNjI5OTgyNjRiYzVhMWY4N2Q2NzY0ZGZlZmM3L3RhYmxlcmFuZ2U6YzY4OTE2Mjk5ODI2NGJjNWExZjg3ZDY3NjRkZmVmYzdfNS0yLTEtMS0w_f3817cd2-f31f-47f1-9b90-79f34b234eee"
      unitRef="usd">-27000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="iac6b52ac45d04a2588c506176895e21f_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmM2ODkxNjI5OTgyNjRiYzVhMWY4N2Q2NzY0ZGZlZmM3L3RhYmxlcmFuZ2U6YzY4OTE2Mjk5ODI2NGJjNWExZjg3ZDY3NjRkZmVmYzdfNS00LTEtMS0w_11c274e7-6276-4609-be7f-45171869abda"
      unitRef="usd">-27000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="iecc89148ecae49e08ec084733d34a7aa_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmM2ODkxNjI5OTgyNjRiYzVhMWY4N2Q2NzY0ZGZlZmM3L3RhYmxlcmFuZ2U6YzY4OTE2Mjk5ODI2NGJjNWExZjg3ZDY3NjRkZmVmYzdfNy0yLTEtMS0w_fd62925d-f54a-4787-8a70-31002a27422c"
      unitRef="usd">-27000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="iac6b52ac45d04a2588c506176895e21f_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmM2ODkxNjI5OTgyNjRiYzVhMWY4N2Q2NzY0ZGZlZmM3L3RhYmxlcmFuZ2U6YzY4OTE2Mjk5ODI2NGJjNWExZjg3ZDY3NjRkZmVmYzdfNy00LTEtMS0w_9158ac94-d17a-40ad-8c84-0c32315f5f73"
      unitRef="usd">-27000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="i0c4c5418937146598e8abc57dcc888bc_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmM2ODkxNjI5OTgyNjRiYzVhMWY4N2Q2NzY0ZGZlZmM3L3RhYmxlcmFuZ2U6YzY4OTE2Mjk5ODI2NGJjNWExZjg3ZDY3NjRkZmVmYzdfOC0yLTEtMS0w_7f907d2b-091c-426b-b044-d6ccfe135547"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i992a828696e04df48d18d2f8bc76598e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmM2ODkxNjI5OTgyNjRiYzVhMWY4N2Q2NzY0ZGZlZmM3L3RhYmxlcmFuZ2U6YzY4OTE2Mjk5ODI2NGJjNWExZjg3ZDY3NjRkZmVmYzdfOC00LTEtMS0w_d079fd0e-159b-4ea8-9ca4-b614e5387822"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i0deb149ab1ef4764ab8d4cdbf04c52b6_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmM2ODkxNjI5OTgyNjRiYzVhMWY4N2Q2NzY0ZGZlZmM3L3RhYmxlcmFuZ2U6YzY4OTE2Mjk5ODI2NGJjNWExZjg3ZDY3NjRkZmVmYzdfOS0yLTEtMS0xMTY1OQ_4eac13e1-b8e6-4173-9394-a2b1968743d2"
      unitRef="usd">-5000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmM2ODkxNjI5OTgyNjRiYzVhMWY4N2Q2NzY0ZGZlZmM3L3RhYmxlcmFuZ2U6YzY4OTE2Mjk5ODI2NGJjNWExZjg3ZDY3NjRkZmVmYzdfOS00LTEtMS0xMTY1OQ_b18596f9-8583-4161-8635-23961a8f6c15"
      unitRef="usd">-5000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i0deb149ab1ef4764ab8d4cdbf04c52b6_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmM2ODkxNjI5OTgyNjRiYzVhMWY4N2Q2NzY0ZGZlZmM3L3RhYmxlcmFuZ2U6YzY4OTE2Mjk5ODI2NGJjNWExZjg3ZDY3NjRkZmVmYzdfMTAtMi0xLTEtMTE2NTk_c9051dd0-e20a-4dd1-a7be-98395d2f3b65"
      unitRef="usd">1000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmM2ODkxNjI5OTgyNjRiYzVhMWY4N2Q2NzY0ZGZlZmM3L3RhYmxlcmFuZ2U6YzY4OTE2Mjk5ODI2NGJjNWExZjg3ZDY3NjRkZmVmYzdfMTAtNC0xLTEtMTE2NTk_565993b2-7e43-4614-8830-7d21f75b9396"
      unitRef="usd">1000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i0deb149ab1ef4764ab8d4cdbf04c52b6_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmM2ODkxNjI5OTgyNjRiYzVhMWY4N2Q2NzY0ZGZlZmM3L3RhYmxlcmFuZ2U6YzY4OTE2Mjk5ODI2NGJjNWExZjg3ZDY3NjRkZmVmYzdfMTEtMi0xLTEtMTE2NTk_8002994c-b3fe-4c7f-98a4-36a46e643543"
      unitRef="usd">-6000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmM2ODkxNjI5OTgyNjRiYzVhMWY4N2Q2NzY0ZGZlZmM3L3RhYmxlcmFuZ2U6YzY4OTE2Mjk5ODI2NGJjNWExZjg3ZDY3NjRkZmVmYzdfMTEtNC0xLTEtMTE2NTk_1c4c6afa-f1a9-4fd1-9c46-7ae5470cb37f"
      unitRef="usd">-6000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="i0ed6144e7375437b82d12e674ba92210_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmM2ODkxNjI5OTgyNjRiYzVhMWY4N2Q2NzY0ZGZlZmM3L3RhYmxlcmFuZ2U6YzY4OTE2Mjk5ODI2NGJjNWExZjg3ZDY3NjRkZmVmYzdfMTItMi0xLTEtMTE2NTk_f0fa277d-759f-43b4-917f-1d882349ff15"
      unitRef="usd">-1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idf9e5d3ecf814b9ab2f88960463e4dd8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmM2ODkxNjI5OTgyNjRiYzVhMWY4N2Q2NzY0ZGZlZmM3L3RhYmxlcmFuZ2U6YzY4OTE2Mjk5ODI2NGJjNWExZjg3ZDY3NjRkZmVmYzdfMTItNC0xLTEtMTE2NTk_fc4f26f0-a575-4861-b38a-4163742534ba"
      unitRef="usd">-1000</us-gaap:StockholdersEquity>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMTA5OTUxMTYzMTMyNw_1b948017-58cd-442b-adb3-1819abfceff9"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMTA5OTUxMTYzMTMyNw_6538d25a-44c3-4e5c-bd77-b02b14a10169"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMTA5OTUxMTYzMTMyNw_7ae40dae-0ea3-4b45-b99f-b757f31872ff"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMTA5OTUxMTYzMTMyNw_8de5bef0-f0a1-42d0-b733-2de622176dfc"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMTA5OTUxMTYzMTM1Mg_1957464f-f91f-4f8c-a99f-6feac10e9763"
      unitRef="usd">4000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:StockholdersEquity
      contextRef="i73a5c9b5040b4db1b63fd576e252a033_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmUxOTU3M2YxMGUwZTRhZWY5YjI4ZWJlYzczNGRmYTMwL3RhYmxlcmFuZ2U6ZTE5NTczZjEwZTBlNGFlZjliMjhlYmVjNzM0ZGZhMzBfMS0yLTEtMS0w_cc22858a-b1cf-42e3-bc2b-1a59723cb6ab"
      unitRef="usd">-27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifca2e3b16c794fc4a70ed80eb0c74b8d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmUxOTU3M2YxMGUwZTRhZWY5YjI4ZWJlYzczNGRmYTMwL3RhYmxlcmFuZ2U6ZTE5NTczZjEwZTBlNGFlZjliMjhlYmVjNzM0ZGZhMzBfMS00LTEtMS0w_42f30fe0-fbcc-47ba-a301-4ad2cae956e0"
      unitRef="usd">-27000</us-gaap:StockholdersEquity>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="ia4e62853255f45b2b31cd2904be103fe_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmUxOTU3M2YxMGUwZTRhZWY5YjI4ZWJlYzczNGRmYTMwL3RhYmxlcmFuZ2U6ZTE5NTczZjEwZTBlNGFlZjliMjhlYmVjNzM0ZGZhMzBfMi0yLTEtMS0w_6c16d7dd-428d-4352-a064-d5965c4d1faf"
      unitRef="usd">10000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="iab3dbd6a7f674d7083db2fa3c9db78a2_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmUxOTU3M2YxMGUwZTRhZWY5YjI4ZWJlYzczNGRmYTMwL3RhYmxlcmFuZ2U6ZTE5NTczZjEwZTBlNGFlZjliMjhlYmVjNzM0ZGZhMzBfMi00LTEtMS0w_dc41d0d1-2cb6-4c55-a010-2987d102974a"
      unitRef="usd">10000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ia4e62853255f45b2b31cd2904be103fe_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmUxOTU3M2YxMGUwZTRhZWY5YjI4ZWJlYzczNGRmYTMwL3RhYmxlcmFuZ2U6ZTE5NTczZjEwZTBlNGFlZjliMjhlYmVjNzM0ZGZhMzBfMy0yLTEtMS0w_6f32b186-c297-4eb7-b138-c043716d43d2"
      unitRef="usd">10000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="iab3dbd6a7f674d7083db2fa3c9db78a2_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmUxOTU3M2YxMGUwZTRhZWY5YjI4ZWJlYzczNGRmYTMwL3RhYmxlcmFuZ2U6ZTE5NTczZjEwZTBlNGFlZjliMjhlYmVjNzM0ZGZhMzBfMy00LTEtMS0w_8634841f-ebd1-48d3-8c54-74e841e20088"
      unitRef="usd">10000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="i57be8b97989949c89b339f60ea0c9c10_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmUxOTU3M2YxMGUwZTRhZWY5YjI4ZWJlYzczNGRmYTMwL3RhYmxlcmFuZ2U6ZTE5NTczZjEwZTBlNGFlZjliMjhlYmVjNzM0ZGZhMzBfNC0yLTEtMS0w_445603f1-2e6c-4904-928d-5943b539c519"
      unitRef="usd">-17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6a09fd187a41481abc00b2e5f81774d2_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmUxOTU3M2YxMGUwZTRhZWY5YjI4ZWJlYzczNGRmYTMwL3RhYmxlcmFuZ2U6ZTE5NTczZjEwZTBlNGFlZjliMjhlYmVjNzM0ZGZhMzBfNC00LTEtMS0w_edf22077-37ac-4e57-8daa-244b3e1e3a92"
      unitRef="usd">-17000</us-gaap:StockholdersEquity>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i078e9e8c3ffe4962a86e337d4adc40ed_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmUxOTU3M2YxMGUwZTRhZWY5YjI4ZWJlYzczNGRmYTMwL3RhYmxlcmFuZ2U6ZTE5NTczZjEwZTBlNGFlZjliMjhlYmVjNzM0ZGZhMzBfNS0yLTEtMS0w_19a6b936-2723-47c6-90ea-9feb30809db6"
      unitRef="usd">352000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i9b2c76fc1f31458f93f96af1cff6f08f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmUxOTU3M2YxMGUwZTRhZWY5YjI4ZWJlYzczNGRmYTMwL3RhYmxlcmFuZ2U6ZTE5NTczZjEwZTBlNGFlZjliMjhlYmVjNzM0ZGZhMzBfNS00LTEtMS0w_88d75a61-67f3-4096-b43c-439a56a7b64c"
      unitRef="usd">352000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i078e9e8c3ffe4962a86e337d4adc40ed_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmUxOTU3M2YxMGUwZTRhZWY5YjI4ZWJlYzczNGRmYTMwL3RhYmxlcmFuZ2U6ZTE5NTczZjEwZTBlNGFlZjliMjhlYmVjNzM0ZGZhMzBfNi0yLTEtMS0w_842ecb03-aa27-4402-8082-041f1e6cf989"
      unitRef="usd">-3000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i9b2c76fc1f31458f93f96af1cff6f08f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmUxOTU3M2YxMGUwZTRhZWY5YjI4ZWJlYzczNGRmYTMwL3RhYmxlcmFuZ2U6ZTE5NTczZjEwZTBlNGFlZjliMjhlYmVjNzM0ZGZhMzBfNi00LTEtMS0w_60558914-04ac-4e5d-8fc7-2d9b8988a964"
      unitRef="usd">-3000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i078e9e8c3ffe4962a86e337d4adc40ed_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmUxOTU3M2YxMGUwZTRhZWY5YjI4ZWJlYzczNGRmYTMwL3RhYmxlcmFuZ2U6ZTE5NTczZjEwZTBlNGFlZjliMjhlYmVjNzM0ZGZhMzBfNy0yLTEtMS0w_b316d714-7b55-457e-bb20-1cab031c167b"
      unitRef="usd">355000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i9b2c76fc1f31458f93f96af1cff6f08f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmUxOTU3M2YxMGUwZTRhZWY5YjI4ZWJlYzczNGRmYTMwL3RhYmxlcmFuZ2U6ZTE5NTczZjEwZTBlNGFlZjliMjhlYmVjNzM0ZGZhMzBfNy00LTEtMS0w_099fb607-5de1-4e99-9181-75fc379d8c2b"
      unitRef="usd">355000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="i284324b6f8f04a0a9d2178e2163abdef_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmUxOTU3M2YxMGUwZTRhZWY5YjI4ZWJlYzczNGRmYTMwL3RhYmxlcmFuZ2U6ZTE5NTczZjEwZTBlNGFlZjliMjhlYmVjNzM0ZGZhMzBfOC0yLTEtMS0w_c3c7a1d8-d236-48d0-b133-a8e5d14aa58a"
      unitRef="usd">338000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib9ef743ad4504fe6a4762417ee298525_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmUxOTU3M2YxMGUwZTRhZWY5YjI4ZWJlYzczNGRmYTMwL3RhYmxlcmFuZ2U6ZTE5NTczZjEwZTBlNGFlZjliMjhlYmVjNzM0ZGZhMzBfOC00LTEtMS0w_1bece6cb-2372-4713-821d-227125a2fd21"
      unitRef="usd">338000</us-gaap:StockholdersEquity>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="iff67e94dbcb44135b28d7b8a3cc93f58_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmUxOTU3M2YxMGUwZTRhZWY5YjI4ZWJlYzczNGRmYTMwL3RhYmxlcmFuZ2U6ZTE5NTczZjEwZTBlNGFlZjliMjhlYmVjNzM0ZGZhMzBfOS0yLTEtMS0w_dc646bb2-5da0-489e-a5af-d3f84d064140"
      unitRef="usd">-138000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmUxOTU3M2YxMGUwZTRhZWY5YjI4ZWJlYzczNGRmYTMwL3RhYmxlcmFuZ2U6ZTE5NTczZjEwZTBlNGFlZjliMjhlYmVjNzM0ZGZhMzBfOS00LTEtMS0xMjM5NA_3c98c588-961a-4159-9945-42d24df601c9"
      unitRef="usd">-138000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="iff67e94dbcb44135b28d7b8a3cc93f58_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmUxOTU3M2YxMGUwZTRhZWY5YjI4ZWJlYzczNGRmYTMwL3RhYmxlcmFuZ2U6ZTE5NTczZjEwZTBlNGFlZjliMjhlYmVjNzM0ZGZhMzBfMTAtMi0xLTEtMA_2fdcf95f-417d-4573-aa94-476824e69116"
      unitRef="usd">-138000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmUxOTU3M2YxMGUwZTRhZWY5YjI4ZWJlYzczNGRmYTMwL3RhYmxlcmFuZ2U6ZTE5NTczZjEwZTBlNGFlZjliMjhlYmVjNzM0ZGZhMzBfMTAtNC0xLTEtMTIzOTQ_9b787067-1be1-4151-b3a8-53bd46d9da03"
      unitRef="usd">-138000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="i88948d106e48468baa525705927f987b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmUxOTU3M2YxMGUwZTRhZWY5YjI4ZWJlYzczNGRmYTMwL3RhYmxlcmFuZ2U6ZTE5NTczZjEwZTBlNGFlZjliMjhlYmVjNzM0ZGZhMzBfMTEtMi0xLTEtMA_ec7a515c-d87d-4ed8-baa1-98bf666e9bc0"
      unitRef="usd">200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibe0cf5fbf4e1438fb46d794ecd6487cc_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RhYmxlOmUxOTU3M2YxMGUwZTRhZWY5YjI4ZWJlYzczNGRmYTMwL3RhYmxlcmFuZ2U6ZTE5NTczZjEwZTBlNGFlZjliMjhlYmVjNzM0ZGZhMzBfMTEtNC0xLTEtMTIzOTQ_7fbbff46-c0a9-4551-b215-a32b80de2503"
      unitRef="usd">200000</us-gaap:StockholdersEquity>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMjQ5Mw_9995b7e7-76b5-4b2a-a5b1-339bb07476c4"
      unitRef="usd">23000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMjUwMA_1455dfd1-7797-4f4e-9631-e499d6acdb6c"
      unitRef="usd">6000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV81OC9mcmFnOjViNTIwYmVjMjhhNjRiYjVhOWVkODhiOGQzMDc2MzhkL3RleHRyZWdpb246NWI1MjBiZWMyOGE2NGJiNWE5ZWQ4OGI4ZDMwNzYzOGRfMjY5NQ_bd5e0f3a-5235-44f7-a2a4-3735b7afd608"
      unitRef="usd">9404000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfNjcxMw_03b44271-cd0d-4150-a398-57b882802e2d">Equity-Based Compensation&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2017 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Awards that may be awarded under the 2017 Equity Incentive Plan include non-qualified and incentive stock options, stock appreciation rights, bonus shares, restricted stock, restricted stock units, performance units and cash-based awards. The number of shares of common stock reserved for issuance under the 2017 Equity Incentive Plan automatically increases on January 1 of each year, beginning on January 1, 2020, by the lesser of (i) 4,600,000 shares, (ii) 5% of the total number of shares of our capital stock outstanding on December 31 of the preceding calendar year, or (iii) a lesser number of shares determined by the Compensation Committee of the Board (the &#x201c;Compensation Committee&#x201d;). The Compensation Committee made the determination to increase the share reserve for the 2017 Equity Incentive Plan by 4,382,567 shares, effective January 1, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, the aggregate number of equity awards available for grant under the 2017 Equity Incentive Plan was 2,558,218.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inducement Grant&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the Company granted stock options to purchase up to 600,000 shares of common stock as a material inducement to Brian C. Bock, the Company&#x2019;s Chief Financial Officer, to enter into employment with the Company (the &#x201c;Inducement Grant&#x201d;).  The Inducement Grant, which was made pursuant to a stand-alone nonstatutory stock option agreement (the &#x201c;Inducement Award Agreement&#x201d;), was approved by the Compensation Committee, was awarded in accordance with Nasdaq Listing Rule 5635(c)(4) and outside of the Company&#x2019;s 2017 Equity Incentive Plan and is subject to the terms and conditions of the Inducement Award Agreement.  As such, any shares underlying the Inducement Grant are not, upon forfeiture, cancellation or expiration, returned to a pool of shares reserved for future issuance.  As of September&#160;30, 2021, stock options to purchase up to 600,000 shares of common stock remained outstanding under the Inducement Grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2017 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;) was adopted by the Board in September 2017 and approved by the Company&#x2019;s stockholders in September 2017. Through the ESPP, eligible employees may authorize payroll deductions of up to 15% of their compensation to purchase common stock. The maximum number of shares that an employee may purchase on any exercise date in an offer period will be the smaller of (i) 7,500 shares or (ii) such number of shares as has a fair market value (determined as of the offering date for such offer period) equal to $25,000 within one calendar year minus the fair market value of any other shares of common stock that are attributed to such calendar year. The purchase price per share at each purchase date is equal to 85% of the lower of (i) the closing market price per share of Exicure common stock on the employee&#x2019;s offering date or (ii) the closing market price per share of Exicure common stock on the exercise date. Each offering period is approximately six-months in duration and the first offering period began on November 16, 2020 and ended on May 14, 2021.  In connection with the end of the first offering period on May 14, 2021, the Company issued 103,096 shares of common stock that were purchased under the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The ESPP provides that the number of shares reserved and available for issuance will automatically increase each January 1, beginning on January 1, 2018 and each January 1 thereafter through January 1, 2027, by the least of (i) 300,000 shares; (ii) 0.3% of the outstanding shares of common stock on the last day of the immediately preceding calendar year; or (iii) a lesser number of shares determined by the Board. On January 1, 2021 and 2020, the number &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of shares of common stock available for issuance under the ESPP increased by 258,207 shares and 262,954 shares, respectively. As of September&#160;30, 2021, there were 1,100,791 shares available for issuance under the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity-based compensation expense is classified in the statements of operations as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unamortized equity-based compensation expense at September&#160;30, 2021 was $7,820, which is expected to be amortized over a weighted-average period of 3.0 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes the Black-Scholes option-pricing model to determine the fair value of common stock option grants. The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable.  The model also requires the input of highly subjective assumptions.  In addition to an assumption on the expected term of the option grants as discussed below, application of the Black-Scholes model requires additional inputs for which we have assumed the values described in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.115%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.857%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.858%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0 to 6.1 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2 to 6.1 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.36% to 1.12%; weighted avg. 1.05%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.31% to 1.68%; weighted avg. 0.61%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.7% to 83.6%; weighted avg. 82.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.0% to 85.8%; weighted avg. 83.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeiture rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected term is based upon the &#x201c;simplified method&#x201d; as described in Staff Accounting Bulletin Topic 14.D.2. Currently, the Company does not have sufficient experience to provide a reasonable estimate of an expected term of its common stock options. The Company will continue to use the &#x201c;simplified method&#x201d; until there is sufficient experience to provide a more reasonable estimate in conformance with ASC 718-10-30-25 through 30-26. The risk-free interest rate assumptions were based on the U.S. Treasury bond rate appropriate for the expected term in effect at the time of grant.  The expected volatility is based on calculated enterprise value volatilities for publicly traded companies in the same industry and general stage of development.  The estimated forfeiture rates were based on historical experience for similar classes of employees.  The dividend yield was based on expected dividends at the time of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the underlying common stock and the exercise price for the common stock options granted during the nine months ended September 30, 2021 and 2020 are summarized in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.833%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.582%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.140%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Common Stock Options Granted During Period Ended:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value of Underlying Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise Price of Common Stock Option&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nine months ended September 30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.15 to $2.57; weighted avg. $1.87&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.15 to $2.57; weighted avg. $1.87&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nine months ended September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.19 to $2.80:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;weighted avg. $1.91&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.19 to $2.80:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;weighted avg. $1.94&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value of common stock options granted in the nine months ended September 30, 2021 and 2020 was $1.30 and $1.33 per common stock option, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of common stock option activity as of the periods indicated is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.551%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value (thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding - December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,227,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,427,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(342,246)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(252,681)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding - September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,059,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable - September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,207,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and Expected to Vest -&lt;br/&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,630,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of common stock options exercised during the nine months ended September 30, 2021 and 2020 was $243 and $74, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of restricted stock unit activity of the periods indicated is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.512%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested balance - December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,875)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested balance - September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant date fair value of restricted stock units is based on the Company&#x2019;s closing stock price at the date of grant. At vesting, each outstanding restricted stock unit will be exchanged for one share of the Company&#x2019;s common stock. The restricted stock units granted during the 2021 period generally vest evenly on a quarterly basis over a period of 4 years in exchange for continued service provided by the restricted stock unit recipient during that vesting period.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares
      contextRef="if0c01f0c5533412a95c4f674b3fca01f_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfNDk4_94afb501-e9ba-4f44-824c-21b9ecb74288"
      unitRef="shares">4600000</xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares>
    <xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding
      contextRef="i9cf18d06bb4048079daf994c18213de9_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfNTE0_484d70da-febe-47fc-ae2c-25994bee8934"
      unitRef="number">0.05</xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding>
    <xcur:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant
      contextRef="iab7fc37403bc4ae2845774e5e03fe94c_D20210101-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfODM1_cb628883-1065-4fe7-9a71-e590f1704adf"
      unitRef="shares">4382567</xcur:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i9cf18d06bb4048079daf994c18213de9_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfOTgz_fba8a4ff-da65-47cf-9962-48ca9d2d3e9e"
      unitRef="shares">2558218</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="id55f75e995434a9dbf67ef6793958099_D20210501-20210531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfMTA2OQ_b1bc604e-c2a8-4fdd-a96d-a1f7d2e756c8"
      unitRef="shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ie212c3441c564ae7beb10ac73b3f5f39_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfMTg1NA_074d0c25-02cf-4fc9-8f63-57c7acd1c7fd"
      unitRef="shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="i4c783d5073c74f03a909d7ebe8913ac0_I20170930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfMjE5Mw_b422e1e9-204b-4cf8-8348-fdbf80ace005"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
      contextRef="i4333b7976f584c9cb7edb39e5c5abebd_D20170901-20170930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfMjM3MA_ae0bcbd5-58a6-4627-8a23-2a07f6fa9542"
      unitRef="shares">7500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
    <xcur:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount
      contextRef="i4333b7976f584c9cb7edb39e5c5abebd_D20170901-20170930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfMjUwNQ_4e49b61b-7967-4911-89dc-cf3c6dab8c54"
      unitRef="usd">25000</xcur:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i4333b7976f584c9cb7edb39e5c5abebd_D20170901-20170930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfMjcwMw_712b3eac-a877-4426-b1b1-86c0159bec41"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <xcur:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod
      contextRef="i4333b7976f584c9cb7edb39e5c5abebd_D20170901-20170930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfNjcxMA_b17c53a5-988f-43cb-9729-4eea1aa4ed2a">P6M</xcur:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="id8d6615560b5454ea9d90fe9e4254cc7_D20210514-20210514"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfMzE0Mw_1236aeb5-0eb4-4d6d-bbc2-d24b7c9e7eae"
      unitRef="shares">103096</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <xcur:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan
      contextRef="i4c783d5073c74f03a909d7ebe8913ac0_I20170930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfMzQzMw_f36b42cc-6896-4d46-8e49-b34bb8cbc507"
      unitRef="shares">300000</xcur:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="i4333b7976f584c9cb7edb39e5c5abebd_D20170901-20170930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfMzQ0OQ_1c2d8be9-f4bb-4998-911d-7c5f5feaca47"
      unitRef="number">0.003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <xcur:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant
      contextRef="i5c0e7a1b94874bc79ecebefc5fac4988_D20210101-20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfMzczMQ_c7c4e560-5206-401d-bfd6-9fbee5ff966d"
      unitRef="shares">258207</xcur:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant>
    <xcur:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant
      contextRef="i982ad11b02e442eabda7ce00ba0f8e6f_D20200101-20200101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfMzc0NQ_24149269-ddfb-47ae-bf6a-405328263ff1"
      unitRef="shares">262954</xcur:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="if7a30565b6414f62b985b9824a0b50b0_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfMzgwMg_85d74788-14c9-434b-bf4c-79950c5e5833"
      unitRef="shares">1100791</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfNjcxOQ_cc51abb9-5e0d-45c4-8766-17e018199156">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity-based compensation expense is classified in the statements of operations as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.845%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if808fd669ed14a3eb6ab7ba40be06723_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjZmMjM3NTEwNTBlOTQ1YmM4YzUxMjU4OTY4NDc4OTNhL3RhYmxlcmFuZ2U6NmYyMzc1MTA1MGU5NDViYzhjNTEyNTg5Njg0Nzg5M2FfMi0xLTEtMS0w_2bda6733-d5cf-4a00-8cfd-9942d360bd16"
      unitRef="usd">427000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7dd8d8dbeff24010a0f6b35ba5d055da_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjZmMjM3NTEwNTBlOTQ1YmM4YzUxMjU4OTY4NDc4OTNhL3RhYmxlcmFuZ2U6NmYyMzc1MTA1MGU5NDViYzhjNTEyNTg5Njg0Nzg5M2FfMi0zLTEtMS0w_56edec06-dccd-4a9c-8917-92594bd71456"
      unitRef="usd">247000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if3196c46080b4a98afd913b13a6d4a34_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjZmMjM3NTEwNTBlOTQ1YmM4YzUxMjU4OTY4NDc4OTNhL3RhYmxlcmFuZ2U6NmYyMzc1MTA1MGU5NDViYzhjNTEyNTg5Njg0Nzg5M2FfMi01LTEtMS0w_8f22e6f6-53f2-4b24-be45-3c1aa45a3cb7"
      unitRef="usd">1045000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i320897d327b3429885b686fa2ddd6d58_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjZmMjM3NTEwNTBlOTQ1YmM4YzUxMjU4OTY4NDc4OTNhL3RhYmxlcmFuZ2U6NmYyMzc1MTA1MGU5NDViYzhjNTEyNTg5Njg0Nzg5M2FfMi03LTEtMS0w_18ead26b-ec02-4e76-a720-03bcd8fc5583"
      unitRef="usd">607000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icc041bea74db41bc8b34b9c2abac7ec1_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjZmMjM3NTEwNTBlOTQ1YmM4YzUxMjU4OTY4NDc4OTNhL3RhYmxlcmFuZ2U6NmYyMzc1MTA1MGU5NDViYzhjNTEyNTg5Njg0Nzg5M2FfMy0xLTEtMS0w_7b7052a9-9a3e-4519-8915-4fac6dff579e"
      unitRef="usd">462000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i999eb37ba3c84d41978cdddb2073c9c0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjZmMjM3NTEwNTBlOTQ1YmM4YzUxMjU4OTY4NDc4OTNhL3RhYmxlcmFuZ2U6NmYyMzc1MTA1MGU5NDViYzhjNTEyNTg5Njg0Nzg5M2FfMy0zLTEtMS0w_6549eb2f-b34e-496a-a5c3-b216f5950117"
      unitRef="usd">371000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id73356acb7214cc990e0f0fdb073fe06_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjZmMjM3NTEwNTBlOTQ1YmM4YzUxMjU4OTY4NDc4OTNhL3RhYmxlcmFuZ2U6NmYyMzc1MTA1MGU5NDViYzhjNTEyNTg5Njg0Nzg5M2FfMy01LTEtMS0w_bb71fd23-293b-4622-afa4-f3b923890dcf"
      unitRef="usd">1125000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3853bdccdca84ad7b18ecb46c72865db_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjZmMjM3NTEwNTBlOTQ1YmM4YzUxMjU4OTY4NDc4OTNhL3RhYmxlcmFuZ2U6NmYyMzc1MTA1MGU5NDViYzhjNTEyNTg5Njg0Nzg5M2FfMy03LTEtMS0w_2dd085c1-4ea7-4bfb-82df-c33b44ec61ec"
      unitRef="usd">996000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjZmMjM3NTEwNTBlOTQ1YmM4YzUxMjU4OTY4NDc4OTNhL3RhYmxlcmFuZ2U6NmYyMzc1MTA1MGU5NDViYzhjNTEyNTg5Njg0Nzg5M2FfNC0xLTEtMS0w_a7abc495-2f53-46f2-bbdd-0fff3bc48227"
      unitRef="usd">889000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjZmMjM3NTEwNTBlOTQ1YmM4YzUxMjU4OTY4NDc4OTNhL3RhYmxlcmFuZ2U6NmYyMzc1MTA1MGU5NDViYzhjNTEyNTg5Njg0Nzg5M2FfNC0zLTEtMS0w_6cc91ef3-dc61-4319-86e3-6009a7177043"
      unitRef="usd">618000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjZmMjM3NTEwNTBlOTQ1YmM4YzUxMjU4OTY4NDc4OTNhL3RhYmxlcmFuZ2U6NmYyMzc1MTA1MGU5NDViYzhjNTEyNTg5Njg0Nzg5M2FfNC01LTEtMS0w_756f0c24-6d25-4474-a405-d7a67ea85697"
      unitRef="usd">2170000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjZmMjM3NTEwNTBlOTQ1YmM4YzUxMjU4OTY4NDc4OTNhL3RhYmxlcmFuZ2U6NmYyMzc1MTA1MGU5NDViYzhjNTEyNTg5Njg0Nzg5M2FfNC03LTEtMS0w_c3397842-61b4-4e4d-9b88-442e590a5f17"
      unitRef="usd">1603000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfNDAwMg_6348f315-073b-42ad-9d47-bd13818d1391"
      unitRef="usd">7820000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfNDA3NA_9b865ee1-abbc-4c46-ade3-9826c2401b13">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfNjcyMw_47f529be-2262-40f5-8838-2d89bf65d7c3">In addition to an assumption on the expected term of the option grants as discussed below, application of the Black-Scholes model requires additional inputs for which we have assumed the values described in the table below:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.115%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.857%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.858%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0 to 6.1 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2 to 6.1 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.36% to 1.12%; weighted avg. 1.05%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.31% to 1.68%; weighted avg. 0.61%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.7% to 83.6%; weighted avg. 82.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.0% to 85.8%; weighted avg. 83.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeiture rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the underlying common stock and the exercise price for the common stock options granted during the nine months ended September 30, 2021 and 2020 are summarized in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.833%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.582%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.140%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Common Stock Options Granted During Period Ended:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value of Underlying Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise Price of Common Stock Option&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nine months ended September 30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.15 to $2.57; weighted avg. $1.87&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.15 to $2.57; weighted avg. $1.87&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nine months ended September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.19 to $2.80:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;weighted avg. $1.91&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.19 to $2.80:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;weighted avg. $1.94&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i6aeb1a850cfb47d0a5ac9c85fe47090e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjFjOWNiMjMxOWYzZTRiYWE4MzcyYTU2ZWM0ZGNmYzdhL3RhYmxlcmFuZ2U6MWM5Y2IyMzE5ZjNlNGJhYTgzNzJhNTZlYzRkY2ZjN2FfMi0xLTEtMS0wL3RleHRyZWdpb246ODFhZjU5MzBkNzkxNGFmM2E4NDYyYWUwZWRhNTRmY2NfNA_f57d0030-584f-4adb-b662-7179ff69801b">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i6b82c3458cdf484196d37803505070a6_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjFjOWNiMjMxOWYzZTRiYWE4MzcyYTU2ZWM0ZGNmYzdhL3RhYmxlcmFuZ2U6MWM5Y2IyMzE5ZjNlNGJhYTgzNzJhNTZlYzRkY2ZjN2FfMi0xLTEtMS0wL3RleHRyZWdpb246ODFhZjU5MzBkNzkxNGFmM2E4NDYyYWUwZWRhNTRmY2NfMTA_273a22de-7405-4a0a-b1f4-ff53afb0661a">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ia356a586489a48ba88f9458d0242cdf9_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjFjOWNiMjMxOWYzZTRiYWE4MzcyYTU2ZWM0ZGNmYzdhL3RhYmxlcmFuZ2U6MWM5Y2IyMzE5ZjNlNGJhYTgzNzJhNTZlYzRkY2ZjN2FfMi0zLTEtMS0wL3RleHRyZWdpb246OTc4NzM0Njg3Y2VkNGY5ZThkNjJlNDhhMGM5NGU3MWJfNA_f9d2aa98-c4c3-4ae5-b719-9fb0949c4ffa">P5Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i773b254eadab4295b1ffc8c03ceb00b8_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjFjOWNiMjMxOWYzZTRiYWE4MzcyYTU2ZWM0ZGNmYzdhL3RhYmxlcmFuZ2U6MWM5Y2IyMzE5ZjNlNGJhYTgzNzJhNTZlYzRkY2ZjN2FfMi0zLTEtMS0wL3RleHRyZWdpb246OTc4NzM0Njg3Y2VkNGY5ZThkNjJlNDhhMGM5NGU3MWJfMTA_160255c1-c4f0-4320-95b3-3469508d0d94">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjFjOWNiMjMxOWYzZTRiYWE4MzcyYTU2ZWM0ZGNmYzdhL3RhYmxlcmFuZ2U6MWM5Y2IyMzE5ZjNlNGJhYTgzNzJhNTZlYzRkY2ZjN2FfMy0xLTEtMS0wL3RleHRyZWdpb246MGU1MjUwNjFkYzQ0NGExNmFlYzM1ZWRmZjEzNjJmMWJfNA_2734277a-fa0c-413e-b031-4b25365c32a4"
      unitRef="number">0.0036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjFjOWNiMjMxOWYzZTRiYWE4MzcyYTU2ZWM0ZGNmYzdhL3RhYmxlcmFuZ2U6MWM5Y2IyMzE5ZjNlNGJhYTgzNzJhNTZlYzRkY2ZjN2FfMy0xLTEtMS0wL3RleHRyZWdpb246MGU1MjUwNjFkYzQ0NGExNmFlYzM1ZWRmZjEzNjJmMWJfMTA_f4b94b2e-dd4b-468c-9224-78dfee377585"
      unitRef="number">0.0112</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ic894455288284da09cf40a767a1e085c_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjFjOWNiMjMxOWYzZTRiYWE4MzcyYTU2ZWM0ZGNmYzdhL3RhYmxlcmFuZ2U6MWM5Y2IyMzE5ZjNlNGJhYTgzNzJhNTZlYzRkY2ZjN2FfMy0xLTEtMS0wL3RleHRyZWdpb246MGU1MjUwNjFkYzQ0NGExNmFlYzM1ZWRmZjEzNjJmMWJfMjg_d7a6106f-a36a-47b4-a9cb-63962a13b980"
      unitRef="number">0.0105</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjFjOWNiMjMxOWYzZTRiYWE4MzcyYTU2ZWM0ZGNmYzdhL3RhYmxlcmFuZ2U6MWM5Y2IyMzE5ZjNlNGJhYTgzNzJhNTZlYzRkY2ZjN2FfMy0zLTEtMS0wL3RleHRyZWdpb246MTVmYTZjZDIyYzE2NDcxNzhhOWIzNTJkZjBiMWQwOTFfNA_cfb932ef-e50e-4d05-af35-5ec2d2aae2cf"
      unitRef="number">0.0031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjFjOWNiMjMxOWYzZTRiYWE4MzcyYTU2ZWM0ZGNmYzdhL3RhYmxlcmFuZ2U6MWM5Y2IyMzE5ZjNlNGJhYTgzNzJhNTZlYzRkY2ZjN2FfMy0zLTEtMS0wL3RleHRyZWdpb246MTVmYTZjZDIyYzE2NDcxNzhhOWIzNTJkZjBiMWQwOTFfMTA_3f31a3f4-8fa4-418e-886e-549d13703dc6"
      unitRef="number">0.0168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="if589413bdfb14e7bbc638c0c928b54e3_D20200101-20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjFjOWNiMjMxOWYzZTRiYWE4MzcyYTU2ZWM0ZGNmYzdhL3RhYmxlcmFuZ2U6MWM5Y2IyMzE5ZjNlNGJhYTgzNzJhNTZlYzRkY2ZjN2FfMy0zLTEtMS0wL3RleHRyZWdpb246MTVmYTZjZDIyYzE2NDcxNzhhOWIzNTJkZjBiMWQwOTFfMjg_9f076083-1093-4088-9b89-a42ce2426c1e"
      unitRef="number">0.0061</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjFjOWNiMjMxOWYzZTRiYWE4MzcyYTU2ZWM0ZGNmYzdhL3RhYmxlcmFuZ2U6MWM5Y2IyMzE5ZjNlNGJhYTgzNzJhNTZlYzRkY2ZjN2FfNC0xLTEtMS0wL3RleHRyZWdpb246ZTExOTBmN2I0Y2I5NDQzN2E0Y2U1ZDg3Y2RlYTk0ODdfNA_4802583a-2001-4590-b950-8230f54cd26f"
      unitRef="number">0.817</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjFjOWNiMjMxOWYzZTRiYWE4MzcyYTU2ZWM0ZGNmYzdhL3RhYmxlcmFuZ2U6MWM5Y2IyMzE5ZjNlNGJhYTgzNzJhNTZlYzRkY2ZjN2FfNC0xLTEtMS0wL3RleHRyZWdpb246ZTExOTBmN2I0Y2I5NDQzN2E0Y2U1ZDg3Y2RlYTk0ODdfMTA_f2699231-a0ec-424d-a617-cb240c282cac"
      unitRef="number">0.836</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjFjOWNiMjMxOWYzZTRiYWE4MzcyYTU2ZWM0ZGNmYzdhL3RhYmxlcmFuZ2U6MWM5Y2IyMzE5ZjNlNGJhYTgzNzJhNTZlYzRkY2ZjN2FfNC0xLTEtMS0wL3RleHRyZWdpb246ZTExOTBmN2I0Y2I5NDQzN2E0Y2U1ZDg3Y2RlYTk0ODdfMjg_805f6209-c65e-468a-b94d-59726e7f8398"
      unitRef="number">0.826</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjFjOWNiMjMxOWYzZTRiYWE4MzcyYTU2ZWM0ZGNmYzdhL3RhYmxlcmFuZ2U6MWM5Y2IyMzE5ZjNlNGJhYTgzNzJhNTZlYzRkY2ZjN2FfNC0zLTEtMS0wL3RleHRyZWdpb246YjU1MzNjMWNmOTVmNDk3MWJhZjM0YTA1YzJhYTNhZjlfNA_98cfe527-7223-41a8-9372-f43c2963a59f"
      unitRef="number">0.810</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjFjOWNiMjMxOWYzZTRiYWE4MzcyYTU2ZWM0ZGNmYzdhL3RhYmxlcmFuZ2U6MWM5Y2IyMzE5ZjNlNGJhYTgzNzJhNTZlYzRkY2ZjN2FfNC0zLTEtMS0wL3RleHRyZWdpb246YjU1MzNjMWNmOTVmNDk3MWJhZjM0YTA1YzJhYTNhZjlfMTA_aee604eb-a3db-4f73-b349-58cea6285490"
      unitRef="number">0.858</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjFjOWNiMjMxOWYzZTRiYWE4MzcyYTU2ZWM0ZGNmYzdhL3RhYmxlcmFuZ2U6MWM5Y2IyMzE5ZjNlNGJhYTgzNzJhNTZlYzRkY2ZjN2FfNC0zLTEtMS0wL3RleHRyZWdpb246YjU1MzNjMWNmOTVmNDk3MWJhZjM0YTA1YzJhYTNhZjlfMjg_92509b74-0273-4140-8ef8-08c73dabdbaf"
      unitRef="number">0.838</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjFjOWNiMjMxOWYzZTRiYWE4MzcyYTU2ZWM0ZGNmYzdhL3RhYmxlcmFuZ2U6MWM5Y2IyMzE5ZjNlNGJhYTgzNzJhNTZlYzRkY2ZjN2FfNS0xLTEtMS0w_7676e5a3-777a-40d1-a3d5-c99bf5454f4b"
      unitRef="number">0.05</xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate>
    <xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjFjOWNiMjMxOWYzZTRiYWE4MzcyYTU2ZWM0ZGNmYzdhL3RhYmxlcmFuZ2U6MWM5Y2IyMzE5ZjNlNGJhYTgzNzJhNTZlYzRkY2ZjN2FfNS0zLTEtMS0w_c0ff12e0-7b90-41de-9758-cda9b9b2dfc6"
      unitRef="number">0.05</xcur:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjFjOWNiMjMxOWYzZTRiYWE4MzcyYTU2ZWM0ZGNmYzdhL3RhYmxlcmFuZ2U6MWM5Y2IyMzE5ZjNlNGJhYTgzNzJhNTZlYzRkY2ZjN2FfNi0xLTEtMS0w_e5e41ca3-6329-4c6a-b694-86894488df3a"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjFjOWNiMjMxOWYzZTRiYWE4MzcyYTU2ZWM0ZGNmYzdhL3RhYmxlcmFuZ2U6MWM5Y2IyMzE5ZjNlNGJhYTgzNzJhNTZlYzRkY2ZjN2FfNi0zLTEtMS0w_3fd8974f-bf1a-47de-b337-4cd289580d52"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharePrice
      contextRef="i02e0beb6fe6341f7a29be934913d195d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOmRiMGRkMDBjNzYyYTRjMmRiOWNjMDQ4OWEzNDNjZjgzL3RhYmxlcmFuZ2U6ZGIwZGQwMGM3NjJhNGMyZGI5Y2MwNDg5YTM0M2NmODNfMS0xLTEtMS0wL3RleHRyZWdpb246MDE1ZjJjZDgxYmYzNGFlMjg3OTk3NjNhMTcyNWE1ZmZfNA_657c07b3-5526-495e-8be7-07c564349781"
      unitRef="usdPerShare">1.15</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="i1ddff9f5fe814e669c4e7af58af7e785_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOmRiMGRkMDBjNzYyYTRjMmRiOWNjMDQ4OWEzNDNjZjgzL3RhYmxlcmFuZ2U6ZGIwZGQwMGM3NjJhNGMyZGI5Y2MwNDg5YTM0M2NmODNfMS0xLTEtMS0wL3RleHRyZWdpb246MDE1ZjJjZDgxYmYzNGFlMjg3OTk3NjNhMTcyNWE1ZmZfMTA_9e607d7e-5d7e-4dc0-b397-c018b8bde992"
      unitRef="usdPerShare">2.57</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="iab9b918edd71485aaa8ea0f447186603_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOmRiMGRkMDBjNzYyYTRjMmRiOWNjMDQ4OWEzNDNjZjgzL3RhYmxlcmFuZ2U6ZGIwZGQwMGM3NjJhNGMyZGI5Y2MwNDg5YTM0M2NmODNfMS0xLTEtMS0wL3RleHRyZWdpb246MDE1ZjJjZDgxYmYzNGFlMjg3OTk3NjNhMTcyNWE1ZmZfMjk_9f18fe3c-b8e7-4e9d-b793-2a8c850d8246"
      unitRef="usdPerShare">1.87</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i02e0beb6fe6341f7a29be934913d195d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOmRiMGRkMDBjNzYyYTRjMmRiOWNjMDQ4OWEzNDNjZjgzL3RhYmxlcmFuZ2U6ZGIwZGQwMGM3NjJhNGMyZGI5Y2MwNDg5YTM0M2NmODNfMS0zLTEtMS0wL3RleHRyZWdpb246YTU4OTdhNjUyYWJkNDEwNmI2YjIxMTgxODQ5NWY1ZDdfNA_66eac5a3-fc47-4497-9673-3fc713d49a17"
      unitRef="usdPerShare">1.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i1ddff9f5fe814e669c4e7af58af7e785_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOmRiMGRkMDBjNzYyYTRjMmRiOWNjMDQ4OWEzNDNjZjgzL3RhYmxlcmFuZ2U6ZGIwZGQwMGM3NjJhNGMyZGI5Y2MwNDg5YTM0M2NmODNfMS0zLTEtMS0wL3RleHRyZWdpb246YTU4OTdhNjUyYWJkNDEwNmI2YjIxMTgxODQ5NWY1ZDdfMTA_2bf064d3-d9a5-4b8a-a807-ecb946b54f13"
      unitRef="usdPerShare">2.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="iab9b918edd71485aaa8ea0f447186603_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOmRiMGRkMDBjNzYyYTRjMmRiOWNjMDQ4OWEzNDNjZjgzL3RhYmxlcmFuZ2U6ZGIwZGQwMGM3NjJhNGMyZGI5Y2MwNDg5YTM0M2NmODNfMS0zLTEtMS0wL3RleHRyZWdpb246YTU4OTdhNjUyYWJkNDEwNmI2YjIxMTgxODQ5NWY1ZDdfMjk_96873492-6272-4e18-b53f-cceb90aa6c66"
      unitRef="usdPerShare">1.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharePrice
      contextRef="ic679721ac45b4f7fb6a4951133fb72b5_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOmRiMGRkMDBjNzYyYTRjMmRiOWNjMDQ4OWEzNDNjZjgzL3RhYmxlcmFuZ2U6ZGIwZGQwMGM3NjJhNGMyZGI5Y2MwNDg5YTM0M2NmODNfMi0xLTEtMS0wL3RleHRyZWdpb246OWE5ZDRhYmE5NjRlNDMxZmI5MDAyZjFiOTk0ZmY5NmZfNA_3098955b-4b5f-4add-8435-54ea446430dd"
      unitRef="usdPerShare">1.19</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="i5da161d8e266400a93c4f383d423b29f_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOmRiMGRkMDBjNzYyYTRjMmRiOWNjMDQ4OWEzNDNjZjgzL3RhYmxlcmFuZ2U6ZGIwZGQwMGM3NjJhNGMyZGI5Y2MwNDg5YTM0M2NmODNfMi0xLTEtMS0wL3RleHRyZWdpb246OWE5ZDRhYmE5NjRlNDMxZmI5MDAyZjFiOTk0ZmY5NmZfMTA_cd7a886e-09a6-4b46-b7e2-d8061f661cd7"
      unitRef="usdPerShare">2.80</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="if76f066c63564146bf012992a98ddce9_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOmRiMGRkMDBjNzYyYTRjMmRiOWNjMDQ4OWEzNDNjZjgzL3RhYmxlcmFuZ2U6ZGIwZGQwMGM3NjJhNGMyZGI5Y2MwNDg5YTM0M2NmODNfMi0xLTEtMS0wL3RleHRyZWdpb246OWE5ZDRhYmE5NjRlNDMxZmI5MDAyZjFiOTk0ZmY5NmZfMjg_f47ad8fc-9bda-4f85-9be1-65e515a41e0f"
      unitRef="usdPerShare">1.91</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="ic679721ac45b4f7fb6a4951133fb72b5_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOmRiMGRkMDBjNzYyYTRjMmRiOWNjMDQ4OWEzNDNjZjgzL3RhYmxlcmFuZ2U6ZGIwZGQwMGM3NjJhNGMyZGI5Y2MwNDg5YTM0M2NmODNfMi0zLTEtMS0wL3RleHRyZWdpb246NDM0OWYxOGJmNzM5NDBkNGI4N2NiMmRlZGJjMTM2ODFfNA_39dbdff3-6a03-4628-8603-c6bc345ac202"
      unitRef="usdPerShare">1.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i5da161d8e266400a93c4f383d423b29f_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOmRiMGRkMDBjNzYyYTRjMmRiOWNjMDQ4OWEzNDNjZjgzL3RhYmxlcmFuZ2U6ZGIwZGQwMGM3NjJhNGMyZGI5Y2MwNDg5YTM0M2NmODNfMi0zLTEtMS0wL3RleHRyZWdpb246NDM0OWYxOGJmNzM5NDBkNGI4N2NiMmRlZGJjMTM2ODFfMTA_a78879f8-ec92-48f1-acbf-196dd8fee202"
      unitRef="usdPerShare">2.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="if76f066c63564146bf012992a98ddce9_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOmRiMGRkMDBjNzYyYTRjMmRiOWNjMDQ4OWEzNDNjZjgzL3RhYmxlcmFuZ2U6ZGIwZGQwMGM3NjJhNGMyZGI5Y2MwNDg5YTM0M2NmODNfMi0zLTEtMS0wL3RleHRyZWdpb246NDM0OWYxOGJmNzM5NDBkNGI4N2NiMmRlZGJjMTM2ODFfMjg_164de140-4654-434a-977c-9246015ccc63"
      unitRef="usdPerShare">1.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfNTg5Ng_0636ec33-7989-42c3-8cea-5ccefe5116ef"
      unitRef="usdPerShare">1.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfNTkwMw_878c555a-5cb7-4c6d-b1fe-06d8e69dbd8f"
      unitRef="usdPerShare">1.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfNjcyMA_92e162e3-67a2-4836-942d-bb7d7ba0591b">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of common stock option activity as of the periods indicated is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.551%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value (thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding - December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,227,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,427,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(342,246)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(252,681)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding - September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,059,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable - September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,207,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and Expected to Vest -&lt;br/&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,630,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjc0MzFkOTIyY2UzMjRkOGZhMjUzNWQ1M2QzZTRlNjA4L3RhYmxlcmFuZ2U6NzQzMWQ5MjJjZTMyNGQ4ZmEyNTM1ZDUzZDNlNGU2MDhfMS0xLTEtMS0w_717e1ab6-c5f6-452a-9122-27bcbfbd371c"
      unitRef="shares">7227296</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjc0MzFkOTIyY2UzMjRkOGZhMjUzNWQ1M2QzZTRlNjA4L3RhYmxlcmFuZ2U6NzQzMWQ5MjJjZTMyNGQ4ZmEyNTM1ZDUzZDNlNGU2MDhfMS0zLTEtMS0w_76f29e38-8289-40a0-96de-b98256a58974"
      unitRef="usdPerShare">2.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i597ea376c91548b4a05158f306bea587_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjc0MzFkOTIyY2UzMjRkOGZhMjUzNWQ1M2QzZTRlNjA4L3RhYmxlcmFuZ2U6NzQzMWQ5MjJjZTMyNGQ4ZmEyNTM1ZDUzZDNlNGU2MDhfMS01LTEtMS0w_64081227-9c3a-4144-ab52-f8375ddc1d56">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i0041572b03444403ad89282293144d76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjc0MzFkOTIyY2UzMjRkOGZhMjUzNWQ1M2QzZTRlNjA4L3RhYmxlcmFuZ2U6NzQzMWQ5MjJjZTMyNGQ4ZmEyNTM1ZDUzZDNlNGU2MDhfMS03LTEtMS0w_e24538c6-757c-40b5-9e8d-344fbbc84638"
      unitRef="usd">1719000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjc0MzFkOTIyY2UzMjRkOGZhMjUzNWQ1M2QzZTRlNjA4L3RhYmxlcmFuZ2U6NzQzMWQ5MjJjZTMyNGQ4ZmEyNTM1ZDUzZDNlNGU2MDhfMi0xLTEtMS0w_9820e8dd-fca2-4afd-9522-c0e09e163539"
      unitRef="shares">4427586</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjc0MzFkOTIyY2UzMjRkOGZhMjUzNWQ1M2QzZTRlNjA4L3RhYmxlcmFuZ2U6NzQzMWQ5MjJjZTMyNGQ4ZmEyNTM1ZDUzZDNlNGU2MDhfMi0zLTEtMS0w_8f570792-87f5-4df7-9bc9-caa1e8d19684"
      unitRef="usdPerShare">1.87</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjc0MzFkOTIyY2UzMjRkOGZhMjUzNWQ1M2QzZTRlNjA4L3RhYmxlcmFuZ2U6NzQzMWQ5MjJjZTMyNGQ4ZmEyNTM1ZDUzZDNlNGU2MDhfMy0xLTEtMS0w_3814d7bf-8faf-4605-990b-41f770f3e946"
      unitRef="shares">342246</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjc0MzFkOTIyY2UzMjRkOGZhMjUzNWQ1M2QzZTRlNjA4L3RhYmxlcmFuZ2U6NzQzMWQ5MjJjZTMyNGQ4ZmEyNTM1ZDUzZDNlNGU2MDhfMy0zLTEtMS0w_bff6d57c-b4a9-4cc7-91d4-a335a0789988"
      unitRef="usdPerShare">1.60</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjc0MzFkOTIyY2UzMjRkOGZhMjUzNWQ1M2QzZTRlNjA4L3RhYmxlcmFuZ2U6NzQzMWQ5MjJjZTMyNGQ4ZmEyNTM1ZDUzZDNlNGU2MDhfNC0xLTEtMS0w_84b306d0-6f6b-48c7-8a90-55ac74941e32"
      unitRef="shares">252681</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjc0MzFkOTIyY2UzMjRkOGZhMjUzNWQ1M2QzZTRlNjA4L3RhYmxlcmFuZ2U6NzQzMWQ5MjJjZTMyNGQ4ZmEyNTM1ZDUzZDNlNGU2MDhfNC0zLTEtMS0w_028dbd50-fcf4-4428-9844-4cbb05461d6d"
      unitRef="usdPerShare">2.38</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjc0MzFkOTIyY2UzMjRkOGZhMjUzNWQ1M2QzZTRlNjA4L3RhYmxlcmFuZ2U6NzQzMWQ5MjJjZTMyNGQ4ZmEyNTM1ZDUzZDNlNGU2MDhfNS0xLTEtMS0w_30cc86ed-3756-4e37-ad83-7d6e650e0d44"
      unitRef="shares">11059955</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjc0MzFkOTIyY2UzMjRkOGZhMjUzNWQ1M2QzZTRlNjA4L3RhYmxlcmFuZ2U6NzQzMWQ5MjJjZTMyNGQ4ZmEyNTM1ZDUzZDNlNGU2MDhfNS0zLTEtMS0w_83cde1f6-1a69-4eeb-b57c-5bdd4c97b017"
      unitRef="usdPerShare">2.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjc0MzFkOTIyY2UzMjRkOGZhMjUzNWQ1M2QzZTRlNjA4L3RhYmxlcmFuZ2U6NzQzMWQ5MjJjZTMyNGQ4ZmEyNTM1ZDUzZDNlNGU2MDhfNS01LTEtMS0w_3f63d46a-a98a-4f48-abd2-40507e8d25b6">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjc0MzFkOTIyY2UzMjRkOGZhMjUzNWQ1M2QzZTRlNjA4L3RhYmxlcmFuZ2U6NzQzMWQ5MjJjZTMyNGQ4ZmEyNTM1ZDUzZDNlNGU2MDhfNS03LTEtMS0w_5ae76e72-654b-43d2-8db8-a3c9910f4e6b"
      unitRef="usd">397000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjc0MzFkOTIyY2UzMjRkOGZhMjUzNWQ1M2QzZTRlNjA4L3RhYmxlcmFuZ2U6NzQzMWQ5MjJjZTMyNGQ4ZmEyNTM1ZDUzZDNlNGU2MDhfNi0xLTEtMS0w_c83d5523-ce05-48a9-8336-ed06b8f95de3"
      unitRef="shares">5207872</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjc0MzFkOTIyY2UzMjRkOGZhMjUzNWQ1M2QzZTRlNjA4L3RhYmxlcmFuZ2U6NzQzMWQ5MjJjZTMyNGQ4ZmEyNTM1ZDUzZDNlNGU2MDhfNi0zLTEtMS0w_6c0606a2-57f6-4efb-88ef-59fa3b138352"
      unitRef="usdPerShare">2.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjc0MzFkOTIyY2UzMjRkOGZhMjUzNWQ1M2QzZTRlNjA4L3RhYmxlcmFuZ2U6NzQzMWQ5MjJjZTMyNGQ4ZmEyNTM1ZDUzZDNlNGU2MDhfNi01LTEtMS0w_9a6893f3-db84-43fd-b64a-308c4aefc678">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjc0MzFkOTIyY2UzMjRkOGZhMjUzNWQ1M2QzZTRlNjA4L3RhYmxlcmFuZ2U6NzQzMWQ5MjJjZTMyNGQ4ZmEyNTM1ZDUzZDNlNGU2MDhfNi03LTEtMS0w_e2f3f440-2c65-442e-a041-acc4ea009530"
      unitRef="usd">389000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjc0MzFkOTIyY2UzMjRkOGZhMjUzNWQ1M2QzZTRlNjA4L3RhYmxlcmFuZ2U6NzQzMWQ5MjJjZTMyNGQ4ZmEyNTM1ZDUzZDNlNGU2MDhfNy0xLTEtMS0w_13d89557-e92f-477a-b6ee-20c20f639f4e"
      unitRef="shares">10630872</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjc0MzFkOTIyY2UzMjRkOGZhMjUzNWQ1M2QzZTRlNjA4L3RhYmxlcmFuZ2U6NzQzMWQ5MjJjZTMyNGQ4ZmEyNTM1ZDUzZDNlNGU2MDhfNy0zLTEtMS0w_f512a49c-6852-4ed4-a87a-80b005405915"
      unitRef="usdPerShare">2.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjc0MzFkOTIyY2UzMjRkOGZhMjUzNWQ1M2QzZTRlNjA4L3RhYmxlcmFuZ2U6NzQzMWQ5MjJjZTMyNGQ4ZmEyNTM1ZDUzZDNlNGU2MDhfNy01LTEtMS0w_1a281bec-03b4-4f33-a7d8-076662c3245f">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjc0MzFkOTIyY2UzMjRkOGZhMjUzNWQ1M2QzZTRlNjA4L3RhYmxlcmFuZ2U6NzQzMWQ5MjJjZTMyNGQ4ZmEyNTM1ZDUzZDNlNGU2MDhfNy03LTEtMS0w_3bbd2e4b-5ad4-485f-b44a-88a26ad68220"
      unitRef="usd">396000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfNjEzNg_6fd8e7f3-29b6-41eb-bf86-45074e034e71"
      unitRef="usd">243000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfNjE0Mw_102173cf-0a8a-420d-ae26-1b8cb873014c"
      unitRef="usd">74000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfNjcyNQ_5345ed9c-6fcc-4d48-ba9f-b54fd3e7ad64">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of restricted stock unit activity of the periods indicated is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.512%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested balance - December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,875)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested balance - September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i5719399e939a44d98b39d249c039d68d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjQ4YWU0MDhiMzk5MjQzZmFhY2E4ZGU5NDVmNjllMzBlL3RhYmxlcmFuZ2U6NDhhZTQwOGIzOTkyNDNmYWFjYThkZTk0NWY2OWUzMGVfMS0xLTEtMS0w_303dea00-0f79-4fee-a60b-7942784315fd"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i5719399e939a44d98b39d249c039d68d_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjQ4YWU0MDhiMzk5MjQzZmFhY2E4ZGU5NDVmNjllMzBlL3RhYmxlcmFuZ2U6NDhhZTQwOGIzOTkyNDNmYWFjYThkZTk0NWY2OWUzMGVfMS0zLTEtMS0w_b9917088-3422-4dcd-a073-089cf14fba86"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i0e30264806374843a74cbde5714a8879_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjQ4YWU0MDhiMzk5MjQzZmFhY2E4ZGU5NDVmNjllMzBlL3RhYmxlcmFuZ2U6NDhhZTQwOGIzOTkyNDNmYWFjYThkZTk0NWY2OWUzMGVfMi0xLTEtMS0w_7efb0911-589b-4279-a4b1-650faf8664ab"
      unitRef="shares">575000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0e30264806374843a74cbde5714a8879_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjQ4YWU0MDhiMzk5MjQzZmFhY2E4ZGU5NDVmNjllMzBlL3RhYmxlcmFuZ2U6NDhhZTQwOGIzOTkyNDNmYWFjYThkZTk0NWY2OWUzMGVfMi0zLTEtMS0w_c6edb9af-c15e-4e12-a934-034cc75d16e9"
      unitRef="usdPerShare">1.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i0e30264806374843a74cbde5714a8879_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjQ4YWU0MDhiMzk5MjQzZmFhY2E4ZGU5NDVmNjllMzBlL3RhYmxlcmFuZ2U6NDhhZTQwOGIzOTkyNDNmYWFjYThkZTk0NWY2OWUzMGVfMy0xLTEtMS0w_c465ed1f-7339-4fa2-b41e-621168f3e5b3"
      unitRef="shares">17875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0e30264806374843a74cbde5714a8879_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjQ4YWU0MDhiMzk5MjQzZmFhY2E4ZGU5NDVmNjllMzBlL3RhYmxlcmFuZ2U6NDhhZTQwOGIzOTkyNDNmYWFjYThkZTk0NWY2OWUzMGVfMy0zLTEtMS0w_adea71a9-676f-471c-97c1-bd219aa6c5d5"
      unitRef="usdPerShare">1.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i0e30264806374843a74cbde5714a8879_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjQ4YWU0MDhiMzk5MjQzZmFhY2E4ZGU5NDVmNjllMzBlL3RhYmxlcmFuZ2U6NDhhZTQwOGIzOTkyNDNmYWFjYThkZTk0NWY2OWUzMGVfNC0xLTEtMS0w_2018590f-7a06-4434-ad61-4433d9b17af0"
      unitRef="shares">10500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i0e30264806374843a74cbde5714a8879_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjQ4YWU0MDhiMzk5MjQzZmFhY2E4ZGU5NDVmNjllMzBlL3RhYmxlcmFuZ2U6NDhhZTQwOGIzOTkyNDNmYWFjYThkZTk0NWY2OWUzMGVfNC0zLTEtMS0w_ad08ed11-1e9f-4e7e-8468-2c46e9e59d89"
      unitRef="usdPerShare">1.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i6d14cf3685554550979e56c0584d59a2_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjQ4YWU0MDhiMzk5MjQzZmFhY2E4ZGU5NDVmNjllMzBlL3RhYmxlcmFuZ2U6NDhhZTQwOGIzOTkyNDNmYWFjYThkZTk0NWY2OWUzMGVfNS0xLTEtMS0w_bc8216d4-de96-430c-a449-a2c839fae6e0"
      unitRef="shares">546625</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i6d14cf3685554550979e56c0584d59a2_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RhYmxlOjQ4YWU0MDhiMzk5MjQzZmFhY2E4ZGU5NDVmNjllMzBlL3RhYmxlcmFuZ2U6NDhhZTQwOGIzOTkyNDNmYWFjYThkZTk0NWY2OWUzMGVfNS0zLTEtMS0w_8cc24032-6de9-42e3-b0a5-9f983670923e"
      unitRef="usdPerShare">1.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <xcur:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting
      contextRef="i6d14cf3685554550979e56c0584d59a2_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfNjQ0MA_671b2cc9-cfa6-40d8-b077-cb56bc9e4002"
      unitRef="shares">1</xcur:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i0e30264806374843a74cbde5714a8879_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82MS9mcmFnOmZiMzllYWU2MmRiNDQyODBiOTNkOWY4ZGJiMzYyOTVkL3RleHRyZWdpb246ZmIzOWVhZTYyZGI0NDI4MGI5M2Q5ZjhkYmIzNjI5NWRfNjU5OA_ce66e960-87c1-4d87-ac85-a1a883b0b10f">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82NC9mcmFnOjc2MDg0MzI2Yzg2ODQ0ODFhMTA1MjNkMTc1ZWY5MzRhL3RleHRyZWdpb246NzYwODQzMjZjODY4NDQ4MWExMDUyM2QxNzVlZjkzNGFfNDYy_8e2c6689-6253-48c0-92f2-ad907a3990d2">Income TaxesThe Company incurred a pretax loss in each of the three and nine months ended September 30, 2021 and 2020, which consists entirely of loss in the United States and resulted in no provision for income tax expense during the periods then ended.  The effective tax rate is 0% in each of the three and nine months ended September 30, 2021 and 2020 because the Company has generated tax losses and has provided a full valuation allowance against its deferred tax assets.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82NC9mcmFnOjc2MDg0MzI2Yzg2ODQ0ODFhMTA1MjNkMTc1ZWY5MzRhL3RleHRyZWdpb246NzYwODQzMjZjODY4NDQ4MWExMDUyM2QxNzVlZjkzNGFfMTg1_3893e5b1-f65e-4bd4-a6ad-685541843ffc"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82NC9mcmFnOjc2MDg0MzI2Yzg2ODQ0ODFhMTA1MjNkMTc1ZWY5MzRhL3RleHRyZWdpb246NzYwODQzMjZjODY4NDQ4MWExMDUyM2QxNzVlZjkzNGFfMTg1_928e9918-99ef-40d2-a7c3-addd5603b525"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82NC9mcmFnOjc2MDg0MzI2Yzg2ODQ0ODFhMTA1MjNkMTc1ZWY5MzRhL3RleHRyZWdpb246NzYwODQzMjZjODY4NDQ4MWExMDUyM2QxNzVlZjkzNGFfMTg1_9e96b0a8-5114-45eb-8b5a-aafa2fafccc3"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82NC9mcmFnOjc2MDg0MzI2Yzg2ODQ0ODFhMTA1MjNkMTc1ZWY5MzRhL3RleHRyZWdpb246NzYwODQzMjZjODY4NDQ4MWExMDUyM2QxNzVlZjkzNGFfMTg1_c2c85d10-5d32-4fb6-90ea-ebda3dae7c68"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82NC9mcmFnOjc2MDg0MzI2Yzg2ODQ0ODFhMTA1MjNkMTc1ZWY5MzRhL3RleHRyZWdpb246NzYwODQzMjZjODY4NDQ4MWExMDUyM2QxNzVlZjkzNGFfMjc5_4a5dd744-fc96-4562-9393-15ac4e068157"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82NC9mcmFnOjc2MDg0MzI2Yzg2ODQ0ODFhMTA1MjNkMTc1ZWY5MzRhL3RleHRyZWdpb246NzYwODQzMjZjODY4NDQ4MWExMDUyM2QxNzVlZjkzNGFfMjc5_9cf361f2-58c1-4525-b7bc-33d30f4daa9c"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82NC9mcmFnOjc2MDg0MzI2Yzg2ODQ0ODFhMTA1MjNkMTc1ZWY5MzRhL3RleHRyZWdpb246NzYwODQzMjZjODY4NDQ4MWExMDUyM2QxNzVlZjkzNGFfMjc5_a64dd311-d57a-490d-8b32-808d6af7ea28"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82NC9mcmFnOjc2MDg0MzI2Yzg2ODQ0ODFhMTA1MjNkMTc1ZWY5MzRhL3RleHRyZWdpb246NzYwODQzMjZjODY4NDQ4MWExMDUyM2QxNzVlZjkzNGFfMjc5_d62c2df5-eca0-4086-8a2d-707c50186b3e"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RleHRyZWdpb246MmE3Y2I4NTg5NzU1NGFmNmE3ZTZmMmQzOWE1ZmRmMzBfMTEzOA_9b01550e-dc88-4d23-816a-09a63ce59145">Loss Per Common Share&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per common share is calculated using the treasury share method by giving effect to all potentially dilutive securities that were outstanding.  Potentially dilutive options, restricted stock units and warrants to purchase common stock that were outstanding during the periods presented were excluded from the diluted loss per share calculation for the periods presented because such shares had an anti-dilutive effect due to the net loss reported in those periods.  Therefore, basic and diluted loss per common share is the same for each of the three and nine months ended September 30, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is the computation of loss per common share for the three and nine months ended September 30, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.551%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,531)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,822)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50,277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,983)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average basic and diluted common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,105,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,227,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,001,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,160,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss per share - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The outstanding securities presented below were excluded from the calculation of loss per common share, for the periods presented, because such securities would have been anti-dilutive due to the Company&#x2019;s loss per share during that period:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.294%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.439%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,059,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,739,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RleHRyZWdpb246MmE3Y2I4NTg5NzU1NGFmNmE3ZTZmMmQzOWE1ZmRmMzBfMTEzOQ_bf4ca112-e7a5-4f27-85b4-99b9fb3fffcf">Basic loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per common share is calculated using the treasury share method by giving effect to all potentially dilutive securities that were outstanding.  Potentially dilutive options, restricted stock units and warrants to purchase common stock that were outstanding during the periods presented were excluded from the diluted loss per share calculation for the periods presented because such shares had an anti-dilutive effect due to the net loss reported in those periods.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RleHRyZWdpb246MmE3Y2I4NTg5NzU1NGFmNmE3ZTZmMmQzOWE1ZmRmMzBfMTE0MA_386f8d0d-2a13-49ce-a03f-80c7ef5a3d80">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is the computation of loss per common share for the three and nine months ended September 30, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.551%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,531)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,822)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50,277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,983)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average basic and diluted common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,105,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,227,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,001,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,160,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss per share - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjQ5ZDljNDc2ZDYzNzQzMzM4Y2Q0Y2MyMmY0NjkyNTEyL3RhYmxlcmFuZ2U6NDlkOWM0NzZkNjM3NDMzMzhjZDRjYzIyZjQ2OTI1MTJfMi0xLTEtMS0w_f7943432-4fb6-4d16-ba6a-69fe01ce70f5"
      unitRef="usd">-23531000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjQ5ZDljNDc2ZDYzNzQzMzM4Y2Q0Y2MyMmY0NjkyNTEyL3RhYmxlcmFuZ2U6NDlkOWM0NzZkNjM3NDMzMzhjZDRjYzIyZjQ2OTI1MTJfMi0zLTEtMS0w_b9f8ec94-63ec-47a1-92e3-77c20db68caf"
      unitRef="usd">-8822000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjQ5ZDljNDc2ZDYzNzQzMzM4Y2Q0Y2MyMmY0NjkyNTEyL3RhYmxlcmFuZ2U6NDlkOWM0NzZkNjM3NDMzMzhjZDRjYzIyZjQ2OTI1MTJfMi01LTEtMS0w_c76bb9d5-e186-4c8b-90a1-87e5b135be13"
      unitRef="usd">-50277000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjQ5ZDljNDc2ZDYzNzQzMzM4Y2Q0Y2MyMmY0NjkyNTEyL3RhYmxlcmFuZ2U6NDlkOWM0NzZkNjM3NDMzMzhjZDRjYzIyZjQ2OTI1MTJfMi03LTEtMS0w_944dcf69-0d95-43a8-8e49-ea0a4edf6917"
      unitRef="usd">-11983000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjQ5ZDljNDc2ZDYzNzQzMzM4Y2Q0Y2MyMmY0NjkyNTEyL3RhYmxlcmFuZ2U6NDlkOWM0NzZkNjM3NDMzMzhjZDRjYzIyZjQ2OTI1MTJfNC0xLTEtMS0w_6a32eb69-b3c4-4883-a9f8-24ec73d714b0"
      unitRef="shares">88105066</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjQ5ZDljNDc2ZDYzNzQzMzM4Y2Q0Y2MyMmY0NjkyNTEyL3RhYmxlcmFuZ2U6NDlkOWM0NzZkNjM3NDMzMzhjZDRjYzIyZjQ2OTI1MTJfNC0xLTEtMS0w_b5bb72be-5235-4905-baaf-f1cd4e6dd852"
      unitRef="shares">88105066</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjQ5ZDljNDc2ZDYzNzQzMzM4Y2Q0Y2MyMmY0NjkyNTEyL3RhYmxlcmFuZ2U6NDlkOWM0NzZkNjM3NDMzMzhjZDRjYzIyZjQ2OTI1MTJfNC0zLTEtMS0w_6e96028f-c740-4f7e-ab2d-52cb737a5ea2"
      unitRef="shares">87227136</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjQ5ZDljNDc2ZDYzNzQzMzM4Y2Q0Y2MyMmY0NjkyNTEyL3RhYmxlcmFuZ2U6NDlkOWM0NzZkNjM3NDMzMzhjZDRjYzIyZjQ2OTI1MTJfNC0zLTEtMS0w_b2d241c0-355b-4bc1-ab64-e2b01f0b5db7"
      unitRef="shares">87227136</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjQ5ZDljNDc2ZDYzNzQzMzM4Y2Q0Y2MyMmY0NjkyNTEyL3RhYmxlcmFuZ2U6NDlkOWM0NzZkNjM3NDMzMzhjZDRjYzIyZjQ2OTI1MTJfNC01LTEtMS0w_d576c33f-a239-41d6-8a68-aa53b3c83431"
      unitRef="shares">88001222</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjQ5ZDljNDc2ZDYzNzQzMzM4Y2Q0Y2MyMmY0NjkyNTEyL3RhYmxlcmFuZ2U6NDlkOWM0NzZkNjM3NDMzMzhjZDRjYzIyZjQ2OTI1MTJfNC01LTEtMS0w_d86f9092-0ac2-4430-9651-343836b66c77"
      unitRef="shares">88001222</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjQ5ZDljNDc2ZDYzNzQzMzM4Y2Q0Y2MyMmY0NjkyNTEyL3RhYmxlcmFuZ2U6NDlkOWM0NzZkNjM3NDMzMzhjZDRjYzIyZjQ2OTI1MTJfNC03LTEtMS0w_0119c157-1c20-41cd-a5c8-65f9a7909137"
      unitRef="shares">87160520</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjQ5ZDljNDc2ZDYzNzQzMzM4Y2Q0Y2MyMmY0NjkyNTEyL3RhYmxlcmFuZ2U6NDlkOWM0NzZkNjM3NDMzMzhjZDRjYzIyZjQ2OTI1MTJfNC03LTEtMS0w_12b8bb9f-804d-424d-a048-7cd3d17797b5"
      unitRef="shares">87160520</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjQ5ZDljNDc2ZDYzNzQzMzM4Y2Q0Y2MyMmY0NjkyNTEyL3RhYmxlcmFuZ2U6NDlkOWM0NzZkNjM3NDMzMzhjZDRjYzIyZjQ2OTI1MTJfOC0xLTEtMS0w_5c818a51-eb86-4593-b214-a61baa199eb3"
      unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjQ5ZDljNDc2ZDYzNzQzMzM4Y2Q0Y2MyMmY0NjkyNTEyL3RhYmxlcmFuZ2U6NDlkOWM0NzZkNjM3NDMzMzhjZDRjYzIyZjQ2OTI1MTJfOC0xLTEtMS0w_91b6fe31-b04e-486c-bbff-79c8a83a8179"
      unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjQ5ZDljNDc2ZDYzNzQzMzM4Y2Q0Y2MyMmY0NjkyNTEyL3RhYmxlcmFuZ2U6NDlkOWM0NzZkNjM3NDMzMzhjZDRjYzIyZjQ2OTI1MTJfOC0zLTEtMS0w_239a3a28-39ee-42e8-bb43-23385b60e1e7"
      unitRef="usdPerShare">-0.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7508d7c37391421a854292655f2865a7_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjQ5ZDljNDc2ZDYzNzQzMzM4Y2Q0Y2MyMmY0NjkyNTEyL3RhYmxlcmFuZ2U6NDlkOWM0NzZkNjM3NDMzMzhjZDRjYzIyZjQ2OTI1MTJfOC0zLTEtMS0w_a8e25838-1079-476d-8596-bf4dc308c33c"
      unitRef="usdPerShare">-0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjQ5ZDljNDc2ZDYzNzQzMzM4Y2Q0Y2MyMmY0NjkyNTEyL3RhYmxlcmFuZ2U6NDlkOWM0NzZkNjM3NDMzMzhjZDRjYzIyZjQ2OTI1MTJfOC01LTEtMS0w_e3fb8312-8b42-4c2c-8911-acabed80a520"
      unitRef="usdPerShare">-0.57</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjQ5ZDljNDc2ZDYzNzQzMzM4Y2Q0Y2MyMmY0NjkyNTEyL3RhYmxlcmFuZ2U6NDlkOWM0NzZkNjM3NDMzMzhjZDRjYzIyZjQ2OTI1MTJfOC01LTEtMS0w_e5b1bdfd-fd4a-4684-85a5-cdd7e3ef1478"
      unitRef="usdPerShare">-0.57</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjQ5ZDljNDc2ZDYzNzQzMzM4Y2Q0Y2MyMmY0NjkyNTEyL3RhYmxlcmFuZ2U6NDlkOWM0NzZkNjM3NDMzMzhjZDRjYzIyZjQ2OTI1MTJfOC03LTEtMS0w_6d61adac-7543-44d5-a864-31eae859827c"
      unitRef="usdPerShare">-0.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i016bcf7b72a341ff9644ba713a550f30_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjQ5ZDljNDc2ZDYzNzQzMzM4Y2Q0Y2MyMmY0NjkyNTEyL3RhYmxlcmFuZ2U6NDlkOWM0NzZkNjM3NDMzMzhjZDRjYzIyZjQ2OTI1MTJfOC03LTEtMS0w_8bcb45f0-2ff0-4491-90b0-440aa1d98e6d"
      unitRef="usdPerShare">-0.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RleHRyZWdpb246MmE3Y2I4NTg5NzU1NGFmNmE3ZTZmMmQzOWE1ZmRmMzBfMTE0MQ_a24dfb34-999d-42a5-baf4-5d9f129d6808">&lt;div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The outstanding securities presented below were excluded from the calculation of loss per common share, for the periods presented, because such securities would have been anti-dilutive due to the Company&#x2019;s loss per share during that period:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.294%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.439%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,059,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,739,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i23729b7c757546618ffd14bfc2bf93dd_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjRlZDAzMzJmZDBhMzRkMDA5ZDFkOWQ0ZWUyZDVmZmI3L3RhYmxlcmFuZ2U6NGVkMDMzMmZkMGEzNGQwMDlkMWQ5ZDRlZTJkNWZmYjdfMi0xLTEtMS0w_cf703a17-30f4-4fa2-9142-c9db753d471f"
      unitRef="shares">11059955</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia7f4cd3d9bdd4d918c745f1ede290f0d_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjRlZDAzMzJmZDBhMzRkMDA5ZDFkOWQ0ZWUyZDVmZmI3L3RhYmxlcmFuZ2U6NGVkMDMzMmZkMGEzNGQwMDlkMWQ5ZDRlZTJkNWZmYjdfMi0zLTEtMS0w_aa85e11d-f4c5-4b47-abbd-351d702499b6"
      unitRef="shares">7739781</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i78855d9d0c4747009459828fe157b733_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjRlZDAzMzJmZDBhMzRkMDA5ZDFkOWQ0ZWUyZDVmZmI3L3RhYmxlcmFuZ2U6NGVkMDMzMmZkMGEzNGQwMDlkMWQ5ZDRlZTJkNWZmYjdfMy0xLTEtMS0w_1f971647-1c07-4bff-b2e8-f874b1d57ffe"
      unitRef="shares">546625</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3521ed35239b4892871886f1c9a86593_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjRlZDAzMzJmZDBhMzRkMDA5ZDFkOWQ0ZWUyZDVmZmI3L3RhYmxlcmFuZ2U6NGVkMDMzMmZkMGEzNGQwMDlkMWQ5ZDRlZTJkNWZmYjdfMy0zLTEtMS0w_5e47d1d1-e8fd-4126-8d58-e0861808bec5"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic2c85780c2fe44a5a264af346e3d74fe_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjRlZDAzMzJmZDBhMzRkMDA5ZDFkOWQ0ZWUyZDVmZmI3L3RhYmxlcmFuZ2U6NGVkMDMzMmZkMGEzNGQwMDlkMWQ5ZDRlZTJkNWZmYjdfNC0xLTEtMS0w_6ec0dfca-9395-4bef-a32c-f7c014b0fe4f"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8414c9548ccf4c85ba53fb4883723dac_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV82Ny9mcmFnOjJhN2NiODU4OTc1NTRhZjZhN2U2ZjJkMzlhNWZkZjMwL3RhYmxlOjRlZDAzMzJmZDBhMzRkMDA5ZDFkOWQ0ZWUyZDVmZmI3L3RhYmxlcmFuZ2U6NGVkMDMzMmZkMGEzNGQwMDlkMWQ5ZDRlZTJkNWZmYjdfNC0zLTEtMS0w_d0070fb1-778a-49d1-99f2-dab25ac750a2"
      unitRef="shares">413320</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RleHRyZWdpb246ZTVmZjE5M2Q0OGI5NDk3MzhmYTc0OTY1NGViNGM2YWRfMTgxNQ_fe5cba10-9322-440b-8fba-f4c1cf251cb8">Fair Value Measurements&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC Topic 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, as follows: Level 1 Inputs - unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date; Level 2 Inputs - other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3 Inputs - unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date. &lt;/span&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets measured at fair value on a recurring basis as of September&#160;30, 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.370%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.487%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.487%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities measured at fair value on a recurring basis as of December 31, 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.557%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.745%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.450%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.450%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.450%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the market approach and Level 1 and Level 2 inputs to value its cash equivalents and Level 2 inputs to value its short-term investments.  The Company&#x2019;s long-term debt bore interest at the prevailing market rates for instruments with similar characteristics and, accordingly, the carrying value for this instrument also approximates its fair value and the financial measurement is also classified within Level 2 of the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, the Company&#x2019;s common stock warrant liability was $0 and no warrants were outstanding (refer to Note 8, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for more information). The following is a reconciliation of the Company&#x2019;s liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3) for the three months ended September&#160;30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.237%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using Significant Unobservable Inputs (Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Common Stock Warrant Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain included in other (expense) income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RleHRyZWdpb246ZTVmZjE5M2Q0OGI5NDk3MzhmYTc0OTY1NGViNGM2YWRfMTgxNg_22fd8ee6-f733-408b-b90f-8cefae6f5e36">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets measured at fair value on a recurring basis as of September&#160;30, 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.370%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.487%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.487%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities measured at fair value on a recurring basis as of December 31, 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.557%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.745%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.450%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.450%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.450%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic82a774e2c8d4a41b3170db670ad8155_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfMy0xLTEtMS0w_c13372c5-57f3-4739-b909-387d2529649c"
      unitRef="usd">27641000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="icf7c24c0d5bd4c578f72a33ccc3c05bf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfMy0zLTEtMS0w_3b2f463d-f93e-467d-981c-a4eebf0907a9"
      unitRef="usd">27641000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i020262a33e8049ff9ab935e2b201f6fb_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfMy01LTEtMS0w_c785c82d-be16-4576-bcf9-a9f01889e81d"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i439032d25541463e8e6c4621ef8fd111_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfMy03LTEtMS0w_6239e83c-6f81-446a-87bd-5c0b68af406e"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8a58bfb15835492ab090e8b81401af85_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfNC0xLTEtMS0xMjExOQ_fe868b4b-cceb-48f3-ba81-c9c8e946b04d"
      unitRef="usd">2000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8ddced473eff483780d1373964171762_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfNC0zLTEtMS0xMjExOQ_c1bc6cd2-8caa-4a13-a688-d5afda20c881"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5731c03b9fc44849a8c3fb5ed3c6949a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfNC01LTEtMS0xMjExOQ_a52af22e-3371-4f58-b355-779725074674"
      unitRef="usd">2000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i56aca844fa034db2b2e2a7b18d0023e7_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfNC03LTEtMS0xMjExOQ_b26477d9-6f59-45e4-b3e9-2d5f00d9f15f"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id9718465693743c3b538b21283198504_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfNS0xLTEtMS0xMjExOQ_b95c8c01-472c-48e5-a5e3-4e6021fcf718"
      unitRef="usd">9999000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i313d98866f5747ea9ad78d453628370d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfNS0zLTEtMS0xMjExOQ_f53a2636-024d-41ec-98c2-4294f9344811"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ibda75316052d4dbe9d661f043c9b1956_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfNS01LTEtMS0xMjExOQ_4328d3f1-c7d4-43cb-8cbf-40a40206cfac"
      unitRef="usd">9999000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib677e14bc757464bb5589291a71b4e61_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfNS03LTEtMS0xMjExOQ_3453b8e3-d44b-4335-9b77-19863cc5db96"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7d8d9676d98849f883d2748566593b17_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfNi0xLTEtMS0w_f789ddb8-a8f8-4492-8c3f-130ca3deb0eb"
      unitRef="usd">6497000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib0974ff1702c42d395bd413417d4a0d9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfNi0zLTEtMS0w_8d064e33-512a-4bfd-a965-346fad759994"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4c8552c18039495daa749078cb358e04_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfNi01LTEtMS0w_ed216515-1ee2-4553-a70c-3323a13c6925"
      unitRef="usd">6497000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i64760482c2c9480ea6bc6748d1d90ce7_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfNi03LTEtMS0w_70e9faaf-7bac-4b93-a006-17d4884abf4e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icea87c7e3d6a4dfba48ae4131cda39e8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfNy0xLTEtMS0w_0d96e737-7a2b-4305-b192-0b195879ac66"
      unitRef="usd">1205000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i86c21c42f5cd42dfa1f7346b010764d4_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfNy0zLTEtMS0w_49a6e24e-cde2-411e-9e70-26cd07ccfa0b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i62ff7db7da784f799e2dfe0c311b9e0f_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfNy01LTEtMS0w_6502d7ce-5a78-4af3-863d-33b4779a3cc4"
      unitRef="usd">1205000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i965562b1554547d1a09c7766cedd87ae_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfNy03LTEtMS0w_6fd1ad28-1c3f-4a89-964f-2f27447b01cd"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9531f369bf98470ba15fba85df910ef3_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfOS0xLTEtMS0w_f71954c7-2178-4a62-9a74-34bf9f011350"
      unitRef="usd">1251000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia886151578c443df8e7d2e02ad3a907b_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfOS0zLTEtMS0w_2065e226-fd68-4d3b-a250-1687f5e7c9b3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ied37c8b6308741fda6f2b2dcb570461d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfOS01LTEtMS0w_ad5388be-7ea3-46ab-ab7e-cdc8c4606ba6"
      unitRef="usd">1251000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibc5f1ed1d0574ff59b0f1eed86e46da0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfOS03LTEtMS0w_b7fa76f4-0072-43c8-8e34-8f3c7528fc71"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5b19f1632fda44cfb2cbf056cb55773e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfMTAtMS0xLTEtMA_7fcecaf9-9683-48f8-beaa-ce2127065745"
      unitRef="usd">48593000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie60c424895d44cb6a873a2f566d9ba85_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfMTAtMy0xLTEtMA_2ecbc464-6678-4b4a-99b5-1fa3c933f889"
      unitRef="usd">27641000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id804d84aba2942da9b78003f9fa2d272_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfMTAtNS0xLTEtMA_8b69e25d-4508-4196-98a7-c558959953b8"
      unitRef="usd">20952000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3cb225e6af3547baa416759169909bcb_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjgzNTE5Nzk1OWZiODRkYzU4NWRjNTAwZDM0NDAxNDAyL3RhYmxlcmFuZ2U6ODM1MTk3OTU5ZmI4NGRjNTg1ZGM1MDBkMzQ0MDE0MDJfMTAtNy0xLTEtMA_2886d2f4-30f8-4b8f-9afe-3d614a50de53"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2cba3845e261446285d53d1b68bd1b2b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfMy0xLTEtMS0w_68ae3814-b471-4e11-a1cd-e9da87aa1558"
      unitRef="usd">24586000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i086920543bec4d90bb757a3cefcb83ef_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfMy0zLTEtMS0w_246096db-deb5-4989-9960-64806b1e6aaf"
      unitRef="usd">24586000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic202372402d84018b4b88f88701033d0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfMy01LTEtMS0w_7becc414-476e-4c28-a650-71d5c0ec8a83"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i83369fca8bab4aab90e8db725e903baf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfMy03LTEtMS0w_dc984af5-bf3a-49dd-b11d-f0532c24378c"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2996ac3939c042e3ab6d42a6553a235a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfNS0xLTEtMS0w_7a267783-351e-4208-90ea-116ab5316b6c"
      unitRef="usd">15991000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8883903151f24f5fa017edecc72b8b35_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfNS0zLTEtMS0w_bc0ba760-1996-45ba-be87-49e7f0e79d3f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i719acee816814d07916c8dfd5ca71de9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfNS01LTEtMS0w_a482edbc-8482-4a33-8a85-818ec3bc0a7c"
      unitRef="usd">15991000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5ca413f9b9054d00bbda5b1373b22305_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfNS03LTEtMS0w_ae779cb7-76d4-43a8-a9d4-b3e8a6a25175"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i34fe6e6e209446768a2cf34d62dad6aa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfNi0xLTEtMS0w_f408e05b-e36d-4f5c-818d-b843e9a2a6dc"
      unitRef="usd">29296000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i62f9200c696c41d78a853e83862f647b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfNi0zLTEtMS0w_183fcd63-5b70-4c29-8d4c-3e747f5583ad"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4d5744490b0d4c738db4cd2bb4e0aa81_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfNi01LTEtMS0w_cd44aba7-208b-4414-933a-d491e475bdac"
      unitRef="usd">29296000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibfc85e952cc2497fbeee275f739aa825_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfNi03LTEtMS0w_082930d4-a905-4cb2-8b69-387f0ff65565"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5ed86c954d924fc8a28507f2891286eb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfNy0xLTEtMS0w_848f4695-6d3c-42e4-be4a-e1d60e8227c3"
      unitRef="usd">2253000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifaf0a15420cb4a7294217b68929d7235_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfNy0zLTEtMS0w_06142ded-fd1f-45ea-898c-560deac1b776"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia1e7126375264b1c93061499c8d47b5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfNy01LTEtMS0w_ed8d1c35-6cbd-4f76-affb-6a7ad8d2e96f"
      unitRef="usd">2253000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i71bd3df32bb94d4fae58db8bff589a4e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfNy03LTEtMS0w_ba734447-4943-4ccf-8815-27a13302f76a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic259c1b511b64ac2978a410b11be349b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfOC0xLTEtMS0w_4da32faa-3348-4ee1-a31c-e08e3cdfa14d"
      unitRef="usd">1278000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7a439123584f4408a9d60d89e70d2703_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfOC0zLTEtMS0w_5a6bd6a2-28a0-4df6-993b-52cd4aca5dc2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0667ee8e62af460ca0b2e1c8843b72c2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfOC01LTEtMS0w_2ec16774-0ef1-4a4d-b2a1-23503cf3060f"
      unitRef="usd">1278000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i64cfed00d63048338a59cf563ea272b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfOC03LTEtMS0w_9c86e67d-caa9-4c93-b349-96a3a65bd92b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1126e3e21a654b5fb23bb497bc28aa43_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfOS0xLTEtMS0w_b6e8b965-0440-4fd5-a1fc-51f5de6e106b"
      unitRef="usd">73404000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2c44bd27d0ac448590035ac735a75a7b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfOS0zLTEtMS0w_a946d776-e6d8-4c36-a07b-546e35da7622"
      unitRef="usd">24586000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0b2c5cfdc76544d29619b3bd1e9955a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfOS01LTEtMS0w_150a9856-4539-4f43-b1e1-9e2d557b410f"
      unitRef="usd">48818000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifa0ce1eb50024db289d3b452e949a956_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfOS03LTEtMS0w_bf36df87-7f2c-4606-82de-224ead3c1105"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <xcur:CommonStockWarrantLiabilityFairValueDisclosure
      contextRef="i1126e3e21a654b5fb23bb497bc28aa43_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfMTItMS0xLTEtMA_89946922-ce22-4b2e-980e-3ac8057209d5"
      unitRef="usd">15000</xcur:CommonStockWarrantLiabilityFairValueDisclosure>
    <xcur:CommonStockWarrantLiabilityFairValueDisclosure
      contextRef="i2c44bd27d0ac448590035ac735a75a7b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfMTItMy0xLTEtMA_795fd9a7-ffa6-48c9-9228-62a367eec91a"
      unitRef="usd">0</xcur:CommonStockWarrantLiabilityFairValueDisclosure>
    <xcur:CommonStockWarrantLiabilityFairValueDisclosure
      contextRef="i0b2c5cfdc76544d29619b3bd1e9955a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfMTItNS0xLTEtMA_ed7f744c-ae1e-4393-aa04-77adbac8f3c1"
      unitRef="usd">0</xcur:CommonStockWarrantLiabilityFairValueDisclosure>
    <xcur:CommonStockWarrantLiabilityFairValueDisclosure
      contextRef="ifa0ce1eb50024db289d3b452e949a956_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfMTItNy0xLTEtMA_b5d2f600-9279-41b6-a5f9-43586f6eca00"
      unitRef="usd">15000</xcur:CommonStockWarrantLiabilityFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i1126e3e21a654b5fb23bb497bc28aa43_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfMTMtMS0xLTEtMA_df89731c-9293-4a4f-96b2-803b4edebef0"
      unitRef="usd">15000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i2c44bd27d0ac448590035ac735a75a7b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfMTMtMy0xLTEtMA_63c17740-4574-497f-8e1c-897e4601e169"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i0b2c5cfdc76544d29619b3bd1e9955a8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfMTMtNS0xLTEtMA_b1e9678d-c417-43c7-b5ab-cb53e4bda8a9"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="ifa0ce1eb50024db289d3b452e949a956_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOmJiM2ZjM2U5NTk0YzRlY2NhZWQ1NGE3OGVlMjUyMzdkL3RhYmxlcmFuZ2U6YmIzZmMzZTk1OTRjNGVjY2FlZDU0YTc4ZWUyNTIzN2RfMTMtNy0xLTEtMA_4211dcfe-c7c9-465b-8ba4-396e5f839d1d"
      unitRef="usd">15000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i27fa1ea6e2df45148c9b25b975903963_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RleHRyZWdpb246ZTVmZjE5M2Q0OGI5NDk3MzhmYTc0OTY1NGViNGM2YWRfMTUzOA_8b50b874-9083-4c90-aed4-027fac0a46bf"
      unitRef="usd">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i27fa1ea6e2df45148c9b25b975903963_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RleHRyZWdpb246ZTVmZjE5M2Q0OGI5NDk3MzhmYTc0OTY1NGViNGM2YWRfMTU0NQ_80c3341b-f060-4f6f-954b-76bfb6f2dbfe"
      unitRef="shares">0</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RleHRyZWdpb246ZTVmZjE5M2Q0OGI5NDk3MzhmYTc0OTY1NGViNGM2YWRfMTgxNw_bc2e252b-87d1-4ce6-9a35-1c3c1f51ad6e">The following is a reconciliation of the Company&#x2019;s liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3) for the three months ended September&#160;30, 2021:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.237%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using Significant Unobservable Inputs (Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Common Stock Warrant Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain included in other (expense) income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i2f8b49f540eb4a5f880bed694d3fd14d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjRmMDFjYzU0NDE5MjQzNDRhMmIxNDFiNTM0ZWM4YjlhL3RhYmxlcmFuZ2U6NGYwMWNjNTQ0MTkyNDM0NGEyYjE0MWI1MzRlYzhiOWFfMi0xLTEtMS0w_cd19eb40-2e00-4d23-93ea-3429c5eb6a28"
      unitRef="usd">15000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="i03125214387d41b9a8017ffe8a649dac_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjRmMDFjYzU0NDE5MjQzNDRhMmIxNDFiNTM0ZWM4YjlhL3RhYmxlcmFuZ2U6NGYwMWNjNTQ0MTkyNDM0NGEyYjE0MWI1MzRlYzhiOWFfMy0xLTEtMS0w_cf13eb87-38ce-4b42-9a71-111bb9066f4a"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i03125214387d41b9a8017ffe8a649dac_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjRmMDFjYzU0NDE5MjQzNDRhMmIxNDFiNTM0ZWM4YjlhL3RhYmxlcmFuZ2U6NGYwMWNjNTQ0MTkyNDM0NGEyYjE0MWI1MzRlYzhiOWFfNC0xLTEtMS0w_c0d456ec-a6c4-498e-8551-5b5c646f5d95"
      unitRef="usd">15000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i9361796fa9024b2182ac08a2f7e2bf59_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83MC9mcmFnOmU1ZmYxOTNkNDhiOTQ5NzM4ZmE3NDk2NTRlYjRjNmFkL3RhYmxlOjRmMDFjYzU0NDE5MjQzNDRhMmIxNDFiNTM0ZWM4YjlhL3RhYmxlcmFuZ2U6NGYwMWNjNTQ0MTkyNDM0NGEyYjE0MWI1MzRlYzhiOWFfNS0xLTEtMS0w_b9028bad-371b-4802-bfdc-e2d66d55b925"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83My9mcmFnOjEzYzhmZTIzYzNhMTQ5YjI4N2NkNTE3YjVlMzQxZjQwL3RleHRyZWdpb246MTNjOGZlMjNjM2ExNDliMjg3Y2Q1MTdiNWUzNDFmNDBfMjgyNw_34a7b6d8-86ad-4abb-9f9b-95c4e893b530">Commitments and Contingencies&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 7,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for a discussion of the commitments associated with the Company&#x2019;s lease agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Northwestern University License Agreements&lt;/span&gt;&lt;/div&gt;On December 12, 2011, (1) AuraSense, LLC, the Company&#x2019;s former parent, assigned to the Company all of its worldwide rights and interests under AuraSense, LLC&#x2019;s 2009 license agreement with Northwestern University (&#x201c;NU&#x201d;) in the field of the use of nanoparticles, nanotechnology, microtechnology or nanomaterial-based constructs as therapeutics or accompanying therapeutics as a means of delivery, but expressly excluding diagnostics (the &#x201c;assigned field&#x201d;); (2)&#160;in accordance with the terms and conditions of this assignment, the Company assumed all liabilities and obligations of AuraSense, LLC as set forth in its license agreement in the assigned field; and (3)&#160;in order to secure this assignment and the patent rights from NU, the Company agreed (i) to pay NU an annual license fee, which may be credited against any royalties due to NU in the same year, (ii) to reimburse NU for expenses associated with the prosecution and maintenance of the license patent rights, (iii) to pay NU royalties based on any net revenue generated by the Company&#x2019;s sale or transfer of any licensed product, (iv) to pay NU, in the event the Company grants a sublicense under the licensed patent rights, the greater of a percentage of all sublicensee royalties or a percentage of any net revenue generated by a sublicensee&#x2019;s sale or transfer of any licensed product, and (v) to pay NU a percentage of all other sublicense payments received by the Company.  In August 2015, the Company entered into a restated license agreement with NU (the &#x201c;Restated License Agreement&#x201d;). In February 2016, the Company obtained exclusive license as to NU&#x2019;s rights in certain SNA technology it jointly owns with NU (the &#x201c;Co-owned Technology License&#x201d;). The Company&#x2019;s license to NU&#x2019;s rights is limited to the assigned field, however the Company has no such limitation as to its own rights in this jointly owned technology. In June 2016, the Company entered into an exclusive license with NU to obtain worldwide rights to certain inhibitors of glucosylceramide synthase and their use in wound healing in diabetes (the &#x201c;Wound Healing License&#x201d;). The Company&#x2019;s rights and obligations in the Co-owned Technology License and the Wound Healing License agreements&#160;are substantially the same as in the Restated License Agreement from August 2015 (collectively referred to as &#x201c;the Northwestern University License Agreements&#x201d;).  All pending patent applications under the Wound Healing License have been abandoned and the Wound Healing License has been terminated.  As of September&#160;30, 2021, the Company has paid to NU an aggregate of $11,413 in consideration of each of the obligations described above.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <xcur:AggregatePaymentsMadeToDateForLicenseAgreements
      contextRef="ia9d6ec897790429f9fceaa0150f61e3d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83My9mcmFnOjEzYzhmZTIzYzNhMTQ5YjI4N2NkNTE3YjVlMzQxZjQwL3RleHRyZWdpb246MTNjOGZlMjNjM2ExNDliMjg3Y2Q1MTdiNWUzNDFmNDBfMjc2Mw_f8b0d727-5eef-4843-859a-d77808c506f4"
      unitRef="usd">11413000</xcur:AggregatePaymentsMadeToDateForLicenseAgreements>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83Ni9mcmFnOjQ3ZjEzODdjODc5ZjQ2ZTA4YTdkYjFlOGY1NzQwOWQ4L3RleHRyZWdpb246NDdmMTM4N2M4NzlmNDZlMDhhN2RiMWU4ZjU3NDA5ZDhfNDE2_24a03e06-213e-46db-8c18-8711b0cc57e0">Related-Party TransactionsThe Company received consulting services from, and paid fees to, one of its co-founders who is not an employee but, through April 30, 2021, served as a member of the Board. The Company recognized $75 as an expense in each of the nine months ended September&#160;30, 2021 and 2020 in connection with these consulting services in the accompanying unaudited condensed consolidated statement of operations.  The consulting agreement with this co-founder and former Board member expired on September 30, 2021 under the terms of the agreement and was not renewed.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i8264fbfff9464a9baa8088b432d019fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83Ni9mcmFnOjQ3ZjEzODdjODc5ZjQ2ZTA4YTdkYjFlOGY1NzQwOWQ4L3RleHRyZWdpb246NDdmMTM4N2M4NzlmNDZlMDhhN2RiMWU4ZjU3NDA5ZDhfMjMy_609a0b92-22db-4e83-9d28-a688e372ca6c"
      unitRef="usd">75000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i18f420eacb594066840b698845eaa3a4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjMwYzUwYzcxOGRkYTQyZDI4ZmJkZDZkY2Q0ZmEyMzY1L3NlYzozMGM1MGM3MThkZGE0MmQyOGZiZGQ2ZGNkNGZhMjM2NV83Ni9mcmFnOjQ3ZjEzODdjODc5ZjQ2ZTA4YTdkYjFlOGY1NzQwOWQ4L3RleHRyZWdpb246NDdmMTM4N2M4NzlmNDZlMDhhN2RiMWU4ZjU3NDA5ZDhfMjMy_acba6b18-d371-44a7-ab31-f6e191857160"
      unitRef="usd">75000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391601955224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Nov. 12, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EXICURE, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-5333008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2430 N. Halsted St.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Chicago<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">IL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">60614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(847)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">673-1700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">XCUR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,120,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001698530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391601998744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 51,885<span></span>
</td>
<td class="nump">$ 33,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">8,953<span></span>
</td>
<td class="nump">48,818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other assets</a></td>
<td class="nump">3,309<span></span>
</td>
<td class="nump">4,231<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">64,147<span></span>
</td>
<td class="nump">86,322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,171<span></span>
</td>
<td class="nump">4,123<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">8,117<span></span>
</td>
<td class="nump">8,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">1,465<span></span>
</td>
<td class="nump">1,393<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">77,900<span></span>
</td>
<td class="nump">100,444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,485<span></span>
</td>
<td class="nump">1,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">5,480<span></span>
</td>
<td class="nump">3,525<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">14,015<span></span>
</td>
<td class="nump">8,343<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">21,980<span></span>
</td>
<td class="nump">13,734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="nump">16,801<span></span>
</td>
<td class="nump">16,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="nump">16,929<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, noncurrent</a></td>
<td class="nump">7,551<span></span>
</td>
<td class="nump">7,959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">656<span></span>
</td>
<td class="nump">656<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">63,917<span></span>
</td>
<td class="nump">38,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value per share; 10,000,000 shares authorized, no shares issued and outstanding, September&#160;30, 2021 and December&#160;31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value per share; 200,000,000 shares authorized, 88,108,543 issued and outstanding, September&#160;30, 2021; 87,651,352 issued and outstanding, December&#160;31, 2020</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">170,217<span></span>
</td>
<td class="nump">167,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss) income</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(156,242)<span></span>
</td>
<td class="num">(105,965)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">13,983<span></span>
</td>
<td class="nump">61,506<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 77,900<span></span>
</td>
<td class="nump">$ 100,444<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391601817400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">88,108,543<span></span>
</td>
<td class="nump">87,651,352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">88,108,543<span></span>
</td>
<td class="nump">87,651,352<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391601990232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_RevenueFromContractWithCustomerNetOfCumulativeCatchUpAdjustment', window );">Collaboration revenue</a></td>
<td class="num">$ (3,677,000)<span></span>
</td>
<td class="nump">$ 2,443,000<span></span>
</td>
<td class="num">$ (2,601,000)<span></span>
</td>
<td class="nump">$ 16,473,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="num">(3,677,000)<span></span>
</td>
<td class="nump">2,443,000<span></span>
</td>
<td class="num">(2,601,000)<span></span>
</td>
<td class="nump">16,473,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">16,457,000<span></span>
</td>
<td class="nump">9,139,000<span></span>
</td>
<td class="nump">37,562,000<span></span>
</td>
<td class="nump">22,222,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="nump">2,947,000<span></span>
</td>
<td class="nump">2,424,000<span></span>
</td>
<td class="nump">8,937,000<span></span>
</td>
<td class="nump">7,227,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">19,404,000<span></span>
</td>
<td class="nump">11,563,000<span></span>
</td>
<td class="nump">46,499,000<span></span>
</td>
<td class="nump">29,449,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(23,081,000)<span></span>
</td>
<td class="num">(9,120,000)<span></span>
</td>
<td class="num">(49,100,000)<span></span>
</td>
<td class="num">(12,976,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeDividend', window );">Dividend income</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">205,000<span></span>
</td>
<td class="nump">139,000<span></span>
</td>
<td class="nump">832,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(455,000)<span></span>
</td>
<td class="num">(27,000)<span></span>
</td>
<td class="num">(1,314,000)<span></span>
</td>
<td class="num">(155,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">(5,000)<span></span>
</td>
<td class="nump">118,000<span></span>
</td>
<td class="num">(7,000)<span></span>
</td>
<td class="nump">271,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (expense) income, net</a></td>
<td class="num">(450,000)<span></span>
</td>
<td class="nump">298,000<span></span>
</td>
<td class="num">(1,177,000)<span></span>
</td>
<td class="nump">993,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Net loss before provision for income taxes</a></td>
<td class="num">(23,531,000)<span></span>
</td>
<td class="num">(8,822,000)<span></span>
</td>
<td class="num">(50,277,000)<span></span>
</td>
<td class="num">(11,983,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (23,531,000)<span></span>
</td>
<td class="num">$ (8,822,000)<span></span>
</td>
<td class="num">$ (50,277,000)<span></span>
</td>
<td class="num">$ (11,983,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (loss) earnings per common share (USD per share)</a></td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.57)<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (loss) earnings per common share (USD per share)</a></td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.57)<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average basic common shares outstanding (in shares)</a></td>
<td class="nump">88,105,066<span></span>
</td>
<td class="nump">87,227,136<span></span>
</td>
<td class="nump">88,001,222<span></span>
</td>
<td class="nump">87,160,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average diluted common shares outstanding (in shares)</a></td>
<td class="nump">88,105,066<span></span>
</td>
<td class="nump">87,227,136<span></span>
</td>
<td class="nump">88,001,222<span></span>
</td>
<td class="nump">87,160,520<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_RevenueFromContractWithCustomerNetOfCumulativeCatchUpAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contract With Customer, Net Of Cumulative Catch-Up Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_RevenueFromContractWithCustomerNetOfCumulativeCatchUpAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391601994536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (23,531)<span></span>
</td>
<td class="num">$ (8,822)<span></span>
</td>
<td class="num">$ (50,277)<span></span>
</td>
<td class="num">$ (11,983)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive (loss) income, net of taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (losses) gains on available for sale securities, net of tax</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(138)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive (loss) income</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(138)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (23,537)<span></span>
</td>
<td class="num">$ (8,960)<span></span>
</td>
<td class="num">$ (50,361)<span></span>
</td>
<td class="num">$ (11,756)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391682643128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in- Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,069,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 80,747<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 162,062<span></span>
</td>
<td class="num">$ (81,297)<span></span>
</td>
<td class="num">$ (27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity-based compensation</a></td>
<td class="nump">441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,081,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">2,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">1,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,150,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">85,114<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">165,269<span></span>
</td>
<td class="num">(80,147)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,069,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">80,747<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">162,062<span></span>
</td>
<td class="num">(81,297)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(11,983)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,228,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">73,428<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">166,499<span></span>
</td>
<td class="num">(93,280)<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,150,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="nump">85,114<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">165,269<span></span>
</td>
<td class="num">(80,147)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity-based compensation</a></td>
<td class="nump">544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(4,311)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,311)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,206,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">$ 81,752<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">165,863<span></span>
</td>
<td class="num">(84,458)<span></span>
</td>
<td class="nump">338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in shares)</a></td>
<td class="nump">22,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity-based compensation</a></td>
<td class="nump">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(138)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(138)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(8,822)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,822)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,228,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">73,428<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">166,499<span></span>
</td>
<td class="num">(93,280)<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,651,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">61,506<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">167,379<span></span>
</td>
<td class="num">(105,965)<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">342,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="nump">546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity-based compensation</a></td>
<td class="nump">517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(12,477)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,477)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,993,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">50,041<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">168,442<span></span>
</td>
<td class="num">(118,442)<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,651,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 61,506<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">167,379<span></span>
</td>
<td class="num">(105,965)<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in shares)</a></td>
<td class="nump">342,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">$ (84)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(50,277)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,108,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">13,983<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">170,217<span></span>
</td>
<td class="num">(156,242)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,993,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">50,041<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">168,442<span></span>
</td>
<td class="num">(118,442)<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity-based compensation</a></td>
<td class="nump">764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock-ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock-ESPP</a></td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(14,269)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,269)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,096,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">36,640<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">169,337<span></span>
</td>
<td class="num">(132,711)<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity-based compensation</a></td>
<td class="nump">889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units and related repurchases (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units and related repurchases</a></td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(23,531)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,531)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,108,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">$ 13,983<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 170,217<span></span>
</td>
<td class="num">$ (156,242)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391598954616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (50,277)<span></span>
</td>
<td class="num">$ (11,983)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAmortizationAndAccretionNet', window );">Depreciation and amortization</a></td>
<td class="nump">829<span></span>
</td>
<td class="nump">494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use asset</a></td>
<td class="nump">489<span></span>
</td>
<td class="nump">518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation</a></td>
<td class="nump">2,170<span></span>
</td>
<td class="nump">1,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of long-term debt issuance costs and fees</a></td>
<td class="nump">213<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of investments</a></td>
<td class="nump">183<span></span>
</td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(343)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">11<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">922<span></span>
</td>
<td class="num">(1,473)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other noncurrent assets</a></td>
<td class="num">(72)<span></span>
</td>
<td class="num">(181)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">629<span></span>
</td>
<td class="nump">535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">1,697<span></span>
</td>
<td class="num">(461)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">22,601<span></span>
</td>
<td class="num">(16,351)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="num">(408)<span></span>
</td>
<td class="num">(119)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(21,022)<span></span>
</td>
<td class="num">(27,463)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of available for sale securities</a></td>
<td class="num">(6,497)<span></span>
</td>
<td class="num">(47,349)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments', window );">Proceeds from sale or maturity of available for sale securities</a></td>
<td class="nump">46,097<span></span>
</td>
<td class="nump">47,093<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="num">(623)<span></span>
</td>
<td class="num">(3,074)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">38,977<span></span>
</td>
<td class="num">(3,330)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from common stock offering</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_PaymentsOfCommonStockFinancingCosts', window );">Payment of common stock financing costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(207)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long-term borrowing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of long-term debt fees and issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(344)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,999)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of employee stock purchase plan</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of common stock options</a></td>
<td class="nump">546<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments for minimum statutory tax withholding related to net share settlement of equity awards</a></td>
<td class="num">(9)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">668<span></span>
</td>
<td class="nump">14,992<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents, and restricted cash</a></td>
<td class="nump">18,623<span></span>
</td>
<td class="num">(15,801)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash - beginning of period</a></td>
<td class="nump">34,462<span></span>
</td>
<td class="nump">48,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash - end of period</a></td>
<td class="nump">53,085<span></span>
</td>
<td class="nump">32,659<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset acquired through operating leases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract', window );"><strong>Non-cash investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital expenditures (accounts payable and accrued expenses)</a></td>
<td class="nump">303<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalCashFlowElementsFinancingActivitiesAbstract', window );"><strong>Non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Debt fees (accrued expense and other noncurrent liabilities)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 834<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalCashFlowElementsFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalCashFlowElementsFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAmortizationAndAccretionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAmortizationAndAccretionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_PaymentsOfCommonStockFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments Of Common Stock Financing Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_PaymentsOfCommonStockFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391601560184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 51,885<span></span>
</td>
<td class="nump">$ 33,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash included in other noncurrent assets</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents, and restricted cash shown in the unaudited condensed consolidated statements of cash flows</a></td>
<td class="nump">$ 53,085<span></span>
</td>
<td class="nump">$ 34,462<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391597341672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business and Basis of Presentation</a></td>
<td class="text">Description of Business and Basis of Presentation<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exicure, Inc. (the &#8220;Company&#8221;) is a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases, and other genetic disorders based on its proprietary Spherical Nucleic Acid, or SNA&#8482;, technology. The Company believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. The Company is in preclinical development of XCUR-FXN, a lipid-nanoparticle SNA-based therapeutic candidate, for the intrathecal treatment of Friedreich&#8217;s ataxia (&#8220;FA&#8221;).  The Company&#8217;s therapeutic candidate cavrotolimod (AST-008) is in a Phase 1b/2 clinical trial in patients with advanced solid tumors. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes one of the key strengths of its proprietary SNAs is that they have the potential for increased cellular uptake compared to conventional linear oligonucleotides and as a result the potential to achieve higher efficacy at the same doses of oligonucleotide administered. The Company has shown in clinical and preclinical studies that SNAs may have therapeutic potential in immuno-oncology and dermatology.  In addition, the Company has shown in preclinical studies that SNAs may have therapeutic potential in neurology, ophthalmology, pulmonology, and gastroenterology. Accordingly, the Company has expanded its pipeline into neurology, for which investigational new drug application (&#8220;IND&#8221;)-enabling activities are ongoing for XCUR-FXN, and is concluding early stage research activities in ophthalmology, pulmonology, and gastroenterology. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout these unaudited condensed consolidated financial statements, the terms the &#8220;Company,&#8221;  &#8220;Exicure,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Exicure, Inc. and where appropriate, its wholly owned subsidiary, Exicure Operating Company.  Exicure Operating Company holds all material assets and conducts all business activities and operations of Exicure, Inc.&#160;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements as of September&#160;30, 2021 and December 31, 2020, and for the nine months ended September&#160;30, 2021 and 2020, have been presented in conformity with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;).  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements include the accounts of Exicure and its wholly owned subsidiary, Exicure Operating Company. All intercompany transactions and accounts are eliminated in consolidation.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Risks and Uncertainties</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Research and License Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, revenue recognized under the AbbVie Collaboration Agreement (as defined in Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Research and License Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for the three and nine months ended September 30, 2021 reflects the cumulative catchup adjustment (reduction) of revenue of $(4,480) recorded in connection with a change in estimate that occurred during the third quarter of 2021.  The Company currently estimates significant additional efforts will be required to satisfy the performance obligation under the AbbVie Collaboration Agreement.  These increased estimated efforts in connection with the change in workplan resulted in less progress occurring relative to the increased estimate of total project hours to complete the research services during the three and nine months ended September 30, 2021 as compared to the amount of revenue recognized at both June 30, 2021 and December 31, 2020, which led to revenue reversals in each respective period.  Due to uncertainties inherent in the estimation process, it is at least reasonably possible that estimated efforts required to complete the research services under the AbbVie Collaboration Agreement will be further revised in the </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">near-term which may result in additional adjustments (reductions of revenue) in future periods.  As discussed in Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Significant Accounting Policies &#8212; Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, determining the estimate of total project hours used to recognize revenue for our collaboration agreements requires significant judgment and any changes to those estimates may have a significant impact on the amount and timing of revenue recognition for the Ipsen Collaboration Agreement or the AbbVie Collaboration Agreement (each, as defined in Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Research and License Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) in future periods.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Risks and Uncertainties</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the ongoing COVID-19 pandemic, the Company has taken and continues to take active measures designed to address and mitigate the impact of the COVID-19 pandemic on its business, such as remote working policies, facilitating management&#8217;s routine communication to address employee and business concerns and providing frequent updates to the Company&#8217;s board of directors (the &#8220;Board&#8221;).  During the third quarter of 2021 and through the date of this report, the Company continues to operate under COVID-19 social distancing guidelines and has generally operated with approximately 100% of its R&amp;D staff on-site.  The Company&#8217;s office and general and administrative team is also working on-site approximately 50% of the time. The Company&#8217;s preclinical development program in Friedreich&#8217;s ataxia (&#8220;FA&#8221;) is ongoing and it began IND-enabling studies for XCUR-FXN in late 2020.  The Company also continues research and development activities with its collaboration partners, Ipsen Biopharm Limited (&#8220;Ipsen&#8221;) and AbbVie Inc. (&#8220;AbbVie&#8221;).  However, if the COVID-19 pandemic continues to persist for an extended period of time, the Company could experience further significant disruptions to its clinical and preclinical development timelines, which would adversely affect its business, financial condition, results of operations and growth prospects.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that the effects of the COVID-19 pandemic or its impact contributed to delays that began during the third quarter of 2020 and continued into the second half of 2021 in its enrollment plans and clinical trial site start-ups for the Phase 2 dose expansion phase of the Phase 1b/2 clinical trial for its cavrotolimod (AST-008) clinical program.  As a result of these delays, pending further delays or any additional unanticipated effects of the COVID-19 pandemic on its clinical development plans, the Company now expects to report overall response rate (&#8220;ORR&#8221;) results of cavrotolimod (AST-008) in the second half of 2022 as opposed to the previously reported first half of 2022. In the third quarter of 2020, the Company implemented, and continues to employ, additional measures to increase the enrollment of patients, including frequent interaction with its clinical trial sites currently open as well as increasing the number of clinical trial sites that potentially are activated for this trial so that the Company may continue to enroll patients as initially planned.  However, any additional delays may require the Company to further lengthen its clinical development timeline for cavrotolimod (AST-008).  The extent to which the COVID-19 pandemic or its impact or effects may continue to impact the Company&#8217;s business, its clinical development and regulatory efforts, its corporate development objectives and the value of and market for its common stock will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration or spread of the COVID-19 pandemic, its impact and effects, the possibility of additional periods of increases or spikes in the number of COVID-19 cases, the introduction and spread of new variants of the virus, travel restrictions, quarantines, social distancing, phased re-openings and business closure requirements in the United States and other countries, and the effectiveness of actions taken globally to contain and treat the disease including, without limitation, the effectiveness and timing of vaccination initiatives in the United States and worldwide.  The global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the COVID-19 pandemic could have a material adverse effect on the Company&#8217;s business, financial condition, results of operations and growth prospects. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is subject to other challenges and risks specific to its business and its ability to execute on its business plan and strategy, as well as risks and uncertainties common to companies in the biotechnology industry with research and development operations, including, without limitation, risks and uncertainties associated with: obtaining regulatory approval of its product candidates; delays or problems in obtaining clinical supply, loss of single source suppliers or failure to comply with manufacturing regulations; identifying, acquiring or in-licensing additional products or product candidates; product development and the </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inherent uncertainty of clinical success; and the challenges of protecting and enhancing its intellectual property rights; and the challenges of complying with applicable regulatory requirements.  In addition, to the extent the ongoing COVID-19 pandemic adversely affects the Company&#8217;s business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each reporting period, the Company evaluates whether there are conditions or events that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. The Company is required to make certain additional disclosures if it concludes substantial doubt exists and it is not alleviated by the Company&#8217;s plans or when its plans alleviate substantial doubt about the Company&#8217;s ability to continue as a going concern.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the Company has generated an accumulated deficit of $175,079 since inception and expects to incur significant expenses and negative cash flows for the foreseeable future. Based on the Company&#8217;s current operating plans and existing working capital at September 30, 2021, it is uncertain whether our current liquidity is sufficient to fund operations over the next twelve months from the date of the issuance of these condensed consolidated financial statements.  As a result, there is substantial doubt about our ability to continue as a going concern. The Company has no committed sources of additional capital at this time and substantial additional financing will be needed by the Company to fund its operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that it will be able to obtain additional funding through equity or debt financings, collaboration agreements, strategic partnerships and licensing arrangements, or other arrangements, such as its &#8220;at the market offering&#8221; program pursuant to its equity distribution agreement with BMO Capital Markets Corp., to fund its current operations and business strategy. However, there can be no assurance that such additional financing will be available and, if available, can be obtained on terms acceptable to the Company.  If the Company is unable to obtain such additional financing, the Company could be forced to delay, reduce or eliminate its research and development programs or clinical efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations.  The Company has historically principally raised capital through the public offerings of its securities.  However, the COVID-19 pandemic continues to rapidly evolve and has already resulted in a significant disruption of global financial markets.  If the disruption continues to persist and deepens, the Company could experience an inability to access additional capital, which could negatively affect its ability to raise capital and ultimately, its operations, liquidity and ability to continue as a going concern. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated interim financial statements have been prepared as though the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim condensed consolidated balance sheet as of September&#160;30, 2021, the interim condensed consolidated statements of operations for the three and nine months ended September&#160;30, 2021 and 2020, the interim condensed consolidated statements of comprehensive (loss) income for the three and nine months ended September&#160;30, 2021 and 2020, the interim condensed consolidated statements of changes in stockholders&#8217; equity for the three and nine months ended September&#160;30, 2021 and 2020, and the interim condensed consolidated statements of cash flows for the nine months ended September&#160;30, 2021 and 2020, are unaudited. The interim unaudited condensed consolidated financial statements have been prepared on the same basis as the annual audited financial statements; and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company&#8217;s financial position as of September&#160;30, 2021, the results of its operations for the three and nine months ended September&#160;30, 2021 and 2020, and the results of its cash flows for the nine months ended September&#160;30, 2021 and 2020. The financial data and other information disclosed in </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">these notes related to the three and nine months ended September&#160;30, 2021 and 2020 are unaudited. The results for the three and nine months ended September&#160;30, 2021 are not necessarily indicative of results to be expected for the year ending December&#160;31, 2021, or any other interim periods, or any future year or period.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Management bases its estimates on certain assumptions which it believes are reasonable in the circumstances and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company&#8217;s financial position, results of operations or cash flows. Actual results in future periods could differ from those estimates.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391598459512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text">Significant Accounting Policies<div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant accounting policies are disclosed in the audited consolidated financial statements and the notes thereto, which are included in the in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020 filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March 11, 2021. Since the date of those audited consolidated financial statements, there have been no material changes to the Company&#8217;s significant accounting policies, except as noted below:</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue recognition</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2018, we adopted the provisions of Accounting Standards Codification, or ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> using the modified retrospective method for all contracts not completed as of the date of adoption.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 606, we recognize revenue when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC 606, we perform the following five steps:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt">Identify the contract with the customer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party&#8217;s rights and obligations regarding the goods or services to be transferred and identifies the related payment terms, (ii) the contract has commercial substance, and (iii) we determine that collection of substantially all consideration for goods and services that are transferred is probable based on the customer&#8217;s intent and ability to pay the promised consideration. We apply judgment in determining the customer&#8217;s intent and ability to pay, which is based on a variety of factors including the customer&#8217;s historical payment experience, or in the case of a new customer, published credit and financial information pertaining to the customer.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt">Identify the performance obligations in the contract.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Performance obligations promised in a contract are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the good or service either on its own or together with other available resources, and are distinct in the context of the contract, whereby the transfer of the good or service is separately identifiable from other promises in the contract. To the extent a contract includes multiple promised goods and services, we must apply judgment to determine whether promised goods and services are both capable of being distinct and distinct in the context of the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt">Determine the transaction price.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The transaction price is determined based on the consideration to which we will be entitled in exchange for transferring goods and services to the customer. To the extent the transaction price includes variable consideration, we estimate the amount of variable consideration that </span></div><div style="margin-bottom:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">should be included in the transaction price utilizing either the expected value method or the most likely amount method, depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in our judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Any estimates, including the effect of the constraint on variable consideration, are evaluated at each reporting period for any changes. Determining the transaction price requires significant judgment.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt">Allocate the transaction price to performance obligations in the contract.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. However, if a series of distinct services that are substantially the same qualifies as a single performance obligation in a contract with variable consideration, we must determine if the variable consideration is attributable to the entire contract or to a specific part of the contract. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative standalone selling price basis unless the transaction price is variable and meets the criteria to be allocated entirely to a performance obligation or to a distinct service that forms part of a single performance obligation. The consideration to be received is allocated among the separate performance obligations based on relative standalone selling prices. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt">Recognize revenue when or as the Company satisfies a performance obligation.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We satisfy performance obligations either over time or at a point in time. Revenue is recognized over time if either (i) the customer simultaneously receives and consumes the benefits provided by the entity&#8217;s performance, (ii) the entity&#8217;s performance creates or enhances an asset that the customer controls as the asset is created or enhanced, or (iii) the entity&#8217;s performance does not create an asset with an alternative use to the entity and the entity has an enforceable right to payment for performance completed to date. If the entity does not satisfy a performance obligation over time, the related performance obligation is satisfied at a point in time by transferring the control of a promised good or service to a customer. Examples of control are using the asset to produce goods or services, enhance the value of other assets, or settle liabilities, and holding or selling the asset.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue allocated to performance obligations relating to provision of research and development activities is recognized as the performance obligations are satisfied using an input method to measure progress, based on an estimate of the percentage of completion of the project based on the actual hours incurred on the project as a percentage of the total expected project hours. The determination of the percentage of completion requires management to estimate the total expected project hours. A detailed estimate of the total expected project hours is re-assessed every reporting period based on the latest project plan and discussions with project teams. If a change in facts or circumstances occurs, the estimate will be adjusted and the revenue will be recognized based on the revised estimate. The difference between the cumulative revenue recognized based on the previous estimate and the revenue recognized based on the revised estimate would be recognized as an adjustment to revenue in the period in which the change in estimate occurs. Determining the estimate of total project hours requires significant judgment and may have a significant impact on the amount and timing of revenue recognition.  For example, as discussed in Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Research and License Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, revenue recognized under the AbbVie Collaboration Agreement (as defined in Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Research and License Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for the three and nine months ended September 30, 2021 reflects the cumulative catchup adjustment (reduction) of revenue of $(4,480) recorded in connection with a change in estimate that occurred during the third quarter of 2021.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses of intellectual property</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from consideration allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the licenses. For licenses that are combined with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or&#160;at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revenue. We evaluate the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone payments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;At the inception of each arrangement that includes development milestone payments, we evaluate the probability of reaching the milestones and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur in the future, the associated milestone value is included in the transaction price. Milestone payments that are not within our control or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received and therefore revenue recognized is constrained as management is unable to assert that a reversal of revenue would not be possible. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues and earnings in the period of adjustment.  To date, we have not recognized any milestone payment revenue from any of its collaboration agreements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;For arrangements that include sales-based royalties, including milestone payments based on levels of sales, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, we have not recognized any royalty revenue resulting from any of its collaboration agreements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2016-13&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2016-13 is a new standard intended to improve reporting requirements specific to loans, receivables and other financial instruments. ASU 2016-13 requires that credit losses on financial assets measured at amortized cost be determined using an expected loss model, instead of the current incurred loss model, and requires that credit losses related to available-for-sale debt securities&#160;be recorded through an allowance for credit losses and limited to the amount by which carrying value exceeds fair value. ASU 2016-13 also requires enhanced disclosure of credit risk associated with financial assets. The effective date of ASU 2016-13 was deferred by ASU 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments&#8212;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842)&#8212;Effective Dates </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the annual period beginning after December 15, 2022 for companies that (i) meet the definition of an SEC filer and (ii) are eligible as &#8220;smaller reporting companies&#8221; as such term is defined by the SEC, with early adoption permitted. The Company is currently assessing the impact of adoption of ASU 2016-13 to its consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391597344472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Research and License Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Research and License Agreements</a></td>
<td class="text">Collaborative Research and License Agreements<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ipsen Collaboration Agreement</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Agreement</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2021 (the &#8220;Ipsen Effective Date&#8221;), the Company entered into a Collaboration, Option and License Agreement with Ipsen (the &#8220;Ipsen Collaboration Agreement&#8221;). Pursuant to the Ipsen Collaboration Agreement, the Company granted to Ipsen exclusive access and options to license SNA-based therapeutics arising from two collaboration programs related to the treatment of Huntington&#8217;s disease and Angelman syndrome (each, an &#8220;Ipsen Collaboration Program&#8221;), respectively. Each such license (obtained in connection with the exercise of an Ipsen Option, as defined and discussed further below) would grant to Ipsen exclusive, royalty-bearing, sublicensable, worldwide rights to develop, manufacture, use and commercialize such SNA therapeutics. Upon written notice to the Company, Ipsen may exercise its option during the corresponding collaboration program&#8217;s applicable option exercise period, (each, an &#8220;Ipsen Option Exercise Period&#8221;).</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the Ipsen Effective Date, the Company and Ipsen have agreed upon a development plan for each Ipsen Collaboration Program that describes the development activities and timelines required to advance each such Ipsen Collaboration Program through its first IND filing (each, an &#8220;Ipsen Development Plan&#8221;).  The activities described in the Ipsen Development Plans are conducted under the supervision of the Ipsen Joint Steering Committee (the &#8220;Ipsen JSC&#8221;) consisting of three members from each of the Company and Ipsen.  Under the terms of the Ipsen Collaboration Agreement, the Company will use commercially reasonable efforts to conduct discovery and development in two collaboration programs for Huntington&#8217;s disease (the &#8220;HD Program&#8221;) and Angelman syndrome (the &#8220;AS Program&#8221;) (the &#8220;Ipsen Development Activities&#8221;) respectively. The Company shall be solely responsible for all costs and expenses of conducting each Ipsen Collaboration Program through the selection of SNA therapeutic candidates for further development (&#8220;Ipsen Selection&#8221;), and Ipsen shall be responsible for all costs and expenses of all activities that are necessary to enable the first filing of an  IND for each proposed product candidate.  In the event that Ipsen exercises an option, Ipsen will be responsible for further development from the license effective date and commercialization of the corresponding licensed product. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the completion of all Ipsen Development Activities for the Ipsen Selection (the &#8220;Ipsen First R&amp;D Term Activities&#8221;), the Company is required to deliver to Ipsen a report that describes the results of the Ipsen First R&amp;D Term Activities and identifies at least one SNA-based compound that satisfies certain criteria for such Ipsen Collaboration Program as determined by the Ipsen JSC (the &#8220;Ipsen First Option Data Package&#8221;).  Following the delivery of the Ipsen First Option Data Package for an Ipsen Collaboration Program, Ipsen will have the ability for a defined period of time (the &#8220;Ipsen First Option Exercise Period&#8221;) to exercise an option (each a &#8220;First Ipsen Option&#8221;) to obtain worldwide rights and license to the Company&#8217;s SNA technology and the Company&#8217;s interest in joint collaboration technology to make, have made, import, use, sell or offer for sale any product (each an &#8220;Ipsen Licensed Product&#8221;) that results from such Ipsen Collaboration Program during the term of the Ipsen Collaboration Agreement.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the event Ipsen (i) does not exercise the First Ipsen Option with respect to an Ipsen Collaboration Program, (ii) the Ipsen Collaboration Agreement has not expired or been terminated with respect to such Ipsen Collaboration Program, and (iii) Ipsen agrees to fully fund additional research activities for an Ipsen Collaboration Program through IND filing, the Company will be responsible for research and development activities for such Ipsen Collaboration Program through IND filing (the &#8220;Ipsen Second R&amp;D Term Activities&#8221;).  Following the completion of the Ipsen Second R&amp;D Term Activities, the Company is required to deliver to Ipsen a report that describes the results of the Ipsen Second R&amp;D Term Activities (the &#8220;Ipsen Second Option Data Package&#8221;).   Following the delivery of the Ipsen Second Option Data Package for an Ipsen Collaboration Program, Ipsen will have the ability for a defined period of time (the &#8220;Ipsen Second Option Exercise Period&#8221;) to exercise an option (each a &#8220;Second Ipsen Option&#8221; and together with the First Ipsen Option, the &#8220;Ipsen Options&#8221;) to obtain worldwide rights and license to the Company&#8217;s SNA technology and the Company&#8217;s interest in joint collaboration technology to make, have made, import, use, sell or offer for sale any Ipsen Licensed Product&#8221; that results from such Ipsen Collaboration Program during the term of the Ipsen Collaboration Agreement.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After Ipsen&#8217;s exercise of an Ipsen Option for an Ipsen Collaboration Program, the Company shall supply to Ipsen the licensed SNAs under current Good Manufacturing Practice, at the Company&#8217;s manufacturing cost pursuant to a clinical supply agreement to be negotiated by the Company and Ipsen in good faith following the Ipsen Effective Date and executed within twelve (12) months after the Ipsen Effective Date (the &#8220;Ipsen Supply Agreement&#8221;). The Ipsen Supply Agreement will provide for the transfer by the Company to Ipsen of all documents and information, and the provision by the Company of technical assistance and support, for Ipsen to manufacture or have manufactured by a third party contractor engaged by Ipsen the applicable licensed SNA to the extent it is intended to be actually used in the development and manufacture of the applicable licensed products.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Ipsen Collaboration Agreement, the Company received an upfront payment of $20,000 (the &#8220;Ipsen Upfront Payment&#8221;).  If Ipsen exercises a First Ipsen Option, Ipsen is required to pay the Company the First Ipsen Option exercise fee of $10,000 for each Ipsen Collaboration Program.  If Ipsen exercises a Second Ipsen  Option, Ipsen is required to pay the Company the Second Ipsen Option exercise fee of $25,000 for each Ipsen Collaboration Program. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ipsen will pay a pre-clinical milestone payment of $5,000 for each Ipsen Collaboration Program upon achievement of such milestone regardless of whether an Ipsen Option is exercised.  In addition to the option exercise fees and the pre-clinical milestones described above, if Ipsen exercises an Ipsen Option for an Ipsen Collaboration Program, development and regulatory milestones will be payable for that program upon the initiation of certain clinical trials and the filing for processing by the United States Food and Drug Administration (&#8220;FDA&#8221;) in the United States and by two additional regulators outside the United States of a marketing application for review, per the Ipsen Collaboration Program, with an aggregate total of up to $180,000 if both Ipsen Options are exercised. Commercial milestones will be payable for that Ipsen Collaboration Program upon first commercial sale of a licensed product in certain jurisdictions and the achievement of specified aggregate sales thresholds for all licensed products from that program, with an aggregate total of up to $762,000 if both Ipsen Options are exercised. In the event a therapeutic candidate subject to the Ipsen Collaboration Agreement results in commercial sales, the Company is eligible to receive tiered royalties at percentages ranging from the mid-single digits to the mid-teens on future net product sales of such commercialized therapeutic candidates. A percentage of the aforementioned payments will be due to Northwestern University upon receipt, pursuant to the terms of the Company&#8217;s existing license agreements with Northwestern University (see Note 13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitment and Contingencies,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information on the Northwestern University License Agreements (as defined below)). In connection with the receipt of the Ipsen Upfront Payment, the Company paid a $3,000 license fee to Northwestern University under the terms of the Northwestern License Agreements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s obligations to conduct activities defined in the Ipsen Development Plan under the Ipsen Collaboration Agreement commenced on July 30, 2021 and continues, unless earlier terminated, until (a) the expiration of the later-to-expire Ipsen Option Exercise Period, if Ipsen does not exercise either Ipsen Option, or (b) the expiration of the last-to-expire royalty term for any licensed product in such country on a licensed product-by-licensed product and country-by-country basis, if Ipsen exercises one or both Ipsen Options. Upon expiration of the royalty term with respect to a particular licensed product in a country, the license for such product in such country will convert to a fully-paid, irrevocable and perpetual license. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Ipsen Collaboration Agreement also contains customary provisions for termination by either party, including by Ipsen for any or no reason in its entirety upon (90) days prior written notice and including in the event of breach of the Ipsen Collaboration Agreement, subject to cure, and by the Company upon a challenge of the licensed patents, subject, in certain cases, to customary reversion rights. Upon termination of the Ipsen Collaboration Agreement by the Company for Ipsen&#8217;s breach or bankruptcy, all licenses granted by the Company to Ipsen will terminate.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Ipsen Collaboration Agreement includes customary representations and warranties on behalf of both the Company and Ipsen. The Ipsen Collaboration Agreement also provides for customary mutual indemnities.  In addition, the Ipsen Collaboration Agreement imposes certain exclusivity obligations on Ipsen and the Company, </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively, with respect to the development, use, manufacture and commercialization of oligonucleotide-based therapeutic targeting the same targets in the collaboration programs and/or certain other specific targets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Either party may assign the Ipsen Collaboration Agreement or delegate its obligations to an affiliate or to a successor to substantially all of the business to which the Ipsen Collaboration Agreement relates without the consent of the other party.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Analysis</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that Ipsen is a customer in this arrangement, and as such the arrangement falls within the scope of the revenue recognition guidance. Under the Ipsen Collaboration Agreement, the Company has identified two performance obligations, as follows: (1) the performance obligation related to the HD Program that includes (i) the Ipsen First R&amp;D Term Activities related to the HD Program (the &#8220;Ipsen HD Program R&amp;D Services&#8221;), (ii) Ipsen JSC services related to the HD Program during the Ipsen First Term (the &#8220;Ipsen HD Program JSC Services&#8221;), and (iii) activities related to the negotiation of the Ipsen Supply Agreement within twelve months of the Ipsen Effective Date; and (2) the performance obligation related to the AS Program that includes (i) the Ipsen First R&amp;D Term Activities related to the AS Program (the &#8220;Ipsen AS Program R&amp;D Services&#8221;), (ii) Ipsen JSC services related to the AS Program during the Ipsen First Term (the &#8220;Ipsen AS Program JSC Services&#8221;), (iii) and activities related to the negotiation of the Ipsen Supply Agreement within twelve months of the Ipsen Effective Date.  The Company has concluded that the Ipsen HD Program R&amp;D Services and the Ipsen AS Program R&amp;D Services are not distinct from the Ipsen HD Program JSC Services and the Ipsen AS Program JSC Services, respectively. The Company has also concluded that the Ipsen HD Program JSC Services and the Ipsen AS Program JSC Services are not distinct from the activities related to entering the Ipsen Supply Agreements for each respective program. The Ipsen JSC provides oversight and management of the overall Ipsen Collaboration Agreement, and the members of the Ipsen JSC from the Company have specialized industry knowledge, particularly as it relates to SNA technology. The Ipsen JSC is meant to facilitate the early stage research being performed and coordinate the activities of both the Company and Ipsen. Further, the Ipsen JSC services are critical to the ongoing evaluation of the Ipsen Collaboration Programs and the drafting and evaluation of the Ipsen First Option Data Package. The Ipsen JSC will also provide oversight and management of the activities to enter into the Ipsen Supply Agreement.  Accordingly, the Company&#8217;s participation on the Ipsen JSC is essential to Ipsen receiving value from the Ipsen HD Program R&amp;D Services and the Ipsen AS Program R&amp;D Services, and as such, (i) the Ipsen HD Program JSC Services, along with the Ipsen HD Program R&amp;D Services and the activities related to entering the Ipsen Supply Agreement within twelve months of the Ipsen Effective Date for that program are considered a single performance obligation (the &#8220;Ipsen HD Program Services&#8221;) and (ii) the Ipsen AS Program JSC Services along with the Ipsen AS Program R&amp;D Services and the activities related to entering the Ipsen Supply Agreement within twelve months of the Ipsen Effective Date for that program are considered a single performance obligation (the &#8220;Ipsen AS Program Services&#8221;). </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the Ipsen Effective Date, the total transaction price was determined to be $20,000, consisting solely of the Ipsen Upfront Payment. The Company also utilized the most likely amount method to estimate any development and regulatory milestone payments to be received. As of the Ipsen Effective Date, there were no milestones included in the transaction price.&#160;The pre-clinical, development, regulatory, and commercial milestones were fully constrained due to the significant uncertainties surrounding such payments.&#160;The Company considered the stage of development and the risks associated with the remaining development required to achieve the milestone, as well as whether the achievement of the milestone is outside the control of the Company or Ipsen.  The Company has determined that any commercial milestones and sales-based royalties will be recognized when the related sales occur and therefore, they have also been excluded from the transaction price. The Company will re-evaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur.  As of September&#160;30, 2021, the Company determined that any pre-clinical, development, regulatory, or commercial milestones continue to be constrained and therefore the related milestone payments continue to be excluded from the transaction price at September&#160;30, 2021.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated the total transaction price to each of the two identified performance obligations under the Ipsen Collaboration Agreement based on an expected cost plus a margin approach, as follows: $10,793 of the </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transaction price allocated to the Ipsen HD Program Services and $9,207 of the transaction price allocated to the Ipsen AS Program Services.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will recognize revenue related to each of Ipsen HD Program Services and the Ipsen AS Program Services as those performance obligations are satisfied using an input method to measure progress for each of those performance obligations. The Company believes the input method that most accurately depicts the measure of progress is the actual hours incurred to date relative to projected hours to complete the activities for the Ipsen HD Program Services and the Ipsen AS Program Services.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2021, the Company recognized revenue under the Ipsen Collaboration Agreement of approximately $803.  As of September&#160;30, 2021 , there was $19,197 of deferred revenue related to the Ipsen Collaboration Agreement, of which is $7,945 is classified as current and $11,252 is classified as noncurrent on the unaudited condensed consolidated balance sheet. Deferred revenue under the Ipsen Collaboration Agreement will be recognized as revenue in future periods as the Company satisfies its obligations under the Ipsen Collaboration Agreement, which the Company currently estimates to be over the next 33 to 42 months.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AbbVie Collaboration Agreement</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Agreement&#160;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 13, 2019 (the &#8220;AbbVie Effective Date&#8221;), the Company entered into a Collaboration, Option and License Agreement (the &#8220;AbbVie Collaboration Agreement&#8221;), with a wholly-owned subsidiary of Allergan plc, Allergan. On May 8, 2020, Allergan plc, including Allergan was acquired by AbbVie. Pursuant to the AbbVie Collaboration Agreement, the Company granted to AbbVie exclusive access and options to license SNA-based therapeutics arising from two collaboration programs related to the treatment of hair loss disorders (each, an &#8220;AbbVie Collaboration Program&#8221;). Under each such license (obtained in connection with the exercise of an AbbVie Option, as defined and discussed further below), the Company would grant to AbbVie exclusive, royalty-bearing, sublicensable, nontransferable, worldwide rights to develop, manufacture, use and commercialize such SNA therapeutics. Under the AbbVie Collaboration Agreement, the Company will use commercially reasonable efforts to conduct the AbbVie Collaboration Programs, each focused on one or more hair loss disorders to discover one or more SNA products that are directed to, bind to or inhibit one or more specific AbbVie Collaboration Program targets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the AbbVie Effective Date, the Company and AbbVie have agreed upon a development plan for each AbbVie Collaboration Program that describes the development activities and timelines required to advance such AbbVie Collaboration Program through its first IND filing (each, an &#8220;AbbVie Development Plan&#8221;).  The activities described in the AbbVie Development Plan are conducted under the supervision of the AbbVie Joint Development Committee (the &#8220;AbbVie JDC&#8221;) consisting of three members from each of the Company and AbbVie. The Company is primarily responsible for performing early-stage discovery and preclinical activities (the &#8220;AbbVie Collaboration Program Initial Development Activities&#8221;) set forth in the AbbVie Development Plan for each AbbVie Collaboration Program and will be solely responsible for all costs and expenses related to the AbbVie Collaboration Program Initial Development Activities. AbbVie may elect, in its sole discretion and at its sole cost and expense, to conduct formulation assessment and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> testing as set forth in an AbbVie Development Plan.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2021, the AbbVie JDC revised the AbbVie Initial Development Plan for each AbbVie Collaboration Program.  In connection with the revised workplan for each AbbVie Collaboration Program, the Company expects to perform additional early stage discovery and preclinical activities to those set forth in the AbbVie Development Plan.  As such, the Company currently estimates significant additional efforts will be required to satisfy the performance obligation under the AbbVie Collaboration Agreement due to the revised workplan for each AbbVie Collaboration Program.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the completion of all AbbVie Initial Development Activities, the Company is required to deliver to AbbVie a report that describes the results of the AbbVie Initial Development Activities and identifies at least one SNA-based compound that satisfies certain criteria for such AbbVie Collaboration Program as determined by the AbbVie JDC (the &#8220;AbbVie Initial Development Report&#8221;).  Following the delivery of the AbbVie Initial Development Report for an AbbVie Collaboration Program, AbbVie will have the ability for a defined period of time (the &#8220;AbbVie Initial Option Exercise Period&#8221;) to exercise an option (each an &#8220;AbbVie Option&#8221;) to obtain worldwide rights and license to the Company&#8217;s SNA technology and the Company&#8217;s interest in joint collaboration technology to make, have made, import, use, sell or offer for sale any product (each an &#8220;AbbVie Licensed Product&#8221;) that results from such AbbVie Collaboration Program during the term of the AbbVie Collaboration Agreement.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At AbbVie&#8217;s sole option, AbbVie may extend the AbbVie Initial Option Exercise Period (the &#8220;AbbVie Option Extension&#8221;) and require the Company to perform IND-enabling activities described in the AbbVie Development Plan (the &#8220;AbbVie IND-Enabling Activities&#8221;), subject to the payment of additional consideration (&#8220;AbbVie Extension Exercise&#8221;). If AbbVie exercises the AbbVie Option Extension, the Company would be responsible for conducting the AbbVie IND-Enabling Activities and would be solely responsible for all costs and expenses associated with such activities.  Upon completion of the AbbVie IND-Enabling Activities, the Company is required to deliver a report that describes the results of the AbbVie IND-Enabling Activities (the &#8220;AbbVie IND-Enabling Activities Data Package&#8221;) to AbbVie. Following the delivery of AbbVie IND-Enabling Activities Data Package, AbbVie will have the ability for a defined period of time (the &#8220;AbbVie Extended Option Exercise Period&#8221;) to exercise an AbbVie Option with respect to such AbbVie Collaboration Program. After the exercise of an AbbVie Option with respect to an AbbVie Collaboration Program, AbbVie will be responsible for all development, manufacturing and commercialization activities, and costs and expense associated with such activities in connection with AbbVie Licensed Products arising from such AbbVie Collaboration Program.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s obligation to conduct the activities defined in the AbbVie Development Plan under the AbbVie Collaboration Agreement commenced on November 13, 2019 and continues until the earlier of (i) the date AbbVie exercises an AbbVie Option, (ii) the date AbbVie abandons an AbbVie Collaboration Program and foregoes its AbbVie Option to that AbbVie Collaboration Program, or (iii) the fifth anniversary of the AbbVie Effective Date (the &#8220;AbbVie Research Term&#8221;). If the AbbVie Initial Option Exercise Period or AbbVie Extended Option Exercise Period is still in effect for an AbbVie Collaboration Program or if the Company has not delivered a complete AbbVie Initial Development Report or, if AbbVie made an AbbVie Extension Exercise for an AbbVie Collaboration Program, a complete AbbVie IND-Enabling Activities Data Package for such AbbVie Collaboration Program, as determined by the AbbVie JDC, then the AbbVie Research Term will automatically extend by one-year increments until such obligation is satisfied, but in no event past the seventh anniversary of the AbbVie Effective Date.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the AbbVie Collaboration Agreement, the Company received a $25,000 upfront, non-refundable, non-creditable cash payment (the &#8220;AbbVie Upfront Payment&#8221;) related to the Company&#8217;s research and development costs for conducting the AbbVie Development Plan for two AbbVie Collaboration Programs, each focused on one or more targets, and certain options to obtain exclusive, worldwide licenses under certain intellectual property rights owned or controlled by the Company to develop, manufacture and commercialize certain products resulting from each such AbbVie Collaboration Programs.  The option exercise fee during the AbbVie Initial Option Exercise Period is $10,000 per AbbVie Collaboration Program.  If AbbVie elects to extend the AbbVie Initial Option Exercise Period, AbbVie is required to pay an additional fee of $10,000.  If AbbVie elects to exercise its option during the AbbVie Extended Option Exercise Period, AbbVie must pay the Company the option exercise fee of $15,000.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the exercise by AbbVie of an AbbVie Option with respect to an AbbVie Collaboration Program, AbbVie would be required to make certain milestone payments to the Company upon the achievement of specified development, product approval and launch, and commercial events, on an AbbVie Licensed Product by AbbVie Licensed Product basis. On an AbbVie Licensed Product by AbbVie Licensed Product basis, for the first AbbVie Licensed Product to achieve the associated milestone event, the Company is eligible to receive up to an aggregate of $55,000 for development milestone payments and $132,500 for product approval and launch milestone payments. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also eligible for up to $175,000 in sales milestone payments on an AbbVie Collaboration Program by AbbVie Collaboration Program basis, associated with aggregate worldwide sales. Certain product approval milestones are subject to certain reductions under specified circumstances, including for payments required to be made by AbbVie to obtain certain third-party intellectual property rights.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, to the extent there is any AbbVie Licensed Product, the Company would be entitled to receive tiered royalty payments of mid-single digits to the mid-teens percentage on future net worldwide product sales of such AbbVie Licensed Products, subject to certain reductions under specified circumstances. Royalties are due on a AbbVie Licensed Product by AbbVie Licensed Product and country by country basis from the date of the first commercial sale of each AbbVie Licensed Product in a country until the latest to occur of: (i) the expiration date in such country of the last to expire valid claim within the licensed intellectual property covering the manufacture, use or sale of such AbbVie Licensed Product in such country, (ii) the tenth anniversary of the first commercial sale of such AbbVie Licensed Product in such country, and (iii) the expiration of regulatory exclusivity for such AbbVie Licensed Product in such country.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie may terminate the AbbVie Collaboration Agreement for any reason or no reason, either in its entirety or on an AbbVie Collaboration Program by AbbVie Collaboration Program basis, at any time on 90 days&#8217; prior written notice to the Company. Unless earlier terminated, the term of the AbbVie Collaboration Agreement shall continue until (i) if both AbbVie Option Exercise Periods expire without AbbVie exercising either AbbVie Option, the expiration of the later to expire AbbVie Option Exercise Period, and (ii) if either or both AbbVie Options are exercised on an AbbVie Licensed Product by AbbVie Licensed Product and country-by-country basis, the expiration of the royalty term for such AbbVie Licensed Product in such country. Either party may terminate the AbbVie Collaboration Agreement if the other party has materially breached or defaulted in the performance of any of its material obligations and such breach or default continues after the specified cure period. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Termination of the AbbVie Collaboration Agreement for any reason will not release either party from any liability which, at the time of such termination, has already accrued to the other party or which is attributable to a period prior to such termination. In addition, termination of the AbbVie Collaboration Agreement will not preclude either party from pursuing any rights and remedies it may have under the agreement or at law or in equity with respect to any breach of the AbbVie Collaboration Agreement. If either party terminates the AbbVie Collaboration Agreement, the license and rights granted to AbbVie with respect to the terminated AbbVie Collaboration Program or AbbVie License Product shall terminate. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Analysis</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that AbbVie is a customer in this arrangement, and as such the arrangement falls within the scope of the revenue recognition guidance. Under the AbbVie Collaboration Agreement, the Company has identified a single performance obligation that includes (i) the research and development activities during the AbbVie Research Term (the &#8220;AbbVie R&amp;D Services&#8221;), and (ii) AbbVie Joint Development Committee services during the AbbVie Research Term (the &#8220;AbbVie JDC Services&#8221;). The Company has concluded that the AbbVie R&amp;D Services is not distinct from the AbbVie JDC Services during the AbbVie Research Term. The AbbVie JDC provides oversight and management of the overall AbbVie Collaboration Agreement, and the members of the AbbVie JDC from the Company have specialized industry knowledge, particularly as it relates to SNA technology. The AbbVie JDC is meant to facilitate the early-stage research being performed and coordinate the activities of both the Company and AbbVie. Further, the AbbVie JDC services are critical to the ongoing evaluation of an AbbVie Collaboration Program and the drafting and evaluation of the AbbVie Initial Development Report and the AbbVie IND-Enabling Data Package. Accordingly, the Company&#8217;s participation on the AbbVie JDC is essential to AbbVie receiving value from the AbbVie R&amp;D Services and as such, the AbbVie JDC Services along with the AbbVie R&amp;D Services are considered one performance obligation (the &#8220;AbbVie Collaboration Program Services&#8221;).  In addition, the Company has concluded that the option to purchase two development and commercialization licenses is considered a marketing offer as the options did not provide any discounts or other rights that would be considered a material right in the arrangement, and thus, not a performance obligation at the onset of the agreement.&#160;&#160;The consideration for these options will be accounted for when they are exercised.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the AbbVie Effective Date, the total transaction price was determined to be $25,000, consisting solely of the AbbVie Upfront Payment. The Company also utilized the most likely amount method to estimate any development and regulatory milestone payments to be received. As of the AbbVie Effective Date, there were no milestones included in the transaction price.&#160;The milestones were fully constrained due to the significant uncertainties surrounding such payments.&#160;The Company considered the stage of development and the risks associated with the remaining development required to achieve the milestone, as well as whether the achievement of the milestone is outside the control of the Company or AbbVie.  The Company has determined that any commercial milestones and sales-based royalties will be recognized when the related sales occur and therefore they have also been excluded from the transaction price. The Company will re-evaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur.  As of September&#160;30, 2021, the Company determined that any development, regulatory or commercial milestones continue to be constrained and therefore the related milestone payments continue to be excluded from the transaction price at September 30, 2021.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will recognize revenue related to the AbbVie Collaboration Program Services as the performance obligation is satisfied using an input method to measure progress. The Company believes the input method that most accurately depicts the measure of progress is the actual hours incurred to date relative to projected hours to complete the research service.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed above, during the third quarter of 2021, the AbbVie JDC revised the AbbVie Initial Development Plan for each AbbVie Collaboration Program.  As a result, the Company has increased its estimate of total hours to complete the research services, requiring an adjustment to cumulative revenue recognized (considered a change in estimate pursuant to ASC 606) as of September 30, 2021.  As such, during the third quarter of 2021, the Company recorded a cumulative catchup adjustment (reduction) of revenue of $(4,480).</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2021, the Company recognized revenue under the AbbVie Collaboration Agreement of approximately $(4,480) and $(3,404), respectively, reflecting the cumulative catchup adjustment (reduction) of revenue of $(4,480) discussed above due to a change in estimate.  The Company currently estimates significant additional efforts will be required to satisfy the performance obligation under the AbbVie Collaboration Agreement due to the revised workplan for each AbbVie Collaboration Program.  These increased estimated efforts in connection with the change in workplan resulted in less progress occurring relative to the increased estimate of total project hours to complete the research services during the three and nine months ended September 30, 2021 as compared to the amount of revenue recognized at both June 30, 2021 and December 31, 2020, which led to revenue reversals in each respective period.  During the three and nine months ended September&#160;30, 2020, the Company recognized revenue under the AbbVie Collaboration Agreement of approximately $2,402 and $16,351, respectively.  As of September&#160;30, 2021, there was $11,747 of deferred revenue related to the AbbVie Collaboration Agreement, of which is $6,070 is classified as current and $5,677 is classified as noncurrent on the unaudited condensed consolidated balance sheet.  Deferred revenue under the AbbVie Collaboration Agreement will be recognized as revenue in future periods as the Company satisfies its obligations under the AbbVie Collaboration Agreement, which the Company currently estimates to be over the next 24 to 27 months.  As of  December&#160;31, 2020, there was $8,343 of deferred revenue related to the AbbVie Collaboration Agreement, which was classified as current on the unaudited condensed consolidated balance sheet based on the estimated contract completion date at that time.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dermelix Collaboration Agreement</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2019, Exicure entered into a License and Development Agreement (the &#8220;Dermelix Collaboration Agreement&#8221;) with Dermelix, LLC d/b/a Dermelix Biotherapeutics (&#8220;Dermelix&#8221;). Under the terms of the Dermelix Collaboration Agreement, Exicure received an upfront payment of $1,000, to be applied against the initial $1,000 of the Company&#8217;s development expenses.  </span></div><div style="margin-bottom:9pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company initially recorded the upfront payment of $1,000 as deferred revenue related to its wholly unsatisfied performance obligation and reduced this balance to zero during 2019 by recognizing revenue as services </span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were provided.  The Company recognized no revenue under the Dermelix Collaboration Agreement during the three and nine months ended September&#160;30, 2021. The Company recognized $41 and $122 of revenue during the three and nine months ended September&#160;30, 2020 which reflected reimbursement by Dermelix for additional costs incurred by Exicure for early-stage development costs beyond the initial $1,000 upfront payment.</span></div><div style="margin-bottom:9pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Contract Liabilities</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Up-front payments are recorded as deferred revenue upon receipt or when due until such time as the Company satisfies its performance obligations under these arrangements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in the balances of the Company&#8217;s contract liabilities (in thousands):</span></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.032%"><tr><td style="width:1.0%"/><td style="width:30.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.474%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.474%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.547%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.474%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.559%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.474%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.972%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Revenue Balance at January 1, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue <br/>(Recognized) Reversed</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Revenue Balance at September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Collaboration Agreement</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(803)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbbVie Collaboration Agreement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,343&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,601&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,944&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391598448552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SupplementalBalanceSheetInformationAbstract', window );"><strong>Supplemental Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Supplemental Balance Sheet Information</a></td>
<td class="text">Supplemental Balance Sheet Information<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid expenses and other current assets</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.711%"><tr><td style="width:1.0%"/><td style="width:72.165%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.646%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.930%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical, contract research and manufacturing costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,133&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,336&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,309&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,231&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and equipment, net</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.230%"><tr><td style="width:1.0%"/><td style="width:72.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.314%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.997%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scientific equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,136&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,544&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,863&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,373)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,740)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,171&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,123&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense was $283 and $159 for the three months ended September 30, 2021 and 2020, respectively, and $829 and $494 for the nine months ended September 30, 2021 and 2020, respectively.</span></div><div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued expenses and other current liabilities</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.551%"><tr><td style="width:1.0%"/><td style="width:72.289%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.950%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical, contract research and manufacturing costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,741&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,372&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,480&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,525&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SupplementalBalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SupplementalBalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391597356984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text">Investments<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021 and December&#160;31, 2020, the Company primarily invested its excess cash in debt instruments of corporations, the U.S. Treasury, financial institutions, and U.S. government agencies with strong credit ratings and an investment grade rating at or above a long-term rating of Aa3/AA- and a short-term rating of P1/A1. The Company has established guidelines relative to diversification and maturities that maintain safety and liquidity. The Company periodically reviews and modifies these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the contract maturity of the available-for-sale securities the Company held as of September&#160;30, 2021:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:282.75pt"><tr><td style="width:1.0pt"/><td style="width:211.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One year or less</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one year but within two years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s available-for-sale securities are available to the Company for use in its current operations. As a result, the Company categorizes all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized holding gains, gross unrealized holding losses and fair value of cash equivalents and available-for-sale securities by type of security at&#160;September&#160;30, 2021&#160;and December&#160;31, 2020 were as follows:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.826%"><tr><td style="width:1.0%"/><td style="width:45.147%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.672%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.672%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.672%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.295%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Holding Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Holding Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,498&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,497&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,954&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,953&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.025%"><tr><td style="width:1.0%"/><td style="width:44.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.680%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.680%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.680%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Holding Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Holding Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,992&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,991&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,735&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,818&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391597259080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MidCap Credit Agreement</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2021, the Company entered into an amendment (&#8220;Amendment No. 3&#8221;) to the Company&#8217;s Credit and Security Agreement, dated as of September 25, 2020, as amended on October 21, 2020 and July 30, 2021, with MidCap Financial Trust, as agent (&#8220;MidCap&#8221;), and the lenders party thereto from time to time (as amended by Amendment No. 3, the &#8220;MidCap Credit Agreement&#8221;).</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MidCap Credit Agreement provides for a secured term loan facility in an aggregate principal amount of up to $25,000 (the &#8220;MidCap Credit Facility&#8221;). The Company borrowed the first advance of $17,500 (&#8220;Tranche 1&#8221;) on September 25, 2020 (the &#8220;Closing Date&#8221;). Amendment No. 3 extends the availability of the second advance of $7,500 (&#8220;Tranche 2&#8221;) under the MidCap Credit Agreement from September 30, 2021 to December 31, 2021, subject to the Company&#8217;s satisfaction of certain applicable funding conditions as described in Amendment No. 3, including  the Company&#8217;s issuance of equity interests, subject to certain limitations, resulting in receipt by the Company of unrestricted net cash proceeds of at least $20,000, and the contribution by the Company, and receipt by Exicure Operating Company, of such cash proceeds to the capital of Exicure Operating Company.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Tranche 1 and if borrowed, Tranche 2, each bear interest at a floating rate equal to 6.25% per annum, plus the greater of (i) 1.50% or (ii) one-month LIBOR. Interest on each loan advance is due and payable monthly in arrears. Principal on each loan advance is payable in 36 equal monthly installments beginning October 1, 2022 until paid in full on October 1, 2025 (the &#8220;Maturity Date&#8221;). Prepayments of the loans under the MidCap Credit Agreement, in whole or in part, will be subject to early termination fees in an amount equal to 3.0% of principal prepaid if prepayment occurs on or prior to the first anniversary of the Closing Date and 1.0% of principal prepaid if prepayment occurs after the first anniversary of the Closing Date and prior to the maturity date.  In connection with execution of the MidCap Credit Agreement, the Company paid MidCap a $125 origination fee.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Maturity Date or on any earlier date on which all amounts advanced to the Company become due and payable in full, or are otherwise paid in full, the Company is required to pay an exit fee equal to 3.75% of the principal amount of all loans advanced to the Company under the MidCap Credit Agreement. Upon the advance of Tranche 1, the Company accrued $656 for the related exit fee.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s obligations under the MidCap Credit Agreement are secured by a security interest in substantially all of its assets, excluding intellectual property (which is subject to a negative pledge). Additionally, the Company&#8217;s future subsidiaries, if any, may be required to become co-borrowers or guarantors under the MidCap Credit Agreement.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MidCap Credit Agreement contains customary affirmative covenants and customary negative covenants limiting the Company&#8217;s ability and the ability of the Company&#8217;s subsidiaries, if any, to, among other things, dispose of assets, undergo a change in control, merge or consolidate, make acquisitions, incur debt, incur liens, pay dividends, repurchase stock and make investments, in each case subject to certain exceptions.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MidCap Credit Agreement also contains customary events of default relating to, among other things, payment defaults, breaches of covenants, a material adverse change, delisting of the Company&#8217;s common stock, bankruptcy and insolvency, cross defaults with certain material indebtedness and certain material contracts, judgments, and inaccuracies of representations and warranties. Upon an event of default, the agent and the lenders may declare all or a portion of the Company&#8217;s outstanding obligations to be immediately due and payable and exercise other rights and remedies provided for under the agreement. During the existence of an event of default, interest on the obligations could be increased by 2.0%.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total proceeds, net of fees and issuance costs, borrowed under Tranche 1 were $16,512.  Fees and issuance costs of $332, as well as fees of $656 that are payable to MidCap at maturity of Tranche 1, are recorded as a reduction to the carrying amount of long-term debt on the Company&#8217;s balance sheet and will be amortized to interest expense through the maturity date of October 1, 2025 using the effective interest method. Fees and issuance costs of $73 attributed to the amount available to be borrowed under Tranche 2 were paid and recorded as deferred financing costs (other assets) and will be (i) recorded as a reduction in the carrying amount of long-term debt in future periods if amounts are borrowed under Tranche 2 or (ii) will be amortized and recorded to interest expense if amounts are not borrowed under Tranche 2. For the three and nine months ended September 30, 2021, the Company recognized $36 and $73, respectively, as interest expense and no balance of the deferred financing costs remains as of September 30, 2021.</span></div><div style="margin-bottom:9pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the aggregate carrying value of the Company&#8217;s long-term debt is $16,801.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the principal maturities of the Company&#8217;s long-term debt were as follows:</span></div><div style="margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:76.749%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (remaining three months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal balance outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,500&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less: unamortized discount and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(699)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,801&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid interest on the MidCap Credit Agreement of $344 and $1,041 during the three and nine months ended September 30, 2021, respectively. The Company paid interest on the Hercules Loan Agreement (as discussed below) of $0 and $142 during the three and nine months ended September 30, 2020, respectively.</span></div><div style="margin-bottom:9pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hercules Loan Agreement</span></div><div style="margin-bottom:9pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 2, 2020, pursuant to the terms of the loan agreement with Hercules Technology Growth Capital (&#8220;Hercules&#8221;) and subsequent amendments thereto  (the &#8220;Hercules Loan Agreement&#8221;), the Company repaid all remaining outstanding obligations under the Hercules Loan Agreement as of the maturity date, including the outstanding principal balance of $4,999 and the end of term fee of $100.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391597343912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">LeasesThe Company&#8217;s lease arrangements at September 30, 2021 consist of (i) a lease for office and laboratory space at its headquarters in Chicago, Illinois that commenced in July 2020 (the &#8220;Chicago Lease&#8221;), (ii) a lease for office <div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">space at a multi-tenant facility in Cambridge, Massachusetts that commenced in March 2019 and is cancelable at any time (the &#8220;Cambridge Lease&#8221;), and (iii) leases for office equipment (the &#8220;Office Equipment Leases&#8221;). Each of these leases are classified as operating leases.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the nature of the Cambridge Lease, the Company determined that this lease represented a short-term lease with an initial term of less than twelve months and, as such, the Cambridge Lease is not recorded on the balance sheet and related lease costs are recognized in the statement of operations as they are incurred. The Company has also elected to not record the Office Equipment Leases on the balance sheet since related payment amounts and lease costs are insignificant. Lease costs for the Office Equipment Leases are recognized in the statement of operations on a straight-line basis over the lease term.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s lease arrangement for office and laboratory space at its former headquarters in Skokie, Illinois ended in February 2021 in accordance with the terms of that lease arrangement. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Chicago Lease</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has approximately thirty thousand square feet of office and laboratory space in Chicago, Illinois (the &#8220;Chicago Lease&#8221;). The original term (the &#8220;Original Term&#8221;) of the Chicago Lease is 10 years, commencing on July 1, 2020 (the &#8220;Commencement Date&#8221;), which is the date the premises were ready for occupancy under the terms of the Chicago Lease.  The Company has options to extend the term of the Chicago Lease for&#160;two&#160;additional successive periods of five years each (the &#8220;Extension Periods&#8221;) at the then prevailing effective market rental rate.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial annual base rent during the Original Term is approximately $1,113 for the first 12-month period of the Original Term, payable in monthly installments beginning on the Commencement Date. Base rent thereafter is subject to annual increases of 3%, for an aggregate amount of $12,761 over the Original Term. The Company must also pay its proportionate share of certain operating expenses and taxes for each calendar year during the term.  During the first 12-month period of the Original Term, the base rent and the Company&#8217;s proportionate share of operating expenses and taxes were subject to certain abatements. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Chicago Lease, the Company will maintain a letter of credit for the benefit of the landlord in an initial amount of $1,200, which amount is subject to reduction over time.  Upon execution of the Chicago Lease, the Company paid to the landlord the first installment of base rent and the estimated monthly amount of its pro rata share of taxes and its pro rata share of operating expenses in the aggregate amount of $87 which amount had been adjusted for the abatement as set forth in the lease agreement. The Company also paid the landlord a net amount of $697 toward tenant improvements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the agreement for the Chicago Lease, the Company is required to maintain a&#160;standby letter of credit during the term of the lease, currently in the amount of $1,200 and subject to reduction over time, which is secured by a restricted certificate of deposit account and presented within other noncurrent assets on the Company&#8217;s unaudited condensed consolidated balance sheet at September&#160;30, 2021.&#160;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized a right of use asset of $8,931 and a lease liability of $8,147 on the Commencement Date. Because the rate implicit in the Chicago Lease is not readily determinable, the Company used its incremental borrowing rate of 8.3% on the Commencement Date to determine the present value of the lease payments over the Original Term. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease. As of September&#160;30, 2021, the Company determined it is not reasonably certain that the renewal option would be exercised.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information related to the Company&#8217;s operating lease asset and related operating lease liabilities were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:76.749%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes lease costs in the Company&#8217;s unaudited condensed consolidated statement of operations:</span></div><div style="margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">980&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease costs</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,877&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,130&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company made cash payments for operating leases of $1,721 and $1,717 during the nine months ended September 30, 2021 and 2020, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of the Company&#8217;s lease liability as of September&#160;30, 2021 were as follows:</span></div><div style="margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:76.749%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (remaining three months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,266&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,275)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,991&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent operating lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,991&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391600470104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021 and December&#160;31, 2020, the Company had 10,000,000 shares of preferred stock, par value $0.0001 authorized and no shares issued and outstanding.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021 and December&#160;31, 2020, the Company had authorized 200,000,000 shares of common stock, par value $0.0001.  As of September&#160;30, 2021 and December&#160;31, 2020, the Company had 88,108,543 shares and 87,651,352 shares issued and outstanding, respectively.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of shares of the Company&#8217;s common stock are entitled to one vote per share on all matters to be voted upon by the Company&#8217;s stockholders and there are no cumulative rights. Subject to preferences that may be applicable to any outstanding preferred stock, the holders of shares of the Company&#8217;s common stock are entitled to receive ratably any dividends that may be declared from time to time by the Board out of funds legally available for that purpose. In the event of the Company&#8217;s liquidation, dissolution or winding up, the holders of shares of the Company&#8217;s common stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock then outstanding. The Company&#8217;s common stock has no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to the Company&#8217;s common stock. The outstanding shares of the Company&#8217;s common stock are fully paid and&#160;non-assessable.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Warrants</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of September&#160;30, 2021, no warrants were outstanding. As of December 31, 2020, warrants to purchase 413,320 shares of common stock at a price of&#160;$3.00&#160;per share were outstanding.  The warrants expired unexercised as follows: 163,174 warrants expired on March 27, 2021, 132,884 expired on April 28, 2021, and 117,262 expired on May 3, 2021.  The warrants were classified as a liability which was remeasured each period at fair value. See Note 12,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;for more information on the fair value of the common stock warrant liability.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income (Loss)</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in each component of accumulated other comprehensive income (loss), net of tax, for&#160;2021:</span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.980%"><tr><td style="width:1.0%"/><td style="width:57.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.754%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.757%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains (losses) on short-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net losses (gains) reclassified from accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net gain reclassified from accumulated other comprehensive loss during the three months ended September 30, 2021 resulted from available-for-sale securities that were called prior to maturity and no gains or losses were recognized for the three and nine months ended September 30, 2021. The basis on which the cost of the securities was determined was specific identification. Proceeds related to these sales were $4,000.</span></div><div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in each component of accumulated other comprehensive income (loss), net of tax, for&#160;2020:</span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.980%"><tr><td style="width:1.0%"/><td style="width:57.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.754%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.757%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains (losses) on short-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net losses (gains) reclassified from accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The net loss reclassified from accumulated other comprehensive loss during the nine months ended September 30, 2020 resulted from sales of available-for-sale securities prior to maturity. The gross realized gains and gross realized losses of these sales were $23 and $6, respectively, for the three and nine months ended September 30, 2020. The basis on which the cost of the securities was determined was specific identification. Proceeds related to these sales were $9,404.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391599393000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity-Based Compensation</a></td>
<td class="text">Equity-Based Compensation<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 Equity Incentive Plan</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Awards that may be awarded under the 2017 Equity Incentive Plan include non-qualified and incentive stock options, stock appreciation rights, bonus shares, restricted stock, restricted stock units, performance units and cash-based awards. The number of shares of common stock reserved for issuance under the 2017 Equity Incentive Plan automatically increases on January 1 of each year, beginning on January 1, 2020, by the lesser of (i) 4,600,000 shares, (ii) 5% of the total number of shares of our capital stock outstanding on December 31 of the preceding calendar year, or (iii) a lesser number of shares determined by the Compensation Committee of the Board (the &#8220;Compensation Committee&#8221;). The Compensation Committee made the determination to increase the share reserve for the 2017 Equity Incentive Plan by 4,382,567 shares, effective January 1, 2021. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the aggregate number of equity awards available for grant under the 2017 Equity Incentive Plan was 2,558,218.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inducement Grant</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company granted stock options to purchase up to 600,000 shares of common stock as a material inducement to Brian C. Bock, the Company&#8217;s Chief Financial Officer, to enter into employment with the Company (the &#8220;Inducement Grant&#8221;).  The Inducement Grant, which was made pursuant to a stand-alone nonstatutory stock option agreement (the &#8220;Inducement Award Agreement&#8221;), was approved by the Compensation Committee, was awarded in accordance with Nasdaq Listing Rule 5635(c)(4) and outside of the Company&#8217;s 2017 Equity Incentive Plan and is subject to the terms and conditions of the Inducement Award Agreement.  As such, any shares underlying the Inducement Grant are not, upon forfeiture, cancellation or expiration, returned to a pool of shares reserved for future issuance.  As of September&#160;30, 2021, stock options to purchase up to 600,000 shares of common stock remained outstanding under the Inducement Grant.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2017 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) was adopted by the Board in September 2017 and approved by the Company&#8217;s stockholders in September 2017. Through the ESPP, eligible employees may authorize payroll deductions of up to 15% of their compensation to purchase common stock. The maximum number of shares that an employee may purchase on any exercise date in an offer period will be the smaller of (i) 7,500 shares or (ii) such number of shares as has a fair market value (determined as of the offering date for such offer period) equal to $25,000 within one calendar year minus the fair market value of any other shares of common stock that are attributed to such calendar year. The purchase price per share at each purchase date is equal to 85% of the lower of (i) the closing market price per share of Exicure common stock on the employee&#8217;s offering date or (ii) the closing market price per share of Exicure common stock on the exercise date. Each offering period is approximately six-months in duration and the first offering period began on November 16, 2020 and ended on May 14, 2021.  In connection with the end of the first offering period on May 14, 2021, the Company issued 103,096 shares of common stock that were purchased under the ESPP.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ESPP provides that the number of shares reserved and available for issuance will automatically increase each January 1, beginning on January 1, 2018 and each January 1 thereafter through January 1, 2027, by the least of (i) 300,000 shares; (ii) 0.3% of the outstanding shares of common stock on the last day of the immediately preceding calendar year; or (iii) a lesser number of shares determined by the Board. On January 1, 2021 and 2020, the number </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of shares of common stock available for issuance under the ESPP increased by 258,207 shares and 262,954 shares, respectively. As of September&#160;30, 2021, there were 1,100,791 shares available for issuance under the ESPP.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity-based compensation expense is classified in the statements of operations as follows:</span></div><div style="margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,045&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,170&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,603&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized equity-based compensation expense at September&#160;30, 2021 was $7,820, which is expected to be amortized over a weighted-average period of 3.0 years. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the Black-Scholes option-pricing model to determine the fair value of common stock option grants. The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable.  The model also requires the input of highly subjective assumptions.  In addition to an assumption on the expected term of the option grants as discussed below, application of the Black-Scholes model requires additional inputs for which we have assumed the values described in the table below:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.115%"><tr><td style="width:1.0%"/><td style="width:56.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.857%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.625%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.858%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 to 6.1 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2 to 6.1 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.36% to 1.12%; weighted avg. 1.05%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.31% to 1.68%; weighted avg. 0.61%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.7% to 83.6%; weighted avg. 82.6%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.0% to 85.8%; weighted avg. 83.8%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeiture rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term is based upon the &#8220;simplified method&#8221; as described in Staff Accounting Bulletin Topic 14.D.2. Currently, the Company does not have sufficient experience to provide a reasonable estimate of an expected term of its common stock options. The Company will continue to use the &#8220;simplified method&#8221; until there is sufficient experience to provide a more reasonable estimate in conformance with ASC 718-10-30-25 through 30-26. The risk-free interest rate assumptions were based on the U.S. Treasury bond rate appropriate for the expected term in effect at the time of grant.  The expected volatility is based on calculated enterprise value volatilities for publicly traded companies in the same industry and general stage of development.  The estimated forfeiture rates were based on historical experience for similar classes of employees.  The dividend yield was based on expected dividends at the time of grant.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the underlying common stock and the exercise price for the common stock options granted during the nine months ended September 30, 2021 and 2020 are summarized in the table below:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.833%"><tr><td style="width:1.0%"/><td style="width:53.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.140%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.636%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.142%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock Options Granted During Period Ended:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value of Underlying Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price of Common Stock Option</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine months ended September 30, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.15 to $2.57; weighted avg. $1.87</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.15 to $2.57; weighted avg. $1.87</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine months ended September 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.19 to $2.80:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">weighted avg. $1.91</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.19 to $2.80:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">weighted avg. $1.94</span></div></td></tr></table></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of common stock options granted in the nine months ended September 30, 2021 and 2020 was $1.30 and $1.33 per common stock option, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of common stock option activity as of the periods indicated is as follows:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.551%"><tr><td style="width:1.0%"/><td style="width:37.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.645%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.645%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.645%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,227,296&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,719&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,427,586&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(342,246)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(252,681)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,059,955&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable - September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,207,872&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and Expected to Vest -<br/>September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,630,872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of common stock options exercised during the nine months ended September 30, 2021 and 2020 was $243 and $74, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of restricted stock unit activity of the periods indicated is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.512%"><tr><td style="width:1.0%"/><td style="width:58.218%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.672%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.674%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance - December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,875)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance - September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546,625&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.57&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date fair value of restricted stock units is based on the Company&#8217;s closing stock price at the date of grant. At vesting, each outstanding restricted stock unit will be exchanged for one share of the Company&#8217;s common stock. The restricted stock units granted during the 2021 period generally vest evenly on a quarterly basis over a period of 4 years in exchange for continued service provided by the restricted stock unit recipient during that vesting period.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391597294504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income TaxesThe Company incurred a pretax loss in each of the three and nine months ended September 30, 2021 and 2020, which consists entirely of loss in the United States and resulted in no provision for income tax expense during the periods then ended.  The effective tax rate is 0% in each of the three and nine months ended September 30, 2021 and 2020 because the Company has generated tax losses and has provided a full valuation allowance against its deferred tax assets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391597352536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss Per Common Share</a></td>
<td class="text">Loss Per Common Share<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per common share is calculated using the treasury share method by giving effect to all potentially dilutive securities that were outstanding.  Potentially dilutive options, restricted stock units and warrants to purchase common stock that were outstanding during the periods presented were excluded from the diluted loss per share calculation for the periods presented because such shares had an anti-dilutive effect due to the net loss reported in those periods.  Therefore, basic and diluted loss per common share is the same for each of the three and nine months ended September 30, 2021 and 2020.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is the computation of loss per common share for the three and nine months ended September 30, 2021 and 2020:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.551%"><tr><td style="width:1.0%"/><td style="width:37.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.645%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.645%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.645%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,531)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,822)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,277)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,983)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic and diluted common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,105,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,227,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,001,222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,160,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share - basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outstanding securities presented below were excluded from the calculation of loss per common share, for the periods presented, because such securities would have been anti-dilutive due to the Company&#8217;s loss per share during that period:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.294%"><tr><td style="width:1.0%"/><td style="width:64.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.439%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.442%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,059,955&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,739,781&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546,625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391599400648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, as follows: Level 1 Inputs - unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date; Level 2 Inputs - other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3 Inputs - unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date. </span><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets measured at fair value on a recurring basis as of September&#160;30, 2021 are as follows:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.269%"><tr><td style="width:1.0%"/><td style="width:42.370%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.487%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.659%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.487%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.478%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,593&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,641&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,952&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value on a recurring basis as of December 31, 2020 are as follows:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.557%"><tr><td style="width:1.0%"/><td style="width:46.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.745%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.450%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.450%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.450%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.423%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,818&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrant liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the market approach and Level 1 and Level 2 inputs to value its cash equivalents and Level 2 inputs to value its short-term investments.  The Company&#8217;s long-term debt bore interest at the prevailing market rates for instruments with similar characteristics and, accordingly, the carrying value for this instrument also approximates its fair value and the financial measurement is also classified within Level 2 of the fair value hierarchy.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the Company&#8217;s common stock warrant liability was $0 and no warrants were outstanding (refer to Note 8, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stockholders&#8217; Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for more information). The following is a reconciliation of the Company&#8217;s liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3) for the three months ended September&#160;30, 2021:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.237%"><tr><td style="width:1.0%"/><td style="width:72.641%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.159%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock Warrant Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain included in other (expense) income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September&#160;30, 2021</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391597287080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 7,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for a discussion of the commitments associated with the Company&#8217;s lease agreements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Northwestern University License Agreements</span></div>On December 12, 2011, (1) AuraSense, LLC, the Company&#8217;s former parent, assigned to the Company all of its worldwide rights and interests under AuraSense, LLC&#8217;s 2009 license agreement with Northwestern University (&#8220;NU&#8221;) in the field of the use of nanoparticles, nanotechnology, microtechnology or nanomaterial-based constructs as therapeutics or accompanying therapeutics as a means of delivery, but expressly excluding diagnostics (the &#8220;assigned field&#8221;); (2)&#160;in accordance with the terms and conditions of this assignment, the Company assumed all liabilities and obligations of AuraSense, LLC as set forth in its license agreement in the assigned field; and (3)&#160;in order to secure this assignment and the patent rights from NU, the Company agreed (i) to pay NU an annual license fee, which may be credited against any royalties due to NU in the same year, (ii) to reimburse NU for expenses associated with the prosecution and maintenance of the license patent rights, (iii) to pay NU royalties based on any net revenue generated by the Company&#8217;s sale or transfer of any licensed product, (iv) to pay NU, in the event the Company grants a sublicense under the licensed patent rights, the greater of a percentage of all sublicensee royalties or a percentage of any net revenue generated by a sublicensee&#8217;s sale or transfer of any licensed product, and (v) to pay NU a percentage of all other sublicense payments received by the Company.  In August 2015, the Company entered into a restated license agreement with NU (the &#8220;Restated License Agreement&#8221;). In February 2016, the Company obtained exclusive license as to NU&#8217;s rights in certain SNA technology it jointly owns with NU (the &#8220;Co-owned Technology License&#8221;). The Company&#8217;s license to NU&#8217;s rights is limited to the assigned field, however the Company has no such limitation as to its own rights in this jointly owned technology. In June 2016, the Company entered into an exclusive license with NU to obtain worldwide rights to certain inhibitors of glucosylceramide synthase and their use in wound healing in diabetes (the &#8220;Wound Healing License&#8221;). The Company&#8217;s rights and obligations in the Co-owned Technology License and the Wound Healing License agreements&#160;are substantially the same as in the Restated License Agreement from August 2015 (collectively referred to as &#8220;the Northwestern University License Agreements&#8221;).  All pending patent applications under the Wound Healing License have been abandoned and the Wound Healing License has been terminated.  As of September&#160;30, 2021, the Company has paid to NU an aggregate of $11,413 in consideration of each of the obligations described above.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391597119608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-Party Transactions</a></td>
<td class="text">Related-Party TransactionsThe Company received consulting services from, and paid fees to, one of its co-founders who is not an employee but, through April 30, 2021, served as a member of the Board. The Company recognized $75 as an expense in each of the nine months ended September&#160;30, 2021 and 2020 in connection with these consulting services in the accompanying unaudited condensed consolidated statement of operations.  The consulting agreement with this co-founder and former Board member expired on September 30, 2021 under the terms of the agreement and was not renewed.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391601582136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of PresentationThe accompanying unaudited condensed consolidated financial statements as of September&#160;30, 2021 and December 31, 2020, and for the nine months ended September&#160;30, 2021 and 2020, have been presented in conformity with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements include the accounts of Exicure and its wholly owned subsidiary, Exicure Operating Company. All intercompany transactions and accounts are eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Management bases its estimates on certain assumptions which it believes are reasonable in the circumstances and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company&#8217;s financial position, results of operations or cash flows. Actual results in future periods could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue recognition</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2018, we adopted the provisions of Accounting Standards Codification, or ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> using the modified retrospective method for all contracts not completed as of the date of adoption.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 606, we recognize revenue when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC 606, we perform the following five steps:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt">Identify the contract with the customer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party&#8217;s rights and obligations regarding the goods or services to be transferred and identifies the related payment terms, (ii) the contract has commercial substance, and (iii) we determine that collection of substantially all consideration for goods and services that are transferred is probable based on the customer&#8217;s intent and ability to pay the promised consideration. We apply judgment in determining the customer&#8217;s intent and ability to pay, which is based on a variety of factors including the customer&#8217;s historical payment experience, or in the case of a new customer, published credit and financial information pertaining to the customer.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt">Identify the performance obligations in the contract.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Performance obligations promised in a contract are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the good or service either on its own or together with other available resources, and are distinct in the context of the contract, whereby the transfer of the good or service is separately identifiable from other promises in the contract. To the extent a contract includes multiple promised goods and services, we must apply judgment to determine whether promised goods and services are both capable of being distinct and distinct in the context of the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt">Determine the transaction price.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The transaction price is determined based on the consideration to which we will be entitled in exchange for transferring goods and services to the customer. To the extent the transaction price includes variable consideration, we estimate the amount of variable consideration that </span></div><div style="margin-bottom:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">should be included in the transaction price utilizing either the expected value method or the most likely amount method, depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in our judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Any estimates, including the effect of the constraint on variable consideration, are evaluated at each reporting period for any changes. Determining the transaction price requires significant judgment.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt">Allocate the transaction price to performance obligations in the contract.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. However, if a series of distinct services that are substantially the same qualifies as a single performance obligation in a contract with variable consideration, we must determine if the variable consideration is attributable to the entire contract or to a specific part of the contract. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative standalone selling price basis unless the transaction price is variable and meets the criteria to be allocated entirely to a performance obligation or to a distinct service that forms part of a single performance obligation. The consideration to be received is allocated among the separate performance obligations based on relative standalone selling prices. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt">Recognize revenue when or as the Company satisfies a performance obligation.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We satisfy performance obligations either over time or at a point in time. Revenue is recognized over time if either (i) the customer simultaneously receives and consumes the benefits provided by the entity&#8217;s performance, (ii) the entity&#8217;s performance creates or enhances an asset that the customer controls as the asset is created or enhanced, or (iii) the entity&#8217;s performance does not create an asset with an alternative use to the entity and the entity has an enforceable right to payment for performance completed to date. If the entity does not satisfy a performance obligation over time, the related performance obligation is satisfied at a point in time by transferring the control of a promised good or service to a customer. Examples of control are using the asset to produce goods or services, enhance the value of other assets, or settle liabilities, and holding or selling the asset.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue allocated to performance obligations relating to provision of research and development activities is recognized as the performance obligations are satisfied using an input method to measure progress, based on an estimate of the percentage of completion of the project based on the actual hours incurred on the project as a percentage of the total expected project hours. The determination of the percentage of completion requires management to estimate the total expected project hours. A detailed estimate of the total expected project hours is re-assessed every reporting period based on the latest project plan and discussions with project teams. If a change in facts or circumstances occurs, the estimate will be adjusted and the revenue will be recognized based on the revised estimate. The difference between the cumulative revenue recognized based on the previous estimate and the revenue recognized based on the revised estimate would be recognized as an adjustment to revenue in the period in which the change in estimate occurs. Determining the estimate of total project hours requires significant judgment and may have a significant impact on the amount and timing of revenue recognition.  For example, as discussed in Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Research and License Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, revenue recognized under the AbbVie Collaboration Agreement (as defined in Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Research and License Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for the three and nine months ended September 30, 2021 reflects the cumulative catchup adjustment (reduction) of revenue of $(4,480) recorded in connection with a change in estimate that occurred during the third quarter of 2021.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses of intellectual property</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from consideration allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the licenses. For licenses that are combined with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or&#160;at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revenue. We evaluate the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone payments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;At the inception of each arrangement that includes development milestone payments, we evaluate the probability of reaching the milestones and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur in the future, the associated milestone value is included in the transaction price. Milestone payments that are not within our control or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received and therefore revenue recognized is constrained as management is unable to assert that a reversal of revenue would not be possible. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues and earnings in the period of adjustment.  To date, we have not recognized any milestone payment revenue from any of its collaboration agreements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;For arrangements that include sales-based royalties, including milestone payments based on levels of sales, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, we have not recognized any royalty revenue resulting from any of its collaboration agreements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2016-13&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2016-13 is a new standard intended to improve reporting requirements specific to loans, receivables and other financial instruments. ASU 2016-13 requires that credit losses on financial assets measured at amortized cost be determined using an expected loss model, instead of the current incurred loss model, and requires that credit losses related to available-for-sale debt securities&#160;be recorded through an allowance for credit losses and limited to the amount by which carrying value exceeds fair value. ASU 2016-13 also requires enhanced disclosure of credit risk associated with financial assets. The effective date of ASU 2016-13 was deferred by ASU 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments&#8212;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842)&#8212;Effective Dates </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the annual period beginning after December 15, 2022 for companies that (i) meet the definition of an SEC filer and (ii) are eligible as &#8220;smaller reporting companies&#8221; as such term is defined by the SEC, with early adoption permitted. The Company is currently assessing the impact of adoption of ASU 2016-13 to its consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss Per Common Share</a></td>
<td class="text">Basic loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per common share is calculated using the treasury share method by giving effect to all potentially dilutive securities that were outstanding.  Potentially dilutive options, restricted stock units and warrants to purchase common stock that were outstanding during the periods presented were excluded from the diluted loss per share calculation for the periods presented because such shares had an anti-dilutive effect due to the net loss reported in those periods.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391598544904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Research and License Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Balance Of The Company's Contract Liability</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in the balances of the Company&#8217;s contract liabilities (in thousands):</span></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.032%"><tr><td style="width:1.0%"/><td style="width:30.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.474%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.474%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.547%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.474%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.559%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.474%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.972%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Revenue Balance at January 1, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue <br/>(Recognized) Reversed</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Revenue Balance at September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Collaboration Agreement</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(803)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AbbVie Collaboration Agreement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,343&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,601&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,944&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391598521624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SupplementalBalanceSheetInformationAbstract', window );"><strong>Supplemental Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Prepaid Expense and Other Current Assets</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid expenses and other current assets</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.711%"><tr><td style="width:1.0%"/><td style="width:72.165%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.646%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.930%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical, contract research and manufacturing costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,133&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,336&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,309&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,231&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and equipment, net</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.230%"><tr><td style="width:1.0%"/><td style="width:72.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.314%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.997%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scientific equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,136&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,544&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,863&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,373)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,740)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,171&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,123&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued expenses and other current liabilities</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.551%"><tr><td style="width:1.0%"/><td style="width:72.289%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.950%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical, contract research and manufacturing costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,741&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,372&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,480&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,525&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SupplementalBalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SupplementalBalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391597355032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTableTextBlock', window );">Investments</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the contract maturity of the available-for-sale securities the Company held as of September&#160;30, 2021:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:282.75pt"><tr><td style="width:1.0pt"/><td style="width:211.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One year or less</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one year but within two years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Debt Securities, Available-for-sale</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized holding gains, gross unrealized holding losses and fair value of cash equivalents and available-for-sale securities by type of security at&#160;September&#160;30, 2021&#160;and December&#160;31, 2020 were as follows:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.826%"><tr><td style="width:1.0%"/><td style="width:45.147%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.672%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.672%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.672%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.295%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Holding Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Holding Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,498&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,497&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,954&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,953&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.025%"><tr><td style="width:1.0%"/><td style="width:44.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.680%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.680%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.680%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Holding Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Holding Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,992&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,991&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,735&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,818&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -URI http://asc.fasb.org/topic&amp;trid=2197064<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -URI http://asc.fasb.org/topic&amp;trid=75115024<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI http://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391597324776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Principal Maturities of Long-term Debt</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, the principal maturities of the Company&#8217;s long-term debt were as follows:</span></div><div style="margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:76.749%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (remaining three months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal balance outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,500&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less: unamortized discount and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(699)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,801&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391598503928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock', window );">Schedule of Operating Leases, Additional Information</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information related to the Company&#8217;s operating lease asset and related operating lease liabilities were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:76.749%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Costs</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes lease costs in the Company&#8217;s unaudited condensed consolidated statement of operations:</span></div><div style="margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">980&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease costs</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,877&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,130&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Rental Payments</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of the Company&#8217;s lease liability as of September&#160;30, 2021 were as follows:</span></div><div style="margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:76.749%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (remaining three months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,266&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,275)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,991&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent operating lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,991&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Operating Leases, Additional Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391597362920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in each component of accumulated other comprehensive income (loss), net of tax, for&#160;2021:</span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.980%"><tr><td style="width:1.0%"/><td style="width:57.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.754%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.757%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains (losses) on short-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net losses (gains) reclassified from accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net gain reclassified from accumulated other comprehensive loss during the three months ended September 30, 2021 resulted from available-for-sale securities that were called prior to maturity and no gains or losses were recognized for the three and nine months ended September 30, 2021. The basis on which the cost of the securities was determined was specific identification. Proceeds related to these sales were $4,000.</span></div><div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in each component of accumulated other comprehensive income (loss), net of tax, for&#160;2020:</span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.980%"><tr><td style="width:1.0%"/><td style="width:57.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.754%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.757%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains (losses) on short-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net losses (gains) reclassified from accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391601308520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Equity-Based Compensation Expense Classification in Statement of Operations</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity-based compensation expense is classified in the statements of operations as follows:</span></div><div style="margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,045&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,170&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,603&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions Used to Determine Fair Value of Common Stock Option Grants</a></td>
<td class="text">In addition to an assumption on the expected term of the option grants as discussed below, application of the Black-Scholes model requires additional inputs for which we have assumed the values described in the table below:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.115%"><tr><td style="width:1.0%"/><td style="width:56.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.857%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.625%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.858%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 to 6.1 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2 to 6.1 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.36% to 1.12%; weighted avg. 1.05%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.31% to 1.68%; weighted avg. 0.61%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.7% to 83.6%; weighted avg. 82.6%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.0% to 85.8%; weighted avg. 83.8%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeiture rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the underlying common stock and the exercise price for the common stock options granted during the nine months ended September 30, 2021 and 2020 are summarized in the table below:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.833%"><tr><td style="width:1.0%"/><td style="width:53.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.140%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.636%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.142%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock Options Granted During Period Ended:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value of Underlying Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price of Common Stock Option</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine months ended September 30, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.15 to $2.57; weighted avg. $1.87</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.15 to $2.57; weighted avg. $1.87</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine months ended September 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.19 to $2.80:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">weighted avg. $1.91</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.19 to $2.80:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">weighted avg. $1.94</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Common Stock Option Activity</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of common stock option activity as of the periods indicated is as follows:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.551%"><tr><td style="width:1.0%"/><td style="width:37.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.645%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.645%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.645%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,227,296&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,719&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,427,586&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(342,246)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(252,681)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,059,955&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable - September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,207,872&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and Expected to Vest -<br/>September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,630,872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Restricted Stock Unit Awards Activity</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of restricted stock unit activity of the periods indicated is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.512%"><tr><td style="width:1.0%"/><td style="width:58.218%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.672%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.936%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.674%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance - December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,875)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance - September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546,625&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.57&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391599398888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of loss per common share</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is the computation of loss per common share for the three and nine months ended September 30, 2021 and 2020:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.551%"><tr><td style="width:1.0%"/><td style="width:37.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.645%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.645%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.645%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,531)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,822)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,277)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,983)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic and diluted common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,105,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,227,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,001,222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,160,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share - basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Antidilutive Securities</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outstanding securities presented below were excluded from the calculation of loss per common share, for the periods presented, because such securities would have been anti-dilutive due to the Company&#8217;s loss per share during that period:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.294%"><tr><td style="width:1.0%"/><td style="width:64.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.439%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.442%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,059,955&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,739,781&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546,625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391598722776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets measured at fair value on a recurring basis as of September&#160;30, 2021 are as follows:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.269%"><tr><td style="width:1.0%"/><td style="width:42.370%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.487%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.659%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.487%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.478%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,593&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,641&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,952&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value on a recurring basis as of December 31, 2020 are as follows:</span></div><div style="margin-top:5pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.557%"><tr><td style="width:1.0%"/><td style="width:46.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.745%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.450%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.450%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.450%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.423%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,818&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrant liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text">The following is a reconciliation of the Company&#8217;s liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3) for the three months ended September&#160;30, 2021:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.237%"><tr><td style="width:1.0%"/><td style="width:72.641%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.159%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock Warrant Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain included in other (expense) income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September&#160;30, 2021</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391600730440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Presentation (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualRiskOrUncertaintyLineItems', window );"><strong>Unusual Risk or Uncertainty [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate', window );">Accumulated deficit generated, since inception</a></td>
<td class="num">$ (175,079)<span></span>
</td>
<td class="num">$ (175,079)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemAxis=xcur_COVID19Member', window );">COVID-19</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualRiskOrUncertaintyLineItems', window );"><strong>Unusual Risk or Uncertainty [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ResearchAndDevelopmentStaffOnSitePercentage', window );">Percentage of R&amp;D staff on site</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_OfficeAndGeneralAndAdministrativeStaffOnSitePercentage', window );">Percentage of time that office and general and administrative staff are on site</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ArrangementNameAxis=xcur_AbbVieCollaborationMember', window );">AbbVie Collaboration | Collaboration Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualRiskOrUncertaintyLineItems', window );"><strong>Unusual Risk or Uncertainty [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice', window );">Cumulative catch-up adjustment to revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,404)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate', window );">Cumulative catch-up adjustments to revenue, change in estimate</a></td>
<td class="num">$ (4,480)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualRiskOrUncertaintyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualRiskOrUncertaintyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Cumulative Catch-up Adjustments To Revenue, Change In Estimate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_OfficeAndGeneralAndAdministrativeStaffOnSitePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Office And General And Administrative Staff On Site, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_OfficeAndGeneralAndAdministrativeStaffOnSitePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ResearchAndDevelopmentStaffOnSitePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Staff on Site, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ResearchAndDevelopmentStaffOnSitePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Retained Earnings (Accumulated Deficit), Inception to Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualOrInfrequentItemAxis=xcur_COVID19Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualOrInfrequentItemAxis=xcur_COVID19Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ArrangementNameAxis=xcur_AbbVieCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ArrangementNameAxis=xcur_AbbVieCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391598761608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ArrangementNameAxis=xcur_AbbVieCollaborationMember', window );">AbbVie Collaboration | Collaboration Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualRiskOrUncertaintyLineItems', window );"><strong>Unusual Risk or Uncertainty [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice', window );">Cumulative catch-up adjustment to revenue</a></td>
<td class="num">$ (3,404)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualRiskOrUncertaintyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualRiskOrUncertaintyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ArrangementNameAxis=xcur_AbbVieCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ArrangementNameAxis=xcur_AbbVieCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391594589064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Research and License Agreements (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 30, 2021 </div>
<div>USD ($) </div>
<div>agreement</div>
</th>
<th class="th">
<div>Nov. 13, 2019 </div>
<div>USD ($) </div>
<div>agreement</div>
</th>
<th class="th">
<div>Feb. 17, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,944,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,944,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,343,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,015,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,015,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,343,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,929,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,929,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ArrangementNameAxis=xcur_IpsenCollaborationMember', window );">Ipsen Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,197,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,197,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ArrangementNameAxis=xcur_IpsenCollaborationMember', window );">Ipsen Collaboration | Ipsen HD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementTransactionPrice', window );">Transaction price allocated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,793,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,793,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ArrangementNameAxis=xcur_IpsenCollaborationMember', window );">Ipsen Collaboration | Ipsen AS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementTransactionPrice', window );">Transaction price allocated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,207,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,207,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ArrangementNameAxis=xcur_AbbVieCollaborationMember', window );">AbbVie Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,747,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,747,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,343,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaboration Arrangement | Ipsen Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_NumberofCollaborationPrograms', window );">Number of collaboration programs | agreement</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds from collaborators</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment', window );">Pre-clinical milestone payment amount</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment', window );">Development and regulatory milestone payment amount</a></td>
<td class="nump">180,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment', window );">Commercial milestone payment amount</a></td>
<td class="nump">762,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementLicensingFeesIncurred', window );">Collaboration agreement, licensing fees incurred</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementTerminationNoticePeriod', window );">Collaboration agreement, termination notice period</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementTransactionPrice', window );">Transaction price allocated</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">803,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">803,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,197,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,197,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,945,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,945,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,252,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,252,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaboration Arrangement | Ipsen Collaboration | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementEstimatedTimingOfRevenueRecognition', window );">Estimated timing of revenue recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">33 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaboration Arrangement | Ipsen Collaboration | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementEstimatedTimingOfRevenueRecognition', window );">Estimated timing of revenue recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">42 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaboration Arrangement | Ipsen Collaboration | Option Exercise Period after the Selection</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementOptionExerciseFee', window );">Collaboration option exercise fee</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaboration Arrangement | Ipsen Collaboration | Option Exercise Period that begins after the first Option Exercise Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementOptionExerciseFee', window );">Collaboration option exercise fee</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaboration Arrangement | AbbVie Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_NumberofCollaborationPrograms', window );">Number of collaboration programs | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementOptionExerciseFee', window );">Collaboration option exercise fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,402,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,351,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,747,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,747,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,070,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,070,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,343,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,677,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,677,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementUpfrontPayment', window );">Non-refundable upfront payment received for research agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee', window );">Collaboration option exercise fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice', window );">Termination period upon written notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice', window );">Cumulative catch-up adjustment to revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,404,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate', window );">Cumulative catch-up adjustments to revenue, change in estimate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,480,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaboration Arrangement | AbbVie Collaboration | Development and Commercialization License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementOptionExerciseFee', window );">Collaboration option exercise fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaboration Arrangement | AbbVie Collaboration | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementEstimatedTimingOfRevenueRecognition', window );">Estimated timing of revenue recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaboration Arrangement | AbbVie Collaboration | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementEstimatedTimingOfRevenueRecognition', window );">Estimated timing of revenue recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">27 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment', window );">Development milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment', window );">Product approval and launch milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment', window );">Sales milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaboration Arrangement | Dermelix License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 41,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 122,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationAgreementUpfrontPayment', window );">Non-refundable upfront payment received for research agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CollaborationDevelopmentExpenses', window );">Collaboration development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CollaborationAgreementEstimatedTimingOfRevenueRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Estimated Timing Of Revenue Recognition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CollaborationAgreementEstimatedTimingOfRevenueRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Extended Option, Additional Exercise Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CollaborationAgreementLicensingFeesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Licensing Fees Incurred</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CollaborationAgreementLicensingFeesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CollaborationAgreementOptionExerciseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Option, Exercise Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CollaborationAgreementOptionExerciseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CollaborationAgreementTerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Termination Notice Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CollaborationAgreementTerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Termination Period Upon Written Notice</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CollaborationAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Transaction Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CollaborationAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CollaborationAgreementUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CollaborationAgreementUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CollaborationDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Development Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CollaborationDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Cumulative Catch-up Adjustments To Revenue, Change In Estimate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_NumberofCollaborationPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Collaboration Programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_NumberofCollaborationPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Multiple-deliverable Arrangements, Collaboration Agreement, Pre-Clinical Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Multiple-deliverable Arrangements, Commercial Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Multiple-deliverable Arrangements, Development And Regulatory Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Multiple-deliverable Arrangements, Development Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Multiple-deliverable Arrangements, Product Approval and Launch Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Multiple-deliverable Arrangements, Sales Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ArrangementNameAxis=xcur_IpsenCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ArrangementNameAxis=xcur_IpsenCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CollaborationAgreementPerformanceObligationAxis=xcur_IpsenHDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CollaborationAgreementPerformanceObligationAxis=xcur_IpsenHDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CollaborationAgreementPerformanceObligationAxis=xcur_IpsenASMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CollaborationAgreementPerformanceObligationAxis=xcur_IpsenASMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ArrangementNameAxis=xcur_AbbVieCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ArrangementNameAxis=xcur_AbbVieCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ExercisePeriodAxis=xcur_ExercisePeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ExercisePeriodAxis=xcur_ExercisePeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ExercisePeriodAxis=xcur_ExercisePeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ExercisePeriodAxis=xcur_ExercisePeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=xcur_DevelopmentandCommercializationLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=xcur_DevelopmentandCommercializationLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ArrangementNameAxis=xcur_DermelixLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ArrangementNameAxis=xcur_DermelixLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391600622904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Research and License Agreements - Other Current Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInDeferredRevenueRollForward', window );"><strong>Movement in Deferred Revenue [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred Revenue Balance at January 1, 2021</a></td>
<td class="nump">$ 8,343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ContractWithCustomerLiabilityAdditions', window );">Additions</a></td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance', window );">Revenue (Recognized) Reversed</a></td>
<td class="nump">2,601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred Revenue Balance at September 30, 2021</a></td>
<td class="nump">30,944<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ArrangementNameAxis=xcur_IpsenCollaborationMember', window );">Ipsen Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInDeferredRevenueRollForward', window );"><strong>Movement in Deferred Revenue [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred Revenue Balance at January 1, 2021</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ContractWithCustomerLiabilityAdditions', window );">Additions</a></td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance', window );">Revenue (Recognized) Reversed</a></td>
<td class="num">(803)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred Revenue Balance at September 30, 2021</a></td>
<td class="nump">19,197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ArrangementNameAxis=xcur_AbbVieCollaborationMember', window );">AbbVie Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInDeferredRevenueRollForward', window );"><strong>Movement in Deferred Revenue [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred Revenue Balance at January 1, 2021</a></td>
<td class="nump">8,343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ContractWithCustomerLiabilityAdditions', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance', window );">Revenue (Recognized) Reversed</a></td>
<td class="nump">3,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred Revenue Balance at September 30, 2021</a></td>
<td class="nump">$ 11,747<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInDeferredRevenueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInDeferredRevenueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ContractWithCustomerLiabilityAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Additions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ContractWithCustomerLiabilityAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Revenue Recognized, Including Opening Balance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ArrangementNameAxis=xcur_IpsenCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ArrangementNameAxis=xcur_IpsenCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ArrangementNameAxis=xcur_AbbVieCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ArrangementNameAxis=xcur_AbbVieCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391601309224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information - Prepaid expenses and other current assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SupplementalBalanceSheetInformationAbstract', window );"><strong>Supplemental Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid clinical, contract research and manufacturing costs</a></td>
<td class="nump">$ 2,133<span></span>
</td>
<td class="nump">$ 2,336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest receivable</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other</a></td>
<td class="nump">1,109<span></span>
</td>
<td class="nump">1,040<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 3,309<span></span>
</td>
<td class="nump">$ 4,231<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SupplementalBalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SupplementalBalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391601036120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information - Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 6,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(2,373)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,373)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,740)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAmortizationAndAccretionNet', window );">Depreciation and amortization</a></td>
<td class="nump">283<span></span>
</td>
<td class="nump">$ 159<span></span>
</td>
<td class="nump">829<span></span>
</td>
<td class="nump">$ 494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Scientific equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">6,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=xcur_ComputersandSoftwareMember', window );">Computers and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAmortizationAndAccretionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAmortizationAndAccretionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=xcur_ComputersandSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=xcur_ComputersandSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391601315224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information - Accrued Expense and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SupplementalBalanceSheetInformationAbstract', window );"><strong>Supplemental Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent', window );">Accrued clinical, contract research and manufacturing costs</a></td>
<td class="nump">$ 2,741<span></span>
</td>
<td class="nump">$ 1,372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll-related expenses</a></td>
<td class="nump">1,388<span></span>
</td>
<td class="nump">1,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability, current</a></td>
<td class="nump">440<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other expenses</a></td>
<td class="nump">911<span></span>
</td>
<td class="nump">772<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 5,480<span></span>
</td>
<td class="nump">$ 3,525<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical, Contract Research And Manufacturing Costs, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SupplementalBalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SupplementalBalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391598785240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_DebtSecuritiesAvailableForSaleCurrentPercent', window );">One year or less</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent', window );">After one year but within two years</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_DebtSecuritiesAvailableforSalePercent', window );">Total</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_DebtSecuritiesAvailableForSaleCurrentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available For Sale, Current, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_DebtSecuritiesAvailableForSaleCurrentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available For Sale, Noncurrent, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_DebtSecuritiesAvailableforSalePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available for Sale, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_DebtSecuritiesAvailableforSalePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391600340328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Available-for-sale Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Costs</a></td>
<td class="nump">$ 8,954<span></span>
</td>
<td class="nump">$ 48,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Holding Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Holding Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">8,953<span></span>
</td>
<td class="nump">48,818<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Costs</a></td>
<td class="nump">6,498<span></span>
</td>
<td class="nump">15,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Holding Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Holding Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">6,497<span></span>
</td>
<td class="nump">15,991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes/bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Costs</a></td>
<td class="nump">1,205<span></span>
</td>
<td class="nump">29,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Holding Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Holding Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">1,205<span></span>
</td>
<td class="nump">29,296<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Holding Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Holding Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Costs</a></td>
<td class="nump">1,251<span></span>
</td>
<td class="nump">1,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Holding Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Holding Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 1,251<span></span>
</td>
<td class="nump">$ 1,278<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391682173528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 25, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 02, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 01, 2022 </div>
<div>installmentPayment</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long-term borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoanProcessingFee', window );">Origination fee</a></td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_DebtInstrumentExitFeePercentage', window );">Exit fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of long-term debt issuance costs and fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 213,000<span></span>
</td>
<td class="nump">39,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,801,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,801,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid on debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 344,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,041,000<span></span>
</td>
<td class="nump">142,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,999,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | MidCap Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Floating interest rate</a></td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Interest rate increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | MidCap Credit Agreement | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments', window );">Number of monthly installment payments | installmentPayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | MidCap Credit Agreement | Prior to first anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_DebtInstrumentEarlyTerminationFeePercentageOfPrincipal', window );">Early termination fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | MidCap Credit Agreement | After first anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_DebtInstrumentEarlyTerminationFeePercentageOfPrincipal', window );">Early termination fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | MidCap Credit Agreement - Tranche 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long-term borrowing</a></td>
<td class="nump">$ 17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Fee amount</a></td>
<td class="nump">656,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from debt, net of fees and issuance costs</a></td>
<td class="nump">16,512,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance costs</a></td>
<td class="nump">332,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | MidCap Credit Agreement - Tranche 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_DebtInstrumentFundingConditionRequiredProceedsFromEquityIssuance', window );">Funding condition, required proceeds from equity issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance costs</a></td>
<td class="nump">$ 73,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of long-term debt issuance costs and fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Loans Payable | Secured Debt | Hercules Technology Growth Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,999,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_PaymentsForDebtEndTermFees', window );">Payments for debt end term fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Incremental percentage increase (decrease) in the stated rate on a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoanProcessingFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses paid for obtaining loans which includes expenses such as application and origination fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoanProcessingFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_DebtInstrumentEarlyTerminationFeePercentageOfPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Early Termination Fee, Percentage of Principal</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_DebtInstrumentEarlyTerminationFeePercentageOfPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_DebtInstrumentExitFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Exit Fee, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_DebtInstrumentExitFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_DebtInstrumentFundingConditionRequiredProceedsFromEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Funding Condition, Required Proceeds From Equity Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_DebtInstrumentFundingConditionRequiredProceedsFromEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Principal Payment, Number of Monthly Installment Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_PaymentsForDebtEndTermFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Debt End Term Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_PaymentsForDebtEndTermFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xcur_MidCapCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xcur_MidCapCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xcur_MidCapCreditAgreementTranche1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xcur_MidCapCreditAgreementTranche1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xcur_MidCapCreditAgreementTranche2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xcur_MidCapCreditAgreementTranche2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=xcur_HerculesTechnologyGrowthCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=xcur_HerculesTechnologyGrowthCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391601906728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Principal Maturities of Long-Term Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2021 (remaining three months)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2022</a></td>
<td class="nump">1,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2023</a></td>
<td class="nump">5,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2024</a></td>
<td class="nump">5,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2025</a></td>
<td class="nump">4,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal balance outstanding</a></td>
<td class="nump">17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">less: unamortized discount and debt issuance costs</a></td>
<td class="num">(699)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">16,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Noncurrent portion</a></td>
<td class="nump">$ 16,801<span></span>
</td>
<td class="nump">$ 16,589<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391599421560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> ft&#178; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 01, 2020 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>extensionPeriod</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease, cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,721<span></span>
</td>
<td class="nump">$ 1,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=xcur_ChicagoMember', window );">Chicago</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_LesseeOperatingLeaseLeaseArea', window );">Lease area | ft&#178;</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Contract term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_LesseeOperatingLeaseNumberOfExtensions', window );">Number of extensions | extensionPeriod</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths', window );">Annual rent payment initial twelve months</a></td>
<td class="nump">$ 1,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_LesseeOperatingLeaseBaseRentAnnualPercentageIncrease', window );">Base rent annual percentage increase</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm', window );">Estimated rental payment over original term</a></td>
<td class="nump">$ 12,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of credit outstanding</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_LesseeOperatingLeaseRentalPaymentAdjustedForAbatement', window );">Rental payment adjusted for abatement</a></td>
<td class="nump">87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForTenantImprovements', window );">Payments for tenant improvements</a></td>
<td class="nump">697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">8,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">$ 8,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Incremental borrowing rate</a></td>
<td class="nump">8.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForTenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForTenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Annual Rent Payment Initial Twelve Months</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_LesseeOperatingLeaseBaseRentAnnualPercentageIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Base Rent Annual Percentage Increase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_LesseeOperatingLeaseBaseRentAnnualPercentageIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Estimated Rental Payment Over Original Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_LesseeOperatingLeaseLeaseArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Area</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_LesseeOperatingLeaseLeaseArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_LesseeOperatingLeaseNumberOfExtensions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number of Extensions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_LesseeOperatingLeaseNumberOfExtensions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_LesseeOperatingLeaseRentalPaymentAdjustedForAbatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Rental Payment Adjusted For Abatement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_LesseeOperatingLeaseRentalPaymentAdjustedForAbatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=xcur_ChicagoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=xcur_ChicagoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391597435176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Right of Use Asset Information (Details)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">8 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">8.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391606103368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 326<span></span>
</td>
<td class="nump">$ 333<span></span>
</td>
<td class="nump">$ 980<span></span>
</td>
<td class="nump">$ 712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short term lease costs</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">231<span></span>
</td>
<td class="nump">172<span></span>
</td>
<td class="nump">803<span></span>
</td>
<td class="nump">322<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">$ 589<span></span>
</td>
<td class="nump">$ 534<span></span>
</td>
<td class="nump">$ 1,877<span></span>
</td>
<td class="nump">$ 1,130<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391692532440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Future Minimum Rental Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2021 (remaining three months)</a></td>
<td class="nump">$ 191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">1,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">1,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">1,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">1,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">1,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">4,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">11,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(3,275)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">7,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liability</a></td>
<td class="nump">440<span></span>
</td>
<td class="nump">$ 223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent operating lease liability</a></td>
<td class="nump">$ 7,551<span></span>
</td>
<td class="nump">$ 7,959<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391597408008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Current Capitalization (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>votePerShare </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">88,108,543<span></span>
</td>
<td class="nump">87,651,352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">88,108,543<span></span>
</td>
<td class="nump">87,651,352<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CommonStockVotingRightsForEachShare', window );">Common stock, voting rights for each share | votePerShare</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CommonStockVotingRightsForEachShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Voting Rights For Each Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CommonStockVotingRightsForEachShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391599332456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Common Stock Warrants (Details) - Common Stock - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>May 03, 2021</div></th>
<th class="th"><div>Apr. 28, 2021</div></th>
<th class="th"><div>Mar. 27, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">413,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ClassofWarrantorRightExpired', window );">Warrant expirations (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,262<span></span>
</td>
<td class="nump">132,884<span></span>
</td>
<td class="nump">163,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ClassofWarrantorRightExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Expired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ClassofWarrantorRightExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391599450200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Accumulated Other Comprehensive Loss (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">$ 36,640,000<span></span>
</td>
<td class="nump">$ 50,041,000<span></span>
</td>
<td class="nump">$ 61,506,000<span></span>
</td>
<td class="nump">$ 81,752,000<span></span>
</td>
<td class="nump">$ 85,114,000<span></span>
</td>
<td class="nump">$ 80,747,000<span></span>
</td>
<td class="nump">$ 61,506,000<span></span>
</td>
<td class="nump">$ 80,747,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(5,000)<span></span>
</td>
<td class="num">(27,000)<span></span>
</td>
<td class="num">(51,000)<span></span>
</td>
<td class="num">(138,000)<span></span>
</td>
<td class="nump">352,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Net losses (gains) reclassified from accumulated other comprehensive loss</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive (loss) income</a></td>
<td class="num">(6,000)<span></span>
</td>
<td class="num">(27,000)<span></span>
</td>
<td class="num">(51,000)<span></span>
</td>
<td class="num">(138,000)<span></span>
</td>
<td class="nump">355,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="num">(84,000)<span></span>
</td>
<td class="nump">227,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">13,983,000<span></span>
</td>
<td class="nump">36,640,000<span></span>
</td>
<td class="nump">50,041,000<span></span>
</td>
<td class="nump">73,428,000<span></span>
</td>
<td class="nump">81,752,000<span></span>
</td>
<td class="nump">85,114,000<span></span>
</td>
<td class="nump">13,983,000<span></span>
</td>
<td class="nump">73,428,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Gross realized gains, available for sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Gross realized losses, available for sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sale of debt securities, available-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,404,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized gains (losses) on short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
<td class="nump">83,000<span></span>
</td>
<td class="nump">338,000<span></span>
</td>
<td class="num">(17,000)<span></span>
</td>
<td class="num">(27,000)<span></span>
</td>
<td class="nump">83,000<span></span>
</td>
<td class="num">(27,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(5,000)<span></span>
</td>
<td class="num">(27,000)<span></span>
</td>
<td class="num">(51,000)<span></span>
</td>
<td class="num">(138,000)<span></span>
</td>
<td class="nump">352,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Net losses (gains) reclassified from accumulated other comprehensive loss</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive (loss) income</a></td>
<td class="num">(6,000)<span></span>
</td>
<td class="num">(27,000)<span></span>
</td>
<td class="num">(51,000)<span></span>
</td>
<td class="num">(138,000)<span></span>
</td>
<td class="nump">355,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">338,000<span></span>
</td>
<td class="num">(17,000)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">AOCI Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
<td class="nump">83,000<span></span>
</td>
<td class="nump">338,000<span></span>
</td>
<td class="num">(17,000)<span></span>
</td>
<td class="num">(27,000)<span></span>
</td>
<td class="nump">83,000<span></span>
</td>
<td class="num">(27,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive (loss) income</a></td>
<td class="num">(6,000)<span></span>
</td>
<td class="num">(27,000)<span></span>
</td>
<td class="num">(51,000)<span></span>
</td>
<td class="num">(138,000)<span></span>
</td>
<td class="nump">355,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="num">$ (1,000)<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 32,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 338,000<span></span>
</td>
<td class="num">$ (17,000)<span></span>
</td>
<td class="num">$ (1,000)<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AOCIAttributableToParentNetOfTaxRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391599669544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 14, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 01, 2020</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted in period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,427,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,059,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,227,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Compensation cost not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,820,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation expense recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.30<span></span>
</td>
<td class="nump">$ 1.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value, stock options, exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 243,000<span></span>
</td>
<td class="nump">$ 74,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember', window );">Chief Financial Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted in period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xcur_ExicureInc.2017EquityIncentivePlanMember', window );">Exicure, Inc. 2017 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares', window );">Number of additional shares authorized, potential maximum additional shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding', window );">Number of additional shares authorized, percentage of common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,558,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock | Exicure, Inc. 2017 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant', window );">Increase in number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,382,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant', window );">Increase in number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">258,207<span></span>
</td>
<td class="nump">262,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum ESPP contribution rate as a percentage of compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Maximum number of shares per employee in purchase period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount', window );">Maximum contribution amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">ESPP purchase price as a percentage of market price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod', window );">Offering period duration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock-ESPP (in shares)</a></td>
<td class="nump">103,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan', window );">Number of additional shares allowable annually under the plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of outstanding shares allowable as annual increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting', window );">Number of shares issued for each vested restricted stock unit (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of shares an employee can purchase under the plan per period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Available for Grant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Allowable Under The Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Of Common Stock Issuable Upon Vesting</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Percentage of Common Stock Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Potential Maximum Additional Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xcur_ExicureInc.2017EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xcur_ExicureInc.2017EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391598952200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Schedule of Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 889<span></span>
</td>
<td class="nump">$ 618<span></span>
</td>
<td class="nump">$ 2,170<span></span>
</td>
<td class="nump">$ 1,603<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">427<span></span>
</td>
<td class="nump">247<span></span>
</td>
<td class="nump">1,045<span></span>
</td>
<td class="nump">607<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 462<span></span>
</td>
<td class="nump">$ 371<span></span>
</td>
<td class="nump">$ 1,125<span></span>
</td>
<td class="nump">$ 996<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391600323336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Assumptions Used for Fair Value Measurement (Details)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.36%<span></span>
</td>
<td class="nump">0.31%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.12%<span></span>
</td>
<td class="nump">1.68%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">81.70%<span></span>
</td>
<td class="nump">81.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">83.60%<span></span>
</td>
<td class="nump">85.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">82.60%<span></span>
</td>
<td class="nump">83.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate', window );">Forfeiture rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.05%<span></span>
</td>
<td class="nump">0.61%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391600703384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity-Based Compensation - Fair Value of Underlying Common Stock and Exercise Price of Stock Options (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of underlying common stock (dollars per share)</a></td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="nump">$ 1.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price of common stock option (dollars per share)</a></td>
<td class="nump">1.15<span></span>
</td>
<td class="nump">1.19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of underlying common stock (dollars per share)</a></td>
<td class="nump">2.57<span></span>
</td>
<td class="nump">2.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price of common stock option (dollars per share)</a></td>
<td class="nump">2.57<span></span>
</td>
<td class="nump">2.80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of underlying common stock (dollars per share)</a></td>
<td class="nump">1.87<span></span>
</td>
<td class="nump">1.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price of common stock option (dollars per share)</a></td>
<td class="nump">$ 1.87<span></span>
</td>
<td class="nump">$ 1.94<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391604114680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - Schedule of Stock Options Rollforward (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,227,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,427,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in shares)</a></td>
<td class="num">(22,240)<span></span>
</td>
<td class="num">(342,246)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(252,681)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,059,955<span></span>
</td>
<td class="nump">7,227,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,207,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,630,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding beginning balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding ending balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.11<span></span>
</td>
<td class="nump">$ 2.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, weighted-average exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest, weighted-average exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value (thousands)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 397<span></span>
</td>
<td class="nump">$ 1,719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, weighted-average remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, aggregate intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value (thousands)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391605726664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation - RSU Activity (Details) - Restricted stock units<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested balance - beginning of period (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">575,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(17,875)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(10,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested balance - end of period (in shares) | shares</a></td>
<td class="nump">546,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested balance - beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">1.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">1.90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">1.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested balance - end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.57<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391600831880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391599081256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share - Computation of Earnings Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (23,531)<span></span>
</td>
<td class="num">$ (14,269)<span></span>
</td>
<td class="num">$ (12,477)<span></span>
</td>
<td class="num">$ (8,822)<span></span>
</td>
<td class="num">$ (4,311)<span></span>
</td>
<td class="nump">$ 1,150<span></span>
</td>
<td class="num">$ (50,277)<span></span>
</td>
<td class="num">$ (11,983)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average basic common shares outstanding (in shares)</a></td>
<td class="nump">88,105,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,227,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,001,222<span></span>
</td>
<td class="nump">87,160,520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average diluted common shares outstanding (in shares)</a></td>
<td class="nump">88,105,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,227,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,001,222<span></span>
</td>
<td class="nump">87,160,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">(Loss) earnings per basic common share (USD per share)</a></td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.57)<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">(Loss) earnings per diluted common share (USD per share)</a></td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.57)<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391601707848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share - Antidilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares excluded from computation of weighted-average diluted common shares outstanding (in shares)</a></td>
<td class="nump">11,059,955<span></span>
</td>
<td class="nump">7,739,781<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares excluded from computation of weighted-average diluted common shares outstanding (in shares)</a></td>
<td class="nump">546,625<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares excluded from computation of weighted-average diluted common shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">413,320<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391594331800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments:</a></td>
<td class="nump">$ 8,953<span></span>
</td>
<td class="nump">$ 48,818<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">48,593<span></span>
</td>
<td class="nump">73,404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CommonStockWarrantLiabilityFairValueDisclosure', window );">Common stock warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">27,641<span></span>
</td>
<td class="nump">24,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CommonStockWarrantLiabilityFairValueDisclosure', window );">Common stock warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">20,952<span></span>
</td>
<td class="nump">48,818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CommonStockWarrantLiabilityFairValueDisclosure', window );">Common stock warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_CommonStockWarrantLiabilityFairValueDisclosure', window );">Common stock warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments:</a></td>
<td class="nump">6,497<span></span>
</td>
<td class="nump">15,991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair Value, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair Value, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments:</a></td>
<td class="nump">6,497<span></span>
</td>
<td class="nump">15,991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Fair Value, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes/bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments:</a></td>
<td class="nump">1,205<span></span>
</td>
<td class="nump">29,296<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes/bonds | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments:</a></td>
<td class="nump">1,205<span></span>
</td>
<td class="nump">29,296<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes/bonds | Fair Value, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes/bonds | Fair Value, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments:</a></td>
<td class="nump">1,205<span></span>
</td>
<td class="nump">29,296<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes/bonds | Fair Value, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasuries | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasuries | Fair Value, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasuries | Fair Value, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasuries | Fair Value, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments:</a></td>
<td class="nump">1,251<span></span>
</td>
<td class="nump">1,278<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government agency securities | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments:</a></td>
<td class="nump">1,251<span></span>
</td>
<td class="nump">1,278<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government agency securities | Fair Value, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government agency securities | Fair Value, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments:</a></td>
<td class="nump">1,251<span></span>
</td>
<td class="nump">1,278<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government agency securities | Fair Value, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">27,641<span></span>
</td>
<td class="nump">24,586<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Fair Value, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">27,641<span></span>
</td>
<td class="nump">24,586<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Fair Value, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Fair Value, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes/bonds | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes/bonds | Fair Value, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes/bonds | Fair Value, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes/bonds | Fair Value, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasuries | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">9,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasuries | Fair Value, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasuries | Fair Value, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">9,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasuries | Fair Value, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_CommonStockWarrantLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Warrant Liability, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_CommonStockWarrantLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391692050168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - Common Stock - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Common stock warrant liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">413,320<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391601281800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis (Details) - Common Stock - Warrant Liability<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at December 31, 2020</a></td>
<td class="nump">$ 15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Gain included in other (expense) income, net</a></td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at September&#160;30, 2021</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=xcur_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=xcur_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391598828024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment and Contingencies (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xcur_AggregatePaymentsMadeToDateForLicenseAgreements', window );">Aggregate consideration paid to NU for agreement obligations</a></td>
<td class="nump">$ 11,413<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xcur_AggregatePaymentsMadeToDateForLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Payments Made To Date For License Agreements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xcur_AggregatePaymentsMadeToDateForLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xcur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140391600275128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Board of Directors | Consulting services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses from transactions with related party</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=xcur_ConsultingServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=xcur_ConsultingServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>84
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M+%Z2I8QK<7&![U IL*:S*A$4-_%#RLC=LQ\R 3WQJ>+5(#2;+&XG6(-&JXI
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MR$:H$+'\.9 %R3(52>KX60<=-6TJQ^[U:_2_JL[+SJQC3A8T^S=-Q.YJ%(Y
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M:"SQ-^C[&YG4N=JO9U:3TTRVW,5G=FM)DJI#&CG[U-9HDA9R#[Q/Y6PTBC2
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M4+?#5-^[L# !>G_.N7J=F).]NLGU_@)02P,$%     @ >SQS4YGS7-UU!0
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M1#_D1L8I-XTAOV7UC4:^4$[C<KY"<9'(+6 K][:UW*G$OA'(6Q]2Z +>ZL
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M63<#G!E>W4^JCF2[\@!>,8G'>=E,\$H'7 'P^X8Q^=I1"9I+XO@_4$L#!!0
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MZA*_0]1U*"%*7Q"B%,C/-(@Z1%V?$J+T%2!* ?8QY0E_ZA!U_1YLR)W.1PJ
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M>L\.8>5,NJ%MQ:R/TR$$6<^#](14HD&D]VK#I!-39"V7]A$Y1"8>0-@ PH.
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M$06%]4E_0*/3K.0:<7!HE:N&/JB/6CS5D?8M/G<W-,AV&$9$@]<@\-(R%&P
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M8N!:5I2(0N4@9U[-)GQ[J)G"!=;5$U"9F.R=V)\W-P,#DLC(F"/B[H+OX!,
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M-Q=[(./BM)W88[P5X)\4&1R^G;<$/SJ8S-.-I\!#W]-Y+!R?34XQO@5F[>!
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M!ZDOFY]+*RTAK!+\'CLJ@S?TTG:G:NYU7W/U/;R1$1,'G *G70K0=VG7^.W
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M+9KWU?T/4I_G,:Z75H6B/Y-[?O?JR4&2MJJIUOIC@&"=E_Q_\4GCP?O@Z=G
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MXR^MUFL$7!3Y_TH^,A S(.-)\LL&3UKG30/@E!7\4AI::=:9:5C78NLPD0,
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M7=L4#&]TBLG6(^9BRKP2?\1(,+K$T2D^Q&0H+)M]#J%.DO=N&$O-XTRHGOL
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M2*51MA#<8>+;G^PHBE.59)2<.-G07%4:VZUC#])>Y2E%<0[JID#. $+G.3P
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MU%MJSG3O]N*XTR\?0XT.Y^_%(KCH=#193%'_FC+UHS'0]>_QTT+]@J): 3]
M@1K8"D4WLP1BY;BTT8>A4Y9T$N5<S/YO*2?[4@X)\;' [(J6DZZ'PCETH&3&
MYBJ0;->[Q&B+?6BL&M)?5;(M3&8V]^)GI!TLW<3+J_H>L][:7&.2.M2C8U+A
M%JB^('3-C7;WLF5 B?9RO)^=0DU 'FTC9J@_:CN9(:!D@T&O+.[?8789E ]#
M"]9=C"XO+YMF#_HR70H0&L;Y7GHR&1_Z/G/6^;[%HP=]Q>,^J?#A4U?SMOE0
M^"9\'VNWAZ^,L/F&,FJFUC@ZP>!_%-J]^H<W)7\M6QF/H8 ?MTH")-J ];4Q
MOOY!#)K/I]?_ U!+ P04    " ![/'-3YP-&ZGD)  "*&0  &0   'AL+W=O
M<FMS:&5E=',O<VAE970Q-2YX;6R=66V3VC@2_BLJ+KE*J@A@8 9(9J8J;UN7
MJ\MN:I/=K:VK^R!L =K8%I'D8;A??T^W9&,SP%[V"QA+:CW]]G1+W.R,_>HV
M2GGQ4.2EN^UMO-^^' Y=NE&%= .S525&5L86TN.G70_=UBJ9\:(B'XY'H^MA
M(779N[OA=Y_LW8VI?*Y+]<D*5Q6%M/LW*C>[VU[2JU_\K-<;3R^&=S=;N5:?
ME?]E^\GBU["1DNE"E4Z;4EBUNNV]3EZ^F=)\GO"K5CO7>A:DR=*8K_3C0W;;
M&Q$@E:O4DP2)KWOU5N4Y"0*,;U%FK]F2%K:?:^D_L.[092F=>FORWW3F-[>]
M>4]D:B6KW/]L=O]049\KDI>:W/&GV(6Y"2:GE?.FB(N!H-!E^)8/T0ZM!?/1
MF07CN&#,N,-&C/*=]/+NQIJ=L#0;TNB!5>75 *=+<LIG;S&JL<[?_4M!)7<S
M])!%;X9I7/<FK!N?6;<0'TWI-TZ\+S.5==</@:$!,JZ!O!E?%/A9;0=B,NJ+
M\6B<7) W:12;L+S)1<7$OU\OG;?P_7\NR)PV,J<L<_K=QKJXCA+KI=O*5-WV
MD#E.V7O5B\*^;)1X:XJM+/=__]M\G,Q>.9'3B)#6RG*MD #>">D%#.15L52V
ML9)(#9+#>6%6XIE^+F1<B53%JY5.(:3,1"Z7QDIO[%XP"!*F(7.#'/Y62>N5
M=4*7XNU&IW)M^N)##@6,=L)O,#4U!3"D*J,Y_ZSR/>T]$L\\D!/D\>A57"E8
M)7Z7O'K>!Z;3H!H44A1('OW"JU*67JQDJG/M]PQ&%DNKL[7JBX_2.9EN*J>\
M/X7IH[3I!J"2!:L+W*G$&-3.PR[E7G@021=R+?\8-(D <"#/0P2U@*MOE=Z2
M0SJB?@J#[YO!X-E:Y$"\!WKR$=; $%&LM$JD.533*PT]I!,@6KA)E^LX92#>
M54IX0^M$*7V%%4&*.$+?#R]#&(&3X%%0!:2RL?Q&US%E%<=?Z6E'X3;&^A<T
M.0[OM-_  #"J]EKF@H>P9:X<&[X4?J?R>R6*D/NP59^0NRK=]$\!(V>4QF/?
MU%CPA  /T[2ES,E%(M0=,KF%OPA5 )(:YX.):.6ZU/\-KJ:USF,BVQG(HLV0
M!X0#PWM>I<NTLE9E ]'*+['!%)D[([@FD'E,"QT+/^/+T[B=IN<:^5;N>84L
M3,4I6S[61B-?H0WV0+P/HHW",(79)03?9PRJ=X*(CXK2"^(CJEWPAKE789\
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M$S"^,L;7/VB#YN^7N_\!4$L#!!0    ( 'L\<U,F&[Q@TP8  *<4   9
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M0P/P_ESA;J@Y(0?=N\GS?P!02P,$%     @ >SQS4T=PB^9D#0  NR4  !D
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M(TK)A@PD;)U2 2LO!<?,J4SRC),?;DO$/KS>-AE\:Y25^80BG'_%93VL5FG
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M5Q'U39FO^?.<>5Z6><J7*P6N:&@ WB_RO*QO:('F>ZWW_P502P,$%     @
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M<*SX24/K _B^,-RUP? )QD=R]0A02P,$%     @ >SQS4U*&T#[M @  H08
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M/$:_[W56/6TG'A*^]:5K;*PE3=70O.1-2L-'#SJ,$O='.C8/M.G&NY./F3A
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M8NGK:4Y&_M+]RO 1H,N\-[L-C /C>F^,"WGOIL$,;_BNLND;/OY<"&O-1&\
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M;"]W;W)K<VAE971S+W-H965T,C0N>&UL?57;;MLP#/T5PANV%@CJ2]SFTB1
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MG0UHXNAV)K4;JQH_!S)E::KX945C'+4SH/M2*;O;.(+NCV'V#U!+ P04
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MKX9T')CNY=!-G&[";;W0CN[^,-S08PN-%Z#]E=9N/_$$_?-M]@]02P,$%
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MAH,);7W5WK]MQ\C:W7FI-'2#NF9!GRRH; *-;R2YUW7L"_J/H-7?4$L#!!0
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M=(I/W_&F ?R'7D0^\Q*PY%:3I5 D K.'U=XI3T-*)I$/:CX-R&P6@FH<S]"
M'Z-1QX\\:S;T)F0@ZT&7]6 PZW,-;:ZJX_. <3:2?.2&JP*C\8D)17ZP?,TQ
ME$"*0F+29?((V;:9^ QL-+T)'_;[!1I=F@IK UPR>.V0$%DG$H.2&,0$<!
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M>,]SEJF_K+A(J5278CTN<L'HLE)*DS%VG&"<TC@;75]6]Q[%]27?RB3.V*-
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MX3D(S:4@"K9S;TE?K&AD#=R.#QR.NC4F-I6-E)_LY%4R]P*+"#*(C77!\'&
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M@>" \ R@[N\8DZ=!YJ#\.#/_'U!+ P04    " ![/'-3SKNE>L<"  ".!P
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M88X/)BAK@/M+*<UF8GMR^P2/_P%02P,$%     @ >SQS4\]1A]8< @  804
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M5EUOFS 4_2L6ZD,K;>4;DHH@-2'3)JU:U;3=P[0')SC!*MC,=I+NW\\VA"5
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MA5'K \-Z8.2RWG,GTN .7E]F>,@"92?@\[F4YGU@M_'VV#;X"U!+ P04
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MF\;6<R!=2\6+!M8*"EK6;[)MZG  ^%$'$#1 \!H(.X"P <*/1H@:(/HH$#=
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MK/B+-M58IX?"/%,BJ8P!0<+3\C]]KA;BP, E+0:X,L"_&G@M!J0R(%T-O,K
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M+1Y?;:B,T)]_@$OTH%B2_64!1/: 2 '(:P'T9:7#9V@!X14$XRE:,<E%A-[
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M5<EEFEM5%0/7"]3\FC'YW-$?:.OLR6]02P,$%     @ >SQS4W2].'#] @
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M[5T/]O83S^ER)=2$,QZM\9+,B'A9/S'YY#1:DC0G!4]I 1A9W/4F\/,4^4I
MKWA-R98?C(%R94[IFWKXDMSU7(6(9"062@66?QOR0+),:9(X?M1*>XU-)7@X
MWFO_0SLOG9EC3AYH]CU-Q.JN%_9 0A:XS,0SW?Y%:H<TP)AF7/^";;W6[8&X
MY(+FM;!$D*=%]8_?:R(.!*0>LP"J!= ' =0EX-4"WJ4"@UI@H)FI7-$\3+'
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MD1<%'Q+;L @&,#('&VK[&K+W-7MBLV8?XX-]%'(?C7[83?DU^6%#/CI+?ML
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MH@DVT8R"HX)C*)NHY7U'@1?XWY"+1(8Y"/M[1+]59:ME]%LU^CN!CTW@D_W
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M_!>NN_/!+X#/S5@C4,(65-IO?[5;C4Y#.S!LC]NYZQ%S52H"Y3!3IEXS5HV
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MW4*KV]#JMF8^EP:0&>7\E33TJFU"8(=:LDMM[7XW2,_H,R@\/BIO--[4K<+
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M, K(I29V5J:-"6RB[GJH2%> N\)F1_VU+<QV/-&N%0,B,SYQESU4J&=".[(
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M3N>C9C]APN%H*WM&NB .P-B9R@59."V^<[<<0%L'I^U .0;-(1Q IV.DN^$
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MCP30U7:L#*L*OY'FRM)^\\>,/BBHG0.]+Y2R6\,EJ#]1P]]02P,$%     @
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MTZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0
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M]9S-[F[GU[?K]MOZ;KF87VVN \@(@8Q."/E'%$#&"&1\2L@X@$P0R.24D$D
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M/<W>39N%1+B]FF'RR8CE<QS3E\8A)B:?[$2K;C"\1=[9X<PP^63$\L%VQ&#
MAYB8?#)B^1S?%/-9*<3$Y)-Y^8S\Q?;RHA [J41Q"[>PT)[S,E\9UGRT_[%(
MTF8S=5>7Y0S:[M12\^+M[Y%O?^V\_ M02P,$%     @ >SQS4]))O&T1 @
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M[Z1Z/-];KH^_++].3M[>"\[IMJ(^_P502P,$%     @ >SQS4\"(;73I 0
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M4]9G:Y=_'#\\\];4W2&?#7^[FKT!4$L! A0#%     @ >SQS4P=!36*!
ML0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M    " ![/'-3;<I5L^X    K @  $0              @ &O    9&]C4')O
M<',O8V]R92YX;6Q02P$"% ,4    " ![/'-3F5R<(Q &  "<)P  $P
M        @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( 'L\
M<U-H0\(T4 4  /X5   8              " @0T(  !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"% ,4    " ![/'-38/F^T:@%  !$%@  &
M        @(&3#0  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%
M  @ >SQS4S(PTQ'P @  U0D  !@              ("!<1,  'AL+W=O<FMS
M:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( 'L\<U.9\US==04  *,8   8
M              " @9<6  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"
M% ,4    " ![/'-3NSB['%,#   P"@  &               @(%"'   >&PO
M=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ >SQS4\O592OQ"
M&3<  !@              ("!RQ\  'AL+W=O<FMS:&5E=',O<VAE970V+GAM
M;%!+ 0(4 Q0    ( 'L\<U,HP&+GT0<  )(@   8              " @?(H
M  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " ![/'-39K6Y
M\+8"  !C!@  &               @('Y,   >&PO=V]R:W-H965T<R]S:&5E
M=#@N>&UL4$L! A0#%     @ >SQS4XP@T>.9%   .4   !@
M ("!Y3,  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( 'L\
M<U/-L8S'@!   !$R   9              " @;1(  !X;"]W;W)K<VAE971S
M+W-H965T,3 N>&UL4$L! A0#%     @ >SQS4V] 5T/A'0  DX<  !D
M         ("!:UD  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
M    " ![/'-30_(AA-4#  !>"0  &0              @(&#=P  >&PO=V]R
M:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( 'L\<U/;MA$5!@4  !L,
M   9              " @8][  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL
M4$L! A0#%     @ >SQS4TX?.G&9"@  2AT  !D              ("!S(
M 'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " ![/'-3YP-&
MZGD)  "*&0  &0              @(&<BP  >&PO=V]R:W-H965T<R]S:&5E
M=#$U+GAM;%!+ 0(4 Q0    ( 'L\<U,F&[Q@TP8  *<4   9
M  " @4R5  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @
M>SQS4T=PB^9D#0  NR4  !D              ("!5IP  'AL+W=O<FMS:&5E
M=',O<VAE970Q-RYX;6Q02P$"% ,4    " ![/'-3V2D<F*\"   6!@  &0
M            @('QJ0  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4
M Q0    ( 'L\<U.GE3U,1@0  *H*   9              " @=>L  !X;"]W
M;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ >SQS4]%VS28N!@
M>Q   !D              ("!5+$  'AL+W=O<FMS:&5E=',O<VAE970R,"YX
M;6Q02P$"% ,4    " ![/'-3=ZC[/4L"   P!0  &0              @(&Y
MMP  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( 'L\<U-2
MAM ^[0(  *$&   9              " @3NZ  !X;"]W;W)K<VAE971S+W-H
M965T,C(N>&UL4$L! A0#%     @ >SQS4S^5M#3%$@  A#H  !D
M     ("!7[T  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( 'L\<U/%1"J@Y@,  )0)   9              "
M@5+>  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ >SQS
M4[U7%4(J!   30P  !D              ("!;^(  'AL+W=O<FMS:&5E=',O
M<VAE970R.2YX;6Q02P$"% ,4    " ![/'-3$*%\-0,&  !W#P  &0
M        @('0Y@  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0
M   ( 'L\<U.J2F?@GP,  #P(   9              " @0KM  !X;"]W;W)K
M<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ >SQS4\4 $(14!   QPL
M !D              ("!X/   'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q0
M2P$"% ,4    " ![/'-3DQ@RS$P#  "\"0  &0              @(%K]0
M>&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( 'L\<U/?V7E$
M6 (  /@$   9              " @>[X  !X;"]W;W)K<VAE971S+W-H965T
M,S0N>&UL4$L! A0#%     @ >SQS4QW3".0A"    #,  !D
M ("!??L  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " ![
M/'-3-,?A>%,#   B#   &0              @('5 P$ >&PO=V]R:W-H965T
M<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( 'L\<U,OARS)L (  %X'   9
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M970T,2YX;6Q02P$"% ,4    " ![/'-3@K@C0=<%  #D&P  &0
M    @(%/& $ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    (
M 'L\<U-:;UNC]0(  ,,(   9              " @5T> 0!X;"]W;W)K<VAE
M971S+W-H965T-#,N>&UL4$L! A0#%     @ >SQS4_CRI_(I!   >@X  !D
M             ("!B2$! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"
M% ,4    " ![/'-3<8@W'08"  ",!   &0              @('I)0$ >&PO
M=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( 'L\<U/3<2$EUP(
M "X)   9              " @28H 0!X;"]W;W)K<VAE971S+W-H965T-#8N
M>&UL4$L! A0#%     @ >SQS4VZ?_,D2 P  P@D  !D              ("!
M-"L! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    " ![/'-3
MGAOON@,#  "."@  &0              @(%]+@$ >&PO=V]R:W-H965T<R]S
M:&5E=#0X+GAM;%!+ 0(4 Q0    ( 'L\<U,61ER3IP(  %,'   9
M      " @;<Q 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%
M  @ >SQS4PMW^$7/!0  ,QX  !D              ("!E30! 'AL+W=O<FMS
M:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    " ![/'-3CJSH<AT&  !?&P
M&0              @(&;.@$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+
M 0(4 Q0    ( 'L\<U.%BX'2'@,  ,<*   9              " @>]  0!X
M;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ >SQS4Z*8L::>
M P  <P\  !D              ("!1$0! 'AL+W=O<FMS:&5E=',O<VAE970U
M,RYX;6Q02P$"% ,4    " ![/'-3=+TX</T"  #R"@  &0
M@($92 $ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( 'L\
M<U,%[GSZZ@0  &$3   9              " @4U+ 0!X;"]W;W)K<VAE971S
M+W-H965T-34N>&UL4$L! A0#%     @ >SQS4X;TC;09 P  7 H  !D
M         ("!;E ! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4
M    " ![/'-31PCWQ7("  "B!P  &0              @(&^4P$ >&PO=V]R
M:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( 'L\<U,1B *XG0,  (,-
M   9              " @6=6 0!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL
M4$L! A0#%     @ >SQS4UY 3&4! P  $ H  !D              ("!.UH!
M 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    " ![/'-3JD/G
M[-\'  !I0P  &0              @(%S70$ >&PO=V]R:W-H965T<R]S:&5E
M=#8P+GAM;%!+ 0(4 Q0    ( 'L\<U.;B1_H60(  % %   9
M  " @8EE 0!X;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @
M>SQS4\7P*'30 @  K@8  !D              ("!&6@! 'AL+W=O<FMS:&5E
M=',O<VAE970V,BYX;6Q02P$"% ,4    " ![/'-3+Y"!@0@"   4!   &0
M            @($@:P$ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4
M Q0    ( 'L\<U/=.BSM80(  )@%   9              " @5]M 0!X;"]W
M;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @ >SQS4Z8?U?(0 P
M,A$   T              ( !]V\! 'AL+W-T>6QE<RYX;6Q02P$"% ,4
M" ![/'-3EXJ[',     3 @  "P              @ $R<P$ 7W)E;',O+G)E
M;'-02P$"% ,4    " ![/'-3/+ZZE D%  !>*@  #P              @ $;
M= $ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ >SQS4]))O&T1 @  %R8
M !H              ( !47D! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ >SQS4\"(;73I 0  ?B4  !,              ( !FGL!
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     $@ 2 "O$P  M'T!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>257</ContextCount>
  <ElementCount>402</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>60</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Description of Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentation</Role>
      <ShortName>Description of Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2106103 - Disclosure - Collaborative Research and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreements</Role>
      <ShortName>Collaborative Research and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2110104 - Disclosure - Supplemental Balance Sheet Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SupplementalBalanceSheetInformation</Role>
      <ShortName>Supplemental Balance Sheet Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2115105 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2119106 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2123107 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2129108 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2134109 - Disclosure - Equity-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/EquityBasedCompensation</Role>
      <ShortName>Equity-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2142110 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2144111 - Disclosure - Loss Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/LossPerCommonShare</Role>
      <ShortName>Loss Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2148112 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2153113 - Disclosure - Commitment and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/CommitmentandContingencies</Role>
      <ShortName>Commitment and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2155114 - Disclosure - Related-Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related-Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Collaborative Research and License Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsTables</Role>
      <ShortName>Collaborative Research and License Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2311302 - Disclosure - Supplemental Balance Sheet Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables</Role>
      <ShortName>Supplemental Balance Sheet Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/SupplementalBalanceSheetInformation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2316303 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/Investments</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2320304 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/Debt</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2324305 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/Leases</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2330306 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/StockholdersEquity</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2335307 - Disclosure - Equity-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/EquityBasedCompensationTables</Role>
      <ShortName>Equity-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/EquityBasedCompensation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2345308 - Disclosure - Loss Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/LossPerCommonShareTables</Role>
      <ShortName>Loss Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/LossPerCommonShare</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2349309 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/FairValueMeasurements</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Description of Business and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails</Role>
      <ShortName>Description of Business and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SignificantAccountingPoliciesDetails</Role>
      <ShortName>Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Collaborative Research and License Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails</Role>
      <ShortName>Collaborative Research and License Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Collaborative Research and License Agreements - Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Collaborative Research and License Agreements - Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Supplemental Balance Sheet Information - Prepaid expenses and other current assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails</Role>
      <ShortName>Supplemental Balance Sheet Information - Prepaid expenses and other current assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - Supplemental Balance Sheet Information - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails</Role>
      <ShortName>Supplemental Balance Sheet Information - Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2414407 - Disclosure - Supplemental Balance Sheet Information - Accrued Expense and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Supplemental Balance Sheet Information - Accrued Expense and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2417408 - Disclosure - Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/InvestmentsDetails</Role>
      <ShortName>Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/InvestmentsTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - Investments - Available-for-sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails</Role>
      <ShortName>Investments - Available-for-sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2421410 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2422411 - Disclosure - Debt - Principal Maturities of Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails</Role>
      <ShortName>Debt - Principal Maturities of Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2425412 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2426413 - Disclosure - Leases - Right of Use Asset Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/LeasesRightofUseAssetInformationDetails</Role>
      <ShortName>Leases - Right of Use Asset Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2427414 - Disclosure - Leases - Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/LeasesLeaseCostsDetails</Role>
      <ShortName>Leases - Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - Leases - Schedule of Future Minimum Rental Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails</Role>
      <ShortName>Leases - Schedule of Future Minimum Rental Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2431416 - Disclosure - Stockholders' Equity - Current Capitalization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails</Role>
      <ShortName>Stockholders' Equity - Current Capitalization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - Stockholders' Equity - Common Stock Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails</Role>
      <ShortName>Stockholders' Equity - Common Stock Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2433418 - Disclosure - Stockholders' Equity - Accumulated Other Comprehensive Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails</Role>
      <ShortName>Stockholders' Equity - Accumulated Other Comprehensive Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2436419 - Disclosure - Equity-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails</Role>
      <ShortName>Equity-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2437420 - Disclosure - Equity-Based Compensation - Schedule of Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/EquityBasedCompensationScheduleofCompensationExpenseDetails</Role>
      <ShortName>Equity-Based Compensation - Schedule of Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2438421 - Disclosure - Equity-Based Compensation - Assumptions Used for Fair Value Measurement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails</Role>
      <ShortName>Equity-Based Compensation - Assumptions Used for Fair Value Measurement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2439422 - Disclosure - Equity-Based Compensation - Fair Value of Underlying Common Stock and Exercise Price of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails</Role>
      <ShortName>Equity-Based Compensation - Fair Value of Underlying Common Stock and Exercise Price of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2440423 - Disclosure - Equity-Based Compensation - Schedule of Stock Options Rollforward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails</Role>
      <ShortName>Equity-Based Compensation - Schedule of Stock Options Rollforward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2441424 - Disclosure - Equity-Based Compensation - RSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/EquityBasedCompensationRSUActivityDetails</Role>
      <ShortName>Equity-Based Compensation - RSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2443425 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/IncomeTaxes</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2446426 - Disclosure - Loss Per Common Share - Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/LossPerCommonShareComputationofEarningsPerShareDetails</Role>
      <ShortName>Loss Per Common Share - Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2447427 - Disclosure - Loss Per Common Share - Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails</Role>
      <ShortName>Loss Per Common Share - Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2450428 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2451429 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2452430 - Disclosure - Fair Value Measurements - Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2454431 - Disclosure - Commitment and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/CommitmentandContingenciesDetails</Role>
      <ShortName>Commitment and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/CommitmentandContingencies</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="xcur-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2456432 - Disclosure - Related-Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exicuretx.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related-Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exicuretx.com/role/RelatedPartyTransactions</ParentRole>
      <Position>64</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="xcur-20210930.htm">xcur-20210930.htm</File>
    <File>exicureexhibit103-93021.htm</File>
    <File>exicureexhibit104-93021.htm</File>
    <File>exicureexhibit105-93021.htm</File>
    <File>exicureexhibit311-93021.htm</File>
    <File>exicureexhibit312-93021.htm</File>
    <File>exicureexhibit321-93021.htm</File>
    <File>xcur-20210930.xsd</File>
    <File>xcur-20210930_cal.xml</File>
    <File>xcur-20210930_def.xml</File>
    <File>xcur-20210930_lab.xml</File>
    <File>xcur-20210930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>xcur-20210930_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>89
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "xcur-20210930.htm": {
   "axisCustom": 3,
   "axisStandard": 26,
   "contextCount": 257,
   "dts": {
    "calculationLink": {
     "local": [
      "xcur-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "xcur-20210930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "xcur-20210930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "xcur-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "xcur-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "xcur-20210930.xsd"
     ],
     "remote": [
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 521,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 5
   },
   "keyCustom": 52,
   "keyStandard": 350,
   "memberCustom": 18,
   "memberStandard": 36,
   "nsprefix": "xcur",
   "nsuri": "http://www.exicuretx.com/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.exicuretx.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Significant Accounting Policies",
     "role": "http://www.exicuretx.com/role/SignificantAccountingPolicies",
     "shortName": "Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106103 - Disclosure - Collaborative Research and License Agreements",
     "role": "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreements",
     "shortName": "Collaborative Research and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110104 - Disclosure - Supplemental Balance Sheet Information",
     "role": "http://www.exicuretx.com/role/SupplementalBalanceSheetInformation",
     "shortName": "Supplemental Balance Sheet Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115105 - Disclosure - Investments",
     "role": "http://www.exicuretx.com/role/Investments",
     "shortName": "Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119106 - Disclosure - Debt",
     "role": "http://www.exicuretx.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123107 - Disclosure - Leases",
     "role": "http://www.exicuretx.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129108 - Disclosure - Stockholders' Equity",
     "role": "http://www.exicuretx.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134109 - Disclosure - Equity-Based Compensation",
     "role": "http://www.exicuretx.com/role/EquityBasedCompensation",
     "shortName": "Equity-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2142110 - Disclosure - Income Taxes",
     "role": "http://www.exicuretx.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2144111 - Disclosure - Loss Per Common Share",
     "role": "http://www.exicuretx.com/role/LossPerCommonShare",
     "shortName": "Loss Per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "ia9d6ec897790429f9fceaa0150f61e3d_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "ia9d6ec897790429f9fceaa0150f61e3d_I20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2148112 - Disclosure - Fair Value Measurements",
     "role": "http://www.exicuretx.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2153113 - Disclosure - Commitment and Contingencies",
     "role": "http://www.exicuretx.com/role/CommitmentandContingencies",
     "shortName": "Commitment and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2155114 - Disclosure - Related-Party Transactions",
     "role": "http://www.exicuretx.com/role/RelatedPartyTransactions",
     "shortName": "Related-Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Significant Accounting Policies (Policies)",
     "role": "http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Collaborative Research and License Agreements (Tables)",
     "role": "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsTables",
     "shortName": "Collaborative Research and License Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311302 - Disclosure - Supplemental Balance Sheet Information (Tables)",
     "role": "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables",
     "shortName": "Supplemental Balance Sheet Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316303 - Disclosure - Investments (Tables)",
     "role": "http://www.exicuretx.com/role/InvestmentsTables",
     "shortName": "Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320304 - Disclosure - Debt (Tables)",
     "role": "http://www.exicuretx.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "xcur:ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2324305 - Disclosure - Leases (Tables)",
     "role": "http://www.exicuretx.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "xcur:ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330306 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.exicuretx.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "ia9d6ec897790429f9fceaa0150f61e3d_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2335307 - Disclosure - Equity-Based Compensation (Tables)",
     "role": "http://www.exicuretx.com/role/EquityBasedCompensationTables",
     "shortName": "Equity-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2345308 - Disclosure - Loss Per Common Share (Tables)",
     "role": "http://www.exicuretx.com/role/LossPerCommonShareTables",
     "shortName": "Loss Per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2349309 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.exicuretx.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "ia9d6ec897790429f9fceaa0150f61e3d_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "xcur:RetainedEarningsAccumulatedDeficitInceptiontoDate",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Description of Business and Basis of Presentation (Details)",
     "role": "http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails",
     "shortName": "Description of Business and Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "ic4e83e9c6d3f41cba0167701375d65af_D20210701-20210930",
      "decimals": "2",
      "lang": "en-US",
      "name": "xcur:ResearchAndDevelopmentStaffOnSitePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "ie6c60cafc25843e7aa83623d15b8db40_D20210101-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Significant Accounting Policies (Details)",
     "role": "http://www.exicuretx.com/role/SignificantAccountingPoliciesDetails",
     "shortName": "Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "ia9d6ec897790429f9fceaa0150f61e3d_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Collaborative Research and License Agreements (Details)",
     "role": "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails",
     "shortName": "Collaborative Research and License Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i7c9b511297334f1596139d6ed967838a_D20210730-20210730",
      "decimals": "INF",
      "lang": "en-US",
      "name": "xcur:NumberofCollaborationPrograms",
      "reportCount": 1,
      "unique": true,
      "unitRef": "agreement",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i0041572b03444403ad89282293144d76_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Collaborative Research and License Agreements - Other Current Liabilities (Details)",
     "role": "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsOtherCurrentLiabilitiesDetails",
     "shortName": "Collaborative Research and License Agreements - Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "xcur:ContractWithCustomerLiabilityAdditions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "ia9d6ec897790429f9fceaa0150f61e3d_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - Supplemental Balance Sheet Information - Prepaid expenses and other current assets (Details)",
     "role": "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails",
     "shortName": "Supplemental Balance Sheet Information - Prepaid expenses and other current assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "ia9d6ec897790429f9fceaa0150f61e3d_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "ia9d6ec897790429f9fceaa0150f61e3d_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413406 - Disclosure - Supplemental Balance Sheet Information - Property and Equipment, Net (Details)",
     "role": "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails",
     "shortName": "Supplemental Balance Sheet Information - Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i0041572b03444403ad89282293144d76_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "ia9d6ec897790429f9fceaa0150f61e3d_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "xcur:AccruedClinicalContractResearchAndManufacturingCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414407 - Disclosure - Supplemental Balance Sheet Information - Accrued Expense and Other Current Liabilities (Details)",
     "role": "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails",
     "shortName": "Supplemental Balance Sheet Information - Accrued Expense and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "ia9d6ec897790429f9fceaa0150f61e3d_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "xcur:AccruedClinicalContractResearchAndManufacturingCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "xcur:RevenueFromContractWithCustomerNetOfCumulativeCatchUpAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "xcur:RevenueFromContractWithCustomerNetOfCumulativeCatchUpAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "xcur:DebtSecuritiesAvailableForSaleCurrentPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417408 - Disclosure - Investments (Details)",
     "role": "http://www.exicuretx.com/role/InvestmentsDetails",
     "shortName": "Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "xcur:DebtSecuritiesAvailableForSaleCurrentPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "ia9d6ec897790429f9fceaa0150f61e3d_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - Investments - Available-for-sale Securities (Details)",
     "role": "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails",
     "shortName": "Investments - Available-for-sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "ia9d6ec897790429f9fceaa0150f61e3d_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfLongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421410 - Disclosure - Debt - Narrative (Details)",
     "role": "http://www.exicuretx.com/role/DebtNarrativeDetails",
     "shortName": "Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "ia9b3e45e1e944cbfa8d1c6fa857fb39c_D20200925-20200925",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LoanProcessingFee",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "ia9d6ec897790429f9fceaa0150f61e3d_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422411 - Disclosure - Debt - Principal Maturities of Long-Term Debt (Details)",
     "role": "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails",
     "shortName": "Debt - Principal Maturities of Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "ia9d6ec897790429f9fceaa0150f61e3d_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "ia9d6ec897790429f9fceaa0150f61e3d_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425412 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.exicuretx.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "xcur:ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "ia9d6ec897790429f9fceaa0150f61e3d_I20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426413 - Disclosure - Leases - Right of Use Asset Information (Details)",
     "role": "http://www.exicuretx.com/role/LeasesRightofUseAssetInformationDetails",
     "shortName": "Leases - Right of Use Asset Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "xcur:ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "ia9d6ec897790429f9fceaa0150f61e3d_I20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427414 - Disclosure - Leases - Lease Costs (Details)",
     "role": "http://www.exicuretx.com/role/LeasesLeaseCostsDetails",
     "shortName": "Leases - Lease Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "ia9d6ec897790429f9fceaa0150f61e3d_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - Leases - Schedule of Future Minimum Rental Payments (Details)",
     "role": "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails",
     "shortName": "Leases - Schedule of Future Minimum Rental Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "ia9d6ec897790429f9fceaa0150f61e3d_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "ia9d6ec897790429f9fceaa0150f61e3d_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431416 - Disclosure - Stockholders' Equity - Current Capitalization (Details)",
     "role": "http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails",
     "shortName": "Stockholders' Equity - Current Capitalization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "ia9d6ec897790429f9fceaa0150f61e3d_I20210930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "xcur:CommonStockVotingRightsForEachShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "votepershare",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i27fa1ea6e2df45148c9b25b975903963_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - Stockholders' Equity - Common Stock Warrants (Details)",
     "role": "http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails",
     "shortName": "Stockholders' Equity - Common Stock Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "ibd76f03fda964ae290754abfcc474c0f_I20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME",
     "role": "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME",
     "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "idd96764703204097bea35e7a9db99a49_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433418 - Disclosure - Stockholders' Equity - Accumulated Other Comprehensive Loss (Details)",
     "role": "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails",
     "shortName": "Stockholders' Equity - Accumulated Other Comprehensive Loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436419 - Disclosure - Equity-Based Compensation - Narrative (Details)",
     "role": "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails",
     "shortName": "Equity-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "ia9d6ec897790429f9fceaa0150f61e3d_I20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437420 - Disclosure - Equity-Based Compensation - Schedule of Compensation Expense (Details)",
     "role": "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofCompensationExpenseDetails",
     "shortName": "Equity-Based Compensation - Schedule of Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438421 - Disclosure - Equity-Based Compensation - Assumptions Used for Fair Value Measurement (Details)",
     "role": "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails",
     "shortName": "Equity-Based Compensation - Assumptions Used for Fair Value Measurement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i02e0beb6fe6341f7a29be934913d195d_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439422 - Disclosure - Equity-Based Compensation - Fair Value of Underlying Common Stock and Exercise Price of Stock Options (Details)",
     "role": "http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails",
     "shortName": "Equity-Based Compensation - Fair Value of Underlying Common Stock and Exercise Price of Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i02e0beb6fe6341f7a29be934913d195d_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i0041572b03444403ad89282293144d76_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440423 - Disclosure - Equity-Based Compensation - Schedule of Stock Options Rollforward (Details)",
     "role": "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails",
     "shortName": "Equity-Based Compensation - Schedule of Stock Options Rollforward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i5719399e939a44d98b39d249c039d68d_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441424 - Disclosure - Equity-Based Compensation - RSU Activity (Details)",
     "role": "http://www.exicuretx.com/role/EquityBasedCompensationRSUActivityDetails",
     "shortName": "Equity-Based Compensation - RSU Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i5719399e939a44d98b39d249c039d68d_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443425 - Disclosure - Income Taxes (Details)",
     "role": "http://www.exicuretx.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i9df77afaf64d4ef89d26409c127aa1e9_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446426 - Disclosure - Loss Per Common Share - Computation of Earnings Per Share (Details)",
     "role": "http://www.exicuretx.com/role/LossPerCommonShareComputationofEarningsPerShareDetails",
     "shortName": "Loss Per Common Share - Computation of Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i23729b7c757546618ffd14bfc2bf93dd_D20210101-20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447427 - Disclosure - Loss Per Common Share - Antidilutive Securities (Details)",
     "role": "http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails",
     "shortName": "Loss Per Common Share - Antidilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i23729b7c757546618ffd14bfc2bf93dd_D20210101-20210930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "ibbd40097533240cc82bcab253f741f47_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "role": "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
     "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "iab3dbd6a7f674d7083db2fa3c9db78a2_D20200101-20200331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "ia9d6ec897790429f9fceaa0150f61e3d_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450428 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details)",
     "role": "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
     "shortName": "Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i5b19f1632fda44cfb2cbf056cb55773e_I20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i27fa1ea6e2df45148c9b25b975903963_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451429 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "role": "http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i27fa1ea6e2df45148c9b25b975903963_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i2f8b49f540eb4a5f880bed694d3fd14d_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452430 - Disclosure - Fair Value Measurements - Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "role": "http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i2f8b49f540eb4a5f880bed694d3fd14d_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "ia9d6ec897790429f9fceaa0150f61e3d_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "xcur:AggregatePaymentsMadeToDateForLicenseAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454431 - Disclosure - Commitment and Contingencies (Details)",
     "role": "http://www.exicuretx.com/role/CommitmentandContingenciesDetails",
     "shortName": "Commitment and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "ia9d6ec897790429f9fceaa0150f61e3d_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "xcur:AggregatePaymentsMadeToDateForLicenseAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i18f420eacb594066840b698845eaa3a4_D20210101-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456432 - Disclosure - Related-Party Transactions (Details)",
     "role": "http://www.exicuretx.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related-Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i18f420eacb594066840b698845eaa3a4_D20210101-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "ia9d6ec897790429f9fceaa0150f61e3d_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)",
     "role": "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical",
     "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "ia9d6ec897790429f9fceaa0150f61e3d_I20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Description of Business and Basis of Presentation",
     "role": "http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentation",
     "shortName": "Description of Business and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xcur-20210930.htm",
      "contextRef": "i654f3b9f02374cd5a76841d337d965c1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 60,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exicuretx.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ChiefFinancialOfficerMember": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Financial Officer [Member]",
        "terseLabel": "Chief Financial Officer"
       }
      }
     },
     "localname": "ChiefFinancialOfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Board of Directors"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r242",
      "r278",
      "r317",
      "r319",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r482",
      "r530",
      "r532",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r242",
      "r278",
      "r317",
      "r319",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r482",
      "r530",
      "r532",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r242",
      "r278",
      "r307",
      "r317",
      "r319",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r482",
      "r530",
      "r532",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r242",
      "r278",
      "r307",
      "r317",
      "r319",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r482",
      "r530",
      "r532",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r127",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r127",
      "r132",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r177",
      "r178",
      "r304",
      "r306",
      "r531",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r177",
      "r178",
      "r304",
      "r306",
      "r531",
      "r545",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r127",
      "r132",
      "r223",
      "r318",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r180",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r458",
      "r460",
      "r463",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "AOCIAttributableToParentNetOfTaxRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r36",
      "r450"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r23",
      "r181",
      "r182"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Amortization of investments"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r34",
      "r216"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r50",
      "r51",
      "r52",
      "r56",
      "r63",
      "r64",
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Unrealized gains (losses) on short-term investments"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r26",
      "r54",
      "r55",
      "r56",
      "r522",
      "r537",
      "r538"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive (loss) income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r63",
      "r64",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r53",
      "r56",
      "r63",
      "r64",
      "r65",
      "r119",
      "r120",
      "r121",
      "r389",
      "r533",
      "r534",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "verboseLabel": "AOCI Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalCashFlowElementsFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Cash Flow Elements, Financing Activities [Abstract]",
        "terseLabel": "Non-cash financing activities:"
       }
      }
     },
     "localname": "AdditionalCashFlowElementsFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Cash Flow Elements, Investing Activities [Abstract]",
        "terseLabel": "Non-cash investing activities:"
       }
      }
     },
     "localname": "AdditionalCashFlowElementsInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r24",
      "r356",
      "r450"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r353",
      "r354",
      "r355",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in- Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r320",
      "r322",
      "r359",
      "r360"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Equity-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r322",
      "r349",
      "r358"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r73",
      "r97",
      "r262",
      "r419"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of long-term debt issuance costs and fees"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Potentially dilutive shares excluded from computation of weighted-average diluted common shares outstanding (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails",
      "http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails",
      "http://www.exicuretx.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r113",
      "r165",
      "r168",
      "r174",
      "r198",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r385",
      "r390",
      "r407",
      "r448",
      "r450",
      "r500",
      "r519"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r7",
      "r9",
      "r48",
      "r113",
      "r198",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r385",
      "r390",
      "r407",
      "r448",
      "r450"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r396"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total financial assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r188"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Holding Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r189"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Holding Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r186",
      "r207"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Costs"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r184",
      "r187",
      "r207",
      "r506"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair Value",
        "verboseLabel": "Short-term investments:"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r323",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r2",
      "r118",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Description of Business and Basis of Presentation"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r101",
      "r102",
      "r103"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Capital expenditures (accounts payable and accrued expenses)"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r32",
      "r99"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents:"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r92",
      "r99",
      "r104"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash - end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash - beginning of period",
        "totalLabel": "Total cash, cash equivalents, and restricted cash shown in the unaudited condensed consolidated statements of cash flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r92",
      "r408"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r110",
      "r113",
      "r135",
      "r136",
      "r137",
      "r139",
      "r141",
      "r149",
      "r150",
      "r151",
      "r198",
      "r228",
      "r232",
      "r233",
      "r234",
      "r237",
      "r238",
      "r276",
      "r277",
      "r280",
      "r284",
      "r407",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of shares called by warrants (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r297",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r379",
      "r380",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborative Research and License Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaboration Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails",
      "http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails",
      "http://www.exicuretx.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails",
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r220",
      "r221",
      "r222",
      "r224",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CommitmentandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r119",
      "r120",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r22",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r22",
      "r450"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value per share; 200,000,000 shares authorized, 88,108,543 issued and outstanding, September\u00a030, 2021; 87,651,352 issued and outstanding, December\u00a031, 2020"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r59",
      "r61",
      "r62",
      "r70",
      "r508",
      "r527"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r106",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in process"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Balance Of The Company's Contract Liability"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r299",
      "r300",
      "r305"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "Deferred Revenue Balance at September 30, 2021",
        "periodStartLabel": "Deferred Revenue Balance at January 1, 2021",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails",
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": {
     "auth_ref": [
      "r301"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.",
        "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price",
        "terseLabel": "Cumulative catch-up adjustment to revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails",
      "http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails",
      "http://www.exicuretx.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r299",
      "r300",
      "r305"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue, current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r299",
      "r300",
      "r305"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, noncurrent"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r308",
      "r316",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate notes/bonds"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r109",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r256",
      "r263",
      "r264",
      "r266",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r16",
      "r18",
      "r19",
      "r112",
      "r117",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r252",
      "r253",
      "r254",
      "r255",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r270",
      "r271",
      "r272",
      "r273",
      "r420",
      "r501",
      "r502",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r19",
      "r267",
      "r502",
      "r517"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "totalLabel": "Principal balance outstanding"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r239",
      "r270",
      "r271",
      "r418",
      "r420",
      "r421"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "auth_ref": [
      "r43"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.",
        "label": "Debt Instrument, Fee Amount",
        "terseLabel": "Fee amount"
       }
      }
     },
     "localname": "DebtInstrumentFeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument.",
        "label": "Debt Instrument, Interest Rate, Increase (Decrease)",
        "terseLabel": "Interest rate increase"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r42",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Floating interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r44",
      "r112",
      "r117",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r252",
      "r253",
      "r254",
      "r255",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r270",
      "r271",
      "r272",
      "r273",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Prior to first anniversary"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "After first anniversary"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r44",
      "r112",
      "r117",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r252",
      "r253",
      "r254",
      "r255",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r265",
      "r270",
      "r271",
      "r272",
      "r273",
      "r292",
      "r293",
      "r294",
      "r295",
      "r417",
      "r418",
      "r420",
      "r421",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r252",
      "r268",
      "r270",
      "r271",
      "r419"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedTerseLabel": "less: unamortized discount and debt issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": {
     "auth_ref": [
      "r101",
      "r102",
      "r103"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.",
        "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction",
        "terseLabel": "Debt fees (accrued expense and other noncurrent liabilities)"
       }
      }
     },
     "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "auth_ref": [
      "r192"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Gain",
        "terseLabel": "Gross realized gains, available for sale securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "auth_ref": [
      "r192"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Loss",
        "terseLabel": "Gross realized losses, available for sale securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Debt Securities, Available-for-sale"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Prepaid Expense and Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r35",
      "r252",
      "r419"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "terseLabel": "Unamortized debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAmortizationAndAccretionNet": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Depreciation, Amortization and Accretion, Net",
        "terseLabel": "Depreciation and amortization",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAmortizationAndAccretionNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Equity-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r71",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r133",
      "r135",
      "r139",
      "r140",
      "r141",
      "r145",
      "r146",
      "r394",
      "r395",
      "r509",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (loss) earnings per common share (USD per share)",
        "verboseLabel": "(Loss) earnings per basic common share (USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LossPerCommonShareComputationofEarningsPerShareDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r71",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r135",
      "r139",
      "r140",
      "r141",
      "r145",
      "r146",
      "r394",
      "r395",
      "r509",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (loss) earnings per common share (USD per share)",
        "verboseLabel": "(Loss) earnings per diluted common share (USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LossPerCommonShareComputationofEarningsPerShareDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r142",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Loss Per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Loss Per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LossPerCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued payroll-related expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r350"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Compensation cost not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Compensation expense recognition period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "verboseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails",
      "http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Scientific equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r63",
      "r64",
      "r65",
      "r119",
      "r120",
      "r121",
      "r123",
      "r129",
      "r131",
      "r148",
      "r201",
      "r291",
      "r296",
      "r353",
      "r354",
      "r355",
      "r370",
      "r371",
      "r393",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r415",
      "r533",
      "r534",
      "r535",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r97",
      "r275"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Change in fair value of warrant liabilities"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r396",
      "r397",
      "r398",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r254",
      "r270",
      "r271",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r316",
      "r397",
      "r455",
      "r456",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r404",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r396",
      "r397",
      "r399",
      "r400",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r254",
      "r308",
      "r309",
      "r314",
      "r316",
      "r397",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r254",
      "r270",
      "r271",
      "r308",
      "r309",
      "r314",
      "r316",
      "r397",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r254",
      "r270",
      "r271",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r316",
      "r397",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "verboseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r401",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r401",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r402"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedTerseLabel": "Gain included in other (expense) income, net"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "auth_ref": [
      "r403"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r401"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance at September\u00a030, 2021",
        "periodStartLabel": "Balance at December 31, 2020"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r254",
      "r270",
      "r271",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r316",
      "r455",
      "r456",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r404",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r190",
      "r191",
      "r194",
      "r195",
      "r196",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r208",
      "r209",
      "r210",
      "r211",
      "r265",
      "r289",
      "r392",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "totalLabel": "Total financial liabilities"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "auth_ref": [
      "r65",
      "r74"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.",
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "terseLabel": "Net loss before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r218",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r114",
      "r367",
      "r368",
      "r369",
      "r372",
      "r374",
      "r376",
      "r377",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r115",
      "r130",
      "r131",
      "r164",
      "r365",
      "r373",
      "r375",
      "r529"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/IncomeTaxesDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r96",
      "r483"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedTerseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r67",
      "r163",
      "r416",
      "r419",
      "r510"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r91",
      "r94",
      "r100"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid on debt"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivable": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.",
        "label": "Interest Receivable",
        "terseLabel": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeDividend": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of dividend income on nonoperating securities.",
        "label": "Investment Income, Dividend",
        "terseLabel": "Dividend income"
       }
      }
     },
     "localname": "InvestmentIncomeDividend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r77",
      "r162"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTableTextBlock": {
     "auth_ref": [
      "r193",
      "r197",
      "r199",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment.",
        "label": "Investment [Table Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments [Abstract]",
        "terseLabel": "Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r193",
      "r498",
      "r513",
      "r544",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/Investments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r435",
      "r437"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/LeasesLeaseCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Lease Costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Incremental borrowing rate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Rental Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r436"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r436"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r436"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r436"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r436"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r436"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r436"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r436"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2021 (remaining three months)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r436"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Contract term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letters of credit outstanding"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r39",
      "r113",
      "r169",
      "r198",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r386",
      "r390",
      "r391",
      "r407",
      "r448",
      "r449"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r29",
      "r113",
      "r198",
      "r407",
      "r450",
      "r503",
      "r524"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r41",
      "r113",
      "r198",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r386",
      "r390",
      "r391",
      "r407",
      "r448",
      "r449",
      "r450"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r37",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r37",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LoanProcessingFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses paid for obtaining loans which includes expenses such as application and origination fees.",
        "label": "Loan Processing Fee",
        "terseLabel": "Origination fee"
       }
      }
     },
     "localname": "LoanProcessingFee",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LoansPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing supported by a written promise to pay an obligation.",
        "label": "Loans Payable [Member]",
        "terseLabel": "Loans Payable"
       }
      }
     },
     "localname": "LoansPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r19",
      "r253",
      "r269",
      "r270",
      "r271",
      "r502",
      "r520"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Long-term debt",
        "totalLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails",
      "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "verboseLabel": "Current portion"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r117",
      "r226",
      "r258"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r117",
      "r226",
      "r258"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r117",
      "r226",
      "r258"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r117",
      "r226",
      "r258"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "terseLabel": "2021 (remaining three months)"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      },
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net",
        "verboseLabel": "Noncurrent portion"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtPrincipalMaturitiesofLongTermDebtDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r44",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInDeferredRevenueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Movement in Deferred Revenue [Roll Forward]",
        "terseLabel": "Movement in Deferred Revenue [Roll Forward]"
       }
      }
     },
     "localname": "MovementInDeferredRevenueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r92",
      "r95",
      "r98"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r57",
      "r60",
      "r65",
      "r69",
      "r98",
      "r113",
      "r122",
      "r124",
      "r125",
      "r126",
      "r127",
      "r130",
      "r131",
      "r138",
      "r165",
      "r167",
      "r170",
      "r173",
      "r175",
      "r198",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r395",
      "r407",
      "r507",
      "r526"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LossPerCommonShareComputationofEarningsPerShareDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other (expense) income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other (expense) income, net:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": {
     "auth_ref": [
      "r56",
      "r66"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.",
        "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss) before reclassifications"
       }
      }
     },
     "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r165",
      "r167",
      "r170",
      "r173",
      "r175"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r428",
      "r437"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/LeasesLeaseCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r423"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total lease liability",
        "verboseLabel": "Lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails",
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r423"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liability, current",
        "verboseLabel": "Current operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails",
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r423"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Noncurrent operating lease liability",
        "verboseLabel": "Lease liability, noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesScheduleofFutureMinimumRentalPaymentsDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r424",
      "r431"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating lease, cash payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r422"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Amortization of right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r434",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesRightofUseAssetInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r433",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesRightofUseAssetInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r40"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued other expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive (loss) income, net of taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r58",
      "r61",
      "r383",
      "r384",
      "r388"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Other comprehensive (loss) income",
        "verboseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r50",
      "r54"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized (losses) gains on available for sale securities, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "verboseLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other (expense) income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r5",
      "r8",
      "r214"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForTenantImprovements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy.",
        "label": "Payments for Tenant Improvements",
        "terseLabel": "Payments for tenant improvements"
       }
      }
     },
     "localname": "PaymentsForTenantImprovements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Payment of long-term debt fees and issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Payments for minimum statutory tax withholding related to net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r81",
      "r84",
      "r185"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedTerseLabel": "Purchase of available for sale securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r323",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r21",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r21",
      "r450"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value per share; 10,000,000 shares authorized, no shares issued and outstanding, September\u00a030, 2021 and December\u00a031, 2020"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r7",
      "r30",
      "r31"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other assets",
        "totalLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r5",
      "r8",
      "r213",
      "r214"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid clinical, contract research and manufacturing costs"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r6",
      "r8",
      "r212",
      "r214"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPrepaidexpensesandothercurrentassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromCollaborators": {
     "auth_ref": [
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from collaborators during the current period.",
        "label": "Proceeds from Collaborators",
        "terseLabel": "Proceeds from collaborators"
       }
      }
     },
     "localname": "ProceedsFromCollaborators",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r87"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "terseLabel": "Proceeds from debt, net of fees and issuance costs"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from common stock offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from long-term borrowing"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.",
        "label": "Proceeds from Sale and Maturity of Other Investments",
        "terseLabel": "Proceeds from sale or maturity of available for sale securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r81",
      "r82",
      "r185"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from sale of debt securities, available-for-sale"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r86",
      "r352"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of common stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from issuance of employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r34",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r33",
      "r215"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r14",
      "r15",
      "r217",
      "r450",
      "r514",
      "r525"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r14",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r14",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.",
        "label": "Reclassification from AOCI, Current Period, before Tax, Attributable to Parent",
        "negatedTerseLabel": "Net losses (gains) reclassified from accumulated other comprehensive loss"
       }
      }
     },
     "localname": "ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r315",
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r315",
      "r441",
      "r442",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r441"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Expenses from transactions with related party"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r315",
      "r441",
      "r445",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r439",
      "r440",
      "r442",
      "r446",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related-Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedTerseLabel": "Repayment of long-term debt",
        "terseLabel": "Repayment of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]",
        "terseLabel": "Research and Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r363",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r363",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r362",
      "r484",
      "r558"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r13",
      "r99",
      "r104",
      "r499",
      "r521"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted cash included in other noncurrent assets"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationRSUActivityDetails",
      "http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r25",
      "r296",
      "r356",
      "r450",
      "r523",
      "r536",
      "r538"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r119",
      "r120",
      "r121",
      "r123",
      "r129",
      "r131",
      "r201",
      "r353",
      "r354",
      "r355",
      "r370",
      "r371",
      "r393",
      "r533",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r160",
      "r161",
      "r166",
      "r171",
      "r172",
      "r176",
      "r177",
      "r179",
      "r303",
      "r304",
      "r485"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Collaboration revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r107",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r68",
      "r113",
      "r160",
      "r161",
      "r166",
      "r171",
      "r172",
      "r176",
      "r177",
      "r179",
      "r198",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r407",
      "r511"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "totalLabel": "Total revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r432",
      "r437"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use asset acquired through operating leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r56",
      "r414",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails",
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Equity-Based Compensation Expense Classification in Statement of Operations"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Computation of loss per common share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r396",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Principal Maturities of Long-term Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r34",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r443",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r323",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationRSUActivityDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r326",
      "r336",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Common Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Assumptions Used to Determine Fair Value of Common Stock Option Grants"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Restricted Stock Unit Awards Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Secured Debt"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Equity-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Unvested balance - end of period (in shares)",
        "periodStartLabel": "Unvested balance - beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Unvested balance - end of period (in dollars per share)",
        "periodStartLabel": "Unvested balance - beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Exercise price of common stock option (dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationRSUActivityDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Maximum ESPP contribution rate as a percentage of compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest quantity of shares an employee can purchase under the plan per period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee",
        "terseLabel": "Maximum number of shares per employee in purchase period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "verboseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable, weighted-average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r338"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, stock options, exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)",
        "verboseLabel": "Options granted in period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r328",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding ending balance (in shares)",
        "periodStartLabel": "Outstanding beginning balance (in shares)",
        "terseLabel": "Options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding ending balance (in dollars per share)",
        "periodStartLabel": "Outstanding beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value (thousands)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r339"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value (thousands)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest, weighted-average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Percentage of outstanding shares allowable as annual increase"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r321",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails",
      "http://www.exicuretx.com/role/EquityBasedCompensationRSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Fair value of underlying common stock (dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationFairValueofUnderlyingCommonStockandExercisePriceofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r343",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r351"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable, aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable, weighted-average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "ESPP purchase price as a percentage of market price"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r17",
      "r504",
      "r505",
      "r518"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r540",
      "r541",
      "r542",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-term Investments [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r429",
      "r437"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/LeasesLeaseCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term Lease, Cost",
        "terseLabel": "Short term lease costs"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r105",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r110",
      "r113",
      "r135",
      "r136",
      "r137",
      "r139",
      "r141",
      "r149",
      "r150",
      "r151",
      "r198",
      "r228",
      "r232",
      "r233",
      "r234",
      "r237",
      "r238",
      "r276",
      "r277",
      "r280",
      "r284",
      "r291",
      "r407",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r46",
      "r63",
      "r64",
      "r65",
      "r119",
      "r120",
      "r121",
      "r123",
      "r129",
      "r131",
      "r148",
      "r201",
      "r291",
      "r296",
      "r353",
      "r354",
      "r355",
      "r370",
      "r371",
      "r393",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r415",
      "r533",
      "r534",
      "r535",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r148",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r21",
      "r22",
      "r291",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock-ESPP (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r21",
      "r22",
      "r291",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Issuance of common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r21",
      "r22",
      "r291",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Vesting of restricted stock units and related repurchases (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r21",
      "r22",
      "r291",
      "r296",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercise of options (in shares)",
        "terseLabel": "Exercise of options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationScheduleofStockOptionsRollforwardDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r21",
      "r22",
      "r291",
      "r296"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock-ESPP"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r21",
      "r22",
      "r291",
      "r296"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r291",
      "r296"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Vesting of restricted stock units and related repurchases"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r46",
      "r291",
      "r296"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r22",
      "r27",
      "r28",
      "r113",
      "r183",
      "r198",
      "r407",
      "r450"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r111",
      "r277",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r290",
      "r296",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Supplemental Balance Sheet Information"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r190",
      "r191",
      "r194",
      "r195",
      "r196",
      "r265",
      "r289",
      "r392",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails",
      "http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails",
      "http://www.exicuretx.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r116",
      "r308",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. Government agency securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r116",
      "r308",
      "r316",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasuries"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.exicuretx.com/role/InvestmentsAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnusualOrInfrequentItemAxis": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by an event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Item, or Both [Axis]",
        "terseLabel": "Unusual or Infrequent Item, or Both [Axis]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnusualOrInfrequentItemDomain": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Item, or Both [Domain]",
        "terseLabel": "Unusual or Infrequent Item, or Both [Domain]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnusualRiskOrUncertaintyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Unusual Risk or Uncertainty [Line Items]",
        "terseLabel": "Unusual Risk or Uncertainty [Line Items]"
       }
      }
     },
     "localname": "UnusualRiskOrUncertaintyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails",
      "http://www.exicuretx.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnusualRiskOrUncertaintyTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the unusual risk or uncertainty and its financial impact or potential financial impact.",
        "label": "Unusual Risk or Uncertainty [Table]",
        "terseLabel": "Unusual Risk or Uncertainty [Table]"
       }
      }
     },
     "localname": "UnusualRiskOrUncertaintyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails",
      "http://www.exicuretx.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r430",
      "r437"
     ],
     "calculation": {
      "http://www.exicuretx.com/role/LeasesLeaseCostsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease costs"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "verboseLabel": "Warrants to purchase common stock"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Common stock warrant liability"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r134",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average diluted common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LossPerCommonShareComputationofEarningsPerShareDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r133",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average basic common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exicuretx.com/role/LossPerCommonShareComputationofEarningsPerShareDetails",
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    },
    "xcur_AbbVieCollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allergan Collaboration [Member]",
        "label": "AbbVie Collaboration [Member]",
        "terseLabel": "AbbVie Collaboration"
       }
      }
     },
     "localname": "AbbVieCollaborationMember",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails",
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsOtherCurrentLiabilitiesDetails",
      "http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails",
      "http://www.exicuretx.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_AccruedClinicalContractResearchAndManufacturingCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical, Contract Research And Manufacturing Costs, Current",
        "label": "Accrued Clinical, Contract Research And Manufacturing Costs, Current",
        "terseLabel": "Accrued clinical, contract research and manufacturing costs"
       }
      }
     },
     "localname": "AccruedClinicalContractResearchAndManufacturingCostsCurrent",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationAccruedExpenseandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_AggregatePaymentsMadeToDateForLicenseAgreements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Payments Made To Date For License Agreements",
        "label": "Aggregate Payments Made To Date For License Agreements",
        "terseLabel": "Aggregate consideration paid to NU for agreement obligations"
       }
      }
     },
     "localname": "AggregatePaymentsMadeToDateForLicenseAgreements",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_ArrangementNameAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement, Name [Axis]",
        "label": "Arrangement, Name [Axis]",
        "terseLabel": "Arrangement, Name [Axis]"
       }
      }
     },
     "localname": "ArrangementNameAxis",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails",
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsOtherCurrentLiabilitiesDetails",
      "http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails",
      "http://www.exicuretx.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "xcur_ArrangementNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Arrangement, Name [Axis]",
        "label": "Arrangement, Name [Domain]",
        "terseLabel": "Arrangement, Name [Domain]"
       }
      }
     },
     "localname": "ArrangementNameDomain",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails",
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsOtherCurrentLiabilitiesDetails",
      "http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails",
      "http://www.exicuretx.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_COVID19Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19",
        "label": "COVID-19 [Member]",
        "terseLabel": "COVID-19"
       }
      }
     },
     "localname": "COVID19Member",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_ChicagoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chicago",
        "label": "Chicago [Member]",
        "terseLabel": "Chicago"
       }
      }
     },
     "localname": "ChicagoMember",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_ClassofWarrantorRightExpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Expired",
        "label": "Class of Warrant or Right, Expired",
        "terseLabel": "Warrant expirations (in shares)"
       }
      }
     },
     "localname": "ClassofWarrantorRightExpired",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityCommonStockWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "xcur_CollaborationAgreementEstimatedTimingOfRevenueRecognition": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Estimated Timing Of Revenue Recognition",
        "label": "Collaboration Agreement, Estimated Timing Of Revenue Recognition",
        "terseLabel": "Estimated timing of revenue recognition"
       }
      }
     },
     "localname": "CollaborationAgreementEstimatedTimingOfRevenueRecognition",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xcur_CollaborationAgreementExtendedOptionAdditionalExerciseFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Extended Option, Additional Exercise Fee",
        "label": "Collaboration Agreement, Extended Option, Additional Exercise Fee",
        "terseLabel": "Collaboration option exercise fee"
       }
      }
     },
     "localname": "CollaborationAgreementExtendedOptionAdditionalExerciseFee",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_CollaborationAgreementLicensingFeesIncurred": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Licensing Fees Incurred",
        "label": "Collaboration Agreement, Licensing Fees Incurred",
        "terseLabel": "Collaboration agreement, licensing fees incurred"
       }
      }
     },
     "localname": "CollaborationAgreementLicensingFeesIncurred",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_CollaborationAgreementOptionExerciseFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Option, Exercise Fee",
        "label": "Collaboration Agreement, Option, Exercise Fee",
        "terseLabel": "Collaboration option exercise fee"
       }
      }
     },
     "localname": "CollaborationAgreementOptionExerciseFee",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_CollaborationAgreementPerformanceObligationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Performance Obligation",
        "label": "Collaboration Agreement, Performance Obligation [Axis]",
        "terseLabel": "Collaboration Agreement, Performance Obligation [Axis]"
       }
      }
     },
     "localname": "CollaborationAgreementPerformanceObligationAxis",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "xcur_CollaborationAgreementPerformanceObligationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Performance Obligation [Domain]",
        "label": "Collaboration Agreement, Performance Obligation [Domain]",
        "terseLabel": "Collaboration Agreement, Performance Obligation [Domain]"
       }
      }
     },
     "localname": "CollaborationAgreementPerformanceObligationDomain",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_CollaborationAgreementTerminationNoticePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Termination Notice Period",
        "label": "Collaboration Agreement, Termination Notice Period",
        "terseLabel": "Collaboration agreement, termination notice period"
       }
      }
     },
     "localname": "CollaborationAgreementTerminationNoticePeriod",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xcur_CollaborationAgreementTerminationPeriodUponWrittenNotice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Termination Period Upon Written Notice",
        "label": "Collaboration Agreement, Termination Period Upon Written Notice",
        "terseLabel": "Termination period upon written notice"
       }
      }
     },
     "localname": "CollaborationAgreementTerminationPeriodUponWrittenNotice",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xcur_CollaborationAgreementTransactionPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Transaction Price",
        "label": "Collaboration Agreement, Transaction Price",
        "terseLabel": "Transaction price allocated"
       }
      }
     },
     "localname": "CollaborationAgreementTransactionPrice",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_CollaborationAgreementUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Upfront Payment",
        "label": "Collaboration Agreement, Upfront Payment",
        "terseLabel": "Non-refundable upfront payment received for research agreement"
       }
      }
     },
     "localname": "CollaborationAgreementUpfrontPayment",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_CollaborationDevelopmentExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Development Expenses",
        "label": "Collaboration Development Expenses",
        "terseLabel": "Collaboration development expenses"
       }
      }
     },
     "localname": "CollaborationDevelopmentExpenses",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_CommonStockVotingRightsForEachShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Voting Rights For Each Share",
        "label": "Common Stock, Voting Rights For Each Share",
        "terseLabel": "Common stock, voting rights for each share"
       }
      }
     },
     "localname": "CommonStockVotingRightsForEachShare",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/StockholdersEquityCurrentCapitalizationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "xcur_CommonStockWarrantLiabilityFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Warrant Liability, Fair Value Disclosure",
        "label": "Common Stock Warrant Liability, Fair Value Disclosure",
        "terseLabel": "Common stock warrant liability"
       }
      }
     },
     "localname": "CommonStockWarrantLiabilityFairValueDisclosure",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_ComputersandSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computers and Software [Member]",
        "label": "Computers and Software [Member]",
        "terseLabel": "Computers and software"
       }
      }
     },
     "localname": "ComputersandSoftwareMember",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/SupplementalBalanceSheetInformationPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_ConsultingServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consulting Services [Member]",
        "label": "Consulting Services [Member]",
        "terseLabel": "Consulting services"
       }
      }
     },
     "localname": "ConsultingServicesMember",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_ContractWithCustomerLiabilityAdditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Additions",
        "label": "Contract With Customer, Liability, Additions",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityAdditions",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with Customer, Liability, Cumulative Catch-up Adjustments To Revenue, Change In Estimate",
        "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustments To Revenue, Change In Estimate",
        "terseLabel": "Cumulative catch-up adjustments to revenue, change in estimate"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentsToRevenueChangeInEstimate",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails",
      "http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with Customer, Liability, Revenue Recognized, Including Opening Balance",
        "label": "Contract with Customer, Liability, Revenue Recognized, Including Opening Balance",
        "negatedTerseLabel": "Revenue (Recognized) Reversed"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_DebtInstrumentEarlyTerminationFeePercentageOfPrincipal": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Early Termination Fee, Percentage of Principal",
        "label": "Debt Instrument, Early Termination Fee, Percentage of Principal",
        "terseLabel": "Early termination fee"
       }
      }
     },
     "localname": "DebtInstrumentEarlyTerminationFeePercentageOfPrincipal",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xcur_DebtInstrumentExitFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Exit Fee, Percentage",
        "label": "Debt Instrument, Exit Fee, Percentage",
        "terseLabel": "Exit fee percentage"
       }
      }
     },
     "localname": "DebtInstrumentExitFeePercentage",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xcur_DebtInstrumentFundingConditionRequiredProceedsFromEquityIssuance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Funding Condition, Required Proceeds From Equity Issuance",
        "label": "Debt Instrument, Funding Condition, Required Proceeds From Equity Issuance",
        "terseLabel": "Funding condition, required proceeds from equity issuance"
       }
      }
     },
     "localname": "DebtInstrumentFundingConditionRequiredProceedsFromEquityIssuance",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Principal Payment, Number of Monthly Installment Payments",
        "label": "Debt Instrument, Principal Payment, Number of Monthly Installment Payments",
        "terseLabel": "Number of monthly installment payments"
       }
      }
     },
     "localname": "DebtInstrumentPrincipalPaymentNumberOfMonthlyInstallmentPayments",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xcur_DebtSecuritiesAvailableForSaleCurrentPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exicuretx.com/role/InvestmentsDetails": {
       "order": 1.0,
       "parentTag": "xcur_DebtSecuritiesAvailableforSalePercent",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available For Sale, Current, Percent",
        "label": "Debt Securities, Available For Sale, Current, Percent",
        "terseLabel": "One year or less"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleCurrentPercent",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/InvestmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xcur_DebtSecuritiesAvailableForSaleNoncurrentPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exicuretx.com/role/InvestmentsDetails": {
       "order": 2.0,
       "parentTag": "xcur_DebtSecuritiesAvailableforSalePercent",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available For Sale, Noncurrent, Percent",
        "label": "Debt Securities, Available For Sale, Noncurrent, Percent",
        "terseLabel": "After one year but within two years"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleNoncurrentPercent",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/InvestmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xcur_DebtSecuritiesAvailableforSalePercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exicuretx.com/role/InvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available for Sale, Percent",
        "label": "Debt Securities, Available for Sale, Percent",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableforSalePercent",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/InvestmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xcur_DermelixLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dermelix License Agreement [Member]",
        "label": "Dermelix License Agreement [Member]",
        "terseLabel": "Dermelix License Agreement"
       }
      }
     },
     "localname": "DermelixLicenseAgreementMember",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_DevelopmentandCommercializationLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development and Commercialization License [Member]",
        "label": "Development and Commercialization License [Member]",
        "terseLabel": "Development and Commercialization License"
       }
      }
     },
     "localname": "DevelopmentandCommercializationLicenseMember",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_ExercisePeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Period",
        "label": "Exercise Period [Axis]",
        "terseLabel": "Exercise Period [Axis]"
       }
      }
     },
     "localname": "ExercisePeriodAxis",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "xcur_ExercisePeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Period [Domain]",
        "label": "Exercise Period [Domain]",
        "terseLabel": "Exercise Period [Domain]"
       }
      }
     },
     "localname": "ExercisePeriodDomain",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_ExercisePeriodOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Period One",
        "label": "Exercise Period One [Member]",
        "terseLabel": "Option Exercise Period after the Selection"
       }
      }
     },
     "localname": "ExercisePeriodOneMember",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_ExercisePeriodTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Period Two",
        "label": "Exercise Period Two [Member]",
        "terseLabel": "Option Exercise Period that begins after the first Option Exercise Period"
       }
      }
     },
     "localname": "ExercisePeriodTwoMember",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_ExicureInc.2017EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exicure, Inc. 2017 Equity Incentive Plan [Member]",
        "label": "Exicure, Inc. 2017 Equity Incentive Plan [Member]",
        "terseLabel": "Exicure, Inc. 2017 Equity Incentive Plan"
       }
      }
     },
     "localname": "ExicureInc.2017EquityIncentivePlanMember",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_HerculesTechnologyGrowthCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hercules Technology Growth Capital [Member]",
        "label": "Hercules Technology Growth Capital [Member]",
        "terseLabel": "Hercules Technology Growth Capital"
       }
      }
     },
     "localname": "HerculesTechnologyGrowthCapitalMember",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_IpsenASMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ipsen AS",
        "label": "Ipsen AS [Member]",
        "terseLabel": "Ipsen AS"
       }
      }
     },
     "localname": "IpsenASMember",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_IpsenCollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ipsen Collaboration",
        "label": "Ipsen Collaboration [Member]",
        "terseLabel": "Ipsen Collaboration"
       }
      }
     },
     "localname": "IpsenCollaborationMember",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails",
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_IpsenHDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ipsen HD",
        "label": "Ipsen HD [Member]",
        "terseLabel": "Ipsen HD"
       }
      }
     },
     "localname": "IpsenHDMember",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Annual Rent Payment Initial Twelve Months",
        "label": "Lessee, Operating Lease, Annual Rent Payment Initial Twelve Months",
        "terseLabel": "Annual rent payment initial twelve months"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAnnualRentPaymentInitialTwelveMonths",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_LesseeOperatingLeaseBaseRentAnnualPercentageIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Base Rent Annual Percentage Increase",
        "label": "Lessee, Operating Lease, Base Rent Annual Percentage Increase",
        "terseLabel": "Base rent annual percentage increase"
       }
      }
     },
     "localname": "LesseeOperatingLeaseBaseRentAnnualPercentageIncrease",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xcur_LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Estimated Rental Payment Over Original Term",
        "label": "Lessee, Operating Lease, Estimated Rental Payment Over Original Term",
        "terseLabel": "Estimated rental payment over original term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseEstimatedRentalPaymentOverOriginalTerm",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_LesseeOperatingLeaseLeaseArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Area",
        "label": "Lessee, Operating Lease, Lease Area",
        "terseLabel": "Lease area"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseArea",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "xcur_LesseeOperatingLeaseNumberOfExtensions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number of Extensions",
        "label": "Lessee, Operating Lease, Number of Extensions",
        "terseLabel": "Number of extensions"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfExtensions",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xcur_LesseeOperatingLeaseRentalPaymentAdjustedForAbatement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Rental Payment Adjusted For Abatement",
        "label": "Lessee, Operating Lease, Rental Payment Adjusted For Abatement",
        "terseLabel": "Rental payment adjusted for abatement"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRentalPaymentAdjustedForAbatement",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_MidCapCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MidCap Credit Agreement",
        "label": "MidCap Credit Agreement [Member]",
        "terseLabel": "MidCap Credit Agreement"
       }
      }
     },
     "localname": "MidCapCreditAgreementMember",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_MidCapCreditAgreementTranche1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MidCap Credit Agreement - Tranche 1",
        "label": "MidCap Credit Agreement - Tranche 1 [Member]",
        "terseLabel": "MidCap Credit Agreement - Tranche 1"
       }
      }
     },
     "localname": "MidCapCreditAgreementTranche1Member",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_MidCapCreditAgreementTranche2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MidCap Credit Agreement - Tranche 2",
        "label": "MidCap Credit Agreement - Tranche 2 [Member]",
        "terseLabel": "MidCap Credit Agreement - Tranche 2"
       }
      }
     },
     "localname": "MidCapCreditAgreementTranche2Member",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xcur_NumberofCollaborationPrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Collaboration Programs",
        "label": "Number of Collaboration Programs",
        "terseLabel": "Number of collaboration programs"
       }
      }
     },
     "localname": "NumberofCollaborationPrograms",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xcur_OfficeAndGeneralAndAdministrativeStaffOnSitePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office And General And Administrative Staff On Site, Percentage",
        "label": "Office And General And Administrative Staff On Site, Percentage",
        "terseLabel": "Percentage of time that office and general and administrative staff are on site"
       }
      }
     },
     "localname": "OfficeAndGeneralAndAdministrativeStaffOnSitePercentage",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xcur_PaymentsForDebtEndTermFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Debt End Term Fees",
        "label": "Payments For Debt End Term Fees",
        "terseLabel": "Payments for debt end term fees"
       }
      }
     },
     "localname": "PaymentsForDebtEndTermFees",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_PaymentsOfCommonStockFinancingCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments Of Common Stock Financing Costs",
        "label": "Payments Of Common Stock Financing Costs",
        "negatedLabel": "Payment of common stock financing costs"
       }
      }
     },
     "localname": "PaymentsOfCommonStockFinancingCosts",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_ResearchAndDevelopmentStaffOnSitePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Staff on Site, Percentage",
        "label": "Research and Development Staff on Site, Percentage",
        "terseLabel": "Percentage of R&amp;D staff on site"
       }
      }
     },
     "localname": "ResearchAndDevelopmentStaffOnSitePercentage",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xcur_RetainedEarningsAccumulatedDeficitInceptiontoDate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Retained Earnings (Accumulated Deficit), Inception to Date",
        "label": "Retained Earnings (Accumulated Deficit), Inception to Date",
        "terseLabel": "Accumulated deficit generated, since inception"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficitInceptiontoDate",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/DescriptionofBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_RevenueFromContractWithCustomerNetOfCumulativeCatchUpAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Contract With Customer, Net Of Cumulative Catch-Up Adjustment",
        "label": "Revenue From Contract With Customer, Net Of Cumulative Catch-Up Adjustment",
        "terseLabel": "Collaboration revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerNetOfCumulativeCatchUpAdjustment",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Multiple-deliverable Arrangements, Collaboration Agreement, Pre-Clinical Milestone Payment",
        "label": "Revenue Recognition, Multiple-deliverable Arrangements, Collaboration Agreement, Pre-Clinical Milestone Payment",
        "terseLabel": "Pre-clinical milestone payment amount"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsCollaborationAgreementPreClinicalMilestonePayment",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Multiple-deliverable Arrangements, Commercial Milestone Payment",
        "label": "Revenue Recognition, Multiple-deliverable Arrangements, Commercial Milestone Payment",
        "terseLabel": "Commercial milestone payment amount"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsCommercialMilestonePayment",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Multiple-deliverable Arrangements, Development And Regulatory Milestone Payment",
        "label": "Revenue Recognition, Multiple-deliverable Arrangements, Development And Regulatory Milestone Payment",
        "terseLabel": "Development and regulatory milestone payment amount"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsDevelopmentAndRegulatoryMilestonePayment",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Multiple-deliverable Arrangements, Development Milestone Payment",
        "label": "Revenue Recognition, Multiple-deliverable Arrangements, Development Milestone Payment",
        "terseLabel": "Development milestone payment"
       }
      }
     },
     "localname": "RevenueRecognitionMultipledeliverableArrangementsDevelopmentMilestonePayment",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Multiple-deliverable Arrangements, Product Approval and Launch Milestone Payment",
        "label": "Revenue Recognition, Multiple-deliverable Arrangements, Product Approval and Launch Milestone Payment",
        "terseLabel": "Product approval and launch milestone payment"
       }
      }
     },
     "localname": "RevenueRecognitionMultipledeliverableArrangementsProductApprovalandLaunchMilestonePayment",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Multiple-deliverable Arrangements, Sales Milestone Payment",
        "label": "Revenue Recognition, Multiple-deliverable Arrangements, Sales Milestone Payment",
        "terseLabel": "Sales milestone payment"
       }
      }
     },
     "localname": "RevenueRecognitionMultipledeliverableArrangementsSalesMilestonePayment",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/CollaborativeResearchandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Operating Leases, Additional Information",
        "label": "Schedule of Operating Leases, Additional Information [Table Text Block]",
        "terseLabel": "Schedule of Operating Leases, Additional Information"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasesAdditionalInformationTableTextBlock",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Available for Grant",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Available for Grant",
        "terseLabel": "Increase in number of shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount",
        "terseLabel": "Maximum contribution amount"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Allowable Under The Plan",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Allowable Under The Plan",
        "terseLabel": "Number of additional shares allowable annually under the plan (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAllowableUnderThePlan",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Of Common Stock Issuable Upon Vesting",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Of Common Stock Issuable Upon Vesting",
        "terseLabel": "Number of shares issued for each vested restricted stock unit (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfCommonStockIssuableUponVesting",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "xcur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period",
        "terseLabel": "Offering period duration"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate",
        "terseLabel": "Forfeiture rate"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationAssumptionsUsedforFairValueMeasurementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Percentage of Common Stock Outstanding",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Percentage of Common Stock Outstanding",
        "terseLabel": "Number of additional shares authorized, percentage of common stock outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPercentageofCommonStockOutstanding",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xcur_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Potential Maximum Additional Shares",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized, Potential Maximum Additional Shares",
        "terseLabel": "Number of additional shares authorized, potential maximum additional shares (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofAdditionalSharesAuthorizedPotentialMaximumAdditionalShares",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/EquityBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "xcur_SupplementalBalanceSheetInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental Balance Sheet Information [Abstract]",
        "label": "Supplemental Balance Sheet Information [Abstract]",
        "terseLabel": "Supplemental Balance Sheet Information [Abstract]"
       }
      }
     },
     "localname": "SupplementalBalanceSheetInformationAbstract",
     "nsuri": "http://www.exicuretx.com/20210930",
     "xbrltype": "stringItemType"
    },
    "xcur_WarrantLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Liability [Member]",
        "label": "Warrant Liability [Member]",
        "terseLabel": "Warrant Liability"
       }
      }
     },
     "localname": "WarrantLiabilityMember",
     "nsuri": "http://www.exicuretx.com/20210930",
     "presentation": [
      "http://www.exicuretx.com/role/FairValueMeasurementsReconciliationofLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "321",
   "URI": "http://asc.fasb.org/topic&trid=75115024"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "http://asc.fasb.org/topic&trid=2196965"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "325",
   "URI": "http://asc.fasb.org/topic&trid=2197064"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r559": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r560": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r561": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r562": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r563": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r564": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r565": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r566": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r567": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r568": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r569": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r570": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r571": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r572": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r573": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.20)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114868883&loc=SL114871943-224233"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>90
<FILENAME>0001698530-21-000105-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001698530-21-000105-xbrl.zip
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MO""\"-GIFX]]]#$7+LKNJU(4XQR9YGO&ZUH( _V7\^&'P9+$0[,%6+1I&[<
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M 8Y6;'!S>ST\N450!_SK\PD[E6BB/@[ZI\L:4.R_J.NE>8MC7.H+R^&OKY
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M7F.:#UQ/C"[HTO>$#AT_PC;<0BD661]T%J4"F&!X&N[$N[ 3+ZW,^F8$[!L
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MGL>8RD\R!8J"2W;61"4L]</L6F?4.\U&UC#01*N.<(@.>YY42[V:;?+8=(V
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MB)Z2,5>E<V86TDON3[@&CSFD[I)EL.O[=SYTK04S%ELS^R'KLR3FGBMF,H6
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MH;H9D8B;M05]/,T47>8X^SLWB\@PK3-$7?LVIC [6O)4*!9G"1TO]RE8UJ,
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M<!@X_#BQ6<E1XU!')R'^Y8HQO4#+4_ZRC:\%\U4VOOZM"1M>0RZXP^8PCI6
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MM,Z5[+ CB@XHS;&$(\395,^XD"Y<.N5;7[<YIH>0*4XIO8@_B<2=!\-$;81
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MK[,,C8-.=!-<M8$YY#RD),3:&D>0E\B+4^L]U)/D@0Z.XW^IF96FHY+$JL<
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MS$(/P0N+3.@*>6="\(8(HCX  JK4K6,KW?64K6-.ZG279Z7"+^MX!)P61;S
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M7[E=0U;S0V^R1<7M^+GG:GNLNG.L/%2;/WHDWQT9_)D>-$$J.*-.^3MO^CD
M+*R]=$N.*=^ORK+_!&SL>AGXHY_#;=)D>-QVQN[8>TFP-Z+(QHA&-0?=C2)
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MM[H@7BB$6JAR1/5EWE/,T7$!?"&_TY,6:6P*0VTS_M"=UAX8+ELC_/!P"?F
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MJ3<KA]%,13H8S+$,JNGA>'2WLOZALKYAC=RNPJ;V202C+L=<""(YNED$3[N
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M(H41#I0WD7&=?C@Y_WAI;H,HW*^?WF%QQU\^_XY5'LGIR=?+LW>$\@79B-?
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M/0-A)X [F[5N8%UG/X_Z>W'^E^APO+&(HT.VV4R5,X7V6"_)RU+=%M*7;[1
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M; P!@LA_U=]C;%/&_\8L23X7@)S3CZZAOLR$1GM.18@UYH*J/]W50#C04>;
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M[FKDK'6OJP8AI?"%G]'RL*J$7/+F/TS,>K><I?<;Z]+'M76/NYO5.B)%VEZ
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M3)2#C_4W:2$,H&^F,S1L.(6%< Y'G51\'CRI5 ; 8&I8[P3%B H22'"O88$
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M;?)Z._9M8%8(DJ5?"$PNADN@I1G=8\L:+)<F1!?>=8H].SGKF,RB^Q"FF%Q
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M8:K/.3]0,\9C_;QA^:L($I7#E#0>HT 4%9TT)MHDE;9NZ<P/T)IDL$^9-.Z
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M$N3)_/9Z%Y$<\? 4]_JKX6<OHU)/C #ZZQSE+Y0EH+9]>8L^(X"K G6U*9=
MJ*? 8&Z.6</E3B@*1C_!N:;%0853/"HJ3K=9&,,<Y (L0KU5P(U/9I48)&PT
MB4W"DYT@HH&9D:#M!=$W#9A7PN0*@R3+XN(,NYF#AW;?P[7?S7P\K&+R,%%=
M!6*K3U\J?;U>5/;R^N+V,9#=2?^E('8/X:L>G_7#M];YUG?NH]%CTIUZ*^Y
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M#75N,/C[ED>J^O7(3<LC.PM#'-F-AR^(V_DM1G<Z[>;?-1$ TII:+.4N//"
MQS#N7J<A1#Z@B]E=I'AUW2/R#+T&(ND8LQ%CXCXB$FG':A^?F3<INF1:!?4.
ML9_4.L+>NAZPF_%YU+XO,1$8G#+>-\=;I(P;R@/T&)7_WK8:IZW^ULFT;CPB
M,')JFCJO+)R" ?KS*:*S_N<G']-J_^K;K=\74]#^L5/YJ. H=1;?-C%I.J=@
M2/ST\-@&U';\,2W9ZQ!"]7GF^(=K['H3P2$'0?7YO&&]MXG"^*9A_19%KO7A
MUS,XDJKCE5\)\15CH,_*9[PQ,?8UPW-N/ ;D7N (+W1+HM>?7Y2<I.$ZIV1&
M#D]ZPLPR/.W#[.K\%4(HV-#<I336+$T73$)&"IS^N;^_;S$*"O-;])'PSB3T
M2]+O#$YZ37CQ9KM],FB>;)QU.37)BW?YX&ZCU^]Y;-\C^9OUO@&'. '3Y->&
M]2E+0WMN7;20Q0^5&&;%->Y'63H+Y*OU\5!3QZY")F-A)^R(C\$8<16+$+7&
M&]MQ['.&EEOZ(FT0MD*([S#PR5'%W1 #OT89P9'!,(")2-'N!B5^P_;!"PWQ
M$3G0&9(<Z/;;?,R[@TZS.QSNKPP0GD)F9]2B0#--YF*!?E[X/OWW%B9BU!L.
M3CN#7KM[V@5Q..S]?.?;_Z=WX<^R\7^,QVT0'1O+C"=K^_5";>N(C]'&W:&?
MN!^?+3J(1%&OO-=&3]YK.G+8\CC1GW[3NRT$):]_@'N"6Q7P!W#@3ND'00<T
MP?V)T.M+FI_R[$'SPD[MYJTP!L,F>NW)V+'Y-R#LS6C2Q$:5GW4^N(EF]\QK
MGK/@;UZSX&_>DN"GR1:X6LM.%M]>NU1^G2/:V_2(OG+[]M[K;XS>DP]FTFG]
MT7?<4)_&T_;):;MW,NS3;X@QX[/H1LZ_]$DE4L<[5@KCTU$?M(';/!E.^LW^
MR>"T>0J;H^EVG>&@,VA[X_&PM7 GN[B5-N\\OQ4O+_&M:[ 4=0-GZ^*L87V>
MV=_2*+1N&Q;6XP4MZV/1Q6,B=A]LIVD4N)9),JGPR2 *'"\(J-4*M0C(H>PM
MZU:XC+OM-IL_O4[W:'!R,CRFO=1I=T_$Q.RT>^W]M(54 W7Y[]R>MJ)X2G_"
M0!\A(>!G>'/Z+[X]_< O#\:/__M7;PD_=7X>3<83MW<R[IX,>_W3D=T=#D:.
MTW8GMCUPG<[ G;2]4<=N$R'.:\_+JTNDAY<"YBQ=+KPN35PZ^1<B+IUD]NH,
M+2\J*X9;D!6[M,@KXP]H[G%3AP!^X1-&].ER"EG7_#:STZ:?-.VP61)L.VNA
M[%57O7]&,URHJ6B/AH%*M&[3S%U:O\11MK#0&%?YAP^>AY?\4'._C0YI;RAE
MJ2:^'/<4*.BG&!/8"69P.H.-?>K.$-,6>[ .IUM8A\_V./;_[:]:B>N<@)T*
M&?;1PEDGXCOJ4L3W3VZ4M'NCTV:?K+I%'$43-DY^*%FWE9YKUQ]O+AX-VV[]
MG,3(DR&- +0/@!\VU:=\=@2;W\RQ^?#IC[5)MI'*?$,M[*9K26*)QEM?;JUS
M+TPR4)EV^@3?H1QU[B$/[#XLS#925==7[V@U&"UW%2:IGV8,V[@VVV%?Z#XC
MF*6Z3>/H*W$-.-Q" XS*7[-@:75/2)=V]E>7^J&;P+^SUC2ZHT_UF]-O9T'0
M+'VB1,:MB(SF50Y8:7ZRIS6]&->EWSMY!&6QDMGL:3UT'L;('%#U/\"W7@55
MWZ\,ZX"JWQ>JST[[.:@^1S58_)7;]B')UF.1591L_5ZK?5)U@=7'W['WU]Q^
MW350? ]IG=OS=Y<77]Y?/A7EL"'!\U.'=](:'MG'L)F?MU?=RZ_+<S);%]3K
MH+H)!QTCXO($!O>^KKSPD8@F_6NS,WH!DN]U)>2HVQT^EJ=XP=4HGVS>3$]>
MH7859GJ8Y^>:Y\.TOOSVK;:^.$ST8?\>IO7/-ZT'K7;8OGL\K0>M]DH3+;?I
M<2SZ10)RAZC-WD1M>H>HS2%JPU&;YP[;5 ,AKQ_(J2^3/2CZ75'T!SOUH.</
M>OX5]/QPU_1\K9KOUJOY[L[HCK74_*@U.'+75*;MC;3IL&[V"JG\?/8ZV]&\
M3P54_.;''N%'XLS@R/^RF,0XS$],!/K*L_/CK\A!F1R4R=.5R>FN*9-ZI['^
M]+5?Y_0]F]/8:;>Z1Y-G]LT*D_4"-?65UZ\_?65Z][Q!1DXN-8F"(+HGZBPO
MOO,=S[KS0I>;U8RJ$NN)DAMF=W3P00ZQ\KV:UH,V_M&U\5_&D;N$_\S2>?"W
M_P]02P,$%     @ >SQS4PD&(#)@(@  ,/P  !L   !E>&EC=7)E97AH:6)I
M=#$P-"TY,S R,2YH=&WM75MSVT:R?C^_8M:IS4I5%$52E*B+-U6RI&RTZ\@J
M2XG//FT-@2&)& 2X X 4SZ\_W3T7#$#P(MF2X)AY<&P"F&M/7[_N>?N7RP\7
M]_^^O6*C=!RRV]_>O;^^8&_V]O<_'5SL[U_>7[)?[G]]S[K-5IO=2QXE01K$
M$0_W]Z]NWK WHS2=G.[OSV:SYNR@&<OA_OW'?6RJNQ_&<2*:?NJ_^>DM_@)_
M"N[_]#]O_[*WQRYC+QN+*&6>%#P5/LN2(!JR3[Y(/K.]/?W613R9RV X2EFG
MU6FS3['\'$RY>IX&:2A^,NV\W5?_?KM/G;SMQ_[\I[=^,&6!__<W04_T1<_W
M6\(_.>SZK6[_A'=:K7[?/^SUN[V.]Y_#8QCE/KRO/DK2>2C^_F8<1'LC@0,X
M/>E,TK-9X*>CTW:K]=<WQ?>X',*K:3PY;36/X,54/*1[/ R&T2F-'UX?Q#!;
M_;X7A[$\_:%%_YWAD[T!'P?A_/1O]\%8).Q&S-C'>,RCOS426/.]1,A@H%Y,
M@O\3I^TV=$+_G*GA]:"=,(B$&>XQ#O'J813T@Y2U6\WNVWU\O6*.2X8*2RA_
M6OI1><+P43 >,AZFL-AC/A3_:?'F'Y/A&Y9(;^$GU88>Z<')Y.%,M]>/TS0>
MGQ["Y*9"IH''0STT&J5Z;':A=SQYV'Q=SV7 PV6KV2FM9K=J-7_\H7W4.EO\
MTRQ2RONA,"/IQ](7<@\&%/))(D[-7\[\()F$?'X:1-0!??24Z1^UFH?=+M)A
M"ON4^J9CO3A-(M']U%]\=G+</&DM?]QJMNVS?6I;M0\S2"8\^ON; [N#$^[[
M<&I/.Y,'UBY2?2@&BY.()\5CH[_?([J#CD]>X^24][K=P;7I= ]:[*;)?N%A
M@NSI+FTV6#<=L9^!K<G-SD4+-[*><VP?PAPO1K YP[C!KM^SH]91>SF/J/$D
M;D<__G!X?,:.N[V]H][!7ALX88/]S!_RGP\/C_:.NNUV<7HY@>_3(;2_F\D_
MF@_B?C^>>Q:H!(_-Z6&S.WG&Y:063X,4]L[;A$H^W/Q\?7EU<W]]_GYA1IO,
M=G%N+NW\D25I,)B_$O7\,POG[  (!O6+/]WLSF&' \[>__A#IWMT-AB$0C;8
M[:AYV=QT.@>++*QS<M!L']9IFE</PLO28"K892"%E\8PR_,DB6'NJ6"W,I[&
M2<H&L637411/.2JPC$<^]?\[*(^9%$F#?LD_^SWP\%N1!#ZJJ?CU1Y$(+KT1
MNXEE.IH)$ PR8K]%T+,$M7C^J$6MS>JUCULM=C<2$EIBYU,19>+;G,C5%#Y.
MXTC+,SC13SK0!>;<WI2E%U;FH-<\/'Q.%KYR'3X*)?K,6%_6\, Q*)KPA1=+
M.FRG603*,+[UYJ<[.$_L?"B%(/,OC=F//QQW.JVSPJ&R+R3TM'W&@@C.7ZC.
M+GQT#;ITQ.ZR/K X$27+2?:+)727]O)%)?3*[;T$'L0N9;/ UFG'-UN#)U%T
MI20X+INZ^ORKGX((&>?IP=$K'H2!D"("/AXD#!B<Z,_9F /Y ?VD(YXR#^P3
M#H3U7M&00Y9B, !!@B*%)RP>L%_YG'5ZJ":TNPW\C<-K/M@%0(W_S"+!VFUZ
M>*SD2CP5X[Z0K'U OYZPG70D#*&_WKD$LP;&GT_S9492O3GZ7.\JN5O8#I"S
M*?F$%O=%FD>P[N?9$.B-M0]IC0^IG?*^70I/[T2'WFJ7-^].3%+UAM[>HT:^
M?4HQ;/>HZ7_R*.-RSMIZ2PL;K=^LU4:WZ[;1L+6"@_KD\40T&!Q&7,*^2&<"
M6/D2G0K)@UV'T&P,ASB*89"QW)O(>!  P<1RHD4,FP5@G',VD4'D!1,>LDG(
MX>0##?31M2@2V/:4'1T<L(N0R\]@T,/:I WF: VZEP8I#\=LIP;;Z*Y*/381
M]^SJ(?! 9X8EB[PF_ 3'+.0S+L43=N2XU3UD[_DX-LIG@]U]CC\'HK@AK5ZO
M%ANBIUZ'O6BR^WKPFB6:6PW6B(T%--) WV6HY$((' 59=)$_:AE$/SOR<;F9
M_#4TJFZ%0M7;0*$Z;)Z\A'%1O=>??KGZ>'5^UW@AZZ)Z=R>93#*NK ?<M24$
MV"@^&('D'TKX3%@.AL)%/'@A\"-0&;0I@:T:5>06E WHYR-VKET$'*10M+?R
MJW]%\6SOEWC&=DC>0;^^&, L?!2!*P:\2QW$\(9D1!$)V\$OXI2'BFQK<-K-
MTJDUJ<$AWP7CYV1#XV=C W"#LWI4[?UX>>NGQB?5$$N@CQ[&>.',Q1-CQR?6
M@K>G!Q0$)/4BG9'-?WMW=</>77^X_>7\XZ_L_?6OU_=7EZA_>/%XPJ,YB^60
M1S \GY''@=H!S81,@:MH&,+Q:K P]LB$ .7C/!G!+#G\^$F*AQ$?@T;CPS9B
MK)!=D:F1/WK_OGW 3G[[N8'J*3;P+YB-'X]KH9>0/Z0.AY&5F?,%1C[[6BEL
ML \3ZWY=,.\:S#?&'7Z)_R"[/1XTK)V0<VY?.X'J8G+ESJBZ&5[91*^H4)[R
MF [9;!2 <%)K.(NS$&TQ.$BPM(Y?3; =1WSEIVJ9!%M4F5Y0,WH]9GOSX1.[
M1X;[\X>/5Z^YZ61E$_: %!(P=6&5+&L%NWD:)+#_B>&R2U4G,-K"#'> 7O/@
M$_'?#)UI2>Y^U=J,F**.! UR!LV,@TC9?V#@%UJ'%Q(DKU@R'H9+V+S+/>Y0
M98>&VJVUH[46:>&-G$=H[Q^\# L31,2:0"9A<(=Q:P74@9$7_>-UX!]-D'<A
M6NNDF,Z"!/G(1,(OX9QI=QQ1 BQH<?0-VNB-B4YIO^J5*F;*I!@C%6>1-^+1
M$$5X1%T/,NAF$$M/.$Y .^R"[KTP1B3'?&+ 20+2#M30/3ZA.#EJ%$C:0#$C
M_'W$0?''8:)]"6<$AIXDP);P-9)Z8W,VJN;QE<W*3= $B^RT+LKK2KUQV7EN
M*$<B'&01*1X5@_!BH1C"[LQ9/\[0LSBOIDG-"^C8&R5E $I*/(.65@=2]!B/
MCG%%8P6%/)44EIJ*I>A #>MJY9_P?A*'6;KXR=+]=O\<R5QN#L5>7PK^>8\/
M8(E.>3CC\Z0$3GPBB'&+Z=MB^K:8OBVF[\^$Z:N,[Q^516:W7>WP>35QN,-W
MEW&JHHM3B3;2UHU"17(NH0AK P-H&)8!K4W)3:-B=YJ]M3KVRIZT'"4G#VGZ
M5N])4! K+1PL225HD^?&*RS?P?K@E7:"W==3[XL$WVDU.P>XSFJ?QGRN=]+=
MQIUT).-L.&+C+$R#"<C%-! RV<7M)G7,*+K&R6[M1.4V,+36:[97:OEIK([Y
MSODN.Q\,@A#Q>&0[:-WOF5?MD?A8,F\034 8AM<TV- #FF2P$8Y3%?8 87UF
M&>TJLED =DPP'@L??P>EV9CN8 0-B'',1O :M3?A,D4G D^4]=\7U8TVT)C:
M>;?K^H^ <6CGD]6QD6OXI @G>J?;N\:"1Z.SW3N#[886AN1(2)2?N# OW^U=
M%OQ5-#$8803CE#%7#BL>K>Q@!MRL3*Y+Z7,B@UC:MVU[#NO#F(\S6!4WVNGL
MNDN/YDI VB5"2W'KN*>,T7&0)-I%5[&C*V9.! @&#V=H$L!7N@6S/9537S-9
MCI*#3CV^DO"Q4(ME^S#,O6EXO!8W,=MYV$5Y@_XG&P: R<N H@"P/6 VF<U)
M9]#9?&\09T! G>XN@SYEDB\U.6[P,_+=N(OKN&\TX,!9$KWR\UVF3ZD=B7[7
MBR=SNV?*.PHKO&'K])/R*N#YV#EH[3(?S"]&MIARC5D\DJ\/BJ*.W.4$??T!
MK^ D84&3."*:D,+GBEO"!JB%M4_!OA5A(*:PRGP"\X)%PK;1W1>/)_"81@IG
M;$#093"1 AB=L^>N<V\ 1S[R,-SAN&EPT:!+-%:GN&E H6-N1@-]P@+@*'>;
MH!,4]0EUSJ48QO"O1M%!:'R&:+,3@:@3PU>R*\GN875]=DLL2,'$8(AID&8H
M%#B!Q63@X;;1.PW=CW+4F&U7A(2T![T357K4F:O3-!Q_(4I >,M*P2)3Q2G'
M65KXVAZN8E=:02+-2[/.+'*V$IL:B=!OY$P1 R"2^0(L2N%3;+.N$N\UA1V1
MPN8;H.D!EM_'D^?KO3"J"HB\@GKKQX+09I: 2J1C."N=W0(DV? $#$RU@2&\
M,UBG2^0,A@'H9@8R'AOV^3,,>I+)29P([2A%WY5N'@P 4!>!W&O@H2Z?N!KX
MJ/7NHC>6]B4EGJ'4%N*&LU$\)G94DMEQ[+,!QS=\X<0NX-74QL3@,Y?/HK@N
MT HQWBB56GYSR[RHYY1_MG(+:1&(2>/C8$^K"1A]ZIGVACN2&GEOQ(2?>5RE
M8$.CBA&:@.I.?Y?X;22&7+'N\01'120G-7H^&043I8*$P6=4_,B9'4?58Y%B
MDJ4.GH^,/!'!'("Y$D=LLD^:'8;!6,GVDA30-%NFF^+>*9$D:/LF8%:@ B11
M[J/PPC57X4IL^K?F71.V;@KC)!F*00$,;R4$#\8N5+ ALG$O\3"!R8'@ [&K
M_HJ-IYC./H"^\+@%J1@7)&/E0( 0!"=%1"NU%]!3' 8J;GWG0?L8#V#O@R0?
ME]"^:,&N48V)S/;=2P2CG_M =?"ZI@IM&6F(P5U*ML^E0%H>ZS#;10QJN_0$
MJ%RP[[Z2&@U:)%+)'$EE^)LUP4E[<D6J0AN1$D:2V) R:J)6K=>!=B!8*U;'
MDS2<E_4[/7@+]3"6H:L+(Y$6A3.,R4;U';ZM-+/RC!S525$$O8CRNB]<'4EI
M4!@C D8N/.# "-Z&KJ#7%!4N5T'"'?;4J@840:C4?A0\:\<SXX=W<,PDB7#:
M*D)DU?:J(2,/AT\<I8]TK0Q=R\KXTHZ4:F4<NP^@C=F:$X>;6(KW2O'?+)#J
M73W>0I0?C&U7?=1!WX(*B=TC]BU+1"FH=XX^85!;VYV5ECVU#&=THN=>-LDN
MW"VY=M5.G#C8E;!0,&%'!06+)!2)C>$ANZ+3;<6Q7D[Q0#B^G!!B?#<44P>H
M8KY5*V55!,H8H=<]V*2*Q_:0KS:EE(3'IWP: \.(E!KAQUD?U$/QX(D)F5MY
M,#(1E'>8CE:&5UT1 >UI9JNQ-<(P65Q!_<C9=O-T1YEYB:%AI-$L43'3S5V$
MFK93\BQ$)@R[F9>O^Q6]?'6!BBQS^]7'[]?N-=O'1;^?$8JKN5!1C4H<=\]"
M(X&LY(5).1\DE[P@K'Q*Y-51=1.F'V22#KEMCGA=+"EJC^^C:0Q'>R)R61KR
MF2OJ\:=IG&HG5"KC,/>(Q5(I2J\7_:THR>*1Y^.U F;;&/0V!KV-06]CT-L8
M]#/$H)^NRKS2DB2%J(ZQ05!/*+K<R%LRY21:BPY6K>5&<2Z00:N=H.,EU1'#
M18_N$]RM&]<W>:+Z>/A=J*O$L$!=?35]%090TE>[S3;%J8NP0.]S%,]"X0_%
M N1AN1H+A$?^N"3-HSM@N&@#*/*=*.4:N^<5T@3KC=[<Z=?)PND=*XIY.O*E
MC'-7KG@7ZXZ.JH",$V!&H$^-UD&=3=!7>:Q4X!P].\H18:(*CVXV4/[O/H\^
MRVR2>G-TU'A"T)1=;'V[36[4BR9#9;-WQ@Z.#A\!ROF:_.^PYL1<'W/=PG1*
M84L*-X,!+((I>5VE=JVJ.#M&FAK%R&W#!J(*1"QSTFLL\?3:Q \3QU_?4*'G
MVF1KW3OCO:$UJD$<*\^UT.N,0DRM]QC!$N@7S;$=RT1;PPEB+XE?ED+?2Y$,
MNI?%Q:K-/MYA?8DA4F)]=K'A9BKP#(QK3O9JJ'SH1I\U_BSK4>:%H^>$IRWV
M)L\*=[.S+/3(8/4(DV=B*FN3]DI.<KWG+N1(=[L ["OG>E8J6COD]N9.0/5I
M[>3X,?& @9K$QIMT3JF;J8@+*X)H=[<VA*IJ$YJDU_J0:16LES8H48R]..Y\
MSW)H$Z67DOB9Y "X\KF$%U(9<UV$PVQT 16U3(2HR GE,B*^IXS5T(/ERT;:
M4#P4CY0+9UT(C5:E'FK<A3J022:G.-^5@WVTSM9D[RC>N(B?6EC#1@E F$-9
M*(;/DR0;5W +W&6,NJ&UTP]"D-L*8;(Q@VB4. 1L!%5K1R:F)S?!F+%&QJSA
M'OT\7KPAY'(MS@PCT]2K%T_L$)S9EV)DU4RG1#YJSQ$#I)5J$[A$)X999>H/
M>Z!(+"]8B^OZ7SUG%2AWL6PX%(IQZYUTH*-N^SLYI,]-;=RMVC4ZCI8>BF%K
MX9*(@Q+0,$_,O(39.0!M'<G.(T$F6OX5)^&$B1K%*+C&[<3H^PYTEG$493RT
ML/0!N:U($JGC$H(FY2/NUI.9 MWUL<)  DTE@Z!(J1:):@+]R\[^RI-N(L )
M_TS+:WD:2"Y$>- NX"DV-+[9"2[PA0F?E[,FYQ5+H1:"@G7(])4-H0L 0!.D
MJY>UQ"*._[#9-1,N55.*W9<.D([S][HNB2LP[#C.(@..!'UU3Q*8IL^3O!0$
M<O ]F*JD*'Y&-?=*6285[$6-E]3EZBU1BZ!GK6..MD$"YQ57DA;I,>9.2719
M/'?%?DQXX @CPQQ<#& _ET7DDP#"C:4"$I#[ZBMN3,E:A(WQ0$$-5"B*#Q%L
MA?HK5DYF,I[SD"AR&=U4BMA%EMMDYTEU/<!"T3FSNTXJ=A07C\=\ 6I29C"6
M"Q,%*!:P$K=MMVZIEO+2Z4Q'*A!49\])?5PG.=)AH69%D0A)OUQ3@2#)X2U%
MN+DN4(#U".8+,FZLD*!<\6AK>5GHFP,M6J<:]#,'T$S0Q%#I@3["0_'"E]9?
MK69F^R)*EQK1M$4YF C'P1;EL$4Y;%$.6Y3#%N7P*BB'I7K,*ZV)Q1*6U=@U
M#@.R%ZHE;CQ3XGG1XU+M[KBCA#.1[L6#@;(!<W&_:/7:;"2W<"BIIIC=:P+A
M>4R 5.9U*@9\H;&3J.N 7I+.OP!5L9FN^A5A%756CFN,J[CB-MU;Q_^$1!@^
M!:@]GBFW*MKIZG=3*(LL(Q//X)ZIE:OS)%1>+?WBBQ!+N^<?*:+-8<'J+7VK
M8])0"<C& 84C"S3&N)#K\=\,SFBQ]!V7"//7 "7*.E70Y>4Y=OW=<MF[O%ZB
M,_:Y.6]H!$LU3LK8-(,VXRGEW0@,Q*&Q7@C9E.V/3?'R"W6^OG)QV[H>'F59
M>O4Q+(\5&&(9ON2HV5GC%BP7.7/ 2SG/CB/*^V8<B!,)JP!XE^@FZPLX; /7
M:5N65S8_:077UW70P7;-PC3/5Z5N3985G&HT4LG%4ABZD]:4XK6NIH+ TKR>
MQP0A"MXAMPIL$0Q1'%"Q6I^2I+:^2+!K.8<3D+#!171OFR_T E25,SEN'NZ(
MW37+FB[D.NW@+658:2.'1E0%H%3K)"PV"/F;UC&7*]';2; B!<D4"Z-(1)B[
MKCD"#7PQ$72^=7HG>1DSE<XW".28<B7=-$;BOUX\5'67+?T/2NG,.1G5A,/5
M%G:I.)Q?'PYG('2?2CY5D_5WO&EY5F0@NAKQNE(,"A.<9^:L2#A"MY?AAO;P
MZKHG97K7RC&%/.@8EW)HR_6QH!D$Q@P-"U79L1)E_R.FC_H#WD,(0G^\UY_O
MZ;]BB -O-R'#@7"KUO^L$0U79CJ7)O.<CI'^O@1,)(F!3,T&[?2RZ0 'J%9T
M1XO67D!+RU1X+<EH2RG=;X 19V$RC?$]T]K=S;FY#J'L7'<'1??Z8!B'')$3
M&<"A#M"8@K,M;*[J/?T+QU^<D&)6QM5>T36B=I&I"ZK_JB.SNE2*PKT9M...
MF]E,VAHLKKX0#/=D8CR5E!8>)$DFG,^U ;4G'KCQ]B.JAE":54NLT'=4D>3&
MEHBXY1*D.9^,V/7O9@*8DAX, D_'*YWZ2A2]TS"[HLH[MS \Q=)S)(PM)I&W
MN%@@G1K&9%XB]_PG*Q>3.-3"4;F6S4A0V.N@"2KZY%\>""14&\>J6GD,I$I=
MZ;] 4?KM2O(IOIB2](UGE+JOW?*1_2U"< -5^@6Y)!%.HD2R>:[8@5';=:)?
MD_V&C*?(2+3\KU0;_H@U>;DS-4J9TX(MVH,R5PW+C'E;MZ6R;@LI/NZJJJN]
MJ+Q%1'6<77+I4]6YU-$0+V4V!)Z!I^P"S@6P%;O9^I0A8)$22<QE5.<8JNE8
MT+,W:K(3"WUNM569G=+S!M5#@+_]KM\T[Q\>P@\'QPB:;GD> =P"!9?"]/*8
MD#_H,IGR$ <3\AFQCGP"[P)8[6'@)4MFX=Q3"P/?J(.%F"VM+](P=FJ]1XZ*
M_@+5BYIEE*GF*Q4Z=D&I3D#O[=!*'.>Q[!7H14TUJF?B4#O%2E4*[9*KVDL$
M69EA!29*K%@LG()EAH<RY:F*AX"-95)KQU3SS"DS@S*<[@]RZ-R <<K#6X0]
MY5;!P5JEPXU+\C")%\V@ADL-94WIZQ)" [V9:2C62(Y^H6[&CH/U6>"[)+/\
M(/&D4'(OOU^F4&[$ [,G0J-*CQS%?%XN@E9B@0JH$@;5$%?#(U7&P=QR]@\L
M@0/;?*L>[AI-#/@.K%@LY[M;YK^L:!>1 %%##L'!\B/!6!F+^!Q%*:E@6"-1
M(3ITEDP03>-PJE_COBF6N%,LW),_('/5U6JI"5@TGQI%KJS/HNYHMWQQA:UJ
M:098K#(D"[@2I+*\@D>>V;@-MQO'=W<;;M^&V[?A]FVX?1MN?^YP^V,<GZ^T
M(KHPGJ/[+D'JE@H4*J%\L4N27GGTULAUNDIS-D*U406UT;.R:[Q<[D6?A42B
M-3=V*L,QQ^2Z%UP7K"T53J1KDQ9JDR[423"5[=S2I=H?\TC[R[4"/@LQ66[
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MB7U2C+_V"H2Q51=W;PM&V#[['IYMP0BO"$;8[\?^'/XW2L?A3_\/4$L#!!0
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M8 A,A<"08R?'3DI'8 @,@2$P%0)#CIT<.RD=@2$P!(; 5 @,.79R[*1T!(;
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ML3")XH3#R+5BEXDOV%Z]L=[=6&_4-^!&ER>Q8/"@C!FH6)^MRPT6*,T&'("
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M%D6JA1)UD2M)]_PRK>GTPS[&SFL%SI^0<2\;/&'%L?)0+MT!O;V;>-1&5=H
M;?^YD.H%9M[]U>*6MY)KD];?:E8FOM,=QTNLF=QXS_F0_X'0^@]3> (2J/WF
ME)<IG6S;:]CF,[X1#N^FS_X+4$L#!!0    ( 'L\<U,7*3^2B0<  )4>   ;
M    97AI8W5R965X:&EB:70S,3(M.3,P,C$N:'1MW5EM;]LX$OY^OX+KXKH)
MX#<Y=I,X:8 V27$!]MINSH?B/AUHB;*(4**6I.SX?OT]',JV$CM;%WMWK2]
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M?(JDK=SVE.]3Y=BNMZ3U9WAA2Z^.K_X-4$L#!!0    ( 'L\<U,@NHZ< @8
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M @)WHC;PY $:% *:1,H[BYGV46GJ0$OS-! ,4!6+!]"9L(&G$!-O,5B]*9$
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MP[."R\%3Z905%"G)</1&1&*)=Y9+Q 2>A]B0Q<+E.=2+9P67K2O+RF"/>#J
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M(-!2[9B""(L*M(S(&0J6&1Z50C9XH9FGT6/FYPJ!WF7&9BU8W.N6Z=8I4>>
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MQA]?MM_^A7;>?N '<,_A9WC6_M'9]H:#M<*UKQ^N^Y0_[W[\ ,_:2FL[.]R
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ME20:9YXPKF</@4VK(4M$Z/+<M+YVT::LZ[/I>B5R1 ,C2"E@0S)@%$- "B]
M<KD"MDA!$>84.<H*OS0*7^,@35;]V51_''#Q(FA'HUB<<P2D0UQ 0T* 0=)'
MQ%;((C-[P"5K_=)H?>UB&UG79]/U<9S"$F.B;BM /$]-=(4 FF (E#7:1$RV
M&)MYQ2D6I?&K4)>T?^Y3U5'G<\/_.$_G-/L/J_6[+T%4OD=][I&#= >^[W7/
MGA2GTES<!$Z[YRE>/5*&%6-17FSL;:K]N9339L=MCZ6T4PHI;]K3;-KM2AS.
M6V8$Q0C P#F@2$I@B P .8I-T))Q-MRT6>[O](R5>=$QM:S,<U/F<: -"4(@
MPA@(9 V@ D<+7$$'D&=>D$ 13-W:5!.1.K5ZRKH\9UV>0[0LZ_+3Z/(X<N9H
M%*'%*50>/* X<* U<8 X%Y22$)&0$F2BR?AD5X.LS,]&F1<=!<O*/#=E'H?&
M-,-&4AZ5F2H,**,&2)QJIZ61&F(KI$MA<-S$N$[*O K1K[NC Z]]Q_?T:1$<
MT.ZLW6GW![VBP&VF^,!]RRZ7&KD6&Q\82BH"U^8U.67L>@!V50^K<2HU8D0#
M0W T1#QFP 1F@(%!0DHH-ZD="VXJ.G. H'Z%TUF;GR9 D+5YKMH\#A$PAKU4
M@0%H<>J6)AA0J;;8>D&0%0(9ZXM:'#PSOVK6YOIJ\V)#!%F;YZK-XR !9Q@'
M9UA49., E21U=X\>!C?<1;7&)G"[MB&;BN2]^1EK\V)C!%F;YZK-XR@!BF L
M.70@*(VC2C,+#.,(0$Z\BWH=A2G6-D03XSII<RXAN,\YG^Y$D4T^\K,$486K
MVJ@AN.7RP&G0;;]ZXL<BK32E'D0W4@&J,07&.0.<DD83X3$E9&T#J2:%<V[M
MD N"GX?J+S8$D55_1M4?!QTTD1Y2Y.,*8A)03S4PRGK /(F^)U,F4!Y5'S49
M7YK*X*SZSS=>D55_1M4?1R@H9I11X8 2/C5SCQN^]A8!B[T5U&FON5S;H+Q)
MU;QJDK+J/RO57VQP(ZO^C*I/*F1+(>"(V0 I'@"%6H/4ZQ1 C3B.JUI8)=8V
M<#3XZ=*H_BI41(S/ YUV^P\+4PR?^KFAUA(PDUP);[=CNV?^391@1K!I$.RP
M$K)0S,*XZ7 0A8,!Y5X"#0T"02#)(/-4X81@I GE'/CB:F.WS#'OLLH(,(=P
M14: )T& 2N3"*DJ%-\![SP&EE@*EHL L4HP$%21#K#A1@2<[?&< 6'$ >"+6
MD@P ,P- )7Z!J/.$:>"XC " )0/&F?A/$Y#AS,'HF*YMT(@ ,"- 1H#YQRXR
M CP) E3I5R%7.M5)"L@ =1H"B1@'#!-#I&$*JI2\P$TE^!(@P"J4:^P/3GRO
M\8]AI<4_&^U"#9J-CA_,U,:L+OVU\CWN<8]5"-7=77FTW?[6=K[CANL_GU1Z
MQ%C=]0UXM_/-E[3GY0X\DD3>A:<A02]WX#(<M_G):4HTM@) 9 *@E@E@F)%
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MR!3%#9Y"QZ"GF./'KSC)0)>!KN9 ]U3'AC+0S0!TE?@8%12AE#J'P:?X&/?
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MS<$R["U$#&EHB:+2$*DP,9X)2@(BE.I[F,N9WKD&%O3.8'\<5J(,<ZD3%Y9
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MOQOF\Y7+>65> "M^95X *WYE7@ K?F5> "M^95X *WYE7@ K?F5> "M^95X
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M#&]:#7UB"O#'19K: ?+]#T%/_?Q+BK"3)YT?!J^KQ$*Y* 3]>86@UD$GH+*
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M'@8+A<200K_D;/D9.#-P+CEP0JR9LAXK82FF1A&A&.=4,J5E=*=O!\Y,%;A
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MR1B,!8BQ*/1(+!C72FG-! -EL1=AO0A[8B)LHX9QGA]%D9<!.[!$!"),(YK
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M#*58?W;V5-=374]USX'J'M+UU&ML6Z:Q+7FJDDQ07U-&L'**L% E1$1Q0%C
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M\:^Z_<U@.D$M$HTY-/^ ZO2L7DJT"P>SRRF.9G0)[U0@#4I7Z'+=*[OK \0
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M]DN14"[.@/,KE+]3[FAA#/2NBOGI@$^G<)!;S:62!P='^Y5 ('H,=G<7-62
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M/4\RBW*EC_K:Q*T%A[\7B4"+($M!560J"I/8AP>H+$J5!SKE=6Z]!SH$,'&
M8-S1:1<8^G;9 OFXK4DV1E39LJ+*EE[S"]Z1S4TVD%4\2M \5CHL_&TSDMN^
MHB8&-C N;%25'*SZP%E2\-.H<&W7YL.X+Y3&S<O'E;YZG?([+ROUT>F@M2*)
MQC=<,I =W8O7KH%*H>O:&I_GZM2H9L;=B,:)4>==Z<VDU"T;I4ZKX)U'Y* O
MP_@FX[:ZC(^;H;_R=(7F;$96.0L.IJ4>K]48)S=SY*#B/!ST[IP[=><LBX.M
M]+=NN@''_SG8)S3=V*>\)1[D V-?3R=(*<Y$K5)^ZJF9%*3S7"ZG)V$BVKA*
MS3"GGV5US$_CUN@\!QO1=*-4&MG<RAN7:6FS-G.3KV2MP8K[;1K=T@BJQ-8J
M]V,X*.=([BB.SI%!T6E@XJ5.5 \'&4?<\YD-EL!R@0&#S%#G/!:3^0QM>3!*
MS^?C*D6J-48-QNKDTIG]==()IC[IP@56;-*J29-"L8@R9#Y5O%5SN)AI*2:\
M4#A-!3)4SB8@B]NIQK_CUZUDS?UK7$)60-K<(W.5JH3^65XZ_/;N[G7VRZ;,
M:&=YUZM>3DS\"O-X74NITWFN3 J:G3>20!.W=D]QV;,F4^B;D?7PW5IOZGB.
M;HT%AZID.@ET*B,59(Q*P3T:Q;%'@S@$58IGUSA4_8ZGM!**>V.UWZ3DOI_Q
M+#L>O\]G^JTN4#,$PJA=H,1_9CY0,%+\P]-/J91>((0D+*8!831E)$TE)SH*
MO3!,*8T#[/.V IGH_ZNR7-_]7WX^_6T?HYY9!OP*TFBFU^0;3S##U#*6(R.K
M.+A44G>JS30_-VZG43FI&=P]>'O([-C,!8CLGW8F\-M>9QX]Q2U0W $[NO@4
M!3[W(AJ1+(HI-A%/$0TK(6$"YUX<2.5[<F<W7$-P1B#"<?AR)7FMR\8W_F.D
MJ?%&2?-(@]79: /U Z%/X<@^.-IO\F>K_.%VPJSQ7*. 1<_M@OO>4'4CC8NV
M"M<>="O+T<A7Y+6N<HZU!$!Z<.99)?CW?#(%V_L<-,%SDZE0Y_WBU_6L\$5.
M(;8E+^XJ^UGK$/K7Y *]R\-!ONYT[APJ<!J40/QF(6"1@.NLG]QJ?V;W8.<6
M3Z7YR':T@WW!Z$/EVFU;"' >%?.IM3?A/68AUF65MU<07V?.KLIW?F'>QA6Z
MS%%Z '^B:=15,)H\#DST<)GDUB:V>?!-NJF18\7D G8'2,RXW:]0<C>LQ]P"
MU7CSDHBJO '# "8FNUZQ*\RZ._T/":G(Q7QFU470.?BE>YIEN6MB9%Y')U4V
M8=[4,& C'%1<1EFM.^56I]3C MC)"H@1=]NY4-%BCAPXV8H9F4_+VNBT)3"^
M*8ZP*?NE84CSL9OR^C*9S,U]39U-?;436]:+4E=QV,?#H^TB#0>F"2ZJHHYU
MW.(9+KQL^W#F0-@ST)*G5:#FFAT:=UFM(U%QP;JL/)Y<&$8VD?B)TT%-+1<F
M;]<VA]$[*Y%S_.Y=+99:++:N &F\9DM]D^@YG4[*)NXVQ>#09%Z.+IMV1EE>
M@'QJW_@2"T;6$E5W@CD&L<Y-/N=PV02R5L.PO=ZU)81"R\4G+7,TE =OJDJF
MABY;K&-6F 0OWHJ9=K:D(=*R%18&"37&%;G0(\RFK]Y=\8]5C<PZKWJ.8;JZ
MV@6E9.%L.YOF9E@ *YGL/9.&YZN%0D=/M39F:<QTF](P,Z3</1TI:8P51,UQ
MLT"VCIZM:]+XH#IO@Q=4E#\R]5?Z"KJMC@0SC=5DYHYK<WS-\.GV[+B)%)L4
M-5<MKH&[8J5I6!\]:X=MX2=/,<<#*T-=C-7=,"FF$\-5G0)$\=D&@4MG*NK!
M5P24QVVWI9/%%SUK1!$8PQ,\0B;RBPVS*HUR!86 <^*TGNZ(! D#2\=@%^O(
MLFLR,\9"2V&X4%G(3$.\F ,-!B4>](9FD(R,3E!9]0:N9^1\F"#S7?LRT ?@
M25RM%5;#]C;@$-P^#%W1&\:J3::,F7]#6\XS96P9QZ&E?5W^I4F];CBF?K&T
ME;E5@>;$.<3-NYNQ8C765PZ,,FX$[=>\F..=!8?UK$%%49\8&OF#,MKH+$O6
M^- >,$@*!'D</BH7G!2C"4J<BD^J'-05^>--2;'Q=A=Y56?<'-Y /.:AN&+.
MVV_=/Z>CB3"\:PL1ZVTWU:G6&V'K;1N!-C3[CU52F(5JJQN&*][5]?M^Y5)B
MRJH)RAB)82EZ[8S 6!RI"Z PQ\1VI ,\,";(KN5H<J$F%^[5U=G4Z)?X4G?/
MF>:CV9E$&B\ORYD^;QC)KEM1^_^Z:16\-!M7T_PZS1E54><.;TJ?K&KJ%J7R
MB:\7&+?55=<7W&V)DKFVG!,D1SDW,L[XLRPEP\F.1X C!KM!.%,T)"K+0;11
M(? #ET)G#JIO6L[1C]9U.IHSRG(VFO;:U"\VQ^LZ0G RU>6_\''>4&X7-0"6
M>0Y/=G4A:PW"9C.'US'6#6GS5S@F\#N;4%4?+\;%\M5V:W1US"C>F@KQ\K>6
MD@G?BA&R!U9\UH]KRFOGTRD6NH)D,B2):@@V7)S,"VP6B=_FB&, 3\IX/D+I
M564,N04!(IIG'&$&6N/$9?AM@&?)+,\NS4)PB4+/B XLHR8C$P\QQGM+X-NY
M5"-?FE?UV>+IV^<7;9Q?%/;Y17U^T;8EL/3Y15N]/<\GO^C:?*&%_"+NAS36
MD9]E7L*2-!0T9G[DB<CG,M/,MX+P841]G4G<:!N7'?\"F'>83_Q;?92V5#7T
M@!2H#LTJ/[L>G[GPHS'J8(U'6. Q;Q"$+@<&VG;M ZWZ@$^H0I.(A8$2K*7F
MM(VD)>00ZT2JG !7!<F7_,GEE4I[U4IB644WV=;H-S 1@AH>IK(%LH%=<V/W
MH5)T65F45]HC3\D?O6$%X#_MAMG _59.Z.I:OUF5T(_N2Y/D8+P574-(HUO'
M&, 79]H0PLP"=Q2Z,0J-NHM)5)7KIN!@H9M"TQFWJ#8(.0VJKG!()DOTVS*3
M:K^6 1>R;.'2(ZJ.\0B-=(F@1$:I:S(4:E_AZG)]&'->EO-%0*&\6TYP;M"0
M*G]3RU&8E\X!4F+(*I]5>#6Z7#%5_2TO9Y49B*] EQ4*D:_60!*7*]?!A@H,
M_HYS-+K@077G3UC5[4R<NJY0=3WRPG)>D<T&,!@(8RQ;MO5L6!NEP7;/C?C[
MKWMI?K)Q8=X[C72HU6M>&(_<7C/Z?3OX@S%J,3#BV63_.=?='>^_#@___*1D
MQGS&4A*$04!8I",B,DV)9HS&*I4T%B&8CW$X].)T*0T '0C2>!;MFEJ-H8D[
MY=@<LA,^QB_'I7,*C?5I51U:=6"JHWKP4Y=:&SW!.KU?(FZHA5=<Q;U5&\I)
M79S?!!*->#$:B$M@D7R*)Q<ZOI<KQZI*J\:/7DESDY/KWC/*00@JE!?&_84)
M*+D+4F3S!22DKT[LCH$G!K,+/?I:EZ]EQ>1\(6G,REU;_U?%%S<!R^^$*(?N
M",I7B5TK"W%6-Y1]2]!R8^,>.L]GIJV6\2.5"V[]UEK700;KP&N-IW6]FY/1
M%VV)V5AKM70(U N-8K]9[$<HG@_KO,@EH,]Z"0P?H'-5+!ZTN 8VFF@3$/%L
M1HT?8\^PQ?5J@DJ[+IU\6/E2$5K/Y;&<Y5/+.RW/75%@/KF[95+!@G8_KH)'
MN"LNL.RT#!?EFH *C8[!"O6LR@>:S@LD^EGE&W;SP(B+24;H#-F:$K\?'@]>
M.>HZ-$\O@3J*Z<MAAS@6)$/E@*^-@,J1_+*)>EJ> 8EER&^"OMIY83C2;(R=
MY%4DR[_R?&0V#5YEDG;J3X;5<^U>.HEFX.8L^%"UURUB1Y,H6_2YS\<+5+%V
M6*OR?(21L;*5XX'1"C5'J5,T "5F!=>ZP=WF&1VL-C#KB*@-ULKK$WV:*,BP
MJA)HQZ^%;LVU%D\MGA\LR240-&!7.FA9A]]D?C?*MJJ%4CMM=SH7(PPC.P*M
MH4-+#11DDK_:@?$;)&$5\!*%I>%?)RCQJZ1=/L*09%7;8PL<^)HDJU80K)'U
MEI/*ABA:UZ_, K/;AD'D\IJ4+X[!O=9AP(VO8(4X[^YN=9)WM[?U'&OCU$<!
M&L8NLHSQB*X('[;.5I.1>L.SZ?%)_LV!C4P*2GZ^VF3K@)W9PG<3QJ\IO-IV
M(Z6N6,MF<^%UY].13:8W]>)@[G_G%66VT"$M@H$S!N"KD8/#: 7:QJC$XWOG
MA<W,JMC?JA4KIZ0FQA2LH)ML-DI3_6:C.'CZ3=SXI DD.XJQ260P2L-8U=!J
MA @S?%?E5%:"I_IS];WM:5G8;-Q.JZ0@IR"\<'EF>**]X*LEV&,Q+C=T]7RH
MB?C 4>N;>FL/QM:4>QHX9!4WKF%6D-I&9RC/--+9]5;X-<_KMJUMJ3,;@?6L
MQ4K<> 2X$H4^0_40!,\+C"IC8B!\K!]L2*[D,7?Y4PAI"X>@LQ(KI?)N!E>Y
MNS<;X+*I^T/O+EKHQE9^5L/X,7"\%6>',[0-\K@PD*@N*8R/Q^C_KUZSZGDV
M&. $/S9?</*SJ0$;5EA1!D^X)=2'-9JVE?F3\>BR.CL*76'.M$^!1O36W@.>
M%\UHZDRU!9=!,_ JQG\3)FW%"[IZRQV3U<)[[H1P%D]:#-RUTL_R1CI7#ERK
MGO;9%AME6T1]MD6?;;%MX?P^VV*KM^?Y9%O<+'MBV]!9K!_>]K(UQUE3WG*;
M\WZ5)E>=_+?2)PHSV%HW@@7!W%9CRG[5U@RV;X%)".VB-KI!6S<18U?-5 '@
MN7?02AUR94V5\F#U3Y?&7W_K2A;,\S#1T^+@W2<4^H=2'V<5TF;YS )]MG'"
MZ2<AXD#*("**9REA GMI)YDBBG(><483[;,G G[^P;J7ZAU_G)X&:X?5GJ>U
MB1HKVAE@(X(&(ZBQN>J$C08(R/:E*N?G54VO*2:R/EQKA;AZO=I-UG'[M?UA
MQLM<IWU8!X'!;C)YVVONF2T%/U=GH]1&T?)P'")1%>IU >96D>IBTL[+P: =
M<S-U1B;D5*\*.M*KG);6XCC#M!6GXZ; QP%QZLK@E7DAY^>F5*@JACG+1Z9R
M;VZL6"MYK>]<Y1APJ +!'9BF87OOU,3US',O=UM5XSS9E^/][2%7OE>4OA9;
MK%WLT@G-7UGGLFPKKRMN,<5\E:V*';8Z<UX"(KI^%:Y!Q%]MC=ZL@R[S'E$'
M7?^G=]!M0:\M=!\"7MV2[B'>X2MW@'Y6GP^___GM\/OI]X]__>?\[\]_AG!%
M?O3]  [-HS,X!.$0/83WXGNZ!R@<K-_!F/A^O']T]O=??Y\?[7_Y_M$_" X_
MPZ'IO[XX_ Z'Z/<S>.9_X "%P_GT4ZCCV.<,#DS&&6&4<<)I&A#?]U(/ODK#
MQ%_,$\XR'BHN.)=*LB3T1"9U(KED2F?:ITOG[370=S_0(O?Z$71'3&.5A$D8
MA32AS MHZBN5Q5I1Y<<L]-5U.D&74;;I.%T4:!V4[E:OGPIFT%A:;1^8\7PV
MGM7KNAVY \L:#":?8#:I7)LFM]*Z-^M'YZOE[I[UM;YS%?SCP1LXZ ?4(_]O
M25/7:K6B[L$(1^T*R \OW[\$PZ&*:INQOO[F3I%7F,Y3ENU6A>]?OZJ1 >#C
M0Y,*0)T5 $_*;6)$^Q@WQ]!-%ZO*MVA\T.-)4X?903'<>!]K2]HD*YFHC(:#
MZ=?[M#\<4F4+J'*K^C'=OT3]++WC?1F B<..3KYXAW]^\KTDXIGT0:8FDK @
M]DCB13&1BB<@J+R,^G2IK9M'(\HRQJ,P9II'(O99*"(:A%I':>1M9LT\F.3:
MT+AYMXR_^?CLF]=5H?G@WQSD6W$Y,-*$)B AL9OMQ+1@,TDYB.Y75O"VK4/Q
M/6C7BA<*4[Y4':,W7H>]]Z\&D1=M&UQHM7-&QZU:B#A J:J+R(/"A [F-2[)
MN5E3 V\P<[E9%D\21+OU$7&70F(G@79)U5E N2A:^T0P6[K<W>HQT.H'@\M8
MT]1%JVE$#89KZ@]L=K#=1Y>25]HEFHQ<9=6Y23X[G1B8BZ+NNC T*6#C"G#7
M5H5T.ND _>?*F5@5@%;EM',8PAHW"!M/5">YU0_P)%YZX<O!R:3&*VZFL8CI
MVT[M;&!&7%F)B0U+,/P,8[:6QS4P<6G<(SAM#8H.#J^<Z6GYZPUI(,(((F:>
MC4_)2&>S7X-H@2K( Y(%?;E-TJ6[4-1[&>+"'+B2_(J&#+.VVKTX8OW9,[E:
MZ SV%H;&&RYR=4&&O5[DOQB:1S>SQ11#8+NQ26(USI>U3S&4:]&D2UO&A5G.
MC0IIZQ=M'+QNN(->_E->J$HB+O&0<YR;1G^9-LV#3,Z#7?.\SIBSH8(IO[0>
M.$ST'<)D8#:=73FS_6I@O%8[MLGQ4MN$ +C>3K]A6C,K3.G6==)=*Z,>,S&M
MA&X)#N1I.P^3LE=/I.+L]EQRDY4KS,J*=N%%M:SU\N4F++J8J@D3K@YP*_4Z
M0WDY^,O A\(P:]ARD"F+$.HW?U>=-5(VH^4&[T?;^E?,342DWP;7:^4+FL3A
M>LN:]-BA1;.P=SIX.6Z A:KG#&T6<7F&$T:\)3O6QNIIIUA,K8NQE;^XQ)&/
M6D3ZCTU$KFZ]53M1*UY]8'GY=LTH:TXS^>2U8#'.ADHHJ2XOKQ,&51E#6R L
MD&@C-4S7+#"TJCP)H9&BE2FYDK.A;5[OBG?JNVT-Q!B$\JRI@<+AM$3L0.>V
M[,K6=DXN#/K8;')JJ[&,F'<U*'6Y1:%=%9*5F\Z+8T;2WD8LQ'(J:K50W8%6
M,Z^N6AP:UE/9^ PFO5?K:\O5<#IV7&Y+EBD(]:]647MKN_*J2O8<,^1!H5[4
M&]N[9?2M\SFF^'=EZ:RMWE7E:U<\Z 8;6<5W;K*6+UUE N;\%[EQY-01:; A
MAMV38<UPG#?'Q:1-LC0<D,*4S*SFU*<A-H-'(#;W6VJ(;C<[QF(;J1]80IZL
M&A.R;,T3"W*PJR;5.),7NI:$R-^SD16N70NK$I$&HG^%/%TXV1<X?^7R-4+
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MSU0/<0AM+CO#V6&@(4V*E<[SO&P2^JQGO!4KZ?3<04.JF%6;T4XYK*,%]1X
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MRQ5&!%Y+G&V\$^25FVB;U\35'E3<4=\F*3:'BW.^Y;\TX)0UG=G\Q462LLX
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M*H*3[@9&)5ULQ)O>RDC(BNS56'PPZA8+7 4N1IV4L5-2<=2D+\"6.U0V$W6
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M=\>38WB=$L$4Y!F @595M,X^8DFB[I(*-SV7TENO1*N7G^VU(DK'A3GOWL[
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M-1ANG,#QK8MD>3BT!:K^T23+?QU0)B>G'\XRY@S+ (_A 1Y1KQB23C+DG%&
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M,X=ET#CF_'$KXA\Y,D0PE&<L2*:5S(C;V4_.'?G/0D2L"-!^'?6(O]I031J
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M\MO[+Q_^>7W3AG?"F')0] R4\>KX\)B 0G]N__97B.,\8Y%!,P2#!-:Q44X
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M2S5!5&0:*8DS) ,AV!NK/#@.^V07YT^<;W"_8CR/B&P#<"\'X+Y)<E4#<$\
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M3?CY'1)K&OQ\ ORL7:MY'JP,&%GFP??-L$'*@1<<6RCR7%ACN=[9I[NPA3\
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MAG D)"6(YC$-&P>/2!XXEX)DP<F=?=X48_W .LIB/A[U6"HMJ#!.9KF3F(;
MF6&!TL86^!XZ.K4%../>2.80MB9#E)@<F: P F=+@R4@.=-V9Y\^54"AB1FL
MIV%OQ@/0J?' )U, ?-GX[R9FL!)FG++$>VVQR355V&CFF*'@:9I<@2T@&U/@
MF\/,3$56P"%8QSP208$IP#U%VMD<62,8PQC;3&>13'^+/(XF+/#D<3V)A?'8
M$PPV>\X5V 1*@)$8E')\D[KL1D>?3D>GI@!5.><B]XA+91#%7"%)P!20EA+M
M#6R89UNFHR\C*M ;C@;C0KTZO=;UH&_]\&&VP(MP.;3--<:4Z\QDE#*J.5'>
MYI1+K+*@&EO@.^!,/6$CHW#F&^(04QE#U 2+I.$9RG4@5&1YGDL!.(/E%OD<
M35S@R1,1@E:*82<$I4J QEKIB-8LSYW(G6V,@>^AI+42;)D3G%.)A!,VLK5Z
M9&!#4":$#-101V-?&HR?J@BO"0RLR\ZVO$S@/(K[8^(#CTL&>]98](V*AAN@
M>BJ@JF<=: O.9/ 2\3P/8$UXC& C,^0!HP)8?U[C$-,_V>.[]&VJ*<\H\O""
MM?\;E;PVVO]TVC\U4\!+R)5C'#F",:(JWESDR@,8,"N99L$K%U,B)7]TUXQO
MI?TO(:;QAQ\.?VUI:\=7XZX>>0>:=3T U2E;+KZHT,9/VV:J'$SWY;"V+?#O
MKH__ /PZN.K# GY)/U^);0VL;0)K]<P);HC7),1R\< 0%9HAQ0U'F3$J\]AY
MIE3JE2$68>WG)C[R(VCZ-S%+&DW_/IH^-6 T4YQQC6,P-$>4:8V4MQG".572
MPJ8[JR+5G5A"=?==-/TE!UGJ7 R;F8L-\])76IKM!OQML^Q6 GC;-QB^"8:?
MU)-;&*?$"JH05RG/E>5(&\*0!1\T#WGNM':1<@F+I^IE\APHZ^Z)3C7 V0#G
M#Q"_:X!S8^"L%2+Y'(#2>*1<D(C"UB/M!47,$4N-#B!C+ $G>>+HW;/DJJNQ
M?=%ORF2V2E-)03HT]1N3O:QK#F/%!-VZT</6_]Q J4$@A-!!!TX=]4$J1SC-
ME,5$:(V]*AGUQ RCWEUY O5AUEW:Z.%:.TC>[@^@RP^GVSO]D)WQ0# WEB#-
M*8Z9.13IX!AB01FE!>;:@R%#Y*(VIIW?9(,%RZ03-A>YPI1@+1D8O80S%DBL
M.1!I@[-J@[-F@Q^_P?;S60ZP&F]+D9 N;C#62,'RHA#R$&R>,<G$SCYFBUD=
M\;!LC2X\_&_@?>L*]O)BV/( /ZZU2,*6Q"'NVVYKX(?7'I[QK^_>[FXL)@]B
MUFS$Y!%B<OGVRUD>E#8Z%XAY8A HID+2AAP1@F$+<F&#T3O[DBP1DTTW.(N
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M9RI DZ4=PHEUWNGUXOE4!1L+.YN >(PZL2MF)]G#8=SMUD.2Q:?8;/1"CXJ
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M+*,O2Z>+7 N:.\7#@08-JOR"_?*I5[*P]_.KU]=OASLG )F,&&(1S+X!X@"
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M1+2F]E7_,^S$QJA:\DH=Y/RA=R66>_C5QOXEH!][[@4GVC!%N!1&1VV=%RH
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MDRQSA&DFRI+_M,I!J-Q"C^T6NEG;;W(+D4K?Y]'WL5O(6*D-2PR!J98[%:2
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MW"5/73(LA(7F.3V0@F\<P_(M4;_N!YGIG]O[M0TPK_\ZWJ_]>5@___RM7ML
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MPGHE<"Y_R0E;93/JDCR?WL\1_Y/_SG+=ZIS884A8/N<MQ8-A+[ '*AZ"Y32
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MKP35R:NE3*!^"PE$90O-(K4ZME.F5=B9S?-^]<2C#FJCKKL,YCMT3W(/W_P
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MUGY!7*>"IU<*3UA+0['@S$7/@\'.*:$L\S%YIUE,%3PM,SQ-).ERB8T,#I;
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MZL%8]6"\)8&>IRCAOQ0;SJ62VE*?& ^2!ANDK1P RPM.K<G^ !SKB(5#D<F
MP/3SF6$$Y#1GT5AJ90":0<TJ-0^.6+@%'ZI>3\_?N<U0C+TTTG,25.::L#\Q
M#6](KN8,D*QHQE-K\M@!0#1+/DB&A%,XG_ ;I /WB$7%51)",[N4O9XJ55ZP
M*O,@%.?<8(=A_173P7$?J',\8FLUJ7;F)=;GL0/ !Y[KNBE$L7:(Y]@=PYA%
M@1L2N1)@!U8[\QM09Y>\%M$(ZCWE1B478Z1*),4,:#.M' !+JLEC!P#6U##
M8C#[L8"=V5&4J_\AIE7"*>4NFXMS "Q0E=_8X7_9++#9*TNF5*T!;W-)YO8D
MW@@>#.6 3I9J@56BVA"J95Q,,E4%2X\!2Y.Y5)KKQ*412 ;F$:>1(Q>Y19$$
MB:.F5'D&!&.5B@>7O*\.&)97FY--V!+!*?:.6Y7K"!/EI#;4!$6KH_]E5>2Q
MY8\EX33 ]*= $N(B6J2-]DA('*+UQ"DEE_& H5+E17?Y)%$1*ID25')'/+!.
M$ UCO Y<.1&KC7F)]7EL^0.]"L0SV)B]RSYY)9%-R2%IE86W:#0R51OSJ]=F
M15Q@(3'JG.&!)QN%#DZ[E(0VEL^IS=7&_-2*/-$:T"K&.<]!>)R!X>\3TIH(
M1)4EC&$*FFV7<6-^8R?_I>%_T(4A=7)Z2V$/8L>?%?U+#:BB &[.#!8&"*8@
MQ$EN/35*6TZP@[\CXZ9R!2PM4&V_GW %\& 93=8BQKA&/$:"+",>1:PC\R%9
MPD/9C%CI)?)/5D<-BV8<EC,#RBHT3YQC;4T $U*;J'"@"K.*<2RG(H]= <)*
M%Z2EB&J+$0])(F.80X+Z /AL1?!T&8\:*E5>=$4A*56,.DIJ$Y?86^QH)%YK
MSIRBGE8;\Q+K\]@50*,G4BF.<$P$<<L#<M02!!B-F4\,2YRJC?G5:[/D/L6
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MO.9:_3?!$W,F8<H4]T%8)34G@3$5C!2>?*V5Z@7_16,]N\;++SCX!"^O#_?
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MHI@KN.=)8K!OC%><K4-_PSXV48SEQ423?[X2!JI6KV+Y<L2"7IW;YXO[M$4
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MG"!VET@+X3P+XPFP#68]QXLZ?-(]-<3AP9[4GO-DVL"'6[2:Q-WIN=!^ VY
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M@!"3K$C[2E4&!6][.61@+-$$]\8+3]8,YA'Q/B+/8G(03'*)66A4"HJ<S!%
MVA9ISF!?X9FJ))Z+B):$.4P)EG5-W5OX. V)F2@<NYZZ04B8O,=]Q>4UFA^[
M(R[DC"/XVXP3",HUC(4Z[Y6J\O$WV9\%9R29=)N"<'2UX_5>U8Y/5-WX4:"P
MLMX4A_0$LP1O,)%-W&)%,6%IHK5%M>-&0M;8!)V\08  +KC/,J%50X:C@?]X
M Q8B5]5*1!FNJ.6,JM -%G!R0/ 1^*^$LE$P7JF(@KCP70O\UQD,2PI5&(H9
M)LPL5'66K@4RGJ</D&>;6-N3LY2V"#RHY I.64?_*S%\3+C1JNE^-7D,1U;=
M&BR73(3&ZD484CI,.8B34":SD#;I1@S@'E'5$B9W251&W8X U]51E8E2/ .]
M"NFSQ&0UC^N_0/X2)@$Z'#-LD:B&*8W=3./KP$3>SX; ,0ZB]8LDXZ]+DD"G
MM=3ZDUH4AVUDPT8N<Y\Z:Z. VJR!VU5&N^&4WM!)203Z=PT90'$6]OC2\0 1
M4%*P0E<J-7B<,(JLGM+%_)1I)Q TFZ/+$SA-1NL%E6B,&;WS.*1Z;<KT"D/9
MQ\ HKA46(CPPX'X"9I\"N^9<5>]+%-^%PI]Q9IG-I9T!"&M9'""5K#O>OT(.
M^()1A*LEJNIJGRJ@;9%0NBA)9$I&%E3F2]BO2@/8)XJH*"!ESE0Y(*3T,M7)
M;:E81PKD&UOM;*W<W+5.YI%4)0:=F$BL/U*O:Q.7&KFR?41#<=F)6S?,V:&T
MJ;[]?HK;.6E8JS^#4LJP;SG#ZL!I0&F!>"@8IHGT\@1,">U]<TQ7*3^O4,;E
M>V0V6J5DUWB),.+HY_H:8'07-L$9R;=1!,29='\AK_.Z'5DAK!4'<Z(2W*#P
MT5$G!QJ.LE41 T4O0F*@3(,$A-S<#:<X)FR$LV.#;KGVW+?ZH\IV]QUKP2)B
M(_G,A: J6M*!S*68$0,N/<&2$"XPAPT,T8)#+Z$78]Y\2AT=S.?3X&LQ.Y[O
MX7/L379-TI5$@I\'_>*#!4C\ 9]61F]UWW6:^SI!II3\S5,SOW_ 5U7!NT0U
MPEH(QA^"PR.PSPHU'4D9:.3F)\8;8KP-M^0Z+8T/S+5V.)7\IC-(./P\\[1T
M;2:*O2K<LI7M/YL7QZ6:%$ZWM#1F>72M4+RI]-'YBBY3PJ^[B/[LO+ QA_PR
M#+Y@\X;%$J1GBC_T7B!K_LXN%?TI^#;[6.03C$XDGZ(C6'FD ]0L8"IZ@RKM
M#N)#IK1&A-A :8HK@+8129XP=\:MWS[";TCS!1X]NHEKN5")*ML:X -#0R[0
MJ(H5]^7 39,YR3NN0. 1%25-92NOHU"IU*%45420WU'J?Z&[DH;Q!*QGD# <
MD2#=:1Z D:Y*&EB<=U6_*@939T^2!.F*J>!.2_Z> M0R[K9":ZZY$_%0)MEE
MODS7;BED1DZ[H!.UI#_+A6^^P2G[&N&WZCFEJC2R9-0X*EJ<\";9^@96%5IR
M\];S3D&_UI>FC_%DX64:1W>=/E)]KLTMIPVCJQ(T?..N9]>+]>'C1X4MM_L6
M6B>18Q&:4,+G>-/]C5H 7?A4$V<FHE'Z4DPQ=T36EFF"10Y]D&J%7!=9LE%$
M;%GR#\>)3KF>!\NT*.*;Q7PC+L!F703_QRAWVF:R4,W3O*"^IDI,,<AIF#4*
ML4=BL&P!)FJ#;C\.^FW0K0VZ/4S0K0GV<+V+D%V UD?M2JZK(3Y)U<%PW%.?
M/]:S>7DVVCL=TLK5'XH.9B[EBW P1P*#PHLJT%7K=$.PJH"2DKFX_2ZN5M>H
M2E7IDC*0JPPC8,V#,W<#+N$L, X[UIOM*HN,1%!7M]+=ZFG7NU(W)*W+4Z4
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MB:W3#P]02YO-94[7Z=W7@O=)J#^GC>L^S/$[B>6_GKO13#R%__WIJ@E>H[0
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M@$0_*\T7L-$P2&K%>:*:=UK"32+A6WZ>T*/PXA*^&?NI!<L KLR$_W(7Y5!
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MI"B\"[(YCTZ5Q?BK2+-@ 0+,O 6S>9#XUA\Y"&^8'PR*T^N<G@9@61_%%%8
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M0K[<"79'U7Q6>1EKUL@\I><@/5*X8% #:!O-! 3*PB39!W?]4J,%:[P("CR
M\ 5EWI?-1%"P4/"=H.13NH$IHZ3P6<(\1:BS V7]<%J*2.8IK:X$WZ]Z!ZB9
MI>Y4 &GOW"32!2,;=Z3&L0MLB>J]Z1F'!W/L6<!5ZV*MD[B1,Z>W$-XIE[(L
M$7*@"(2AQF?@,+#J3+27.38U5")W=8W%0*94*C4G0Q@CL^-VE'VVH#ODT6V
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MJM@'C.<'JKVK_!#']62R+YO:'%A!-2B11[;F6QMU7W2;LD8C0PC2UU#N2"-
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M*E)\<OJ^K#0;)DCXGTH(*]F\:-_BR>>?JMZ6NIQTMB_KLM<%Q4O'GA%\PM*
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M&>Q+6V<"C&*=&[R*E=ZB/R?2/++D6*F!Y"X(P?*>>8MA?VSZHM=W+&OZ+RB
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M<#?1G[Z/>?E$[,F+='BT*89SIC34DG(4OWL3-A]2"N*4=ALCZB#9R%XZWA3
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M/@?VO\6,9G+(J>XPDHYZ]ANV3$4_,EC->3H_C9""Z/BX7Q\-YSR7$CTZZA3
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M[=O>EX6G5U3-:E]D"*=JU1%9M:DPW[O0,&G&ID$]>WRG/3X@I!*9ICW9$I8
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M)_H47M$/WHGH?6+&(EGH#V>R,5R&(K)=KA=A0Q,_!@,7H(X1(EDZ8H ;"(_
MKX8ZZ'7;O<M6O+!+\+J"5DR*YXK6*E^<L-N<V>M10O-^CZFBDV.. AJB.P3.
M/(!4'EY8 'IXZ^O>6G6CA1!9;+3#+BO#)Q+TTMB&$()]T=XSC;N?V@V6O+%8
M KK5&\O<KL<(*UQ*T\E.C?5=C3E0_+W1!F\YC>2/*!GW5=D1)*W9I*"FN\4D
M3K+5=2MIHDL*\9TX>W*&B-T@_ #B>;!' %Q*.2B<Z'*X/T;/>"%-K!,@Z RM
MPOLYHHT1AU.Q3FV3\%7=?<)N9BE_1&X7[%/B,A(^)5TX@EP0'T\>3SU>ZYAP
M3^<YE816)+UBXB9Q\!Q6P+Z^:IMQO:_:@13'!%]VK#?\? 0$@YD@H%#PH^U5
MV@_UFF%OR2MZ"Q@'$BG(TM9DY (S7 3-56D 2T'17)9]S=G*4R;P8W?3[.0L
MP!5CS!-?ROMH\F:%WVN%*1:QIZ9:%TXK*CBQBAV;V8KJ6V<ADI !4E9A\)E!
M5NN;X$A9:@F^N^?_2I1]4TQ*2JSF05_L:#+A+<E3#$S!;ZCRSF 8<Y.-5]K6
MR)'8\YP*O<]E?Y3]_W(N^Y_+_@]'>/&)'-IO<?3Z TM!R%L0Z"SB=AWBJP5J
M\PJ*G::#(BV&%=';SPNAA##&SB$^1KTY/(R]X'U=ROK$T4I7P,JX:BF[VRH_
M5VV%4WVQ]V$2-YS9"H?,D,JX+&BV>(@IL&\W)U,\KMM!F@>06,\'VF?7U]^^
M?,W'"+J=WB.8 80[QJSNW.ZRX:(L3I\_'1XBS]-0?D]P&*"XO]Q+M:,7$%O=
M6&PD#&HTA(5QA'2QK*/5K=09<.Z1Y83B <Z><K_D*L^DD2)0722F,T\R=1^A
M=4B!+\/38W659X(8EK-B_KH\&D:9J4[$X\/K^>B^R:'_9=,*L:(YO$5*8Y#E
M"C8(^J<%PS"(7##$$D EVBE' HK,+M2[X/^D\.0(G\D'YD0/J2'_ZW^,%4M+
MM<&5J09J-5&-^K"/Z@:A3EQJ/C.'$8P88.7OBOY(6H!W0I+A;KOZDHG\1_94
M"TXH$$LYLWF%,9Q]6TS$9-BYV+/:AI'EVH_+N^@\H)-!,0.J$72=9L/:K(J#
MYT@& "O$]P$HZ:ITB%3L>$]_Z(T(!_4SKW&W^4,RW JF<?89JYS;!J'PY%47
MNW8NT]^2:,SV)M;(*(V3/+\VA_0^3#++ND'7 G[M;9!ZU 27WY3=1C.M2(WM
MO7%WM4BNJBKK< _)49.%!3LN/:LG$9H^+?O3\^+(,WV!RQU36?:-YI^> ^P(
MFZMJ>*2Q>B293<6L3^56:#4Q<$CIH&9X!VR]S0YIF-I6&GH'.^,4)Z2M1KGA
MY:Q9D1V@TV1K4AB*"SWJ$\_5C]R!R,4B?R3.S#^:-?K!S@!OY$X@,WSIG-OW
M'3N2[A(M"\.8:<#M-WMLU1*KT\9]>2(A)IB%F15>W"LAO90"7^ZN/7$&^:()
MIT[$Y;2WL*X?C]P'Z5FE><];7$)OBN!BG6H7]@+*I0NA*:3S'*]G@H4'99M*
MNVAF!2+O"FDZ29["5'8N6W7F/'EPO0;T_X^7P?47O@1_?.Q5G+*(C(/3;W$M
MMSAAT\[S^)#S",IL!1RT5JIF-VR&</<\&P]*&<9Y&-HFRZ6,DV8P[< /[OVQ
MDBAM,1]RGM*')8=R3@SYYPA,P25".AI*C$W.^AHD.>6 ?KZ3TWQFAGKH::M]
MZHZ,H<9#R,HP$]O$/5[(L%(!*76#D IU("!F<9MM;[D#KG)HCY^4-OB+15!.
MZN-7S'OHTJ"<00ECOJ%D#H5(#D5&!=NP12BU6Z[?>:V5$W(E>LU=14W8J^I8
MXP/<3;^U& C=&0N4O(0^/L%%?A8P2(BK%$JX(,=3 ]+%<2^%LA*Q&RA/\3R^
M+8?1)OTJA$?2PIP8I/XF1,2'WO+>WU2;KS\HA\6 ];HG=@=N>>(8#,7,&I0*
MD1C">)(DG[S>,1W))FG^EOA8\T(IQF81"[+88GTKHFIVM@QAY=D@?CV(E3Y3
M?*0[(:YHT<[@K6) [+BO3J&N9L$'F!<P!XD;F'>Y.WS6,Z4XN"="JT^J1C(9
M'PG9^L6A6MTAR23<!VKU96:;/QGHU8](EF?D1I3BUM8Y'B"N!O!BB)BG6_*K
M=GP1Y<A@4N7"0Y630!FSDUZ6_MBTI %C*ID"F8WU@F-8193=ZPG94B$->&@W
MI<M?NR\KAH^-4.] YY-[3PEBY"G5U&5?6 Q763 O?%!O (;B-DVJ%'62D?07
MPAF'7W [!EBU3I#=G8 FGZX-S;5L/;Y,]]L9&HY9\HVE D /%AXA4A&2#8"T
M^-_:5^72A0=T5EH'V0(Y&4].B+5X,C89K5E"@Q?6 ]5*>K]2M1-3]UO8@6/#
M!$JVL+60*N"L$-L1,;23P'*=K=G^+;#.W#9#V6-OYOZ,'[H%/_2?9_S0&3_T
M8/BAWVA5GP!J"KRFZKVAC%[;4AW[N?NR_XX[SQ4URU6SZ&N4^_"=S8UTMBEE
MH#1]5K[+[@#^ &9="D92T0+"<>ANQ3W&< TYD@!#$EG[2^G/9$Q.@L^,EM\'
MX=R*:J"32;%!]5@-.YX$?!%NFGBCA>L^EH=FQ(T22Z>8EP-XYNY0YU:X;V2H
MY!A&?)** AUUP-0%E =+CJTB/^YP"J5HYW24MG6U!^IY5^^![D\&FE;.F^^?
MK?P="+7D8K]Y91)M:NJA@TPS%3T]/!BQ$U[LVNO55<U=MV6R;H/S$Z96"(N'
M'0'>0E14%5,G^  !(X&(=Q458V<.5UW#>_)S&41S60UAG5V0?!V%W,FX%9DW
M<.LP.L[3E\$W)$@>=]3O^S;U5(S.EL+040%4\4H_PZ-X?-[ACUQ5+Z_I_Q,8
M/+Q\EWAI1J/J7:%L)LSACZ'&S(1=</B1)NK>6FR1KY07;1-6W>MD601G\$6S
M?E*$V+FYV9>'I8^_JJGUMES\=7<9)KY?_;5N>=D%*]P=PP<_DEG]KMY6JS?K
MFA,)WPT;_*)KKW?!VBY=\G77_M\?8$1L(7W_Y+_#!V^&]EV5?* _^;X::41F
M/WM!9)B+C_^^WI -#X_?RV,6J^>[:OV.4("+8W+3S-_K68B#::_/?OBZ.GY+
M',_TK[@!;.+BEO!3F.PW152NNY'Q;IE)XH0'MT&4>SL8R(ZKLB7LS#+)\>/;
M=J]&(ZGDH )8'!Q\$:MS(J85UH74<-E.[<NMF-@T3.;06B:*N2C<3A2+K?GU
M%F*BT5E('A?(N<TH?=D505DYX5QO%ZX?'ZR8!N\=TS\QKZH]*$YY?XEK,T*/
M<<Y?G"Q"P@JK"Z<^CLL"*?XI.E3'L>M'8,70YXYYR4)RY-_SV#[W]NBJ53TP
MSWG.H1%OQZX@Y4">+3E\>&RZ.M#=?1OV=%\+#(D2D5*?:!OG6THB?RZ9RNSE
M$U_/+ES8,\ECT''%K\P U ,5!P]M\(W&/0#7[ZA$<1303-6U]88Y8VJDEM8.
MML[$]0:_*BE==A@/Y666LS:6:&"^1RI(T2LNO!%&* Z,O5;P_AA,WRLDL28_
MO;VJ&EXE&#M]MD,5S'58CPR-/E"^790]? Z0ULJN.K3)>M.'+,(X;81TG;_
MFSSXA')K_S/*[%^VP!CI,]3'6@8D6.NA^F<XZO_)_SI6A\M._YF<&(]OR[YT
MO0>33%$J:7]%0Q_VA#4?%]'7SG";CII!6=]=C282C+2=KQ#%M*C"(9/$IF*P
M[X1!C<C025X[IHCIUX1MK^ M3Y7>L?K(HLL!809=&7CSJBRO5Z2W'>];_BVM
M8)2;<*80S+23F-9C9EOY<2150<"[TA3;G@/;L#,'H9R6JREI^! U7S'VZ^#P
M<Q_G%&FEYKBO9EY'XM3898/Z%R5!%Z:<[X=9]WT7!3=24O=F?;BD%@ZF(J=
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M_? PQUHJL[9+A7)M$XNSIY^_5(7GL*S7^[$GT2"J@/74\HW2T$1V1Z["/%Q
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M>C(;=;^3L904K;[/<&IQWJHC+;GNN\@+S4N!,9S%WV;&V*%*2N1T>Y!LXN<
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M+E$B)HOD BL_$W^,)%H\]CTEAI<VC!G0Y)1-:IEG?AYU:2PC_RI\8L+:N>(
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MA51KZ9:J\,=7FOFU8I0Y&[C77]"IPGP'#&PI8O<@V5+!R/B2+5>X;LS-T/9
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M)<WX*,L;II=('\IEL=@=(R\Q1TD4JZW6?>DRU0<6QC)865IICC^ET[CJ.GJ
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M6J5KM?LKL/;S@Y$U?HD@E$F>#(!/>;OS0HO7^L1IKP<"3&;VX:B:Z%L7IRB
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MW@F2POO$QH6CGRCC;ECF[E]L<JVQE=?7'I75)G9DX?=NM)\Q(%_#=&GL;.@
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M)'_>46P&5ZOLE/W)B7B;)J+E!Q?W4[OA9AM#BVCX?RL?-_NE[;[:2^?'C.J
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ME_9D"[>_A[F?TU"I'\A%,IL0*L:D,CNP#ORL&\(YIM4+.O2Z+SF/6EZMAF:
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MQ6=N&Z=9.NF#Z0/2+A!GT+KK7BD\,D'8N#XD"&EB7-QS]\\"BZ20&Z8"-"&
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M/E[+0@+<5]UCS\/6;8ML.N==3?PM2,!2YC4N@^I) 0%/!6E*+=J'S4'J<03
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MBM0+,^9SQ2?1HW6>5_-V6:.ULP9RG/T@;#DW"/0)-EW0GF/KJ7 \$&IE)E=
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M<9.\UW"^EZ/7Y3IK<M:.$&]X(!;;.3!??:!VLI4""=2LZ>2OAS_L/[%J.M$
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M,ZQ@CSWF0\]:L[=]VO!?EXCET_#7I^*UD--L-(U&RTA*LOTU65+,V6GX\@1
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M^@M.JE([6#[%^?S;>/KII"0YB1BUC@J*JL>X0HIU SU (G6711*^V$Y[>)O
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M,W.=V')[HNX^8FAY0&%>&V0]RR?_TB!/2[M.VV2=-K(-M&31T0BUJXTY6="
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MS_9 SBZ&.[T4[F":KG7/KD>O+'HNHTS@:I<\I6,$ITD;4O3!@G2,B[UPY][
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M<VC:W#0SH&]E;B"RW64&"!]R(9\!R*9PM2>$ 1ITO2S'HS!1!IY]-T4>=&;
M1L+OEAFPB>1VEAD@6%2T>9!G'GP$Y9T$;S6"SU(2947(W#WUS(#[;+C]2?T
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M&KN5 %N(N_D2L*PNP@4S/@K@/E9LY!!'Q1-$*:75,2>!C:ZS[XP"=]AYNV#
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M:'$S@)X'F4U!S(T*(=Z![''QHU<]M&B3<17:><](C=%DPSEX3B:SJO?X0B:
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MYOFPIA_&LW!\^>_/Q]/9F_'L_^#L':;QIU'-F1GP&&D2VP0EVUK=W-0ZB#Q
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MX7QOX8_[D%S/!586\;MEI1=%>T!" 4S41KH\(004!73,.EI!8)CJ3X677_T
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MKS@9S??V3TACOY[3MFPDCE(&YPWHQ%.]O2J)Z@1;,Q,91QU5,T)U0_BDZ=5
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MSCGV:YV9>V;.F?/NN_>>[_US_V/Y+;KVVFNO7:O""E6U2_0P&@60WE125@)
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M3UW/,B\R+P>O+F\N[PCO!1\EGVQ?B*^Y;[/?1;]@ORE_>?^, %# O8#F0);
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M/X+/']" 0=HF; '3BK[G%;(HV>[R7" SDN-?"K]J*<P[T  O&N@Y^+6K_ N
M<.*/G=#VYK^NQC_WH8''F^<5V?JULEL!L,&@J[F8*N.*+CJ GDSV?EW.*O!O
M.C_8O0JZ/[9^Y23K2+N"JFK<Y "^G6?U+Z_"?P, B]XYAR&/=9/NK\!:#M'
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M)<-6])[G--O"F-W%--H=)I%VUR=]I>U>>UE-WX@K!NS-4^\<2#IV?IO)>LN
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M\IH26\C;*?$"<9%96Z+GT@GG=5?.0W;A+U^(0FV%%!K3MN9H3DG0@(+-#AJ
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M\:7Z*&G535LO?G&2S$$3(4KN\-CC_V'OO<.B7)+%X9<X9 0!08:@H" 8R,P
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MGP8[>(L442(':@-'UR8.]#% "/R0J.,W@AT\>-82%D,BE%YTRW_B#IO0[X#
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M<6;X90Q)6&^H,RLR):M;?J6?&,^P9LK<W/GC8/H+.5ZKT3%-X4#"1B@L\V'
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MGBIS8EFC(#\B0&3&2J\,EZ*I0[K2_B-.WT-ZT]45(V-5"_W!4('K3E?'-&T
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M H !NLC@1(O\O^1M2O[#Z"N9_3(+;D_PEBFI2?[A0/&/R:S^-XMZ[)$V!HB
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M%3H-OATC?G<%WG6K4]5 :%GGT.^9'W\X\L!N!M^@X68@E%D/G59O<2132./
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MT=(*J3:C0N)"<; &'X=7+EB(/#CBLD(PM84 5W8/(E@*VMR[)XD!;C#MM&(
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MH,KTA.J'&C7\@?:+'8LU%\YQL2EP$09 4L G"K\ZO/Q0$WU?#BHP]NG66<<
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MFM=RTH:3"QW)=R-E1&=EE9UP<G@#A^ION:+,A=E,#%_CW_+&+M<[,+H?*'S
M2,X?QUD9\$&0/>.A3@%91OFDS>331J5>NU1<8Q =>"<7.B!BNM/:U-+DT0H.
M8<0!Q#G:'CR%L 0*V_"&FG'9.8!8@U022N%T3E.48Y))<2)C9/VXES7DL,5K
M1DNW5X3/EZSM:@<NX!6//WQ*R>M-+](D+T?A$UO[T3EQJ(C^9:1.HZ:DX0*2
MH_CS2&N4.'T7=MT3$5\0@U,'[W#6%Y<VH8Q5KUJO 09II988BABPH?UP2L<
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M_U2]>X(-',-6225V5S9:ZR8#I[!7&F%20F"')8F,0^LN7<.AO>B4>DM+>JF
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M(S20H#)E&*1U\\[PREF'Z/_=+G:_Z797\.("SU[N"P+.EG.^X$GE'O482*.
M(QH0OHX&ZJQ1%*MNL=;P(]71SQ0ZJB^CV%W$3AAB];<;]8_WSD2I](\W>IN2
MZH.@)YYQPB 4Z:>"P^G;I\>0;PB_/_\N<$D)S15M6.G]B@ 0H@OI/@]9/Q-C
M7R%^_W3CWDSN^7B/Q#CT*P* W3+*Y0$:\)K\">+WESO6+\RIRR2%[CQ_O3\@
M#4^_D=2ON>]IOB:[/ULF3);_A/'[X^U^$//1QQ6Z3CJ2K[B^0R<;L:C3NI]
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M_%E+=W\K=R58$+LJ3E%7\J%.'U4*^O[^W,.OQ=)_4/Y!^5N4*B"SPY,.+U
MZ[UO/)A5Z%H!ITOR!X3^*X?S!^7O3YED:3^+A,YG?%=18UA$"="=Y8.!NJN>
MN+/,Y\J_Z[/4[R]03?I6OG6YQ^NN-^MWA2;VT_,UOY6&_D'X?Y$PL^2;XX_>
MM[K,[RF6@,__5)#YO^3Z%\?:_2==-\V_93^QB#OP$9(P[WJ>0VB017^Z2ROI
M:O(CX*C6W<B(2J[$OX9PFGU4O0;^ST-<_;?CTJX+$R *2I^TSZ*V4P10MR69
MCK\$'E2!XM=O*IKIF)LESI$K:E[ZY8!#]9:VRJN'T$[NQ]+SX&3:3H/1<5V+
M!_,G/6,P<2S7#A$[KX53SR-5YCL%/;&LI@X17]*D'XMQHD@_>=H(P#_(!5<G
M&"ZK.E1<>REF!V!M+X$](MM$*^?SE=R(OD5S?PVCPB(;LS8X7 SMZ=_YG0$L
M_@".^+NWOI5$M*A K9H7VB+N!"J-T$IQPS@[-2,D+K W82O(,DX!@A$6GWA
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MY7AZ Y0D<"2Q2/M)X^KTG%,]^/P4RF5/6B:OF;"H&S"5<<B.NHAQM.%F6(*
MQ?(J30MW_R9J69WW143A]:-P8#9R3'A#MK.=M+B8[-G*0B[U.F7S4YLRX@AK
M)W'BWL+U>MSK/BWR)+02.WFT)JJZ-VY4AI%E0?T;A,,^M.[N9LZY$2]42]I%
MG$CY,G^>CE!XS^U_J,YD/)[TH6\>3MM FUEW$&UFVL)9]="1TUM=@('J2>41
MU&^X;\]NA:9U:2%;2ZJ +H^RXOD<6'&<;DGZB=@1@MY/,VX_>'5'_4);91+5
M-0[BR8>S(;6)MFU+7%':3@2I>MM*09_H++*MNO@*=1#Y7-)Y8!I?!5H9EOH+
M$JWT._1#40?'38H6+['"(K?>W&,UX#A^W8JUN^+F1>\SRO2"H2?7$AG%J19R
M_1!@NB&\S_ YK\^,?4:I?Y$Y7^-$JO1+./L>%]9Q$#7VYE8"301WJX(K(K+9
MPD*/T4^*ZDW],R/FN6X= W<$%3_5DKGK]6'GOR*6U74V&;6$']@=&CD!E!LC
MXP28;9B4="7\LD*X7+R9^4KK,ZKI%4I\G$^QG@/1K;A8$3BN2*PI7V(6F=IK
M(S7&3YI(3[#E3[9]?,*[!)&8#(S&(;).Q$8..^J<:5]%Z.REY4JJ*JISWN"G
MK89MJ[ /@E.TG6#55P_ @L;XE9A,3)'#&!$0XA$1;*9+B;X+Y9)VE]  ^:WK
M!KF,XI"740:023;X%L4@G#X*5PF_$.N"'9X('@]_:<6--QU_&]AXZ>\"-L98
MK,7>'!HM>FH'<>VE00.74R)/U^^=Z))T[E>W'XY^X*NO%3Q68\L'KPLR),WL
M*$$^+$!>O3VLW1?1TE5,8^K]NJ35N/)5M-)<%/>XEU5BMTV4.0V^Z[(DTM;=
M@Z$[9S]49=MG!2E)Q4I[5?:4)ASZN'X=:A J+VD5GT8POT;-F3B"H*O,8Q&U
MT+8@Q;88;QZP@KQ?8XCV6D%:A-I"^?I-DLRS9FY3WDF\ZLN+E<^ES3]KXLVI
MF&Q-.LY63XK%Y MYX9?4'_KI2_EZ+GVB7WNVCD-KVTGU(&J6QC5ZHE0_O.VX
M/3S>[[VU]"'J^BM6/]LK[5($S/P[K9U/#L::K).;BJ7(8VSJ[MA"+PZ'RDW>
MBYNI94,#\!+([C!DX9:&DIPJV8+CHXJ&?0[(C]F"<GIX3E7S+2]M^%0T:6/R
M=W'KD>H-I$!:!<26Q\\^R8WRICZHTONEIW?3TB9&6B"-(Q5G9H(MZM'9\E,E
MS$.QND*(C-%P(7L6)3YT7N_51A"'QQZ<X1,5&JC-D2M9;+PUW)4HVZ564;>1
MN"3V2UQ9@?TF^];0.1E5^SZ[,[.#6R]11[W9$6> Q)89#?1H%6;PR\G:I9JU
M*+[R:+E5T)PE0?=,3KWVL\2IO>[ _LMK)67'KFUWDS-IY=?\3G8*\ KN#HG-
MDI ,B.V9#Y;B,5$[&CODR&;II[!V;IK;><GTD'@VH0Q"YY2U/:0_5%&G^F@0
M+X5(+UAT+X]Z@;CBF<L0!\6ANBU!/1GR?(5*"?.K]@EGIM2Z(AI(LCX)9#H8
M2!1JCHO>?M%<H0!F:UT"=MMXO_3JK.5"HJFS[5#&UUT]NYL?O$@,8W118TAU
M$EM7S_PA JVDL9';:O8)$W.ZX?O F>CQIFM24'@R_BQ*(AMYPJ05>G(,F;TI
MUE)<2\[,Q^YY3>R(;"A7.7?ZO'8T?D0"PAUF>V:*#J:B =')0WSP9KZ/L*R@
M1NG.BTNJW>VJWL?#-!=AT7V#)"%UB';K?6G4<U9VT[9T"W.S3\SOUCV)&5"7
M.N$GVZ%;UBB6O,6D2QH5ETGS&UUO)H1ZD-EKU!)MM"_W=E/-W">-LKZW;>,9
M"NFJ'/O$]]XI0**T?\I/UZL]*CZX5)JO)#,B>D?4]U?)CV:_8&PF[1D2:(:N
M:6R -RZ>DD#D:TN7 60<(D>V+SHDVY%\H(NU!<8?>_>UQ)6W.!PCSY",A2O2
MZ8ZCC@V5+Z^+Z%*$"-IA%+ ?Y*$!T ,TH',V97?==CZ0H$2FSY9OLF=&0U!V
MF%R"OIU96V7;Y<R4H*;^OR=LBN6GF+)HIY]BS,0OF_Z#\5=_?GV/*<O^'F+V
MNSSSFR/T3XZ+@]'&__]VETA8_J?T2(&;^O[L;.S$J<;GL<L]$JJ*IFN5(QI>
M,GE+G<<"! *5!W<?/19M-S B%K]^S;%5V*"8#! YLNU'\%;K=/)T])7V6D]?
M/JF!C-T^A17MC#%^&(B["3SE[I 1(9Y8X5YN7>S9$5:WG;(FI"5FF#?LC/(=
M7@$.U?.)N>RD[4/$<2J#+\O&B:AT]5:$=B6L,3?8W)M"4B*%%3OB([<(3%^*
MLDMA^&SPD=(ST4Q9UG=_C;?.V+3\*)FNG9V JT'Q 1Y;#8KS4_)0['OZ84LX
MS61LWN1)3(N3(3_NYU*K$WY'3U%6M4,CC136,Z-)%1/+RV"WQ=Y7DO$S5&HP
M-W1Z/I'RO=HH]YW30ZJ)@*< LHP?+E_[KI*$4#NO+&>.OC&M.)/6YEP%9EQ?
MC^.M>W?O&5B^:16["F]/KYR+HG@<F53#V<KTN2Y@1RA'5_)I(C5CM9"_$-=F
MD1@'M5L"C2T,6VU\=(V]27#_). RJEH;#3#F@5["0+ UE<J7!/GUS^G9ZGWA
M8;CW8'4P_HXK@Y$\<9F)AO:@1(QQTJ IK+8NSA:!?+_F(4'_5+8R;YX';:J/
MNOL)+\@RTC5SB#.)8*1[&EHU6'993<(OC<;EE>X0E$IA2O>Z4C:>S@$8B;FR
M+9Q^/@6(PT%6K$L'&ND.]:KX^&&?B3DX(S!6(%JMFS3E>DPWKXR4/".9-+ 3
MQR7X$ W01/JZ\L-%W&0]R)\6Z@J\IKHXKX8TM6RNN_TZWW8=NGEO[I%8/<7$
MQ_]AXLZ6G=/\#K0MUYKJE#IA0H2$MVE#N-N0.)5$EU7K-G8LC0<[CNT+_1G9
MU]R2KP;(N]"'2'GRU> ^=<4O_L+]N*A(UX^/@3%A+M  1TKT6;Z-N3$L'_%*
MBR;_AZ"I!="F\$!-Y:%J=#]Q*BD.O0'2KWR>=LO-.,^TZF'OTCNGX"8O!Z2M
M%($O")<?+C"3?Y#:6#RF@P;,-0&9JV\D&L:YJWV@ 9AAYXT9-SNUS=' M6>K
MVSRHZQJWFE/E)MUN*&5 3SK(H8BW72YKN.E&IHJ?"LR4M-D)4BT?1K;>#<$!
MSPH"'/S+CP8+;GLHY1C'K.*O8;^* 7SJVUAJ"&>AG/Q8Q*PIY;TW>E?\/[R;
M%&:7?1S6(=WIM[5]^KD>"E"'W#_A?)#7/C$^Y7";5';:>Z]/V_<]-)R>>98.
M8/2+GMH,2=ON5W>=.G[%6K@UDBS5I4/QD0CN Y,B'O=7]ED@,BAX>3OF1EEE
MB5D\HQ6S' T=5[:_-FX%/2G4OBU^>LC_1I]F_CPUWXT!Y?U"N3)PQD.#[2%Z
MPU@AGB_=V^3. K<)EMY+.@S!E,$WB8<?^A+0Z>-G]$,-:4Y9U@J'^(8>9$I;
M7..*8J0(;S 2OKA58("#FY&51\5#78"O2YVCT1%6Q(!/0)MK7QBB84C#Q_#.
M+3I/Z):^\@ [)J/70P;@I7*(1%L;?H?GN2D'7$S&OIARM6%9!\Y:UG%N,,W]
MDYQ+4R(C+Y@V1\585D[NI=Z-41*_\"R(R8C.7R7,?DA@R7T6*<#[!H$&\$0+
M+\T A)EWHIFH8P4H&:<L&8^,+G8#5T"C1R'%),,>OB'+I7,VBG(P$L+D<Q)(
M*A&Y3 1IC:&5_[,1T)^VEIQ&?Y*G.J&-JW>T;XMU2CWZHL>7I8/PL@T3L<C_
MV<0/JJ.FN?,;KN(2$K^7P_K?>>$F>&CTMW%J0J<P&6PX[*/UW#8#NJVD]3H'
M2JL%2C:?A+R[?Q^^-D[TR;>)S ^[$@E%)ACULR:WS1!)IL.8+EQBC,BC9/$S
M]UP!Q6/2V[<QT%9-'J@/BGT#-8Q$ T%YZY1IT)4Q8_W&SH?CXGMP ?^**4.+
M69\E+X,F9+_]8L=BF:Q[#H\2T&[R.LR-MGK89"B\[^V"2QZ(8)';5-"/*0;U
MX/*C.:J OG;:=LXV@L@>(R3M;XMOY5X!T07!:^!7X=X&'D1-,N?A_-0VW%^A
MGK-K^2J>%A>] $6G$$I7I0 0(OAVGGZ0X+/R6NDHZ+%'QXK2<%>'"7"DFFC1
M&)PS7!_$*<QY ],(5(')Q-_ 3^L.M3G/D\H8)9'A9'[@+N6_DNJ=/,(FTR7R
M@)D1F6_?LU??PL'ZXM=Q9'U]O(\DGJ ZMBA%"2TXQ[.S<;C#.)R@TSY(*(Z(
M_=?@Q#XT,'1FP/1\?L5+A;TKR9HS+QC?H=#1QCU]F3[I]E71!3%G4Q%BVVZW
MHIFABDU,QI3/*D^5TE:=6KO$C_THVXZ0HZ4UTM,YP2S+Q_*=SK[-03X5ON,<
M8PEA(TQSBY%]P$#@T*Z(DHH&/4?V5'E<W<U9$[;V&O?;G?W0/>>1G&>L5M#U
ME_8\FUJR]*,K(1H&4#(&1H,M#D_S;FC=[&4+-/ ,LJ.L,GG1H:T N^*^&=7]
M>*AID]'*"I\A/S]64E:&2_&C&$_!448I$WTFENP'A/?K9S'"_9J92TV/@M<Z
M08%Q#D_:M$T[QO9G39RHHC!APPA:P:,X1"V5YO7.7G:,+01;Y4I#%.:!2>B]
M;@76V@W>8FW-9IH@U8"3 "S26,.>H>L;?;)Q77-?-";(&S^R0U.%(J'ALF+0
M6QM1M3=;R!9E@$O^LO5+SAQMNU,8.^>J()0NOGV/HFD19.--7!7\8Y$MB*/,
M!OKM%HE<_9=N#X=BF3>EUE(HJ.X;4XV?&.$[0W<(7MS&23U'A;,P;*D[;$39
MH"KTXE"B"T!2=2H5*^(ZVC/ !=.JWH28&7!X4TFMK#\S@+V5QY'B;Y&=W0XI
MUSLS,@3/OB U9#[:;V;!VG'W023F-:;VHJWUF*[Y>H5ZCV0[W"?<D;J7"LSW
MKRCX*[YZ\5:WFMI+-8QC5,JE8;4/%@7KW<7NS]IXUX;%I6/@&G"WNGH5/X-N
M'.;ITBVA(4H+E<R)4CB7V^<-U .X]>>JZ@)BE#3'!.6@4&/#0*4,:N6$*PV]
M#F]2!QZN4K\X6>R:@5[&$B6V#;%OOCSXV))TT3%PYL4MZ[Z5<B46.TIC22G*
MUM:)@Q )6O?!.3N8\$:DA?G[>Z%WA'?YQRNZQA'Y7FLRF$PB%LQ:<Y\,DY*F
M=^=C"#0[9.B-6"E?)QR9F-4+M#V>#-5&X6XF#$7R1D^R.UM>=RID'< #B+UA
MME#2+BEFZ1D1M5[1KL?&3[&=7R?&AW!7T.:%P+'H,D36#E@;N=G@RE7ME6P-
M+FWLQ!H^?>MT_ ++4(/EV_[;&OZU?EZL9MB#0@,@YUG[+AM7?0.,UFZ:,('5
M!_"C_;'5O%B6ASGS_,H1>+H52S9<&O;CAL)7UDM7.<S#9"U;=.6Y9*@#6>0%
MIKW%>H9B76[T+%_F2#6XE;V&\+W;JN.&!JBW^^;V4^+E^5;(M(YB/?X?>]\9
M%U62O7T)THH(HB @35!0$ QD:#(Z1"7GC("2<Q2$)H@HTS19!)H&R1D1D)R4
MG!HD2H8FYQR;[A=GG+1YW]_\=V=W_5 ?[CUU3X5;M^I4W7.>!YIV[O99(5NN
M[Z_;R]+"/]2;(;4BCD^YG%_H_IA*J4YMI3('FX%YECB-"X<\(#'!+ZQF77@W
M=D"OPKVRQ5UPWT2($T&PH#O^V&YYC=UB?%>^PM[-K+61<P""ID!4#1X&W])N
MQ_P23MUO^+&T,=6CYP$!AT8$,Y3&Y>"MP*K#_!.PKV["V:+/UI4X@)>&_XG[
M6*I3\$&C^$[6!7-^ XIR?HV"F"O&4A27A+3F'H+?-@K82C_885<;F@U?92Z2
MV#!NN>J>ID30#.:DVUT93DCSV&D$/53]=<"UTH8IU="Z[BO?<%XA%8ZS8AWQ
M[>*TY?GVH-%:"//2_E_^>L]*4M"U0<EX!+S;Z#Y>+8*U#\>HA:H'P<"F)K;>
M9;P=(?M(RS$]3%;K(DCYA?]Y#J>ZX2W2 Q%N_1K?W-BA3M9IE1S^:0Y&6 7]
M\S(<0.&NX6F5L'*?\0PA-ZN T',W>\[06D>\F_5(2*;*7@I?D51"??:ITB(+
MW;7O6M4V$F+\PA#.$!1=[78>U^IQWG:*YEQK^2 9I#;XM8M(B9$'<,K&2C.Z
M^H9ZX7W7 #?\AC9 ?,(TRH#(48H:@0^B9'F)X>C7>:H1^L9-6SW!^!5SE$V3
M#RF7_1DZCG,"GIDL(XJZA9I_Q8PL77NN(>OD?-_G:6G;;4^.1P"6!MVUU4N\
M5GG.NK_?0?IJU,.:*[Z$CP:W>5N>\GQZ7%CF]HI?DN-M6S)KYS2:6441??;I
MM3M!#L_*58!3;U3L!>/;N;S< 2\@$_OGEDC<E$$$[TRKL')%1H"4,LUS-S$:
M_/>5T$E0/_Z(.%X4T:<4M.,<$R'B7$K" [\G$P3*X7J)/;T?!UQN%-]W,+V9
M*A[GRC#&-UI)RD>"*0,C#Y;T^3_6OV)7IFA6:ERFX(IB!O/9>PV&?"B@;1",
MW+AYQG:)DY'FQ&[S6'DT5(9F1KA,.,!1]RZ^B%Z1?#KB]-8$[#;MYR53BP*,
M3.NW@P/IV@W_=O@MZU/FWI&33>6@S]]#[,U<SD'N]%/[FIGX@ XP*'$(C[:V
MR%(.)WYG$T"V=8#T<;0:K&2:I.A293G'3193LZN\<AC1LDRHEI$8!+.UF.]_
MI_,A[,'1M/I'_OQ]=)HB"XUP;(4D9>,.'_%=A_LR4N;X126!*99ZV).MO1?#
M0L2*5O2A2F.:9SH>=\(M1R94#\082I;J7-QR$SH<#6/& >IVW9X7$=[I8CX-
M=O>R/]_2770RILLIL?E\.X%K)G4Y>EA=.NQ,XYCHXUWP0Z\*9%^QS>/WX\Z.
M'A$M8BI/>)E#7TI( 9F+9'+U(<J">DN/;K0[X1N;M!"ZW/4\HJ^"*_*2Z@U;
M3%M1.]IEK]IIDF^8845.NBWO(PZ0L%Q9>K%?B /HNT]6C8<X(+&80NR%7TDM
MBBW?LEML&IRPLPK=OFC _IMSL?("SSNJ"><JMH4U_C+$DMZ,A]@'^A-+:UCL
M.+8X[Y._C5YGD*U5XOB^H@O9P2X.:':$!IOL1VA5#T09AU]25T7<M&MI%)KK
MK_(.0JLG4[E0N)2K6'9*^P_M&RS./],R3%!G$^/V-2AC>'Y!E[<G=9H0"%N$
M-&.L'(/4V5M=%XS2)>_.Q;2M!]<=/-;SS 1M7X^G^O!Y<M*,8)X:RJ0ONW$<
MBNY@V&O[ MZ>L/[V)G0N P=4&^* E]F[43@@1;$P]9@[.FZR>,A/ \U,2J1G
MMM%A/SYTX<W16ACVI&<N[QQ47_G,>).YA2!1HV5WFGCC):T#2V]_+WC&^]$^
M=;]R<)GVPCC)4\E;>S$VW%2#!#=,(F 3L+V5H"U/'+ 3@CV"<NN7?)"1?:6Y
M?)[D*")A04\>!QPV?0E^CLE*"\]D?T)L4^Y0ECDI0BS_6".(9;/YKA/J@2]<
MM+@/^J'H9-)*"#DFPU@EK)-6T(?8F[Z>I"&>QK=W))- 66XK[FOQB?V ?0_%
M7B_,90O2N25R-OFRK>#:HM+ZFL^X8J0B3\/NMG(H]Z+CDT.-])_/R]CN_/K)
MI W1=/KT]#8>%D=RV 0<QMU+_''<23XO;6SQ>YDY[/F=A 4&+$IW3&#=O3^B
M V;L#(86B95#W^0P/!,Q.Y3^ M&1HIK+<CGWC4I0%'/,5D[8ZQ8-:L8)_UYR
M@X#UK<8XAX>0W> 0K \T?69!LYK1_<Y*[5BMF#NH/7G?9U5LB"%C;VFFBCU3
M8,"WLS>C>1G+#FWZ=#(H*4^,4635G7LX(,0=NA0.G;]:*:;>S]Q'+)Q^\\5%
MD6;"4,4:WM7+#!C/D_&L=S+F)"B?7[W-$<27?.U&2W1&4M",X#]T,O0-ENGW
M3W\L8I0_33DH<@M'2V7JR;"D4' V.V4+L.[020HE\._D<)Y/B_>9[.@OO/"Z
MLG0DN%8VLF7I.8%'2)KFHF!? MX^I$B^IR.$LQ>@B"AR840^BX#'- JP\ YT
MJ\VN&#^Y&\2:P?JW^F46H\J+?:#AD"VU,5$]D4<]#:9;@I&<=^B/F3 \RQ=
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M./STT!/?.K5YCC-,C)S,)J%$( B$4#EI?^/.HR/FC:*+%WWRNZ;QB614SJ
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M02T^V&R5N#TU2[ZQ$+:@5X)ANW-HAP-":XX$5W9NCX=L9Q<K(Y*3+@:9Q>.
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MJY"_=O[[+?V/I)_6J4+UHK\9"HG7Y=6]S=!:NG89FF=X."NV?3VOD:Q<U/]
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MA+Z.FC6FO/-Y[&N: SUG(^ZF-V!3Z!V40-MD=H:WS,P'&)ITZ1#/5U^?8M+
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M !/+FP6-7!?JU8A.J5-$CAXF=$X(DXV5#M(+NFG$LJ_,<Z(WU-]=2%,(?%?
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MKCI=^X&E+&A-3">-40S$ASSC775.P7B2ZX$:?3AI<34>D"XWN]W;GQO5HK1
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M%"6*X2)I]_.U,^SN(4S;W]2_#1ROKNYB$YN=Q23OSH]> BZP:R4*X0=M3*]
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MA#3_^KU/UO2@-1R@_*GE^]Q^LP;F]?P14$L#!!0    ( 'L\<U/ 7.()9?4
M &F$"@ 5    >&-U<BTR,#(Q,#DS,%]L86(N>&ULW+UK<]PXEBWZ_?P*W.X3
M<UT10A4?( ETS\P)E6QW*Z[+\K7D[C/AN)&!I\13J4P-F:FRY]=?@(]\*%\
M$Z3HB>BN4DDDL?8"N; ![+WQK__KV^,4/,NBS.>S?_M3^'/P)R!G?"[RV?V_
M_>G+W7N(__2__OU__(]__;\@_-^_?OX WL[Y\E'.%N"JD'0A!?@C7SR ?PI9
M_@Y4,7\$_YP7O^?/%,)_KVZZFC]]+_+[AP6(@BA\^=?B+Y)'7,64P2#B"428
M$$B)0I!&+$W"$&.:J(O[OT@F]0]40I7H:Y% %.(DS&"LI$BP4AF1JGKH-)_]
M_A?S#T9+";1QL[+ZSW_[T\-B\?277W[YXX\_?O[&BNG/\^+^ER@(XE_:J__4
M7/YMY_H_XNKJD!#R2_77U:5EON]"_=CPE__]VX=;_B ?*<QGY8+.N&F@S/]2
M5K_\,.=T47%^$A<X>(7Y+]A>!LVO8!C!./SY6RG^].__ X":CF(^E9^E N;?
M7SY?'VR2_&*N^&4F[TW/?I)%/A>W"UHL/E FIQI]];3%]R?Y;W\J\\>GJ6Q_
M]U!(M?^QTZ+8>JI!20S*,#4H_WRHL5_.@.\)[V(7JP=PE;D??6$\QNE';W#O
MM#[(_@%O-',VY/J%>C<30[V[JZ;.AMX_8E^OQ7Q!IP.\%NMF-B!/S2\^Z)^:
M9LR#CHAIU4XCW1M0Y;>%G E9J^76HT$N_NU/^J?)LH3WE#Y-+KD>^9;3YLOZ
M,M/CWS3_+RFN9\^R7)@Q\6\TGWV8E^5O\I')8B(S2I(DX#"4+(4H1 RR5!&8
M2!&E0432(*.3Q>J=G\@9_'+;PJLPG ?@3P[,+ Y\X84LY\N"K\?&Q^F^ 4^/
M=69TQ+_,Z*,LGVAS@[;"N!&U8?^^1@SN-= 2O)EJK++\"<QGH'R8%PNH83R"
M?&5/^:^_K,GHH8>FK\[[M%_*+V^NKB_ A@' 0 5O#-B?+L!;R1;@5O)ED2]R
M6>HKGVFN(4VUGS4O8$FG\@)\HH7Q][[6QOU_![MDSK?,F!H'9UZ\Y'7.S^9U
M+2BEIJ0B5=&25:PTS_[%.)N_R.FB;'\#S6]@$#;>T9\[@_AEYSV\+%K+:<%/
M='ISQ2]\KOW!IP7<ZG_C/_NA:#'W\PK77:E!_PG,"R$+/4/80\#.A_B.%C,]
M@2CUR'C[H%^?3_-ISK_?:;']55OW^R1*":)<I3 )4P)1QBDD8:H@R])8#P$L
M1%BZ*..)]L8FA(9GH+&"J_GCH]:^"K.;U)UBV$[9//+6LY"U2"O:*JQ:F"JT
MX&OS;P,;5+@]:I0E0UXEZ52;@RJ0)0$O!<?VMF[Z4CWR5SWG%?H+>I*SLII*
M7Q:%?F6D4;-?OZ\O^42_FU]=_D$+\>X_E_GB^[6>CQ?5*D9YLWB0Q=T#G=T\
MF4>4_]!R:&2Q]NDG).8L#$@,E0JT"\>9%JHTQ#"*,I+(* EQRB8[LY>3W]U0
M^*T^8+NIGL^/N08)WN3&[=-FEC^YB=]@W6^GHJ/JS6'DN+('FE4G 3:-!AM6
M _8=;%[76 XJTR] ;3S8L!Y4YH.%MA\T!%R YEW1KTI-@C]I'[K;O(X1@X$?
M=+ 9NDM>CEJ#M]]M^'M/\^(?=+J4OTE:+HL*6;GZY=]S6>A'/GQ_.W_43OTD
M#7" M4,-,4D$1&DH]$\I@D$:8R*D"$24N#C;3JV/S?4V.$$%%*R0 CH3X./E
M/\#7&O-A]]%#;]@-*;UQW/.X<!Z]SA+>B2:O.NR&8% Q[43.2T7L]I!NLO9!
M-R$?YE-Q_?A4S)_KMIJ5.AZI.*49UZHE(HB2E$ JM".N8IG26&9)%#NMI1YI
M:VR2M8(*\@VL;AIUC%H[1?)$6,_ZL^9J$V8/:Y<6='C5F6/M#:HJ%H:_U!";
M6[HIQD>YN)[Q^:,T*VJ32&91*+1GHU*E-8+$"C(511"'E+(0LYC%Z62QVDPZ
M^<IO/=U)%0[LB_E\TS4X8+9/W'1@FS 99PD*DE2_;QA#% 0(TAAS* +.,I11
M(AAR$=7NA T@HSX(LY/*SC3T+(Z&@1I8LP$$+A>+(F?+A=GQ 8MYL]7C3R7W
M,N%5%[=;&%0)]QKW4OOV7^2F=D+FDW>SA9Y@OGN4Q7T^N_];,?]C\6#FJ'3V
M?1++A(A829A*H2=XG&3:-V("9BA1C(0H9<KJ,S[1SM@^Z!HJ:+&"&BQHT-I]
MYJ>H/?[!>R2L[^V3;EQ9?_"63.SY]$O)?[Z?/_^BGU!_]?J'ZF.O/O-3SQWD
M@[<TKOWT;2_OYO+</.DIUT(_M/*J/IO(RAOUI92792D7DS1+4V+6>E@F(R,%
M5$N!"B'"4<B(Y!&F3M.DHZV-31 J>'"NX+*4@!J$;F/]<6KMQGYOA/4L""N<
MH )Z 5;D:;#@\BAYSFZ %2E>W8+C+0[J)E@9_])ML+O)34&^\671?87[-_HM
M?UP^OGM\FLZ_2WF[9"4O\FIQ^_)QOIPM)E)H>C(401Y1/9N(]$^$"@D%TNZ)
MI-HEP8&-]O2,<VRJU0 &^G6JG7&SC48KJ';RU7>_'A>^$?76^/<\V[YN[06;
M!H/+$76Z:-(\JB?^")V_!?B_[TM@/?8.U#7UJ&T:JX;B@,1!-1#WW?P@0_A
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M/8\(#2Q0X0(;H.O0LG4OW>WTTM:M_D8%3]QZ%?US,0VJZ9X(?"G9OAY[YG[
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M7M0%TRE? -V,_@[Y0U7UZY'.EDK_=EG458;*A>/Y2OLYMU.\LYGL6<E:$AN
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MC0VK)$D/ZT9G\^<WQ=$9Q;!9BEU)VDDT[/P@]R(9O^6S_''YV+@9@O $819
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MC[)X]XU/EVT2AOZ?,(5W8XY#KD@(,Q7J&66<$8BU:L/_G[HW[9$;U[8%_XJ
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MG*8)-OLJN0 0TPQ@5A!0T 3)."<L44YE>FP:G1I5G-90O37ZYP+,=ESA&[S
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M<XMBFD 7]T9'O:5]XT5=3: 7CJ*YIF#/@*G@;DY933BKK3E*F,J0J0I(XAA
M(P9/1$)!CM."41/4&UMM:G8\?VH3I_TZL3+1O1+>!0@MIB.W 1-XEA "$X=!
M]#9L1AK;3C#R-+ATN][+^1=N&X^*NVT^8LB>RX9M[OXNMZ8BS^?-^OM"&!&*
M/S2UWJ]V(;1W?+OX7AT![2*T,HB(S"0'+$X9@$0JH!E- D6ABM-"KTN54XU
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M3F?X7JR:VL#2.E7ECQ\5Z-K[-8M:SZKMHMJWJEAT[=UL>+*GGYZV&VY&[[_
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ML[SFF 2@S.B;L)0"G,<Q2/,B0TF"%6=.BED6;4Z->@XLC7:F1G_6QCIF#-A
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M>RT_JK_<?Z6?O)[C0/&[Y_5FN_AOL_]5;BMAA7E"XSS%1DDS-\K9A#) <BX
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M-?Q'KD3W#?S&FW_L1/JU2^8@;%,O?P^\,O)(M5_^EK*> /:Z;+W5IE&7J)X
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M*#!!NX#C)IIXS?G;11,[6QA/-/&:DT>BB5<O]K%/]%'*NV>3'S%/B4Q27""
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MX[\F8=$@::>E_GF]J>U]W$A9E_/:RI603:GPO6U-<7#Y49K5+"8HR3#03DD
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M"Q2GM.1T[]!0_%+JFY[N5N*]?O9R_5(I(^\"\Q-()1,Y(#"-]6P(,3TO*C*
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ME,- >*Y(>6&PB6M1#JM\6H7RRO7C./BXA<"NS&J<P$+!# -60 &0U#_1-",
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M1H.H4^$NVBD1[;4(4AWJ)AR]<MDX22:ENIO .F;"VQXV\DR ?Y7BR1P>7D@
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M0MO@[52\W$U%ITC4::)7 1$=Z!+5RNS*D4PT)PY5D">:FXF*( >=([>BR!Z
M':R)?,OSIRN)[ &%@XK(/IYW<\_3;@>V]T+D!4M1C'. <A@#A%$,&,HSH+<Z
M<<Q8PB0;V^#T9+"Y+5&'/38[[\3X=CR#0-NZL_W %]R#/1JY6WJ27H0D5 /2
MTP&?J]OH1=4'6HM>OF<<D;Q;K]9=-?<F(^/5=Q-.L._*&Q>Q8A G0-!$ 9/$
M"5@2YT!FA<Q328AD3DZ2JR/.C5*:PK\O9"/E+U%9"WT7K>36T:E\'6P[1O$*
M86!:Z<NZJY?\JL,R!+E8H^.58:Z/.BG-6(-PS#7V-X[M#5A54AYVD#"G:NNG
M5=T3?B%81@J9<D 3"O7F.],_,:4 3E-8F+1.6#@%;5X;<&YTHT%O\FCI,F+K
MS6;]I_ERW,.'K@)MQS4^X0M,-8VH=\<-9^ZB3E[/84*VT'CN27AET(F[%-I!
M<-JWT/*^$9Z_7^7F02[+[V]+7O/6EXVLOZ>V;$*L-T14:6 +2CE *DL 24D.
M$IKD"E*5\#RQ=NX-CS4W:NFDC5IQHYV\#JZ@*_!:>.#\@1:84"[C=;TBA3-P
M#FXR?P!.Y F[!4@W1Y<=-(.^K"N/F,Y=9:?+@4?*\I:1_2HV4I3;UY37I;'J
M#%%A8HT8*@"1G *$T@+0C.MU2_*8*\PS1J538XJ3(>;&H8V$42?BJ&3;,T#:
M&6.WP1.8+1V1<6\?<5%YOWTB3H>9MB'$135/.C]<OG*D,TANC7_IPV;]K112
M_.W'[Y44;U9G8GH67"6,%XJ;@!D&$)8*D*P@@,5Y$<,,LASGB^U:;V(LO4+6
M0SL1PDZ @ X.N8WJJ,/'5G93XOC%D\GH*E>_G(U%=/0:V<^*I?LH"-:A_4@:
MYMHK_:$/\^\=S.>"#CVZE)P1\^M;LA]^6B>3,RPGWB;W)XRN(K:I-YFR^>^;
MU6[S^9(^EIHF=CY8G&4RE2(&.<':IB&$  (Y!B)&,)9("26<CL_LAYZ=K5.W
M@*Q+L.]]N%3OW-O"GUV95/?P:H?IL..T," 'YK1.Z.A%)[99+WK^JU;T(&YR
M=\1\%R^S'7[J4F:.L)PI;.;ZA)L;J_XJ'S>2E_4V7O^\E.:'^Y6X?UAOMN6_
MZM]KDM5R;']\T._@5O_-9+4\FLWA(B6I(APKD'&JC3EBJK;*. -)*KF$BA8\
M%R-ZA_B2S^J+G;ZCB/%A_O6@_9;H:3FZ]>IM4VG'EI/.S/2M6OLZW44[K>HU
MJZ_77=1IIG\RNMW5E^S4"]+$U0O@H9J[WB;<<S5]]0+I0#-8/\_WVIRK+KK[
MZN%QN?XA97W-!_TE?=7+C1%@P6624PDA@)":$+"D #11%,0%QR*!%&6N(6 C
MI)B;.6ODI_K=,@%.O%?V'[SZ].&#EP905V;%CIR#8QV8B9MB0HT"4:/!KO%A
M6]F[4Z,M/-0I4I-P\#9/=D!.T>GIBB1S:/9D!Y9EOR?+AXTX\_VM%-JV;ARB
MNT./SQO]M7^527O QC/*66)JA3.I]_5QS@%C- 4IYRFG4I(XL^)$VP'G1G^-
MR%'KIM^?P(&HE3M*'$XS;1"W. OVC&-@:K. <,S)L V6#L?#GC&=Z(SXEM?3
M[8S8 9_!@V*;YTQW6NR@U<&1L<M]8XN&*;G9F$IE)O^A<8&4_Y+BPT8^TE)H
M8[D.L;VO'8OGRL;0'"HH8P547G" :,$ Q5R E&'*48$0=.LJ<ZM <V/V5NZH
MC=2L-[%-U')7 +51Q;7^V(W39F?N3CD9@9>'3I5=#M=>&^-JJ/6YZ\U.H]-A
MA:!P"=>^@/9<[>Q&H2:N@N8'PM/J:)Z>Z_7<?^>V/E/I!HHD0:C 0& ]J?H'
M"+"DV 1MJS270E$HG+)"G$68&PG7A].J3IFJJROT3LS&%B$:,2\W10!X0OMY
M(P'VIV>!RP^-!W&*X( A,>80)& !DV6P@,V31OI>SQ;9[=5G_MN/_25M^>:Z
MD7E3,&Y?[[*JZ?OS5[IJB_/^0U9;(WOC%SEJ!?MWT\+15%#?=5=;**((1S@&
MA=3_()YR@.-"@#@M<)YD,L70K5+17#2;&XLWXM?=K,5ZN:2;*M*O5]/9VK&Q
M]6PPMO4[ST7>&:TU_?KL?53Z1=K-\G.VCKO!YJZK!=J#I[7^MQJ@MKZ[WBNT
M+YY^[SI?^4DC\!JING=%M&^3Z=%=/K?Y]^N"GXUVT[KU9Z/VI:."V0DXXOCA
MH_PF5T_RH^3K+ZNZ,N)O3\MM^;B40BY+,Z+>U?=TJC[1I:Q^*_4_V_5*MFHM
MA$"X7N Y(MB<VNI5/D<IH"I)LJ1 $(G"^H3"CTQS6Y]K(:.'3LKHL1'3P=GN
M::XLSC:FGX' JV&K4-33Z"[J= (]I?K+HU[;FDG;*=:MD--/FL,ARO23-]$Y
MRU23Z'8FXQ?NP6,;3T--=[+C%YN#PQ_/CQZWS?Z[7.F!EB:@2CR4J]+LW4WI
MR/8XHST 3:C@L<@0R!$O %*I7A>%-O5D B'+LBS-<ZO%T6G4N2U_K=#U&0(]
M$#MJZ].X[5'MH+?;/WH'-/!JUL?R4.+=09J_Y.11('G= -F-/.GFQ F,XXV#
MV\TC,Y[U-F*]+$43X:E_XC]ZW04ITD8Y2;2AGBN XH0!BA*JE] TEA"F2<Z=
M>C ,#38W'OJP*5?<+!-572VN+[EC*O00PG:\XPNWP'1S(.9=U @:_='^-\B)
MKPTR?G.GAP:<-HO:0O63?&J;>VXX26#7O1SLV,NQ<T_<5]730^/8, S'FR27
MAV2A,D@XRW* 4I@"E*%"VT4H!IQ)*A'*!):Y\]% $%'G1F*=<)%I43W"MQ]F
M/AV<]<\^2_/WON\=Y5%/X;MH-_>?A^9^G \]Z+3X=XJ'$7=Z+W=0V,^ZK<..
M.+*^XCXGNRO K@A,*2I2D,6I (B94M!)'@/"BUCD!.&$2)=:':=#.#'[!#4Y
M/ILQ(MX&/_;2U!U+*)YB:<?.MR$4F%5[PGDL,W]==;]E$$^'F;;PX44U3TH=
M7KYRW!=^D$#3>FA@'(L,P@(0I+0E6" *J"3FGT+E11H7:>+D'#LSQNRLMX,<
M,K</^QR$=E_VC< $_K2/\NK\NZ\&U/?Z>9\;9]+O>T#1XP]\Z-*1;J<EK:KW
MJG[@K^L'6JX67!&6HX(!H; "*(DY()!Q("05)$[UUD\X!8"=#C&W[[N6T'B7
MVG>YD=*UTMXIDI9.I9OP">U*<H3&W7%T47N_[J+38:9U$EU4\\0U=/G*<9]X
MNR6H/LJZPL#G]6?Z_3_+[5?3<;A<?7F]WIP/C%EP!A5+8M.WW+B>B13:CA<2
M%"BC60)))@D<4:MEK#Q67\7TM5DZ=2*UWD3F=.#AZ2&JMG3[I%_\']&6?H_^
MW&L7;1JMH^W:='5HHCVC2FZWRUU'%-F$\5&SAW/<1HR>:SNJ"CIUTQ!:J\)=
MI$6/>K+?G7?M['?9_BCO5A2]$N-H82:ESULA.R;9FY\W(G+/^/Q-Q,/JRR>Y
M^59R6;7;@5PA2>)" 251IGDV2?5;F!.@$L@A9KR(,;6.Q;LTRNQLKIV<FOT:
M01V"M"YB.<QCWA":X "O!:>3<4RR_T64'(+3?* U4;C9*-3<8L>NH3$8#7;Q
MYNGBNZ[)?Q"Q=?7B<?;H;^N5_/$;W?Q3;E\_K<3NG2PHDK&  #)LFO$4>MN9
M0 IR7J1<%05BF14+#@\S-QJLI8P>:C$C9>1T,_@N@&EGSMT.46 >;-!I)(QJ
M$0,XFH91\&IL71AJ4E-J6-UC0^G*U1,G.QZD6YC*=]UIUMK\ZOW35N^[5L:
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M>C___"M]\*]5'O6+M6#60KFUW$8X^]%]N0/?T>].LN3<)FNA!*Y "2,A!,%
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M:E,L^ !18R?4CH>P@]31([(N#G[.M3&,Q,,,JWVWK(5@Z\L2F9,G%IDKS>_
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MK/?9&I.SWRZ=L,.BXZ:Y^L!F*QWUB;UWN/@XG:V_]VJ^(B8W#PTF4F5%?I(
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M+V84_ZPO2W@4V063P9( R,5@%J*5&E+@0?HH65!M2DAN4O)(7+(!C-!^PN\
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M_:<JZ0W^^_F4*+K*]&9"[B7KDUP$I\^,%#T*DJ6JLN0R@G&A:%,*PW CQ?G
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M:8@<M/'*>*V]ZN%TOR)W_+;HL:&YL](Z0.;=*L6;L%C\G,Z^K)M-9.2:I!>
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M?95+Y8GUP0GD"8(."91/&1SC#%CQ(0LK<E*-3&)G6D_TZ6]#Q+=5]^Z ]I>
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M]K:P'[B(\[%M[*%$SK_BXO/7L);8DF3W8U4%O9I;Z%U(41= $VI#C>80#;.
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MGS_@_H!JUY[?U.J@WYW-YF% 5C(@^4S!LJJ@DE!G.E(8*.L&:BMBH_'IK<*
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M.\@-#T5)GZ$X%NKJ53(!QPN4B%&&D(M@;1KZ=B!R7-\U*([NAUVM5'5RWNJ
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MMH-H$Y6V+^ZO_Z#^$,,2_\?_\W\!4$L! A0#%     @ >SQS4SA)13K\- $
MSJT* !L              ( !     &5X:6-U<F5E>&AI8FET,3 S+3DS,#(Q
M+FAT;5!+ 0(4 Q0    ( 'L\<U,)!B R8"(  ##\   ;              "
M 34U 0!E>&EC=7)E97AH:6)I=#$P-"TY,S R,2YH=&U02P$"% ,4    " ![
M/'-3?5"E$B$8    # ( &P              @ '.5P$ 97AI8W5R965X:&EB
M:70Q,#4M.3,P,C$N:'1M4$L! A0#%     @ >SQS4SILD5NP!P  ]AX  !L
M             ( !*' ! &5X:6-U<F5E>&AI8FET,S$Q+3DS,#(Q+FAT;5!+
M 0(4 Q0    ( 'L\<U,7*3^2B0<  )4>   ;              "  1%X 0!E
M>&EC=7)E97AH:6)I=#,Q,BTY,S R,2YH=&U02P$"% ,4    " ![/'-3(+J.
MG (&   T'0  &P              @ '3?P$ 97AI8W5R965X:&EB:70S,C$M
M.3,P,C$N:'1M4$L! A0#%     @ >SQS4UZ2,A"550, ?;H? !$
M     ( !#H8! 'AC=7(M,C R,3 Y,S N:'1M4$L! A0#%     @ >SQS4Y.-
M$89;$P  2L\  !$              ( !TML$ 'AC=7(M,C R,3 Y,S N>'-D
M4$L! A0#%     @ >SQS4\2L!TZ&'P  GC8! !4              ( !7.\$
M 'AC=7(M,C R,3 Y,S!?8V%L+GAM;%!+ 0(4 Q0    ( 'L\<U-6^2FE)E,
M $NT P 5              "  14/!0!X8W5R+3(P,C$P.3,P7V1E9BYX;6Q0
M2P$"% ,4    " ![/'-3!#W!UW1> 0"@T ( %               @ %N8@4
M>&-U<BTR,#(Q,#DS,%]G,2YJ<&=02P$"% ,4    " ![/'-3P%SB"67U  !I
MA H %0              @ $4P08 >&-U<BTR,#(Q,#DS,%]L86(N>&UL4$L!
M A0#%     @ >SQS4X+*?6#GCP  X<4& !4              ( !K+8' 'AC
I=7(M,C R,3 Y,S!?<')E+GAM;%!+!08     #0 - ((#  #&1@@    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
